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P01.001.A
Prenatal diagnostics of 15q11.2 microdeletion syndrome -
the possibilities and challenges
K. Belemezova1,2, P. Chaveeva1, V. Stratieva3,4, M.
Yankova3,5, V. Peycheva6, R. Bozhilova6, M. Rizov1, S.
Yovinska1, M. Hristova-Savova1, R. Kaneva6, I. Dimova1,6
1SAGBAL „Dr Shterev“, Sofia, Bulgaria, 2University
Hospital “St. Ivan Rilski”, Department of Immunology,
Medical University of Sofia, Sofia, Bulgaria, 3O.S.С.A.R.
Clinic, Sofia, Bulgaria, 4First Specialized Hospital of
Obstetrics and Gynecology „St. Sofia”, Sofia, Bulgaria,
5University Hospital "Lozenetz", Sofia, Bulgaria, 6Center of
Molecular medicine, Medical University of Sofia, Sofia,
Bulgaria
Microdeletion in 15q11.2 has been described as a distinct
syndrome encompassing an area between two fragile sites in
15q (BP1 and BP2), with approximately 500 bp size,
containing NIPA1, NIPA2, TUBGCP5, and CYFIP1 genes.
It is a multisystemic disease affecting mostly the nervous
system (intellectual deficits, delayed psychomotor devel-
opment, ataxia, epilepsy, behavioral problems, etc.), fol-
lowed by congenital heart defects and various
dysmorphisms. This microdeletion was found in 0.57-
1.27% of pediatric patients targeted for microarray analysis,
mainly with developmental delay and intellectual deficits.
However, not all of the deletion carriers have a clinical
manifestation - it is found in 0.25% of the population of
healthy controls. The penetrance of 15q11.2 microdelection
syndrome is estimated at 10.4%, which is significantly
higher in de novo occurrence. We report 4 cases of pre-
natally established 15q11.2 microdeletion, in 3 of the cases
the microdeletion was inherited from clinically healthy
mothers. The indications for aCGH prenatal diagnosis were:
1) ultrasound data for unilateral cleft lip and palate in
combination with an increased nuchal translucency of 3.3
mm- mother was the carrier; 2) second pregnancy after the
first case; 3) increased risk from the biochemical screening
(1:6) and tricuspid regurgitation, brother with neu-
ropsychiatric disability - mother was a carrier; 4) Increased
NT of 7.3 mm. Our results highlight the importance of















pregnancies which are abnormal in early fetal screening. We
emphasize the difficulties of genetic counseling in the
inheritance and the incomplete penetrance of the
aberrations.
K. Belemezova: None. P. Chaveeva: None. V. Stra-
tieva: None. M. Yankova: None. V. Peycheva: None. R.
Bozhilova: None.M. Rizov: None. S. Yovinska: None.M.
Hristova-Savova: None. R. Kaneva: None. I.
Dimova: None.
P01.002.B
Improvement of prenatal care in case of fetal anomaly of
the corpus callosum using exome sequencing during the
pregnancy
S. Heide1, M. Spentchian1, S. Valence2, J. Buratti3, C.
Mach3, E. Lejeune3, V. Olin3, M. Massimello1, C. Garel4, E.
Blondiaux4, G. Quenum-Miraillet5, S. Chantot-Bastaraud5,
M. Milh6, V. des Portes7, M. Spodenkiewic8, V. Layet9, R.
Dard10, S. Moutton11, M. Gorce12, M. Nizon13, S. Mercier13,
M. Vincent13, C. Beneteau13, J. Jouannic14, M. Moutard2, B.
Keren3, D. Héron3
1UF de Génétique Médicale et CRMR « Déficience
intellectuelle », Département de Génétique, Groupe Hospi-
talier Pitié-Salpêtrière, APHP Sorbonne Université, Paris,
France, 2Service de Neurologie Pédiatrique, Hôpital
Armand Trousseau, APHP Sorbonne Université, Paris,
France, 3UF de Génomique du Développement, Départe-
ment de Génétique, Groupe Hospitalier Pitié-Salpêtrière,
APHP Sorbonne Université, Paris, France, 4Service de
Radiologie Pédiatrique, Hôpital Armand Trousseau, APHP
Sorbonne Université, Paris, France, 5Service de Cytogéné-
tique, Hôpital Armand Trousseau, HUEP, APHP Sorbonne
Université, Paris, France, 6Service de Neurologie Pédia-
trique, Hôpital La Timone, APHM, Marseille, France,
7Service de Neurologie Pédiatrique, Hospices Civils de
Lyon, Bron, France, 8Service de Génétique Clinique, CHU
de Reims, Reims, France, 9Service de Génétique Clinique,
Hôpital du Havre, Le Havre, France, 10Service de
Génétique Clinique, Hôpital de Poissy, Poissy, France,
11Centre de Référence des anomalies du développement,
Service de Génétique Médicale, CHU de Dijon, Dijon,
France, 12Service de génétique clinique, CHU d’Angers,
Angers, France, 13Service de Génétique Clinique, CHU de
Nantes, Nantes, France, 14Service de Médecine Fœtale,
Hôpital Armand Trousseau, HUEP, APHP Sorbonne
Université, Paris, France
Purpose: Anomalies of the corpus callosum (ACC) are
usually diagnosed by prenatal ultrasound. This malforma-
tion is characterized by its uncertain prognosis especially
when isolated which makes the prenatal counseling
difficult. Among genetic etiologies, only chromosomal
anomalies are investigated during the prenatal period while
ACC is due to single gene mutation in most cases and
neurodevelopmental prognosis depends on the
underlying cause.
Methods: In order to evaluate the feasibility and
contribution of prenatal exome sequencing (pES) during
the pregnancy, we included 66 fetuses with ACC for trio
analysis. Only pathogenic variants in known ACC and/or
ID genes were considered.
Results: pES results were available within a median delay
of 22 days. A pathogenic SNV was identified in 12 cases
(18%). Moreover, a pathogenic CNV was identified in 4
cases. Thus, the genetic cause was determined in 22% of
cases. In all cases with diagnoses, pES results enlightened
the neurodevelopmental prognosis of the fetus and enabled
the parents to choose to continue with or terminate the
pregnancy knowingly.
Conclusions: This is the first study of pES focusing on a
single malformation characterized by an uncertain prog-
nosis. Our results demonstrate the feasibility of pES in
fetuses with prenatal diagnosis of ACC. pES has an evident
clinical impact. The impact of pES when negative remains
to be evaluated
S. Heide: None. M. Spentchian: None. S. Valence:
None. J. Buratti: None. C. Mach: None. E. Lejeune:
None. V. Olin: None. M. Massimello: None. C. Garel:
None. E. Blondiaux: None. G. Quenum-Miraillet: None.
S. Chantot-Bastaraud: None. M. Milh: None. V. des
Portes: None. M. Spodenkiewic: None. V. Layet: None.
R. Dard: None. S. Moutton: None. M. Gorce: None. M.
Nizon: None. S. Mercier: None. M. Vincent: None. C.
Beneteau: None. J. Jouannic: None. M. Moutard: None.
B. Keren: None. D. Héron: None.
P01.003.C
Genetic management of a small deletion in the PWS/AS
imprinting center in a prenatal case
C. Pérez1, E. Pestaña2, C. Rivera2, M. Augé1, L. Barranco1,
A. Canellas1, M. Costa1, C. de la Iglesia1, D. Fernández1,
N. Palau1, B. Méndez1, M. Piqué1, M. Herrero1, D. Yeste1,
L. Puig1, R. Ferreti1, M. Punzón1, S. Martín1, J. Mendoza1,
N. Pinedo1, M. Rodríguez1, L. Linares1, E. Lloveras1
1Synlab, Esplugues de Llobregat, Spain, 2Synlab, Madrid,
Spain
Introduction: Imprinted genes involved in PWS and AS
are under control of an imprinting center comprising two
regulatory regions, PWS-SRO (around the SNRPN pro-
moter) and the AS-SRO (35 kb upstream). A very few AS
patients have small and/or atypical deletions in AS-SRO.
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Patient and Results: Pregnant patient (13 weeks) was
referred because a daughter of 4 years old with development
delay and peculiar phenotype and a 62Kb copy number loss
at 15q11.2, arr[GRCh37] 15q11.2(25119854_25177138)x1.
In extended familial studies, mother (pregnant) and grand-
father have both the same deletion. MS-MLPA was
performed in the daughter and the pregnant. The 15q11.2
deletion was confirmed in both and an altered methylation
pattern in the daughter was detected correlating with an AS
diagnosis. ArrayCGH analysis (CytoSure™ Constitutional
v3 8x60k, OGT, UK) was performed in chorionic villus
sample and the same deletion of 62Kb involving U5 exon of
AS-SRO (exon 4 according NM sequence of SNRPN gene)
was detected. MS-MLPA (PW/AS MS-MLPA Kit, MRC
Holland) was performed in amniotic fluid with alteration of
the methylation pattern, compatible with hypomethylation
of the probes located in the CpG islands region of SNRPN
gene was detected. Considering all the results, a prenatal
diagnosis of AS was performed.
Comments: IC deletion have been described in a small
fraction of AS patients with ID, with no disease-causing
variants detected to date.Deletions involving AS-SRO are a
molecular defect that must be determined as the recurrence
risk in case of a familial IC deletion. Caution should be
made in prenatal diagnosis and is appropriate recommend-
ing MS-MLPA analysis.
C. Pérez: None. E. Pestaña: None. C. Rivera: None. M.
Augé: None. L. Barranco: None. A. Canellas: None. M.
Costa: None. C. de la Iglesia: None. D. Fernández: None.
N. Palau: None. B. Méndez: None. M. Piqué: None. M.
Herrero: None. D. Yeste: None. L. Puig: None. R.
Ferreti: None. M. Punzón: None. S. Martín: None. J.
Mendoza: None. N. Pinedo: None. M. Rodríguez: None.
L. Linares: None. E. Lloveras: None.
P01.005.B
START: Thestudy of assistedreproductive technologies
R. Lyle1, C. Page2, Y. Lee2, K. L. Haftorn2, A. Jugessur2, J.
Bohlin2, H. K. Gjessing2, P. Magnus2, S. Håberg2
1Oslo University Hospital, Oslo, Norway, 2Norwegian
Institute of Public Health, Oslo, Norway
In the last few decades there have been marked changes in
patterns of fertility and family structure in rich countries.
These include increasing age at childbirth, a lower number
of children born to each woman or man, greater use of
assisted reproductive technology (ART), higher frequency
of family disruptions and increasingly complex family
structures. The Centre for Fertility and Health (CeFH;
www.cefh.no) consists of a multidisciplinary research team
of epidemiologists, geneticists, demographers, sociologists
and economists with research themes including fertility
problems and intergenerational transmission of health.
The START project aims to understand the causes and
health consequences of subfertility and how genetic influ-
ences and epigenetic differences are associated with sub-
fertility and Assisted Reproductive Technologies (ART).
ART may introduce epigenetic changes in the embryo since
the procedures are during a period of extensive epigenetic
repatterning. It is unknown which genes may be affected
and the potential health consequences for the children.
START uses data from the Norwegian Mother, Father and
Child Cohort Study (MoBa; https://www.fhi.no/en/studies/
moba/), which follows more than 110 000 children and their
parents. We have collected genetic and epigenetic data from
1000 trios with children born after ART, and 1000 trios
from naturally conceived children analyzed with the Illu-
mina EPIC array and the Illumina HumanCoreExome chip.
Investigations are focussed on the effect of ART treatment
on imprinted genes and fertility genes, and how epigenetic
age acceleration interacts with fertility and ART treatment.
Our results show DNA methylation changes due to both
parental subfertility and ART procedures.
R. Lyle: None. C. Page: None. Y. Lee: None. K.L.
Haftorn: None. A. Jugessur: None. J. Bohlin: None. H.K.
Gjessing: None. P. Magnus: None. S. Håberg: None.
P01.006.C
Beckwith Wiedemann Syndrome: a prenatal case report
with a novel CDKN1C mutation
P. Maia Almeida1,2, S. Moreira Ribeiro1, L. Abreu3, A.
Isabel Rei3, M. Branco3, E. Galhano3, J. Saraiva1,4,5, F.
Ramos1,3
1Medical Genetics Unit, Centro Hospitalar e Universitário
de Coimbra, Coimbra, Portugal, 2Faculty of Health
Sciences, University of Beira Interior, Covilhã, Portugal,
3Prenatal Diagnostic Center, Maternidade Bissaya Bar-
reto, Centro Hospitalar e Universitário de Coimbra,
Coimbra, Portugal, 4University Clinic of Pediatrics,
Faculty of Medicine, University of Coimbra, Coimbra,
Portugal, 5Clinical Academic Center of Coimbra, Coimbra,
Portugal
Introduction: Beckwith Wiedemann Syndrome (BWS) is a
genomic imprinting disorder typically diagnosed after birth.
Some ultrasound features that include polyhydramnios,
omphalocele, and visceromegaly may raise the clinical
suspicion in prenatal. Most reported BWS cases are
sporadic, but around 15% may be familial. Delineation of
the molecular defects can predict familial recurrence risks
and make invasive prenatal diagnosis possible.
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Case Report: We report a case of a 41-year-old pregnant
woman in whom ultrasound revealed at 24-weeks corpus
callosum hypoplasia, macroglossia, omphalocele, short long
bones and enlarged kidneys. The pregnancy was terminated
and autopsy confirmed the ultrasound findings and also
enlarged ovaries and pancreas, cytomegaly of the adrenal
cortex and a placental mesenchymal dysplasia. Family
history was irrelevant.
Materials and Methods: Clinical and molecular char-
acterization of a prenatal case with diagnosis of BWS. We
performed array-CGH, methylation analysis at 11p15.5
BWS locus and Sanger sequencing of CDKN1C gene. The
presence of the variant identified in the foetus was tested in
the parents.
Results: Array-CGH and 11p15.5 methylation analysis
(MS-MLPA) were normal. CDKN1C Sanger sequencing
found a heterozygous novel probable pathogenic frameshift
variant: NM_000076.2:c.479del p.(Pro160Argfs*112) of
maternal origin.
Conclusions: This case demonstrates that search for a
clear specific molecular diagnosis is key not only to confirm
the diagnosis but also to provide proper genetic counselling.
Although present in only 5% of the patients with no family
history the identification of a CDKN1C pathogenic variant
of maternal origin increases the recurrence risk to 50%.
P. Maia Almeida: None. S. Moreira Ribeiro: None. L.
Abreu: None. A. Isabel Rei: None. M. Branco: None. E.
Galhano: None. J. Saraiva: None. F. Ramos: None.
P01.007.A
Prenatal phenotype in Beckwith-Wiedemann spectrum
D. Carli, C. Bertola, S. Cardaropoli, V. P. Ciuffreda, M.
Pieretto, G. B. Ferrero, A. Mussa
Department of Public Health and Pediatrics, University of
Torino, Torino, Italy
Introduction: the prenatal phenotype of Beckwith-
Wiedemann spectrum (BWSp) is not well characterized.
Here we investigate the prenatal features of large series of
BWSp patients.
Methods: postnatal phenotype, genotype, prenatal ultra-
sound (US) features, pregnancy course and biochemical
screening tests of 88 patients with BWSp (51 females) were
reviewed.
Results: molecular tests had been performed in 86
patients, 80 resulted positives for BWSp-related anomalies,
6 negative with a clinical diagnosis. Seventeen (19.3%) were
conceived through artificial reproductive techniques. Twin-
ning occurred in 9 pregnancies and resulted in 13 BWSp
newborns. Pregnancy biochemical screening tests showed
increased serum markers: PAPP-A at 10-13 weeks of
gestational age (n = 44, 1.13 ± 0.61 MoM, p < 0.001),
and αFP (1.52 ± 0.80 MoM, p = 0.003), uEstriol
(1.41 ± 0.37 MoM, p < 0.001) and total hCG (2.10 ± 2.17
MoM, p < 0.001) at 15-18 weeks (n = 27). Morphology US
scan (available in 64) revealed abdominal and head
circumferences higher than normal (1.41 ± 1.10 SD,
p < 0.001 and 0.44 ± 1.04, p = 0.003, respectively) with
normal femur lengths. Fifty-eight patients (66%) had a
various combination of pathologic US findings, including
enlarged abdominal circumference at 20 weeks’ scan
(n = 17), macrosomia at a subsequent scan (n = 35, of
these 14 normal at 20 weeks’ scan), omphalocele (n = 12),
enlargement of abdominal organs (n = 6), macroglossia
(n = 15), adrenal cysts/masses (n = 2), nephroureteral
anomalies (n = 11), polyhydramnios (n = 24), placental
enlargement (n = 2) or mesenchymal dysplasia (n = 4).
Thirty cases had no detected anomaly at any US.
Conclusions: on the basis of these findings, we propose a
new embryo-fetal BWSp scoring system, mirroring the
post-natal one, that will implement the prenatal clinical
approach of this developmental syndrome.
D. Carli: None. C. Bertola: None. S. Cardaropoli:
None. V.P. Ciuffreda: None. M. Pieretto: None. G.B.
Ferrero: None. A. Mussa: None.
P01.008.B
Prenatal diagnosis of a severe form of BICD2-opathy :
further evidence of an extreme phenotypic spectrum
E. Marchionni1, E. Agolini2, G. Mastromoro1, D.
Guadagnolo1, F. Di Palma1, C. Pajno3, V. D’Ambrosio3, M.
Roggini4, A. Giancotti3, A. Novelli2, A. Pizzuti1
1Department of Experimental Medicine, Sapienza Univer-
sity of Rome, Rome, Italy, 2Laboratory of Medical Genetics,
Ospedale Pediatrico Bambino Gesù, Rome, Italy, 3Depart-
ment of Maternal and Child Health and Urologic Science,
Sapienza University of Rome, Rome, Italy, 4Pediatrics and
Child Neuropsychiatry Department, Sapienza University of
Rome, Rome, Italy
Introduction: Arthrogryposis multiplex congenita (AMC)
is characterized by the development of multiple joint con-
tractures. Neurogenic and myogenic-types have been
described, resulting in complete or partial movement
restriction. In prenatal diagnosis decreased fetal movement
is observed, the most severe forms being lethal in utero or
after birth. We report a case of a male fetus at 22 gestational
weeks with evidence of AMC on ultrasound, presenting
fixed extended legs and flexed arms, bilateral clubfoot and
absent fetal movements. Frontal oedema was also observed.
After amniocentesis, karyotype and SNParray resulted
normal.
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Materials and Methods: Trio-based Whole Exome
Sequencing (WES) was performed on fetus genomic DNA
and his unaffected parents.
Results: WES analysis disclosed a de novo heterozygous
pathogenic deletion (NM_015250.3: c.1636_1638delAAT;
p. Asn546del) in BICD2 gene, associated with autosomal
dominant spinal muscular atrophy, lower extremity-
predominant 2 (SMALED2). The couple decided to
terminate the pregnancy. Babygram showed bilateral genu
recurvatum, bilateral clubfoot and clubhand and multiple
joints contractures.
Conclusions: BICD2 mutations are associated with
severe prenatal-onset forms of spinal muscular atrophy,
lower extremity-predominant 2B (SMALED2B) or milder
forms with childhood-onset (SMALED2A). In literature
few prenatal cases are reported, mostly with early lethal
outcome. The same variant was previously described in two
children with a severe postnatal phenotype but belated or
milder prenatal signs. This observation expands BICD2
phenotypic spectrum, with further evidence of early-onset
extreme prenatal forms. To date, the localization of the
disease-causing mutations does not seem to correlate with
disease severity, other molecular mechanisms should be
investigated to elucidate genotype-phenotype correlations.
E. Marchionni: None. E. Agolini: None. G. Mastro-
moro: None. D. Guadagnolo: None. F. Di Palma: None.
C. Pajno: None. V. D’Ambrosio: None. M. Roggini:
None. A. Giancotti: None. A. Novelli: None. A.
Pizzuti: None.
P01.010.A
Development and validation of an expanded pan-ethnic
carrier screening test
S. Kyriakou, A. Achilleos, M. Georgiadou, C. Loizides, M.
Nicoalou, V. Soteriou, C. Kkoufou, L. Constantinou, G.
Billioud, K. Tsangaras, E. Kypri, M. Ioannides, G.
Koumbaris, P. C. Patsalis
NIPD Genetics, Nicosia, Cyprus
Introduction: Carrier screening increasingly becomes more
prevalent as prospective parents become more aware that
the cumulative risk of having an affected child with an
autosomal or X-linked condition can be higher than that for
common aneuploidies. The changing admixture of popula-
tions, and the increase in gamete donation in assisted
reproductive technologies have led professional organiza-
tions and professional bodies to recommend expanded
carrier screening to the general population.
Materials and Methods: The test was developed using
targeted in-solution hybridization enrichment followed by
next generation sequencing covering all gene exons, and
intron-exon boundaries, associated with 229 autosomal
recessive and X-linked conditions. The sensitivity and
specificity for single nucleotide variant (SNV), indel and
copy number variant (CNV) detection was ascertained in a
blind validation study.
Results: SNVs and indels were detected at high
sensitivity (>99.0%) and specificity (>99.9%). The algo-
rithm was also designed to detect CNVs to a single or a few
exons with high sensitivity and specificity. Each positive
call was confirmed with an orthogonal method.
Conclusions: We have developed and validated an
expanded pan-ethnic carrier screening test which includes
229 autosomal recessive and X-linked conditions. The test
provides individuals and prospective parents with clinical
information, helping them understand and evaluate their
reproductive options.
S. Kyriakou: A. Employment (full or part-time);
Significant; NIPD Genetics. A. Achilleos: A. Employment
(full or part-time); Significant; NIPD Genetics. M. Geor-
giadou: A. Employment (full or part-time); Significant;
NIPD Genetics. C. Loizides: A. Employment (full or part-
time); Significant; NIPD Genetics. M. Nicoalou: A.
Employment (full or part-time); Significant; NIPD Genetics.
V. Soteriou: A. Employment (full or part-time); Signifi-
cant; NIPD Genetics. C. Kkoufou: A. Employment (full or
part-time); Significant; NIPD Genetics. L. Constantinou:
A. Employment (full or part-time); Significant; NIPD
Genetics. G. Billioud: A. Employment (full or part-time);
Significant; NIPD Genetics. K. Tsangaras: A. Employment
(full or part-time); Significant; NIPD Genetics. E. Kypri:
A. Employment (full or part-time); Significant; NIPD
Genetics. M. Ioannides: A. Employment (full or part-
time); Significant; NIPD Genetics. G. Koumbaris: A.
Employment (full or part-time); Significant; NIPD Genetics.
P.C. Patsalis: A. Employment (full or part-time); Sig-
nificant; NIPD Genetics.
P01.014.B
CGH-array as first-tier test in all undergoing invasive
prenatal samples: an experience for a reference Centre.
M. A. Mori1, J. Nevado1, E. Mansilla1, F. A. Garcia-
Santiago1, E. Antolín2, C. Peña1, C. Adam1, P. D.
Lapunzina1
1INGEMM-IdiPaz, Madrid, Spain, 2Sº Fisiopatología Fetal,
HULP, Madrid, Spain
Introduction: In the last years microarrays (CMA) has
demonstrated to be a significant tool useful in the prenatal
area, mainly in fetuses with sonography anomalies. How-
ever, using array-CGH in an invasive prenatal context is
still under a significant and controversial debate especially
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regarding the use of CMA in advance maternal age or
maternal anxiety samples. Previous studies supported the
evidence on the feasibility of introducing a-CGH as a first-
line diagnostic testing routine prenatal diagnosis practice
(1). Indeed, others and our laboratory have reported sig-
nificant diagnostic yields also in low-risk pregnancies,
between 1.6-4% (2,3).
Methods: We used customized Karyoarray®v3.0 platform
(4) to study consecutive invasive prenatal samples along
two-year period. QF-PCR positive cases were excluded.
Results: We analyzed 800 samples and we found globally
6% of pathogenic CNVs and 2% of VUS. We segregated
low-risk pregnancy samples (positive biochemical screen-
ing, soft markers, maternal anxiety, and antenatal death
without sonographic anomalies). Diagnostic yield in this
group was 4.5% (17/379).
Discussion: In conclusion, the use of the array-CGH in
the prenatal context demonstrated a greater diagnostic
capacity not only in fetuses with ultrasound abnormalities
but also in low-risk pregnancies. Therefore, we definitively
recommend the possibility of using the array-CGH in all
those gestations that undergo invasive prenatal diagnosis,
after excluding by QF-PCR the most common aneuploidies.
(1)Kan AS. et al., 2014. PLoS One. 9(2):e87988. (2)Wapner
RJ. et al., 2012. N Engl J Med.367:2175-2184. (3)Armengol
L. et al. 2012. Hum Genet. 131:513-523. (4)Vallespin E.
et al,. 2013. Am J Med Genet A.161A:1950-60.
M.A. Mori: None. J. Nevado: None. E. Mansilla: None.
F.A. Garcia-Santiago: None. E. Antolín: None. C. Peña:
None. C. Adam: None. P.D. Lapunzina: None.
P01.016.A
DERIVATIVE(9)T(2;9)(P23;P22) IN HIGH RISK
TWIN PREGNANCY
M. Kadkhoda zadeh, s. seyedhassani, f. harrazi zadeh
yazdi, a. danafar, m. mirjalili, f. saeb
yazdgenetic, yazd, Iran, Islamic Republic of
Introduction:A 39- year- old mother was referred with
GA=16 w + 5 d and high risk pregnancy screening test for
T 21. The first child of this patient was a 14- years old
suffering from developmental delay and mental retardation.
On the other hand, this family had two spontaneous abor-
tion. These evidences revealed enough reasons for prob-
ability of chromosomal abnormalities such as Down
syndrome, monosomy X, and other chromosomal disorder
in fetus. Amniocentesis was suggested for complementary
investigation.
Methods and materials: Twenty metaphases cells were
studied on the basis of G-Banding technique from culture of
amniocytes in two flasks. Then, karyotypig was done on the
basis of G-Banding for the parents.
Result: In this study, we described a paternal chromo-
somal aberration of twins. Through a combination of
cytogenetic assessment of fetus and parents 46, XY, der (9)
t(2;9) (p23;p22)pat was shown. Mother’s karyotype was
46XX but father’s karyotype revealed an abnormal
chromosome complement in all cells with balanced 46,
XY,t(2;9)(p23;p22).
Conclusions: Paternal chromosomal balanced transloca-
tion can explain repeated abortions in this family. On the
other hand, unbalanced chromosomal translocation result-
ing from paternal inheritance lead to developmental delay in
his son. This study was highly emphasized the priority of
genetic counseling and attention to the family history and
genetic basis of parents in evolution of repeated sponta-
neous abortion. Legal abortion was recommended to
unbalance chromosomal abnormalities.
M. Kadkhoda zadeh: None. S. seyedhassani: None. F.
harrazi zadeh yazdi: None. A. danafar: None. M.
mirjalili: None. F. saeb: None.
P01.017.B
Karyotype analysis of 8531 pregnancies in prenataly
identified cases with amniocentesis from south of Turkey
A. Pazarbasi1, D. Alptekin1, N. S. Ilgaz1, I. N. Uslu1, G. Ay1,
S. Kocaturk-Sel1, O. Demirhan1, U. Luleyap1, M. B.
Yilmaz1, N. Çetinel1, G. Evyapan1, G. Comertpay-Tufan1, S.
Buyukkurt2
1Çukurova University, Faculty of Medicine, Dept. of
Medical Biology, Adana, Turkey, 2Çukurova University,
Faculty of Medicine, Dept. of Obstetrics and Gynecology,
Adana, Turkey
Amniocentesis is a very crucial diagnostic procedure for
preventing the birth of genetically defective fetuses in order
to decrease the prevalence of genetic diseases in popula-
tions. A retrospective review of our amniocentesis database
for the period from January 2000 to February 2020 was
carried out. The karyotyping of 8531 fetuses was carried out
in Department of Medical Biology from the samples of
amniotic fluids which were sent from Department of
Gynecology and Obstetrics of Balcali Hospital. A standart
nomenclature has been developed to describe each of types
of abnormality found in human chromosomes. A total of
8531 amniocentesis specimens were processed during the
study period. 620 fetuses (7.26%) had various chromosomal
abnormalities. 54.51% of abnormal karyotypes (338 cases)
were numerical and 43.38% (269 cases) were structural.
Both numerical and structural chromosomal aberrations
were observed in 13 cases (2.09%). The ratios were as:
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trisomy 21 (49.70%), trisomy 18 (17.75%), monosomy X
(9.46%), trisomy 13 (6.80%), Triploidy (4.73%), Klinefelter
Syndrome (3.25%), Trisomy X (1. 18%), XYY Syndrome
(0.88%), and the others in all numerical abnormalities. The
frequent structural abnormalities were as: 46,XX/XY, inv
(9) (p11;q12)/(p11;q13)(28.25 %), 46,XX/XY, 1qh(+)
(11.89%), 46,XY, Yqh(-)(7.43%), 46,XX/XY, 16qh(+)
(7.06%), 46,XX/XY, 9qh(+)(4.46%) and 46,XY, Yqh(+)
(4.08%). Balanced and unbalanced translocations, deletions
and duplications were also found in less ratio. According to
the literature and our results, advanced maternal age is the
main cause of fetal chromosomal abnormalities. Fetal
chromosomal abnormality ratio that we found was 7.26%.
This ratio emphasize the importance of prenatal diagnosis.
A. Pazarbasi: None. D. Alptekin: None. N.S. Ilgaz:
None. I.N. Uslu: None. G. Ay: None. S. Kocaturk-Sel:
None. O. Demirhan: None. U. Luleyap: None. M.B.
Yilmaz: None. N. Çetinel: None. G. Evyapan: None. G.
Comertpay-Tufan: None. S. Buyukkurt: None.
P01.018.C
Microarray testing in pregnancies with nuchal translu-
cency 3-3.4 mm - time to change the cut-off.
L. Sagi-Dain1, I. Maya2, A. Singer3
1Carmel Medical Center, Haifa, Israel, 2Rabin Medical
Center, Petach Tikva, Israel, 3Sheba Medical Center,
Ramat Gan, Israel
Objective: To examine the risk for chromosomal microarray
analysis (CMA) aberrations in fetuses with nuchal translu-
cency (NT) of 3 to 3.4 mm. Methods: The results of all
CMA tests performed due to an NT of 3 to 3.4 mm were
retrospectively retrieved from the Ministry of Health com-
puterized database. The rates of clinically significant
(pathogenic and likely pathogenic) microarray findings
were compared to a previously published local control
population, encompassing 5541 fetuses with normal ultra-
sound. Results: Overall, 619 CMA analyses were performed
due to a sonographic indication of NT of 3 to 3.4 mm. Of
these, 29 (4.7%) clinically significant copy number variants
were detected, a considerably increased risk compared to
control pregnancies. Fetal karyotyping would have missed
31% of the abnormal cases, while non-invasive prenatal
screening (NIPS) would have overlooked 31-49% of the
anomalies, depending on the method. Conclusions: The
outcomes of our study, representing the largest number of
CMA results in fetuses with NT of 3 to 3.4 mm, suggest that
the rate of abnormal CMA findings in these pregnancies is
significantly higher compared to pregnancies with normal
ultrasound. Our results support the consideration to perform
invasive prenatal testing for CMA in pregnancies with NT
above 3 mm. In addition, as several of the CMA findings in
these pregnancies are not associated with major sonographic
anomalies, it seems that NIPS with later sonographic survey
cannot adequately replace NT measurement.
L. Sagi-Dain: None. I. Maya: None. A. Singer: None.
P01.020.B
Three fetuses with achondrogenesis type 2 explained by
maternal mosaicism
S. Z. Jan1, R. F. Suijkerbuijk1, Y. J. Vos1, P. M.
Grootscholten1, L. Zijlstra1, K. Bouman1, M. T. M.
Franssen2, M. H. Schoots3, N. Corsten-Janssen1, B.
Sikkema-Raddatz1
1Univeristy Medical Center Groningen, Department of
Genetics, Groningen, Netherlands, 2Univeristy Medical
Center Groningen, Department of Obstetrics, Groningen,
Netherlands, 3Univeristy Medical Center Groningen,
Department of Pathology and Medical Biology, Groningen,
Netherlands
Background: Adding whole exome sequencing (WES) to
the standard diagnostic procedure in fetuses with ultrasound
anomalies improves the diagnostic yield. Identifying a
diagnosis is important for parental choice and informed
reproductive decision making, amongst other factors. Here
we describe three fetuses in whom a diagnosis of achon-
drogenesis type 2 (COL2A1 variant) due to maternal
mosaicism was made using WES.
Materials & Methods: A couple expecting dichorionic
diamniotic twins, both with severe limb shortening and fetal
hydrops, was referred to our department. A previous
pregnancy had been terminated for the same reasons. QF-
PCR and SNP array were performed on DNA of chorionic
villi from both fetuses of the current pregnancy. WES was
performed on parental DNA (extracted from blood) and
fetal DNA.
Results: QF-PCR and SNP-array showed no abnormal-
ities for both fetuses. WES revealed a pathogenic,
apparently de novo, COL2A1 variant c.3062_3079del p.
(Pro1021_Gly1026del) in both samples, which explained
the ultrasound abnormalities. Retrospective analysis con-
firmed the presence of the same COL2A1 variant in the
previous pregnancy. Re-analysis of parental WES data
revealed the variant in less than 1% of maternal reads,
implying an extremely low grade of mosaicism, which was
confirmed by Sanger sequencing.
Conclusions: This case study highlights the added value
of WES in prenatal diagnostics, including the capacity to
identify extremely low-grade parental mosaicism that
profoundly impact the recurrence risk of a genetic disease.
It also suggests that the possibility of very low-grade
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parental mosaicism should be closely investigated when an
apparently de novo variant is identified.
S.Z. Jan: None. R.F. Suijkerbuijk: None. Y.J. Vos:
None. P.M. Grootscholten: None. L. Zijlstra: None. K.
Bouman: None. M.T.M. Franssen: None. M.H. Schoots:
None. N. Corsten-Janssen: None. B. Sikkema-
Raddatz: None.
P01.021.C
Prenatal diagnostics in Estonia: a 2-year prospective
study assessing the performance of combined first-
trimester screening, chromosomal microarray analysis,
and next-generation sequencing
K. Ridnõi1,2, K. Muru1,3, M. Keernik1, S. Pajusalu1,3,4, E.
Ustav5, P. Tammur1, T. Mölter-Väär1, T. Kahre1,3, U.
Šamarina1, K. Asser5, F. Szirko2, T. Reimand1,3,6, K.
Õunap1,3
1Department of Clinical Genetics, United Laboratories,
Tartu University Hospital, Tartu, Estonia, 2Centre for
Perinatal Care, Women’s Clinic, East-Tallinn Central
Hospital, Tallinn, Estonia, 3Department of Clinical Genet-
ics, Institute of Clinical Medicine, University of Tartu,
Tartu, Estonia, 4Yale University School of Medicine,
Department of Genetics, New Haven, CT, United States,
5Women’s Clinic, Tartu University Hospital, Tartu, Estonia,
6Department of Biomedicine, Institute of Biomedicine
and Translational Medicine, University of Tartu, Tartu,
Estonia
Introduction: The implementation of cell-free fetal DNA
(cff-DNA) testing in maternal blood opened possibilities to
improve performance of combined first trimester screening
(cFTS). On the other hand, use of new molecular methods,
such as chromosomal microarray analysis (CMA) and next-
generation sequencing (NGS), have shown benefits in
diagnosis of chromosomal and genetic diseases, which are
not detectable with cff-DNA screening, but require invasive
procedure. We prospectively evaluated performance of
cFTS in Estonia during 2 years using national guidelines
with application of CMA and NGS in high-risk
pregnancies.
Material and methods:We investigated 14,566 singleton
pregnancies (60% of all pregnancies). We selected 334
high-risk pregnancies for CMA diagnostic performance
evaluation and 28 cases of highly dysmorphic fetuses for
NGS analysis. CMA study group was divided into two
groups based on the indications for testing: group A patients
with high-risk for trisomies after cFTS, but normal
ultrasound and group B patients who met criteria for
CMA as a first-tier diagnostic test.
Results: We found the first trimester detection rate 94%,
100% and 100% for trisomies 21, 18 and 13, respectively,
with false-positive rate of 3.1%. The diagnostic yield of
CMA was overall 3.6% (1.7% in Group A and 6.0% in
Group B). In NGS analysis group we report diagnostic yield
of 17.9%. Combining these three methods, overall detection
rate of all genetic anomalies was 101 (0.7%).
Conclusions: the use of CMA and NGS in high-risk
pregnancies after cFTS is justified and increase diagnostic
yield. Funding: Estonian Research Council grants PUT355,
PRG471, and PUTJD827.
K. Ridnõi: None. K. Muru: None. M. Keernik: None.
S. Pajusalu: None. E. Ustav: None. P. Tammur: None. T.
Mölter-Väär: None. T. Kahre: None. U. Šamarina:
None. K. Asser: None. F. Szirko: None. T. Reimand:
None. K. Õunap: None.
P01.023.B
Higher incidence of congenital anomalies in children
born after assisted reproduction in the Czech Republic:
Population based study
A. Sipek Jr1,2,3, V. Gregor2,4, J. Klaschka5,6, M. Maly5,7, A.
Sipek Sr2,4,8
1Institute of Biology and Medical Genetics, First Faculty of
Medicine, Charles University, Prague, Czech Republic,
2Department of Medical Genetics, Thomayer Hospital,
Prague, Czech Republic, 3Institute of Medical Genetics,
Third Faculty of Medicicne, Charles University, Prague,
Czech Republic, 4Department of Medical Genetics, Prona-
tal Sanatorium, Prague, Czech Republic, 5Institute of
Computer Science of the Czech Academy of Sciences,
Prague, Czech Republic, 6Institute of Biophysics and
Informatics, First Faculty of Medicine, Charles University,
Prague, Czech Republic, 7National Institute of Public
Health, Prague, Czech Republic, 8GENNET, Prague, Czech
Republic
Introduction: The number of children conceived by
assisted reproduction techniques (ART) is increasing in the
Czech Republic. The main goal of this study was to eval-
uate the incidence of congenital anomalies in ART con-
ceived children.
Methods: The retrospective epidemiological analysis was
performed using data from the National Registry of
Congenital Anomalies and National Registry of Newborns,
run by the Institute of Health Information and Statistics of
the Czech Republic. All diagnoses of congenital anomalies
(Q00-Q99) were included. We compared the incidences of
congenital anomalies in naturally conceived children and
ART conceived children born in the Czech Republic during
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5 years period (2013-2017). Statistical analysis was
performed by Fisher’s exact test.
Results: During the selected period there were 547 675
children born in the Czech Republic (531 064 were
naturally conceived children and 16 611 were ART
conceived children). The incidence of congenital anomalies
was 3.90% in naturally conceived children group and 4.35%
in ART conceived children. This difference is statistically
significant (p = 0.003). Analyzing different subgroups of
congenital anomalies we have found a significantly
increased incidence of anomalies in two subgroups:
Congenital malformations of the circulatory system (Q20-
Q28) and Congenital malformations of the respiratory
system (Q30-Q34).
Discussion: The increased risk of congenital anomalies in
ART conceived children was highlighted in many studies
however the results are often diverse. In our population-
based study, we confirmed a significantly higher general
incidence of congenital anomalies in ART conceived
children.
The study is supported by the RVO project: “Thomayer-
ova nemocnice - TN, 00064190”.
A. Sipek Jr: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; Research grant provided
by Ministry of Health of the Czech Republic, RVO project:
“Thomayerova nemocnice TN, 00064190”. V. Gregor: B.
Research Grant (principal investigator, collaborator or
consultant and pending grants as well as grants already
received); Modest; Research grant provided by Ministry of
Health of the Czech Republic, RVO project: “Thomayerova
nemocnice TN, 00064190”. J. Klaschka: B. Research
Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received); Modest;
Research grant provided by Ministry of Health of the Czech
Republic, RVO project: “Thomayerova nemocnice TN,
00064190”. M. Maly: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Modest; Research grant
provided by Ministry of Health of the Czech Republic,
RVO project: “Thomayerova nemocnice TN, 00064190”.
A. Sipek Sr: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; Research grant provided
by Ministry of Health of the Czech Republic, RVO project:
“Thomayerova nemocnice TN, 00064190”.
P01.024.C
A low-cost microsatellite marker method for quick andA
low-cost microsatellite marker method for quick and
reliable prenatal 22q11.2DS screening and detection in
fetuses with suspected congenital heart defects
L. Torres-Juan1, M. Coll-Ferrer1, M. Prado-Farnos1, R.
Martorell-Riera1, E. Amengual-Cloquell1, A. Perez-
Granero1, A. Tubau2, M. Juan2, J. Rosell1, I. Martinez-
Lopez1, D. Heine-Suñer1
1Institute of Health Research of the Balearic Islands
(IDISBA) and Hospital Son Espases, Palma, Spain, 2Insti-
tute of Health Research of the Balearic Islands (IDISBA)
and Hospital Son Llatzer, Palma, Spain
Congenital heart defects (CHD) are the most common form
of birth defects and affect 1% of newborns and an even
higher percentage of unborn fetuses. CHDs are a frequent
finding during routine ultrasound prenatal screening. Once
detected, it is important to determine their etiology. The
22q11.2 deletion syndrome (22q11.2 DS) is the most fre-
quent known genetic cause of CHDs (1.9% prevalence). We
present a multiplex marker PCR kit to detect 22q11.2
deletions and duplications which we prospectively used in
1630 individuals and 450 fetal cases with a congenital heart
defect referred by an obstetrician. Important features: 1)
Low cost (there are 2 mixes of 11 pairs of primers and 2
conventional PCR reactions). 2) Fast, results can be given
within hours of receiving the sample (DNA extraction ->
PCR 1.5 hours -> automatic sequencer). 3) Safely rules out
sample contamination by maternal DNA. 4) Uses small
amounts of DNA (10 ng) and can be performed starting
from amniotic fluid or non-cultured chorion biopsy or any
other tissue. 5) In prenatal samples, it would be com-
plementary to the QF-PCR (negative samples for trisomy
13, 18 or 21). 6) The parental origin of the deletion/dupli-
cation is determined when the fetus is analyzed with the
parents. 7) Detects atypical and typical deletions, extending
the analysis far beyond that given by the FISH probe that
has been historically used (TUPLE1). 8) We have devel-
oped a panel of 31 additional markers, not included in the
multiplex, to be used in case of lack of informativity.
L. Torres-Juan: None. M. Coll-Ferrer: None.
M. Prado-Farnos: None. R. Martorell-Riera: None.
E. Amengual-Cloquell: None. A. Perez-Granero: None.
A. Tubau: None. M. Juan: None. J. Rosell: None.
I. Martinez-Lopez: None. D. Heine-Suñer: None.
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The effects of the CFTR genotype on the reproductive
system in adult male patients with cystic fibrosis
S. Repina1, S. Krasovskiy1,2, M. Shtaut1, G. Shmarina1,
T. Adyan1, V. Chernykh1
1Research Centre for Medical Genetics, Moscow, Russian
Federation, 2Pulmonology Research Institute, Moscow,
Russian Federation
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Background: Commonly male patients with Cystic Fibro-
sis (CF) is infertile due to obstructive azoospermia (OA), at
that an influence of CFTR genotype on reproductive system
is poor understood.
Materials and methods: We examined 93 Russian male
CF patients (17-45 y.o., mean - 24.9 ± 5.7 y.o.). Physical
examination, scrotal ultrasonography, hormonal, biochem-
ical, and semen analysis were done. Standard and
biochemical semen examination were done according to
the WHO’s (2010) recommendations. The CFTR gene
variants were analyzed using by AFPL, MLPA and DNA
sequencing (Sanger’s method and MPS).
Results: CFTR mutations were detected in 100% CF
alleles. Folowing genotypes were found: F508del/F508del
(20.4%); F508del/3849+10kbC>T (15.1%); F508del/2789
+5G>A (4.3%); F508del/CFTRdele2.3 (4.3%); F508del/
E92K (3.2%); F508del/L138ins (3.2%); F508del/3272-
16T>A (2.2%); F508del/W1282X (2.2%); others (45.3%).
The spectrum of CFTR gene pathogenic variants and
genotypes showed high frequency of “mild” pathogenic
variants (25.8%) and genotypes (50.5%), as well as a
relatively high frequency of 3849+10kbС>T variant
(12.4%), which was identified in 8.2% patients with OA
and 94.4% with no OA (p < 0.00001). Statistically
significant difference was found between patients with
F508del/3849+10kbC>T and F508del/F508del genotypes
for a prevalence of OA/seminal ducts obstruction (14.3% vs
100%, p < 0.05) and testicular hypoplasia (26.9% vs 66.7%,
p = 0.03).
Conclusions: CF dramatically affects reproductive
organs, male fertility and semen parameters in CF patients,
at that 3849+10kbС>T mutation in the CFTR genotype is
major genetic factor of male fertility.
S. Repina: None. S. Krasovskiy: None. M. Shtaut:
None. G. Shmarina: None. T. Adyan: None. V.
Chernykh: None.
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First and second trimester biochemical screening:
additional value in the era of NIPS
R. Michaelson-Cohen1,2,3, A. Lahad3,4
1Medical Genetics Institute, Shaare Zedek Medical Center,
Jerusalem, Israel, 2Department of Obstetrics and Gynecol-
ogy, Shaare Zedek Medcial Center, Jerusalem, Israel,
3Hebrew University, Jerusalem, Israel, 4Clalit Health
Services, Jerusalem, Israel
Background: Since implementation of NIPS, first and
second trimester biochemical tests may no longer be
necessary for Down Syndrome screening. However, studies
suggest their ability to predict pregnancy complications. We
sought to evaluate whether screening tests have value for
this purpose.
Methods: Our cohort included all women who had first
and/or second trimester screening from 2015-2018 and
subsequently delivered in our center. Data was collected on
demographics, medical history, biochemical screening and
maternal-fetal pregnancy outcomes. Logistic regression was
performed to examine correlations between biochemical
markers and pregnancy complications using SPSS version
25.0 (SPSS, Inc).
Results: Over 3.5 years, 5400 women had screening tests
and later delivered in our center. Decreased PAPP-A was
associated with preeclampsia, gestational diabetes, IUGR
and preterm delivery (PTD), OR=1.792, 1.364, 1.403 and
1.277, respectively, p < 0.005. Elevated AFP was associated
with PTD, maternal blood administration, IUGR and low 5-
minute Apgar-score, OR=2.044, 1.95, 1.452 and 1.22,
respectively, p < 0.033. Decreased HCG in second trimester
was correlated with IUGR, OR=1.346, p < 0.05. Elevated
HCG in second trimester was correlated with PTD and
newborn NICU admission, OR=1.192, 1.285, respectively,
p < 0.015. In both first and second trimesters, elevated HCG
was associated with preeclampsia, OR= 1.169, 1.309,
respectively, p < 0.05. Low estriol was correlated with
IUGR, OR=3.597, p < 0.001. After controlling for
confounders (age, ethnicity, IVF, parity, etc.) most associa-
tions remained significant.
Discussion: Despite superiority of NIPS for Down
Syndrome screening, biochemical screening is still valuable
for prediction of pregnancy complications. Identifying
women with high-risk pregnancies has clinical implications
for prenatal care and risk-reducing management strategies.
R. Michaelson-Cohen: None. A. Lahad: None.
P01.034.A
Use of prenatal exome sequencing in fetuses with
ultrasound anomalies
M. Segura-Puimedon, B. Campos, J. Luna, C. Sintas,
M. de Castro-Miró, H. Díez, S. B. Estruch, R. Garcia,
L. Quintana, J. Rodríguez, L. Armengol
Quantitative Genomic Medicine Laboratories, qGenomics,
Barcelona, Spain, Esplugues de Llobregat, Spain
Introduction: Whole exome sequencing (WES) is an
established diagnostic tool in postnatal settings for indivi-
duals with a suspected genetic condition. Recently, it is
increasingly used as a diagnostic tool in prenatal settings as
well. We present here our experience using this technology
in fetuses with ultrasound anomalies.
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Material and Methods: WES was performed in 166 fetal
samples with ultrasound anomalies. 104 samples were from
evolutive pregnancies and 62 were from legal interruptions
or stillbirths. In 61 samples, previous prenatal CGH-array
was performed with negative result. Segregation studies
were performed in cases with a candidate variant when
possible.
Results: Common reasons for referral were skeletal
anomalies, polymalformated fetuses, cerebral anomalies or
specific syndrome suspicion. Pathogenic or likely patho-
genic variants were identified in n = 42 (25%) of samples.
In n = 40 (24%) cases, variants of unknown significance
were identified, and in 13 of them inheritance was
consistent with expected pattern, including a probable
mosaicism case. In half of the cases (50,6%) no candidate
variant was identified. Diagnostic yield was higher in
fetuses with skeletal anomalies, where pathogenic or likely
pathogenic variants were identified in (n = 10) 31% of
cases, and in fetuses with increased nuchal translucency or
hidrops (Noonan syndrome suspicion), where a pathogenic
variant was found in 24% (n = 6) of the samples. No
pathogenic variants were found in fetuses with cardiovas-
cular anomalies (n = 9).
Conclusions: Exome sequencing is a valuable diagnostic
tool in fetuses with ultrasound anomalies, especially when
skeletal anomalies are present or when Noonan syndrome is
suspected.
M. Segura-Puimedon: A. Employment (full or part-
time); Significant; Quantitative Genomic Medicine Labora-
tories, qGenomics, Barcelona, Spain. B. Campos: A.
Employment (full or part-time); Significant; Quantitative
Genomic Medicine Laboratories, qGenomics, Barcelona,
Spain. J. Luna: A. Employment (full or part-time);
Significant; Quantitative Genomic Medicine Laboratories,
qGenomics, Barcelona, Spain. C. Sintas: A. Employment
(full or part-time); Significant; Quantitative Genomic
Medicine Laboratories, qGenomics, Barcelona, Spain. M.
de Castro-Miró: A. Employment (full or part-time);
Significant; Quantitative Genomic Medicine Laboratories,
qGenomics, Barcelona, Spain. H. Díez: A. Employment
(full or part-time); Significant; Quantitative Genomic
Medicine Laboratories, qGenomics, Barcelona, Spain. S.
B. Estruch: A. Employment (full or part-time); Significant;
Quantitative Genomic Medicine Laboratories, qGenomics,
Barcelona, Spain. R. Garcia: A. Employment (full or part-
time); Significant; Quantitative Genomic Medicine Labora-
tories, qGenomics, Barcelona, Spain. L. Quintana: A.
Employment (full or part-time); Significant; Quantitative
Genomic Medicine Laboratories, qGenomics, Barcelona,
Spain. J. Rodríguez: A. Employment (full or part-time);
Significant; Quantitative Genomic Medicine Laboratories,
qGenomics, Barcelona, Spain. L. Armengol: A.
Employment (full or part-time); Significant; Quantitative
Genomic Medicine Laboratories, qGenomics, Barcelona,
Spain.
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AnDDI-Prenatome: The French exome sequencing study
in prenatal diagnosis: causal diagnosis identified in
nearly half of fetuses
F. Tran Mau Them1,2, A. Bruel1,2, A. Vitobello1,2,
S. Nambot3, S. Moutton3, A. Sorlin1,2,3, J. Delanne3,
A. Ziegler4, E. Colin4, A. Guichet4, M. Legendre5,
C. Colson6,7, C. Abel8, A. Putoux9, J. Amiel10,11,
A. Lavillaureix12, C. Quelin12, A. Guerrot13, A. Brehin13,
L. Faivre3,2, C. Philippe1,2, V. Couturier1,2, Y. Duffourd2, C.
Thauvin-Robinet1,2,14
1Unité Fonctionnelle d’Innovation diagnostique des mala-
dies rares, FHU-TRANSLAD, Dijon, France, 2Inserm – UB
UMR 1231 GAD « Génétique des Anomalies du Dével-
oppement », FHU-TRANSLAD, Dijon, France, 3Centre de
Référence Maladies rares « Anomalies du Développement
et syndromes malformatifs », Centre de Génétique, FHU-
TRANSLAD, Dijon, France, 4Biochemistry and Genetics
Department, University Hospital of Angers, Angers,
France, 5Service de Génétique Médicale, CHU de Bordeaux
– Hopital Pellegrin, Bordeaux, France, 6CHU Lille,
Clinique de Génétique Guy Fontaine, Lille, France,
7EA7364, RADEME, Université de Lille, Lille, France,
8Service de génétique et centre de diagnostic anténatal,
Lyon, France, 9Service de Génétique, Centre de Référence
Anomalies du Développement et Syndromes Malformatifs,
Lyon, France, 10Service de Génétique Médicale et Clinique,
Hôpital Necker-Enfants Malades, Paris, France, 11Equipe
"Embryologie et Génétiques des malformations congéni-
tales", Institut Imagine - INSERM U1163, Paris, France,
12Centre de Référence Maladies Rares CLAD-Ouest, CHU
Hôpital Sud, Rennes, France, 13Normandie Univ, UNI-
ROUEN, Inserm U1245 and Rouen University Hospital,
Department of Genetics and Reference Center for Devel-
opmental Disorders, F 76000, Normandy Center for
Genomic and Personalized Medicine, Rouen, France,
14Centre de Référence « Déficiences Intellectuelles de
causes rares », Centre de Génétique, FHU-TRANSLAD,
Dijon, France
Introduction: Exome sequencing (ES) is the most powerful
and current test for patients with developmental abnormal-
ities (DA). It has considerably been deployed in postnatal
indications with a diagnostic yield ranging from 30 to 40%.
Several prenatal studies report a diagnostic yield ranging
from 15% to 35%, depending on the exome strategy and the
inclusion criteria. The French national network for rare
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diseases with AD deployed a pilot project of feasibility for
rapid prenatal exome sequencing.
Materials and methods: We aimed to include 61 fetuses
and both parents. The main inclusion criteria were: 2 major
malformations or, 1 major and 1 minor malformation or, 1
malformation and a strong genetic suspicion. The feasibility
aim was to emit a diagnostic report in 5-6 weeks. Array-
CGH and ES-trio were concomitantly performed. ES-trio
was captured with the TWIST-v2 kit and sequenced on a
NovaSeq6000 device with a 70X average depth.
Results: We included 23 patients. The turnaround time
from receipt of samples to the diagnostic report was on
average of 27 days for the negative patients and of 40 days
for the positive patients. The diagnostic yield was of 44%
with 7 SNV and 3 CNV, including a tetrasomy 12p. Array-
CGH allowed a diagnosis in 13% and exome in 44%.
Results were concordant for CNV detection between array-
CGH and ES-trio.
Discussion: Prenatal trio-ES appears feasible in a useful
time and strongly helpful for decision in 65 % and genetic
counseling was impactful in at least 44%.
F. Tran Mau Them: None. A. Bruel: None.
A. Vitobello: None. S. Nambot: None. S. Moutton: None.
A. Sorlin: None. J. Delanne: None. A. Ziegler: None.
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Preconception carrier screening in consanguineous
couples by whole exome sequencing
A. Abulí, I. Valenzuela, M. Codina, E. Rovira, D. Palau, S.
Ourani, A. Cueto-González, I. Paramonov,
E. García-Arumí, E. Tizzano, I. Cusco
Hospital Vall d’Hebron, Barcelona, Spain
Consanguineous couples have an increased risk of severe
abnormalities and mortality in offspring due to autosomal
recessive disorders. Exome-sequencing provides the possi-
bility of wide preconception carrier screening (PCS) in
consanguineous couples who may be at risk of rare genetic
disorders. The efficacy of this strategy has been poorly
explored. We retrospectively analyzed exome sequencing
data from 27 affected children and 3 fetuses (after termi-
nation of pregnancy) of consanguineous couples. We
explored diagnostic yield and carrier status for recessive
disorders. Overall diagnostic yield was 67% (20/30
patients). We detected homozygous causative variants in 19
cases and one de novo heterozygous variant. Out of 20
causal variants, 18 were classified as pathogenic or likely
pathogenic and two as unknown significance, which were
reclassified as likely pathogenic because of highly specific
phenotype. Based on our results and considering diagnostic
yield and variant classification, causative pathogenic
recessive mutations would have been detected in at least
60% of consanguineous couples by preconception exome-
sequencing. Most of these conditions (16/20) would not
have been detected in PCS panels for most prevalent dis-
eases considering a carrier frequency of 1/250. Most of the
patients were carriers of one additional heterozygous
recessive mutation (70%, 21/30) and a smaller number were
carriers of two (17%, 5/30) or more (13%, 4/30). The
average carrier burden of autosomal recessive conditions
was of 1.7 pathogenic mutations per patient. PCS by
exome-sequencing increases the detection rate of rare
recessive conditions in consanguineous couples and could
potentially increase their reproductive autonomy and facil-
itate informed decision making.
A. Abulí: None. I. Valenzuela: None.M. Codina: None.
E. Rovira: None. D. Palau: None. S. Ourani: None.
A. Cueto-González: None. I. Paramonov: None.
E. García-Arumí: None. E. Tizzano: None.
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Does maternal blood exosomal DNA effective for the
fetal RHD and SRY genotyping?
B. Yaşa1, O. Şahin2, S. Sözer1
1Aziz Sancar Institute of Experimental Medicine, Istanbul,
Turkey, 2Clinic of Obstetrics and Gynecology, Okmeydanı
Training and Research Hospital, Istanbul, Turkey
Introduction: Recent advances have led to the develop-
ment of important techniques in extracellular fetal DNA
derived from maternal blood for prenatal diagnosis. Exo-
somes’ DNA content is not affected structurally by nuclease
activity and have a potential clinical application. Determi-
nation of fetal Rhesus D(RhD) and sex is important for
prenatal diagnosis in some diseases.
Material And Method: Fetal RHD and SRY genotyping
was performed using exosomal DNA(exoDNA) from
peripheral blood of 81 RhD negative pregnant women with
exosome isolation kit. Specific primers were applied for the
SRY and RHD genes amplifications by Real-Time poly-
merase chain reaction. The average age of the cases in the
study was 28.5 ± 5.5(year ± SD). The mean gestational
week of the cases was 25.81 ± 9.02. The exoDNA
concentrations obtained were between 1.8-21.9 ng/μL with
an average of 11.65 ± 8.08 ng/μL.
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Results: The results were confirmed with the hospital’s
New Born Follow Up System. After analysis of the 81
cases, no amplification was observed in 16 samples,
including the GAPDH gene. 100% accuracy was achieved
in the RHD and SRY detection from the remaining
65 samples.
Conclusions: It was determined that fetal RHD and SRY
genotyping could be performed with exoDNA from
maternal plasma. The isolation technique of exoDNA could
be enhanced and improved for high concentration with
more sensitive detection covering early pregnancy age. This
technique might provide a new perspective to the prenatal
diagnosis as well as to the treatment options all which
require more detailed studies. The present work was
supported by the Research Fund of Istanbul University.
Project No. 29083
B. Yaşa: None. O. Şahin: None. S. Sözer: None.
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Population-based preconception expanded carrier
screening for severe recessive disorders: Does a GP-
provided test offer with couple results meet criteria for
responsible implementation?
J. Schuurmans1,2, M. Plantinga1, E. Birnie1, K. M. Abbott1,
A. D. Diemers1, D. M. Van der Kolk1, L. M. Van den
Heuvel1, M. Y. Berger1, M. Verkerk1, A. Fenwick2, A. V.
Ranchor1, A. Lucassen2, I. M. Van Langen1
1University Medical Center Groningen, Groningen, Nether-
lands, 2University of Southampton, Southampton, United
Kingdom
Introduction: Expanded carrier screening (ECS) enables
the identification of couples who are at increased risk of
having children with recessive conditions. Based on pre-
liminary research, we conducted a pilot study of GP-
provided population-based preconception ECS (2016-2018)
to evaluate whether this approach would meet criteria for
responsible implementation as specified by Henneman
et al., EJHG, 2016. The free test-offer consisted of
50 severe early-onset childhood conditions. Only couple-
results were reported. We discuss key insights to guide
large-scale implementation.
Methods: We used a mixed-methods approach. Trained
GPs from nine practices invited their female patients (n =
4295, aged 18-40) and partners. We addressed uptake,
feasibility (e.g. pre-test counselling possible within 20 min-
utes), informed-choice, psychological outcomes (e.g. anxi-
ety, decisional conflict) and reproductive intentions using a
longitudinal survey (couples) and semi-structured
interviews (GPs).
Results: 190 couples were included. 130 (approximately
15% of the eligible population) accepted the test-offer
within one month and attended pre-test counselling. 117
(90%) proceeded with testing. More than 90% of test-
participants made an informed-choice. GPs felt confident to
conduct counselling, although having to make a GP-
appointment with both partners was a barrier. Most
participants reported low anxiety and decisional conflict;
this was relatively higher in test-offer decliners than
acceptors.
Conclusions: Population-based preconception ECS for a
specific set of severe conditions provided by motivated and
trained GPs is feasible. We will discuss how responsible
implementation can best be facilitated. The possibility of
prenatal ECS, ECS to high-risk couples or which HCPs
should offer this (e.g. midwives, fertility clinics) should
now also be investigated.
J. Schuurmans: None. M. Plantinga: None. E. Birnie:
None. K.M. Abbott: None. A.D. Diemers: None. D.M.
Van der Kolk: None. L.M. Van den Heuvel: None. M.Y.
Berger: None. M. Verkerk: None. A. Fenwick: None. A.
V. Ranchor: None. A. Lucassen: None. I.M. Van
Langen: None.
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Donor oocyte pregnancies and fetal fraction: managing
patient expectations and providing accurate information
M. Pastrick, M. K. Maisenbacher, G. Goldring,
W. DiNonno, A. Ryan
Natera, Inc, San Carlos, CA, United States
Objective: Retrospective analysis to determine if differ-
ences in fetal fraction (FF) are observed in donor oocyte
pregnancies compared to the general population.
Methods: Noninvasive prenatal testing samples from
singleton pregnancies were analyzed at a single reference
lab. NIPT was performed using a SNP-based method with
FF measured as previously described.1 FF from 1611 donor
oocytes was analyzed and compared to a large set of
reference cases matched for maternal weight (MW) and
gestational age (GA). A z-score was calculated for each
donor oocyte compared to its reference data. If no impact to
FF from the use of donor or in vitro fertilization (IVF), the
average z-score is expected to be zero. Statistical analysis
was performed using a z-test to establish if this was
the case.
Results: The average z-score for the donor oocyte cases
was -0.4. A z-test determined this deviation from normal to
be significant (p < 0.00001), indicating lower FF in donor
oocyte cases vs. corresponding reference data.
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Conclusions: Previous studies have reported lower FF in
patients undergoing IVF and in donor oocyte populations.2,3
Lower FF has also been associated with increased MW,
early GA, certain maternal health conditions, and abnormal
fetal results (T18/T13/triploidy).2,3,4 Our results reveal
statistically significant lower FF in donor oocyte pregnan-
cies compared to matched reference data.
References 1. Zimmerman et al., Prenatal Diagnosis
2012; 32: 1-9 2. Revello R. et al., Ultrasound Obstet
Gynecol. 2016 Jun;47(6):698-704. 3. Yanaihara A. et al., J
Assist Reprod Genet. 2018 Mar;35(3):431-434. 4. Ebbing
C. et al., PLoS One. 2013 Jul 30;8(7):e70380.
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Repeat Associated Non-AUG (RAN)-Translation in
fragile X associated Premature Ovarian Insufficiency
(FXPOI): FMRpolyG as predictive tool?
X. Nguyen1, B. Messmer1, K. Hinderhofer2, T. Strowitzki3,
J. Rehnitz1,3
1Division of Reproduction Genetics, Department of Gyne-
cological Endocrinology and Fertility Disorders, University
Women’s Hospital, Heidelberg, Germany, 2Institute of
Human Genetics, University Heidelberg, Laboratory of
Molecular Genetics, Heidelberg, Germany, 3Department of
Gynecological Endocrinology and Fertility Disorders,
University Women’s Hospital, Heidelberg, Germany
Fragile-X-associated-primary-ovarian-insufficiency
(FXPOI) is characterized by oligo/amenorrhea and hyper-
gonadotropic hypogonadism by reason of the expansion of
CGG-repeats in the 5′UTR of FMR1, called permutation
(PM) (n: 55-200). RAN-translation depending on variable
CGG-repeat length is also hypothesized to cause FXPOI
due to the production of a polyglycine-containing FMR1-
protein, FMRpolyG. FMRpolyG expression in granulosa
cells (GCs) of FXPOI-model-mice leads to perturbed
ovarian function. However, the expression of FMRpolyG in
leukocytes and GCs of women with different ovarian
response and variable CGG repeat length has not been
investigated yet. We performed Western-blot (WB) to
analyze the expression of FMRP and FMRpolyG in patient
´s leukocytes and GCs in parallel with FMR1-gene-
expressionanalysis. Firstly, we detected FMRP, both in
leukocytes and GCs of women with variable ovarian reserve
and different CGG-repeat-length. FMR1/FMRP was detec-
ted in a larger amount in GCs than in leukocytes, since it is
a major regulator of folliculogenesis. We therefore started a
pilot project investigating if variable expression-levels of
FMRP and FMRpolyG detected by WB can be related to
women with different ovarian reserve parameters and vari-
able CGG repeats including “normal” and premutated ran-
ges. Preliminary data already showed, in a PM patient
undergoing oocytes cryopreservation because of her risk of
developing FXPOI, a decreased level of FMRP, even
though the FMR1 transcription level was within the normal
range, fitting to the hypothesis of kind of a perturbed protein
production in this patient. We plan to further evaluate if
results made in GCs can be translated to leukocytes. This
would offer prospectively a predictive tool or marker of
progression.
X. Nguyen: None. B. Messmer: None. K. Hinderhofer:
None. T. Strowitzki: None. J. Rehnitz: None.
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Investigation of single nucleotide variants (SNVs) in a
fertile population in association with oocyte and embryo
quality
G. Kakourou1, T. Mamas1, C. Vrettou1, E. Tsorva2, S.
Zacharia2, C. Oraiopoulou3, E. Chatzi4, G. Kourlaba5,
D. Christopikou2, M. Mastrominas2, M. Moisidou3, A.
Chatziparasidou3, I. Georgiou4, J. Traeger-Synodinos1
1Department of Medical Genetics, National & Kapodistrian
University of Athens, St. Sophia’s Children’s Hospital,
Athens, Greece, 2Embryogenesis, Assisted Reproduction
Unit, Athens, Greece, 3Embryolab SA, IVF Unit, Thessalo-
niki, Greece, 4Genetics and IVF Unit, Department of
Obstetrics and Gynecology, Faculty of Medicine, University
of Ioannina, Ioannina, Greece, 5Center for Clinical
Epidemiology and Outcomes Research (CLEO), Athens,
Greece
Introduction: Human and animal studies have provided
information on a number of genes potentially impacting
gamete quality and preimplantation development (with a
role on meiosis, mitosis, DNA repair etc.). SNVs in these
genes have been investigated in mostly infertile couples
undergoing IVF, in search of potential biomarkers of IVF
success. Recently, maternal SNVs in infertile women
(rs1801133/rs1801131 in MTHFR, rs2305957 on chromo-
some 4 linked to INTU-SLC25A31-HSPA4L-PLK4-
MFSD8-LARP1B and PGRMC2) were associated with
embryo quality or chromosomal status. We investigated
the potential association of SNVs in 26 selected genes with
a possible role in preimplantation development, with
oocyte/embryo quality in fertile women undergoing
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Preimplantation Genetic Testing for Monogenic Disorder
(PGT-M).
Materials/Methods: Maternal DNA was genotyped
using exonic NGS (QiaseqTM-Targeted Custom Panel,
Miseq) for 18 genes (AIRE-AMH-AURKA-AURKB-
AURKC-FSHR-HSPA4L-HUWE1-INTU-KHDC3L-
LARP1B-MFSD8-MTHFR-PGRMC2-PLK4-SENP7-
SLC25A31-WBP1) and 9 selected SNVs in a further 8
genes: rs175080(MLH3), rs1799963(F2), rs6025(F5),
rs5918(ITGB3), rs5985(F13A1), rs1805087(MTR),
rs1801394(MTRR), rs28756992(MLH3), rs2305957
(HSPA4L). The study involved 85 women and 107 PGT-
M cycles performed between 2013-2019. Maternal geno-
typing was investigated in association with number of
oocytes collected/fertilized and blastocyst formation.
Results: A 20x coverage was achieved in all regions
investigated, identifying 121 variants. Significant associa-
tions (p < 0.05) were revealed for 16 SNVs in: AIRE-AMH-
AURKB-HSPA4L-KHDC3L-MTHFR-PLK4-SENP7-MLH3.
No significant associations were revealed for rs1801131 and
rs2305957.
Conclusions: Our understanding of genes that may
impact the preimplantation stage and the search for genomic
biomarkers predicting IVF-success may benefit by investi-
gating a fertile population, minimizing many confounding
variables. This study was supported by the State Scholar-
ships Foundation (IKY), co-funded by national grants and
the European union (ESPA 2014-2020).
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Further indication of a role for de novo mutations in
cases of severe idiopathic male infertility
H. E. Smith1, M. S. Oud2, P. F. de Vries2, B. Alobaidi1,
A. Virdi1, B. J. Houston3, R. M. Smits4, L. Batty1, M. K.
O’Bryan3, J. Coxhead5, S. Cockell6, J. Greenwood7, G. van
der Heijden2,4, K. McEleny7, L. Ramos4, L. E. L. M.
Vissers2, M. J. Xavier1, J. A. Veltman1,2
1Biosciences Institute, Newcastle University, Newcastle
Upon Tyne, United Kingdom, 2Department of Human
Genetics, Donders Institute for Brain, Cognition and
Behaviour, Radboudumc, Nijmegen, Netherlands, 3School
of Biological Sciences, Monash University, Melbourne,
Australia, 4Department of Obstetrics and Gynaecology,
Radboudumc, Nijmegen, Netherlands, 5Genomics Core
Facility, Newcastle University, Newcastle Upon Tyne,
United Kingdom, 6Bioinformatics Support Unit, Newcastle
University, Newcastle Upon Tyne, United Kingdom, 7New-
castle Fertility Centre, Newcastle University, Newcastle
Upon Tyne, United Kingdom
Infertility affects 1 in 6 couples worldwide and in
approximately 50% of these cases the infertility can be
attributed to a male factor. Whilst causes such as Kline-
felter’s and Y chromosome microdeletions have been well
distinguished, the genetic causes behind severe spermato-
genic failure are largely unknown, with around 40% of all
male infertility cases remaining idiopathic. De novo muta-
tions (DNMs) arise spontaneously in the germline or post-
zygotically, and are known to be associated with early onset
disorders with reduced reproductive fitness. These muta-
tions, however, are vastly understudied in the field of male
infertility due to the difficulty in obtaining parental samples.
Here we report on the continuation and expansion of exome
sequencing in our cohort of infertile patients in order to
identify novel genes involved in male infertility. The role of
DNMs was investigated in a total of 194 patients suffering
from non-obstructive azoospermia or severe oligozoos-
permia and their fertile parents by adding 95 additional trios
to the previously reported 99 cases. In these additional 95
trios, we have identified and validated 75 protein-altering
DNMs, of which 19 are likely to affect normal gene func-
tion. Genes of particular interest are PPP1R7, RBM5 and
MSH5, all of which are involved in spermatogenesis and
linked to infertility in mice. At this moment, none of these
genes have been recognised as human male infertility genes.
Our data further indicates that DNMs may play an impor-
tant role in severe male infertility and emphasises the need
for further replication studies in larger cohorts.
H.E. Smith: None. M.S. Oud: None. P.F. de Vries:
None. B. Alobaidi: None. A. Virdi: None. B.J. Houston:
None. R.M. Smits: None. L. Batty: None. M.K. O’Bryan:
None. J. Coxhead: None. S. Cockell: None. J. Green-
wood: None. G. van der Heijden: None. K. McEleny:
None. L. Ramos: None. L.E.L.M. Vissers: None. M.J.
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A case report of a rare nonsense ZP1 variant in a patient
with oocyte maturation defect
E. G. Berkay, B. Karaman, G. Toksoy, B. Ozsait Selcuk, Z.
O. Uyguner, S. Basaran
Istanbul Medical Faculty, Istanbul University, Istanbul,
Turkey
Introduction: Oocyte maturation defect (OOMD) is a rare
condition causing female infertility that can be diagnosed
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during assisted reproduction techniques (ART). OOMD
related genes are ZP1, ZP2, ZP3, PANX1, PATL2, TUBB8,
WEE2 (OMIM, 2020). We report a case of a 31-year-old
woman who had four ART failures diagnosed as empty
follicle syndrome and OOMD. She has short stature (-3
SD), bilateral limited extension-flexion on elbows.
Materials and Methods: Chromosome analysis and
fluorescence in-situ hybridization (FISH) using X chromo-
some centromeric and SHOX-probe on interphase nuclei of
lymphocytes and mucosal cells was investigated. Whole-
exome sequencing (WES) performed via the Illumina
platform. Confirmation and familial segregation analysis
were performed by Sanger sequencing.
Results: Karyotyping and FISH resulted in normal,
possible mosaicism was excluded. WES analysis revealed
a known, rare, pathogenic homozygous variant in exon 3
(c.628C>T; p.Q210*) of ZP1 gene, and her parents being
first degree cousins were carriers for this variant.
Conclusions: ZP1 with autosomal recessive inheritance is
related to OOMD-1 (MIM_615774). Zona pellucida (ZP) is
a glycoprotein structure surrounding oocytes and is essential
for oocyte development. ZP contains four types of receptor
proteins (ZP1-4). Our variant in ZP1 is nonsense, premature
stop codon causes to truncate ZP1 receptor proteins. This is
the first homozygous occurrence of this variant associated
with OOMD. WES findings were also analyzed for known
genes related to short stature and no pathogenic variant has
been observed. WES is a valuable method to identify the
genetic origin in complex, multigenic conditions like in
infertility. Istanbul University Project-Number:TSA-2018-
32135
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Prenatal diagnosis and molecular characterization of a
jumping translocation leading to 18p monosomy
J. B. Gaillard1, T. Guignard1, J. Puechberty2, A.
Schneider1, V. Gatinois1, M. Duport-Percier3, J. M. Faure3,
F. Fuchs3, F. Pellestor1, P. Blanchet4, C. Wells4
1Génétique Chromosomique, CHU, Montpellier, France,
2Maladies Génétiques de l’Enfant et de l’Adulte, CHU,
Montpellier, France, 3Médecine Maternelle et Foetale,
CHU, Montpellier, France, 4Génétique Prénatale et
Foetopathologie, CHU, Montpellier, France
Jumping translocations are rare events in cytogenetics,
characterised by a donor chromosome and multiple
recipient chromosomes. To date, only ten prenatal cases
have been described.
Patient: This pregnancy was a second spontaneous
pregnancy of a non-consanguinous couple. A first trimester
ultrasound showed an increased nuchal translucency
persisting at 18 gestational weeks (GW) along with
retrognatia, cleft palate and femoral shortening. Choriocent-
esis was performed at 14 GW.
Results: Direct examination on cytotrophoblast found a
der(18)t(18;18) whereas the cultured karyotype on
mesenchyme showed a der(18)t(2;18). Due to tissue
discordance, an amiocentesis was performed at 18 GW.
Surprisingly, we found, neither of the two previously
identified cell lines, but a mosaic der(18)t(12;18) with a ring
18. In addition, array CGH provided breakpoints for
chromosomes 2 and 12 in REEP1 gene (2p11.2) and
TAOK3 gene (12q24.23) respectively. Whole genome
sequencing on minION (Nanopore) was conducted to
clarify breakpoint in chromosome 18. Using data obtained
by array CGH, a long read with hard clipping showed a
breakpoint in repeated sequence with about 90% homology
with D18Z1 alpha satellite. Finally, all identified cell lines
carried a 18p monosomy which could explain ultrasound
abnormalities. The pregnancy was terminated. Following
fetal autopsy, FISH analysis was performed on blood,
thymic, lung and liver tissue and confirmed 18p monosomy
in all tissues.
Conclusion: We report here a new case of jumping
translocation with precise molecular characterization of
breakpoints : D18Z1 as donor region and at least 3 recipient
chromosomes : 2p11.2, 12q24.3 and 18q21.
J.B. Gaillard: None. T. Guignard: None. J. Puechb-
erty: None. A. Schneider: None. V. Gatinois: None. M.
Duport-Percier: None. J.M. Faure: None. F. Fuchs:
None. F. Pellestor: None. P. Blanchet: None. C.
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Molecular biomarkers of ageing in men with Klinefelter
syndrome
E. Pohl1, S. Muschal2, S. Kliesch3, M. Zitzmann3, J.
Rohayem3, J. Gromoll2, S. Laurentino2
1Institute of Human Genetics, University of Münster,
Münster, Germany, 2Centre of Reproductive Medicine and
Andrology (CeRA), Institute of Reproductive and Regen-
erative Biology, University Hospital Münster, 48149
Münster, Germany, Münster, Germany, 3Centre of Repro-
ductive Medicine and Andrology (CeRA), Department of
Clinical and Surgical Andrology, University Hospital
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Introduction: Males with Klinefelter syndrome (non-
mosaic karyotype 47,XXY), the most common sex chro-
mosome aneuploidy, exhibit increased rates of ageing-
related morbidities and mortality. Associated with that, a
significantly reduced life span has been observed. The aim
of this study was to investigate whether Klinefelter patients
show molecular signs of premature ageing.
Patients and Methods: We assessed age-associated
DNA methylation patterns (by pyrosequencing) and relative
telomere length (TL; by quantitative polymerase chain
reaction) as molecular ageing biomarkers in blood from
Klinefelter patients (n = 178 and 266 for DNA methylation
and TL, respectively) aged 18-71 years. Age-matched
healthy males (n = 184 and 196 for DNA methylation
and TL, respectively) and females (n = 50) served as
controls.
Results: Age-associated DNA methylation patterns did
not indicate accelerated ageing/premature ageing in men
with Klinefelter syndrome. In young Klinefelter individuals
aged 18-24 years, we observed significantly longer
telomeres compared to controls (mean = 1.51 vs. 1.09
and 1.26 in female and male controls, respectively).
Telomere length in subsequent age groups, however, were
not significantly different to controls.
Conclusions: We did not find molecular hints for
premature ageing in Klinefelter patients based on DNA
methylation patterns. However, we observed higher base-
line TL at adolescent age but comparable TL with
progressive age in other age groups. Whether this is due
to an accelerated TL attrition, putatively related to the
observed co-morbidities in Klinefelter syndrome, remains to
be addressed in a further longitudinal study.
Funding: German Research Foundation (DFG No.
GR1547/19-1; CRU 326 No. GR1547/25-1), IZKF Münster
(Grant CRA03/09)
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Maternally inherited copy-number variations may
explain cases of severe idiopathic male infertility
F. K. Mastrorosa1, M. J. Xavier1, A. Mikulasova1, M. S.
Oud2, R. M. Smith3, G. Astuti2, B. Alobaidi1, J.
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Sheth1, G. van der Heijden2,3, K. McEleny4, L. Ramos3, J. A.
Veltman1,2
1Biosciences Institute, Newcastle University, Newcastle
upon Tyne, United Kingdom, 2Department of Human
Genetics, Donders Institute for Brain, Cognition and
Behaviour, Radboudumc, Nijmegen, Netherlands, 3Depart-
ment of Obstetrics and Gynaecology, Radboudumc, Nijme-
gen, Netherlands, 4Newcastle Fertility Centre, Newcastle
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formatics Support Unit, Newcastle University, Newcastle
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Genetics, Radboud Institute for Molecular Life Sciences,
Radboudumc, Nijmegen, Netherlands, 7Genomics Core
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Severe cases of infertility such as azoospermia and oligo-
zoospermia often have genetic causes, with Klinefelter
syndrome and chromosome Y microdeletions being the
most common. However, of all infertile men, 40% have
unknown aetiology after being tested for all known causes.
In this study, we explored for the first time the role of
maternally inherited copy-number variations (CNVs) on a
large scale, sequencing the exome of 160 patient-parents
trios, a methodology primarily used to detect single
nucleotide variants (SNVs) but also robust for CNV
detection. Among all rare maternally inherited CNVs
detected, 3 were considered of potential pathogenicity. One
is a large duplication (~1.7 Mb) involving, among others,
VCX gene, an X-linked multi-copy gene that leads to
apoptosis and cell growth inhibition when duplicated in
murine germ cells in vitro. A second case carried a ~80 kb
duplication involving two genes, one of which was FAS, a
known regulator of testicular germ cell apoptosis. The third
CNV, instead, was a deletion of ~200 kb affecting, among
others, PSME4, a gene required for normal fertility in male
mice but dispensable in females. The results of this study,
although preliminary, provide a first indication that mater-
nally inherited CNVs may explain cases of severe sper-
matogenic failure. Currently, additional 35 patient-parents
trios and 149 patients are being screened to detect variations
affecting the same genes and additional rare variations.
Genome sequencing data will soon be available for all the
trios, which will improve CNV detection and clarify the
contribution of these variations to the disorder.
F.K. Mastrorosa: None. M.J. Xavier: None. A.
Mikulasova: None. M.S. Oud: None. R.M. Smith: None.
G. Astuti: None. B. Alobaidi: None. J. Greenwood: None.
S.J. Cockell: None. C. Gilissen: None. J. Coxhead: None.
H. Sheth: None. G. van der Heijden: None. K. McEleny:
None. L. Ramos: None. J.A. Veltman: None.
P01.056.B
Improved classification of testicular histopathology to
promote uniform diagnosis and discovery of genetic
causes for male infertility
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G. W. van der Heijden1, M. J. Wyrwoll2, L. Ramos1, J.
Veltman3, F. Tüttelmann4
11. Division of Reproductive Medicine, Department of
Obstetrics and Gynecology, Radboud University Medical
Center, Nijmegen, Netherlands, 2Centre of Reproductive
Medicine and Andrology, Department of Clinical and
Surgical Andrology, University of Münster, Münster,
Germany, 3Institute of Genetic Medicine, Newcastle Uni-
versity, Newcastle, Netherlands, 4Institute of Human
Genetics, University of Münster, Münster, Germany
With the availability of Next Generation Sequencing the
genetic causes of male infertility are increasingly being
chartered. A genetic diagnosis combined with a clear
unambiguous description of accompanying testis histology
will hugely benefit interpretation of the function of identi-
fied genes. However, a universal ontology for testis histo-
pathology is lacking. The Human Phenotype Ontology
(HPO) is a formal ontology, which describes phenotypes
encountered in human diseases. The HPO allows phenotype
driven differential diagnostics in clinical routine and
research. The current hierarchy of terms regarding azoos-
permia, is not a systematical one. Moreover, the majority of
testicular phenotypes are not annotated yet. Building on
what has been published previously and our own experience
we propose a framework for testis histopathology that
consists of five main categories. Four of these are sub-
divided to obtain information on the timing of a germ cell
arrest or the severity of overall loss of spermatogenesis. To
establish a lower threshold for complete spermatogenesis
we determined the number of tubules containing elongating
spermatids in a collection of samples of men with an
obstructive azoospermia due to a previous vasectomy
(N=117). This analysis suggested 50% to be a reasonable
cut-off to distinguish hypospermatogenesis from complete
spermatogenesis. The framework is easy to understand and
straightforward in its application. It gathers most relevant
information to study the impact of an identified mutation on
spermatogenesis. We conclude that once this framework is
incorporated in the HPO, the standardized vocabulary will
facilitate communication and interpretation in both a clinical
routine and research.
G.W. van der Heijden: None. M.J. Wyrwoll: None. L.
Ramos: None. J. Veltman: None. F. Tüttelmann: None.
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Identification of two homozygous mutations, in the male
reproductive tract specific β-defensin 126/128 genes,
potentially underlie a severe sperm dysfunction.
S. Kane1, D. Lester1, S. Cameron1, C. Barratt2, S. Martins
da Silva2, S. Brown1
1School of Science, Engineering & Technology, Abertay
University, Dundee, United Kingdom, 2Reproductive and
Developmental Biology, School of Medicine, Ninewells
Hospital and Medical School, University of Dundee,
Dundee, United Kingdom
Introduction: Idiopathic infertility affects 15% couples
globally and recent evidence suggests genetic abnormalities
are a causative factor in a significant number of cases.
Hence, we conducted whole exome sequencing of men
undergoing assisted conception to identify genetic lesions.
The β-defensin 126 (DEFB126) and β-defensin 128
(DEFB128), are genes preferentially expressed in the epi-
didymis, where these proteins may help protect the matur-
ing sperm cells and play a vital role during sperm
capacitation.
Materials and Methods: DNA extracted from the blood
of 26 unrelated, sub-fertile men were sequenced using
whole exome sequencing. Pathogenic rare variants were
identified using bioinformatics analysis and validated using
Sanger sequencing.
Results: A novel and rare homozygous pathogenic 1-bp
frame-shift insertion causing a premature stop codon was
identified in DEFB128 gene from one patient. Six patients
showed a previously reported homozygous 2bp deletion,
causing a frame-shift mutation in the DEFB126 gene (p.
Pro106ArgfsTer?). All patients ascertained with the
DEFB126/DEFB128 mutations were unable to naturally
conceive and hence were sub-fertile.
Conclusions: The DEFB128 mutation (rs11396059), is
rare and has not been associated with any disease to date.
As the patient with the DEFB128 mutation has no other
medical condition we predict that it is the cause of
infertility. The DEFB126 mutation (rs140685149), is a
common variant, and this homozygous variant in sub-fertile
men has previously been implicated in facilitating sperm
movement in the female reproductive tract. These results
suggest that, β-defensin genes play a significant role in male
reproduction.
This work was supported by the R-LINCS studentship,
Abertay University.
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The sperm epigenome does not display recurrent
epimutations in patients with severely impaired
spermatogenesis
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Introduction: Previous studies have identified aberrant
DNA methylation of imprinted genes (e.g. MEST and H19)
in the sperm of infertile patients, but the prevalence and
genomic extent of these abnormal methylation patterns have
remained unknown.
Material and Methods: We collected swim-up sperm
samples from 40 normozoospermic and 93 oligoasthenoter-
atozoospermic patients and determined H19 and MEST
methylation levels by deep bisulfite sequencing. Based on
this screening, we defined three groups: normal controls
(NC), abnormally methylated infertile (AMI; n = 7) and
normally methylated infertile (NMI; n = 86), and performed
whole genome bisulfite sequencing of five NC, five AMI
and six NMI samples.
Results: Whole-genome comparison of NC and AMI
samples revealed that each AMI sample had abnormal
methylation levels of all 50 imprinting control regions and
>2,000 germ cell-specific genes with distinct DNA
methylation differences in blood and germ cells. This is
consistent with the presence of somatic cell DNA in AMI
samples. The comparison of NC and NMI samples revealed
19 differentially methylated regions, none of which could
be validated in an independent cohort of 40 men. Analysis
of the H19 CTCF-binding region 6 in samples without
somatic cell DNA revealed an association between DNA
methylation levels and genotype (rs2071094), but not
fertility phenotype.
Conclusions: Our results suggest that somatic DNA
contamination and genetic variation confound methylation
studies in sperm of infertile men and that the prevalence of
aberrant methylation in infertile men has been over-
estimated, which is reassuring for patients undergoing
assisted reproduction. Funded by DFG grants HO 949/23-1
and NE 2190/3-1.
E. Leitao: None. S. Di Persio: None. S. Laurentino:
None. M. Wöste: None. M. Dugas: None. S. Kliesch:
None. N. Neuhaus: None. B. Horsthemke: None.
P01.059.B
miR-200 family inhibits trophoblast invasion through
regulating epithelial-mesenchymal transition
M. Su1, H. Tsai1, C. Wang2
1Department of Obstetrics and Gynecology, National
Cheng-Kung University Hospital, Tainan, Taiwan,
2Department of Cell Biology and Anatomy, National
Cheng-Kung University, Tainan, Taiwan
Epithelial-to-mesenchymal transition (EMT) is a biologi-
cal process that epithelial cells lose cell polarity and cell-
cell adhesion, and gain migratory and invasive abilities to
become mesenchymal cells. In human placenta, the chor-
ionic villi gradually transform from proliferative cyto-
trophoblasts and extravillous trophoblasts into a migratory
and invasive trophoblast phenotype. Failure in altering the
behavior and morphology of trophoblasts in placenta may
result in insufficient trophoblast invasion, which leads to
placental dysfunction and the diseased placenta. MiR-200
family, including miR-200a and -141, were highly
expressed in human placenta and were upregulated in
patients of preeclampsia. miR-200a and miR-141 were
demonstrated to inhibit the formation of primary clila in
trophoblasts and therefore have a less ability for cell
invasion. In this study, miR-200a and miR-141 were
shown to inhibit trophoblasts (HTR-8/SVneo) invasion
and migration by a transfection assay. In western blotting
and qRT-PCR, miR-200a and miR-141 stimulated epi-
thelial markers, such as E-cadherin and ZO-1, whereas
suppressed mesenchymal and transcriptional factors, such
as ZEB1, MMP2, MMP9 and TGF-b1. These results
suggest trophoblast migration and invasion mediated by
miR-200 family may through the mechanism of EMT, and
may therefore predispose to develop preeclampsia in
human pregnancy.
M. Su: None. H. Tsai: None. C. Wang: None.
P01.060.C
Identification of plasma miRNAs associated with endo-
metriosis in Bulgarian patients
V. Spasova1, V. Karamisheva1,2, O. Antonova1, Z.
Hammoudeh1, L. Koleva3, R. Staneva1, M. Ganev1, D.
Nesheva1, A. Nachev1,2, D. Toncheva1, S. Hadzhidekova1
1Medical University of Sofia, Sofia, Bulgaria, 2University
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Bulgaria, 3University Hospital “Pirogov”, Sofia, Bul-
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Introduction: Diagnosis of endometriosis still poses a
significant challenge for it usually requires surgery.
The need of invasive procedure significantly contributes
to late diagnosis and less effective treatment. The aim
of this study is to screen for changes in miRNAs
expression in peripheral blood that could be further
researched as potential non-invasive diagnostic tool for
endometriosis.
Materials and methods: 15 patients with surgically
confirmed advanced endometriosis and 15 healthy controls
were included in the study. Peripheral blood samples were
collected after signed informed consent. Plasma RNA was
isolated with miRNeasy-Serum/Plasma Kit in conjunction
with Plasma Spike-in-Control (Qiagen®). Equimolar
amounts of RNA were used to prepare two pools: 1)late
stage endometriosis and 2)healthy controls. Reverse
transcription of the pool samples was performed by
miScript II RT Kit (Qiagen®). Expression spectra of 84
miRNAs (miScript miRNA-PCR-Array-Human Serum &
Plasma, Qiagen®) by real-time PCR quantification via
miScript-SYBRGreen PCR Kit (Qiagen®) were analyzed on
Applied Biosystems™7500 instrument.
Results: The preliminary results revealed 65 upregulated
miRNAs and no downregulated miRNAs between cases and
controls. The fold change between 5 and 10 was detected in
21 miRNAs and fold change above 10 was detected in 44
miRNAs. The most significantly overexpressed miRNAs
were miR-106a and miR-17-3p which are associated with
cell proliferation and apoptosis.
Conclusions: MiRNA expression level differences were
found in blood between endometriosis patients and healthy
controls. This may lay the foundations for future in-depth
research on novel non-invasive biomarker for endometrio-
sis. Acknowledgements: Contract Д-212/12.12.2018
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Sequence variants in TBX6 are associated with disorders
of the Müllerian ducts - an Update
A. Tewes1, J. Hucke2, T. Römer3, K. Kapczuk4, C.
Schippert5, P. Hillemanns5, A. Bohring1, P. Wieacker1, S.
Ledig1
1Institute of Human Genetics, Münster, Germany, 2Depart-
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Germany, 4Division of Gynecology, Poznan, Poland,
5Department of Obstetrics and Gynecology, Hannover,
Germany
Müllerian anomalies include formation, fusion or absorp-
tion defects of the Müllerian ducts such as unicornuate,
didelphys, bicornuate or septate uterus and vaginal septa as
well as the Mayer-Rokitansky-Küster-Hauser syndrome
(MRKHS) which is characterized by the congenital absence
of uterus and vagina. The incidence of MRKHS is estimated
to be 1:4.500 and 1:250 in other Müllerian anomalies. Most
cases of Müllerian anomalies are sporadic; familial cases
seem to be autosomal dominant inherited with reduced
penetrance. Until now the knowledge about the etiology of
anomalies of the Müllerian ducts is very limited. In
approximately 1% of patients with Müllerian anomalies
recurrent deletions in 16p11.2 encompassing TBX6 were
found as causative in these patients. Moreover, in previous
studies, we and others found possibly pathogenic variants in
patients with Müllerian anomalies in TBX6. Since TBX6
encodes a conserved transcription factor playing an essen-
tial role in developmental processes like mesoderm forma-
tion and specification, we suggested TBX6 as strong
candidate gene. Thus we performed analysis of the TBX6
gene (NM_004608) in additional 126 patients with Mül-
lerian anomalies. We detected 4 possibly pathogenic var-
iants (c.358A>G p.(Met120Val), c.704G>A p.
(Gly235Asp), c.815G>A p.(Arg272Gln), c.1146C>A p.
(Tyr382*)) in TBX6 in 5/126 patients and could exclude the
previously reported variant c.484G>A p.(Gly162Ser) as
being causative for disorders of the Müllerian ducts in the
European non-Finnish population. In summary, we present
increasing evidence for the association of variants in TBX6
with malformations of the Müllerian ducts.
A. Tewes: None. J. Hucke: None. T. Römer: None. K.
Kapczuk: None. C. Schippert: None. P. Hillemanns:
None. A. Bohring: None. P. Wieacker: None. S.
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Circulating fetal trophoblastic cell eligible for NIPD: the
exception rather than the rule
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M. Willems4, C. Liautard-Haag2, N. Molinari5, C. Zordan6,
V. Dorian6, A. Chaussenot7, L. Monteil8, C. Miry9, Y.
Petrov10, E. Le Boette11, M. Fradin12, C. Alix-Panabiere1,
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1Laboratoire de cellules circulantes rares humaines_Uni-
versity Medical Center of Montpellier, Montpellier, France,
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Introduction: Non-Invasive Prenatal Diagnosis (NIPD),
based on the analysis of circulating cell-free fetal DNA (cff-
DNA), is successfully implemented for an increasing
number of monogenic diseases. However, technical issues
related to cff-DNA characteristics remain, and not all
mutations can be screened with this method, particularly
triplet expansion mutations that frequently concern prenatal
diagnosis requests. The objective of this study was to
develop an approach to isolate and analyze Circulating
Trophoblastic Fetal Cells (CFTCs) for NIPD of monogenic
diseases caused by triplet repeat expansion or point
mutations.
Materials and Methods: We developed a method for
CFTC isolation based on DEPArrayTM sorting and used
Huntington’s disease as the clinical model for CFTC-based
NIPD. Then, we investigated whether CFTC isolation and
Whole Genome Amplification (WGA) could be used for
NIPD in couples at risk of transmitting different monogenic
diseases.
Results: Our data showed that the allele drop-out rate was
3-fold higher in CFTCs than in maternal cells processed in
the same way. Moreover, we gave new insights into CFTCs
by compiling data obtained by extensive molecular testing
by microsatellite multiplex PCR genotyping and by WGA
followed by mini-exome sequencing.
Conclusions: CFTCs appear to be often characterized by
a random state of genomic degradation. This might
challenge CFTC use for routine NIPD. This emphasizes
the importance to have not a single diagnostic cell but
multiple diagnostic cells.
This research was funded by French Ministry of Health -
DGOS, grant number PHRCI-16-068 (DIACCIMEX) and
by Agence de la biomédecine, grant number 18AMP009
(DIAFEXOME)
L. Cayrefourcq: None. M.C. Vincent: None. S.
Pierredon: None. C. Moutou: None. M. Imbert-Bou-
teille: None. E. Haquet: None. J. Puechberty: None. M.
Willems: None. C. Liautard-Haag: None. N. Molinari:
None. C. Zordan: None. V. Dorian: None. A. Chausse-
not: None. L. Monteil: None. C. Miry: None. Y. Petrov:
None. E. Le Boette: None. M. Fradin: None. C. Alix-
Panabiere: None. C. Guissart: None.
P01.063.C
Development of non-invasive prenatal diagnosis for
monogenic diseases: the example of Marfan syndrome
and GCK diabetes
T. Nouspikel1, A. Bottani2, V. Schwitzgebel1
1University Hospitals of Geneva, Geneva, Switzerland,
2Hôpital du Valais, Sion, Switzerland
Introduction: The presence of foetal DNA in maternal
plasma allows for non-invasive prenatal diagnosis of
Mendelian diseases, through detection of known parental
mutations. While identifying paternal mutations is
straightforward, determining whether a maternal mutation is
present in the foetus requires relative dosage of maternal
haplotypes (RHDO), via heterozygous SNPs on either side
of the mutation.
Results: A custom library of 95 SNPs spread over a ~1
Mb region around the FBN1 gene was used for a posteriori
analysis of two pregnancies in a couple with a paternal
FBN1:c.5143delA mutation causing Marfan syndrome. In
both cases, the mutation was detected in maternal plasma
and confirmed in amniotic fluid or cord blood. We also
verified that the method could determine which maternal
haplotype each foetus had inherited.
In another couple with a maternal GCK:p.Gly246Arg
mutation causing MODY2, a panel of 99 SNPs over 0.7 Mb
around GCK was used to analyse maternal plasma at 16 and
30 weeks gestation. In both samples, we correctly
determined the maternal haplotype inherited by the foetus
and diagnosed the presence of the mutation, confirmed by
cord blood DNA analysis. The same results were obtained
by quantifying the number of DNA molecules, obtained
through molecular barcodes, rather than sequence reads.
Bioinformatic reduction of foetal fractions showed that
determination of maternal haplotypes remained possible
down to 4.3% foetal DNA.
Conclusions: Although preliminary, our results indicate
that a molecular barcode library of ~100 SNPs is adequate
to achieve non-invasive prenatal diagnosis of monogenic
diseases, even at low foetal fractions.
T. Nouspikel: None. A. Bottani: None. V.
Schwitzgebel: None.
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NIPT revealed in a pregnant woman 5Mbp-13q
duplication, proved as a familial CNV by array CGH
I. Dimova1, I. Bradinova2, V. Peycheva3, R. Bozhilova3, R.
Raynova2, K. Kercheva1, A. Savov2, I. Kremensky3, R.
Kaneva3
1Medical University Sofia, Sofia, Bulgaria, 2SBALAG
"Maichin dom", Medical University Sofia, Sofia, Bulgaria,
3Molecular Medicine Center, Medical University Sofia,
Sofia, Bulgaria
Subchromosomal copy number variations (CNVs), known
as segmental deletions and duplications, are extensively
distributed in human genome. A substantial proportion of
these CNVs are associated with severe diseases, even with
some newly identified microdeletion and microduplication
syndromes. Recently it was showed that NIPT has a good
performance in detecting fetal subchromosomal CNVs,
especially for CNVs >10 Mb, and can be incorporated into
the routine NIPT chromosomal aneuploidies screening with
high sensitivity and specificity. The prenatal detection of
CNVs with clinical significance would benefit all the
pregnant women in genetic counselling and clinical man-
agement of the pregnant outcomes. We report here a result
from NIPT performed in a first trimester of a pregnant
woman with third normal pregnancy. The test revealed
5Mbp-13q duplication and array CGH was indicated for
confirmation of the aberration after amniocentesis. Array
CGH confirmed the aberration in a fetus with the following
size: 13q21.2q21.31 (60,540,987-65,431,854)x3 (4.89 Mb).
Such duplications in 13q are described in the literature to be
associated with the developmental delay, intellectual defi-
cits, behavioral problems, and facial dysmorphisms. We
tested all family members by array CGH for the presence of
the aberrations - the parents and two siblings (9 years old
girl and 12 years old boy). The same aberration was
detected in clinically healthy mother and sister, thus deter-
mining the familial character of the aberration. In conclu-
sion, careful evaluation should be done for each
submiscroscopic aberration detected by NIPT in order to
make proper classification and give an adequate genetic
counselling.
I. Dimova: None. I. Bradinova: None. V. Peycheva:
None. R. Bozhilova: None. R. Raynova: None. K.
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False positive trisomy 21 NIPT-result due to maternal
inherited CNV
M. Blankenburg1, A. Weber1, S. Rauschke1, R. Becker2, K.
Pötschick3, M. Stumm1
1Medicover Genetics GmbH, Berlin, Germany, 2Zentrum
für Pränataldiagnostik Kudamm 199, Berlin, Germany,
3Medicover Humangenetik-Berlin-Mitte, Berlin, Germany
Introduction: Noninvasive prenatal tests (NIPT) are screening
methods to detect fetal aneuploidies with high specificity and
sensitivity. Nevertheless, maternal factors as copy number
variations (CNV) are reasons for discrepancies between NIPT-
results and fetal karyotypes. We report a case with a con-
spicuous trisomy 21 result after NIPT, an unsuspicious fetal
ultrasound and a normal karyotype following conventional
chromosome analysis (CA) of amniotic fluid cells.
Material and Methods: Next Generation sequencing
(NGS) of cfDNA, CA from peripheral blood, amniotic fluid
and placental cells, Fluorescence-in-situ-Hybridization
(FISH) on metaphases and interphases, array-CGH (aCGH)
and quantitative PCR (qPCR).
Results: NIPT indicated a fetal trisomy 21. In contrast,
ultrasound examination and amniocentesis showed normal
results. Reanalysis of NIPT by WISECONDOR algorithm
showed a 10 Mb gain on chromosome 21. No comparable
cases were described in literature or databases. The parents
declined further diagnostics until birth. Postpartum CA and
FISH from blood and placental cells resulted in normal
karyotypes. In contrast, aCGH confirmed a 1,44 Mb gain in
chromosomal region 21q21.3q22.11 and the aberration was
classified as variant of unclear significance (VUS). Addi-
tional qPCR analyses confirmed the gain and showed it was
maternal inherited. Therefore, we reclassified the aberration
as a familial benign CNV.
Conclusions: To best of our knowledge, this is the first
report of a small benign maternal chromosome 21 CNV
leading to a false positive trisomy 21 NIPT result. That case
demonstrates again the importance of a critical reflection of
genotype/phenotype correlations after NIPT.
M. Blankenburg: None. A. Weber: None. S. Rauschke:
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Circulating miRNAs as biomarkers to assess fetal
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Non-invasive prenatal testing (NIPT) methods are widely
used as screening tool for fetal aneuploidies. They are based
on the isolation of cell-free DNA (cfDNA) from maternal
plasma which for the majority is maternal, but a small
percentage of it comes from the placenta (cell-free fetal
DNA or cffDNA). cffDNA percentage or fetal fraction (FF)
ranges from < 4% to >30% and it influences NIPT out-
come. According to neoBona® NIPT method used in our
laboratory, invalidation occurs with a FF <4%. Recently,
circulating microRNAs (miRNAs) have been investigated
as potential biomarkers for screening in pregnancy. We
aimed to investigate them as biomarkers in relation to FF
level. Previously tested neoBona® samples were divided
into one “control group” (FF >4%) and one “test group” (FF
<4%). Samples were analysed in the nanostring nCounter®
platform by using a pre-customised panel of 799 miRNAs.
Each miRNA expression value was normalised to 1 in the
“control group” and “test group” samples were analysed for
expression defects. Data filtering was set using 1.5-fold of
changes in signal as threshold. Ninety-three per cent of
miRNAs showed no significant changes of expression
whilst 4 miRNAs (named miR-579, miR-3144, miR-612
and miR-6721) were significantly over- or under-expressed.
Bioinformatic analysis showed involvement of these miR-
NAs and their target genes in several biological pathways.
Further investigations of these preliminary data could pro-
vide a new insight into the biological roles of the miRNAs
in relation to FF level and in their potential use as
biomarkers.
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offering non invasive aneuploidy screening test based on
cfDNA (NIPT)
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DI PISTOIA, Pistoia, Italy, 8Consultori e Diagnosi
Prenatale USL 4, Prato, Italy
Introduction: Non invasive prenatal testing (NIPT) to
investigate the risk for fetal aneuploidies (chromosomes 13,
18 e 21 trisomies and X/Y aneuploidies) has been demon-
strated to have high sensitivity and specificity and it is
worldwide accepted both as contingent screening as primary
test in first trimester.
Materials and Methods: since March 2019, NIPT is
offered by public healthcare system in Tuscany to pregnant
women with conventional first trimester screening test
(FTS) risk (nuchal translucency and biochemical measure-
ments) ranging from 1:301-1:1000 or 1:2-1:300 if they opt-
out invasive prenatal diagnosis. Women are counseled in
different centers spread out over the regional area. Blood
samples are collected in a single regional center authorized
to perform the test for chromosomes 13, 18, 21, X and Y by
CE-IVD VeriSeq™ NIPT Solution (Illumina Inc.).
Results: Since March to December 2019, 2199 women
have been screened of which 429 with a FTS risk ranging
from 1:2-1:300 and 940 from 1:301-1:1000. 396 out of 429
NIPT results were at low risk for fetal aneuploidies whereas
7/429 resulted at high risk for T21 (n = 4), T18 (n = 1)and
XXX (n = 2). All these results have been confirmed by
IPD. In the FTS 1:301-1:1000 risk group, 738 cases resulted
at low risk for fetal aneuploidies and 5 at high risk for T21
(n = 1), T18 (n = 1), XXY (n = 2) and XXX (n = 1). Only
sex chromosome aneuploidy results have been confirmed by
IPD. Conclusions. Preliminary data show that of the
Tuscany region protocol improve the pregnancy care
pathway by reducing inappropriate invasive tests.
C. Pescucci: None. F. Gerundino: None. C. Giuliani:
None. B. Minuti: None. F. Sbernini: None. S. Frusconi:
None. F. Marin: None. L. Giulietti: None. C. Berni:
None. L. Pasquini: None. C. Luchi: None. F. Severi:
None. A. Cordisco: None. B. Melani: None. E. Mainandi:
None. E. Pelo: None.
P01.075.C
THE FREQUENCY OF RARE CHROMOSOMAL
TRISOMIES USING GENOME WIDE NIPT
I. M. TEKIN1, H. OZDEMIR2, H. OZGUR1, Y. SAHIN1
1Genoks Genetic Diseases Diagnostic Center, Ankara,
Turkey, 2Department of Obstetrics and Gynecology, Divi-
sion of Perinatology, Gazi University Faculty of Medicine,
Ankara, Turkey
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Objective: When non invasive prenatal testing (NIPT)
incorporating whole genome sequencing (WGS) is per-
formed, the autosomal aneuploidies other than trisomy 21,
18 and 13 has the potential to be detected. We present the
frequency of rare chromosomal trisomies (RATs) that were
identified between 1 July 2018 and 31 December 2019
Methods: Standard centrifugation methods were used for
plasma isolation. Cell free DNA (cfDNA) was isolated and
library construction was prepared according to BGI’s
documented protocol. WGS of cfDNA was performed with
BGISEQ-500 sequencer. Data was analysed using BGI’s
proprietary bioinformatic programme, HALOS.
Results: WGS data was generated from 13,802 NIPT
cases. The mean maternal age was 33 years, fetal fraction
was 10.7% and gestational age at testing was 14 weeks.
Over an 18-month period, there were 30 RATs identified.
The overall frequency of RATs was 0.21% in our study.
Trisomies 16 and 22 were the most frequently observed
RATs while other chromosomes were less frequently
involved. Invasive prenatal diagnosis was performed in
37% (11/30) of cases with RATs. Three fetal aneuploidies
were confirmed with amniocentesis; one was T16 and the
others were T22.
Conclusions: Rare autosomal aneuploidies are not
uncommon in clinical practice when performing genome-
wide NIPT. The review of the published reports show a
significant risk for obstetric pathology and fetal anomalies
such as early miscarriage, true fetal mosaicism, intrauterine
growth restriction, in utero fetal demise, and uniparental
disomy. We advise genetic counseling in all cases of rare
chromosomal trisomies to improve pregnancy management.
I.M. Tekin: None. H. Ozdemir: None. H. Ozgur: None.
Y. Sahin: None.
P01.076.A
Next generation sequencing detects premeiotic errors in
human oocytes and provides evidence of genetic
influence
H. Ghevaria1, S. SenGupta1, R. Naja2, R. Odia3, P. Serhal4,
X. Viñals Gonzalez3, X. Sun1, J. Delhanty1
1Preimplantation Genetics Group, University College
London, London, United Kingdom, 2Molecular Genetics
Laboratory, Igenomix UK Ltd, London, London, United
Kingdom, 3Embryology Department, The Centre For
Reproductive and Genetic Health, London, United King-
dom, 4Clinical Department, The Centre For Reproductive
and Genetic Health, London, United Kingdom
As women age the risk of an aneuploid oocyte increases
with most errors affecting meiosis I/II. Application of next
generation sequencing (NGS) has allowed us to confirm our
finding, from molecular cytogenetics, that a significant
proportion of apparently meiotic aneuploidy is in fact pre-
sent in the early embryo, leading to a risk of oocyte aneu-
ploidy irrespective of age. It has also provided evidence that
genetic factors influence premeiotic oocyte aneuploidy.
NGS was performed on oocytes using Ion ReproSeqPGS
(ThermoFisher)/VeriSeqPGS (Illumina). Immature oocytes
(84) included germinal vesicles & metaphase I oocytes.
Mature oocytes (27) were metaphase II - 1st polar body
complexes. Totally, 111 oocytes from 33 women, (average
maternal age, 35.09 years) were tested. Overall 15/111
(13.5%) oocytes showed premeiotic (PM) errors. Eight of
33 patients had oocytes with PM errors. Aneuploidy ana-
lysis was based on the reproductive histories of female
partners donating oocytes. Interestingly the first two groups
of infertility patients showed almost identical aneuploidy
rates in contrast to the social oocyte freezing group. Two
young women preserving oocytes prior to breast cancer
treatment showed complex aneuploidies. We conclude that
the application of NGS has provided accurate information
regarding the frequency of aneuploidy that is due to pre-
meiotic errors compared with that caused by errors at MI of
oogenesis and that on an individual basis this is influenced
by genetic factors. Grant support: CRGH













13 32 5 (15.6%)
2. Females not known to be
infertile (probable male
factor infertility)
11 32 4 (12.5%)
3. Oocyte preservation due
to social reasons
2 21 1 (4.7%)
4. Oocyte preservation due
to breast cancer
2 10 5 (50%)









H. Ghevaria: None. S. SenGupta: None. R. Naja:
None. R. Odia: None. P. Serhal: None. X. Viñals
Gonzalez: None. X. Sun: None. J. Delhanty: None.
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P01.080.B
Interrogating the parental and zygotic origin of de novo
mutations in severe male infertility using long read
sequencing
G. S. Holt1, B. Alobaidi1, L. Batty1, M. Oud2, H. Smith1, P.
de Vries2, R. Smits2, L. Vissers2, L. Ramos2, M. Xavier1, J.
Veltman1
1Biosciences Institute, Newcastle University, Newcastle
Upon Tyne, United Kingdom, 2Department of Human
Genetics, Donders Institute for Brain Cognition and
Behavior, Radboud University, Nijmegen, Netherlands
Male infertility affects approximately 7% of the male
population and while genetic abnormalities are predicted to
make up at least 15% of the cases, only ~4% are currently
identified. In severe forms of male infertility, patients are
found to have high numbers of genetic abnormalities and de
novo mutations (DNMs). Interestingly DNMs are known to
play an important role in severe genetic diseases with
reduced reproductive fitness. Our research investigates the
role of DNMs in severe male infertility by studying a
unique cohort of azoospermic and severe oligozoospermic
patients, and their fertile parents. Employing the Illumina’s
Novaseq6000, 100 DNMs were identified in the exomes of
99 patients. While short-read sequencing data was used to
collect the location and genotypes of all informative SNPs
(iSNPs) surrounding the DNMs, limitations in fragment size
prevented further investigation. In-depth examination of
DNMs in context with their surrounding iSNPs requires
targeted capture approaches for long-read sequencing that
span the entire region of interest. Using PCR amplicon
sequencing on the Oxford-Nanopore MinION platform we
have been able to phase ~90% of the DNMs. Phasing
analysis indicated that ~71% of DNMs occurred in the
paternal gamete pre-fertilization, which is in concordance
with current literature. A link between paternal DNMs and
likely causation for disease has been noted, though not all
data was available for this association at this time. Inves-
tigation of allele frequency identified 91% of the DNMs
occurred pre-zygotically, why they failed to impact father
spermatogenesis is of particular interest for further study.
G.S. Holt: None. B. Alobaidi: None. L. Batty: None.M.
Oud: None. H. Smith: None. P. de Vries: None. R. Smits:
None. L. Vissers: None. L. Ramos: None. M. Xavier:
None. J. Veltman: None.
P01.082.A
Polycystic ovary syndrome: Does it affect the gene
expression patterns in human oocytes?
P. Tulay, Z. Al-Omar, B. Ozbakir
Near East University, Nicosia, Cyprus
Polycystic ovary syndrome is a common disorder among
women of reproductive age. The aim of this study was to
investigate the gene expression levels of a number of genes
that is functioning in steroidogenesis and in the main-
tenance of telomeres.
The spare oocytes were collected from IVF patients with
polycystic ovaries and routine IVF patients as controls.
DNA and RNA were extracted from each oocyte. Reverse
transcription of RNA was performed and real time PCR was
conducted to quantify the expression levels of eleven genes,
TERF1, TRF2, TINF2, TPP1, POT1, RAP1, CYP11,
CYP17, CYP19, HSD17B1 and HSD3B2.
The results of this study showed that the expression levels
of TERT, TRF, TINF, TPP, RAP, CYP19 and HSD3B2 were
similar between the two groups. However, the expression
levels of POT and CYP11A1 genes were shown to be
statistically different in the oocytes obtained from control
patients (p < 0.05), whereas statistically significant expres-
sion levels were observed for CYP17 in the oocytes
obtained from the study group (p < 0.05). The expression
level of HSD17B1was also shown to be statistically
different in the oocytes (p < 0.05).
The results of this study showed that different gene
expression levels are observed in the oocytes obtained from
females with polycystic ovaries compared to the controls.
The extrapolation of the results indicates that the genes
essential in maintaining DNA chromosome end integrity
and steroidogenesis are crucial for the correct development
of the oocytes. Any variations of the expression levels of
these genes may result in anomalies of the oocyte
maturation.
P. Tulay: None. Z. Al-Omar: None. B. Ozbakir: None.
P01.085.A
Regulatory variants upstream of FLT1 as risk factors
for preeclampsia
T. Kikas1, R. Inno1, K. Ratnik1,2, K. Rull1,3,4, M. Laan1
1University of Tartu, Institute of Bio- and Translational
Medicine, Tartu, Estonia, 2SYNLAB Estonia OÜ, Tartu,
Estonia, 3Women’s Clinic, Tartu University Hospital, Tartu,
Estonia, 4Department of Obstetrics and Gynecology,
University of Tartu, Tartu, Estonia
Introduction: The first GWAS assessing the genetic risk to
preeclampsia (PE) in placental samples by McGinnis et al.,
2017 identified one statistically significant variant asso-
ciated with PE (rs4769613 C>T; OR=1.2, P=5.4×10−11).
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The variant is located near a well-known PE gene FLT1
encoding sFlt-1. The aim of this study was to further
investigate the link between two variants highlighted in
GWAS near FLT1 gene (rs4769613, rs12050029; 69kb/
158kb, respectively) and PE in two independent cohorts.
Materials and Methods: The study utilized placental
samples from Estonian REPROMETA and HAPPY PREG-
NANCY (placentas n=329/1768, respectively) sample sets,
including PE and non-PE controls (total n=96/2001). SNPs
(rs4769613, rs12050029) were genotyped using Taqman
assays. Association analyses and case-control testing were
conducted in PLINK (linear or logistic regression, covari-
ates gestational age, sex).
Results: Case-control testing showed an increased risk
for PE with rs4769613 C allele in both Estonian sample
sets, concordant with the previous study. Meta-analysis
across the two cohorts improved the significance
(OR=1.75, P = 2.49×10−3). As a novel finding, no
associations between rs4769613 and other gestational
complications (gestational diabetes, fetal growth, preterm
birth) were detected, which suggests the variant is PE-
specific. The gene expression of FLT1 was upregulated only
in PE placentas carrying CC- and CT genotypes (t-test, P <
0.05), whereas in maternal serum, sFlt-1 was increased in
PE cases in all genotype groups.
Conclusions: The study emphasizes the placental
rs4769613 as the only known robust and specific risk
variant for PE, modulating placental FLT1 expression.
Funding: IUT34-12 (Estonian Research Council);
HAPPY PREGNANCY, 3.2.0701.12-0047 (European
Regional Development Fund)
T. Kikas: None. R. Inno: None. K. Ratnik: A.
Employment (full or part-time); Significant; SYNLAB
Estonia OÜ. K. Rull: None. M. Laan: None.
P01.086.B
The role of new genetic markers and natural selection in
the formation of a hereditary predisposition to
preeclampsia
V. Serebrova, E. Trifonova, V. Stepanov
Research Institute of Medical Genetics, Tomsk National
Research Medical Center of the Russian Academy of
Sciences, Tomsk, Russian Federation
Introduction: Preeclampsia (PE) is a pregnancy-specific
complication with the poorly understood etiopathogenesis.
There is a hypothesis that the risk to the development of PE
may be a consequence of natural selection affecting on
placental genes responsible for trophoblast invasion and
remodeling of spiral arteries. The aim of this work was to
characterize the genetic components of PE by analysis of
regulatory single-nucleotide polymorphisms (rSNPs) of
differentially expressed genes (DEGs) in placenta and to
detect the role of natural selection in its formation.
Materials and Methods: In this report we analyzed 46
rSNPs in 21 DEGs, associated with PE according to the
analysis of the transcriptome in 551 patients with PE and
718 women with uncomplicated pregnancies of Buryat,
Russian and Yakut populations using MassArray iPLEX
(Sequenom). For detection of the signals of natural selection
we used new INSIGHT method.
Results: We have detected significant associations of PE
with 14 rSNPs in 10 genes: BHLHE40, CORO2A, INHA,
LHB, NDRG1, PPP1R12C, PLIN2, RDH13, SASH1,
SYDE1. The effect of weak negative selection has being
shown for 4 rSNPs in 4 DEGs: rs10985257 in CORO2A
gene, rs72959687 in INHA gene, rs34845949 in SASH1
gene, rs2227262 in NDRG1 gene. It should be noted that
these results corresponds to number of evolutionary
hypotheses of the occurrence of PE.
Conclusions: Our results demonstrate the significant role
of studied rSNPs of DEGs and their adaptive changes in the
hereditary predisposition to PE. This work was supported
by the Russian Foundation for Basic Research (grant №18-
29-13045).
V. Serebrova: None. E. Trifonova: None. V.
Stepanov: None.
P01.087.C
Genetic risk factors for pre-eclampsia in the Finnish
population
T. Kaartokallio1, S. Ruotsalainen2, T. Palviainen2, T.
Hiekkalinna3,4, K. Auro2,5, M. Perola5,6, FINNPEC, K.
Kivinen2, H. Laivuori1,2,7
1Medical and Clinical Genetics, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland, 2Institute
for Molecular Medicine Finland, Helsinki Institute of Life
Science, University of Helsinki, Helsinki, Finland, 3Finnish
Institute for Health and Welfare, Helsinki, Finland, 4Clin-
ical and Molecular Metabolism Research Program, Uni-
versity of Helsinki, Helsinki, Finland, 5National Institute for
Health and Welfare, Helsinki, Finland, 6Diabetes and
Obesity Research Program, University of Helsinki, Hel-
sinki, Finland, 7Department of Obstetrics and Gynecology,
Tampere University Hospital and Tampere University,
Faculty of Medicine and Health Technology, Tampere,
Finland
Introduction: Pre-eclampsia (PE) is a vascular pregnancy
disorder with maternal and fetal genetic components. As the
disease negatively affects reproductive success, the risk
variants are assumed to be under purifying evolutionary
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selection. The amount of low-frequency pathogenic variants
has shown to be increased in Finland due to recent bottle-
necks, increasing statistical power in genetic studies. We
aim to screen for genetic risk factors for PE in the families
mainly originating from a northeastern Finland population
isolate, and generalise the results for the whole population.
Methods: The PE family cohort consists of 15 extended
families. DNA is available for 174 family members
(mothers: 62 PE+32 ctrl; babies: 41 PE+39 ctrl). Using
genome-wide imputed data, we have performed linkage and
family-based association analyses with PSEUDOMARKER
and PLINK to study segregation of loci with both maternal
and fetal phenotypes. We will seek replication of the
findings by association analysis in two Finnish cohorts with
genome-wide imputed data available, the FINRISK popula-
tion survey (426 PE+8357 ctrl) and the FINNPEC case-
control cohort (mothers:1533 PE+995 ctrl; babies:818 PE
+925 ctrl).
Results: In the linkage screen, we identified ~35 maternal
and 40 fetal candidate loci when using a lenient p-value
threshold p < 5x10−5. The FINRISK association analysis
showed suggestive replication (p < 5x10−6) of two of the
loci, maternal signal in chr9 close to GAS1 and fetal signal
in chr16 in CDH13. Next steps include association analysis
in FINNPEC and meta-analysis in both cohorts to verify
these preliminary findings.
Funding: Academy of Finland, Erkko, Kordelin and
Sohlberg Foundations, and VTR funding.
T. Kaartokallio: None. S. Ruotsalainen: None. T.
Palviainen: None. T. Hiekkalinna: None. K. Auro: None.
M. Perola: None. K. Kivinen: None. H. Laivuori: None.
P01.089.B
A Retrospective Study of In Vitro Fertilization and
Preimplantation Genetic Testing for chromosomal
aberrations (PGT-SR and PGT-A) combined with
Clinical Outcome
M. Baetens1, I. De Croo2, A. Dheedene1, K. Tilleman2, B.
Menten1
1Center for Medical Genetics, Ghent University Hospital,
Ghent, Belgium, 2Department for Reproductive Medicine,
Ghent University Hospital, Ghent, Belgium
PGT for structural rearrangements (PGT-SR) can be offered
to patients carrying an inversion, balanced reciprocal or
Robertsonian translocation, and PGT for aneuploidy
screening (PGT-A) to patients with fertility problems or
recurrent miscarriages. Selecting against embryos without a
chromosomal rearrangement could improve live birth rates
while reducing miscarriage rates or avoiding birth of an
affected child. PGT is an extended, stressful trajectory while
precise outcome predictions are still hard to grasp. Coun-
seling PGT couples remains delicate due to numerous
parameters influencing outcome. Comparing success rates
to (inter)national reference data is part of good clinical
practice. PGT technologies evolve at high speed, going
from different biopsy timepoints to more extensive genetic
methodologies, making good comparisons difficult. By
detailed evaluation of our in-house data, and comparison to
published data from (inter)national clinics, we obtained
additional insights and can provide couples with more
patient-focused information. We performed a retrospective
cohort study at the Department for Reproductive Medicine
and the Center for Medical Genetics (Ghent University
Hospital), including patients who underwent ICSI-IVF
(January 2016-April 2019) followed by PGT-SR or PGT-
A after trophectoderm biopsy (68 and 90 oocyte retrieval
cycles respectively). Making use of comprehensive chro-
mosome screening (shallow whole genome sequencing or
sWGS), we detected chromosomal abnormalities in 65% of
PGT-SR embryos. In the PGT-A group, 40% of embryos
showed a numerical or structural rearrangement. For
translocation carriers, pregnancy rate per transfer was 58%
and live birth rate per transfer 44%. For PGT-A patients,
pregnancy rate and live birth rate were 39% and 25%
respectively.
M. Baetens: None. I. De Croo: None. A. Dheedene:
None. K. Tilleman: None. B. Menten: None.
P01.090.C
Preimplantation Genetic Testing (PGT) for cancer
predisposition: A single center large cohort experience
S. Zuckerman1, O. Freireich1, T. Eldar-Geva2, S.
Lieberman1, S. Shaviv1, A. Yadin1, E. Farhi1, E. Hakam-
Spector1, M. Ben-Shlomo1, T. Azar1, E. Zivi2, E.
Rubinstein2, O. Schonberger2, I. Ben-Ami2, G. Altarescu1
1Medical Genetics Institute, Shaare Zedek Medical Center,
Jerusalem, Israel, 2IVF unit, Shaare Zedek Medical Center,
Jerusalem, Israel
In the last decade an increasing number of people carriers of
cancer predisposition mutations (CCPM) are performing
PGT-M. PGT-M for these late-onset and partial penetrant
conditions implies that the procedure selects against
embryos that might have been cancer-free. Moreover, pre-
ventive and therapeutic options for decreasing morbidity
and mortality are available and ongoing cancer research
might reveal treatments altering the natural history of cancer
in the future. Most studies exploring perceptions of PGT-M
among CCPM, were based on participants’ theoretical
declarative intentions. Actual use has rarely been reported
and analyzed. Between 2006-2019 overall 173 CCPM were
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counseled in our center: One couple between 2006-2008
and gradual increase until 102 CCPM between 2018-2019.
Six were single women (3.4%) and 167 couples (96.5%).
Among them 145(83.8%) were BRCA1/BRCA2 carriers
(92/48 respectively; 5 BRCA1+BRCA2), 10(5.8%) Lynch
carriers, 10(5.8%) APC carriers, 4(2.3%) TP53 carriers, 2
(1.2%) MEN2 carriers, 1(0.6%) CHEK2 carrier and 1
(0.6%) BMPR1A carrier. Overall, 150(86.7%) of the car-
riers were healthy and 23(13.2%) were diagnosed with
cancer or related condition. In 120(69.4%) couples the
carrier was the women partner; in 51(29.5%) couples the
carrier was the men partner and in 2(1.2%) couples both
partners were carriers. Five)2.8%) couples had additional
reason for PGT-M/PGT-SR. Overall Live birth rate for
embryo transfer was 32%. Reproductive decision-making
regarding PGT-M for CCPM is a complex process. While
this application for PGT-M becomes acceptable, health
professionals involved in the process should be aware and
address the specific issues and concerns of this group
regarding medical, emotional and moral aspects.
S. Zuckerman: None. O. Freireich: None. T. Eldar-
Geva: None. S. Lieberman: None. S. Shaviv: None. A.
Yadin: None. E. Farhi: None. E. Hakam-Spector: None.
M. Ben-Shlomo: None. T. Azar: None. E. Zivi: None. E.
Rubinstein: None. O. Schonberger: None. I. Ben-Ami:
None. G. Altarescu: None.
P01.091.A
Obstetric risks associated with preimplantation genetic
testing for monogenic disorders and structural chromo-
somal rearrangements (PGT-M/SR) compared to
regular IVF/ICSI.
M. Heijligers1, Y. Arens1, R. van Golde1, M. van der
Hoeven1, J. Dumoulin1, I. Homminga2, C. van Tilborg3, C.
de Die-Smulders1, A. van Montfoort1
1Maastricht University Medical Centre+, Maastricht,
Netherlands, 2University Medical Center Groningen, Gro-
ningen, Netherlands, 3University Medical Center Utrecht,
Utrecht, Netherlands
Introduction: Earlier studies on the obstetric outcome in
pregnancies following PGT are inconclusive since both an
increased risk and no increased risk for adverse obstetric
outcome are reported. Moreover, not all of these studies
distinguish between PGT for monogenic disorders or
structural chromosomal rearrangements (PGT-M/SR) and
PGT for aneuploidies (PGT-A).
Methods: This retrospective cohort study included all
pregnancies resulting from PGT-M/SR (n = 389) and IVF/
ICSI treatments (n = 1667) conducted between 2004 and
2014. Data were collected from the medical files and from
questionnaires. These data included parental characteristics,
characteristics of the treatment preceding the pregnancy and
obstetric and neonatal characteristics.
Results: Obstetric complications were reported in 18%
and 19% of the singleton pregnancies in the PGT and
regular IVF/ICSI group, respectively (P = 0.103). The risk
for stillbirth was lower in the PGT group (P = 0.044). Birth
weights of all singletons were converted into z-scores and
showed a comparable birth weight for the two groups (0.09
vs. -0.02; P = 0.084). Within the multiple pregnancies, the
risk for obstetric complications (P = 0.535) and the
incidence of fetal loss (P = 0.617) was comparable between
the PGT and IVF/ICSI group. The mean pregnancy duration
was longer (P = 0.037) and the mean birth weight was
higher (P = 0.010) in the PGT group. More monozygotic
pregnancies were observed in the PGT group (P = 0.009).
Conclusions: The more invasive nature of the PGT-M/
SR technique does not lead to an increased risk for obstetric
complications as compared to a regular IVF/ICSI treatment.
M. Heijligers: None. Y. Arens: None. R. van Golde:
None. M. van der Hoeven: None. J. Dumoulin: None. I.
Homminga: None. C. van Tilborg: None. C. de Die-
Smulders: None. A. van Montfoort: None.
P01.092.B
Results gained from fetal exome sequencing inform
clinical management. A report of 100 cases.
E. Dempsey1, L. Ive2, R. Dubis2, E. Serra2, H. Savage2, A.
Haworth2, S. Mansour1, T. Homfray1, S. Drury2
1St George’s University of London, London, United King-
dom, 2Congenica Ltd, Cambridge, United Kingdom
Introduction: Exome sequencing in cases of fetal structural
malformation has been shown to increase diagnostic yield
(over traditional diagnostic methods) by 8-80%, depending
on phenotype. This technique is soon to be made available
throughout England as part of a centralisation and stan-
dardisation of genetic laboratory services.
Materials and Methods: We have undertaken exome
sequencing in 100 cases of fetal anomaly as part of a service
improvement project at St George’s Hospital. In half of
cases sequencing was undertaken with the intention of
informing the management of an ongoing pregnancy. In the
remaining cases exome sequencing was undertaken post-
mortem. Exome data was analysed via the application of
patient-specific phenotype panels, reducing the risk of
incidental findings.
Results: Our diagnostic rate across all cases is ~ 40 %
and higher in cases with skeletal and oedema phenotypes.
Exome results have influenced the management of preg-
nancy and labour. They have also directed early neonatal
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care, including enabling the treatment of a newborn with
enzyme replacement therapy. The results of exome sequen-
cing have been used for accurate assessment of recurrence
risk. In addition, results can be used for prenatal testing or
preimplantation genetic diagnosis in a future pregnancy.
Conclusions: Using specific case examples we will
describe the way in which the results of fetal exome
sequencing have influenced clinical management. We will
also describe the challenges we have encountered in the
implementation of a fetal exome sequencing service,
including the analysis of variants of uncertain significance
in phenotype-limited situations.
E. Dempsey: None. L. Ive: A. Employment (full or part-
time); Significant; Congenica Ltd. R. Dubis: A. Employ-
ment (full or part-time); Significant; Congenica Ltd. E.
Serra: A. Employment (full or part-time); Significant;
Congenica. H. Savage: A. Employment (full or part-time);
Significant; Congenica Ltd. A. Haworth: A. Employment
(full or part-time); Significant; Congenica Ltd. S. Mansour:
None. T. Homfray: None. S. Drury: A. Employment (full
or part-time); Significant; Congenica Ltd.
P01.093.C
Whole-exome sequencing in the prenatal setting: relat-
ing fetal phenotype to genotype
L. Leeuwen, K. Bouman, N. Corsten-Janssen
UMCG, Groningen, Netherlands
Introduction: Whole-exome sequencing (WES) is
increasingly being used in the prenatal setting. However,
interpretation of WES data is complicated due to various
factors including limited knowledge on the prenatal fetal
phenotype of rare monogenic disorders. We therefore aimed
to describe the prenatal fetal phenotype of genetic variants
found by WES.
Methods: In this single-center study, we included fetuses
in whom WES was indicated in a prenatal diagnostic setting
between March 1, 2018 and January 1, 2020 during
pregnancy or after termination of pregnancy. We performed
trio WES using a phenotype-dependent filtering strategy.
We documented prenatal and postnatal characteristics of
fetuses and compared the phenotype with literature using
PubMed.
Results: WES was performed in 93 fetuses. A pathogenic
or likely pathogenic variant was found in 29 (31.2%)
fetuses (21 different genes). For eight genes, it was the first
time a causative genetic variant was found in a prenatal
setting (C2CD3,CNOT1,GATA6, PLD1,POMK,SAMD9,
SMC3,THOC6). In three fetuses, some detected structural
anomalies have not previously been described (PEX1-,
POMK-,THOC6-variants). In three fetuses, diagnosis was
filtered out in the prenatal setting due to various reasons, but
could be established using additional postnatal phenotypic
characteristics. In general, the prenatal phenotype on
ultrasound corresponded well with postnatal phenotype
although some features were not detected by the prenatal
ultrasound examination.
Conclusions: Increased knowledge about the prenatal
fetal phenotype is important for improving the interpretation
and classification of fetal genetic variants. This will lead to
improvement of parental genetic counseling as well as
prenatal and neonatal care.
L. Leeuwen: None. K. Bouman: None. N. Corsten-
Janssen: None.
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Lessons learned from rapid Exome Sequencing(rES)as a
standard diagnostic test in a prenatal setting for fetuses
with ultrasound abnormalities.
N. Corsten-Janssen1, K. Bouman1, A. J. Scheper1, M. T.
Meems-Veldhuis1, J. B. G. M. Verheij1, R. Suijkerbuijk1, L.
K. Duin2, G. T. R. Manten3, I. M. van Langen1, B. Sikkema-
Raddatz1, H. Westers1, C. C. van Diemen1
1Department of Genetics, University of Groningen, Uni-
versity Medical Centre Groningen, Groningen, Nether-
lands, 2Department of Obstetrics, Gynecology and Prenatal
Diagnosis, University Medical Centre Groningen, Gronin-
gen, Netherlands, 3Department of Obstetrics and Gynecol-
ogy, Isala, Zwolle, Zwolle, Netherlands
Background: Adding rES to conventional genetic tests for
fetuses with ultrasound abnormalities improves the diag-
nostic yield, but differs from performing postnatal rES for
instance by its rapid turnaround time and the impact of a
diagnosis. We will present the lessons we learned by per-
forming rES as a diagnostic test in prenatal care from
March 2018.
Methods: We performed trio rES analysis using a custom
virtual gene panel of ~4,300 OMIM genes during
pregnancy. Inclusion criteria were: 1) two or more
independent major fetal anomalies, or 2) hydrops fetalis
or bilateral polycystic kidneys, or 3) one major fetal
anomaly and a first-degree relative with the same anomaly.
Results: We established a genetic rES-based diagnosis in
14 out of 54 (26%) eligible fetuses with a mean turnaround
time of 14 days. We learned the following lessons: (1) We
made unexpected diagnoses using our broad virtual panel,
like Zellweger syndrome in a fetus suspected of a
ciliopathy. (2) We missed four diagnoses that were made
postnatally using additional phenotypic information and
adapted our filter strategy. 3) We were confronted with
incidental unsolicited findings and changed our filter
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strategy to minimize them. (4) There is a lack of knowledge
about prenatal phenotype of known genetic conditions,
which hinders diagnostics. Further, we experienced the
impact of time pressure to generate a diagnosis in limited
time and had to deal with changing fetal phenotypes.
Conclusion: rES in the prenatal setting is feasible but
challenging, and improves by adapting the process based on
insights from previous experiences.
N. Corsten-Janssen: None. K. Bouman: None. A.J.
Scheper: None. M.T. Meems-Veldhuis: None. J.B.G.M.
Verheij: None. R. Suijkerbuijk: None. L.K. Duin: None.
G.T.R. Manten: None. I.M. van Langen: None. B.
Sikkema-Raddatz: None. H. Westers: None. C.C. van
Diemen: None.
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Improved fetal sex determination in twin pregnancies in
low coverage whole-genome based non-invasive prenatal
testing
T. Sedlackova1, M. Hyblova2,3, J. Budis1,4,5, M.
Harsanyova1,6, M. Kucharik1,5, O. Pos1,6, M. Sekelska2,3, B.
Nagy7, G. Minarik2,3, T. Szemes1,5,6
1Geneton Ltd., Bratislava, Slovakia, 2Medirex Inc., Brati-
slava, Slovakia, 3Trisomy Test Ltd., Bratislava, Slovakia,
4Slovak Centre of Scientific and Technical Information,
Bratislava, Slovakia, 5Comenius University Science Park,
Bratislava, Slovakia, 6Department of Molecular Biology,
Faculty of Natural Sciences, Comenius University,
Bratislava, Slovakia, 7Semmelweis University, Budapest,
Hungary
Introduction: Fetal sex determination is already a common
part of the standard non-invasive prenatal testing (NIPT).
The current classification methods are almost entirely
accurate for fetal sex prediction in singleton pregnancies,
but they still show the limitations for multiple pregnancies,
with 98% reported accuracy of fetal sex prediction in twins.
Methods: We enrolled 99 maternal samples with twin
pregnancies and confirmed fetus sex in this study. Since a
precise estimation of the fetal fraction is a key for correct
sex determination, we used a previously published
improved predictor utilizing two different attributes of
analyzed genomic material - length and genomic location of
the sequenced DNA fragments. Subsequent fetal sex
prediction was performed using an SVM classifier.
Results: Our method has shown perfect prediction
accuracy in distinguishing between pregnancies with two
female fetuses and pregnancies with at least one male fetus.
We observed one incorrect prediction between one and two
male fetuses. Overall, the accuracy of fetal sex prediction
was 98.99%.
Conclusions: Here we described a novel bioinformatic
algorithm to determine the sex of both fetuses in twin
pregnancies, by the analysis of cell-free fetal DNA from the
maternal plasma. Our algorithm achieved superior accuracy
in fetal sex prediction in twins compared to known
bioinformatics tools. Moreover, it provides supporting
graphs for visual inspection and calculation of prediction
confidence.
Keywords: non-invasive prenatal testing, twin preg-
nancy, whole-genome sequencing, fetal sex prediction
T. Sedlackova: A. Employment (full or part-time);
Modest; Geneton Ltd.. M. Hyblova: None. J. Budis:
None. M. Harsanyova: None. M. Kucharik: None. O.
Pos: None. M. Sekelska: None. B. Nagy: None. G.
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The value of prenatal array to detect submicroscopic
chromosomal imbalances in cases with abnormal fetal
ultrasonographic findings; a retrospective study
L. OZER, M. Aydin, S. Aktuna, E. Unsal
MIKROGEN GENETIC DIAGNOSIS CENTER, ANKARA,
Turkey
Chromosomal microarray (CMA) is used in prenatal diag-
nosis for detecting CNVs which are too small to detect by
karyotyping. Here we report our laboratory’s array data of
prenatal samples and describe phenotype-genotype corre-
lations. Methods: 180 specimens (149 amniotic fluid, 23
chorionic villi and 8 cord blood samples) were analyzed by
array CGH. Detection of genomic CNVs was performed
using Agilent, 8x60K CGH Microarray. Interpretation was
done according to the ACMG guidelines. Results: %16.1 of
patients (29/180), CNVs were detected. 24 of them had
segmental duplication or deletion, 5 had trisomy and 1 had
monosomy X. 3.3% of patients had aneuploidy, 4.4% of
patients had VUS variants and %8.8 of patients had
pathogenic segmental deletions/duplications. 61.1% of the
segmental pathogenic variants were deletions and most of
the VUS variants were duplications (62.5%). 50% of the
segmental pathogenic variants were < 7 Mb and the
smallest size was 0.5MB (deletion). 22.2% of pathogenic
variants were well-defined CNV syndromes. The most
prevalent indications were ultrasonographic anomalies,
increased triple test risk and advanced maternal age. While
30% of patients with normal results have normal ultrasound,
all patients with a pathogenic variant had an ultrasound
anomaly. The most defined ultrasonographic findings in
cases with pathogenic variants were cardiac anomalies,
increased NT and brain anomalies. Conclusion: Detection
of submicroscopic imbalances by CMA increases the power
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of prenatal diagnosis. Our data emphasize the importance of
CMA in the prenatal diagnosis of the fetuses with abnormal
ultrasonographic findings whereas conventional karyotyp-
ing resolution is inadequate to detect submicroscopic
changes.
L. Ozer: None. M. Aydin: None. S. Aktuna: None. E.
Unsal: None.
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Targeted prenatal exome sequencing in a series of fetal
structural anomalies detected by ultrasonography: first
experience of the University Hospitals of Geneva
L. Quteineh1, J. Pellegrinelli2, M. Billieux2, M. Guipponi1,3,
S. Laurent1, E. Hammar1, A. Murphy1, M. Carminho Amaro
Rodrigues1, T. Ait-Mouhoub1, F. Sloan-Béna1, S. Unger4, F.
Giuliano4, C. Rieubland5, J. Fluss6, P. Extermann7, J.
Blouin1,3, M. Abramowicz1, S. Fokstuen1
1Service of Genetic Medicine, Geneva, Switzerland,
2Department of gynecology and obstetrics, Geneva, Swit-
zerland, 3Department of Genetic Medicine and Develop-
ment, Geneva, Switzerland, 4Service of Genetic Medicine,
Lausanne, Switzerland, 5Department of Pediatrics, Division
of Human Genetics, Bern, Switzerland, 6Pediatric Neurol-
ogy Unit, Geneva, Switzerland, 7Dianecho echographic
center, Geneva, Switzerland
Introduction: Diagnostic genome-wide sequencing
approaches to investigate prenatally detected anomalies are
increasingly used in fetal medicine. We aimed to evaluate
the value of targeted whole exome sequencing (WES) in
fetuses with prenatal sonographic abnormalities and normal
microarray and karyotype.
Materials and Methods: After informed consent was
obtained, we sequenced the DNA from amniotic fluid cells
of 17 fetuses by WES (Illumina NextSEQ500). We then
performed bioinformatic analysis of a selected gene panel.
All cases were ongoing pregnancies. The genomic results
were obtained within 2 weeks.
Results: The 17 fetuses presented with the following
anomalies: isolated brain malformations (n = 6), sustained
increased nuchal translucency (n = 3), multiple structural
anomalies (n = 3), polyhydramnios (n = 1), situs inversus
(n = 1), renal cysts (n = 1), hydrops fetalis (n = 1) and
skeletal dysplasia (n = 1). Causing variants were identified
in 4 cases (24%): two with sustained increased nuchal
translucency presented with a de novo variant in RAF1 (p.
Ser267Arg) and in BRAF (p.Thr241Arg) genes, compatible
with a RASopathy, the fetus with skeletal dysplasia had a de
novo variant in COL11A1 gene (p.Gln921_Pro926del)
causing Stickler/Marshall syndrome and the fetus with
hydrops fetalis had 2 variants in PIEZO1 gene (p.Ser182*
and p.Phe1294del) causing autosomal recessive lymphatic
dysplasia. Pregnancy was terminated in all 4 cases.
Conclusions: targeted WES is an adequate approach of
genome-wide sequencing for ongoing pregnancies with
fetal structural abnormalities suspicious for a genetic
etiology and normal microarray. It has a diagnostic utility
and might facilitates genetic counseling.
L. Quteineh: None. J. Pellegrinelli: None. M. Billieux:
None. M. Guipponi: None. S. Laurent: None. E.
Hammar: None. A. Murphy: None. M. Carminho
Amaro Rodrigues: None. T. Ait-Mouhoub: None. F.
Sloan-Béna: None. S. Unger: None. F. Giuliano: None.
C. Rieubland: None. J. Fluss: None. P. Extermann:
None. J. Blouin: None. M. Abramowicz: None. S.
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Prenatal diagnosis of trisomies in CVS: are non-mosaic
biallelic QF-PCR results prognostic?
A. R. Pendlebury-Watt1, K. Mann1, C. Ogilvie2
1Viapath analytics, London, United Kingdom, 2Genetics
Department, Guys and St. Thomas’ NHS Foundation Trust,
London, United Kingdom
Placental mosaicism for chromosome aneuploidy compli-
cates prenatal analysis of chorionic villus (CV) samples and
has a reported incidence of up to 2%. Quantitative
fluorescence-PCR (QF-PCR) analysis of microsatellite
repeats is widely used to establish chromosome copy
number of uncultured CV samples; if recommended pre-
paration methods are employed, both cytotrophoblast and
mesoderm should be represented. In the case of trisomy
results, the presence of three different alleles is observed in
~90% of cases, confirming meiotic non-disjunction as the
origin of the abnormal cell line. Where only biallelic 2:1
ratios are observed, the trisomy may have arisen by mitotic
non-disjunction following a normal conception, in which
case a normal cell line may be present; European and UK
best practice guidelines recommend that non-mosaic bial-
lelic (NMB) results should be reported more cautiously,
given the increased risk of mosaicism. However, the like-
lihood of finding a normal cell line following an NMB
result is not established. We have therefore audited 10 years
of cases and compared NMB results to the follow-up kar-
yotype and/or amniocentesis results. In total, 133 CVS
showed NMB results for common trisomies, of which 131
were concordant with follow-up tests. Two trisomy 18 cases
showed a normal result on amniocentesis, indicating con-
fined placental mosaicism; neither case had ultrasound
abnormalities present at referral. Therefore, in this cohort,
~1.5% of NMB QF-PCR cases subsequently showed
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evidence of mosaicism, this is reduced to 0% for cases with
USS abnormalities. These figures may inform the reporting
and pregnancy management of NMB cases.
A.R. Pendlebury-Watt: None. K. Mann: None. C.
Ogilvie: None.
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Parental experiences of rapid Exome Sequencing in case
of serious ultrasound abnormalities during pregnancy
M. Plantinga1, L. Zwienenberg1, E. van Dijk1, H. Breet1, J.
Diphoorn1, J. el Mecky2, K. Bouman1, J. Verheij1, A.
Ranchor3, N. Corsten-Janssen1, I. van Langen1
1UMCG, Clinical Genetics, Groningen, Netherlands, 2Uni-
versity of Southampton, CELS, Southampton, United King-
dom, 3UMCG, Health Psychology, Groningen,
Netherlands
Objective: Adding rapid Exome Sequencing (rES) to con-
ventional genetic tests (QF-PCR and SNP-array) can
improve the diagnostic yield of pregnancies showing
ultrasound abnormalities but also includes a higher chance
of unsolicited findings. rES was offered in the context of a
prenatal rES implementation study with a turnaround time
of 14 days. We evaluated how this offer was experienced in
an explorative mixed-methods parental experience study.
Methods: We investigated reasons for accepting and
declining rES, the impact of rES on decision making,
experiences of the counseling and test process, and
understanding of test information and possible test out-
comes. All couples were asked to fill two surveys, one after
pre-test and one after post-test counseling. Part of the
couples were approached for an interview until data
saturation was reached.
Results: 44 couples participated in the survey study, 11 in
the interview study. In 22% of pregnancies, a diagnosis was
found, in 31% an unsolicited finding. 95% wanted to be
informed about unsolicited findings. The most important
reason for accepting rES was to find a diagnosis. Most
parents already decided to terminate the pregnancy on the
basis of the ultrasound abnormalities, although rES results
impacted decision in a few cases. The impact for future
pregnancies was higher than with conventional testing and
the fast turnaround was valued highly. The counseling and
test process was experienced positive. Parents suggested to
add information of other parents’ experiences and decisio-
nal process to the test information.
Conclusion: Parents evaluate rES positively, despite the
risk of unsolicited findings.
M. Plantinga: None. L. Zwienenberg: None. E. van
Dijk: None. H. Breet: None. J. Diphoorn: None. J. el
Mecky: None. K. Bouman: None. J. Verheij: None.
A. Ranchor: None. N. Corsten-Janssen: None. I. van
Langen: None.
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When to test fetuses for RASopathies? Proposition from
a systematic analysis of 353 multicenter cases and a
postnatal cohort
A. Scott1, N. Di Giosaffatte2, V. Pinna2, P. Daniele2, S.
Corno3, V. D’Ambrosio3, E. Andreucci4, A. Marozza5, F.
Sirchia6, G. Tortora7, D. Mangiameli8, C. Di Marco9, I.
Donati10, A. Zonta11, E. Grosso11, G. Mastromoro12, P.
Versacci13, F. Pantaleoni14, F. C. Radio14, T. Mazza15, L.
Papi5, T. Mattina8, A. Giancotti3, A. Pizzuti12, A. Laberge1,
M. Tartaglia14, M. Delrue1, A. De Luca2
1Pediatrics Department, Medical Genetics Division, CHU
Sainte-Justine, University of Montreal, Montreal, QC,
Canada, 2Medical Genetics Unit, Fondazione IRCCS-
Casa Sollievo della Sofferenza, San Giovanni Rotondo,
Italy, 3Department of Maternal and Child Health and
Urologic Science, "Sapienza" University, Policlinico
Umberto I Hospital, Rome, Italy, 4Medical Genetics Unit,
Meyer Children’s University Hospital, Florence, Italy,
5Section of Medical Genetics, Department of Experimental
and Clinical Biomedical Sciences, University of Florence,
Florence, Italy, 6Institute for Maternal and Child Health,
IRCCS "Burlo Garofolo", Trieste, Italy, 7Azienda
Ospedaliero-Universitaria Ospedali Riuniti di Ancona,
Ancona, Italy, 8Department of Pediatrics, Medical Genet-
ics, University of Catania, Catania, Italy, 9Ospedale Santa
Maria Nuova, Florence, Italy, 10Genetic Department,
Infermi Hospital, Rimini, Italy, 11Città Della Salute e Della
Scienza University Hospital, Medical Genetics Unit,
Torino, Italy, 12Department of Experimental Medicine,
Università Sapienza, Rome, Italy, 13Department of Pedia-
trics, Università Sapienza, Rome, Italy, 14Genetics and Rare
Diseases Research Division, Ospedale Pediatrico Bambino
Gesù, IRCCS, Rome, Italy, 15Laboratory of Bioinformatics,
IRCCS Casa Sollievo della Sofferenza, San Giovanni
Rotondo, Italy
Introduction: Recent studies have identified some evoca-
tive prenatal features of RASopathies e.g. lymphatic dys-
plasia (cystic hygroma, hydrops, effusions), congenital
heart disease, polyhydramnios, and renal anomalies. The
aim of this study was to better define the prenatal indica-
tions for RASopathy testing and the genotype-phenotype
correlations.
Methods: 353 cases sent for prenatal RASopathy testing
between 2012-2019, after a normal a-CGH, were collected.
For most, 11 RASopathy genes were tested. Detailed
ultrasound findings were available for 313 fetuses, whereas
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40 cases had only clinical indications for testing collected.
Twenty-five RASopathy patients diagnosed postnatally
were added to widen the phenotypic spectrum.
Results: See tables below for detailed results. The overall
diagnostic yield was 14% (51/353). The largest contributors
of mutations were PTPN11 (29%), RIT1 (15%), RAF1
(13%) and HRAS (12%). Severe postnatal phenotypes were
in majority diagnosed prenatally and associated with
mutations in HRAS, RIT1 and RAF1.
Conclusions: After normal a-CGH, RASopathies should
be considered when any ultrasound finding of lymphatic
dysplasia or suggestive congenital heart disease is found
alone or in association. In the presence of persistent or
associated hygroma, NT>6 mm, hypertrophic cardiomyo-
pathy, or any finding combined with polyhydramnios or
renal anomaly, the likelihood of RASopathy diagnosis is
significantly increased.
Table 1 Prenatal ultrasound findings in 313 patients with
a normal array-CGH











































Mean NT (mm)b 5,01 (0,7-
14,9)


























































NF > 15 5/68 (7%) 3/18 (17%) 2/50 (4%)
Mean NF (mm)b 6,94 (3,0-
28)






























































































No US finding N/A N/A N/A - 12/25 (48%)
a : chi-square statistic or Fisher exact test, as appropriate. α;;; error =
0,05, b : t-student test, * without another finding, except increased NT
Table 2 Diagnostic yield of prenatal ultrasound findings
Prenatal findings Diagnostic yield for NSD
according to indications








n = 353 n = 313
Global diagnostic
yield
14% (51/353) - 15% (48/313) -
Increased NT 11% (29/258) 0,4 13% (30/231) 0,7
NT > 3 < 3,5 0% 0%
NT ≥ 3,5 9% 0,02 12% 0,1
NT > 6 20% 20%
alone 1% 0,005 0% N/A
in association 18% 100%
Increased NT
without CH
4,5% 0,03 8% 0,09
Cystic hygroma 16% (30/189) 0,6 17% (31/183) 0,9
1st trimester CH N/A N/A 7% 0,02
Persistent CH N/A 22%
Isolated* 9% 0,02 6% 0,0003
in association 28% 28%
CH without ↑ NT 23% 0,2 26% 0,1
CH with ↑ NT 14% 15%
NT > 3 < 3,5 - N/A 0% 0,08
NT ≥ 3,5 - 12%
NT > 6 - 26%
Increased NF 26% (13/50) 0,03 26% (18/68) 0,02
NF > 6 22% 0,1 24% 0,1
NF > 15 60% 60%
Hydrops 35% (17/48) 0,0001 33% (20/60) 0,0004
1st trimester
hydrops
N/A N/A 14% 0,1
Persistent hydrops N/A 39%




30% (12/40) 0,01 41% (22/54) < 0,0001
Congenital heart
disease
23% (12/53) 0,1 25% (18/71) 0,03
cardiac defect 23% (11/48) 0,002 23% (15/64) < 0,0001
HCM 60% (6/10) 69% (9/13)
combined HCM
+ CD
100% (5/5) 100% (6/6)
Other associated findings
Polyhydramnios 50% (8/16) N/A 39% (14/36) < 0,0001
Renal anomaly 29% (4/14) N/A 30% (14/46) 0,01
Macrosomia 57% (4/7) N/A 50% (6/12) N/A
Mild
ventriculomegaly
- N/A 54% (7/13) N/A
Short long
bones




9% (13/143) 0,03 3% (2/61) 0,002
Two or more US
findings
18% (38/210) 18% (46/252)
N.B. Diagnostic yield of each major US finding was
compared with the global diagnostic yield for p-value’s
calculation
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Gene ontology enrichment analysis of congenital renal
agenesis-associated genes
S. Kalantari1,2,3, I. Filges1,2,3
1Medical Genetics, Institute of Medical Genetics and
Pathology, University Hospital Basel, Basel, Switzerland,
2Department of Clinical Research, University Hospital
Basel, Basel, Switzerland, 3University of Basel, Basel,
Switzerland
Introduction: Uni- or bilateral renal agenesis (RA) is a
commonly occurring major congenital anomaly impacting
fetal and neonatal outcomes. Although chromosomal
abnormalities, CNVs and pathogenic variants in many
genes have been associated to RA, the etiology is still
poorly understood. Our aim was to better understand the
biological pathways involved in RA and to identify inter-
acting candidate pathways useful for further gene
identification and molecular diagnosis in clinical care when
applying genome-wide sequencing.
Materials and Methods: We used Phenolyzer to obtain
all genes known as causative for syndromic and non-
syndromic uni- and bilateral RA. Using ClueGO gene
enrichment analysis we classified the relationship between
these genes and biological processes as defined by gene
ontology.
Results: We identified 289 genes described to be
involved in the pathogenesis of RA when mutated. We
obtained 69 groups of enriched biological processes. About
50% included pathways directly related to the development
of urogenital organ tissues (e.g. metanephros, nephric duct,
ureter). Furthermore, several ciliary, axis specification,
hindgut development and endocrine pathways are enriched,
which may relate to different clinical presentations of RA.
The results also support the hypothesis that RA is part of the
ciliopathy spectrum and developmentally related to dys-
plastic kidneys.
Conclusions: Our gene ontology analysis shows that
genes representing distinct biological pathways are sig-
nificantly enriched. They may relate to different clinical
presentations of RA, which will lead to an improved
delineation of candidate genes and molecular diagnosis of
this congenital anomaly in clinical practice.
S. Kalantari: None. I. Filges: None.
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Is mitochondrial DNA (mtDNA) copy number in human
cleavage-stage embryos a marker of embryonic quality
and development, or modified by the presence of a
mtDNA mutation?
J. Steffann1, K. Chatzovoulou1, N. Gigarel1, A. Mayeur2, F.
Jabot-Hanin3, S. Monnot1, L. Hesters2, N. Frydman2, J.
Bonnefont1
1Hopital Necker-Enfants Malades, Paris, France, 2Hopital
Antoine-Béclère, Clamart, France, 3Université de Paris,
Paris, France
Mitochondria play a critical role during the early stages of
human embryo development by supplying sufficient levels
of energy required for embryo survival. Because mtDNA
replication is silenced during early embryonic development,
the presence of a large number of mtDNA copies in the
mature oocyte is mandatory. In human, several studies on
blastocysts day-5 embryos have paradoxically evidenced a
positive correlation between high quantities of mtDNA
molecules and severe conditions, like aneuploidy, poor
embryo quality, and implantation failure. However, data
from day-3 embryos are much more limited and contra-
dictory, making this point a highly controversial one.
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We have quantified the mtDNA copy number (CN) in
residual DNA of 1 or 2 cells, sampled from day-3 embryos,
in a context of preimplantation genetic analysis for a non-
metabolic, non-mitochondrial DNA disorder (n = 165,
control group) and for a mtDNA mutation (n = 16, mito-
chondrial group). A great dispersion of the mtDNA CN was
found, among the different cells of a given embryo, and the
different embryos from a given patient. A maternal effect
regulating the mtDNA CN was observed, but remained of
unknown origin. In particular, no correlation was detected
between mtDNA CN and maternal age or ovarian reserve.
mtDNA CN did not correlate with embryonic quality and
ability of an embryo to implant and give a viable pregnancy.
Finally, the mtDNA CN was not influenced by the presence
of a mtDNA mutation. Based on these findings, mtDNA CN
at day 3 of development cannot be used to select the best
embryo to transfer.
J. Steffann: None. K. Chatzovoulou: None. N. Gigarel:
None. A. Mayeur: None. F. Jabot-Hanin: None. S.
Monnot: None. L. Hesters: None. N. Frydman: None. J.
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A FAST AND NON-INVASIVE METHOD TO
DETERMINE FETAL RHD GENE STATUS
B. Schreiner, E. Lindström, B. Vanherberghen, A. Hedrum
Devyser, Hägersten, Sweden
Background: Hemolytic disease of the fetus and newborn
(HDFN) is a serious complication of maternal and fetal
blood group incompatibility. This occurs when a Rhesus-D
negative woman, carrying a Rhesus-D positive fetus during
her first pregnancy, is alloimmunized against RhD antigen
and carries another Rhesus-positive fetus during a sub-
sequent pregnancy. Nowadays, HDFN is rare since anti-D
prophylaxis is provided to all RhD negative pregnant
women. However, 40% of these women carry a Rhesus-
negative fetus and are administered unnecessary treatment
including all risks connected to blood-based products.
Aims: We set out to develop a fast and reliable diagnostic
test assessing the fetal RHD gene status from maternal
blood at the end of the first pregnancy trimester to enable
targeted anti-D prophylaxis.
Methods: A real-time PCR-based assay was developed to
detect cell-free fetal DNA (cffDNA) in maternal blood. The
assay contains primer-probe combination specific for the
RHD gene and the GAPDH house-keeping gene as internal
control. CffDNA from clinical samples was automatically
extracted from 1mL of plasma.
Results: Devyser RHD exhibits high experiment repeat-
ability between different reagent lots. The analytical
sensitivity is down to DNA concentrations corresponding
to less than 7 gene copies per reaction with 95% probability.
Summary/conclusions: Devyser RHD provides a fast,
non-invasive procedure to assess the fetal RHD status in
Rhesus-D negative mothers. This product is validated
together with an automated DNA extraction process and
reaction set-up (QIASymphony AS/SP), enabling high-
throughput sample analysis with low-risk for sample mix-
up. Various kit sizes are available offering flexibility with
sample throughput.
B. Schreiner: A. Employment (full or part-time);
Significant; Devyser. E. Lindström: A. Employment (full
or part-time); Significant; Devyser. B. Vanherberghen: A.
Employment (full or part-time); Significant; Devyser. A.
Hedrum: A. Employment (full or part-time); Significant;
Devyser.
P01.110.B
Diagnosis of Rothmund Thomson Syndrome by whole
genome sequencing
Q. Zhou, J. Sun, T. Wang, Y. Xing, Z. Wan, X. Yang, Z. Liu,
W. Wang
Genomics Institute of Beijing, Shenzhen, China
Introduction: Rothmund-Thomson Syndrome (RTS) is a
rare disorder and has been described in all ethnicities, with
several identified pathogenic variants. Since there is fewer
than hundreds of individuals have been described, the
population prevalence is unknown. The genetic features and
follow-up data of individuals with RTS are limited.
Methods: We performed a whole genome sequencing
(WGS) using cord blood for an infant, who had RTS like
clinical features in infancy.
Results: The infant showed a developmental delay in
infancy, with a small size in both height and weight. The
erythema started appearing on her face at the age of three
months and then spread to the entire body. Besides, she had
neither eyelashes nor eyebrows, with sparse scalp hair.
After analyzing the WGS data, we found a heterozygous
nonsense mutation c.2752G>T (p.Glu918*) and a novel
frameshift-insertion c.1547_1548insC (p.Ala516fs) in the
gene RECQL4, which is a known pathogenic gene of RTS.
Both variants had potential effects on protein synthesis or
function. Further validation indicated these were compound
variants inheriting from parents.
Conclusions: Taking together with the clinical character-
istics and the identification of biallelic pathogenic variants
in a recessive manner, we report a diagnosed infant with
RTS. Our findings provide potential application of WGS for
newborn to clinical diagnosis. The follow-up study can help
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to further understand the clinical features and the genotype-
phenotype interactions of RTS.
Grant: The Shenzhen Municipal Government of China
(NO.JCYJ20170412152854656)
Q. Zhou: None. J. Sun: None. T. Wang: None. Y.
Xing: None. Z. Wan: None. X. Yang: None. Z. Liu:
None. W. Wang: None.
P01.111.C
Simpson-Golabi-Behmel syndrome familial case series
with an emphasis on prenatal diagnosis
N. Krasovskaja1,2, A. Matulevičienė1,2, K. Šiaurytė2,3, K.
Grigalionienė1,2, L. Ambrozaitytė1,2, A. Utkus2
1Vilnius University Hospital Santaros Klinikos, Vilnius,
Lithuania, 2Department of Human and Medical Genetics,
Institute of Biomedical Sciences, Faculty of Medicine,
Vilnius University, Vilnius, Lithuania, 3Faculty of Medicine,
Vilnius University, Vilnius, Lithuania
Introduction: Simpson-Golabi-Behmel syndrome (SGBS)
is a rare recessively inherited X-linked condition, with less
than 300 reported cases. Characteristic features of SGBS
include pre/postnatal overgrowth, distinctive craniofacial
features (macrocephaly, coarse face with macroglossia),
visceromegaly and increased risk of neoplasia. This condi-
tion is almost always diagnosed postnatally.
Materials and methods: A 23-y/o woman with unin-
formative anamnesis on the 21 weeks’ gestation was
referred due to abnormal fetal ultrasound findings (poly-
hydramnios, macrocephaly, corpus callosum agenesis,
abdominal visceromegaly and abnormal genitalia). The
results of fetal DNA qPCR and SNP-CGH tests from
amniotic fluid revealed no chromosomal abnormalities. The
precise evaluation of mother’s phenotype (tall stature,
coarse facial features, macroglossia) and fetal scan were
key to directly sequence GPC3 gene and make the correct
SGBS diagnosis prenatally.
Results: Sanger sequencing from amniotic fluid revealed
hemizygous pathogenic variant NM_004484.3:c.1159C>T,
(NP_004475.1:p.(Arg387Ter), rs122453121, CM073110)
in exon 4 of the GPC3 gene, which determines SGBS.
Mother was also found to be a carrier. Despite severe
polyhydramnios progression on 33 weeks’ gestation,
condition of the fetus was manageable and, pregnancy
was carried to 38th weeks. The newborn’s phenotype
presented with classical SGBS features.
Conclusions: An accurate evaluation of maternal pheno-
type and fetal scan are essential pathognomonic signs for
early suspicion of SGBS. Successful prenatal diagnosis
enables to make decisions on time for family and physicians
about the outcomes of pregnancy and delivery.
N. Krasovskaja: None. A. Matulevičienė: None. K.
Šiaurytė: None. K. Grigalionienė: None. L. Ambrozai-
tytė: None. A. Utkus: None.
P01.112.A
Prenatal diagnosis of skeletal dysplasias/anomalies: high
diagnostic yield using microarray and sequencing data
I. Mademont-Soler1, A. Maroto1, J. Meléndez2, A.
Cherino1, J. Perapoch1, N. Artigas1, B. Campos3, M.
Segura3, C. Pérez4, E. Lloveras4, J. Hernando1, X. Queralt1,
M. Obón1
1Hospital Universitari de Girona Dr. Josep Trueta, Salt,
Spain, 2Hospital Santa Caterina, Salt, Spain, 3Quantitative
Genomic Medicine Laboratories, Barcelona, Spain,
4Synlab, Barcelona, Spain
Introduction: Skeletal dysplasias (SDs) are severe con-
genital disorders, mostly of genetic origin. Etiology remains
unknown in ~50% of cases. Materials and Methods: Nine
pregnancies with ultrasound findings compatible with SDs
were recruited prospectively from 2017 to 2019. A diag-
nostic algorithm combining microarray, Sanger and Next-
Generation Sequencing was used.
Results: Definite diagnosis was achieved in 6 cases,
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Conclusions: A combination of molecular cytogenetics
and sequencing offers a high diagnostic yield (6/9),
facilitating genetic counselling and clinical management.
An individualized approach, multidisciplinary teams and
the contribution of new sequencing technologies to
diagnosis are recognized.
I. Mademont-Soler: None. A. Maroto: None. J.
Meléndez: None. A. Cherino: None. J. Perapoch: None.
N. Artigas: None. B. Campos: None. M. Segura: None.
C. Pérez: None. E. Lloveras: None. J. Hernando: None.
X. Queralt: None. M. Obón: None.
P01.114.C
Embryo haplotype phasing based on non-invasive
procedures
L. A. Alcaraz1, C. Pérez-Pelegrín1, S. González-Reig1, P.
Brígido1, P. Piqueras2, A. Martí2, F. Sánchez-Martín2, V.
Penacho1
1Bioarray, SL, Elche, Spain, 2Ginemed, Sevilla, Spain
Introduction: Preimplantation genetic testing (PGT)
represents a widely applied genetic procedure for many IVF
centers. Nowadays, for these purposes embryo material is
needed. The removal of three cells in a day 5 embryo,
represents an invasive procedure that could concern the
embryo viability and increase the cost of a PGT. In the past
few years there have been an increasing interest in the
possibility of obtaining reliable DNA in the spent culture
media (SCM) where the embryo is growing (1, 2).
Materials and Methods: For optimal PGT-M results, we
aim to compare embryo biopsy and SCM. After that, we
want to go further: discern whether the SCM is even a better
choice to diagnose an embryo in comparison with the
trophectoderm biopsy, comparing a complete embryo. All
based on next generation sequencing (NGS) with
PGDSeqTM (Journey Genomics S.L.U.) technology.
Results:We can confirm a high coincidence of SCM with
complete embryo and the embryo biopsy. Tis primary
results are promising, even if there are less polymorphisms
obtained from this kind of material, we were able to study
the haplotypes and the inheritance of the embryos.
Conclusions: A non-invasive perspective on the PGT
world is certainly to be the next generation of samples.
Bibliography:1. Huang, L. et al. Noninvasive preimplanta-
tion genetic testing for aneuploidy in spent medium may be
more reliable than trophectoderm biopsy. Proc. Natl. Acad.
Sci. 116, 14105-14112 (2019).2. Li, P. et al. Preimplanta-
tion Genetic Screening with Spent Culture Medium/
Blastocoel Fluid for in Vitro Fertilization. Sci. Rep. 8,
9275 (2018).
L.A. Alcaraz: None. C. Pérez-Pelegrín: None. S.
González-Reig: None. P. Brígido: None. P. Piqueras:
None. A. Martí: None. F. Sánchez-Martín: None. V.
Penacho: None.
P01.115.A
Sperm protamine mRNA ratio in relation to DNA
fragmentation and semen analysis
M. A. Ishchuk1,2, E. M. Komarova2, O. V. Malysheva2, I.
D. Mekina2, E. A. Lesik2, A. M. Gzgzyan2,1, V. S.
Baranov2,1, I. Y. Kogan2
1St. Petersburg State University, Saint-Petersburg, Russian
Federation, 2The Research Institute of Obstetrics, Gynecol-
ogy and Reproductology named after D.O.Ott, Saint-
Petersburg, Russian Federation
Introduction: Sperm contain a complex population of
RNA, and the utility of sperm RNA in fertility research are
currently being explored. During mammalian spermato-
genesis, the chromatin structure undergoes substantial
condensation. The key role in this process is played by
protamines 1 and 2 (PRM1, PRM2). Abnormal condensa-
tion could lead to DNA breaks, which is linked to preg-
nancy loss after assisted fertilization, disturbances in
embryo development and increased risk of abortions. The
aim of this study was to estimate the relations between
protamine mRNA ration and semen quality and further
DNA fragmentation. Finding sperm-quality markers would
help to understand the causes of male infertility and to
improve the male reproductive health.
Materials and Methods: Human ejaculates were
obtained from 33 patients and semen analyses were
assessed by WHO criteria (2010). We evaluated the sperm
DNA fragmentation measured by TUNEL assay. Patient’s
ejaculates were purified by density-gradient centrifugation,
sperm cells were lysed, mRNA extracted, reverse tran-
scribed and subjected to real-time qPCR using specific
primer pairs for protamine-1 and protamine-2.
Results: The sperm protamine mRNA ratio in normo-
zoospermic men (n = 19; 2,86 ± 0,67) differed significantly
from that of patozoospermic patients (n = 14; 3,43 ± 0,79;
p<0,05). A significant correlation was shown between
sperm DNA fragmentation and the PRM2/PRM1 mRNA
ratio (r=0,33; p <0,05). In the group of patients with an
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increased sperm DNA fragmentation (n = 14; 3,26 ± 0,19)
the PRM2/PRM1 ratio was significantly higher than in the
group of patients with normal rates (n = 19; 2,74 ± 0,18; p
< 0,05).
Conclusions: Abnormal sperm protamine ratio associated
with poor semen quality and DNA fragmentation.
M.A. Ishchuk: None. E.M. Komarova: None. O.V.
Malysheva: None. I.D. Mekina: None. E.A. Lesik: None.
A.M. Gzgzyan: None. V.S. Baranov: None. I.Y.
Kogan: None.
P01.116.B
Investigating PHF13 induced infertility through single
cell transcriptomics and non-vertebrate model
organisms
E. Bosch1, S. Lukassen2, A. Gregor1, A. B. Ekici1, C.
Zweier1, A. Winterpacht1
1Institute of Human Genetics, FAU Erlangen-Nürnberg,
Erlangen, Germany, 2Digital Health Center, Berlin Institute
of Health (BIH) and Charité, Berlin, Germany
Infertility is a common medical problem worldwide. Of all
infertility cases, approximately 40 - 50% are due to “male
factor” infertility, mostly caused by spermatogenic failure.
Despite extensive research, there is still limited knowledge
of the genetic causes and underlying molecular mechan-
isms. We previously showed that deficiency for the epige-
netic reader PHF13 in the mouse results in testis hypoplasia
due to a spermatogenic defect.
Here, we obtained single-cell RNA expression profiles
from Phf13−/− and Phf13+/- testis and compared them with
wild type data. The results revealed a loss of meiotic sex
chromosome inactivation (MSCI) in pachytene spermato-
cytes of PHF13 deficient mice. This is remarkable, since
canonical PHF13 is only expressed in spermatogonia. In
combination with ChIPseq data demonstrating an enrich-
ment of PHF13 binding sites on the X- and Y-chromosome,
we hypothesize that PHF13 mediates epigenetic changes on
the sex chromosomes in spermatogonia, rendering the
chromosomes competent for later inactivation.
PHF13 is evolutionarily conserved down to Bilateria
including sea urchin, acorn worm and several insects like
the flour beetle (Tribolium), but strikingly not in the
evolutionary “young” genus Drosophila. Consequently, we
ubiquitously overexpressed the Tribolium Phf13-homolog
in D. melanogaster and compared these lines with wild type
lines and lines overexpressing neuronal control genes.
Phf13-overexpressing strains but not the control strains
show a high grade of infertility in seemingly normal flies.
This strongly indicates a conserved and very specific
function of this protein in germ cell development, making
PHF13 an interesting infertility factor and a fundamental
player in germ cell differentiation.
E. Bosch: None. S. Lukassen: None. A. Gregor: None.
A.B. Ekici: None. C. Zweier: None. A.
Winterpacht: None.
P01.118.A
Telomere length in karyotypically normal and abnormal
chorion in progressing pregnancies and embryonic
losses
A. V. Tikhonov1, M. I. Krapivin1, A. V. Petrovskaia-
Kaminskaia1, A. A. Smirnova2, Y. M. Sagurova3, O. A.
Efimova1, A. A. Pendina1, O. G. Chiryaeva1, L. I. Petrova1,
V. S. Dudkina1, V. S. Baranov1,3
1D.O. Ott Research Institute of Obstetrics, Gynecology and
Reproductology, St. Petersburg, Russian Federation, 2St.
Petersburg State Pediatric Medical University, St. Peters-
burg, Russian Federation, 3St. Petersburg State University,
St. Petersburg, Russian Federation
Telomere length (TL) is considered to be an indicator of
biological age. Its correct regulation during pregnancy is
crucial for embryonic development. The possible contribu-
tion of TL to the developmental capacity of embryos with
abnormal karyotype remains unknown so far. Here, we
studied TL in karyotypically normal and abnormal chorion
in progressing pregnancies and embryonic losses. The
chorionic villus samples were obtained by chorion biopsy
from 15 patients with progressing first trimester pregnancy
referred to invasive prenatal diagnosis and by curettage
from 15 patients with missed abortion. The karyotypically
abnormal samples included trisomy 21 and trisomy 16 cases
in both progressing pregnancies (n = 7) and missed abor-
tion (n = 7). The telomeric regions were detected on direct
metaphase preparations by qFISH. Relative TLs were
measured by dividing telomeric by subtelomeric fluores-
cence intensity assessed in ImageJ1.49v. The results were
compared by the Mann-Whitney U-test. In progressing
pregnancies, the relative TL was higher in karyotypically
abnormal samples compared to karyotypically normal ones
(p < 0.0001). In missed abortions, we observed the same
tendency although the difference did not reach statistical
significance (p=0.4652). When comparing the relative TL
between the samples with normal karyotype in progressing
pregnancies and missed abortions, we revealed no differ-
ence (p=0.8890). However, the relative TL was higher in
the samples with abnormal karyotype in progressing preg-
nancies compared to those in missed abortions (p=0.0013).
Our results suggest that in the case of karyotype abnorm-
ality, longer telomeres in chorionic villi may contribute to
pregnancy success. Supported by RSF №19-75-00023.
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Y.M. Sagurova: None. O.A. Efimova: None. A.A.
Pendina: None. O.G. Chiryaeva: None. L.I. Petrova:
None. V.S. Dudkina: None. V.S. Baranov: None.
P01.120.C
Telomere length of maternal and paternal chromosomes
in human triploid zygotes
M. I. Krapivin1, A. A. Pendina1, O. A. Efimova1, I. D.
Mekina1, E. M. Komarova1, Y. M. Sagurova2, I. V.
Mayorova2, A. M. Gzgzyan1, I. Y. Kogan1, V. S. Baranov1,2
1D.O. Ott Research Institute of Obstetrics, Gynecology and
Reproductology, St. Petersburg, Russian Federation, 2Saint
Petersburg State University, St. Petersburg, Russian
Federation
Telomeres are complex structures of tandem DNA repeats
and proteins at chromosome ends. Telomere shortening due
to cell divisions, oxidative stress or genetic effects may
result in end-to-end chromosome joining, their degradation,
and cell death. In contrast to short telomeres in oocytes,
sperm telomeres become longer with age. Telomere length
(TL) correlates with embryo developmental potential
advocating the importance of TL analysis after fertilization.
The study was performed on metaphase chromosomes of 23
triploid human zygotes from 20 couples (women aged
32.04 ± 0.8; men aged 34.15 ± 1.2) referred for in vitro
fertilization. Paternal (sperm-derived) chromosomes were
identified immunocytochemically by weak DNA methyla-
tion and strong hydroxymethylation which contrasted them
with strongly methylated and poorly hydroxymethylated
maternal (oocyte-derived) chromosomes. After qFISH,
relative TL was measured by dividing telomeric by sub-
telomeric fluorescence assessed in ImageJ1.49v. The rela-
tive TL was significantly higher in the paternal compared to
the maternal chromosomes (Wilcoxon signed-rank test, р <
0.0001). Rare zygotes demonstrated the opposite pattern:
higher TL in the maternal chromosomes. However, they
seem to be the exception rather than the rule suggesting that
some cases of developmental arrest may be caused by
altered TL pattern. Neither in sperm- nor in oocyte-derived
chromosomes the relative TL correlated with paternal (r=-
0.058;р=0.736) or maternal age (r=0.155;р=0.44),
respectively. Thus, after fertilization, TL in paternal chro-
mosomes is “reprogrammed”. Being hypomethylated,
paternal chromosomes are prone to recombination and,
thus, to alternative lengthening of telomeres, which may be
part of developmental program and explains the absence of
correlation of TL in sperm-derived chromosomes with
paternal age. Supported by RSF№18-75-10046.
M.I. Krapivin: None. A.A. Pendina: None. O.A.
Efimova: None. I.D. Mekina: None. E.M. Komarova:
None. Y.M. Sagurova: None. I.V. Mayorova: None. A.M.
Gzgzyan: None. I.Y. Kogan: None. V.S. Baranov: None.
P01.121.A
Transcriptomics of placental tissue: identification of
potential biomarkers and biological pathways in the
great obstetrical syndromes
E. Trifonova1,2, A. Markov1, A. Zarubin1, T. Gabidulina2,
V. Stepanov1
1Research Institute of Medical Genetics, Tomsk National
Research Medical Center of the Russian Academy of
Sciences, Tomsk, Russian Federation, 2Siberian State
Medical University, Tomsk, Russian Federation
The great obstetrical syndromes (GOS) are common preg-
nancy complications that can have detrimental effects on
morbidity and mortality of the mother and fetus as well as
long-term health outcomes. Although they are distinct
conditions, they are often considered together as they share
a common etiology of inadequate placental perfusion. The
aim of the work was to search for new genetic markers of
GOS on the basis of integrative analysis of transcriptomic
data. Genome-wide expression profiling was performed on
placental tissue from preeclamptic and normal (n = 47)
pregnancies. Thirty original datasets from patients with
preterm birth, intrauterine growth restriction, preeclampsia
(n = 434) were downloaded from Gene Expression
Omnibus and were further integrated and analyzed with our
data. Subsequently, 5023 differentially expressed genes
(DEGs) between GOS patients and healthy women were
identified. We found that the transcriptional activity of 64
DEGs changes in at least two GOS diseases. Weighted gene
co-expression network analysis identified distinct gene
modules associated with preterm birth, intrauterine growth
restriction or preeclampsia. Using Gene Set Enrichment
Analysis we identified the significant role of disturbance of
intercellular interactions and regulation of proteins mod-
ification in placental tissue during the development of the
GOS. We applied upstream analysis approach implemented
in geneXplain platform and identified master regulators
(MECOM, CDC34, UBE2E1, UBE2D4, STAT3 and
UBE2R2) that are new therapeutic targets. These key genes
may be potential biomarkers of diagnosis, therapy and
prognosis for GOS. This work was supported by the Rus-
sian Foundation for Basic Research (grant No. 18-29-
13045, No. 18-44-700007).
E. Trifonova: None. A. Markov: None. A. Zarubin:
None. T. Gabidulina: None. V. Stepanov: None.
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The importance of trio WES integration into prenatal
diagnosis
C. Rodriguez-Solera1, M. Martinez-Garcia1, I. Diez1, I.
Sanchez-Navarro1, E. Barroso1, D. Rodriguez1, P. Maietta1,
G. Martin-Serrano1, S. Izquierdo2, M. Miramar2, A.
Rodriguez2, F. Diaz-Flores3, M. Zeleniuc4, L. Martorell5, J.
Bermejo6, C. Toledo7, S. Lopez8, M. Sanchez8, S. Alvarez1
1NIMGenetics S.L, Madrid, Spain, 2Hospital Universitario
Miguel Servet, Zaragoza, Spain, 3Hospital Universitario de
Canarias, Tenerife, Spain, 4Personal Genetics, Bucharest,
Romania, 5Hospital Sant Joan de Déu, Barcelona, Spain,
6Hospital General de Segovia, Segovia, Spain, 7Hospital
Virgen de la Salud, Toledo, Spain, 8Hospital Clínico de
Santiago, Santiago de Compostela, Spain
Background: Exome sequencing has proved to be a useful
diagnostic tool when fetal structural anomalies suggest a
genetic etiology, but other standard prenatal genetic tests
did not provide a diagnosis. We describe a single laboratory
experience with prenatal and fetal samples.
Material and Methods: This study includes 13 samples
with ultrasound images suggesting skeletal abnormalities or
rasopathies, among others. The samples origin were
amniotic fluid (69%) and fetal tissues (31%). In six cases
a whole exome sequencing with a trio analysis was
performed. The genomic libraries were generated using
SureSelectXT and sequenced on a Novaseq 6000. Data
alignment, calling and filtering was performed using an in-
house developed pipeline. Informed consent was obtained
from all participants.
Results: A molecular diagnosis was obtained on 1
amniotic fluid prenatal sample and on 1 fetal specimen
(15% global diagnostic yield). All positive cases were
obtained after trio analysis. Two pathogenic variants in the
ESCO2 gene associated with Roberts syndrome were
identified in the prenatal sample and one homozygous
variant in the ASPM gene, associated with a primary
microcephaly 5, was identified in fetal tissue. Both variants
were cosegregated with the disease. Ultrasound studies did
not suggest the candidate genes due to the insufficient and
nonspecific information about the prenatal clinical presenta-
tion of these syndromes.
Conclusion: This study highlights the importance of trio
WES integration into prenatal diagnosis. Compared to
ultrasound studies alone, prenatal molecular diagnoses led
to a refined recurrence risk estimation, altered medical
management and allows an informed reproductive planning
for families.
C. Rodriguez-Solera: None. M. Martinez-Garcia:
None. I. Diez: None. I. Sanchez-Navarro: None. E.
Barroso: None. D. Rodriguez: None. P. Maietta: None.
G. Martin-Serrano: None. S. Izquierdo: None. M.
Miramar: None. A. Rodriguez: None. F. Diaz-Flores:
None. M. Zeleniuc: None. L. Martorell: None. J.
Bermejo: None. C. Toledo: None. S. Lopez: None. M.
Sanchez: None. S. Alvarez: None.
P01.125.B
Pregnancy outcome after failure of emergency contra-
ception with ulipristal acetate - an observational study
M. Hoeltzenbein, J. K. Wagner, C. Schaefer, K. Dathe
Pharmakovigilanzzentrum Embryonaltoxikologie, Institut
für Klinische Pharmakologie und Toxikologie, Charité-
Universitätsmedizin Berlin, Berlin, Germany
Introduction: Ulipristal acetate (UPA) is a selective pro-
gesterone receptor modulator used for emergency contra-
ception (EC) after unprotected sexual intercourse. Data on
pregnancy outcome after failure of EC is very limited.
Material and Methods: Observational study of prospec-
tively ascertained pregnancies after UPA exposure for EC.
In addition, retrospectively reported pregnancy outcomes
were evaluated separately.
Results: Among 216 requests to the German Embryotox
institute related to EC with UPA, 95 concerned prospec-
tively ascertained pregnancies after failed EC. Follow-up
data on pregnancy outcome was obtained in 56 pregnancies:
7 spontaneous abortions, 12 terminations of pregnancy
(ETOP) and 37 live births. Major birth defects were not
reported. Only 34% of women had taken UPA during the
fertile window. Among the 4 retrospectively reported
pregnancies there was one child diagnosed with
Beckwith-Wiedemann-syndrome (BWS) due to hypo-
methylation of IC2.
Conclusions: We provide a preliminary basis for
reassuring women who wish to carry their pregnancy to
term after failed EC with UPA. However, due to the
retrospective case report of a child with BWS after maternal
UPA exposure possible epigenetic effects could not be
excluded and require further evaluation. As ovarian
stimulation alone (independent of artificial reproductive
techniques) was previously discussed as a predisposing
factor for disturbance of imprinting maintenance, UPA
might have influenced preimplantation development and
disturbed epigenetic processes.
This work was performed with financial support from the
German Federal Institute for Drugs and Medical Devices
(BfArM).
M. Hoeltzenbein: None. J.K. Wagner: None. C.
Schaefer: None. K. Dathe: None.
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Chromosomal microarray confirms a rare prenatal case
of WAGR syndrome
M. Shetty, P. Venkatesh, S. Menezes, S. Hegde
Manipal Hospital, Bangalore, India
Introduction: WAGR syndrome is a rare genetic disorder
with prevalence of 1 in 500,000 to 1 million. It affects many
body systems and is named for its main features: wilms
tumor, aniridia, genitourinary anomalies and range of
developmental delays. Children with WAGR syndrome
present with aniridia, genito-urinary defects in the new born
period and are at an increased risk for developing malig-
nancies, varying range of intellectual disability and obesity
in childhood. The syndrome is a contiguous gene deletion
syndrome involving chromosome 11p13 containing WT1
and PAX6 genes.
Materials and Methods: We report a case of 29-year-old
Asian (Indian ethnicity) primigravida with non-
consanguineous marriage. Her mid trimester anomaly scan
at 18 weeks gestation showed bilateral ventriculomegaly,
small cavum septum pellucidum and partial agenesis of
corpus callosum. Amniocentesis was performed for chro-
mosomal microarray analysis which was performed using
an Agilent 8x60K array. The cytogenomic microarray
analysis showed 4.9MB deletion in chromosome 11
(11p13-p12).
Discussion: The prenatal diagnosis of WAGR syndrome
is associated with borderline ventriculomegaly, absent
corpus callosum and absent cavum septum pellucidum. In
order to diagnose rare syndrome, microarray should be the
first choice of investigation in the presence of any structural
abnormality. This would help in understanding the prenatal
presentation, potential co-morbid condition, counseling and
accordingly decision making.
Conclusions: The clinical association of WAGR syn-
drome in postnatal period is well established but the
antenatal presentation is not well-understood and reported
twice in the literature earlier. Microarray study confirms
these rare non-classical prenatal manifestations of WAGR
syndrome.
M. Shetty: None. P. Venkatesh: None. S. Menezes:
None. S. Hegde: None.
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Whole Exome Sequencing in 53 fetuses with abnormal
ultrasound: 37% of diagnostic yield
D. Trost1, A. Boughalem1, P. Blanchet2, C. Cenni2, R.
Dard3, A. Benachi4, V. Ciorna-Monferrato5, R. Touraine6,
P. Kleinfinger1, L. Lohmann1, A. Luscan1, M. Valduga1, J.
Costa1
1Laboratoire Cerba, Saint Ouen l’Aumone, France,
2Hôpital Arnaud de Villeneuve, Montpellier, France,
3Hôpital Poissy, Poissy, France, 4Hôpital Antoine Béclère,
Clamart, France, 5Hôpital Metz-Thionville, Metz, France,
6Hôpital Nord, Saint Etienne, France
Introduction: Fetal structural abnormalities detected by
ultrasonography, have a range of genetic causes. Chromo-
somal aneuploidy and structural abnormalities are explored
by karyotype testing and chromosomal microarray (CGH).
The utility of prenatal whole exome sequencing (WES) is
discussed. Information on the interest of prenatal WES
remains limited.
Methods and results: In our cohort of 53 fetuses with
normal karyotype and CGH, Trio WES was performed. All
fetuses had ultrasound abnormalities of poor prognosis.
Most fetuses (26) were analyzed after medical termination
of pregnancy, 24 analyzes were performed on ongoing
pregnancies and 3 analyzes after intrauterine fetal demise.
Pathogenic or likely pathogenic variants were found in 20
cases resulting in a diagnostic yield of 37%. Of these, 55%
(11) were autosomal dominant with de novo variants, 45%
of the diagnoses followed an autosomal recessive inheri-
tance pattern (5 homozygous variants, 4 compound
heterozygous variants). In urgent cases turn-around-time
was 2 weeks. Reporting results for an antenatal Trio WES
varies between 2-4 weeks.
Conclusions: Whole exome sequencing identified a
genetic cause for the fetal anomalies in 20 of the 53
(37%) cases analyzed. This made it possible to carry out
genetic counseling for families and to offer targeted prenatal
diagnosis for recessive diseases in case of a new pregnancy.
D. Trost: None. A. Boughalem: None. P. Blanchet:
None. C. Cenni: None. R. Dard: None. A. Benachi: None.
V. Ciorna-Monferrato: None. R. Touraine: None. P.
Kleinfinger: None. L. Lohmann: None. A. Luscan: None.
M. Valduga: None. J. Costa: None.
P02 Sensory Disorders (Eye, Ear, Pain)
P02.01.C
Disruption of PAX6 translation by 5′ UTR variants
causes Congenital aniridia
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A. Filatova, T. Vasilyeva, A. Marakhonov, R. Zinchenko, M.
Skoblov
Research Centre for Medical Genetics, Moscow, Russian
Federation
Introduction: Congenital aniridia (AN) is a rare autosomal
dominant panocular disorder caused by mutations in the
PAX6 gene. Previously, we performed a molecular genetic
study of a large cohort of Russian patients with AN and
found six PAX6 nucleotide variants in 5ʹ-UTR. It is known
that 5′-UTR variants could influence the translation effi-
ciency and cause some diseases, but for AN such a
mechanism has not been previously shown. Thus, to
investigate the pathogenicity of 5′-UTR PAX6 variants the
functional studies are required.
Materials and Methods: To study 5ʹ-UTR variants we
generated luciferase constructs with full-length PAX6 5ʹ-UTR
(wt and mutants). The translation efficiency was measured by
luciferase dual-assay, mRNA structure and expression level
were determined by RT-PCR and qPCR respectively.
Results: Six patient-derived 5ʹ-UTR-variants were found to
lead to a significant decrease in the translation efficiency,
while mRNA expression level was not significantly reduced.
Three of these variants also affect splicing. Further bioinfor-
matics analysis allows us to suggest the mechanism of 5ʹ-UTR
variants pathogenicity through disruption of an upstream ORF
which possibly exists in PAX6 5ʹ-UTR. To validate this
hypothesis, we performed additional mutagenesis experiments
and confirmed the essential role of uORF in the molecular
pathogenesis of the disease. Moreover, we showed that this
uORF normally affects the main protein translation.
Conclusions: We have identified uORF in 5′-UTR of the
PAX6 gene and found that mutations that disrupt this uORF
cause the congenital aniridia. In addition, we hypothesized
that this uORF may participate in the normal regulation of
PAX6 expression.
A. Filatova: None. T. Vasilyeva: None. A. Marakho-
nov: None. R. Zinchenko: None. M. Skoblov: None.
P02.02.A
Evaluating diagnostic challenges with ABCA4-related
retinal disease - experience with a 7500 IRD patient
cohort sent for genetic diagnostics
J. Känsäkoski1, K. Kämpjärvi1, S. Tuupanen1, K. Wells1, L.
Sarantaus1, P. von Nandelstadh1, K. Merkkiniemi1,
H. Västinsalo1, E. Mårtensson1, R. Perez Carro1, E.
Sankila2, J. W. Koskenvuo1, S. Myllykangas1, T. Alastalo1
1Blueprint Genetics, Espoo, Finland, 2Helsinki University
Eye Hospital, Helsinki, Finland
Introduction: ABCA4 variants cause autosomal recessive
Stargardt disease (STGD1), the most prevalent hereditary
macular disease. Major challenges in STGD1 molecular
diagnostics include (i) non-coding variants typically not
targeted by available genetic tests (ii) copy number variants
(CNV) missed by standard testing, and (iii) interpretation
challenges with common hypomorphic variants. We eval-
uated the significance of challenging ABCA4 variants and
their contribution to STGD1 diagnostic yield in a cohort of
inherited retinal disease (IRD) patients.
Materials and Methods: We included 7500 IRD patients
tested at a CLIA laboratory between 2017 and 2019.
Sequencing analysis, including established non-coding
ABCA4 variants and high resolution CNV detection, was
done by using in-house developed and validated NGS
platform.
Results: Two disease-causing ABCA4 variants were
identified in 663 patients, of which 20 (20/663; 3%) had
an established non-coding variant and 11 (11/663; 1.5%) a
CNV. In 192 patients with clinically diagnosed ABCA4-
related disease, only one disease-causing variant was
identified. Among those, the hypomorphic allele ABCA4
c.5603A>T, p.(Asn1868Ile) was identified in 109 patients
(109/192: 57%), with a significantly increased allele
frequency (126/384=0.328) compared to controls in
gnomAD (AF 11928/282712=0.042) (OR: 11.087, 95%
CI: 8.953-13.73, p < 0.001). The median age at genetic
testing among the 109 patients was 56 years, which was
significantly higher compared to 37 years among the 663
patients with two disease-causing variants.
Conclusions: Non-coding variants and CNVs contribute
significantly to diagnostic yield in ABCA4-related disease.
Our large dataset supports the important role of the
hypomorphic allele ABCA4 c.5603A>T, p.(Asn1868Ile) in
diagnostics of late-onset STGD1.
J. Känsäkoski: A. Employment (full or part-time);
Significant; Blueprint Genetics. K. Kämpjärvi: A.
Employment (full or part-time); Significant; Blueprint
Genetics. S. Tuupanen: A. Employment (full or part-time);
Significant; Blueprint Genetics. K. Wells: A. Employment
(full or part-time); Significant; Blueprint Genetics. L.
Sarantaus: A. Employment (full or part-time); Significant;
Blueprint Genetics. P. von Nandelstadh: A. Employment
(full or part-time); Significant; Blueprint Genetics. K.
Merkkiniemi: A. Employment (full or part-time); Sig-
nificant; Blueprint Genetics. H. Västinsalo: A. Employ-
ment (full or part-time); Significant; Blueprint Genetics.
E. Mårtensson: A. Employment (full or part-time);
Significant; Blueprint Genetics. R. Perez Carro:
A. Employment (full or part-time); Significant; Blueprint
Genetics. E. Sankila: A. Employment (full or part-time);
Modest; Blueprint Genetics. J.W. Koskenvuo: A. Employ-
ment (full or part-time); Significant; Blueprint Genetics.
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P02.03.B
A novel splicing variant confirms COL11A1 as a cause
of autosomal dominant non-syndromic hearing loss in
the DFNA37 locus
B. Vona1, A. Tropitzsch1, A. Rad1, F. Schneider1, M.
Müller1, T. Schade-Mann1, S. Biskup2, H. Löwenheim1
1Dept of Otolaryngology—Head & Neck Surgery, Tuebin-
gen Hearing Research Centre, University of Tuebingen,
Tuebingen, Germany, 2CeGaT GmbH and Praxis für
Humangenetik Tuebingen, Tuebingen, Germany
Introduction: Hereditary hearing loss (HL) is a clinically
and genetically heterogeneous disorder. Many genes exhi-
biting either non-syndromic or syndromic HL have also
been identified as causing both, owing to extensive phe-
notypic manifestations in the form of pleiotropy. The gene
COL11A1 has long been associated with autosomal domi-
nant Marshall syndrome and Stickler syndrome type II, as
well as autosomal recessive fibrochondrogenesis. Each of
these syndromes have overlapping phenotypes including
skeletal abnormalities, dysmorphic features, variable cleft
palate, ocular and auditory phenotypes that can include
mild-to-moderate HL, and outer ear malformations.
Recently, COL11A1 has been associated with autosomal
dominant non-syndromic HL (DFNA37) through the
genetic analysis of a large European-American family pre-
senting a novel splice-site altering variant.
Materials and Methods: A proband from a four
generation family with non-syndromic HL was ascertained.
DNA from the proband was subjected to a custom-designed
high-throughput sequencing panel consisting of 160 HL-
associated genes. An in vitro splice assay was performed to
study the RNA-level effect of the variant.
Results: The patient was diagnosed with moderate
sensorineural HL. Additional syndromic features were
absent. A heterozygous variant (c.4338+2T>C, p.?,
NM_080629.2) was uncovered in COL11A1 that is
predicted to abolish the 5′ splice site in exon 58 out of
the 68 exons comprising COL11A1. Furthermore, this novel
variant affects a highly conserved nucleotide in the alpha
chain domain. In vitro splice testing confirmed abnormal
splicing.
Conclusions: We report on the second DFNA37-
associated splice-altering variant, providing confirmatory
evidence of COL11A1 as a bona fide autosomal dominant
non-syndromic HL gene.
B. Vona: None. A. Tropitzsch: None. A. Rad: None.
F. Schneider: None. M. Müller: None. T. Schade-Mann:
None. S. Biskup: None. H. Löwenheim: None.
P02.05.A
Non-Mendelian inheritance in Bardet-Biedl syndrome:
triallelism
I. Perea-Romero1,2, F. Blanco-Kelly1,2, I. Lorda-Sanchez1,
I. Sanchez-Navarro3, O. Zurita1,2, R. Riveiro-Alvarez1,2, M.
Trujillo-Tiebas1,2, A. Avila-Fernandez1,2, M. Corton1,2, D.
Valverde4,5, C. Ayuso1,2
1Department of Genetics, Instituto de Investigación Sani-
taria – Fundación Jiménez Díaz University Hospital –
Universidad Autónoma de Madrid (IIS-FJD, UAM),
Madrid, Spain, 2Center for Biomedical Network Research
on Rare Diseases (CIBERER), ISCIII, Madrid, Spain,
3Medical Department, NIMGenetics, Madrid, Spain,
4Department of Biochemistry, Genetics and Immunology,
Biology Faculty, Vigo University, Pontevedra, Spain, 5Cen-
ter for Biomedical Network Research on Rare Diseases
(CIBERER), ISCIII, Pontevedra, Spain
Introduction: Bardet-Biedl syndrome (BBS) is a ciliopathy
characterized by retinal dystrophy, obesity, polydactyly,
cognitive impairment, renal failure and hypogonadism.
Typically, it has an autosomal recessive mode of inheri-
tance, but this heterogeneous disease has variable expres-
sivity between and within families, which might be partially
explained by oligogenic inheritance, like triallelism.
Materials and methods: A total of 61 families (78
affected cases) with an “a priori” diagnosis of BBS or BBS-
like were studied using different molecular approaches
(commercial genotyping microarrays, Sanger sequencing of
specific genes and/or NGS technologies).
Results: The characterization rate in our cohort was 79%
(48/61 families). In 5 of the families, we found a possible
triallelic inheritance, involving 6 out of the 7 affected cases.
Three families carried biallelic BBS1 variants together with
one allele in MKKS, one family with biallelic MKKS
variants and one allele in BBS5 and one additional family
carried biallelic C8orf37 variants and one allele in WDPCP.
The MKKS (c.724G>T; p.Ala242Ser) variant was found to
be part in 3 families accompanying different biallelic
variants in BBS1. In one family, the triallelic case showed a
more severe phenotype than the biallelic affected sibling.
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However, the phenotypic modifier effect of the triallelism
could not be stablished in 4 of the families, as they were
either unique cases or both affected showed triallelism.
Conclusions: Our study presents triallelism as an option
in BBS diagnosis, being important to consider it in genetic
counselling.
Funding: FIS (PI16/00425 and PI19/00321), University
Chair UAM-IIS-FJD Genomic Medicine and FEDER
(European Regional Development Fund)
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P02.07.C
Molecular genetic cause of non-syndromic congenital
and juvenile cataracts in the Czech population
J. Moravikova1, L. Dudakova1, M. Schwarz2, L. Hlavata1,
F. Malinka1,3, P. Liskova1,4
1Department of Paediatrics and Adolescent Medicine, First
Faculty of Medicine, Charles University and General
University Hospital in Prague, Prague, Czech Republic,
2Department of Biology and Medical Genetics, Second
Faculty of Medicine, Charles University and University
Hospital Motol, Prague, Czech Republic, 3Department of
Computer Science, Czech Technical University in Prague,
Prague, Czech Republic, 4Department of Ophthalmology,
First Faculty of Medicine, Charles University and General
University Hospital in Prague, Prague, Czech Republic
Introduction: Congenital and juvenile cataracts are phe-
notypically and genetically very heterogeneous group. In
this study, we aimed to investigate the molecular genetic
cause in Czech patients with bilateral congenital or juvenile
cataracts not associated with other ocular or systemic clin-
ical findings.
Materials and Methods: Whole exome sequencing was
performed in 10 probands of Czech origin. Variants with
minor allele frequency less than 0.005 as per GnomAD v.2
were filtered and those located in genes known to be
associated with cataract development as per Cat-Map
database were given a priority for further evaluation.
Conventional sequencing was used to follow segregation
of the presumably pathogenic variants in available first
degree relatives.
Results: Out of the 10 probands 6 had a family history of
congenital or infantile cataracts. In total 5 variants classified
as pathogenic or likely pathogenic as per American College
of Medical Genetics and Genomics guidelines were
identified. Two variants were novel; c.299T>A in GJA3
(NM_021954) and c.2665G>A in EPHA2
(NM_001329090). No pathogenic variants were found in
5 probands.
Conclusions: Herein we report for the first time
mutational spectrum of non-syndromic cataracts in Czech
patient population. The failure to identify disease-causing
variants in half of the analysed cases suggests, that either
the underlying mechanisms are not of genetic origin and/or
that the pathogenic changes are not located in coding
regions of the genome. Only two probands with family
history of cataracts remained unsolved. Alternatively, larger
structural variants or rearrangement could be also
implicated.
Supported by AZV 17-30500A.
J. Moravikova: None. L. Dudakova: None. M.
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Insights into the retinal function of ciliopathy proteins
gained through zebrafish models
M. Masek, R. Bachmann-Gagescu
University of Zurich- Medical Genetics, Zürich, Switzer-
land
Ciliopathies are disorders caused by dysfunction of primary
cilia, ubiquitous organelles involved in signal transduction.
In retinal photoreceptors (PRs), light sensation occurs in the
outer segments (OSs), which represent highly specialized
ciliary compartments. Consequently, retinal disease is a
common manifestation in ciliopathy patients. Our efforts to
elucidate the molecular functions of ciliopathy proteins rely
on zebrafish mutants in genes associated with Joubert syn-
drome, an iconic ciliopathy associated with retinal disease
in 25% of patients. We focus on genes that encode proteins
participating in distinct ciliary complexes: Cc2d2a at the
transition zone, representing the gate to the cilium, or Tal-
pid3/KIAA0586 at the basal body (BB), anchoring the
cilium in the cell. While both mutants display decreased
visual function, we identify distinct ultra-structural pheno-
types indicating specific roles for each protein in primary
cilium function. We find that Cc2d2a organizes the vesicle
fusion machinery at the periciliary margin and provides a
docking point for incoming vesicles through a chain of
interactions linking CC2D2A to NINL-MICAL3-RAB8. In
contrast, Talpid3 is involved in BB docking and ciliogen-
esis upstream of Rab8a activation. Retina-specific tran-
scriptomics identifies both shared and distinct effects on
gene transcription: while transcription of phototransduction
genes is decreased in both mutants, likely as a secondary
effect, we observe downregulation of the BBSome, a multi-
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protein complex associated with the ciliopathy Bardet-Biedl
syndrome, only in talpid3 mutants, while Nek8 is upregu-
lated only in cc2d2a mutants. In conclusion, our findings
demonstrate how mutations in genes causing the same
human disorder result in similar phenotypes through distinct
mechanisms.
M. Masek: None. R. Bachmann-Gagescu: None.
P02.09.B
Analysis of copy number variants in a large cohort of
individuals with anophthalmia, microphthalmia and
coloboma
F. Ceroni1, D. A. Bax1, R. J. Holt1, Y. Kesim1, A. Cole2, C.
Ogilvie3, D. Bunyan4,5, L. Cooper-Charles2, D. McMullan2,
M. Griffiths2, N. K. Ragge1,2
1Faculty of Health and Life Sciences, Oxford Brookes
University, Oxford, United Kingdom, 2West Midlands
Regional Genetics Service, Birmingham Women’s and
Children’s NHS Foundation Trust, Birmingham, United
Kingdom, 3Guy’s and St Thomas’ NHS Foundation Trust,
London, United Kingdom, 4Wessex Regional Genetics
Laboratory, Salisbury District Hospital, Salisbury, United
Kingdom, 5Faculty of Medicine, University of Southampton,
Southampton, United Kingdom
Introduction: Anophthalmia, microphthalmia and colo-
boma (AMC) are a genetically heterogenous collection of
developmental eye disorders, with variants in >100 genes
implicated. However, only 25-60% of patients receive
genetic diagnoses. Structural variants are an important
source of genetic variation, and have led to the identification
of numerous eye development genes, including SOX2 and
OTX2. However, few studies systematically address their
contribution to AMC. Here, we investigate a large cohort of
AMC families for known and novel copy number variants
(CNVs).
Materials and methods: A cohort of 320 unrelated
probands was screened using either diagnostic genome-
wide aCGH platforms (n = 156), including the customised
OGT CytoSure 4x180K eye array, or the Illumina Infinium
Global Screening Array (n = 164). SNP data were analysed
using the algorithms QuantiSNP and PennCNV. Variants of
interest were validated using qPCR and long-range PCR.
Results: Our analysis identified multiple variants of
interest, including likely pathogenic CNVs affecting known
AMC genes and rare CNVs highlighting new candidates.
We describe a novel homozygous 113kb deletion 19kb
upstream of MAB21L2, a developmental gene involved in
eye morphogenesis. This deletion removes multiple con-
served cis-regulatory elements. We also identified deletions
in regions with recurrent CNVs (1q21.1, 6q16, 10q11,
16p11.2, 22q11.2).
Conclusions: Our study supports the importance of CNV
screening in routine diagnostic testing. It also highlights
how CNVs affecting noncoding elements can provide
insights into the role of regulatory regions of eye
development genes in AMC. Further investigation of such
variants will improve the genetic diagnostic yield and our
understanding of the aetiology of these conditions.
F. Ceroni: None. D.A. Bax: None. R.J. Holt: None. Y.
Kesim: None. A. Cole: None. C. Ogilvie: None. D.
Bunyan: None. L. Cooper-Charles: None. D. McMullan:
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P02.10.C
Cataract and retinal dystrophy inVps13bΔEx3/ΔEx3mice.
V. R. M. Lhussiez1, Q. Cesar2, E. Dubus2,3, M. Simonutti2,
E. Lizé1, S. Nguyen1, A. Geissler3, A. Bouchot3, S. Picaud2,
E. F. Nandrot2, N. Acar4, L. Faivre1,5,6, C. Thauvin1,5,7, L.
Duplomb1,5, R. Da Costa1,5
1INSERM, UMR1231, Equipe GAD, Université de Bour-
gogne Franche Comté, Dijon, France, 2Sorbonne Univer-
sité, INSERM, CNRS, Institut de la Vision, Paris, France,
3Plateforme d’Imagerie Cellulaire CellImaP/DimaCell,
Inserm LNC UMR1231, Dijon, France, 4Centre des
Sciences du Goût et de l’Alimentation, AgroSup Dijon,
CNRS, INRAE, Université Bourgogne Franche-Comté,
Dijon, France, 5FHU TRANSLAD, CHU Dijon, Dijon,
France, 6Centre de Référence Anomalies du Développement
et Syndromes Malformatifs, CHU Dijon, Dijon, France,
7Centre de Référence Déficiences Intellectuelles de Causes
Rares, CHU Dijon, Dijon, France
Cohen syndrome (CS) is a rare genetic disorder due to
variation in the VPS13B gene. It is characterized by a wide
variety of clinical features that includes a typical facial
dysmorphism, hypotonia, neutropenia, microcephaly, intel-
lectual disability and severe visual impairments. In their
early childhood, CS patients already suffer from myopia
and a retinal dystrophy that affects both peripheral and
central vision. In addition, long-term outcome studies
showed that cataract reaches a high prevalence in adults
with CS in their forties. To understand how VPS13B var-
iants lead to these visual impairments and have the possi-
bility to assess therapeutic approaches, we generated the
Vps13bΔEx3/ΔEx3 mouse model. Cataract was almost sys-
tematic in 2-month-old animals. Eye fundi appeared normal
until cataract development, but OCT, ERG and histological
data suggest that rod homeostasis may be affected in the
few Vps13bΔEx3/ΔEx3 mice without cataract after 5 months of
age. Immunostaining of the lens revealed that cataract
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formation was associated with the appearance of large
vacuoles in the cortical area, epithelial-mesenchymal tran-
sition and fibrosis. In later stages, cataracts became hyper-
mature, lens capsules ruptured, and sclerotic nuclear parts
dissociated. Altogether, our results show that Vps13b has a
function in lens homeostasis in mice and that the
Vps13bΔEx3/ΔEx3 mouse line is a useful model to study the
pathomechanism leading to CS-related cataract. This work
was supported with funds from the JED Fondation and from
the Fondation Maladies Rares.
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P02.12.B
Dominant cone rod dystrophy (CORD7) previously
assigned to mutation of RIMS1, is fully explained by
co-inheritance of a dominant allele of PROM1
G. Arno1,2, E. Schiff2, G. Wright2, N. Waseem1, Genomics
England Research Consortium, M. Michaelides1,2, A. T.
Moore1,2,3, A. R. Webster1,2
1UCL Institute of Ophthalmology, London, United King-
dom, 2Moorfields Eye Hospital, London, United Kingdom,
3University of California, San Francisco, San Francisco,
CA, United States
A single missense variant (p.Arg820His) in RIMS1 has been
associated with autosomal dominant cone rod dystrophy 7
(CORD-7) and enhanced cognition. This was discovered in
2003 following linkage (LOD 3.61) to a 7cM region on
chromosome 6q, in a four generation British family in 1998.
The RIMS1 gene is often included in diagnostic panels for
retinal dystrophy. However, despite this, no further families
with CORD7 have been reported.
Widespread availability of massively parallel sequencing
has enabled detection of genomic variation at a scale not
possible in the early 2000s. Access to vast datasets in
gnomAD and Genomics England 100k genomes project
(GE100KGP) now enables better understanding of the
validity of previously accepted genetic associations.
Interrogation of the gnomAD datasets reveal 10 carriers
of RIMS1 p.Arg820His (Non Finnish European allele
frequency 0.0001). This would be unusual given the
severity of visual impairment in adulthood and absence of
the variant in further patient cohorts. Four members of the
original CORD7 family were recruited to the GE100KGP,
where WGS showed the two affected members to be
heterozygous for a well characterised dominant allele (p.
Arg373Cys) of PROM1 located on chromosome 4p. All
affected individuals subsequently were heterozygotes for
this variant. Cytogenetic analysis excluded a balanced
translocation that might explain co-segregation of a region
on 6q and 4p.
This finding suggests the rare occurrence of an alpha error
despite robust linkage analysis in a large family. So far there
is no evidence that perturbation of RIMS1 affects the retina
in humans.
G. Arno: None. E. Schiff: None. G. Wright: None. N.
Waseem: None. M. Michaelides: None. A.T. Moore:
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P02.14.A
CRB1-related retinopathy superimposed on a S-adeno-
sylhomocysteine hydrolase deficiency phenotype.
M. Di Scipio1, M. K. Grudzinska Pechhacker1,2, A. Vig1, A.
Anupreet1, E. Tavares1, A. Vincent1,2,3, E. Heon1,2,3
1Genetics and Genome Biology, The Hopsital for Sick
Children, Toronto, ON, Canada, 2Department of Ophthal-
mology and Vision Sciences, University of Toronto,
Toronto, ON, Canada, 3Department of Ophthalmology
and Vision Sciences, The Hospital for Sick Children,
Toronto, ON, Canada
Background: S-adenosylhomocysteine deficiency is a rare
metabolic disorder for which no eye phenotype has been
documented. CRB1 gene is known to cause wide spectrum
of autosomal recessive retinal diseases such as Leber’s
congenital amaurosis, early onset cone-rod dystrophy, reti-
nitis pigmentosa, isolated maculopathy and familial foveal
retinoschisis; or autosomal dominant pigmented paravenous
chorioretinal atrophy.
Materials and Methods: The present report describes a
non-consanguineous family, where two children were
affected with S-adenosylhomocysteine deficiency and one
of them presented with reduced vision due to maculopathy.
Comprehensive eye examination was performed in avail-
able family members together with color vision test,
contrast sensitivity, visual fields, fundus images, OCT, full
field electroretinogram, pattern electroretinogram and visual
evoked potentials. Genetic testing included WES, retinal
dystrophy panel and segregation analysis.
Results: Clinical whole exome sequencing revealed
homozygous missense mutations in AHCY gene
(c.148G>A, p.Ala50Thr) as a cause of S-adenosylhomo-
cysteine deficiency. Because of a maculopathy in the
proband, retinal dystrophy gene panel sequencing revealed
two heterozygous missense mutations in CRB1 gene
(c.1831T>C, p.Ser611Pro) and (c.3955T>C, p.
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Phe1319Leu) in the proband (III-1) and her mother.
Mutations segregated with disease phenotype in family
members.
Conclusions: Establishing an ocular genetic diagnosis
may be complicated by the co-existence of a rare systemic
genetic disease with previously unknown eye involvement.
Extensive phenotyping and genotyping of available family
members, and genotype-phenotype correlations helps to
establish a diagnosis.
Grant References: Henry Brent Research Chair; Cana-
dian Foundation Fighting Blindness; Career Development
Award (Foundation fighting Blindness, USA).
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Fundus albipunctatus in a pedigree with autosomal-
dominant transmission of G116R mutation in RLBP1
K. Mihova1, K. Kamenarova1, S. Cherninkova2, I. Dimova1,
F. Shakola1, V. Mitev1, R. Kaneva1
1Department of Medical Chemistry and Biochemistry,
Molecular Medicine Center, Medical University of Sofia,
Sofia, Bulgaria, 2Department of Neurology, University
Hospital Alexandrovska, Medical University of Sofia, Sofia,
Bulgaria
Introduction: Fundus albipunctatus (FA) is a rare form of
congenital stationary night blindness in which white or
yellow dots can be seen scattered through the fundus.
Individuals complain of night blindness early in childhood
without progression. By next-generation sequencing of
clinical exome including all inherited retinal degeneration
causative genes, we aimed to identify the disease-causing
mutation in a patient with clinical signs of FA.
Materials and Methods: Using Illumina® platform and
TruSight One, we identified heterozygous RLBP1-mutation
in a young patient, which results in phenotype consistent
with FA.
Results: A 5-years-old patient presenting ophthalmo-
scopic phenotype including delayed dark adaptation,
aggregation of yellowish-white lesions of various sizes in
the retina, and slight vascular abnormalities, was screened
for mutations in all known genes previously associated with
inherited retinal degeneration. We identified a heterozygous
mutation, c.346G>C (p.G116R), in the gene for cellular
retinaldehyde-binding protein 1 (RLBP1), already described
in a pedigree affected by autosomal-recessive FA. All other
genetic variants detected in the patient’s DNA were
excluded after applying commonly used filtering criteria.
Pedigree analysis showed the presence of p.G116R
mutation in the patient’s mother who was a heterozygous
carrier. Мother’s ophthalmological examination subse-
quently confirmed pre-existing stationary night blindness,
prolonged dark adaptation with preserved visual acuity
strongly suggesting a phenotype consistent with FA.
Conclusions: Most reported pedigrees are consistent with
a recessive pattern of Mendelian inheritance of FA,
although autosomal-dominant inheritance has been also
reported. Our results suggest that mutation RLBP1-p.
G116R may be considered as dominant-acting in pedigrees
with autosomal-dominant FA.
Acknowledgements: D01-285; КП-06-Н33/12.
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The G-EAR Consortium study: new candidate genes for
normal hearing function (NHF) and age-related hearing
loss (ARHL) in a large and deeply phenotyped cohort.
M. Brumat1, A. Morgan1,2, A. P. Nagtegaal3, B. C.
Oosterloo3, S. Seshadri4,5, N. L. Heard-Costa4,6, G. Van
Camp7, E. Fransen8, P. Gasparini1,2, G. Girotto1,2
1Department of Medicine, Surgery and Health Sciences,
University of Trieste, Trieste, Italy, 2Institute for Maternal
and Child Health – IRCCS Burlo Garofolo, Trieste, Italy,
3Department of Otorhinolaryngology, Erasmus Medical
Center, Rotterdam, Netherlands, 4Framingham Heart
Study, Framingham, MA, United States, 5Glenn Biggs
Institute for Alzheimer’s and Neurodegenerative Diseases,
University of Texas Health Sciences Center, San Antonio,
TX, United States, 6Department of Neurology, Boston
University School of Medicine, Boston, MA, United States,
7Center of Medical Genetics, University of Antwerp and
Antwerp University Hospital, Antwerp, Belgium, 8Depart-
ment of Biomedical Sciences, University of Antwerp,
Antwerp, Belgium
Understanding the genetic basis of hearing traits and dis-
eases (e.g. NHF and ARHL) is central to the development
of precision medicine for the hearing impaired; to pursue
this aim, fully audiometrically characterised cohorts are
fundamental.
Through the international G-EAR Consortium, we united
data from ten such cohorts from Europe, USA, Caucasus
and Central Asia (overall >9000 individuals) and performed
a GWAS meta-analysis on NHF and ARHL, analysing in
the former case single hearing thresholds or their average
value across specific frequencies, and in the latter a case-
control phenotype (PMID:29725052). Analyses used linear
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mixed model/logistic regression; meta-analysis was per-
formed with METAL.
Suggestive association signals were detected on chromo-
somes 3, 8, 11, 16 and 18. In particular, three genes -
CADM2, CALB1 and LRRC4C - result to be potentially
associated with NHF and two more - CDH13 and CTIF -
with ARHL.
CADM2 encodes a protein of the nectin-like family,
members of which are fundamental for the development of
the inner ear; CALB1 encodes a calcium-binding protein
that regulates the development of murine cochlear hair cells;
LRRC4C encodes a transmembrane protein abundantly
expressed in mouse inner ear. Finally, CDH13 and CTIF
have been associated with NHF in previous studies,
suggesting their possible role also in ARHL.
Replication is in progress in an independent cohort of
~1500 individuals, fully phenotyped; updated results will be
presented. These findings provide a strong contribution to
our understanding of the genetic bases of both NHF and
ARHL, laying the foundation of future therapeutic targets.
M. Brumat: None. A. Morgan: None. A.P. Nagtegaal:
None. B.C. Oosterloo: None. S. Seshadri: None. N.L.
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Further evidence of involvement of CDC14A in auto-
somal recessive non-syndromic hearing loss
J. Doll1, S. Kolb1, L. Schnapp1, A. Rad2,3, F. Rüschendorf4,
I. Khan5, A. Adli2, A. Hasanzadeh2, D. Liedtke1, S. Knaup1,
M. A. H. Hofrichter1, T. Müller6, M. Dittrich1,6, I. Kong7, H.
Kim8, T. Haaf1, B. Vona1,3
1Institute of Human Genetics, Julius Maximilians University
Würzburg, Würzburg, Germany, 2Cellular and Molecular
Research Center, Sabzevar University of Medical Sciences,
Sabzevar, Iran, Islamic Republic of, 3Tübingen Hearing
Research Centre, Department of Otorhinolaryngology,
Head and Neck Surgery, Eberhard Karls University,
Tübingen, Germany, 4Max Delbrück Center for Molecular
Medicine in the Helmholtz Association, Berlin, Germany,
5Department of Chemistry, Bacha Khan University, Char-
sadda, Pakistan, 6Institute of Bioinformatics, Julius Max-
imilians University, Würzburg, Germany, 7Department of
Animal Science, Division of Applied Life Science
(BK21plus), Institute of Agriculture and Life Science,
Gyeongsang National University, Jinju, Korea, Republic
of, 8Neurological Disorders Research Center, Qatar
Biomedical Research Institute, Hamad Bin Khalifa
University, Doha, Qatar
Introduction: Hearing loss (HL) is a highly heterogeneous
sensory disorder with a prevalence of 1-3 affected in 1000
newborns. Since 2016, the gene CDC14A (Cell Division
Cycle 14A) is associated with autosomal recessive non-
syndromic HL (DFNB32) and hearing impairment and
infertile male syndrome (HIIMS).
Materials and Methods: In order to identify likely
pathogenic variants of already known and novel HL genes
in Iranian and Pakistani families with sensorineural HL,
exome sequencing, gene mapping approaches and bioinfor-
matics analysis was performed. Segregation testing of
variants ensued. To investigate functional consequences
on the RNA-level of both loss-of-function variants and to
evaluate altered expression levels, we used a minigene
assay for the splice variant (c.1421+2T>C, p.?) and RT-
qPCR for the c.1041dup variant.
Results: We identified a novel homozygous CDC14A
splice site variant (c.1421+2T>C, p.?) responsible for the
disruption of a splice donor site based on in silico prediction
tools. Moreover, we identified a novel homozygous frame-
shift variant (c.1041dup, p.Ser348Glnfs*2) in the gene
CDC14A. We observed that the c.1421+T>C variant is
responsible for the activation of a cryptic splice site
resulting in a truncated transcript (c.1414_1421del, p.
Val472Leufs*20). Significantly reduced CDC14A mRNA
levels indicated a defective transcript due to the c.1041dup
variant, which is likely targeted by nonsense-mediated
mRNA decay (NMD).
Conclusions: In summary, we identified and assessed the
pathogenicity of two novel variants on the RNA-level and
expand the spectrum of clinically relevant mutations in the
gene CDC14A.
J. Doll: None. S. Kolb: None. L. Schnapp: None. A.
Rad: None. F. Rüschendorf: None. I. Khan: None. A.
Adli: None. A. Hasanzadeh: None. D. Liedtke: None. S.
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P02.21.B
Causes of congenital hearing loss and cochlear implant
outcome
C. Landgraf1, S. von Hardenberg1, A. Lesinski-Schiedat2,
A. Büchner2, B. Schlegelberger1, B. Auber1
1Department of Human Genetics, Hannover Medical School
(MHH), Hannover, Germany, 2Department of Otorhinolar-
yngology, Hannover Medical School (MHH), Hannover,
Germany
Aim: Personalize prognosis and therapy through genetic
screening of potential cochlear implant patients.
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Background: Hearing loss (HL) can be divided into
syndromic and non-syndromic hearing loss (NSHL,
approximately 70 %). While pathogenic variants affecting
the gene GJB2 account for roughly 10-30 % of NSHL, the
majority of NSHL is distributed among more than 100 other
genes. For many patients who do not benefit sufficiently
from hearing aids, cochlear implants (CIs) are the device of
choice. Performance of CI recipients is expected to depend
on genetic background and a favorable outcome has been
associated with pathogenic variants in genes affecting the
function of the cochlear sensory organ (CSO); a negative
outcome was reported for patients with variants in genes
associated with spiral ganglion neuron (SGN) function.
Patients: 129 unrelated hearing impaired children and
adults without pathogenic variants in GJB2 and without
evidence for acquired HL.
Methods: Whole exome sequencing was performed
analyzing 148 genes associated with HL listed in the
Deafness Variation Database and additional 681 genes
listed in the Human Phenotype Ontology database based on
hearing impairment.
Results: In 33 of 129 patients we identified pathogenic or
likely pathogenic variants in 30 different genes, confirming
the genetic heterogeneity of hereditary HL. Among these
was one patient with a (homozygous) pathogenic variant in
a gene proven to affect SGN function (DFNB59).
Conclusions: For meaningful results, a significantly
higher number of cases is required. In addition, a further
functional subdivision of patients with gene alterations
influencing CSO function should be considered.
C. Landgraf: None. S. von Hardenberg: None. A.
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gelberger: None. B. Auber: None.
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In silico and in vivo analyses of novel variants identified
by Whole Exome Sequencing in Argentinean deaf
patients: to be or not be pathogenic
P. I. Buonfiglio1, C. D. Bruque2, E. Goldschmidt3, V.
Lotersztein4, S. Menazzi5, B. Paoli6, P. Plazas7, A. B.
Elgoyhen1, V. K. Dalamón1
1Instituto de Investigaciones en Ingeniería Genética y
Biología Molecular “Dr. Héctor Torres” - INGEBI/
CONICET, Ciudad Autónoma de Buenos Aires, Argentina,
2Centro Nacional de Genética Médica “A.N.L.I.S. – Dr.
Carlos G. Malbrán “, Ciudad Autónoma de Buenos Aires,
Argentina, 3Servicio de Genética del Hospital General de
Agudos “Dr. Juan A. Fernández”, Ciudad Autónoma de
Buenos Aires, Argentina, 4Servicio de Genética del Hospital
Militar Central Cirujano Mayor “Dr. Cosme Argerich”,
Ciudad Autónoma de Buenos Aires, Argentina, 5Servicio de
Genética del Hospital de Clínicas “José de San Martín”.,
Ciudad Autónoma de Buenos Aires, Argentina, 6Servicio de
Otorrinolaringología Infantil del Hospital de Clínicas
“José de San Martín”., Ciudad Autónoma de Buenos
Aires, Argentina, 7Tercera Cátedra de Farmacología,
Facultad de Medicina, Universidad de Buenos Aires,
Ciudad Autónoma de Buenos Aires, Argentina
Hereditary hearing loss (HHL) is the most common sensory
disorder affecting 1 in 500 newborn children. Since HHL is
related to more than 150 target genes, we designed a
diagnosis strategy in order to identify pathogenic variants.
A total of 1250 patients were analyzed for frequent muta-
tions in GJB2 and GJB6 genes by Sanger Sequencing,
genotyping 25% of them. From undiagnosed patients, 29
families were selected to perform Whole exome sequencing.
After filtering and analysis process, 45% of patients were
genotyped, identifying 23 causative mutations (11 novel, 12
reported) classified according to ACMG Standards. Some of
the novel variants were further studied in silico by structural
and stability studies of the mutated proteins. In addition,
datasets from deafness and specific variant databases were
correlated with different protein motifs in order to predict
the theoretical pathogenicity effect of the aminoacid chan-
ges. Furthermore, knock-down phenotype rescue assays in
zebrafish are underway to accomplish in vivo validation. In
some cases, extensive analysis reinforced the pathogenicity
prediction effect of variants and surprisingly, in one case,
discouraged the deleterious effect of a genetic variant to the
protein. Preliminary results in zebrafish confirmed the
pathogenicity of one novel variant in the hair cell function
and auditory system. This study shows that our algorithm is
successful for the genetic diagnosis of deafness. Compre-
hensive analysis is crucial to strengthen prediction of var-
iant pathogenicity. These findings highlight the importance
of genetic studies followed by in silico and in vivo vali-
dation to better understand the genetic basis of HHL.
P.I. Buonfiglio: None. C.D. Bruque: None. E. Gold-
schmidt: None. V. Lotersztein: None. S. Menazzi: None.
B. Paoli: None. P. Plazas: None. A.B. Elgoyhen: None. V.
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Genetic spectrum of hereditary hearing loss in multi-
generational families with autosomal dominant mode of
inheritance
M. Oldak1, M. L. Leja1,2, D. Ozieblo1,3, A. Sarosiak1,3, H.
Skarzynski4
1Department of Genetics, Institute of Physiology and
Pathology of Hearing, Warsaw, Poland, 2Postgraduate
School of Molecular Medicine, Medical University of
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Poland, 43. Oto-Rhino-Laryngology Surgery Clinic, Insti-
tute of Physiology and Pathology of Hearing, Warsaw,
Poland, Warsaw, Poland
Introduction: Hearing loss (HL) is the most common dis-
ability of human senses and genetic factors play an
important role in its development. Autosomal dominant HL
(ADHL) is the second most common form of inherited HL,
characterized by postlingual age of onset and progression.
To date 63 loci with 47 different genes were causally
involved in ADHL.
Materials and Methods: Multigenerational families with
ADHL were recruited for the study (n = 44). Genomic
DNA was isolated from whole blood and buccal swabs
samples. A high-throughput sequencing with custom
multigene panel was performed on probands’ DNA
samples. Family segregation analysis of the identified
variants was conducted using Sanger sequencing. All
detected variants were analyzed in the context of population
databases and available literature. Pathogenicity of the
identified variants was predicted by different computational
approaches.
Results: Genetic testing revealed probably pathogenic
variants in about 52% (23/44) of the analyzed families. The
majority of identified variants were novel, previously not
reported and hitherto not linked to the disease. The most
frequent genes with identified causative variants were
MYO6, COCH, DFNA5, KCNQ4, TECTA and POU4F3.
Conclusions: Our study revealed a high involvement of
novel probably pathogenic variants in the development of
ADHL and confirmed a high heterogeneity of the identified
genetic changes. High-throughput sequencing in HL
patients generates large amount of data that should be
interpreted carefully and confirmed by family studies. There
is also a need for functional validation of the detected novel
variants. Supported by: NCN Research Grant no. 2016/22/
E/NZ5/00470 SONATA BIS6
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Wide spectrum of genetic hearing loss causes and large
number of novel variants in cochlea implanted children
D. Ozieblo1,2, M. L. Leja1,2, H. Skarzynski3, M. Oldak1
1Department of Genetics, Institute of Physiology and
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Introduction: Every year, approximately 1-6/1000 children
are born with severe to profound hearing loss (HL). For this
group of patients cochlear implantation (CI) is the treatment of
choice. In the majority of deaf children HL is determined by
DFNB1 locus pathogenic variants. Here, we aim to dissect the
genetic background of HL in DFNB1-negative CI patients.
Materials and Methods: Genomic DNA was isolated
from blood samples of carefully selected DFNB1-negative
patients with profound prelingual HL (n = 50) and their
family members. In all probands whole exome sequencing
(WES) followed by bioinformatics and expert analysis were
performed. Standard Sanger sequencing was used for
validation of selected variants, family segregation analysis
and detection of the CEVA haplotype. Copy number
variants were confirmed with qPCR.
Results: In every tested subject WES revealed at least 5
probably pathogenic variants in HL-related genes. Causa-
tive variants were identified in 33 patients and in 39% (13/
33) of them they were inherited in an autosomal dominant
manner. Among the detected 53 disease-causing alleles,
55% (29/53) contained novel genetic alterations.
Conclusions: Obtained results show a high heterogeneity
of genetic HL causes in the population of Polish DFNB1-
negative cochlea-implanted patients. In children with no
family history of HL, the possibility of identifying causative
variants inherited in both autosomal recessive and dominant
manner should be taken into account. In patients with an
unknown genetic cause of HL, the tested area should be
expanded with whole genome analysis. Supported by NCN
grant: 2017/27/N/NZ5/02369
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Diagnostic Efficiency of Clinical Exome Solution Panel
in patients with Hearing loss/Hereditary Deafness by
using Next Generation Sequencing
S. G. Temel1,2, A. Alemdar1, M. Yılmaz3, L. Aliyeva2, S.
Ozemri Sag2
1Department of Translational Medicine, Bursa Uludag
University, Bursa, Turkey, 2Department of Medical Genet-
ics, Bursa Uludag University, Bursa, Turkey, 3Faculty of
Medicine, Bursa Uludag University, Bursa, Turkey
Hearing loss (HL)/Hereditary Deafness (HD) is a hetero-
geneous disease which multiple genes have been found to
be implicated in the disease etiopathogenesis. Genetic
diagnosis is highly important for HL/HD patients in order to
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ensure the etiology of the condition and counsel the patients
properly. In this study, 41 patients (22M/19F) who admitted
to our clinic between February 2018 and November 2019
with HL/HD were screened for 110 genes related with
syndromic/non-syndromic HL/HD. NGS is considered to be
the best practice for diagnosis. Large gene panels also can
evaluate non-prevelant genes and candidate variants specific
to populations. All exons and exon-intron boundaries were
amplifed by using Clinical Exome (Sophia Genetics)
Solution (CES) kit in MiSeq NGS instrument. Variant
analyis (SNV, Indel and CNV) and annotations were per-
formed by Sophia DDM platform, classified according to
ACMG criteria with in-silico tools and also investigated by
HGMD Professional 2019-4 and other available online
bioinformatic tools. We identified CNV in three patients, 26
pathogenic and likely pathogenic variants in 19 of 41 HL/
HD patients (46 %) in 10 different genes. Similarly, 23
variants of uncertain significance are determined in 18 of 41
HL/HD patients (43 %) in 18 distinct genes. Besides these
variations, we found 31 novel variations that are not
reported before in literature or databases. Our study affirms
that genetic screening of patients with HL by using CES
panel not only easily diagnoses but also help counseling the
patients and their family for their future risk of developing
the disease.
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None. L. Aliyeva: None. S. Ozemri Sag: None.
P02.26.A
NGS approach for molecular diagnosis of hereditary
hearing loss
F. Gerundino1, C. Pescucci1, C. Giuliani1, B. Bianchi2, G.
Traficante3, S. Bargiacchi3, S. Romano4, A. Cecconi5, C. Di
Marco6, A. Orrico7,8, M. Mencarelli9, L. Candita1, C.
Deledda1, M. Trafeli1, B. Minuti1, A. Renieri9, E. Pelo1
1SOD Diagnostica Genetica, AOU Careggi, Firenze, Italy,
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Italy, 5Ambulatorio Integrato Genetica Medica, Usl Tos-
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7Interdipartimental Program for molecular diagnosis and
characterization of pathogenic mechanisms of rare genetic
diseases, Siena, Italy, 8Clinical Genetics. ASL Toscana
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9Genetica Medica, Azienda Ospedaliera Universitaria
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Introduction: hearing loss (HL) is one of the most
genetically heterogeneous disorders. Although pathogenic
variants in GJB2 account for a large proportion of cases,
many patients remain undiagnosed after DFNB1 testing.
NGS analysis of HL-genes to simultaneously search for
nucleotide variants and copy number variants (CNVs)
greatly improve the detection rate.
Materials and methods: clinical exome sequencing
followed by in silico analysis of HL-gene panel (106
genes) was carried out on 117 patients on which DFNB1
pathogenic variants were previously excluded. Eighty
cases show prelingual or childhood deafness while in 37
patients HL was progressive with variable age of onset.
Clinical interpretation of genetic variants was performed
according to ACMG2015 by InterVar and Varsome tools
and revised according to the specific guidelines for HL-
genes.
Results: Forty-eight pathogenic or likely pathogenic
variants and eight pathogenic CNVs (6 STRC -CATSPER2
and 2 OTOA whole gene deletions) were identified with an
overall detection rate of 26.5%. Specific detection rate was
32% (12/37) for adult cases and 24% in children. In
particular, NGS identified 12 different pathogenic variants
in dominant, 28 in recessive and 8 in dominant/recessive
genes. The genes most involved were SLC26A4 and STRC.
A single pathogenic variant in SLC26A4 gene was found in
7 cases.
Conclusions: overall detection rate of the test is in line
with available data. MLPA analysis in target genes such as
SLC26A4 should be performed to exclude the presence of a
deletion at exonic level in cases where a single variant as
been identified.
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Complex assessment of pathogenicity of novel variant
c.516G>C (p.Trp172Cys) in the GJB2 gene associated
with hearing loss in indigenous peoples of Southern
Siberia (Russia)
E. A. Maslova1,2, M. V. Zytsar1, V. Y. Danilchenko1, K. E.
Orishchenko1,2, O. L. Posukh1,2
1Institute of Cytology and Genetics, Novosibirsk, Russian
Federation, 2Novosibirsk State University, Novosibirsk,
Russian Federation
Assessment of pathogenicity of novel variants is a primary
task for molecular diagnostics of hereditary diseases.
Mutations in gene GJB2 encoding transmembrane protein
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Cx26 are the common cause for hearing loss worldwide.
We present a complex assessment of pathogenicity of novel
non-synonymous variant c.516G>C (p.Trp172Cys) in GJB2
found with high frequency in deaf patients belonging to
indigenous peoples of Southern Siberia (Tuvinians and
Altaians).
Materials & Methods: Genetic analysis was performed
in group of deaf patients and ethnically matched controls.
The GJB2 knockout HeLa cell line (obtained by CRISPR/
Cas9 system) was used to establishment of transgenic HeLa
cell lines with different pathogenic GJB2-variants and
GJB2-wt. Cellular Cx26 localization was investigated by
immunocytochemistry (ICC). The Cx26-channels perme-
ability was analyzed by dye (PI) loading assay.
Results: Segregation of variant c.516G>C (p.Trp172Cys)
with hearing loss was established in analysis of pedigrees of
deaf patients and its frequency was significantly higher in
patient’s group than in controls. Most of in silico programs
predicted a likely damaging effect of p.Trp172Cys. ICC
showed predominantly cytoplasmic localization of the
Cx26-p.Trp172Cys protein in contrast to Cx26-wt which
represented distinct conglomerates on cell membrane. Dye
(PI) loading assay revealed lower PI loading efficiencies in
cells expressing mutant variant Cx26-p.Trp172Cys com-
pared to Cx26-wt while the absence of PI accumulation was
shown for other mutant Cx26-variants with known
pathogenic effects.
Conclusions: Several lines of evidences support patho-
genicity of novel variant c.516G>C (p.Trp172Cys) in gene
GJB2 and its involving in hearing loss.
Study was supported by Project #0324-2019-0041-C-01
and RFBR grant #17-29-06016_ofi-m.
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Genetic heterogeneity underlying hearing loss and Usher
syndrome in Saudi population
K. Ramzan, F. Imtiaz, M. Al-Owain, S. Alhazzaa
King Faisal Specialist Hospital and research centre,
Riyadh, Saudi Arabia
Hearing loss is one of the most common sensory disorders
in humans with both genetic and environmental etiologies.
Usher syndrome (USH) is the most common cause of
combined blindness and deafness. Molecular diagnosis is of
great significance in revealing the molecular pathogenesis
and aiding the clinical diagnosis of this disease.
Our study aims to comprehensively delineate the genetic
basis of hearing loss in the individuals of Saudi Arabian
origin. The identification of the causative gene in affected
families with hearing loss is difficult due to extreme genetic
heterogeneity and lack of phenotypic variability. Consan-
guineous families are a powerful resource for genetic
linkage studies/homozygosity mapping for recessively
inherited hearing impairment. Homozygosity mapping,
linkage analysis and next generation sequencing Deafness
Gene-panel and Whole Exome sequencing were conducted.
Using the combined approaches, so far mutations in 32
different deafness genes including novel genes first time
identified in this population, have been identified. More
than 300 familial/sporadic cases were solved, including
novel variants in known HL genes.
Using these innovative molecular approaches, we were
able to document the most common forms of hereditary
hearing loss, their incidence and distribution in the Saudi
population. The overall results of this study are highly
suggestive that the underlying molecular basis of hearing
loss in Saudi Arabia is very genetically heterogeneous. The
benefit of this study will hopefully provide the foundation
for knowledge and awareness through screening of carrier
status and genetic counselling, thereby having a major
impact upon early intervention for and prevention of
hereditary hearing loss.
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ENT- Genetics Genome Boards: Over 50% diagnostic
yield
M. Carminho-Rodrigues1, P. Senn2, M. Abramowicz1, E.
Hammar1, L. Quteineh1, A. Murphy1, S. Laurent1, M.
Guipponi1, H. Cao-Van2, A. Paoloni-Giacobino1
1Medical Genetics Unit, Geneva University Hospitals,
Geneva, Switzerland, 2ENT Unit, Geneva University
Hospitals, Geneva, Switzerland
Introduction: Hearing impairment (HI) is the most com-
mon sensory impairment. It can be isolated or syndromic.
Molecular diagnosis through whole exome sequencing
(WES) can allow an improved management and surveil-
lance of HI and possible associated anomalies. Here we
show the results of a 3 years’ experience of Ear-nose-and-
throat (ENT) Genetics Genome boards.
Materials and Methods: Our cohort includes children
with mild to profound, unilateral or bilateral HI referred by
ENT clinic from 2017 to 2019. We performed WES with
bioinformatics analysis of 189 genes associated with HI.
The results are discussed during a genome board where
geneticists and ENT specialists confront the genetic variants
found by WES with the auditory phenotype of the patients.
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Results: We tested 38 children, most often with
moderate, bilateral sensorineural hearing loss. The diag-
nostic rate was 52.6% (20/38). Among the results we found
variants associated with: syndromic forms: Usher, Wol-
fram-like, Branchio-oto-renal, Alport, Perrault, GATA3;
non-syndromic forms: Cx26, ACTG1, OTOA, ILDR1,
SLC17A8, LOXHD1, TBC1D24 and STRC related HI
associated or not with infertility in males.
Conclusions: The diagnostic yield of our study (52.6%)
is comparable to recent data in the literature. A genetic
assessment of HI in young children makes the identification
of the molecular cause possible, and permits to anticipate
possible complications particularly in the case of syndromic
forms with medical problems involving other organs or
systems. Collaboration between ENT specialists and
geneticists is essential to make an accurate and precise
diagnosis and to personalize the follow-up and treatment of
these young patients.
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Guipponi: None. H. Cao-Van: None. A. Paoloni-
Giacobino: None.
P02.30.B
The utility of exome sequencing for hereditary eye
diseases: single-centre experience
M. Volk1, N. Teran1, A. Maver1, H. Jaklič1, A. Fakin2, M.
Hawlina2, B. Peterlin1
1Institute of Genomic Medicine, UMC Ljubljana, Ljubljana,
Slovenia, 2Eye hospital, UMC Ljubljana, Ljubljana,
Slovenia
Introduction: Over 650 heritable conditions with ocular
involvement have been described to date. These include
isolated eye diseases (retinal degeneration, cataract, corneal
dystrophy, optic atrophy, developmental ocular anomalies),
as well as complex genetic syndromes with ocular mani-
festations. This group of disorders is genetically hetero-
geneous and diagnostically challenging. The aim of our
study was to determine the clinical diagnostic utility of
exome sequencing in hereditary eye diseases.
Materials and Methods: 243 Slovene unselected con-
secutive patients were referred to our institution from
November 2013 to October 2019 because of suspected
hereditary eye disease. We performed exome sequencing
with the mitochondrial sequence analysis based on the off-
target exome reads. Filtered variants were analyzed
according to population frequency, characterization in the
ClinVar database, the putative impact of the variant, and
predicted pathogenicity. Variants were classified according
to ACMG standards and guidelines for variant
interpretation.
Results: We found causative pathogenic or likely
pathogenic variants in 102 patients. The diagnostic yield
was 50% for retinal degeneration (78/156), 20% for optic
atrophy (6/30), 75% for high myopia (3/4), 29% for cataract
(2/7), 45% for retinoblastoma (4/9), 20% for developmental
ocular anomalies (3/15), 67% for corneal dystrophy (2/3),
and 56% for syndromic ocular disease (11/19).
Conclusions: The overall diagnostic yield for ophtalmo-
genetic referral in a cohort of unselected consecutive
patients was 42%. Therefore, the exome sequencing is a
cost-effective and efficient comprehensive approach that
should be considered as a first-tier investigation for
diagnostics of hereditary eye diseases.
M. Volk: None. N. Teran: None. A. Maver: None. H.
Jaklič: None. A. Fakin: None. M. Hawlina: None. B.
Peterlin: None.
P02.31.C
Analysis of recurrent mutations in different Iranian
families with hearing loss
M. A. H. Hofrichter1, A. Rad2,3, S. Kolb1, J. Weingart1, J.
Doll1, T. Müller4, C. Remmele5,1, M. Dittrich1,4, R.
Maroofian6, T. Haaf1, B. Vona1,3
1Institute of Human Genetics, Julius Maximilians Univer-
sity, Würzburg, Germany, 2Cellular and Molecular
Research Center, Sabzevar University of Medical Sciences,
Sabzevar, Iran, Islamic Republic of, 3Department of
Otorhinolaryngology, Head and Neck Surgery, Tübingen
Hearing Research Centre (THRC), Eberhard Karls Uni-
versity, Tübingen, Germany, 4Institute of Bioinformatics,
Julius Maximilians University, Würzburg, Germany, 5Cen-
ter for Rare Diseases, University Hospital Würzburg,
Würzburg, Germany, 6Genetics and Molecular Cell
Sciences Research Centre, St George’s, University of
London, Cranmer Terrace, London, United Kingdom
Introduction: Hereditary hearing loss (HL) is one of the
most genetically heterogeneous disorders. The genetic
landscape of non-syndromic HL includes over 100 genes. In
aggregate, these genes harbor several thousand causally
implicated variants. The observation of recurrent variants
raises the question about whether variants arose from a
single ancestral allele or were the result of independent
mutational events. In our study that includes 150 Iranian
probands, we identified 15 families with recurrent likely
pathogenic variants in the genes SMPX, SLC26A4, TECTA
and TMIE.
Methods: DNA samples from index patients were exome
sequenced following Illumina exome protocols. Libraries
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were sequenced with a NextSeq500 benchtop sequencer.
Variant and copy number variation analysis were performed
using GensearchNGS and an in-house exome analysis
pipeline. Segregation analysis was performed for all
families. Haplotype reconstruction allowed comparison
across families.
Results: Haplotype analysis of the c.99del variant in
SMPX that was identified in three Iranian families suggested
a common descent. Interestingly, this X-linked variant was
described as a founder mutation in an isolated Newfound-
land population. In addition, more than one recurrent
mutation was identified in the genes SLC26A4 and TECTA
in families with autosomal recessive HL that was consistent
with a founder effect. In three additional families, the
c.250C>T variant in TMIE was implicated in autosomal
recessive HL without sharing further common variants,
suggesting a mutational hotspot.
Conclusions: The genetic origin of recurrent mutations
could be interesting for further characterization of HL genes
with respect to ethnic background and susceptibility of
mutational events.
M.A.H. Hofrichter: None. A. Rad: None. S. Kolb:
None. J. Weingart: None. J. Doll: None. T. Müller: None.
C. Remmele: None. M. Dittrich: None. R. Maroofian:
None. T. Haaf: None. B. Vona: None.
P02.32.A
Genomic approaches for the analysis fo more than 700
Italian patients affected by Hereditary Hearing Loss
(HHL) reveal new genes/alleles.
A. Morgan1,2, G. Pelliccione1, F. Faletra1, D. Dell’Orco3,
M. Brumat2, P. Gasparini4,2, G. Girotto1,2
1Institute for Maternal and Child Health – IRCCS Burlo
Garofolo, Trieste, Italy, 2Department of Medicine, Surgery
and Health Sciences, University of Trieste, Trieste, Italy,
3Department of Neurosciences, Biomedicine and Movement
Sciences, Section of Biological Chemistry, University of
Verona, Verona, Italy, 4Institute for Maternal and Child
Health – IRCCS, Burlo Garofolo, Trieste, Italy
Discerning the complex genetic basis of HHL is funda-
mental to facilitate a correct genetic counselling and
molecular diagnosis. The use of high-throughput genome
technologies has made great strides in the discovery of new
alleles/genes identification. Here, 714 deeply clinically
characterized patients were screened with a Targeted Re-
Sequencing (TRS) panel of 96 deafness genes and, in
negative cases, SNP-arrays were applied. Afterwards,
families negative to both approaches were analysed by
Whole Exome Sequencing (WES) for new candidates
identification. TRS and SNP-arrays characterized ~28% of
the HL cases (42% familial and 20% sporadic cases)
highlighting STRC and TECTA as the second major players
in the Italian population after GJB2. Then, WES allowed
the identification of five new HHL genes, two of them
(SLC12A2 and USP48) just identified. As regards
SLC12A2, a heterozygous missense variation
(NM_001046.2, exon25, c.3431C>A, p.(T1144N)) has
been identified in a three-generation HHL family. The
variant is predicted as deleterious by several bioinformatic
prediction tools and is not reported in any public database.
Interestingly, studies in mouse and zebrafish models
demonstrated Slc12a2 expression in the inner ear and its
involvement in hearing loss. Moreover, to better evaluate
the pathogenic effect of the identified variant, an in silico
protein modelling has been performed suggesting that the
substitution identified might alter the correct folding of the
protein. Thanks to this approach ~35% (60% familial cases
and 20% sporadic ones) of cases have been characterized
confirming the large mutation’s spectrum of HHL, and the
importance of an accurate clinical diagnosis.
A. Morgan: None. G. Pelliccione: None. F. Faletra:
None. D. Dell’Orco: None. M. Brumat: None. P.
Gasparini: None. G. Girotto: None.
P02.33.B
Genetic causes of paediatric hereditary retinal diseases
in Polish population
K. H. Chrzanowska1, B. Kocyła-Karczmarewicz2, A. M.
Tracewska3, E. Ciara1, M. Rydzanicz4, P. Stawiński4, R.
Płoski4
1Department of Medical Genetics, The Children’s Memorial
Health Institute, Warsaw, Poland, 2Department of Ophthal-
mology, The Children’s Memorial Health Institute, War-
saw, Poland, 3DNA Analysis Laboratory, PORT Polish
Center for Research Technology, Wrocław, Poland,
4Department of Medical Genetics, Medical University of
Warsaw, Warsaw, Poland
Introduction: Every year, Children’s Memorial Health
Institute admits approximately 100 children suffering from
vision impairment with suspicion of inherited retinal
degeneration (IRD), which is confirmed in half of the cases.
In many paediatric patients, genetic diagnosis is crucial for
prognostics and future planning.
Methods: 76 probands and 22 affected family members
were ascertained, and a detailed medical and family history
was obtained. Ophthalmological assessment consisted,
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when feasible, of: best-corrected Snellen visual acuity
(BCVA), colour vision, visual field test, dilated ophthalmo-
scopy, colour fundus photography, autofluorescence ima-
ging, spectral-domain optical coherence tomography (SD-
OCT), fluorescein angiography and electrophysiological
assessment. DNA was isolated from blood samples, and
proband samples underwent targeted next-generation
sequencing for 108 known IRD genes.
Results: In the vast majority of affected individuals the
genetic analyses confirmed the initial diagnosis; some
diagnoses, however, needed to be revised. Causal variants
were found in 2/3 of the families. In five cases, monoallelic
pathogenic alterations were found in autosomal recessive
genes. Most commonly mutated genes in this cohort were
ABCA4 (23 individuals), CNGA3 (5) and CEP290 (4).
Conclusions: Genetic analysis is crucial to achieve
accurate diagnosis and prognosis, which enables informed
choices for the future of the affected children. Many
probands were the first individual suffering from IRD in the
family. An important role of genetic diagnostics is to inform
the parents about their risk for having another child with the
disease. Finally, emerging targeted gene therapies indicate a
chance of slowing or stopping the disease progression.
Funding: National Science Centre (Poland) grant no.
UMO-2015/19/D/NZ2/03193.
1
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None. A.M. Tracewska: None. E. Ciara: None.
M. Rydzanicz: None. P. Stawiński: None. R.
Płoski: None.
P02.35.A
Diagnostic exome sequencing in 50 patients with high
myopia
V. J. M. Verhoeven1,2, A. E. G. Haarman2,3, M. van
Tienhoven1, A. A. H. J. Thiadens2, S. E. Loudon2, A. de
Klein1, E. Brosens1, J. R. Polling2,4, A. Bouman1, C. C. W.
Klaver5,3,2, A. J. A. Kievit1, L. H. Hoefsloot1
1Dept. of Clinical Genetics, Erasmus Medical Center,
Rotterdam, the Netherlands, Rotterdam, Netherlands,
2Dept. of Ophthalmology, Erasmus Medical Center,
Rotterdam, the Netherlands, Rotterdam, Netherlands,
3Dept. of Epidemiology, Erasmus Medical Center, Rotter-
dam, the Netherlands, Rotterdam, Netherlands, 4Dept. of
Orthoptics, School of Applied Science Utrecht, Utrecht,
Netherlands, 5Dept. of Ophthalmology, UMC St Radboud,
Nijmegen, the Netherlands, Nijmegen, Netherlands
Introduction: High myopia (HM; ≤-6 diopters) is a het-
erogeneous condition, and without clear accompanying
features it can be difficult to pinpoint a genetic cause. The
aim of this study was to evaluate the diagnostic yield of
whole exome sequencing (WES) in patients with HM.
Materials and methods: Patients with HM were
recruited by ophthalmologists and clinical geneticists.
Clinical features were categorized into isolated HM, HM
with other ocular features or syndromic HM with systemic
involvement. WES was performed using a vision gene
panel including 477 genes.
Results:WES was performed in 50 patients with HM; the
majority had isolated HM (75%). A genetic cause was
identified in 11 patients (22%; mean age at diagnosis 9.4
years (SD 7.5); mean refractive error -12.60 diopters (SD
6.22)). Four patients had mutations in known retinal
dystrophy genes (GUCY2D; FAM161A; PDE6H; CAC-
NA1F); 3 female patients had a ARR3 mutation (X-linked
female limited high myopia); 2 patients had homozygous or
compound heterozygous COL18A1 mutations (Knobloch
syndrome); 1 patient had a COL2A1 mutation (Stickler
syndrome); 1 patient had a PAX6 mutation. In 14 patients
(28%) a variant of unknown significance was found; follow-
up examinations are necessary.
Conclusions: The diagnostic yield of our WES vision
gene panel for HM was 22%. It enabled us to diagnose
various causes of HM, i.e. retinal dystrophies, connective
tissue diseases, and non-syndromic HM, allowing appro-
priate follow up of systemic and ocular features and genetic
counselling.
Horizon 2020 (grant 648268); NWO (grants 91815655,
91617076); Oogfonds; ODAS; Uitzicht (grant 2017-28).
V.J.M. Verhoeven: None. A.E.G. Haarman: None. M.
van Tienhoven: None. A.A.H.J. Thiadens: None. S.E.
Loudon: None. A. de Klein: None. E. Brosens: None. J.
R. Polling: None. A. Bouman: None. C.C.W. Klaver:
None. A.J.A. Kievit: None. L.H. Hoefsloot: None.
P02.37.C
Genetic architecture of inherited retinal degeneration in
Germany: A large cohort study from a single diagnostic
center over a 9-year period
N. Weisschuh1, C. D. Obermaier2,3, A. Bernd1, L.
Kühlewein1,4, F. Nasser5, D. Zobor1, F. Battke3, E.
Zrenner1,6, E. Weber1, B. Wissinger1, S. Biskup2,3, K.
Stingl5, S. Kohl1
1Institute for Ophthalmic Research, Centre for Ophthalmol-
ogy, University of Tübingen, Tuebingen, Germany, 2Praxis
fuer Humangenetik Tuebingen, Tuebingen, Germany, 3Cen-
ter for Genomics and Transcriptomics, CeGaT GmbH,
Tübingen, Germany, 4University Eye Hospital, Center for
Ophthalmology, University of Tübingen, Tübingen, Ger-
many, 5University Eye Hospital, Center for Ophthalmology,
University of Tübingen, Tuebingen, Germany, 6Werner
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Reichardt Centre for Integrative Neuroscience (CIN),
University of Tübingen, Tübingen, Germany
Introduction: The aim of this cohort study was to unravel
the molecular basis of inherited retinal degeneration (IRD)
in a large cohort of 2,156 affected patients diagnosed and
followed-up in the largest center for inherited retinal dis-
eases in Germany. Our study cohort accounts for approxi-
mately 7% of the estimated 30,000 IRD patients in
Germany, thereby providing representative data for the
prevalence and the mutation spectrum of IRD genes and
mutations for the population in Germany. Presently, more
than 260 `disease genes’ are known to cause IRDs. The
identification of the underlying disease-causing mutations
has been accelerated by the introduction of next-generation-
sequencing technologies (NGS). Within the field of NGS
platforms, the targeted capture of known ‘disease genes’
with its strong optimization of coverage on relevant targets
has been proven superior over whole exome sequencing
with respect to read depth and on-target efficiency.
Materials and Methods: DNA samples were analyzed
by targeted NGS and, whenever indicated, multiplex
ligation-dependent probe amplification (MLPA). Patients
with single-gene disorders were analyzed by Sanger
sequencing and MLPA.
Results: We achieved an overall molecular diagnostic
solving rate of 70.8%. A total of 1,161 distinct variants
were identified, including 501 novel variants, reaffirming
the known vast genetic heterogeneity of IRD in a mainly
outbred European population.
Conclusions: Our study demonstrates the clinical utility
of panel-based NGS in a large and highly heterogeneous
cohort from an outbred population and for the first time
gives a comprehensive representation of the genetic land-
scape of IRDs in Germany.
N. Weisschuh: None. C.D. Obermaier: None. A.
Bernd: None. L. Kühlewein: None. F. Nasser: None. D.
Zobor: None. F. Battke: None. E. Zrenner: None. E.
Weber: None. B. Wissinger: None. S. Biskup: None. K.
Stingl: None. S. Kohl: None.
P02.38.A
Retinal disease as the leading clinical manifestation in
patients with unexpected inherited systemic disorders
detected by whole genome sequencing
A. Liebmann1,2, P. Mazzola1,2, K. Stingl3, T. Heinrich1,2, K.
Schäferhoff1,2, S. Ossowski1,2, M. Sturm1,2, S. Kohl4, N.
Weisschuh4, B. Wissinger4, O. Riess1,2, T. Haack1,2
1Institute of Medical Genetics and Applied Genomics,
University of Tübingen, Tübingen, Germany, 2Centre for
Rare Diseases, University of Tübingen, Tübingen,
Germany, 3University Eye Hospital, Center for Ophthal-
mology, University of Tübingen, Tübingen, Germany,
4Institute for Ophthalmic Research, Centre for Ophthalmol-
ogy, University of Tübingen, Tübingen, Germany
Introduction: Implementation of genome-wide sequencing
approaches such as exome and genome sequencing in
routine diagnostics implicates the possibility of incidental
findings and unexpected diagnoses. Here we present two
patients, a 9-year-old girl with cone dystrophy and a 43-year
old man with rod-cone dystrophy, initially referred to the
Department of Ophthalmology to confirm inherited retinal
disease.
Material and Methods: Genomic DNA was processed
using the TruSeq DNA PCR-free Kit (Illumina) for library
preparation and paired-end whole genome sequencing
(WGS) was performed on a NovaSeq6000 System (Illu-
mina). Data analysis was conducted using an in-house
bioinformatics pipeline optimized for structural/copy num-
ber variant detection.
Results: WGS of the girl identified a clinically relevant
homozygous deletion in CLN3. The detected deletion c.461-
280_677+382del, p.? is the most frequent pathogenic
deletion in CLN3 associated with autosomal recessive
neuronal ceroid lipofuscinosis. This lysosomal storage
disease is characterized by seizures, psychomotor degenera-
tion and visual failure. Clinical course is progressive and
unfavorable. WGS of the man identified a pathogenic
homozygous missense variant c.635G>T, p.Gly212Val in
TMEM126B. Variants of TMEM126B are associated with
autosomal recessive complex 1 deficiency. This mitochon-
drial disease is characterized by a variable clinical
phenotype including neuromuscular, cardiovascular and
metabolic symptoms and visual impairment. The detected
variant has been described before in another patient with
rod-cone dystrophy.
Conclusions: This study highlights the importance to
inform patients about the possibility of retinal disease being
the leading clinical manifestation of unexpected inherited
systemic disorders. Thus, comprehensive genetic counsel-
ing and appropriate documentation of informed consent is
crucial prior to performing WGS.
A. Liebmann: None. P. Mazzola: None. K. Stingl:
None. T. Heinrich: None. K. Schäferhoff: None. S.
Ossowski: None. M. Sturm: None. S. Kohl: None. N.
Weisschuh: None. B. Wissinger: None. O. Riess: None.
T. Haack: None.
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Shift of T-cell repertoire in cornea of keratoconus
patients
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L. Skorodumova1, A. Kanygina1, A. Belodedova2, E.
Sharova1, B. Malyugin2
1Federal Research and Clinical Center of Physical-
Chemical Medicine of Federal Medical Biological
Agency, Moscow, Russian Federation, 2S. Fyodorov Eye
Microsurgery Complex Federal State Institution, Ministry
of Health of Russian Federation, Moscow, Russian
Federation
Introduction: Keratoconus is a pathologic condition of the
eye which results in thinning and cone-shaped deformation
of cornea. While its precise cause is still unknown, kera-
toconus is considered to be a multifactorial disease, and
immune processes are assumed to contribute to its devel-
opment, yet little data is available so far on the immune
microenvironment of cornea in affected patients. Here we
present the assessment of T cell repertoire in cornea and
blood samples from 3 patients with keratoconus who
underwent cornea transplantation.
Materials and Methods: RNA was extracted from
PBMC and cornea samples with RNeasy Micro Kit
(Qiagen). RNA libraries of TCR-alpha and TCR-beta
transcripts were prepared using SMARTer Human TCR a/
b Profiling Kit (Takara Bio USA Inc.) and sequenced using
Illumina MiSeq platform. TRA and TRB clonotypes were
assembled and quantified with MiXCR package.
CDR3 sequences were annotated against VDJdb, PIRD
and McPAS-TCR databases.
Results: Cornea samples for all 3 patients demonstrated
significantly lower clonotype diversity than corresponding
PBMC samples. We observed a shift of T cell repertoire in
cornea compared to PBMC samples. The top abundant
TCR clones in cornea were poorly represented or absent in
corresponding blood samples, which indicates that they
represent a tissue-specific population. For most of
the CDR3 variants detected in cornea, no specificities
against known antigens were found, and further research is
needed to identify possible functions of these T cell
populations.
This study was supported by RFBR as part of the research
project № 17-29-06077.
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Genomic landscape in spanish patients with ocular
malformations by next generation sequencing
A. Damián1, A. Tamayo1, J. Moya1, C. Villaverde1,
A. Avila-Fernández1, A. Arteche1, V. López2, M. Ballesta2,
E. Guillen2, S. Tahsin Swafiri1, I. Lorda1, F. Blanco-Kelly1,
M. Trujillo1, C. Ayuso1, M. Corton1
1Instituto de Investigación Sanitaria Fundación Jiménez
Díaz, Madrid, Spain, 2University Hospital Virgen de la
Arrixaca, Murcia, Spain
Human eye development is coordinated by complex
developmental processes which involves several hundreds
of genes. Any disruption in this regulation during the eye
organogenesis can lead to ocular malformations such as
Microphthalmia- Anophthalmia-Coloboma (MAC). These
diseases are very clinically and genetically heterogeneous
conditions with overlapping phenotypes; consequently the
mutational load is not well known and the genotype-
phenotype correlations can be difficult to define. Our aim
was to perform a comprehensive molecular screening in a
cohort of Spanish patients with ocular malformations using
different approaches of next-generation sequencing (NGS).
We have findings in around 52% of the patients. One-third
carried likely causal mutations, 8% were partially char-
acterized and 8% had VUS. Different casual mutations were
found and the most prevalent in our cohort are transcription
factors such as OTX2, SOX2, VSX2 and PAX6. In contrast,
others variants have expanded the phenotypic spectrum of
some genes classically associated with other phenotypes
such as GJA8, KERA, or the lens crystallins family genes
suggesting new roles of them in the early development of
the eye. This results show that not only NGS is efficient for
the genetic analysis of ocular malformations but also for
achieving new candidate genes. Therefore, we have update
our gene panels resulting in an increase in our diagnostic
yield. In contrast, 34% of patients remain uncharacterized,
mostly unilateral or non-syndromic cases. So that, our
future purposes are to understand the mechanisms involved
in this disease by identifying novel genetic causes and
exploring their functional role.
A. Damián: None. A. Tamayo: None. J. Moya: None.
C. Villaverde: None. A. Avila-Fernández: None. A.
Arteche: None. V. López: None. M. Ballesta: None. E.
Guillen: None. S. Tahsin Swafiri: None. I. Lorda: None.
F. Blanco-Kelly: None. M. Trujillo: None. C. Ayuso:
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P02.46.C
Exome-based panel testing as an efficient method to
diagnose the highly heterogeneous ocular disorder
spectrum Microphthalmia, Anophthalmia, Coloboma
and Anterior Segment Dysgenesis (MAC-ASD)
H. Verdin1, T. Rosseel1, S. Vermeer2, I. Balikova3,
P. Kestelyn4, C. Meunier5, F. Meire6, J. Van De Velde1,
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1Center for Medical Genetics, Ghent University Hospital,
Ghent, Belgium, 2Center for Human Genetics, University
Hospitals Leuven, Leuven, Belgium, 3Department of
Ophthalmology, University Hospitals Leuven, Leuven,
Belgium, 4Department of Ophthalmology, Ghent University
and Ghent University Hospital, Ghent, Belgium, 5Center for
Human Genetics, Institute of Pathology and Genetics,
Gosselies, Belgium, 6Department of Ophthalmology, Hôpi-
tal Universitaire des Enfants Reine Fabiola, Brussels,
Belgium, 7Center for Medical Genetics, University of
Antwerp and Antwerp University Hospital, Antwerp,
Belgium, 8Department of Ophthalmology, Antwerp Uni-
versity Hospital, Antwerp, Belgium, 9Center for Human
Genetics, Cliniques Universitaires St-Luc, Universite Cath-
olique de Louvain, Brussels, Belgium, 10Division of
Ophthalmology and Center for Cellular & Molecular
Therapeutics, The Children’s Hospital of Philadelphia,
Philadelphia, PA, United States
Introduction: Microphthalmia and anophthalmia are part
of a spectrum with ocular coloboma, a structural mal-
formation resulting from incomplete fusion of the optic
fissure, which likely have a shared, although heterogeneous
genetic basis. They are collectively named MAC (Micro-
phthalmia-Anophthalmia-Coloboma), characterized by a
tremendous clinical heterogeneity and often associated with
other ocular abnormalities such as anterior segment dys-
genesis (ASD). We aimed to set up an exome-based gene
panel test for MAC-ASD.
Materials and Methods: Sample preparation was done
with the SureSelectXT Low Input Human All Exon V7 kit
using Bravo (Agilent Technologies) and pooled libraries
were sequenced on a HiSeq 3000 or NovaSeq 6000
(Illumina) aiming for a minimal coverage of 20x for at
least 90% of the investigated regions. Data analysis was
executed with a bcbio-based pipeline and variant filtering
with in-house Seqplorer software. Copy number variant
(CNV) analysis was done using ExomeDepth.
Results: As of May 2018, 26 patients, 12 with MAC
(46.2%) and 14 with ASD (53.8%), underwent MAC-
ASD panel analysis. The overall diagnostic yield was 9/
26 (34.6%), in line with the reported range (11-36%).
ASD has the highest yield (50%), compared to MAC
(16.7%). In seven out of the nine cases a (likely)
pathogenic variant was identified in ALDH1A3,
CPAMD8, FOXE3, MFRP, PAX6, PITX2 and PITX3. In
two of the nine patients a CNV encompassing FOXC1
was found.
Conclusions: Exome-based MAC-ASD panel analysis
revealed a molecular diagnosis in 34.6% of a MAC-ASD
cohort, highlighting the efficacy of exome-based panel
testing in heterogeneous conditions.
Funding: FWO/12R3419N; FWO/1802220N; BOF15/
GOA/011.
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The enigma of Midfacial Toddler Excoriation Syndrome
(MiTES), a second PRDM12 poly-alanine tract expan-
sion disorder
N. Sarveswaran1, G. Woods1, C. Moss2
1Cambridge Institute for Medical Research, Cambridge,
United Kingdom, 2Birmingham Children’s hospital, Bir-
mingham, United Kingdom
Mid-face toddler excoriation syndrome (MiTES) is a new
sensory disease first described in 2017 (PMID: 28028858).
We report 12 cases in 7 families. The phenotype is of
intense itch in early childhood, which causes mutilating
self-injury by scratching. The intense itch is localised only
to the midface and no other body parts; is not associated
with altered sweating; it spontaneously subsides by 4-6
years; cognition and pain sensing is normal; there is no
excess of Staph Aureus infections (on the face or else-
where). Inheritance appeared recessive, as parents were
unaffected, males and females were equally affected, and
most cases were consanguineous. Older individuals “grow
out” of the condition, facial injuries heal, and have normal
whole-body itch and pain sensing. In six of seven families,
we found the same mutation in affected individuals - a
homozygous poly-Alanine repeat expansion from the nor-
mal range (7-13) to 18. Parents were always carriers. This
was also found in a non-Asian, Caucasian, non-
consanguineous family. In the seventh family, we found
only a heterozygous 7 base pair deletion in PRDM12, but
no second mutation. What is extraordinary is that a
PRDM12 homozygous 19 poly-Alanine repeat expansion
causes Congenital Insensitivity to Pain; which is not asso-
ciated with excess itch, leads to self-inflicted lip, tongue and
corneal damage, and always cause excess S. Aureus infec-
tions. No other poly-alanine tract expansion disease has two
phenotypes. We present our cellular studies to try and
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understand the disease mechanism whereby a single addi-
tional alanine can cause such different phenotypes.
N. Sarveswaran: None. G. Woods: None. C.
Moss: None.
P02.49.C
Mutational analysis of 256 Russian patients with
congenital aniridia and overlapping phenotypes
T. A. Vasilyeva, A. V. Marakhonov, V. V. Kadyshev, R. A.
Zinchenko
Research Centre for Medical Genetics, Moscow, Russian
Federation
Congenital aniridia (OMIM#106210) is an autosomal
dominant eye disorder mainly caused by heterozygous
PAX6 mutations or 11p13 chromosome rearrangements.
Pathogenic variants in some other genes could cause
overlapping phenotypes, also, PAX6 missense mutations
could be associated with other than aniridia phenotypes. A
total of 208 unrelated families (256 patients) with clinical
diagnoses of either congenital aniridia, counting WAGR
syndrome, or overlapping ophthalmological diagnoses
characterized by iris hypoplasia were included in the
study. Familial to sporadic proportion counted for 44/164.
A combination of Sanger PAX6 sequencing, whole-exome
sequencing, followed by MLPA analysis of 11p13, 4q25,
6p25.3 loci was implemented. 204 out of 208 families
(98%) were found to have either heterozygous pathogenic
nucleotide sequence variant or chromosome deletion.
Disease-causing variants in PAX6 and deletions in 11p13
were found in 92.7%. Four other genes (FOXC1, PITX2,
NDP, CRYAA) explained 5.3% of the examined families.
30.3% of the cohort carried pathogenic CNVs (62 in
11p13 and 1 in 6p25.3). A frequent 11p13 deletion of
PAX6 3′-cis-regulatory region was determined (16/208,
7.7%). The frequency of this deletion in the cohort was
higher than PAX6 hotspot c.718C>T rate (9/208, 4.3%). In
total, repeated PAX6 variants were determined in 39/208
(18,8%) families, together with 11p13 downstream dele-
tion they explained 55/208 (26.4%) of the families. PAX6
missense variants counted for 6/208 (2.8%). Mutational
spectrum peculiarities in a large cohort of Russian families
with congenital aniridia were established. Supported by
grant RFBR 19-015-00122 and state task of the Ministry
of education and science of Russia.
T.A. Vasilyeva: None. A.V. Marakhonov: None. V.V.
Kadyshev: None. R.A. Zinchenko: None.
P02.50.A
Revealing the role of enhancers in myopia
J. Swierkowska1,2,3, M. S. Tedja1,2, A. E. G. Haarman1,2, M.
Ghanbari1, S. J. Erkeland4, M. Meester-Smoor1,2, C. C. W.
Klaver5,6,7, V. J. M. Verhoeven1,2,8
1Department of Epidemiology, Erasmus Medical Center,
Rotterdam, Netherlands, 2Department of Ophthalmology,
Erasmus Medical Center, Rotterdam, Netherlands, 3Institute
of Human Genetics, Polish Academy of Sciences, Poznan,
Poland, 4Department of Immunology, Erasmus Medical
Center, Rotterdam, Netherlands, 5Epidemiology and
Ophthalmology Departments, Erasmus Medical Center,
Rotterdam, Netherlands, 6Department of Ophthalmology,
Radboud University Medical Center, Nijmegen, Nether-
lands, 7Institute of Molecular and Clinical Ophthalmology,
Basel, Switzerland, 8Department of Clinical Genetics,
Erasmus Medical Center, Rotterdam, Netherlands
Introduction: Previous studies have indicated a crucial role
of the non-coding genome in myopia (nearsightedness), a
complex genetic trait. We aimed to identify enhancers, cis-
regulatory elements regulating gene expression, associated
with myopia leveraging summary statistics of previous
genome-wide association studies (GWAS).
Materials and Methods: GWAS on myopia related
phenotypes (148,485 European, 11,935 Asian individuals)
from CREAM and 23andMe were used to examine the
association between enhancer-related SNPs and myopia.
We obtained enhancer regions (Ntotal=12,244) active in eye-
related human tissues from the FANTOM5 database and
performed a look-up of these regions in the GWAS. We
prioritized enhancers and ANNOVAR determined target
genes by ranking system based on LD, eQTLs, enhancer
histone marks (HaploReg v4.1) and the association with
myopia/ocular phenotype (GWAS catalog).
Results: We selected enhancers expressed in ≥3 eye-
related tissue types (N=7,944), of which 4,610 enhancers
(NSNPs=9,253) were available in the GWAS for analysis.
The look-up of these regions yielded 15 significant SNPs
clustering in 12 enhancers regions exceeding the Bonferroni
significance threshold (P = 0.05/4,610=1.08x10−5). The
highest ranked rs9535268 (P = 1.04x10−9) and rs4415919
(P = 3.76x10−8) were annotated to an intergenic enhancer
region between RCBTB1 (~16 kb) and ARL11 (~27 kb)
genes. Interestingly, SNPs within RCBTB1 were associated
with myopia in the GWAS.
Conclusions: We selected enhancers with putative target
genes, as RCBTB1 (RCC1 and BTB domain containing
protein 1), that could explain significant loci identified in
GWAS and play a role in myopia pathogenesis. Support:
Horizon 2020 (648268); NWO (91815655, 91617076);
Uitzicht (2017-28; Oogfonds; Landelijke Stichting voor
Blinden en Slechtzienden; MaculaFonds), EMBO (8529).
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J. Swierkowska: None. M.S. Tedja: None. A.E.G.
Haarman: None. M. Ghanbari: None. S.J. Erkeland:
None. M. Meester-Smoor: None. C.C.W. Klaver: None.
V.J.M. Verhoeven: None.
P02.53.A
Functional analysis of a novel Myo6variant in hereditary
hearing loss family from Qatar
M. K. Al-Kowari1,2, S. Da’as1, M. Guarch1, D.
Abdurahman1, W. Hasan1, N. Krishnamoorthy1, H. Horn2,
X. Estivill1,2
1Sidra Medicine, Doha, Qatar, 2Biological and Biomedical
Program, Hamad Bin Khalifa University, Doha, Qatar
Introduction: Hereditary Hearing Loss (HHL) is a com-
mon genetic disorder accounting for at least 60% of pre-
lingual deafness in children. The long tradition of con-
sanguinity among Qatari population increases the pre-
valence of HHL. A novel missense variant in Myo6 was
detected in two siblinges diagnosed with severe to profound
HL (Alkowari et al. 2017). Prediction tools revealed that
this variant is pathogenic and conserved.
Materials and methods: We functionally validate the
pathogenicity of the novel variant using both cellular and
animal models. HeLa cells were transiently transfected with
plasmids carrying wildtype and mutated human Myo6. A
zebrafish model was generated using morpholino knock
down and co-injection with synthetic RNA (Myo6WT and
Myo6p.E60Q) to further characterize the phenotype.
Results: HeLa cells transfected with Myo6WT and Myo6p.
E60Q, overexpressed the same amount of protein. Cells with
Myo6WT showed localization of the protein in both
cytoplasm and the plasma membrane. In contrast, Myo6p.
E60Q is not expressed in the plasma membrane but it’s
restricted to the cytoplasm. Zebrafish model resulted in
severe otic defects. Myo6p.E60Q RNA injection resulted in
alterations in the saccule that is responsible for hearing in
zebrafish ear. Additionally, we found that zebrafish with
Myo6p.E60Q displayed shorter, less abundant and disordered
hair bundles in otic hair cells when compared to control and
Myo6WT injected zebrafish.
Conclusions: In this study we functionally characterized
a novel genetic variant associated with hearing loss; in vitro
studies demonstrated that c.G178C variant affects Myo6
protein trafficking. A zebrafish model confirmed the
pathogenicity and identified significant otic defects.
M.K. Al-Kowari: None. S. Da’as: None. M. Guarch:
None. D. Abdurahman: None. W. Hasan: None. N.
Krishnamoorthy: None. H. Horn: None. X.
Estivill: None.
P02.55.C
Characterizing a large Iranian cohort of non-syndromic
hearing loss families using molecular inversion probe
and exome sequencing
A. Rad1, R. Maroofian2, N. Mazaheri3, J. Oostrik4, S.
Loum1, H. Löwenheim1, T. Haaf5, H. Galehdari6, H.
Kremer4, B. Vona1
1Department of Otorhinolaryngology, Head and Neck
Surgery, Tübingen, Germany, 2Department of Neuromus-
cular Disorders, UCL Queen Square Institute of Neurol-
ogy,, London, United Kingdom, 3Department of Genetics,
Faculty of Science, Shahid Chamran University of Ahvaz,
Ahvaz, Iran, Islamic Republic of, 4Department of Otorhi-
nolaryngology, Radboud University Medical Center,,
Nijmegen, Netherlands, 5Institute of Human Genetics,
Julius Maximilians University, Würzburg, Germany,
6Department of Genetics, Faculty of Science, Shahid
Chamran University of Ahvaz,, Ahvaz, Iran, Islamic
Republic of
Introduction: Hearing loss (HL) is the most prevalent
sensory deficit. With about 120 genes implicated, non-
syndromic hearing loss (NSHL) is extremely genetically
heterogeneous. In this study, we investigated extended
Iranian families with hereditary NSHL to uncover the
genetic landscape and characterize its genetic heterogeneity.
Materials and Methods: Using molecular inversion
probes (MIPs), we targeted 89 genes involved in NSHL in
20 patients. Exome sequencing (ES) was performed in 102
GJB2-negative and unresolved MIP-screened NSHL pro-
bands. Sanger sequencing, homozygosity mapping, and
in vitro functional assays were used to confirm selected
variants.
Results: Our analysis resolved 50% (10/20) of the MIP-
screened patients and about 76% (78/102) of patients
subjected to ES. The overall diagnostic rate is about 78.5%
(88/112). Nearly half of the diagnostic yield was attributed
to the genes SLC26A4 (13.4%), MYO15A (8.0%), LOXHD1
(7.0%), MYO7A (6.2%), CDH23 (5.3%) and TMC1 (4.5%).
Our data also identified CLRN2 as a novel NSHL gene in a
family. A novel variant in the SPATA5 gene, known to
cause epilepsy, hearing loss, and mental retardation
syndrome, was implicated in a family with HL as the sole
clinical feature.
Conclusions: Using two approaches, we could resolve
roughly 78.5% of the patients undergoing genetic screening
for NSHL. Our cohort also uncovered LOXHD1 as a highly
prevalent gene in NSHL diagnoses that was not similarly
observed in large cohort screenings of Iranian HL patients.
Furthermore, we introduce CLRN2 and SPATA5 as novel
autosomal recessive NSHL genes. Select unresolved
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families from this cohort have been followed-up with
genome sequencing.
A. Rad: None. R. Maroofian: None. N. Mazaheri:
None. J. Oostrik: None. S. Loum: None. H. Löwenheim:
None. T. Haaf: None. H. Galehdari: None. H. Kremer:
None. B. Vona: None.
P02.56.A
Multitopographical effect of mutations in the gene PAX6
for pediatric ophthalmology
V. V. Kadyshev, T. A. Vasilyeva, A. V. Marakhonov, S. I.
Kutsev, R. A. Zinchenko
FSBSI Research Centre for Medical Genetics, Moscow,
Russian Federation
The expression of the PAX6 gene is realized in the forma-
tion of almost all structures of the eye - the cornea, iris, lens,
optic nerve and central part of the retina. Accounting this
fact, the clinical spectrum expands when there is a single
pathogenetic process. Materials and methods. The sample of
patients with hereditary ophthalmological pathology was 31
children (0-16 years old). The examination included clinical
(ophthalmoscopy, biomicroscopy, gonyoscopy, visometry,
tonometry), instrumental (electrophysiological, ultrasound,
etc.), genealogical and molecular genetic (NGS, direct
Sanger sequencing, MLPA) research methods. Results.
Accounting the topographical principle, mutations in the
PAX6 gene led to lesions in both the anterior and posterior
segments of the eyeball. Structures such as the optic disc
and/or macular zone (posterior segment) are affected in
100% of cases. The lesion of the anterior segment of the eye
is characterized by the involvement of different structures in
the process: 6 patients had corneal changes of different
grades (ex.; c. 1184-2_1184delAGGinsGGA PAX6 het; c.
1184-2_1184delAGGinsGGA PAX6 het); in 5 cases -
pathology of the lens (NM_000280. 4(PAX6_v001):c.
765G>A het synchronous splicing); 7 patients had different
grades of iris pathology. One patient with mutation
NM_000280.4(PAX6_v001):c.109dupG had a congenital
malformation-colobomatous microphthalmos. Two patients
had anterior segment dysgenesis (corneal, iris, anterior
chamber angle, lens) (c.142-139T>C PAX6 IVS5a-3T>C
het; c.718C>T, p.(Arg240*)). Mutations in the PAX6 gene
have a multitopographic effect on the eye, with the devel-
opment of pathology in the anterior and posterior segments
of the eyeball. Supported by RFBR grant 18-015-00090. All
authors haven’t conflict of interest.
V.V. Kadyshev: None. T.A. Vasilyeva: None. A.V.
Marakhonov: None. S.I. Kutsev: None. R.A.
Zinchenko: None.
P02.57.B
Nine Tunisian patients with typicalPeters plus syndrome
M. Guirat, S. Guidara, H. Kanoun, I. Boujelbene,
N. Gharbi, I. B. Ayed, F. Abdelhedi, H. Kamoun,
N. Belguith
Service de génétique médicale, CHU Hedi Chaker, Sfax,
Tunisia
Peters plus syndrome is an autosomal recessive rare dis-
order comprising ocular anterior segment dysgenesis, short
stature, hand abnormalities, distinctive facial features. It
was related only to mutations in the B3GALTL gene
(13q12.3), leading to the inactivation of the B1, 3-
glucosyltransferase. In this study, we report 9 patients
with typical Peters plus syndrome. Ocular abnormality,
facial dysmorphism, and rhizomelic dwarfism were present
in all cases. We noted the presence of 2 new anomalies not
previously described in Peters Plus syndrome, namely renal
malformation and sexual ambiguity. Total sequencing of the
B3GALTL gene showed the presence of the splicing muta-
tion (c.597-2A> G) in the B3GALTL gene in 7 patients. This
mutation harbours a novel splice site mutation in the
B3GALTL gene that modulates the mRNA secondary
structure. These data confirm a key role of the genetic study
that provides diagnosis confirmation and improves genetic
counseling for the families
M. Guirat: None. S. Guidara: None. H. Kanoun: None.
I. Boujelbene: None. N. Gharbi: None. I.B. Ayed: None.
F. Abdelhedi: None. H. Kamoun: None.
N. Belguith: None.
P02.58.C
Severe forms of presbycusis are caused by very rare
variants in genes underlying early-onset forms of
deafness
S. boucher1, F. Wong Jun Tai2, A. Lelli3, S. Delmaghani3,
A. Singh-Estivalet3, T. Dupont3, V. Michel3, N. Wolff4, A.
Bahloul3, M. Niasme-Grare5, A. Bouaita3, D. Oficjalska-
Pham3, S. Chardenoux3, Y. Bouyacoub6, D. Bouccara7, O.
Deguine8, B. Fraysse8, L. Collet9, H. Thai-Van10, E.
Ionescu9, J. Kemeny11, F. Giraudet12, J. Lavieille13, A.
Devèze13, A. Roudevitch-Pujol14, V. Christophe15, C.
Renard16, V. Franco-Vidal17, C. Thibult-Apt17, V.
Darrouzet17, E. Bizaguet18, A. Coez19, A. Aubois14, G.
Lefèvre3, N. Michalski3, P. Avan20, C. Bonnet3, C. Petit21
1INSERM UMRS1120, Institut de l’Audition, Pasteur
Institute and University Hospital of Angers, Paris, France,
2INSERM UMRS1120 and Institut de l’Audition, Pasteur
Institute, Paris, France, 3INSERM UMRS1120, Institut de
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l’Audition, Pasteur Institute, Paris, France, 4Institut
Pasteur, Unité de RMN des Biomolécules, UMR 3528,
CNRS, Paris, France, 5Service de Biochimie et Biologie
Moléculaire, Hôpital d’Enfants Armand-Trousseau, AP-
HP, Paris, France, 6INSERM UMRS1120, Pasteur Institute,
Paris, France, 7Hôpital Beaujon, Hôpitaux Universitaires
Paris Nord val-de-Seine, APHP, Paris, France, 8Centre
Hospitalier Universitaire de Toulouse, Hôpital Larrey,
Service d’Oto-Rhino-Laryngologie et Chirurgie Cervico-
Faciale, Toulouse, France, 9Centre Hospitalier Universi-
taire, Hôpital Lyon-Sud, Audiologie et Explorations
Orofaciales, Lyon, France, 10Centre Hospitalier Universi-
taire, Hôpital Lyon-Sud, Audiologie et Explorations
Orofaciales and Institut de l’Audition, Lyon and Paris,
France, 11Centre Hospitalier Universitaire de Clermont
Ferrand, Hôpital Gabriel Montpied, Service d’Anatomo-
Pathologie, Clermont Ferrand, France, 12Centre Hospita-
lier Universitaire de Clermont Ferrand, Hôpital Gabriel
Montpied, Service d’Anatomo-Pathologie, UMR 1107,
INSERM and Centre Jean Perrin, Clermont Ferrand,
France, 13Centre Hospitalier Universitaire de Marseille,
Hôpital Nord, Service d’Oto-Rhino-Laryngologie, Mar-
seille, France, 14Centre Hospitalier National d’Ophtalmo-
logie des Quinze-Vingts, Centre d’Investigation Clinique,
Paris, France, 15Centre Hospitalier Universitaire de Lille,
Hôpital Roger Salengro, Service d’Otologie et Otoneur-
ologie, Lille, France, 16Laboratoire d’Audiologie Renard,
Lille, France, 17Centre Hospitalier Universitaire de Bor-
deaux, Hôpital Pellegrin, Service d’Oto-Rhino-Laryngolo-
gie et Chirurgie Cervico-Faciale, Bordeaux, France,
18Laboratoire de Correction Auditive, Paris, France,
19Laboratoire de Correction Auditive and CEA-Inserm
U1000 Neuroimaging and Psychiatry and DRM, DSV,
Service Hospitalier Frédéric-Joliot, Paris, France,
20INSERM UMR 1107, Laboratoire de Biophysique Neu-
rosensorielle, Université d’Auvergne, Facultés de Médecine
et de Pharmacie, Clermont Ferrand, France, 21INSERM
UMRS1120, Institut de l’Audition, Pasteur Institute and
Collège de France, Paris, France
Introduction: Presbycusis is a major public health issue
world wide with half its variance due to genetic predis-
position. The aim of this study was to identify presbycusis
causative genes by whole exome sequencing (WES).
Patients and methods: We analysed 105 families,
122 simplex cases and 120 normal-hearing controls. After
an in silico bioinformatic analysis to select predicted
pathogenic variants, and according to the autosomal
dominant mode of inheritance in 95% of the families, we
studied very rare heterozygous variants (allele frequency :
AF≤0.0001).
Results: We found a significative higher ratio of
pathogenic variants in autosomal dominant deafness genes
carried by 24.7% of mARHL and 21,8% of sARHL (aside
from three individuals carrying GJB2 biallelic variants) than
in the controls (6,7%) (p < 0,001). By studing a mouse
model Tmc1N321I, we confirmed the pathogenicity of the
mutation leading to congenital moderate hearing loss in
homozygous mice due to a reduced mechanotransduction
current amplitude, and to a progressive hearing loss
beginning at 7 months and affecting the high frequencies
in heterozygous carriers, validating also the mutation as
responsible for a monogenic form of presbycusis.
Conclusions: WES unraveled that a large proportion of
severe presbycusis is due to new mutations in autosomal
dominant deafness genes arguing for a genetic continuum
between early-onset deafness and presbycusis. We demon-
strated also the existence of monogenic forms of presby-
cusis that could be targetted by new personnalized therapies
like gene therapy. This study was supported by a grant from
“Fondation pour l’Audition” and also by the LabEx
Lifesenses (ANR-10-LABX-65).
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P02.59.A
Genetic analysis of a Dutch discovery cohort suggests an
association between primary open-angle glaucoma and
the mitochondrial variant m.11915G/A in the MT-ND4
gene
V. Lo Faro1, I. Nolte1, J. ten Brink2, H. Snieder1, N.
Jansonius1, A. Bergen2
1UMCG, Groningen, Netherlands, 2AMC, Amsterdam,
Netherlands
Introduction: To determine a possible association between
mitochondrial variations and primary open-angle glaucoma
(POAG) in a Dutch discovery cohort.
Materials and Methods: 140 mtDNA single nucleotide
polymorphisms (SNPs) were genotyped using the Illumina
Infinium Global Screening Array-24 (GSA) 700K array set.
Genetic analysis was performed in a case-control discovery
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cohort of 734 patients with POAG and 1,417 controls. The
variants were classified and analyzed both as single SNPs
and as haplogroups. SNP association was performed using
logistic regression. The bioinformatics software HaploGrep
was used to determine the haplogroup. The Chi-square test
and Fisher’s two-sided exact test were used for haplogroups
association.
Results: For discovery, a nominal association with
POAG was found for the allele A of m.11915G/A
(rs2853496, p=0.016), within the MT-ND4 gene. The odds
ratio was 0.80 (95% confidence interval 0.67-0.95) per copy
of the rare allele and adjusted for gender. No haplogroup
was associated with POAG in our cohort.
Conclusions: The present study reinforces the concept
that mitochondrial variation contributes to POAG suscept-
ibility. Further genetic and functional studies are required to
highlight the pathophysiological mechanisms underlying
primary open-angle glaucoma.
V. Lo Faro: None. I. Nolte: None. J. ten Brink: None.
H. Snieder: None. N. Jansonius: None. A. Bergen: None.
P02.61.C
Whole Exome analysis versus a targeted panel for Polish
patients with retinal dystrophies
E. Matczyńska1,2, P. Łyszkiewicz1, A. Wasowska1,2, R.
Szymańczak1, K. Stradomska1, E. Suchecka1, M.
Jędrzejowska1, S. Teper2, M. Wiącek3, A. Machalińska3, A.
Boguszewska-Chachulska1
1Genomed SA, Warsaw, Poland, 2Chair and Clinical Dept.
of Ophthalmology, Medical University of Silesia, Katowice,
Poland, 3Pomeranian Medical University, Szczecin,
Poland
A Whole Exome Sequencing (WES) approach was adopted,
as a part of the recently accomplished NeuStemGen project,
for identifying genetic causes of inherited retinal dystro-
phies (IRD) in a cohort of Polish patients. Project outcomes
prompted the development of a targeted retinal panel,
covering most pathogenic variants occurring in the Polish
population.
WES was performed for 105 patients with clinical
symptoms of retinal dystrophies. A targeted panel, consist-
ing of 278 IRD genes (including deep intronic regions for
ABCA4), was used to sequence 29 IRD samples, including
6 samples not resolved by WES. Bioinformatic analysis was
performed using standard BWA-GATK best practice pipe-
line and several databases, including POLGENOM, for
variant frequency filtration. Copy number variants (CNVs)
were analysed using the CoNVaDING program.
Over 50 pathogenic/potentially pathogenic variants were
identified using the WES analysis, involving genes already
known to cause IRD. The diagnostic yield of this approach,
however, did not exceed 60%. The pilot sequencing of the
targeted retinal panel resulted in a significantly higher
coverage (389x vs 78x), 98-99% concordance of identified
variants and allowed to develop a CNV analysis pipeline.
Data obtained using these two approaches were compared
and support the decision of applying the large targeted panel
for routine diagnostics of retinal dystrophies. This approach,
focused on the complete set of retinal genes, assuring a high
quality coverage and allowing for reliable analysis of CNVs
and deep intronic variants, should be most efficient and
cost-effective for a large cohort of Polish patients.
Partially supported by STRATEGMED1/234261/2/
NCBR/2014.
E. Matczyńska: None. P. Łyszkiewicz: None. A.
Wasowska: None. R. Szymańczak: None. K. Stra-
domska: None. E. Suchecka: None. M. Jędrzejowska:
None. S. Teper: None. M. Wiącek: None. A. Macha-
lińska: None. A. Boguszewska-Chachulska: None.
P02.63.B
A genetic and clinical study of families with non-
syndromic retinopathy consequent upon sequence var-
iants in HGSNAT, the gene causing Sanfilippo C
mucopolysaccharidosis
E. R. Schiff1,2, G. Arno1,2,3, K. Pierpoint1, R. Ba-Abbad1,2,
S. Nutan4, O. A. Mahroo1,2,5, M. Michaelides1,2, K. Harvey6,
A. R. Webster1,2
1Genetics Service, Moorfields Eye Hospital, London, United
Kingdom, 2UCL Institute of Ophthalmology, London,
United Kingdom, 3North East Thames Regional Genetics
Service, Great Ormond Street Institute of Child Health,
London, United Kingdom, 4London North Genomic
Laboratory Hub, Great Ormond Street NHS Foundation
Trust, London, United Kingdom, 5Section of Ophthalmol-
ogy, King’s College London, London, United Kingdom,
6Enzyme Unit, Chemical Pathology, Paediatric Laboratory
Medicine, Great Ormond Street Hospital for Children NHS
Foundation Trust, London, United Kingdom
Distinct genotypes in several genes (e.g. USH2A, FLVCR1,
CEP290, CLN3, MFSD8) have been shown to be associated
with either syndromic or non-syndromic forms of retinitis
pigmentosa (RP), a progressive degenerative condition
initially affecting rod photoreceptors with subsequent cone
phototreceptor loss; RP is the most prevalent form of
inherited retinal disease (IRD), which is the commonest
cause of blindness in the working-age population of Eng-
land and Wales. HGSNAT (heparan-α-glucosaminide N-
acetyltransferase) sequence variants cause mucopoly-
saccharidosis type IIIC (MPS-IIIC) or Sanfilippo C
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syndrome - a severe childhood-onset lysosomal storage
disorder. Specific genotypes have, however, been associated
with isolated retinal disease in a few reported individuals,
thereby further extending the genes that can result in both
syndromic and non-syndromic IRD. We have identified
likely pathogenic variants in 13 individuals (11 families)
with late onset (30s to 60s) and slowly progressing RP.
None showed any other symptoms of MPS-IIIC. 7/11
families were compound heterozygotes with the allele
c.1843G>A, p.(Ala615Thr). We detected 6 novel sequence
variants (p.(Ser296Leu); p.(Phe428Cys); p.(Gly248Ala); p.
(Gly418Arg), c.1543-2A>C; c.1708delA), and 5 variants
that were previously described in MPS-IIIC patients. In one
family, two siblings, genetically identical for the HGSNAT
locus, were discordant for retinal disease. A mild but sig-
nificant reduction of HGSNAT enzyme activity in leuko-
cytes was observed in affected individuals but urinary
glucosaminoglycans were not elevated. This case series
expands the phenotypic and genotypic spectrum of non-
syndromic HGSNAT-associated retinopathy, and in one
family suggests the influence of trans-acting modifying
factors. Funding: NIHR BRC, Moorfields Eye Hospital and
UCL Institute of Ophthalmology.
E.R. Schiff: None. G. Arno: None. K. Pierpoint: None.
R. Ba-Abbad: None. S. Nutan: None. O.A. Mahroo:
None. M. Michaelides: None. K. Harvey: None. A.R.
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P02.64.C
First systematic molecular genetic analysis using NGS
analysis of 100 Greek patients with retinal dystrophy
S. Kamakari1, S. Koukoula2, V. Kokkinou1, L. Haer-
Wigman3, I. Datseris4, M. Tsilimbaris5
1Ophthalmic Genetics Unit, Athens, Greece, 2Ophthalmica
Institute of Ophthalmology and Microsurgery, Thessaloniki,
Greece, 3Department of Human Genetics, Donders Centre
for Neuroscience, Radboud University Nijmegen Medical
Centre, Nijmegen, Netherlands, 4Department of Retinal
Disorders, OMMA Ophthalmological Institute of Athens,
Athens, Greece, 5Department of Ophthalmology, University
of Crete School of Medicine, Heraklion, Greece
Purpose: Inherited Retinal Dystrophies (IRDs) are char-
acterized by clinical variability and genetic heterogeneity.
The aim of this study was to molecularly diagnose 100
Greek patients with different forms of IRDs.
Materials and Methods: 100 unrelated Greek patients
were analyzed by Next Generation Sequencing (NGS), 13
and 87 of them using a 105 retinal and a 287 ophthalmic
gene panel, respectively as described (Ellingford JM et al. J
Med Genet 2016, Haer-Wigman L et al. Eur J Hum Genet.
2017). Additional analysis methods were used (Sanger,
MLPA, array-CGH) in 6 cases.
Results: Potentially pathogenic mutations were detected
in 45 retinal dystrophy genes including ABCA4, PRPF31,
SPATA7, MERTK, FAM161A, CDHR1, USH2A,
CNGB1, PROM1 and RP2 genes. The detection mutation
rates were 46.15% (6/13) and 81.6% (71/87) for the 105 and
287 gene panels, respectively. These mutation rates were
achieved using complementary methods in 6 cases. Final
diagnoses included retinitis pigmentosa, Usher syndrome,
cone-rod dystrophy and Leber congenital amaurosis and
two rare cases of Knobloch and Oliver-McFarlane syn-
dromes due to mutations in the COL18A1 and PNPLA6
genes, respectively.
Conclusions: This is the first systematic investigation of
the molecular identity of 100 Greek patients with various
subforms of IRDs by NGS and complementary methods
leading to an overall mutation rate of 77%. A plethora of
novel mutations was documented further expanding the
genetic heterogeneity. The molecular identification estab-
lished the complete diagnosis of the patients thus
contributing to family making decision, prognosis and
candidacy to current and future treatments.
S. Kamakari: None. S. Koukoula: None. V. Kokkinou:
None. L. Haer-Wigman: None. I. Datseris: None. M.
Tsilimbaris: None.
P02.65.A
A possible epistatic interaction of two variants in
autosomal dominant retinitis pigmentosa
R. A. Zinchenko, T. A. Vasilyeva, V. V. Kadyshev, A. V.
Marakhonov
Research Center for Medical Genetics, Moscow, Russian
Federation
Retinitis pigmentosa (RP) refers to a heterogeneous group
of inherited ocular diseases that result in a progressive ret-
inal degeneration affecting 1 in 3,000 to 5,000 people. To
date, more than 80 genetic forms of RP are described. Here
we perform genetic analysis of the two-generation family
with 5 affected members with the terminal severe stage of
RP. Whole exome sequencing (WES) of one of the patients
revealed two candidate variants. The first one is pathogenic
variant in the exon 16 of SNRNP200 gene
(chr2:96958829G>A), leading to the missense substitution
(p.Arg681Cys, NM_014014.4) in the heterozygous state.
Mutations in the SNRNP200 gene in heterozygous state
were described in patients with RP33 (OMIM 610359). The
second variant is a novel single nucleotide variant in exon 1
of the PRPH2 gene (chr6:42689991C>T) resulting in the
missense substitution (p.Val28Met, NM_000322.4) in a
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heterozygous state. Mutations in the PRPH2 gene in het-
erozygous, compound heterozygous and homozygous states
were described in patients with Leber congenital amaurosis
18 (OMIM:608133), RP7 (OMIM:608133), retinitis punc-
tata albescens (OMIM:136880), in heterozygous state - in
patients with choroidal dystrophy, central areolar 2
(OMIM:613105), macular dystrophy, patterned, 1
(OMIM:169150), macular dystrophy, vitelliform, 3
(OMIM:608161). Segregation analysis revealed SNRNP200
to be co-segregated with the disease while PRPH2 variant
was not found in 2 out of 5 patients. Nevertheless, it could
make an impact on the clinical presentation by aggravation
of clinical picture in patients bearing two variants. Sup-
ported by grant RFBR № 18-015-00090 and state task of
the Ministry of education and science of Russia.
R.A. Zinchenko: None. T.A. Vasilyeva: None. V.V.
Kadyshev: None. A.V. Marakhonov: None.
P02.68.A
Loss of function of RIMS2, a synaptic membrane
exocytosis gene, causes a new phenotype characterized
by congenital cone-rod synaptic disease associated with
neurodevelopmental and pancreatic involvement
S. Mechaussier1, B. Almoallem2, C. Zeitz3, K. Van Schil2, L.
Jeddawi4, J. Van Dorpe5, C. Condroyer3, O. Pelle6, M.
Polak7, N. Boddaert8, N. Bahi-Buisson9, M. Cavallin10, J.
Bacquet11, A. Mouallem-Bézière11, O. Zambrowski11,12, J.
Sahel3,13,14, I. Audo3,14,15, J. Kaplan1,11, J. Rozet1, E. De
Baere2, I. Perrault1
1Laboratory of Genetics in Ophthalmology (LGO),
INSERM UMR1163, Institute of Genetic Diseases, Imagine
and Paris University, Paris, France, 2Center for Medical
Genetics, Ghent University and Ghent University Hospital,
Ghent, Belgium, 3Sorbonne Université, INSERM, CNRS,
Institut de la Vision, Paris, France, 4Pediatric Ophthalmol-
ogy Division, Dhahran Eye Specialist Hospital, Dhahran,
Saudi Arabia, 5Department of Pathology, Ghent University
and Ghent University Hospital, Ghent, Belgium, 6Cell
Sorting Facility, INSERM UMR1163, Institute of Genetic
Diseases, Imagine and Paris University, Paris, France,
7Endocrinology, Gynecology and Pediatric Diabetology
Department, University Hospital Necker-Enfants Malades,
Paris, France, 8Department of Pediatric Radiology, Hôpital
Necker-Enfants Malades, Paris University, Paris, France,
9Pediatric Neurology Department, University Hospital
Necker-Enfants Malades, Paris, France, 10Laboratory of
Embryology and genetics of human malformation, INSERM
UMR1163, Institute of Genetic Diseases, Imagine and Paris
University, Paris, France, 11Service d’Ophtalmologie,
Centre Hospitalier Intercommunal de Créteil (CHIC),
Créteil, France, 12Ophthalmology Department, University
Hospital Necker-Enfants Malades, Paris, France,
13Department of Ophthalmology, The University of Pitts-
burgh School of Medicine, Pittsburgh, PA, United States,
14Centre Hospitalier National d’Ophtalmologie des Quinze-
Vingts, INSERM-DHOS CIC 1423, Paris, France, 15Insti-
tute of Ophthalmology, University College of London,
London, United Kingdom
Introduction: Anomalies in pre- and post-synaptic trans-
mission of visual information from photoreceptors to
bipolar cells are responsible for stationary congenital night
blindness (CSNB). Pre-synaptic disorders, characterized by
congenital nystagmus and photophobia, night blindness, are
known as cone-rod synaptic disorder (CRSD) can be mis-
taken for Leber congenital amaurosis (LCA). Full-field
electroretinogram is crucial for the differential diagnosis,
but it can be difficult to perform in young children. Here, we
report (i) the identification of biallelic mutations in the
RIMS2 gene encoding a pre-synaptic protein not yet asso-
ciated with human diseases in 3/4 families initially referred
for LCA and (ii) the diagnostic adjustment to CRSD with
variable associated alteration including autistic behavior
and insulinopathy.
Methods: Exome sequencing combined with targeted
RIMS2 testing were performed in 46 prescreened patients
with CRSD and 94 with LCA. Biallelic RIMS2-mutated
cases underwent ophthalmologic, neurologic and metabolic
assessment. RIMS2 immunostaining was performed on
human retina, brain and pancreas. Nonsense variants were
functionally investigated in mammalian cells.
Results: Biallelic RIMS2 sequence variants were found in
four unrelated families. RIMS2, a protein regulating
synaptic membrane exocytosis localizes in the human
retinal outer plexiform layer, Purkinje cells and pancreatic
islets. Apart from CRSD, neurodevelopmental disease was
observed in all cases, and abnormal glucose homeostasis in
the eldest patient. Nonsense variants lead to truncated
RIMS2 and decreased insulin secretion in mammalian cells.
Conclusions: This is the first report of syndromic CRSD
with neurodevelopmental or pancreatic involvement due to
RIMS2 loss-of-function. The disease presentation is con-
sistent with the localization and function of RIMS2.
S. Mechaussier: None. B. Almoallem: None. C. Zeitz:
None. K. Van Schil: None. L. Jeddawi: None. J. Van
Dorpe: None. C. Condroyer: None. O. Pelle: None. M.
Polak: None. N. Boddaert: None. N. Bahi-Buisson: None.
M. Cavallin: None. J. Bacquet: None. A. Mouallem-
Bézière: None. O. Zambrowski: None. J. Sahel: None.
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P02.69.B
Whole exome sequencing in Slovak patients with
bilateral sensorineural hearing impairment
Z. Slobodova1,2, L. Varga1,2, S. Borecka2, I. Masindova1, D.
Danis1, L. Langova3, M. Skopkova1, M. Profant2, D.
Gasperikova1
1Biomedical Research Center, Slovak Academy of Sciences,
Bratislava, Slovakia, 2Department of Otorhinolaryngology–
Head and Neck Surgery, Faculty of Medicine, Bratislava,
Slovakia, 3Pediatric ENT Department of Medical Faculty
and National Institute of Child Diseases, Bratislava,
Slovakia
Background: The genetic heterogeneity of sensorineural
hearing loss (SNHL) is a major hurdle to the discovery of
disease-causing variants. Whole exome sequencing (WES)
is a method that allows an efficient analysis of all known
genes associated with hereditary hearing loss.
Aim: Using WES to identify new genetic causes of
hearing impairment in the Caucasian and Roma populations
in Slovakia, where standard genetic tests performed so far
have not elucidated the etiology of deafness.
Patients and methods: We collected 1,369 individuals
from 870 families with bilateral SNHL. The previous
analysis revealed that 30% of the families have mutations in
the DFNB1 locus. From the DFNB1 negative patients we
selected 52 families, 42 of Caucasian and 10 of Roma
ethnicity, for WES.
Results: Using WES, we identified the genetic etiology in
22 probands of Caucasian ethnicity and in 1 proband of
Roma ethnicity. The detected variants were found in 18
genes (COCH, COL4A5, CREBBP, EDNRB, EYA4, ILDR1,
LOXHD1, MYO6, MYO15A, OTOA, OTOG, P2RX2, SIX1,
TECTA, TMC1, TMPRSS3, DIAPH1, USH1C) harboring 17
pathogenic variants and 11 likely pathogenic variants
responsible for hearing impairment. 16 variants have not
yet been described in the literature. In one Roma family the
causal variants were found in two genes (PTPRQ and
MYO15A) in one individual.
Conclusion: Using WES, we detected the genetic
etiology of hearing impairment in 52% probands of
Caucasian ethnicity and 10% of Roma probands. WES
dramatically increases the detection of pathogenic variants
in known genes associated with HL. Supported by: VEGA
1/0214/16, APVV 15-067
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P02.70.C
Genotype-phenotype correlations in a Spanish cohort of
506 families with bi-allelic ABCA4 mutations
M. del Pozo-Valero1, R. Riveiro-Álvarez1, F. Blanco-Kelly1,
J. Aguirre-Lamban1, I. Martín-Mérida1, I. Iancu1, S.
Swafiri1, I. Lorda-Sanchez1, E. Rodriguez-Pinilla1, M.
Trujillo-Tiebas1, B. Jiménez-Rolando2, E. Carreño2, I.
Mahillo-Fernandez3, C. Rivolta4, M. Corton1, A. Avila-
Fernandez1, B. García-Sandoval2, C. Ayuso1
1Department of Genetics, Instituto de Investigación
Sanitaria–Fundación Jiménez Díaz University Hospi,
Madrid, Spain, 2Department of Ophthalmology, Instituto
de Investigación Sanitaria–Fundación Jiménez Díaz Uni-
versity Hospi, Madrid, Spain, 3Department of Epidemiol-
ogy, Instituto de Investigación Sanitaria–Fundación
Jiménez Díaz University Hospi, Madrid, Spain, 4Institute
of Molecular and Clinical Ophthalmology Basel (IOB),
Basel, Switzerland, Basel, Switzerland
Introduction: ABCA4 is the most mutated gene in inherited
retinal dystrophies. A genotype-phenotype correlation
model was described in 1999 with few cases reported. Here,
we define genotype-phenotype correlations in the largest
cohort study worldwide of patients: 434 with Stargardt
disease (STGD1) and 72 with cone-rod dystrophy (CRD),
all carrying biallelic ABCA4 mutations.
Methods: Conventional genetic tools and Next Genera-
tion Sequencing technologies. Medical history and ophthal-
mological data were obtained for 372 patients. Genotype-
phenotype correlation studies were carried out for the
following variables: variant type, age at onset of symptoms
(AO), and clinical phenotype (STGD1 or CRD).
Results: Genotype-phenotype correlations showed that
patients with biallelic truncating variants represented 41%
of CRD and 6.5% of STGD1 patients in our cohort; these
cases had a significantly earlier AO than patients carrying
two mutations, one of which is a missense variant. CRD
patients presented earlier AO than STGD1 patients.
Conclusions: Our study, conducted in the largest
ABCA4-associated disease cohort reported to date, supports
the genotype-phenotype model established for ABCA4
variants, and broadens the mutational spectrum of the
gene. ABCA4 truncating variants were mostly associated
with earlier AO and a CRD phenotype. According to
our observations, ABCA4 patients presenting with two
truncating variants may first present features of STGD1
but eventually develop rod dysfunction, underscoring
the importance of an accurate genetic diagnosis.
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3721), Conchita Rábago Foundation, Autonomous Com-
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P02.73.C
Functional characterization of a Xenopus tropicalis
knockout and a human cellular model of RCBTB1-
associated inherited retinal disease shows involvement of
RCBTB1 in the cellular response to oxidative stress
M. Carron1,2, T. Naert1, G. Ascari2, S. Demuynck1, T. Van
Nieuwenhuyzen1, T. Rosseel2, D. Priem3,4, A. Kremer4, H.
Van Landeghem1, S. Hoogstoel2, F. Coppieters2, C.
Guérin5, K. Vleminckx1, E. De Baere6
1Ghent University, Biomedical Molecular Biology, Ghent,
Belgium, 2Ghent University, Center for Medical Genetics
and Dept of Biomolecular Medicine, Ghent, Belgium,
3Ghent University, Ghent, Belgium, 4VIB-UGent Center
for Inflammation Research, Ghent, Belgium, 5VIB Bioima-
ging Core, Ghent, Belgium, 6Ghent University and Ghent
University Hospital, Center for Medical Genetics and Dept
of Biomolecular Medicine, Ghent, Belgium
Introduction: The function of RCBTB1, recently impli-
cated in syndromic and non-syndromic inherited retinal
disease (IRD), remains unknown so far. Patients with
biallelic missense variants in RCBTB1 display diverse IRD
phenotypes such as retinitis pigmentosa. Here, we tested the
hypothesis that RCBTB1 is involved in NRF2-regulated
protection against reactive oxygen species in the eye, more
specifically in the retinal pigment epithelium (RPE).
Materials and Methods: A Xenopus tropicalis rcbtb1−/−
knockout (KO) was generated using CRISPR/Cas9 editing.
Histology and three-dimensional electron microscopy was
performed on retinas of rcbtb1−/− frogs. RNA-seq analysis
was performed on RCBTB1-mutated patients’ lymphocytes,
treated with H2O2, as well as on embryos from the rcbtb1
−/− KOs treated with CdCl2. An RCBTB1 knockdown cell
line was generated in ARPE-19 cells and functional assays
(flow cytometry, MTT-assay, cell death kinetics) assessed
the consequences of RCBTB1 loss-of-function.
Results: Rcbtb1−/− animals showed changes in the RPE,
similar to observations in human cases, including loss of
apical-basal cell polarity, cuboidal cell morphology,
spreading of the pigment granules and vacuolisation.
NRF2 downstream targets and several metallothioneins
were found to be differentially expressed, both in the KO
and cellular models. Functional assays in ARPE-19 cells
revealed that RCBTB1 depletion affects cellular responses
to external insults of oxidative stress.
Conclusions: We showed that the Xenopus tropicalis
rcbtb1−/− KO recapitulates the human IRD phenotype.
Both in vivo and in vitro functional data show involvement
of RCBTB1 in the cellular response to oxidative stress. This
provides insight into the mechanism underlying RCBTB1-
associated IRD and uncovers potential therapeutic
opportunities.
Funding: FWO/1802220N; FWO/1S52818N; BOF15/
GOA/011; BOF20/GOA/023.
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P03 Internal Organs & Endocrinology (Lung, Kidney,
Liver, Gastrointestinal)
P03.01.A
A cost effective experience in diagnosis of autosomal-
dominant polycystic disease by custom-target NGS
panel in a reference center.
J. NEVADO1,2, R. Mena1, R. Peces3, M. Melgosa4, A.
Alonso4, R. Selgas3, L. Espinosa4, P. Barruz1, P. D.
Lapunzina1,2
1INGEMM-IdiPaz, Madrid, Spain, 2CIBERER, Madrid,
Spain, 3Sº Nefrología Adultos, HULP, Madrid, Spain, 4Sº
Nefrología Infantil, HULP, Madrid, Spain
ADPKD is the most common inherited kidney disease that
is caused by mutations in the PKD1/PKD2. Most mutations
take place in PKD1. Its molecular diagnosis is a challenge
by the high allelic heterogeneity and overlap of pseudo-
genes between 1-32 exons. So far, there are few data on
PKD1/PKD2 variants in the Spanish population. The main
objective of this study has been to establish and know the
mutations in ADPKD in our cohort. Mutational analysis of
both PKD1 and PKD2 was performed on 158 unrelated
families, by NGS using a custom exon-target panel from
inherited nephropathies, Nephroseq®. To confirm SNVs,
Long-Range-PCR and Sanger sequencing were performed
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on PKD1 or PCR, and Sanger sequencing for PKD2. In
addition, MLPA was used to rule out CNVs. SNVs were
identified in 122 families (77.23%): 96 families in PKD1
(78.7%) and 26 families in PKD2 (22.3%). Globally: 64
frameshift and nonsense; 11 splicing, 36 missense, 8 in
frame ins/del, and 4 large-deletions). Overall, 15% of var-
iants were de novo and 50% were not previously described.
This study demonstrates that NGS is a cost-effective
experimental approach for simultaneous analysis of the
PKD1 and PKD2. The analysis of mutations in the
ADPKD-Spanish population expands the understanding of
the genetic diversity of the different ethnic groups, enriches
the databases with the new mutations, and contributes to
their genetic counselling. As well as, reproductive (six
pregnancies were currently successful) and/or therapeutic
decision-making (a significant number of patients with
highly pathogenic variants are currently under treatment
with Tolvaptan).
J. Nevado: None. R. Mena: None. R. Peces: None. M.
Melgosa: None. A. Alonso: None. R. Selgas: None. L.
Espinosa: None. P. Barruz: None. P.D.
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P03.04.A
Clinical and molecular characteristics of young Russian
patients with homo- and heterozygous AIRE mutations
E. N. Suspitsin1,2, L. V. Ditkovskaya1, T. V. Gabrusskaya1,
N. B. Ulanova1, D. L. Strekalov1, M. N. Guseva1
1St.-Petersburg State Pediatric Medical University, St.-
Petersburg, Russian Federation, 2N.N. Petrov Institute of
Oncology, St.-Petersburg, Russian Federation
Introduction: Hereditary defects of the AIRE gene are
associated with a rare autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy syndrome (APECED).
The disorder has been found in many populations world-
wide. The clinical manifestations are quite variable even
within families, but major features include hypoparathyr-
oidism, Addison disease, and mucocutaneous candidiasis.
Although the condition usually follows autosomal-recessive
inheritance there is an increasing body of evidence that
some cases may be caused by monoallelic gain-of-function
(GOF) mutations.
Materials and methods: 10 Russian patients (age 3-18
years) were subjected to the AIRE gene analysis. Of those,
5 had clinical signs of APECED syndrome suspected by
immunologist, gastroenterologist or endocrinologist. In
these patients Sanger sequencing of AIRE was performed.
Another 5 patients underwent targeted sequencing of
primary immunodeficiency (PID) genes including AIRE
because of suspected PID condition.
Results: 6 patients had biallelic AIRE mutations with the
common c.769C>T (p.R257*) allele being detected in 4
individuals. One patient was homozygous for c.173C>T (p.
A58V) variant recently described in Russian patients
(Orlova et al, 2017). Rare c.32T>C (p.L11P) mutation
was reported in Russian population for the first time. All
monoallelic mutations (n = 4) were represented by the
c.901G>A (p.V301M) allele. This variant altering func-
tional properties of the protein was once reported in a
Russian female with late-onset classical APECED (Oftedal
et al, 2015).
Conclusions: Our study indicates that some GOF variants
of AIRE are common in young Russian patients with
manifestations of autoimmune disease.
This work was supported by RFBR grant 17-29-06069
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Genetic and molecular analysis of urinary magnesium
concentration in Scottish and Croatian populations
C. B. Joseph1, C. M. Stanton1, C. Drake1, T. S. Boutin1, J.
F. Wilson2, O. Polasek3, O. Devuyst4, T. Hurd1, C.
Hayward1
1MRC Human Genetics Unit, Institute of Genetics and
Molecular Medicine, University of Edinburgh, Edinburgh,
United Kingdom, 2Centre for Global Health Research,
Usher Institute for Population Health Sciences and
Informatics, University of Edinburgh, Edinburgh, United
Kingdom, 3Split Medical School, Split, Croatia, 4Institute of
Physiology, University of Zurich, Zurich, Switzerland
Magnesium is the second most abundant bivalent cation in
the body and is essential for many cellular processes. Renal
magnesium handling plays an important role in maintaining
magnesium homeostasis, however the exact biological
mechanisms remain unclear. A recent genome-wide asso-
ciation study (GWAS) identified an association between
urinary magnesium concentration (uMg) and variants in the
ARL15 gene on chromosome 5. ARL15 encodes a GTP-
binding protein that regulates the magnesium transporter
channel TRPM6, and other proteins involved in magnesium
homeostasis in physiologically relevant cell lines. We
conducted meta-analyses for urinary magnesium in 11, 617
individuals from Scottish and Croatian populations to
determine possible genes involved in these traits. Mass
spectrometry analysis was conducted to determine inter-
actors of Arl15 and in-vitro knockout models of Arl15 was
established using CRISPR-Cas9. The top SNP associated
with uMg in our meta-analyses lies within a transcription
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factor binding site in an enhancer region of ARL15. Indi-
viduals homozygous for the alternate allele of rs35931 has
lower urinary magnesium levels compared to individuals
with the homozygous reference allele. Arl15 interacts with
magnesium transporters within the distal convoluted tubule
segment of the kidneys. Furthermore, we find that homo-
zygous deletion of Arl15 is lethal at the organismal level.
We hypothesise that the variant found affects the expression
of ARL15, which, in turn modulates magnesium transport
by regulating magnesium transporters. We are performing
further functional studies to elucidate the role ARL15 plays
in magnesium homeostasis both in vitro and in vivo.
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P03.08.B
Blood chimerism in monochorionic dizygotic twins
(MCDZT) identified at molecular genetic testing of
permanent neonatal diabetes mellitus
B. Lorenz-Depiereux1, U. Ahting2, G. Eckstein1, K.
Warncke3, T. Meitinger1,2, S. Andres2
1Helmholtz Zentrum München German Research Center for
Environmental Health, Institute of Human Genetics, Neuher-
berg, Germany, 2Technical University of Munich, Institute of
Human Genetics, Munich, Germany, 3Technical University of
Munich School of Medicine, Kinderklinik München Schwab-
ing, Department of Pediatrics, Munich, Germany
In most cases dizygotic (DZ) twins have a dichorionic pla-
centa, but in some cases - especially in the context of assisted
reproduction - blood chimerism in DZ twins due to placental
sharing has been shown, identifying them as monochorionic
dizygotic twins (MCDZT). Here we report the first case of
blood chimerism in MCDZT detected as an additional finding
at molecular genetic testing. Dizygotic twin brothers were
born to a female couple after assisted reproduction (IVF,
in vitro fertilization). One presented with permanent neonatal
diabetes mellitus. Molecular genetic analysis identified a
heterozygous pathogenic variant within the insulin gene (INS,
dominant inheritance). Interestingly, the donor of the oocytes
for IVF had been diagnosed with type 1 diabetes as an infant.
Screening for the INS variant in her blood DNA was positive
and altered the diagnosis to permanent neonatal diabetes
mellitus. Testing of the unaffected brother for the INS variant
surprisingly showed that he also carried the INS variant in
blood DNA but not in DNA from buccal membrane cells.
Additional microsatellite studies confirmed blood chimerism
in both twins but ruled out chimerism in buccal membrane
cells. Whether our findings should be classified as confined
blood chimerism which is relatively common, or as an
exceedingly rare reported tissue chimerism has to be eluci-
dated by studies of other tissues.
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Ultra-rare variants in the TRPV6 gene cause autosomal
dominant chronic pancreatitis
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de la Reproduction, Brest, France, 3Department of Gastro-
enterology and Pancreatology, Beaujon Hospital, APHP,
Clichy, and Paris-Diderot University, Paris, France, 4Ser-
vice d’Hépato-Gastro-Entérologie, Cancérologie Digestive
et Assistance Nutritionnelle, CHU Nantes, Nantes, France,
5Médecine ‘Chauvet’ à Orientation Gastro-Entérologique,
CH Gabriel Martin, Saint Paul, France, 6Service de
Gastroentérologie, Hépatologie et Nutrition Pédiatriques,
HCL, Bron, France, 7Service de Médecine à Orientation
Hépato-–Gastro- Entérologique, CH Sud Gironde, Langon,
France, 8Service d’Hépato-Gastro-Entérologie, CHD Ven-
dée, La Roche-Sur-Yon, France, 9Service de Pédiatrie,
CHU Saint-Etienne, Saint-Etienne, France, 10Service d’Hé-
pato-Gastro-Entérologie et Oncologie Digestive, CHR
Orléans, Orléans, France, 11Service de Gastroentérologie
et Pancréatologie, CHU Toulouse, Toulouse, France
Until very recently, variants in the so far reported chronic
pancreatitis (CP) genes such as PRSS1 have been found to
cause/predispose to the disease through increasing trypsin
activity or eliciting endoplasmic reticulum stress. In January
2020, an international collaboration reported association of
functionally deficient variants in the TRPV6 gene with CP,
identifying a novel mechanism of pancreatitis due to Ca2+
dysregulation. This discovery was made essentially by ana-
lyzing young patients with idiopathic CP. Whether TRPV6
variants are responsible for autosomal dominantly inherited
CP remains unknown. Herein, we analyzed the TRPV6 gene
in probands of 235 such families by NGS. All families had at
least two affected members and had remained genetically
unexplained prior to the current analysis. We identified 11
ultra-rare variants (all were absent in 570 French controls and
had an allele frequency of 0-0.000008 in gnomAD) in 11
families. Of the 11 variants, 5 were previously reported to be
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 209
pathogenic. All the remaining six variants were novel, com-
prising a clear loss-of-function variant, a single amino acid
deletion variant, and four missense variants. All these four
missense variants were predicted to be of pathogenic rele-
vance by Polyphen and/or SIFT and had a CADD score
comparable to known pathogenic missense variants. In sum-
mary, we identified ultra-rare TRPV6 variants in ~5% of the
studied families. This establishes TRPV6 as a relatively fre-
quent autosomal dominant CP gene for which genetic testing
is warranted. Our results also suggest that haploinsufficiency
of the TRPV6 gene is sufficient to cause CP. (Work supported
by INSERM).
E. Masson: None. J.M. Chen: None. V. Rebours: None.
M. Le Rhun: None. H. Audin: None. A. Lachaux: None.
B. Caumont: None. D. Lorenzo: None. M. Fron: None.
K. Billiemaz: None. R. Besnard: None. L. Buscail: None.
C. Férec: None.
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TruncatingLBX1mutation in Congenital Central Hypo-
ventilation Syndrome
M. Elbracht, M. Begemann, I. Kurth
Institute of Human Genetics, Aachen, Germany
Undine syndrome, a congenital central hypoventilation
syndrome (CCHS), derives its name from the legend of the
water nymph Ondine/Undine who punished her mortal
husband for his unfaithfulness with a curse of stopping
breathing and dying when he fell asleep. Normally,
increasing CO2 blood levels induce the hypercapnic reflex
which accelerates breathing via specialized neurons of the
pre-Bötzinger complex in the ventral hindbrain. Polyalanine
expansions in PHOX2B and rarely other genes have been
described to cause genetic forms of CCHS by disturbing the
breathing reflex. Recently, a homozygous mutation in the
homeodomain transcription factor LBX1 was reported in
two brothers with neonatal hypoventilation and complex
autonomic symptoms. The mutation affects the C-terminus
of the protein and impairs cooperativity with PHOX2B,
without disrupting the DNA-binding domain. We here
report a female patient with severe hypoventilation who
required continuous mechanical ventilation immediately
after birth. During her first 11 years of life she was supplied
with a tracheostomy and mask ventilation at night because
of episodes of apnea. In childhood, she had severe con-
stipation and, developed a paralytic ileus like Hirschsprung
disease. Since the age of 11 she used a respiratory mask for
sleeping and showed normocapnia. With consequent
breathing control starting immediately after birth the now
23 years old woman developed excellently and completes a
university education. Trio exome sequencing identified a
homozygous frameshift-mutation in LBX1 (hg19:
chr10:102987166del, NM_006562.4:c.707del, p.
(Val236Alafs*59)). Our patient corroborates the role of C-
terminal LBX1 mutations in CCHS and emphasizes the
favorable clinical outcome in case of consequent treatment.
M. Elbracht: None. M. Begemann: None. I.
Kurth: None.
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Deletion and duplication: unusual case of diagnostics for
patient with cystic fibrosis
S. Deryabina1,2, O. Lagutina1, N. Nikitina1, E. Nikolaeva1
1Medical Center “Health Care of Mother and Child”,
Yekaterinburg, Russian Federation, 2Federal State Auton-
omous Educational Institution of Higher Education «Ural
Federal University named after the first President of Russia
B.N. Yeltsin, Yekaterinburg, Russian Federation
Background: Cystic fibrosis (CF) is an autosomal recessive
disease caused by a mutation in the CFTR (cystic fibrosis
transmembrane conductance regulator) gene. Newborn
screening for CF was introduced in the Russian Federation
in 2006. The incidence of CF varies among different
regions, in Sverdlovsk region it is 1: 9,500. The vast
majority of recurrent CFTR variants are point mutations, but
several populations have larger deletions and duplications,
involving one or more complete exons. Here we want to
report a case of CF with simultaneously existing deletion
and duplication of different regions of 11 exon CFTR.
Case presentation: The patient (a 1-month-old girl) was
born at term to non-consanguineous parents. For newborn’s
diagnostics CF we use a three-step IRT/IRT1↑/DNA
algorithm. Our patient had elevated levels of immunor-
eactive trypsinogen both times (328.6 ng/ml and 299.8 ng/
ml respectively). Moreover, the girl had pathological sweat
chlorides - 110 mmol/L.
Results: The trio genetic sequencing of the CFTR gene
showed heterozygous delF508 mutation in exon 11 for the
child and her father. For searching another variant we were
done Multiplex Ligation-mediated Probe Amplification
(MLPA) of the CFTR gene. We have found heterozygous
deletion of exon 9 for the girl and her mother and have proved
the deletion F508 for father, but this analysis has shown also
duplication of exon 11 and 2 copies F508 for proband.
Conclusions: We assume the proband has 3 copies of
exon 11: two normal and one with del508F, and it is the
defect copy, that is crucial for protein synthesis.
S. Deryabina: None. O. Lagutina: None. N. Nikitina:
None. E. Nikolaeva: None.
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Genotypic spectrum of cystic fibrosis in Cyprus with
emphasis on the endemic L346P and the novel
CFTRdup2 cases
A. Matthaiou1, P. Anagnostopoulou1,2, P. Kouis1, V.
Neocleous3, T. Adamidi4, P. Ioannou5, P. Fanis3, C. Costi3,
A. Georgiou4, L. A. Phylactou3, P. Yiallouros1,5
1Medical School, University of Cyprus, Nicosia, Cyprus,
2Institute of Anatomy, University of Bern, Bern, Switzer-
land, 3Cyprus Institute of Neurology and Genetics, Nicosia,
Cyprus, 4Department of Pulmonology, Nicosia General
Hospital, Nicosia, Cyprus, 5Pediatric Pulmonology Unit,
Archbishop Makarios III Hospital, Nicosia, Cyprus
Introduction: The aim of this study was to describe the
epidemiology of CFTR mutations in the cystic fibrosis
population in Cyprus with particular emphasis on the
endemic L346P (p.Leu346Pro) cases and a novel case
which bears the poorly described CFTRdup2 in
homozygosity.
Materials and Methods: The national cystic fibrosis
patients’ registry in Cyprus was searched for the demo-
graphic, diagnostic, and genotypic data of all cases whose
diagnosis was genetically confirmed via the identification of
two mutant CFTR alleles. In all cases, genotyping was done
by Sanger sequencing for the detection of common
mutations and was followed by next-generation sequencing
for the identification of uncommon mutations.
Results: From an overall of 47 cases, the most common
mutation was p.Phe508del with an allelic frequency of
46.9%, which is compatible with its northwest-to-southeast
decreasing frequency gradient in Europe. Most mutations
were classified as CFTR protein processing (class II, 50%)
or conductance (class IV, 12.3%) defects. Multiple muta-
tions were detected in 3 cases. Seven patients with mild
clinical manifestations, mostly presenting with dehydration
and/or electrolyte imbalance, carried p.Leu346Pro (7.1%), a
class IV mutation detected solely in individuals of Cypriot
descent. A novel case of a patient homozygous for the
CFTRdup2 mutation was associated with a severe pheno-
type with hepatic involvement, biliary cirrhosis and
eventually hepatic failure leading to death.
Conclusions: The small population of cystic fibrosis
patients in Cyprus follows the regional genotypic trends,
although several cases bear unique mutational profiles,
which contribute to the wide genotypic and phenotypic
spectrum of the disease.
A. Matthaiou: None. P. Anagnostopoulou: None. P.
Kouis: None. V. Neocleous: None. T. Adamidi: None. P.
Ioannou: None. P. Fanis: None. C. Costi: None. A.
Georgiou: None. L.A. Phylactou: None. P.
Yiallouros: None.
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Distinct regulatory elements enhance SLC6A14 expres-
sion modifying cystic fibrosis pancreas and lung
phenotypes
M. Esmaeili1, N. Panjwani1, G. He1,2, F. Lin1, J. M.
Rommens1,3, L. J. Strug1,2
1Program in Genetics and Genome Biology, The Hospital
for Sick Children, Toronto, ON, Canada, 2Division of
Biostatistics, Dalla Lana School of Public Health, Uni-
versity of Toronto, Toronto, ON, Canada, 3Department of
Molecular Genetics, University of Toronto, Toronto, ON,
Canada
Introduction: Cystic Fibrosis (CF) individuals with the
same CFTR mutations have variable lung and pancreatic
disease severity. Genome wide association studies (GWAS)
have indicated that SNP clusters in the immediate promoter
region and far upstream of SLC6A14 modify meconium
ileus (MI) occurrence at birth and progressive lung disease,
respectively. SLC6A14 is a sodium- and chloride-dependent
neutral and cationic amino acid transporter that is expressed
in several tissues including lung and pancreatic duct.
Materials and Methods: We are using public data and
in vitro transcriptional reporter studies to understand how
the SLC6A14 promoter and upstream SNPs contribute to
modification of CF.
Results: Colocalizing SLC6A14 promoter SNPs with
expression quantitative trait loci (eQTL) of multiple organs
from Genotype-Tissue Expression (GTEx) suggests that the
pancreas drives MI susceptibility and indicates that the
eQTL effect is driven primarily by males. Reporter assays
in the CFPAC-1 pancreas cell line with a 2.4kb segment
containing MI-associated SNPs display increased gene
expression with the risk haplotypes, and exhibit transrepres-
sion with a steroid hormone receptor. The core promoter
activity and haplotype effects were also evident in the lung
cell lines Calu-3 and HBE. Analyses of ReMap and
JASPAR databases pinpoint a series of transcription
binding elements in the upstream region for ongoing
investigations to understand how these segments crosstalk
with the core promoter of SLC6A14 in the lung.
Conclusions: Our studies implicate differences in gene
regulation of SLC6A14 in the lung versus the pancreas, with
increased expression level being detrimental to CF
phenotypes in both organs.
M. Esmaeili: None. N. Panjwani: None. G. He: None.
F. Lin: None. J.M. Rommens: None. L.J. Strug: None.
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Impact of next-generation sequencing on diagnosis of
cystic kidney diseases
L. Obeidová1, T. Seeman2, V. Elisakova1, K.
Hirschfeldova1, I. Zednikova1, B. Janosikova1, M.
Urbanova1, F. Liska1, O. Seda1, B. Chylikova1, J. Stekrova1
1Institute of Biology and Medical Genetics of the First
Faculty of Medicine, Charles University and General
University Hospital in Prague, Prague, Czech Republic,
Prague, Czech Republic, 2Department of Pediatrics, 2nd
Faculty of Medicine, Charles University in Prague and
Motol University Hospital, Prague, Czech Republic,
Prague, Czech Republic
Introduction: Cystic kidney diseases are a very hetero-
geneous group of chronic kidney diseases with sometimes
ambiguous phenotype. Thus, the clinical diagnosis is often
difficult to be made. The aim of our study was to test the
ability of next-generation sequencing (NGS) to improve the
diagnosis precision in a heterogeneous group of children
with clinically suspected cystic kidney diseases.
Materials and Methods: Next-generation sequencing of
genes responsible for the formation of cystic kidneys was
performed in 32 unrelated patients with various clinically
diagnosed cystic kidney diseases without a definitive
genetic diagnosis.
Results: The underlying pathogenic variants were
detected in 69% of patients (n = 22). The result of NGS
correlated with the clinical diagnosis made before the NGS
in 53% of patients (n = 17), in the remaining 15 children
(47%) the result of NGS revealed another type of cystic
kidney disease than clinically suspected or did not find any
causal mutation. The most common unexpected findings
were variants in nephronophthisis (NPHP) genes in children
with clinically suspected autosomal recessive polycystic
kidney disease (n = 4). Overall, we found 25 (probably)
pathogenic variants in the PKHD1 gene, 8 variants in the
TMEM67 gene, 4 variants in the PKD1 gene, 2 variants in
the HNF1B gene and 2 variants in BBS1 and NPHP1 genes,
respectively.
Conclusions: NGS is a valuable tool in the diagnostics of
various forms of cystic kidney diseases. Its results changed
the clinically based diagnoses in 15% of the children.
Supported by the ESIF - Operational programme Prague
CZ.07.1.02/0.0/0.0/17_049/0000828, GAUK 1015 and
PROGRES- Q25/LF1
L. Obeidová: None. T. Seeman: None. V. Elisakova:
None. K. Hirschfeldova: None. I. Zednikova: None.
B. Janosikova: None. M. Urbanova: None. F. Liska:
None. O. Seda: None. B. Chylikova: None. J.
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P03.18.C
Circulating miRNA as a predictive biomarker of type 2
diabetes in prediabetic patients-outcomes of 5-year
prospective observational study
I. Sidorkiewicz, M. Niemira, K. Maliszewska, A. Bielska, A.
Szałkowska, J. Raczkowska, G. Sokołowska, M. Górska, A.
Krętowski
Medical University of Bialystok, Bialystok, Poland
Introduction: Type 2 Diabetes Mellitus (T2DM) remains
the most prevalent form of diabetes. The detection of cur-
rent T2DM diagnostic markers is generally late and occurs
when displaying metabolic imbalance thus, novel bio-
markers that could be useful as a new tool for predicting the
progression from prediabetes to T2DM are needed. The
goal of this study was to conduct a baseline comparison of
serum-circulating miRNA in prediabetic individuals with
distinction between those who later progressed to T2DM
and those who did not.
Materials and methods: The study group was divided –
patients with newly diagnosed T2DM over 5 year
observational period (n = 18) and control group (n = 12)
with no known history of dysglycemia. The expression
level of 798 miRNAs in serum samples using the Nano-
String technology was examined.
Results: The study revealed that 18 miRNAs were
deregulated in serum samples of patients who developed
T2DM after 5 years versus non T2DM patients. Pathway
analysis showed that miRNA target genes were mainly
significantly enriched in homeostasis, neuronal signaling,
protein complex oligomerization and core matrisome. ROC
analysis demonstrated that miR-491-5p, miR-1307-3p,
miR-298 and miR-1290 can be introduced as a diagnostic
tool for the prediction of T2DM (AUC=0.940; 0.894;
0.877; 0.722, respectively).
Conclusions: The results suggest that circulating miR-
NAs could potentially be used as predictive biomarkers of
T2DM in prediabetic patients.
I. Sidorkiewicz: None. M. Niemira: None. K. Mal-
iszewska: None. A. Bielska: None. A. Szałkowska: None.
J. Raczkowska: None. G. Sokołowska: None.M. Górska:
None. A. Krętowski: None.
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Identification of a germline interstitial deletion
in14q32.13 in a child and mother with DICER1
syndrome
212 J. del Picchia
I. Wieland1, I. Schanze1, A. Gnekow2, M. Kuhlen2, F.
Maier3, D. Wahl3, M. Frühwald2, M. Zenker1
1Institute of Human Genetics, University Hospital, Otto-
von-Guericke University, Magdeburg, Germany, 2Swabian
Children’s Cancer Center, University Children’s Hospital,
Augsburg, Germany, 3Praxis für Humangenetik, Augsburg,
Germany
Introduction: DICER1 syndrome (MIM 601200) is a rare
tumor predisposition syndrome with autosomal dominant
inheritance usually manifesting in childhood and adoles-
cence. Tumor development follows Knudson’s two-hit
model involving the gene DICER1 located on chromo-
some 14q32.13. Predisposing germline pathogenic variants
(first hit) are mainly small loss-of-function mutations.
Tumor-related driver mutations are specific hot-spot mis-
sense mutations in trans (second hit) located in the RNAse
IIIb domain of the DICER1 protein.
Patients: We report on a female child with cystic
nephroma of the right kidney and developmental delay at
age 1 year. Facial features included frontal bossing, flat
nasal bridge, hypertelorism and small mouth with thin lips.
Body measurements were unremarkable. Her mother was
reported with Sertoli-Leydig cell tumor (SLCT) and multi-
nodular goiter at age 12 to 16 years. Clinical presentation of
mother and child suggested familial inheritance of
DICER1 syndrome.
Results: No typical DICER1 loss-of-function germline
mutation was detected in the child by standard Sanger
sequencing. The child’s tumor tissue of the right kidney
revealed DICER1 hot-spot mutation c.5437G>A p.
Glu1813Lys. Subsequent molecular karyotyping of DNA
from blood of the child using Affymetrix CytoScan HD
SNP-Array showed a 2.31MB interstitial contiguous gene
deletion in 14q32 (arr[hg19] 14q32.12q32.13
(93835222_96155830)x1). The interval harbors 23
OMIM-listed genes including DICER1. The array result
was finally confirmed in the blood of child and mother
by MLPA.
Conclusions: Patients with DICER1 syndrome and
germline 14q32 contiguous gene deletions infrequently
have been detected. In the few patients reported to date
various deletion intervals were identified suggesting no
consistent chromosomal breakpoints.
I. Wieland: None. I. Schanze: None. A. Gnekow: None.
M. Kuhlen: None. F. Maier: None. D. Wahl: None. M.
Frühwald: None. M. Zenker: None.
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Two cases with central precocious puberty caused by
paternally inherited novel variants in DLK1gene
V. Karaman1, E. Karakılıç Özturan2, F. Baş2, S. Başaran1,
Z. Uyguner1
1Department of Medical Genetics, Istanbul Faculty of
Medicine, Istanbul University, Istanbul, Turkey, 2Depart-
ment of Pediatric Endocrinology, Istanbul Faculty of
Medicine, Istanbul University, Istanbul, Turkey
Introduction: Gonadotropin-dependent or central pre-
cocious puberty (CPP) is caused by premature activation of
the hypothalamic-pituitary-gonadal (HPG) axis. There are
several genes playing roles in this pathway and two of them
are maternally imprinted; 1) MKRN3 gene, located at
15q11.2, upstream suppressor of HPG axis, 2) DLK1 gene,
located at 14q32, affecting kisspeptin signaling pathway
hence important role for regulating pubertal timing.
Materials and Methods: Coding regions of the MKRN3
(NM_005664.3) and DLK1 (NM_003836.6) genes were
Sanger sequenced in 17 patients (15 female, 2 male). In
presence of pathogenic variant, segregation analysis were
performed in families.
Results: We identified two novel heterozygous variants
in two unrelated cases in DLK1 gene. The first variant was
in exon 4 (c.357C>G (p.Tyr119Ter)) and the second was in
intron 1 (c.67+78C>T), both were classified under probably
pathogenic by in silico analysis. Segregation analysis
presented the paternal inheritance of both, complying with
the inheritance model of the genes. No pathogenic variant
identified in MKRN3 gene in our cases.
Conclusions: Previously, three small and one gross
deletions of DLK1 were associated with CPP. Nonsense and
splicing variant have first time presented in our study. The
alteration identified in intron one needs further investigation
on transcript level to show whether it causes splicing defect.
Nevertheless, inheritance pattern complies with imprinted
gene model of DLK1. These results suggest that investiga-
tion of DLK1 gene may contribute to the elucidation of the
genetic assosiation of familial CPP. This study was
supported by Scientific Research Projects Coordination
Unit of Istanbul University (TDK-2018-32682)
V. Karaman: None. E. Karakılıç Özturan: None. F.
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Elucidating the molecular mechanism underlying later-
ality defects
D. Antony1,2,3, A. Maver4, M. A. Deardorff5,6, L. Slagter2,
K. Wu2, Z. Bakey1,2, E. Y. Gulec7, A. Gezdirici7, H.
Brunner2,3, M. Schmidts1,2,3
1Center for Pediatrics and Adolescent Medicine, University
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Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 213
Division, Department of Human Genetics, Radboud UMC,
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lian Genomics, Clinical Institute of Medical Genetics, UMC
Ljubljana, Ljubljana, Slovenia, 5Department of Pediatrics
and Pathology, The Perelman School of Medicine,
University of Pennsylvania, Pennsylvania, PA, United
States, 6Laboratory Medicine, The Perelman School of
Medicine, University of Pennsylvania, Pennsylvania, PA,
United States, 7University of Health Sciences, Kanuni
Sultan Suleyman training and research Hospital, Depart-
ment of Medical Genetics, Istanbul, Turkey
Introduction: Laterality defects are rare developmental
disorders, occurring isolated or as part of complex syn-
dromes. Underlying cause is frequently dysfunction of
motile cilia causing Primary Ciliary Dyskinesia (PCD) and
rarely, non-motile cilia defects or non-ciliary causes. In
addition to randomization of the left right body axis, PCD is
characterized by frequent respiratory infections and
infertility.
Methods: We used Whole Exome Sequencing (WES) to
delineate the underlying molecular cause in 37 mainly
consanguineous families with laterality defects.
Results: We identified causative variants in 32% with
majority of mutations detected in genes previously
associated with PCD, including 2 small homozygous
CNVs. Variants in non PCD genes, PKD1l1 and GJA1
were also detected. We further identified homozygous null
mutations in two genes not previously associated with
human disease, MNS1 and DNAH9, both in cases with situs
inversus but little or no respiratory symptoms. Gene
matcher database revealed two additional families with
biallelic DNAH9 mutation and immunofluorescence analy-
sis revealed complete absence of DNAH9 from respiratory
cilia of one affected while DNAH9 localises to the distal
half of cilia in controls. Further, we found direct interaction
of DNAH9 with the ODA docking complex protein
CCDC114 using Y2H screening also interaction with
DNAH5 and DNAI2 using co-Immunoprecipitation.
Conclusions: We could only solve a third of the laterality
cases genetically using WES, pointing towards non coding
variations, genetic mosaicism or epigenetic effects while we
were able to identify two novel human disease causing
genes, MNS1 and DNAH9, both causing laterality defects
with no or little respiratory disease.ERC: TreatCilia
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Insights into the proteomics of renal function: a trans-
ethnic meta-analysis and Mendelian randomization
study
P. R. Matias-Garcia1,2,3, R. Wilson1,2, Q. Guo4, S. B.
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Hopkins Bloomberg School of Public Health, Baltimore,
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ovascular Research (DZHK), partner site Munich Heart
Alliance, Munich, Germany, 9German Center for Diabetes
Research (DZD), München-Neuherberg, Neuherberg, Ger-
many, 10Department of Clinical Epidemiology, Leiden
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fic Service Group Biomolecular Mass Spectrometry, Max
Planck Institute for Heart and Lung Research, W.G.
Kerckhoff Institute, Bad Nauheim, Germany, 12German
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munity Medicine, University Medicine Greifswald, Greifs-
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Introduction: Renal health is reflected in the kidneys’
ability to filter blood, clinically measured as the estimated
glomerular filtration rate (eGFR). A number of plasma
proteins have been found to be associated with renal phe-
notypes, but prior studies have been limited by smaller
sample sizes and fewer proteins. Moreover, the causal
mechanisms underlying these associations have not been
investigated.
Methods: We conducted the largest observational study
of plasma proteins and renal function in terms of sample
size (up to N=5,285 across four studies: KORA, INTER-
VAL, HUNT, QMDiab) and number of proteins (k=1,100).
Associations with eGFR and chronic kidney disease (CKD)
were tested using regression models in a trans-ethnic
discovery-replication approach. We further examined the
causal nature of these associations using two-sample
bidirectional Mendelian randomization.
Results: 57 proteins were found to be consistently
associated with eGFR in population samples of European
and admixed ancestry; of these, 18 were associated with
CKD. Many well-known biomarkers of renal function (e.g.
cystatin-C) were identified, as were JAM-B and contactin-4
as novel biomarkers. The strongest evidence of causality
was observed in the positive effect of eGFR on testican-2
(p=2.84E-04), a finding consistent with the biological role
of testican-2 in glomeruli remodeling and kidney injury
repair.
Conclusions: Our study uncovers novel plasma proteo-
mic biomarkers for renal function and presents evidence for
selected causal relationships. Plasma levels of testican-2 are
reflective of mechanisms underlying progressive renal
function loss, thus suggesting its applicability as a
biomarker of early renal dysfunction and disease progres-
sion in the general population.
P.R. Matias-Garcia: None. R. Wilson: None. Q. Guo:
None. S.B. Zaghlool: None. S. Sharma: None. P.
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Gain-of-function variant of the calcium-sensing receptor
gene is associated with longer survival on renal
replacement therapy in Caucasian patients
H. M. Rothe1,2, S. Komolka2, C. Wanner3, G. Mayer4
1Centre for Nephrology and Metabolic Disorders, Weiss-
wasser, Germany, 2Coburg University for Applied Sciences,
Coburg, Germany, 3University of Würzburg, Division of
Nephrology, University Hospital, Würzburg, Germany,
4Medical University Innsbruck, Department of Internal
Medicine IV, Nephrology and Hypertension, Innsbruck,
Austria
Introduction: Patients with end-stage kidney disease
require renal replacement therapy, i.e. dialysis or kidney
transplantation, for survival. Here we report for the first
time a genetic variant which is associated with longer sur-
vival on renal replacement therapy in Caucasian patients.
Materials and Methods: We conducted a survival
analysis of three European end-stage kidney disease patient
populations in Austria and Bavaria. 198 patients (118 male,
80 female) were genotyped for three variants of the
calcium-sensing receptor gene after signing the consent
form. The study started in 2005 and survival analysis was
performed in 2018. During these years all patients received
care according to the standards of the Austrian and German
societies of nephrology.
Results: Survival on renal replacement therapy was
significantly different (age and sex adjusted Cox regression
p=0.04) between carriers of the glycine and arginine alleles
at position 990 of the calcium-sensing receptor molecule
(rs1042636.) The two rs1042636 cohorts AA (two arginine
alleles) and GA/GG (at least one glycine allele) were in
Hardy Weinberg equilibrium with a minor allele
frequency of 7%.
Conclusions: The glycine variant of rs1042636 calcium-
sensing receptor molecules has been shown to result in a
gain-of-function, as compared with the arginine variant, in
cell culture studies with transfected human embryonic
kidney cells. It was also associated with lower baseline
parathyroid hormone levels in the Caucasian patient cohort
of the Evaluation of Cinacalcet Hydrochloride Therapy to
Lower Cardiovascular Events (EVOLVE) trial. Our study
shows that it is associated with longer survival on renal
replacement therapy in Caucasian patients.
H.M. Rothe: None. S. Komolka: None. C. Wanner:
None. G. Mayer: None.
P03.26.B
Genes regulating enteric nervous system development
are impacted by Copy Number loss and modify
penetrance in epistasis with RET
L. Kuil1, C. S. Tang2, J. D. Windster1,3, T. Le4,5, A. Karim2,6,
B. M. de Graaf1, R. van der Helm1, Y. van Bever1, C. E. J.
Sloots3, C. Meeussen3, D. Tibboel3, A. de Klein1, R. M. H.
Wijnen1, J. Amiel4,7,5, S. Lyonnet4,7,5, M. Garcia-Barcelo2,
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P. K. H. Tam2, M. M. Alves1, A. S. Brooks1, R. M. W.
Hofstra1,8, E. Brosens1
1Clinical Genetics department, Erasmus Medical Centre –
Sophia Children’s Hospital, Rotterdam, Netherlands,
2Department of Surgery, Li Ka Shing Faculty of Medicine,
University of Hong Kong, Hong Kong, China, 3Paediatric
Surgery department, Erasmus Medical Centre – Sophia
Children’s Hospital, Rotterdam, Netherlands, 4Paris Des-
cartes - Sorbonne Paris Cité University, Imagine Institute,
Paris, France, 5Laboratory of embryology and genetics of
congenital malformations, INSERM UMR1163, Paris,
France, 6Chittagong Research Institute for Children
Surgery (CRICS), Chittagong, Bangladesh, 7Service de
Génétique, Necker Enfants Malades University Hospital,
APHP, Paris, France, 8Stem Cells and Regenerative
Medicine, UCL Great Ormond Street Institute of Child
Health, London, United Kingdom
Hirschsprung disease (HSCR) is characterized by absence
of enteric ganglia, primarily in the distal colon. Approxi-
mately 18% of patients have additional anatomical mal-
formations or associated neurodevelopmental disorders
(HSCR-complex). We hypothesized that genes affected by
rare Copy Number Variants contribute to disease develop-
ment in “HSCR-complex” patients. Indeed, we could con-
firm that Copy Number (CN) losses (n = 11) are enriched in
these patients (n = 23), if no other causal variant was
identified (p=3.64E−7). At least five patients had a large de
novo CNV (3 losses, 2 gains). The identified rare CN losses
are enriched for variant intolerant genes, overexpressed in
the developing mouse enteric nervous system (p=1.760E-
10): SLC8A1, GNL1, GABBR1, MAPK8, UFD1L, AKT3,
TBX2, USP32 and TUBB. Additionally, a loss of function
variant in TUBB was identified in a HSCR patient without a
deleterious CNV, and AKT3 as well as UFD1L are impacted
by CN losses in other patients. The contribution of the
known HSCR predisposing risk haplotypes was comparable
between patients with a pathogenic coding variant and
controls (P=0.826). All other HSCR subgroups differed
significantly with controls and between each subgroup
(P=0.02 or lower), patients with isolated HSCR and with-
out a RET coding variant had the highest burden, unaffected
controls the lowest. Our zebrafish model reveals that dis-
ruption of six of these 9 genes - alone or via epistasis with
ret- results in a HSCR phenotype. This confirms the epi-
static effect of losing a copy of a gene regulating enteric
nervous system development with the predisposed down-
regulation of RET expression.
L. Kuil: None. C.S. Tang: None. J.D. Windster: None.
T. Le: None. A. Karim: None. B.M. de Graaf: None. R.
van der Helm: None. Y. van Bever: None. C.E.J. Sloots:
None. C. Meeussen: None. D. Tibboel: None. A. de
Klein: None. R.M.H. Wijnen: None. J. Amiel: None. S.
Lyonnet: None. M. Garcia-Barcelo: None. P.K.H. Tam:
None. M.M. Alves: None. A.S. Brooks: None. R.M.W.
Hofstra: None. E. Brosens: None.
P03.27.C
Identification of disease-causing variants in children and
adolescents with focal segmental glomerulosclerosis
S. Draut1, M. C. Braunisch1,2, K. M. Riedhammer1,2, P. M.
Herr1, R. Günthner1,2, M. Wagner1,3,4, B. Alhaddad1, L.
Renders2, U. Heemann2, C. Schmaderer2, J. Hoefele1
1Institute of Human Genetics, Klinikum rechts der Isar,
Technical University of Munich, School of Medicine,
Munich, Germany, 2Department of Nephrology, Klinikum
rechts der Isar, Technical University of Munich, School of
Medicine, Munich, Germany, 3Institute of Human Genetics,
Helmholtz Zentrum München, Neuherberg, Germany,
4Institute of Neurogenomics, Helmholtz Zentrum München,
Neuherberg, Germany
Introduction: A monogenic cause can be identified in
approximately 30% of young patients (< 25 years of age)
with steroid-resistant nephrotic syndrome (SRNS). SRNS in
children and adolescents is mostly inherited in an autosomal
recessive pattern. The histological correlate of SRNS is
often focal segmental glomerulosclerosis (FSGS). The aim
of this study was to identify genetic causes in a cohort of
children and adolescents with FSGS.
Material and Methods: 35 unrelated individuals with
disease onset <18 years of age and suspected hereditary
FSGS were analyzed using exome sequencing. Suspected
hereditary FSGS was defined if at least one of the following
criteria was present: absence of a secondary cause, <18
years of age, kidney biopsy with suspicion of a hereditary
cause, extrarenal manifestations, and/or positive familial
history/consanguinity. Variants were rated according to the
ACMG classification. The clinical phenotype was assessed
using a standardized questionnaire.
Results: In seven patients, (likely) pathogenic variants
according to ACMG were identified in known disease-
causing genes (diagnostic yield: 20%). Three variants in
two different FSGS genes (INF2, TRPC6) had to be
classified as VUS (Table 1).
Conclusions: The diagnostic yield of 20% highlights the
importance of genetic testing in patients <18 years of age
with nephrotic syndrome. Early genetic diagnosis could
allow a personalized treatment approach with weaning of
unnecessary immunosuppressive treatment, avoidance of
renal biopsies and provision of well-informed genetic
counselling.
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c.3346C>T p.(Arg1116*) n.d. homozygous solved
m, maternal; n.d., not determined; p, paternal; VUS,
variant of unknown significance
S. Draut: None. M.C. Braunisch: None. K.M. Ried-
hammer: None. P.M. Herr: None. R. Günthner: None.
M. Wagner: None. B. Alhaddad: None. L. Renders:
None. U. Heemann: None. C. Schmaderer: None. J.
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P03.29.B
Genetic linkage analysis identifies a genomic region in
2q24.3 as a candidate modulator of reduced penetrance
in heritable pulmonary arterial hypertension.
I. Madrigal1,2, I. Blanco3,4, J. Barberà3,4, C. Badenas1,2, D.
Geiger5, P. Puigdevall6, L. Piccari3, R. Castelo6,7
1Biochemistry and Molecular Genetics, IDIBAPS, Hospital
Clinic, Barcelona, Spain, 2Centro de Investigación Biomé-
dica en Red de Enfermedades Raras (CIBERER), Barce-
lona, Spain, 3Hospital Clínic de Barcelona, Institut
d’Investigacions Biomèdiques August Pi i Sunyer (IDI-
BAPS), Barcelona, Spain, 4Centro de Investigación Biomé-
dica en Red de Enfermedades Respiratorias (CIBERES),
Madrid, Spain, 5Faculty of Computer Science, Technion
Israel Institute of Technology, Haifa, Israel, 6Department of
Experimental and Health Sciences, Universitat Pompeu
Fabra, Barcelona, Spain, 7nstitut Hospital del Mar
d’Investigacions Mèdiques (IMIM), Barcelona, Spain
Hereditary pulmonary arterial hypertension (hPAH) is an
autosomal dominant disease caused, in most cases, by
mutations in the BMPR2 gene. However, not all BMPR2
mutation carriers develop the disease, highlighting the
presence of reduced penetrance. In order to identify geno-
mic regions that could be contributing to incomplete
penetrance, high-throughput genotyping arrays and next
generation sequencing were conducted in an hPAH family.
The family comprises 65 Spanish individuals spanning five
different generations. One BMPR2 mutation (c.1472G> A;
p.Arg491Gln) was identified in 22 members, but only 9 of
them developed the disease. The SNP arrays analysis was
performed in 33 family members and we identified a
genomic region in 2q24.3, located at 38 Mb from the
BMPR2 gene, which could contribute to increase the sus-
ceptibility of pulmonary hypertension in mutation carriers
(Puigdevall et al., J Med Genet, 2019). Several genetic
association studies have identified variants in this region
associated with phenotypes involved in cardiovascular
pathology, such as hypertension or ischemic cardiomyo-
pathy, which could be related to some of the symptoms of
pulmonary hypertension. In order to identify the specific
variant/s that may act as genetic modifiers of hPAH within
the candidate region, we have performed whole-genome
sequencing in 16 BMPR2 mutation carriers: 6 affected
individuals and 7 asymptomatic carriers. The identification
of a possible genetic modifier in this family will allow us to
advance in our understanding of reduced penetrance
in hPAH.
Acknowledgments: ISCIIII (PI15/00483), ‘fondos
FEDER’, Agència de Gestió d’Ajuts Universitaris i de
Recerca (2017SGR1134), “CERCA Programme / General-
itat de Catalunya”
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C. P. Cristalli1,2, A. Mattiaccio2, C. Graziano3, I. Capelli1,
O. Baraldi1, G. Comai1, M. Pariali2,3, L. Gargano2,3,
M. Seri3, G. La Manna1, V. Mantovani2,3
1Nephrology Dialysis and Transplantation Unit, DIMES,
Bologna University, Bologna, Italy, 2Center for Applied
Biomedical Reasearch (CRBA), Bologna University,
Bologna, Italy, 3Medical Genetics Unit, S.Orsola-Malpighi
University Hospital, Bologna, Italy
Molecular defects of HNF1B are associated with RCAD
syndrome, a clinically heterogeneous disorder characterized
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by diabetes (MODY5), kidney abnormalities (cysts), cho-
lestasis and uro-genital malformations. We performed tar-
geted NGS of 15 genes and MLPA on 118 patients recruited
by nephrology or diabetology units. 19 index cases showed
molecular defects in HNF1B gene (10 pediatric and 9
adult). Six patients carried a likely pathogenic novel variant
(p.G83D p.R295C, c.-67C>T, c.1207-1G>A, p.S379*, p.
Q484Sfs*22) and 4 a VUS (p.G76C, p.E105K, p.A453T, p.
M532V). A functional analysis for c.-67C>T indicated
reduced activity in Caco2 and Mcf7 cells. Nine cases
showed the whole HNF1B gene deletion (de novo in five
patients). The median age of diagnosis was 19 (SNVs) and
6 (deletion) years old, respectively. Clinical presentation
included earlier onset in deleted patients (median 6 vs 19
years) and different spatial cysts localization (cortical for
SNVs and medullary in at least 3 deleted cases). Diabetes
was present in six patients only, possibly due to the young
age of many cases involved. Two patients with urogenital
malformation and 3 with cholestasis were identified. A 21-
year-old woman had mild developmental delay: additional
array-CGH was performed and a large (1.3 Mb) deletion
was found. Contrary, a 29-years-old man homozygous for
p.G83D did not show intellectual disability. In conclusion,
the patients with SNVs developed a milder phenotype than
those deleted, and the molecular defects were frequently of
de novo origin. We confirm the wide phenotypic hetero-
geneity of HNF1B-related disorders and we point out that
liver disease can be a major complication.
C.P. Cristalli: None. A. Mattiaccio: None. C. Gra-
ziano: None. I. Capelli: None. O. Baraldi: None. G.
Comai: None. M. Pariali: None. L. Gargano: None. M.
Seri: None. G. La Manna: None. V. Mantovani: None.
P03.33.C
Impact of common genetic risk variants on familial
aggregation of inflammatory bowel disease
H. Lee1,2, L. Hannes1, M. Vancamelbeke1, V. Ballet3, M.
Ferrante3,4, S. Vermeire3,4, I. Cleynen1
1KU Leuven, Leuven, Belgium, 2University of Ulsan College
of Medicine, Seoul, Korea, Republic of, 3University
Hospitals Leuven, Leuven, Belgium, 4KU leuven, Leuven,
Belgium
Family history is the strongest risk factor for inflammatory
bowel disease (IBD). The contribution of common genetic
variants to familial aggregation in multiple-affected IBD
families, however, remains unclear. We included 54
multiple-affected families (≥ 3 first-degree relatives affec-
ted), including 189 affected (IBD), and 133 unaffected first-
degree relatives; as well as 1768 sporadic cases and 868
unrelated non-IBD controls. For all individuals,
Immunochip genotypes were available. Weighted polygenic
risk scores (PRS) were calculated using PRSice-2.0 across
different p-value thresholds (pTs), and compared between
groups. The association between PRS and familial IBD was
further evaluated in age- and sex-adjusted generalized
mixed regression models including family id as random
effect. Using pT=0.05, the affected relatives had a higher
PRS than unaffected relatives (P=1.0x10−02), sporadic
cases (P=4.6x10−02), and non-IBD controls (P < 2.2x
10−16). The risk of IBD in families increased by 1.23-fold
for every incremental standard deviation in PRS. However,
the proportion of the explained variance between affected
and unaffected family members was smaller than that
between sporadic IBD and non-IBD controls (5% versus
17%, respectively). Of note, in familial IBD, variance
explained by the PRS dropped dramatically for pT>0.01. A
plausible hypothesis is that while familial cases differ from
sporadic cases in low-risk (high p-value) variants, familial
cases differ from their unaffected relatives mostly in high-
risk (low p-value) variants. Higher PRS increases the risk
for familial IBD as it does for sporadic IBD. The proportion
of the explained variance in families however is limited,
because of shared genetic background between family
members. BIRD Grant
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Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan,
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Sandoz, Takeda. S. Vermeire: B. Research Grant (principal
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as well as grants already received); Modest; MSD, Abbvie,
Takeda, Janssen, Pfizer. D. Speakers Bureau/Honoraria
(speakers bureau, symposia, and expert witness); Modest;
AbbVie, MSD, Takeda, Ferring, Hospira, Pfizer, Janssen,
and Tillots. F. Consultant/Advisory Board; Modest; Abb-
Vie, MSD, Takeda, Ferring, Genentech/Roche, Shire, Pfizer
Inc, Galapagos, Mundipharma, Hospira, Celgene, Second
Genome, Progenity, Lilly, Arena, Gilead and Janssen.
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P03.34.A
Combined exome/genome sequencing with in-house
variant data repository mining confirm USP53 as a
causal gene for intrahepatic cholestasis
S. Alawbathani1, M. Rocha1, H. Arshad Cheema2, R.
Boustany3, S. Nampoothiri4, A. Alswaid5, N. El Koofy6,
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V. Karageorgou1, I. Hövel1, S. Khan1, C. Beetz1, A. Rolfs1,7,
P. Bauer1, A. M. Bertoli-Avella1
1Centogene AG, Rostock, Germany, 2Children’s Hospital
and Institute of Child Health, Lahore, Pakistan, 3AUBMC
American University of Beirut Medical Center, Beirut,
Lebanon, 4Amrita Institute of Medical Sciences, Kerala,
India, 5King Abdulaziz Medical City, Riyadh, Saudi Arabia,
6Abu El Reesh Children’s Hospital, Cairo, Egypt, 7Uni-
versity of Rostock, Rostock, Germany
Cholestatic liver disease is a significant cause of morbidity
and mortality in the paediatric population, starting in the
early postnatal life. Severity is variable, from benign idio-
pathic neonatal hepatitis to intrahepatic cholestasis leading
to liver failure and transplant. There are several genes
described for different genetic diseases that lead to choles-
tasis. USP53 has been recently suggested as a candidate
gene for paediatric intrahepatic cholestasis based on one
family with two affected siblings. Interestingly, USP53
interacts with tight junction protein 2 (TJP2) for which
pathogenic variants are known to cause progressive familial
intrahepatic cholestasis. To date, the USP53 gene has not
been linked to an OMIM phenotype. By combining exome/
genome sequencing and mining our in-house variant data-
base we identified five patients from unrelated families. All
affected individuals display a similar phenotype, mainly
including early onset intrahepatic cholestasis. Moreover,
one family showed hearing loss as an additional phenotype.
All patients were homozygotes for different loss-of-function
variants in the USP53 gene. USP53 (ubiquitin specific
peptidase 53) is a tight junction-associated protein that is
known to involve in the survival of auditory hair cells and
hearing. Our results confirm USP53 as a novel gene for
autosomal recessive intrahepatic cholestasis. Additionally,
we demonstrate that combined exome/genome sequencing
and variant database mining is an effective approach to
discover and confirm novel genes related to human diseases.
This accelerate the process of gene discovery and ultimately
shortens the diagnostic odyssey in rare genetic disorders.
S. Alawbathani: A. Employment (full or part-time);
Significant; Centogene AG, Rostock, Germany. M. Rocha:
A. Employment (full or part-time); Significant; Centogene
AG, Rostock, Germany. H. Arshad Cheema: None. R.
Boustany: None. S. Nampoothiri: None. A. Alswaid:
None. N. El Koofy: None. V. Karageorgou: A. Employ-
ment (full or part-time); Significant; Centogene AG,
Rostock, Germany. I. Hövel: A. Employment (full or
part-time); Significant; Centogene AG, Rostock, Germany.
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Centogene AG, Rostock, Germany. C. Beetz: A. Employ-
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part-time); Significant; Centogene AG, Rostock, Germany.
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P03.35.B
A common haplotype of the alternative serotonin
transporter gene SLC6A4 promoter P2 impacts gene
expression and shows disease association in women with
Irritable Bowel Syndrome
S. Mohr1, N. Hattensperger1, C. Hammer2, C. Martinez3, S.
Berens4, S. Schmitteckert1, L. A. Houghton5,6, M. Goebel-
Stengel7, I. Vulic8, M. D’Amato9,10, T. Zheng9,10, H.
Mönnikes11, F. Engel4, A. Gauss12, J. Tesarz4,
V. Andresen13, T. Frieling14, J. Keller13, C. Pehl15,
G. Clarke16, R. Spiller17, T. G. Dinan16, E. M. Quigley16,
C. Beltrán18, E. A. Mayer19, G. Sayuk20, M. Gazouli21,
L. Kapur-Pojskic8, M. Bustamante22, K. Rabionet22,
X. Estivil22, G. Boeckxstaens23, M. M. Wouters23,
M. Simrén24, G. A. Rappold1, M. Vicario25, J. Santos25,
R. Schäfert4,26, J. Lorenzo Bermejo27, B. Niesler1
1Department of Human Molecular Genetics, Heidelberg
University, Heidelberg, Germany, 2Department of Cancer
Immunology, Genentech, South San Francisco, CA, United
States, 3Institut de Recerca Biomèdica de Lleida, Lleida,
Spain, 4Department of General Internal Medicine and
Psychosomatics, University Hospital Heidelberg, Heidel-
berg, Germany, 5Division of Gastroenterology & Surgical
Sciences, Leeds, United Kingdom, 6Mayo Clinic, Jackson-
ville, FL, United States, 7Helios Klinikum Rottweil,
Rottweil, Germany, 8Institute for Genetic Engineering and
Biotechnology, Sarajevo, Bosnia and Herzegovina, 9School
of BioSciences, Monash University, Melbourne, Australia,
10Karolinska Institute, Solna, Sweden, 11Martin-Luther-
Krankenhaus, Berlin, Germany, 12Department of Gastro-
enterology, University Hospital Heidelberg, Heidelberg,
Germany, 13Israelitisches Krankenhaus, Hamburg, Ger-
many, 14Helios Klinik Krefeld, Krefeld, Germany, 15Kran-
kenhaus Vilsbiburg, Vilsbiburg, Germany, 16Department of
Psychiatry and Neurobehavioral Science, University Col-
lege Cork, Cork, Ireland, 17Nottingham Digestive Diseases
Centre, University of Nottingham, Nottingham, United
Kingdom, 18Laboratory of Immuno-Gastroenterology, Uni-
versidad de Chile, Santiago de Chile, Chile, 19Oppenheimer
Centre for Neurobiology of Stress, University of California,
Los Angeles, CA, United States, 20Washington University
School of Medicine, St. Louis, MO, United States, 21Biology
National and Kapodistrian University of Athens, Medical
School Athens, Athens, Greece, 22Centre for Genomic
Regulation, Barcelona, Spain, 23TARGID, University
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University of Gothenburg, Gothenburg, Sweden, 25Institut
de Recerca Vall d’Hebron, Hospital Vall d’Hebron,
Barcelona, Spain, 26Universitätsspital Basel, Basel, Swit-
zerland, 27Institute of Medical Biometry and Informatics,
Heidelberg University, Heidelberg, Germany
Background: Irritable bowel syndrome (IBS) is a gut-brain
disorder in which imbalances within the central and per-
ipheral serotonergic systems contribute to disease patho-
physiology and thereby shape the phenotype. The serotonin
transporter gene SLC6A4 has earlier been implicated in IBS.
Material and Methods: We sequenced the alternative
promoter P2 that primarily drives SLC6A4 expression in the
gut and analyzed single nucleotide polymorphisms (SNP)
for association with IBS. We also assessed their functional
relevance by gene reporter assays, in silico analysis and
comparative expression studies. In addition, we correlated
detected SNPs with expression data and IBS symptoms.
Results: Detected SNPs were linked in different haplo-
types and the tagging SNP rs2020938 associated with
female IBS with constipation (IBS-C) in a discovery sample
comprising 287 individuals. Subsequent validation and
meta-analysis of rs2020938 in 2175 IBS patients and 6128
controls from eight countries confirmed the association with
female IBS-C. Expression data obtained from different
intestinal regions showed that the alternative promoter
drives SERT expression primarily in the small intestine.
Additionally, gene reporter assays pointed to a functional
impact of the SNPs within this region. In silico analyses
indicated differential expression regulation by transcription
factors that have previously been implicated in GI disorders.
Further follow up in tissue samples and clinical data from
IBS patients and controls revealed that rs2020938 correlates
with differential expression in the jejunum and stool
consistency.
Conclusions: Our results indicate differential expression
regulation driven by a functionally relevant polymorphic
promoter in female IBS-C and consolidates the importance
of SLC6A4 in IBS pathogenesis.
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Application of NGS sequencing for improved diagnosis
in the pediatric nephrology setting
O. Beltcheva1, K. Kamenarova1, K. Mihova1, G.
Zlatanova2, F. Shakola1, D. Roussinov2, M. Gaydarova2, V.
Mitev1, R. Kaneva1
1Molecular Medicine Center, Dept. of Medical Chemistry
and Biochemistry, Medical University-Sofia, Sofia, Bul-
garia, 2SBAL Pediatric Diseases, Nephrology and Hemo-
dialysis Clinic, Department of Pediatrics, Medical
University - Sofia, Sofia, Bulgaria
Introduction: Renal disease first diagnosed in childhood
often progresses towards chronic or end-stage kidney failure
in adults. Identifying the molecular cause of the condition in
each case may allow a more personalized approach to
therapy and consequently increase the likelihood of pre-
serving the renal function of the patients in adulthood.
Materials and Methods: TruSight One Sequencing
Panel (Illumina) on MiSeq platform was used for mutation
screening in 10 children with hematuria, proteinuria and/or
compromised renal function, who did not respond well to
standard treatment or presented with unusual course of the
disease. Sanger sequencing was applied for confirmation
and establishing the origin of the mutations. The patho-
genicity of each novel variant was evaluated according to
the established ACMG criteria.
Results: The NGS yielded both known and novel
mutations in the sample set. In addition to well-known
genes, such as WT1, GATA3, SALL1, AGXT and
COL4A4/5, the analysis of the data revealed that pathogenic
variants in CD96, HNF1? and TREX1 may also contribute
to the etiology of renal disease in children.
Conclusions: The application of massive parallel sequen-
cing of a large gene panel allowed us to identify the
molecular cause of renal disease in a number of pediatric
patients where diagnoses were hindered by atypical
presentation. In several of the cases the findings allowed
us to expand the clinical spectrum of the phenotypic
presentation of the mutations in certain genes.
Grant references: D-73/2019; D01-285/17.12.2019
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New LUTO-candidate genes identified by systematic
analysis of copy number variations in 152 patients
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trics, University Hospital Bonn, Bonn, Germany, 2Institute
of Human Genetics, Children’s Hospital, University of
Bonn, Bonn, Germany, 3Department of Genomics, Life &
Brain Centre, Bonn, Germany, 4Department of Pediatrics,
University Hospital Marburg, Marburg, Germany, 5Depar-
ment of Pediatric Urology, St. Hedwig Krankenhaus
Barmherzige Brüder, Regensburg, Germany, 6Department
of Obstetrics and Prenatal Medicine, University of Bonn,
Bonn, Germany, 7Division of Pediatric Nephrology,
Children’s Hospital, University of Zürich, Zürich, Switzer-
land, 8Department of Neonatology and Pediatric Intensive
Care, Children’s Hospital, University of Bonn, Bonn,
Germany, 9Department of Pediatrics, University of Zielona
Góra, Zielona Góra, Poland
Introduction: Lower urinary tract obstruction (LUTO) is
caused by anatomical blockage of the bladder outflow tract
or by functional impairment of urinary voiding. For ana-
tomical blockages so far only variants in BNC2 have been
described as causal. Genomic copy number variations
(CNVs) have been previously described as a cause of
congenital anomalies of the kidneys and the urinary tract.
Used Methods: Array-based molecular karyotyping was
performed in 152 LUTO patients. Raw intensity data were
collected for all persons and CNVs were called with
CNVPartition, QuantiSNP and PennCNV. Using PLINK
version 1.07 and Excel the CNVs, identified in the patients,
were compared to CNVs of 4168 controls. Overlapping
CNVs between both groups were discarded. Further
filtering steps were used.
Results: We identified 30 potential disease causing
CNVs: 8 deletions and 22 duplications. Based on expres-
sion of the comprised genes in developing mouse urethra
we prioritized 6 CNVs. One of those CNVs comprised the
gene GPC5 (MIM 602446), located on chromosome
13q31.3. Interestingly, of 8 patients reported in the literature
with 13q duplications that comprise GPC5, four showed
urogenital malformations. So far, GPC5 was not yet
correlated with a specific clinical phenotype.
Conclusions: Systematic analysis of copy number
variations in patients with LUTO is suitable for the
identification of new candidate genes. We prioritized
GPC5 as candidate gene. For further verification of this
candidate gene, re-sequencing of LUTO patients to identify
further mutation carriers and functional characterization in
zebrafish is warranted.
Acknowledgment: A.C.H. is supported by BONFOR
grant O-149.0123.
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ZSCAN12, a candidate gene for congenital lower urinary
tract obstruction (LUTO)
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versity of Bonn, Bonn, Germany, 2Center for Molecular
Medicine Cologne (CMMC), University of Cologne,
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versity of Cologne, Cologne, Germany, 4University of
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Congenital lower urinary tract obstruction (LUTO) is
usually characterised by urinary bladder outflow obstruc-
tion, it can be functional, based on a congenital dysfunction
in voiding or on anatomical blockage of the urethra. LUTO
has a birth prevalence of about three per 10.000
pregnancies.
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Whole-Exome-Sequencing (WES) in eight families
revealed two rare variants in the ZSCAN12 gene. The first
variant (c.1695-2A>C, minor allel frequency (MAF):
0,00005814) was identified in three affected brothers, the
second variant (c.62T>C; p.Ile21Thr, MAF: 0,00002595)
was identified in an affected father and his affected son. Re-
sequencing of ZSCAN12 in 263 LUTO patients identified
three further patients who all carried the same variant
c.637T>C, p.Phe213Leu (MAF: 0.0002046). It has not been
reported homozygous. Currently no genetic material of the
parents is available for testing.
ZSCAN12 is expressed in the developing mouse urethra at
embryonic day 15.5 (GUDMAP: 5824; GUDMAP Con-
sortium) and has been found to be differentially methylated
in prostate carcinoma.
Based on these preliminary data we suggest ZSCAN12 as
a novel LUTO candidate gene. Further functional studies
are warranted.
A.C.H. is supported by BONFOR grants O-149.0123.
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Biallelic mutations in the LSR gene cause a novel type of
infantile intrahepatic cholestasis
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Suzuki1, T. Fujisawa2, T. Takenouchi4, A. Inui2, K. Kosaki1
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LSR is expressed in the liver and other organs, and repre-
sents a component protein of tricellular tight junctions. The
roles of LSR in human health and disease have not been
established. Only one patient with intrahepatic cholestasis
with a rare variant of LSR has been reported. Herein, we
report a patient who fulfilled this criterion establishing LSR
deficiency as a novel cause of human liver disease. The
proband was a 5-year-old female patient. At 5 months of
age, the infant developed severe and uncontrollable itching.
The results of blood examination at 9 months of age showed
elevated serum AST, ALT and TBA. Her verbal milestones
were slightly delayed. A needle biopsy of the liver at 5
years of age showed paucity of interlobular bile duct. At 6
years of age, whole-exome analysis of the samples from the
patient and her parents was performed. The de novo non-
synonymous variant (c.602C>T) and the maternally derived
heterozygous frameshift variant (c.1396dup) were detected
in the LSR gene. Immunohistochemical staining using anti-
LSR antibodies showed absent expression of LSR at the
tricellular tight junctions in the patient. Documentation of
biallelic pathogenic variants of the LSR gene and lack of
LSR protein expression in the liver in our patient with
infantile intrahepatic cholestasis presented in this report
establishes LSR deficiency as a novel cause of infantile
intrahepatic cholestasis.
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Neo-TAD formation on 7q36.3 causes lung agenesis in
three affected fetuses
U. Melo1, J. Piard2, M. Klever3, M. Mensa4, R. Schöpflin3,
M. Holtgrewe3, F. Arbez-Gindre2, V. Guigue2, D. Gaillard2,
V. Kremer2, R. Ramanah2, C. Cabrol2, D. Beule3, F.
Harms3, K. Kutsche3, M. Spielmann3, B. Fischer-Zirnsak3,
L. Van Maldergem3, S. Mundlos3
1MPI, Berlin, Germany, 23Centre de Génétique Humaine,
Université de Franche-Comté, Besançon, France, 31Max
Planck Institute for Molecular Genetics, RG Development
& Disease, Berlin, Germany, Berlin, Germany, 41Max
Planck Institute for Molecular Genetics, RG Development
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Lung development is a tightly regulated process under the
control of a large number of signaling molecules. The sonic
hedgehog (SHH) signaling pathway is one of the main
regulators of lung development during embryogenesis and
mutations in SHH-related genes can lead to lung mal-
formation. Here we report on three fetuses from one family
with severe malformation of the respiratory system. By
ultrasound screening and autopsy after termination, a
complete bilateral lung agenesis and near-complete agenesis
of the tracheae was observed in all fetuses. Using a com-
bination of array-CGH, Illumina whole-genome sequencing
and Hi-C we identified a complex rearrangement at 7q36.3,
~580 kb downstream the SHH gene. The rearrangement
consisted of a 449 kb triplication, a 232 kb duplication and a
61 kb deletion, involving parts of the SHH and NOM1/
MNX1/UBE3C topologically associated domains (TADs).
Due to incorporation of a boundary between two TADs in
the triplicated CNV, the rearrangements lead to the forma-
tion of two neo-TADs each containing the known SHH
enhancer MACS1 which is now placed next to MNX1, a
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transcription factor involved in caudal development. This
situation can be expected to result in an ectopic activation of
MNX1 in the lung at a time and place where SHH is nor-
mally expressed; a misexpression that likely explains the
lung aplasia. The rearrangement was present in mosaic state
in the clinically unaffected father, explaining the recurrence
of the phenotype in his offspring’s. Thus, whole-genome
sequencing in combination with Hi-C is a powerful tool to
resolve and functionally interpret complex rearrangements.
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Recessive and dominant patterns in Noonan Syndrome
associated with LZTR1 variants
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Noonan syndrome (NS) is an autosomal dominant disease
caused by germline mutations in genes involved in the Ras/
MAPK pathway. Nevertheless, a recessive form related to
biallelic variants in LZTR1 gene was described in 2018.
Following publications discussed phenotype and inheritance
patterns associated with this gene. Here we report seven
unrelated patients with clinically suspected NS and LZTR1
variants. Clinical features are provided in table1. Three
novel variants and four previously reported variants were
identified. Two patients, NS1564 and NS960, presented a
recessive form of NS. In the first patient, c.2074T>C;p.
(F692L) and c.2070-2A>G were identified and the second
one was homozygous for c.2074T>C;p.(F692L), both affect
the BTB/POZ domain. In the rest of patients only one
affected allele was identified: NS1414 had a stop-gain var-
iant, c.1084C>T;p.(R362*), located on kelch-5 domain;
NS895 presented c.742G>A;p.(G248R), which lies in kelch-
4 domain; NS883 presented c.851G>A;p.(R284H), located
on kelch-5 domain; NS1199 presented a splicing variant,
c.791+1G>T; and the patient 99 was heterozygous for
c.905C>T;p.(Ala302Glu), located on kelch-5 domain.
Overall, these cases provide more evidence on the clinical
phenotype of NS associated with LZTR1 variants. These
results are in accordance with the model that specifies that
the location throughout the gene determines the inheritance
form of NS. Our experience indicates that LZTR1 is a not
infrequent cause of NS, so this gene should be included in
next-sequencing panels for molecular diagnosis of NS.
Patient NS1564 NS960 NS1414 NS895 NS883 NS1199 NS99
Sex Male Male Female Male Female Female Female
Face
dismorphology
Typical Suggestive Suggestive Typical Suggestive Suggestive Typical










Short stature Yes Yes No No No No Yes
Cardiac defect HCM HCM HCM PVS(mild) HCM HCM HCM
Cryptorchidism Yes Yes Yes
Developmental
delay
Yes No Yes No No Yes No
Prenatal findings Yes No No No No No No
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Profiling of microRNA isoforms in ulcerative colitis
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Skiecevičienė1
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nia, 2Kiel University, Institute of Clinical Molecular
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Introduction: Recent research has shown that so far widely
studied reference miRNA sequences in miRNA databases
have a large number of isoforms that can be involved in
other physiological pathways compared to the reference
miRNA. Ulcerative colitis (UC) is a chronic disease of the
digestive system of the autoimmune origin and is attributed
to the group of inflammatory bowel diseases. The aim of
this study was to perform isomiRNA analysis in ulcerative
colitis tissue.
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Materials and Methods: In total, 76 individuals were
included in this study (32 controls, 24 patients with active
UC and 20 patients with UC in remission phase). Small
RNA sequencing was performed using the TruSeq protocol
and the HiSeq2500 platform (Illumina, USA). Bioinfor-
matic microRNA analysis was performed using the
following software tools: MiRDeep2, mirAligner, Cutadapt,
FASTX, RNAfold, Bowtie, BioPerl, BLASTn and R.
Results: The analysis revealed that the reference micro-
RNA sequences make up 2.1% of all microRNA sequences
and 97.9% are microRNA isoforms. Altered microRNAs
and their isoforms (padj <0.01, log2FC> | 0.9 |) were
detected in three groups: (i) active UC group compared to
the HC (healthy control group) - 874; (ii) UC in the
remission group compared to the HC - 93; (iii) active UC
group compared to UC remission group - 632. The
expression of 9 isomiRNA was strongly correlated with
the intensity of the inflammation (rho> 0.7).
Conclusions: An altered profile of microRNAs and their
isoforms was found in UC colon tissue, which also
correlated with inflammation intensity.
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Screening for genetic polymorphisms in Bulgarian
children with non-alcoholic fatty liver disease
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is
a highly prevalent liver disease in children. NAFLD is
associated with insulin resistance, obesity, and dyslipide-
mia. NAFLD is a multifactorial disease. Growing evidence
suggest the leading role of certain gene variants, associated
with rapid progression of the liver disease and dyslipidemia.
The aim of this study was to investigate whether various
single-nucleotide polymorphisms play any role in the
development of NAFLD in Bulgarian children.
Materials and Methods: We prospectively included 22
patients with NAFLD and 10 healthy controls. Ten of the
children with NAFLD underwent liver biopsy. PCR
amplification with specific primers pairs for variants in the
genes PNPLA3 (c.444C>G, p.I148 M), GCKR (c.1337C>T,
p.P446L) and TM6SF2 (c.499C>T, p.E167K) was
performed followed by direct sequencing using BigDye
Terminator v.3.1 Cycle Sequencing kit.
Results: The GCKR P446L gene polymorphism was
found in 75.0% (24/32) of the study participants (homo- or
heterozygous carriers). It was significantly higher in
homozygous patients with NAFLD than in healthy controls
(54.5% vs. 10.0%, p=0.025). PNPLA3 I148M was detected
in 9 of the patients and 7 of the controls. TM6SF2 E167K
was the rarest genetic variant, only 3 children (2 patients
and 1 healthy child) were carriers. Two of the patients, who
underwent liver biopsy had significant fibrosis F2. Patient
N1 was homozygous for PNPLA3 I148M and heterozygous
for GCKR P446L. Patient N2 was GCKR P446L hetero-
zygous carrier.
Conclusions: GCKR P446L polymorphism is associated
with development of NAFLD in Bulgarian children.
Medical University Sofia, Grant "Young Investigator"
Contract № D-142/02.05.2017
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Molecular characterization of familial intrahepatic
cholestasis by multi-gene panel analysis
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Introduction: Progressive Familial Intrahepatic Cholestasis
(PFIC) is a group of autosomal recessive diseases that
affects especially newborns and children, with progression
to liver failure in the first decades of life. PFIC is classified
into five types (PFIC1-5) based on the genetic defect
involved in bile transport. Other benign late-onset pheno-
types and non-progressive forms (BRIC, LPAC, DIC and
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ICP) are caused by heterozygous mutations in the same
gene pattern.
Materials and Methods: DNA analysis of 15 candidate
genes involved in PFIC and other related benign phenotypes
was carried out. Amplicon-based NGS on 80 patients was
performed. Bioinformatic and statistic pipelines were
applied.
Results: A total of 184 different variants has been
identified in our cohort: 18 pathogenic, 46 VUS, 44 likely
benign and 76 benign. P/LP mutations were found in 12%
of patients: 2 in ATP8B1, 3 in ABCB11, ABCB4 and TJP2
each, one in ABCC2, JAG1, NOTCH2. Many patients had
multiple variants in several genes. Patients had from 7 to 35
variants each and some SNPs were significantly associated
with biochemical parameters and phenotypic features that
could better explain clinics and accelerate the progression to
liver failure.
Conclusions: Our detection rate is according to other
studies proposing multi-gene panels. Our analysis may be
useful for the molecular diagnostics of PFIC and a better
characterization and understanding of the linking between
molecular defects and different subtypes of the disease. The
high SNPs prevalence let us to hypothesize a synergistic
haplotype effect in determining different multifactorial
cholestasis phenotypes and overlapping features.
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Telomere length (TL) and oxidative stress in C57BL/6J
mice
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Fairbrother1
1London Metropolitan University, London, United King-
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High levels of oxidative stress may lead to an increased rate
of telomere shortening and contribute to loss of telomere
integrity. Most in vivo studies have looked for correlations
between biomarkers of oxidative stress and TL, and have
used leucocytes. We have used a murine model to investi-
gate the potential impact of oxidative stress on TL in a
tissue-specific manner and to assess telomere oxidation
directly. Our model is a C57BL/6J mouse strain with a
naturally occurring nicotinamide nucleotide transhy-
drogenase (NNT) deficiency. The absence of Nnt results in
high levels of reactive oxygen species (ROS) in cells. DNA
was extracted from healthy control mice, Nnt-deficient mice
and Nnt-rescued mice (Nnt reinserted at the blastocyst
stage) and their telomeres analysed. Two qPCR methods
were used: mmQPCR to assess relative telomere length
(RTL), and a formamidopyrimidine DNA glycosylase
(FPG) enzyme-based qPCR method to directly determine
the extent of telomere oxidation. Analysis of RTL from
kidney revealed no significant difference (p>0.05) between
the three groups. This is predictable since rapidly dividing
leucocytes probably best represent early life replicative
responses and tissues such as kidney, a slowly dividing
tissue, represents the heritable load of TL. QPCR analysis
of the DNA extracts, before and after FPG digestion showed
there was no significant difference in the ΔCT values
between the three groups (p>0.05), implying there was no
discernible difference in telomere oxidation levels. Further
analysis will investigate tissues with variable metabolic and
cellular turnover rates such as the brain, spleen, liver, heart
and adipose tissue.
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Introduction: Nonalcoholic fatty liver disease (NAFLD) is
one of the most common parenchymal liver disorders. There
are no reliable markers for assessment of progression of
NAFLD from steatosis to steatohepatitis that leads to liver
fibrosis and cirrhosis. Polymorphism I148M in PNPLA3
gene is associated with inhibition of lipid hydrolysis.
Pathological variants of SERPINA1 gene promote accu-
mulation of mutant alpha-1-antitrypsin in endoplasmic
reticulum. Polymorphisms in HFE gene leads to intracel-
lular iron accumulation and fatty degeneration of liver.
Materials and Methods: Group of 59 patients with
NAFLD was selected. The assessment of structural changes
in liver was carried out by transient elastometry with
controlled attenuation parameter. Polymorphisms in
PNPLA3, SERPINA1 and HFE genes were determined by
real-time PCR.
Results: Association between homozygous carriage of
I148M polymorphism and increase of ALT was found
(p=0.011). A connection was established between the
presence of the polymorphism and more severe steatosis
(p=0.045). AST activity was higher in PiZ carriers than in
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patients without changes in this gene (p=0.049). H63D and
C282Y polymorphisms of the HFE gene are associated with
higher ALT (p=0.020 and p=0.030). A correlation between
changes in mentioned genes and more severe fibrosis was
not demonstrated.
Conclusions: Polymorphisms in the PNPLA3, SER-
PINA1, and HFE genes are associated with an increase in
ALT and AST in patients with NAFLD. The homozygous
variant of the I148M polymorphism in PNPLA3 gene and
the heterozygous C282Y in HFE gene are associated with
more severe steatosis. However, conflicting data regarding
liver fibrosis rates need further study.
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previously obese subjects.
M. Tessarech1, E. Mileti2, K. Kwok2, P. Arner3, D.
Bonneau1, E. Colin1, M. Rydén3, C. Daub2
1CHU Angers, Angers, France, 2Karolinska Institutet,
Stockholm, Sweden, 3Karolinska University Hospital Hud-
dinge, Stockholm, Sweden
Obesity is a worldwide public health issue associated with
many comorbidities. Understanding its underlying causes
and mechanisms is one of the keys to prevent and treat this
condition. Besides obvious environmental causes, as phy-
sical inactivity or poor nutrition, genetics is one of the main
component of obesity. Here, we perform a transcriptomic
study by 5′Cap-mRNA sequencing of subcutaneous white
adipose tissue of non-obese (NO), obese (OB) and pre-
viously obese (POB) subjects, at fasting and hyper-
insulinemia states. Differential gene expression analysis
showed few difference in the analysis of NO compared to
POB subjects, while the comparison of OB subjects versus
NO and versus POB displayed many transcriptomic chan-
ges, with most of the genes in common in both comparison.
Moreover, many genes were specifically involved in
expression changes between OB and POB subjects. Gene
ontology analysis revealed that those genes were involved
in metabolic and cellular process pathways and in cardio-
vascular diseases. Fasting and hyperinsulinemia metabolic
states had little influence on the results. This study
demonstrates that a major gene expression difference is
observed between obese and lean subjects, whether they
were never obese or got rid of their fat mass after a weight
loss surgery, and that after this kind of surgery, many
changes in gene expression appear. Further studies are
needed to identify precisely which genes are involved and if
they can be a target for personalized medicine in the treat-
ment of obesity by weight loss surgery.
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Introduction: The genetic diagnosis of Autosomal Domi-
nant Polycystic Kidney disease (ADPKD) is complicated by
the genomic structure of the main causative gene PKD1,
due to the presence of overlapping pseudogenes. Classifi-
cation of the missense variants is challenging as allelic
heterogeneity is rife, and few recurrent variants are known.
Data on ADPKD in Israeli populations is yet unavailable.
Materials and methods: Patient samples (n = 112) From
Israel were referred to Rambam Genetics Institute for
ADPKD gene panel testing (PKD1, PKD1, HNF1B). Next
generation sequencing (NGS) was performed using either
Trusight One (Illumina, n = 77), or exome sequencing (ES,
n = 35); analysis employed the Genoox platform. NGS was
supplemented by Sanger sequencing to achieve full cover-
age of panel. GANAB, DNAJB11 were included in ES
testing.
Results: A clinically significant variant (CSV) was
identified in 82% of the patients (PKD1-88%, PKD2-7%,
HNF1B-5%). Three PKD1 CSVs were identified only
following Sanger sequencing. Truncating CSVs comprised
~55% of pathogenic variants. Most CSVs (72%) were
unique; however, eight PKD1 CSVs recurred in two or
more patients, notably, in Jews of Persian and Ethiopian
descent. HNF1B-related kidney disease was diagnosed in
four individuals. Positive family history was linked with
higher CSV detection rates, 81%, compared with 60% when
negative.
Conclusions: This first report on ADPKD genetics in
Israel highlights recurrent CSVs in Israeli sub-ethnicities.
HNF1B CSVs can account for an ADPKD-like phenotype.
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Family history was a strong predictor for detection of a
CSV. Our experience underscores the importance of
utilizing ES as well as Sanger sequencing for variant
detection.
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Genome-wide association study identifies CDH12 as
candidate gene for renal injury in patients with poster-
ior urethral valves
L. F. M. van der Zanden1, I. A. L. M. van Rooij1, J. S. L. T.
Quaedackers2, R. Nijman2, M. Steffens3, L. L. L. de Wall1,
E. M. H. F. Bongers1, F. Schaefer4, M. Kirchner5, R.
Behnisch5, A. K. Bayazit6, S. Caliskan7, L. Obrycki8, G.
Montini9,10, A. Duzova11, M. Wuttke12, R. Jennings13,14, N.
A. Hanley13,14, N. J. Milmoe15, P. J. D. Winyard15, K. Y.
Renkema16, M. F. Schreuder1, N. Roeleveld1, W. F. J. Feitz1
1Radboud university medical center, Nijmegen, Nether-
lands, 2University Medical Center Groningen, Groningen,
Netherlands, 3Isala, Zwolle, Netherlands, 4University
Hospital Heidelberg, Heidelberg, Germany, 5University of
Heidelberg, Heidelberg, Germany, 6Cukurova University,
Adana, Turkey, 7Istanbul University-Cerrahpasa, Istanbul,
Turkey, 8Children`s Memorial Health Institute, Warsaw,
Poland, 9Fondazione IRCCS Ca’ Granda – Ospedale
Maggiore Policlinico di Milano, Milan, Italy, 10University
of Milan, Milan, Italy, 11Hacettepe University Faculty of
Medicine, Ankara, Turkey, 12University of Freiburg, Frei-
burg, Germany, 13University of Manchester, Manchester,
United Kingdom, 14Manchester University NHS Foundation
Trust, Manchester, United Kingdom, 15UCL Great Ormond
Street Institute of Child Health, London, United Kingdom,
16University Medical Center Utrecht, Utrecht, Nether-
lands
Introduction: Posterior urethral valves (PUV) and ureter-
opelvic junction obstruction (UPJO) are congenital
obstructive uropathies that may impair renal development.
We performed the first GWAS for renal injury in obstruc-
tive uropathy patients.
Methods: We included patients with pyeloplasty or PUV
resection before age 18. Signs of renal injury were defined
as dialysis, nephrectomy, kidney transplantation, estimated
glomerular filtration rate<60 ml/min/1.73m2, high blood
pressure, antihypertensive medication use, proteinuria, and/
or one kidney functioning<45%. In the GWAS, we
compared 141 and 216 obstructive uropathy patients with
and without signs of renal injury 5 years post-surgery,
respectively. For the associated SNPs, we performed
stratified analyses for PUV and UPJO, and Kaplan-Meier
and Cox regression analyses in the discovery and two
replication samples of 102 PUV patients each. For the
associated gene, we performed RNA and protein expression
analyses in fetal tissues.
Results: We observed suggestive associations with six
SNPs in three loci, of which rs6874819 in CDH12 was the
strongest (P = 7.5×10−7). This SNP also seemed to be
associated with time to renal injury in the PUV discovery
and replication samples. RNA expression analyses showed
clear expression in fetal kidneys, which was confirmed by
protein immunolocalization.
Conclusions: This study identified CDH12 as candidate
gene for renal injury in PUV. CDH12 is a target of the
proinflammatory MCP-1-MCPIP pathway. We hypothesize
that in PUV, MCP1 pathway upregulation due to increased
urinary tract pressure is augmented in carriers of the CDH12
variant, exacerbating renal injury.
Grant support: Dutch Kidney Foundation (13OKJ36),
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RNA-seq approach to detect splicing alterations in
primary ciliary dyskinesia and non-CF bronchiectasis
J. Legebeke1, G. Wheway1, H. Wai1, W. Walker1,2, J. S.
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1University of Southampton, Southampton, United King-
dom, 2University Hospital Southampton, Southampton,
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Mutations that cause PCD have been reported in >40 genes.
Most cases are recessive, caused by biallelic changes in
these genes. These account for around 70% of cases, sug-
gesting that additional genes, and non-coding or synon-
ymous changes in known genes, remain to be identified.
Non-CF bronchiectasis is a heterogeneous group of
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disorders and adults may need to be investigated for PCD.
Here we present an optimised pipeline for RNA analysis
from nasal brushings taken from the inferior turbinate of
patients with suspected PCD or non-CF bronchiectasis. We
present analysis pipelines to investigate differences in gene
expression, alternative splicing and the identification of
deleterious splicing events. We developed gene-neutral and
gene-specific analysis protocols, from both nasal brushings
stored in RNA-later and cells from nasal brushings cultured
at the air-liquid interface (ALI). We present this RNA-seq
approach as a particularly useful diagnostic tool to inves-
tigate patients in whom a single pathogenic variant has been
identified in a known PCD gene and where we suspect an
alteration in splicing of the same gene due to a second
intronic or synonymous / non-synonymous exonic variant.
This represents a step towards using RNA analysis for
increasing diagnostic yield in rare recessive respiratory
disease. JL, DB and HT are supported by a NIHR Research
Professorship to DB (RP- 2016-07-011). JL is further sup-
ported by Southampton NIHR BRC. GW is funded by a
Wellcome Trust Seed Award in Science (Grant No. 204378/
Z/16/Z) and a University of Southampton Faculty of Med-
icine Research Management Committee research grant.
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Primary hyperparathyroidism (PHPT) is common with a
prevalence of 0.86%. 10% are familial. Syndromic PHPT
includes multiple endocrine neoplasia (MEN)1, MEN4,
MEN2A and CDC73-related disorders. Non-syndromic
causes include familial hypocalciuric hypercalcaemia
(FHH), familial isolated HPT and neonatal severe PHPT.
Establishing the underlying genetic cause allows for tar-
geted, cost effective management. The 2019 National
Genomic Test Directory PHPT testing criteria are PHPT
and calcium creatinine clearance ratio (CCCR) >0.02 pre-
senting <35y or <45y with one of a) multi-glandular dis-
ease, or b) hyperplasia, or c) ossifying fibromas of the jaw,
or d) a family history (FH) of PHPT. The testing criteria for
FHH is CCCR <0.02.
We reviewed 121 PHPT patients from the Cambridge and
Guy’s Endocrine Genetics clinic over a 4y period referred
with multi-glandular disease, relevant FH, CCCR <0.01,
age <50y, or >1 risk factor. We offered NGS panel gene
testing of all known PHPT genes. Of the 121 patients, (92F,
mean age 41y), a pathogenic variant was identified in 16%
(11 CASR, 6 MEN1, 1 CDC73, 1 AP2S1) and we detected 4
VUS’s. The mean CCCR was 0.0073 in those with a CASR
pathogenic variant vs 0.016 in those without (p 0.003). A
CCCR <0.01 had a sensitivity of 82% and specificity of
81% for FHH. A positive FH was a strong predictor of a
pathogenic variant whereas multi-glandular disease was not.
In summary, genetic testing is recommended in PHPT at
any age with i) syndromic PHPT, ii) relevant FH iii) a
CCCR<0.01 and iv) multiple risk factors.
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Biallelic loss of function GFRA1 variants cause bilateral
renal agenesis
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Congenital anomalies of the kidney and urinary tract com-
prise a broad spectrum of renal and urinary tract mal-
formations with renal agenesis being at the most severe end
of the spectrum. It usually results in death in utero or in the
perinatal period. Only three genes have been identified so
far as causing renal agenesis. By exome/genome sequencing
within a diagnostic setting, with combined database ana-
lyses, we identified two unrelated patients presenting with
congenital bilateral renal agenesis and homozygous loss of
function variants (LoF) in the GFRA1 gene. Both patients
had parental consanguinity and similarly affected, deceased
siblings, suggesting an autosomal recessive inheritance.
Patient 1 was homozygote for the nonsense variant
NM_001348097.1:c.676C>T, p.(Arg226*). The second
patient was homozygote for a frameshift variant
(NM_001348097.1:c.1294delA, p.(Thr432Profs*13)). Both
variants are novel, identified for first time in our database,
and presumed to lead to LoF. The GFRA1 gene is not
reported to be associated to any human phenotype in
OMIM, but GFRA1 missense variants have been reported as
associated to Hirschsprung disease in several patients, based
on an oligogenic model. Gfra1-deficient mice demonstrate
absence of enteric neurons and agenesis of the kidney,
characteristics that are reminiscent of both Gdnf-and Ret-
deficient mice. The phenotype described in our patients is
identical to the renal phenotype reported in Gfra1 null mice,
however, no abnormalities of the enteric nervous system
was reported in these two cases. In conclusion, these find-
ings strongly support the causal role of GFRA1 inactivating
variants for an autosomal recessive form of bilateral renal
agenesis.
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Silver-Russell syndrome (SRS) is one of the most promi-
nent growth retardation disorders. However, both, the
phenotype and underlying molecular alterations of SRS
show a marked heterogeneity. SRS itself is an imprinting
disorder, mainly associated with specific molecular changes
at specific imprinted chromosomal regions. Disease causing
point mutations are less common and vary widely in means
of the affected gene. The suitability of panel-based NGS
assays to identify monogenetic causes of SRS-like pheno-
types has already been proven. The reasonableness of whole
exome sequencing to identify point mutations in patients
with Silver-Russel syndrome features however, is still the
subject of ongoing discussions. We examined samples of 75
patients referred for molecular testing for SRS using dif-
ferent NGS-based approaches. The typical SRS-associated
molecular alterations had been excluded before. The results
of multi gene panel, whole exome sequencing, and trio-
based whole exome sequencing approaches were compared.
Taking together the results of all different approaches, in
19/75 patients a disease-causing variant could be identified.
Most of these variants are associated with monogenetic
differential diagnoses of Silver-Russell syndrome. The
diagnostic yield raised from panel to whole exome
sequencing to trio-based whole exome sequencing. Broad-
ening the molecular sequencing approach increases the
mutation detection rate in patients referred for molecular
testing of SRS without one of the typical molecular
alterations. Some of the monogenetic disorders detected in
our cohort have an important impact on the clinical man-
agement and genetic counseling of affected families mainly
in terms of recurrence risks, tumor development, and mental
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Androgen Insensitivity Syndrome (AIS) is a Disorder of
Sex Development (DSD) that occurs at a frequency of 1 in
20,000 live births, is the most common DSD in people with
karyotype 46, XY, caused by mutations in the Androgen
Receptor (AR) gene. More than 1000 AR gene mutations
have been described in patients with AIS and prostate
cancer. Almost 400 of them are located in ligand binding
domain (LBD). The pathogenicity of mutations detected in
AIS patients from Ukraine was analyzed. Directional
sequencing of the PCR products of LBD-coding exons 7
and 8 was performed on DNA samples of AIS patients after
informed consent. The substitution X:67722905 T>C
(rs9332970), exon 7, missense mutation Ile843Thr was
identified in PAIS-patient. In another PAIS-patient the
substitution X: 67723745 C>T (rs137852594) samesence
variant was identified. It was predicted the creation of a new
enhancer motif for SRp55 splisosome protein, and as a
consequence a new donor splice site at the end of the last
exon 8. The substitution X:67722943 C> T (rs886041132),
exon 7 - missense mutation Arg856Cys, was identified in
CAIS-patient. Mutation X: 67722884 T> G, exon 7, a
missense mutation Ile836Ser, was identified in CAIS-
patient was not annotated in Varsome, gnomAD and
ARDB and identified as novel. The effect of listed missense
mutations was predicted according to SIFT and PolyPhen
values and classified as damaging. Analysis the substitution
Ile836Ser on 3D model showed that the mutant protein does
not get the correct conformation and binds dihy-
drotestosterone ~ 460 times worse than wild-type AR.
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Introduction: Ulcerative colitis is an inflammatory bowel
disease (IBD) characterised by chronic inflammation of the
human digestive tract. Despite efforts, the availability of
effective non-invasive diagnostics assays is still limited.
Cell free DNA (cfDNA) represents extracellular genetic
information that already showed promises for various fields
of genetic testing, including, non-invasive prenatal testing
(NIPT) and cancer testing.
Materials and methods: Using a murine dextran sulfate
sodium (DSS) induced colitis model we collected blood
from 46 laboratory mice, grouped by stage of ulcerative
colitis modeled by the duration of DSS administration.
cfDNA was isolated and sequenced using the MiSeq
Illumina System. Preprocessed sequenced data were
mapped against mouse genome (GRCm38.p6). Statistical
analyses were performed by in-house Python and R scripts.
Results: Besides the observed different fragment length
distributions between control and colitis groups, we
observed also a significantly increasing amount of mouse
genomic material with the advancing stage of the disease,
measured by the proportion of sequenced reads mappable to
the mouse genome. In addition, to further investigate the
pathophysiological processes behind the observed changes,
we performed a sequence based differentiation of reads
according to their mappability to the mouse nuclear and
mitochondrial genomes, as well as of the detected bacterial
communities.
Conclusions: We observed significant differences
between the control group and various disease stages in
sequenced data. Our results suggest the utility of cfDNA as
a potential screening marker for IBD and even its specific
stages and pathophysiological processes behind them.
Funded by: Slovak Research and Development Agency,
grant APVV-17-0526.
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Introduction: Wilson disease (WD) is an autosomal
recessive disorder of copper excess due to pathogenic
ATP7B variants. ATP7B codes for a copper-transporting
ATPase. Sequencing of ATP7B is an important tool to
diagnose the disease. However, variants of unknown sig-
nificance (VUS) are detected frequently, impeding a clear
diagnosis. Functional analyses can help to unambiguously
classify VUS. We aimed to functionally characterize four
ATP7B VUS, detected in patients with clinically distinct or
suspected WD.
Methods: The ATP7B open reading frame was cloned
into an expression vector and the VUS were generated by
site-directed mutagenesis. After HEK293T cell transfection,
ATP7B expression of the mutants was quantified at mRNA
and protein level by qRT-PCR and western blot. To assess
the mutant’s ability to export copper a copper-sensitive
luciferase-based assay was used.
Results: For all VUS ATP7B mRNA expression was
significantly reduced compared to wild-type and a benign
polymorphism. Three VUS also led to decreased protein
expression and copper transport capacity. These VUS had
been detected in clinically distinct WD patients. One VUS
led to protein expression and copper transport capacity at
wild-type level. It had been detected in a patient with
suspected WD.
Conclusions: Our results strongly suggest a pathogenic
effect for three of the VUS. For one VUS our results hint at
a benign effect. On-going immunofluorescence assays will
further address a possible protein mislocalization. Besides
clarifying the clinical relevance of variants, functional
characterization will help to understand the variant’s
pathomechanism contributing to personalized treatment
with fewer side effects.
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Geleophysic and acromicric dysplasias: clinical and
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Introduction: Geleophysic dysplasia (GD) and acromicric
dysplasia (AD) are skeletal dysplasia characterized by short
stature, brachydactyly and progressive joint limitation.
Cardiorespiratory involvement may be responsible for a
severe prognosis in GD. Dominant mutations in the FBN1
and LTBP3 genes are associated with AD and GD, whereas
recessive mutations in the ADAMTSL2 gene only with GD.
These three genes encode for proteins of microfibrillar
network. The aim of this study is to improve understanding
of natural history and genotype-phenotype correlations.
Materials and methods: This retrospective study
included patients with AD and GD followed in our center,
with identified mutation(s). Data from the medical records
were abstracted, recorded in an Excel spreadsheet and
analyzed using simple frequency analysis.
Results: We described clinical and molecular data from
38 patients (20GD, 18 AD) with a mean age of 17 years.
Mutations in the FBN1, ADAMTSL2 and LTBP3 genes were
identified in 23, 12 and 3 patients, respectively. Early death
occurred in nine cases. 45% of patients presented with
valvulopathy, progressive in half of cases. Respiratory
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 231
disorders were asthma (50%), non-cardiogenic restrictive
syndrome (30%), laryngo-tracheo-bronchial involvement
(18%) and acute non-cardiogenic pulmonary hypertension
(four cases). Patients with a variant involving a cysteine in
the FBN1 gene or mutations in the ADAMTSL2 gene
presented a higher proportion of severe cardiorespiratory
complications compared to a more benign course in patients
with other mutations.
Conclusions: Genetic findings could have importance not
only in the diagnosis, but also in risk stratification and
clinical management of patients with suspected acromelic
dysplasia.
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Background: Acromesomelic Dysplasia, type Maroteaux
(AMDM), is an autosomal recessive skeletal dysplasia
caused by loss of function mutations of NPR2 gene which
encodes C-type natriuretic peptid reseptor B. This rare type
of dwarfizm characterized with shortening of the middle and
distal segments of the limbs. Herein we reported nine
patients from eight families with seven novel NPR2
mutations.
Methods: Nine patients were diagnosed AMDM in a
single centre from 2015 to 2020 were enrolled in this study.
Their clinical, radiological and molecular genetic findings
examined retrospectively. The mutations in NPR2 gene
were confirmed with direct sequencing.
Results: All nine patiens in this group were admitted to
hospital with the complaint of short stature. All had short
limb type dwarfism with marked shortening middle and
acral segment of the limbs. All had typical dysmorphic
signs, brachydactyly, significant greater toes and normal
intelligence. We identified one previously reported (c.2729
C>T), five novel missense (c.3029 A>G, c.1738-1739 del
ins TT, c.1163 G>A, c.3058 C>T, c.329 G>A) and two
novel nonsense (c.1213 delT fs*, c.14 C>A fs*) mutations.
All new mutations identified in this group are likely
pathogenic and meaningfull with the patients typical clinical
presentations.
Conclusions: Reporting new patients with novel muta-
tions would contribute to better clinical dealination of this
rare dysplasia and would help to established pathogenic
mutations.
References:1. Maroteaux P, Martinelli B, Campailla E.
[Acromesomelic dwarfism]. Presse Med. 1971; 79:1839-
42.2. Khan S, Basit S, Khan MA, et al. Genetics of human
isolated acromesomelic dysplasia. Eur J Med Genet.
2016;59:198-203.
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Introduction: Autosomal recessive cutis laxa type 2D is a
severe multisystem disease due to pathogenic variants
affecting ATP6V1A, encoding a component of the V-Type
H+ATPase. Affected individuals show a strong cutis laxa
phenotype with large skin folds at birth, hypotonia and
cardiac abnormalities.
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Material and Methods: We performed single whole
exome sequencing (WES) to identify the causative
molecular defect in our index patient. Furthermore, Sanger
sequencing, qRT-PCR and Immunoblot analyses were
performed to further investigate causality of the variants
identified.
Results: Here we report on two affected individuals from
a non-consanguineous family from Hungary suffering from
a multisystem condition with severe, generalized muscle
hypotonia and and strong juvenile cutis laxa. One child died
in infancy, while the other significantly improved. Using
WES and co-segregation analyses we found our proband to
be compound heterozygous for a novel missense and the
first so far described nonsense pathogenic variant affecting
ATP6V1A. Expression studies revealed a strong degradation
of the allele carrying the nonsense alteration. Additionally,
patients’ dermal fibroblasts showed strong alteration of
Cathepsin D processing indicating alterations of lysosomal
function.
Conclusions: This is the second report on pathogenic
variants in ATP6V1A as the cause for a severe condition
with cutis laxa. Our data expand the clinical spectrum of
ATP6V1A-related phenotypes and show that beside mis-
sense, also nonsense pathogenic variants are a possible
cause of ATP6V1A-ARCL. Funding: The study was
supported by the Deutsche Forschungsgemeinschaft (FI
2240/1-1) to BF-Z and by EURO-CDG-2 to UK.
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Brachydactyly type A2 (BDA2, MIM 112600) is an auto-
somal dominant pathology characterized by deviation and
shortening of the middle phalanx of the index and / or
second toe. It may be due to mutations in the BMPR1B gene
(MIM 603248) or the GDF5 gene (MIM 601146) but may
also depend on structural changes in 20p12.3 involving the
BMP2 gene. Indeed, microduplications downstream of the
BMP2 gene have been described in 5 families (2 German
and 3 Chinese). Using an SNP-array technique, we identi-
fied a new duplication of 45kb downstream of the BMP2
gene in a French family. We describe the phenotypic and
genotypic characteristics of this family and review the
literature.
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Introduction: Localized autosomal recessive hypotrichosis
has been associated with pathogenic variants in DSG4,
encoding a desmosomal protein as well as in LIPH and
LPAR6, encoding respectively lipase H, which catalyzes the
formation of 2-acyl lysophosphatidic acid (LPA), and
lysophosphatidic acid receptor 6, a receptor for LPA. LPA
promotes hair growth and differentiation. In this study, we
aimed at delineating the genetic basis of LAH in patients
without pathogenic variants in these three genes.
Materials and Methods: Variant analysis was conducted
using exome and Sanger sequencing. We then performed
RT-qPCR, immunofluorescence staining, immunoblotting,
enzymatic and co-immunoprecipitation assays in cell
cultures and hair follicles to evaluate the consequences of
the identified variants.
Results:We identified homozygous variants in C3ORF52
in four individuals from two families with LAH. C3ORF52
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was found to be co-expressed with lipase H in the inner root
sheath of the hair follicle and the two proteins were found to
directly interact. The LAH-causing variants were associated
with decreased C3ORF52 expression and resulted in
markedly reduced lipase H-mediated LPA biosynthesis.
Conclusions: We could connect C3ORF52 to the LPA-
mediated signaling pathway which, together with LPAR6
and LIPH, plays a crucial role in hair growth. LAH can be
caused by abnormal function of any of these three proteins.
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Introduction: Carpal tunnel syndrome (CTS) is the most
common form of peripheral entrapment neuropathy.
Although CTS is quite common, its pathogenesis remains
largely unknown. An estimated heritability index of 0.46
and a familial occurrence in 27-39% of the cases indicate
that genetic factors must play a role in the pathogenesis. We
report on a peculiar family in which CTS occurred in sub-
sequent generations at an usually young age. Additional
clinical features included brachydactyly and short Achilles
tendons resulting in toe walking in childhood.
Material and methods: We performed exome sequen-
cing and genome-wide linkage analysis to identify the
pathogenic variant in this family. Several functional assays
were performed to further study the causality of the variant.
In addition, we sequenced a cohort of 216 patients to assess
the role of this new candidate gene in the pathogenesis of
CTS in a larger population.
Results: We identified a heterozygous variant
(c.5009T>G; p.Phe1670Cys) in the fibrillin-2 (FBN2) gene
that co-segregated with the phenotype in the family.
Functional assays showed that the FBN2 variant impaired
integrin-mediated cell adhesion and migration. Moreover,
we observed an increased TGF-β signaling and fibrosis in
the carpal tissues of affected individuals. A variant burden
test in a large cohort of CTS patients revealed a significantly
increased frequency of rare FBN2 variants in patient alleles
compared to controls.
Conclusions: Our data strongly suggest a role of FBN2 in
the pathogenesis of CTS.
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L. Volozonoka, D. Rots, I. Kempa, A. Kornete, D.
Rezeberga, L. Gailīte, A. Miskova
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Introduction: Cervical insufficiency is phenotypically
distinguishable condition causing pregnancy loss or preterm
delivery. A strong genetic component and few syndromic
forms of cervical insufficiency are described. Knowledge
about the genetics of human cervix remodelling during
pregnancy is scarce - only 12 maternal genes and their
variants are implicated in cervical insufficiency so far as
identified by our systematic gene analysis before.
Material and methods: We sequenced DNA from 21
patients with clinical presentation of isolated cervical
insufficiency using Illumina’s TruSight One NGS kit.
Genes having rare deleterious variants identified in our
patients (n = 694) were annotated for the pathway
enrichments using ConsensusPathDB. Variants in genes
from enriched phenotype-relevant pathways were manually
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curated based on variant’s pathogenicity, gene’s expression
pattern, mode of inheritance and disease mechanism, to
assign likelihood for contribution to the patients’
phenotype.
Results: Pathway-enrichment analysis revealed increased
variant burden in 15 pathways (max p-value 2.47E-03)
playing roles in tissue mechanical and biomechanical
properties, i.e. collagen biosynthesis, cell-extracellular
matrix communications and previously unnoticed pathways
of hemidesmosome assembly, laminins, integrins and focal
adhesion. Fourteen variants of unknown significance and
(likely) pathogenic variants in 11 genes - TGM2, ITGA6,
COMP, COL11A1, including COL1A1, COL1A2, COL6A3,
P3H1, PLOD1, PPIB and TNXB causing collagenopathies -
in 11 patients were classified as potential to increase
susceptibility to the development of non-syndromic cervical
insufficiency.
Conclusions: Cervical insufficiency being an expression
point in a phenotypic continuum of collagenopathies should
be investigated further using multiple approaches. This
might open up new opportunities to improve patient
evaluation and management in the future.
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Introduction: Chitayat Syndrome is characterized by hand
hyperphalangism with shortened index fingers and ulnar
deviation, hallux valgus, severe respiratory distress requir-
ing assisted ventilation and mild facial dysmorphism. It is
caused by the recurrent heterozygous missense variant
NM_006494.2:c.266A>G; p.Tyr89Cys in ERF, which
encodes the ETS2 repressor factor (ERF) protein. The ETS
family of transcription factors are involved in cellular pro-
liferation and differentiation, embryological development,
hematopoiesis, lymphocyte function and apoptosis. The
exact pathomechanism of Chitayat syndrome remains
unknown. So far, only seven individuals with molecularly
confirmed Chitayat syndrome have been documented in the
literature.
Methods: We performed a systematic phenotype analysis
of six unpublished individuals with Chitayat syndrome.
Results: We found unreported phenotypic features and a
great variability of pulmonary manifestations. Only one
individual presented with a history of assisted ventilation,
and one of the remaining presented with an atypical
phenotype lacking any obvious pulmonary compromise.
Conclusions: Our findings extend the phenotype spec-
trum associated with the recurrent ERF variant c.266A>G
and contribute to improved diagnostic strategies in
individuals with hand hyperphalangism.
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Chondrocalcinosis (CCAL) is a common condition caused
by calcium pyrophosphate accumulation and resulting in
destruction of articular cartilage, affecting 4-7% of adults.
CCAL is usually seen in polygenic disorders (hypercalce-
mia, gout, arthritis), but in rare cases runs in families as a
dominant trait (usually CCAL2, MIM #118600, ANKH
gene). CCAL1 is extremely rare with only four families
known to date: an Ashkenazy-Jewish kindred (PMIDs
2383078 and 29578045), a family from Maine (PMID
7887424), a family from the Netherlands and France (PMID
24743232), and a Long Island NY family (PMID
29578045). These families all demonstrated a specific het-
erozygous TNFRSF11B variant, c.1205A>T, modifying the
stop codon (AAT>ATT) and predicting an elongated pro-
tein (p.Ter402Leuext*19). We report another 4-generation
CCAL1 kindred from Rhineland-Palatinate (comprising 8
females and 3 males) also demonstrating the TNFRSF11B
c.1205A>T variant. All patients (11/11, 100%) had early-
onset osteoarthritis and chondrocalcinosis with an onset of
symptoms between 16 and 30 years, and all had swelling of
joints, motion restriction, and intense pain. Three probands
(3/10, 30%; no data in a deceased family member) also had
digital polyarthritis. First, knee, elbow, ankle and wrist
joints were affected, followed by spinal destruction.
Remarkably, ball-and-socket joints (e.g. hip joints) were
only minimally affected (only an affected 30-year-old
male). The early onset and familial clustering led to the
molecular diagnosis. This is the first CCAL1 family from
Germany, providing further understanding of the clinical
signs and treatment (including physical therapy, orthoses,
antirheumatic drugs, experimental treatment with inter-
leukin inhibitors, and multiple joint surgery).
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Introduction: Glycine substitutions in the Gly-X-Y-triplet
disrupt the type I collagen triple helix structure and folding,
and typically result in osteogenesis imperfecta (OI) and
have not yet been associated with Ehlers-Danlos syndrome
(EDS). OI is characterized by bone fragility, whereas EDS
affects the connective tissue resulting in joint hypermobi-
lity, skin hyperextensibility, and tissue fragility. Although,
an OI/EDS overlap” syndrome characterized by clinical
hallmarks of EDS and mild or absent OI-phenotype is also
described. The underlying mutation spectrum is wide, but
includes glycine substitutions.
Material and Methods: Here, we report three patients
mainly showing joint hypermobility and unusual skin. Panel
diagnostic via sequencing by synthesis was conducted
including candidate genes contributing to connective tissue
disorders. Sanger sequencing was used for analyses of
segregation patterns in parents.
Results: All index patients carried each an undescribed,
heterozygous glycine substitution. In two cases the variant
(c.1270G>A/p.(Gly424Ser) in COL1A1 gene; c.434G>A/p.
(Gly145Arg) in COL1A2 gene) was maternal inherited and
segregated with the symptoms in both families. In the other
case the substitution occurred de novo (c.179G>A/p.
(Gly60Asp) in COL1A2 gene). Comparable to our patients,
glycine substitutions in the more N-terminal region of both
genes are already described with “OI/EDS overlap”
syndrome. In detail, one of our families showed an EDS-
phenotype with additional minimal OI-symptoms (short
stature, blue sclera), whereas the others were clinical
classified as EDS-phenotype.
Conclusions: Despite the detection of glycine substitu-
tion, the patients could manifest a more typical EDS
phenotype rather than OI. Certainly, subclinical symptoms
for OI can additionally occur and should be considered.
S. Döhnert: None. H. Reichenbach: None. S. Demuth:
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Morphological and molecular characterization of ecto-
pic cartilage in Crouzon Syndrome
E. Candelo
Fundacion Valle del Lili, Cali, Colombia
Background: Craniosynostosis is the premature closure of
the skull sutures. Patients with these condition undergo
several surgical procedures, which are not able to fully
restore appearance and functionality due to insufficient bone
growth and suture refusion. Most mutations disrupt genes
that encode for members of the fibroblast growth factor
receptor (FGFR) family.
Materials and Methods: A knock out mouse with
Fgfr2c342Y/C342Y was generated for phenotypic analysis
by histological staining of sections of WT, Fgfrc342y/+
heterozygous (HET) and Fgfr2c342Y/C342Y homozygous
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(HOM) mouse embryos from embryonic day (E) 14.5 and E
16.5 stages. Morphological characterisation of the ectopic
cartilages in the mutant specimens was done against the
HET and WT by calculating the surface area, perimeter,
width on the parietal cartilage in each genotype and cellular
characterisation by obtaining the cellular density and shape
descriptors. Molecular characterisation was determined by
mmunohistochemistry of Collagen I and II.
Results: We identified a significant parietal cartilage
expansion in HOM embryos since E14.5 with higher
perimeter, surface area, and high cellular density. Addi-
tionally, characteristic cell morphology comprised; high
cellular area and perimeter and circular or rounded shape.
These findings were associated with abnormal intensity and
localization pattern of Collagen type I and II.
Conclusions: A possible switch off on the intramem-
branous ossification of the parietal and frontal primordial
bone and switch on of endochondral ossification process
supported by the cellular, morphological and molecular
findings of the abnormal cartilage expansion lead to a novel
hypothesis of coronal suture fusion that can future drug
target on this condition.
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Introduction: Dyssegmental dysplasia (DD) is a rare,
autosomal recessive disorder characterized by micromelia
and anisospondyly. Two distinct forms are described;
Silverman-Handmaker (DDSH) characterized by severe
shortening of limbs and perinatal lethality, and Rolland-
Desbuquois (DDRD) with survival beyond infancy and
milder skeletal findings. DDSH is caused by biallelic var-
iants in HSPG2 but the aetiology of DDRD has not been
explained. Here, we present the first DDRD patient reported
to have an HSPG2 variant.
Materials and Methods: Detailed phenotyping and next-
generation sequencing were performed.
Results: The patient is a 15-month-old female with short
bones, flared metaphyses, camptodactyly, anisospondyly,
pes equinovarus, flat face, micrognathia, cleft palate and the
history of respiratory distress in infancy. She was diagnosed
as DDRD given milder skeletal findings and a prolonged
survival in comparison to DDSH. Whole exome analysis
revealed a homozygous NM_005529.7:c.9970G>A(p.
Gly3324Arg) variant on HSPG2 which was predicted to
be pathogenic by in silico analyses.
Conclusions: The phenotypic heterogeneity and clinical
overlap between DDSH and DDRD raise the question of
whether HSPG2 variants lead to distinct DD forms or
represent a single disorder with variable phenotypic
spectrum. In a review of the literature, we recognised three
patients reported as DDSH whereas they had milder skeletal
findings and survival age between 13 months and 7 years,
compatible with DDRD. Strikingly, they harboured novel
HSPG2 variants, one of which was detected in our case. In
the light of all these findings, we conclude that DDSH and
DDRD are allelic and represent a single disorder with a
spectrum of severity.
T. Kalayci: None. N. Balanda: None. C.R. Ferreira:
None. U. Altunoglu: None.
P04.23.B
FROM CEREBRAL HEMORRAGE AND SUSPIC-
TION OF CHILD ABUSE TO DIAGNOSIS OF
FAMILIAR EHLERS DANLOS SYNDROME DUE
TO DELECION IN COL5A1 GENE
P. Marin Reina1, A. Zuñiga Cabrera1, A. Parra Llorca1, P.
Molina Aguilar2, J. Blasco2, A. Monzo Blasco2, M. Evole
Buselli1
1Hospital UyP La Fe, Valencia, Spain, 2Forensic Depart-
ment, Valencia, Spain
Introduction: The misdiagnosis of Ehler Danlos syndrome
(EDS) and child abuse is well known, usually in relation-
ship to skin lesions or bone fractures. At our case, the first
manifestation was an aborted lethal episode in an infant due
to a cerebral hemorrhage.
Clinical Case: A 4-month-old boy was founded uncon-
scious after sleep. He was admitted to the pediatric intensive
care unit with a subdural and subarachnoid hemorrhage and
severe cerebral edema. Child abuse was suspected. Familiar
antecedents: Mother, 34 years, first gravida. She was
followed up during infancy due to small size. She has joint
hypermobility. Her brother died at sixth month due to
supposed sudden infant death. One 50 years old aunt
presented a cerebral hemorrhage. Healthy father, 30 years
old. No consanguinity. The child presented hypermovility
and skin hyperextensibility. EDS vascular type was
suspected. NGS analysis was performed using Illumina
(NextSeq 500) technology with a ClearSeq Inherited
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Disease panel (Agilent Thecnologies) and consisted in the
analysis of the coding and intronic regions of collagen
deficiency related gene. The study did not show any
pathogenic variant and was completed by analysis of gene
dosage by MLPA (P331; P332), resulting in patient
HETEROZYGOUS for deletion of exons 5-7 of the
COL5A1 gene. Presence of deletion was confirmed in
affected familial members.
Conclusions: Vascular complications in nonvascular
subtypes of the EDS could be life-threatening. - Misdiag-
nosis of child abuse should be considered in EDS - The
relevance of study microdeletions in cases not diagnosed by
gene sequencing.
P. Marin Reina: None. A. Zuñiga Cabrera: None. A.
Parra Llorca: None. P. Molina Aguilar: None. J. Blasco:
None. A. Monzo Blasco: None. M. Evole Buselli: None.
P04.25.A
Follow-up findings and genotype-phenotype correlation
in 18 Turkish patients with biallelic mutation in the
FKBP10 gene
A. Yüksel Ülker1, D. Uludag Alkaya1, G. Yeşil2, G. Toksoy3,
Z. Uyguner3, B. Tüysüz1
1Istanbul University, Cerrahpasa Medical Faculty, Istan-
bul, Turkey, 2Bezmialem Vakif University, Medical Faculty,
Department of Medical Genetics, Istanbul, Turkey, 3Istan-
bul University, Medical Faculty, Department of Medical
Genetics, Istanbul, Turkey
Introduction: Osteogenesis Imperfecta (OI)-typeXI and
Bruck syndrome type-I are two very rare disorders caused
by biallelic FKBP10 gene mutations. While both disorders
are characterized by early onset bone fractures, progressive
bone deformity and scoliosis, Bruck syndrome type 1 also
has congenital contractures and pterygium. FKBP10/
KRT14 mutations have been reported to be present in
patients with OI-typeXI and Epidermolysis bullosa simplex
(OIEBS). The aim of this study is to investigate the clinical
findings and genotype-phenotype correlation in the Turkish
cohort with FKBP10 mutation.
Materials and Methods: Eighteen patients from fifteen
families were enrolled. FKBP10 mutations studied via
sanger sequencing or next generation sequencing. The
parents of all patients had consanguineous marriages. 16
patients were followed up for 6.2 years (7 months-15.5
years).
Results: We identified p.Gly300Ter in eleven patients
and p.Gly278Argfs*95 in one patient who live same region.
Ten of these patients were compatible with OI-XI, two
patients had Bruck1 phenotype. One patient with Bruck1
who lives different region had a novel (c.1256+1G>A)
mutation. We also found same mutation (c.321_353del) in
five patient with OIEBS who lives same city. Pamidronate
treatment was given to 16 follow-up patients.
Conclusions: The clinical course of the patients was
progressive; bone fractures were started in the infantile
period (15/18) and continued as more than 1 fracture (9/16)
per year. During the follow-up period, severe limb
deformity (7/16) and scoliosis (11/16) developed and no
patient could walk (16/16). Although most families are not
related, they had the same mutation which is attributed to
the founder effect.
A. Yüksel Ülker: None. D. Uludag Alkaya: None. G.
Yeşil: None. G. Toksoy: None. Z. Uyguner: None. B.
Tüysüz: None.
P04.26.B
Wide sutures and fontanels, delayed speech development
and a hoarse voice useful signs in diagnosing KBG
syndrome, clinical, molecular and cytogenetic descrip-
tion of 12 patients.
A. Kutkowska-Kazmierczak1, M. Gos1, J. Castaneda1, M.
Boczar1, A. Barczyk1, A. Pietrzyk1, O. Kordowska1, T.
Gambin1, P. Własienko1, B. Wiśniowiecka-Kowalnik1, K.
Kowalczyk1, M. Bartnik-Głaska1, M. Smyk1, M.
Paczkowska1, I. Plaskota1, K. Niepokój1, J. Kelly2, B.
Nowakowska1, E. Obersztyn1, J. Bal1
1Institute of the Mother and Child, Warsaw, Poland, 2Quest
Diagnostics Nichols Institute, Chantilly, VA, United
States
Introduction: KBG syndrome is a neurodevelopmental
disorder characterized by short stature, macrodontia,
developmental delay, behavioral problems as hyperactivity,
velopharyngeal insufficiency causing feeding problems and
speech delay and by delayed closing of sutures and fonta-
nels. Most of the patients with KBG syndrome have a
mutation of ANKRD11 gene or micro-rearrangement
encompassing this gene.
Patients and methods:We present clinical evaluations of
12 patients with the clinical features of KBG syndrome at
the age from 4 months to 17 years. The mutation analysis in
these patients was performed using panel next generation
sequencing (6pts), whole exome sequencing (WES) (2pts)
and array CGH (4pts).
Results: Besides typical dysmorphic features for KBG
syndrome found in all patients, the majority of patients had
wide sutures and fontanels (7/12), delayed speech (9/11),
feeding problems (9/12). Hoarse voice was noticed in 4
patients and short stature, below 2 SD in two patients,
between -1-2 SD in 7 patients. Abnormal behavior was
noted in 4 patients, macrodontia in 3 patients.
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Conclusions: The fact that the delayed closing of sutures
and fontanels was observed in more than half of our patients
with KBG syndrome caused by mutations or rearrange-
ments of ANKRD11 gene confirms the role of this gene in
skull and suture formation. Speech delay is found in
majority of patients with this syndrome. Rarely described
sign - hoarse voice could reinforce clinical knowledge in
diagnosing KBG syndrome. The studies on craniosynos-
toses were supported from Institute of Mother and Child in
Warsaw intramural grant no. OPK-510-18-63
A. Kutkowska-Kazmierczak: None. M. Gos: None. J.
Castaneda: None. M. Boczar: None. A. Barczyk: None.
A. Pietrzyk: None. O. Kordowska: None. T. Gambin:
None. P. Własienko: None. B. Wiśniowiecka-Kowalnik:
None. K. Kowalczyk: None. M. Bartnik-Głaska: None.
M. Smyk: None. M. Paczkowska: None. I. Plaskota:
None. K. Niepokój: None. J. Kelly: None. B. Now-
akowska: None. E. Obersztyn: None. J. Bal: None.
P04.27.C
Patients with suspected Erythrodermia variabilis of a
large family carry variants in GJB3 and KRT10
A. Hotz1, S. Redler2, J. Kopp1, A. Zimmer1, J. Fischer1
1Institute of Human Genetics, University Medical Center
Freiburg, Faculty of Medicine, Freiburg, Germany, 2Insti-
tute of Human Genetics, Heinrich-Heine-University, Med-
ical Faculty, Düsseldorf, Germany
Introduction: Erythrokeratoderma variabilis (EKV) is a
rare skin disease characterized by two features: red skin
areas with sharp borderlines, which tend to shift positions;
and hyperkeratosis, which can either be generalized or
localized as thickened plaques. EKV is mostly inherited in
an autosomal dominant manner and is mainly caused by
pathogenic variants in GJB3, GJB4 or GJA1.
Results: We describe a large family with twelve patients
of five generations affected by a skin disorder. The index
patient shows typical features of EKV. Mutation analysis in
seven affected members from three generations using Next
Generation and Sanger sequencing methods revealed that all
of them carry both the heterozygous unclear variant
c.783G>C, p.(Gln261His) in GJB3 and the novel hetero-
zygous pathogenic variant c.1346A>C, p.(Tyr449Ser) in
KRT10. Pathogenic variants in KRT10 lead to Epidermo-
lytic ichthyosis, which is characterized by diffuse erythro-
derma and blistering at birth and progressive hyperkeratosis
later in life and is usually inherited in an autosomal
dominant manner. Furthermore, two unaffected members
were analyzed, one of them carries none of the variants, the
other only the GJB3 variant.
Conclusions: It is remarkable, that all seven tested
affected family members from three generations carry both
variants in GJB3 and KRT10. Although the KRT10 variant
is pathogenic, it cannot be excluded that the GJB3 variant
has an impact on the phenotype, since the initial suspected
diagnosis was EKV. However, it cannot be excluded that
the GJB3 variant is neutral. In this case, analysis of patients
with suspected EKV should include pathogenic variants in
KRT10.
A. Hotz: None. S. Redler: None. J. Kopp: None. A.
Zimmer: None. J. Fischer: None.
P04.30.C
When textbooks fall short - earlier detection of
Hypochondroplasia - a large UK cohort experience
and systematic review.
A. Sabir1, E. Morley2, J. Sheikh2, A. Singh2, A. Cocca1, M.
Cheung1, M. Irving1
1Guy’s and St Thomas’ Hospital, London, United
Kingdom, 2University of Birmingham, Birmingham,
United Kingdom
Introduction: Hypochondroplasia (HCH) is a rare auto-
somal dominant skeletal dysplasia caused by FGFR3
mutations leading to disproportionate short stature. Classi-
cally HCH presents in toddlers or school-age children, as
limb-to-trunk disproportion is often mild and easily over-
looked during infancy. We report experiences from our UK
HCH cohort of ~30 patients and review recent literature to
explore the antenatal detection of HCH.
Methods: We reviewed the rate of antenatal HCH
detection in our 29 patient cohort and describe relevant
case-date. We then conducted a systemic, retrospective
literature review using PUBMED and MEDLINE, identify-
ing antenatally suspected / detected HCH cases. Paper
inclusion criteria: Antenatally suspected HCH. Molecular
confirmation of denovo HCH. Exclusion criteria: unclear
antenatal scanning history.
Results: Antenatally suspected (and concurrent or
deferred molecularly confirmation) HCH has been reported
10 times in the literature (between 2004-2019) and in 6 of
our 29 patient cohort. Key sonographic markers included
reduced; femur length, biparietal diameter and humeral
length.
Conclusions: HCH is increasingly detected both antena-
tally and in infancy, contrary to previous descriptions. This
is likely due to greater HCH awareness, improved imaging
and easier molecular testing. Thus one should consider
HCH outside the classical presenting period. Studying the
natural history of earlier cases is important with the advent
of several targeted FGFR3 therapies currently in trials for
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 239
Achondroplasia (Biomarin’s Vosorotide, Ascendis’ Trans-
chon, QED’s Infagratinib and Pfizer’s TA-46) as such
therapies may soon be trialled in HCH and are likely most
efficacious during earliest skeletal maturation.
A. Sabir: None. E. Morley: None. J. Sheikh: None. A.
Singh: None. A. Cocca: None. M. Cheung: None. M.
Irving: None.
P04.31.A
Mono-allelic deleterious variants in autosomal recessive
skeletal dysplasia genes are strongly associated with
idiopathic short stature
C. T. Thiel1, N. Hauer1, C. Vogl1, S. Uebe1, H. Sticht2, A. B.
Ekici1, C. Kraus1, H. Dörr3, A. Reis1
1Institute of Human Genetics, Friedrich-Alexander-Univer-
sität Erlangen-Nürnberg FAU, Erlangen, Germany, 2Insti-
tute of Biochemistry, Friedrich-Alexander-Universität
Erlangen-Nürnberg FAU, Erlangen, Germany, 3Depart-
ment of Pediatrics and Adolescent Medicine, Friedrich-
Alexander-Universität Erlangen-Nürnberg FAU, Erlangen,
Germany
Short stature is a common concern in childhood with an
incidence of 3%. After exome analysis about 60% remain
without diagnosis (idiopathic short stature, ISS). Recent
identification of heterozygous mutations in ACAN in 1.4%
of ISS individuals confirmed that single, large-effect var-
iants strongly affect height (appr. 15cm final adult height).
We therefore hypothesized that heterozygous variants in
other autosomal recessive skeletal dysplasia genes also
contribute to ISS. We selected exome data from 368 ISS
families where previous analysis showed no mutations in a
known growth-associated gene and selected 114 genes
known to be involved in autosomal recessive inherited
skeletal dysplasia, extracted from the “Nosology and Clas-
sification of Genetic Skeletal Disorders” (Bonafe et al.
2015). From a total of 391 heterozygous variants we
selected 33 variants in 26 genes which were classified as
ACMG class 4/5 and compatible with segregation in the
families and were thus considered strong candidates for ISS.
This accounted for 31 patients (8.4%). No class 4/5 variant
in any of the 26 genes was detected in 343 controls (p<1e-
85). Frequently affected genes were ACAN (6 individuals)
and NPR2 (3 individuals) representing 2.5% of the study
group. In addition to missense variants in 17 genes, a
nonsense variant was observed in ADAMTS10, CHST3,
CYP27B1, TCIRG1, TRIP11, WDR35 and CUL7. Our
findings suggest a strong association between rare mono-
allelic deleterious variants in genes for recessive skeletal
dysplasia and idiopathic short stature and provide further
evidence for the contribution of rare, large-effect variants to
the etiology of this common trait.
C.T. Thiel: None. N. Hauer: None. C. Vogl: None. S.
Uebe: None. H. Sticht: None. A.B. Ekici: None. C.
Kraus: None. H. Dörr: None. A. Reis: None.
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IRAK1 gene SNPs rs1059703 and rs3027898 polymorph-
isms is associated with psoriasis
L. Kucinskas1, A. Bruzaite1, J. Cepaite1, V. Kucinskiene2,
R. Ugenskiene1, S. Valiukeviciene2
1Institute of Biological System and Genetic Research
LUHS, Kaunas, Lithuania, 2Department of Skin and
Venereal Diseases, Lithuanian University of Health
Sciences (LUHS), Hospital of LUHS Kauno Klinikos,
Kaunas, Lithuania
Psoriasis vulgaris and psoriatic arthritis are multifactorial
diseases with an important genetic component. The clinical
significance of IRAK1 genes SNPs rs1059703 ir rs3027898
are unknown for psoriasis pathogenesis. The aim of present
study was to determinate IRAK1 gene SNPs rs1059703 and
rs3027898 clinical importance for psoriatic arthritis and
psoriasis development.Methods. 106 patients with psoriasis
from Skin and Veneral disease department of Lithuanian
University of Helath Sciences hospital and 52 healthy
control group subjects were genotyped. The IRAK1 gene
SNPs rs1059703 and rs3027898 genotyping was performed
using Mva1269I (BSMI) and Eco57I (AcuI) restriction
enzymes. Data and statistical analysis was performed using,
Microsoft Office Excel“ and, IBM SPSS Statistics 20.0“
programs.Results. The number of patients of IRAK1 gene
rs3027898 with C/A, C/C and C genotypes outnumbered
control group (32 persons (30 %) vs 5 persons (10 %). The
number of patients of IRAK1 rs1059703 with C/T, C/C and
C genotype was higher compare with control group (30
persons (30 %) vs 6 persons (11 %). The statistical analysis
of patients genotypes and psoriatic arthritis corelation
showed no significant data of association (p < 0,05). Odds
of ratio calculation (OR) showed IRAK1 rs3027898 C/A, C/
C, C and IRAK1 rs1059703 C/T, C/C and C genotypes
association with psoriasis (OR 4,06) and (OR 3,39)
respectively.Conlusions. Statistically significant association
of IRAK1 rs3027898 and IRAK1 rs3027898 SNPs with
psoriatic arthritis was not determinated. IRAK1 rs3027898
C/A, C/C, C genotypes and IRAK1 rs1059703 C/T, C/C and
C genotypes are associated with psoriasis development.
L. Kucinskas: None. A. Bruzaite: None. J. Cepaite:
None. V. Kucinskiene: None. R. Ugenskiene: None.
S. Valiukeviciene: None.
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Skin cancer screening is indicated in IWC patients due
to the identification of heterozygous KRT10 variants in
patients with MAUIE syndrome
B. Burger1, A. Ghosh1,2, C. K. Y. Ng3, S. Piscuoglio1, I.
Spoerri1, P. H. Itin1, K. Greer4, D. Elbaum5
1University of Basel and University Hospital Basel, Basel,
Switzerland, 2University of Zurich and ETH Zurich, Zurich,
Switzerland, 3University of Bern, Bern, Switzerland, 4Uni-
versity of Virginia, Charlottesville, VA, United States,
5Mercy Hospitals of Bakersfield, Bakersfield, CA, United
States
Ichthyosis with confetti (IWC) is an autosomal dominant
skin disorder characterized by a congenital erythema and
the development of numerous pale spots. About 20% of the
patients are reported to develop skin cancer at young
adulthood. All IWC patients are carriers of a heterozygous
keratin (KRT)10 or KRT1 variant leading to a shifted
reading frame and the translation of an aberrant carboxyl
(C)-terminus. This results in the nuclear localization of the
KRT10/KRT1 protein instead of cytoplasmic. About 20
years ago, two patients were described as MAUIE patients.
They showed the typical IWC-phenotype including the
development of pale spots. Both patients developed
aggressive and fatal cutaneous squamous cell carcinoma
(cSCC). A genetic analysis is not yet done. Our study aimed
to identify an IWC-correlated frameshift variant in both
patients and to clarify whether they suffered from IWC. We
performed whole exome sequencing on genomic DNA from
FFPE cSCC tissue of both deceased patients and screened
for variants similar to IWC-associated variants. A hetero-
zygous KRT10 variant, encoding for the aberrantly shifted
C-terminus, was identified in each patient and the nuclear
localization of KRT10 was confirmed by immuno-
fluorescence staining. Our study reclassified both MAUIE
patients as patients with a specific form of IWC. The fatal
course of the disease is not typical for the other IWC forms,
but it emphasizes the importance of skin cancer screening in
all IWC-patients. We recommend the regular intensive
examination of their skin for cancers and a good education
of the patients with reference to their disease.
B. Burger: None. A. Ghosh: None. C.K.Y. Ng: None. S.
Piscuoglio: None. I. Spoerri: None. P.H. Itin: None. K.
Greer: None. D. Elbaum: None.
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Kinesin family member 13A, KIF13A, is a novel gene for
hypomelanosis of Ito
C. LAM
The University of Hong Kong, Hong Kong, China
Introduction: Hypomelanosis of Ito is a neurocutaneous
syndrome, characterized by distinctive skin manifestations,
with or without multisystem involvements. While the exact
cause of hypomelanosis of Ito is unknown, chromosomal
mosaicism as a result of sporadic gene mutation has been
suggested in literature.
Materials and Methods: In our Clinics for Rare diseases
Referral (CRareDr), we encountered a 3-year-old girl
presenting with characteristic skin pigmentation and devel-
opmental delay, suggesting hypomelanosis of Ito This case
was enrolled in our undiagnosed diseases program (UDP)
for ending diagnostic odyssey. We initiated genetic analysis
for neurodevelopmental impairment using whole-genome
(WGS) and whole exome sequencing (WGS).
Results: A heterozygous de novo variant NM_022113.6:
c.2357dupA; p.Asn786Lysfs*18 in the KIF13A gene was
identified in the patient. The variant is a single nucleotide
duplication causing a shift in the translational reading frame
and premature termination of the protein. The variant is
absent in control population in gnomAD exomes and
genomes.
Conclusions: KIF13A is a relatively new gene with a
limited number of studies on its function and has not been
reported to cause any hereditary conditions. To date,
KIF13A is known to interact with adaptor complex AP-1,
forming a complex that is responsible for the transportation
of a number of proteins and receptors to plasma membrane
and endosomal organelles. The role of KIF13A in
melanosome biogenesis is well-demonstrated in in-vitro
studies and may explain the underlying pathogenesis of skin
hypopigmentation in hypomelanosis of Ito.
C. Lam: None.
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Functional evidence supporting the hypothesis that
Neanderthals and Denisovans had a genetically specified
high bone mass negatively selected in anatomically
modern humans
N. Roca-Ayats1, I. Maceda2, C. Bruque3, M. Cozar1, N.
Garcia-Giralt4, L. Mellibovsky4, W. van Hul5, O. Lao2, D.
Grinberg1, S. Balcells1
1University of Barcelona, CIBERER, IBUB, IRSJD, Barce-
lona, Spain, 2Centre Nacional d’Anàlisi Genòmica CNAG-
CRG, Barcelona, Spain, 3Centro Nacional de Genética
Médica, ANLIS, Instituto de Biología y Medicina Experi-
mental, CONICET, Buenos Aires, Argentina, 4Musculoske-
letal Research Group, IMIM (Hospital del Mar Medical
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Red de Fragilidad y Envejecimiento Saludable
(CIBERFES), ISCIII, Barcelona, Spain, 5Department of
Medical Genetics, University of Antwerp, Antwerp, Bel-
gium
Introduction: Bone density underwent gracilization through
hominin evolution; while Neanderthals and Denisovans had
robust and dense bones, anatomically modern humans
(AMH) show a more gracile skeleton. In this context, muta-
tions in the first β-propeller of LRP5 result in high bone mass
(HBM) in AMH, suggesting this gene as a suitable candidate
for studying the hominin evolution of bone mass.
Material and Methods: Variants were looked for in the
publically available Neanderthal and Denisovan genomes
and functionally tested by a luciferase assay in Saos-2 cells.
A molecular homology model of LRP5 was generated using
MODELLER (v.9.22). Introgression was inferred in the
Simons Genome Diversity Project using the CRF method.
Evidences of selective pressures at LRP5 in AMH were
sought using PopHuman browser.
Results: We identified five Neanderthal or Denisovan
missense mutations in LRP5. Four displayed significantly
greater Wnt pathway stimulation, and two also showed
reduced inhibition by DKK1. Modelling suggested that
these mutations either affected the 3D structure of the first
β-propeller, or impinged on the interaction of LRP5 with
DKK1. We observed that the LRP5 genomic region in
AMH is depleted of introgression from Neanderthals and/or
Denisovans and that the functional Neanderthal and
Denisovan mutations are at a very low frequency in current
human populations.
Conclusions: The variants identified in Neanderthal and
Denisovan genomes, together with the evolutionary ana-
lyses in the LRP5 region suggest that this gene may have
been involved in HBM determination in archaic hominins.
Funding: Spanish MINECO (SAF2016-75948-R;
PGC2018-098574-B-I00); CIBERER (U720); AGAUR
(2017 SGR 937).
N. Roca-Ayats: None. I. Maceda: None. C. Bruque:
None. M. Cozar: None. N. Garcia-Giralt: None. L.
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Looking for genetic modifiers in Marfan syndrome
E. Ramos-Luis1,2, G. Teixidó3, J. Limieres3, R. Cruz4,2, C.
Granato3, B. Sobrino5,2, J. Amigo5,2, A. Blanco-Verea1,2, A.
Carracedo5,2,4, A. Evangelista3, M. Brion1,2
1Xenética Cardiovascular, Instituto de Investigación Sani-
taria de Santiago, Santiago de Compostela, Spain, 2Grupo
de Medicina Xenómica, Universidade de Santiago de
Compostela, Santiago de Compostela, Spain, 3Hospital
Vall d’Hebron, Servicio de Cardiología, Barcelona, Spain,
4CIBER enfermedades Raras, Santiago de Compostela,
Spain, 5Fundación Pública Galega de Medicina Xenómica,
Santiago de Compostela, Spain
Introduction: Marfan syndrome is an autosomal dominant
disorder of connective tissue manifested in the ocular,
skeletal and cardiovascular systems. It is most frequently
caused by mutations in FBN1 with high clinical penetrance,
but showing a high inter and intra-familial variability, that
cannot be explained by the current knowledge of genotype-
phenotype correlation. In order to improve knowledge of
the whole genetic background of this disease, this study
aims to identify genetic modifiers of the phenotypic
expression of Marfan syndrome, looking for the intra-
familial variability with known causal mutation in FBN1.
Material and Methods: A total of 22 Marfan syndrome
patients with different severity from 8 families with known
FBN1 mutation, were exome sequenced. For exome wide
gene-set analyses F-SKAT (familial sequence kernell
association test) was performed. At the intra-family level,
non-common rare protein changing variants among first-
degree relatives with severe and mild phenotypes were
selected for discriminant analysis of principal components
(DAPC).
Results: F-SKAT test showed no gene with significant
differences after Bonferroni test between severe and mild
phenotype group of patients. Nevertheless, DAPC showed
two genes of retinal homeostasis, NXNL1 gene and RP1L1
gene, as one of the principal contributors to the discrimina-
tion analysis between mild and severe phenotype.
Conclusions: The genetic architecture of Marfan syn-
drome is very complex, however, as it was previously
described in the literature, this study point to the genes
related to retinal homeostasis as possible genetic modifiers
of the disease. Founding: Instituto de Salud Carlos III and
Fondo Europeo de Desarrollo Regional (PI14/01062, PI16/
00903)
E. Ramos-Luis: None. G. Teixidó: None. J. Limieres:
None. R. Cruz: None. C. Granato: None. B. Sobrino:
None. J. Amigo: None. A. Blanco-Verea: None. A.
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Reciprocal translocation as a possible cause of familial
connective tissue disorder
B. Herr, K. Komlosi, A. Tzschach, J. Fischer, B. Gläser
Department of Human Genetics, Freiburg, Germany
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Introduction: Monogenic disorders due to apparently
balanced reciprocal translocations are rarely reported. There
are few reports of interstitial deletions involving FBN1-gene
and only one case of a patient with Marfan syndrome and a
complex chromosome rearrangement. However, no disrup-
tion of FBN1 due to a translocation has been reported so far.
Clinical report: We report on a mother and daughter
with clinical symptoms of connective tissue disorder. The
39-year-old mother presented with congenital strabismus,
muscle weakness, muscle hypotrophy of forearms and
calves, reduced exercise tolerance and muscle and joint
pain. Skeletal manifestations included arachnodactyly, joint
laxity and foot deformity. Her father and a paternal uncle
had skeletal abnormalities and died unexpectedly in young
adulthood. Her 18-year-old daughter fulfilled the Ghent
criteria for Marfan syndrome.
Methods and Results: Connective tissue panel diagnos-
tics did not reveal pathogenic variants in the mother. R-
banded karyotyping of lymphocyte cultures revealed the
same reciprocal translocation in mother and daughter: 46,
XX,t(2;15)(q22;q21.1). Chromosome microarray analysis
revealed no imbalances. Subsequent FisH analysis with
region-specific BAC probes for 2q and 15q narrowed down
the translocation break point to a region of approximately
110 kb from g.43663778 proximal the 3`end of FBN1 to
g.48772449 in intron 32-33 of FBN1.
Conclusions: In order to prove a possible disruption of
FBN1 we plan to perform long range PCR, next generation
mapping and RNA sequencing. We emphasize the impor-
tance of a combination of cytogenetic and molecular
diagnostic techniques to reveal the cause of monogenic
diseases typically caused by point mutations.
B. Herr: None. K. Komlosi: None. A. Tzschach: None.
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Variant classification in Marfan syndrome: illustrating
an underestimated issue in DNA-diagnostics
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1Amsterdam UMC, Genome Diagnostics laboratory,
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Introduction: Correct classification is crucial for reliable
diagnostic DNA-testing of patients. The classification of
variants ranges from benign (class 1) to pathogenic (class
5). General recommendations for classification have been
developed, like the American College of Medical Genetics
(ACMG). Variant classification differs per method used.
We compared three different guidelines, by reanalyzing
patients’ data of the FBN1 gene.
Materials and Methods: Variants in the FBN1 gene,
found in our lab, were used to compare the outcome of three
different variant classifications: the ACMG guidelines, the
methods of our accredited laboratory (ISO15189-RvA-
M174) and recommendations from the Revised Ghent
nosology of Marfan syndrome (Loeys et al. 2010).
Results: We classified, by using our guidelines, 869
variants as pathogenic. 77 of these are classified as benign
according to Loeys et al. or VUS according to ACMG. A
large number of variants that we classified as benign would
be classified as likely benign or VUS according to the other
guidelines.
Conclusions: Comparison of various variant interpreta-
tions shows that pathogenic variants were classified as VUS
or even benign by using the other guidelines. This was
mainly caused by using an incorrect consensus sequence for
the amino acid motif of the 47 EGF domains in fibrillin-1
(Loeys et al.) or not using specific properties of the protein.
Different use of frequency data causes a large difference in
interpretation of benign variants. These data emphasize that
knowledge of the disease and the protein involved are
indispensable in correct interpretation of variants.
G. Pals: None. S.A. Stolk: None. A. Maugeri: None. D.
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Identifying the molecular cause in Marfan and Marfan
like phenotype in a cohort of patients from Romania - 5-
year single center experience
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A. Popoiu2, A. Dumitrescu3, A. Lacatusu4, C. Zimbru5
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and Pharmacy “Victor Babes”, Timisoara, Romania,
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canu”, Timisoara, Romania, 4“Victor Babes,” University of
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Background: Connective tissue disorder represent a group
of life-threatening disorders. The prevalence of these dis-
eases is relatively low, but Marfan, Ehlers-Danlos, and
Loeys-Dietz syndromes are ubiquitous, affect both genders
and involve several organs, particularly the cardiovascular
system, eyes, and skeleton. Mortality generally results from
cardiovascular complications, mainly aortic dissection.
Identifying the molecular cause can lead to a different
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therapeutic management and the possibility for prevention
of reoccurrence in the family.
Aim: We aimed to retrospectively evaluate the diagnostic
yield in these group o patients and present the variants
identified.
Methods: Using targeted Next Generation Sequencing
(NGS) with a panel for 174 genes (TruSightCardio
Illumina) related to cardiologic diseases we screened 52
patients (37 males/15 females) evaluated for a Marfan/
Marfan like phenotype using Ghent nosology, between
2015-2020 at the Center for Genomic Medicine University
of Medicine and Pharmacy Timisoara, Romania.
Results: Diagnosis was identified in 55.7% (29/52)
patients, most(25) pathogenic/likely pathogenic variants
were found in FBN1 gene, 3 splicesite, 5 frameshift and 17
missense variants, including two variants associated with
neonatal Marfan Syndrome (NM_000138.4:c.3143T>C and
c.3217G>A). Of these, 10 are previously unreported
variants. Nine out of 52 patients originated from 3 families.
Diagnosis in 3 other patients involved COL3A1, TGFBR1
and SLC2A10 genes.
Conclusions: This study broadens the spectrum of
pathogenic variants in FBN1 gene, providing an update of
the molecular basis of Marfan Syndrome in Romania.
M. Puiu: None. A. Chirita-Emandi: None. N.
Andreescu: None. G. Doros: None. A. Popoiu: None. A.
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MDPL defines a multisystem disorder identified in 22
patients worldwide and associated to mutations inPOLD1
gene, encoding the DNA polymerase δ, involved in DNA
replication and repair. We identified an in-frame deletion (p.
Ser605del), segregating for the first time as an autosomal
dominantmutation, in a MDPL patient from whom dermal
fibroblasts (HDFs) have been derived. Cells displayed
in vitro abnormalities of nuclear envelope morphology,
presence of micronuclei, a large number of autophago-
somesand a significant accumulation of prelamin A,
strongly linked to altered cellular proliferation and geno-
micinstability. DNA damage-induced treatment in MDPL-
HDFs revealed a poor capacity of DNA repair, an arrestin
G0/G1 phase transition, and a lower number of cells in the S
phase. Moreover, Western Blot analysesshowed a nuclear
reduction of POLD1 in MDPL-HDFs compared to WT in
basal condition but a statisticallysignificant and persistent
increase after cisplatin/1-Gy X-ray damage when compared
to WT. Analysis of telomere length exhibited an increased
rate of telomere shortening, accompanied by anaccumula-
tion of unrepaired telomeric DNA damage. Furthermore, the
evaluation of H2AX and TelomereInduced Foci after 1-Gy
X-ray treatment enabled us to figure out that POLD1 repairs
less efficiently DNAdamage and its activity is mainly
associated with the homologous recombination phase.
Finally, we also generated human induced pluripotent stem
cells from patient’s fibroblasts showing thepeculiar pre-
sence of micronuclei. Knowing the mechanistic basis for the
association of DNA damage and failed DNA repair with
aging wouldopen up new therapeutic possibilities for this
rare disease.
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Molecular analysis of Polish patients with Mendelian
Disorders of Cornification
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Kaźmierczak1, J. Sawicka1, M. Jackiewicz1, O. Kordowska1,
M. Gos1, A. M. Rygiel1, K. Niepokój1, K. Woźniak2, C.
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Introduction: Mendelian Disorders of Cornification
(MeDOC) comprise syndromic or non-syndromic hetero-
geneous disorders manifesting by skin hyperkeratosis and/
or scaling. Mutations in approximately 40 different genes
can cause MeDOCs, that can be inherited in autosomal
recessive/dominant or X-linked patterns. Identification of
molecular defect is essential for prognosis, proper medical
interventions and genetic counseling. Nonetheless, genetic
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diversity, low incidence of majority of MeDOCs and
overlapping phenotypes make diagnosis challenging. The
aim of the study was to characterize molecularly Polish
MeDOC patients.
Materials and methods: A group of 161 patients with
clinical symptoms of MeDOC was enrolled to the study.
Genetic analysis was performed using self-designed custo-
mized NGS panel. Sanger sequencing or MLPA were used
for mutations verification.
Results: We identified full genotype in 125 (78%)
patients. In 17 (11%) patients we didn’t detect any
mutation, while in 19 (12%) we found mutation in one
allele only, despite expected autosomal recessive inheri-
tance. Overall, we detected mutations in 27 distinct genes.
The 33 patients had mutations in more than one gene
involved in skin barrier functioning: 13 of them had
pathogenic mutations in two genes, while in remaining 20
cases variant of unknown significance was detected in at
least one of the genes.
Conclusions: Our diagnostic strategy proved to be an
efficient and sensitive diagnostic tool for MeDOC patients.
Our data provide further information regarding molecular
epidemiology of skin barrier defects and also focus on the
presence of secondary mutations, which have important
impact on genetic counseling and, presumably, may affect
therapy. Supported by NCN:2014/13/D/NZ5/03304
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Nonsyndromic cleft lip with/without cleft palate (nsCL/P) is
among the most common congenital malformations and has
a multifactorial etiology. Common risk loci explain parts of
the trait heritability, but a substantial fraction needs to be
elucidated. Parts of the missing heritability could be
explained by rare, penetrant mutations that might occur de
novo in genes potentially involved in craniofacial devel-
opment. A previous study by our group identified three
nsCL/P susceptibility genes with rare recurrent de novo
mutations (PAXIP1, MDN1, ANK1). The present study aims
at assessing a contribution of the rare mutations found in
these nsCL/P susceptibility genes to cleft development by
using CRISPR/Cas9 generated mouse models. We created
five knock-in mouse strains that carried human missense
mutations in Paxip1 (1 mutation), Ank1 (1 mutation), and
Mdn1 (3 different mutations). Embryos at embryonic day
E18.5 were dissected and assessed for craniofacial anoma-
lies using skeletal preparations and microscopic assessment.
No craniofacial anomalies were observed for E18.5
embryos in the F0 generation in any of the five knock-in
strains. In the F1 generation, 2/31 E18.5 pups carrying the
knocked-in Paxip1 missense mutation in a heterozygous
state presented with abnormal body posture, a broader snout
and a subtle increase in distance between the palatal pro-
cesses, suggesting a role of the missense variant in Paxip1
in craniofacial development. Further follow-up studies in
mice homozygous for the variants and more precise phe-
notyping methods are ongoing.
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High-throughput screen for rare variants in candidate
genes for orofacial clefting
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Nonsyndromic cleft lip with/without cleft palate (nsCL/P) is
a common birth defect with multifactorial etiology.
Genome-wide association studies (GWAS) have revealed
>40 risk loci that contribute to nsCL/P risk, and it has been
suggested that ~30% of phenotypic variance is explained by
common genetic variation. In the absence of surgery, nsCL/
P is a detrimental phenotype, which implies a considerable
effect on reproductive fitness. Thus, rare variants are likely
to also contribute to nsCL/P etiology. First studies have
suggested nsCL/P candidate genes that harbor causative rare
variants, or a burden thereof. These studies included the
analysis of established “syndromic” genes (n = 6 genes),
genes with established role in craniofacial development (n
= 5), and the identification of mutations in genes of the
epithelial cadherin-p120-catenin complex segregating
within multiply affected families (n = 5). However, inde-
pendent replication is lacking. Here, we aimed at providing
further genetic evidence for an involvement of these genes
in nsCL/P etiology, through the identification of additional
evidence for rare variants from a large Central-European
cohort. Using single molecule molecular inversion probes
(smMIPs), we obtained high-confident sequencing results
for 14 of the 16 genes in 711 nsCL/P cases, 761 population-
based controls, and 234 case-parent trios. At individual
level, we identified four novel loss-of-function (LoF) var-
iants (3 cases / 1 control). The variants observed in cases
were LoF-mutations in CDH1, CTNND1 and MTRR. Fur-
ther statistical analyses, including analyses of missense
variants, burden and pedigree analyses, are currently
ongoing and will help to further understand the etiology of
nsCL/P.
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Phenotypic spectrum of NPR2 mutations: study of 12
patients with acromesomelic dysplasia, Maroteaux type
and 8 patients with short stature.
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Introduction: Acromesomelic dysplasia, Maroteaux type
(AMDM, MIM 602875) associates disproportionate short
stature, short limbs and extremities with cone-shaped epi-
physes. AMDM is caused by biallelic mutations of NPR2
(natriuretic peptide receptor B). Heterozygous NPR2
mutations are involved in idiopathic or dyschondrosteosis-
like short stature.
Materials and methods: Our study reviewed the clinical
and molecular findings of AMDM and short stature patients
with NPR2 mutations. 12 AMDM DNAs and more than
200 short stature DNAs were tested, after SHOX MLPA
testing, in the molecular biology laboratory of Necker
Hospital.
Results: NPR2 mutations were identified in all AMDM
cases and in 8 short stature patients. 23 different mutations
were identified: nonsense, frameshift, splice and missense
ones in AMDM and mostly missense variants in short
stature. Heterozygous parents of AMDM patients were
relatively small. All AMDM patients were of short birth and
final heights (125-130 cm). Apart small extremities, 6 had
large hallux and 7 had curved radius with limited pronation.
Out of 12 cases, 8 had hyperlaxity, 7 scoliosis and 8 dental
misalignment and arched palate. All heterozygous patients
were of normal birth size and grew between -2,5 to -1,5 SD.
They had normal envergure/height ratio, even if X-rays
showed thick radius. 2/8 had IV and V brachymetacarpia.
Conclusions: our study supports AMDM genetic homo-
geneity. We underline the importance of specific assess-
ments, including laxity, scoliosis and orthodontics. We
confirm that NPR2 heterozygous mutations should be
considered in short stature with minor skeletal changes.
NPR2 function in C-natriuretic peptide signaling might lead
to therapeutics options.
C. Michot: None. S. Prévost: None. C. Haudry: None.
A. Tourré: None. A. Dieux-Coeslier: None. M. Mathieu-
Dramard: None. M. Rossi: None. A. Toutain: None.
246 J. del Picchia
G. Baujat: None. S. Rondeau: None. V. Cormier-
Daire: None.
P04.55.A
Non-syndromic cleft lip with/without cleft palate:
Genome-wide association study in patients from The
Netherlands and Belgium identifies a suggestive risk
locus at 16p12.1 and supports SH3PXD2A as a clefting
susceptibility gene.
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Nonsyndromic cleft lip with or without cleft palate (nsCL/P)
ranks among the most common human congenital mal-
formations. The etiology of nsCL/P is multifactorial, whereby
genetic risk factors, environmental exposures, and potential
gene-environment interactions all contribute to susceptibility.
The present project is a genome-wide association study
(GWAS) in a medium-sized nsCL/P cohort encompassing a
total of 285 nsCL/P patients and 1,212 controls from The
Netherlands and Belgium. Twenty of 40 previously reported
nsCL/P susceptibility loci were replicated, and at the well-
established nsCL/P susceptibility locus at chromosome
8q24.21, the analyses identified 62 genome-wide significant
SNVs. These findings underline the validity of this sample.
SNV-based analysis of the data identified a yet unreported
suggestive locus at chromosome 16p12.1 (p-value of the lead
SNV: 4.17×10-07). This association was replicated in two of
three patient/control replication series (Central European and
Yemeni). The lead SNV rs56383345 maps to a 930 kb non-
coding region at 16p12.1, and is not located in any currently
known regulatory element. Gene-based analysis of the
GWAS data prioritized SH3PXD2A at chromosome 10q24.33
as a candidate gene for nsCL/P. To date, support for this gene
as a cleft gene has been restricted to data from zebrafish and a
knockout mouse model. The present GWAS is the first to
implicate SH3PXD2A in non-syndromic cleft formation in
humans. In summary, although performed in a relatively
small sample, the present GWAS generated novel insights
into nsCL/P etiology, and demonstrates how medium-sized,
clinically well characterized GWAS samples can improve
knowledge of the genetic basis of nsCL/P.
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GWAS candidate genes for cleft lip with or without cleft
palate: Analysis of expression data during embryonic
craniofacial development.
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Molecular defects during craniofacial embryonic develop-
ment may result in nonsyndromic cleft lip with/without cleft
palate (nsCL/P), one of the most common birth defects.
Despite the possibility of surgical correction, follow-up
treatment is long-term and requires an interdisciplinary
approach. Also, epidemiological data indicate that indivi-
duals with nsCL/P show an increased risk for morbidities
and suffer from a considerable psycho-social burden.
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The molecular pathways underlying these observations are
currently unknown. We here used nsCL/P-GWAS data and
array-based expression data from embryonic mice (gesta-
tional days E10.5-E12.5, Hooper et. al 2017), to identify
pathways in which nsCL/P candidate genes are enriched.
The 45 nsCL/P risk loci comprise ~400 genes within their
topologically associated domains. Using gene-based ana-
lysis, we identified 86 genes with enrichment of common
variants, suggesting their involvement in nsCL/P etiology.
For each of these genes, we analyzed the expression pattern
in ectodermal or mesodermal tissues of mandibular, max-
illary and fronto-nasal prominences, and performed hier-
archical clustering. One of the three clusters we identified
comprised 33 genes, including established nsCL/P-genes
like IRF6 and TFAP2a. A pathway analysis of genes within
this cluster revealed a significant overrepresentation of
cancer-related pathways and processes related to molecular
signaling. Interestingly, affecteds with nsCL/P have been
reported to be at increased risk of cancer. We will next
extend our approach at single-cell level, using systematic
data as recently provided (Cao et. al 2019) and the analy-
tical ecosystem FASTGenomics (Scholz et. al 2018). This
will generate novel insights into gene regulatory networks
across development, and their contribution to nsCL/P.
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Osteogenesis imperfecta (OI) comprises a genetically het-
erogeneous group of skeletal fragility diseases. It is often
clinically impossible to predict the underlying causative gene,
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thus necessitating broad multi-gene panel testing or exome
sequencing. We report on five independent families with a
progressively-deforming type of OI with the distinguishing
feature of oligodontia. We identified four homozygous trun-
cation or frameshift mutations in a novel gene for OI, namely
MESD. MESD encodes an endoplasmic reticulum (ER)
chaperone protein for the canonical Wingless-related inte-
gration site (WNT) signaling receptors LRP5 and LRP6.
Because complete absence of MESD causes embryonic
lethality in mice, we hypothesized that the OI-associated
mutations are hypomorphic alleles since these mutations
occur downstream of the chaperone activity domain but
upstream of ER-retention domain. This would be consistent
with the clinical phenotypes of skeletal fragility and oligo-
dontia in persons deficient for LRP5 and LRP6, respectively.
Further functional analysis showed that OI-associated MESD
mutations produce hypomorphic alleles whose failure to
remain within the ER significantly reduces but does not
completely eliminate LRP5 and LRP6 trafficking. Since these
individuals have no eye abnormalities (which occur in indi-
viduals completely lacking LRP5) and have neither limb nor
brain patterning defects (both of which occur in mice com-
pletely lacking LRP6), we infer that bone mass accrual and
dental patterning are more sensitive to reduced canonical
WNT signaling than are other developmental processes.
Multigene panels do not yet include MESD. Therefore, if an
undiagnosed patient with severe OI and oligodontia presents,
it may be prudent to think first of MESD.
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Adult osteopetrosis with osteonecrosis of the jaws and
abnormal osteoclast resorption due to a LRRK1 splice
site mutation
A. Howaldt1, A. Hennig1, T. Rolvien2, U. Roessler1, A.
Knaus3, S. Boettger4, S. Geißler1, R. Oheim2, M. Amling2,
H. Howaldt4, U. Kornak5
1Charité-Universitaetsmedizin Berlin, Berlin, Germany,
2University Medical Center Hamburg-Eppendorf, Ham-
burg, Germany, 3School of Medicine & University Hospital
Bonn, Bonn, Germany, 4Justus Liebig Universität Gießen,
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We report on a 34 year-old patient with sandwich vertebrae,
platyspondyly, osteosclerosis of long bones, pathologic
fractures, and anemia. In the third decade, he developed
osteonecrosis of the jaws, which was progressive in spite of
repeated surgical treatment. An iliac crest bone biopsy
revealed an elevated trabecular density (BV/TV [%] 32.2
vs. 21.5 + 14.8) and the presence of hypermineralized
cartilage remnants leading to an overall increase in miner-
alization (CaMean [wt%] 25.65 vs. 21.8). We also found
large multinucleated osteoclasts with abnormal morphology
and inadequate bone resorption. Although these findings
were reminiscent of autosomal dominant osteopetrosis type
2, no mutations in CLCN7 were detected. Subsequent whole
exome sequencing identified the novel homozygous splice-
site mutation c.261G>A in the gene LRRK1. cDNA
sequencing showed nearly complete skipping of exon 3
leading to a frameshift (p.Ala34Profs*33), very likely
leading to a loss of function. LRRK1 encodes a protein
kinase and its dysfunction can cause osteosclerotic meta-
physeal dysplasia (OSMD; OMIM # 615198). Osteoclasts
differentiated in vitro from the patient’s peripheral blood
monocytes formed quickly and became unusually large. In
resorption assays these cells formed large areas with
superficial pseudo-resorption but excavated only few
resorption pits (resorption pit surface surface [%] 1.3 + 0.6
vs. 15 + 3.6; p < 0.01). Phosphorylation of L-plastin was
strongly reduced in patient-derived osteoclasts, thus corro-
borating a LRRK1 loss of function (0.26 + 0.1 vs. 1 +
0.08; p < 0.01). Our analysis indicates a strong overlap of
LRRK1-related OSMD with other late-onset forms of
osteopetrosis, but an exceptionally leaky osteoclast
resorption.
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P04.62.B
The lrp5 knockout zebrafish as a model to study
osteoporosis
P. J. Coucke, J. Bek, H. De Saffel, A. De Clercq, A. Boel, A.
Willaert
Center for Medical Genetics, Gent, Belgium
Osteoporosis-pseudoglioma syndrome (OPPG) is an auto-
somal recessive disorder characterized by reduced bone
mass and strength, caused by loss-of-function mutations in
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LRP5 (low-density lipoprotein receptor-related protein 5), a
co-receptor in the WNT signaling pathway. Here we
describe the first reliable genetically induced form of
osteoporosis in the zebrafish in a lrp5 knockout (KO).
Molecular analysis confirmed reduced lrp5 transcripts and
absence of Lpr5 protein. Reduced survival was observed in
lrp5 KO larvae after the onset of mineralization. The frac-
tion of larvae that did survive, displayed delayed ossifica-
tion as was shown via mineral staining. Subsequently, these
fish were grown to adulthood and analyzed via μCT. This
revealed decreased bone volume and decreased bone
mineralization in the vertebral column, which are hallmark
features of osteoporosis. Next, we performed CRISPR/Cas9
mediated mutagenesis targeted at lrp5 followed by F0
phenotype analysis (crispant screening). Miseq sequencing
of the mosaic larvae revealed out-of-frame mutations in on
average 90% of the reads. Consequently, we showed a
similar skeletal phenotype in the F0 ‘crispants’ to that of the
stable lrp5-/- larvae, showing that crispant screening in
zebrafish is a promising approach to functionally screen a
large set of osteoporosis candidate genes. In summary, we
present lrp5−/− zebrafish as the first genetic osteoporosis
zebrafish model that can be used as a screening platform for
potential therapeutics. Additionally, we show that F0 cris-
pant screening can be used for functional validation of
candidate genes for osteoporosis as high rates of out-of-
frame mutations in the lrp5 gene are sufficient to induce
phenotypes.
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The p.R321C mutation in p62 protein, associated to
Paget’s Disease of Bone, leads to a relocation of the
protein in human osteoclasts
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Cerrajero2,1, A. I. Turrión Nieves1,3, J. Del Pino-Montes1,3,
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Background: The most important known genetic factor
predisposing to Paget´s disease of bone (PDB) is mutation
in SQSTM1 gene, which encodes p62 protein. We detected
the c.961C>T SQSTM1 gene mutation in three PDB
patients, that causes the p.R321C mutation. It has been
reported that p.R321C mutation causes a blockade of
autophagy and an activation of NF-kB pathway. The aim of
this study was to characterize the effect of the p.R321C
mutation in human osteoclasts.
Methods: Peripheral blood mononuclear cells (PBMCs)
were isolated from blood samples for generating human
osteoclasts. Cells were differentiated by adding M-CSF and
RANKL for 3 weeks. Human osteoclasts were transiently
transfected with total plasmid DNA (pCEFL-Flag-
SQSTM1-321C and pCEFL-Flag-SQSTM1-321R con-
structs). Finally, we performed a co-immunofluorescence
assay to detect Flag and p62.
Results and discussion: Our results showed that, while
321R-p62 protein remained scattered though the cytoplasm,
321C-p62 was concentrated in the periphery of osteoclasts.
This relocation of p62 protein caused by p.R321C mutation
could be a consequence of autophagy blockade, which has
been reported that could have a crucial role in the etiology
of PDB. The p.R321C mutation causes a blockade of
autophagy and an activation of NF-kB pathway, therefore
the alteration of the cell metabolism could be the cause of
the relocation of p62 protein in human osteoclasts.
Conclusion: The p.R321C mutation in p62 protein leads
to a relocation of the protein in human osteoclasts. This
reinforces the hypothesis that an alteration of autophagy
could be involved in PDB etiology.
This work was supported by FIS-FEDER:PI16/01920.
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Penttinen syndrome and infantile myofibromatosis in a
patient carrying the tyrosine kinase-activating variant
Asn666Ser in PDGFRB
D. Horn1, A. T. Abad-Perez1, V. Stephan2
1Institute of Medical Genetics and Human Genetics,
Charité-Universitätsmedizin, Berlin, Germany, 2Sana Chil-
dren´s Hospital Lichtenberg, Berlin, Germany
Introduction: Penttinen syndrome belongs to the group of
progeroid disorders and is characterized by progressive
subcutaneous lipoatrophy, sclerotic skin lesions and acro-
osteolysis. This very rare condition is caused by a few
distinct missense mutations of PDGFRB, other distinct
mutations of this gene have been shown to be associated
with different conditions such as infantile myofibromatosis.
Material and Methods: Here, we describe a 5-year-old
male patient with infantile myofibromatosis diagnosed in
his first month of life who in addition developed a
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prematurely aged appearance with lipoatrophy, scar-like
skin nodules on the hands and joint contractures.
Results: Sanger sequencing revealed the heterozygous de
novo mutation c.1997A>G; p.Asn666Ser in the PDGFRB
gene. Recently, this mutation has been described in two
patients affected with a severe form of Penttinen syndrome
presenting a more pronounced connective tissue
destruction.
Conclusions: This is the first report of an individual
affected with both conditions, infantile myofibromatosis
and Penttinen syndrome. This mutation lead to increased
phosphorylation of downstream signalling proteins such as
PTPN11. Imatinib is a strong inhibitor of phosphorylation
of these targets representing a treatment option.
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Blood secreted miRNA hsa-miR-374b-5p inhibits
osteoblast-differentiating gene UHMK1 and is upregu-
lated in periodontitis patients
R. Wiehe1, D. Bajric2, A. El Sharawy3, A. Keller4, H.
Dommisch1, A. Schaefer1
1Charité-Universitymedicine Berlin, Institute for Dental
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Germany, 3Institute for Clinical Molecular Biology,
Christian-Albrechts-University Kiel, Kiel, Germany, 4Clin-
ical Bioinformatics, Saarland University, Saarbrücken,
Saarbrücken, Germany
microRNAs interact with the 3’UTRs of target mRNAs to
suppress gene expression. MicroRNAs act tissue specifi-
cally but some are secreted into blood. Recent studies
reported upregulation of specific miRNAs in the inflamed
oral mucosa of periodontitis patients. The regulatory targets
of these miRNAs may reveal genes that are conducive to
oral health. If secreted into blood, these miRNAs could
serve as biomarkers to diagnose periodontitis before clinical
manifestation. To identify such miRNAs, we quantified 863
miRNAs in the blood of 18 periodontitis patients and 70
periodontitis-free controls (Geniom Biochip array). miRNA
hsa-miR-421 and hsa-miR-374b-5p were most significantly
upregulated in blood of periodontitis cases (Padjusted < 5x10
−6). Two previous studies that profiled microRNAs in the
inflamed and healthy oral mucosa independently reported
>2fold upregulation of hsa-miR-374b-5p, but not hsa-miR-
421. Using mirVana miRNA mimics (ThermoFisher Sci-
entific), we overexpressed hsa-miR-374b-5p in primary
gingival fibroblasts (3 biological and 3 technical replicates)
and quantified the mRNA levels in 24h transfected and
mock-transfected cells (Clariom D Array, ThermoFisher
Scientific). The gene U2AF homology motif kinase 1
(UHMK1) was significantly downregulated in the miRNA
mimic transfected cells (Fold Change= -1.8, P=0.00025).
Two binding sites of hsa-miR-374b-5p were predicted at the
3’UTR of UHMK1. To validate the functional mechanism,
we cloned the respective 3’UTR of UHMK1 into a reporter
plasmid (pGL4.24, Promega). After co-transfection of the
plasmid and hsa-miR-374b-5p mimic into HeLa cells for
24 hours, the reporter gene expression was significantly
reduced (Fold Change= -1.5, p=0.02, 3 independent
replicates). UHMK1 has a role in the coordination of
osteoblast differentiation.
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POP1-Skeletal Dysplasias : Description of two new
families.
J. HARVENGT, S. ALKAN, B. FLORKIN, S. BULK, V.
BOURS
CHU Liège, Liège, Belgium
Background: POP1 mutations should be considered in
anauxetic dysplasia (AD) patients without RMRP mutations
but also in skeletal dysplasia (SD) of different severities. To
date, only 5 patients were reported.
Methods: Cartilage Hair Hypoplasia (CHH) was sus-
pected in two siblings based on clinical and radiological
evaluation. In family 1, a 4 years boy was investigated. His
older sister is also affected by SD but currently refuses to
pursue genetic testing. In family 2, two sisters presented a
severe short stature : the older has 120 cm as final adult
height. The second aged of 13 also suffered from an
immune deficiency.
Results: A skeletal dysplasia gene panel revealed in the
POP1 gene:Family N°1 : a composite heterozygous variant
c.1846A>C, class3 (paternally inherited) and c.1747G>T,
class 4 (maternally inherited). Family N°2 : a homozygous
variant c.632G>A, class 4.
Discussion: POP1 patients are characterized by severe
short stature of prenatal-onset and very short adult height
(classically less than 1 meter, but our adult patients were
120 cm and near 160 cm), hypodontia, midface hypoplasia,
mild intellectual disability and radiological specific findings
including systematic bullet-shaped middle phalanges.
Notably, none of the 5 published cases were reported with
immune deficiency.
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Conclusions: We describe two new families with POP1
mutations encountered in patients clinically suspected for
CHH and achondroplasia, enhancing that the phenotypical
spectrum is larger than AD type 2. Larger cohorts of
patients are needed to improve the clinical characterization,
especially the risk of having associated symptoms such as
immune deficiency.
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Coding variants of the CARD14 NF-kB adaptor are
associated with palmar plantar pustulosis
A. Niaouris1, S. Haddad1, A. PushpaRajah2, N. Benzian-
Olsson1, P. Baum3, S. Visvanathan4, T. he APRICOT and
PLUM study team2, J. Barker2, C. Smith2, F. Capon1
1King’s College London, London, United Kingdom, 2St
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ringer Ingelheim Pharma GmbH & Co. KG, Biberach,
Germany, 4Boehringer Ingelheim Pharma GmbH & Co.
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Caspase recruitment domain containing protein 14
(CARD14) is a soluble NF-kB adaptor protein, which is
mostly expressed in keratinocytes. In the presence of
inflammatory stimuli, free CARD14 molecules oligomerise,
recruit a BCL10/MALT1 signalosome and activate NF-kB
signalling. Gain-of-function CARD14 variants have pre-
viously been associated with inflammatory skin diseases
such as psoriasis vulgaris and generalised pustular psoriasis.
However, the involvement of CARD14 in palmar plantar
pustulosis (PPP), a localised form of pustular psoriasis,
remains unclear. Here, we analysed CARD14 changes in
160 PPP cases (125 females, 35 males; mean age of onset:
41 years) ascertained across the UK. We identified 11 rare
variants predicted to have a deleterious effect on protein
function. A burden test (comparing PPP cases vs controls
sequenced by the ExAC consortium) demonstrated a sig-
nificant association between these changes and PPP (OR:
2.5; 95% CI: 1.39-4.65; p = 0.0023). We also detected a
low-frequency allele with deleterious potential (E422K) that
occurred more frequently in affected individuals compared
to controls (OR: 1.7; 95% CI: 1.07-2.69; p= 0.025). To
assess the effect of disease-associated variants, CARD14
FLAG-tagged plasmids were mutagenized and transfected
into HEK293 cells. The depletion of free CARD14 from the
cytoplasm (which is an indirect measurement of protein
oligomerization) was then analysed by western blotting.
This confirmed that most variants promote the formation of
insoluble CARD14 oligomers. These findings implicate
CARD14 in the pathogenesis of PPP. They also suggest that
the proteins encoded by disease alleles are prone to con-
stitutive oligomerization, which will cause abnormal NF-kB
activation.
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Further delineation of Roifman syndrome: report of
four new Spanish patients
I. Valenzuela1, I. Cusco1, I. Paramonov1, F. López-
Grondona1, S. Garcia-Miñaur2, M. Palomares-Bralo2, A.
Martin1, J. Riviere1, M. Garcia-Prat1, P. Soler1, R.
Colobran1, E. Garcia-Arumí1, E. Tizzano1
1Hospital Vall d’Hebron, Barcelona, Spain, 2Hospital La
Paz, Madrid, Spain
Roifman Syndrome (RS, OMIM 300258) is a rare disorder
characterized by pre- and postnatal growth retardation,
cognitive delay, spondyloepiphyseal dysplasia, antibody
deficiency and facial dysmorphism. Biallelic mutations in
RNU4ATAC have been reported as the molecular cause. Our
series expand the phenotypic spectrum of Roifman patients.
We report four patients from three unrelated families with
RS. Due to the complexity of variant annotation in
RNU4ATAC, molecular studies are not usually straightfor-
ward. Indeed, in families 1 and 2 exome sequencing was
inconclusive. In patient 1 the diagnosis was finally uncov-
ered by genome sequencing, in sisters 2 and 3 by Sanger
sequencing upon clinical suspicion and in patient 4 by a
customized gene panel. Main clinical characteristics include
skeletal dysplasia (4/4), short stature (4/4), intellectual dis-
ability (4/4), antibody deficiency (3/4) and retinal dystrophy
(2/4). Main dysmorphic features included markedly long
philtrum and thin upper lip. Hepatomegaly was identified in
2/4 and patient 1 presented hepatic cavernoma (unreported
so far in Roifamn patients). Molecular results showed var-
iants n.8C>T and n.50 G>A (patient 1); variant n.13C>T
and n.17 G>C (sisters 2 and 3) and two novel variants,
n.37G>A and n.53C>T (patient 4). Segregation analysis
indicated that each variant was inherited from a healthy
parent in the three families. The inclusion of new patients
with Roifman increases the knowledge of mutational
spectrum and it’s essential to delineate the phenotype of this
syndrome. The recognition of the syndrome is indispensable
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for the orientation of molecular diagnosis, prompt follow up
and counseling.
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Identification of the deregulated NEK1 protein network
in skeletal ciliopathies
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A. B. Ekici1, A. Reis1, C. T. Thiel1
1Institute of Human Genetics, FAU Erlangen-Nürnberg,
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The primary cilium is an organelle, which is present on
almost all vertebrate cells. Cilia consist of the axoneme and
the basal body and present various ciliary membrane
receptors, which receive extracellular signals. Those signals
are transmitted into the cell, where they modulate different
intracellular signaling pathways. Mutations in ciliary pro-
teins are involved in formation, maintenance and function
of the primary cilium and associated with developmental
defects, like brain malformations, polydactyly, kidney cysts
and skeletal abnormalities. This phenotypic spectrum is
present among patients with short-rib polydactyly syn-
dromes (SRPS). This group constitutes the most frequent
lethal autosomal recessive osteochondrodysplasias.
Diallelic mutations in NEK1, encoding for a basal body
protein, are the underlying cause of SRPS II. To gain further
insight into the pathogenic mechanism, we used two
approaches: RNA sequencing of CRISPR/Cas9 mediated
genomic edited HEK293T cells and scRNASeq in limb
buds of E13 embryos of the Nek1 knock down mouse, and
respectively compared the knock out and the wildtype in
order to find differentially expressed genes. Analysis of
significantly enriched pathways revealed an activation of
genes in early growth response and cell cycle control and
silencing of different collagens and ribosomal and histone
proteins. One of the main findings was a severely reduced
expression of Acan, coding for Aggrecan the most abundant
cartilaginous protein, explaining the severe growth
phenotype.
These results underline that the NEK1 associated defect
of the primary cilium causes the deficiency in cell cycle and
gene expression, mainly aggrecan, in the growth plate.
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Russell syndrome
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Introduction: Silver-Russell syndrome is a rare imprinting
disorder characterized by prenatal (SGA) and postnatal
growth retardation (PNGR), relative macrocephaly at birth,
a prominent forehead, body asymmetry and feeding diffi-
culties and/or low BMI. The most common underlying
mechanisms are hypomethylation at H19/IGF2:IG-DMR
and UPD(7)mat. Rarely, rearrangements involving 11p15,
or inactivating point variants have been identified (maternal
CDKN1C or paternal IGF2 variants). Recently PLAG1 and
HMGA2 genes, which participate in the IGF2 pathway,
have been associated with this syndrome.
Patients and Methods: We present a 9 years-old girl
who was initially referred to pediatric endocrinology
because of short stature. A clinical geneticist suggested
the clinical diagnosis of SRS (NHC score=4: SGA, PNGR,
prominent forehead and problems for feeding manifested as
poor food intake). She also showed dental crowding with
delayed teeth eruption, triangular face, small and bulbous
nose, prominent maxillary, high ojival palate, fine voice,
fine hair and learning difficulties. Her mother and maternal
grandmother presented the same phenotype. After discard-
ing alterations in 11p15 and chromosome 7 (MS-MLPA), a
custom NGS panel for genes associated with growth
was run.
Results: The study of the NGS panel revealed an
heterozygous novel variant within exon 5 of PLAG1
[NM_001114634.2:c.551delA; p.(Lys184Serfs*45)], bioin-
formatically predicted as likely pathogenic (ACMG: PVS1;
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PM2; PP1). Familial studies by Sanger sequencing
confirmed cosegregation.
Conclusions: We report the second familial case of SRS
caused by a novel PLAG1 frameshift alteration, and we
expand the clinical spectrum to the previously described.
Funding: Instituto de Salud Carlos III (PI16/00073); Basque
Department of Health (GV2017/111040).
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Increased yield of genetic diagnoses in skeletal ciliopa-
thies using massively parallel sequencing, structural
variant and RNA analyses
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F. Taylan5, D. Batkovskyte5, B. Anderlid1, A. E. Lin6, K.
Shimizu7, A. Beleza-Meireles8,9, B. Chung10,11, U. Voss12, A.
Nordgren1, G. Nishimura13, A. Lindstrand1, G.
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Introduction: Cilia are important for cell migration and
signaling using multiple pathways and proteins essential for
development of many body organs and systems, including
the skeleton. Skeletal ciliopathies are a heterogenous group
of disorders with overlapping features, caused by patho-
genic variants in at least 30 genes, coding for different
structural cilia proteins.
Materials and Methods:We examined 28 probands with
radiographic findings of skeletal ciliopathies. For single
nucleotide variant (SNV) analysis, we used whole exome
and genome sequencing with in silico filtering for variants
in known skeletal ciliopathy genes.
Results: We identified biallelic variants in 23 patients in
DYNC2H1, KIAA0753, WDR19, C2CD3, TTC21B, EVC
and EVC2. Subsequent examination of four potential splice
variants showed that cDNA analyses are important in
facilitating molecular diagnoses in a significant proportion
(20%) of the patients and that aberrant splicing in
DYNC2H1, EVC and KIAA0753 can be confirmed with
RNA extracted from blood. Copy number variant (CNV)
analyses was performed for the same cohort and we found
one individual with an intragenic deletion of DYNC2H1 and
another with 1q24q25-microdeletion syndrome.
Conclusions: In conclusion, combined SNV, CNV and
RNA analyses result in a high yield of genetic diagnoses
(86%) in a cohort of patients with a clinical, autopsy and
radiological findings consistent with skeletal ciliopathy.
Grants: AnH - Sällskapet Barnavård and Karolinska
Institutet. GG - Stiftelsen Samariten, Promobilia and
Stiftelsen Frimurare. GG, AL and AN - Stockholm County
Council. AN and AL - The Swedish Research Council. AN
- The Swedish Childhood Cancer Foundation.
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Lack of bone mineralization in a TANGO1 deficient
patient
B. Guillemyn1, S. Nampoothiri2, O. Foresti3, I. Raote3, V.
Malhotra3, F. Malfait1, S. Symoens1
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Introduction: TANGO1 (Transport and Golgi organization-
1) encodes a transmembrane protein, located at
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Endoplasmic Reticulum (ER) exit sites. TANGO1 binds
collagen in the lumen, COPII-coats in the cytoplasm and
recruits membranes from the ERGIC (ER-Golgi inter-
mediate compartment) to create an export route for bulky
cargos like collagen. Recently aberrant expression of trun-
cated TANGO1 was linked to a severe collagenopathy
associated with primary obesity, diabetes mellitus and
intellectual disability. We show that complete loss of
TANGO1 results in human embryonic lethality with near-
total bone loss.
Material and Methods: Fetal DNA and parental blood/
fibroblast samples were obtained. Whole exome sequencing
(WES) was performed. RTqPCR, Western blot, immuno-
cytochemical staining and collagen secretion assays were
conducted.
Results: Ultrasound examination of a 13-weeks-old fetus
of healthy Indian consanguineous parents revealed tetra-
micromelia, increased nuchal translucency, absent nasal
bone, pingpong appearance of the skull, shortened limb
segments, and extreme skeletal hypomineralization. The
pregnancy was terminated and the infantogram showed an
almost boneless fetus. Fetal WES detected a homozygous 4-
basepair deletion in TANGO1, heterozygously present in
both parents. Parental fibroblast studies demonstrated
decreased TANGO1 expression and protein, and severe
defects in collagen secretion.
Conclusions: Our findings underscore the importance of
TANGO1 in cellular protein secretion. While absence of
TANGO1 results in human embryonic lethality, aberrant
expression of truncated TANGO1 results in a severe
collagenopathy. This further supports the physiological role
of TANGO1 in collagen export, which is necessary for bone
mineralization, skin and tissue biogenesis. Moreover, the
data clearly reveal the severity of human pathologies in
association with levels of functional TANGO1 expression.
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TAR syndrome: clinical and molecular characterization
of a cohort of 26 patients and description of novel non-
coding variants ofRBM8A
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Thrombocytopenia-Absent Radius (TAR) syndrome is
characterized by radial defect and neonatal thrombocyto-
penia. It is caused by bi-allelic variants of RBM8A gene
(1q21.1) with the association of a null allele and a hypo-
morphic non-coding variant. RBM8A encodes Y14, a core
protein of the Exon Junction Complex involved in mRNA
maturation. To date, only two hypomorphic variants have
been identified. We report on a cohort of 26 patients
affected with TAR syndrome. Half patients carried a 1q21.1
deletion and one of the two known hypomorphic variants.
Four novel non-coding variants of RBM8A were identified
in the remaining patients. We developed experimental
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models enabling their functional characterization in vitro.
Two variants, located respectively in the 5’-UTR and 3’-
UTR regions, are responsible for a diminished expression
whereas two intronic variants alter splicing. Our results
bring new insights into the molecular knowledge of TAR
syndrome and enabled us to propose genetic counseling for
patients’ families.
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P05 Cardiovascular Disorders
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Improving family screening of abdominal aorta aneur-
ysm patients
R. L. Lechner, A. S. IJpma, D. Heijsman, J. W. Roos-
Hesselink, H. J. M. Verhagen, S. ten Raa, R. M. W. Hofstra,
D. F. Majoor-Krakauer
Erasmus MC, Rotterdam, Netherlands
Relatives of abdominal aneurysm patients (AAA) have an
increased risk of developing aneurysms. To improve early
detection and reduce risk of rupture in relatives, guidelines
recommend screening of first degree relatives. Current
guidelines do not specify the method or extend of aorta
screening in relatives. In practice, mostly male relatives are
referred for abdominal echographic screening of the
abdominal aorta, possibly missing thoracic aneurysms
(TAA) in relatives. To determine in which part of the aorta
affected relatives of AAA patients have an aneurysm or
dilatation, we reviewed the results of family history taking
and family screening of families of 471 AAA patients with
familial aneurysms of which medical records and/or CT
images relatives were available. In total 475 affected rela-
tives (311 male, 164 female) in 237 families had an aorta
dilatation or aneurysm: 258 (54,3%) had abdominal and 147
(31%) thoracic aneurysm. Male relatives were more likely
to have AAA (40% vs 28%, p < 0.05), females to have TAA
(32% vs 17%, p < 0.05). Co-occurrence of AAA and TAA
was observed in 7% of relatives. In 17% an iliac and in 2%
a popliteal dilation occurred. In conclusion: relatives of
AAA patients have an increased risk for dilatation of the
abdominal and the thoracic aorta. To prevent
underdiagnosis of aortic aneurysm in relatives and improve
early detection of aortic aneurysms, a CT-scan of the total
aorta and the iliac arteries should be considered as the
method of choice for family screening.
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Yield of whole exome sequencing of aneurysm genes in
858 patients with an abdominal aorta aneurysm
R. L. Lechner, A. S. IJpma, D. Heijsman, J. W. Roos-
Hesselink, H. J. M. Verhagen, S. ten Raa, R. M. W. Hofstra,
D. F. Majoor-Krakauer
Erasmus MC, Rotterdam, Netherlands
A growing number of genes are associated with risk for
aortic aneurysms. Similar mechanisms of remodeling of the
extracellular matrix influencing the integrity of the aortic
wall may play a role in abdominal and thoracic aneurysms.
This helps to explain co-occurrence of AAA and TAA
(25%), relatives with AAA in familial TAA and relatives
with TAA in familial AAA.
To establish the role of aneurysm genes in AAA, the yield
of diagnostic whole exome sequencing (WES) of a panel of
aneurysm genes in AAA patients is presented.
As part of an ongoing genetic AAA study consecutively
diagnosed patients at the department of Vascular Surgery
were invited for genetic counseling. In this way WES DNA
testing was performed in 858 AAA patients (738 unique
families, 345 with familial AAA).
A pathogenic (PV) variant occurred in 20 (3%) AAA
index cases and 7 family members and 301 AAA patients
(41%) had a variant of unknown clinical significance
(VUS). PV occurred in FBN1 (n = 4), COL3A1 (n = 6),
DSCH1 (n = 1), TGFBR2 (n = 3), NOTCH1 (n = 1),
PLOD1 (n = 1), MYLK (n = 1), MFAP5 (n = 1) SMAD6
(n = 1) and SLC2A10 (n = 1, heterozygous). VUS were
observed in FBN2, COL5A1, MYH11, PLOD1, TGFB2,
COL1A1 and COL1A2. There was no difference between
familial and sporadic AAA in the WES yield. The outcome
was comparable to that found in thoracic aneurysm patients.
The conclusion is that DNA diagnostics may improve
stratification of familial risk for aortic aneurysms and
distinguish relatives who benefit most from close
surveillance.
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ADAMTS19 associated heart valve defects: novel genetic
variants consolidating a recognizable cardiac phenotype
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Recently, ADAMTS19 was identified as a novel causative
gene for heart valve disease (HVD), affecting mainly the
aortic and pulmonary valves as described in four patients
from two families and supported by a mouse
knockout model.
Exome sequencing and data repository (CentoMD®)
analyses were performed to identify patients with
ADAMTS19 variants (two families). A third family was
recognized based on cardiac phenotypic similarities and
SNP array homozygosity. Three novel loss of function
(LoF) variants were identified in six patients from three
families. Clinically, all patients presented anomalies of the
aortic/pulmonary valves, which included thickening of
valve leaflets, stenosis and insufficiency. Three patients
had (recurrent) subaortic membrane, suggesting that
ADAMTS19 is the first gene identified related to discrete
subaortic stenosis. In contrast to previous publication, none
of these patients were reported as having a bicuspid aortic
valve. However, one case presented a bi-commissural
pulmonary valve. All patients displayed some degree of
atrioventricular valve insufficiency. Other cardiac anomalies
included atrial/ventricular septal defects, persistent ductus
arteriosus, and mild dilated ascending aorta.
Our findings confirm that biallelic LoF variants in
ADAMTS19 are causative of a specific and recognizable
cardiac phenotype. We recommend considering
ADAMTS19 genetic testing in all patients with multiple
semilunar valve abnormalities, particularly in the presence
of subaortic membrane. ADAMTS19 screening in patients
with semilunar valve abnormalities is needed to estimate the
frequency of the HVD related phenotype, which might be
not so rare.
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Aortic aneurysm and dissection, an underestimated
finding in JAG1 mutation carriers
I. Van Gucht1, J. R. Bento1, A. Van Berendoncks2, E. Van
Craenenbroeck2, J. Saenen3, S. Laga3, J. Meester1,
A. Verstraeten1, N. Boeckx1, L. Van Laer1, B. Loeys1
1Center of Medical Genetics Antwerp, University of
Antwerp, University Hospital Antwerp, Edegem, Belgium,
2Department of Cardiac Surgery, University Hospital
Antwerp, University of Antwerp, Edegem, Belgium,
3Department of Cardiology, University Hospital Antwerp,
University of Antwerp, Edegem, Belgium
Loss-of-function Jagged-1 mutations classically lead to
Alagille syndrome (AGS), a dominantly inherited disorder
affecting liver, heart, eye, face and skeleton. Pulmonary
artery stenosis, present in two thirds of AGS patients, is
considered as a hallmark of the condition. Other vascular
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anomalies are identified in up to 10% of AGS patients. We
describe a unique family with a JAG1 missense variant that
segregates with a wide range of cardiovascular anomalies.
Whole exome sequencing in a fetus with left hypoplastic
heart and left renal agenesis revealed a missense variant
(c.2242T>C; p.Cys748Arg) in JAG1, which was absent
from gnomAD, predicted likely pathogenic by prediction
programs and maternally inherited. The mother underwent
surgery for aortic coarctation at age 10. The JAG1 variant
was present in the mother’s monozygotic twin-sister and
brother but absent in another sister. Subsequent familial
clinical evaluation revealed normal eye exam (no embry-
otoxon), normal ultrasound of kidneys and absence of
hemivertebrae in all mutation carriers. Echocardiographic
evaluation revealed a normal aorta in the mother, borderline
aortic dilatation (40 mm) in her monozygotic twin-sister and
a huge aortic sinus aneurysm (58 mm) in the brother. The
brother also has scoliosis. Remarkably, in literature another
JAG1 variant affecting a Cys-residu has been linked to
severe congenital heart disease (Tetralogy of Fallot). Aortic
aneurysm was previously reported in four patients, three of
which were only diagnosed on autopsy after fatal dissection.
Our family data warrant regular echocardiographic follow-
up in JAG1 mutation carriers as severe aortic aneurysms
remain asymptomatic and predispose to fatal aortic
dissection.
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Expanding the genetic and phenotypic spectrum of
ACTA2-related vasculopathies in a Dutch cohort
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Introduction: Heterozygous variants in the ACTA2 gene,
encoding the smooth muscle cell specific isoform of alpha-
actin, confer a high risk for thoracic aortic aneurysms and
aortic dissections. The purpose of this retrospective multi-
center study was to review the clinical and genetic data of
47 new individuals with a pathogenic or likely pathogenic
ACTA2 variant and elucidate the clinical outcome of
ACTA2-related vasculopathies.
Material and Methods: Index patients and relatives with
a pathogenic or likely pathogenic variant in the ACTA2 gene
were included in this study. Data were collected through
retrospective review of available medical records using a
standardized questionnaire.
Results: Forty-seven individuals from 26 families
participated in our study. Mean age at last evaluation was
50.8 ± 17.0 years. A total of 21 different ACTA2 variants
were detected in our cohort, including 19 missense variants,
1 splice site variant and 1 frameshift variant. Four variants
are novel. Aortic events occurred in 30/47 (63.8%) of
patients. Mean age at first aortic event was 55.6 ± 13.7
years. Male gender and the presence of hypertension
emerged as significant predictors of aortic events. Men
were also at higher risk of aortic aneurysms compared to
women. Other clinical findings included congenital heart
disease in 6/47 and iris flocculi in 6/47.
Conclusions: We provide further insight into the
genotype and phenotype of ACTA2-related vasculopathies.
Male gender and hypertension are predisposing factors for
aortic events in individuals with a pathogenic ACTA2
variant.
Supported by Dutch Heart Foundation (2014T007) and
Erasmus University Rotterdam Fellowship to IvdL.
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Prevalence of TTR mutations associated with transthyr-
etine amyloidosis (ATTR) estimated from national
exome sequencing data.
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Introduction: Amyloidosis is a rare, frequently under-
diagnosed systemic disease due to protein deposition that
develops when a native protein misfolds into insoluble
amyloid fibrils. These fibril deposits alter function of most
affected organs, including the myocardium. Transthyretin
amyloidosis (ATTR) is one of the two main causes of
cardiac amyloidosis and occurs as a result of mutations in
TTR. Under or misdiagnosis of affected individuals and
incomplete penetrance make estimates of prevalence chal-
lenging. While worldwide prevalence is estimated to be
around 50,000 individuals, with TTR V142I being the most
common cardiac ATTR associated mutation, no data on
TTR mutations or their frequency in Middle Eastern coun-
tries are available to date.
Materials and Methods: Blinded from clinical informa-
tion, we undertook data mining of 13,906 exomes of
unrelated Saudi individuals, sequenced between 2015 and
2019 as part of the Saudi Human Genome Project (SHGP).
Pathogenic or highly pathogenic TTR variants were
identified following filtration to remove common, synon-
ymous, non-coding and other benign variants.
Results and conclusion: We identified seven missense
variants (known or predicted pathogenic) in TTR, three of
which have been previously reported in amyloidosis
patients worldwide. The most frequent variants were
c.424G>A:p.V142I (1:435) and c.370C>T:p.R124C
(1:2,318). Prevalence of TTR variants in the general Saudi
population was much higher than the actual estimated rate
of ATTR cases nationally (1:10,000), which may be
explained by incomplete penetrance or sub-clinical mani-
festation of the disease.
D. Monies: None. D. Mohty: None. B. Fadel: None. B.
Meyer: None. I. Alayary: None. M. Abouelhoda: None.
P05.13.A
Investigation of NOTCH1mutation frequency in bicus-
pid aortic valve disease
S. E. Hamby1,2, R. Debiec1,2,3, M. Nath1,2, P. D. Jones1,2, S.
Coolman1,2, M. Asiani1,2, S. Kharodia1,2, G. J. Skinner3, N.
J. Samani1,2, A. Bolger1,2,3, T. R. Webb1,2
1University of Leicester Department of Cardiovascular
Sciences, Leicester, United Kingdom, 2NIHR Leicester
Biomedical Research Centre, Leicester, United Kingdom,
3East Midlands Congenital Heart Centre, Glenfield Hospi-
tal, Leicester, United Kingdom
Background: Bicuspid Aortic valve (BAV) is a common
congenital heart defect present in around 1% of the
population. Familial BAV has an autosomal dominant pat-
tern of inheritance with reduced penetrance, however, the
majority of BAV cases are sporadic. Pathogenic and likely
pathogenic NOTCH1 variants have been reported in famil-
ial, as well as up to 4% of sporadic cases.
Aim: To investigate the frequency of causative NOTCH1
mutations in a large cohort of patients of sporadic and
familial BAV disease recruited to the Bicuspid aoRtic
vAlVe gEnetic research (BRAVE) study.
Methods: Whole exome sequencing (WES) was per-
formed in 12 families (30 affected and 25 unaffected family
members). Targeted NOTCH1 sequencing was carried out
in 383 sporadic BAV cases. NOTCH1 variants were filtered
by gnomAD allele frequency (< 0.001) and potential
deleterious effect (Combined Annotation Dependent Deple-
tion (CADD) score>20). We also compared cumulative
frequency of rare NOTCH1 variants between sporadic BAV
patients and 1102 apparently healthy controls.
Results: One BAV family had a truncating NOTCH1
variant (c.873C>G/p.Tyr291*). There were no candidate
NOTCH1 variants in any of the other 11 families. We
identified seven rare and potentially deleterious NOTCH1
variants in the sporadic patient group. Among which, there
were no protein truncating mutations. There was no
enrichment of NOTCH1 variants between cases and
controls (1.83% vs 3.09%, p-value 0.18).
Conclusions: Our data suggest that whilst occasionally
responsible for familial cases of BAV, NOTCH1 mutations
are an infrequent cause of sporadic forms of the disease.
S.E. Hamby: None. R. Debiec: None. M. Nath: None.
P.D. Jones: None. S. Coolman: None.M. Asiani: None. S.
Kharodia: None. G.J. Skinner: None. N.J. Samani:
None. A. Bolger: None. T.R. Webb: None.
P05.14.B
Bicuspid aortic valve: a pilot candidate gene-based
approach in a representative Czech cohort
P. Votýpka1, P. Peldová1, A. Krebsová2, V. Zoubková1,
M. Balaščaková1, M. Macek, Jr.1
1Department of Biology and Medical Genetics, 2nd Faculty
of Medicine, Charles University and Motol, Prague, Czech
Republic, 2Department of Cardiology, Institute for Clinical
and Experimental Medicine, Prague, Czech Republic
Aim: Analysis of the genetic basis in a representative cohort
of Czech patients with familiar bicuspid aortic valve (BAV)
with / without aortic aneurysm (MIM# 109730).
Materials and Methods: Altogether 100 unrelated cases
were clinically examined, underwent genetic counselling
and positive cases were subjected to “cascade screening” of
first-degree relatives. Massively parallel sequencing (MiSeq
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platform; Illumina.com) was utilised for a custom-made
panel comprising either 136, 229 or 100 cardiac/aortic
conditions-related candidate genes (Sophia Genetics.com).
Presence of pathogenic variants was validated by Sanger
sequencing and via their segregation in respective families.
Results: Pathogenic/likely pathogenic variant (ACMG
Class ≥ 4) were found in 3/100 patients (3 %) within
TGFB2, SMAD6 and FBN1. Variants of unknown sig-
nificance (Class 3) were detected in 9/100 patients (9 %)
comprising genes FLNA, FBN1, MYH11, TAB2, TGFB2
and GATA5. A family with concurrent familial dilated
cardiomyopathy, BAV and ectopia lentis was analysed as
well. Likely causative DNA variants in MYBPC3 and FBN1
were identified, but FBN1 variants did not co-segregate
with BAV.
Conclusions: The yield of genetic testing in familial
forms of BAV is rather low in our cohort. Moreover, the
identification of pathogenic variant in BAV-related gene is
not a guarantee of their causality, hence detected variants
should be carefully interpreted. The genetic basis for the
familial forms of BAV will be further studied, e.g. by whole
exome analysis together with improved clinical stratifica-
tion of our patient cohort.
Supported by Ministry of Health of the Czech Republic,
grant Nr. NV18-02-00237
P. Votýpka: None. P. Peldová: None. A. Krebsová:
None. V. Zoubková: None. M. Balaščaková: None. M.
Macek, Jr.: None.
P05.16.A
Electrophysiological characterization of a Brugada
syndrome SCN5A Belgian founder mutation in induced
pluripotent stem cell cardiomyocytes
E. Simons1, A. Nijak1, B. Vandendriessche1, D. Van de
Sande2, E. Sieliwończyk1, A. J. Labro2, D. Snyders2, D.
Schepers1, B. Loeys1,3, M. Alaerts1
1Centre of Medical Genetics, faculty of Medicine and
Health Sciences, University of Antwerp & Antwerp
University Hospital, Antwerp, Belgium, 2Laboratory of
Molecular Biophysics, Physiology & Pharmacology,
Department of Biomedical Sciences, University of Antwerp,
Antwerp, Belgium, 3Department of Human Genetics,
Radboud University Medical Centre, Nijmegen, Nether-
lands
Introduction: SCN5A encodes the α-subunit of voltage-
gated cardiac sodium channel Nav1.5. Mutations in SCN5A
are identified in about 20% of patients with Brugada syn-
drome (BrS), an inherited cardiac arrhythmia. We have
identified an SCN5A founder mutation (c.4813+3_4813
+6dupGGGT), leading to a loss-of-function of Nav1.5 in 25
different families. Mutation carriers show variable expres-
sion of the phenotype: from asymptomatic to syncopes and
SCD. We used induced pluripotent stem cell derived car-
diomyocytes (iPSC-CM) to investigate the underlying
pathophysiology.
Material & Methods: Dermal fibroblasts of three
patients with different severity, and one unrelated healthy
control were reprogrammed using the CytoTune™-iPS 2.0
Sendai Reprogramming Kit. iPSC-CMs were differentiated
following a published protocol. T3 hormone addition was
tested to improve maturity of the cells. We performed
several differentiation rounds and investigated expression of
cardiac markers using qPCR and immunocytochemistry and
electrophysiological properties using patch-clamping and
calcium imaging.
Results: All iPSC-CMs expressed tested markers. We
observed reduction in sodium current density in patient
iPSC-CMs, together with shortening of the action potential
and calcium transient duration compared to the control.
However, our data display variability between the differ-
entiation batches, as well as between clones generated from
one donor. Addition of T3 improved organization of the
sarcomeres and decreased result variability.
Conclusions: We established iPSC-CM models for a
unique Belgian SCN5A founder mutation. Despite observed
variability, we could detect expected differences in electro-
physiological properties of patient cells compared to
controls. We prove that T3 addition improves the maturity
of the cells, with a positive impact on the variability.
E. Simons: None. A. Nijak: None. B. Vandendriessche:
None. D. Van de Sande: None. E. Sieliwończyk: None. A.
J. Labro: None. D. Snyders: None. D. Schepers: None. B.
Loeys: None. M. Alaerts: None.
P05.18.C
Network-based identification of novel Shox2-dependent
genes in cardiac rhythm control
S. Hoffmann1,2, S. Schmitteckert1, K. Raedecke1,2, D.
Rheinert1, S. Diebold3, R. Roeth1, B. Weiss1, M. Granzow4,
B. Niesler1,2, A. Griesbeck1, V. Eckstein5, W. H.
Zimmermann6,7, S. Just3, G. A. Rappold1,2
1Department of Human Molecular Genetics, Institute of
Human Genetics, University of Heidelberg, Heidelberg,
Germany, 2DZHK, German Center for Cardiovascular
Research, Partner Site Heidelberg/Mannheim, Heidelberg,
Germany, 3Department of Internal Medicine II, University
of Ulm, Ulm, Germany, 4Department of Human Genetics,
Institute of Human Genetics, University of Heidelberg,
Heidelberg, Germany, 5FACS Core Facility, Department of
Medicine V, University Hospital Heidelberg, Heidelberg,
Germany, 6Institute of Pharmacology, University Medical
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Center Goettingen, Goettingen, Germany, 7DZHK, German
Centre for Cardiovascular Research, Partner Site
Goettingen, Goettingen, Germany
The transcription factor SHOX2 is involved in the devel-
opment and function of the sinoatrial node (SAN), which is
crucial for initiating and controlling heart rhythm. SHOX2
has been associated with cardiac arrhythmias such as atrial
fibrillation (AF) and sinus node dysfunction. Yet, our
knowledge on co-regulatory networks associated with car-
diac rhythm control in health and disease still remains
limited. To dissect the role of Shox2-dependent networks,
we utilized a murine embryonic stem cell (ESC) model that
allowed us to investigate molecular pathways involving
Shox2 in SAN-like cardiomyocytes. Differential RNA-seq-
based expression profiling of Shox2+/+ and Shox2-/- ESCs
revealed 94 regulated transcripts in Shox2-/- SAN-like cells.
Fifteen putative target genes were selected for further
validation based on comparative expression analysis of our
dataset with publicly available RNA-seq data of SAN and
right atria enriched genes at different mouse embryonic
stages. Network-based analyses integrating data from the
Mouse Organogenesis Cell Atlas and the Ingenuity pathway
analysis tool as well as validation in mouse and zebrafish
confirmed a species conserved regulation for Shox2 target
genes in cardiac rhythm control. Our results indicate that
co-regulatory networks involving SHOX2 participate in the
development of conduction traits through regulatory
mechanisms, thereby affecting the expression of multiple
genes. This work was supported by grants from the DFG
(RA 380/14-4) and DZHK (81X2500110 and
81X2500171).
S. Hoffmann: None. S. Schmitteckert: None. K.
Raedecke: None. D. Rheinert: None. S. Diebold: None.
R. Roeth: None. B. Weiss: None. M. Granzow: None. B.
Niesler: None. A. Griesbeck: None. V. Eckstein: None.
W.H. Zimmermann: None. S. Just: None. G.A.
Rappold: None.
P05.19.A
Diagnostic yield of targeted versus broad next genera-
tion sequencing data analysis in inherited cardiomyo-
pathy and arrhythmia syndromes
K. Kolokotronis1, N. Pluta1, E. Klopocki1, S. Störk2, S.
Rost1, B. Gerull2
1Institute of Human Genetics, University of Wuerzburg,
Wuerzburg, Germany, 2Comprehensive Heart Failure
Center and Department of Medicine I, University Hospital
Würzburg, Wuerzburg, Germany
Introduction: Although next generation sequencing has
drastically changed cardiogenetics, the fact that many cases
with positive family history remain unsolved after routine
panel diagnostics suggests that some genetic causes remain
to be discovered. In this study we examined the diagnostic
yield of targeted gene panels compared to whole exome
data analysis.
Methods: The cohort consisted of 61 consecutive patients
with a diagnosis of cardiomyopathy or primary arrhythmia
syndrome, with DCM being the most common diagnosis.
The genetic analysis involved whole exome sequencing
with subsequent stepwise bioinformatic analysis starting
from virtual gene panels till whole exome data. Genetic
variants were classified according to ACMG-criteria.
Results: Overall, in 39 out of 61 (64%) patients a variant
of interest was detected. The detection rate was highest in
patients with a diagnosis of HCM (7/9; 77%) or DCM (25/
36; 69%). In DCM the diagnostic yield was better compared
to current literature. The majority of variants of interest
were found in the disease-specific panel (46%; 28/61),
while the further analysis of an extended panel and whole
exome data led to an additional diagnostic yield of 13% and
5%, respectively. Whole exome data analysis also detected
variants in thus far not well characterized candidate genes
whose expression and function profile suggested a probable
pathogenetic role.
Conclusions: Targeted gene panel analysis led to the
identification of the genetic cause in the majority of solved
cases. The additional diagnostic yield of whole exome data
analysis was low, enabled though the detection of
potentially causal variants in candidate genes.
K. Kolokotronis: None. N. Pluta: None. E. Klopocki:
None. S. Störk: None. S. Rost: None. B. Gerull: None.
P05.20.B
Diagnostic yield of core panels for cardiomyopathy- and
arrhythmia genes versus a larger panel of heart-disease
related genes
D. M. E. I. Hellebrekers1, B. J. C. van den Bosch1, G. R. F.
Claes1, I. Roozen1, Y. E. G. Barrois1, N. Vergoossen1, A. T.
M. Hendrickx1, W. van Dijk1, C. L. M. Marcelis2, M.
Kempers2, Y. M. Hoedemaekers2, A. T. J. M. Helderman-
van den Enden1, E. K. Vanhoutte1, I. P. C. Krapels1, A. van
den Wijngaard1
1Maastricht University Medical Center, Maastricht, Nether-
lands, 2Radboud University Medical Center, Nijmegen,
Netherlands
Introduction: We evaluated the prevalence of (likely)
pathogenic variants in our cardiomyopathy- and arrhythmia
core panels in patients with cardiac disease. Furthermore,
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the additional diagnostic value of a larger panel of heart
disease-associated genes was assessed.
Methods: This study included a large population of
~2000 patients suspected of a heritable cardiac condition
who underwent cardiogenetic testing at the laboratory of the
Clinical Genetics Department in Maastricht. Sequencing a
diagnostic panel of 46 cardiomyopathy genes and/or 27
arrhythmia genes was performed using single-molecule
molecular inversion probes (smMIPs). For 347 of these
patients, whole exome sequencing was performed for the
analysis of a panel of 350 heart disease-associated genes.
Results: A (likely) pathogenic variant was found in 20%
(336/1719) and 8% (34/408) of patients tested for the
cardiomyopathy or arrhythmia gene panel, respectively. The
majority of these variants were found in the MYBPC3,
MYH7, LMNA, TNNT2, MYL2 and PKP2 genes for
cardiomyopathy and SCN5A, KCNQ1, RYR2 and KCNH2
genes for arrhythmia. Sequencing the larger panel of 350
genes in 347 patients identified an additional pathogenic
variant explaining the clinical phenotype in only 3 patients.
Conclusions: Our data support parallel sequencing of
core genes as the preferred strategy for genetic testing of
patients suspected of having a genetic cardiomyopathy or
arrhythmia. The incremental diagnostic yield of a larger
panel of heart disease-associated genes is minimal. There-
fore, focus should not be on analysing more genes, but on
developing functional assays to predict pathogenicity of
variants of unknown significance (VUS’s) in the core
panel genes.
D.M.E.I. Hellebrekers: None. B.J.C. van den Bosch:
None. G.R.F. Claes: None. I. Roozen: None. Y.E.G.
Barrois: None. N. Vergoossen: None. A.T.M. Hendrickx:
None. W. van Dijk: None. C.L.M. Marcelis: None. M.
Kempers: None. Y.M. Hoedemaekers: None. A.T.J.M.
Helderman-van den Enden: None. E.K. Vanhoutte:
None. I.P.C. Krapels: None. A. van den
Wijngaard: None.
P05.21.C
Dominant mild Carvajal syndrome: arrhythmogenic
cardiomyopathy caused by the heterozygous p.R1113*
nonsense variant in the DSP gene.
A. T. J. M. Helderman-vd Enden1, J. G. Post2, K. J. A. F.
van Kaam1, R. H. Lekanne Deprez3, D. Dooijes4, A. A. M.
Wilde5, I. P. C. Krapels1
1Department of Clinical Genetics, Maastricht University
Medical Center, Maastricht, Netherlands, 2Department of
Clinical Genetics, University Medical Center Utrecht,
Utrecht, Netherlands, 3Department of Clinical Genetics,
Amsterdam University Medical Center, Amsterdam, Nether-
lands, 4Department of Clinical Genetics, University
Medical Center Utrecht, Utrecht, Netherlands, 5Depart-
ment of Cardiology, Amsterdam University Medical Center,
Amsterdam, Netherlands
Introduction: Arrhythmogenic cardiomyopathy (ACM) is
a dominant inherited cardiac disease characterized by pro-
gressive fibrofatty replacement of the myocardium that
predisposes to ventricular tachycardia and sudden death.
Carvajal syndrome is a rare recessive form of ACM asso-
ciated with woolly hair and palmo-plantar keratoderma and
pathogenic variants in the desmoplakin (DSP) gene. Some
families have been described with a dominantly inherited
DSP variant with features of Carvajal.
Materials and Methods: In a four generation family
seggregation analysis was done for a dominantly inherited
DSP p.R1113* variant. The phenotypes are described and
the results are compared to literature.
Results: In the large sibship (4M + 8F) at least three
siblings are obligate carrying the DSP pathogenic variant
and have offspring with cardiac abnormalities. Five family
members died suddenly, 2/5 obligate carriers, 3/5 the status
is unknown. The curly hair is co-seggregating with the
variant. Not all carriers have keratoderma. A number of
individuals with the variant have no cardiac complaints so
far, cardiological investigations are planned. An overview
will be presented at the conference and compared to the six
families described by Maruthappu et al in 2019, one of
these families also has the p.R1113* variant.
Conclusion: The p.R1113* variant in the DSP gene leads
to a well recognizable phenotype of mild Carvajal
syndrome. Drawing the attention to this phenotype by
presenting this large four generation family may help in
identifying other families with this disease and in prevent-
ing sudden death.
A.T.J.M. Helderman-vd Enden: None. J.G. Post:
None. K.J.A.F. van Kaam: None. R.H. Lekanne Deprez:
None. D. Dooijes: None. A.A.M. Wilde: None. I.P.C.
Krapels: None.
P05.22.A
Chromosome 22q11 copy number variations in paedia-
tric and adult patients with congenital heart defects
G. K. ZODANU, D. Nagy, M. Széll, M. Oszlánczi,
K. Havasi, A. Kalapos, M. Katona
UNIVERSITY OF SZEGED, SZEGED, Hungary
Introduction: Congenital heart defect (CHD) is the most
common birth defect, affects ~1% of newborns. Chromo-
some 22q11 microdeletion syndrome is often associated
with CHDs and is the most common human microdeletion,
occurs in ~1/4000 live births in the general population and
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in 2.8-14.9% of CHD patients. 22q11 copy number variants
(CNVs) are caused by non-allelic homologous recombina-
tion events in the flanking low copy repeat regions (LCRs),
labeled A-H.
Materials and Methods: Our aim was to evaluate the
prevalence of 22q11 CNVs in Hungarian CHD patients. 175
blood samples were obtained from children and adults with
different isolated and combined CHDs. Samples were
analyzed using multiplex ligation-dependent probe ampli-
fication (MLPA) to detect CNVs in the given chromosomal
region. Positive MLPA results were confirmed with locus-
specific FISH. Genotype-phenotype comparison and family
screening was also performed.
Results: CNVs were detected in overall 10 cases (5.7%).
Six cases with typical microdeletion (between LCRs A and
D) also known as DiGeorge syndrome, 2 cases with
microduplication and 2 cases with combined microdeletion
and microduplication were detected. The phenotypical
appearance of patients was highly variable. CNVs were
familiar in 3 cases.
Conclusions: Until present this was the largest systemic
genetic screening of Hungarian CHD patients. Since the
clinical diagnosis of 22q11 microdeletion/microduplication
syndrome may be challenging due to its variable manifesta-
tion, systematic genetic testing may be of utmost benefit in
the early diagnosis and proper management of these
patients.
Funding grant: GINOP-2.3.2-15-2017-00039
G.K. Zodanu: None. D. Nagy: None. M. Széll: None.
M. Oszlánczi: None. K. Havasi: None. A. Kalapos: None.
M. Katona: None.
P05.23.B
Genetic variation in participants of the 100,000 Gen-
omes Project with congenital heart disease
S. L. Baross1, S. G. Williams1, K. E. Hentges2, A. D.
Sharrocks3, B. D. Keavney1
1Division of Cardiovascular Sciences, University of Man-
chester, Manchester, United Kingdom, 2Division of Evolu-
tion and Genomic Sciences, University of Manchester,
Manchester, United Kingdom, 3Division of Molecular and
Cellular Function, University of Manchester, Manchester,
United Kingdom
Congenital heart disease is the most common birth defect,
affecting approximately 1% of live births globally. Con-
genital heart disease shows a high degree of heritability but
the genetic causes are still poorly understood.
The 100,000 Genomes Project provides whole genome
sequences for patients with rare disease or cancer and their
families. Over 600 participants were recruited to the project
under the congenital heart disease arm of the project, almost
all of whom have no known causative variant. In addition,
analysis of phenotyping and clinical data identified an
additional ~2,500 participants with congenital heart disease
who were recruited to the project for other conditions.
We will present rare, likely pathogenic single nucleotide,
short insertions/deletions and structural variants, both
transmitted and de novo, from this cohort of 3,100
participants with congenital heart disease. Short variants
are filtered for variants with moderate or high impact on
protein function; CADD (combined annotation dependent
depletion) score ≥ 20; and absent in gnomAD v3.
This research was made possible through access to the
data and findings generated by the 100,000 Genomes
Project (http://www.genomicsengland.co.uk).
Grant reference: BHF FS/16/58/32734.
S.L. Baross: None. S.G. Williams: None. K.E. Hentges:
None. A.D. Sharrocks: None. B.D. Keavney: None.
P05.24.C
Mutation spectrum of congenital heart disease in
73consanguineous Turkish families
W. Dong1, H. Kaymakcalan2, N. Diab1, S. Chih Jin1,
C. Tanıdır3, A. Yalcin2, S. Mane1, K. Bilguvar1, M.
Brueckner1, R. Lifton1
1Yale University, New Haven, CT, United States, 2Demir-
oglu Bilim University, Istanbul, Turkey, 3Mehmet Akif
Ersoy Hospital, istanbul, Turkey
Mutation spectrum of congenital heart disease in 73 con-
sanguineous Turkish families
Introduction: Congenital heart disease (CHD) is the
most frequent defect among live births and the leading
cause of mortality from a birth defect. Nearly 90% of CHD
cases have a suspected genetic etiology, but in 56% of cases
the genetic etiology is unknown. Few gene discovery efforts
have been made with consanguineous CHD cohorts. We
recruited 74 CHD patients from 73 consanguineous families
in Turkey and used whole exome sequencing to identify
affected genes in these patients. In 13.7% of the cohort, we
could identify a genetic etiology and we discovered four
new genes that are putatively causative for CHD. This
represents an important advance in our understanding of the
genetic consequences of consanguinity in CHD.
Materials and methods: 74 samples from 73 families
were recruited from two pediatric cardiology clinics in
Istanbul, Turkey. Cardiac phenotypes were classified into 5
major categories and whole exome sequencing was
performed at the Yale Center for Genomic Analysis using
Illumina.
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Result: 7 out of 73 (9.6%) patients carried damaging
homozygous variants in known CHD genes and 3 out of 73
(4.1%) of them harbored other types of CHD-related
genomic alterations, which explained 13.7% of the cohort.
Conclusions: Our findings is consistent with the hypoth-
esis that high consanguinity is more likely to be associated
with recessive cardiac abnormalities. Additionally, it fits the
perception that the heritability for severe defects is higher
than milder malformations.
Grant: Yale-National Institutes of Health Center for
Mendelian Genomics
W. Dong: None. H. Kaymakcalan: None. N. Diab:
None. S. Chih Jin: None. C. Tanıdır: None. A. Yalcin:
None. S. Mane: None. K. Bilguvar: None. M. Brueckner:
None. R. Lifton: None.
P05.26.B
Altered microRNA and target gene expression related to
Tetralogy of Fallot
M. Grunert, S. Appelt, S. Rickert-Sperling
Charité - Universitätsmedizin Berlin, Berlin, Germany
MicroRNAs (miRNAs) play an important role in guiding
development and maintaining function of the human heart.
Dysregulation of miRNAs has been linked to various con-
genital heart diseases including Tetralogy of Fallot (TOF),
which represents the most common cyanotic heart mal-
formation in humans. Several studies have identified dys-
regulated miRNAs in right ventricular (RV) tissues of TOF
patients. In the study presented here, we profiled genome-
wide the whole transcriptome and analyzed the relationship
of miRNAs and mRNAs of RV tissues of a homogeneous
group of 22 non-syndromic TOF patients. Observed profiles
were compared to profiles obtained from right and left
ventricular tissue of normal hearts. To reduce the large list
of predicted target genes of dysregulated miRNAs, we
applied a stringent target prediction pipeline integrating
probabilities for miRNA-mRNA interaction. The final list of
disease-related miRNA-mRNA pairs comprises novel as
well as known miRNAs including miR-1 and miR-133,
which are essential to cardiac development and function by
regulating KCNJ2, FBN2, SLC38A3 and TNNI1. Overall,
our study provides additional insights into post-
transcriptional gene regulation of malformed TOF hearts.
M. Grunert: None. S. Appelt: None. S. Rickert-
Sperling: None.
P05.28.A
Circulating lncRNA ANRIL a potential biomarker in
Tanzanian patients with coronary artery disease
G. AKAN1, E. Nyawawa2, B. Nyangasa2, M. K. Turkcan3,
E. Mbugi1, O. Ozgen4, M. Janabi2, F. Atalar1
1MUHAS Genetics Laboratory, Biochemistry Department,
School of Medicine, Muhimbili University of Health and
Allied Science, Dar es Salaam, Tanzania, United Republic
of, 2Muhimbili National Hospital Jakaya Kikwete Heart
Institute, Dar es Salaam, Tanzania, United Republic of,
3Department of Electrical Engineering, Columbia Univer-
sity,, New York, NY, United States, 4Molecular Medicine
Department, Aziz Sancar Experimental Medicine Research
Institute, Istanbul University, Istanbul, Turkey
Background: 9p21.3 locus was identified as a hot spot
locus associated with coronary artery disease(CAD) and it
contains CDKN2A and CDKN2B genes which encode the
cell cycle regulators and a non-coding RNA ANRIL gene.
Role of 9p21.3 locus variations in molecular mechanisms of
CAD pathogenesis and the expression of neighbour-genes
remain unknown. The study aims to assess of expressions of
CDKN2A, CDKN2B, ANRIL and ANRIL splices variants
association with CAD susceptibility, and to investigate the
impact of 9p21.3 locus variations on the expression of
studied genes in peripheral blood, Epicardial Adipose Tis-
sue(EAT), Mediastinal Adipose tissue(MAT) and Sub-
cutaneous Adipose Tissue(SAT) in Tanzanian CAD
patients.
Methods&Results: Expression of CDKN2A, CDKN2B,
ANRIL, and its splice variants (circANRIL, NR003529,
EU741058 and DQ485454)were measured by QRT-PCR in
peripheral blood, EAT, MAT and SAT of 25 patients
undergoing coronary artery bypass grafting due to CAD and
25 non-CAD patients undergoing heart valve surgery.
ANRIL gene expression levels were significantly up-
regulated while expression levels of circANRIL were
significantly down-regulated in peripheral blood of CAD
patients. Moreover, increased expression levels of circAN-
RIL were associated with less severity of CAD. ROC
analysis data has also confirmed that circANRIL could act
as a potential biomarker for detecting CAD.
Conclusions: Our results are the first data presenting the
expressions of ANRIL and its splice variants in cardiac
adipose tissues of CAD patients. We demonstrate circAN-
RIL has a synergistic effect with ANRIL and plays a
protective role in CAD. circANRIL could possibly be used
as a biomarker for CAD in Tanzania.
G. Akan: None. E. Nyawawa: None. B. Nyangasa:
None. M.K. Turkcan: None. E. Mbugi: None. O. Ozgen:
None. M. Janabi: None. F. Atalar: None.
P05.29.B
Members of subgingival plaque bacterial complexes are
present in blood of patients with coronary artery disease
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A. Suarez-Molina1, C. Fong2, L. Cifuentes-C2, S. Guauque-
Olarte2
1Instituto Departamental de Salud de Nariño, Pasto,
Colombia, 2Universidad Cooperativa de Colombia, Pasto,
Colombia
Introduction: It has been hypothesized that oral bacteria
can migrate, through the blood, from the mouth to the artery
plaques exacerbating atherosclerosis. This study compared
the bacteria present in peripheral blood of individuals with
and without coronary artery disease.
Materials and Methods: RNA sequences from blood
downloaded from GEO (GSE58150) correspond to 8 cases
with coronary artery calcium (CAC) >514 and 8 controls
(CAC=0). After quality controls, the sequences were
aligned to the hg38 reference genome using Hisat2. The
unmapped sequences were fed into Kraken to determinate
bacterial taxa. Ecological indices were calculated using
Vegan. The counts of bacteria between groups was
compared using a Mann-Whitney U test.
Results: The mean number of species was different
between cases (433.4) and controls (226.1) (p-value =
0.0001). A total of 129 species were found only in cases and
74 were exclusive of controls. According to the Jaccard
similarity index 16% of the species identified is not shared
between cases and controls (p=0.001). The Alcaligenaceae
family was more frequent in cases than in controls (FDR:
0.048). The red complex bacteria Treponema denticola was
detected only in 2 cases. The mean count of bacteria
belonging to subgingival plaque bacterial complexes was
higher in cases (573.5) than in controls (249) (p-value =
0.0206).
Conclusions: This study identified periodontopathogens
in blood of patients with coronary artery disease. The list of
microorganisms presented only in cases will be key to
identify new periodontopathogens that can relate period-
ontitis and this cardiovascular disease. SGO received
funding by CONADI-Universidad Cooperativa de Colom-
bia, grant 1839.
A. Suarez-Molina: None. C. Fong: None. L. Cifuentes-
C: None. S. Guauque-Olarte: None.
P05.30.C
Molecular genetic screening in patients with sponta-
neous coronary artery dissection
M. Antonutti1, F. Baldan2, L. Spedicato1, D. Zanuttini1, T.
Bisceglia1, E. Favaretto1, C. Tioni1, D. Sut1, M. Ghidina1,
C. Lanera3, D. Gregori3, D. Fabbro1, G. Damante1,
A. Proclemer1
1ASUFC, Udine, Italy, 2University of Udine, Udine, Italy,
3DCTVPH, Padova, Italy
Spontaneous coronary artery dissection (SCAD) is
increasingly recognized as an important cause of myo-
cardial infarction, particularly in women often with few
cardiovascular risk factors. SCAD is defined as a sponta-
neous tear in the coronary arterial wall that is not traumatic
or iatrogenic. Studies are still underway to investigate the
role of genetics in promoting SCAD; genetic diseases fre-
quently associated with SCAD are connective tissue dis-
eases. Considering the role of SCAD for sudden cardiac
death and the increased risk for future cardiac events, an
early diagnosis is crucial. We enrolled 60 patients with
nonatherosclerotic angiographic diagnosis of SCAD. All
patients’ genomic DNA was analyzed by NGS with gene
panel involved in collagenopathies and arteriopathies
(ACTA2, CBS, COL3A1, COL5A1, COL5A2, ELN, FBN1,
FBN2, LTBP2, MYLK, NOTCH1, MYH11, SMAD3,
SMAD4, SLC2A10, TGFB2, TGFB3, TGFBR1, TGFBR2,
PLOD1). Seven patients result to carry potential SCAD-
related mutations. In particular, we observed a pathological
COL3A1 mutation; 3 different VUS mutations in: LTBP2
(two patients), MYLK and NOTCH1. Moreover, we found a
new nonsense mutation in SMAD3 and a missense alteration
in COL5A2; both not enlisted in public database, but that
could be categorized as pathogenetic and VUS, respec-
tively, according to the ACMG classification. These data
support the use of sequencing of genes inclusive of col-
lagenopathies and arteriopathies as an approach to evaluate
genetically mediated SCAD. However,, considering that
only a minority of patients have clear SCAD-causative
mutations, these results remark the need of further studies to
define genetic mechanisms of SCAD.
M. Antonutti: None. F. Baldan: None. L. Spedicato:
None. D. Zanuttini: None. T. Bisceglia: None.
E. Favaretto: None. C. Tioni: None. D. Sut: None. M.
Ghidina: None. C. Lanera: None. D. Gregori: None. D.
Fabbro: None. G. Damante: None. A. Proclemer: None.
P05.32.B
Comparison of variant detection rate in 100 candidate
genes between two representative cohorts of Czech
living patients versus victims of sudden cardiac death
with clinical. or post mortem diagnosis of dilated-,
arrhythmogenic- and hypertrophic cardiomyopathy.
A. Krebsova1, P. Votýpka2, P. Peldová2, K. Ruecklova3,
V. Zoubkova2, S. Pohlova-Kucerova4, A. Pilin5, M.
Kulvajtova6, M. Kubanek1, M. Bilek5, T. Tavacova7,
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J. Petrkova8, M. Dobias9, P. Tomasek10, M. Macek Sr.2, M.
Macek Jr.2, J. Janousek7, J. Kautzner1
1Institute for Clinical and Experimental Medicine, Prague,
Czech Republic, 2Department of Biology and Medical
Genetics, 2nd Faculty of Medicine, Charles University and
Motol University Hospital, Prague, Czech Republic, 3Pae-
diatric Department, 3rd Faculty of Medicine, Charles
University, Prague, Czech Republic, 4Department of
Forensic Medicine, Faculty of Medicine in Hradec Králové,
Charles University, Hradec Kralove, Czech Republic,
5Institute for forensic medicine and toxicology, 1st Faculty
of Medicine, Charles University, Prague, Czech Republic,
6Institute for Forensic Medicine, 3rd Faculty of Medicine,
Charles University, Prague, Czech Republic, 7Children´s
Heart Centre, 2nd Faculty of Medicine, Charles University
and Motol University Hospital, Prague, Czech Republic,
8Department of Cardiology, Faculty Hospital Olomouc and
Palacký University, Olomouc, Czech Republic, 9Institute for
Forensic Medicine, Faculty Hospital Olomouc, Olomouc,
Czech Republic, 10Institute for Forensic Medicine, Hospital
Bulovka, 2nd Faculty of Medicine, Charles University,
Prague, Czech Republic
Introduction: Hereditary cardiomyopathy is associated
with risk of sudden cardiac death (SCD). Genetic aetiology
of SCD in a representative Czech cohort with post mortem
diagnosis of cardiomyopathy was studied and results com-
pared to those in living cases.
Patients and Methods: Altogether 47 victims of SCD
with post mortem diagnosis of hypertrophic- (HCM; 18/47),
arrhythmogenic- (ACM; 19/47) and dilated cardiomyopathy
(DCM; 10/47) were ascertained. Concurrently, genetic
testing was performed in 114 living patients (HCM 54/
114, ACM 22/114, DCM 38/114). NGS (MiSeq platform;
Illumina.com) was utilised for a custom-made panel
comprising 100 candidate genes (Sophia Genetics,
Switzerland).
Results: The causative detection rate (according to
ACMG.net classes 4 or 5) in SCD victims with DCM was
60 % (6/10) and in living patients with DCM 47.4 % (18/
38). Variants in TTN, RBM20, DES and FLNC prevailed.
Detection rate in ACM was 5 % (1/19 in SCN5A gene) in
SCD victims and 31.8 % (7/22) [JJ1] in living patients. The
detection rate in SCD victims with HCM was 16 % (3/18)
and in living patients 35 % (19/54). The most prevalent
gene was MYBPC3, while PRKAG2 was detected in SCD
victim and in cardiac arrest survivor.
Conclusion: Post-mortem genetic analysis in DCM
yields a high detection rate and allows effective primary
prevention of SCD in at risk relatives. In contrast, molecular
autopsy of HCM and ACM renders a much lower yield
which could reflect more complex genetic aetiology
in SCD. Supported by Ministry of Health of the Czech
Republic, grant Nr. NV18-02-00237 and 00064203/6003
A. Krebsova: None. P. Votýpka: None. P. Peldová:
None. K. Ruecklova: None. V. Zoubkova: None.
S. Pohlova-Kucerova: None. A. Pilin: None. M. Kulvaj-
tova: None. M. Kubanek: None. M. Bilek: None.
T. Tavacova: None. J. Petrkova: None. M. Dobias:
None. P. Tomasek: None. M. Macek Sr.: None. M.
Macek Jr.: None. J. Janousek: None. J. Kautzner: None.
P05.33.C
Genome wide association analysis in dilated cardiomyo-
pathy revealed two new susceptibility loci for systolic
heart failure
S. Garnier1,2, M. Harakalova3,4, S. Weiss5,6, M. Mokry3,7,8,
J. van Setten3, C. Proust9, L. Duboscq-Bidot1,2,10, A.
Boland11,12, J. Deleuze11,12,13, M. Dörr6,14, F.
Asselbergs3,15,16, F. Cambien9, E. Villard1,2,10,
D. Trégouët9, P. Charron1,2,10,17
1Sorbonne Université, INSERM, UMR-S1166, research unit
on cardiovascular disorders, metabolism and nutrition,
Team Genomics & Pathophysiology of Cardiovascular
Diseases, Paris, France, 2ICAN Institute for Cardiometa-
bolism and Nutrition, Paris, France, 3Department of
Cardiology, Division Heart & Lungs, University Medical
Center Utrecht, Utrecht University, Utrecht, Netherlands,
4Regenerative Medicine Utrecht (RMU), University Medi-
cian Center Utrecht, Utrecht, Netherlands, 5Interfaculty
Institute for Genetics and Functional Genomics, Depart-
ment of Functional Genomics, University Medicine Greifs-
wald, Greifswald, Germany, 6DZHK (German Centre for
Cardiovascular Research), partnersite Greifswald, Greifs-
wald, Germany, 7Laboratory of Clinical Chemistry and
Haematology, University Medical Center, Heidelberglaan
100, Utrecht, Netherlands, 8Laboratory for Experimental
Cardiology, University Medical Center Utrecht, Heidelber-
glaan 100, Utrecht, Netherlands, 9INSERM UMR_S 1219,
Bordeaux Population Health Research Center, University
of Bordeaux, Bordeaux, France, 10APHP, Pitié-Salpêtrière
Hospital, Cardiology Department, Paris, France, 11Centre
National de Recherche en Génomique Humaine (CNRGH),
Institut de Biologie François Jacob, CEA, Université Paris-
Saclay, Evry, France, 12Laboratory of Excellence
GENMED (Medical Genomics), Paris, France, 13Centre
d’Etude du Polymorphisme Humain, Fondation Jean
Dausset, Paris, France, 14Department of Internal Medicine
B, University Medicine Greifswald, Greifswald, Germany,
15Institute of Cardiovascular Science, Faculty of Population
Health Sciences, University College London, London,
United Kingdom, 16Health Data Research UK and Institute
of Health Informatics, University College London, London,
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United Kingdom, 17AP-HP, Département de génétique,
Centre de Référence Maladies Cardiaques Héréditaires,
Hôpital Pitié-Salpêtrière, Paris, France
We conducted the largest Genome Wide Association Study
performed so far in Dilated Cardiomyopathy (DCM), a
leading cause of systolic heart failure and cardiovascular
death. Using a discovery phase of 2,719 cases and 4,440
controls and a replication phase of 584 independent cases
and 966 controls, we identified and replicated two new
DCM-associated loci one on chromosome 3p (meta-analysis
p = 5.3 10−13) and the second on chromosome 22q (meta-
analysis p = 5.0 10−10) while confirming the two previously
identified DCM loci on chromosome 10 and 1, BAG3 and
HSPB7 for an estimated heritability of 31% ± 8%. The
genetic risk score constructed from the number of lead risk-
alleles at these 4 loci revealed a 27% risk increased in
individuals with 8 risk-alleles compared to the 5 risk alleles
reference group. The two association signals were then fine-
mapped by combining in silico and functional genomics
investigations. While a few genes remain candidates at the
second locus and deserve further investigations, our work
clearly identified one gene as responsible for the association
at the first locus whose role in the pathophysiology of DCM
is supported by recent observations in human and mice. As
the biological pathway in which this gene is involved is a
potential target for pharmacological agents, our finding
opens novel therapeutic perspectives for treating or pre-
venting heart failure. These results provide new findings
that add both on the understanding of the genetic archi-
tecture of heart failure and on potential new players
involved in the pathophysiology of this devastating disease.
S. Garnier: None. M. Harakalova: None. S. Weiss:
None. M. Mokry: None. J. van Setten: None. C. Proust:
None. L. Duboscq-Bidot: None. A. Boland: None. J.
Deleuze: None. M. Dörr: None. F. Asselbergs: None. F.
Cambien: None. E. Villard: None. D. Trégouët: None. P.
Charron: None.
P05.34.A
Utility of genetics for risk stratification in paediatric
dilated cardiomyopathy
J. C. Herkert1, M. H. van der Meulen2, S. L. den Boer2, G.
J. du Marchie Sarvaas3, N. Blom4,5, A. D. J. ten Harkel4, H.
M. P. J. Breur6, L. A. J. Rammeloo7, R. Tanke8, C.
Marcelis9, I. M. B. H. van de Laar10, J. M. A. Verhagen10,
A. Baas11, A. Sammani11, I. Christiaans1, D. Q. C. M.
Barge-Schaapveld12, R. H. Lekanne dit Deprez13, J. P. van
Tintelen11, M. Dalinghaus2
1University of Groningen, University Medical Center
Groningen, Department of Genetics, Groningen,
Netherlands, 2Erasmus MC, University Medical Center
Rotterdam, Department of Paediatric cardiology, Rotter-
dam, Netherlands, 3University of Groningen, University
Medical Center Groningen, Department of Paediatric
cardiology, Groningen, Netherlands, 4University of Leiden,
Leiden University Medical Center, Department of Paedia-
tric cardiology, Leiden, Netherlands, 5Amsterdam Univer-
sity Medical Center, location AMC, Department of
Paediatric cardiology, Amsterdam, Netherlands, 6Univer-
sity of Utrecht, Wilhelmina Children’s Hospital, University
Medical Center Utrecht, Department of Paediatric cardiol-
ogy, Utrecht, Netherlands, 7Amsterdam University Medical
Center, location Free University Medical Center, Depart-
ment of Paediatric cardiology, Amsterdam, Netherlands,
8Radboud University Medical Center, Department of
Paediatric cardiology, Nijmegen, Netherlands, 9Radboud
University Medical Center, Department of Genetics,
Nijmegen, Netherlands, 10Department of Clinical Genetics,
Erasmus MC, University Medical Center Rotterdam,
Rotterdam, Netherlands, 11University of Utrecht, University
Medical Center Utrecht, Department of Genetics, Utrecht,
Netherlands, 12University of Leiden, Leiden University
Medical Center, Department of Clinical Genetics, Leiden,
Netherlands, 13Amsterdam University Medical Center,
location AMC, Department of Clinical Genetics, Amster-
dam, Netherlands
Introduction: Dilated cardiomyopathy (DCM) in children
may have an underlying genetic cause in a substantial
number of cases. We describe the current practice and
results of genetic evaluation in children with DCM and
evaluate genotype-phenotype correlations that may guide
prognosis.
Methods: We performed a multicentre prospective
observational study in children diagnosed with DCM from
2010-2017.
Results: One hundred forty-four patients were included.
Initial diagnostic categories consisted of idiopathic DCM in
67 children (47%), familial in 18 (13%), neuromuscular in 7
(5%), inborn error of metabolism in 4 (3%), malformation
syndrome in 2 (1%), myocarditis in 23 (16%) and ‘other’ in
23 (16%). Median follow-up time was 2.1 years [IQR 1.0-
4.3]. Hundred-seven patients (74%) underwent genetic
testing. A likely pathogenic (LP) or pathogenic (P) variant
was found in 39 children (36%); the majority in MYH7 (n =
9). Three patients had more than one LP/P variant. In at
least 5/39 patients (13%) the variant occurred de novo.
During the study, 39 patients (27%) reached a study
endpoint (SE: all-cause death or heart transplantation).
Transplant-free survival was significantly lower in patients
with a LP/P variant (P = 0.005). Children who carried a LP/
P variant were 2.8 times more likely to reach a SE compared
to children without, while clinical characteristics at
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diagnosis did not differ (hazard ratio 2.8; 95%CI 1.3-5.8,
P = 0.007).
Conclusions: Genetic testing is useful to predict clinical
outcome in children with DCM and should be incorporated
into the initial work-up. Patients with a LP/P variant have a
poorer prognosis than patients without LP/P variant.
J.C. Herkert: None. M.H. van der Meulen: None. S.L.
den Boer: None. G.J. du Marchie Sarvaas: None. N.
Blom: None. A.D.J. ten Harkel: None. H.M.P.J. Breur:
None. L.A.J. Rammeloo: None. R. Tanke: None. C.
Marcelis: None. I.M.B.H. van de Laar: None. J.M.A.
Verhagen: None. A. Baas: None. A. Sammani: None. I.
Christiaans: None. D.Q.C.M. Barge-Schaapveld: None.
R.H. Lekanne dit Deprez: None. J.P. van Tintelen: None.
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P05.35.B
Non-segregation of truncating TTN variants in families
with dilated cardiomyopathy (DCM)
A. G. Fleming, L. Brett, S. Wilkinson, S. John, L. Briggs, M.
Edwards, D. J. Morris-Rosendahl
Clinical Genomics Laboratory, London, United Kingdom
DCM is a highly heterogeneous condition with over 30
genes implicated in inherited forms, including TTN. TTN
truncating variants are found in ~2% of the general popu-
lation (Roberts et al. (2015) Sci Transl Med. 7(270); 270)
but there is a higher association with DCM for truncating
variants in cardiac isoforms of titin; therefore, only trun-
cating variants in exons which are spliced into >90% of
TTN cardiac transcripts are reported as potentially patho-
genic in DCM by our laboratory. We have identified TTN
truncating variants that have been classified as either likely
pathogenic or pathogenic in 82 of 613 DCM patients in our
cohort. Due to the prevalence of TTN truncations in healthy
individuals, predictive testing for truncating TTN variants is
offered with caution, and instead segregation testing in
affected relatives is first undertaken. Within our cohort we
have found several variants which do not segregate with
DCM. Out of a total of 36 individuals, across 25 families,
we have 5 cases of non-segregation of truncating TTN
variants; 3 frameshift, 1 splice site and one exonic deletion.
All of these non-segregating variants are absent from
populations databases and occur in exons which are spliced
into 100% of cardiac TTN isoforms; and were therefore
initially classified as likely pathogenic. These findings
highlight the importance of a cautious approach when
interpreting TTN truncating variants, as well as the risks of
predictive testing; especially if this results in clinical dis-
charge for individuals who do not carry the familial trun-
cating TTN variant.
A.G. Fleming: None. L. Brett: None. S. Wilkinson:
None. S. John: None. L. Briggs: None. M. Edwards:
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P05.37.A
Optimization and refinement of the diagnosis of genetic
dyslipidemias by targeted NGS
L. Zuurbier, O. R. F. Mook, M. A. Haagmans, J. C.
Defesche
Amsterdam University Medical Centers, Amsterdam,
Netherlands
Introduction: Genetic and acquired dyslipidemias are very
frequent in the general population and strongly associated
with premature atherosclerosis, myocardial infarctions,
arterial complications and sudden death at young age.
Genetic lipoprotein abnormalities can be explained by a
limited number of genes. For optimal clinical management,
risk assessment and prevention of cardiovascular disease an
accurate diagnosis is an absolute requirement, but the
interconnection between the metabolic pathways of differ-
ent lipoprotein fractions jeopardizes this when only lipid
levels are assessed.
Materials and Methods: In order to pinpoint the culprit
lipoprotein fraction of clinical dyslipidemia in 4277
patients, we evaluated NGS and CNV data, including 29
dyslipidemia-associated genes that enabled to examine all
separate lipoprotein components simultaneously. With this
approach 10 types of dyslipidemia can be discriminated.
Moreover, this panel includes a genetic risk factor for statin
intolerance.
Results: A genetic cause for dyslipidemia was found in
32% of the patients. Of these, 4% carried a CNV. The
specific initial clinical diagnoses of hypercholesterolemia or
hypertriglyceridemia were confirmed in only 17 and 35% of
patients, respectively. However, unsolicited findings causal
for a second or an unexpected type of dyslipidemia, were
encountered in 17% of cases, and suggest a broader role
than initially anticipated for variants causing dysbetalipo-
proteinemia or hypertriglyceridemia.
Conclusions: The use of the NGS-Dyslipidemia gene
panel accurately separated genetic from acquired dyslipi-
demias and within the detected genetic dyslipidemias the
diagnosis was refined based on unsolicited findings in a
substantial number of patients. This allows targeted and
optimal treatment to reduce cardiovascular risk.
L. Zuurbier: None. O.R.F. Mook: None. M.A.
Haagmans: None. J.C. Defesche: None.
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Hypermethylation of NRG1 gene correlates with the
presence of heart defects in Down’s syndrome
A. Dobosz, A. Grabowska, M. Bik-Multanowski
Department of Medical Genetics, Jagiellonian University
Medical College, Krakow, Poland
Congenital heart defects can decrease the quality of life and
life expectancy in affected individuals, and constitute a
major burden for the health care systems. Endocardial
cushion defects are among the most prevalent heart mal-
formations in the general population, and are extremely
frequent (approximately a 100-fold higher prevalence) in
children with Down syndrome. Several genes have been
proposed to be involved in the pathogenesis of these mal-
formations, but no common pathogenic DNA variants have
been identified so far. Here, we focussed on constitutive,
epigenetic alterations of function of selected genes, poten-
tially important for endocardial cushion development. We
used two types of microarrays, dedicated for assessment of
gene promoter methylation and whole genome expression.
First, we compared the gene promoter methylation
profiles between two groups of Down syndrome patients,
with and without heart defects of endocardial cushion-type.
Then, to determine the functional role of the detected
methylation alterations, we assessed the expression of the
genes of interest. We detected significant hypermethylation
of the NRG1 gene promoter region in children with heart
defects. NRG1 is a key factor in maturation of endocardial
cushions. Supplementary gene expression assessment
revealed significantly decreased activity of the ERBB3,
SHC3 and SHC4 genes in children with heart defects. The
above three genes are closely related to the NRG1 gene and
are crucial elements of the NRG/ErbB pathway. The results
of this pilot study show that hypermethylation of the NRG1
gene promoter can reflect the functional genome alteration
contributing to development of congenital heart defects of
endocardial cushion-type.
A. Dobosz: None. A. Grabowska: None. M. Bik-
Multanowski: None.
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How Effective is Genetic Testing for Familial Hyperch-
olesterolaemia Patients in Tayside?
C. Leung, E. Gellatly, J. Berg
Ninewells Hospital and Medical School, University of
Dundee, Dundee, United Kingdom
Background: DNA analysis for Familial
Hypercholesterolaemia (FH), including the LDLR, PCSK9
and ApoE genes, is available to Scottish individuals with
high cholesterol who fulfil Simon Broome criteria. The aim
of mutation identification is to allow more effective man-
agement of the proband, as well as cascade testing and
identification of at risk individuals. The ultimate aim is
early statin treatment of affected individuals with prevention
of cardiovascular morbidity.
Method: 60 index patients with causative LDLR muta-
tions were identified between 2010 and 2018 in NHS
Tayside (Scotland). We used record linkage to assess the
effect of genetic testing on cholesterol levels on probands
and the number of subsequent cascade tests performed on
family members. The main endpoint we used was achieving
a 50% reduction of LDL cholesterol levels, as recom-
mended by the UK National Institute of Clinical Excellence
(NICE).
Results: 49/189 (25.9%) eligible first degree relatives
received cascade testing. Where data was available, 6/22
(27.3%) patients met the 50% reduction target in LDL-C
levels. There was no demonstrable relationship between
cholesterol reduction and attendance at a cardiovascular risk
clinic.
Conclusions: The number of cascade tests following
diagnosis in a proband is low. Even if a causative LDLR
mutation was identified, there was limited impact on the
clinical improvement of cholesterol levels, with only a
minority of patients achieving recommended cholesterol
lowering following diagnosis. A better mechanism for
cascade testing and management of FH is required to gain
the maximum clinical benefit from DNA analysis in
Familial Hypercholesterolaemia.
C. Leung: None. E. Gellatly: None. J. Berg: None.
P05.41.A
Mutation spectrum and polygenic score in German
patients with familial hypercholesterolemia
L. Rieck1, F. Bardey1, T. Grenkowitz1, L. Bertram2,
J. Helmuth3, C. Mischung3, J. Spranger1, T. Bobbert1,
U. Kassner1, I. Demuth1
1Charité Universitätsmedizin Berlin, Berlin, Germany,
2Lübeck Interdisciplinary Platform for Genome Analytics,
Institutes of Neurogenetics and Cardiogenetics, Lübeck,
Germany, 3Department Molecular Diagnostics, Labor
Berlin, Berlin, Germany
Introduction:Autosomal-dominant familial hypercholes-
terolemia (FH) is a genetic disorder characterized by
increased plasma concentrations of LDL-Cholesterol and a
substantially elevated risk for cardiovascular disease.
Mutations in three major genes are known to cause FH: the
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LDL receptor gene (LDLR), the apolipoprotein B gene
(APOB) and the proprotein convertase subtilisin/kexin 9
gene (PCSK9). Our aim is to analyze the mutation spectrum
and to determine a polygenic risk score in a cohort of
hypercholesterolemic patients.
Methods: We screened 336 patients who were clinically
assessed by the Dutch Lipid Clinic Network (DLCN) score
and suspected to have FH for disease causing variants and
genotyped six single nucleotide polymorphisms (SNPs) to
calculate the polygenic risk score for the FH patients and a
control group of 1,946 healthy participants.
Results: We identified an FH causing variant in 117 of
the 336 patients (12 novel variants) from the FH cohort.
Most sequence variants were found in the LDLR gene
(84.9%) out of which 44.4% were of the missense type. The
discriminatory power of the DLCN score distinguished FH
mutation carriers from non-carriers with an AUC = 0.76 (p
< .001) in a receiving operator characteristic (ROC) curve,
similar to the value for native LDL-C (AUC = 0.77 (p <
.001)). Similar to previous studies, the mean polygenic risk
score was significantly higher in FH mutation negative
subjects than in FH mutation positive patients (p < .05) and
healthy controls (p < .001).
Conclusions: This study substantiates the known clinical
and genetic variability of FH for German hypercholester-
olemic patients and examines a possible polygenic
aetiology.
L. Rieck: None. F. Bardey: None. T. Grenkowitz:
None. L. Bertram: None. J. Helmuth: None. C.
Mischung: None. J. Spranger: None. T. Bobbert: None.
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P05.43.A
FLNC gene in Hypertrophic Cardiomyopathy: an effort
to accurate variant classification
E. Cuesta-Llavona, R. Lorca, B. Díaz-Molina, J. Lambert,
B. Alonso, S. Iglesias-Álvarez, J. Reguero, E. Coto, J.
Gómez
Hospital Universitario Central de Asturias, Oviedo,
Spain
Hypertrophic Cardiomyopathy (HCM) is the most common
inherited heart disease. Recent studies have identified the
Filamin C (FLNC) gene as a HCM-associated gene. The
aim of this study is to assign the percentage of HCM cases
which could be relationated with FLNC variants.
We sequenced 924 index cases of HCM for a compre-
hensive cardiovascular gene panel of 194 genes, in an Ion
GeneStudio S5 Sequencer. We identified 365 patients
(39%) with variants in the sarcomeric and FLNC genes.
Among them, 330 (90%) were carriers of sarcomeric
variants, and 35 (10%) harbored rare FLNC variants (either
not described or ≤ 10 cases in gnomAD). Eleven patients
were carriers of both sarcomeric and FLNC variant, thus
their were excluded to the further analysis and variant
classification since their pathogenicity is complex to
measure. In this way, we finally selected 24 carriers of 20
different FLNC variants. Family studies were performed in
16/24 cases. In total, we identified 55 relatives who harbor a
FLNC variant, thirty nine of them have a HCM diagnosis
(71% penetrance). According to the ACMG criteria, and the
performed family studies, seven variants (35%) have been
classified as pathogenic or likely pathogenic, twelve as
variants of unknown significance (60%), and a variant
classified as benign or likely benign (5%). In conclusion, at
least 1.2% of HCM index cases harbor a FLNC likely
pathogenic variant. However, further co-segregation and
functional studies have to be performed in order to
accomplish an accurate variant classification, specially in
VUS variants.
E. Cuesta-Llavona: None. R. Lorca: None. B. Díaz-
Molina: None. J. Lambert: None. B. Alonso: None. S.
Iglesias-Álvarez: None. J. Reguero: None. E. Coto:
None. J. Gómez: None.
P05.44.B
A founder truncating mutation in GDF1 causes
autosomal-recessive right isomerism in multiplex Arab
kindreds.
D. Yagel1,2, Y. Bolkier3,2, O. Barel4, A. Vardi3,2, D.
Mishali3,2, A. Veber1, N. Shalva1, U. Katz3,2, S. Abudi1,2, N.
Kol4, A. Raas-Rothschild5,2, G. Rechavi4,2,6, B. Pode-
Shakked1,7,2, Y. Anikster1,2,6
1Metabolic Disease Unit, Edmond and Lily Safra Chil-
dren’s Hospital, Sheba Medical Center, Ramat Gan, Israel,
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv,
Israel, 3Department of Pediatric Cardiac Intensive Care,
Edmond Safra International Congenital Heart Center,
Edmond and Lily Safra Children’s Hospital, Sheba Medical
Center, Ramat Gan, Israel, 4Sheba Cancer Research
Center, Sheba Medical Center, Ramat Gan, Israel, 5The
Institute for Rare Diseases, The Danek Gertner Institute of
Human Genetics, Sheba Medical Center, Ramat Gan,
Israel, 6The Wohl Institute for Translational Medicine,
Sheba Medical Center, Ramat Gan, Israel, 7Talpiot Medical
Leadership Program, Sheba Medical Center, Ramat Gan,
Israel
The genetic basis of congenital heart malformations asso-
ciated with disruption of left-right (L-R) asymmetry is
broad and heterogenous, with variants in over twenty five
genes implicated thus far. Of these, deleterious mutations in
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the Growth/Differentiation Factor 1 (GDF1) gene have
recently been shown to cause heterotaxy with varied com-
plex heart malformations of left-right patterning, in 23
individuals reported to date, either in monoallelic or bial-
lelic state. We report three unrelated individuals exhibiting
heterotaxy with congenital heart defects, each originating
from consanguineous kindreds of Arab-Muslim descent.
Using Whole exome sequencing, a shared novel homo-
zygous truncating c.608G>A (p.W203*) mutation in the
GDF1 gene, was revealed as the molecular basis of their
disease. Subsequently, targeted sequencing of this variant
showed full segregation with the disease in these families,
with over 15 reportedly affected individuals, enabling
genetic counselling, prenatal diagnosis and planning of
future pregnancies. Our findings further confirm the asso-
ciation of GDF1 variants, heterotaxy and congenital heart
defects of left-right patterning, and expand the previously
described phenotypic spectrum and mutational profile.
Finally, given the high rate of consanguinity and high fre-
quency of the p.W203* mutation in the Arab-Muslim
population residing near the city of Hebron, we suggest
targeted screening for this variant in relevant clinical
circumstances.
D. Yagel: None. Y. Bolkier: None. O. Barel: None. A.
Vardi: None. D. Mishali: None. A. Veber: None. N.
Shalva: None. U. Katz: None. S. Abudi: None. N. Kol:
None. A. Raas-Rothschild: None. G. Rechavi: None. B.
Pode-Shakked: None. Y. Anikster: None.
P05.46.A
Pathogenic variationin the copper binding domain of
lysyl oxidase causes aortic dilation modified by sex and
mechanical forces
K. Tsang1, R. H. Knutsen1, C. J. Billington Jr1, E.
Lindberg1, H. Steenbock2, A. Wardlaw-Pickett1, C. K. E.
Bleck1, J. Brinckmann2, B. A. Kozel1
1National Institutes of Health, Bethesda, MD, United States,
2University of Luebeck, Luebeck, Germany
Mutations in lysyl oxidase (LOX) contribute to familial
thoracic aortic aneurysm. GnomAD reveals variation
throughout LOX, with more variants reported in the region
encoding the N-terminal pro-domain. While ClinVar
showed disease-associated stopgain and frameshift variants
throughout LOX, the majority of pathogenic missense
mutations were identified near the copper binding domain,
within the relatively variant-poor C-terminal catalytic
domain.
We then studied theLoxb2b370.2Clo (c.G854T; p.C285F)
mouse whose mutationfalls within the copper binding
domain. The LoxC285F protein was stably secreted but
exhibited decreased enzymatic activity and altered elastin
crosslinks. Structural analysisby two photon and scanning
electron microscopyrevealed holes in the elastic lamellar
sheets that increased with age and blood pressure. As in
humans, the rate of aortic dilation was higher in males, but
was also amplified by pregnancy. Lox mutants showed
altered transcription of matrisome genes and their aortas
showed increased susceptibility to elastase.
Taken together, these findings suggest that missense
variation surrounding the LOX copper binding domain
increases risk for aortic aneurysm while missense variation
in the region encoding the N-terminal pro-domain appears
largely tolerated. Novel gene-first studies are underway to
test this hypothesis in a large hospital-based cohort. Our
mouse studies confirm that copper binding domain LOX
variants cause disease through the production of a
dysfunctional extracellular matrix that is unusually suscep-
tible to proteolytic damage. In both humans and mice, the
progressive weakening of the connective tissue leads to
worsening aortic disease, modified by sex and blood
pressure.
Funding: NIH HL006244, USA
K. Tsang: None. R.H. Knutsen: None. C.J. Billington
Jr: None. E. Lindberg: None. H. Steenbock: None. A.
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Rare variants in HCN4 identified in the general
population are associated with complete atrioventricular
(AV) block, 1. degree AV block and bundle branch
block, results from 50.000 exomes
J. S. Jensen1,2, O. B. Vad1,2, C. Paludan-Müller2,1, P. R.
Lundegaard1, J. H. Svendsen2,3, S. Haunsø2,3, H.
Bundgaard2,3, M. S. Olesen1,2
1Department of Biomedical Sciences, Faculty of Health and
Medical Sciences, University of Copenhagen, Copenhagen,
Denmark, 2Laboratory for Molecular Cardiology, Depart-
ment of Cardiology, Centre for Cardiac, Vascular,
Pulmonary and Infectious Diseases, Rigshospitalet, Copen-
hagen University Hospital, Copenhagen, Denmark,
3Department of Clinical Medicine, Faculty of Health and
Medical Sciences, University of Copenhagen, Copenhagen,
Denmark
Introduction: Cardiac conduction disorders cover disorders
such as atrioventricular (AV) block and bundle branch
block (BBB). Genome-wide association studies have iden-
tified more than 100 genetic loci for atrial fibrillation,
including HCN4 loci associated with duration of the PR
interval, a proxy for AV dysfunction. Recent candidate
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studies suggest an association between HCN4 variants and
AV-block. We seek to determine the contribution of rare
genetic variants in HCN4 to complete AV-block, 1. degree
AV-block and BBB in the general population.
Materials/methods: The UK Biobank is a population-
based study of 500 000 individuals including a subset with
genome-wide genotyping and exome sequencing (n =
45,596). In this case-control study, we included persons of
genetically determined white-European ancestry and ana-
lyzed their exome data. Analyses were performed using a
logistic mixed-effects model. A gene-based burden analysis
and single variant test were performed to examine the
relationship between HCN4 variants and complete AV-
block, 1. degree AV-block and BBB in the general
population.
Results: The study included 43,371 persons. In an
analysis of the HCN4 genes a significant association
between rare variants (MAF < 0.01) in HCN4 gene was
found (complete AV-block, P=2.5 x 10−5, 1. degree AV-
block, P=1.3 x 10−3 and BBB, P=0.01). The association to
complete AV block was mostly driven by the variants
Ser835Phe (P=2.7e−3), Glu153Gly (P=3.5e−3) and
Arg378Cys (P=6.3e−3).
Conclusions: Rare HCN4 variants contribute to the risk
of complete AV-block, 1. degree AV-block and BBB in the
general population. These HCN4 variants seem to confer a
substantial penetrance. Clinical screening for some of these
variants seems appropriate.
J.S. Jensen: None. O.B. Vad: None. C. Paludan-
Müller: None. P.R. Lundegaard: None. J.H. Svendsen:
None. S. Haunsø: None. H. Bundgaard: None.
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MicroRNAs as biomarkers of heart failure
A. M. Peterlin1, K. Pocivavsek2, D. Petrovic1, B. Peterlin3
1Institute of Histology and Embriology, Faculty of Medi-
cine, University of Ljubljana, Ljubljana, Slovenia, 2Depart-
ment of Cardiovascular Surgery, University Medical Centre
Ljubljana, Ljubljana, Slovenia, 3Clinical Institute of
Genomic Medicine, University Medical Centre Ljubljana,
Ljubljana, Slovenia
Introduction: MicroRNAs are highly investigated for their
role in the pathogenesis of cardiovascular diseases. Never-
theless, evidence for clinical implementation is still lacking.
In our systematic review, we evaluated the potential of
microRNA as pathophysiological and diagnostic bio-
markers of heart failure.
Materials and methods: The literature search was
conducted in the PubMed database up to August 2019.
Newcastle-Ottawa quality assessment scale was used to
assess the quality of included research papers. Using
miRTarBase, we identified all known gene targets for
selected miRNAs that were differentially expressed in
research papers included in the systematic review. We then
comprised the list of all target genes and performed gene set
enrichment analysis using Enrichr. Results from KEGG,
BioPlanet, and Panther databases were analyzed.
Results: We identified 72 differentially expressed micro-
RNA molecules among groups of heart failure patients and
control groups. There was no substantial overlap of
differentially expressed miRNAs among different studies,
only five miRNAs (miR-1228, miR-122, miR-423-5p, miR-
142-3p, and exosomal miR-92b-5p) were differentially
expressed in more than one included study. Gene set
enrichment analysis, based on the gene targets of micro-
RNAs presented in included studies, showed that gene
targets of differentially expressed miRNAs were enriched in
MAPK signaling pathway, TGFβ signaling pathway, PI3K-
Akt signaling pathway, IL-2 signaling pathway, apoptosis
pathway, p53 activity regulation, angiogenesis pathway,
and PDGF signaling pathway.
Conclusions: Results of our systematic review show that
currently, there is insufficient support for the use of any of
the presented miRNAs as a pathophysiological or prog-
nostic biomarker in the clinical setting.
A.M. Peterlin: None. K. Pocivavsek: None. D.
Petrovic: None. B. Peterlin: None.
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Germline variants in transcription factor HEY2 func-
tional domains lead to congenital heart defects and
thoracic aortic aneurysms
E. S. van Walree1,2, G. Dombrowsky3, I. E. Jansen2,
M. Umićević Mirkov2, R. Zwart4, A. Ilgun4, D. Guo5, S. B.
Clur6, A. S. Amin7, J. E. Savage2, A. C. van der Wal8,
Q. Waisfisz9, A. Maugeri9, A. Wilsdon10, F. A. Bu’lock11, M.
E. Hurles12, S. Dittrich13, F. Berger14, E. Audain Martinez3,
M. Hitz3, D. M. Milewicz5, D. Posthuma2, H. Meijers-
Heijboer1, A. V. Postma1,4, I. B. Mathijssen1
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de Boelelaan 1085, Amsterdam, Netherlands, 3Department
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Universitätsklinikum Schleswig-Holstein Kiel, Kiel, Ger-
many, 4Department of Medical Biology, Amsterdam UMC,
University of Amsterdam, Meibergdreef 9, Amsterdam,
Netherlands, 5Department of Internal Medicine, McGovern
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6Department of Pediatric Cardiology, Emma Children’s
Hospital, Amsterdam UMC, University of Amsterdam,
Meibergdreef 9, Amsterdam, Netherlands, 7Department of
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University of Amsterdam, Meibergdreef 9, Amsterdam,
Netherlands, 8Department of Pathology, Amsterdam UMC,
University of Amsterdam, Meibergdreef 9, Amsterdam,
Netherlands, 9Department of Clinical Genetics, Amsterdam
UMC, Vrije Universiteit Medisch Centrum, de Boelelaan
1118, Amsterdam, Netherlands, 10School of Life Sciences,
University of Nottingham, Queen’s Medical Centre, Not-
tingham, United Kingdom, 11East Midlands Congenital
Heart Centre and University of Leicester, Glenfield
Hospital, Leicester, United Kingdom, 12Wellcome Trust
Sanger Institute, Wellcome Trust Genome Campus, Hinx-
ton, United Kingdom, 13Department of Pediatric Cardiol-
ogy, University of Erlangen-Nürnberg, Loschgestrasse 15,
91054, Erlangen, Germany, 14German Heart Center Berlin,
Department of Congenital Heart Disease, Pediatric Cardi-
ology, Berlin, Germany
Background: Affecting approximately 1% of all newborns,
cardiovascular defects (CVDs) are the most common con-
genital anomaly worldwide. Here, we present a large family
from a genetically isolated population presenting with
CVDs, including congenital heart defects (CHD) and
familial thoracic aortic aneurysms (FTAA), caused by a
loss-of-function mutation in the Notch target gene HEY2,
which hasn’t been associated with hereditary CVDs in
humans previously.
Methods: The index patient, who has severe CVD,
underwent trio WES. The identified variant was subse-
quently screened in 30 members of this patient’s family,
which has a high prevalence of CVDs. Additionally, 3011
unrelated cases and 4940 controls from two datasets (one
with CHD and one with FTAA) were screened for rare risk
variants in HEY2. To investigate how the various identified
variants influence gene function, the regulatory activity of
mutated and wildtype HEY2 on a target gene was measured
with luciferase assays and qPCR.
Results: A homozygous frameshift variant (p.G108*) in
HEY2 was identified in three individuals with life-
threatening CVDs. Twenty family members were found to
be heterozygous for this variant, of whom 80% had CVD.
Two additional CVD datasets show enrichment for rare,
likely deleterious variants in HEY2 after meta-analysis.
Lastly, we demonstrate that these variants induce failure of
repression of HEY2 target genes.
Conclusions: We find that rare HEY2 variants predispose
to a broad spectrum of CVDs and advise clinicians to
consider HEY2 as a causative gene in unsolved CVD
patients. Identifying a potentially deleterious variant in
HEY2 warrants clinical follow-up.
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The Unknown Genetic Architecture of Severe Hyperch-
olesterolemia in Finland
N. Junna1, S. Ruotsalainen1, S. Ripatti1,2, E. Widén1
1FIMM, Helsinki, Finland, 2Department of Public Health,
Clinicum, Faculty of Medicine, University of Helsinki,
Helsinki, Finland
While severe hypercholesterolemia is a significant risk
factor for ischemic heart disease (IHD), Finnish patients
remain inadequately identified and only a part of their
mutation load is known. To elucidate the genetic archi-
tecture of severe hypercholesterolemia in Finland, we have
screened participants of the GeneRISK-study (n = 7 342)
originating from South-eastern Finland for novel mutations
and utilized the FinnGen-cohort (n = 110 654) to assess the
mutation prevalence, impact, and nationwide distribution.
Five percent (n = 366) of GeneRISK-participants had
severe hypercholesterolemia (LDL ≥ 5 mmol/l) and exome-
sequencing revealed 3 carriers of previously known
mutations (LDLR R594Q, LDLR P309Kfs and APOB
R3527Q, which has not previously been reported in
Finland). We also identified a novel, likely pathogenic
mutation, LDLR R574L. We assessed the geographical
distribution of the mutation and the cardiometabolic status
of mutation carriers in the nationwide FinnGen-cohort and
compared them with 5 previously described
hypercholesterolemia-mutations (LDLR R594Q, LDLR
G844D, LDLR L401H, LDLR D579N, LDLR C352W).
The novel LDLR R574L-mutation was unevenly distributed
in the country with a high prevalence among individuals
born in the Southeast (the ceded Karjala region) and
prevalence of cardiovascular disease among mutation
carriers was elevated (22% had been diagnosed with IHD
and 14% with stroke). The data further showed that less
than half of mutation carriers (both the novel and previously
known mutations) were on statin therapy.
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Our data show that the genetic spectrum of severe
hypercholesterolemia in Finland is more diverse than
previously anticipated, and further highlight the urgent
need for better recognition and treatment of this disease.
N. Junna: None. S. Ruotsalainen: None. S. Ripatti:
None. E. Widén: None.
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Mendelian randomisation identifies pleiotropy between
uric acid and cardiovascular diseases
E. M. Wigmore1, O. Chazara1, . FinnGen Consortium2, K.
Carss1, A. Matakidou1, C. Haefliger1
1AstraZeneca, Cambridge, United Kingdom, 2University of
Helsinki, Helsinki, Finland
Elevated levels of uric acid (UA), hyperuricaemia, leads to
the formation of urate crystals that cause gout. Hyperur-
icaemia has also been linked to cardiovascular and meta-
bolic diseases but, unlike gout, causality has not been
ascertained. Here we utilised biomarker data from the UK
Biobank (UKB, n = ~500,000) and health outcome data
from a Finnish biobank, FinnGen (n = ~135,000) to explore
the causal relationship between biomarkers and disease.
Genome-wide association studies (GWAS) of 48 available
biomarkers were conducted in UKB and FINEMAP was
applied to ascertain putative causal variants. We assessed
the genetic correlation of these biomarkers with 1,485 dis-
ease endpoints in FinnGen using LD score regression.
Those with a significant correlation following FDR cor-
rection were assessed for causal associations using Men-
delian randomisation (MR). GWAS of UA corrected for
allopurinol treatment (a UA-lowering medication) was
completed on 389,114 individuals and FINEMAP identified
320 putative causal signals. Significant genetic correlations
were found with multiple diseases (n = 183) including
hypertensive diseases (rg=0.25, PFDR=6.2x10−38), type 2
diabetes (rg=0.29, PFDR=6.2x10−38), cardiovascular dis-
ease (rg=0.23, PFDR=9.6x10−29) and gout (rg=0.70,
PFDR=8.3x10−21). Results from MR analyses confirmed the
known causal association of UA with gout (IVW esti-
mate=1.6, PFDR=7.8x10−62) as well as with poly-
arthropathies (IVW estimate=0.37, PFDR=1.9x10−12) but
not with other diseases. A significant causal association was
found with hypertension (IVW estimate=0.20,
PFDR=0.0015) but horizontal pleiotropy was also detected
(MR-Egger intercept P= 0.0069). Our finding suggests that
although MR does not support the direct association
between UA and cardiovascular disease, we observe
pleiotropic effects which could support therapies targeting
shared pathways.
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Pathogenic variant in the MYBPC3 gene with founding
effect in Galician population
A. Blanco-Verea1,2, R. Cruz3,2, M. Álvarez-Barredo4,1,5, B.
López-Abel6,1, R. Gil1,2, E. Ramos-Luis1,2, L. Martínez-
Campelo1,2, I. Quintela7,2, J. González-Juanatey4,5, Á.
Carracedo8,2,3,7, M. Brion1,2,5
1Xenética Cardiovascular, Instituto de Investigación Sani-
taria de Santiago, Santiago de Compostela, Spain, 2Grupo
de Medicina Xenómica, Universidade de Santiago de
Compostela, Santiago de Compostela, Spain, 3CIBER
Enfermedades Raras, Santiago de Compostela, Spain,
4Complejo Hospitalario Universitario de Santiago, Servicio
de Cardiología, Santiago de Compostela, Spain, 5CIBER
Cardiovascular, Santiago de Compostela, Spain, 6Com-
plejo Hospitalario Universitario de Santiago, Servicio de
Pediatría, Santiago de Compostela, Spain, 7Centro Nacio-
nal de Genotipado (CEGEN-PRB3-ISCIII), Santiago de
Compostela, Spain, 8Fundación Pública Galega de Medi-
cina Xenómica, Santiago de Compostela, Spain
Introduction: The Myosin Binding Protein C3 gene
(MYBPC3) is one of the main genes in which mutations
involved in familial hypertrophic cardiomyopathy (HCM)
appear. One of these pathogenic variants is the deletion
rs397515926 that appears in the gnome AD database in
only one individual of Latino origin (Allele Fre-
quency=0.000004913). However, we have found 18 unre-
lated patients with HCM from Galicia with this variant,
which has led us to think about a possible founding effect of
this variant in the Galician population.
Materials and Methods: Trying to unmask a possible
founding effect or a distant family relationship between
patients, we made a genotyping with the Applied
BiosystemsTM AxiomTM Spain Biobank Array in 6 of these
patients and in a cohort of healthy Galician and Spanish
population. Principal components analysis and discriminant
analysis of principal components were performed in Plink
and adegenet package of R software.
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Results: discriminant analysis of principal components
taking into account rare variants of the array and comparing
our patients with the general Spanish and Galician
population clearly differentiate our patients with respect to
the rest.
Conclusions: Considering the results of the analysis of
the genotypes between our cases and the general popula-
tion, the practically null bibliographic mention and very
scarce presence in databases of this variant, we could
assume a possible common origin for the presence of this
variant in the Galician population, highlighting a possible
founding effect. Founding: Instituto de Salud Carlos III and
Fondo Europeo de Desarrollo Regional (PI16/00903, CB16/
11/00226, CB03/07/0088).
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The potential diagnostic value of circulating serum-
derived miRNAs in ischemic heart disease (IHD) as a
complication of type 2 diabetes mellitus (T2DM).
A. Bielska1, W. Bauer1,2, I. Sidorkiewicz1, A. Szalkowska1,
J. Raczkowska1, D. Ostrowski1, P. Prokopczuk3, S.
Dobrzycki3, M. Niemira1, A. Kretowski1,4
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Introduction: Currently, IHD is the most common cause of
death in patients with diabetes and it develops much earlier
before clinical diagnosis. Therefore, there is an urgent need
for the detection of sensitive and specific early biomarkers
to predict the risk of the IHD development. We postulate
that non-coding miRNAs may have higher diagnostic value
for early detection of IHD than inflammatory mediators like
chemokine CXCL12 and macrophage migration-inhibitory
factor (MIF).
Materials and Methods: We obtained serum samples
from 43 T2DM patients (24 with IHD and 19 without IHD).
The levels of 798 miRNAs were analysed using NanoString
nCounter Technology. Additionally, we predicted the key
miRNA regulatory network and miRNAs targets and
pathways that may be critical in IHD development using
the Ingenuity Pathway Analysis software. The
concentration of MIF and CXCL12 was estimated by
enzyme-linked immunosorbent assay. Receiver operating
characteristic analysis was used to assess the diagnostic
value of each miRNA.
Results: Our data showed 9 miRNAs (miRNA-1224-5p,
miRNA-1303, miRNA-3147, miRNA-4455, miRNA-498,
miRNA-548b-3p, miRNA-548d-3p, miRNA-615-3p,
miRNA-651-5p) significantly upregulated in T2DM IHD
group compared to T2DM noIHD (FC>1.4 and FDR <
0.05). Furthermore, all miRNAs showed high diagnostic
value (AUC>0.85). Targeted genes were identified in
canonical pathways involved in the pathology of the
cardiovascular system. No statistical differences were
observed in the concentration of MIF and CXCL12 between
tested groups.
Conclusions: Our findings suggest that circulating
miRNAs might have a pivotal role in the development of
IHD in T2DM patients and may be used as non-invasively
biomarkers for early diagnosis.
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Derivation and validation of a polygenic risk score
associated with ischemic heart failure in multiethnic
cohorts
I. Paranjpe1, J. De Freitas1, N. Tsao2, R. Judy2, K.
Chaudhary3, I. Forrest4, CBIPM Genomics Team,
Regeneron Genomics Team, S. Coca5, J. Narula6, B.
Glicksberg1, R. Do3,4, S. Damrauer2, G. Nadkarni1,3,7
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Icahn School of Medicine at Mount Sinai, New York, NY,
United States, 4Department of Genetics and Genomic
Sciences, Icahn School of Medicine at Mount Sinai, New
York, NY, United States, 5Division of Nephrology, Depart-
ment of Medicine, Icahn School of Medicine at Mount Sinai,
New York, NY, United States, 6Division of Cardiology,
Department of Medicine, Icahn School of Medicine at
Mount Sinai, New York, NY, United States, 7Renal
Program, James J Peters VA Medical Center at Bronx,
New York, NY, United States
Introduction: Mortality from heart failure (HF) secondary
to coronary artery disease (CAD) is 50% and risk-
stratification approaches are limited. We aimed to stratify
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risk of progression to HF in CAD patients by developing a
polygenic risk score (PRS).
Methods: Using summary statistics from a recent GWAS
for HF secondary to CAD (ischemic HF), we computed risk
scores by varying the rho parameter in LDPred and varying
the p-value threshold and r2. We selected the PRS that
maximized the association with ischemic HF (PRSiHF) from
the multiethnic Mount Sinai BioMe Biobank(N=6276). We
validated the association in Penn Medicine BioBank
(PMBB; N=6674). We performed association analysis
using logistic regression adjusted for age, sex, smoking
history, hypertension, BMI, type 2 diabetes, and ten genetic
principal components.
Results: In BioMe, one standard deviation (SD) increase
in PRSiHF was significantly associated with HF (OR=1.1;
p=0.001; 2530 cases, 3746 controls HF risk increased
monotonically with PRSiHF in a subset of individuals with
CAD but no evidence of obstructive CAD on coronary
catheterization (N=4775). In PMBB, PRSiHF was asso-
ciated with ischemic HF in European Americans (adjusted
OR=1.07; p=0.02; 2692 cases, 2472 controls) but not
African Africans (adjusted OR=0.94; p=0.3; 921 cases,
589 controls).
Conclusions: We derived and validated a PRS for
ischemic HF in two multiethnic cohorts and demonstrated
association with and without obstructive CAD. PRSiHF
replicated in patients of European ancestry, but not in
African ancestry. Although studies on clinical utility and in
more diverse populations are needed, our results suggest
application in early risk stratification.
I. Paranjpe: None. J. De Freitas: None. N. Tsao: None.
R. Judy: None. K. Chaudhary: None. I. Forrest: None. S.
Coca: None. J. Narula: None. B. Glicksberg: None. R.
Do: None. S. Damrauer: None. G. Nadkarni: None.
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Identifying Long QT syndrome (LQTS) patients in
primary care, an approach for rare diseases.
W. R. H. Evans1, S. F. Weng1, R. K. Akyea1, A. D. Simms2,
J. Kai1, N. Qureshi1
1University of Nottingham, Nottingham, United Kingdom,
2Department of Cardiology, Leeds Teaching Hospital NHS
Trust, Leeds, United Kingdom
Introduction: LQTS is a rare (~1 in 2000 births) inherited
cardiac arrhythmia that predisposes patients to syncope and
sudden cardiac death. Identification and treatment can
substantially reduce this risk. We aimed to identify the
clinical features that precede the diagnosis of LQTS in
primary care and use these to develop a predictive model.
Methods:1495 patients diagnosed with LQTS and 7475
propensity-score matched controls were identified in a
database of primary care electronic records (CPRD). A
range of clinical features that occurred at greater frequency
in cases than control (p <0.05) before diagnosis were
identified and incorporated into a multivariable logistic
regression model.
Results:18 clinical features were incorporated into the
final model, including: epilepsy (1.70 (1.12, 2.56)),
palpitations (2.22 (1.80, 2.74)), collapse (1.636 (1.32,
2.03), mitral valve disease (2.64 (1.41, 4.91)), atrial
fibrillation (1.91 (1.41, 2.60)) and IBS (1.78 (1.41, 2.26))
(OR (95% CI)). The discriminative accuracy of the model
assessed by area under the curve (AUC) was 0.74, (95% CI
0.73 to 0.75), with comparable performance in two more
tightly phenotyped subgroups: LQTS diagnosis <45 years
and those commenced on a betablocker &/or fitted with an
Implantable Cardioverter Defibrillator (ICD) post-diagnosis.
Conclusion: This study demonstrates that it is possible to
develop a predictive model for LQTS that performs with
similar accuracy to other widely adopted cardiovascular risk
models. Furthermore, it shows the potential of primary care
records to phenotypically identify patients that are at an
increased risk of having a rare disease.
W.R.H. Evans: D. Speakers Bureau/Honoraria (speakers
bureau, symposia, and expert witness); Modest; Intrabio
inc. F. Consultant/Advisory Board; Modest; Mendelian.co.
S.F. Weng: D. Speakers Bureau/Honoraria (speakers
bureau, symposia, and expert witness); Modest; Amgen.
R.K. Akyea: None. A.D. Simms: None. J. Kai: None. N.
Qureshi: D. Speakers Bureau/Honoraria (speakers bureau,
symposia, and expert witness); Modest; Amgen.
P05.60.C
Functional investigation of possible pathogenic EPHB4
variants associated with lymphatic related fetal hydrops
and hereditary haemorrhagic telangiectasia
E. Sackey, S. Martin-Almedina, K. Ogmen, D. Grigoriadis,
S. Mansour, P. Ostergaard
St. George’s University, London, United Kingdom
The use of next generation sequencing (NGS) technologies
has increased the capacity of rare and novel variant detec-
tion. However, this brings challenges to confirm patho-
genicity of the identified variants and evaluate them
functionally, both needed for precise clinical diagnostics.
This study investigates nine novel possible pathogenic
nonsynonymous variants in the EPHB4 (Ephrin Receptor
B4) gene. EPHB4 mutations have been associated with
lymphatic related fetal hydrops (LRFH) and hereditary
haemorrhagic telangiectasia (HHT) both with autosomal
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dominant inheritance. Non-immune fetal hydrops is char-
acterised by fluid accumulation in at least two extravascular
fetal compartments and about 15% of the cases result from a
lymphatic abnormality. HHT presents commonly with
arteriovenous malformations (AVMs) in the liver and lung,
in connection with cutaneous and mucosal telangiectasias.
Functional analysis including immunoprecipitation, western
blotting, and immunofluorescence assays were performed
on nine novel variants on EPBH4 to investigate their
pathogenicity. This study demonstrates the pathogenic
effect of eight variants out of nine. Most of the LRFH-
associated EPHB4 variants presented similar protein
expression levels compared to the wildtype protein but
reduced tyrosine kinase activity while HHT-associated
EPHB4 variants showed a reduction or total absence of
protein expression. Based on these results, we suggest there
could be two distinct EPHB4-associated disease phenotypes
distinguished by two distinctive molecular mechanisms, but
further research is necessary to elucidate this.
E. Sackey: None. S. Martin-Almedina: None. K.
Ogmen: None. D. Grigoriadis: None. S. Mansour: None.
P. Ostergaard: None.
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Identifying metabolomic fingerprints of microRNAs in
cardiovascular disorders
R. Mustafa1, M. Mens2, R. Pinto1, I. Karaman1, G.
Roshchupkin3,4, J. Huang1, P. Elliott1, M. Evangelou5, A.
Dehghan1, M. Ghanbari2
1Department of Epidemiology and Biostatistics, Imperial
College London, London, United Kingdom, 2Department of
Epidemiology, Erasmus Medical Center, Rotterdam,
Netherlands, 3Department of Radiology and Nuclear
Medicine, Erasmus Medical Center, Rotterdam,
Netherlands, 4Department of Medical Informatics, Erasmus
Medical Center, Rotterdam, Netherlands, 5Department
of Mathematics, Imperial College London, London,
United Kingdom
Introduction: microRNAs (miRNAs) are small non-coding
RNAs that regulate gene expression. Despite an increasing
evidence that supports miRNAs as potential biomarkers in
cardiovascular disorders, the underlying mechanisms
remain to be elucidated. We aimed to identify metabolites
that mediate the effect of miRNAs on cardiovascular
disorders.
Methods: We performed two steps of two-sample
Mendelian Randomization (MR) to study the causal
association between miRNAs and metabolites, and between
the metabolites and cardiovascular disorders. We conducted
genome-wide association studies (GWAS) on miRNA
expression data (N=1,687) in the Rotterdam Study to
identify genetic instruments for miRNAs. MR was
performed in a hypothesis-free manner between 591
miRNAs and 886 metabolites measured by the Metabolon
platform. The association of the genetic instruments with
metabolites were examined in the Airwave Study
(N=1,942). We further performed MR to investigate the
causal role of identified metabolites on cardiovascular
disorders using publicly available GWAS summary results.
Results: Our analysis indicated causal associations
between 16 miRNAs and 21 metabolites after multiple
testing correction. Among the identified metabolites,
nominally significant associations were found between
androsterone sulfate, cysteine sulfinic acid, and N-
palmitoylglycine with stroke, and 3-hydroxy-5-
cholestenoic acid with coronary artery disease. Taken
together, we were able to identify metabolites that might
link miR-1273h-5p, miR-3937, and miR-4753-5p with
stroke, and miR-181a-2-3p with coronary artery disease.
Conclusions: Our study has added insight into under-
standing the role of metabolites in the link between
miRNAs and cardiovascular disorders. This approach could
offer a way for finding candidate biomarkers and therapeu-
tic targets in cardiovascular disorders.
R. Mustafa: None. M. Mens: None. R. Pinto: None. I.
Karaman: None. G. Roshchupkin: None. J. Huang:
None. P. Elliott: None. M. Evangelou: None. A.
Dehghan: None. M. Ghanbari: None.
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The detection of mosaic mutationsin hereditary aortic
disease through next-generation sequencing
Z. G. Yan, H. Yang, Y. H. Zhang, Z. Zhou
State Key Laboratory of Cardiovascular Disease, Beijing
Key Laboratory for Molecular Diagnostics of Cardiovas-
cular Diseases, Diagnostic Laboratory Service, Fuwai
Hospital, National Center for Cardiovascular Diseases,
Chinese Academy of Medical Sciences, Beijing, China
Background: The mosaic carriers have been clinically
normal or had only minor manifestations when the pro-
portion of mutated cells is low, which makes it difficult to
be detected. However, if the mutations were transmitted
from asymptomatic carriers to their children, it will cause
unexpected occurrence of diseases. So genetic tests are
often required.
Methods: We choosed 563 patients with suspected
marfan syndrome (MFS) or thoracic aortic aneurysm/
dissection, who had been detected by Panel. Among them,
we selected 56 patients who carried likely pathogenic
(pathogenic) mutations and were not de novo, their parents
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who harbored the same mutation were clinically normal.
For these Trio families, we used the Life PGM TM DX
platform to perform deep sequencing of single amplicon
(approximately 5000×) on DNA samples extracted from
whole blood.
Results: We detected two mosaic mutations in these Trio
families. The first patient AD700-1 who had typical MFS
features carried the mutation FBN1, C1305F. After deep
sequencing,23% mutated alleles were detected in healthy
father who harbored the same mutation. The second
mutation FBN1, c.2167+1G>A was identified in patient
AD1833, who was suspected to be MFS. The mutation was
also carried by healthy father, who was found to carry 17%
of the mutant allele through deep sequencing.
Conclusions:Mosaic mutations could be a more common
phenomenon in aortic diseases than has been realized so far.
Therefore, whenever children are identified with harmful
mutations, the parents who lack obvious phenotypic
characteristics should be detected by genetic testing, which
will provide more accurate guidance for genetic counseling.
Z.G. Yan: None. H. Yang: None. Y.H. Zhang: None. Z.
Zhou: None.
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Familial aortic aneurysm syndrome caused by a +3
variant at a donor splice site of MYH11.
B. Chesneau1,2, A. Plancke1, G. Rolland1, B. Marcheix3, Y.
Dulac2, T. Edouard2, M. Aubert-Mucca2,4, S. Julia4, M.
Langeois2,4, V. Gaston4, P. Khau Van Kien1
1Unité de génétique médicale et cytogénétique, Hôpital
Carémeau, CHU de Nîmes, Nîmes, France, 2Centre de
Référence du syndrome de Marfan et des syndromes
apparentés, Hôpital des Enfants, CHU de Toulouse,
Toulouse, France, 3Département de chirurgie cardiaque,
Hôpital Universitaire de Rangueil, Toulouse, France, 4Ser-
vice de génétique médicale, Hôpital Universitaire de
Purpan, Toulouse, France
Pathogenic variants in the myosin smooth muscle heavy
chain 11 (MYH11) are associated with familial aortic
aneurysm (FAA) and patent ductus arteriosus (PDA) syn-
drome. We report a family with two siblings who presented
with type A aortic dissections. The sister made an aortic
dissection at 45 years-old. The brother made an aortic dis-
section at 22 years-old treated with an aortic graft proce-
dure, at 46 years-old he had revision surgery because of
pseudoaneurysms complications. His daughter was diag-
nosed with a patent ductus arteriosus. Their father suddenly
died at 28 years-old. Molecular analysis of a panel of 15
aortic aneurysm genes in the brother revealed only the
variant c.4599+3A>C at the 5’ donor splice site (5’ss) of
the exon 33 of MYH11 (NM_00104114.1) with a potential
splicing impact. This variant was also present in the affected
sister. It was absent from GnomAD and internal variant
database (>1000 patients) and never reported in the litera-
ture. Interestingly, a single-nucleotide polymorphism is
described at this position: c.4599+3A>G (rs143288748).
Interpretation of variations at the position +3 of the 5’ss is
difficult because data of the literature are conflicting with
variations reported to induce aberrant splicing in some cases
but not in others. We performed transcript analysis with
RNA extracted from an aortic biopsy during the brother’s
second intervention. RT PCR revealed a skipping of the
exon 33 of MYH11 predicting a truncated myosin tail and a
dominant negative effect. This report confirms genotype-
phenotype correlations for MYH11 and FAA/PDA.
B. Chesneau: None. A. Plancke: None. G. Rolland:
None. B. Marcheix: None. Y. Dulac: None. T. Edouard:
None. M. Aubert-Mucca: None. S. Julia: None. M.
Langeois: None. V. Gaston: None. P. Khau Van
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A founder pathogenic variant in MYH7 causing hyper-
trophic cardiomyopathy in Catalonia
P. Fernández-Álvarez1, M. Codina1, J. Limeres2, C. Serra-
Juhé3, M. Masas Castro1, A. Cordero Lopez1, E. García-
Arumí1,4, E. Tizzano1,4
1Department of Clinical and Molecular Genetics and Medicine
Genetics Group, VHIR, University Hospital Vall d’Hebron,
Barcelona, Spain, 2Department of Cardiology, Hospital
Universitari Vall d’Hebron, Barcelona, Spain, 3Department
of Genetics, Hospital de la Santa Creu i Sant Pau, Barcelona,
Spain, 4CIBERER, Centro de Investigación Biomédica en Red
de Enfermedades Raras, ISCIII, Madrid, Spain
Pathogenic variants in MYH7 are the second most common
cause of inherited hypertrophic cardiomiopathy (HCM). 262
unrelated HCM probands were screened using the Illumina
TruSightCardio kit. Twenty-nine patients were heterozygous
for MYH7 pathogenic variants, 6 (21%) of them had the same
variant c.2674C>A p.(Gln892Lys). This variant has been pre-
viously described as a VUS in a HCM patient which harbored
another pathogenic variant in MYH7 and in ClinVar, and is
absent in GnomAD. In all our six patients p.(Gln892Lys) was
the only probably pathogenic variant found. Patients (4 males/2
females) were of Catalan origin and had been diagnosed of
HCM around 30 years-old. Familial sudden death before the
fifth decade of life were reported. We extended the genetic and
cardiologic study to 20 relatives of the probands. Twelve were
carriers, 9 of them symptomatic and p.(Gln892Lys) co-
segregated with the HCM in all the families. We studied the
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possibility of a founder effect by haplotype analysis using the
SNP data from the TruSightCardio kit. We used 14 SNPs,
flanking an area of 49,35 kb before MYH6 and after MYH7. A
common haplotype with a calculated haplotype frequency in
Iberia population of 0.0187 was shared in the 6 patients and
was not found in our remaining 256 patients with HCM. Our
results indicate a possible founder effect of this MYH7 patho-
genic variant in HCM patients of Catalan origin.









rs8006357 23853629 T C T C T C T C C C T C
rs178640 23855569 A G A G G G A G G G A G 1,94
rs2071634 23855849 C T C T C T C T T T C T 0,28
rs365990 23861811 A A G A A A A A A A A A 5,962
rs61731179 23869993 G A G A G A G A G A G A 8,182
rs434273 23872666 C T C T C T T T C T C T 2,673
rs2331979 23882855 A A A A A A A A A A A A 10,189
rs2277475 23888665 A A T A A A A A T A A A 5,81
rs7157716 23892888 A A G A A A A A G A A A 4,223
p.
(Gln892Lys)
23893983 G T G T G T G T G T G T 1,095
rs2231126 23898994 G G A G G G G G G G G G 0,066
rs735712 23899060 G G G G G G G G G G G G 0,066
rs2069542 23900794 G G A G G G G G A G G G 1,734
rs2069540 23902753 G A A A G A A A A A G A 1,959
rs3729992 23902974 C C C C C C C C A C C C 0,221
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Biallelic variants in MYL3 cause autosomal recessive
cardiomyopathy
D. P. S. Osborn1, L. Emrahi2, M. T. Tabrizi3, M. Yazdchi3,
N. Mazaheri4, A. Mitchell5, C. Hesse6, H. Goullée7, D.
Burkardt5, N. Laing7, A. Y. B. Wan1, H. Galehdari4, R.
Maroofian1, G. Shariati4, H. Tajsharghi8, Y. Jamshidi1
1Genetics Centre, London, United Kingdom, 2Tarbiat
Modares University, Tehran, Iran, Islamic Republic of,
3Tabriz University of Medical Sciences, Tabriz, Iran,
Islamic Republic of, 4Shahid Chamran University of Ahvaz,
Ahvaz, Iran, Islamic Republic of, 5Case Western Reserve
University, Cleveland, OH, United States, 6University of
Gothenburg, Gothenburg, Sweden, 7The University
of Western Australia and the Harry Perkins Institute of
Medical Research, Nedlands, Australia, 8University of
Skovde, Skovde, Sweden
MYL3 encodes the slow-twitch specific myosin essential
light chain (ELC), and pathogenic variants in this gene are a
rare cause of hypertrophic cardiomyopathy. The majority of
cases reported in the literature involve MYL3 missense
variants transmitted in an autosomal dominant mode of
inheritance. Here, through exome sequencing of four
unrelated consanguineous families we identify biallelic
MYL3 sequence variants. Affected individuals present with
hypertrophic or dilated cardiomyopathy of variable severity
from early- to late-onset of cardiomyopathy, and sudden
cardiac death in 10 individuals. We report homozygous and
compound heterozygous missense variants p.Ala57Asp, p.
Met173Lys and p.Glu177Gly, a novel homozygous trans-
lational stop codon variant p.Glu36Ter, and a homozygous
splice variant c.482-1G>A in MYL3. G0 zebrafish larvae
with CRISPR/Cas9 gene disruption or transient knockdown
of the major ELC orthologue in zebrafish, cmlc1, display
significantly larger ventricular chamber volume and com-
promised cardiac function, which cannot be rescued by re-
introduction of human mutant RNA. Our genetic and
functional data expand the mutational and phenotypic
spectrum of MYL3 variants, identifying for the first time a
homozygous loss of function variant, and highlighting the
role of MYL3 in recessive hypertrophic and dilated cardi-
omyopathy with occurrence of sudden cardiac death.
D.P.S. Osborn: None. L. Emrahi: None. M.T. Tabrizi:
None. M. Yazdchi: None. N. Mazaheri: None. A.
Mitchell: None. C. Hesse: None. H. Goullée: None. D.
Burkardt: None. N. Laing: None. A.Y.B. Wan: None. H.
Galehdari: None. R. Maroofian: None. G. Shariati:
None. H. Tajsharghi: None. Y. Jamshidi: F. Consultant/
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Impact of abdominal obesity on postprandial lipid
concentrations
M. R. Christiansen1, T. I. A. Sorensen1,2, T. Hansen1, T. O.
Kilpeläinen1
1Novo Nordisk Foundation Center for Basic Metabolic
Research, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark,
2Department of Public Health, Section of Epidemiology,
University of Copenhagen, Copenhagen, Denmark
Introduction: Humans spend most of the day in a post-
absorptive state, and thus prolonged and high postprandial
lipemia can have major implications for the risk of cardio-
vascular disease. Abdominal adiposity may influence post-
prandial lipemia by influencing lipid metabolism after a
meal. To date, >400 genetic loci have been discovered for
association with abdominal adiposity, assessed by waist-hip
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ratio adjusted for body mass index (WHRadjBMI). Whether
these variants are associated with postprandial lipid con-
centrations, remains unknown. We thus examined whether
genetic risk score for increased waist-hip ratio adjusted for
body mass index (WHRadjBMI) is associated with lipid
concentrations at fasting state and after a high-fat meal.
Materials and Methods: 771 individuals of European
ancestry and with obesity from the NUGENOB study
consumed a liquid high-fat meal (95% fat of the energy
content). The postprandial concentrations of HDL choles-
terol, LDL cholesterol, free fatty acids, glycerol and
triglycerides were measured at fasting state and postpran-
dially for 3 hours. The associations between the
WHRadjBMI score and lipid concentrations were examined
using linear models.
Results: At fasting state, the genetic risk score for
WHRadjBMI was associated with higher fasting triglycer-
ides (P=0.0013) and lower HDL cholesterol (P=0.0059).
Postprandially, the genetic risk score was not associated
with changes in triglycerides or HDL cholesterol (P>0.05),
but was significantly associated with elevated glycerol
concentrations (P=0.012).
Conclusions: Genetic predisposition to abdominal adip-
osity is associated with elevated blood glycerol concentra-
tion after a high-fat meal.
M.R. Christiansen: None. T.I.A. Sorensen: None. T.
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Familial pulmonary arterial hypertension by KDR
heterozygous loss of function
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Salpêtrière - Charles Foix,, Paris, France, 2Service de
Pneumologie, Centre de Référence de l’Hypertension
Pulmonaire, Hôpital Bicêtre, Le Kremlin Bicêtre, France,
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France, 5Centre de génétique, FHU TRANSLAD, Institut
GIMI et UMR INSERM 1231, CHU de Dijon et Université
de Bourgogne, Dijon, France, 6UMR_S 999, Université
Paris-Saclay, INSERM, Hôpital Marie Lannelongue, Le
Plessis Robinson, France, 7NIHR Bioresource – Rare
Diseases, Department of Medicine, Department of Haema-
tology, Cambridge Biomedical Campus, Cambridge, United
Kingdom, 8Department of Medicine, University of
Cambridge School of Clinical Medicine, Addenbrooke’s
and Royal Papworth Hospitals, Cambridge, United King-
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Introduction: Pulmonary arterial hypertension (PAH) is a
rare and devastating disease, resulting from progressive
obliteration of small caliber pulmonary arteries leading to
cardiac failure. PAH can occur in the context of family
history or genetic mutations causing heritable PAH, or is
considered as idiopathic in the absence of an identified
predisposing factor. Beyond the major gene BMPR2, a gene
encoding a type 2 receptor of the BMP signaling pathway
several new genes predisposing to PAH have been identi-
fied during the last decade. Recently, preliminary evidence
of the involvement of the KDR gene was found in a large
genetic association study.
Methods: We prospectively analysed the KDR gene by
targeted panel NGS sequencing in a series of 311 PAH
patients referred to a clinical molecular laboratory for
genetic diagnosis of PAH.
Results: Two index cases with severe PAH were found to
carry a loss-of-function mutation in the KDR gene. These
two patients were clinically characterized by low diffusing
capacity for carbon monoxide adjusted for hemoglobin
(DLCOc) and radiological evidence of parenchymal lung
disease. Segregation analysis in one family revealed that all
KDR mutations carriers have a low DLCOc that is more
pronounced in affected subjects compared to non-affected
Conclusions: Our study provided genetic evidence for
considering KDR as a newly identified PAH causing gene
since we describe the segregation of KDR mutations with
PAH in two families. Furthermore, KDR mutations are
associated with a particular form of PAH characterized by
low DLCOc and parenchymal lung disease.
M. Eyries: None. D. Montani: None. B. Girerd: None.
N. Favrolt: None. M. Riou: None. L. Faivre: None. G.
Manaud: None. F. Perros: None. S. Gräf: None. N.
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PHACTR1 mRNA expression is affected by rs9349379 in
PBMC of patients six months after the first MI
J. Kuveljic1, T. Djuric1, M. Dekleva2, N. Markovic Nikolic2,
A. Stankovic1, D. Alavantic1, M. Zivkovic1
1Vinca Institute of Nuclear Sciences, Laboratory for
Radiobiology and Molecular Genetics, University of
Belgrade, Belgrade, Serbia, Belgrade, Serbia, 2Department
of Cardiology, University Clinical Center “Zvezdara”,
Belgrade, Serbia; Faculty of Medicine, University of
Belgrade, Belgrade, Serbia, Belgrade, Serbia
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Aim: Phosphatase and actin regulator 1 (PHACTR1) was at
first associated with early onset myocardial infarction (MI).
Later on, it was associated with other vascular disorders, but
still the mechanism of its effect is unknown. Rs9349379 is
an eQTL for PHACTR1 in coronary arteries, where A allele
leads to higher expression. Also PHACTR1 mRNA
expression is elevated in the heart after MI, indicating its
up-regulation in pathological conditions. The aim of our
study was to investigate the association of rs9349379 with
the first MI in Serbian population and its effect on
PHACTR1 mRNA expression in PBMC of MI patients and
controls.
Methods: Blood samples from 171 controls and 156
patients with the first MI were obtained for DNA extraction.
For RNA extraction, we collected 32 control samples and
65 samples of patients six months after the first MI.
Genotyping and expression analysis were performed with
Taqman technology. Statistical analyses were done by
Statistica 8 software.
Results: The association of rs9349379 with the first MI
was not significant (p=0.13). PHACTR1 mRNA expression
was significantly higher in MI patients compared to controls
(p=0.02). We have found that rs9349379 has no effect on
PHACTR1 mRNA expression in control group (p=0.90),
while AA genotype led to higher expression in patient
group (p=0.04).
Conclusions: Rs9349379 affects PHACTR1 mRNA
expression in PBMC of MI patients, six months after the
MI. In order to accurately estimate its association with MI,
further analysis and larger sample size are needed. Funded
by Serbian Ministry, grant III41028.
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Polygenic risk scores for hypertension risk stratification
O. Borisov1, E. Salvi2, L. Citterio3, C. Lanzani3, C.
Barlassina4, N. Glorioso5, P. Krawitz1, D. Cusi4, P.
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Milan, Italy, 4Dept. Of Health Sciences, University of
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Introduction: Hypertension (HTN) is a major cardiovas-
cular risk factor and responsible for ~50% of cardiovascular
morbidity and mortality. Blood pressure (BP) is also a
complex genetic trait with heritability estimates of 30-50%.
Genome-wide association studies (GWAS) have identified a
high number of genetic loci associated with HTN and BP
traits, indicating underlying polygenic architectures. This
study proposes to compute polygenic risk scores (PRS) for
HTN and BP for potential genetic risk stratification.
Materials and Methods: We investigated the additive
effect of common genetic variants on HTN and BP by
means of regression models based on PRS. We used
genotyping data of 561 cases and 731 controls from
Hypergenes cohort. We computed PRS based on clumping
and thresholding method using GWAS summary statistics
of systolic/diastolic BP measurements from GERA cohort
(99,785 health records) and the HTN case-control cohort of
the UK Biobank (144,793 cases and 313,761 controls).
Results: PRS for HTN and diastolic/systolic BP are
strongly associated with hypertensive status and BP
measurements. The highest significance is achieved for
the case-control status by considering UK Biobank effect
sizes (p=6.4e-28, R2=0.09). The area under the curve is
0.68. The model remains significant after adjusting for sex
and body mass index (p=4.1e-27).
Conclusions: PRS modeling shows a strong polygenic
component both for HTN status and for BP levels. Despite
the limited predictive accuracy expected for BP, which is
largely influenced by environmental factors, the strength of
associations suggests that PRS could be potentially used for
genetic risk stratification.
O. Borisov: None. E. Salvi: None. L. Citterio: None. C.
Lanzani: None. C. Barlassina: None. N. Glorioso: None.
P. Krawitz: None. D. Cusi: None. P. Manunta: None. C.
Maj: None.
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Biallelic variants in PPP1R13L cause paediatric dilated
cardiomyopathy
H. K. Robinson1, E. Zaklyazminskaya2, I. Povolotskaya3, Y.
Surikova4, L. Mallin1, C. Armstrong5, M. R. Chrisant6, P. J.
Benke7, M. McDonald8, C. C. Marboe9, K. McWalter10, G.
Douglas10, K. Agre11, D. Deyle11, K. M. Balashova3, V.
Kaimonov3, N. Shirokova3, E. Pomerantseva3, C. Turner12,
S. Ellard1,13
1Exeter Genomics Laboratory, Exeter, United Kingdom,
2Center of Syncope and Cardiac Arrhythmias in Children
and Adolescents, Moscow, Russian Federation, 3Centre of
Genetics and Reproductive Medicine “Genetico”, Moscow,
Russian Federation, 4B.V. Petrovsky Russian National
Centre of Surgery, Moscow, Russian Federation,
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5Paediatric Cardiac Service, Bristol Royal Hospital for
Children, Bristol, United Kingdom, 6Joe DiMaggio Chil-
dren’s Hospital, Hollywood, FL, United States, 7Charles E.
Schmidt College of Medicine, Florida Atlantic University,
Hollywood, FL, United States, 8Department of Pediatrics,
Division of Medical Genetics, Duke University Medical
Center, Durham, NC, United States, 9Department of
Pathology and Cell Biology, Columbia University Medical
Centre, New York, NY, United States, 10GeneDx Inc.,
Gaithersburg, MD, United States, 11Mayo Clinic, Depart-
ment of Clinical Genomics, Rochester, MN, United States,
12Peninsula Clinical Genetics Service, Department of
Clinical Genetics, Royal Devon and Exeter NHS Founda-
tion Trust, Exeter, United Kingdom, 13Institute of Biome-
dical and Clinical Science, College of Medicine and Health,
Exeter, United Kingdom
Introduction: Childhood DCM is a leading cause of heart
failure requiring cardiac transplantation, with ~5% of cases
resulting in sudden death. Knowledge of the underlying
genetic cause can aid prognostication and clinical man-
agement and enables accurate recurrence risk counselling.
Here our aim was to identify the causative genetic variant(s)
in families with children affected by severe DCM.
Materials and Methods: Exome/genome sequencing
was performed on leukocyte DNA from seven children
affected with severe DCM and their unaffected parents from
five independent families, followed by inheritance-based
gene-agnostic variant filtering. Families were brought
together by an international collaborative effort facilitated
by GeneMatcher.
Results: DCM presented early (range: 3 months – 9
years) and was progressive, resulting in death (n = 3) or
transplant (n = 3), with one child currently awaiting
transplant. Biallelic variants in PPP1R13L were identified
in the affected children in each family. PPP1R13L encodes
inhibitor of apoptosis-stimulating protein of p53 protein
(iASPP). iASPP has roles in apoptosis, acts as a regulator of
desmosomes and has been implicated in inflammatory
pathways. Spontaneous biallelic loss-of-function variants in
PPP1R13L orthologues have been shown to underlie
bovine and murine models of DCM and biallelic variants
were previously reported in a single consanguineous family
with paediatric DCM.
Conclusions: Gene-agnostic exome/genome sequencing
is valuable for the identification of novel and emerging
candidate genes. The identification of these five families
now provides sufficient evidence to support a robust gene-
disease association between PPP1R13L and severe paedia-
tric DCM. PPP1R13L is therefore recommended for
inclusion in panel-based genetic testing for paediatric DCM.
H.K. Robinson: None. E. Zaklyazminskaya: None. I.
Povolotskaya: None. Y. Surikova: None. L. Mallin:
None. C. Armstrong: None. M.R. Chrisant: None. P.J.
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P05.75.C
Identification of ANGPT2 mutations as a novel cause of
primary lymphedema
V. Leppänen1, P. Brouillard2, E. Korhonen1, N. Revencu3,
G. Koh4, P. Saharinen1, K. Alitalo1, M. Vikkula2,5
1Wihuri Research Institute, Biomedicum Helsinki, Helsinki,
Finland, 2Human Molecular Genetics, de Duve Institute,
UClouvain, Brussels, Belgium, 3Center for Human Genet-
ics, Cliniques universitaires Saint-Luc, UCLouvain, Brus-
sels, Belgium, 4Center for Vascular Research, Korea
Advanced Institute of Science and Technology (KAIST),
Daejoen, Korea, Republic of, 5Walloon Excellence in
Lifesciences and Biotechnology (WELBIO), UCLouvain,
Brussels, Belgium
Purpose: Primary lymphedema (PLE) is caused by devel-
opmental and functional defects of the lymphatic system
resulting in accumulation of protein-rich fluid in tissues.
The 28 currently known genes causing lymphedema explain
<30% of cases. We search for additional genes to better
understand pathophysiology.
Methods: We used WES to screen 543 patients within
our cohort of >900 index patients. We filtered variants using
our in-house developed Highlander software. In vitro and
in vivo studies were performed to validate functional
effects.
Results: We identified a complete angiopoietin-2
(ANGPT2) gene deletion in one family, and four variants
of interest in four other families. All are extremely rare or
absent in controls and databases, and predicted to be
pathogenic by several algorithms. Functional analyses of
the substitution-mutants unraveled that 3/4 showed
decreased ANGPT2 secretion and even inhibited secretion
of the wild-type ANGPT2, suggesting that they have a
dominant-negative effect. The fourth mutant, located in the
dimerization interphase, showed reduced integrin-α5 bind-
ing and its expression in mouse skin promoted hyperplasia
and dilation of cutaneous lymphatic vessels.
Conclusions: We identified five mutations in the TIE2-
ligand ANGPT2 as a novel cause of primary lymphedema.
The mutations alter ANGPT2 structure and/or function. The
data underscore loss of ANGPT2 function as the
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mechanism leading to primary lymphedema, and provide
new insights into TIE2 signaling. The ANGPT2 gene is now
included in the diagnostic panel used in our hospital to
perform diagnostic testing for primary lymphedema. These
studies were supported by Walloon Excellence in Life-
sciences and Biotechnology (WELBIO).
V. Leppänen: None. P. Brouillard: None. E. Korho-
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Saharinen: None. K. Alitalo: None. M. Vikkula: None.
P05.76.A
Novel variants in ABIN2 and TRAF2 implicated in
pathogenesis of pulmonary arterial hypertension
N. Gallego1, D. Condon2, S. Pienkos2, V. de Jesús Pérez2, I.
Hernández3, C. Pérez-Olivares4, N. Ochoa4, P. Spanish
Consortium5, P. Lapunzina6, P. Escribano7, J. Tenorio6
1Instituto de Genética Médica y Molecular, Madrid, Spain,
2Stanford University, Standford, CA, United States, 3Hos-
pital Universitario Fundación Jiménez Díaz, Madrid,
Spain, 4Hospital Universitario Doce de Octubre, Madrid,
Spain, 5Instituto de Genética Médica y Molecular, Centro
de Investigación Biomédica en Red de Enfermedades
Raras, Madrid, Spain, 6Instituto de Genética Médica y
Molecular, Centro de Investigación Biomédica en Red de
Enfermedades Raras, Madrid, Spain, 7Hospital Universi-
tario Doce de Octubre, Centro de Investigación Biomedica
en Red en Enfermedades Cardiovasculares, Madrid,
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Introduction: Pulmonary Arterial Hypertension (PAH) is
an infrequent cardiopathy with poor prognosis despite
therapeutic advances. Mutation in several known risk genes
predispose to disease however, some cases remain geneti-
cally undefined. Increasing knowledge of the underlaying
molecular mechanisms may lead to a better understanding
of the disease and the opening of new drug targets that can
improve the treatment of patients. The advance in massive
paralleled sequencing technologies has allowed improving
the characterization of the molecular profiling of the
patients and a better clinical characterization.
Material and methods: The aim of this project is to
study 20 patients and available relatives by whole exome
sequencing (WES) technology in order to identify new
genes and regions that can be involved in PAH. Variant
prioritization was performed through bioinformatic tools
and a custom algorithm. In addition, to stablish mechanistic
significance, a series of in vitro studies were performed.
Results: Several candidate genes were identified after the
variant prioritization. We have identified two genes (TRAF2
and TNIP2) in two unrelated families, which are related to
the NFƙβ pathway, associated with the progression of PAH.
In vitro studies demonstrate a possible impairment of NFƙβ
transcription factors localization of a modulation of
NFƙβ-inducible genes after inhibition of ABIN2
and TRAF2.
Conclusions: Although these results have to be validated
through more different functional assays, they suggested an
association between disease and new genes which may also
be considered for inclusion in genetic screening for PAH
patients.
Grants: FIS-PI18/01233, Janssen unrestricted grant,
FCHP.
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P05.77.B
Association of two novel SCN5A intragenic duplications
with epilepsy, ventricular tachycardia, fibrillation and
Brugada-like Syndrome
N. Marziliano1, A. Medoro2, D. Fiscella3, A. Fiscella4, L.
Tursi1, L. Greco1, C. Reverberi5, S. Folzani6, M. Intrieri2
1ASL TARANTO, Taranto, Italy, 2Università degli Studi del
Molise, Campobasso, Italy, 3Ospedale Garibaldi, Catania,
Italy, 4Fondazione Floresta Longo, Catania, Italy, 5Centro
Clinico Gemini, Parma, Italy, 6Poliambulatorio Città di
Collecchio, Collecchio, Italy
In the last years, the increasing evidences about the co-
existence of genetically based cardiac arrhythmias and
epilepsy brings out the emerging concept of cardio-cerebral
channelopathy. In this view, we describe two unrelated
cases presenting cardiac and epileptic phenotypes in which
two novel intragenic duplications in the SCN5A gene
(c.1627_1653dup, p.Phe543_Ala551dup and
c.1846_1863dup, p.Ser616_Pro621dup, respectively) were
identified. The SCN5A gene encodes for the α-subunit of the
Nav1.5 channel and mutations in this gene are mainly
involved in electrical channelopathies that lead to life-
threatening arrhythmias (Brugada syndrome, Long-QT
syndrome, Sudden Infant Death syndrome, etc.) or struc-
tural changes in the myocardium, such as in the dilated
cardiomyopathy (DCM). With the aim of characterizing the
biological effects of such genetic defects, we studied the
biophysical properties of the Nav1.5 channels revealing that
duplication might prompt for a loss-of-function of the
Nav1.5-mediated current in a zebrafish model without
alterations in the heart structure and function (at least for the
first mutation). Taking together, clinical and biochemical
data support the idea that the intragenic in-frame
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duplications within the SCN5A gene could be responsible
for both cardiac and epileptic phenotypes.
N. Marziliano: None. A. Medoro: None. D. Fiscella:
None. A. Fiscella: None. L. Tursi: None. L. Greco: None.
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Clonal occurrence of the Hutchinson-Gilford progeria
syndrome lamin A mutation in chronic kidney disease
G. Revechon1, H. Helgadottir1, N. Viceconte1, A. Witasp2,
A. Sola Carvajal1, D. Whisenant1, D. McGuinness3, G.
Artiach4, E. Wallen Arzt1, A. Thorell5, A. Babler6, S.
Ziegler6, R. Kramann6, M. Bäck4, P. G. Shiels3, A.
Wernerson2, P. Stenvinkel2, M. Eriksson1
1Karolinska Institute, Dept of Biosciences and Nutrition,
Huddinge, Sweden, 2Karolinska Institute, Dept of CLIN-
TEC, Huddinge, Sweden, 3University of Glasgow, Institute
for Cancer Sciences, Glasgow, United Kingdom, 4Karo-
linska Institute, Dept of Medicine, Stockholm, Sweden,
5Karolinska Institute, Dept of Clinical Sciences, Dept of
Surgery, Ersta hospital, Stockholm, Sweden, 6University
hospital RWTH Aachen, Aachen, Germany
Somatic mutagenesis occurs continuously across the life
course, resulting in tissues composed of clones with dif-
ferent genetic makeups. While the majority of mutations
have no functional significance, some can contribute to
disease and aging. The nature of the arterial wall, with its
media being composed of clonal smooth muscle cells,
makes this tissue particularly sensitive to somatic muta-
genesis. Here we analyzed progerin, the protein responsible
for the premature aging disorder Hutchinson-Gilford pro-
geria syndrome (HGPS), for its possible involvement in the
accelerated vascular aging process observed in chronic
kidney disease (CKD), due to similarities in vascular phe-
notypes. We provide evidence for expression of progerin,
and the occurrence of the HGPS-causing LMNA c.1824C>T
mutation as a somatic mutation in CKD patient arteries.
Clonal populations of vascular cells with the 1824C>T
mutation was supported by clusters of progerin positive
cells in the media and a high frequency of the mutant allele
in several CKD arteries. Further analysis of proliferation
and DNA damage in the CKD arteries indicated regenera-
tion and progerin-induced genomic damage. Our results
implicate somatic mutations in the functional decline of the
vascular wall and support that somatic mutations may
become a risk factor during extensive tissue damage.
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Enrichment of rare variants in Loeys-Dietz syndrome
genes in spontaneous coronary artery dissection but not
in severe fibromuscular dysplasia
J. Meester1, A. Verstraeten1, M. Perik1, L. Van Den
Heuvel1, M. Kempers2, I. Krapels3, L. Van Laer1, N.
Samani4, F. Van Dijk5, A. Persu6, D. Adlam4, B. Loeys1
1Centre of Medical Genetics, University of Antwerp,
Antwerp University Hospital, Antwerp, Belgium, 2Depart-
ment of Human Genetics, Radboud University Nijmegen
Medical Center, Nijmegen, Netherlands, 3Department of
Clinical Genetics, Maastricht University Medical Centre,
Maastricht, Netherlands, 4Department of Cardiovascular
Sciences and National Institute for Health Research
Leicester Biomedical Research Centre, Glenfield Hospital,
Leicester, United Kingdom, 5Ehlers-Danlos Syndrome,
National Diagnostic Service, Northwick Park and St.
Mark’s Hospitals, Harrow, United Kingdom, 6Pole of
Cardiovascular Research, Institut de Recherche Expéri-
mentale et Clinique, Université Catholique de Louvain, and
Division of Cardiology, Cliniques Universitaires Saint-Luc,
Université Catholique de Louvain, Brussels, Belgium
Spontaneous coronary artery dissection (SCAD) is char-
acterized by separation of the inner intimal lining of the
coronary artery from the outer vessel wall. It is the prime
cause of acute myocardial infarction in women below the
age of 50. Fibromuscular dysplasia (FMD) presents with
condensed areas of arterial stenosis, aneurysm, tortuosity
and dissection. It has become clear that FMD is prevalent in
SCAD cohorts and vice versa. However, the genetic etiol-
ogy of both conditions remains largely elusive. We aimed to
investigate the contribution of rare genetic variants in vas-
cular Ehlers-Danlos and the Marfan, Loeys-Dietz (LDS),
Shprintzen-Goldberg syndrome genes to the etiology of
SCAD and FMD in a large multi-center patient cohort.
Haloplex-based gene panel sequencing of COL3A1, FBN1,
TGFB2/3, SMAD2/3, TGFBR1/2 and SKI was performed in
191 SCAD patients with or without FMD and 111 isolated
FMD patients. Subsequent variant filtering was performed.
The gnomAD database was used as an independent control
dataset and filtered identically. Case-control burden ana-
lyses were performed. Rare variants in SMAD2 are sig-
nificantly enriched in SCAD patients compared to controls
(p=0.001). A combined LDS-gene burden analysis was
performed, revealing a highly significant association (4.5%
vs 1.5%; p=0.000003). When performed for FMD, none of
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the analyses yielded a significant p-value or showed a trend.
We here provide evidence for an important contribution of
rare genetic variants in LDS genes to the etiology of SCAD.
Our findings suggest a strong role for the TGFbeta signaling
in the pathogenesis of SCAD but not FMD.
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P05.80.B
Genetic association study of eight steroid hormones and
implications for sexual dimorphism of coronary artery
disease
J. Pott1,2,3, Y. J. Bae4,2, K. Horn1,2, A. Teren2,5, A.
Kühnapfel1,2,3, H. Kirsten1,2, U. Ceglarek4,2, M. Loeffler1,2,
J. Thiery4,2, J. Kratzsch4,2, M. Scholz1,2,3
1Institute of Medical Informatics, Statistics und Epidemiol-
ogy, University of Leipzig, Leipzig, Germany, 2LIFE
Research Center for Civilization Diseases, University of
Leipzig, Leipzig, Germany, 3IFB AdiposityDiseases, Uni-
versity Hospital, Leipzig, Germany, 4Institute of Laboratory
Medicine, Clinical Chemistry and Molecular Diagnostics,
University Hospital, Leipzig, Germany, 5Heart Center
Leipzig, Leipzig, Germany
Introduction: Steroid hormones act as important regulators
of physiological processes in the body. Our aim is to
identify genetic factors that influence steroid hormone
metabolism, to detect genetic sexual dimorphisms and to
investigate possible causal implications for atherosclerotic
vascular disease phenotypes.
Materials and Methods: In two independent cohorts, we
performed genome-wide sex-specific meta-association stu-
dies of eight steroid hormones: progesterone, 17-
hydroxyprogesterone (17-OHP), androstenedione, testoster-
one, estradiol, dehydroepiandrosterone sulfate (DHEA-S),
cortisol, and aldosterone (LIFE-Adult, LIFE-Heart, max. n
= 7667). Genome-wide significant loci (p < 5x10−8) were
tested for sex differences in effect size. The causal
relationships between hormone levels and atherosclerotic
vascular diseases were investigated using sex-specific eQTL
analyses and Mendelian Randomization (MR) approaches.
Results: We detected 22 genome-wide significant loci for
seven steroid hormones of our panel, of which nine
displayed significant sexual dimorphisms. Eight loci relate
to genes coding for enzymes involved in steroid biosynth-
esis, almost completing the list of genes of this pathway
with genetic associations. Other loci correspond, e.g., to the
WNT4/β-catenin pathway. MR revealed that cortisol,
androstenedione, 17-OHP and DHEA-S had sex-specific
causal effects on coronary artery disease.
Conclusions: Our study greatly improves insight into
genetic regulation of steroid hormones and their dependence
on sex. The significant MR estimates support the hypothesis
that steroid hormones influence the development of
atherosclerosis, which partly explains the higher risk for
men. These results could serve as a basis for analyzing sex-
dimorphisms in other complex diseases.
This project was supported by the HI-MAG Project
Funding for Young Scientists of the Medical Faculty of the
University Leipzig.
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Genetic post-mortem in drug users with sudden cardiac
death
H. Massey, J. Dean, L. Deboys, D. O’Sullivan
Aberdeen royal infirmary, Aberdeen, United Kingdom
Aim: To quantify our ability to make a genetic diagnosis in
drug users with sudden cardiac death (SCD).
Background: While there are European recommenda-
tions for genetic testing in SCD1, these guidelines do not
extend to drug users with positive toxicology at post-
mortem. We wanted to gain a better understanding of the
genetic pick up rate in this population.
Method: We undertook a 10-year retrospective study
looking at genetic diagnoses in drug related deaths
discussed at the joint pathology-genetic MDT. This was
compared to age and provisional aetiology matched
controls.
Results: 60 drug related deaths were identified, and 40
patients underwent genetic testing. 7 variants were found of
which 3 were classified as benign and 4 VUS. The most
common reason for genetic testing was enlarged heart at
post mortem; however the genetic pick up in this group was
0. Patients with structurally normal hearts had the most
variants detected. This would coincide with the majority of
variants being found in arrhythmogenic genes. Family
history did not influence genetic pick up. In the control
group variants in arrhythmogenic genes again predominated
correlating with the highest genetic pick up in patients with
normal post-mortems. However in the control group 17
variants were detected of which 3 were pathogenic.
Conclusions: Our ability to make a genetic diagnosis in
drug users with SCD is low. We need to undertake a larger
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study to characterise those drug users with a positive
genetic diagnosis so testing can be rationalised.
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O’Sullivan: None.
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Insights into the genetic basis of ventricular tachycardia
in Kazakhstani patients. Targeted next generation
sequencing
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Rakhimova1, A. Akhmetova1, U. Kairov1, S. Trajanoski2, G.
Akilzhanova3, M. Bekbosynova4, Z. Zhumadilov1
1Center for life sciences, National Laboratory Astana,
Nazarbayev University, Nur-Sultan, Kazakhstan, 2Center
for Medical Research, Medical University of Graz, Graz,
Austria, 3Medical University of Semey, Pavlodar branch,
Pavlodar, Kazakhstan, 4National Research Cardiac Sur-
gery Center, Nur-Sultan, Kazakhstan
Introduction: Recent advances in genetic screening and the
potential of therapeutic intervention in patents with cardiac
arrhythmias have garnered this group of disorders much
attention in the scientific community. The purpose of the
study was to identify the genetic basis of ventricular
tachycardia (VT) in Kazakhstani patients.
Material and Methods: using predeveloped a targeted
panel of 96 known cardiac disease genes, associated with
cardiomyopathy and arrhythmia we screened 92 indivi-
duals, diagnosed with VT and dilated cardiomyopathy (VT
DCM) or idiopathic VT (iVT). Results. Targeted sequen-
cing and stepwise filtering of the annotated variants
identified 307 unique variants in 74 genes totaling up in
456 variants for the overall study group. Variants included
one in/del, four splice-site and 451 single-nucleotide
variants (SNV) within the coding exonic regions. Seven
(0.15%) of the SNVs were unique stop-gain variants, three
of those residing in the TTN gene. 168 HGMD mutations
(61 unique) were observed in 37 genes. According to
ACMG all variants were classified as 9 pathogenic (KCNJ2
R218Q and TTN R5338X in iVT patients, KCNQ1 c.477
+1G>A, LMNA Q353X, MYH7 F244L, TTN L17465X
and W21011X, DSG2 c.2334+1G>A, GAA W746C in VT
DCM patients), 11 likely pathogenic, 97 variants with
uncertain significance and rest as benign.
Conclusions: Individuals with VT either secondary to
DCM or of idiopathic etiology carry multiple rare mutations
and potentially pathogenic sequence variants in cardiac risk
genes in a similar pattern and at a comparable frequency.
Study support: grant from the Ministry Education and
Science, Republic of Kazakhstan (AP05134683).
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Identification of the major genetic contributors to
Tetralogy of Fallot
R. M. Monaghan1, D. J. Paige2, S. G. Williams1, B. D.
Keavney1
1University of Manchester, Manchester, United Kingdom,
2Manchester Metropolitan University, Manchester, United
Kingdom
Tetralogy of Fallot (TOF) is the most common cyanotic
congenital heart defect. Rare genetic variants have been
identified as important contributors to the risk of congenital
heart disease, but relatively small numbers of TOF cases
have been studied. We used whole exome sequencing to
assess the prevalence of unique, deleterious variants in the
largest cohort of nonsyndromic TOF patients reported to
date. The presence of such variants was defined by their
absence in the Genome Aggregation Database and bioin-
formatic prediction of their deleterious effect on function.
The enrichment of variants in two genes, NOTCH1 and
FLT4, surpassed thresholds for exome-wide significance (P
< 5×10-8) after correction for multiple comparisons.
NOTCH1 was most frequently found to harbour unique,
deleterious variants (4.5%; 95% CI, 3.2%-6.1%). Three
NOTCH1 variants were subjected to functional evaluation,
and two showed a reduction in Jagged1-induced NOTCH
signalling. FLT4 variants were found in 2.4% (95% CI,
1.6%-3.8%) of our cohort. In addition, variants in the well-
established TOF gene, TBX1, and the genes were also sig-
nificantly enriched. Our study underlines the importance of
sequencing large cohorts of CHD cases in order to further
discover their genetic basis.
Grant reference: BHF (RG/15/12/31616)
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In search of genetic modifiers that explain the pheno-
typic variability in SMAD3-related aortopathy
J. D. Velchev1, M. Perik1, I. M. B. H. van de Laar2, J.
Richer3, A. Verstraeten1, M. Alaerts1, B. L. Loeys1,4
1Center of Medical Genetics, University of Antwerp and
Antwerp University Hospital, Antwerp, Belgium, 2Department
of Clinical Genetics, Erasmus MC, University Medical Center
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versity Nijmegen Medical Center, Nijmegen, Netherlands
Introduction: Thoracic aortic aneurysm and dissection
(TAAD) is a frequent cause of mortality in the Western world.
Loeys-Dietz syndrome (LDS), an early-onset TAAD syn-
drome is caused by mutations in genes coding for components
of the TGFbeta signaling, including SMAD3. Remarkably, a
fraction of SMAD3 mutation carriers remains cardiovascularly
unaffected throughout life, suggesting the existence of genetic
modifiers for aortopathy. This study implements a combina-
tion of linkage analysis and whole-genome sequencing
(WGS) in order to identify genetic modifiers that explain the
variability in SMAD3-related aortopathy.
Material and Methods: In two large LDS families (n =
41 mutation carriers) segregating SMAD3 missense muta-
tions and presenting variable TAAD expressivity genome-
wide SNP-based linkage analysis was performed. LOD
scores were obtained using MERLIN and SUPERLINK and
linkage was complemented with WGS of six affected and
six unaffected mutation carriers.
Results: In the first family linkage analysis identified a
chromosomal region (chr2:149,604,077-155,607,398) with
a LOD score of 2.68, suggesting the presence of an
aggravating modifier. Linkage peak was observed in the
second family with a LOD score of 2.86 (chr18:43,013,157-
57,021,550). Additionally, the WGS data analysis of the
second family resulted in the discovery of a rare variant in
TGFB2, a known TAA causative gene, exclusively present
in affected mutation carriers.
Conclusions: The obtained data indicate that variants in
known TAAD genes may play a role in modulating a
primary causative mutation; chromosomal regions segregate
with disease severity suggesting a presence of genetic
modifiers and that distinct families may bear different
genetic modifiers as indicated by the linkage analysis.
J.D. Velchev: None. M. Perik: None. I.M.B.H. van de
Laar: None. J. Richer: None. A. Verstraeten: None. M.
Alaerts: None. B.L. Loeys: None.
P05.85.A
Identification of Clinically Relevant Variants by Whole
Exome Sequencing in Chinese Patients with Sporadic
Non-syndromic Type A TAAD
J. Guo, C. Hao, X. Hu, F. Leng, X. Liu
Genetics and Birth Defects Control Center, Beijing
Children’s Hospital, Beijing, China
Introduction: Thoracic aortic aneurysm and dissection
(TAAD) is a life-threatening disease, of which genetic
abnormalities are considered as important risk factors. The
present research aims at identifying causal variants in Chi-
nese patients with sporadic non-syndromic type A TAAD
(ATAAD).
Materials and Methods: Whole exome sequencing
(WES) was performed on 73 sporadic Chinese patients
with ATAAD, 30 TAAD associated genes were curated for
bioinformatic analyses. Clinical differences were compared
between patients with and without causal variants.
Results: 15 pathogenic/likely pathogenic variants were
identified (8 novel and 7 previously described) in 4 known
TAAD-causal genes (FBN1, TGFBR2, SMAD3 and ACTA2)
in 15 individuals, including 11 variants in FBN1 (7
missense, 3 truncating, and 1 splicing variants), 2 missense
variants in TGFBR2, 1 ACTA2 frameshift variant and 1
SMAD3 frameshift variant. Significant clinical differences
were found between patients with and without causal
variants. Patients with TAAD-causal variants proved to
have an earlier onset age, a more dilated aorta, and
relatively intractable subtypes. Even without risk factor
like hypertension, they might still suffer from TAAD with
TAAD-causal variants.
Conclusions: The variants identified in our research
might not only result in the occurrence of ATAAD, but also
add complexities and difficulties to the clinical practice. Our
data demonstrated that WES was an effective tool for
determining genetic etiologies of non-syndromic ATAAD
and could be helpful in genetic counseling for ATAAD
patients and their at-risk family members.
J. Guo: None. C. Hao: None. X. Hu: None. F. Leng:
None. X. Liu: None.
P05.87.C
Investigating the role of pathogenic TTN variants in
heart failure by whole-exome sequencing
O. Chazara1, G. Povysil2, S. Deevi1, J. Armisen1, D. B.
Goldstein2, C. Haefliger1
1Astrazeneca, Melbourn, United Kingdom, 2Institute for
Genomic Medicine, Columbia University Medical Center,
New York, NY, United States
Heart failure (HF) affects ~40 million people globally.
Estimates of the genetic predisposition of developing HF is
1.69 if one parent is affected and 1.92 if both parents have
HF (Framingham cohort study, Lopez et al. 2013).
Recent studies suggest higher cardiovascular genetic risk
in patients with and without diagnosed heart failure if they
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carry a pathogenic loss of function variant in the gene
encoding titin (TTN).
Here, we assess the role of pathogenic TTN variants by
whole-exome sequencing in 5916 patients with heart failure
from two clinical studies CHARM and CORONA, and
268,451 unrelated Europeans from the UK Biobank
prospective cohort study, including 4634 individuals with
ICD-10 codes for heart failure (HF, based on hospital in-
patient diagnoses).
In both types of cohorts, we detect a significant
enrichment of pathogenic TTN variants in subjects with
HF diagnosis. Furthermore, after restricting the analysis to
the variants located in exons that are predominantly spliced
in the heart, the genetic risk was increased: from 2.54 (95%
CI, 1.96-3.31) to 4.52 (95% CI, 3.10-6.68) in the clinical
studies, and from 2.95 (95% CI, 2.42-3.57) to 4.97 (95%
CI, 3.94-6.19) in the UKBB. The enrichment observed is
similar in clinical trial data and routine care health records.
As expected, individuals with a diagnosis of cardiomyo-
pathy had the highest rate of TTN mutations, but we also
observed TTN variants in up to 5% of HF patients due to
other aetiologies, such as ischaemic and hypertensive
disease. This result highlights the importance of TTN
variants beyond cardiomyopathies.
O. Chazara: A. Employment (full or part-time);
Significant; Astrazeneca. G. Povysil: None. S. Deevi: A.
Employment (full or part-time); Significant; Astrazeneca. J.
Armisen: A. Employment (full or part-time); Significant;
Astrazeneca. D.B. Goldstein: F. Consultant/Advisory
Board; Modest; Astrazeneca. C. Haefliger: A. Employment
(full or part-time); Significant; Astrazeneca.
P05.88.A
Non-amyloidotic transthyretin cardiomyopathy
J. Gimeno Blanes1, M. Sabater Molina1, I. San Roman1, L.
Polo2, I. Garrido3, C. Salas4, F. Lopez Andreu5
1Inherited Cardiac Disease Unit. Universitary Hospital
Virgen de la Arrixaca., Murcia, Spain, 2Hospital Uni-
versitario Virgen Arrixaca, Department of Pathological
Anatomy., Murcia, Spain, 3Department of Cardiology
Universitary Hospital Virgen de la Arrixaca., Murcia,
Spain, 4Hospital Puerta de Hierro, Department of Patho-
logical Anatomy, Madrid, Spain, 5Hospital General Reina
Sofia, Service of Internal Medicine, Murcia, Spain
Introduction: We aim to present an unsolved case of a
young patient with unclassified cardiomyopathy associated
with a genetic TTR variant predicted to cause a dramatic
change in protein structure. Clinical course went from
asymmetric hypertrophy with restrictive phenotype to
cardiac dilatation and systolic dysfunction. Pulmonary
pressures were strikingly elevated.
Case: A 33 years old woman was admitted in 1997 with
limiting dyspnoea. Echocardigram showed non-obstructive
asymmetrical septal hypertrophy of 17mm maximum at the
septum and restrictive physiology. Sarcoid cardiomyopathy
was ruled out with negative scintigraphy and unspecific
biopsy in the absence of other extracardiac features. Atrio-
ventricular ablation and permanent pacing were required in
2002. Clinical deterioration led to frequent heart failure
admissions and one episode of syncope. Implantable
cardioverter defibrillator was implanted. Emergency trans-
plant was performed with a postoperative complicated
course in 2006. Patient remained stable to date. Study of the
explanted heart demonstrated macro and microscopic
hypertrophy, extensive fibrosis, unspecific vacuolization
and disarray. There were no signs of amyloid with usual
stains and immunohistochemical typing. Sequencing of the
TTR gene led to identification of a de novo frameshift
mutation p.S132fs*25(g.6903_6906delinsGTAGGG) caus-
ing original stop codon lost, results in prolonged protein.
Cardiac evaluation of her brother, sister and parents ruled
out any sign of cardiomyopathy. All relatives were free for
the TTR variant.
Conclusions: Case of cardiomyopathy associated with a
TTR variant. Severe right and left heart failure clinical
course with very particularly severe pulmonary hyperten-
sion ended up in heart transplant. Mechanisms of disease in
this case remain unknown.
J. Gimeno Blanes: None. M. Sabater Molina: None. I.
San Roman: None. L. Polo: None. I. Garrido: None. C.
Salas: None. F. Lopez Andreu: None.
P05.89.B
Searching for genes associated with primary varicose
veins using targeted next-generation sequencing
E. Strauss1,2, M. Zmyslowski3, B. Budny4, L.
Dzieciuchowicz3, E. Wrotkowska4, M. Ruchala4, K.
Ziemnicka4, G. Oszkinis5, Z. Krasinski3
1Institute of Human Genetics of the Polish Academy of
Sciences in Poznan, Poznan, Poland, 2Department of
Vascular, Endovascular Surgery, Angiology and Phlebol-
ogy Poznan University of Medical Sciences, Poznań,
Poland, 3Department of Vascular, Endovascular Surgery,
Angiology and Phlebology Poznan University of Medical
Sciences, Poznan, Poland, 4Department of Endocrinology,
Metabolism and Internal Medicine, Poznan University of
Medical Sciences, Poznan, Poland, 5Department of General
and Vascular Surgery, Poznan University of medical
Sciences, Poznan, Poland
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Introduction: The aim of this study was to search for genes
involved in the pathogenesis of the primary varicose veins
(PVV) using targeted next-generation gene sequencing.
Sporadic cases with the onset of the first symptoms of
disease below or equal 40 years of age were considered.
Methods: A cohort of 66 PVV patients was collected and
exome sequencing of the 35 candidates´ genes was
performed, which focused on the genes encoding structural
elements of the vessel wall, metalloproteinases, and their
protein inhibitors, proteins involved in the homeostasis of
the coagulation system and regulation of sex hormones
system, as well as genes previously associated with VV
development.
Results: Most of the patients (91.9%) had a positive
family history of VV, considering first-, second- or third-
degree relatives. 26 potentially pathogenic changes: 12
mutations in 9 genes (7 known and 5 novel), 5 rare SNPs
and 9 common SNPs were found. 40% of the patients had a
potentially causative mutation in the candidate genes: 33%
of them had 1 mutation, 3% had 2 mutations and 1.5% had
3 mutations. The association between one SNP in the
MMP-9 gene and the age of the onset of PVV symptoms
was also observed.
Conclusions: This report provides evidence for the
heterogeneity and complexity of the genetic background
of PVV in sporadic cases and shows the influence of genetic
factors on the age of the onset of this disease. It also reveals
attractive targets for further research in a larger group of
patients and functional analyses.
E. Strauss: None. M. Zmyslowski: None. B. Budny:
None. L. Dzieciuchowicz: None. E. Wrotkowska: None.
M. Ruchala: None. K. Ziemnicka: None. G. Oszkinis:
None. Z. Krasinski: None.
P06 Metabolic and Mitochondrial Disorders
P06.01.C
Identification of AADC patient through combined
determination of 3-OMD biomarker and DDC gene
sequencing and copy number variation analysis
C. Pereira1, C. Cozma1, L. Demuth1, G. Morales Torres1,
M. Iurascu1, P. Bauer1, A. Rolfs1, C. Lourenco2
1Centogene AG, Rostock, Germany, 2Universidade de São
Paulo, Sao Paulo, Brazil
L-amino acid decarboxylase (AADC) deficiency is caused
by bi-allelic variants in the DDC gene. This very rare
neurometabolic disorder is clinically characterized by
vegetative symptoms, oculogyric crises, dystonia, and
severe neurologic dysfunction, usually beginning in infancy
or childhood. Treatment has become available recently. We
quantified 3-OMD (3-O-Methyldopa), a suggested AADC-
specific biomarker, in dried blood spots by tandem mass
spectrometry. Upon suggestive findings, we subsequently
analyzed the DDC gene by amplicon-based next generation
sequencing (NGS) and copy number variant (CNV)
screening. This two-step approach identified several
patients. The ones with at least one hitherto undescribed
variant are described here in detail. All three patients had
pathological levels of 3-OMD. In patient 1, we identified a
novel whole DDC gene duplication in homozygosity. In
patient 2, we identified the two missense variants p.
(Ser147Ile) and p.(Val60Ala) in compound heterozygosity;
interestingly, variant p.(Ser147Ile) was not only novel, but
shown to have occurred de novo. In patient 3, p.
(Trp121Arg) and p.(Arg347Gln) were identified in com-
pound heterozygosity. The former is novel, while the latter
has frequently been described in AADC patients previously.
Using a combined biochemical, NGS and CNV approach, a
positive identification and diagnosis of AADC deficiency
patients is reliably reached. This allows for an early treat-
ment of the patients, leading to an improvement of their
quality of life. Moreover, the identification of novel DDC
variants and the establishment of correlations with 3-OMD
levels can be expected to increase our understanding of the
disease.
C. Pereira: None. C. Cozma: A. Employment (full or
part-time); Significant; Centogene AG. L. Demuth: A.
Employment (full or part-time); Significant; Centogene AG.
G. Morales Torres: A. Employment (full or part-time);
Significant; Centogene AG. M. Iurascu: A. Employment
(full or part-time); Significant; Centogene AG. P. Bauer: A.
Employment (full or part-time); Significant; Centogene AG.
A. Rolfs: A. Employment (full or part-time); Significant;
Centogene AG. C. Lourenco: None.
P06.04.C
Patients affected by autosomal recessive or dominant
cutis laxa type 3 show diverse degrees of collagen
alterations
N. El Choubassi1,2, L. Lugli3, C. Spada4, D. de Silva5, O.
Klein1, D. Meierhofer2, D. Horn1, U. Kornak1,2,6, B.
Fischer-Zirnsak1,2
1Charité Universitaetsmedizin Berlin, Berlin, Germany,
2Max Planck Institute for Molecular Genetics, Berlin,
Germany, 3Division of Neonatal Intensive Care Unit,
Department of Pediatrics, University Hospital, Modena,
Italy, 4Department of Medical and Surgical Sciences for
Mothers, Children and Adults, Post Graduate School of
Paediatrics, University of Modena & Reggio Emilia,
Modena, Italy, 5Department of Physiology, Faculty of
Medicine, University of Kelaniya, Ragama, Sri Lanka,
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Introduction: Mutations in ALDH18A1, encoding the
mitochondrial enzyme pyrroline-5 carboxylate synthase
(P5CS), lead to a broad spectrum of rare genetic conditions.
Besides hereditary spastic paraplegia, ALDH18A1 muta-
tions are causative for autosomal recessive (ARCL3) and
dominant (ADCL3) cutis laxa with progeroid features.
Materials and Methods: We performed whole exome
(WES) and gene panel sequencing to identify pathogenic
variants in our probands. These analyses were complemen-
ted by mRNA expression studies, immunofluorescence,
immunoblot and mass-spectrometry approaches on patient
derived fibroblasts.
Results: We report on novel pathogenic variants in three
affected individuals with ARCL3/ADCL3. These variants
have variable impacts on the stability of the protein and its
localization within the mitochondrial network. However,
targeted metabolomics revealed substantial alterations of
mitochondrial proline synthesis rates. Additionally, gene
expression profiling, comparative proteomics and subse-
quent immunoblot analyses showed alterations in expres-
sion of different collagens.
Conclusions: Our data expand the mutational spectrum
of ALDH18A1-related diseases and demonstrate the impor-
tance of correct ALDH18A1 localization within the
mitochondria for proper functioning. Additionally, they
suggest a potential connection of the mitochondrial proline
synthesis pathways with the regulation of collagen
synthesis.
Funding: The study was supported by the Deutsche
Forschungsgemeinschaft (FI 2240/1-1) to BF-Z
N. El Choubassi: None. L. Lugli: None. C. Spada:
None. D. de Silva: None. O. Klein: None. D. Meierhofer:
None. D. Horn: None. U. Kornak: None. B. Fischer-
Zirnsak: None.
P06.06.B
Clinical study of the relationship between histamie
intolerance and variants in the AOC1/ABP1 Gene
J. Vinas-López1, P. Ojeda2, I. Ojeda2, A. Duelo3, B.
García-Velasco1, C. Lenz2, T. Perucho1, M. Berbel3, A.
Vásquez3, E. Ruiz-Casares1,4
1Genyca, Majadahonda, Spain, 2Clínica Ojeda de Asma y
Alergia Dres. Ojeda, Madrid, Spain, 3Centro de Nutrición
AD Dietistas, Barcelona, Spain, 4Universidad San Pablo
CEU, Madrid, Spain
Introduction: Histamine is a biogenic amine with many
essential physiological activities. However, its deregulation
and accumulation can cause a multitude of pathologies such
as histamine intolerance. There are two enzymes involved in
the metabolism of histamine: histamine N-methyltransferase
(HNMT) is responsible for degrading histamine inside cells.
Diamine-oxidase (DAO) is the other enzyme involved in the
degradation of histamine, mainly exogenous histamine,
ingested with the diet. The deficiency of DAO activity could
be one of the main causes of histamine intolerance, an
alteration in homeostasis that is caused by a reduced intestinal
degradation of histamine, with the consequent increase in its
plasma levels. Variants in AOC1/ABP1 gene, coding DAO
enzyme, have been associated with a reduction in DAO
activity and accumulation of histamine.
Objective: The present study aims to demonstrate the
negative effect that the variants rs10156191, rs1049742 and
rs1049793 have on DAO plasma activity in Caucasian male
patients with clinical manifestations associated with hista-
mine intolerance.
Methods: We analyzed 78 white male patients with a
clinical manifestation associated with histamine intolerance.
Variants analyzed were genotyped by multiplex SNPE
(Single Nucleotide Primer Extension).
Results: The variants rs10156191 and rs1049742 reduce
significantly DAO plasma activity. Factors such as worsen-
ing symptoms after eating a diet rich in histamine or
NSAID-type drugs (non-steroidal anti-inflammatory) are
associated with a greater number of alternative alleles in the
SNVs analyzed, and reduced DAO plasma activity.
Conclusions: These results show the predictive value of
this genetic study in patients who have a clinical
manifestation associated with histamine intolerance.
J. Vinas-López: C. Other Research Support (supplies,
equipment, receipt of drugs or other in-kind support);
Modest; Genyca. P. Ojeda: None. I. Ojeda: None. A.
Duelo: None. B. García-Velasco: None. C. Lenz: None.
T. Perucho: None. M. Berbel: None. A. Vásquez: None.
E. Ruiz-Casares: None.
P06.10.C
Low prevalence of classic galactosemia in the Sverdlovsk
Region (Russian Federation)
O. Lagutina1, S. Deryabina1,2, T. Belyaeva1, N. Nikitina1, E.
Nikolaeva1
1Medical Center “Health Care of Mother and Child”,
Yekaterinburg, Russian Federation, 2Federal State Auton-
omous Educational Institution of Higher Education «Ural
Federal University named after the first President of Russia
B.N. Yeltsin, Yekaterinburg, Russian Federation
Introduction: Classic galactosemia is one of the five her-
editary metabolic diseases, which has been included in the
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State Program of Neonatal Screening of the Russian Fed-
eration in 2006.
Aim of the study: To estimate the incidence of
galactosemia in the Sverdlovsk Region based on neonatal
screening data.
Patients and methods: 698 550 children born in the
Sverdlovsk Region from 2006 to 2019 were examined.
Initially, the level of total galactose and galactose-1-
phosphate was determined in a dry blood spot, then an
activity of the enzyme galactose phosphate-uridyl transfer-
ase (GALT) has been selected as a biochemical marker of
galactosemia. The diagnosis of galactosemia should then be
confirmed by genetic analysis.
Results: During the 13-year study period 657 newborns
were included in the risk group and assigned for molecular
genetic testing. Eight children were identified as having
classical galactosemia on the basis of the enzymatic and
molecular genetic analysis. Moreover,142 babies had a
galactosemia Duarte, another 134 had decreasing activity of
the GALT enzyme due to non-genetic reasons. The
spectrum of revealed mutations in the GALT gene: K285N
(31.3%), Q188R (25.0%), M142K (12.5%), E352Q
(12.5%), W316X (6.2%), R262W (6.2%) and one new
variant P140L (6.2%), not described earlier. Conclusion.
Based on the results of newborn screening programs, the
prevalence of classic galactosemia in the Ural population is
1:87 318 live birth and unlikely that it will undergo
significant changes with further increase in the screening
period.
O. Lagutina: None. S. Deryabina: None. T. Belyaeva:
None. N. Nikitina: None. E. Nikolaeva: None.
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What is beyond the congenital lactic acidosis? From
variants to personalized medicine
I. Bravo-Alonso, R. Navarrete, P. Ruiz-Sala, F. Leal, M.
Ugarte, C. Pérez-Cerdá, B. Merinero, B. Pérez, P.
Rodríguez-Pombo
Centro de Diagnóstico de Enfermedades Moleculares,
Centro de Biología Molecular Severo Ochoa, UAM-CSIC,
CIBERER, IDIPAZ, Madrid, Spain
Implementation of Next Generation Sequencing has dra-
matically increased the diagnosis success-rate of highly
heterogeneous inborn-errors of metabolism such as those
underlying congenital lactic acidosis. However, the lack of
integrated phenotypic data, the scarce number of datasets of
global metabolomics and the necessary expertise to analyze
the functional effects of variants of unknown significance,
are limiting the transfer of genetic data into clinical practice.
Our aim in this study was to evaluate the powerful of an
adequate clinical-biochemical and genetic analysis to drive
a clinical response in a timely manner preventing the use of
major invasive techniques. With a pipeline that combined
specific datasets from metabolomics sub-sections and phe-
notypic information, with DNA and/or RNA analysis, we
identified likely pathogenic variants in strong-candidate
genes in 64% of a cohort of 39 patients with clinical sus-
picion of congenital lactic acidosis. These variants, 14 of
which were new, were found in 19 different nuclear and two
mitochondrial genes. Specific biochemical test and/or
bioenergetics analysis in fibroblasts including measures of
oxygen consumption rate, steady-state levels of OxPhos
proteins using Blue-native geles, and changes in mito-
chondrial morphology, sustained the diagnosis for patients
carrying novel genotypes. RNA analysis contributed to
solve miss or undiagnosed patients, providing a direct
insight into transcriptional perturbations caused by specific
genetic changes. Finally, by rescuing normal splicing in a
GFM1-patient cells carrying in heterozygous fashion the
c.689+908G>A change with antisense oligonucleotide
treatment, we corroborated the importance of molecular
analysis to investigate personalized therapeutic options.
LCF/PR/PR16/11110018; PI16/00573; CAM, B2017/
BMD3721
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P06.13.C
Hypoglycemia-some of its many reasons-a molecular
update.
K. Brusgaard1, Y. Alhaidan2, M. Balwi2, H. Christesen1
1Odense University Hospital, Odense, Denmark, 2King
Abdullah International Medical Research Center, Riyadh,
Saudi Arabia
Hypoglycemia can be caused by numerous somatic or
hereditary causes. Three major reasons are; diabetes,
hyperinsulinism and ketotic/non-ketotic hyperglycemia.
The brain accounts for 60% of the glucose consumption in
the infants’ resting state, leaving the brain vulnerable to
hypoglycemia. Tight plasma glucose control is ensured by a
number of complex mechanisms. In the majority of cases
the underlying pathophysiology are unexplained. The goal
in the presented study was to find new reasons underlying
these disorders.
38 families were included for trio analyses performing
exome sequencing for germline variation. Where available
exome sequencing was performed on resected pancreatic
tissue if no germline cause was elucidated. Data was
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analyzed using VarSeq and various filters considering
recessive, X-linked, de-novo or autosomal dominant modes
of inheritance. Candidate genes was analyzed by in vitro
studies using RIN-m β-cell lines and KO of target genes
using siRNA or Crispercas9. Measurement of RNA
expression levels was performed by Q-RT-PCR or micro-
array analysis. Insulin measurements were performed.
In 10 (26%) cases the hypoglycemia was explained. In
three ketotic hypoglycemia patients the reason was found in
a known GSD gene, four patients was explained by novel
genes. In one diabetic and one hyperinsulinism patient a
novel genetic cause was found. A single hyperinsulinism
patient was explained by a previously undetected mutation
in a known hyperinsulinism gene. 10 additional candidate
genes are currently under in vitro cellular investigation for
their role in manifestation of disease in individual families.
As a result of the current study the treatment was changed in
three individuals
K. Brusgaard: None. Y. Alhaidan: None. M. Balwi:
None. H. Christesen: None.
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Biochemical and molecular landscape of Fabry disease
in Portugal
F. E. Laranjeira1,2, P. Rodrigues1,3, C. Caseiro1, I.
Ribeiro1,2, H. Carmo3, D. Quelhas1,2
1Unidade de Bioquímica Genética, Centro de Genética
Médica Doutor Jacinto Magalhães, Centro Hospitalar
Universitário do Porto, Porto, Portugal, 2Unidade Multi-
disciplinar de Investigação Biomédica, Instituto de Ciên-
cias Biomédicas Abel Salazar, Universidade do Porto,
Porto, Portugal, 3UCIBIO, REQUIMTE – Laboratório
de Toxicologia, Departamento de Ciências Biológicas,
Faculdade de Farmácia, Universidade do Porto, Porto,
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Introduction: Fabry disease is an X-linked progressive
inborn error of metabolism originated by mutations in the
GLA gene causing a deficiency of the lysosomal α-galac-
tosidase (α-Gal) hydrolase activity. The breakdown of
glycolipids is impaired and the lysosomal substrate accu-
mulation triggers the onset of this lysosomal storage dis-
order. Male patients usually present very low α-Gal activity
and marked substrate accumulation, and at least some of the
clinical hallmarks. In females, however, there is a wide
range of phenotypes leading to great controversy regarding
clinical diagnosis and therapeutic decisions. Patients and
methods
Data concerning leukocytes and plasma α-Gal activity
together with plasma and urine substrate accumulation for
141 males and 210 females were obtained. Correlation
among biochemical parameters and with the molecular
defect was evaluated.
Results: 37 genetic variants were found and the most
prevalent genetic variant is c.337T>C p.(F113L), found in
50% of males and females. Males usually present a
correlation of reduced α-Gal activity with increased
substrate accumulation. In this group it was possible to
identify some genetic variant-specific patterns. Heterozy-
gous females show less pronounced effect on substrate
accumulation and enzyme deficiency. The variability of
patterns within carriers of the same genetic variant is also
noticed.
Conclusions: Some genetic variants whose pathogenicity
is controversial are indeed associated with milder biochem-
ical phenotypes. Plasma α-Gal activity is not recommended
as only diagnosis testing because in the presence of specific
variants it may give false negatives. Heterogeneity among
heterozygous females should be further evaluated with
relation to X chromosome inactivation profile.
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Mutation spectrum and corresponding clinical manifes-
tation of patients with hypertriglyceridemia in a Ger-
man outpatient clinic
F. Bardey1, L. Rieck1, D. Spira1, W. März2, S. Schwab2, P.
Binner2, T. Bobbert1, J. Spranger1, E. Steinhagen-
Thiessen1, I. Demuth1, U. Kassner1
1Charite Universitätsmedizin Berlin, Berlin, Germany,
2SYNLAB MVZ Humangenetik GmbH, Mannheim,
Germany
Introduction: A sizeable proportion of patients with severe
hypertriglyceridemia (HTG) do have the monogenetic
familial chylomicronemia syndrome (FCS). It remains dif-
ficult to clinically distinguish FCS from the multifactorial
chylomicronemia syndrome (MCS) in the absence of
genetic testing. Our aim was to characterize the genotype of
our HTG patients with respect to MCS and FCS as well as
to apply the clinical FCS-score proposed by Moulin and
colleagues.
Methods: We studied 90 genotyped patients with severe
HTG in our clinic during the last seven years. We classified
the identified genetic variants (SHERLOC-criteria), fol-
lowed by categorization into MCS or FCS. Clinical data
were gathered from the medical records and the FCS-score
was calculated for each patient.
Results: The gene sequencing revealed ten FCS patients.
Four were compound heterozygous and six were
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homozygous for a pathogenic variant. Another 53 patients
were categorized as MCS, of which seven were hetero-
zygous carriers of a pathogenic variant. Altogether, we
found 16 pathogenic variants of which six have not been
described before. The most common was a missense variant
(c. 644G>A, p.G215E) in the LPL gene. In 27 (30%) of our
patients we were unable to detect any genetic alterations. In
our cohort the FCS-score yielded a sensitivity of 80% and a
specificity of 92.5%.
Conclusions: At 11% the prevalence of FCS among our
patients with severe HTG was higher than expected. The
FCS score performed similar to the original study, however
20% of the FCS patients will not be detected correctly,
relying on the score only.
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Gene expression and pathway analysis of omental
adipose tissue from Type 2 diabetic and non diabetic
Asian obese patients
R. Dehghan1,2, R. Dorajoo1, M. H. Liu3, L. Wang1, Y. Y.
Sia1, C. B. Lin1, T. H. Koh1, S. Huang4, E. Chan4, W. Liew4,
Y. Z. Tan5, C. M. Khoo6, X. Sim7, J. Liu1,6, A. Shabbir5, E. S.
Tai4,6,8
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Technology, National University of Singapore, Singapore,
Singapore, 4Division of Endocrinology, Department of
Medicine, National University Health System, Singapore,
Singapore, 5Department of Surgery, National University
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Yong Loo Lin School of Medicine, National University of
Singapore, Singapore, Singapore, 7Saw Swee Hock School
of Public Health, National University of Singapore,
Singapore, Singapore, 8Duke-National University of Singa-
pore Medical School, Singapore, Singapore
Introduction: Asians may have increased propensity to
central obesity and related Type 2 diabetes mellitus (T2DM)
risks, as compared to populations of European ancestry.
Gene expression profiling of omental fat in Asians may
identify additional T2DM relevant pathways.
Methods: We performed RNA-seq on 37 (16 T2DM and
21 non-T2DM) omental fats from Asian obese patients,
obtained during bariatric weight-loss surgery. DESeq2 was
used for differential expression analysis.
Results: 266 differentially expressed genes (DEGs)
showed higher and 197 showed lower expression in
T2DM vs non-T2DM samples (Padj < 0.05). We identified
GABRB2 as the top novel upregulated gene, highlighting a
role for GABAergic system in omental fat with T2DM
while ACVR1C expression was most significantly down-
regulated and loss of function variants in ACVR1C have
been reported for reduced central obesity and T2DM risks.
Upstream regulator analysis using our DEGs revealed OSM
as the most significant regulator of up-regulated DEGs and
PPARG for down-regulated DEGs. Pathway-based analyses
using our DEGs connected with OSM revealed significant
associations for immune-related pathways, validating recent
associations of increased HMGB1 and TREM1 signaling
for increased T2DM risks. Similar analyses on PPARG
revealed pathways associated with adipogenesis, glucose
and lipid metabolism and validated the protective associa-
tion between increased Apelin signaling in omental fat
and T2DM.
Conclusions: Our study on omental fat identified novel
DEGs associated with T2DM. Omental fats from T2DM
subjects exhibit upregulation of immune pathways probably
modulated by OSM, and downregulation in genes involved
in adipogenesis, glucose and lipid metabolism probably
modulated by PPARG.
R. Dehghan: None. R. Dorajoo: None.M.H. Liu: None.
L. Wang: None. Y.Y. Sia: None. C.B. Lin: None. T.H.
Koh: None. S. Huang: None. E. Chan: None. W. Liew:
None. Y.Z. Tan: None. C.M. Khoo: None. X. Sim: None.
J. Liu: None. A. Shabbir: None. E.S. Tai: None.
P06.18.B
Lipodystrophy-associated PPARγ mutants define sub-
classes of target genes
M. F. Broekema1, M. Stahl Madsen2, M. Rønn Madsen2, A.
Koppen1, M. E. Kranendonk1, M. Groot Koerkamp1, N.
Hamers1, A. Borgmans1, A. M. Bonvin3, F. C. Holstege1, W.
Spiering1, H. Monajemi4, D. Cassiman5, S. Mandrup2, E.
Kalkhoven1
1University Medical Center Utrecht, Utrecht, Netherlands,
2University of Southern Denmark, Odense, Denmark,
3Utrecht University, Utrecht, Netherlands, 4Rijnstate Hos-
pital, Arnhem, Netherlands, 5Leuven University Hospitals,
Leuven, Belgium
Introduction: The nuclear receptor PPARγ, encoded by the
PPARG gene, is pivotal for adipocyte differentiation and
function. How the different domains of PPARγ exactly
communicate on intra- and intermolecular level to generate
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the appropriate transcriptional output in the context of
chromatin is unresolved. New insights can be obtained from
natural PPARG mutations, as found in patients suffering
from familial partial lipodystrophy subtype 3 (FPLD3),
characterized by repartitioning of adipose tissue causing
insulin resistance and type 2 diabetes. We identified two
FPLD3 mutations (E379K and R212Q) - located in distinct
PPARγ domains - that impair the adipogenic capacity.
Methods and materials: We have used genome-wide
sequencing-based strategies in PPARG knockout mouse
embryonic fibroblasts transduced with PPARγ to determine
how these PPARG mutations affect the ability of PPARγ to
activate PPARG target genes in the context of native
chromatin structure.
Results: Both mutations impair the ability of PPARγ to
induce an overlapping subset of target genes, including
classical PPARγ target genes such as Lpl, while retaining
the ability to activate other genes including Acox1.
Genome-wide DNA binding profiles indicated that regula-
tory regions that require PPARγ for chromatin remodeling
are particularly sensitive to the mutations. In addition, the
exact nucleotide sequence of the PPARγ binding sites can
potentially contribute to target gene sensitivity.
Conclusions: We propose a model in which recruitment
of PPARγ to chromatin is determined by multiple protein-
protein and protein-DNA interfaces. Our findings indicate
that relatively subtle molecular defects in PPARγ are
sufficient to cause lipodystrophy by dysregulating a subset
of PPARγ target genes.
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D. Cassiman: None. S. Mandrup: None. E.
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‘Congenital Nicotinamide adenine dinucleotide (NAD)
Deficiency Disorder treated with niacin
supplementation’
A. M. Cueto-González, S. Arevalo, M. Del Toro, G. Giralt,
A. Creus, M. Torres, I. Valenzuela, A. Abuli, E. Tizzano
Hospital Vall d’Hebron, Barcelona, Spain
Congenital NAD Deficiency is an extremely ultrarare dis-
order (OMIM 617660, ORPHA 521438) with only two
previous cases reported (Shi et al. 2017). We report a new
case diagnosed during pregnancy presenting cardiac
malformations (Shone syndrome with high risk of aortic
coarctation) and progressive intrauterine growth
retardation since 20w with preserved head circumference
and abdominal perimeter, without renal malformations or
vertebral segmentation. Prenatal exome revealed a
homozygous frameshift mutation in exon 1 of the HAAO
gene (p.R15Gfs*99). The parents were heterozygous car-
riers and referred non-consanguinity. After birth the
length was -3.2SD, we performed an abdominal ultra-
sound (normal), skeletal X-rays (normal) and cranial MRI
(normal). The patient had elevated levels of 3-
hidroxyanthralinic acid (3HAA) and 3-OH-kynurenina
and normal levels of niacin, similar to the two previously
reported cases. Given that defects in Haao-null mice owing
to NAD deficiency can be prevented with supplementation
with nicotinic acid (Shi et al., 2017), compasive use of
niacin supplementation was started at one month. Follow-
up at 3 months shows a normal length (-1.63SD). There
are only two reported patients from Australia with
homozygous variants in HAAO predicting loss-of-function
changes in HAAO (different mutations that our patient).
Cardiac, vertebral and renal malformation and hearing
loss were present in both and Mondini defect and intel-
lectual disability in one of them. To our knowledge, this is
the third patient reported with NAD Deficiency and the
first treated with niacin. Our patient has only three months
and long term follow-up is required to determine efficacy.
A.M. Cueto-González: None. S. Arevalo: None. M. Del
Toro: None. G. Giralt: None. A. Creus: None. M.
Torres: None. I. Valenzuela: None. A. Abuli: None. E.
Tizzano: None.
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Research Priorities for Primary Mitochondrial Disor-
ders: Defined by Patients, their Carers and Clinicians.
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Sharpe5, S. Holmes6, M. Votruba7, C. Feeney2, L. Weaver8,
L. Curtis9, L. Butterworth9, P. Hossain8, K. Staley10, A.
Hunter10, S. Upadhyaya11
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Kingdom, 6National Hospital for Neurology and Neurosur-
gery, London, United Kingdom, 7Cardiff University and
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Lily Foundation, London, United Kingdom, 10Genetic
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Introduction: Primary mitochondrial disorders are clini-
cally and genetically heterogeneous, for which there is
currently a lack of effective therapies. It is therefore vital to
know that competitively funded research meets the needs of
patients and their clinicians. The Priority Setting Partner-
ships (PSPs) are an established, collaborative methodology
that brings patients, charity representatives and clinicians
together to try to establish the most pressing and unan-
swered research priorities for a particular disease group.
Methods: After a scoping exercise to identify relevant
partners, we chose to include questions relevant to both
children and adults with primary mitochondrial disorders. A
web-based questionnaire was developed and widely dis-
seminated; asking for patients, carers and clinicians to pose
their important research questions. This yielded 709
questions from 50 patients, 47 carers and 50 clinicians.
These were grouped in to themes and filtered to exclude
statements that were personal stories. Extensive literature
searching was performed to determine which questions are
unanswered based on current evidence. This process
resulted in a list of 42 discrete questions. In a second
web-based questionnaire, patients, carers and clinicians
were invited to rank these 42 questions. This identified 24
questions that were taken forward to a workshop attended
by a diverse range of patients, carers, charity representatives
and clinicians. The relative merits and strengths of each
question were debated to create a definitive ‘top 10 of
unanswered research questions’.
Results/Conclusion: Here we present the ‘top 10 of
unanswered research questions for primary mitochondrial
disorders’, as defined by the patients, their carers and
clinicians.
J. Lowndes: None. R. Thomas: None. S. Rahman:
None. R. Wheeler: None. J. Sharpe: None. S. Holmes:
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None. L. Curtis: None. L. Butterworth: None. P.
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High coverage NGS of mtDNA proofs apparent de novo
variant to be in fact not de novo
U. Ahting1, B. Lorenz-Depireux2, R. Berutti2, M.
Radivojkov-Blagojevic2, F. Radelfahr3, C. Stendel3, J. U.
Walther1
1Institut für Humangenetik. TUM, München, Germany,
2Helmholtz-Zentrum München, Institut für Humangenetik,
Neuherberg, Germany, 3Friedrich-Baur-Institut, München,
Germany
Introduction: Maternally inherited pathogenic mtDNA
variants increase in heteroplasmy during passage from
mother to affected offspring. A pathogenic variant, which is
present in an affected offspring, is often not detectable in
various tissues of the mother, and therefore classified as “de
novo”. Here we present a case, where an apparent “de
novo” variant is actually not de novo, as it is detectable by
high coverage NGS in the mother and other maternal
relatives.
Case: The male index patient is affected by Leigh
syndrome, a classical mitochondrial disease. Symptoms are
psychomotor delay and generalized dystonia and MRI brain
scans show bilateral symmetrical lesions in the basal
ganglia and brainstem. Muscle biopsy showed ragged red
fibers. Mother and grandfather are affected by Parkinson´s
disease.
Results: Whole exome sequencing identified pathogenic
variant m.10158T>C in mtDNA isolated from blood. High
coverage NGS revealed that the variant is present in this
sample with heteroplasmy of 62% (2710 of 4371 reads).
Testing of mother and healthy siblings showed that the
variant is present in all investigated tissues with low
heteroplasmy (~1%). Therefore the variant is inherited.
Discussion: Apparent de novo mtDNA-variants may be
inherited and maternal relatives may be carriers of such
variants. High coverage NGS of mtDNA can detect such
cases. Increase of heteroplasmy in cases like this must be
due to a strong bottleneck effect. If the bottleneck works by
unequal partitioning (segregation), at least 6 cell divisions
without mtDNA replication must have happened in the
reported affected case.
U. Ahting: None. B. Lorenz-Depireux: None. R.
Berutti: None. M. Radivojkov-Blagojevic: None. F.
Radelfahr: None. C. Stendel: None. J.U. Walther: None.
P06.32.A
Molecular mitochondrial DNA analysis in patients with
suspected mitochondrial disorder
K. Grigalionienė, B. Burnytė, D. Vansevičiūtė, G.
Žukauskaitė, L. Ambrozaitytė, A. Utkus
Department of Human and Medical Genetics, Institute of
Biomedical Sciences, Faculty of Medicine, Vilnius Uni-
versity, Vilnius, Lithuania
Introduction: Mitochondrial diseases represent important
and common source of inherited metabolic disorders.
Mitochondrial dysfunction is characterized by defects in
oxidative phosphorylation and caused by pathogenic var-
iants in either mitochondrial DNA or nuclear mitochondrial
genes. A correct diagnosis is challenging due to the com-
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 295
plexity of the clinical presentations, lack of classical diag-
nostic clues and genetic heterogeneity.
Patients and methods: In this study, mtDNA was
examined in a cohort of 71 affected individuals (69
unrelated families) with suspected mitochondrial disorder.
Comprehensive analysis of mtDNA was performed using
following molecular genetic methods: Sanger sequencing of
whole-length mtDNA for detection of point variants, long
PCR and MLPA for detection of mtDNA deletions/
duplications and RT-PCR for mtDNA copy number
analysis.
Results: Six (8.70%) patients were identified with
pathogenic mtDNA variants in the cohort of 69 unrelated
patients. Common mtDNA pathogenic variant
NC_012920.1:m.3243A>G with variable heteroplasmy
levels was identified in three unrelated female patients with
heterogeneous phenotype of MELAS. Homoplasmic
mtDNA pathogenic variants NC_012920.1:m.8993T>C
and NC_012920.1:m.9185T>C were identified in patients
presenting with Leigh syndrome. Novel heteroplasmic 5888
bp mtDNA deletion NC_012920.1:m.6069_11956del caus-
ing Kearns-Sayre syndrome was identified using long PCR
and Sanger sequencing while MLPA profile was normal.
MtDNA haplogroup analysis revealed a 43.5% frequency of
the most common H haplogroup in the patients group.
Conclusions: Benefits of mtDNA analysis manifest in the
identification of pathogenic variants that could direct
patients care, but limitations of the methods should be
taken into account while selecting the best investigation
strategy.
Supported by grant TAP LLT-02/2015
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Mitochondrial disorder diagnosis; a combined genomic
and transcriptomic approach
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Universitat Pompeu Fabra (UBF), Barcelona, Spain, 3Cen-
tro Nacional de Analisis Genomico (CNAG-CRG); Centre
for Genomic Regulation; Barcelona Institute of Science and
Technology (BIST); Universitat Pompeu Fabra (UBF),
Barcelona, Spain, 4Department of Health Sciences and
Centre for Molecular Medicine and Biobanking, University
of Malta, Msida, Malta, 5Department of Paediatrics, Mater
Dei Hospital, Msida, Malta, 6Department of Pathology,
Mater Dei Hospital, Msida, Malta, 7Department of
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Molecular Medicine and Biobanking, Msida, Malta
Mitochondrial disorders are rare, genetically heterogenous
diseases which affect the oxidative phosphorylation
(OXPHOS) system. A combined genomic and tran-
scriptomic approach was adopted to diagnose mitochondrial
disorders in a cohort of 14 Maltese patients. Phenotypic data
was recorded in the RD-Connect PhenoTips instance. The
nuclear and mitochondrial genome were evaluated by whole
exome sequencing. Variant filtration and prioritisation was
undertaken using the RD-Connect Genome Phenome Ana-
lysis Platform (GPAP). The full transcriptome was analysed
by RNA sequencing. Differential expression of candidate
variants was confirmed by q-PCR. A HEK-293 cell model
was used to functionally characterise the effect of a rare
homozygous missense variant on mitochondrial complex 1
activity in one of the patients. Pathogenic variants were
characterised according to their functional roles in
OXPHOS biogenesis (see Table). The most variants were
identified in Complex 1 OXPHOS subunits (N=8) and
Complex 1 assembly factor variants were also identified in
4 of these patients. Two patients were diagnosed with































































































This combined genomic and transcriptomic approach
could aid in establishing a diagnosis for these rare disease
patients.
J. Vella: None. S. Laurie: None. L. Matalonga: None.
J. Borg: None. D. Soler: None. E. Said: None. I. Borg:
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Mitochondriopathy in pediatric patients with unspecific
neuropediatric disease
A. van der Ven1, J. Denecke2, K. Tsiakas2, S.
Wortmann3,4,5, D. Lessel1, F. Kortüm1, T. Bierhals1, H.
Prokisch3,4, R. Santer2, M. Hempel1
1Dept. Human Genetics, UKE Hamburg-Eppendorf, Ham-
burg, Germany, 2Dept. Pediatrics, UKE Hamburg-Eppen-
dorf, Hamburg, Germany, 3Dept. Human Genetics, TU
Munich, Munich, Germany, 4Dept. Human Genetics,
Helmholz Centre Munich, Neuherberg, Germany,
5Dept. Pediatrics, Paracelsus Medical University,
Salzburg, Austria
Introduction: Mitochondriopathies account for an impor-
tant subgroup of neuropediatric conditions but often the
clinical presentation may be too unspecific to hint to an a
priori disease hypothesis.
Materials and Methods: We report on a deep phenotyp-
ing and trio-WES study of 492 unrelated children affected
by previously undiagnosed and diverse complex neurope-
diatric disorders. All children underwent a standardized and
comprehensive clinical work-up and trio-WES. In a subset
of 31 children we had an a priori clinical suspicion of a
mitochondriopathy.
Results: Within this group of patients with a clinical
suspicion of an underlying mitochondriopathy, we con-
firmed the diagnosis by identifying a pathogenic variant in a
known mitochondriopathy-associated gene in 9/31 children
(29%). In 10/31 children (32%) we discovered a pathogenic
variant in a disease gene not associated with a mitochon-
driopathy. For 3/31 children we detected a pathogenic
mutation in a candidate gene for a mitochondriopathy. In
the group of 461 children with no suspicion of a
mitochondriopathy, we identified pathogenic mutations in
known mitochondriopathy-associated genes in 13 children
(3%). In 226/461 children (49%) we detected pathogenic
mutations in other known disease genes. For 222/461 (48%)
patients no definite genetic diagnosis could be established.
Conclusions: Overall, we molecularly established the
diagnosis of a mitochondriopathy in 22 of 492 (4,5%)
unselected neuropediatric patients. This study highlights the
importance of WES for the identification of children with a
clinically less characteristic presentation of their underlying
mitochondriopathy.
A. van der Ven: None. J. Denecke: None. K. Tsiakas:
None. S. Wortmann: None. D. Lessel: None. F. Kortüm:
None. T. Bierhals: None. H. Prokisch: None. R. Santer:
None. M. Hempel: None.
P06.36.B
Mitochondrial DNA sequence context in the penetrance
of all mt-tRNA mutations across many species: A study
diagnostic implications
H. O’Keefe, R. A. Queen, J. S. Steyn, P. Lord, J. L. Elson
Newcatsle University, Newcastle, United Kingdom
Introduction: Mitochondrial disorders are heterogeneous,
showing variable presentation and penetrance. Over the last
three decades, our ability to recognize mitochondrial
patients and diagnose these mutations, linking genotype to
phenotype, has greatly improved. However, it has become
increasingly clear that these strides in diagnostics have not
benefited all population groups. It has been suggested that
haplogroup (or lineage) context might influence the pre-
sentation and penetrance of mtDNA disease; thus, the
spectrum of mutations that are associated with disease in
different populations.
Methods and Materials: This paper conducted the most
extensive investigation to date into the importance of
haplogroup context on the pathogenicity of mtDNA
mutations. We searched for proven human point mutations
across 726 multiple sequence alignments derived from 33
non-human species absent of disease.
Results: 58 pathogenic point mutations arise in the
sequences of these species. We assessed the sequence
context and found evidence of population variants that
could modulate the phenotypic expression of these point
mutations masking the pathogenic effects seen in
humans.
Conclusions: This supports the theory that sequence
context is influential in the presentation of mtDNA disease
and has implications for diagnostic practices. Our current
understanding of the pathogenicity of mtDNA point
mutations, primarily built on studies of individuals with
haplogroups HVUKTJ, will not present a complete picture.
This will impair our understanding of disease mechanisms
and create a diagnostic inequality, whereby individuals who
do not belonging to more commonly studied lineages will
be less likely to receive a genetic diagnosis.
H. O’Keefe: None. R.A. Queen: None. J.S. Steyn:
None. P. Lord: None. J.L. Elson: None.
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Unraveling Atypical Phenotypes in Neuronal Ceroid
Lipofucinosis type 2
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1Faculdade de Medicina - Centro Universitario Estacio de
Ribeirao Preto, Ribeirao Preto, Brazil, 2Centro Paulista de
Diagnostico e Pesquisa, Ribeirao Preto, Brazil, 3Hospital
de Clínicas de Porto Alegre, Porto Alegre, Brazil, 4Hospital
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Introduction: Late-infantile neuronal ceroid lipofuscinosis
(NCL), also called neuronal ceroid lipofuscinosis type 2
(CLN2), is caused by the deficiency of lysosomal enzyme
tripeptidyl peptidase-1 (TPP1) due to mutations in the
CLN2 gene. The classical phenotype is late infantile pre-
senting with language developmental delay, with its clinical
signs usually appearing between the ages of 2 to 4 years
with seizures and a rapid decline of psychomotor functions.
Most children are bedridden at 5 years and die around the
age of 10 years. Nevertheless, atypical phenotypes have
been reported in the literature, creating a clinical challenge
to avoid diagnosis without significant delay.
Methods: Clinical, biochemical and neuroradiological
data retrospective analysis of five CLN2 patients showing
atypical/protracted phenotypes
Results: All four patients (3 males; 2 females) showed an
atypical late onset phenotype. First symptons started around
5 - 10 years of age being cerebellar ataxia the most
prominent feature. Abnormal findings in brain MRI were
found in all patients (cerebellar atrophy and periventricular
white matter changes). Seizures were present in three
patients, cognitive decline was seen in 4 patients and mild
learning disabilities in one. TPP1 enzyme was decreased in
all patients, although not in the typical range found in
“classical” CLN2 patients.
Discussion: The protracted CLN2 phenotype was pre-
viously considered globally rare. In South America, the
frequency is approximately 50% of affected individuals.
Recently with the recent approval of intraventricular
enzyme replacement therapy (ERT) with cerliponase alpha
for CLN2 disease, early diagnosis is essential to start
treatment before disease progression.
A.M. Amaral: None. F. Fola: None. Z.A. Carneiro:
None. L. Vagnini: None. C. Fischinger Moura De Souza:
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Comprehensive characterization of a large cohort of
patients with Niemann Pick disease
P. Guatibonza, C. Beetz, J. Gutierrez, S. Zafari, V.
Skrahina, C. Cozma, P. Bauer, A. Rolfs
Centogene AG, Rostock, Germany
The term Niemann Pick disease (NPD) denotes a geneti-
cally and clinically heterogeneous group of lysosomal sto-
rage disorders. A deeper insight into NPD would benefit
from large and uniformly characterized cohorts of patients.
We queried our database for patients that had received a
genetic diagnosis of NPD between December 2015 and
August 2019. Information was compiled on: affected gene,
age, gender, and country of origin, along with available
clinical and metabolic data. A genetic diagnosis of NPD
was issued for 733 patients. With n=472 (64.4%), the
majority had variants in NPC1, while SMPD1 and NPC2
were identified as the affected genes in 255 (34.8%) and 6
cases (0.8%), respectively. Most patients were infants
(median age at diagnosis 3.6 years; range 0 to 76 years).
They had been referred from 52 distinct countries, with the
top 4 countries (Iran, Germany, Brazil and Egypt) collec-
tively accounting for more than 50% of referrals. Transla-
tion of the available clinical information into human
phenotype ontology (HPO) terms revealed that hepato- and/
or splenomegaly was present in 76.5% of patients, intel-
lectual disability in 27.9%, and jaundice in 19.0%. Further
frequent HPO terms (i.e. present in >10%) included,
abnormality of movement, ataxia, failure to thrive, and
seizures. The NPD-specific biomarker LysoSM-509 was
pathologically increased in 97.9% of the patients. Our
cohort is amongst the largest described to date. By being
well-characterized at numerous levels, it represents a valu-
able basis for discovering novel correlations and, thereby,
for increasing our understanding of Niemann Pick disease.
P. Guatibonza: A. Employment (full or part-time);
Significant; Centogene AG. C. Beetz: A. Employment (full
or part-time); Significant; Centogene AG. J. Gutierrez: A.
Employment (full or part-time); Significant; Centogene AG.
S. Zafari: A. Employment (full or part-time); Significant;
Centogene AG. V. Skrahina: A. Employment (full or part-
time); Significant; Centogene AG. C. Cozma: A. Employ-
ment (full or part-time); Significant; Centogene AG. P.
Bauer: A. Employment (full or part-time); Significant;
Centogene AG. A. Rolfs: A. Employment (full or part-
time); Significant; Centogene AG.
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A novel 160Kb deletion identified in PCCA gene using
whole exome sequencing in a patient with propionic
acidemia
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Tehran, Iran, Islamic Republic of, 5IVF Center, Cuypers
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Background: Propionic acidemia (PA) is a severe meta-
bolic disorder characterized by various clinical features.
Herein, we present an 18-month-old male patient from
consanguineous parents with early-onset of symptoms such
as anemia, respiratory problem, and developmental delay.
Urine examination exhibited an increased level of 3-
hydroxypropionic acid and methylcitric acid, led to the
primary diagnosis of PA.
Methods: To identify the causative variant, DNA was
extracted from the peripheral blood of the child and exons
were captured and enriched to perform whole exome
sequencing (WES). Data were analyzed using bioinfor-
matics techniques and in silico predictors. Conventional
PCR and Sanger sequencing were used to confirm the
findings in WES. Additionally, comparative genomic
hybridization (CGH)-array was carried out to study the
accurate size of the copy number variation (CNV).
Results: Surprisingly, no pathogenic variants in propionic
academia causing genes (PCCA and PCCB) or phenotypi-
cally related disorders’ genes. Assuming the probably low
coverage, we analyzed the PCCA and PCCB regions in the
BAM file. In the PCCA, unlike PCCB, exons 12 to 21 were
identified with no coverage, probably suggesting deletion of
the approximately 220kb-size region. Not only we con-
firmed the novel PCCA deletion via PCR but also
performing CGH-array revealed the approximate deletion
size of 160Kb.
Conclusions: We identified a novel homozygous deletion
in the PCCA in the patient with PA using WES. Our results
showed that WES can be used for identifying CNVs instead
of CGH-array. However, a lot of studies should be done to
improve the accuracy of this approach.
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A novel hemizygous loss-of-function variant in the
PRPS1 gene found in a patient with features of Arts
syndrome, but without hearing loss and normal levels of
purine/pyrimidine metabolites
S. Puusepp1,2, K. Reinson1,2, S. Pajusalu1,2,3, A. B. P. van
Kuilenburg4, D. Dobritzsch5, W. Stenzel6,7, K. Õunap1,2
1Department of Clinical Genetics, Institute of Clinical
Medicine, Faculty of Medicine, University of Tartu, Tartu,
Estonia, 2Department of Clinical Genetics, United Labora-
tories, Tartu University Hospital, Tartu, Estonia, 3Depart-
ment of Genetics, Yale University School of Medicine, New
Haven, CT, United States, 4Department of Clinical
Chemistry, Cancer Center Amsterdam, Amsterdam Gastro-
enterology & Metabolism, Amsterdam UMC, University of
Amsterdam, Amsterdam, Netherlands, 5Department of
Chemistry – BMC, Uppsala University, Uppsala, Sweden,
6Department of Neuropathology, Charité–
Universitätsmedizin Berlin, corporate member of Freie
Universität Berlin, Humboldt-Universität zu Berlin, and
Berlin Institute of Health, Berlin, Germany, 7Leibniz
Science Campus Chronic Inflammation, Berlin, Germany
Introduction: The PRPS1 gene, located on Xq22.3,
encodes phosphoribosyl-pyrophosphate synthetase (PRPS),
a key enzyme in purine de novo synthesis. Three clinical
phenotypes are associated with loss-of-function PRPS1
variants and decreased PRPS activity: Arts syndrome,
Charcot-Marie-Tooth disease type 5 (CMTX5) and X-
linked non-syndromic deafness. Hearing loss is present in
all of these patients. CMTX5 patients additionally present
with peripheral neuropathy and optic atrophy. Arts syn-
drome includes developmental delay, intellectual disability,
ataxia and susceptibility to infections.
Case report: We report a boy who presented with
marked generalized muscular hypotonia, progressive global
developmental delay, lack of speech, trunk instability,
exercise intolerance, hypomimic face with opened mouth,
oropharyngeal dysphagia, dysarthria, and very frequent
upper respiratory tract infections. Cardiac, audiological and
ophthalmological investigations were normal. A novel
hemizygous variant c.130A>G p.(Ile44Val) was found in
the PRPS1 gene by panel sequencing. PRPS activity in
erythrocytes was markedly reduced confirming the patho-
genicity of the variant. In retrospect, serum uric acid levels
and the first urine purine/pyrimidine analysis were normal,
but analysis of the follow-up sample showed nearly absent
hypoxanthine.
Conclusions: We describe a patient with features of Arts
syndrome and a novel PRPS1 loss-of-function variant.
However, at the current age of five years, our patient does
not present with hearing loss, which has so far been
reported in all of the Arts syndrome patients as congenital/
early-onset. We would also like to emphasize that the first
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purine/pyrimidine analysis was normal giving no clues
towards a dysfunction in the purine-pyrimidine metabolism.
Funding: Estonian Research Council grants PUT355,
PRG471, PUTJD827.
S. Puusepp: None. K. Reinson: None. S. Pajusalu:
None. A.B.P. van Kuilenburg: None. D. Dobritzsch:
None. W. Stenzel: None. K. Õunap: None.
P06.43.C
Infantile and early childhood onset mitochondrial
myopathy due to mutations in the TK2 gene with a
phenotype of spinal muscular atrophy 5q. The first cases
in Russia.
P. Tsygankova1, S. Kurbatov2,3, I. Bychkov1, Y. Itkis1, A.
Galushkin1, K. Molewa4, V. Zabnenkova1, E. Zakharova1
1Research centre for medical genetics, Moscow, Russian
Federation, 2Voronezh Regional Clinical Consulting and
Diagnostic Center, Voronezh, Russian Federation, 3Asso-
ciation of Neuromuscular Disorders Specialists, Medical
Center “Practical Neurology”, Moscow, Russian Federa-
tion, 4Department of Neurology, "Dagestan State Medical
University", Machachkala, Russian Federation
Mitochondrial myopathy (MM) due to thymidine kinase 2
deficiency and spinal muscular atrophy (5q) (SMA-5q) are
two potentially curable hereditary diseases with different
levels of damage to the neuromuscular system and etiology.
Early childhood forms have a similar phenotype and are
difficult for differential diagnosis. We present the clinical
characteristics and molecular defect of MM with TK2
deficiency and informing health care specialists about the
possibility of optimizing differential diagnosis. Materials
and methods. This study involved 9 patients with excluded
SMA-5q diagnosis. TK2 mutations were detected by NGS-
gene panel in 3 of them. In addition, 96 DNA samples of
patients with SMA-phenotype were screened for TK2
mutations by Sanger sequencing. Results. Nine patients
with MM with TK2 from 6 unrelated families have been
diagnosed. Three of them have been found retrospectively
by analysis of 96 SMA-5q negative samples. Screening for
mutations in the TK2 gene can be recommended for all
children with a manifestation of the disease up to 2 years
old, with rapidly progressing muscle weakness, increased
CPK and/or lactate in the blood and/or detection of damage
to the leg muscles on MRI. The study revealed four pre-
viously undescribed mutations in the TK2 gene: c.169G>A
(p.Gly57Ser), c.310C>T (p.Arg104Cys), c.338T>A (p.
Val113Glu), c.655T>C (p.Trp219Arg). Early molecular
diagnostic is important for the choice of experimental
nucleoside bypass treatment for this group of mitochondrial
diseases.
P. Tsygankova: None. S. Kurbatov: None. I. Bychkov:
None. Y. Itkis: None. A. Galushkin: None. K. Molewa:
None. V. Zabnenkova: None. E. Zakharova: None.
P06.44.A
TYPE 2 DIABETES AND CANCER CO-MORBIDITY:
IS THERE SHARED GENETIC SUSCEPTIBILITY?
L. Zudina1, A. Demirkan1, I. Pupko1, M. J. Gunter2, M.
Kaakinen1, I. Prokopenko1
1Department of Clinical & Experimental Medicine, Uni-
versity of Surrey, Guildford, United Kingdom, 2Nutrition
and Metabolism Section, International Agency for Research
on Cancer, World Health Organization, Lyon, France
A plethora of epidemiological studies showed relationships
between Type 2 Diabetes (T2D) and common cancers,
reporting increased risks for postmenopausal breast
(RR=1.20), colorectal (RR=1.30) and pancreatic
(RR=1.94) cancers, and decreased risk for prostate cancer
(RR=0.84) in T2D patients. We aimed to dissect the genetic
factors shared between T2D, pancreatic and three common
cancers using genome-wide genetic variability in a large
case-control and population-based context.
We evaluated the role of signals established for T2D on
the susceptibility to postmenopausal breast, prostate, color-
ectal and pancreatic cancers in EPIC (European Prospective
Investigation into Cancer and Nutrition) a combined nested
case-control study of 14,553 individuals, including 4,345/
2,120/426/499 with postmenopausal breast/colorectal/pros-
tate/pancreatic cancer diagnosis and 476 prevalent cases of
T2D. We generated polygenic risk scores (PRS) for breast/
colorectal/prostate/pancreatic cancers and T2D using 171/
90/154/21 and 403 established DNA variants for each
disease, respectively. To perform reciprocal evaluation of
PRS effects on diabetes and four cancer risks, we used the
variants from original phenotype and the estimates of per-
allele genetic effects from the other outcome.
For all individual PRSs, we observed significant (P <
5x10−5) increase in the risk of original outcomes. T2D PRS
was significantly associated with risk of pancreatic cancer
(OR=3.82[1.65-8.84], P=1.71x10−3). This effect was
stronger compared to the T2D PRS effect on T2D risk
(OR=1.53[1.35-1.75], P=9.87x10−11). The T2D and pan-
creatic cancer share signals at GRP, HNF1B BCAR1 and
LINC-PINT/KLF14 loci only.
Using the pan-European EPIC study data, we provide
evidence for shared genetic factors between T2D and
pancreatic cancer.
Funding: WCRF-2017/1641
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P06.45.B
Milder form of Vici syndrome due to novel missense
variant affecting splicing
M. Skopkova1, K. Brennerova2, M. Ostrozlikova3, S.
Borecka1, D. Gasperikova1
1Institute of Experimental Endocrinology, Biomedical
Research Center, Slovak Academy of Sciences, Bratislava,
Slovakia, 2Department of Pediatrics, Medical Faculty of
Commenius University and National Institute of Children’s
Diseases, Bratislava, Slovakia, 3Department of Laboratory
Medicine, National Institute of Children’s Diseases,
Bratislava, Slovakia
Introduction: Vici syndrome is a rare autosomal recessive
syndrome caused by mutations in the gene EPG5 encoding
ectopic P granules protein involved in autophagy. It is a
neurodevelopmental disorder with multisystem involvement
including corpus callosum agenesis, cataracts, hypo-
pigmentation, cardiomyopathy, and immunodeficiency. It
has been hypothesized that the severity of phenotype is
related to residual level of functional EPG5.
Patient: A 4 years old boy of Roma ethnicity with
preterm birth, hypotonia, severe hypotrophy and growth
retardation, developmental delay, mild brain atrophy, and
urine organic acid profile suggesting mitochondrial disease
was referred for whole-exome sequencing.
Results: We have found a novel variant c.4205G>A (p.
Arg1402Lys) in the EPG5 gene. As it is the last base of
exon 23, we performed a mini-gene assay to estimate its
effect on splicing. This has shown decreased inclusion of
exon 23 compared to wild-type (40% vs. 72%, respec-
tively). RNA sequencing confirmed only presence of the
correctly spliced transcript. The patient was further
examined for symptoms common in Vici syndrome and
hypopigmented skin areas and immunodeficiency were
confirmed. Interestingly, the patient has present corpus
callosum, although thin, no seizures, no cataracts and no
cardiomyopathy. Additionally, he has hemodynamically
important stenosis of left pulmonary artery. The typical sign
- pale skin and hair were also not present.
Conclusions: Novel variant c.4205G>A causes aberrant
splicing only in a proportion of transcripts, therefore, milder
presentation of Vici syndrome in our patient is probably due
to the residual presence of the EPG5 protein. Supported by
VEGA 2/083/17 and APVV-17-0296.
M. Skopkova: None. K. Brennerova: None. M.
Ostrozlikova: None. S. Borecka: None. D.
Gasperikova: None.
P07 Immunology and Hematopoietic System
P07.05.A
A rare pair in one patient - Bernard-Soulier syndrome
unraveled by 22q11.2 microdeletion syndrome
G. Taurina1,2, D. Murmane1,2, I. Voitovica1, S. Nikulsins1, I.
Micule1,3
1Childrens Clinical University Hospital, Riga, Latvia, 2Riga
Stradins University, Riga, Latvia, 3Biomedical Research
and Study Centre, Riga, Latvia
Introduction: The 22q11.2 deletion syndrome is one of the
most common microdeletion syndromes. Bernard-Soulier
syndrome, in turn, is a rare autosomal recessive bleeding
disorder (prevalence <1:1 000 000) with dysfunctional
glycoprotein Ib-V-IX complex, responsible for the adhesion
activity of platelets. We report a patient having both
diseases.
Case report: A boy who was admitted to hospital on the
third day of life due to epistaxis, petechias and umbilical
cord bleeding. Brain MRI showed subdural hematoma
among cerebellar lobes. Blood count revealed severe
thrombocytopenia (8 x 103/uL), that required several
platelet infusions and did not improve with immunoglobulin
treatment. An NGS analysis for Bleeding disorder gene
panel was ordered, with CNV analysis. On the second
month of life flow cytometry revealed reduced CD42b
expressivity.
Results: The NGS gene panel results revealed a
heterozygous pathogenic 22q11.2 microdeletion, encom-
passing 73 genes with GP1BB gene included. The analysis
also showed a heterozygous likely pathogenic variant in
GP1BB gene c.395T>A, p.(Leu132Gln). The combination
of the microdeletion on one and the mutation on the other
GP1BB allele explains the bleeding disorder of our patient
and confirms in him Bernard-Soulier syndrome. 22q11.2
microdeletion syndrome was not suspected before the DNA
analysis. Afterwards at a repeated consultation the patient
demonstrated signs of velopharyngeal insufficiency but as
yet no other signs of the Velocardiofacial syndrome.
Conclusions: In patients with early onset bleeding
disorder genetic testing with CNV analysis must be
performed in order to not miss an autosomal recessive
disease unmasked by a seemingly presymptomatic frequent
microdeletion syndrome.
G. Taurina: None. D. Murmane: None. I. Voitovica:
None. S. Nikulsins: None. I. Micule: None.
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 301
P07.08.A
High intrafamilial variability in a C15orf41 associated
Congenital Dyserythropoietic Anemia family indicates
involvement of C2orf69 in infantile epilepsy
A. Gurel1, S. Unal2, N. Yarali3, P. Simsek Kiper4, S.
Ceylaner5, O. A. Bilir3, F. Gumruk2, N. A. Akarsu1, A.
Cetinkaya1
1Department of Medical Genetics, Faculty of Medicine,
Hacettepe University, Ankara, Turkey, 2Pediatric Hematol-
ogy Unit, Department of Pediatrics, Faculty of Medicine,
Hacettepe University, Ankara, Turkey, 3Division of Pedia-
tric Hematology, Ankara Child Health and Diseases
Hematology Oncology Training and Research Hospital,
Ankara, Turkey, 4Pediatric Genetics Unit, Department of
Pediatrics, Faculty of Medicine, Hacettepe University,
Ankara, Turkey, 5Intergen Genetic Diagnosis Center,
Ankara, Turkey
Congenital dyserythropoietic anemias (CDAs) are a het-
erogenous group of disorders characterized by dysplastic
erythroblasts, ineffective erythropoiesis, iron overload,
splenomegaly and occasionally congenital limb abnormal-
ities. Here, we report a CDA family with a novel homo-
zygous mutation in C15orf41, one of six CDA associated
genes, and unusually high intrafamilial clinical variability.
The proband, 3-month-old male born to consangineous
parents, presented with transfusion-dependent anemia,
malnutrition, recurrent pulmonary infections, hypotonia,
refractory seizures and cerebral atrophy. His affected sibling
had a milder neonatal anemia with no additional findings.
Whole exome sequencing in proband revealed a homo-
zygous missense mutation in C15orf41 (c.58C>A,p.
Pro20Thr), which is not present in GnomAD and also
found in the affected sibling. Another mutation in this
codon (c.58C>T,p.Pro20Ser) had already been associated
with CDA. In order to discover a second mutation that may
explain the neurological findings in the proband, we
focused on twelve >4Mbp runs of homozygosity and
detected a nonsense mutation in C2orf69 (c.929G>A,p.
Trp310Ter), which is absent in GnomAD and in-house
databases. No other family member was homozygous for
this variant. C2orf69 is highly uncharacterized, but we
predict that absence of any homozygous truncating muta-
tions in GnomAD indicates selective pressure on C2orf69.
A high expression in brain is apparent in GTEx dataset.
In conclusion, we demonstrate that a novel mutation in
C15orf41 affects a hotspot codon leading to CDA. In
addition, we associate biallelic mutations in C2orf69 with
intractable infantile epilepsy. Multiple molecular diagnoses
not only underlie the apparent phenotypic variability but
also is useful in uncovering previously unidentified genes.
A. Gurel: None. S. Unal: None. N. Yarali: None. P.
Simsek Kiper: None. S. Ceylaner: None. O.A. Bilir:
None. F. Gumruk: None. N.A. Akarsu: None. A.
Cetinkaya: None.
P07.09.B
A novel disorder involving dyshematopoiesis, inflamma-
tion and HLH due to aberrant CDC42 function
S. Coppola1, M. Lam2,3,4, O. H. Krumbach5, G. Prencipe6,
A. Insalaco6, C. Cifaldi7,8, I. Brigida9, E. Zara1, S. Scala9,
S. Martinelli10, M. Di Rocco10,11, A. Pascarella6, M.
Niceta12, F. Pantaleoni12, A. Ciolfi12, F. Carisey2,4, M.
Akbarzadeh5, L. Farina1,6, L. Pannone10,12, H. C.
Erichsen13, A. C. Horne14,15, Y. Bryceson16,17, L. Torralba-
Raga16, K. Ramme18, A. Finocchi19,8, F. Locatelli20, C.
Cancrini19,8, A. Aiuti9, M. R. Ahmadian5, J. S. Orange2, F.
De Benedetti6, M. Tartaglia12
1National center for rare diseases, Istituto Superiore di
Sanità, Rome, Italy, 2Department of Pediatrics, Columbia
University, Irving Medical Center, New York, NY, United
States, 3Translational Biology and Molecular Medicine
Graduate Program and Medical ScientistTraining Pro-
gram, Baylor College of Medicine, Houston, TX, United
States, 4Department of Pediatrics, Baylor College of
Medicine, Houston, TX, United States, 5Institute of
Biochemistry and Molecular Biology II, Medical Faculty
of the Heinrich-Heine University, Düsseldorf, Germany,
6Division of Rheumatology, Ospedale Pediatrico Bambino
Gesù, IRCCS, Rome, Italy, 7Department of Pediatrics,
Ospedale Pediatricon Bambino Gesù, IRCCS, Rome, Italy,
8Department of Systems Medicine, University of Rome Tor
Vergata, Rome, Italy, 9San Raffaele Telethon Institute for
Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific
Institute, Milan, Italy, 10Department of Oncology and
Molecular Medicine, Istituto Superiore di Sanità, Rome,
Italy, 11Department of Cellular Biotechnology and Haema-
tology, Sapienza University of Rome, Rome, Italy, 12Genet-
ics and Rare Diseases Research Division, Ospedale
Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 13Depart-
ment of Pediatric and Adolescent Medicine, Oslo University
Hospital, Oslo, Norway, 14Pediatric Rheumatology, Astrid
Lindgren Childrens Hospital, Karolinska University Hos-
pital, Stockholm, Sweden, 15Department of Women’s and
Children’s Health, Karolinska Institutet, Karolinska Uni-
versity Hospital Solna, Stockholm, Sweden, 16Department
of Medicine, Karolinska Institutet, Karolinska University
Hospital Huddinge, Stockholm, Sweden, 17Broegelmann
Research Laboratory, Institute of Clinical Sciences,
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University of Bergen, Bergen, Norway, 18Pediatric Hema-
tology, Immunology and HCT Section, Astrid Lindgren
Children’s Hospital, Karolinska University Hospital, Stock-
holm, Sweden, 19Department of Pediatrics, Ospedale
PediatricoBambino Gesù, IRCCS, Rome, Italy, 20Depart-
ment of Pediatric Hematology and Oncology, Ospedale
Pediatrico Bambino Gesù, IRCCS, Rome, Italy
Introduction: The diagnosis and delineation of novel genetic
syndromes is often difficult given the limited availability of
patients, genetic heterogeneity, and clinical variability.
Hemophagocytic lymphohistiocytosis (HLH) is characterized
by hyper-inflammation driven by excessive activation and
expansion of macrophages and defective Natural Killer (NK)
cytotoxicity; it can be fatal if untreated. Here, we identify a
previously unrecognized hematological and autoinflammatory
condition in four unrelated patients with superimposable
features, including neonatal-onset trilinear cytopenia with
dyshematopoiesis, autoinflammation, rash, and HLH.
Methods: To delineate this new syndrome, we performed
phenotype and whole-genome/exome analyses. In silico,
in vitro and in vivo (C. elegans) assays allowed to
characterize the impact of mutation on localization and
function.
Results: All patients shared the same de novo CDC42
mutation (Chr1:22417990C>T, p.R186C) and altered
hematopoietic compartment, immune dysregulation, and
inflammation. We documented unique effects of the p.
R186C on CDC42 localization and function. Indeed,
CDC42^R186C showed impaired interaction with known
CDC42 regulators and effectors, including RHOGDI,
IQGAP1 and WASP, leading to aberrant Golgi accumula-
tion, cytoskeleton rearrangement and reduced growth and
migration, which likely underlie the distinctiveness of the
trait of this syndrome. Aberrant CDC42 function caused
defective NK cytotoxicity, which likely contributes to the
HLH phenotype. Timely therapeutic neutralization of IL-1β
and IFNγ was critical to the survival of one patient, who
underwent successful bone marrow transplantation.
Conclusions: The presented data emphasize the crucial role
played by CDC42 in hematopoiesis and inflammation. Early
recognition of the disorder and establishment of treatment
followed by bone marrow transplant are important to survival.
S. Coppola: None. M. Lam: None. O.H. Krumbach:
None. G. Prencipe: None. A. Insalaco: None. C. Cifaldi:
None. I. Brigida: None. E. Zara: None. S. Scala: None. S.
Martinelli: None. M. Di Rocco: None. A. Pascarella:
None. M. Niceta: None. F. Pantaleoni: None. A. Ciolfi:
None. F. Carisey: None. M. Akbarzadeh: None. L.
Farina: None. L. Pannone: None. H.C. Erichsen: None.
A.C. Horne: None. Y. Bryceson: None. L. Torralba-
Raga: None. K. Ramme: None. A. Finocchi: None. F.
Locatelli: None. C. Cancrini: None. A. Aiuti: None. M.R.
Ahmadian: None. J.S. Orange: None. F. De Benedetti:
None. M. Tartaglia: None.
P07.11.A
Studying known autoimmune risk loci in patients with
CFS-ME
R. Hajdarevic, B. Lie, M. Viken
University of Oslo, Oslo, Norway
Introduction: CFS/ME is a chronic debilitating disease of
unknown origin and cause, but a heritable component is
implicated, likely harbouring a multifactorial aetiology
Evidence from recent studies suggest an involvement of the
immune system as well as a high degree of comorbidity
with other autoimmune disorders. This has led us to explore
the genetic architecture of CFS/ME to further explore the
immune component of this pathology. Previous genetic
studies of CFS/ME were limited by heterogeneous diag-
nostic criteria as well as sample size (<100 patients),
thereby lacking statistical substance.
Materials and Methods: We have genotyped 426 CFS/
ME patient (diagnosed according to the strict Canadian
criteria) and 973 controls with the Illumnia immunochip.
The Immunochip is designed to screen for more than
250,000 common genetic variants covering genetic regions,
previously associated with autoimmune and inflammatory
diseases like rheumatoid arthritis and multiple sclerosis.
Results: Our analysis has shown 16 significant and close
to significant (P values ranging from 6.35E-14 to 9.90E-05)
genetic associations with CFS/ME scattered over several
different chromosomes. The most robust finding is a block
of 4 genetic variants located on chromosome 2.
Conclusions: To the best of our knowledge, our study is
the first of this magnitude in CFS/ME. The results from our
discovery cohort are promising and replication studies in 2
different cohorts are in progress at the time of writing this
abstract (independent Danish cohort with >700 samples and
a UK Biobank cohort with >1500 samples). Grant provided
by the Research Council of Norway Project number: 27268
R. Hajdarevic: None. B. Lie: None. M. Viken: None.
P07.14.A
Clonal relationship and mutational landscape of diffuse
large B-cell lymphoma recurrences
M. R. Berendsen, M. van den Brand, J. Rijntjes, G. Astuti,
C. J. Hess, K. M. Hebeda, W. B. C. Stevens, P. J. T. A.
Groenen, J. H. van Krieken, B. Scheijen
Radboudumc, Nijmegen, Netherlands
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Introduction: Diffuse large B-cell lymphoma (DLBCL) is
an aggressive disease, with a 30-40% relapse rate after first-
line chemoimmunotherapy treatment. Some patients
develop multiple recurrences, but the clonal relationship
between the initial diagnosis and subsequent lymphomas is
not routinely assessed. The molecular mechanisms under-
lying therapy response or failure are still poorly understood.
To support diagnostics, guide therapy choices and even-
tually improve outcome of patients with DLBCL, we aim to
define the clonal relationship and mutational landscape of
DLBCL recurrences.
Materials and Methods: In a cohort of 37 matched
DLBCL diagnosis and one to three relapse biopsies,
clonality analyses were performed by next-generation
sequencing (NGS) of immunoglobulin (IG) gene rearrange-
ments. The clonotypes for the different IG gene rearrange-
ments were identified by ARReST/Interrogate
bioinformatics. Mutation analysis by whole exome sequen-
cing is currently being performed on a subset of the paired
diagnosis-relapse samples.
Results: IG-NGS clonality analyses on matched diagnosis-
relapse(s) samples revealed identical dominant clonotype(s) in
33/37 of the recurrences, even in cases with an interval period
of 14 years. However, in 4/37 DLBCL patients, at least one of
the recurrences was clonally unrelated.
Conclusions: DLBCL recurrences are clonally unrelated
lymphomas in ~10% of the cases, suggesting the occurrence
of second primary lymphoma, possibly linked to a genetic
predisposition or immunodeficiency. Our cohort of clonally
related cases will be subjected to mutational analyses to
define the patterns of clonal evolution and identify genes
related to therapy resistance. These studies will help to
define the genetic landscape of relapsed DLBCL.
M.R. Berendsen: None. M. van den Brand: None. J.
Rijntjes: None. G. Astuti: None. C.J. Hess: None. K.M.
Hebeda: None. W.B.C. Stevens: None. P.J.T.A. Groe-
nen: None. J.H. van Krieken: None. B. Scheijen: None.
P07.17.A
Clinical and cytogenetic assessment in a cohort of
Egyptian patients with Fanconi anemia: A 10 year
experience
M. Farid1, M. M. Thomas2, G. Y. Kamah2, M. M. Eid1
1Human Cytogenetics Department, Human Genetics and
Genome Division, National Research Centre, Cairo, Egypt,
2Clinical Genetics Department, Human Genetics and
Genome Division, National Research centre, Cairo,
Egypt
Introduction: Fanconi anemia (FA) is a rare autosomal
recessive disorder. Common clinical presentations include
progressive bone marrow failure, abnormal skin pigmenta-
tions, skeletal malformations and high risk of malignancy.
Due to its rarity and heterogeneous presentation, it is rather
challenging to establish a definite registry on a national
level. Therefore, this study describes the FA cases in the
NRC 10 year registry, focusing on family history, clinical,
hematological and cytogenetic findings.
Methods: This study included 225 patients. Their age
ranged from 4 months to 26 years. All patients were
subjected to thorough clinical examination, pedigree
construction, hematological and radiological investigations.
Cytogenetic assessment using diepoxybutane(DEB)-
induced chromosomal breakage was done to differentiate
Fanconi anemia from acquired aplastic anemia.
Results: 131 patients (58%) showed positive chromoso-
mal breakage and were diagnosed with FA. 93% of them
were of consanguineous parents and 21% showed positive
family history as an affected sibling. Clinical examination
showed; limb anomalies (20%), abnormal skin pigmenta-
tion (31%), bleeding tendency (22%) and kidney anomalies
(10%) of the cases. Hematological investigations showed:
cytopenia in one or more of blood cell types (52%), bone
marrow failure (42%) and 34% had received blood /blood
products at least once at the time of diagnosis. Cytogenetic
study showed mosaicism in 10% of the FA cases which is
significant for treatment assessment.
Conclusions: This study is the first to present the clinical
and cytogenetic characterizations of a cohort of Egyptian
FA patients. Further large scale studies are needed to
identify the prevalence of FA in the Egyptian society.
M. Farid: None. M.M. Thomas: None. G.Y. Kamah:
None. M.M. Eid: None.
P07.19.C
Myeloperoxidase modulates inflammation in generalized
pustular psoriasis and further rare pustular skin
diseases
S. Haskamp
Institute of Human Genetics, University Hospital Erlangen,
Erlangen, Germany
Generalized pustular psoriasis (GPP) is a severe multi-
systemic inflammatory disease characterized by neutrophilic
pustulosis and triggered by pro-inflammatory IL-36 cyto-
kines in skin. While 19-41% of patients carry bi-allelic
mutations in IL36RN, the majority of patients do not carry
mutations in known genes. In order to identify and char-
acterize new pathways involved in the pathogenesis of GPP
we performed whole exome sequencing in 31 GPP patients
and demonstrated effects of mutations in MPO encoding the
neutrophilic enzyme myeloperoxidase (MPO) in myeloid
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cells. We discovered eight MPO mutations resulting in
MPO-deficiency in neutrophils and monocytes. Mutations
were associated with GPP, primarily those resulting in
complete MPO-deficiency (p=3.49E-10; OR=8.63).
Dosage of mutant MPO alleles showed significant differ-
ences between 82 patients and >3,600 controls (p=2.67E-
10); this effect was stronger when including IL36RN
mutations (p < 2.20E-16) and correlated with a younger age
of onset (p=0.0018). Activity of four proteases, previously
implicated as activating enzymes of IL-36 precursors, cor-
related with MPO-deficiency. Formation of neutrophil
extracellular traps (NETs) was reduced following phorbol
myristate acetate induction (p=0.015). Phagocytosis assays
in MPO-deficient mice and human suggested that altered
neutrophil function together with impaired clearance of
neutrophils by monocytes (efferocytosis) allowed prolonged
neutrophil persistence in patients’ skin.MPO mutations
contribute significantly to GPP’s pathogenesis. Our study
implicates MPO as an inflammatory modulator in humans
by regulating protease activity and NET formation, and
modifying efferocytosis. Our findings confine using MPO
inhibitors in cardiovascular diseases. MPO and affected
pathways represent attractive targets for inducing resolution
of inflammation in neutrophil-mediated skin diseases.
S. Haskamp: None.
P07.21.B
A rare cause of Acute Myeloid Leukemia and a delayed
diagnosis of Fanconi Syndrome: Mutations in FANCE
B. Cavdarli1, G. Yigit2, Y. Li2, V. Topcu1, B. Wollnik2
1Ankara Bilkent City Hospital, Ankara, Turkey, 2Institute of
Human Genetics, University Medical Center Göttingen,
Göttingen, Germany
Introduction: Genomic instability syndromes are a group
of inherited disorders that include a high variety of symp-
toms such as congenital anomalies, bone marrow failure,
and cancer susceptibility. Fanconi Syndrome(FS) is a rare
syndrome belonging to this family characterized by neuro-
developmental delay, radial-ray defects, microcephaly and
progressive deficiency of bone marrow production. Material
and Methods: We present a 33-year-old female who was
monitored for Acute Myeloid Leukemia. Clinical findings
of the patient included short stature, microcephaly, neuro-
developmental delay, patchy hypopigmented dark-colored
skin, signs of premature aging and chronic liver disease.
Results: Chromosomal breakage rate was detected high
after mitomycin-C(MMC) treatment of cells suggesting
chromosomal instability syndrome. We performed whole-
exome-sequencing on the DNA of the index patient and her
affected brother who had parental consanguinity. We
identified an intronic variant, c.1114-8G>A in FANCE that
was homozygous in the index patient as well as her affected
brother, and it is predicted to generate a new acceptor
splice-site resulting in alternative-splicing and premature
protein truncation (p.Ile372Leufs*2). So far, this variant has
only been described in a single case also of Turkish origin
with a similar phenotype. Besides this patient, there are
currently only four additional patients carrying biallelic
mutations in FANCE. All of these patients were diagnosed
in the first decade of their lives.
Conclusions:We expand the clinical spectrum of patients
with FANCE mutations and show that the absence of renal,
cardiac and radial ray anomalies might be the cause of late
diagnosis of FS caused by FANCE mutations.
B. Cavdarli: None. G. Yigit: None. Y. Li: None. V.
Topcu: None. B. Wollnik: None.
P07.25.C
Cell-free DNA in plasma—an essential immune system
regulator
M. Korabecna1, A. Zinkova1, I. Brynychova1, B.
Chylikova1, P. Prikryl1, L. Sedova1, P. Neuzil2,3, O. Seda1
1First Faculty of Medicine, Charles University, Prague,
Czech Republic, 2Northwestern Polytechnical University,
Xi’an, China, 3Brno University of Technology, Brno, Czech
Republic
Cell-free DNA (cfDNA) is always present in plasma, and it
is utilized in prenatal diagnostics as well as in oncology and
transplantology for therapy efficiency monitoring. But does
the cfDNA have a physiological role? Here we show that
cfDNA presence in plasma of healthy individuals plays an
indispensable role in immune system regulation. We
exposed THP1 cells to healthy individuals’ plasma with
(NP) and without (TP) cfDNA. In cells treated with NP, we
found elevated expression of genes whose products main-
tain immune system homeostasis. Exposure of cells to TP
triggered an innate immune response (IIR), documented
particularly by elevated expression of pro-inflammatory
interleukin 8. The results of mass spectrometry showed a
higher abundance of proteins associated with IIR activation
due to the regulation of complement cascade in cells cul-
tivated with TP. Our results provide evidence that the pre-
sence of cfDNA in plasma of healthy individuals blocks
fundamental mechanisms of the inflammation process. The
expression profiles show that this process could play an
important role in the regulation of tissue homeostasis. This
finding epitomizes one of many intriguing properties and
features of the human immune system. Its detailed under-
standing is of crucial interest for future medical applica-
tions. Financial support: grants LTACH19005 and Progres
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Q25/LF1 of the Ministry of Education, Youth and Sport of
the Czech Republic, grant RVO-VFN 64165 of the Ministry
of Health of the Czech Republic. P.N. would like to
acknowledge financial support from State Administration of
Foreign Experts Affairs number W099109 and CEITEC
Nano+ project (CZ.02.1.01/0.0/0.0/16_13/0001728).
M. Korabecna: None. A. Zinkova: None. I. Bryny-
chova: None. B. Chylikova: None. P. Prikryl: None. L.
Sedova: None. P. Neuzil: None. O. Seda: None.
P07.27.B
The impact of rare and common genetic variation in the
Interleukin-1 pathway for human cytokine responses
R. C. van Deuren1,2,3, P. Arts2,4, G. Cavalli1,5,6, M.
Jaeger1,3, M. Steehouwer2, M. van der Vorst2, C. Gilissen2,3,
L. A. B. Joosten1,3,7, C. A. Dinarello1,6, M. M. Mhlanga8,9,
V. Kumar1,10, M. G. Netea1,3,11, F. L. van de Veerdonk1,3, A.
Hoischen1,2,3
1Department of Internal Medicine, Radboud University
Medical Center, Nijmegen, Netherlands, 2Department of
Human Genetics, Radboud University Medical Center,
Nijmegen, Netherlands, 3Radboud Institute of Molecular
Life Sciences (RIMLS), Radboud University Medical
Center, Nijmegen, Netherlands, 4Department of Genetics
and Molecular Pathology, Centre for Cancer Biology, SA
Pathology and the University of South Australia, Adelaide,
Australia, 5Unit of Immunology, Rheumatology, Allergy
and Rare Diseases, IRCCS San Raffaele Hospital and Vita-
Salute San Raffaele University, Milan, Italy, 6Department of
Medicine, University of Colorado, Aurora, CO, United
States, 7Department of Medical Genetics, Iuliu Hatieganu
University of Medicine and Pharmacy, Cluj-Napoca,
Romania, 8Division of Chemical Systems & Synthetic
Biology, Institute for Infectious Disease & Molecular
Medicine (IDM), Department of Integrative Biological &
Medical Sciences, University of Cape Town, Cape Town,
South Africa, 9Faculty of Health Sciences, Department of
Integrative Biomedical Sciences, University of Cape Town,
Cape Town, South Africa, 10University of Groningen,
University Medical Center Groningen, Department of
Genetics, Groningen, Netherlands, 11Department for Geno-
mics & Immunoregulation, Life and Medical Sciences
Institute (LIMES), University of Bonn, Bonn, Germany
Interleukin(IL)-1 signaling is of major importance in human
innate cytokine responses. Common genetic variants in
underlying genes have been linked to various inflammation-
mediated diseases and pathogen induced cytokine respon-
ses, but the role of rare variants remains to be elucidated. In
this study, we characterize the role of rare and common
genetic variation in 48 genes related to the IL-1 pathway, on
in vitro stimulation-specific human cytokine responses from
463 healthy individuals. We identified strong NCF4 and
CASP1 rare variant associations with IL-6 cytokine pro-
duction induced by phytohaemagglutinin (P=7.2E−05) and
lipopolysacharide (LPS) (P=3.0E−05). Additionally, com-
mon variants in IL36A and IL38 were associated to both C.
albicans induced IL-1β and IL-6 (IL36A P=0.0442 and
0.0037; IL38 P=0.0092 and 0.0082), an effect that was
magnified on the respective IL-30 subpathway level (IL-1β
P=0.0017; IL-6 P=1.8E−04). The common variant sig-
nature for the immunological response to C.albicans was
confirmed by an association with the anti-inflammatory
phenotype group (IL-1β P=1.87E−03; IL-6 P=5.75E−04),
and we validated this for non-coding common variants.
Lastly, we detected an association between rare variants in
pro-inflammatory genes and LPS-induced IL-6 cytokine
(P=2.42E−04), and discovered a role for rare variants in
anti-inflammatory genes on S.aureus induced IL-6 produc-
tion (P=6.71E−03). In conclusion, we show that both
common and rare genetic variation in genes of the IL-1
pathway differentially influence in vitro cytokine responses
to various stimuli in healthy individuals. This study there-
fore provides insight into potential mechanisms relevant for
the characterization of genetic variant involvement in
variability of immune responses and possibly inflammatory-
mediated diseases.
R.C. van Deuren: None. P. Arts: None. G. Cavalli:
None. M. Jaeger: None. M. Steehouwer: None. M. van
der Vorst: None. C. Gilissen: None. L.A.B. Joosten:
None. C.A. Dinarello: None. M.M. Mhlanga: None. V.
Kumar: None.M.G. Netea: None. F.L. van de Veerdonk:
None. A. Hoischen: None.
P07.28.C
Correcting clinical diagnosis with targeted immundefi-
ciency gene panel sequencing: the critical role of genetic
counselling
K. Arvai1, A. Illés1, B. Kocsis-Deák1, V. Klujber1, B.
Tóbiás1, B. Balla1, H. Pikó1, P. Lakatos2, J. Kósa1,2
1PentacoreLab Ltd., Budapest, Hungary, 2Semmelweis
University 1st Department of Internal Medicine, Budapest,
Hungary
Immunodeficiency results from a failure or absence of ele-
ments of the immune system including lymphocytes, pha-
gocytes and complement system. These
immunodeficiencies can be either primary such as Bruton’s
disease or secondary as the one caused by HIV infectionIn
our case, a 35 years old healthy female patient was referred
to our lab, who lost two of her brothers with severe
immunodeficiency. She is about to have her first child and
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wanted to be tested before the pregnancy. The suspected
familiar diagnosis, based only clinical symptoms, was X-
linked agammaglobulinemia which is a X-linked mono-
genic disorder. After sequencing of the BTK gene, MLPA
were carried out, both returned with negative results. After
second genetic counselling it was revealed by the counsellor
that the suspected phenotype is not fit entirely and targeted
gene panel test was ordered, included 200 genes which are
linked to immunodeficiencies. A pathogenic heterozygous
deletion in the CD40LG gene (c.67dupA) was identified,
which is a known cause of X-linked immunodeficiency,
with hyper-IgM. HIGM is a rare immunodeficiency char-
acterized by normal or elevated serum IgM levels associated
with markedly decreased IgG, IgA, and IgE, resulting in a
profound susceptibility to bacterial infections and an
increased susceptibility to opportunistic infections. Patients
also tend to have neutropenia, as well as a high rate of
gastrointestinal and central nervous system infections.
Based on estimation only 20% of patients will reach the
third decade of life. Our results emphasize the importance
of multiple genetic counselling and highlights the difficul-
ties to interpret clinical results decades ago.
K. Arvai: None. A. Illés: None. B. Kocsis-Deák: None.
V. Klujber: None. B. Tóbiás: None. B. Balla: None. H.
Pikó: None. P. Lakatos: None. J. Kósa: None.
P07.31.C
Hyperinflammation and secondary HLH in a patient
with Interferon alpha/beta receptor 2 (IFNAR2)
deficiency
C. Passarelli1, A. Civino2, M. N. Rossi3, V. Lanari1, G. M.
Moneta3, A. Pascarella3, C. Bracaglia3, R. Montinaro4, F.
De Benedetti3, A. Novelli1, G. Prencipe3
1U.O.C. Laboratory of Medical Genetics, IRCCS Paediatric
Hospital “Bambino Gesu”, Rome, Italy, 2Rheumatology
and Paediatric Immunology, PO "Vito Fazzi", Lecce, Italy,
3Division of Rheumatology, IRCCS Paediatric Hospital
“Bambino Gesu”, Rome, Italy, 4Division of Pediatry, PO
"Santa Caterina Novella", Galatina, Italy
Introduction: Interferons α/β (Type I IFNs) play an
important role in defense against viral infections. Here we
report the case of a 22-months-old Caucasian boy present-
ing with high fever and lethargy five days after live-
attenuated MMR (measles-mumps-rubella) vaccine.
Laboratory parameters were suggestive for secondary
Hemophagocityc lymphohistiocytosis (HLH), with pro-
gressive decrease in cell blood count, hyperferritinemia,
elevation of liver enzymes and lactate dehydrogenase and
hypofibrinogenemia.
Materials and Methods: Clinical Exome, using a custom
panel including 6920 genes known as associated to genetic
diseases, was sequenced on Illumina NovaSeq6000® plat-
form. In silico analysis was performed on the basis of the
patient’s clinical phenotype. Peripheral blood mononuclear
cells (PBMCs) were isolated from the patient and his family
and stimulated with IFNα or IFNγ; phosphorylation of
STAT1 and Type I and II IFN signatures were analyzed by
FACS analysis and RT-PCR.
Results:We identified the two novel frameshift mutations
c.234delT and c.555_559delAAAAG, in a compound
heterozygous status, in IFNAR2 gene (OMIM# 602376),
resulting respectively in p.Leu79Ter and p.Ile185Metf-
sTer12 variants. Ex vivo studies on patient’s PBMCs
confirmed the defect in the activation of the type I IFN
signaling, but not in type II IFN response. Treatment with
high dose of intravenous methylprednisolone allowed a
progressive improvement of patient condition and of
clinical and laboratory features.
Conclusions: Our data demonstrate that HLH episodes
following administration of live-attenuated MMR vaccine
could suggest the presence of a defect in the type I IFN
response.
C. Passarelli: None. A. Civino: None. M.N. Rossi:
None. V. Lanari: None. G.M. Moneta: None. A.
Pascarella: None. C. Bracaglia: None. R. Montinaro:
None. F. De Benedetti: None. A. Novelli: None. G.
Prencipe: None.
P07.32.A
Genome wide association study of circulating interleukin
6 levels identifies novel loci
T. S. Ahluwalia1, N. J. Armstrong2, S. Aslibekyan3, M.
Beekman4, Y. Cheng5, E. deGeus6, G. E. Delgado7, D.
Marek8, S. Kanoni9, I. M. Nolte10, E. Porcu11, I. Seppälä12,
M. Standl13, A. Teumer14, A. Thalamuthu15, S. Trompet16, E.
J. Benjamin17, M. F. Feitosa18, G. Homuth19, J. Lahti20, Y.
Liu21, N. J. Timpson17, S. Visvikis-Siest22, U. Völker19, B. T.
Baune23, D. Boomsma24, I. J. Deary25, D. M. Evans17, M. A.
Ferreira26, T. Gaunt17, V. Gudnason27, A. Hamsten28, S. E.
Humphries29, W. Koeing30, M. Kumari31, D. A. Lawlor17,
M. Nauck32, J. F. Price33, T. I. A. Sørensen34, D. Stacey35,
M. G. Stathopoulou22, T. Tanaka36, S. G. Wannamethee37,
J. I. Rotter38, A. Dehghan39, E. Boerwinkle40, H. Sneider10,
B. M. Psaty41, B. P. Prins10, B. Z. Alizadeh10
1Steno Diabetes Center Copenhagen, Gentofte, Denmark,
2Murdoch university, Perth, Australia, 3University of
alabama at birmingham school of public health, Birming-
ham, AL, United States, 4Leiden university medical center,
Leiden, Netherlands, 5University of Maryland school of
medicine, Baltimore, MD, United States, 6Vrije universiteit
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amsterdam, Amsterdam, Netherlands, 7Vth department of
medicine university of heidelberg, Mannheim, Germany,
8SIB swiss institute of bioinformatics, Lausanne, Switzer-
land, 9William harvey research institute, queen mary
university of london, London, United Kingdom, 10university
of groningen, university medical center groningen,, Gro-
ningen, Netherlands, 11Istituto di ricerca genetica e
biomedica, consiglio nazionale delle ricerche, Cagliari,
Italy, 12Department of clinical chemistry, tampere univer-
sity, Tampere, Finland, 13Institute of epidemiology, helm-
holtz zentrum münchen - german research center for
environmental health, Neuherberg, Germany, 14Institute
for community medicine, university medicine greifswald,
Greifswald, Germany, 15Neuropsychiatric institute, prince
of wales hospital, Sydney, Australia, 16Department of
cardiology, leiden university medical center,, Leiden,
Netherlands, 17MRC integrative epidemiology unit, uni-
versity of bristol, Bristol, United Kingdom, 18Department of
genetics, washington university school of medicine, St.
Louis, MO, United States, 19Interfaculty institute for
genetics and functional genomics, university medicine
Greifswald, Greifswald, Germany, 20Turku institute for
advanced studies, university of turku, Turku, Finland,
21Department of epidemiology and prevention, wake forest
school of medicine, winston-Salem, NC, United States,
22Université de lorraine, INSERM, Nancy, France,
23Department of psychiatry and the Florey institute of
neuroscience and mental health the university of Mel-
bourne, Melbourne, Australia, 24Department of biological
psychology, behaviour and movement sciences, vrije
universiteit Amsterdam, Amsterdam, Netherlands, 25Centre
for cognitive ageing and epidemiology, university of
edinburgh, Edinburgh, United Kingdom, 26QIMR berghofer
medical research institute, Brisbane, Australia, 27Faculty of
medicine, university of iceland, Reykjavik, Iceland,
28Department of medicine solna, center for molecular
medicine, karolinska institutet, Stockholm, Sweden, 29Insti-
tute of cardiovascular science, university college london,
London, United Kingdom, 30German Heart Centre Munich,
Technical University Munich, Munich, Germany, 31Depart-
ment of epidemiology and public health, university college
london, London, United Kingdom, 32Institute of clinical
chemistry and laboratory medicine, university medicine
greifswald, Greifswald, Germany, 33Usher institute of
population health sciences and informatics, university of
edinburgh, Edinburgh, United Kingdom, 34Department of
public health, university of copenhagen, Copenhagen,
Denmark, 35MRC cardiovascular epidemiology unit, uni-
versity of cambridge, Cambridge, United Kingdom,
36Translational gerontology branch, national institute on
aging, Baltimore, MD, United States, 37Institute of
epidemiology & health care, UCL, London, United King-
dom, 38Departments of pediatrics and medicine, harbor-
ucla medical center, Los Angeles, CA, United States,
39Department of epidemiology, erasmus mc, Rotterdam,
Netherlands, 40Human genetics center, university of texas,
Houston, TX, United States, 41Cardiovascular health
research unit, department of medicine, university of
washington, Seattle, WA, United States
Interleukin-6 (IL-6) is a multifunctional cytokine with both
pro and anti-inflammatory properties, synthesized by a wide
range of tissues and cell types. Increased levels of circu-
lating IL-6 in blood is associated with the pathophysiology
of complex disorders like type 2 diabetes, cardiovascular
and autoimmune diseases. Albeit, IL-6 levels are heritable
with estimates up to 61%, only a few common genetic loci
associated with circulating IL-6 levels have been identified.
We therefore conducted a two stage (discovery and repli-
cation) meta genome-wide association study (GWAS) of
circulating serum IL-6 concentrations comprising up to
67,428 individuals of european ancestry. About 2.5 million
single nucleotide polymorphisms (SNPs) were available for
testing after imputation to Hap Map 2 reference panel. We
conducted an inverse variance based fixed effects meta-
analysis. We identified three IL-6 associated, independent
signals on chromosomes (chr) 2q14, 6p21 and 1q21,
reaching genome-wide significance (p < 5.0 × 10−8) in the
combined meta-analyses. Among the identified loci IL1F10/
IL1RN (chr 2q14, p = 1.8 × 10−11), and HLA-DRB1/DRB5
(chr 6p21, p =1.5 × 10−10) were novel while IL6R (chr
1q21, p = 1.2 × 10−122) was a known locus. Our study
identifies 2 novel loci for circulating IL-6 levels uncovering
new immunological and inflammatory pathways that may
influence IL-6 pathobiology.
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KIR-HLA class I ligand combinations among cystic
fibrosis patients
K. Sosnina1, D. Zastavna1,2, O. Terpyliak1, H. Makukh1, L.
Bober3
1SI “Institute of Hereditary Pathology Ukrainian National
Academy of Medical Sciences”, Lviv, Ukraine, 2Department
of Biotechnology and Bioinformatics, Faculty of Chemistry,
Rzeszow University of Technology, Al. Powstańców Wars-
zawy 6, Rzeszow, Poland, 3Lviv Regional Children’s
Specialized Clinical Hospital, Lviv, Ukraine
KIR and HLA loci play a critical role in NK cell regulation.
Different compound KIR-HLA genotypes can impart dif-
ferent thresholds of activation to the NK repertoire and such
genotypic variation has been found to confer altered risk in
a number of human diseases including infectious diseases.
The aim of this study was to establish and analyze the
spectrum of KIR-HLA genes in people with a confirmed
diagnosis of CF, homozygote of F508del mutation of the
СFTR gene for understanding the genetic predisposition of
congenital immunity key part functioning during CF.
Results: KIR and HLA class I ligands (C1,C2) genes dis-
tribution was established in 48 CF patients and 104 prac-
tically healthy individuals of control group. HLAC
genotypes frequency did not differ in the CF group and in
the control. The lower frequency of KIR2DL3, KIR2DS1
and KIR2DS4 genes (37.5%, 6.25% and 0%) was found
among CF patients (p < 0.05) compared to control group
(67.3%, 20.2% and 10.5%) indicating a strong inhibitory
effect on NK cells. Respectively, the frequency of KIRBB
haplotype 8.34% in CF patients was significantly higher
compared to the control 0.96 % (p < 0.05). Analysis of
combined frequencies for iKIR+HLA (> = <) aKIR+HLA
showed no significant difference between the study groups.
iKIR+ HLA⁄aKIR analysis showed significantly lower fre-
quency iKIR+HLA<aKIR combinations in the CF group
compared to controls (p < 0.05). Thus, the results indicate
that people with cystic fibrosis have genetically predis-
possition of weak activation and a strong inhibition of NK
functional activity, that possibly contributing to bronco-
pulmonary infection process development.
K. Sosnina: None. D. Zastavna: None. O. Terpyliak:
None. H. Makukh: None. L. Bober: None.
P07.34.C
Transcriptome-based elucidation of gender bias in
systemic lupus erythematosus (SLE)
K. Varvagiannis1, D. Gerasoudis1, A. Filia1, N. Panousis2,
E. Dermitzakis1,3,4,5, G. Bertsias6,7, D. Boumpas1,8,7,9, A.
Banos1, P. Makrythanasis1,3
1Biomedical Research Foundation Academy Of Athens,
Athens, Greece, 2Wellcome Trust Sanger Institute, Hinxton,
Cambridge, United Kingdom, 3Department of Genetic
Medicine and Development, University of Geneva Medical
School, Geneva, Switzerland, 4Institute of Genetics and
Genomics in Geneva (iGE3), University of Geneva, Geneva,
Switzerland, 5Swiss Institute of Bioinformatics, Geneva,
Switzerland, 6Department of Rheumatology, Clinical Immu-
nology and Allergy, University of Crete, Medical School,
Heraklion, Greece, 7Institute of Molecular Biology and
Biotechnology, Foundation for Research and Technology -
Hellas (FORTH), Heraklion, Greece, 8Joint Academic
Rheumatology Program, National and Kapodistrian Uni-
versity of Athens, Medical School, Athens, Greece, 9Medical
school, University of Cyprus, Nicosia, Cyprus
Background: Systemic lupus erythematosus (SLE) is a
chronic autoimmune disease that can affect virtually any
organ/system. Clinical features in individual patients can be
highly variable, ranging from mild arthritis, skin manifes-
tations and antinuclear antibody production to life-
threatening organ disease. SLE exhibits a striking female
predominance, with ratios exceeding 9:1. The disease often
displays a more aggressive clinical course in men, resulting
in poorer prognosis. Several hypotheses have been put
forward to explain this gender bias, including X-
chromosome inactivation, sex hormones and TLR/miR-
NAs altered expression.
Methods: By employing data from mRNA sequencing in
whole blood samples from 142 SLE patients and 58 healthy
volunteers we explore gender/disease specific patterns of
gene expression and their putative functional gene networks
as suggested by DAVID analysis.
Results: Genes displaying a stepwise up-/down-regula-
tion upon comparison of their expression in the order of
healthy males (HM), healthy females (HF), affected females
(AF) and affected males (AM) groups, were the most over-
represented among all possible combinations. These genes
appeared to belong to pathways highly relevant to SLE
pathogenesis, including NOD-/Toll-like receptor signaling,
ubiquitin mediated proteolysis, nucleotide excision repair
and spliceosome (p-values < 0.05).
Conclusions: Although preliminary, our results suggest
that gender bias may - at least partially - be reflected by
patterns of altered expression of genes/pathways relevant to
SLE. Future analysis in lupus mouse model will reveal
genetic impact on gender-specific gene expression.
K. Varvagiannis: None. D. Gerasoudis: None. A. Filia:
None. N. Panousis: None. E. Dermitzakis: None. G.
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MicroRNAs expression may affect the lymphocyte
concentration in Down syndrome
M. F. Mattos1, O. B. Nascimento1, G. A. S. Passos2, J. M.
Biselli3, E. M. Goloni-Bertollo1, É. C. Pavarino1
1Unidade de Pesquisa em Genética e Biologia Molecular
da Faculdade de Medicina de São José do Rio Preto, São
José do Rio Preto, Brazil, 22 Faculdade de Medicina de
Ribeirão Preto da Universidade de São Paulo – USP,
Ribeirão Preto, Brazil, 33Universidade Estadual Paulista
Júlio de Mesquita Filho- UNESP, São José do Rio Preto,
Brazil
Introduction: Studies have showed the importance of
microRNAs in Down syndrome(DS) pathology and
impaired T cell proliferation may result of altered micro-
RNAexpression. Therefore, in this study we investigated
the relationship between expressionpattern of hsa-miR-
378a-3p, hsa-miR-668-3p and hsa-miR 942-5p and
lymphocytesconcentration in DS.
Material and Methods: Peripheral blood mononuclear
cells were obtained from 52healthy individuals with full
trisomy 21 (DS) (age 1 to 20) and 53 healthy control (HC)
(age 1 to 12). MicroRNAs expression was investigated by
real time polymerase chainreaction using Taqman assays.
Statistical analysis was performed using One-
SampleWilcoxon Signed Rank Test, in the GraphPad Prism
6 software. Bioinformatic analysiswas carried out to
identify genes regulated by expressed differentially micro-
RNAs andthe interaction between proteins using MiRTar-
base v9 and STRING t-v11.0 tool.
Results: DS individuals presented over-expression of
hsa-miR-378a-3p (RQ 1.22, P=0.036) and down-
expression of hsa-miR-668-3p (RQ 0.42, P=0.018). More-
over, thisindividuals presented lower lymphocytes concen-
tration than HC (mean 36.70, 48.68; respectively,
P=0.007). Network analysis showed that genes regulated
by hsa-miR-378a-3p and hsa-miR-668-3p are significantly
involved in cell differentiation, celldivision, cell cycle
(P=<0.001) and regulation of cell growth (P=0.02).
Conclusions: The lower lymphocytes concentration in
DS may in part explain the highfrequency of immune
alterations. Genes that regulates the lymphocyte concen-
trationsare probably affected by impaired microRNA
expression. MicroRNA target genes areinvolved in biolo-
gical process relevant to immune response as cell
proliferation.
Grants: FAPESP (2018/09126-0 and 2018/24825-2),
CNPQ (310806/2018-6), CAPES(001), FAMERP/
FUNFARME.
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P07.36.B
Surprising genetic results in a case of neurofibromatosis-
like syndrome
M. T. Bataneant1,2, M. Puiu1,2, M. Baica3, E. Boeriu1,2, P.
Urtila1,2, C. Zaica3, A. Beloia4, A. Chirita-Emandi1
1University of Medicine and Pharmacy "Victor Babes",
Romania, Romania, 2Clinical Emergency Hospital for
Children „Louis Turcanu”, Timisoara, Romania, 3Louis
Turcanu Emergency Children Hospital, Timisoara, Roma-
nia, 4Louis Turcanu Emergency Children Hospital, Roma-
nia, Romania
Introduction: Neurofibromatosis is an autosomal dominant
disorder consisting in cutaneous, neurologic, ophthalmolo-
gic and tumoral signs. But always other disorders that can
mimic neurofibromatosis should be excluded.
Case presentation: A 10-year-old girl, from consangui-
neous gipsy parents, was admitted for anemia. Family
history showed a sister who died due to cerebral tumors at
the age of 3. The personal medical history was insignificant.
The clinical examination revealed more than 6, cafe au lait”
spots larger than 0,5cm and multiple axillary freckling,
signs which support the diagnosis of neurofibromatosis. The
clinical exam of the parents was normal. Laboratory
explorations showed a normochromic, normocytic anemia,
normal ferritin level, liver and kidney function, folate
deficiency, but also immunological abnormalities: IgA,
IgG2 and IgG4 deficiency, poor response to vaccination,
low memory B cells and a normal number of T cell
subpopulations. Ophthalmologic examination was normal.
The cerebral MRI-scan highlighted multiple 0,5 and 4 cm in
diameter tumors. The cerebral biopsy revealed a diffuse
astrocytoma IDH mutant and she started chemotherapy.
Taking in account the consanguinity, family history and the
negative clinical exam of the parents we performed genetic
exam - WES that revealed a pathogenic homozygous
c.2653A>T mutation in MSH6 gene, parents being carriers
for the same mutation.
Conclusions: Homozygous mutation in MSH6 gene is a
very rare type of immunodeficiency from DNA repair
syndromes and it must be suspected in atypical cases of
neurofibromatosis associating immunological abnormal-
ities. A correct diagnosis allows genetic counseling and
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monitoring for the cancer development in other members of
the family.
M.T. Bataneant: None. M. Puiu: None. M. Baica:
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Novel candidate genes and sequence variants for
susceptibility to mycobacterial infections revealed by
exome sequencing
A. M. Varzari1,2, M. Dembic3,4,5, G. Hoffmann Bruun3, I. V.
Deyneko6, W. Hofmann7, V. M. Cebotari8, E. G. Privalova9,
B. S. Andresen3, T. Illig2,7
1Laboratory of Human Genetics, Chiril Draganiuc Institute
of Phthisiopneumology, Kishinev, Moldova, Republic of,
2Hannover Unified Biobank, Hannover Medical School,
Hannover, Germany, 3Department of Biochemistry and
Molecular Biology and The Villum Center for Bioanalytical
Sciences, University of Southern Denmark, Odense M,
Denmark, 4Department of Clinical Genetics, Odense
University Hospital, Odense, Denmark, 5Department of
Mathematics and Computer Science, University of Southern
Denmark, Odense, Denmark, 6Group of Functional Geno-
mics, К.А. Timiryazev Institute of Plant Physiology,
Moscow, Russian Federation, 7Department of Human
Genetics, Hannover Medical School, Hannover, Germany,
8Department of Paediatrics, Municipal Hospital of Phthi-
siopneumology, Kishinev, Moldova, Republic of, 9Labora-
tory of Immunology, Chiril Draganiuc Institute of
Phthisiopneumology, Kishinev, Moldova, Republic of
Introduction: Mendelian Susceptibility to Mycobacterial
Disease (MSMD) is a rare genetic disorder with impaired
immunity against mycobacterial infections; however only
half of patients with MSMD have an identified genetic
etiology. Here, we attempt to detect causal mutations in
three paediatric patients with possible presentations
for MSMD.
Methods: Whole exome sequencing was performed on
two patients with severe localized BCG infection (#1 and #2)
and their parents, and another individual patient with
disseminated TB (#3). The functional effects of the identified
variants were characterized using RT-PCR analysis of
endogenous and minigene transcripts, and SPRi analysis.
Results: Six rare heterozygous variants were detected in
the established MSMD genes: IL12B (case #1, compound
heterozygote), TYK2 (cases #1 and #2), IL12RB1 and
STAT1 (case #3). In addition, four disease-associated
variants in three presumed causative genes were identified
by trio-based analysis: compound missense and intronic
variants in GBP2 (case #2), a de novo heterozygous
frameshift mutation in HEATR3 (case #1), and a homo-
zygous missense mutation in IFNW (case #1). cDNA
analysis for splice-site mutation c.373-2A>C in STAT1
demonstrated abnormalities in STAT1 pre-mRNA splicing.
Characterization of the c.1149+14T>C variant in GBP2 via
minigene assay revealed some exon-skipping event from
the mutant construct. Additionally, SPRi analysis showed a
greater affinity of silencer-bound hnRNP A1 protein to
RNA oligonucleotides harboring c.1149+14T>C compared
to the wild type oligonucleotides, providing support to the
minigene assay.
Conclusions: Our findings expand the spectrum of
genetic variation possibly predisposing to mycobacterial
infections in children. Funding: Alexander von Humboldt
Foundation and Hanover Unified Biobank.
A.M. Varzari: None. M. Dembic: None. G. Hoffmann
Bruun: None. I.V. Deyneko: None. W. Hofmann: None.
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P07.38.A
An indel in the promoter region of NFKB1 confers
protection against infection but increases risk of allergy
A. Y. Chong1, N. Brenner2, A. Jimenez Kaufmann3, A.
Cortes4, R. Almond5, M. Hill6, T. J. Littlejohns7, J. J.
Gilchrist1,8, B. P. Fairfax9, F. Hodel10,11, J. Fellay10,11,12, G.
McVean4, T. Waterboer2, A. Moreno Estrada3, A. V. S.
Hill1,13, A. J. Mentzer1,4
1Wellcome Centre for Human Genetics, University of
Oxford, Oxford, United Kingdom, 2Infections and Cancer
Epidemiology, German Cancer Research Center, Heidel-
berg, Germany, 3Human Population Genomics Lab,
Laboratorio Nacional de Genómica para la Biodiversidad,
Irapuato, Mexico, 4Big Data Institute, Li Ka Shing Centre
for Health Information and Discovery, University of
Oxford, Oxford, United Kingdom, 5UK Biobank, Stockport,
United Kingdom, 6MRC-Population Health Research Unit,
University of Oxford, Oxford, United Kingdom, 7Nuffield
Department of Population Health, University of Oxford,
Oxford, United Kingdom, 8Department of Paediatrics,
University of Oxford, Oxford, United Kingdom, 9Depart-
ment of Oncology, University of Oxford, Oxford, United
Kingdom, 10Global Health Institute, School of Life Sciences,
EPFL, Lausanne, Switzerland, 11Swiss Institute of Bioinfor-
matics, Lausanne, Switzerland, 12Precision Medicine Unit,
Lausanne University Hospital and University of Lausanne,
Lausanne, Switzerland, 13Jenner Institute, University of
Oxford, Oxford, United Kingdom
Introduction: Infectious agents contribute significantly to
the global burden of diseases, through both acute infection
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and increasing risk of diverse chronic conditions. We
leveraged the rich phenotypic data in the UK Biobank to
identify genetic loci that influence response to multiple
infections.
Methods: We undertook 45 genome-wide association
studies of antibody responses against common pathogens,
in 9,611 participants from UK Biobank, identifying NFKB1
as a common locus. Using incidence of disease in 487,409
UK Biobank participants, we investigated the association
between NFKB1 variation and 91 infection and inflamma-
tion phenotypes. To better understand the impact of
variation on underlying immune mechanisms, we also
explored the effect of these variants on eight blood cell traits
and cellular expression data.
Results: We identified an insertion-deletion variant
(rs28362491), known to affect NFKB1 promoter binding,
as a likely causal variant. The insertion allele has a
protective effect against infection, but increases the risk of
allergic disease. The same variant was associated with shifts
in haematopoietic pathways, and likely impacts cell
survival, antibody production and inflammation. Interest-
ingly, this variant is relatively common in all human
populations, suggesting that variation within this locus is
largely maintained through balancing selection.
Conclusions: We find that disruptions to the tightly
regulated immune responses and inflammatory processes
can tip the balance between exacerbated immune responses
and allergy, or increased risks of infection and impaired
resolution of inflammation. This subtle yet demonstrable
effect across the population is likely driven by modulation
of NFKB1 gene expression.
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Moreno Estrada: None. A.V.S. Hill: None. A.J.
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P07.39.B
CN-LOH in PIGV causes PNH, in a case of ET and
nephrotic syndrome
A. Maurel-Ribes1, A. Knaus2, C. Garcia1, H. Engels3, S.
Sivalingam2, H. Hundertmark3, D. Ribes4, S. Tavitian5, B.
Payrastre6, S. Faguer4, P. Krawitz2, F. Vergez7
1Laboratoire d’Hématologie, Centre Hospitalier Universi-
taire de Toulouse, Toulouse, France, 2Institute for Genomic
Statistics and Bioinformatics, University of Bonn, School of
Medicine & University Hospital Bonn, Bonn, Germany,
3Institute of Human Genetics, University of Bonn, School of
Medicine & University Hospital Bonn, Bonn, Germany,
4Department of Nephrology and Organ Transplantation,
University Hospital of Rangueil, Toulouse, France, 5Service
D’Hématologie, Centre Hospitalier Universitaire de Tou-
louse, Institut Universitaire du Cancer de Toulouse,
Toulouse, France, 6Inserm U1048 and Paul Sabatier
University, Institute of Cardiovascular and Metabolic
Diseases, Toulouse, France, 7Department of Biology
Hematology, Toulouse-Oncopole University Cancer Insti-
tute (IUCT-O), Toulouse, Germany
Classical paroxysmal nocturnal hemoglobinura (PNH) is an
acquired glycosylphosphatidylinositol (GPI) anchor defi-
ciency in a hematopoietic stem cell (HSC) due to mutations
in PIGA. However, the reasons for clonal expansion in an
acquired loss of function of GPI biosynthesis, is still a
matter of debate. Here we describe, how PNH also mani-
fested in a patient with essential thrombocythemia (ET)
after a copy number neutral loss-of-heterozygosity (CN-
LOH) in PIGV, another gene of the GPI-anchor deficiency.
Similar to other proliferative myeloid malignancies, the
clonal expansion of the HSC with ET resulted in our case
from a de novo mutation in MPL (p.W515L) on chromo-
some 1 (1p34.2). 16.7 MB upstream of the acquired MPL
mutation in cis, the patient carried a heterozygous
pathogenic mutation in PIGV (p.R469X, 1p36.11), con-
genitally. A somatic CN-LOH in the HSC comprised almost
the entire p-arm of chromosome 1. Hence, the MPL
mutation p.W5151L gained dominance and deteriorated
ET and while homozygosity of p.R469X in PIGV resulted
in a GPI-anchor deficiency and manifestation of PNH. In
addition to ET and PNH, the patient presented with
nephrotic syndrome that ceased after treatment with
eculizumab and hydroxycarbamide. We determined the
origin of kidney injury as a result of podocyte instability
due to an increase of non-GPI linked soluble uPAR. In this
report we identified PIGV as a novel gene causing PNH and
provide insights into the pathomechanism of acquired GPI
anchor deficiency and expansion of PNH cells. Further-
more, we discuss the contribution of PNH to kidney injury.
A. Maurel-Ribes: None. A. Knaus: None. C. Garcia:
None. H. Engels: None. S. Sivalingam: None. H.
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P07.40.C
Human genomics of the humoral response against
polyomaviruses
F. Hodel1,2, A. Y. Chong3, P. Scepanovic4, C. W.
Thorball1,2, Z. M. Xu1,2, P. Marques-Vidal5, M. Begemann6,
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Lausanne, Switzerland, 2Swiss Institute of Bioinformatics,
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Genetics, University of Oxford, Oxford, United Kingdom,
4Roche Pharmaceutical Research and Early Development,
F. Hoffmann-La Roche Ltd, Basel, Switzerland, 5Service of
Internal Medicine, Department of Medicine, Lausanne
University Hospital and University of Lausanne, Lausanne,
Switzerland, 6Clinical Neuroscience, Max Planck Institute
of Experimental Medicine, DFG Research Center for
Nanoscale Microscopy and Molecular Physiology of the
Brain, Göttingen, Germany, 7Infections and Cancer Epide-
miology, German Cancer Research Center, Heidelberg,
Germany, 8Big Data Institute, Li Ka Shing Centre for
Health Information and Discovery, University of Oxford,
Oxford, United Kingdom, 9The Jenner Institute, Oxford,
United Kingdom, 10Department of Cancer Immunology,
Genentech Inc., San Francisco, CA, United States,
11Department of Human Genetics, Genentech Inc., San
Francisco, CA, United States, 12Precision Medicine Unit,
Lausanne University Hospital and University of Lausanne,
Lausanne, Switzerland
Introduction: Human polyomaviruses are widespread in
human populations and some cause severe disease in
immunocompromised individuals. There remains an
incomplete understanding of the potential impact of human
genetic variation on inter-individual responses to
polyomaviruses.
Material and methods: To identify human genetic
determinants of the humoral immune response against
polyomaviruses, we performed genome-wide association
studies and meta-analyses of immunoglobulin G (IgG)
responses against the major capsid protein VP1 of Human
polyomavirus 6 (HPyV6), BK virus (BKV), JC virus (JCV)
and WU polyomavirus (WUPyV), using data from three
independent studies grouping 15’660 individuals of Eur-
opean ancestry.
Results: We found evidence for an involvement of HLA
class II variation in the determination of antibody responses
to JCV (P=1.5e-78) and HPyV6 (P=3.2e-14). We also
observed associations in ABO for JCV (P=6.2e-11), and
FUT2 for BKV, JCV and WUPyV (P=2.3e-18; P=9.7e-26;
P=9.0e-09, respectively), involved in blood group determi-
nation and secretor status. Lastly, we found a functional
variant in MUC1, previously associated with the risk of
developing gastric cancer and Helicobacter pylori asso-
ciated gastritis, to be associated with IgG levels against
WUPyV (rs4072037, P=3.6e-33).
Conclusions: These results provide insights into the
human genetic control of a family of very prevalent viruses,
highlighting polymorphisms that play a modulating role on
the humoral immune response against specific human
polyomaviruses. Functional follow-up studies will be
needed to uncover the biological mechanisms responsible
for the newly discovered associations.
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Increasing the diagnostic yield in patients suspected for
primary immunodeficiency
A. Niskakoski, P. Kokkonen, I. Saarinen, J. Sistonen, H.
Junnila, A. Kere, M. Andreevskaya, M. Muona, J.
Djupsjöbacka, L. Koskinen, H. Duzkale, S. Myllykangas, J.
Koskenvuo, T. Alastalo
Blueprint Genetics, Espoo, Finland
Background: Finding the genetic diagnosis for patients
with suspicion of primary immunodeficiency (PID) is
becoming increasingly important in the management of
primary immunodeficiency and estimating the risk for
family members. Simultaneous sequence and copy number
variant analysis combined with customized analysis for
difficult to sequence regions in specific genes such as NCF1
improves the diagnostic yield in patients suspected for PID.
Methods: A retrospective review of nearly 1700 patients
suspected for PID and referred for genetic testing at
Blueprint Genetics between 2018 and 2019 was performed.
Patients were tested with Blueprint Genetics next generation
sequencing panels related to immunology.
Results: Diagnostic yield including all immunology
related panels was 14.9% (253/1698). The diagnostic yield
was highly variable between the different panels; diagnostic
yield for Primary Immunodeficiency Panel was 13.3% (138/
1036), whereas for Severe Combined Immunodeficiency
Panel it was 46.7% (7/15). The diagnostic yield for Chronic
Granulomatous Disease Panel is high (10/21, 48%)
although analysis of the NCF1 gene included in this panel
is complicated by two highly homologous pseudogenes
NCF1B and NCF1C. Out of the 296 reported diagnostic
sequence variants, 234 (79%) were unique, and only 7
diagnostic variants were reported over 3 times. Copy
number variants, including deletions and duplications, were
reported for 19 patients from 17 different genes.
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Conclusions: We constantly increase the diagnostic yield
for PIDs by improving the sequencing technology, updating
the panels with new genes discovered related to PID, and
finding diagnoses from difficult to sequence regions and
regions with high homology.
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Common RUNX3 missense variant contributes to
psoriatic arthritis by affecting splicing and modifying
signaling, activation and differentiation of T-cells
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Psoriatic Arthritis (PsA) is a chronic inflammatory joint
disease occurring in up to 30% of patients with the most
common psoriatic skin manifestation, psoriasis vulgaris
(PsV). PsA is considered a T-cell mediated disease with a
complex genetic basis. To date, GWAS identified >60 lar-
gely overlapping susceptibility loci for PsA/ PsV including
RUNX3, while the respective disease-contributing mechan-
ism remained mostly uncertain. RUNX3 encodes a tran-
scription factor expressed e.g. in immune cells, including T-
cells, and skin. As genotyping arrays had insufficient cov-
erage at this locus, we selected 32 tagging SNPs for further
fine-mapping. Association analysis in 3,049 PsA patients
and 6,178 controls of the Psoriatic Arthritis Genetics in
Europe consortium showed significant association to an
LD-wise isolated intronic SNP (p=1.50E-11) and to 5 SNPs
(5.43E-12≤p≤2.78E-07) within one intragenic LD block.
Genomic annotations for 38 SNPs in high LD (r2≥0.9) with
the SNPs were inconclusive, including histone modifica-
tions and DNAse-sensitive sites in immune cells. Haplotype
and conditional analyses, though, pointed to disease-
contribution of the common, evolutionary conserved var-
iant c.53T>A/p.Ile18Asn in alternative exon 1. Targeted
deep-sequencing of cDNA from CD8+ T-cells unveiled
alternative splicing in homozygous wildtype carriers, but a
reduced number of splicing products and lack of alternative
splicing in homozygous risk-allele carriers. Comparative
transcriptome analysis in CD8+ T-cells of homozygous
carriers provided evidence for differentially expressed genes
involved in T-cell exhaustion signaling, Th1/ Th2 activation
and T-helper-cell differentiation. Our study indicates that
the RUNX3 risk-allele in PsA reduces splicing variability
thereby contributing to altered signaling, activation and
differentiation of T-cells.
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Functional study of peptidylarginine deiminases in
collagen-induced arthritis mice
A. Suzuki, T. Shibuya, K. Yamamoto
RIKEN, Yokohama, Japan.
Previously, peptidylarginine deiminase type 4 (PADI4) was
identified as a susceptibility gene for Rheumatoid arthritis
(RA) by genome-wide association studies in Japanese
population. PADI genes can provide peptidyl citrulline
which is a target antigen of anti-citrullinated peptide anti-
bodies (ACPAs) that is highly sensitive and specific anti-
bodies in RA. After that, PADI2 was also identified as
susceptibility gene with RA. But, it is not clear how these
PADI genes are involved in the development of rheumatoid
arthritis. The aim of this study was to investigate the rela-
tionship between PADI4 gene and PADI2 gene in the
progression of RA.
To clarify the physiological function of PADI4 and
PADI2, we used collagen-induced arthritis (CIA), known as
a RA model mouse. We examined that localization of
PADI4 and PADI2 protein was indicated by immunohis-
tochemistry in CIA mice. We also measured expression of
PADI genes and various inflammatory cytokines in immune
cells by real-time TaqMan assay and ELISA, respectively.
We generated PADI4−/− and PADI2−/− mice, and
performed experimental arthritis. We demonstrated that
the clinical disease score was significantly decreased in
PADI4−/− mice and PADI2−/− mice.
PADI4 expression was induced by CII immunization.
Interestingly, PADI2 expression was compensationally
induced in CD11b+ cells of PADI4-/- mice. However, in
PADI2-/- mice, conpensational induction of PADI4 was not
obsered. It appears that PADI4 and PADI2 enhance
collagen-initiated inflammatory responses.
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Likely pathogenic variant within zinc finger domain 4 of
BCL11B in a child with facial and dermal abnormalities
and severe combined immunodeficiency
L. Olfe1, S. v. Hardenberg1, C. Klemann2, U. Baumann2, E.
Tolosa3, D. Lessel4, B. Auber1
1Department of Human Genetics, Hannover Medical
School, Hanover, Germany, 2Department of Pediatric
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Germany, 4Institute of Human Genetics, University Medical
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BCL11B encodes a Cys2His2 zinc finger transcription fac-
tor involved in the development of nervous and immune
systems. BCL11B heterozygous loss-of-function variants
have been associated with a neurodevelopmental disorder,
alterations in the T-cell development and reduced number of
type 2 innate lymphoid cells (ILC2s). Moreover, a single
patient presenting with syndromic features and severe
combined immunodeficiency (SCID) due to a pathogenic
missense variant in BCL11B has been reported. Here we
report a newborn with developmental SCID diagnosed
through neonatal SCID screening based on T-cell receptor
excision circles. The child presented with microcephaly,
hirsutism, loose skin folds and dysmorphic facial features,
which include thin eyebrows, hypertelorism, short palpebral
fissures, broad nasal bridge, anteverted, small nares, thin
upper and lower lip vermillion and long philtrum. Immu-
nophenotyping showed absence of T-cells with remaining
B- and NK-cells, and in strong contrast to loss-of-function
BCL11B cases a normal amount of ILC2-cells. Whole-
exome sequencing identified a likely pathogenic BCL11B
missense variant c.2428A>C, p.(Asn810His), affecting one
of the four specificity residues of the DNA-contacting
alpha-helix within the fourth zinc finger domain. Bioinfor-
matic prediction algorithms suggest this missense variant
binds to identical alternative genomic sequences, resulting
in acquisition of novel DNA-binding regions, as the pre-
viously reported one. Thereby, providing an explanation for
the striking clinical similarities of the two missense cases.
Our findings further suggest that only specific BCL11B
missense variants result in a severe immunodeficiency. This
case further highlights the importance of neonatal SCID
screening for early diagnosis and consequently the ther-
apeutic option of hematopoietic stem cell transplantation.
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An atypical presentation of Immunodeficiency Centro-
meric Instability Facial anomalies syndrome
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University Medical Center, Beirut, Lebanon, 3Pediatrics
Department, American University of Beirut, Beirut, Leba-
non, 4American University of Beirut, Beirut, Lebanon
Severe Combined Immunodeficiency Diseases (SCID) are
genetic disorders characterized by profound impairment of
cellular and humoral immunity. They are defined by a sig-
nificant deficiency in T lymphocytes. Patients with SCID are
asymptomatic at birth but infections can lead to their early
death unless appropriate treatment is applied. A 10 day old
girl, born to consanguineous Lebanese parents was referred to
our Medical Genetics Unit for genetic evaluation, because of
a family history of SCID. Lymphocytic immunophenotyping
and serum immunoglobulin testing revealed a low absolute
lymphocyte count, T cell lymphopenia with a significant
decrease in naïve T cells and normal circulating B cells count
including mainly immature B cells. SCID/atypical SCID was
suspected in the patient. Whole Exome Sequencing (WES)
was conducted and did not reveal any mutation in the SCID
genes. However, reanalysis of WES data showed the presence
of a homozygous missense variant, likely pathogenic, in the
DNMT3B gene (NM_ 006892; c.2477G>A, p.R826H). This
gene is involved in the autosomal recessive ICF1 syndrome
(Immunodeficiency- Centromeric instability- Facial anomalies
syndrome). A reevaluation of the patient’s clinical presenta-
tion and laboratory findings revealed undetectable immu-
noglobulin levels and facial dysmorphism (hypertelorism,
micrognathia and low set ears), both characteristic of ICF1. T
cell lymphopenia presenting at an early age in our proband is
an unusual feature in ICF1 patients. Altogether, this case
describes a severe presentation of ICF1 and highlights the
heterogeneity of primary immunodeficiencies. It also stresses
on the importance of early management of patients born to
families with a history of SCID.
C. Mehawej: ; Research council of Saint-Joseph
University (FM362). H. Khalife: None. G. Dbaibo: None.
R. Wakim: None. C. Farra: None.
P07.51.B
Uncovering rare hematological entities: Shwachman
Diamond syndrome in a pair of siblings with congenital
neutropenia and recurrent infections
J. Trizuljak1,2, Z. Vrzalová1,2, I. Blaháková1,2, L. Radová2,
Š. Pospíšilová1,2, M. Doubek1,2
1University Hospital, Brno, Czech Republic, 2Central
European Institute of Technology, Brno, Czech Republic
Shwachman-Diamond syndrome (SDS) is an autosomal
recessive disorder with clinical features that include pan-
creatic exocrine insufficiency, hematologic dysfunction, and
skeletal abnormalities, Haematological malignancies occur
in one third of patients. SDS is caused by homozygous or
compound heterozygous mutations in SBDS gene.
We present a sibling pair with mild to moderate
neutropenia, episodes of autoimmune hemolysis and
recurrent infections of the oral cavity and respiratory
airways. Prior investigations were inconclusive. Family
history suggested AR mode of inheritance. We performed
whole-exome sequencing of siblings and parents. Whole-
exome libraries were prepared according to the Nimblegen
SeqCap EZ Exome v3 protocol and sequencing was
performed on NextSeq 500 for all of them. Furthermore,
we performed in silico analysis of a virtual gene panel,
focused on congenital neutropenias. Whole-exome sequen-
cing identified a compound heterozygous genotype in
SBDS gene in both siblings. We identified a likely
pathogenic missense variant c.355T>C; p.(Cys119Arg) in
exon 3 of SBDS gene, leading to substitution of strongly
conserved cysteine for arginine. This variant has been
previously reported in a French family with SDS (Donadieu
et al., 2012). Furthermore, we identified a rare, previously
undescribed missense variant, c.536C>T; p.(Pro179Leu),
leading to prolin - leucine substitution. In-silico analysis
(Align GVGD, SIFT, MutationTaster) predicts pathogenic
or likely pathogenic effect. Molecular-genetic analysis of
parents confirmed heterozygous carrier status. Compound
heterozygous mutations in SBDS leads to disruption of
SBDS gene and clinical manifestation of Shwachman-
Diamond syndrome in the siblings. This study was
supported by Czech Ministry of Health (grant AZV 16-
29447A) and Masaryk University (grant MUNI/A/1395/
2019).
J. Trizuljak: None. Z. Vrzalová: None. I. Blaháková:
None. L. Radová: None. Š. Pospíšilová: None. M.
Doubek: None.
P07.52.C
Genome-to-genome analysis identifies an Asian-specific
variant in the gene encoding NTCP that leads to specific
HBV escape mutations during chronic infection
Z. Xu1, S. Rüeger1, P. Shea2, M. Buti3, H. L. Y. Chan4, P.
Marcellin5, O. Podlaha6, Z. Jiang6, V. Suri6, A. Gaggar6,
M. Subramanian6, E. Gane7, D. Goldstein2, J. Fellay1,8
1School of Life Sciences, École Polytechnique Fédérale de
Lausanne, Lausanne, Switzerland, 2Institute for Genomic
Medicine, Columbia University, New York, NY, United
States, 3Liver Unit, Hospital Universitario Vall d’Hebron
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and CIBEREHD del Instituto Carlos III, Barcelona, Spain,
4The Chinese University of Hong Kong, Hong Kong, China,
5Service d’Hépatologie, Hôpital Beaujon, Clichy, France,
6Gilead Sciences Inc, Foster City, CA, United States,
7Auckland Clinical Studies, Auckland, New Zealand, 8Pre-
cision Medicine Unit, Lausanne University Hospital,
Lausanne, Switzerland
Introduction: Hepatitis B virus (HBV) is a major cause of
chronic liver diseases, including liver cirrhosis and hepa-
tocellular carcinoma. In chronic infections, the interplay
between human and viral genetics contributes to HBV
evolutionary changes. Here, we use a genome-to-genome
(G2G) approach to identify sites of host-pathogen genomic
interactions.
Materials and Methods: We obtained paired human
exome and HBV genome data from 424 chronically
infected individuals of Asian ancestry from three Phase
3 studies evaluating tenofovir-based regimens. For each
variable HBV amino acid, a genome-wide association study
was conducted using generalized linear mixed models and
controlling for human and viral population structures.
Results: We identified strong associations (p=1.9E-12)
between an Asian-specific missense SNP in the SLC10A1
gene encoding the HBV receptor NTCP (rs2296651) and
amino acids in HBV large surface (preS1 domain) and
polymerase proteins. The minor allele is present in 7% of
East Asians (1KG Project) and was previously reported to
associate with decreased risk of cirrhosis and hepatocellular
carcinoma in chronic HBV. We also identified significant
associations (p=8.7E-13) between variants of HLA-A
protein and amino acids in HBV polymerase and core
proteins.
Conclusions: Our joint analysis of human and viral
genomes shows that variation in NTCP exerts selective
pressure on HBV during chronic infection, and confirms the
impact of HLA class I variation on HBV epitopes. These
results demonstrate the power of the G2G approach to
identify host restriction factors and identify specific HBV
amino acids likely to be involved in the interaction between
HBV and its cellular receptor.
Z. Xu: None. S. Rüeger: None. P. Shea: None. M. Buti:
None. H.L.Y. Chan: None. P. Marcellin: None. O.
Podlaha: A. Employment (full or part-time); Significant;
Gilead Sciences Inc. Z. Jiang: A. Employment (full or part-
time); Significant; Gilead Sciences Inc. V. Suri: A.
Employment (full or part-time); Significant; Gilead
Sciences Inc. A. Gaggar: A. Employment (full or part-
time); Significant; Gilead Sciences Inc. M. Subramanian:
A. Employment (full or part-time); Significant; Gilead
Sciences Inc. E. Gane: None. D. Goldstein: None. J.
Fellay: None.
P07.53.A
Relationships between smoking methylation biomarkers
and GPR15+ helper T cell levels in peripheral blood
W. Philibert1, S. R. H. Beach2, A. M. Andersen1
1University of Iowa, Iowa City, IA, United States, 2Uni-
versity of Georgia, Athens, GA, United States
Introduction: Smoking causes epigenetic changes asso-
ciated with inflammatory diseases and elevated mortality.
Of particular interest are changes in the level of T cells
expressing G-protein-coupled receptor 15 (GPR15), a che-
mokine receptor linked with inflammatory bowel disease,
multiple sclerosis and psoriasis. Accordingly, a better
understanding of the mechanisms by which smoking
influences variation in GPR15+ T cell subpopulations is of
potential interest.
Materials and Methods: Flow cytometry and digital
PCR assays were used to measure the GPR15+CD3+CD4+
helper T (Th) populations in peripheral blood from n = 62
primarily African American young adults (aged 27-35
years) with a high rate of tobacco and cannabis use.
Results: Tobacco and cannabis smoking predicted
GPR15+ (Th) cell levels using linear regression models.
Methylation of two candidate CpGs, cg19859270, located
in GPR15, and cg05575921, located in Aryl Hydrocarbon
Receptor Repressor (AHRR), were both significant pre-
dictors of GPR15+ Th cell levels, mediating the relationship
between smoking and increases in GPR15+ Th cells. As
hypothesized, the interaction between cg05575921 and
cg19859270 was significant, indicating that low
cg05575921 methylation was more strongly associated
with GPR15+ Th cell levels for those with lower
cg19859270 methylation.
Conclusions: Smoking leads changes in two CpGs,
cg05575921 and cg19859270, that mediate 38.5% of the
relationship between tobacco and cannabis smoking and
increased GPR15+ Th levels in this sample. The impact of
cg19859270 in amplifying the association between
cg05575921 and increased GPR15+ Th levels is of potential
theoretical interest because it may reflect a permissive
interaction between different parts of the immune system.
W. Philibert: None. S.R.H. Beach: None. A.M.
Andersen: None.
P07.54.B
Somatic mutations in HLA loci in patients with myeloid
leukemia
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 317
J. Neupauerová1, P. Crivello2, Š. Půbalová1, C. Šálek1, S.
Nazarová1, M. Vraná1
1Institute of hematology and blood transfusion, Prague 2,
Czech Republic, 2Institute of experimental cellular therapy,
University Hospital Essen, Essen, Germany
Introduction: In the HLA department of Institute of
hematology and blood transfusion in Prague we deal with
HLA typing of hematooncological patients and their related/
unrelated donors. The best donor compatibility is important
for succesful hematopoetic stem cell transplantation
(HSCT).
Materials and methods: Using NGS (Omixon, Hun-
gary), we investigated more than 2000 patients and their
HSC donors. New alleles found were confirmed by Sanger
sequencing (Inno-train, Germany; CareDx, USA).
Results:. From our recent studies (2017 - 2019), in our
cohort of patients, 15 new alleles were detected. Two of
them were a somatic mutation in patients suffering from
acute myeloid leukemia (AML); one was in the HLA-B and
the other in the HLA-C locus. In both cases, the somatic
mutation represents a single nucleotide polymorphism.
Conclusions: Our findings are in agreement with the
known genome instability in AML. In the HLA region,
somatic mutations are not so common, however, they
should be given more attention since they can affect disease
progression and may impact also on HSCT. Our future
studies will focus on the precise identification of the new
allelles and their characterization in HLA typing.
Supported by the Ministry of Health, Czech Republic-
conceptual development of research organization
(CZ00023736, UHKT).
J. Neupauerová: None. P. Crivello: None. Š. Půbalová:
None. C. Šálek: None. S. Nazarová: None. M.
Vraná: None.
P07.55.C
High-throughput sequencing of T-cell receptor alpha
chain clonal rearrangements in B-lineage acute lympho-
blastic leukemia
A. Miroshnichenkova1, A. Komkov1,2, A. Popov1, E.
Volchkov1, M. Maschan1, A. Karachunskiy1, Y.
Olshanskaya1, I. Mamedov2
1Dmitry Rogachev National Research Center of Pediatric
Hematology, Oncology and Immunology, Moscow, Russian
Federation, 2Shemyakin-Ovchinnikov Institute of bioor-
ganic chemistry, Moscow, Russian Federation
Introduction: Rearrangements of T- and B-cell receptor
(TCR and BCR) genes are useful markers for clonality
assessment and minimal residual disease (MRD) monitoring
during the treatment of hematological malignancies. Despite
their estimated lineage, B-cell leukemias manifest a
remarkably high incidence of TCR gene rearrangements.
According to indirect estimation, TCR alpha (TRA) inci-
dence in B-cell precursor ALL could reach 46%. Currently,
rearrangements of all BCR and 3/4 TCR loci are used for
this purpose with the exception of TRA due to the large
number of multiplex primers needed to amplify all TRA
segments.
Materials and Methods: We developed the first targeted
sequencing-based method for identification of TRA clonal
rearrangements. gDNA was extracted from a bone marrow
of children with B-ALL. Amplification of TRA rearrange-
ments was performed in multiplex PCR and subsequently
sequenced on Illumina platform.
Results: TRA rearrangements were detected in 5/
45 samples and associated with myeloid CD33+ co-
expression (p-value 0.0147, two-tailed Mann-Whitney U-
test). Clonal rates of TRA varied from 31% to 98% and
corresponded to main leukemic clones. All found TRA
rearrangements were nonfunctional. TRA clones arose after
leukemic transformation and have high clonal rate, which
indicates these clones are most viable of all other leukemic
clones.
Conclusions: The innovative study provides pathbreak-
ing analyses of TRA occurrence in B-ALL at the DNA level
and suggests that particular TRA rearrangements may be of
clinical relevance in childhood B-ALL by adding a
significant marker to MRD detection panel based on
TCR/BCR rearrangements analysis.
The study is supported by PFBR grants 20-015-00462,
18-29-09132.
A. Miroshnichenkova: None. A. Komkov: None. A.
Popov: None. E. Volchkov: None. M. Maschan: None. A.
Karachunskiy: None. Y. Olshanskaya: None. I.
Mamedov: None.
P07.56.A
Gene mutation spectrum of thalassemia patients from
Azerbaijan
A. AGHAYEV1, V. Huseynov2, E. Aliyev2, A. Najafli2, K.
Jafarova2, A. Mammadova2, R. Bayramli2, Z. Uyguner3
1National Hematology and Transfusiology Center, Depart-
ment of Genetic Diagnosis, Baku, Azerbaijan, 2National
Hematology and Transfusiology Center, Baku, Azerbaijan,
3Department of Medical Genetics, Istanbul Medical
Faculty, Istanbul, Turkey
Introduction: Thalassemias are defined by the absence or
decrease of globin chain(s), which may lead imbalances of
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globin chains, ineffective erythropoiesis, hemolysis, and
eventually to a variable degree of anemia. With the esti-
mated carrier frequency of β-thalassemia is 4%-8.6% in
country, the importance of premarital genetic testing,
informed family counseling and preventive medical treat-
ment cannot be overstated. Screening for traits by hemo-
globin electrophoresis and biochemical analysis has become
a routine application test prior to the issuance of a marriage
license throughout Azerbaijan.
Methods: We aimed to evaluate prevalent mutations
spectrum, the effect and their co-inheritance and/or role of
polymorphisms (BCL11A, HBS1L-MYB and Xmn1 SNP)
on disease phenotype by using reverse dot-blot hybridiza-
tion using customized strips, sequencing analysis of the
complete genes and MLPA.
Results: We report here a summary finding of HBB gene
analysis for 265 patients and HBA1-HBA2 genes analysis
for 28 patients, along with their family members totaling
570 individuals. β; thalassemia-66 were found to have
homozygous, 76 possessed compound heterozygous and 80
possessed heterozygous mutations. Overall, a total of 416
alleles were found to have 34 mutations. The first 20
frequented mutations covered 87% of the entirety of all
mutations. The summary range is as following:
c.25_26delAA(p.Lys9Valfs) 27.9%; c.93-21G>A(IVS1
+110G>A) 11.3%; c.315+1G>A(IVS2+1G>A) 8.9%.
α; thalassemia-Genotyping of 45 alleles revealed 9
mutations, the 3.7 kb deletion is the most frequent mutation
(35.6%), followed by 20.5 kb deletion (24.4%) and α2
polyA2(HBA2:c.*92A > G, 13.3%).
Conclusions: The results may help inform decisions in
the design and implementation of prevention strategies and
diagnostic approaches.
A. Aghayev: None. V. Huseynov: None. E. Aliyev:
None. A. Najafli: None. K. Jafarova: None. A. Mamma-
dova: None. R. Bayramli: None. Z. Uyguner: None.
P07.59.A
Genome-wide association study of susceptibility to
respiratory syncytial virus infection during infancy
D. Lawless1, C. Rosas-Salazar2, T. Gebretsadik2, K. Turi2,
B. Snyder2, P. Wu2, J. Fellay1, T. Hartert2
1Global Health Institute, Lausanne, Switzerland, 2Vander-
bilt University School of Medicine, Nashville, TN, United
States
Introduction: Human respiratory syncytial virus (RSV)
infection is associated with asthma development. However,
this association is confounded by shared heritability, and
genetic studies have focused exclusively on severe infection.
Longitudinal, population-based studies of RSV infection are
thus required to assess the causal association between RSV
and asthma. To determine whether there are genetic variants
involved with susceptibility or resistance to infection, we
performed the first GWAS on non-severe RSV infection.
Methods:We performed GWAS analyses of healthy term
infants in a population-based birth cohort (INSPIRE)
specifically designed to determine the effect of infant
RSV infection on later child health. We compared infants
who were and were not infected with RSV in the first year
of life as determined by biweekly surveillance for RSV
infection and serology at age 1 year.
Results: Among 1959 enrolled, 54% of infants were RSV
infected and 46% were uninfected at age 1. There were
significant differences in environmental factors associated
with RSV infection, including daycare (p=0.001), siblings
(p=0.002) and black race (p=0.002). GWAS analyses of a
subset of 663 participants with available genotyping data,
adjusted for birth month, sex, race, daycare and siblings
revealed no significant associations.
Conclusions: We found no genome wide associations
with risk of infant RSV infection; environmental factors
were significantly associated with infection risk. These
findings support using RSV infection as a means of natural
randomization free from genetic confounding to study the
effects of RSV infection on long-term outcomes.
Grants: NIH-U19AI095227, NIH-UL1RR024975, SNSF
IZSEZ0_191968
D. Lawless: None. C. Rosas-Salazar: None. T.
Gebretsadik: None. K. Turi: None. B. Snyder: None. P.
Wu: None. J. Fellay: None. T. Hartert: None.
P07.60.B
The HLA and ABO genetic background impact on
SARS-CoV-2 infection and COVID-19 severity
T. Vaisitti1, A. Amoroso2, P. Magistroni3, F. Vespasiano4,
F. Puoti4, S. Alizzi3, P. Grossi5, S. Trapani4, L.
Lombardini4, P. Pezzotti6, M. Cardillo4
1Department of Medical Sciences, University of Turin,
Turin, Italy, 2Department of Medical Sciences, University of
Turin and Immunogenetics and Transplant Biology Service,
Città della Salute e della Scienza University Hospital,
Turin, Italy, 3Immunogenetics and Transplant Biology
Service, Città della Salute e della Scienza University
Hospital, Turin, Italy, 4National Transplant Center, Istituto
Superiore di Sanità, Rome, Italy, 5Department of Medicine
& Surgery University of Insubria – ASST-Sette Laghi,
Varese, Italy, 6Epidemiology, Biostatistics and Mathema-
tical models, Istituto Superiore di Sanità, Rome, Italy
At the beginning of 2020, the SARS-CoV-2 outbreak has
been defined by the WHO as a global health emergency. A
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peculiar feature of this infection is the extreme variability in
clinical presentation, ranging from very mild sub-clinical
flu-like symptoms to acute respiratory distress syndrome
with high mortality. This heterogenous presentation poses
the question whether individual variability of immune
response to the virus can be influenced by genetic factors.
Specifically, it is unknown whether HLA and AB0 can
explain the different prevalence in population of SARS-
CoV-2 infection and its clinical evolution. To address this
point, a retrospective analysis was performed on an Italian
cohort composed by subjects who received organ trans-
plantation and candidates in a waiting list in a 2002-March
2020 time frame. A total of 56,304 cases were studied with
the aim of comparing HLA and AB0 frequencies according
to the presence (COVID+) or absence (COVID−) of SARS-
CoV-2 infection. The prevalence of COVID was 0.112% in
the Italian population and 0.462% in waitlisted and trans-
planted patients. HLA-B*51 and HLA-DRB1*08 were
more frequent in COVID+ compared to COVID−, while
HLA-DRB1*07 showed a protective effect. In transplant
recipients, HLA-DRB1*08 was an indicator of mortality
(1.9% in living vs 15.2% in the deceased, OR=9.4 95%CI
[1.9-47.3]; P=.006). Moreover, blood group A was more
frequent in COVID+ (45.5%) than in COVID− (39.0%).
Overall, this study shows for the first time that some HLA
antigens influence SARS-CoV-2 infection and its clinical
evolution and confirms that blood group A subjects are at
greater risk of infection.
T. Vaisitti: None. A. Amoroso: None. P. Magistroni:
None. F. Vespasiano: None. F. Puoti: None. S. Alizzi:
None. P. Grossi: None. S. Trapani: None. L. Lombar-
dini: None. P. Pezzotti: None. M. Cardillo: None.
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Angelman syndrome: a novel UBE3A splice variant
M. G. Williams1,2, B. Hanna3, M. Freckmann4, S.
Bommireddipalli5, A. Bournazos5, S. Cooper5, J.
Harraway6, P. Dawson1, H. Heussler1,2,7
1Mater Research Institute – The University of Queensland,
Woolloongabba, QLD, Australia, 2Faculty of Medicine,
University of Queensland, St Lucia, QLD, Australia, 3Clin-
ical Genetics, Westmead Hospital, Westmead, NSW,
Australia, 4Clinical Genetics, Royal North Shore Hospital,
St Leonards, NSW, Australia, 5Kids Neuroscience Centre,
The Children’s Hospital at Westmead, Westmead, NSW,
Australia, 6Mater Pathology, South Brisbane, QLD,
Australia, 7Child Development, The Queensland Children’s
Hospital, South Brisbane, QLD, Australia
Introduction: Angelman syndrome (AS) is a neurodeve-
lopmental disorder characterised by moderate to severe
developmental delay, absent or near absent speech, gait
ataxia, microcephaly and seizures. Deficient expression or
function of the maternally inherited UBE3A allele results in
AS. Pathogenic UBE3A sequence variants (predominantly
loss-of-function) account for ~11% of Angelman
syndrome cases.
A maternally inherited c.1900G>C (p.(Val634Leu))
variant of uncertain significance was identified in a seven-
year-old male with clinical features consistent with Angel-
man syndrome (although no seizures noted). This variant
affects the first nucleotide of UBE3A exon 7 (transcript
NM_130838.2) and in silico splicing tools predict weaken-
ing of the canonical 3’-splice site.
Methods: RT-PCR and Sanger sequencing of gel-purified
amplicons was performed on mRNA isolated from the
proband and maternal peripheral blood mononuclear cells
(PBMCs). To detect aberrantly spliced transcripts targeted
by nonsense-mediated mRNA decay (NMD), PBMCs were
cultured in the presence of cycloheximide (CHX) to
inhibit NMD.
Results: The UBE3A:c.1900G>C variant causes aberrant
splicing and use of a cryptic 3’splice site (r.1899_1900ins
[1900-38_1900-1]) resulting in a frameshift: p.(Val634-
Phefs*19). Cycloheximide inhibition of transcripts demon-
strated an increase in the relative abundance of abnormally
spliced transcripts, suggesting targeting by NMD. The
c.1900G>C variant was re-classified as a pathogenic.
Conclusions: The maternally inherited UBE3A:
c.1900G>C variant induces abnormal splicing of the
predominant UBE3A isoforms expressed in blood and
brain, introducing a frameshift consistent with the patho-
genesis of Angelman syndrome. Therefore, UBE3A splicing
outcomes observed in mRNA isolated from blood can
inform the molecular consequences of cryptic splice
variants for diagnosis and genetic counselling of Angelman
syndrome.
M.G. Williams: None. B. Hanna: None. M. Freck-
mann: None. S. Bommireddipalli: None. A. Bournazos:
None. S. Cooper: None. J. Harraway: None. P. Dawson:
None. H. Heussler: None.
P08.004.A
De novo loss of function mutations in ANK2 cause a
neurodevelopmental disorder with autism and early
onset epilepsy
M. W. A. Teunissen1, E. Lewerissa2, C. Ockeloen3, D.
Koolen3, M. R. F. Reijnders4, R. Pfundt4, S. Seiffert5, M.
Primiano6, E. Brilstra7, J. L. Howe8, S. Scherer9, R. J.
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Vermeulen1, R. P. W. Rouhl1,10, H. Brunner1,3, N. Nadif
Kasri3,11, M. H. Willemsen3
1Maastricht University Medical Centre, Maastricht, Nether-
lands, 2Cognitive Neuroscience, RadboudUMC, Nijmegen,
Netherlands, 3RadboudUMC, Nijmegen, Netherlands,
4Maastricht University Medical Centre, The Netherlands,
Maastricht, Netherlands, 5Hertie Institute for Clinical Brain
Research, Tuebingen, Germany, 6Morgan Stanley Chil-
dren’s Hospital of New York-Pretbytarian, New York, NY,
United States, 7Universitair Medisch Centrum Utrecht,
Utrecht, Netherlands, 8Centre for Applied Genomics, The
Hospital for Sick Children, Toronto, ON, Canada, 9The
Hospital for Sick Children, Toronto, ON, Canada, 10Aca-
demic Center for Epileptology Kempenhaeghe/MUMC,
Maastricht, Netherlands, 11Donders Institute for Brain,
Cognition, and Behaviour, Nijmegen, Netherlands
Aim: Mutations in Ankyrin 2 (ANK2), previously known to
cause cardiac arrhythmia, may also cause neurodevelop-
mental disorders and epilepsy. We will provide insight in
the spectrum of neurodevelopmental phenotypes associated
with ANK2 and explore the effects of ANK2 mutations on
neuronal function.
Methods: We describe clinical and molecular data of
seven individuals with de novo loss-of-function (LoF)
mutations in ANK2. These patients were collected through
our database, international contacts and contacting authors
of previous reports. Furthermore, we generated a hetero-
zygous loss-of-function of ANK2 using CRISPR/Cas9 in
human induced pluripotent stem cells (hIPSCs). HiPSCs
were differentiated towards excitatory neurons to study
neuronal function. We measured axon initial segment (AIS)
plasticity, which plays an important role in regulating
homeostatic plasticity in response to increased neuronal
excitability. We stimulated ANK2-CRISPR neurons with
KCl to induce chronic depolarization. We immunostained
neurons for AnkG, a scaffolding protein that acts as marker
for AIS.
Results: All patients had intellectual disability or
developmental delay. Six patients had a formal or suspected
diagnosis of autism, four patients had early onset epilepsy.
Two patients had concurrent cardiac abnormalities. All
patients with neurodevelopmental disorders have LoF
mutations, in contrast almost all reported patients with
cardiac problem had missense mutations. Functionally,
heterozygous loss of ANK2 causes a more diffuse AnkG
staining and showed impaired AIS plasticity upon KCl
treatment.
Conclusions: We show that heterozygous de novo ANK2
LoF mutations cause a novel neurodevelopmental disorder
with early onset epilepsy. Furthermore, we showed that
heterozygous heterozygous LoF mutations in ANK2 affect
neuronal function.
M.W.A. Teunissen: None. E. Lewerissa: None. C.
Ockeloen: None. D. Koolen: None. M.R.F. Reijnders:
None. R. Pfundt: None. S. Seiffert: None. M. Primiano:
None. E. Brilstra: None. J.L. Howe: None. S. Scherer:
None. R.J. Vermeulen: None. R.P.W. Rouhl: None. H.
Brunner: None. N. Nadif Kasri: None. M.H.
Willemsen: None.
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Biallelic variants in ANKRD12 cause intellectual dis-
ability, developmental delay, aphasia, hypotonia and
hearing loss
M. Ansar1,2, S. A. Paracha3, E. Wohler4, M. T. Sarwar3, E.
Ranza1,5,6, F. A. Santoni1,7, J. Ahmed3, H. Goel8, D. A.
Scott9, S. E. Antonarakis1,5,10
1Department of Genetic Medicine and Development,
University of Geneva, Geneva, Switzerland, 2Clinical
Research Center, Institute of Molecular and Clinical
Ophthalmology Basel (IOB), Basel, Switzerland, 3IInstitute
of Basic Medical Sciences, Khyber Medical University,
Peshawar, Pakistan, 4McKusick-Nathans Institute of
Genetic Medicine, Johns Hopkins University, Baltimore,
MD, United States, 5Service of Genetic Medicine, Uni-
versity Hospitals of Geneva, Geneva, Switzerland, 6Medi-
genome, The Swiss Institute of Genomic Medicine, Geneva,
Switzerland, 7Department of Endocrinology Diabetes and
Metabolism, University Hospital of Lausanne, Lausanne,
Switzerland, 8Medicine and Public Health, University of
Newcastle, Callaghan, New South Wales, Australia,
9Department of Molecular and Human Genetics, and
Department of Molecular Physiology and Biophysics
Baylor College of Medicine, Houston, TX, United States,
10iGE3 Institute of Genetics and Genomics of Geneva,
Geneva, Switzerland
The Ankyrin repeat domain-containing protein 12 is enco-
ded by the ANKRD12 gene. The function of this protein,
and its role in human health is unclear. However, is highly
expressed in the cerebellum and cerebellar hemisphere
regions of brain (gtexportal.org). It is hypothesized that
ANKRD12 plays a role in inhibiting the ligand dependent
transactivation by recruiting histone deacetylases (HDACs)
to the p160 coactivators/nuclear receptor complex. HDACs
are involved in the regulation of gene expression. Patho-
genic variants in another member of the Ankyrin repeat
domain-containing protein, ANKRD11, cause the KBG
syndrome whose phenotypes include intellectual disability,
developmental delay and seizures in some patients. Here,
we report six affected individuals from three unrelated
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families that carry homozygous or compound heterozygous
variants in ANKRD12. Four of these individuals are from a
consanguineous Pakistani family, and have a homozygous
non-synonymous variant c.3425A>C,p.(Lys1142Thr) in
ANKRD12 (NM_015208.4). The other two are from the
USA and carry compound heterozygous variants in
ANKRD12; c.4511C>T,p.(Ser1504Leu)/c.3375_3377del in
one, and c.5251C>G, p.(Leu1751Val)/deletion of exon 1 of
the transcript NM_001204056.1 in the other. Phenotypes
noted in these individuals include intellectual disability,
aphasia, delayed motor milestones, hypotonia, mild hearing
loss, and seizures (in one patient). Functional experiments
in drosophila are in progress and will be presented in the
meeting. Further investigations need to be done to under-
stand the disease mechanism. However, the phenotypic
similarity of the patients and the expression data from GTEx
indicate that pathogenic ANKRD12 variants may cause a
recessive disease characterized by intellectual disability,
developmental delay, hypotonia and mild hearing loss.
M. Ansar: None. S.A. Paracha: None. E. Wohler:
None. M.T. Sarwar: None. E. Ranza: None. F.A.
Santoni: None. J. Ahmed: None. H. Goel: None. D.A.
Scott: None. S.E. Antonarakis: None.
P08.007.A
Loss-of-function variants in CAPRIN1 in patients
affected by autism spectrum disorder, language delay
and intellectual disability with variable expressivity and
incomplete penetrance
L. Pavinato1, J. L. Howe2, D. Carli3, E. Agolini4, D. A.
Coviello5, I. M. B. H. Van de Laar6, P. Y. B. Au7, E. Di
Gregorio8, E. Giorgio1, E. Pozzi1, M. Ferrero1, S.
Cardaropoli3, A. Delle Vedove9,10,11, V. Salpietro12,13,14, F.
Zara12, A. Novelli4, B. Wirth9, G. B. Ferrero3, S. W.
Scherer15,16,2, A. Brusco1
1Department of Medical Sciences, University of Turin,
Turin, Italy, 2The Centre for Applied Genomics, The
Hospital for Sick Children, Toronto, ON, Canada, 3Depart-
ment of Public Health and Pediatrics, University of Turin,
Turin, Italy, 4Laboratory of Medical Genetics, Bambino
Gesù Children’s Hospital, Rome, Italy, 5Laboratory of
Human Genetics, IRCCS Istituto Giannina Gaslini, Gen-
ova, Italy, 6Department of Clinical Genetics, Erasmus MC,
University Medical Center Rotterdam, Rotterdam, Nether-
lands, 7Department of Medical Genetics, Alberta Children’s
Hospital Research Institute, University of Calgary, Cal-
gary, AB, Canada, 8Medical Genetics Unit, Città della
Salute e della Scienza University Hospital, Turin, Italy,
9Institute of Human Genetics, Center for Molecular
Medicine Cologne, Cologne, Germany, 10Institute for
Genetics, University of Cologne, Cologne, Germany,
11Center for Molecular Medicine Cologne, University of
Cologne, Cologne, Germany, 12Pediatric Neurology and
Muscular Diseases Unit, IRCCS "G. Gaslini" Institute,
Genova, Italy, 13Department of Neurosciences, Rehabilita-
tion, Ophthalmology, Genetics, Maternal and Child Health,
University of Genoa, Genova, Italy, 14Department of
Neuromuscular Diseases, Queen Square Institute of
Neurology, University College of London, London, United
Kingdom, 15McLaughlin Centre, University of Toronto,
Toronto, ON, Canada, 16Genetics & Genome Biology
Program, The Hospital for Sick Children, Toronto, ON,
Canada
CAPRIN1 gene is highly expressed in brain and its product,
Caprin-1 protein, is involved in the transport of mRNAs in
neurons and it localizes at neuronal RNA granules, where is
able to directly interact with the Fragile X Mental Retar-
dation protein. Genome-wide studies have suggested
CAPRIN1 as a new autism spectrum disorders (ASD) can-
didate gene. Interestingly, Caprin-1+/- animal models show
defects in the development of dendrites and dendritic spines
and are characterized by a reduction in social interactions
and lower response to novelty. Despite a clear involvement
of Caprin-1 in neurodevelopment, the gene is still not
associated with a human disease. Here we report the
description of seven affected individuals with de novo and
three cases with inherited loss-of-function (LoF) variants in
CAPRIN1. Our cases show a broad spectrum of phenotypes,
that ranges from ASD to language delay, intellectual dis-
ability, attention deficit hyperactivity disorder and epileptic
seizures. Other traits, such as abnormal facial features and
skeletal anomalies are observed in subgroup of cases.
CAPRIN1 is predicted to be an haploinsufficient gene by
computational pLI score (GnomAD). Taking advantage of
the availability of patients-derived cells, we demonstrated a
half-dose of CAPRIN1 mRNA levels, caused by nonsense
mediated decay of the transcripts with LoF variants, that is
followed by a parallel protein level half-dose. Our data lay
the bases for further characterization of the involvement of
CAPRIN1 in neurodevelopmental disorders, suggesting the
haploinsufficiency of this gene as causative of a form of
ASD with a possible incomplete penetrance and variable
expressivity.
L. Pavinato: None. J.L. Howe: None. D. Carli: None.
E. Agolini: None. D.A. Coviello: None. I.M.B.H. Van de
Laar: None. P.Y.B. Au: None. E. Di Gregorio: None. E.
Giorgio: None. E. Pozzi: None. M. Ferrero: None. S.
Cardaropoli: None. A. Delle Vedove: None. V. Salpietro:
None. F. Zara: None. A. Novelli: None. B. Wirth: None.
G.B. Ferrero: None. S.W. Scherer: None. A.
Brusco: None.
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P08.008.B
TLK2-associated intellectual disability: expanding the
disease phenotype and characterizing missense variants
at the molecular level
L. Pavinato1, M. Villamor-Paya2, M. Sanchiz-Calvo2, C.
Andreoli3, S. Martinelli4, E. Giorgio1, D. Carli5, V.
Antona6, K. Ranguin7, C. Colson7, S. De Rubeis8, B.
Alessandro4, T. Pippucci9, P. Dimartino10, M.
Scaramuzzino1, V. Rizzo1, A. Ciolfi11, C. Radio11, J.
Buxbaum8, G. B. Ferrero5, T. Marco11, T. H. Stracker2, A.
Brusco1
1Department of Medical Sciences, Turin, Italy, 2Institute for
Research in Biomedicine (IRB Barcelona), The Barcelona
Institute of Science and Technology, Barcelona, Spain,
3Department of Environment and Health, Istituto Superiore
di Sanità, Rome, Italy, 4Department of Oncology and
Molecular Medicine, Istituto Superiore di Sanità, Rome,
Italy, 5Department of Pediatrics and Public Health and
Pediatric Sciences, University of Turin, Turin, Italy,
6Department of Sciences for Health Promotion and Mother
and Child Care "G. D’Alessandro", University of Palermo,
Palermo, Italy, 7Centre de référence Maladies rares et
Anomalies du développement, Service de génétique, Caen,
France, 8Department of Psychiatry, Icahn School of
Medicine at Mount Sinai, New York, NY, United States,
9Medical Genetics Unit, Polyclinic Sant’Orsola-Malpighi
University Hospital, Bologna, Italy, 10Department of
Medical and Surgical Sciences, University of Bologna,
Bologna, Italy, 11Genetics and Rare Diseases Research
Division, Ospedale Pediatrico Bambino Gesù, Rome,
Italy
The Tousled-Like Kinase 2 (TLK2) gene was recently
associated with “Mental Retardation Autosomal Dominant
57” (MIM:618050), a neurodevelopmental disorder char-
acterized by a highly variable phenotype, including mild-to-
moderate intellectual disability, behavioural abnormalities,
facial dysmorphisms, microcephaly, epilepsy and skeletal
anomalies. By whole-exome sequencing, we identified a
novel patient with a de novo likely pathogenic variant
(c.1586A>G; p.(Asp529Gly)) and a familial case with three
siblings who inherited a nonsense change from an affected
mother (c.1357G>T; p.(Glu453*)). Moreover, we report a
de novo 39-kb deletion encompassing TLK2 gene. Clinical
phenotype included intellectual disability, facial dys-
morphisms, microcephaly and anomalies of the hands as
prevalent features, in accordance with previously reported
cases.TLK2 is involved in many fundamental processes,
including DNA replication, cell cycle checkpoint recovery
and chromatin remodelling, through its regulation of the
ASF1 histone chaperone. TLK2 is essential in mice for
placental development but how TLK2 mutated protein
affects central nervous system development remains largely
unclear. Using spatial proteomics (BioID), we have inves-
tigated the proximity interaction landscape of TLK2 and
analysed the effects of missense mutations on TLK2 inter-
actions, localization and activity. These results demon-
strated that TLK2 activity is strongly impaired by the p.
(Asp529Gly) mutation and identified new links between
TLK2 and other proteins implicated in neurological dis-
orders. Moreover, single cell gel electrophoresis demon-
strated a more relaxed state of chromatin in lymphoblastoid
cells harbouring the p.(Asp529Gly) variant compared to
control cells. In conclusion, our study has identified novel
TLK2-patient pathogenic variants and provided new
insights into the role of TLK2 in intellectual disability.
L. Pavinato: None. M. Villamor-Paya: None. M.
Sanchiz-Calvo: None. C. Andreoli: None. S. Martinelli:
None. E. Giorgio: None. D. Carli: None. V. Antona:
None. K. Ranguin: None. C. Colson: None. S. De Rubeis:
None. B. Alessandro: None. T. Pippucci: None. P.
Dimartino: None. M. Scaramuzzino: None. V. Rizzo:
None. A. Ciolfi: None. C. Radio: None. J. Buxbaum:
None. G.B. Ferrero: None. T. Marco: None. T.H.
Stracker: None. A. Brusco: None.
P08.009.C
Exposure of heterozygous Tsc2 KO mice to chronic
social defeat stress leads to improvement in specific
behavioural domains
A. Arlt1, M. Wendelmuth1, K. Rolski2, R. Schneider2, S.
Schweiger1,3
1Institute of Human Genetics, University Medical Centre
Mainz, Mainz, Germany, 2Center of Molecular Biosciences
(CMBI), Institute of Biochemistry, University of Innsbruck,
Innsbruck, Austria, 3Leibniz Institute for Resilience
Research (LIR), Mainz, Germany
Autism is a neurodevelopmental disorder characterized by
impairment of communication and social interaction, as
well as by high levels of repetitive behaviours. Due to
atypical information processing within the brain, indivi-
duals with Autism highly rely on predictable procedures,
e.g. daily routines. Changes of these procedures increases
stress in the individuals. To investigate stress effects on
autistic phenotype development, we used a Tsc2 hetero-
zygous KO mouse model. Heterozygous mutations in the
TSC1 or TSC2 genes, which both negatively regulated the
mTOR kinase cause tuberous sclerosis, which is frequently
associated with mental retardation, autism and epilepsy. We
assessed sociability, anxiety, cognition and sensorimotor
gating, and found significant deficits in Tsc2 heterozygous
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KO animals. In a second step we asked, how chronic social
defeat stress affects the behavior of these mice. The chronic
social defeat stress (CSD) procedure used had been shown
to effectively induce a depression-like phenotype in wild-
type animals. Interestingly, in Tsc2 heterozygous KO mice
exposure to CSD stress lead to an improvement in some
behavioural domains including repetitive behavior, senso-
motoric gating and working memory suggesting an inverse
stress reaction in these animals. Proteomic analysis of
synaptosomal fractions of the prefrontal cortex in stressed
and non-stressed animals revealed a significant overlap of
pathways affected in Tsc2 animals and stressed wildtype
and Tsc2 KO animals. This data suggests that the mTOR
kinase is involved in the response following chronic social
defeat stress and surprisingly point towards a potentially
beneficial effect of manageable stress in autistic children.
A. Arlt: None. M. Wendelmuth: None. K. Rolski:
None. R. Schneider: None. S. Schweiger: None.
P08.010.A
Germ cell mosaicism for AUTS2 exon 6 deletion
L. Gieldon1, A. Jauch1, K. Hinderhofer1, K. Obeid1, U.
Haug2, U. Moog1
1Institute of Human Genetics, University Hospital Heidel-
berg, Heidelberg, Germany, 2Center for Child Neurology
and Social Pediatrics Maulbronn, Maulbronn, Germany
Introduction: Genomic rearrangements causing hap-
loinsufficiency of AUTS2 have been associated with neu-
rodevelopmental disorders and dysmorphic features. Over
50 patients have been described, mostly carrying de novo
single exon deletions, including eight patients with exon 6
deletions. Small in-frame 5’ deletions have been associated
with a mild phenotype and parental inheritance.
Clinical Report and Methods: We report on two
siblings, a girl and a boy aged 11 and 13 years, in whom
we identified the same pathogenic 85 kb deletion on
7q11.22 encompassing exon 6 of AUTS2 by SNP-array and
subsequent confirmation with MLPA and FISH. Both
children had typical symptoms of AUTS2-syndrome such
as intellectual impairment and behavioral problems, but
with markedly different expression. As in most children
with exon 6 deletions, there were no feeding difficulties,
which are otherwise common in AUTS2-syndrome. We
subsequently performed targeted testing of both parents.
Results: MLPA and FISH excluded the deletion in blood
samples of both parents. Conventional karyotyping did not
show any structural rearrangements. Additional FISH
analysis marking the flanking regions of the deletion
showed normal arrangement of the signals on chromosome
7 in both parents. Parenthood was molecularly confirmed.
Conclusions: We suggest germline mosaicism as the
most probable explanation for occurrence of the same
deletion in these two siblings. To our knowledge this is the
first report of germline mosaicism for AUTS2 syndrome.
This report additionally provides further evidence of
intrafamilial phenotypic variability and adds clinical
information to the phenotypic spectrum of patients with
AUTS2 exon 6 deletions.
L. Gieldon: None. A. Jauch: None. K. Hinderhofer:
None. K. Obeid: None. U. Haug: None. U. Moog: None.
P08.011.B
Disruption of the STK24 and KLF13 genes in a female
patient with a de novo balanced chromosomal translo-
cation t(13;15) and a severe neurological phenotype
M. Kucharczyk1, V. Murcia Pieńkowski2, K.
Wojciechowska3, M. Lejman4, A. Pollak2, M. Rydzanicz2, M.
Młynek1, K. Pachota1, A. Madej-Pilarczyk1, A.
Cieślikowska1, D. Wicher1, M. Białecka1, A. Marczak1, D.
Sielska-Rotblum1, P. Berko1, A. Gutkowska1, K.
Chrzanowska1, M. Krajewska-Walasek1, R. Płoski2
1Children’s Memorial Health Institute, Department of
Medical Genetics, Warsaw, Poland, 2Warsaw Medical
University, Department of Medical Genetics, Warsaw,
Poland, 3University Children’s Hospital, Division of
Pediatric Hematology, Oncology and Transplantology,
Lublin, Poland, 4Medical University of Lublin, Department
of Pediatric Hematology, Oncology and Transplantology,
Lublin, Poland
Background: Mapping the breakpoints in de novo
balanced chromosomal translocations (BCTs) in symp-
tomatic individuals provides a unique opportunity to
identify in an unbiased way the likely causative genetic
defect and thus find novel human disease candidate
genes. The aim was to fine-map breakpoints of de
novo BCT in a female patient with the global develop-
mental delay. At the age of 13 years she was referred to
genetic counseling because of severe intellectual dis-
ability, macrocephaly and the lack of the speech. The
autistic features and outbursts of aggression were also
observed.
Methods and results: Conventional G-banding karyo-
typing revealed a de novo balanced chromosomal transloca-
tion 46,XX,t(13;15)(q32;q13). Microarray-based
comparative genomic hybridization did not detect any
imbalance. Shallow genome-wide mate pair sequencing
(SGMPS) was applied to identify the exact structure of the
breakpoints in the translocation. The breakpoint on
chromosome 13 disrupted the STK24 gene, while the
breakpoint on chromosome 15 was located in KLF13 gene.
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Discussion: The BCT identified in the presented girl
disrupted genes with so far unknown (STK24) or poorly
delineated impact on the phenotype (KLF13; only one
previous report on mutation in this gene in the context of
neurodevelopmental disorders). The function of STK24 and
KLF13 genes will be discussed based on available literature
data. Their role as good candidates for disease loci will be
suggested.
Conclusions: SGMPS in symptomatic carriers of BCTs is
a powerful approach to delineate novel human gene-disease
associations. This study was supported by the NCN Grant
No. UMO-2016/21/B/NZ5/02541.
M. Kucharczyk: None. V. Murcia Pieńkowski: None.
K. Wojciechowska: None. M. Lejman: None. A. Pollak:
None. M. Rydzanicz: None. M. Młynek: None. K.
Pachota: None. A. Madej-Pilarczyk: None. A. Cieśli-
kowska: None. D. Wicher: None. M. Białecka: None. A.
Marczak: None. D. Sielska-Rotblum: None. P. Berko:
None. A. Gutkowska: None. K. Chrzanowska: None. M.
Krajewska-Walasek: None. R. Płoski: None.
P08.013.A
Unexpected phenotypic variability in a family with
epilepsy explained by independent segregation of
biparental CACNA1A loss-of-function variants
C. Kraus1, D. Mammadova2, T. Leis2, A. Ekici1, C. Thiel1,
A. Reis1, R. Trollmann2
1Institute of Human Genetics, Friedrich-Alexander Uni-
versität Erlangen-Nürnberg, Erlangen, Germany, 2Depart-
ment of Pediatrics, Neuropediatrics, Friedrich-Alexander
Universität Erlangen-Nürnberg, Erlangen, Germany
CACNA1A encodes a transmembrane subunit of a voltage-
gated calcium channel. Autosomal dominant mutations are
causative for familial hemiplegic migraine, episodic ataxia
type 2, spinocerebellar ataxia type 6, and neurodevelop-
mental disorders.
We now report on a family with five members affected
with variable CACNA1A-associated neurological pheno-
types. The mother was diagnosed with episodic ataxia type
2 due to the heterozygous mutation p.(Ala868Profs*24). A
similarly affected son was tested negative for this variant.
Three further children presented with severe muscular
hypotension, refractory epileptic seizures, optic atrophy and
dysphagia, fatal in all within the first years. One of them
was positively tested for the known maternal CACNA1A
variant. However, as this was not sufficient to explain the
very severe phenotype, we performed exome sequencing.
Surprisingly, we identified a second heterozygous variant
p.(His1826Thrfs*30) in the CACNA1A gene, which was
shown to be paternally inherited. The same compound-
heterozygous situation was confirmed in material from one
of the other two deceased children. Furthermore, the mildly
affected son was found to be heterozygous for the paternal
CACNA1A variant, thus confirming his initial clinical
diagnosis of episodic ataxia type 2.
In conclusion, we report two different variants in
CACNA1A segregating in either heterozygous or
compound-heterozygous states in a single family with
variable neurological phenotypes. To our knowledge, this is
only the second observation of a severe, fatal epileptic
encephalopathy associated with bi-allelic variants in
CACNA1A. This case demonstrates the necessity of
additional analyses to clarify unusual phenotypes even if a
pathogenic variant has already been identified.
C. Kraus: None. D. Mammadova: None. T. Leis: None.
A. Ekici: None. C. Thiel: None. A. Reis: None. R.
Trollmann: None.
P08.015.C
Next generation candidates - Case-Level Evaluation of
Candidate Genes for Neurodevelopmental Disorders
C. Klöckner, R. A. Jamra, K. Platzer
Institute of Human Genetics, University of Leipzig Medical
Center, Leipzig, Germany
Recent work on discovery of genes to cause neurodeve-
lopmental disorders (NDD) has indicated that probably over
1000 monogenetic causes, including those with reduced
penetrance, remain to be discovered. To fulfil the aspira-
tions of personalized medicine and power downstream
research, a validation and extensive description of every
candidate gene turned morbid gene is inevitable. This
requires case-level evaluations to provide detailed pheno-
typic information and functional validation on every gene
that is usually beyond the scope of large meta-analyses such
as DDD.
If single exome sequencing of the index individual does
not identify a genetic cause for NDD, we follow this up
with parental exome sequencing on a research basis to
identify novel candidate genes. In a subset of 120
individuals consisting of 60 individuals with NDD +
epilepsy and 60 individuals with NDD, we identified more
than 150 candidate genes using our in-house scoring system
of 0-15 points considering variant and gene attributes,
literature research and inheritance. A prerequisite for all our
candidate genes is a minimal expression in brain tissue
derived from the GTEx database. Recurrent pathways with
multiple candidate genes identified in our cohort include
axon guidance, mTOR signaling, Ras signaling and
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regulation of transcription. As of now, we contributed seven
patients to promising efforts validating novel NDD genes.
At the time of the conference, we will present comprehen-
sive data on our full cohort of candidate genes and
progression on ongoing validation efforts.
C. Klöckner: None. R.A. Jamra: None. K.
Platzer: None.
P08.016.A
Core clinical features of CENPFrelated disorder
M. Gensini1, G. Cappuccio1,2, S. Douzgou3, E. Bijlsma4, T.
Koopmann4, L. Hendon5, B. Isidor6,7, B. Cogné8,9, M.
Pinelli1,2, A. Torella2,10, V. Nigro2,10, N. Brunetti-Pierri1,2
1Federico II University, Naples, Italy, 2Telethon Institute of
Genetics and Medicine, Pozzuoli, Naples, Italy, 3Division of
Evolution & Genomic Sciences, School of Biological
Sciences, Faculty of Biology, Medicine and Health,
University of Manchester, Manchester M13 9PL, UK;
Manchester Centre for Genomic Medicine, St Mary’s
Hospital, Manchester University NHS Found, Manchester,
United Kingdom, 4Department of Clinical Genetics, Leiden
University Medical Center, Leiden, Netherlands, 5Depart-
ment of Pediatrics, University of Mississippi Medical
Center,, Jackson, MS, United States, 6CHU de Nantes,
Service de Génétique Médicale, Nantes 44093 Cedex 1,,
Nantes, France, 7INSERM, CNRS, UNIV Nantes, l’institut
du thorax,, Nantes, France, 8CHU de Nantes, Service de
Génétique Médicale, Nantes 44093 Cedex 1, Nantes,
France, 9INSERM, CNRS, UNIV Nantes, l’institut du
thorax, Nantes, France, 10Department of Precision Medi-
cine, University of Campania ‘Luigi Vanvitelli’, Naples,
Italy
Introduction: Exome sequencing (ES) allows both expan-
sion of the phenotype of known disorders and discovery of
novel disease-causing genes. Biallelic loss-of-function
(LOF) variants in CENPF gene are responsible for
Stromme disease, a condition presenting with intestinal
atresia, anterior ocular chamber anomalies, and
microcephaly.
Cases: Through an international collaboration, 5 indivi-
duals (2 females and 3 males) carrying novel CENPF
biallelic variants (1 missense and 4 LOF) were identified by
ES. Four individuals were lacking the distinctive clinical
abnormalities of Stromme disease, such as intestinal atresia
or anterior chamber malformation of the eye. All individuals
had microcephaly (average -3.2 SDS, ranging from -2 SDS
to -5.1 SDS) and developmental delay/intellectual disability
(DD/ID). Genitourinary malformations (3/5), short stature
(2/5), and epilepsy (2/5) were also observed. The five
individuals shared a recognizable pattern of dysmorphic
facial features with sloping forehead, flat philtrum, and
anteverted nares.
Discussion: ES is rapidly changing the diagnostic process
and the ‘genotype-first’ approach is rapidly becoming the
method of choice. In the context of ES, reverse-phenotyping
(i.e., refinement of clinical presentations in light of the
identified genetic variants) is important for gene variant
interpretation. The small case series of individuals with
biallelic CENPF variants herein presented offers evidence
of clinical variability of Stromme disease. Microcephaly,
DD/ID and dysmorphic features are consistent even in the
absence of intestinal atresia or malformation of the anterior
chamber of the eye.
M. Gensini: None. G. Cappuccio: None. S. Douzgou:
None. E. Bijlsma: None. T. Koopmann: None. L.
Hendon: None. B. Isidor: None. B. Cogné: None. M.
Pinelli: None. A. Torella: None. V. Nigro: None. N.
Brunetti-Pierri: None.
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Further evidence to link CHD family-chromatin remo-
deler genes and neurodevelopment: de novo variants in
CHD5 are associated with intellectual disability, epilepsy
and autism
D. Lehalle1, T. Mizuguchi2, C. Nava1, N. Matsumoto3, H.
Cope4, S. de Man5, J. Friedman6, P. Joset7,8, M. Kato9, I.
Muffels10, K. Nakamura11, R. E. Person12, F. Petit13, A.
Rauch7, V. Shashi14, T. Smol15, K. Steindl7, E. Torti12, I.
Van de Laar16, S. Fuchs17, C. Depienne1,18, C. Mignot1
1Service de Génétique, Hôpital Pitié Salpêtrière, Paris,
France, 2Department of Human Genetics, Yokohama City
University Graduate School of Medicine, 3-9 Fukuura,
Kanazawa-ku,, Yokohama, Japan, 3Department of Human
Genetics, Yokohama City University Graduate School of
Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan,
4Department of Pediatrics, Division of Medical Genetics,
Duke University School of Medicine, Durham, NC, United
States, 5Department of Pediatrics, Amphia Hospital, Breda,
Netherlands, 6Rady Children’s Institute for Genomic
Medicine, San Diego, CA, United States, 7Institute of
Medical Genetics, University of Zurich, Zurich, Switzer-
land, 8radiz - "Rare Disease Initiative Zurich, Clinical
Research Priority Program for Rare Diseases University of
Zurich,", Zurich, Switzerland, 9Department of Pediatrics,
Showa University School of Medicine, Tokyo, Japan,
10Department of Metabolic Diseases, University Medical
Centre Utrecht, Utrecht, Netherlands, 11Department of
Pediatrics, Yamagata University Faculty of Medicine,
Yamagata, Japan, 12GeneDx, Inc., Gaithersburg, MD,
United States, 13CHU Lille, Clinique de Génétique, Lille,
France, 14Program in Genetics and Genomics, Duke
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University School of Medicine, Durham, NC, United States,
15EA7364, RADEME, Université de Lille, Lille, France,
16Department of Clinical Genetics, Erasmus MC, University
Medical Center Rotterdam, Rotterdam, Netherlands,
17Department ofMetabolic Diseases, University Medical
Centre Utrecht, Utrecht, Netherlands, 18Institute of Human
Genetics, University Hospital Essen, University Duisburg-
Essen, Essen, Germany
Introduction: Located in the critical region for 1p36
microdeletion syndrome, CHD5 encodes a member of the
chromodomain helicase DNA-binding protein (CHD)
family of proteins, which play a role in regulating gene
transcription via modifications of histone marks and chro-
matin remodeling. To date, six of the nine members of the
CHD family (CHD1, CHD2, CHD3, CHD4, CHD7 and
CHD8) have been associated with dominant neurodeve-
lopmental disorders. Either CHD3, CHD4 or CHD5 form
the core of the nucleosome remodeling and deacetylation
(NuRD) complex, required for neural development.
Material and methods: We assembled 10 unrelated
individuals with a de novo CHD5 variant and a neurode-
velopmental phenotype in different centers through Gene-
Matcher. All patients were diagnosed through exome
sequencing performed in a diagnostic setting.
Results: The patients (seven males and three females)
were aged 3-18 years old. They presented with moderate to
severe intellectual disability (ID) (8/10), speech impairment
(7/10), epilepsy (7/10) - including suppression bursts
encephalopathy (1/10), West syndrome (3/10), generalized
tonic-clonic seizures (2/10) and atypical absences (1/10) -,
autistic features (6/10), and/or hypotonia (4/10). Brain MRI
showed non-specific white matter changes in two patients
and focal cortical dysplasia in one. Of the ten de novo
CHD5 variants, nine were missense and one was a splice
site variant. Seven were absent from the gnomAD database,
while three were present at a low frequency.
Conclusions: Our findings suggest that, in line with other
CHD-related disorders, heterozygous CHD5 variants are
associated with a variable neurodevelopmental disorder
including ID, epilepsy and autism as the main features.
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CLTC mutations are also associated with familial forms
of intellectual disability
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Missense and nonsense variants in CLTC are responsible for
a form of intellectual disability (ID) with variable non-
specific morphological features of autosomal dominant
transmission (OMIM #617854). Since 2016, 32 patients
with mild to severe ID have been reported in the literature
[AS1], all carrying de novo variations. We report here new
patients carrying a pathogenic CLTC variant, including
inherited mutations, suggesting the existence of familial
forms. By a collaboration throught the French AnDDi-Rares
reference centers network, we collected 10 patients (4 girls
and 6 boys), from 8 families, with CLTC pathogenic var-
iants (diagnosed by solo exome sequencing or array-CGH).
They presented with mild to moderate ID, variably asso-
ciated with epilepsy, stereotypies, developmental delay and
autism spectrum disorders. For five patients, from three
families, the variation was inherited from a parent initially
considered asymptomatic, including one with a somatic
mosaicism (52%). After being questioned again about their
personal history, it turned out that these parents had initially
presented with learning difficulties or behavioural disorder
and a favorable evolution. The identification of pathogenic
CLTC variations inherited from paucisymptomatic parents
allows us to envisage that this gene’s phenotype is not
limited to the initially described forms, exclusively caused
by de novo variations. Familial forms appear to be less
severe and permit to expand the phenotypic spectrum
associated with CLTC mutations. This work also illustrates
how difficult it is to interpret inherited variations, and that it
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is sometimes necessary to reconsider the initial clinical
hypothesis with a more precise familial history.
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CMIP is candidate gene for a neurodevelopmental
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In 2012 we reported on a 16q23.2 de novo deletion in a
patient with autism spectrum disorder, developmental delay
and intractable epilepsy. The region contained CMIP as the
only candidate gene for the clinical presentation of the
patient. More recently we have gathered an additional 6
deletion cases with CMIP as the only commonly deleted
gene. Three of those were reported as de novo, in two cases
the deletion was inherited and in one case parental testing
was not performed. One of the two inherited cases was from
an affected parent. Two more de novo deletions were
reported by others in the literature. In an additional patient
we diagnosed a de novo stop mutation in CMIP. Common
clinical features of the patients include: developmental
delay and intellectual disability, autism spectrum disorder
and epilepsy. Other neurological symptoms are coordina-
tion disorders and behavioural problems. CMIP encodes a
protein that is part of the scaffold that links the plasma
membrane to the cytoskeleton. Cytoskeletal remodelling is
essential in neuronal migration and synaptic formation.
Association studies found an association between CMIP
and specific language impairment (SLI1). According to
gnomAD, the gene is intolerant to genetic LoF variation
(pLi=1). Thus, we report in total 9 CMIP containing
deletions, the majority de novo or inherited form an affected
parent and one de novo stop mutation. In combination with
the predicted function of the gene our data strongly suggest
that haploinsufficiency of CMIP is causative of a novel
neurodevelopmental disorder.
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Typical Cornelia de Lange syndrome (CdLS) is a severe,
highly-characteristic multisystem neurodevelopmental dis-
order almost exclusively caused by heterozygous loss-of-
function de novo mutations (DNM) in the gene encoding
the cohesin loader, NIPBL. Atypical CdLS shows locus
heterogeneity and can be caused by monoallelic DNM in
genes encoding components of the cohesin system and other
chromatin associated proteins. The MRC HGU cohort of
CdLS individuals (HGUCdLS) has been extensively screened
by arrayCGH, Sanger-, targeted gene panel-, and exome
sequencing, identifying pathogenic variants in the known
cohesin-related genes (NIPBL, SMC1A, SMC3, RAD21,
HDAC8) and in core SFARI genes (SETD5, ANKRD11,
KMT2A). We have now performed whole genome
sequencing (WGS) of DNA from 107 “mutation-negative”
CdLS individuals from 105 families, analysed as 42 nuclear
trios, 2 quads (affected sibs and parents), and 63 singletons
(197 individuals WGS in total). We have identified intra-
genic likely causative variants in EP300 (2), MED13L (1),
EHMT1 (2), and ARID1B (1), together with previously
unidentified mutations in NIPBL (9), ANKRD11 (6),
KMT2A, and SETD5. We have also identified plausibly
causative DNM in the 5’UTR (2) and deep intronic regions
of NIPBL together with both balanced and unbalanced
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structural variants (SV) at this and other loci. In total WGS
has identified a likely pathogenic variant in 30% of affected
individuals providing a higher than expected diagnostic
uplift from known loci. This also provides us with a cohort
of genuinely undiagnosed individuals for new gene
discovery.
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CTR9 heterozygous variants result in a neurodevelop-
mental disorder by disruption of the PAF1 complex
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The PAF1 complex (PAF1C), consisting of several subunits
including PAF1, CTR9, CDC73, RTF1 and LEO1, plays a
crucial role in transcription regulation by binding of CTR9
to RNA polymerase II. It is involved in transcription-
coupled histone modification, by promoting H3K4 and
H3K36 methylation. Moreover, CTR9 also modulates the
cellular trafficking of the dopamine transporter. Through
GeneMatcher, molecular and clinical data of 11 probands
were collected. In all probands, whole exome sequencing
identified CTR9 missense variants, encompassing 10 de
novo and 1 inherited from an affected father. Recurrent
patient findings were intellectual disability, ranging from
borderline to severe (10/11), speech delay (8/11), autism
spectrum disorder (5/11) associated with regression and
aggressive behavior during late childhood (3/11), hypotonia
(6/11), joint hyperlaxity (5/11), fatigability (4/11), coordi-
nation problems (3/11) and mild dysmorphism. EM and
crystal structure modelling of the activated human tran-
scription complex Pol II-DSIF-PAF-SPT6 and the PAF1/
CTR9 complex predict a likely disruptive effect on local
CTR9 structure and/or protein interaction of the different
missense variants. In yeast, the role of the PAF1C in H3K4
and H3K36 methylation is exerted by regulating the activity
of Set1 and Set2. Interestingly, pathogenic variants on the
human orthologues SETD1A, SETD1B and SETD2 are
known causes of neurodevelopmental deficits. In skin
fibroblasts from four of the CTR9 mutant patients, an effect
on H3K4 and H3K36 methylation is currently under
investigation. In conclusion, we describe a novel dominant
neurodevelopmental disorder caused by (mainly) de novo
variants in CTR9, likely affecting PAF1C function.
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Expanding the clinical and molecular spectrum of the
novel CYFIP2-related neurodevelopmental disorder and
functional proof of aberrant WRC-mediated actin
dynamics
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We and others have recently described de novo missense
variants in CYFIP2 as a novel cause of severe intellectual
disability with seizures and muscular hypotonia in a total of
18 patients, with Arginine at protein position 87 recurrently
substituted in the majority. CYFIP2 plays an important role
in the regulation of actin polymerization as a member of the
WAVE regulatory complex (WRC) and in transcription
regulation via the interaction with the fragile X mental
retardation protein. We evidenced that the pathogenic
CYFIP2 variants spatially cluster and are predicted to
weaken the interaction of CYFIP2 with WASF1 or
NCKAP1 of the WRC-complex. We now have identified
further 18 patients harboring two previously described, one
novel recurrent and 10 novel unique pathogenic missense
variants, as well as the first three loss-of-function variants.
Genotype-phenotype correlation indicates a profound
phenotype for substitutions at the mutational hotspot p.
Arg87 and a more variable phenotype in other recurrent
missense alterations, while there is currently no evidence
that haploinsufficiency leads to a similarly severe pheno-
type. Consistent with the role of CYFIP2 in WRC-mediated
actin polymerization our functional studies demonstrate
aberrant regulation of the actin cytoskeleton in all six
available patient fibroblasts. Our study further delineates the
clinical and molecular spectrum of this novel disease and
provides evidence for WRC-mediated actin dynamics as a
cellular pathomechanism.
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Introduction: Synapses are the basic functional structures
that allow the transmission of information between neurons.
PSD-95 protein, encoded by DLG4, is located in the post-
synaptic density and regulates excitatory synaptic maturation
and function. Only a few patients heterozygous for pathogenic
variants in DLG4 have been reported to date. The character-
istic features include intellectual disability (ID) (some with
marfanoid habitus (MH)), developmental disorders including
autism spectrum disorders (ASD) and schizophrenia.
Materials and Methods: A total of 44 patients (33
unpublished) were included. The unpublished cases were
identified through GeneMatcher or Decipher and clinical
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investigations were carried out by the local clinicians.
Pathogenic variants in DLG4 were identified through next-
generation sequencing (NGS) based technologies.
Results: Mean age of clinical onset was 1.4 years and
mean age at last evaluation was 14 years (1.5-47). The most
frequent manifestations were developmental delay (25
patients) (developmental regression; 12), ID (37)(severe 9,
moderate 15, mild 9), ASD (20), epilepsy (19), ADHD (16),
ophthalmological manifestations (16). MH was present in 5
cases. MRI abnormalities were reported in 11 cases. Most
of the DLG4 variants were truncating whereas 6 were
missense, located in the functional domains of the protein.
There were no differences in clinical severity between
patients with the two groups of variants.
Conclusions: Clinical manifestations associated with
DLG4 variants are similar to those of other synaptopathies,
mainly ID, ASD and epilepsy. MH is not a characteristic
feature of the condition. NGS is fundamental to establish a
molecular diagnosis, given the non-specific clinical spec-
trum here reported.
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Towards personalized treatment of Dravet syndrome
using induced neurons as an ex-vivo tool
E. J. H. van Hugte1,2,3, E. Lewerissa1,3, M. Frega1,3, J.
Nicolai2, H. J. M. Majoie2, H. J. Schelhaas2, J. S.
Verhoeven2, J. H. L. M. van Bokhoven1,3, N. Nadif Kasri1,3
1RadboudUMC, Nijmegen, Netherlands, 2Academic Centre
for Epileptology Kempenhaeghe, Heeze, Netherlands,
3Donders Institute, Nijmegen, Netherlands
Dravet syndrome (DS) is a severe epileptic encephalopathy,
characterized by recurrent and prolonged seizures. In
addition, DS is associated with substantial cognitive and
neuropsychological decline as a result of seizures during
brain development. It is therefore important to timely con-
trol seizure activity. Although numerous antiepileptic drugs
are available, it remains a challenge for clinicians to select
effective drugs with minimal side effects for each specific
patient, and a predictive tool to investigate treatment
options is lacking. Moreover, Dravet syndrome is asso-
ciated with both genetic and phenotypic heterogeneity,
which increases the complications of finding an appropriate
treatment. ln 70%-80% of the cases, DS results from de
novo mutations in the SCN1A gene, encoding the voltage
gated sodium channel Nav1.1. Conversely, not every patient
with a mutation in SCN1A develops DS, and also milder
clinical phenotypes can arise. In addition to SCN1A, other
genes have been associated with a DS phenotype. Animal
models can neither recapitulate mutation-specific effects nor
genetic background factors, and are unsuitable for devising
personalized medicine interventions. This research proposes
the development of human induced pluripotent stem cells
(hiPSC), differentiated into induced neurons as a patient-
specific disease model. The neurons are cultured into a
neuronal network on micro-electrode arrays (MEAs), able
to record network activity by embedded micro-electrodes.
Here, we report a patient specific neuronal network (PNN)
fingerprint of DS on both the single cell and the network
level. With this PNN, we aim to provide a predictive tool to
model DS and to explore treatment options in vitro.
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Exome Pool-Seq Reloaded
B. Popp1,2, G. Vasileiou2, M. Zweier3, A. B. Ekici2, S.
Moortgat4, D. Lederer4, I. Maystadt4, A. Destrée5, S.
Drunat5, A. Verloes5, A. Rauch3, K. Steindl3, L. Van
Maldergem6, J. Piard6, E. B. Brischoux6, C. Engel6, M.
Serey-Gaut6, A. Reis2, C. Zweier2
1Institute of Human Genetics, University of Leipzig
Hospitals and Clinics, Leipzig, Germany, 2Institute of
Human Genetics, Friedrich-Alexander-Universität Erlan-
gen-Nürnberg (FAU), Erlangen, Germany, 3Institute of
Medical Genetics, University of Zurich, Zurich, Switzer-
land, 4Centre de Génétique Humaine, Institut de Pathologie
et de Génétique, Gosselies, Belgium, 5Department of
Genetics, APHP-Robert DEBRE University Hospital, Denis
Diderot School of Medicine, Paris University, France;
INSERM UMR1141, Paris, France, 6Centre de génétique
humaine CHU, Université de Franche-Comté, Besançon,
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Falling sequencing costs has greatly advanced the identifi-
cation of genetic causes for neurodevelopmental disorders
(NDDs), but trio-based exome/genome sequencing remains
expensive and time-consuming for large cohorts.
To screen for known and novel genetics causes of NDDs
at scale we recently developed Exome Pool-Seq. This
approach combines DNA pooling and capture-based exome
sequencing with variant filtering in curated lists of known
NDD genes and candidate genes.
We now performed Exome Pool-Seq in a cohort of 576
individuals with unsolved NDDs, collected and clinically
characterized by a collaboration of five institutions from
four European countries. Most individuals had previous
normal microarray analysis (93.7%) and Fragile-X testing
(67.7%). Remarkably, 48.7% already had gene panel testing
without conclusive result.
We identified (likely) pathogenic truncating or previously
described variants in known NDD genes in 11.5%. This
includes four cases with truncating ANKRD11 and other
commonly mutated genes like SYNGAP1, ARID1B and
MED13L. Several pathogenic variants in autosomal domi-
nant NDD genes (MED13, CNOT3) were inherited, high-
lighting a potential pitfall when filtering only for de novo
variants. Analysis of missense variants absent from public
databases but predicted as deleterious by novel ensemble
scores increased the diagnostic yield by 5.2%. Finally, we
analyzed truncating variants in candidate and constrained
genes and identified several candidate variants, e.g. in
KMD2B and MARK2, which have subsequently been
submitted to matchmaking platforms.
This study provides new insights into the clinical and
mutational spectrum of a representatively pre-analyzed
European cohort of individuals with NDDs and highlights
the value of curated disease gene lists.
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DISSEQ: Double-blind Next-Generation-Sequencing
technologies (exome and gene panel) in the diagnosis
of a cohort of 330 patients with an intellectual disability:
concordance, discrepancies, and efficiencies.
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University, CRNL, CNRS UMR 5292, INSERM U1028,
Lyon, France, 12Service de génétique médicale, CHU de
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The introduction of Next Generation Sequencing (NGS)
technologies, in combination with a broad panel of bioin-
formatics tools and databases, has revolutionized the field of
human genetics, making it possible to have the unprece-
dented ability to establish molecular diagnoses in a time-
and cost-effective manner. The DISSEQ study aims to
assess the efficiency of different NGS strategies in the
diagnosis of patients with intellectual disability from a
cohort of 330 patients (205 males/127 females) without
previous genetic investigation, using double-blind strategy
1 (array-CGH+FRAXA+large gene panel sequencing (459
genes)) and strategy 2 (FRAXA+exome (ES)). Preliminary
results in 235/330 patients display a positive diagnosis in
85/235 (36 %) (62 SNV, 21 CNV, 1 FRAXA, 4 double-
hits): 29.7% with strategy 1 and 30% with strategy 2. The
results were concordant in 88%. Gene panel and ES iden-
tified a positive diagnosis in 58/235 (25%) and 66/235
(28%), respectively. No SNV interpretation was missed in
gene panel sequencing. Different reasons explain the
defects in ES interpretation (28/235; 12%): atypical phe-
notype, double-hits, bioinformatics misalignments and dif-
ficulties to interpret missense variants within a solo strategy.
But ES identified variants in new disease-causing genes,
recently described and new candidate genes. For CNV
diagnosis, gene panel sequencing appeared limited and
required to be coupled with array-CGH, whereas ES
appeared efficient. Overall, solo ES obtain slightly higher
results than gene panel but a trio-based analysis should be
preferred for a greater efficiency. Moreover, the possibility
to reanalyze ES data confers a significant benefit due to the
continuous development of knowledge.
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DOES GENDER AFFECT THE FACIAL FEATURES
OF FETAL ALCOHOL SYNDROME? EVIDENCE
FROM A COHORT STUDY
M. F. Urban1, L. T. Brink1, C. Lombard2, H.
Bezuidenhout1, G. de Jong1, H. J. Odendaal1
1Faculty of Medicine and Health Sciences, University of
Stellenbosch, Cape Town, South Africa, 2Medical Research
Council of South Africa, Cape Town, South Africa
Background: By Institute of Medicine criteria, smooth
philtrum and thin vermilion border of the upper lip, and
short palpebral fissure length (PFL) are cardinal features of
fetal alcohol syndrome (FAS). Lip assessment is by visual
comparison with a photographic 5-point Likert scale (Astley
score), and PFL by measurement. Astley scores of philtrum
and vermilion >4, and PFL<10th centile define the facial
features. We assessed gender differences in these features.
Methods: The Safe Passage Study is an international
cohort study of prenatal alcohol exposure effects on infant
outcomes. Data from 7060 pregnancies were assessed at the
Cape Town site. Case report forms prospectively collected
exposure information. Dysmorphologists examined one-
year-olds. Multivariate statistical analysis included gender,
alcohol and smoking levels per trimester, maternal mea-
surements, socio-economic status, and excluded drug users.
Results: After exclusions, 4399 one-year-olds were
compared: 2224 (50.6%) females and 2175 (49.4%) males.
Astley score >4 was commoner in males than females for
philtrum (21.0% versus 13.3%, p < 0.001) and vermilion
(20.6% versus 17.3%, p=0.005). On multivariate analysis
males had relative risk of Astley score >4 for philtrum of
1.53 (95%CI=1.33-1.76; p < 0.001) and vermilion of 1.14
(95%CI=1.01-1.35; p=0.03). Males had wider PFLs
(correlation coefficient 0.53; p < 0.001).
Conclusions: Gender differences in facial features for
FAS diagnosis are independent of alcohol use and may
confound dysmorphic assessment. Males are more likely to
score positive on lip features but less likely on PFL. Caution
is warranted in reifying cut-off measurements for FAS
diagnosis.
Funding support: National Institutes of Health grants
U01HD055154, U01HD045935, U01HD055155,
U01HD045991, and U01AA016501
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Floating-Harbor Syndrome: iPSCs with atypical mor-
phology from patient-derived cells with mutation in the
SRCAP gene
L. Hagenau1, M. Franz1, R. Koch1, S. Neubauer2, B.
Nowack2, L. R. Jensen1, A. W. Kuss1
1Department of Functional Genomics, Interfaculty Institute
for Genetics and Functional Genomics, University Medi-
cine Greifswald, Greifswald, Germany, 2SensID GmbH,
Rostock, Germany
Introduction: Floating-Harbor syndrome (FLHS) is a rare
genetic disease characterized by growth deficiency, facial
dismorphism, language delays and often mild to severe
intellectual disability. It is caused by mutations in the
SRCAP gene, which encodes a core component of the
chromatin-remodeling complex and also acts as a tran-
scriptional activator. We identified a de novo truncating
mutation in the SRCAP gene of a patient diagnosed with
FLHS and aimed to establish an induced pluripotent stem
cell (iPSC) line that can serve as a model for FLHS.
Material and methods: Gingival fibroblasts from the
patient and skin fibroblasts from the unaffected father were
reprogrammed into iPSCs using a virus-free episomal
vector system. iPSCs were tested for pluripotency marker
expression (immunofluorescence and qPCR) and differen-
tiation capability (embryoid bodies). Two and three iPSC
clones were generated for the patient and the control,
respectively.
Results: We were able to create iPSCs from primary
fibroblasts of a FLHS patient and his father. However, the
patient iPSCs displayed an atypical colony morphology
with fuzzy borders and loose cell grouping. Despite the
atypical appearance, the patient iPSCs were pluripotent and
able to differentiate into the 3 germ-layers.
Conclusions: The patient derived iPSCs we describe can
be instrumental in furthering our knowledge about the
molecular mechanisms involving SRCAP and contribute to
a better understanding of the aetiology of FLHS.
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Ethnicity is an independent Risk Factor for Full
Mutation Expansion in FMR1 Premutation Carriers
N. Domniz1, L. Ries Levavi2, M. Berkenstadt2, E. Pras2, Y.
Cohen1, H. Raanani1, S. Ben-Shachar3, D. Brabbing
Goldstein3, S. Elizur1
1IVF Unit, Ramat Gan, Israel, 2The Genetic Institute,
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Design: A cohort population-based study.
Materials and Methods: All Jewish FMR1 premutation
carriers who underwent chorionic villus sampling (CVS) or
amniocentesis (AC) at Sheba Medical Center and the Tel
Aviv Medical center during the period of 2011-2018 were
included in this study. Ethnicity was determined by self-
report as appeared in the medical records. Long range PCR
for FMR1 (Asuragen, TX, USA) was performed in order to
determine the number of CGG repeats and AGG interrup-
tions in all women and fetuses. General distribution and
data analysis were calculated using SPSS 18.0 and
Microsoft Excel.
Results: 766 FMR1 premutation carriers underwent CVS
or AC. Of them, 592 carriers had parents’ concordance for
ethnic background. The number of CGG repeats was
significantly higher among the Ashkenazi carriers compared
to Non-Ashkenazi women (median 69 vs. 64; p < 0.0001).
The number of AGG interruptions was lower in Ashkenazi
(35% with no AGG’s) compared to the Non-Ashkenazi
carriers (20% with 0 AGG’s); p < 0.0001.
Multivariate analysis using CGG repeats, AGG interrup-
tions and ethnicity, revealed that women’s ethnicity was an
independent risk factor for a full mutation expansion
(p=0.01).
Conclusions: Carrier’s ethnicity may be an independent
risk factor for a full mutation expansion among FMR1
premutation carriers, suggesting the existence of further
components affecting the mother-to-offspring transmission
process. Further research is needed in order to identify other
ethnic groups at risk and to better understand the process of
CGG inter-generation expansion and the different variables
that affect it. In addition, these findings may contribute for a
precise genetic counselling.
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Heterozygous variants disturbing the transcriptional
repressor activity of FOXP4 cause a disorder with
expressive language deficits, congenital abnormalities
and divergent growth parameters
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Introduction: Germline variants in FOXP4 have not yet
been definitively linked to a Mendelian disorder. Although
a single individual has been reported in the literature with a
homozygous possibly pathogenic variant, suggesting a
recessive inheritance pattern, it is currently unclear whether
heterozygous FOXP4 variants can also cause a phenotype.
Methods: We assembled a cohort of eight individuals with
heterozygous and mostly de novo variants in FOXP4: seven
individuals with six different missense variants and one
individual with a frameshift variant. We used functional
assays to assess pathogenicity of the variants, and collected
clinical data to delineate the associated phenotypic spectrum.
Results: Four missense variants clustered in the DNA-
binding forkhead-box (FOX) domain of the encoded
transcription factor. Luciferase assays showed loss-of-
function effects for these four missense variants, and
aberrant subcellular localization was seen for three out of
four. The two missense variants located outside the
functional domains of FOXP4 showed transcriptional
repressor capacities similar to wild-type FOXP4, as well
as normal subcellular localization patterns. Clinical data
were collected for the six individuals with variants likely
affecting FOXP4 functions. Recurrent features included
growth abnormalities, language deficits, congenital dia-
phragmatic hernia, cervical spine abnormalities and ptosis.
Conclusions: Although a dominant-negative effect can-
not be excluded for the missense variants, it seems that loss-
of-function of FOXP4 can already be sufficient to cause a
phenotype. Our findings show that heterozygous variants in
FOXP4 can cause an autosomal dominant disorder that is
characterized by growth defects, congenital abnormalities
and mild developmental delays, mainly affecting speech
and language.
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Altered mitochondrial function in cells carrying a
premutation or unmethylated full mutation of the
FMR1 gene
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V. Marzano3, M. Castagnola1, G. Maulucci1, C. De
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1Catholic University, Roma, Italy, 2The Hospital for Sick
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dren’s Hospital IRCCS, Roma, Italy, 4Saint Camillus
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Roma, Italy, 5University of Rome Tor Vergata, Roma, Italy,
6Sapienza University, Roma, Italy
Fragile X related-disorders are due to a dynamic mutation of
the CGG repeat at the 5’ UTR of the FMR1 gene, coding for
the RNA-binding protein FMRP. As the CGG sequence
expands from premutation (PM, 56-200 CGGs) to full
mutation (>200 CGGs), FMRP synthesis decreases until it
is practically abolished in fragile X syndrome (FXS)
patients, mainly due to FMR1 methylation. Cells from rare
individuals with no intellectual disability and carriers of an
unmethylated full mutation (UFM) produce slightly ele-
vated levels of FMR1-mRNA and relatively low levels of
FMRP, like in PM carriers. With the aim of clarifying how
UFM cells differ from CTRL and FXS cells, a comparative
proteomic approach was undertaken, from which emerged
an overexpression of SOD2 in UFM cells, also confirmed in
PM but not in FXS. The SOD2-mRNA bound to FMRP in
UFM more than in the other cell types. The high SOD2
levels in UFM and PM cells correlated with lower levels of
superoxide and Reactive Oxygen Species (ROS), and with
morphological anomalies and depolarization of the mito-
chondrial membrane detected through confocal microscopy.
The same effect was observed in CTRL and FXS after
treatment with MC2791, causing SOD2 overexpression.
These mitochondrial phenotypes reverted after knock-down
with siRNA against SOD2-mRNA and FMR1-mRNA in
UFM and PM. Overall, these data suggest that in PM and
UFM carriers, which have high levels of FMR1 transcrip-
tion and may develop FXTAS, SOD2 overexpression helps
to maintain low levels of both superoxide and ROS with
signs of mitochondrial degradation.
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A frameshift mutation in ZFHX4, located on chromo-
som 8q21, phenocopies the 8q21.11 microdeletion
syndrome.
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Introduction: Patients with 8q21.11 microdeletion syndrome
including the ZHFX4 gene present with a recognizable phe-
notype of variable intellectual disability, behavioral abnorm-
alities, ptosis, a round face, down-turned corners of the
mouth, low-set ears, and sensorineural hearing loss.
Materials and Methods: We report a female patient and
her son with the following clinical features: macrocephaly,
ptosis, prominent low-set ears, a round face, down-turned
corners of the mouth, developmental delay, hearing loss and
behavioral abnormalities. After exclusion of the 8q21.11
microdeletion syndrome and other relevant chromosomal
anomalies by chromosome and microarray analysis and
after exclusion of fragile-X-syndrome, we applied clinical
exome sequencing on an Illumina System followed by
phenotype-based evaluation strategies.
Results: A heterozygous point mutation in ZFHX4
(c.5850_5851delAT, p.(Cys1951fs)), was identified and
confirmed by sanger sequencing in both mother and son,
and excluded in further unaffected family members.
Conclusions: This is the first report of a point mutation in
ZFHX4 leading to the same phenotypic features as the
known 8q21.11 microdeletion syndrome including ZFHX4.
M. Wenzel: None. A. Schneider: None. M. Feigl: None.
T. Richter: None. F. Oeffner: None. B. Zirn: None.
P08.043.A
Human FMR1 gene expression regulation by microRNA
in a cellular model
A. A. Dolskiy1, L. V. Krainikova1, A. V. Pindyurin2, L. V.
Boldyreva2, D. V. Yudkin1
1FBRI SRC VB “Vector”, Rospotrebnadzor, Novosibirsk
Region, Russian Federation, 2IMCB SB RAS, Novosibirsk,
Russian Federation
Introduction: FRAXopathies are widespread pathologies
due to CGG repeat expansion in the 5’-UTR of the FMR1
gene. Changes in the repeat length lead to FMR1 expression
alteration. Previously, microRNA involvement in FMR1
gene expression regulation was demonstrated in an animal
model. We described nine microRNAs complementary to
the 3’-UTR of FMR1 with expression alterations dependent
on the FMR1 gene allele. Here, we present a study on the
identified microRNA interactions with the 3’-UTR of FMR1
in a plasmid model system.
Materials and methods: A plasmid expressing two
reporter genes was designed. Both reporters were driven by
constitutive promoters. One reporter was fused with the 3’-
UTR of the FMR1 gene, while microRNA expression was
driven by an inducible promoter. Measuring the protein
expression of the reporter in the control and after
microRNA expression induction allowed us to quantify
the interaction between the microRNA and the 3’-UTR.
Results: The model plasmid was confirmed by sequen-
cing. The activity of reporter genes was detected after
transfection of HEK293 cells. The genes of nine micro-
RNAs were cloned into a plasmid and separately transfected
into the cells. The expression of reporter proteins was
measured, and the interaction of every microRNA and the
FMR1 gene was quantified.
Conclusions: Screening of microRNA expression
allowed us to study its involvement in the regulation of a
specific gene. The use of a molecular model helped us to
show the interaction of microRNAs and the regulatory
region of the gene. The study is supported by Russian
Science Foundation grant 18-15-00099.
A.A. Dolskiy: None. L.V. Krainikova: None. A.V.
Pindyurin: None. L.V. Boldyreva: None. D.V. Yudkin:
None.
P08.044.B
Protein abundance profiling in murine model for
intellectual disability induced by FTSJ1 deficiency
L. R. Jensen1, V. Dhople1, M. Depke1, U. Völker1, F.
Schmidt2, A. W. Kuss1
1Department of Functional Genomics, Interfaculty Institute
for Genetics and Functional Genomics, University
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Medicine Greifswald, Greifswald, Germany, 2Proteomics
Core, Weill Cornell Medicine-Qatar, Doha, Qatar
Congenital forms of intellectual disability (IQ < 50) are
genetically heterogeneous but affect up to 0.5% of the
population. Mutations in most known intellectual disability
genes often only account for a comparatively small number
of cases, as exemplified by mutations in the X-linked gene
FTSJ1, which are a rare cause for non-syndromic intellec-
tual disability in affected males. FTSJ1 encodes a tRNA
methyl-transferase that methylates tRNA phenylalanine at
position 32 and 34 (wobble position) in yeast and man. We
have recently established a mouse model for Ftsj1 defi-
ciency and found that in male Ftsj1-deficient mice the
phenotype is not restricted to cognitive functions. In order
to investigate the effects of Ftsj1 deficiency in different
mammalian tissues, we generated protein extracts
from brain, liver, kidney and heart from five wild type and
Ftsj1−/y littermate pairs, generated protein abundance pro-
files and compared the normalized label-free quantitation
values (LFQ). The fold changes between control and
Ftsj1−/y tissues were generally at or below factor 3, but still
between 54 and 131 proteins from each tissue showed a
significantly different abundance (p < 0.01). Among these
we found enrichment of proteins involved in protein
synthesis, energy metabolism and actin dynamics. Our
results suggest that a common pathway is affected in all
four different tissues but that the evolutionarily compara-
tively young cognitive aspects of brain function are more
sensitive to changes in this functional context. It also raises
the question whether additional characteristic features might
not also be detectable in patients with FTSJ1 deficiency at
cellular or tissue levels.
L.R. Jensen: None. V. Dhople: None. M. Depke: None.
U. Völker: None. F. Schmidt: None. A.W. Kuss: None.
P08.048.C
De novo noncoding variants upstream of MEF2C cause
severe developmental disorders
N. Whiffin1,2,3, P. Danecek3, N. M. Quaife1,4, J. Kaplanis3,
K. Samocha3, Genomics England Research Consortium, J.
Juusola5, K. Retterer5, P. J. R. Barton1,2,4, H. V. Firth3,6, M.
E. Hurles3, C. F. Wright7
1National Heart and Lung Institute, Imperial College
London, London, United Kingdom, 2Royal Brompton and
Harefield NHS Foundation Trust, London, United King-
dom, 3Wellcome Sanger Institute, Hinxton, United King-
dom, 4MRC London Institute of Medical Sciences, London,
United Kingdom, 5GeneDx, Gaithersburg, MD, United
States, 6Clinical Genetic Department, Addenbrooke’s
Hospital Cambridge University Hospitals, Cambridge,
United Kingdom, 7University of Exeter Medical School,
Royal Devon & Exeter Hospital, Exeter, United Kingdom
Trio exome sequencing to profile protein-coding regions in
patients from the Deciphering Developmental Disorders
(DDD) study identifies a genetic diagnosis in only ~35% of
patients. We searched 9,858 patients for de novo variants
directly upstream of genes known to cause developmental
disorders and identified six likely disease-causing variants
upstream of MEF2C. All six probands have phenotypes that
are consistent with disruptions in MEF2C, including global
developmental delay (6/6) and seizures (4/6), and no other
likely diagnostic variants.
These variants are predicted to cause loss-of-function
through three distinct mechanisms. (1) Two 5’UTR single
nucleotide variants (SNVs) create upstream open reading
frames (uORFs) that overlap with the MEF2C coding
sequence out-of-frame, negatively regulating translation. (2)
Two further 5’UTR SNVs create upstream start codons that
extend the coding sequence by three and nine amino acids,
respectively. These variants are also observed de novo in
four additional patients (two with each variant) sequenced
by Genomics England and GeneDx. Protein structure
modelling suggests that these variants disrupt DNA binding
of MEF2C protein, impairing its function as a transcription
factor. (3) The final two variants are large deletions (294Kb
and 97Kb) that remove the N-terminal exon of the 5’UTR
and the entire promoter sequence, completely ablating
transcription of one allele. We will present ongoing
functional assays to prove the mechanism through which
these variants cause disease.
Our analyses show that non-coding variants upstream of
known disease-causing genes are an important cause of
severe disease and demonstrates that sequencing 5’UTRs
can increase diagnostic yield.
N. Whiffin: None. P. Danecek: None. N.M. Quaife:
None. J. Kaplanis: None. K. Samocha: None. J. Juusola:
A. Employment (full or part-time); Significant; GeneDx,
Inc. K. Retterer: A. Employment (full or part-time);
Significant; GeneDx, Inc.. E. Ownership Interest (stock,
stock options, patent or other intellectual property);
Significant; OPKO Health, Inc.. P.J.R. Barton: None. H.
V. Firth: None.M.E. Hurles: E. Ownership Interest (stock,
stock options, patent or other intellectual property);
Significant; Congenica Ltd. F. Consultant/Advisory Board;
Significant; Congenica Ltd. C.F. Wright: None.
P08.049.A
Exploring the transcriptional landscape of hippocampus
cells in homozygous Pigv c.1022C>A knock-in mice by
single-cell RNA-sequencing
338 J. del Picchia
F. S. David1,2, M. Rodríguez de los Santos2,3,4, A. Knaus2,
D. Mattei5, B. Timmermann6, P. M. Krawitz2
1Institute of Human Genetics, University of Bonn, School of
Medicine & University Hospital Bonn, Bonn, Germany,
2Institute for Genomic Statistics and Bioinformatics, Uni-
versity of Bonn, School of Medicine & University Hospital
Bonn, Bonn, Germany, 3Institute for Medical Genetics and
Human Genetics, Charité - Universitätsmedizin Berlin,
Berlin, Germany, 4Max-Planck-Institute for Molecular
Genetics, FG Development and Disease, Berlin, Germany,
5Insitute of Veterinary Pharmacology and Toxicology,
University of Zurich, UZH, Zürich, Switzerland, 6Sequen-
cing Core Facility, Max Planck Institute for Molecular
Genetics, Berlin, Germany
Introduction: Biallelic hypomorphic mutations in PIGV
are a known cause of congenital glycosylpho-
sphatidylinositol biosynthesis defects (GPIBD), a group of
recessive syndromes with shared phenotypic features such
as intellectual disability. In particular, the c.1022C>A
transversion is frequently reported in European patients
with GPIBD.
Materials and Methods: To gain further insight into the
pathophysiology of neurological features observed in
patients with GPIBD, we performed a single-cell RNA
sequencing analysis of hippocampus samples from a
recently established Pigv c.1022C>A knock-in (Pigv341E)
mouse model.
Results: Based on the gene expression profiles of around
8,800 Pigv341E and 7,100 wild type cells, we identified 17
cellular subgroups. Cells of both genotypes were present in
all subgroups, but the distribution was skewed in Pigv341E
mice, e.g. with an increased fraction of subicular neurons
and decreased fractions of granule cells and oligodendro-
cytes. The most extensive changes in transcriptional profiles
due to glycosylphosphatidylinositol anchor deficiency were
observed in a microglia subgroup as well as in subicular
neurons. Among the affected genes, several synapse-related
Gene Ontology terms were found to be enriched. Across all
cellular subgroups, expression of Abl1 was decreased and
expression of Hdc, Cyp4x1, and Gm14216 was increased in
Pigv341E cells.
Conclusions: This single-cell RNA sequencing study of
hippocampus cells in the Pigv341E mouse model allowed us
to generate new hypotheses regarding the pathophysiology
of cognitive impairment in GPIBDs. In particular, differ-
ential expression of Abl1 suggests an involvement of the
Eph/ephrin signaling pathway, which is known to play a
major role in synapse formation and function.
F.S. David: None. M. Rodríguez de los Santos: None.
A. Knaus: None. D. Mattei: None. B. Timmermann:
None. P.M. Krawitz: None.
P08.051.C
Expanding the clinical phenotype of X-linked mental
retardation 103: new patient with deleterious mutation
in KLHL15 gene
M. Ballesta-Martinez1,2,3, M. Sanchez Soler1,2, A. Serrano
Anton1,2, V. López-Gonzalez1,2,3, L. Rodriguez Peña1, L.
Armengol Dulcet4, E. Guillen Navarro1,2,3
1Hospital Clinico Universitario Virgen de la Arrixaca,
Murcia, Spain, 2Insituto Murciano de Investigación Bio-
medica (IMIB), Murcia, Spain, 3CIBER-ER, Murcia, Spain,
4Quantitative Genomic Medicine Laboratory, qGenomics S.
L., Barcelona, Spain
Introduction: X-linked mental retardation 103 is caused by
loss of function mutations in KLHL15 gene. Only 2
families have been reported. First reported patient had
intellectual disability (ID), epilepsy, brain anomalies and
coarse features. Array-CGH: 22kb deletion Xp22.11
involving the first three of the four exons of KLHL15 gene;
mother carried the deletion with skewed XCI in lymphocyte
DNA. Second report includes a large family with several
affected members with mild to moderate ID in which a
protein-truncating variant in KLHL15 which segregated
with the phenotype was detected by exome sequencing. We
report on a new case with a new causal variant in KLHL15
which further supports its implication in ID, and delineate
the phenotype. Clinical description: 5 year-old boy, second
child of healthy non-consanguineous parents. Mother had
deceased twin brothers with ID and brain atrophy. Patient
had global developmental delay, OFC 3rd centile, coarse
facial features, braquidactyly, thyroglosal cyst and ocular
malformation (posterior polar cataract and choroidal colo-
boma of left eye). Brain MRI, abdominal and cardiac
sonogram were normal. No epilepsy. Array-CGH was
normal, and clinical exome sequencing detected a pre-
viously not reported variant c.417_418delGA; P.
Leu139ArgfsTer2 in KLHL15 gene, of maternal origin; she
presented skewed XCI in lymphocyte DNA (100:0).
Conclusions: 1- We report on a new case of X-linked
MR due to loss of function mutation in KLHL15 supporting
its implication in ID. 2- This case expands clinical
phenotype of patients with KLHL15 mutations with ocular
involvement. 4-Achieving molecular diagnosis with NGS
permits adequate genetic counseling in families.
M. Ballesta-Martinez: None. M. Sanchez Soler: None.
A. Serrano Anton: None. V. López-Gonzalez: None. L.
Rodriguez Peña: None. L. Armengol Dulcet: None. E.
Guillen Navarro: None.
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P08.053.B
Functional predictors of causative cisregulatory muta-
tions in mendelian disease
H. Bengani1, D. Grozeva2, L. Moyon3, S. Bhatia1, S.
Ribeiro dos Louros4, J. Hope5, A. Jackson4, J.
Prendergast6, M. Naville3, O. Spasic-Boskovic7, V. v.
Heyningen1, P. Kind4, C. M. Abbott5, E. Osterweil4, L.
Raymond7, H. R. Crollius3, D. R. FitzPatrick1
1MRC Institute of Genetics & Molecular Medicine,
Edinburgh, United Kingdom, 2Cambridge Institute for
Medical Research, Edinburgh, United Kingdom, 3Institut
de biologie de l’Ecole normale supérieure, Paris, France,
4Centre for Integrative Physiology, Patrick Wild Centre,
University of Edinburgh, Edinburgh, United Kingdom,
5Centre for Genomics and Experimental Medicine, IGMM,
University of Edinburgh, Edinburgh, United Kingdom,
6Roslin Institute, University of Edinburgh, Edinburgh,
United Kingdom, 7Cambridge Institute for Medical
Research, Cambridge, United Kingdom
Rare variants altering cis-regulatory elements (CRE) appear
enriched in undiagnosed neurodevelopmental disease but
few highly penetrant variants have been identified. We
present a pipeline which aims to discriminate likely diag-
nostic CRE variants from those of neutral/low-penetrant
effect. Six rare testable CRE variants were identified using
targeted and whole genome sequencing in 48 unrelated
males with apparent X-linked intellectual disability (XLID)
but without detectable coding region variants. These variant
segregated appropriately in families and altered conserved
bases in CREs targeting known XLID genes. Three were
unique and three were rare but too common to be plausibly
causative for XLID. Cis-regulatory activity was initially
tested by comparing wild-type and mutant alleles in zeb-
rafish embryos using dual-color fluorescent enhancer
reporters. Two variants showed striking changes: one
plausibly causative (FMR1CRE) and the other likely neutral/
low-penetrant (TENM1CRE). These regulatory variants were
then “knocked-in” to mice and both caused abnormal
embryonic neural expression of their target gene. Only mice
carrying the plausible FMR1CRE showed disease-relevant
behavioral defects. We consider FMR1CRE to be plausibly
disease-associated and resulting in complex misregulation
of FMR1/FMRP rather than loss-of-function. This is con-
sistent with absence of typical physical features of Fragile X
in affected individuals and electrophysiological anomalies
in the brains of post-natal FMR1CRE mice. Thus, extreme
rarity and the presence of relevant phenotypic features in
knock-in mice were the only discriminative factors for
causative CRE variants. Importantly, disruption of the
normal in vivo pattern of target gene expression in disease-
relevant tissues cannot be used as strong evidence for
Mendelian disease association.
H. Bengani: None. D. Grozeva: None. L. Moyon:
None. S. Bhatia: None. S. Ribeiro dos Louros: None. J.
Hope: None. A. Jackson: None. J. Prendergast: None.M.
Naville: None. O. Spasic-Boskovic: None. V.V. Heynin-
gen: None. P. Kind: None. C.M. Abbott: None. E.
Osterweil: None. L. Raymond: None. H.R. Crollius:
None. D.R. FitzPatrick: None.
P08.054.C
Detection rate and re-analysis of exome sequencing data
in a cohort of 207 individuals with neurodevelopmental
disorders
M. Hebebrand, C. T. Thiel, C. Kraus, A. Ekici, A. Reis, C.
Zweier
Institute of Human Genetics, Friedrich-Alexander-Univer-
sität Erlangen-Nürnberg (FAU), Erlangen, Germany
Exome sequencing is the most efficient test to diagnose
patients with neurodevelopmental disorders (NDD). Given
the constantly growing number of NDD associated genes,
improvements in analysis tools and information on variants,
regular re-analysis of negative or unclear cases is recom-
mended. In a long-term study aiming at identifying the
genetic basis of NDDs we performed exome sequencing
(SureSelect_v.6; HiSeq2500) in 205 individuals from 197
families presenting with NDDs who had negative test
results including CMA. Filtering against known NDD genes
(SysID database) followed by identification of de novo
variants in all genes resulted in a diagnostic rate of 45% (89/
197). Interestingly, the diagnostic yield in singletons was
higher than in trios (52% vs. 42%). We now re-analysed
105 unsolved sporadic cases regarding homozygous, com-
pound-heterozygous, X-linked, de novo and autosomal
dominant variants in all genes, considering also an updated
list of 1,164 NDD genes and 1,127 candidate genes. One
additional case could be diagnosed: an affected boy inher-
ited a stop mutation in SETD5 from his healthy mother,
which previously was missed due to filtering for de novo
variants in a trio setting, highlighting the relevance of
reduced penetrance. Furthermore, we identified 20 candi-
date variants in 17 genes compatible with the clinical pre-
sentation but a firm diagnosis could not be made due to lack
of functional validation, including a de novo missense
variant in the candidate gene NEUROD2. The relatively low
re-analysis detection rate is probably due to the high initial
detection rate based on a combination of diagnostic and
research analysis strategy.
M. Hebebrand: None. C.T. Thiel: None. C. Kraus:
None. A. Ekici: None. A. Reis: None. C. Zweier: None.
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P08.055.A
Exome-based gene panel analysis in patients with
intellectual disability and epilepsy
E. D’haenens, E. Pouillie, S. Vergult, M. De Smet, T. Sante,
B. Callewaert, O. Vanakker, B. Menten, A. Dheedene
Center for Medical Genetics Ghent (CMGG), Ghent,
Belgium
The implementation of whole exome sequencing (WES) in
the clinic has led to a steep increase in diagnostic yield in
patients with (syndromic) intellectual disability (ID) and/or
epilepsy. Since 2017 the Center for Medical Genetics Ghent
(UZ Ghent) offers a WES-based gene panel analysis for
genes related to ID and epilepsy. Here we present an
overview our findings. WES was performed in ~1000 pro-
bands and both parents (if available) using the SureSelect
All Exon kit (Agilent technologies) enrichment followed by
2x150bp sequencing on a HiSeq3000 or NovaSeq 6000
platform (Illumina). Data analysis was done with a com-
munity developed pipeline based on the Broad Institute Best
Practices (bcbio-nextgen). Virtual panel analysis was per-
formed for 1175 genes and variant classification was based
on ACMG-AMG guidelines. In 21% of cases a definitive
genetic causal defect (class 4 or 5 variant) could be iden-
tified: in 60% of these patients a de novo variant was found
while in 40% the causal variant was inherited. From the
latter 12,5% are variants in genes related to an X-linked
disorder, 41,5% to an autosomal dominant and 46% to an
autosomal recessive disorder. In addition, in 25% of the
patients an interesting variant of unknown significance
(class 3) was reported. Currently, follow-up studies are
ongoing to evaluate these class 3 variants, e.g. collecting
additional phenotypic data, performing segregation and
transcriptome analysis. With a diagnostic yield between
21% and 46%, we can conclude that WES is a game-
changer in the diagnostic workup of patients with ID/
epilepsy.
E. D’haenens: None. E. Pouillie: None. S. Vergult:
None. M. De Smet: None. T. Sante: None. B. Callewaert:
None. O. Vanakker: None. B. Menten: None. A.
Dheedene: None.
P08.056.B
A de novo missense mutation highlights the role of
FBXO28 gene in 1q41-q42 microdeletion syndrome
phenotype
N. Spataro, E. Gabau, N. Baena, M. Guitart, A. Ruiz
Corporació Sanitaria Parc Taulí, Sabadell, Spain
Introduction: Microdeletion 1q41-q42 has been associated
with a distinctive neurodevelopmental syndrome. The
reported clinical features include: intellectual disability,
seizures, dysmorphia and brain anomalies among others.
Haploinsufficiency of different genes has been proposed as
the causal mechanism. Since most of the reported 1q41-q42
microdeletions encompass both FBXO28 and WDR26
genes, their causal role has been debated in recent years.
Materials and Methods: Sequencing was carried out on
an Illumina platform (MiSeq) considering a panel of 460
genes related to neurodevelopmental disorders. Raw reads
were mapped to the human genome using BWA. PCR
duplicates were removed using Picard Tools; GATK was
used for base quality score recalibration and variant
discovery. Variants were annotated using Annovar and
filtered according to their frequency in gnomAD database.
Results: We identify a de novo c.1043 G>T substitution
not reported in gnomAD and causing a p.Arg348Leu
change in FBXO28. The patient is affected by severe
intellectual disability, epilepsy, brain alterations and absent
speech, with a global phenotype resembling that of the
1q41-q42 microdeletion syndrome. To date, only a single de
novo loss of function mutation in FBXO28 gene has been
reported for a patient having similar clinical features.
Conclusions: This second case evidences the critical role
of FBXO28 gene in 1q41-q42 microdeletion syndrome
phenotype. FBXO28 protein is a component of the Skp-
Cullin-F-Box complex, which mediates proteasomal degra-
dation. Dysfunctions of the ubiquitin proteasome system
have been associated to several neurodevelopmental
disorders, such as: X-linked spinal muscular atrophy,
Angelman syndrome and Opitz BBB/G.
N. Spataro: None. E. Gabau: None. N. Baena: None.
M. Guitart: None. A. Ruiz: None.
P08.058.A
Next generation sequencing of a cohort of individuals
with syndromic intellectual disability
F. Santos-Simarro1,2, M. Pacio-Miguez1, S. García-
Miñaúr1,2, V. Rufo-Rabadán1, M. Solís1,2, R. Mena1,2, C.
Rodríguez-Jiménez1,2, V. E. Fdez-Montaño1,2, R. Martín-
Arenas1, H. González-Pecellín1, Á. del Pozo1,2, E.
Vallespín1,2, M. Palomares-Bralo1,2
1INGEMM, Hospital Universitario La Paz, Madrid, Spain,
2U753, CIBERER, ISCIII, Madrid, Spain
Introduction:Global developmental delay (GDD) / intel-
lectual disability (ID) has an estimated prevalence in the
general population of 1-3%. The genetic causes of GDD/ID
are highly heterogeneous, traditionally limiting the possi-
bility to reach a specific diagnosis. In recent years, with the
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advent of next generation sequencing (NGS), the genetic
diagnosis of GDD/ID has greatly improved and expanded
with currently more than a 1000 genes involved.
Methods: We present the results of NGS testing in a
cohort of 456 individuals with syndromic GDD/ID (defined
as GDD/ID plus additional manifestations such as con-
genital malformations, growth abnormalities or dysmorphic
features) evaluated in our clinical genetics department over
a 42-month period (Jul2016-Dec2019). All had a previous
normal 60K array-CGH (KaryoArray v3.0, Agilent). NGS
trio analysis was performed either using a customized NGS
panel containing 1253-1663 genes associated with neuro-
developmental disorders (RD-Seq© v1.0-v6.0) and/or by
whole exome sequencing (WES).
Results:Causal variants were identified in 131 different
genes in a total of 207 probands (45%), the majority
autosomal dominant de novo variants (66%). Two novel
GDD/ID causing genes have been identified and confirmed
with further cases identified through international collabora-
tion. Detailed results of the cohort will be presented.
Conclusions:This study reflects the vast genetic hetero-
geneity associated to GDD/ID. Comprehensive clinical and
molecular evaluation are key to a successful etiological
diagnosis, increasing our genomic understanding of GDD/
ID and ultimately allowing improved medical management
and genetic counselling for these patients and their families.
F. Santos-Simarro: None. M. Pacio-Miguez: None. S.
García-Miñaúr: None. V. Rufo-Rabadán: None. M.
Solís: None. R. Mena: None. C. Rodríguez-Jiménez:
None. V.E. Fdez-Montaño: None. R. Martín-Arenas:
None. H. González-Pecellín: None. Á. del Pozo: None. E.
Vallespín: None. M. Palomares-Bralo: None.
P08.059.B
Inositol monophosphatase 1 (IMPA1) mutation in
intellectual disability patients impairs neurogenesis but
not gliogenesis
T. Figueiredo1,2,3, A. Mendes2, G. Kobayashi3, D.
Moreira3, D. Oliveira3, E. Goulart3, S. Stern2, F. Kok3, M.
Marchetto2, R. Santos4,2, F. Gage2, M. Zatz3
1Federal University of Alagoas, Faculty of Medicine,
Maceio, Brazil, 2The Salk Institute for Biological Studies,
La Jolla, CA, United States, 3Human Genome and Stem
Cell Research Center, University of Sao Paulo, Sao Paulo,
Brazil, 4Institute of Psychiatry and Neuroscience of Paris,
Paris, France
A homozygous mutation in the inositol monophosphatase 1
(IMPA1) gene was recently identified in nine individuals
with severe intellectual disability (ID) and disruptive
behavior. These individuals belong to the same family from
Northeastern Brazil, which has 28 consanguineous mar-
riages and 59 genotyped family members. IMPA1 is
responsible for the generation of free inositol from de novo
biosynthesis and recycling from inositol polyphosphates
and participates in the phosphatidylinositol signaling path-
way. To understand the role of IMPA1 deficiency in ID, we
generated induced pluripotent stem cells (iPSCs) from
patients and neurotypical controls and differentiated these
into hippocampal dentate gyrus-like neurons and astrocytes.
IMPA1-deficient neuronal progenitor cells (NPCs) revealed
substantial deficits in proliferation and neurogenic potential.
At low passage NPCs (P1 to P3), we observed cell cycle
arrest, apoptosis, progressive change to a glial morphology
and reduction in neuronal differentiation. These observa-
tions were validated by transcriptome profiling. Tran-
scriptome analysis showed that NPCs and neurons derived
from ID patients have extensive deregulation of gene
expression affecting pathways necessary for neurogenesis
and upregulation of gliogenic genes. IMPA1 deficiency did
not affect cell cycle progression or survival in iPSCs and
glial progenitor cells or astrocyte differentiation. Therefore,
this study shows that the IMPA1 mutation specifically
affects NPC survival and neuronal differentiation.
This study was financially supported by the CEPID-
FAPESP (2013/08028-1), INCT/FAPESP (2014/50931-3)
and FAPESP (Process Number: 2017/19877-0 and 2016/
09618-5).
T. Figueiredo: None. A. Mendes: None. G. Kobayashi:
None. D. Moreira: None. D. Oliveira: None. E. Goulart:
None. S. Stern: None. F. Kok: None. M. Marchetto:
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P08.060.C
Early diagnosis ofNPHP1-associated developmental
delay
K. Komlosi1, A. Tzschach1, K. Prückner-Engesser2, E.
Komini2, N. Hirt1, J. Fischer1, B. Gläser1
1Institute of Human Genetics, Medical Center-University of
Freiburg, Faculty of Medicine, University of Freiburg,
Freiburg, Germany, 2Department of Pediatrics,
Schwarzwald-Baar Klinikum, Villingen-Schwenningen,
Germany
Introduction: Homozygosity for a recurrent 290 kb dele-
tion of NPHP1 is the most frequent cause of isolated
nephronophthisis. It has also been detected in patients with
Joubert syndrome (JS). JS is a rare autosomal recessive
disorder characterized by a distinctive malformation of the
cerebellum and brainstem, hypotonia, ataxia, developmental
delay and variable additional features.
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Clinical report: We report on a 3-year-old girl born of
consanguineous parents with significant psychomotor delay,
expressive language disorder, muscular hypotonia, gait
ataxia and increased reflexes in the lower extremities.
Cranial MRI at age 8 and 33 months did not show any
structural abnormality apart from a pineal cyst and lipoma
of the filum terminale in spinal MRI. A detailed examina-
tion revealed bitemporal narrowing, a depressed nasal
bridge, hypertelorism, convergent strabismus, long, curly
eyelashes, a high-arched palate, pointed teeth and a low-set
hairline.
Methods and Results: Chromosomal microarray analysis
(CMA) showed a homozygous deletion of 88.97 kb at 2q13
(110879075-110968043) encompassing the entire NPHP1
gene. Both parents carry the deletion in heterozygous form.
Conclusions: Homozygous NPHP1 deletion represents
the first molecular defect associated with JS (JBTS4, OMIM
#609583) in a subset of mildly affected patients. Reports
without the pathognomic molar tooth sign are very rare,
though, subtle findings that may be missed have been
reported. In our patient many features may evolve only
later; there is a high risk for nephronophthisis and
ophthalmologic abnormalities. Our case adds to the
spectrum of JS and emphasizes the clinical utility of
CMA in the elucidation of syndromic developmental delay.
K. Komlosi: None. A. Tzschach: None. K. Prückner-
Engesser: None. E. Komini: None. N. Hirt: None. J.
Fischer: None. B. Gläser: None.
P08.061.A
When a seemingly heterozygous CNV turns out to be
compound-heterozygous - from NRXN1-associated neu-
rodevelopmental disorder to Pitt-Hopkins-like syn-
drome 2
A. C. Teichmann1, M. Stiller1, S. Schubert1, S. Redler2, R.
Jamra1, K. Platzer1, N. Rahner3
1Institute of Human Genetics, University of Leipzig Medical
Center, Leipzig, Germany, 2Heinrich-Heine-University,
Medical Faculty, Institute of Human Genetics, Düsseldorf,
Germany, 3Institute of Clinical Genetics, Bonn, Germany
Introduction: Heterozygous CNVs and SNVs of NRXN1
have been associated with a wide spectrum of neurodeve-
lopmental and neuropsychiatric disorders, including mild to
moderate intellectual disability (ID), autism spectrum dis-
orders (ASD) and schizophrenia with reduced penetrance.
Furthermore homozygous and compound-heterozygous
variants of NRXN1 are associated with the autosomal
recessive Pitt-Hopkins-like syndrome 2, including severe
ID and a spectrum of ASD, epilepsy and breathing
anomalies.
Materials and Methods: We report on an 11-year old
female presenting with moderate ID, no active speech
development, muscular hypotonia, one febrile seizure
during childhood and suspected autism. Family history
includes the father with learning difficulties and a paternal
aunt and cousin with learning difficulties, epilepsy and
autism.
Results: SNP-Array revealed a heterozygous 0.27 Mb
deletion disrupting the exons 8-19 of NRXN1. As the
phenotype of our patient was more severe than would be
expected, we additionally performed NGS-panel-diagnos-
tics, which revealed unremarkable findings in the index
individual. Segregation analysis in the parents unexpectedly
revealed a heterozygous deletion of exons 10-19 in the
father and a heterozygous deletion of exons 8-9 in the
mother. The mother is unaffected.
Conclusions: The initial diagnosis of NRXN1-associated
developmental delay due to a seemingly heterozygous
deletion turned into a Pitt-Hopkins-like syndrome 2 caused
by a compound-heterozygous deletion in NRXN1. Further
genetic testing including segregation analysis are therefore
key for patients not phenotypically matching the initial
diagnosis, especially in genes where multiple modes of
inheritance are known.
A.C. Teichmann: None. M. Stiller: None. S. Schubert:
None. S. Redler: None. R. Jamra: None. K. Platzer:
None. N. Rahner: None.
P08.062.B
Comprehensive genetic analysis of intellectual disability
patients from the Kashubian population using homo-
zygosity mapping and exome sequencing
A. Charzewska1, T. Gambin1, J. Wierzba2, E.
Kaczorowska2, E. Obersztyn1, B. Wojtaś3, B. Gielniewski3,
R. Szlendak1, P. Górka-Skoczylas1, R. Tataj1, K. Kanabus1,
S. Rzońca-Niewczas1, J. Bal1, D. Hoffman-Zacharska1
1Institute of Mother and Child, Warsaw, Poland, 2Medical
University of Gdańsk, Gdańsk, Poland, 3Nencki Institute of
Experimental Biology, Warsaw, Poland
Introduction: Autosomal recessive intellectual disability
(ARID) is the most common form of intellectual disability
(ID) in populations with frequent parental consanguinity.
However, ARID is extremely heterogeneous, and the vast
majority of ARID genes are still unknown. The main
research hypothesis of the study was the assumption that
patients with ID belonging to the isolated Kashubian
population have, because of parental consanguinity,
homozygous regions in the genome where pathogenic,
recessive mutations are present.
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Materials and Methods: The project included 45
families of Kashubian origin. There were 64 patients
diagnosed with ID in this group. To identify regions where
pathogenic, homozygous mutations may be present, an
innovative, computational method combining homozygos-
ity mapping and exome sequencing was used. In this
method homozygous regions were indicated by coverage
analysis involving biallele frequency calculation, transfor-
mation and segmentation.
Results: No evident homozygous regions were identified
in patients of Kashubian origin. Mutations responsible for
ARID were rare. It has been shown that the molecular basis
of ID in this group is not ARID, but autosomal dominant ID
and X-linked ID. Overall, clearly pathogenic variants have
been identified in 29% of examined families.
Conclusions: This project was the first in Poland, and one
of the first in Europe aiming to identify recessive risk
factors involved in the pathogenesis of ID based on
genomic data obtained by testing an isolated European
population. The molecular basis of ID in the group of
Kashubian patients proved to be not autosomal recessive,
but autosomal dominant and X-linked ID.
Grant Number: NCN 014/15/D/NZ5/03426
A. Charzewska: None. T. Gambin: None. J. Wierzba:
None. E. Kaczorowska: None. E. Obersztyn: None. B.
Wojtaś: None. B. Gielniewski: None. R. Szlendak: None.
P. Górka-Skoczylas: None. R. Tataj: None. K. Kanabus:
None. S. Rzońca-Niewczas: None. J. Bal: None. D.
Hoffman-Zacharska: None.
P08.063.C
Identification the role of TUB in Intellectual Disability
using RNA-seq
F. Peymani1, K. InanlooRahtloo2
1Genetic Research Center, University of social welfare and
Rehabilitation, Sciences, Tehran, Iran, Islamic Republic of,
2School of Biology, University College of Science, Uni-
versity of Tehran, Tehran, Iran, Islamic Republic of
Intellectual disability (ID) is a genetically and phenotypi-
cally heterogeneous disorder with more than 1000 candidate
genes to date. Despite the accelerating rate of gene dis-
covery for ID, the molecular mechanisms underlying the
disease remain elusive. In a previous study, whole exome
sequencing in a consanguineous family with five affected
individuals representing ID led to the identification of a
splice site variant (NM_003320:c.1281+1G>A) in TUB, a
novel ID candidate gene, whose mutations have already
been associated with Retinal dystrophy and obesity. TUB
acts both as a membrane bound transcription regulator and
an adaptor molecule in insulin signaling and GPCR
trafficking in neuronal cilia. In order to investigate TUB
role in the etiology of ID and identify dysregulated mole-
cular pathways in patients, we conducted whole blood
transcriptome profiling of patients and their age and sex
matched healthy individuals, using RNA-seq technique.
The transcription profile demonstrates deregulation of 1045
genes (p-value < 0.01, fold change > 1.5), of these 155
genes were upregulated and 890 genes were downregulated.
Upregulated genes show enrichment in Insulin synthesis
and processing, diabetes and metabolism pathways and the
molecular function of downregulated genes mainly include
constituent of ribosome, transcription regulator and DNA
binding. Signaling pathways involved in the regulation of
translation and insulin synthesis and processing were
amongst the most significant dysregulated pathways in
patients. Here, we put an emphasis on the role of insulin and
translation pathways in the molecular pathophysiology of
ID. This study was funded by National Institute For Med-
ical Research Development (NIMAD).
F. Peymani: None. K. InanlooRahtloo: None.
P08.064.A
Identification and functional characterization of a novel
homozygous mutation in KCNMA1 encoding voltage
and calcium sensitive potassium channel is associated
with dyskinesia, epilepsy, intellectual disability, cerebel-
lar and corticospinal tract atrophy
E. Yucesan1, B. Goncu2, A. Aslanger3, C. Ozgul4, S.
Hasanoglu2, G. Yesil3
1Bezmialem Vakif University, Faculty of Medicine, Depart-
ment of Medical Biology, Istanbul, Turkey, 2Bezmialem
Vakif University, Experimental Research Center, Istanbul,
Turkey, 3Bezmialem Vakif University, Faculty of Medicine,
Department of Medical Genetics, Istanbul, Turkey, 4Medi-
pol University, Regenerative and Restorative Medical
Research Center, Istanbul, Turkey
Introduction: KCNMA1 encodes, alpha subunit of the
voltage, and calcium-sensitive potassium channel, pre-
dominantly expressed in the central nervous system.
Therefore abnormal function in this gene may occur neu-
rological conditions.
Materials and Methods: We report 15 year-old patient
who was born at term with healthy conditions. Motor
signals were delayed, and also seizures started at the age of
18 months. EEG revealed generalized spike-wave activities.
Brain MRI performed, atrophy of the cerebellum was
detected. Recent clinical examination;contractures on the
large joints, and dyskinetic tremor. Whole exome sequen-
cing (WES) was performed and in-slico analyses were
conducted. MCF7 and 293T cells transfected with either
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wild-type or mutant expression vectors. Cellular distribution
was determined by immunofluorescence. Functional analy-
sis was performed using electrophysiological approach
based on whole-cell patch-clamp.
Results: WES revealed homozygous variation
(NM_001161352.1:c.1372C>T, p.Arg458Ter). The variant
was not observed in publicly available or in-house
databases. Immunofluorescent staining revealed that novel
variant is not interfering with synthesis of KCNMA1
however mutation exhibit dominant-negative effect on cell
viability when compared to wild-type. 293T and MCF7
cells transfected with homozygous p.Arg458Ter mutation
showed markedly increased KCNMA1 currents compared
to controls on patch clamp recording, and these data support
loss-of-function effect of all KCNMA1 mutants.
Conclusions: Herein we report a 15-year old boy who
has neurological conditions. A novel homozygous stop-gain
mutation detected by WES and confirmed by conventional
sequencing. Afterwards, functional characterization was
conducted using two step-approach, immunostaining to
detect subcellular effect of the variation and patch-clamp to
detect difference between mutant vs. wild-type of the
protein. Homozygous mutation was considered as causative
for this clinical condition.
This study was supported by Bezmialem Vakif Uni-
versity, Scientific Research Projects Unit, Project No:
2.2019/7
E. Yucesan: None. B. Goncu: None. A. Aslanger:
None. C. Ozgul: None. S. Hasanoglu: None. G.
Yesil: None.
P08.065.B
A next generation sequencing solution to detect copy
number variants, single nucleotide variants and loss of
heterozygosity in intellectual disability and developmen-
tal delay samples
J. Reid, S. Kachhia, P. Dougall, J. Shovelton, D. Molha, J.
Kasturiarachchi, J. Holdstock, E. Marek, V. Pullabhatla, L.
Parkes, D. Hurd
Oxford Gene Technology, Oxford, United Kingdom
The detection of copy number variants (CNVs) in intel-
lectual disability (ID) and developmental delay (DD) sam-
ples is crucial in elucidating the genetic cause of
abnormality. We have developed a targeted NGS panel and
analytical software to accurately detect CNVs, as well as
SNVs, indels and LOH.
The assay uses a bait capture approach, which is able to
capture the exons and untranslated regions (UTRs) from
over 700 genes, chosen for their relevance in ID/DD, as
well as a range of backbone regions across the genome.
Combined with the CNV detection algorithm in the
software, both intragenic and large ‘backbone’ CNVs can
be confidently detected.
We implemented a web-based data analysis solution that
runs OGT’s NGS analysis pipeline, comprising many state-
of-the-art open-source NGS software tools. These tools
were carefully chosen and deployed using containers to
ensure cross-platform compatibility and reproducibility.
Pipeline optimisation and performance was assessed using
equivalent array data and reference materials.
We will outline the results from over 200 intellectual
disability and developmental research samples to demon-
strate the efficiency of the CNV, SNV and LOH detection.
The study demonstrated that the assay automatically called
97% of CNVs (including small intragenic CNVs), 99% of
LOHs over 5Mb and 100% of SNVs. The assay was able to
call CNV deletions as small as 1.42 kb and CNVs in
samples with mosaicism as low as 10%. We have described
an improved method to investigate ID/DD, providing
critical information on not just CNVs, but SNVs and Indels
as well.
J. Reid: A. Employment (full or part-time); Significant;
Oxford Gene Technology. S. Kachhia: None. P. Dougall:
A. Employment (full or part-time); Significant; Oxford
Gene Technology. J. Shovelton: None. D. Molha: None. J.
Kasturiarachchi: None. J. Holdstock: None. E. Marek:
None. V. Pullabhatla: None. L. Parkes: None. D. Hurd:
A. Employment (full or part-time); Significant; Oxford
Gene Technology.
P08.066.C
Clinical and genetic aspects in 26 patients with KBG
syndrome caused by mutation of ANKRD11.
M. Rio1, S. Rondeau1, G. Barcia1, V. Benoit2, A. Munnich1,
C. Ormières1, A. Guimier1, S. Marlin1, J. Amiel1, S.
Lyonnet1, G. Baujat1, N. Garcelon2, V. Cormier-Daire1
1Department of genetics, Necker Hospital, Assistance
Publique - Hôpitaux de Paris, Paris, France, 2Data Science
plateform, IMAGINE Institut, Université Paris Descartes,
Sorbonne Paris Cité,, Paris, France
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drome (OMIM 148050), first described in 1975, is a rare
autosomal dominant disorder characterized by distinctive
facial features, developmental delay, short stature, and
skeletal anomalies. In 2011, heterozygous mutations in the
ANKRD11 gene were identified in patients with KBG
syndrome. Since then, 200 cases have been described
expanding the clinical phenotype. Here we present 26
unrelated patients with pathogenic mutations in ANKRD11.
We compare these patients with previously reported cases to
further expand and update the phenotypic and mutational
spectrum of this condition. The mutation occurred de novo
in the 22 families where parental DNA was available and
was inherited from a parent in two patients. Age at diag-
nosis ranged from 7 to 58 years. Developmental delay was
reported in 94% of the patients. Intellectual disability was
not a constant finding. Three patients attended regular
school. 68% of patients have behavioral disorders, and 30%
of patients have methylphenidate therapy for attention
deficit hyperactivity disorder. Gastrointestinal findings were
common. 56% of patients had deafness. This study allowed
us to confirm clinical features already reported in the lit-
erature (deafness, feeding difficulties, cerebellar atrophy). In
addition, agenesis of the olfactory bulbs, a sign not
described in the literature to our knowledge, was identified
in 3 patients.
M. Rio: None. S. Rondeau: None. G. Barcia: None. V.
Benoit: None. A. Munnich: None. C. Ormières: None. A.
Guimier: None. S. Marlin: None. J. Amiel: None. S.
Lyonnet: None. G. Baujat: None. N. Garcelon: None. V.
Cormier-Daire: None.
P08.067.A
Pathogenic variants in KCNQ2 cause intellectual defi-
ciency without epilepsy: broadening the phenotypic
spectrum of a potassium channelopathy.
E. Schaefer1, L. Mary2, E. Nourrisson2, C. Feger2, B.
Isidor3, G. Lesca4,5,6, D. Ville7, B. Keren8,9, A. Afenjar10, T.
Billette11, D. Trost12, C. Cieuta-Walti13, J. Mandel14,2, B.
Gérard2, A. Piton2,14
1Service de Génétique Médicale, Hôpitaux Universitaires
de Strasbourg, Institut de Génétique Médicale d’Alsace,
Strasbourg, France, 2Laboratoire de Diagnostic Génétique,
Hôpitaux Universitaires de Strasbourg, Strasbourg,
France, 3Service de génétique médicale, Unité de Génétique
clinique, CHU de Nantes, Nantes, France, 4Service de
Génétique, Hôpitaux Universitaires de Lyon, Lyon, France,
5Université Claude Bernard Lyon 1, Lyon, France, 6Centre
de recherche en Neuoscience, CNRS UMRS5292, INSERM
U1028, Lyon, France, 7Service de Neurologie Pédiatrique,
Hôpital Femme Mere Enfant, Centre Hospitalier Universi-
taire de Lyon, Lyon, France, 8Service de Génétique,
Université Pierre et Marie Curie, Hôpital de la Pitié-
Salpêtrière, Paris, France, 9Université Pierre et Marie
Curie (Université Paris 06), UMRS 1127, INSERM U 1127,
CNRS UMR 7225, Institut du Cerveau et de la Moelle
Épinière, Paris, France, 10Unité de Génétique Clinique,
Hôpital Armand Trousseau, Groupe Hospitalier Universi-
taire de l’Est Parisien, Paris, France, 11Service de
Neuropédiatrie, Hôpital Armand Trousseau, Groupe Hos-
pitalier Universitaire de l’Est Parisien, Paris, France,
12Laboratoire Cerba, Saint-Ouen-l’Aumône, France,
13Institut Jérôme Lejeune, Paris, France, 14Institut de
Génétique et de Biologie Moléculaire et Cellulaire, CNRS
UMR-7104, Inserm U964, Université de Strasbourg,
Strasbourg, France
High-throughput sequencing improved the molecular diag-
nosis in individuals with intellectual deficiency (ID) and,
through its unbiased approach, to broaden the clinical
spectra associated with each gene involved. We report
herein 6 patients with isolated intellectual disability (ID),
carriers of a likely pathogenic variant in KCNQ2, a gene
usually implicated in benign familial neonatal seizures
(BFNS) or early-onset epileptic encephalopathy (EOEE).
Patients were diagnosed either by targeted HTS (panel of
450-556 epilepsy- and/or ID-related genes) or exome
sequencing. Pathogenicity of the variants and predictions of
proteic structural changes were assessed by multiple in
silico tools. All patients were children at diagnosis. Patients’
ID ranged from mild to severe with predominance of speech
disturbance and autistic features. All patients carried a
heterozygous likely pathogenic missense variant in KCNQ2,
4 of them disrupted the same amino-acid (Arg144, pre-
viously reported in EOEE). We compiled all the pathogenic
variants previously reported (>130). We observed that
missense variants in the voltage-sensing domain and the
pore are significantly more associated to EOEE than BFNS
(p < 0.01, Fisher test). However, there was a strong overlap
between variants causing EOEE, isolated ID and BFNS and
an important intra-familial phenotypic variability. To con-
clude, pathogenic variants in KCNQ2 can be associated
with isolated ID. We did not highlight strong correlations
between KCNQ2-related phenotypes and the associated
variants’ localization. A second genetic hit, a burden of rare
variants or other extrinsic factors may explain such a phe-
notypic variability. However, it is of interest to study
encephalopathy genes in non-epileptic ID patients.
E. Schaefer: None. L. Mary: None. E. Nourrisson:
None. C. Feger: None. B. Isidor: None. G. Lesca: None.
D. Ville: None. B. Keren: None. A. Afenjar: None. T.
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Brain-on-a-chip: altered neuronal network development
in neural cells derived from patients with intellectual
disability
N. Nadif Kasri, M. Frega, B. Mossink, K. Linda, H. van
Bokhoven
Radboudumc, Nijmegen, Netherlands
Great progress has been made over recent years towards the
identification of intellectual disability (ID)-related genes,
resulting in hundreds of genes. A remaining challenge,
however, is to connect the genetic causes of ID to processes
that establish and/or modify neuronal circuit function. The
recent developments in induced pluripotent stem cells
(iPSCs) have provided us with the ability to model patient-
specific neuronal networks. We studied the development of
neuronal networks of iNeurons derived from patients with
Kleefstra Syndrome, Koolen-de Vries Syndrome, and
Kabuki Syndrome. These are three well-described intellec-
tual disability syndromes caused by mutations in different
histone modifiers, respectively in EHMT1, KANSL1and
KMT2D. Little is known as to how disruption in these genes
lead to altered neuronal network development. Here, we
monitored the electrophysiological activity of neuronal
networks coupled to multi-electrode arrays (MEAs) over
time and compared their activity to healthy controls and
between syndromes. Interestingly, independent clustering
analysis revealed that all tested patient lines deviated from
healthy control lines, which functionally clustered together.
Whereas Koolen-de Vries patient lines showed a general
reduced level of activity, Kleefstra syndrome and Kabuki
syndrome patient lines were mainly characterized by
changes in neuronal network burst activity and organisation.
Interestingly, patient lines from the same syndrome phe-
notypically clustered together, but separately between syn-
dromes. These data indicate that neuronal network
measurement of iNeurons on MEAs is a robust and sensi-
tive method to perform genotype-phenotype analyses for
NDDs and can be a powerful platform for drug
screening assays
N. Nadif Kasri: None. M. Frega: None. B. Mossink:
None. K. Linda: None. H. van Bokhoven: None.
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Novel missense mutation of the KMT2D gene in a girl
with Kabuki syndrome
S. Riedel, M. Linné, B. Eichhorn
MVZ Mitteldeutscher Praxisverbund Humangenetik GmbH,
Dresden, Germany
Introduction: Kabuki syndrome (KS) is a rare congenital
disorder characterized by typical facial features, postnatal
growth deficiency, intellectual disability, skeletal anomalies
and cardiac defects with variable expressivity. Mutations in
the KMT2D gene (lysine-specific methyltransferase 2D) and
the KDM6A gene (lysine-specific demethylase 6A) have
been identified as the main cause of KS. Both genes are
involved in cellular differentiation processes during
embryonic development. Here, we report a 4 10/12-year old
girl with the clinical diagnosis of KS due to typical facial
dysmorphism, slightly reduced head circumference and
speech delay.
Materials and Methods:We performed multi-gene panel
testing via sequencing by synthesis, which includes among
others the two core genes KMT2D and KDM6A associated
with KS.
Results: We revealed a novel missense variation
c.15869G>A / p.(Gly5290Asp) in exon 49 of the KMT2D
gene in the index patient. This mutation occurred de novo,
since it was absent in the clinically unaffected parents.
Conclusions: The majority of mutations (about 87 %)
causing KS produce premature termination codons. How-
ever, the role of missense mutations remains weakly
explored, although they may be disease-relevant dependings
on the localization in the gene. The detected missense
variant is situated in the functional "FY-rich" domain C-
terminal (FYRC) of the protein, suggesting that it may
affect function. It has previously not been annotated in
GnomAD or Ensembl and is classified as “probably
damaging” by several prediction data bases like
PolyPhen-2. There is also a strong evidence for the
disease-causing effect due to de novo occurrence and the
patient´s phenotype.
S. Riedel: None. M. Linné: None. B. Eichhorn: None.
P08.070.A
Refining the phenotypic & mutational spectrum in a
multinational cohort of O’Donnell-Luria-Rodan
Syndrome
C. Velmans1, A. O’Donnell-Luria2,3, E. Argilli4, F. Tran-
Mau-Them5, A. Vitobello5, M. Rech6, A. Abicht7, M. Aubert-
Mucca8, J. Carmichael9, N. Chassaing8, R. Clark10, C.
Coubes11, K. de Dios12, B. Funalot13, M. Joseph9, C.
Kenendy9, I. van de Laar14, D. Lehalle13, K. Leppig15, L.
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School, Boston, MA, United States, 3Program in Medical
and Population Genetics, Broad Institute of MIT and
Harvard, Cambridge, MA, United States, 4Brain Develop-
ment Research Program, Department of Neurology, Uni-
versity Hospital California San Francisco, San Francisco,
CA, United States, 5Inserm UMR 1231 Genetics of
Developmental Disorders, FHU-TRANSLAD, University
Hospital Dijon-Bourgogne, Dijon, France, 6Molecular
and Human Genetics, Baylor College of Medicine,
Houston, TX, United States, 7Medical Genetics Center
(MGZ), Munich, Germany, 8Department of Medical Genet-
ics, University Hospital Toulouse, Toulouse, France, 9Val-
ley Children`s Hospital, Madera, CA, United States,
10Pediatrics Specialty Clinics, Loma Linda University
Medical Center, San Bernardino, CA, United States,
11Department of Medical Genetics, University Hospital
Montpellier, Montpellier, France, 12Department of Medical
Genetics, Dayton Children`s Hospital, Dayton, OH, United
States, 13Department of Clinical Genetics, University
Hospital Henri Mondor, Créteil, France, 14Department of
Clinical Genetics, Erasmus University Medical Center,
Rotterdam, Netherlands, 15Genetic Services, Kaiser Perma-
nente of Washington, Seattle, WA, United States, 16Institute
of Human Genetics, University of Heidelberg, Faculty of
Medicine and University Hospital Heidelberg, Heidelberg,
Germany
Introduction: The KMT2E-associated neurodevelopmental
disorder named O’Donnell-Luria-Rodan Syndrome
(ODLURO) was first described by O’Donnell-Luria et al. in
20191. This previous study included 38 patients with het-
erozygous, mostly truncating de novo variants in KMT2E or
microdeletions disrupting the gene. We present the second
case series of patients with ODLURO, refining the muta-
tional and phenotypic spectrum of this not-so-rare
syndrome.
Results: We report 13 additional patients with ODLURO
from clinical centers in Europe and the US. We detected ten
heterozygous nonsense or frameshifting variants, two with
predicted deleterious effects on splicing, and one micro-
deletion encompassing >90% of KMT2E’s coding sequence
(eleven changes confirmed de novo). Eleven variants and
the microdeletion are novel, one has been previously
observed1. We confirm and refine the phenotypic spectrum
of the KMT2E-related neurodevelopmental disorder, espe-
cially concerning developmental delay with rather mild
intellectual disability and macrocephaly with subtle facial
features in most patients. In contrast to the study of
O’Donnell-Luria et al.21, the rate of autism in our cohort
was higher with ~40%, whereas seizures were reported in
only a single patient with recurring febrile seizures.
Furthermore, we describe additional anomalies and symp-
toms reported only in one or two patients, for which a
potential causal relation to the disruption of KMT2E
remains to be investigated. Our study, bringing the total
of known patients to more than 50 within a year of the first
publication, also illustrates a surprisingly high relative
frequency of ODLURO worldwide.
Footnotes1 O‘Donnell-Luria et al., Am J Hum Genet.
2019 Jun 6; 104(6): 1210–1222
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Minimal 239-kb microdeletion spanning KMT2E in a
boy with neurodevelopmental disorder.
K. Varvagiannis1,2, K. Kosma2, A. Mitrakos2, J. Traeger-
Synodinos2, M. Tzetis2
1Biomedical Research Foundation Academy Of Athens,
Athens, Greece, 2Department of Medical Genetics, Medical
School, National and Kapodistrian University of Athens,
Athens, Greece
Background: Disruptive KMT2E variants have been
recently reported to cause a neurodevelopmental disorder
characterized by developmental delay (DD), intellectual
disability (ID) and subtle dysmorphism. Epilepsy, autism
and macrocephaly are part of the phenotype in a subset of
the affected individuals.
The occurrence of truncating variants in most of these
subjects and the overlapping features observed in cases with
microdeletions spanning this gene suggest haploinsuffi-
ciency as the mechanism underlying this type of variants.
Clinical description and molecular findings: A male
was referred for genetic evaluation at the age of 2 months in
the context of prenatal-onset hydronephrosis, DD and
dysmorphic features. Investigation with chromosomal
microarray (CMA) revealed a 239-kb microdeletion of
7q22-q23 spanning 2 protein coding genes, namely KMT2E
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and LHFPL3. The deletion was classified as VUS at the
time of initial reporting.
Re-evaluation of the CMA result upon last examination of
the child at the age of 3 years and 3 months, resulted in re-
classification of the variant to likely pathogenic. Similarly to
other individuals harboring variants affecting KMT2E, our
proband presented DD, dysmorphic features albeit without
occurrence of autistic features, epilepsy or abnormal growth
parameters. Review of his medical records revealed
persistence of hydronephrosis without associated anomalies
of the urogenital tract. The boy had extensive work-up for
severe constipation, raising suspicion of possible Hirsch-
sprung disease.
Conclusions: We provide a detailed clinical description
of our proband, focusing on ill-defined previously reported
issues such as bowel dysmotility while extending the
phenotypic spectrum of the disorder with additional features
such as hydronephrosis.
K. Varvagiannis: None. K. Kosma: None. A. Mitrakos:
None. J. Traeger-Synodinos: None. M. Tzetis: None.
P08.072.C
MEA-seq for combined gene expression and neuronal
network measurements in iPSC-derived neurons from
Koolen-de Vries patients
A. H. A. Verboven, K. Linda, M. Hogeweg, C. A. Albers, B.
B. A. de Vries, P. A. C. ‘t Hoen, N. Nadif Kasri
Radboudumc, Nijmegen, Netherlands
Koolen-de Vries Syndrome (KdVS) is an intellectual dis-
ability syndrome caused by haploinsufficiency of KANSL1,
due to a loss-of-function mutation in KANSL1 or a micro-
deletion in region 17q21.31. To study KdVS in vitro, we
generated induced pluripotent stem cells (iPSCs) from
fibroblasts of three KdVs patients and three healthy con-
trols. Additionally, we introduced a loss-of-function muta-
tion in KANSL1 in one control line using the CRISPR/
Cas9 system. For all cell lines, iPSCs were differentiated
into neurons (iNeurons) by forced expression of
neurogenin-2 (Ngn2) resulting in a homogeneous popula-
tion of mature excitatory neurons within 30 days. MEA-seq
was performed to measure neuronal activity of iNeurons
using micro-electrode arrays (MEAs), followed by RNA
sequencing (RNA-seq). The RNA-seq method used allows
us to screen many samples at low cost by barcoding and
pooling samples during the library preparation. MEA
measurements revealed a decreased network burst rate and
more irregular firing pattern in KdVS iNeurons. RNA-seq
was performed on these iNeurons as well as on iPSCs from
the same individuals. Differential expression (DE) analysis
was performed to identify changes in gene expression in
KdVS patients compared to controls. Gene set enrichment
analysis (GSEA) revealed cell type-specific enrichment of
up- and down-regulated genes in gene sets involved in
processes such as cell cycle regulation, cellular respiration
and early development. These results show that MEA-seq
allows for characterization of iPSC-derived neurons both on
a functional and transcriptional level, and therefore is a
powerful tool to study mechanisms underlying neurodeve-
lopmental disorders.
A.H.A. Verboven: None. K. Linda: None. M. Hoge-
weg: None. C.A. Albers: None. B.B.A. de Vries: None. P.
A.C. ‘t Hoen: None. N. Nadif Kasri: None.
P08.073.A
Mutations in KPTN, a rare cause of macrocephaly and
intellectual disability
M. Pacio Miguez1, F. Santos Simarro1,2, S. García-
Miñaúr1, C. Rodríguez Jiménez1, Á. del Pozo1,2, M. Solís1,
R. Velázquez Fragua3, V. Rufo-Rabadán1, V. Fdez
Montaño1, I. Rueda Arenas1, M. Gomez del Pozo1, N.
Gallego Onís1, M. Palomares Bralo1,2
1Instituto de Genética Médica y Molecular, INGEMM,
Madrid, Spain, 2CIBERER, Centro de Investigación
Biomédica en Red de Enfermedades Raras, ISCIII, Madrid,
Spain, Spain, 33 Servicio de Neurología Infantil. Hospital
Universitario La Paz, Madrid, Spain
Introduction: Pathogenic homozygous or compound het-
erozygous variants in KPTN have emerged as a novel
autosomal recessive neurodevelopmental disorder asso-
ciated to developmental delay, intellectual disability, mac-
rocephaly and language deficit with only 13 individuals
described in the medical literature so far. We report two
additional siblings with a homozygous pathogenic variant in
the KPTN gene.
Materials and Methods: Variants were identified using a
NGS custom panel containing 1663 genes involved in
neurodevelopmental disorders (RD-Seq © V6.0).
Results: A homozygous dinucleotide duplication Chr19
(GRCh37):g.47984018_47984019dup; NM_007059.3:
c.597_598dup; p.(Ser200Ilefs*55) in KPTN was found in
a 7-year-old girl and her 3-year-old sister born to non-
consanguineous healthy parents with no family history of
note. Both presented with developmental delay, macro-
cephaly, frontal bossing, language deficit and delayed
anterior fontanel closure. Brain MRI revealed anatomical
changes in one. None of them had seizures or behavioral
problems. A clinical description our cases and a review of
the previously reported individuals will be provided.
Conclusions: Cardinal features of KPTN-related disease
observed in all 15 cases are developmental delay
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/intellectual disability, language deficit, macrocephaly (of
prenatal or postnatal origin) and frontal bossing. Variable
clinical features include seizures, behavioral problems,
craniosynostosis, brain MRI changes and endocrine
abnormalities. In summary, homozygous or compound
heterozygous variants in KPTN may be a hitherto under-
recognized cause of macrocephaly, developmental delay,
intellectual disability and language deficit. We suggest
including KPTN in gene panels for the study of patients
with these features.
M. Pacio Miguez: None. F. Santos Simarro: None. S.
García-Miñaúr: None. C. Rodríguez Jiménez: None. Á.
del Pozo: None. M. Solís: None. R. Velázquez Fragua:
None. V. Rufo-Rabadán: None. V. Fdez Montaño: None.
I. Rueda Arenas: None. M. Gomez del Pozo: None. N.
Gallego Onís: None. M. Palomares Bralo: None.
P08.074.B
The simultaneous presence of microcephaly, seizures,
and developmental delay due to PNKP gene mutation
and infantile hypophosphatasia caused by mutation in
ALPL gene
I. Sansovic, A. Bobinec, A. Measic, M. Kero, I. Barisic
Department of Medical Genetics and Reproductive Health,
Children’s Hospital Zagreb, Scientific Centre of Excellence
for Reproductive and Regenerative Medicine (CERRM),
University of Zagreb School of Medicine, Zagreb, Croa-
tia
Introduction: Microcephaly, seizures, and developmental
delay (MCSZ; MIM #613402) is neurodevelopmental dis-
order with onset in infancy caused by homozygous or
compound heterozygous mutations in the PNKP gene.
There is a range of phenotypic severity: some patients have
early infantile epileptic encephalopathy (EIEE), whereas
others have more well-controlled seizures and a protracted
course. Infantile hypophosphatasia (MIM #241500) is
caused by a pathogenic mutation in the ALPL gene char-
acterized by defective bone mineralization, a combination
of typical radiological signs, hypercalcemia, hyperpho-
sphatemia, and low alkaline phosphatase activity. We
describe a family with three affected children born of
allegedly nonconsanguineous parents: a twelve-year-old
boy with microcephaly, craniosynostosis, EIEE, patchy/
polymicrogyria, polyneuropathy and global developmental
delay (MCSZ), his eleven-year-old sister with infantile
hypophosphatasia and nine-year-old sister with infantile
hypophosphatasia, microcephaly, global developmental
delay and paroxysmal seizures with vomiting.
Method: Clinical exome sequencing was performed in all
family members using Illumina TruSight One Kit.
Results: A boy with MCSZ has a homozygous
c.1253_1269dup17 pathogenic variant in the PNKP gene,
the older sister has homozygous c.542C>T pathogenic
variant in ALPL gene and the younger sister has
homozygous pathogenic variants in both genes.
Conclusions: The simultaneous presence of infantile
hypophosphatasia and MCSZ has never been reported
before. The overlapping clinical features of infantile
hypophosphatasia and MCSZ (hypotonia, craniosynostosis,
seizures, short stature, failure to thrive) as well as the milder
clinical course of MCSZ, resulted in delayed diagnosis of
MCSZ in the female patient.
Acknowledgement: supported by CERRM and EU
through the European Regional Development Fund by
grant No. KK.01.1.1.01.0008.
I. Sansovic: None. A. Bobinec: None. A. Measic: None.
M. Kero: None. I. Barisic: None.
P08.075.C
Updated insight into the mutational and phenotypic
spectrum of MED13L-related intellectual disability
R. Asadollahi1, P. Boonsawat1, B. Popp2,3, E. Torti4, I.
Bader5, A. Vitobello6, S. Moutton6, L. Pinson6, L. Lambert6,
A. C. Thuresson7, M. Sobol7, C. Soussi Zander7, K.
Platzer8, V. Strehlow8, F. Hornemann8, P. Zacher9, F. Tran
Mau-Them6, A. L. Bruel6, M. J. Hajianpour10, R. Kovacs-
Nagy11, G. Lay-Son12, L. Amlie-Wolf13, J. Kaplan14, A.
Chassevent15, C. Smith-Hicks16, A. Slavotinek17, M. K.
Kukolich18, K. Nugent19, E. Roeder19, Y. A. Zarate20, Y.
Toshiyuki21, C. Jackel-Cram22, I. Maystadt23, S. G. Mehta24,
T. A. Briggs25, K. Chandler25, A. van Haeringen26, C.
Kraus2, C. Zweier2, A. Reis2, A. Rauch1
1University of Zurich, Zurich, Switzerland, 2Friedrich-
Alexander-Universität Erlangen-Nürnberg, Erlangen, Ger-
many, 3University of Leipzig Hospitals and Clinics, Leipzig,
Germany, 4GeneDx, Gaithersburg, MD, United States,
5Paracelsus Medical University, Salzburg, Austria,
6Inserm-Université Bourgogne-Franche Comté, Dijon,
France, 7Uppsala University, Uppsala, Sweden, 8Univer-
sity of Leipzig Medical Center, Leipzig, Germany, 9Saxon
Epilepsy Center Kleinwachau, Radeberg, Germany, 10East
Tennessee State University, Tennessee, TN, United States,
11Semmelweis University, Budapest, Hungary, 12Pontificia
Universidad Catolica de Chile, Santiago, Chile, 13Nemours
A.I. Dupont Hospital for Children, DE, USA, Wilmington,
DE, United States, 14Nemours A.I. Dupont Hospital for
Children, Wilmington, DE, United States, 15Kennedy
Krieger Institute, Baltimore, MD, United States, 16Johns
Hopkins Medical Institutions, Baltimore, MD, United
States, 17University of California, San Francisco, CA,
United States, 18Cook Children’s Medical Center, Fort
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Worth, TX, United States, 19Baylor College of Medicine,
Houston, TX, United States, 20University of Arkansas for
Medical Sciences, Little Rock, AR, United States, 21Tokyo
Women’s Medical University, Tokyo, Japan, 22Royal
University Hospital, Saskatoon, SK, Canada, 23Centre de
Génétique Humaine, Gosselies, Belgium, 24Cambridge
University Hospitals NHS Foundation Trust, Cambridge,
United Kingdom, 25University of Manchester, Manchester,
United Kingdom, 26Leiden University Medical Center,
Leiden, Netherlands
MED13L-related intellectual disability (MIM #616789) is
an autosomal dominant neurodevelopmental syndrome with
~80 cases reported so far. To further delineate its spectrum,
we have studied 28 clinically well-characterized new
patients (age 7 months to 31 years) harbouring pathogenic
or likely pathogenic (P/LP) MED13L sequence or copy
number variants. We found 21 likely gene-disrupting
(LGD) de novo variants distributed throughout the gene
and 7 deleterious missense variants (5 de novo, 2 unknown
inheritance). We observed clustering of our new and pre-
viously reported P/LP missense variants between the two
LxxLL motifs, between Leu-Zipper and Ser-rich motifs, and
within the C-terminus of the MED13L protein, which are
deprived of missense variants in gnomAD. Clinically, we
have been able to ascertain details of developmental mile-
stones and growth parameters, and to find multiple novel
features. Remarkably, we noticed previously unreported
mild global developmental delay in 3/28 (~11%) and verbal
dyspraxia in 6/28 (~21%) patients harbouring LGD var-
iants. Moreover, we observed a higher frequency of epi-
lepsy (~86% vs. ~29%) and severe congenital heart defects
requiring surgery (~29% vs. 0%) in our patients with mis-
sense compared to LGD variants. We also report the first
MED13L patient with no obvious congenital heart defect
who passed away at the age of ~10 years possibly due to
respiratory insufficiency and right-heart failure. Altogether,
our findings highlight new aspects of the syndrome and
suggest a critical role for the MED13L C-terminus, mis-
sense defects of which may even cause a more severe
phenotype than MED13L haploinsufficiency.
R. Asadollahi: None. P. Boonsawat: None. B. Popp:
None. E. Torti: None. I. Bader: None. A. Vitobello: None.
S. Moutton: None. L. Pinson: None. L. Lambert: None.
A.C. Thuresson: None. M. Sobol: None. C. Soussi
Zander: None. K. Platzer: None. V. Strehlow: None. F.
Hornemann: None. P. Zacher: None. F. Tran Mau-
Them: None. A.L. Bruel: None. M.J. Hajianpour: None.
R. Kovacs-Nagy: None. G. Lay-Son: None. L. Amlie-
Wolf: None. J. Kaplan: None. A. Chassevent: None. C.
Smith-Hicks: None. A. Slavotinek: None. M.K. Kuko-
lich: None. K. Nugent: None. E. Roeder: None. Y.A.
Zarate: None. Y. Toshiyuki: None. C. Jackel-Cram:
None. I. Maystadt: None. S.G. Mehta: None. T.A.
Briggs: None. K. Chandler: None. A. van Haeringen:
None. C. Kraus: None. C. Zweier: None. A. Reis: None.
A. Rauch: None.
P08.076.A
Investigation of the MMP2 haplotype as a risk factor for
the development of cerebral palsy
A. S. Djuranovic1, N. Cerovac2, D. Perovic1, M. Grk1, M.
Pesic1, T. Damnjanovic1
1Institute of Human Genetics, Belgrade, Serbia, 2Clinic of
Neurology and Psychiatry for Children and Youth,
Belgrade, Serbia
Introduction: Hypoxic-Ischemic Encephalopathy (HIE) is
the most important cause of cerebral palsy (CP). Perinatal
brain damage activates the immune system and inflamma-
tion mediators. Matrix metalloproteinases (MMPs) are
necessary in inflammation and might be involved in neu-
rodegeneration. Aim of this study was to examine possible
association between MMP2 promoter polymorphisms and
CP onset in children with perinatal asphyxia.
Material and methods: Study included 96 patients aged
1 to 16 years with anamnesis of perinatal asphyxia. Detailed
neurological evaluation and neuroimaging (ultrasound,
computed tomography, magnetic resonance imaging) were
performed for all subjects. TaqMan assays were used for
genotyping rs243864 and rs243866 MMP2 gene poly-
morphisms. Haplotypes were calculated with Haploview
software.
Results: Frequencies of rs243866 and rs243864 haplo-
types in patients who developed CP were: 72.2% GT,
22.3% AG, 2.8% GG and 2.7% AT, while in the group of
those who did not develop CP were 89.0% GT, 10.0% AG,
and 1.0% GG. AG haplotype was significantly more
frequent in patients with CP (p=0.018). Also, in patients
with AG haplotype, HIE and pathological neuroimaging
finding were more frequently observed (p=0.012, p=0.048,
respectively)
Conclusions: MMP2 promoter haplotype could be a risk
factor for CP in patients with perinatal asphyxia.
A.S. Djuranovic: None. N. Cerovac: None. D. Perovic:
None. M. Grk: None. M. Pesic: None. T.
Damnjanovic: None.
P08.077.B
Uncovering molecular mechanisms and neuronal path-
ways involved in SETBP1 disorder using human stem
cell models
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M. M. K. Wong1, J. den Hoed1, M. Heide2, W. B. Huttner2,
B. W. van Bon3, S. E. Fisher1,4
1Max Plank Institute for Psycholinguistics, Nijmegen,
Netherlands, 2Max Planck Institute of Molecular Cell
Biology and Genetics, Dresden, Germany, 3Radboud
University Nijmegen Medical Centre, Nijmegen, Nether-
lands, 4Donders Institute for Brain, Cognition and
Behaviour, Radboud University, Nijmegen, Netherlands
Introduction: Haploinsufficiency of the SETBP1 gene
causes a neurodevelopmental syndrome (SETBP1 disorder)
involving expressive speech impairment and mild-moderate
developmental delay. The precise functions of SETBP1,
encoding the SET-binding protein 1, are yet to be dis-
covered. Therefore, the molecular mechanisms or neuronal
pathways by which rare loss-of function SETBP1 mutations
cause a neurodevelopmental disorder remain largely
unknown.
Materials and Methods: By employing induced plur-
ipotent stem cell (iPSC)-derived brain organoids and
transcriptomic approaches, we aim to dissect the underlying
neuronal pathways. We will differentiate patient-derived
iPSCs carrying de novo heterozygous SETBP1 mutations
and SETBP1 knockout iPSCs generated with CRISPR/Cas9
gene-editing into brain organoids. Their transcriptomic
profiles will be analysed at both whole organoid and
single-cell levels. Morphological examination, clustering,
cell-type specific differential gene expression analysis and
cell lineage tracing will be performed.
Results: We have identified six truncating mutations in
the SETBP1 gene in a Dutch cohort. We have generated
homozygous and heterozygous SETBP1 knockout iPSC
lines using CRISPR/Cas9 gene-editing. Moreover, we have
characterized a robust protocol for generating cerebral
organoids using the isogenic control iPSC line that we used
to generate SETBP1 knockout iPSCs.
Conclusions: These iPSC lines are ready for cerebral
organoid differentiation and subsequent downstream ana-
lyses. In the long-term, we hope that cell-culture models can
provide a platform for testing drug panels with the potential
to rescue aberrant molecular/cellular phenotypes that we
observe. Together, this work promises to offer insights into
fundamental neuronal mechanisms that go awry in SETBP1
disorder and, ultimately, to accelerate development of
therapeutic applications.
M.M.K. Wong: None. J. den Hoed: None. M. Heide:
None. W.B. Huttner: None. B.W. van Bon: None. S.E.
Fisher: None.
P08.080.B
Smith-Kingsmore Syndrome: a case report and delinea-
tion of phenotype
D. J. Josifova1, R. Marcinkute1, C. Deshapnde2, T.
Serafimova3, S. Byrne4, M. Lim4, A. Siddiqui5
1Guy’s Hospital, London, United Kingdom, 2Manchester
Centre for Genomic Medicine, St. Mary’s Hospital,
Manchester, United Kingdom, 3University Hospital Bristol
NHS Trust, Bristol, United Kingdom, 4Evelina Children’s
Hospital, London, United Kingdom, 5St. Thomas Hospital,
London, United Kingdom
Smith-Kingsmore Syndrome (SKS) [MIM#616638] is a
rare multisystem disorder characterised by macrocephaly,
dysmorphic features, malformations of cortical develop-
ment (MCD) and intellectual disability, caused by hetero-
zygous, germline variants in the mammalian target of
rapamycin (MTOR). At 31 months old, our patient was
referred with significant global developmental delay, dys-
morphic features and large head circumference (HC).
Antenatally, moderate bi-ventricular dilatation and macro-
cephaly were observed. Ventricular dilatation was rapidly
progressed in the first 6 months and stabilised by one year
old. There was no history of seizures. Clinical examination
revealed HC >4SD above the mean, curly hair, dysmorphic
facial features, fleshy hands and feet with prominent fetal
finger pads. She had peripheral and, more marked, core
hypotonia, and was not independently mobile. Neurometa-
bolic investigations were unremarkable. Serial MRI ima-
ging demonstrated moderate, stable ventriculomegaly, thin
corpus callosum, subtle bilateral anterior/opercular poly-
microgyria and subepemdymal nodular heterotopia. Array
CGH was normal. Whole exome sequencing revealed a de
novo, likely pathogenic MTOR c.7217T>G p.(Val2406Gly)
variant located in a highly conserved nucleotide and amino
acid position in the Kinase domain. The gene encodes
serine/threonine-protein kinase mTOR, member of the
phosphatidylinositol 3-kinase (PI3K) family. The mTOR
engages in two complexes, mTORC1 and mTORC2, and is
a potent regulator of cell growth, energy metabolism,
autophagy and cytoskeletal organisation. Deregulation of
the mTOR pathway has been implicated in cancer, cardio-
vascular, autoimmune and neurodegenerative diseases,
often referred to as mTORopathies. We present a new case
of SKS and review the literature to further delineate the
phenotype.
D.J. Josifova: None. R. Marcinkute: None. C.
Deshapnde: None. T. Serafimova: None. S. Byrne: None.
M. Lim: None. A. Siddiqui: None.
P08.081.C
Things you might miss in your sequencing study -
Reanalyzing 152 cases with neurodevelopmental
disorders
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T. Bartolomaeus, R. Abou Jamra, B. Popp
Institute of Human Genetics, University of Leipzig Medical
Center, Leipzig, Germany
Clinical guidelines recommend iterative re-analysis in
undiagnosed cases. Re-interpretation and reporting research
in light of novel data is not well investigated. Of 152
consanguineous families with NDDs we previously found a
diagnosis in 56 and identified VUS or candidate genes in
53. In total 116 variants were reported in 109 families. We
re-evaluated all reported variants according to updated
classification guidelines or our internal candidate gene
scoring system. Variants in candidate genes were uploaded
to GeneMatcher and collaborations were joined/initiated.
We re-processed all data using up-to-date tools, references
and databases for case-level re-analysis. In 26/116 (22%)
variants the clinical relevance changed through variant
classification or increased significance of candidate genes.
In 4 (9%) of the 43 undiagnosed cases a possible diagnosis
was found. Of the 53 originally identified candidate genes 8
were in the meantime associated with NDDs, 2 are in
submission and 3 collaborations were entered in the course
of this project. Two reported variants were missed by the
updated computational pipeline due to alignment (old data)
or reference (ambiguous region in hg38) issues. We sub-
mitted all relevant variants to public databases and revised
their previous classification. Our results support the need to
re-evaluate research screening studies. We highlight
potential benefits and pitfalls of computational re-analysis.
Its complexity for old data should be weighed against the
decreasing re-testing costs. Published variants in established
and candidate disease genes are not assessable unless
reported in databanks. Future studies should incorporate
post-publication variant management and bio-banking of
patient cells for upcoming methods.
T. Bartolomaeus: None. R. Abou Jamra: None. B.
Popp: None.
P08.082.A
Missense variants in NDD-associated FBXO11 impair its
localization and Fbxo11 deficiency leads to neuronal
impairment in Drosophila melanogaster
A. Gregor1, T. Meerbrei1, L. Distel1, T. Gerstner2, A.
Gupta3, A. Toutain4, S. A. Lynch5, C. Maxton6, J. R.
Lemke7, J. A. Bernat8, H. M. Bombei8, N. Foulds9, A.
Kuechler10, A. Bouman11, M. Palomares Bralo12, F. Santos
Simarro12, S. Garcia-Minaur12, C. Zweier1
1Institute of Human Genetics, Friedrich-Alexander-
University Erlangen-Nürnberg, Erlangen, Germany,
2Department of Pediatrics, Sørlandet Hospital, Arendal,
Norway, 3Center for Individualized Medicine, Mayo Clinic,
Rochester, MN, United States, 4Service de Génétique, CHU
de Tours, Tours, France, 5Dept of Clinical Genetics,
Temple Street Children’s Hospital Dublin 1, Dublin,
Ireland, 6Praxis für Kinderneurologie, Hamburg Altona,
Hamburg, Germany, 7Institute of Human Genetics, Uni-
versity of Leipzig Hospitals and Clinics, Leipzig, Germany,
8Division of Medical Genetics, Department of Pediatrics,
University of Iowa, Iowa City, IA, United States, 9Wessex
Clinical Genetics Services, University Hospital South-
ampton, Southampton, United Kingdom, 10Institut für
Humangenetik, Universitätsklinikum Essen, Essen, Ger-
many, 11Department of Clinical Genetics, Erasmus MC,
University Medical Center Rotterdam, Rotterdam, Nether-
lands, 12Institute of Medical and Molecular Genetics,
University Hospital La Paz, Madrid, Spain
Recently, we identified de novo FBXO11 variants as cau-
sative for a variable neurodevelopmental disorder (NDD).
We now assembled clinical and mutational information on
13 additional cases. The phenotypic spectrum remains
highly variable, and the mutational spectrum includes
intragenic deletions, likely gene disrupting and missense
variants distributed across the protein, in line with hap-
loinsuffiency of FBXO11 as the most likely disease
mechanism.
We analyzed the effects of ten different missense variants
on protein expression and localization by overexpression of
mutant constructs in HEK293 and Hela cells. Variants
located close to the N-terminal F-Box domain lead to
altered subcellular localization and exclusion from the
nucleus, and to reduced protein levels in western blot. In
contrast, variants localized in the C-terminal Zn-finger UBR
domain lead to an accumulation in cytoplasmatic granules
and to increased protein levels in the cell. Together, these
results indicate that some missense variants impair function
through mislocalization or reduced expression.
Using Drosophila melanogaster as a model organism, we
investigated the effects of Fbxo11 deficiency on neuronal
development. We found a mild impairment of basic
locomotor function in the climbing assay upon neuronal
knockdown and a stronger impairment upon glial knock-
down. We also found decreased dendrite branching and
total dendrite length upon Fbxo11 knockdown in multiple
dendrite neurons of the larval body wall.
Our study further characterizes the FBXO11 associated
NDD and the underlying pathomechanism and highlights
the importance of Drosophila Fbxo11 for neuronal devel-
opment and basic neuronal functioning.
A. Gregor: None. T. Meerbrei: None. L. Distel: None.
T. Gerstner: None. A. Gupta: None. A. Toutain: None. S.
A. Lynch: None. C. Maxton: None. J.R. Lemke: None. J.
A. Bernat: None. H.M. Bombei: None. N. Foulds: None.
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Bralo: None. F. Santos Simarro: None. S. Garcia-
Minaur: None. C. Zweier: None.
P08.083.B
Using RNA-sequencing to expand the diagnostic toolset
for neurodevelopmental disorders: a pilot study
M. Radtke, D. Le Duc, R. Jamra
Medical University Leipzig, Leipzig, Germany
Introduction: Despite the inclusion of next generation
sequencing in routine genetic diagnostics, around 50 % of
cases remain unsolved. One cause for this is the difficulty of
assessing synonymous and non-coding SNVs. RNA-
sequencing is one way to unravel their potential causality
and gain first insights in potential pathomechanisms.
Materials and Methods: We extracted RNA from PAX-
blood of a first cohort of 26 individuals with syndromic
neurodevelopmental disorders that remained unsolved after
exome sequencing. The RNA-sequencing data was ana-
lyzed with respect to gene expression and splicing
alterations.
Results: A first evaluation of the sequencing data shows a
strong inter-individual fluctuation, stressing the importance
of selecting appropriate control groups. Differentially
expressed genes were then analyzed with regard to function,
interaction and disease association. In at least two
individuals, we identified disruptive splicing events in
genes with a known disease association. In one individual
we found a significant enrichment in differentially
expressed genes involved in synaptic signaling and
neuronal processes. This implies a possible disturbance of
neuronal pathways and offers a set of potential candidate
genes for further investigations. We are still in the process
of interrogating the sequencing data and will present a full
report of our findings at the conference.
Conclusions: The blending of exome and transcriptomic
sequencing data allows for more in depth exploration and
offers the potential to identify disruptive variants which
remain unnoticed by exome sequencing.
M. Radtke: None. D. Le Duc: None. R. Jamra: None.
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Diagnostic array-CGH and exome sequencing in a
cohort of patients with neurodevelopmental disorders:
genetic heterogeneity and phenotypic variability
A. Pelle1,2, G. Mandrile3,2, E. Di Gregorio4, P. Dentelli4, E.
Giorgio5, L. Pavinato5, M. Tartaglia6, A. Brusselles7, T.
Pippucci8, P. Dimartino8, S. De Rubeis9, G. B. Ferrero10, A.
Brusco5, D. F. Giachino2,1
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6Genetics and Rare Diseases Research Division, Ospedale
Pediatrico Bambino Gesù IRCSS, Roma, Italy, 7Department
of Oncology and Molecular Medicine, Istituto Superiore di
Sanità, Roma, Italy, 8Department of Medical and Surgical
Sciences, University of Bologna, Bologna, Italy, 9Seaver
Autism Center for Research and Treatment, Icahn School of
Medicine at Mount Sinai, New York, NY, United States,
10Department of Pediatrics and Public Health and
Pediatric Sciences, University of Torino, Torino (TO),
Italy
Neurodevelopmental disorders (NDDs) are a heterogeneous
category of neuropsychiatric disorders, with onset during
childhood/adolescence and a worldwide prevalence of 0,5-
2%. The etiology of NDDs include both environmental and
genetic causes. In this study we evaluated the genotype-
phenotype correlation of 201 patients with NDDs con-
secutively admitted to our Unit for a clinical genetic eva-
luation from 2006 to 2019. Based on the clinical evaluation,
the appropriate genetic testing was performed for each
patient: array-CGH and FMR1 analysis were used as first-
tier tests and specific genetic testing/WES as second-tier
analysis. Array-CGH was performed in 158 cases and
positive in 13 (DR 8.2%). Two patients were carriers of a
complex chromosomal rearrangements (one due to chro-
mothripsis), a family had a recurrent 4p15.31p15.2 deletion.
Specific genetic tests revealed a pathogenic variant in 7.5%.
WES was performed in 52 patients and revealed a mutation
in HNRNPH2, DLG4, IQSEC2, ATP1A3 genes (DR 16%).
Overall, 16 different genetic conditions were diagnosed and
Fragile-X syndrome was the most frequent (3 cases).
Detection rate of array-CGH in our cohort was roughly in
line with the 10% estimated by in literature. In our cohort,
the results of WES are encouraging but certainly under-
estimated: DR of this test would be higher if WES was
employed also instead of other second-tier specific gene
analysis (DR estimated: 23%). The new knowledge and
technologies would probably change the multi-step genetic
testing approach, indicating WES or WGS as first step
analysis after FMR1 test as routine diagnostic test in all
patients with NDDs.
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Exome sequencing of Slovenian children with neurode-
velopmental disorders
D. Krgovic, S. Stangler Herodez, A. Golub, N. Kokalj
Vokac
Laboratory of Medical Genetics, Maribor, Slovenia
Introduction: Since the implementation of molecular kar-
yotyping in diagnostics of neurodevelopmental disorders
(NDDs), the understanding of the genetic causes of these
diseases has significantly improved. However, with the
introduction of the NGS, the setting of the genotype-
phenotype correlations has become even more straightfor-
ward. By determining causative mutations in individual
genes, it enabled us to understand the role of individual
genes in the etiology of the disease, and significantly
increased the diagnostic yield for genetic diagnostic of
NDDs in Slovenian children.
Methods: Clinical exome sequencing was performed by
using the TruSight One Illumina Kit (4813 genes) and
focusing on phenotype driven analysis on a small serie (N
45) of pediatric patients with various NDDs.
Results: With NGS analysis, we were able to identify the
genetic origin of the disorder (pathogenic Single Nucleotide
Variant - pSNV) in 29% of screened patients. In 24% of
patients, a SNV classified as variant of unknown signifi-
cance (VOUS) has been determined within the disease-
associated genes.
Discussion: With phenotype-genotype driven analysis,
we were able to identify rare and clinically poorly defined
syndromes in previously undiagnosed patients. Among
them, disorders such as Kabuki and Noonan syndrome,
Menkes disease, mutations in IQSEC2 gene causing the
Rett-like phenotype etc. were identified. A high percent of
pSNV are also partly due to the selection of suitable patients
for NGS testing based on their good clinical characteriza-
tion. Our study confirmed a high efficiency of NGS in
diagnostic of NDDs and enabled the diagnosis of rarely
described cases which will be presented.
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Loss-of-function truncating and missense variants in
NSD2 cause decreased methylation activity and are
associated with a distinct neurodevelopmental
phenotype
P. Zanoni1, K. Steindl1, D. Sengupta2, H. Sticht3, P. Joset1,
A. Baar1, C. M. A. van Ravenswaaij-Arts4, M. Shinawi5, I.
Maystadt6, N. Belnap7, V. Benoit6, B. B. A. de Vries8, D.
Lacombe9, A. Larson10, R. Pfundt8, K. Ramsey7, L. Snijders
Blok8, P. G. Wheeler11, M. R. Wevers8, O. Gozani2, A.
Rauch1
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United States, 11Arnold Palmer Hospital, Orlando Health,
Orlando, FL, United States
Introduction: NSD2 (alias WHSC1) has been suspected to
be critical for the Wolf-Hirschhorn syndrome (WHS) phe-
notype for decades. Recently, few case reports described the
first patients harbouring heterozygous truncating NSD2
variants. In order to understand the full clinical spectrum
and molecular mechanism, we investigated 15 new indivi-
duals carrying truncating or missense NSD2 variants.
Materials and Methods: Detailed phenotypic informa-
tion was collected for 15 new sporadic and familial affected
individuals. Clinical data were compared to the available
information of 10 previously described carriers of NSD2
truncating variants or small deletions. The structural effect
of missense variants was modelled in silico. Each missense
variant was tested in vitro for methyltransferase activity and
for the ability to reconstitute H3K36me2 in knockout
cell lines.
Results: the core phenotype associated with NSD2
pathogenic variants overlaps only partially with WHS and
includes mild to moderate DD, prenatal-onset growth
retardation, failure to thrive and characteristic facial features
distinct from WHS. Carriers of missense variants were
significantly taller and had more frequent behavioural/
psychological issues compared to carriers of truncating
variants. BMI was significantly higher in older patients. All
missense variants in known structures are supposed to
interfere with NSD2’s folding and function in silico. In vitro
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data showed that missense variants lead to a reduction of
methylation activity.
Conclusions: We present the first comprehensive patient
series with NSD2 pathogenic variants, providing a sig-
nificant refinement of the clinical spectrum. Furthermore,
we report the first missense variants and provide evidence
for pathogenicity through decreased methylation activity.
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A novel TBL1XR1 variant in Pierpont syndrome
M. Stefanova1, H. Klang Åstrand1, M. Frid2, I. Hüning3
1University Hospital Linköping, Linköping, Sweden, 2Ryhov
County Hospital, Jönköping, Sweden, 3University of
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Pierpont syndrome (PS) (OMIM #602342) is a rare disorder
characterized by intellectual impairment, characteristic
facial gestalt, microcephaly, fetal finger/toes pads and
anteromedial fat pads of the heels (Pierpont et al, 1998). A
recurrent de novo TBL1XR1 variant [c.1337A>G; p.
(Tyr446Cys)] is known to be disease-causing for the syn-
drome (Heinen et al, 2016). Additionally, other TBL1XR1
variants [c.974G > A;p.(Cys325Tyr) and c.1336 T > C;p.
(Tyr446His)] have been reported in patients with a typical
PS (Lemattre et al, 2018). The authors suggest compar-
ability between the functional consequences of all these
variants. TBL1XR1 haploinsufficiency, though, is reported
to cause a different entity, MRD41 (OMIM# 616944). Here
we report on a four-year-old girl with a typical PS pheno-
type and a novel de novo heterozygous TBL1XR1 variant,
c.1184A>G;p.(Tyr395Cys). We studied the three-
dimensional structure of TBLR1 protein and noted that
the amino acid affected by this variant is located in the
WD6 repeat of the WD40 domain and lies in the close
vicinity of the amino acids affected by the other PS causing
variants (Tyr446 and Cys325). The WD40 domain has a
β-propeller-like-structure where hotspot residues at the
domain’s top as identified by WDSPdb (Wang et al, 2015)
are likely to interact with β-catenin. Tyr395 and Tyr446 are
hotspot residues and therefore predicted to be of importance
for the function. In summary, a review of the clinical and
molecular data of all the reported patients so far, inclusive
the present patient, suggests that the TBL1XR1 variants
causing PS affect most likely protein structures with com-
parable gene function.
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PPP2R5D variants in patients with variable neurodeve-
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of Padova, Padova, Italy, 4U.O.S. Genetica Medica Azienda
ULSS9, Treviso, Italy, 5UO Genetica Medica AUSL
Romagna, Ravenna, Italy, 6Neuroscience Department,
Children’s Hospital A. Meyer-University of Florence,
Firenze, Italy
PPP2R5D is the B regulatory subunit of protein phospha-
tase 2A (PP2A) and has been recently associated with a
neurodevelopmental disorder (NDD), characterized by mild
to severe Intellectual Disability (ID), Autism Spectrum
Disorder (ASD), pronounced hypotonia, macrocephaly and
speech impairment. To date, only 23 individuals with de
novo PPP2R5D mutations have been described. Here we
report five PPP2R5D variants in five unrelated individuals
with NDD: two novel missense, one rare intronic variants
and two recurrent missense pathogenic mutations,
Glu198Lys and Glu200Lys. The Glu198Lys mutations,
located in the PP2A catalytic subunit interaction interface, is
associated with a more severe phenotype due to its severe
effects on the binding properties of the B regulatory subunit
PP2A. All but one the mutations were detected by targeted
NGS analysis of a ID/ASD multigenic panel in 600 NDDs
subjects. Among these cases we report for the first time a
dual diagnosis. A girl carrying a de novo Glu198Lys
mutation, identified by whole-exome sequencing, exhibiting
a very severe NDD with ID, ASD, absent speech, marked
hypotonia, and typical dysmorphisms, also carry a full
FMR1 gene mutation. The fragile X phenotype seemed to
be overshadowed by the severe PPP2R5D clinical features.
The other individuals carrying PPP2R5D mutations (seg-
regation analysis is currently underway) showed a rather
mild ID phenotype, very variable dysmorphic features, no
hypotonia and, only in case of the Glu200Lys mutation,
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absence of ASD features. These new cases confirm the
phenotype correlations in recurring mutations and con-
tribute to highlighting the variability of PPP-related NDDs.
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A novel mutation in WDR62 gene in a patient who had
autosomal recessive primary microcephaly with con-
comitant sarcoglycanopathy
S. Gürsoy1, F. Hazan2, G. Akıncı3, A. Ünalp3
1Department of Pediatric Genetics, Dr. Behcet Uz Chil-
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3Department of Pediatric Neurology, Dr. Behcet Uz
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Introduction: Autosomal recessive primary microcephaly
is a rare form of primary microcephaly, characterized by a
marked reduction in brain size and intellectual disability.
WDR62, which is the second most frequently mutated gene,
plays a significant role in neuronal progenitor cell pro-
liferation and spindle formation.
Materials and Methods: Herein, we present a novel
WDR62 gene mutation in a 11 year-old girl. The index girl
patient was referred to our genetic clinic for microcephaly,
epilepsy and developmental delay. Her parents had a
consanguineous marriage and the patient had a 2 year-old
brother who had microcephaly and developmental delay
and a 10 year-old healthy brother. She had increased serum
CK levels and muscle biopsy findings were compatible with
sarcoglycanopathy. An autosomal recessive microcephaly
panel (including 9 gene) and limb-girdle muscular dystro-
phy panel (including 31 gene) with MiSeq® NGS system,
were performed in the patient. Sanger seguencing was used
for family segregation analysis.
Results: We detected a novel homozygous frameshift
mutation (c.621_622delAG; p.Glu208GlyfsTer23) in
WDR62 gene. The 2 year-old brother was homozygous,
whereas the healthy parents were heterozygous for this
mutation. No pathogenic mutation was detected in limb-
girdle muscular dystrophy panel.
Conclusions: We have identified a novel frameshift
mutation in WDR62 gene and to our knowledge, this is the
first case who had autosomal recessive primary micro-
cephaly with concomitant sarcoglycanopathy. Further
molecular studies for sarcoglycanopathies will allow us to
better understand the genetic etiology in this patient.
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Biallelic variants in PSMB1 encoding the proteasome
subunit b6 cause impairment of proteasome function,
microcephaly, intellectual disability, developmental
delay and short stature
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The molecular cause of the majority of rare autosomal
recessive disorders remains unknown. Consanguinity due to
extensive homozygosity unravels many recessive pheno-
types and facilitates the detection of novel gene-disease
links. Here, we report two siblings with phenotypic signs
including intellectual disability, developmental delay, and
microcephaly from a Pakistani consanguineous family in
which we have identified homozygosity for p(Tyr103His) in
the PSMB1 gene (Genbank NM_002793) that segregated
with the disease phenotype. PSMB1 encodes a β-type pro-
teasome subunit (i.e. β6). Modeling of the p(Tyr103His)
variant indicates that this variant presumably weakens the
interactions between PSMB1/β6 and PSMA5/α5 protea-
some subunits and thus destabilizes the 20S proteasome
complex. Biochemical experiments in human SHSY5Y
cells revealed that the p(Tyr103His) variant affects both the
processing of PSMB1/β6 and its incorporation into protea-
some, thus impairing proteasome activity. CRISPR/Cas9
mutagenesis or morpholino knock-down of the single
psmb1 zebrafish orthologue resulted in microcephaly,
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microphthalmia and reduced brain size. Genetic evidence in
the family and functional experiments in human cells and
zebrafish indicate that PSMB1/β6 pathogenic variants are
the cause of a recessive disease with intellectual disability,
microcephaly and developmental delay due to abnormal
proteasome assembly.
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Expanding the PTEN-associated phenotype: two
patients with de novo PTEN mutations and MPS-like
phenotype
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Hempel1
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Introduction: Heterozygote PTEN variants are associated
with different but overlapping diseases, such as PTEN
hamartoma tumor syndrome, Cowden syndrome,
Bannayan-Riley-Ruvalcaba syndrome and macrocephaly
autism syndrome. We report on two patients with de novo
PTEN mutations who presented with an MPS-like
phenotype.
Case reports: Patient 1: A 3-year-old boy, who is the first
child of healthy parents, was referred to hospital due to
developmental delay, macrocephaly, splenomegaly and
facial dysmorphism leading to suspicion of a metabolic
disease. Results after extended metabolic work up were
normal. The brain MRT revealed occipital white matter
anomalies and enlarged perivascular spaces. Trio whole
exome sequencing (WES) identified the de novo missense
variant c.80A>T [p.(Tyr27Phe)] in PTEN. Patient 2: A 4-
year-old girl, who is the second child of healthy parents,
was referred to hospital due to macrocephaly, mild motor
developmental delay and dysmorphic features resembling a
storage disorder. Extended metabolic work up was normal.
Brain MRT showed some enlarged perivascular spaces.
Trio WES detected a de novo missense mutation c.103A>G
[p.(Met35Val)] in PTEN.
Discussion: Both patients were initially referred to
hospital due to suspicion of a metabolic disease, most
likely MPS, which could not be verified. Instead, de novo
PTEN mutations were found. The phenotype does not
match the currently described PTEN-associated diseases.
This leads to the assumption that there might be an
additional PTEN-associated phenotype. Children who are
suspected of having a lysosomal storage disease that cannot
be confirmed should be considered for an extended genetic
analysis including PTEN.
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Introduction: The RBL2 locus has been associated with
intelligence but not with a monogenic disorder to date.
RBL2 encodes p130, a member of the retinoblastoma pro-
tein family. Previous studies on p130 knockout mice dis-
playing embryonic death and impaired neurogenesis
highlight the importance of RBL2 in brain development.
Material & Methods: We performed Exome sequencing
(ES) in two siblings with a neurodevelopmental disease and
their parents. Subsequent segregation analysis was done
with haplotype analysis by GSA-Array in all four (two
affected and two unaffected) siblings and their parents.
Results: The two siblings share a phenotype character-
ized by severe intellectual disability (no ability to stand/
walk, no expressive language), stereotypies, autoaggressive
behavior, dysmorphic features and supra- and infratentorial
atrophy in cMRI. ES identified compound-heterozygous
variants in RBL2 as the sole candidate (NM_005611.3) in
both patients: A heterozygous nonsense variant c.556C>T,
p.(Arg186Ter) and heterozygous in-frame deletion of exon
13-17. Subsequent haplotype analysis showed that the two
disease haplotypes segregate in the family.
Discussion: RBL2, that has not been linked to a
monogenic disorder yet, is the key regulator of maintaining
neuron survival among the Rb family members. The
hypothesis of RBL2 as a disease gene is underscored by
the gnomAD gene constraint metrics showing a depletion of
loss of function variants and p130 knockout mice exhibiting
impaired neurogenesis and embryonic lethality. Our data
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establish RBL2 as a candidate gene for an autosomal
recessive neurodevelopmental delay.
231 words
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Cell system with inducible transcription for the study of
CGG repeat instability
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Introduction: The molecular basis of certain hereditary
neurodegenerative diseases is trinucleotide repeat expan-
sion, which dramatically increases the number of triplet
repeats. However, the expansion mechanism has yet to be
defined. A failure of the DNA repair system at sites with
alternative DNA structures formed by repeats can lead to
expansion. This work aimed to design a cellular system for
studying the instability of CGG repeats involved in
FRAXopathy development during transcription and TCR-
NER.
Materials and Methods: CGG repeats were amplified by
PCR from GC-rich templates. We transfected HEK293A
cells with plasmids containing CGG repeats of different
lengths. Transfected cells were selected using flow cyto-
fluorometry or puromycin. Changes in CGG repeats were
evaluated by fragment analysis. Reporter gene expression
was measured by qPCR.
Results: To control transcription levels, DNA fragments
of CGG repeats and the EGFP ORF were inserted into
plasmids under the inducible promoter TRE. Additionally,
vectors encoded DsRedExpress or puromycin-N-
acetyltransferase driven by a constitutive promoter. Several
types of plasmids carrying CGG repeats of various lengths
were generated. HEK293A cells were transfected, and
transformants were selected. In the obtained cell lines,
plasmid integration sites, expression levels of fluorescent
proteins and changes in (CGG)n repeat length upon
induction of TRE were determined.
Conclusions: Cell lines with controlled transcription
across repeats were produced. This system allows tracking
changes in the repeat region. The obtained cell lines can be
used as a model to study the effect of transcription and
TCR-NER on repeat instability. The study is supported by
Russian Science Foundation Grant 18-15-00099.
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The advent of next generation sequencing (NGS) allowed
identifying a number of genes responsible of RTT and
associated phenotypes (RTT-like). However, the etiology of
the condition in a subset of RTT and RTT-like patients still
remains unknown. Using the Ion Torrent platform, we
developed a low-cost NGS gene panel and sequenced ca.
630 samples for early ID/ASD diagnosis. The gene panel
contains 74 ID and ASD related genes, including 18 known
and candidate genes associated with RTT-like disorders.
We identified de novo causative mutations or likely
pathogenic variants in 18 of the 90 (20%) sequenced indi-
viduals with RTT-like disorders. Among negative cases
with clinical features in the spectrum of Rett-like disorders,
we performed whole exome sequencing in 31 family trios,
1 singleton, and 2 multiplex families. Pathogenic or likely
pathogenic mutations were identified in 24 cases (70%).
Our findings bring additional supportive (SHANK3,
GRIN2A, SYNGAP1, KCNQ2, KCNB1, PDHA1, WAC
genes) or unsupportive (PTPN4) evidences for the impli-
cation of previously reported candidate genes in RTT-like
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disorders. Furthermore, we identified causative mutations in
novel candidate genes and genes associated with defined
syndromes, e.g. KAT6A, that have never been associated
with RTT-like phenotypes. Funding: Italian Ministry of
Health Young Investigator Grant GR-2011-02347754 to E.
L and S.C.E.T.; Fondazione Istituto di Ricerca Pediatrica -
Città della Speranza, Grant 18-04 to E.L.
E. Leonardi: None. M. Bellini: None. M.C. Aspro-
monte: None.M. Necci: None. E. Bettella: None. R. Polli:
None. S. Bigoni: None. S. Negrin: None. A. Danieli:
None. I. Mammi: None. F. Soli: None. S. D’Arrigo: None.
A. Simonati: None. L. Turolla: None. R. Vittorini: None.
S. Sartori: None. S.C.E. Tosatto: None. A.
Murgia: None.
P08.100.A
The adult phenotype of Schaaf-Yang syndrome
F. Marbach1, M. Elgizouli2,3, M. Rech4, J. Beygo3, F.
Erger5, C. Velmans5, C. T. R. M. Stumpel6, A. P. A.
Stegmann6, S. Beck-Wödl7, G. Gillessen-Kaesbach8, B.
Horsthemke3, C. P. Schaaf1,4, A. Kuechler3
1Institute of Human Genetics, Heidelberg University,
Heidelberg, Germany, 2Institute of Medical Genetics,
University of Zurich, Zurich, Switzerland, 3Institute of
Human Genetics, University Duisburg-Essen, Essen, Ger-
many, 4Department of Molecular and Human Genetics,
Baylor College of Medicine, Houston, TX, United States,
5Faculty of Medicine, University of Cologne; Institute of
Human Genetics, University Hospital Cologne, Cologne,
Germany, 6Department of Clinical Genetics and GROW-
School for Oncology and Developmental Biology, Maas-
tricht University Medical Center, Maastricht, Netherlands,
7Institute of Medical Genetics and Applied Genomics,
University of Tübingen, Tübingen, Germany, 8Institute of
Human Genetics, University of Lübeck, Lübeck, Germany
Introduction: MAGEL2-associated Schaaf-Yang-Syn-
drome/SHFYNG is a rare genetic disorder, which was
identified in 2013. The phenotype of SHFYNG in child-
hood partially overlaps with that of the well-established
Prader-Willi-Syndrome/PWS. While several studies of
younger individuals with SHFYNG have been recently
published, the phenotype in adulthood is not well estab-
lished. We recruited 7 adults (aged 18-36) with molecularly
confirmed SHFYNG and collected data regarding eating
habits, sleep, behavior, autonomy, psychiatric, and medical
conditions, as well as information about the respective
phenotypes in childhood.
Methods: Participating individuals with SHFYNG and
their families received a questionnaire covering the
aforementioned areas. The legal guardians of all participants
provided signed consent under the IRB-approved human
research protocol H-34578, Baylor College of Medicine.
Results: We identified common symptoms within our
cohort, such as disturbed sleep, hypoactivity, social with-
drawal, and anxiety, but noted considerable differences at
the level of personal autonomy and skills. Behavioral
problems were frequent, and a majority of individuals
displayed weight gain, food-seeking behavior, and mild
intellectual disability or borderline intellectual function.
Typical symptoms of SHFYNG in childhood were reported
for most individuals.
Conclusions: Our findings indicate a high variability of
functional abilities and social participation of adults with
SHFYNG. The prevalence of obesity was high, and lack of
satiety was of concern for some caregivers. The phenotypes
of PWS and SHFYNG might be more difficult to
distinguish in adults than in children. Molecular genetic
testing for SHFYNG should be considered in adults with the
suspected diagnosis of PWS, if testing for PWS has been
negative.
F. Marbach: None. M. Elgizouli: None. M. Rech:
None. J. Beygo: None. F. Erger: None. C. Velmans:
None. C.T.R.M. Stumpel: None. A.P.A. Stegmann: None.
S. Beck-Wödl: None. G. Gillessen-Kaesbach: None. B.
Horsthemke: None. C.P. Schaaf: None. A.
Kuechler: None.
P08.102.C
SETD5 gene haploinsufficiency in three patients with
suspected KBG syndrome
M. Crippa1,2, I. Bestetti1,2, S. Maitz3, K. Weiss4, A. Spano3,
S. Smithson5, L. Larizza1, L. Cohen6, K. Low5, P. Finelli1,2
1IRCCS Istituto Auxologico Italiano, Cusano Milanino,
Italy, 2Department of Medical Biotechnology and Transla-
tional Medicine, University of Milan, Milan, Italy, 3Clinical
Pediatric Genetic Unit, Pediatric Clinic, Fondazione
MBBM, San Gerardo Hospital, Monza, Italy, 4The Genetics
Institute, Rambam Health Care Campus, Haifa, Israel,
5Clinical Genetics, St. Michael’s Hospital, University
Hospitals NHS Trust, Bristol, United Kingdom, 6Raphael
Recanati Genetic Institute, Schneider Children’s Medical
Center of Israel, Petah Tiqva, Israel
Mendelian disorders of the epigenetic machinery
(MDEMs), also called chromatin modifying disorders, are a
broad group of neurodevelopmental disorders, caused by
mutations in functionally related chromatin genes. KBG and
the mental retardation autosomal dominant 23 (MRD23)
syndromes, caused by ANKRD11 and SETD5 gene muta-
tions respectively, belong to this broad group of disorders.
We performed high resolution array CGH and trio-based
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WES on three molecularly unsolved patients with an initial
KBGS diagnosis, found to carry SETD5 gene hap-
loinsufficiency. A de novo deletion of 116 kb partially
involving SETD5 and two de novo frameshift variants in
SETD5 were identified in the patients. The clinical re-
evaluation of the patients was consistent with the molecular
findings, however still compatible with KBGS. Phenotypic
features of KBGS and MRD23 overlap to some extent, but
the presence of facial features not fully consistent with
KBGS can suggest differential diagnosis. Our results pro-
vide further examples that loss-of-function pathogenic var-
iants in genes encoding factors shaping the epigenetic
landscape lead to a wide phenotypic range with significant
clinical overlap. To conclude we recommend clinicians to
consider SETD5 gene haploinsufficiency in the differential
diagnosis of KBGS, enhancing deep phenotyping and
genotyping of KBGS overlapping conditions.
M. Crippa: None. I. Bestetti: None. S. Maitz: None. K.
Weiss: None. A. Spano: None. S. Smithson: None. L.
Larizza: None. L. Cohen: None. K. Low: None. P.
Finelli: None.
P08.104.B
Expression of circadian rhythm genes in patients with
neurodevelopmental syndromes displaying sleep
disturbance
A. Sironi1,2, I. Bestetti1,2, S. Cipri1,2, M. Bonati3, S.
D’Arrigo4, D. Milani5, A. Selicorni6, L. Spaccini7, M.
Bedeschi8, L. Larizza2, P. Finelli1,2
1Department of Medical Biotechnology and Translational
Medicine, University of Milan, Milan, Italy, 2Lab. of
Medical Cytogenetics and Molecular Genetics, IRCCS
Istituto Auxologico Italiano, Cusano Milanino, Milan, Italy,
3Clinic of Medical Genetics, San Luca Hospital, IRCCS
Istituto Auxologico Italiano, Milan, Italy, Milan, Italy,
4Developmental Neurology Division, IRCCS Fondazione
Istituto Neurologico C. Besta, Milan, Italy, Milan, Italy,
5Medical Genetic Unit, Pediatric Highly Intensive Care,
Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, Milan, Italy, Milan, Italy, 6Pediatric Unit,
ASST Lariana, Como, Italy, Como, Italy, 7Clinical Genetics
Unit, Department of Obstetrics and Gynecology, V. Buzzi
Children’s Hospital, University of Milan, Milan, Italy,
Milan, Italy, 8Medical Genetic Unit, IRCCS Ca’Granda
Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy
Patients with neurodevelopmental disorders (NDDs) show a
higher rate of sleep disturbances as compared to the general
population. Sleep anomalies are a heterogeneous set of
problems, including difficulties with initiating or maintain-
ing sleep, excessive daytime sleepiness, and parasomnias.
The relationship between abnormal sleep patterns and
NDDs is complex and potentially synergistic. Indeed, sleep
anomalies exacerbate an already compromised neurobeha-
vioral phenotype. Smith-Magenis Syndrome (SMS)
[MIM:182290], caused by haploinsufficiency of RAI1 gene,
is a NDD characterized by sleep disturbances, which in 95%
of the patients results from disruption of circadian rhythm
with an inverted melatonin secretion. Based on the assessed
role of RAI1 in the regulation of circadian rhythm, we
evaluated through RT-qPCR the expression of circadian
genes in peripheral blood of 18 clinically suspected SMS/
SMS-like patients, three with confirmed RAI1 mutation,
manifesting sleep disturbance except three. Out of the 6
tested genes CLOCK, BMAL2, PER2, and NR1D1 were
found deregulated in at least one patient with sleep pro-
blems: gene expression alterations were observed in 9 out
15 patients, whereas no dysregulation was identified in the 3
patients without sleep disturbance. Our data confirms a few
studies suggesting a correlation between sleep disturbance
in patients with molecularly defined syndromes and
expands the correlation to patients with sleep disturbance
who are molecularly unsolved. Our pivotal study needs to
be validated on a larger cohort of patients and by testing
also the melatonin receptor genes which due to their lack of
expression in blood, need alternative tissues, such as
buccal smears
A. Sironi: None. I. Bestetti: None. S. Cipri: None. M.
Bonati: None. S. D’Arrigo: None. D. Milani: None. A.
Selicorni: None. L. Spaccini: None. M. Bedeschi: None.
L. Larizza: None. P. Finelli: None.
P08.105.C
Variants inSLITRK2in individuals with neurodevelop-
mental manifestations including intellectual disability,
behavioral troubles and possible dystonia
S. EL CHEHADEH1,2, S. Bakhtiari3,4, J. Wynn5, W. K.
Chung5,6, G. Vitiello7, I. Cutcutache8, M. Page8, J.
Gecz9,10,11, K. Harper12,11, A. de Brouwer13, A. Vulto-van
Silfhout13, M. Willems14, A. Fernández Jaén15, A.
Selicorni16, S. Maitz17, E. K. Vanhoutte18, M. Armstrong19,
J. Symonds20, J. Muller21,22, M. Kruer3,4, A. Piton23,24
1Service de génétique médicale, Institut de Génétique
Médicale d’Alsace (IGMA), Centre de Référence des
Déficiences Intellectuelles de Causes Rares, STRAS-
BOURG, France, 2Laboratoire de Génétique Médicale,
INSERM U1112, Institut de Génétique Médicale d’Alsace
(IGMA), Université de Strasbourg, Strasbourg, France,
3Pediatric Movement Disorders Program, Division of
Pediatric Neurology, Barrow Neurological Institute, Phoe-
nix Children’s Hospital, Phoenix, AZ, United States,
4Departments of Child Health, Neurology, Cellular &
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Molecular Medicine and Program in Genetics, University
of Arizona College of Medicine, Phoenix, AZ, United States,
5Departments of Pediatrics and Medicine, Columbia
University Medical Center, New York, NY, United States,
6Department of Medicine, Columbia University, New York,
NY, United States, 7Department of Translational Medicine,
Federico II University, Naples, Italy, 8Translational
Medicine, UCB Pharma, Slough, United Kingdom, 9Ade-
laide Medical School, Faculty of Health and Medical
Sciences, The University of Adelaide, Adelaide, Australia,
10Robinson Research Institute, The University of Adelaide,
Adelaide, Australia, 11Women and Kids, South Australian
Health and Medical Research Institute, Adelaide, Australia,
12Robinson Research Institute, The University of Adelaide,,
Adelaide, Australia, 13Department of Human Genetics,
Radboud University Medical Center, Nijmegen, Nether-
lands, 14Service de Génétique Médicale, CHU de Mon-
tpellier, Montpellier, France, 15Department of Pediatrics
Neurology, Quirón Hospitals, Madrid, Spain, 16Department
of Pediatrics, ASST Lariana Sant’Anna Hospital, San
Fermo della Battaglia, Como, Italy, 17Fondazione MBBM,
Monza, Italy, 18Department of Clinical Genetics, Maas-
tricht University Medical Centre, Maastricht, Netherlands,
19Translational Medicine, UCB Pharma, Braine-l’Alleud,
Belgium, 20Paediatric Neurosciences Research Group,
Royal Hospital for Children, Queen Elizabeth University
Hospitals, Glasgow, United Kingdom, 21Laboratoire de
Génétique Médicale, INSERM U1112, Institut de Génétique
Médicale d’Alsace (IGMA), Université de Strasbourg,
STRASBOURG, France, 22Laboratoires de Diagnostic
Génétique, Institut de Génétique Médicale d’Alsace
(IGMA), Hôpitaux Universitaires de Strasbourg, Nouvel
Hôpital Civil, Strasbourg, France, 23Laboratoires de
Diagnostic Génétique, Institut de Génétique Médicale
d’Alsace (IGMA), Hôpitaux Universitaires de Strasbourg,
Nouvel Hôpital Civil, STRASBOURG, France, 24INSERM
U964, Institut de Génétique et de Biologie Moléculaire et
Cellulaire, Illkirch-Graffenstaden, France
SLITRK2 is a member of the transmembrane SLITKR
protein family, known to regulate neurite outgrowth and to
interact with proteins involved in synapse architecture such
as SHANK3. Two missense variants have been reported in
SLITRK2, located on the X chromosome, in patients with
schizophrenia (Piton et al., 2011). Through a collaborative
study, we report on seven individuals (1 female and 6
males, including two siblings) carrying rare variants in
SLITRK2 identified by WES. These variants include one
nonsense (p.Glu461*), and five missenses changes (p.
Thr312Ala, p.Arg426Cys, p.Val511Met, p.Pro691Ser and
p.Val201Ile), that were never reported at the hemizygous
state in gnomAD populations. Three variants were de novo
and three were maternally inherited. All patients had mod-
erate to severe intellectual disability and speech delay,
mostly severe. Neurological regression was observed in one
patient after six years-old. Patients present behavioral issues
(anxiety, aggressiveness or autism spectrum disorder) (5/6),
spasticity and/or dystonia (4/7), unsteady gait (4/7), seizures
(3/6), short stature (4/7), cyphoscoliosis (3/5), and variable
nonspecific facial features. Nonspecific brain MRI anoma-
lies (3/6) included white matter reduction, ventricles dila-
tion and thin corpus callosum. Based on these observations
and the role of SLITRK2 in synapse development and
organization, we believe that these variants contribute to the
neurodevelopmental phenotype of our patients. We aim to
gather more patients with pathogenic SLITRK2 variants and
to continue with functional studies, to confirm the impli-
cation of this gene in neurodevelopmental disorder and to
better delineate the clinical manifestations associated to
mutations in this gene, especially at the behavioral level.
S. El chehadeh: None. S. Bakhtiari: None. J. Wynn:
None. W.K. Chung: None. G. Vitiello: None. I.
Cutcutache: None. M. Page: None. J. Gecz: None. K.
Harper: None. A. de Brouwer: None. A. Vulto-van
Silfhout: None. M. Willems: None. A. Fernández Jaén:
None. A. Selicorni: None. S. Maitz: None. E.K.
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P08.106.A
Do SMARCC2 truncating and splicing variants cause
intellectual disability and developmental delay?
Ö. Baysal, R. Pfundt, C. L. M. Marcelis
Department of Human Genetics, Radboud University
Medical Center, Nijmegen, Netherlands
BAFopathies are a heterogeneous group of disorders caused
by variants in genes encoding the various subunits of the
chromatin-remodelling complex BRG1-associated factor
(BAF). De novo variants in SMARCC2, one of core sub-
units of the BAF complex, have been described as a cause
of intellectual disability (ID) in 2019. Missense and splice
variants affecting the highly conserved SMARCC2 DNA-
interacting domains (SANT and SWIRM) present with a
more severe phenotype overlapping with the phenotype of
other BAfopathies, like Coffin-Siris and Baraitser-Winter
syndrome. Truncating and splice variants affecting other
regions show a much milder phenotype. According to data
from the gnomAD database the SMARCC2 gene is highly
intolerant to loss-of-function variants (pLI-score=1), sup-
porting pathogenicity of this type of variants. However, we
have now identified four unrelated patients harbouring
predicted loss of function variants in SMARCC2 that are
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inherited from healthy (grand)parents. Whole exome
sequencing was performed on these patients because of
developmental delay (DD)/ID. Two unrelated patients have
the same frameshift variant (c.3129del, p.Gly1044fs),
inherited from their healthy father. The brother of one of
these patients, who had a similar DD, did not have this
variant. A third patient (c.574C>T (p.(Arg192*)) inherited a
nonsense variant from his unaffected father and grandfather.
The fourth patient has a predicted splice donor variant
(c.317+2T>A (r.spl.?)) inherited from her healthy mother.
The presence of these truncating variants in healthy indi-
viduals in four different families seems to contradict the
suspected pathogenicity of this type of SMARCC2 variants.
We’ll discuss the possible relation between truncating
SMARCC2 variants and ID.
Ö. Baysal: None. R. Pfundt: None. C.L.M.
Marcelis: None.
P08.107.B
SPOP: One Gene, Two Distinct Neurodevelopmental
Phenotypes
M. J. Nabais Sá1, G. El Tekle2,3,4, A. P. M. de Brouwer1, S.
L. Sawyer5, D. del Gaudio6, M. J. Parker7, F. Kanani7, M.
H. van den Boogaard8, K. van Gassen8, M. I. Van Allen9, K.
Wierenga10, G. Purcarin10, E. Roy Elias11, K. W. Gripp12,
R. Procopio12, C. Mignot13, E. Argilli14, E. Sherr14, G.
Cappuccio15,16, N. Brunetti-Pierri15,16, A. Begtrup17, J.
Keller-Ramey17, E. Ryan17, T. Bernasocchi2,3,4, L. van de
Wiel18,19, H. Venselaar18, C. Gilissen19, R. Pfundt1, L. E. L.
M. Vissers1, J. P. Theurillat2,3, B. B. A. de Vries1
1Radboudumc/Donders Institute for Brain, Cognition and
Behaviour, Nijmegen, Netherlands, 2Functional Cancer
Genomics, Institute of Oncology Research, Oncology
Institute of Southern Switzerland, Bellinzona, Switzerland,
3Faculty of Biomedical Science, Università della Svizzera
Italiana, Lugano, Switzerland, 4University of Lausanne,
Lausanne, Switzerland, 5Department of Genetics, Chil-
dren’s Hospital of Eastern Ontario and Children’s Hospital
of Eastern Ontario Research Institute, University of
Ottawa, Ottawa, ON, Canada, 6Department of Human
Genetics, University of Chicago Genetic Services Labora-
tory, The University of Chicago, Chicago, IL, United States,
7Department of Clinical Genetics, Sheffield Children’s NHS
Foundation Trust, Sheffield, United Kingdom, 8Department
of Genetics, UMC Utrecht, Utrecht, Netherlands, 9Depart-
ment of Medical Genetics, University of British Columbia,
Vancouver, BC, Canada, 10University of Oklahoma Health
Sciences Center, Oklahoma City, OK, United States, 11Spe-
cial Care Clinic, Children’s Hospital Colorado, and
University of Colorado School of Medicine, Aurora, CO,
United States, 12Division of Medical Genetics, Department
of Pediatrics, A.I. duPont Hospital for Children/Nemours,
Wilmington, DE, United States, 13Assistance Publique-
Hôpitaux de Paris, Département de Génétique and Centre
de Référence Déficiences Intellectuelles de Causes Rares,
Groupe Hospitalier Pitié-Salpêtrière, Paris, France,
14Departments of Neurology and Pediatrics, Weill Institute
of Neuroscience and Institute of Human Genetics, Uni-
versity of California, San Francisco, CA, United States,
15Telethon Institute of Genetics and Medicine, Pozzuoli,
Italy, 16Department of Translational Medicine, Federico II
University, Naples, Italy, 17GeneDx, Gaithersburg, MD,
United States, 18Center for Molecular and Biomolecular
Informatics, Radboud Institute for Molecular Life Sciences
(RIMLS), Radboudumc, Nijmegen, Netherlands, 19Depart-
ment of Human Genetics, RIMLS, Radboudumc, Nijmegen,
Netherlands
Pathogenic variants in an increasing number of genes are
associated with cancer, if somatic, and with neurodevelop-
mental disorders, if in the germline. SPOP (MIM: 602650)
is recurrently somatically mutated in endometrial cancer and
prostate cancer, resulting in gain-of-function and dominant-
negative effects, respectively, towards ubiquitin ligase
substrates, such as BRD2, BRD3 and BRD4 proteins
(BETs). Using clinical exome sequencing, we identified
eleven patients with nine different germline de novo mis-
sense SPOP variants, including two recurrent variants.
These patients presented with developmental delay/intel-
lectual disability, facial dysmorphisms and congenital
anomalies. Interestingly, three individuals shared craniofa-
cial dysmorphisms, including microcephaly, which were
strikingly different from those observed in the other indi-
viduals, which included (relative) macrocephaly and
hypertelorism. Based on these findings, we hypothesized
that two distinct molecular pathophysiological mechanisms
underlie the phenotypic differences, similarly to the
observed effect of somatic SPOP variants in cancer. Indeed,
measurement of BETs levels in human Ishikawa endo-
metrial cancer cells and patient-derived cell lines showed
that de novo variants identified in the microcephalic indi-
viduals result in a gain-of-function, while the other variants
lead to a dominant-negative effect. These results suggest
that divergent functional effects on BETs are related to
distinct and clinically recognizable syndromic forms of
intellectual disability with contrasting craniofacial
dysmorphisms.
M.J. Nabais Sá: None. G. El Tekle: None. A.P.M. de
Brouwer: None. S.L. Sawyer: None. D. del Gaudio:
None. M.J. Parker: None. F. Kanani: None. M.H. van
den Boogaard: None. K. van Gassen: None. M.I. Van
Allen: None. K. Wierenga: None. G. Purcarin: None. E.
Roy Elias: None. K.W. Gripp: None. R. Procopio: None.
C. Mignot: None. E. Argilli: None. E. Sherr: None. G.
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P08.108.C
A new patient with a de novo SSR4 variant revealed
using exome sequencing contributes to the definition of
phenotype and genotype of the congenital disorder of
glycosylation type Iy
M. Hančárová1, M. Vlčková1, Š. Bendová1, D. Prchalová1,
V. Stránecký2, Z. Sedláček1
1Department Of Biology And Medical Genetics, 2nd
Faculty of Medicine, Charles University, Prague, Czech
Republic, 2Department of Pediatrics and Adolescent
Medicine, Diagnostic and Research Unit for Rare Diseases,
Charles University 1st Faculty of Medicine and General
University Hospital, Prague, Czech Republic
Congenital disorders of glycosylation (CDG) are char-
acterized by deficiency in processing of glycans. CDG type
Iy (MIM300934) is a rare X-linked disorder caused by loss-
of-function variants in SSR4 encoding signal sequence
receptor 4. CDG Iy is associated with developmental delay
(DD), intellectual disability (ID), hypotonia, microcephaly,
facial dysmorphism, failure to thrive and epilepsy. Carrier
females are only mildly affected. SSR4 was linked with
CDG Iy in 2014, and since then only 10 patients with
sufficient genotype and phenotype details have been
reported. We describe a 5-year-old boy with hypotonia,
feeding problems, failure to thrive, DD, speech delay,
microcephaly, abnormal EEG, history of seizures and facial
dysmorphism (low-set dysplastic ears, preauricular pit,
enophthalmos, broad nasal bridge, telecanthus, midface
hypoplasia, long smooth philtrum and thin upper lip ver-
milion). Exome sequencing (ES) revealed a de novo
hemizygous frameshift SSR4 variant NM_006280.3:
c.200_2001delA, p.Y67Cfs*2 which was absent from all
databases. Our patient confirms that males with CDG due to
SSR4 variants show consistent phenotype with DD/ID,
hypotonia, microcephaly, facial dysmorphism, feeding
problems, failure to thrive and gastrointestinal and eye
abnormalities. Seizures have been reported in 6/10 previous
patients, and our patient supports their involvement in the
syndrome. On the contrary, skeletal, coagulation, cardiac
and renal abnormalities mentioned among minor features
were absent in our patient. A similar clinical picture is seen
in many CDG types, and changes in serum transferrin levels
in CDG Iy patients are easily overlooked. Therefore ES is
indispensable in the deciphering of this rare disorder. Sup-
ported by 17-29423A, LM2018132 and 00064203.
M. Hančárová: None. M. Vlčková: None. Š. Bendová:
None. D. Prchalová: None. V. Stránecký: None. Z.
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A novel SUZ12 nonsense mutation in patient with mild
Cornelia de Lange-syndrome
B. Hanker1, Y. Hellenbroich1, M. Wagner2, F. J. Kaiser3, I.
Hüning1
1Institut für Humangenetik, Universität zu Lübeck, Lübeck,
Germany, 2Institute of Human Genetics, Technical Uni-
versity Munich, Munich, Germany, 3Institut für Humangen-
etik, Universitätsklinikum Essen, Essen, Germany
Polycomb-group proteins (PcGs) are evolutionarily con-
served and are best known for their role in gene silencing.
SUZ12 codes for the polycomb repressive complex 2 sub-
unit protein. Variants in genes encoding other components
of PRC2 (EZH2 and EED) have been reported as causative
for Weaver syndrome and Cohen-Gibson syndrome. In
2017, Imagawa et al. reported first of a patient with
Weaver-like syndrome due to a mutation in SUZ12.
We report on an eight year old girl, born at term after
uneventful pregnancy with body measurements within
normal range. Postnatally a VSD and a persistent left vena
cava were detected. Our patient has mild intellectual
disability and facial features including synophrys, hyperte-
lorism, long and deep seated ears. She showed no
overgrowth, had mild hearing impairment and
hypermetropia.
In suspicion of mild Cornelia de Lange-syndrome
sequencing analysis of known CdLS genes on DNA
isolated from blood or fibroblast were conducted but could
not identify a causative variant. Karyotyping was normal
and array-CGH showed a paternally inherited microdupli-
cation 16p11.2. Subsequent trio-exome sequencing revealed
a de novo heterozygous nonsense variant in SUZ12
(NM_015355.2: c.1657C>T, p.Gln553Ter).
Systematic review of the literature showed only 13
patients with pathogenic variants in SUZ12 reported so far.
Nine of them had overgrowth. Missense variants appear to
be stronger associated with overgrowth rather than nonsense
variants (Cyrus et al., 2020). Facial features suggestive for
CdLS were not reported. Our findings expand the
phenotypical spectrum of variants in SUZ12 and link the
spectrum of CdLS-like phenotypes with another chromatin
associated complex.
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P08.110.B
Mild clinical features aid in the interpretation of
syndromic gene variants in apparent non-syndromic
intellectual disability patients
H. Syryn, O. Vanakker
Center for Medical Genetics, Ghent University Hospital,
Gent, Belgium
Introduction: Before the common use of whole exome
sequencing (WES) in routine diagnostics, hereditary syn-
dromes were defined by distinct clinical features. However,
with the increasing use of WES-based diagnostics, in par-
ticular for indications with large numbers of causal genes
such as intellectual disability (ID), very mild or atypical
phenotypic presentations of known syndromic causes can
be observed.
Methods: We present several patients with thorough
clinical description, presenting with ID in whom no
syndromic diagnosis was made prior to testing. A confirmed
molecular diagnosis via whole exome sequencing of a
targeted panel of ID genes was made with (likely)
pathogenic variants in genes such as WAC, CHD8, TBR1,
and SOX5. We compare their phenotype to what has been
traditionally reported in the syndromes associated with
these genes and delineate mild key features useful for
evaluating causality of the sequencing results.
Results: A first patient with a WAC mutation presents
with a duplicated ureter and aggressive behavior. In patients
with CHD8-related ID, early bone maturation is seen.
Furthermore, pathogenic variants in TBR1 can lead to
exclusively developmental delay and absent speech.
Finally, lower limbs abnormalities such as seen in Lamb-
Shaffer syndrome (SOX5) contribute to determining the
diagnosis.
Conclusions: We define several mild but characteristic
features in patients having a variant in syndromic genes,
even if an overt syndromic diagnosis in them was not clear.
Taking into account these mild symptoms in patients with
apparent non-syndromic ID is an important help in
interpreting sequencing results, particularly in case of
variants of unknown significance.
H. Syryn: None. O. Vanakker: None.
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Combined comprehensive approach in patients within
Rett/Angelman phenotypic spectrum
A. Alexandrou1, A. Theodosiou1,2, I. Papaevripidou1, A.
Chrysanthou1,2, N. Salameh1, P. Evangelidou1,2, V.
Christophidou-Anastasiadou3, G. A. Tanteles4,2, C.
Sismani1,2
1Cytogenetics and Genomics Department, The Cyprus
Institute of Neurology and Genetics, Nicosia, Cyprus,
2The Cyprus School of Molecular Medicine, The Cyprus
Institute of Neurology and Genetics, Nicosia, Cyprus,
3Clinical Genetics Department, Archbishop Makarios III
Medical Centre, Nicosia, Cyprus, 4Clinical Genetics
Department, The Cyprus Institute of Neurology and
Genetics, Nicosia, Cyprus
Angelman and Rett syndromes are rare neurodevelopmental
disorders sharing a range of phenotypic characteristics
between them but also with many disorders, making accu-
rate diagnosis challenging.
Here, we present a targeted custom NGS panel (Agilent-
SureDesign), developed for patients in the Rett/Angelman
phenotypic spectrum. The panel includes coding regions
and splice site junctions of 25 genes, causing disorders with
overlapping clinical phenotypes such as Pitt-Hopkins and
Mowat Wilson. Bioinformatics analysis was performed for
detecting SNVs, indels and CNVs using Surecall (Agilent)
along with in-house established pipelines. The panel design
proved successful with a mean target depth of 550X and
mean uniformity of 99%.
Upon validation, 74 patients were referred for testing.
Thirty patients had classic Rett or Angemann Syndrome
features and were tested by Sanger sequencing and MLPA/
MS-MLPA analyses for MECP2 or UBE3A as a first tier
test. Six were found positive for deletions or point
mutations (one of which mosaic) and were included in the
panel only as blind positive samples. All positive blind
samples were successfully identified.
Out of the 68 undiagnosed patients that were analysed
with the panel, 9 (6 novel) were found to have de novo
pathogenic variants in UBE3A, EHMT1, CTNNB1, IQSEC2,
EHMT1, WDR45 and SCN1A genes and were confirmed
with Sanger sequencing. Additional 11 patients were found
to have a VOUS, yielding a total detection rate of at
least 13%.
This custom designed panel will improve clinical
detection rate and provide a comprehensive accurate testing
for individuals suggestive of a disorder in Rett/Angelman
spectrum.
A. Alexandrou: None. A. Theodosiou: None. I.
Papaevripidou: None. A. Chrysanthou: None. N. Sala-
meh: None. P. Evangelidou: None. V. Christophidou-
Anastasiadou: None. G.A. Tanteles: None. C.
Sismani: None.
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P08.112.A
Neurodevelopmental and neurologic spectrum in
TECPR2-associated congenital disorder of autophagy
S. Neuser1, I. Brösse2, L. O’Grady3, D. A. Sweetser3, S.
Schubert1, R. Jamra1, B. Popp1
1Institute of Human Genetics, University of Leipzig Medical
Center, Leipzig, Germany, 2Department of Pediatrics
Hospital for Children and Adolescents, Heidelberg Uni-
versity Hospital, Heidelberg, Germany, 3Department of
Medical Genetics and Metabolism, Massachusetts General
Hospital, Boston, MA, United States
Autophagosomes are subcellular compartments necessary to
degrade cytoplasmic content. Macro-autophagy is vital for
long-lived, non-regenerating and metabolically active neu-
rons. In 2012 a truncating founder variant in the autophagy-
related gene TECPR2 was identified in three Bukharian
Jewish families. The five affected individuals were homo-
zygous and showed spastic paraplegia complicated by
syndromic intellectual disability. Subsequent reports of five
unrelated individuals with this or novel truncating/missense
variants confirmed autonomic involvement as a leading
feature of spastic paraplegia 49 (SPG49).By trio-based
exome sequencing we now identified the homozygous fra-
meshifting TECPR2-variant c.2829del, p.(Asn944Thrfs*7)
in male individual of Turkish descent with neurodevelop-
mental disorder (NDD) and epilepsy. RT-PCR on PAXgene
stabilized blood showed normal expression of the c.2829del
allele in the heterozygous parents and gel electrophoresis
indicated no expression reduction in the index. Together
these results suggest escape from nonsense-mediated decay.
Through matchmaking we identified one additional unre-
lated individual with NDDs due to homozygosity for the
known Ashkenazi TECPR2-variant (c.1319del, p.
(Leu440Argfs*19)). Based on these cases and comparison
with the 10 literature cases, we now provide a Human
Phenotype Ontology (HPO) standardized clinical synopsis.
The neurologic spectrum comprises muscular hypotonia
with progression to spastic paraplegia in the first decade,
abnormal reflexes and autonomic involvement. The variable
neurodevelopmental disorder present in 11/12 cases can be
complicated by structural brain abnormalities (7/8 cases
with brain MRI) and seizures (3/12). Because NDD is a
central feature in addition to the neurologic presentation, we
propose to classify this disease as TECPR2-associated
congenital disorder of autophagy.
S. Neuser: None. I. Brösse: None. L. O’Grady: None.
D.A. Sweetser: None. S. Schubert: None. R. Jamra:
None. B. Popp: None.
P08.113.B
Thauvin-Robinet-Faivre Syndrome: Report of a new
patient
A. Sezer1, A. Savaş1, G. Kayhan1, A. T. Aslan2, E. F.
Perçin1
1Gazi University, Faculty of Medicine, Department of
Medical Genetics, Ankara, Turkey, 2Gazi University
Faculty of Medicine, Department of Pediatrics, Division
of Pediatric Pulmonology, Ankara, Turkey
Introduction: Biallelic mutations in the acidic fibroblast
growth factor intracellular-binding protein gene (FIBP)
cause Thauvin-Robinet-Faivre syndrome (OMIM #617107,
TROFAS), which is characterized by overgrowth. To date,
only four different patients have been reported from two
unrelated families.
Patient and Methods: Whole-exome sequencing (WES)
analysis was performed in a 4-year-old male patient with
tall stature, macrosomia, macrocephaly, dysmorphic facial
features, recurrent pulmonary infections, cryptorchidism,
spontaneous erection, elbow joints laxity, prominent super-
ficial blood vessels, developmental delay and speech delay.
He had consanguineous parents.
Result: A homozygous frameshift variant
c.415_416insCAGTTTG (Asp139AlafsTer3) in FIBP gene
(NM_004214.5) was detected and classified as pathogenic
variant. Additionally, in the Toll-Like receptor 5 gene
(TLR5) (NM_003268.6), c.974A>G (p.Asn325Ser) homo-
zygous missense variant was detected and was classified as
uncertain significance.
Conclusions: Two variants in FIBP gene previously
detected in patients with TROFAS have a loss-of-function
effect putatively similar to the variant in our patient which
caused putatively a premature protein. The patient had a
history of recurrent pulmonary infections, cryptorchidism
and spontaneous erection, unlike reported patients. It is not
known whether our patient’s history of recurrent pulmonary
infections is a component of TROFAS because of
the limited number of patient reports. Primary immunode-
ficiencies and polymorphisms in TLRs are associated with
susceptibility to infections in humans and animal models
and also TLR5 has protective effects against bacterial
infections. Owing to the limited number of reported patients
with TROFAS, new patient reports and further studies are
needed to clarify the clinical properties of the disease.
A. Sezer: None. A. Savaş: None. G. Kayhan: None. A.
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P08.115.A
A new case of Kaufman Oculocerebrofacial Syndrome
caused by two new splicing variants in UBE3B.
366 J. del Picchia
K. Uguen1,2,3, C. Ka1,3, M. Planes1,2, S. Audebert-
Bellanger1,2, S. Redon1,2,3, C. Benech1,3, S. Küry4,5, S.
Peudenier2, S. Autret1,3, I. Gourlaouen3, D. Bonneau6, S.
Odent7, S. Bézieau4,5, B. Gilbert-Dussardier8, A. Boland9, J.
Deleuze9, C. Le Maréchal1,2,3, G. Le Gac1,3, C. Ferec1,2,3
1Service de Génétique Médicale et Biologie de la
Reproduction, CHRU de Brest, Brest, France, 2Centre de
Référence Déficiences Intellectuelles de causes rares, Brest,
France, 3Univ Brest, Inserm, EFS, UMR 1078, GGB, F-
29200, Brest, France, 4CHU de Nantes, Service de
Génétique Médicale, 9 quai Moncousu, 44093 Nantes
CEDEX 1, Nantes, France, 5Université de Nantes, CNRS,
INSERM, l’institut du thorax, F-44000, Nantes, France,
6Département de biochimie et génétique, CHU d’Angers,
Angers, France, 7Service de Génétique Clinique, CHU de
Rennes, UMR6290 CNRS, Université Rennes, Rennes,
France, 8Service de Génétique, CHU de Poitiers, Poitiers,
France, 9Centre National de Recherche en Génomique
Humaine (CNRGH), CEA, Evry, France
Introduction: UBE3B encodes a member of the E3
ubiquitin-conjugating enzyme family. Biallelic variants
(missense, nonsense, splicing) are responsible of the
Kaufman Oculocerebral Syndrome (KOS), characterized by
severe intellectual disability, distinctive facial features,
short stature and multiple congenital abnormalities. Here we
report a patient presenting with KOS and harboring two
undescribed splicing variants in UBE3B. We describe new
clinical features and in vitro characterization of the two
variants.
Case presentation: The propositus is an 18-year-old boy
presenting with intellectual disability, microphtalmia,
bilateral deafness, tetralogy of Fallot, scoliosis, hip
malformation and facial dysmorphism consistent with
KOS. Other clinical features not described in KOS include
anal imperforation and cryptorchidism.
Results: Through a French collaborative study (HUGO-
DIMS), trio-based whole exome sequencing identified two
variants in UBE3B : c.1956+3G>C and c.1622+1G>C,
each one inherited from a healthy parent. None of the
variants was found in population databases. Minigene
assays were performed to evaluate the effects of both
variants in transiently transfected HEK293T cells. The
c.1956+3G>C induced skipping of exon 18 with a shift in
the reading frame. The c.1622+1G>C variant resulted in
the retention of the first 61 bp of intron 15 and the
immediate insertion of a stop codon. The two variants were
therefore predicted to be highly deleterious.
Conclusions: We expand the phenotype of KOS, further
highlighting the interest of in vitro assays to demonstrate
causality of new splicing variants.
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P08.116.B
A novel loss of function mutation of the WAC gene in a
subject with intellectual disability and autistic features
associated with encephalopathy related to status epilep-
ticus during slow sleep
E. Leonardi1,2, M. Bellini1,2, M. C. Aspromonte1,2, R.
Polli1,2, A. Mercante1, C. Ciaccio3, E. Granocchio3, E.
Bettella1,2, S. Sartori1, I. Donati4, C. Pantaleoni3, C.
Boniver1, A. Murgia1,2
1Dept. Woman and Child Health, University of Padua,
Padova, Italy, 2Pediatric Research Institute - Città della
Speranza, Padova, Italy, 3Developmental Neurology Unit,
Fondazione IRCCS Istituto Neurologico Carlo Besta,
Milano, Italy, 4AUSL Romagna Infermi Hospital, Rimini,
Italy
Alterations of the WAC gene have been recently associated
with a neurodevelopmental disorder characterized by intel-
lectual disability, neonatal hypotonia, behavioral problems,
and mildly dysmorphic features. To date only 20 indivi-
duals have been reported with WAC mutations, which, in
the majority of the cases, are de novo loss of function (LoF).
Using targeted deep sequencing, we screened a cohort of
600 individuals with variable degrees of intellectual dis-
ability and identified five WAC rare variants: two variants
were inherited from healthy parents; two previously repor-
ted de novo mutations, c.1661_1664del (p.Ser554*) and
c.374C>A (p.Ser125*);and a novel c.381+2T>C variant
causing the skipping of exon 4 of the gene, inherited from a
reportedly asymptomatic father with somatic mosaicism. A
phenotypic evaluation of this individual evidenced areas of
cognitive and behavioural deficits. The two individuals with
previously reported WAC mutations presented phenotypic
differences in comparison with reported cases. The patient
carrying the novel splicing mutation had a clinical history of
encephalopathy related to Status Epilepticus during slow
Sleep (ESES), only recently reported in WAC individuals.
This first report of a WAC somatic mosaic remarks the
contribution of mosaicism in the etiology of neurodeve-
lopmental and neuropsychiatric disorders. We summarized
the clinical data of reported individuals with WAC LoF
variants, which together with our findings allowed
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expanding the phenotypic spectrum of WAC-related
disorders.
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Genotype-phenotype correlation on 45 individuals with
West syndrome
I. Krey1, J. Krois-Neudenberger2, J. Hentschel1, S. Syrbe3,
T. Polster4, B. Hanker5, B. Fiedler6, G. Kurlemann7, J. R.
Lemke1
1Institute of Human Genetics, University of Leipzig Medical
Center, Leipzig, Germany, 2Department of General Pedia-
trics, Division of Neuropediatrics, University Hospital,
University Hospital Muenster, Germany, Germany, 3Divi-
sion of Child Neurology and Metabolic Medicine, Center
for Paediatrics and Adolescent Medicine, University
Hospital Heidelberg, Heidelberg, Germany, 4Bethel Epi-
lepsy Center, Mara Hospital, Bielefeld, Bielefeld, Germany,
5Institute of Human Genetics, University of Lübeck, Lübeck,
Lübeck, Germany, 6Department of General Pediatrics,
Division of Neuropediatrics, University Hospital Muenster,
Münster, Germany, 7Hospital for Children, Bonifatius
Hospital Lingen, Lingen, Germany
West syndrome is an epilepsy syndrome characterized by
repetitive epileptic spasms (ES) and hypsarrhythmia, typi-
cally leading to developmental delay/intellectual disability
(DD/ID). It is considered a classic epileptic encephalopathy
(EE). We designed a diagnostic sequencing panel targeting
131 genes associated with epilepsy and/or EE and screened
a cohort of 45 individuals with clinical diagnosis of West
syndrome. We identified disease-causing single nucleotide
variants in 11 out of 45 individuals affecting genes com-
monly associated with West syndrome (such as CDKL5,
ARX) but also in genes pre- dominantly linked to other
epileptic disorders (such as DEPDC5, SCN1A, WDR45,
AARS). Panel analysis revealed copy number variants in
two additional cases, comprising a 6,7 Mb Duplication on
chromosome 2 including SCN2A and SCN3A and a
supernumerary marker chromosome 15 leading to an overall
diagnostic yield of 29% (13/45).
In our cohort, individuals with a disease-causing variant
had significantly more severe phenotypes with respect to
DD/ID, therapy resistant epilepsy and cerebral atrophy
compared to genetically unclarified cases.
In addition to investigating the genotypic spectrum of
West syndrome, we compared the phenotypic spectrum of
clarified versus unclarified cases. Our study illustrates that
West syndrome is an electro- clinical syndrome caused by
various genetic disorders. Individuals without detectable
genetic cause might have less encephalopathy leading to a
less severe course.
© 2019 European Paediatric Neurology Society. Pub-
lished by Elsevier Ltd. All rights reserved.
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Wiedemann-Steiner Syndrome: clinical and molecular
characterization of 11 patients from four Portuguese
hospital centers
S. Fernandes1, C. S. Rosas1, M. Soeiro e Sá2, I. Carvalho3,
M. Rodrigues3, P. Louro4,5, J. de Sá1, G. Soares6, P. Dias2,
L. Ramos1,5, J. M. Saraiva1,7, S. B. Sousa1,8
1Medical Genetics Unit, Hospital Pediátrico, Centro
Hospitalar e Universitário de Coimbra, Coimbra, Portugal,
2Serviço de Genética Médica, Departamento de Pediatria,
Centro Hospitalar Lisboa Norte, Hospital de Santa Maria,
EPE, Centro Académico de Medicina de Lisboa, Lisboa,
Portugal, 3Medical Genetics Unit, Hospital Dona Estefâ-
nia, Centro Hospitalar Lisboa Central, Lisboa, Portugal,
4IPO, Lisboa, Former worker at Medical Genetics Unit,
Hospital Pediátrico, Centro Hospitalar e Universitário de
Coimbra, Coimbra, Portugal, 5Faculty of Health Sciences,
Universidade da Beira Interior, Covilhã, Portugal, 6Serviço
de Genética Médica Dr. Jacinto Magalhães, Centro
Hospitalar do Porto, Porto, Portugal, 7University Clinic
of Pediatrics, Faculty of Medicine, Universidade de
Coimbra, Coimbra, Portugal, 8University Clinic of Genet-
ics, Faculty of Medicine, Universidade de Coimbra,
Coimbra, Portugal
Context: Wiedemann-Steiner Syndrome (WSS) is an
autosomal dominant condition comprising intellectual dis-
ability, short stature, typical facial features and hyper-
trichosis. It is caused by loss-of-function variants in KMT2A
gene, leading to chromatin remodelling defects.
Methods: Clinical and molecular characterization of all
cases with WSS diagnosis from 4 Portuguese hospital
centres based on retrospective analysis of patient medical
records. Clinical exome (7/11) or KMT2A targeted NGS (4/
11) was or is being performed in all cases.
Results: We describe 8 male and 3 female unrelated
patients. The age of diagnosis ranged between 2 and 18
years. The main reasons for referral were intellectual
disability (8/11) and dysmorphic features (7/11). Most
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individuals had mild to moderate intellectual disability (11/
11), behavioural problems (9/9), narrow palpebral fissures
(10/11) and downslanted (8/10), long eyelashes (6/11),
thick eyebrows (5/10) and wide nasal bridge (10/11).
Hypertrichosis cubiti was present in 10/10. Short stature
was present in 3/11 individuals, recurrent infections in 4/7
and sleep apnoea in 2/6 cases, one requiring non-invasive
ventilation. We identified 7 novel KMT2A heterozygous
variants and 3 previously described pathogenic variants.
One case is awaiting for results.
Discussion: Our data are in accordance with the
literature, except for short stature which seems to have
lower prevalence than expected. Clinical suspicion is often
challenging as the phenotypic variability is wide. In 6/10
cases, the diagnosis was not initially considered and in 4 of
those only achieved by reverse phenotyping. Detailed
description of national cohorts of WSS patients contributes
to awareness and better-informed counselling and
management.
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Biallelic ZNF407 mutation in a neurodevelopmental
disorder with ID, short stature and variable micro-
cephaly, hypotonia, ocular anomalies and facial
dysmorphism
M. Koprulu1, Q. Zahra2, C. Cakmak3, M. Shuaib2, N.
Sobreira4, L. Kalsner5, J. Sobreira6, M. Guillen Sajoto7, S.
Malik2, A. Tolun1
1Istanbul Technical University, Istanbul, Turkey, 2Quaid-i-
Azam University, Islamabad, Pakistan, 3Bogazici Univer-
sity, Istanbul, Turkey, 4Johns Hopkins University School of
Medicine, Baltimore, MD, United States, 5University of
Connecticut School of Medicine and Connecticut Chil-
dren’s Medical Center, Farmington, CT, United States,
6Universidade Federal de Sao Paulo, Sao Paulo, Brazil,
7GeneDx, Gaithersburg, MD, United States
Background: We describe five members of a con-
sanguineous Pakistani family (Family I) plus two unrelated
patients of different ethnic origins presenting with neuro-
developmental disorders with overlapping features and
biallelic ZNF407 variants. Homozygous c.5054C>G (p.
(Ser1685Trp)) has been reported in two brothers with an
intellectual disability (ID) syndrome.
Methods: SNP genotype data were used for mapping the
disease locus in Family I. Gene variants were identified by
exome sequencing.
Results: All of the patients we describe have ID, ranging
from mild to profound, and reduced motor and cognitive
skills plus variable features including short stature, micro-
cephaly, developmental delay, hypotonia, dysarthria, deaf-
ness, visual problems, enuresis, encopresis, behavioural
anomalies, delayed pubertal onset and facial dysmorphism.
We first mapped the disease locus in the large family
(Family I) and identified homozygous ZNF407
c.2814_2816dup (p.(Val939dup)) in the four patients of
the family, and then added to the study two patients of
different ethnic origins with biallelic ZNF407 variants:
homozygous c.2405G>T (p.(Gly802Val)) in patient of
Family II and compound heterozygous variants
c.2884C>G (p.(Arg962Gly)) and c.3642G>C (p.
(Lys1214Asn)) in patient of Family III.
Conclusions: Our findings confirm that ZNF407 is a
recessive neurodevelopmental disease gene, biallelic var-
iants of which can manifest with ID and wide phenotypic
variability. The observation that all four variants found in
our patients are predicted as benign on canonical transcripts
by computational algorithms indicates that many other
variants may have escaped identification as causal in this
large gene with extreme loss-of-function intolerance.
M. Koprulu: None. Q. Zahra: None. C. Cakmak:
None. M. Shuaib: None. N. Sobreira: None. L. Kalsner:
None. J. Sobreira: None. M. Guillen Sajoto: A. Employ-
ment (full or part-time); Modest; GeneDx. S. Malik: None.
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P09 Neurogenetic and Psychiatric Disorders
P09.002.C
Epilepsy, neuropsychogical phenotype, and neuroima-
ging findings in 22q11.2 deletion syndrome: a case
series.
A. M. Alhashem, N. Alsaleh, H. El Ghezal, H. AlKalaf, I. B.
Bouhjar, K. Tlili, B. T. Melaiki
Prince sultan military and medical city, Riyadh, Saudi
Arabia
Background: The 22q11.2 deletion syndrome affects
multiple organ systems, and the neurological manifestations
are an important aspect of this disorder. Many are aware of
cardiac anomalies associated with this uncommon genetic
disorder. However, the different types of seizures, neu-
ropsychological profile, EEG, and MRI findings seen in this
condition are not well appreciated.
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Methods: Through 2010 tell 2019, Medical records of
patients with 22q11.2 deletion syndrome were retrospec-
tively reviewed for documentation of Neurological/neurop-
sychological evaluation, seizure types, EEG, and brain MRI
findings.
Results: 28 patients were collected. 6 (21.4%) patient
have epilepsy, 3 have focal epilepsy and 3 have generalized
epilepsy and all of them were controlled on AED. Brain
MRI performed in 16 patients: normal in 6 patients (37.5%),
abnormal in 10 patients: polymicrogyri and cortical
dysplasia: 2, thin corpus callosum: 3, vermis hypoplasia:
1, biliateral pallidal calcifications: 1, developmental cere-
bellar veinous anomalies: 1, cervical pilocytic astrocytoma:
1, atrophic changes: 5 Neuropsychological assessment: 3
with average intellectual ability, 9(30%) with intellectual
disabilities of variable range. 3 patients suffered of
neuropsychiatric illness.
Conclusions: Patients with 22q11.2DS have a high risk of
epilepsy. Patients with brain malformations should have a
chromosomal microarray (CMA) performed to screen for the
22q11.2 deletion syndrome. The specific genetic locus is
critically linked to seizure type, and neurodevelopmental status.
A.M. Alhashem: None. N. Alsaleh: None. H. El
Ghezal: None. H. AlKalaf: None. I.B. Bouhjar: None.
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Confirmation of ADD3 pathogenic variants as a genetic
cause of cerebral palsy
T. Beyltjens1, C. Dielman2, D. Beysen1, E. Reyniers3,4, K.
Janssens3,4, M. Meuwissen4,3
1Department of Pediatric Neurology, Antwerp University
Hospital, Edegem, Belgium, 2Department of Pediatric
Neurology, Queen Paola Children’s Hospital, Antwerp,
Belgium, 3Center for Medical Genetics, University of
Antwerp, Edegem, Belgium, 4Center for Medical Genetics,
Antwerp University Hospital, Edegem, Belgium
Introduction: Cerebral palsy (CP) is a clinical descriptive
term that defines a heterogeneous group of non-progressive,
neurodevelopmental disorders of motor impairment, which
co-occur with a wide range of medical conditions, such as
intellectual disability (ID), speech/language deficits, autism,
epilepsy and visual and/or hearing impairment. CP is caused
by a cerebral anomaly/dysfunction that develops during
pregnancy, birth or infancy. CP is still the most common
cause of physical disability in childhood with an important
impact on the quality of life of patients and, by its high
prevalence of 1.5-2.5 per 1000 live births, even on society.
Recent studies demonstrate an important contribution of
genetic factors.
Methods: At the Antwerp University Hospital, we
therefore perform genetic testing for CP using SNP-array
and a targeted whole exome sequencing-based gene panel
consisting of approximately 200 genes associated with CP
and CP-mimics.
Results: We report the findings on two siblings from a
consanguineous family presenting with spastic CP, and mild
to moderate ID. Brain MRI showed hypoplastic corpus
callosum and periventricular white matter abnormalities.
WES demonstrated the homozygous pathogenic variant
c.1100G>A (p.Gly367Asp) in ADD3 in both cases.
Conclusions: In literature, only one report describes a
homozygous ADD3 variant as a cause of CP in a
consanguineous family with similar clinical findings of
spastic quadriplegia or diplegia, variable ID and cerebral
white matter abnormalities. Interestingly, the same variant
was identified in our family, which suggests the possibility
of a founder mutation. Our findings confirm the role of
ADD3 in CP.
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Dissecting genetic factors involved in the relation
between behavioural laterality and neurodevelopmental
conditions
J. Schmitz1, M. Zheng2, K. F. H. Lui2, C. S. H. Ho3, C.
McBride2, S. Paracchini1
1School of Medicine, University of St Andrews, St Andrews,
United Kingdom, 2Department of Psychology, Chinese
University of Hong Kong, Hong Kong, Hong Kong,
3Psychology Department, The University of Hong Kong,
Hong Kong, Hong Kong
Introduction: The cerebral hemispheres differ in structure
and function underpinning specialisation for cognition,
perception, and motor control. Atypical brain asymmetries
have been implicated in psychiatric and neurodevelop-
mental conditions. Handedness is often used as a proxy for
brain asymmetries and recent genome-wide association
studies (GWAS) suggest a genetic association with schi-
zophrenia, while other laterality measures are less explored.
Here, we investigate shared genetic components between
behavioural laterality phenotypes and their relevance to
these conditions.
Methods and Results: We performed GWAS on hand,
foot, eye and ear preference in a longitudinal British cohort
(ALSPAC, n >= 5770). Our results suggest an involvement
of genes associated with immune response (footedness) and
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axonogenesis (eye, ear preference). In line with previous
research, genes involved in body asymmetries were
associated with handedness. The relevance of neurodeve-
lopmental conditions was tested using gene set enrichment
analyses and polygenic risk scores (PRS) for schizophrenia,
ADHD, autism spectrum disorders and bipolar disorder.
PRS for ADHD were associated with left- and more
strongly with non-right-handedness, but not with other
laterality phenotypes. Multivariate structural equation
models (SEM) (genome-wide genetic markers in ALSPAC
and classic multivariate SEM in a Chinese twin cohort (n =
486)) revealed shared genetic factors for hand and foot, but
not eye preference, suggesting a dissociation of motor and
sensory laterality.
Conclusions: These results give further support to a
shared biology between laterality and neurodevelopment,
which is potentially mediated by brain asymmetry. Funding:
JS is a DFG fellow (SCHM 3530/1-1). This work was
funded by Royal Society grants (SP).
J. Schmitz: None. M. Zheng: None. K.F.H. Lui: None.
C.S.H. Ho: None. C. McBride: None. S.
Paracchini: None.
P09.006.A
Assessment of SORL1 rare variants segregation in
Alzheimer disease families and in vitro models show
reduced penetrance and oligogenic inheritance
G. Nicolas, C. Schramm, L. Miguel, M. Lacour, S.
Rousseau, D. Wallon, C. Charbonnier, A. Zaréa, T.
Frebourg, D. Campion, A. Rovelet-Lecrux, M. Lecourtois
Normandie Univ, UNIROUEN, Inserm U1245 and Rouen
University Hospital, Department of Genetics and CNR-
MAJ, F 76000, Normandy Center for Genomic and
Personalized Medicine, ROUEN, France
Introduction: SORL1 rare loss-of-function (LOF) and
missense predicted damaging (Mis3) variants have first
been identified in early-onset Alzheimer Disease (EOAD,
onset ≤65) probands with a pedigree suggesting autosomal
dominant inheritance. Then, increased burdens of rare
SORL1 LOF and Mis3 variants were reported in AD
patients with odds ratios ranging from 1.9 to 29. Hence,
using SORL1 rare variants for genetic counseling appears
debatable. In addition, a functional effect of Mis3 variants
cannot be inferred from bioinformatics predictions only.
Methods: We included families with a rare LOF or Mis3
variant, evaluated their segregation, and developed a
functional assay.
Results: We studied 20 families with a LOF variant
(mean age at onset (AAO) in probands, 55.4 years, range:
[48-65]). Seventeen showed a positive family history. Mean
AAO in affected relatives was 66.3 [50-80]. One patient
carried two LOF compound heterozygous variants. DNA
was available in 18 relatives: 5/6 affected relatives carried
the familial variant (AAO=[61-78]) while 3/12 unaffected
were also carriers, aged 42, 71 and 95, respectively.
Strikingly, 57% affected carriers were APOE4+, a strong
AD risk variant, including one being homozygous, who also
carried a LOF ABCA7 risk variant.
We introduced one LOF variant and one Mis3 variant
using CRISPR/Cas9 in iPSCs and observed increased levels
of Aβ in the supernatant. The proband carrying this Mis3
variant was APOE4+ and carried a LOF rare ABCA7 risk
variant. We are now assessing additional missense variants.
Conclusions: SORL1 LOF variants are not fully penetrant
and can be observed in an oligogenic context.
G. Nicolas: None. C. Schramm: None. L. Miguel:
None. M. Lacour: None. S. Rousseau: None. D. Wallon:
None. C. Charbonnier: None. A. Zaréa: None. T.
Frebourg: None. D. Campion: None. A. Rovelet-Lecrux:
None. M. Lecourtois: None.
P09.008.C
Albumin did not increase with Coenzyme Q10 treatment
in AOA1 patients
P. CHARLES1, V. LADEVEZE2, C. TRANCHANT3, M.
ANHEIM3, C. GOIZET4, T. KUNTZER5, F. OCHSNER5, F.
ROELENS6, N. DECONINCK7, E. PETIT8, C. JAUFFRET8,
S. RIVAUD-PECHOUX9, I. LEBER10, A. BRICE11, S.
TEZENAS DU MONTCEL12, A. DURR11
1APHP, Genetic Department, Medical Genetic UF,
Armand-Trousseau and Pitié Salpêtrière Hospitals, Centre
de référence Déficiences intellectuelles de causes rares,
Département de Neurologie, Hôpital de La Salpêtrière, 47
Bd de l’Hôpital 75651 Paris Cedex 13, Paris, France,
2Sorbonne University, INSERM, Institut Pierre Louis
d’Epidémiologie et de Santé Publique IPLESP, 75013
Paris, France, Paris, France, 3Service de Neurologie,
Hôpitaux Universitaires de Strasbourg, Strasbourg,
France. Institut de Génétique et de Biologie Moléculaire
et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/
Université de Strasbourg, Illkirch, France. Fédération de
Médecine Translati, Strasbourg, France, 4CHU Bordeaux,
Service de Génétique Médicale, Centre de Référence
Maladies Rares «Neurogénétique», Laboratoire MRGM,
INSERM U1211, Univ. Bordeaux, Bordeaux, France,
Bordeaux, France, 5Unité Nerf-Muscle, Service de Neuro-
logie, Département des neurosciences cliniques, CHU
Vaudois (CHUV) et université de Lausanne, 1011 Lau-
sanne, Suisse, Lausanne, Switzerland, 6Pediatric Neurol-
ogy, AZ Delta, Roeselare, Belgium, Roeselare, Belgium,
7Neurologie pédiatrique, HUDERF av J.J. Crocq, 15 1020
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Bruxelles, ULB, Belgique et NMRC Gent, UZ Gent,
Belgique, Bruxelles, Belgium, 8Groupe Hospitalier Pitié
Salpêtrière ICM - Institut du Cerveau et de la Moelle
Epinière 47, Boulevard de l’Hôpital CS21414 75646 PARIS
Cedex 13, Paris, France, 9INSERM U-1127 Institut du
cerveau et de la moelle épinière Hôpital de la Salpêtrière
47-91 boulevard de l’Hôpital 75651 Paris CEDEX 13
France, Paris, France, 10Sorbonne Universités, UPMC
Univ Paris 06, Inserm U1127, CNRS UMR 7225, Institut du
Cerveau et la Moelle épinière (ICM), Centre de référence
des démences rares ou précoces, IM2A, Département de
Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris,
France, Paris, France, 11Sorbonne Université, Institut du
Cerveau et de la Moelle épinière (ICM), AP-HP, Inserm,
CNRS, University Hospital Pitié-Salpêtrière, Paris, France,
Paris, France, 12Sorbonne Université, INSERM, Institut
Pierre Louis d’Epidémiologie et de Santé Publique IPLESP,
AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles
Foix, F75013 Paris, France, Paris, France
Ataxia with oculomotor apraxia type 1 (AOA1) is a rare
autosomal recessive cerebellar ataxia associated with ocu-
lomotor apraxia, hypoalbuminaemia and hypercholester-
olaemia linked to Aprataxin (APTX) gene mutations.
Aprataxin gene mutations are associated with decreased
Coenzyme Q10 levels in muscle and plasma. Disease
duration and disability are negatively correlated with albu-
minemia. We included 19 patients in a multicenter (six
centers) controlled randomized double blind trial with
Coenzyme Q10 with 2 phases, a controlled randomized
phase Coenzyme Q10 versus placebo during 1 year, and an
open-labelled phase with all patients treated with Coenzyme
Q10 during 1 year, to estimate longer term potential side
effects and tolerance. Inclusion criteria were AOA1 con-
firmed by genetic molecular analysis; age older than 18,
hypoalbuminemia, informed consent signed. Primary end-
point was hypoalbuminemia rate evolution. Secondary
endpoints were cerebellar ataxia severity (SARA and
quantitative evaluations), ocular movements evaluation,
quality of life (EQ5-D), depression and anxiety (PHQ-9),
biological measurements (prealbuminemia, cholesterolemia,
alphafoetoprotein), safety (blood counts and hepatic check)
and compliance (CoEnzyme Q10 dosage). Evaluations were
performed each 6 months with a phone call between each
visit. Results: Albuminemia evolution was not significantly
different between the 2 groups (Phase1: coQ10: -1.2 [-3.0;
1.1], Placebo: +1.0 [+0.8; +2.0], p = 0.0511) and no
significant difference on all other evaluation criteria.
Treatment was well tolerated with minor side effects: 6
during phase 1 (3 in each group) and 2 during phase 2.
Conclusion: despite good tolerance, we failed to demon-
strate an increase of albuminemia under Coenzyme Q10
treatment in AOA1 patients.
P. Charles: None. V. Ladeveze: None. C. Tranchant:
None. M. Anheim: None. C. Goizet: None. T. Kuntzer:
None. F. Ochsner: None. F. Roelens: None. N. Deco-
ninck: None. E. Petit: None. C. Jauffret: None. S.
Rivaud-pechoux: None. I. Leber: None. A. Brice: None.
S. Tezenas du montcel: None. A. Durr: None.
P09.010.B
A nonsense variant in the ARSD gene associated with
young-onset Parkinson’s disease
S. MIURA1, T. Shimojo2, R. Fujioka3, Y. Uchiyama4, H.
Shibata2
1Department of Neurology & Geriatric Medicine, Ehime
University Graduate School of Medicine, Toon, Japan,
2Division of Genomics, Medical Institute of Bioregulation,
Kyushu University, Fukuoka, Japan, 3Department of Food
and Nutrition, Beppu University Junior College, Beppu,
Japan, 4Department of Radiology, Kurume University
School of Medicine, Kurume, Japan
Parkinson’s disease (PD) is one of the common neurode-
generative disorder defined as bradykinesia plus rest tremor
or rigidity. It has been reasonable that the younger age at
onset is, the higher the risk of genetic condition gets. To
identify the causative nucleotide variant for the disease, we
studied a Japanese pedigree consisting of a trio of a patient
with sporadic young-onset PD and unaffected parents. The
patient was a 35-year-old male. He had noted involuntary
movement of slow torsion in his right shoulder and forearm
at the age of 31. He also noticed slow torsion in his left toe
and dragged his left foot in every evening at the age of 34.
On neurological examination, he showed dystonic posture
in his right wrist, mild hypertonus and bradykinesia in his
right upper limb, hyperreflexia and mild spasticity in the
lower extremities. Brain MRI showed no abnormality.
Meta-iodobenzylguanidine (MIBG) myocardial scinti-
graphy showed no decrease of the heart/mediastinum ratio.
Dopamine transporter (DAT) SPECT imaging showed
moderately reduced dopamine uptake in the bilateral stria-
tum. L-dopa was effective for his bradykinesia. Whole-
exome sequencing of the trio combined with strict criteria
revealed an X-linked nonsense variant (NM_001669:
c.1556C>T [p.Arg498X]) in the ARSD gene encoding
arylsulfatase D. Quantitative real-time PCR analysis ver-
ified that the mRNA expression level of ARSD was sig-
nificantly reduced in the patient’s peripheral blood cells
probably due to the nonsense mediated decay. This is the
first record of a disease associated with a variant of the
ARSD gene.
S. Miura: None. T. Shimojo: None. R. Fujioka: None.
Y. Uchiyama: None. H. Shibata: None.
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P09.011.C
Variations in genes of the mTOR-pathway link ASD and
ICV
M. Arenella1,2, N. R. Mota1, M. W. A. Teunissen3, H. G.
Brunner1,4, J. Bralten1
1Department of Human Genetics, Radboud University
Medical Center, Nijmegen, Netherlands, 2Institute of
Psychiatry, Psychology & Neuroscience, King’s College
London, London, United Kingdom, 3Academic Center for
Epileptology Kempenhaeghe, Maastricht University Medi-
cal Center, Maastricht, Netherlands, 4Department of
Human Genetics, Maastricht University Medical Center,
Maastricht, Netherlands
Introduction: Large brains are commonly observed in
autism spectrum disorder (ASD), but the underlying mole-
cular basis is unclear. Brain volume is highly heritable and
is partly regulated by variation in the mammalian target of
rapamycin (mTOR) pathway. Rare mTOR-related variants
associate with macrocephaly in syndromic intellectual dis-
ability (ID), and common mTOR-related variants are asso-
ciated with intracranial volume (ICV) in the general
population. We hypothesized that variations in mTOR-
related genes could mediate the occurrence of enlarged
brains in ASD.
Materials and methods: Looking at rare de-novo
mTOR-related variants, we estimated enrichment of macro-
cephaly and ASD using a local ID cohort (N=2,257) and
publicly available resources (n = 32,991). Looking at
common variants in a unique set of mTOR-related genes,
we estimated association with ASD (N=46,350) and ICV
(N=25,974) using publicly available data. Using the same
data, we estimated 1) genome-wide genetic correlation
between ASD and ICV and 2) mTOR-restricted ASD-ICV
genetic correlation.
Results: We found a significant enrichment of syndromic
macrocephaly and ASD in de-novo mTOR-related variants
carriers. Gene-set analyses for common mTOR-related
variants revealed significant independent associations with
ASD (p=0.002) and ICV (p=0.021). While no significant
genome-wide ASD-ICV genetic correlation was present
(p=0.81), we show a significant positive mTOR-stratified
genetic correlation (p=0.027).
Conclusions: Our study shows that both rare and
common mTOR-related genetic variations contribute to
ASD and brain volume. These results are compatible with a
model in which variable mTOR activation may drive both
larger brain volume and ASD risk.
M. Arenella: None. N.R. Mota: None. M.W.A.
Teunissen: None. H.G. Brunner: None. J. Bralten: None.
P09.013.B
Novel MAG variant in autosomal recessive cerebellar
ataxia with oculomotor apraxia: molecular basis and
expanded clinical phenotype
M. Santos1, J. Damásio1,2,3, C. Kun-Rodrigues4, C.
Barbot2, J. Sequeiros1,2, J. Brás4,5, I. Alonso1,2, R.
Guerreiro4,5
1UnIGENe, IBMC - Institute for Molecular and Cell
Biology, i3S - Instituto de Investigação e Inovação em
Saúde, Universidade do Porto, Porto, Portugal, 2CGPP,
IBMC - Institute for Molecular and Cell Biology, i3S -
Instituto de Investigação e Inovação em Saúde, Universi-
dade do Porto, Porto, Portugal, 3Neurology Department,
Centro Hospitalar do Porto, Porto, Portugal, 4Center for
Neurodegenerative Science, Van Andel Institute, Grand
Rapids, MI, United States, 5Division of Psychiatry and
Behavioral Medicine, Michigan State University College of
Human Medicine, Grand Rapids, MI, United States
Hereditary cerebellar ataxias (HCAs) are a heterogeneous
group of neurodegenerative disorders, characterized by
motor incoordination and unsteady gait, often associated
with speech and eye movement disturbances. HCAs share
clinical features and disease mechanisms with hereditary
spastic paraplegias (HSPs), with several ataxia-related
genes found to cause HSPs and vice-versa. In this study,
we used homozygosity mapping and exome sequencing to
unravel the disease-causing variant in a Portuguese family
with early-onset, autosomal recessive, cerebellar ataxia with
neuropathy and oculomotor apraxia. We identified a novel
homozygous missense variant in MAG (c.124T>C; p.
Cys42Arg), the gene encoding the myelin-associated gly-
coprotein (MAG). Cellular studies confirmed its detrimental
effect. Our results showed that this variant reduces protein
stability, impairs post-translational processing (N-linked
glycosylation) and subcellular localization of MAG.
Homozygous variants in MAG have been previously asso-
ciated with complicated forms of HSP. Our findings newly
associate MAG variants with ataxia with oculomotor
apraxia. The low expression and premature degradation of
the mutant protein showed the variant to cause protein loss-
of-function. This work has also expanded the clinical phe-
notype associated with disease-causing variants in MAG.
Genotyping MAG variants should, therefore, be considered
in the diagnosis of HCAs, in addition to HSPs.
M. Santos: None. J. Damásio: None. C. Kun-Rodri-
gues: None. C. Barbot: None. J. Sequeiros: None. J.
Brás: None. I. Alonso: None. R. Guerreiro: None.
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NPTX1 mutations cause a novel form of autosomal
dominant cerebellar ataxia
M. Coutelier1, M. Jacoupy1, A. Janer2, F. Renaud3, G.
Saripella4, F. Ancien5, R. Larivière2, N. Sgarioto2, R.
Valter1, F. Pucci5, M. Rooman5, I. Le Ber1, P. Charles1, D.
A. Tregouet4, A. Brice1, E. Shoubridge2, D. Gilis5, A. Durr1,
G. Stevanin1
1Institut du Cerveau et de la Moelle, Paris, France, 2McGill
university, Montreal, QC, Canada, 3Institut Gustave
Roussy, Villejuif, France, 4Institut ICAN, Paris, France,
5Universite Libre de Bruxelles, Bruxelles, Belgium
Introduction: Autosomal dominant spinocerebellar ataxias
(SCA) are characterized by a marked genetic heterogeneity,
with more than forty causative genes identified so far, and
half the patients lacking a molecular diagnosis.
Material and Methods: In a large family with 9 sympto-
matic patients, we aimed at identifying a new genetic cause
of SCA by performing exome sequencing combined to
whole genome linkage analysis.
Results: We identified a G389R missense mutation in
NPTX1, segregating in all affected cases. This mutation was
recurrent in 2 independent pedigrees without a common
founder effect and another missense mutation, E327G, was
identified in a smaller pedigree with two affected patients.
The phenotype in these 4 families is a late onset (range 34-
71 years) slowly progressive cerebellar ataxia, nystagmus,
cognitive impairment, myoclonic tremor and mild cerebellar
atrophy on MRI. Both mutations affect conserved amino-
acid residues in the NP1 protein and are extremely rare or
missing from public databases. We show that both
mutations alter the endoplasmic reticulum morphology
and induce ATF6-mediated stress, ultimately leading to
increased cell cytotoxicity in COS7 cells. The E327G
change also abolishes the protein secretion, as well as the
formation of NP1 complexes. In silico modeling of the
complex evidenced a destabilizing effect for the E327G
change, located at the interface between monomers. No
phenotype-genotype correlation could be established.
Conclusions: We suggest that mutations in NPTX1 can
lead to spinocerebellar ataxia via endoplasmic stress,
following a dominant negative complex-destabilizing pro-
cess or a direct alteration of the protein function.
M. Coutelier: None. M. Jacoupy: None. A. Janer:
None. F. Renaud: None. G. Saripella: None. F. Ancien:
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Novel dominantly inherited spinocerebellar ataxia sub-
type caused by SAMD9L mutation triggering mitochon-
drial and lysosomal dysregulation
M. Corral-Juan1, P. Casquero2, N. Giraldo Restrepo2, S.
Laurie3, A. Martinez-Piñeiro4, R. Mateo Montero2, L.
Ispierto5, V. Volpini6, D. Vilas5, R. Álvarez-Ramo5, I.
Sánchez1, A. Matilla-Dueñas1
1Functional and Translational Neurogenetics Unit, Depart-
ment of Neuroscience, Research Institute Germans Trias i
Pujol (IGTP), Universitat Autònoma de Barcelona-Can
Ruti Campus, Badalona, Spain, 2Neurology and neurophy-
siology Section, Hospital Mateu Orfila, Mahón, Spain,
3CNAG-CRG, Centre for Genomic Regulation (CRG),
Barcelona Institute of Science and Technology (BIST),
Barcelona, Spain, 4Neuromuscular and functional studies
Unit, Neurology Service, University Hospital Germans
Trias i Pujol (HUGTiP), Universitat Autònoma de
Barcelona-Can Ruti Campus, Badalona, Spain, 5Neurode-
generation Unit, Neurology Service, Department of Neu-
roscience, University Hospital Germans Trias i Pujol
(HUGTiP), Universitat Autònoma de Barcelona-Can Ruti
Campus, Badalona, Spain, 6IDIBELL, L’Hospitalet de
Llobregat, Spain
Introduction: Spinocerebellar ataxias (SCAs) consist of
rare movement disorders characterised by progressive cer-
ebellar ataxia variably associated with other neurological
signs. At least 43 different SCA subtypes have been
described to date evidencing the high clinical and genetic
heterogeneity.
Materials and Methods: Whole-genome linkage and
exome studies were performed in a Spanish five-generation
family from the Balearic island of Menorca with seven
affected individuals variably presenting with ataxia, nys-
tagmus, dysarthria, polyneuropathy and pyramidal signs.
Results: Here we present a novel spinocerebellar ataxia
with autosomal dominant inheritance with affected indivi-
duals presenting nystagmus as initial clinical sign and a
variable age at onset ranging from 15 to 50 years old. MRI
revealed cerebellar atrophy with cerebral demyelination,
and EMG showed nerve conduction deficits. We identified
the c.1877C>T (p.Ser626Leu) germline variant in the
SAMD9L gene as the disease causative genetic defect with
a significant LOD score Zmax=3.43 (θ= 0.00; P < 3.5E10-
5). We demonstrate the mitochondrial location of human
SAMD9L protein and found its levels decreased in patients’
fibroblasts. The p.Ser626Leu variant is located on a
predicted microtubule binding motif in SAMD9L leading
to its subcellular mislocalization. Furthermore, we detected
a high-copy number of the mitochondrial MT-D-LOOP
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region along with increased ATP5H, DRP1 and LAMP1
protein levels evidencing both mitochondrial and lysosomal
deficits in patients’ fibroblasts.
Conclusions: This study describes a new spinocerebellar
ataxia subtype caused by SAMD9L, mitochondrial, and
lysosomal dysregulation. This work was funded by the
Spanish Health Institute Carlos III (FIS PI14/00136; PI14/
01159; FIS PI17/00534).
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None. R. Mateo Montero: None. L. Ispierto: None. V.
Volpini: None. D. Vilas: None. R. Álvarez-Ramo: None.
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P09.017.C
Linked-read whole genome sequencing reveals unde-
tected variants in autism spectrum disorder
F. A. Cupaioli1, E. Mosca1, N. Di Nanni1, P. Pelucchi1, L.
Milanesi1, M. E. Raggi2, L. Villa2, A. Mezzelani1
1National Research Council, Institute of Biomedical
Technologies, Segrate, Italy, 2Scientific Institute, IRCCS
Eugenio Medea, Bosisio Parini, Italy
Introduction: Autism Spectrum Disorder (ASD) is a neu-
rodevelopmental condition with complex etiology.
Although genetics play a key role in ASD, causative or
predisposing genetic variants have been detected only in
30% of patients. Here, for the first time, linked-read whole
genome sequencing of ASD patients is used to access dis-
ease associated regions unmappable by short-reads NGS.
Materials and Methods: 10 children with ASD,
including 3 couples of affected siblings, were enrolled
and HMW DNA isolated from peripheral blood. DNA was
submitted to 10Xgenomics microfluidics partitioning and
barcoding, library preparation and Illumina WG-NGS. Data
were analyzed through 10x Long Ranger pipelines to find
SNVs, in/dels and larger structural variants in comparison
to 1000 genomes, genome aggregation database and
NHLBI-ESP populations. Genes affected by variants were
compared with those already known to be associated with
ASD (SFARI database, large-scale sequencing studies,
bioinformatics predictions).
Results: this approach successfully produced sequences
up to 9mln bp in length. Among the detected variants, 405
were listed in SFARI, 43 confirmed bioinformatics predic-
tions and 3,210 were new. Among the latter variants, 22
were homozygous in all the 3 couples of siblings.
Conclusions: this powerful approach deciphered under-
lying genomic heterogeneity and missing variations in
ASD. Further studies will be performed to validate the new
ASD variants in a large size of samples and in public data.
Data integration will be also performed to identify pathways
and gene networks involved in the disorder to understand
disease mechanisms and design target-driven treatment.
Acknowledgements: EU project GEMMA (grant agree-
ment No 825033).
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Changes in transcriptional activity of mitochondrial
genes in patients with autism spectrum disorder
Y. Chudakova1, G. Shmarina1,2,3, A. Poletkina1, M.
Konkova1, E. Ershova1,2, N. Veiko1,2, S. Nikitina4, N.
Simashkova4, S. Kostyuk1,2
1Research Center for Medical Genetics, Moscow, Russian
Federation, 2N. I. Pirogov Russian National Research
Medical University, Moscow, Russian Federation, 3Gabri-
chevsky Institute of Epidemiology and Microbiology,
Moscow, Russian Federation, 4Scientific Center for Mental
Health, Russian Academy of Medical Sciences, Moscow,
Russian Federation
Introduction: Mitochondrial dysfunction with concomitant
oxidative stress is evidenced in the brains and periphery of
many patients with autism spectrum disorder (ASD). This
study aimed to compare the level of mitochondrial DNA
(mtDNA) and transcriptional activity of mitochondrial
genes in peripheral blood lymphocytes (PBL) of ASD
patients (ASDP) and healthy controls (HC).
Materials and Methods: The study included 20 ASDP
and 15 HC aged 4 to 10 years. PBL DNA was isolated from
plasma using phenol extraction. mtDNA content in PBL
DNA samples was determined by non-radioactive quanti-
tative dot-hybridization. PBL RNA was isolated with
RNeasyPlusMiniKit(‘Qiagen’). Expression of 85 mitochon-
drial genes including those involved in regulating redox
metabolism, mitochondrial response to stress, mitophagy,
mitochondrial fusion, mitochondrial fission, mitochondrial
transports, and those that encode for proteins of I-V
respiratory complexes, was evaluated using real-time PCR.
Results: There were no significant differences in mtDNA
levels between patient and control groups. Analysis of
mitochondrial gene expression revealed 3-5 fold elevation
of transcript levels for UQCRFS1, SC01, and MT-ATP6
genes (complex III, IV, and V, respectively) in PBL of ASD
patients compared to those of HC. Besides, PBL of ASDP
were characterized by heightened expression of PINK1 gene
(tenfold) involved in mitophagy as well as FIS1 (twofold)
and MFN2 (fourfold) genes regulated mitochondrial fission
and fusion, respectively.
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Conclusions: Increased transcriptional activity of fusion,
fission and mitophagy genes in PBL of ASDP may be
associated with adaptive response maintaining functional
mitochondria under disease-related metabolic or/and envir-
onmental stresses. The study was supported by RFBR grant
№ 17-29-06017ofi_m.
Y. Chudakova: B. Research Grant (principal investiga-
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Exploring mechanisms of gene-environment interactions
contributing to the onset of idiopathic Autism Spectrum
Disorder
J. X. Santos1,2, H. Martiniano1,2, A. R. Marques1,2, C.
Rasga1,2, J. Vilela1,2, A. M. Vicente1,2
1Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon,
Portugal, 2Faculdade de Ciências, BioISI - Biosystems &
Integrative Sciences Institute, Universidade de Lisboa,
Lisbon, Portugal
Sequencing studies have yielded several candidate genes for
Autism Spectrum Disorder (ASD). However, the biological
mechanisms underlying its onset are still unclear. Envir-
onmental factors may modulate ASD risk, with heritability
estimates of 50-80% supporting a role for gene-environment
interactions in idiopathic cases. We hypothesize that ASD
candidate genes interact with reported ubiquitous environ-
mental risk factors. Thus, we interrogated the Comparative
Toxicogenomics Database (CTD) for interactions between
1144 ASD candidate genes and 59 ASD-risk chemicals. A
proportion analysis was performed to identify genes that
selectively interact with ASD risk chemicals (and vice-
versa). Genetic data from ASD-individuals was inspected to
identify SNVs (n = 2674) and CNVs (n = 3570). Eleven
genes, including genes encoding for sex hormone receptors
(AR, ESR1 and ESR2), signaling kinases (MAPK1 and
MAPK3) and xenobiotics-responding molecules (GSTM1
and SLC7A5) were found to selectively interact with ASD-
chemicals. Meanwhile, heavy metals, endocrine disruptors
(pesticides, benzo(a)pyrene and a phthalate) and valproic
acid were found to selectively target ASD-candidate genes.
In ASD-cases, we found 22 loss-of-function or deleterious
missense SNVs in 8/11 genes, of which 3 (ESR1, ESR2, and
MAPK3) were also targeted by CNVs. External cues may
dysregulate the MAPK signaling cascade, leading to neu-
rodevelopmental problems. Hormone-mimicking toxins act
as agonist/antagonist ligands to hormone receptors, while
SLC7A5 is a blood-brain barrier (BBB) transporter. Sex
hormones and BBB are fundamental during early devel-
opment. We highlight the need of considering genetics and
environment as interacting entities. Efforts to collect early-
life exposure data from genetically susceptible patients may
accelerate the implementation of health management stra-
tegies for ASD.
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Transcriptomic analysis unveils functional consequences
of complex rearrangements associated to autism spec-
trum disorder
M. Costa-Roger1, M. López-Sánchez1, T. Vendrell2, P.
Muñoz-Cabello1,3, B. Gener4, E. Gabau5, N. Capdevila5, L.
Pérez-Jurado1,6, I. Cuscó2
1Genetics Unit, Departament de Ciències Experimentals i
de la Salut, Pompeu Fabra University, Hospital del Mar
Research Institute (IMIM), Parc de Salut Mar and Centro
de Investigación Biomédica en Red de Enfermedades Raras
(CIBERER), Barcelona, Spain, 2Department of Clinical and
Molecular Genetics and Medicine Genetics Group, VHIR,
University Hospital Vall d’Hebron, Barcelona, Spain, 3Unit
of Clinical Genetics, Hospital del Mar, Parc de Salut Mar,
Barcelona, Spain, 4Osakidetza Basque Health Service,
Cruces University Hospital. Department of Genetics,
Biocruces Bizkaia Health Research Institute, Bizkaia,
Spain, 5Service of Clinical Genetics and Genetics Labora-
tory of Paediatric Unit, Parc Taulí University Hospital,
Institut d’Investigació I Innovació Parc Taulí I3PT,
Universitat Autònoma de Barcelona, Sabadell, Spain, 6SA
Clinical Genetics, Women’s and Children’s Hospital, South
Australian Health and Medical Research Institute
(SAHMRI) and University of Adelaide, South Australian
Health and Medical Research Institute, Adelaide, South
Australia, Australia
Introduction: Autism Spectrum Disorder (ASD) is a group
of neurodevelopmental disorders characterized by social-
communication difficulties, restricted interests and repeti-
tive behaviors. ASD has a complex multifactorial etiology
with high genetic involvement. Previous unpublished data
suggested that inversions 17q21.31 and 8p23.1 could act as
susceptibility variants. The purpose of this project is to
elucidate the transcriptional consequences of these
rearrangements.
Materials and Methods: We performed RNAseq
analysis of peripheral blood in 13 idiopathic ASD patients
and 11 controls grouped by homozygous inversion
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genotypes: non-inverted; inv8p23.1; inv17q21.31. We used
HTSeq/DESeq2 to discover the differentially expressed
genes (DEGs) with p.adj.value < 0.05.
Results: We found that inversions affect the expression
of genes encompassed in each inverted region and genes
elsewhere in the genome. Regarding inv17q21.31, we
discovered 38 DEGs, 8 from the region and some of them
associated to neuronal diseases (LRRC37A,LRRC37A2,
KANSL1-AS1,IL1B) or brain-related functions (ROBO1,
RIN1). When exploring the interaction of phenotype-
genotype, no regional genes were found deregulated. We
discovered 27 DEGs for inv17q21.31 including some
related to neuronal function (ATOH8,MAP1B,VSNL1),
whereas for inv8p23.1 we found 73 DEGs of which 4
have been previously related to ASD (ABCA13,SLC7A8,
STX1A,SLC24A2).
Conclusions: Our data indicate that inversions have a
direct effect on gene expression patterns both in inverted
regions and elsewhere in the genome. Moreover, we note
that ASD carriers of the susceptibility alleles (inv17q21.31/
inv8p23.1) have differential expression of brain function-
related genes. Further studies are needed to determine the
involvement of these deregulated genes to the ASD
phenotype. Funded by grants from the Spanish-Ministry-
of-Economy-and-Competiveness (FIS PI16/00369) and
Ministry-of-Education-Culture-and-Sport (FPU16/06907).
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Systems Biology approach for the identification of
neurotransmission and synaptic risk genes and dis-
rupted biological processes in Autism Spectrum
Disorder
J. Vilela1,2, H. Martiniano1,2, S. Luzi1,2, C. Rasga1,2, A.
Marques1,2, J. Santos1,2, G. Oliveira3,4, A. Vicente1,2,5
1INSA - Instituto Nacional de Saúde Dr. Ricardo Jorge,
Lisboa, Portugal, 2University of Lisboa Faculty of Sciences,
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Lisboa, Portugal, 3Neurodevelopment and Autism Unit
(UNDA), Serviço do Centro de Desenvolvimento da
Criança, Centro de Investigação e Formação Clínica,
Hospital Pediátrico, Centro Hospitalar e Universitário de
Coimbra, Coimbra, Portugal, 4University Clinic of Pae-
diatrics, Faculty of Medicine, University of Coimbra,
Coimbra, Portugal, 5Instituto Gulbenkian de Ciência,
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Autism Spectrum Disorder (ASD) is a neurodevelopmental
disorder characterized by communication deficits and
repetitive behavioral patterns. ASD has a strong genetic
component and there is evidence supporting many putative
risk genes. However, the genetics underlying the disease is
unclear. Our objective was to identify neurotransmission
and synaptic (NS) genes that play a role in ASD. For this
purpose, we defined 1216 NS candidate genes filtering for
the terms ‘neurotransmitter’ and ‘synapse’ in Gene Ontol-
ogy, Reactome and KEGG, and overlapping the gene list
obtained with the synaptic databases SynaptomeDB and
SynSysNet, and with literature review. We then searched
the Whole Exome Sequencing dataset from the Autism
Sequencing Consortium (3938 cases) for ultra-rare loss of
function (LoF) Single Nucleotide Variants (MAF < 0,1%;
gnomAD 60146 controls) in these genes. We selected 434
LoF variants in 244 genes and identified the biological
pathways enriched in these genes using Reactome. Apply-
ing the Louvain community detection algorithm to the
network spanned by the selected genes and edges from the
STRING database of protein-protein interactions, we iden-
tified several biological communities within the network:
MAP Kinase, Calcium and G alpha signaling, Interleukins
and Toll-like receptors, Energy/Insulin metabolism, Phos-
pholipids, Nicotinic acetylcholine and NMDA/AMPA
receptors. Finally, we constructed a network-based gene
rank through the computation of topological parameters and
centrality measures in Cytoscape. The genes PRKCA,
GNG13 and ANK2 involved in phosphorylation, trans-
membrane signaling and membrane stabilization of ion
transporters and channels, which are important processes for
the brain function, are the top-ranked genes.
Fundação para a Ciência e Tecnologia: (PD/BD/131390/
2017)
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Family-based whole exome sequencing allows a 25%
diagnostic yield in patients with autism spectrum
disorder
D. Carli1, E. Giorgio2, L. Pavinato2, E. Riberi1, P.
Dimartino3,4, A. Bruselles5, S. Cardaropoli1, A. Mussa1, A.
Pelle6, G. Mandrile6, V. Antona7, L. Sorasio8, E. Biamino1,
E. F. Belligni1, V. Rizzo2, F. Sirchia9, I. Bagnasco10, G.
Zacchetti11, V. G. Naretto11, G. Gai11, A. Zonta11, E.
Grosso11, C. Davico12, R. Keller13, T. Pippucci3,4, M.
Tartaglia14, S. De Rubeis15, A. Brusco2,11, G. B. Ferrero1
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ment of Oncology and Molecular Medicine, Istituto Super-
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Cuneo, Italy, 9Institute for Maternal and Child Health -
IRCCS “Burlo Garofolo”, Trieste, Italy, 10Neuropsichiatria
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School of Medicine at Mount Sinai, New York, NY, United
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Introduction: autism spectrum disorders (ASD) represent a
major health issue, whose genetic bases are not yet fully
delineated.
Methods: we performed family-based whole exome
sequencing (WES) in collaboration with the Autism
Sequencing Consortium (Icahn School of Medicine at
Mount Sinai) in 88 families with at least one subject
presenting with ASD. Array-CGH and FMR1 analysis were
negative. Patients have been clinically stratified in isolated
ASD, ASD associated with other neurological signs
(seizures, brain anomalies, micro/macrocephaly) and syn-
dromic ASD (dysmorphisms, short stature/overgrowth,
congenital anomalies).
Results: we found pathogenic variants in 22/88 cases
(25%). Diagnostic yield was 5/54 (9.3%) in patients with
isolated ASD (genes DSCAM, FOXP1, GRIA3, NF1,
TLK2), 13/22 (59.1%) in patients with associated neurolo-
gic signs (ARID1B, DEAF1, GRIN1, HNRNPH2, IRF2BPL,
PHF8, PTEN, SATB2, SCN2A, SRCAP, TLK2, WDR26) and
4/12 (33.3%) in syndromic ASD (ARID1B, NAA15,
SHANK3, SETBP1). In other 9 families we identified
potentially causative variants in 10 new candidate genes
(ARHGAP4, ARHGAP5, CASKIN2, CTSZ, METRN, NRC2,
PCDHA3, SEPT2, SLC4A2, TSPYL2). Variants of unknown
significance were found in 12 families (13.6%).
Conclusions: these data confirm that family-based WES
has a high diagnostic rate in ASD. Notably, the genes found
mutated in patients with isolated ASD are known to be
associated with genetic syndromes (e.g. NF1), suggesting a
wide phenotype variability ranging from complex syn-
dromes to isolated ASD.
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Application of oligonucleotide array comparative geno-
mic hybridization in clinical diagnostics of 500 patients
with autism spectrum disorders
B. Wisniowiecka-Kowalnik1, I. Plaskota1, M. Kędzior1, J.
Bernaciak1, E. Obersztyn1, A. Kutkowska-Kaźmierczak1, N.
Braun-Walicka1, M. Geremek1, A. Pietrzyk1, J. Castañeda1,
A. Barczyk1, P. Szyld1, J. Klapecki1, A. Sobczyńska-
Tomaszewska2, K. Czerska2, B. Nowakowska1
1Institute of Mother and Child, Warsaw, Poland, 2MED-
GEN, Warsaw, Poland
Autism Spectrum Disorders (ASDs) are a heterogeneous
group of neurodevelopmental disorders with an estimated
prevalence of 1.4-2% in the general population. ASDs have
a complex multifactorial etiology, with genetic causes being
recognized in 25-35% of cases. Array comparative genomic
hybridization studies showed that copy numer variants
(CNVs), in particular rare and those encompassing brain-
related genes, are associated with idiopathic ASDs. We
applied oligonucleotide microarrays (OGT) with average
resolution of 30 kpz to evaluate its usefulness for identifi-
cation and characterization of CNVs in a cohort of 528
patients with ASDs. The analyses of the patients’ genomes
were performed using genome-wide, high-resolution
(180K) array to accurate detection of copy number varia-
tion at the exon level. Probes have been designed to target
4645 genes including 227 genes relevant for etiopatho-
genesis of ASDs. Chromosomal microarray analysis
revealed 116 nonpolymorphic CNVs, ranging in size from
9.3 kb to 8.16 Mb, in 100 (19%) patients. Pathogenic or
likely pathogenic CNVs were identified in 42 (8%) patients,
whereas CNVs with uncertain clinical significance were
identified in 68 (12.8%) of cases. Due to high resolution of
the selected microarray, it was possible to identify 37 CNVs
that could not have been detected using the clinical
microarrays (OGT, 60k). Our study confirmed the potential
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of aCGH in elucidating the etiology of ASDs, demonstrated
by the identification of one novel gene LRRTM4 as candi-
date for ASDs. The work was supported by projects 510-18-
09 and 510-18-54 from the Ministry of National Education
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Identification of rare risk variants in 12 multiply
affected families with bipolar disorder
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Institute of Mental Health, University Medical Center
Mannheim/University of Heidelberg, Mannheim, Germany,
7Department of Mental Health, Institute of Biomedicine
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8Unidad de Gestión Clínica del Dispositivo de Cuidado-
sCríticos y Urgencias del Distrito Sanitario Málaga,
Malaga, Spain, 9Department of Experimental Neurology,
Division of Neurology, Goethe University Hospital, Frank-
furt, Germany, 10Isar Amper Klinikum München Ost, kbo,
Haar, Germany, 11Department of Mental Health, University
Hospital of Reina Sofia, Cordoba, Spain, 12Department of
Mental Health, University Hospital of Jaen, Jaen, Spain,
13Department of Mental Health, University Hospital of
Jerez de la Frontera, La Frontera, Spain, 14Department of
Mental Health, University Hospital of Puerto Real,
Department of Mental Health, Cadiz, Spain, 15Department
of Mental Health, Hospital Punta de Europa, Algeciras,
Spain, 16Department of Psychiatry, Carlos Haya Regional
University Hospital, Malaga, Spain, 17Institute of Human
Genetics, University of Bonn, School of Medicine &
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Introduction: Bipolar disorder (BD) is a common, highly
debilitating neuropsychiatric disorder. It has a life-time
prevalence of about 1%. The disease manifests itself by
reoccurring episodes of depression and mania. BD is a
complex disorder caused by a combination of genetic and
environmental factors. Formal genetic studies have esti-
mated a relatively high heritability of approximately 75-
80%. Our actual project focuses on the identification of rare
risk variants for BD that segregate in 12 multiply affected
families from Andalusia/Spain with a total of 71 indivi-
duals, using whole exome data.
Methods: To identify risk variants that segregate within
the pedigree we set up an analysis pipeline using a
commercial software. The workflow includes trimming of
reads, mapping to the reference genome, removal of
duplicates, local realignment and variant detection. Variants
that matched the segregation pattern were further analyzed
using different prediction tools and for known
candidate genes.
Results: We have identified 138’000 missense variants,
which were familywise present in all affected and none of
the healthy members. These variants were annotated using
dbNSFP, including several different prediction scores. As a
first approach to identify causative variants, we looked at
the overlap with the 30 loci described in the BP2 GWAS
from the PGC (Stahl, E.A. et al. 2019). We found 18
mutations in BD associated genes, 3 of them being rare.
SYNE1 is outstanding, as 9 mutations pertain to this gene.
Next steps will comprise following up of these mutations
using biological pathway analysis tools and starting analysis
of identified frame-shift mutations.
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Decrease of mitochondrial DNA copy number in
C9ALS/FTD
M. I. Alvarez-Mora1, P. Podlesniy2, T. Riazuelo3, N.
Serra4, L. Rodriguez-Revenga5
1Hospital 12 de Octubre, IDIBAPS and CIBERER, Madrid,
Spain, 2CIBERNED, BARCELONA, Spain, 3Hospital Clinic
of Barcelona, BARCELONA, Spain, 4IIBB and CIBERNED,
Barcelona, Spain, 5Hospital Clinic of Barcelona, IDIBAPS
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Introduction: Hexanucleotide repeat expansion in C9orf72
gene is the most common genetic cause of amyotrophic
lateral sclerosis and frontotemporal dementia (C9ALS/
FTD). Loss of C9orf72 protein function, a toxic RNA gain-
of-function and a gain of function by RAN translation have
been proposed as triggering pathological mechanisms. In
addition, mitochondrial defects have been described to be a
major driver of disease initiation. MtDNA copy number has
been proposed as a useful biomarker of mitochondrial
dysfunction. Therefore, we investigated the role of mtDNA
copy number in the pathogenesis C9ALS/FTD.
Material and Methods: Total mitochondrial and geno-
mic DNA was extracted from postmortem human prefrontal
cortex brains from 18 C9orf72 samples and 11 controls. The
mtDNA copy number was assessed by digital droplet PCR.
Results: A statistically significant decrease was obtained
when comparing C9orf72 samples (3923 mtDNA copies/
diploid genome ± 566) and controls (7017 mtDNA copies/
diploid genome ± 909), with a significant decrease of 55%
of mtDNA copy number in C9orf72 frontal cortex brain
samples. This association was independent of age and
gender.
Conclusions: A growing number of studies demonstrated
the influence of mtDNA copy number reduction on
neurodegeneration. Our results provide new insights into
the role of mitochondrial dysfunction in the pathogenesis of
C9ALS/FTD
Acknowledgements: This work was supported by the
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Study of the C9ORF72 repeat expansion in Greek
patients with neurodegenerative disorders.
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A hexanucleotide repeat expansion located in C9ORF72
gene is as an established cause of amyotrophic lateral
sclerosis (ALS) and/or frontotemporal dementia (FTD).
Since its discovery in 2011, many research groups have
tried to assess its frequency in several neurodegenerative
disorders, reporting differences among populations and
phenotypic heterogeneity. The aim of the present study is to
identify the C9ORF72 expansion in a broad spectrum of
neurodegenerative disorders in Greece (ALS, HD-like
syndromes, dementia, Parkinson’s disease-PD, Hereditary
Spastic Paraplegia—HSP) and healthy controls. Using
molecular biological techniques including Repeat-Primed
PCR (RP-PCR) 860 patients (399 with ALS, 44 with HD-
like syndromes, 224 with dementia, 178 with PD and 15
with hereditary spastic paraplegia, HSP) and 321 controls
were tested for the C9ORF72 repeat expansion. Thirty-eight
patients with ALS (9.5%), 2 with HD-like syndromes
(4.5%), 8 with FTD (8.5%), 1 with AD (1.7%), and 2 with
PD (1.1 %) were expansion-positive. The expansion was
not detected in the HSP or control group. The results of this
study provide an update on the spectrum of C9ORF72-
related neurodegenerative diseases, emphasizing the
importance of establishing C9ORF72 as a diagnostic test in
laboratory routine for both familial and sporadic patients.
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The Cdkl5 phenotype at single cell resolution
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In recent years, a multitude of single-cell sequencing tech-
nologies have been developed that now enable the study of
neurodevelopmental disorders at the organismal scale and
allow for detailed investigations of the roles of specific
genes and regulatory sequences during development.
Here we aim to understand the underlying pathomechan-
ism of the CDKL5 deficiency disorder (CDD), a rare
genetic disorder that causes seizures, developmental delay,
and severe intellectual disability, by studying the Cdkl5
phenotype at single cell resolution. The CDKL5 encoded
protein is a kinase responsible for normal neuronal
development, synapse formation and signal transmission,
but the mechanism(s) by which loss of CDKL5 expression
leads to disease remains unclear.
We studied total brain isolated whole cells from
hemizygous Cdkl5-knockout male mouse embryos
(E18.5) by single-cell RNA sequencing and were able to
identify numerous cell-type-specific phenotypes. Our
single-cell approach provided the necessary resolution to
detect previously unidentified transcriptional changes and
molecular states compared to wildtype mice. Additionally
we identified altered pseudotemporal trajectories of Cdkl5
deficient brain cells during embryonic development. Our
data provides new insights into the molecular pathomechan-
ism of CDD and highlights the potential of single-cell RNA
sequencing as a phenotyping tool for mouse models of
neurodevelopmental disorders.
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Introduction: Autosomal dominant cerebral cavernous
malformations (CCM) are leaky vascular lesions that can
cause epileptic seizures and stroke-like symptoms. Germ-
line mutations in either CCM1, CCM2 or CCM3 are found
in the majority of patients with multiple CCMs or a positive
family history. Recently, we have identified the first copy
number neutral inversion in CCM2 by whole-genome
sequencing in an apparently mutation-negative CCM
family.
Material and Methods: We here asked the question
whether further structural genomic rearrangements can be
detected within NGS gene panel data of unsolved CCM
cases. Hybrid capture NGS data of eight index patients
without a pathogenic single nucleotide, indel or copy
number variant were analyzed using two bioinformatics
pipelines.
Results: In a 58-year-old male with multiple CCMs in his
brain and spinal cord, we identified a 294 kb insertion
within the coding sequence of CCM2. Fine mapping of the
breakpoints, molecular cytogenetic studies, and multiplex
ligation-dependent probe amplification verified that the
structural variation was an inverted unbalanced insertion
that originated from 1p12-p11.2. As this rearrangement
disrupts the CCM2 gene on 7p13, it was classified as
pathogenic.
Conclusions: Our study demonstrates that efforts to
detect structural variations in known disease genes increase
the diagnostic sensitivity of genetic analyses for well-
defined Mendelian disorders.
This study was funded by the Deutsche Forschungsge-
meinschaft (DFG, German Research Foundation, RA 2876/
2-1).
R.A. Pilz: None. K. Schwefel: None. A. Weise: None. T.
Liehr: None. P. Demmer: None. A. Spuler: None. S.
Spiegler: None. E. Gilberg: None. C.A. Hübner: None.
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P09.032.C
Microcephaly-causing dynein mutations lead to severe
neural stem cell proliferation defects in human cerebral
organoïds
S. FARCY1,2, A. Di Cicco2, A. Baffet2, N. Bahi-Buisson1
1Institut Imagine, Paris, France, 2Institut Curie, Paris,
France
The cortex is the centre for our complexes cognitive capa-
cities. Its development is a highly regulated process. The
dynein protein is a unique molecular motor and is crucial
for intra-cellular trafficking. Our team identified mutations
in the gene coding for the dynein in patients with micro-
cephaly. Interestingly, distinct mutations within this same
gene lead to a different phenotype, the spinal muscular
atrophy (SMA). Why some mutations affect the cortex
development and some doesn’t remain unclear. The project
is focus on the cortex, and aim to investigate which specific
neuronal dynein functions are altered, and how it can lead to
microcephaly. In order to study dynein-dependant functions
during cortex development, I generate cerebral organoids,
3D structures that fully recapitulate the human features of
the developing cortex. I reprogrammed two cell lines from
patients caring mutations leading either to microcephaly or
to SMA into pluripotent stem cells (IPSC) and differentiate
them into cerebral organoids. Neuronal defects have been
observed only in the organoids mutated for the micro-
cephaly. The first observation was a strong reduction in the
size of the organoids, which correlates with the patient’s
phenotypes. In those same organoids, an alteration of the
neural stem cells proliferation have been observed as well as
an increase in the number of apoptotic cells. I am using the
live imaging technique, a new outcome in the field. This
technique allows me to investigate in real time the division
of the neural stem cells as well as the newborn neurons
migration to their final location.
S. Farcy: None. A. Di Cicco: None. A. Baffet: None. N.
Bahi-Buisson: None.
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Cerebral palsy is caused by genomic variants in 27% of
patients undergoing exome sequencing
F. Millan1, A. Moreno-De-Luca2,3,4, S. Lewis5,6, H. Z.
Elloumi1, D. R. Pesacreta2,7, S. Shetty5,6, C. Teigen1, M. T.
Oetjens2, J. Heim6, J. Scuffins1, K. E. Wain2, B. Norton5,6,
R. I. Torene1, S. M. Myers2,7, V. Gainullin1, K. Arvai1, D. H.
Ledbetter2,3, M. Fahey8, K. Retterer1, C. L. Martin2,3, M. C.
Kruer5,6
1GeneDx, Gaithersburg, MD, United States, 2Autism &
Developmental Medicine Institute, Geisinger, Danville, PA,
United States, 3Genomic Medicine Institute, Geisinger,
Danville, PA, United States, 4Department of Radiology,
Geisinger, Danville, PA, United States, 5Departments of
Child Health, Neurology, Genetics, and Cellular &
Molecular Medicine, University of Arizona College of
Medicine, Phoenix, AZ, United States, 6Cerebral Palsy &
Pediatric Movement Disorders Program, Barrow Neurolo-
gical Institute at Phoenix Children’s Hospital,, Phoenix,
AZ, United States, 7Bucknell University, Lewisburg, PA,
United States, 8Department of Paediatrics, Monash Uni-
versity, Melbourne, Australia
Introduction: Cerebral palsy (CP) describes a hetero-
geneous group of developmental brain disorders character-
ized by posture and movement impairments. Accumulating
evidence suggests a significant genetic contribution.
Materials and Methods: Exome sequencing (ES) was
performed on 1,777 patients with CP. Positive cases
harbored one or two pathogenic or likely pathogenic alleles,
depending on mode of inheritance, in a single gene.
Results: ES yielded a positive result in 27.5% of patients
(488/1777). Causative variants were identified in genes
associated with autosomal dominant (66.0%), autosomal
recessive (19.9%), and X-linked disorders (14.1%), encom-
passing 238 different genes. Trio testing revealed a high de
novo rate (71.5%). Linear modeling indicated that the
likelihood of harboring a pathogenic variant was higher in
patients with multiple co-morbid neurodevelopmental
disorders (OR=1.34; 95% CI=1.18-1.53; p=7.28x10−6).
Subset analysis from one study center (n = 208) showed
that individuals lacking CP risk factors were 8-fold more
likely to have a genetic etiology when controlling for
GMFCS score (95% CI=2.33-52.59; p=0.0052).
Conclusions: ES identified a genetic etiology in more
than a quarter of CP patients, supporting genetic testing in
this group. Although recurrent CP-associated genes were
elucidated, the results revealed vast genetic heterogeneity,
underscoring the need for a broad genetic testing approach
for CP. The high rate of de novo findings supports utilizing
trio-testing. Individuals with multiple co-morbidities were
more likely to have a positive finding, as were those lacking
traditional CP risk factors. Genetic testing of patients with
CP can inform an accurate recurrence risk, and provide
information for prognosis, adjusted therapies, and manage-
ment options.
F. Millan: A. Employment (full or part-time); Significant;
GeneDx. A. Moreno-De-Luca: None. S. Lewis: None. H.Z.
Elloumi: A. Employment (full or part-time); Significant;
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SLC12A6 gene: De novo variants cause dominant-
intermediate Charcot-Marie-Tooth
J. Park1,2, B. Flores3, K. Scherer4, H. Küpper5, M. Rossi6,
K. Rupprich7, M. Rautenberg1, N. Deininger1, A.
Weichselbaum5, A. Grimm2, M. Sturm1, U. Grasshoff1, E.
Delpire3, T. Haack1,8
1Institute of Medical Genetics and Applied Genomics,
University of Tübingen, Tübingen, Germany, 2Department
of Neurology and Epileptology, Hertie Institute for Clinical
Brain Research, University of Tübingen, Tübingen, Ger-
many, 3Department of Anesthesiology, Vanderbilt Univer-
sity School of Medicine, Nashville, TN, United States,
4Children’s Clinic for Rehabilitative Services, Tucson, AZ,
United States, 5Department of Neuropediatrics, University
of Tübingen, Tübingen, Germany, 6Clinical Genomics,
Ambry Genetics, Aliso Viejo, CA, United States, 7Depart-
ment of Neuropediatrics, Essen University Hospital, Essen,
Germany, 8Centre for Rare Diseases, University of
Tübingen, Tübingen, Germany
Introduction: Charcot-Marie-Tooth (CMT) is the most
common peripheral neuropathy. Biallelic truncating and
missense variants in SLC12A6 coding for the potassium
chloride cotransporter KCC3 have been associated with
autosomal-recessive Andermann syndrome. This condition
is characterized by agenesis of the corpus callosum, per-
ipheral neuropathy and developmental delay. One hetero-
zygous de novo missense alteration (Thr991Ala) has been
reported in a patient with progressive, early-onset neuro-
pathy with normal cognition.
Materials and Methods: We performed diagnostic trio
exome sequencing on three affected individuals and their
parents. We collected clinical and electrophysiological data.
Wild-type and mutant KCC3 cotransporters were measured
in Xenopus laevis oocytes using unidirectional 86Rb
uptakes.
Results: In three unrelated individuals, we identified two
different de novo missense alterations (Arg207His and
Tyr679Cys) in SLC12A6. Arg207His was found recurrent
in two patients. Functional analyses demonstrated a
significant reduction of K+ influx in all mutant KCC3
cotransporters (Arg207His, Arg207Cys and Tyr679Cys).
All patients presented early-onset sensorimotor, axonal and
demyelinating neuropathy with normal cognition and
brain MRI.
Conclusions: We conclude that heterozygous de novo
SLC12A6 alterations can cause intermediate CMT, a milder
phenotype than the autosomal-recessive disorder, Ander-
mann syndrome. Although the patients with de novo
variants in SCL12A6 had a homogenous phenotype, the
biophysical properties of all mutant cotransporters were
different. Furthermore, less is known about the role of
histidine or cysteine on Arg207 that causes different
inheritance patterns.
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Küpper: None. M. Rossi: None. K. Rupprich: None. M.
Rautenberg: None. N. Deininger: None. A. Weichsel-
baum: None. A. Grimm: None. M. Sturm: None. U.
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Homozygous frameshift mutation in CHDH associated
with adult-onset Spastic Ataxia
C. Catalli1, H. Maortua Olabe1, M. Gonzalez Bouzas1, L.
Garcia Naveda1, I. Llano Rivas1, B. Gener Querol1, I.
Rouco Axpe2
1Osakidetza Basque Health Service, Cruces University
Hospital, Department of Genetics, Barakaldo, Spain, 2Osa-
kidetza Basque Health Service, Cruces University Hospital,
Department of Neurology, Barakaldo, Spain
Introduction: Spastic ataxias (SAs) are a heterogeneous
group of diseases, sharing symptoms and molecular path-
ways with other classes of neurodegenerative entities, like
Spinocerebellar Ataxias (SCAs) and Hereditary Spastic
Paraplegias (HSPs), often manifesting with complicated
neurological features. Here we describe a new association
with a truncating homozygous mutation in CHDH gene, not
associated with any disease until now.
Materials and methods: A 70 years old man, son of
second-cousins, presented with progressive spastic ataxia
since his fifties, associated with ptosis, autonomic features,
diffuse leukoencephalopathy and cortical atrophy. Routing
screening for acquired forms was performed, along with
common causes of ataxia caused by dynamic expansions.
Exome was sequenced with xGen Exome Panel v1.0, IDT,
on a NextSeq 500 by Illumina. Validated OMIM genes
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were analyzed and broad search in all candidate genes was
performed in search of homozygous potentially pathologic
mutations.
Results: No common SCAs nor Friedreich Ataxia
expansions were detected. Exome analysis failed to find
any variation amongst 33 validated genes causing auto-
somal recessive SA. Broad analysis extended to all OMIM
and no OMIM genes led to identify a ultrarare frameshift
mutation, c.386del (p.G129Vfs*89) in CHDH gene in
homozygous state. No other potentially pathological varia-
tions were found.
Conclusions: CDHD is a mitochondrial enzyme involved
in mitophagy and interacts with other genes like SQSTM1,
PARK2 and TMEM70, which cause different neurodegen-
erative diseases through mitochondrial dysfunction when
mutated. Functional studies are ongoing. We propose
CHDH as candidate gene for autosomal recessive neuro-
generative diseases presenting with SA, inexplicable
leukoencephalopathy or cognitive decline.
C. Catalli: None. H. Maortua Olabe: None. M.
Gonzalez Bouzas: None. L. Garcia Naveda: None. I.
Llano Rivas: None. B. Gener Querol: None. I. Rouco
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Evaluation of recurrent copy number variations in
patients with neurodevelopmental disorders
L. Morozin Pohovski1, A. Bobinec1,2, A. Measic1,2, N.
Vidan Rogulj1, I. Sansovic1,2, M. Kero1,2, L. Boban1,2, I.
Barisic1,2
1Children’s Hospital Zagreb, Medical School University of
Zagreb, Zagreb, Croatia, 2Department of Medical Genetics
and Reproductive Health, Children’s Hospital Zagreb,
Scientific Centre of Excellence for Reproductive and
Regenerative Medicine (CERRM), University of Zagreb
School of Medicine, Zagreb, Croatia
Background: Neurodevelopmental disorders (NDDs) are a
wide range of neuropsychiatric conditions caused by
impaired growth and development of the central nervous
system. NDDs include autism spectrum disorders, intellec-
tual disability/developmental delay, communication dis-
orders, attention-deficit/hyperactivity, epilepsy, specific
learning problems and motor disorders. The risk of devel-
oping NDDs seems to be highly influenced by the effect of
rare but recurrent copy number variations (CNVs).
Methods: We have analysed the findings of CNV studies
from a cohort of 1170 patients with NDDs referred for
clinical geneticist evaluation. The analysis was conducted
using Agilent 60K oligonucleotide array-based comparative
genomic hybridization.
Results: Chromosome microarray analysis was per-
formed in 1170 patients with NDDs and CNVs were
identified in 89 children (7,6%). We identified 45 duplica-
tions and 44 deletions involving chromosomal regions
1q21.1, 3q29, 15q11.2, 15q13.3, 16p11.2, 16p13.11 and
22q11.2. 47 (52,8%) were considered to be pathogenic, 11
(12,3%) likely pathogenic and 31 were variants of unknown
significance (VUS). In 15 patients two or three copy
number alterations were present.
Conclusions: A rare CNVs contribute to a significant
proportion to the risk of developing NDDs. Counselling for
CNVs remains challenging because of variable penetrance and
expressivity. Further data collection is needed to fully evaluate
the impact of rare CNVs on complex the etiology of NDDs.
Acknowledgement: This work was supported by Scientific
Center of Excellence for Reproductive and Regenerative
Medicine and by the European Union through the European
Regional Development Fund, under grant agreement No.
KK.01.1.1.01.0008, project „Reproductive and Regenerative
Medicine - Exploring New Platforms and Potentials.
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DCTN1 mutation analysis in Italian patients with PSP,
MSA and DLB
R. Procopio1,2, M. Gagliardi1, M. D’Amelio3, L. Brighina4,
G. Nicoletti1, M. Morelli2, G. Bonapace5, A. Quattrone6, G.
Annesi1
1Institute of Molecular Bioimaging and Physiology,
National Research Council, Section of Germaneto, Catan-
zaro, Italy, 2Institute of Neurology, Department of Medical
and Surgical Sciences, University Magna Graecia, Catan-
zaro, Italy, 3Department of Experimental Biomedicine and
Clinical Neuroscience (BioNeC), University of Palermo,
Palermo, Italy, 4Department of Neurology, Milan Center
for Neuroscience, San Gerardo Hospital, University of
Milano-Bicocca, Monza, Italy, 5University Magna Graecia,
Faculty of Medicine, Pediatrics, Catanzaro, Italy, 6Neu-
roscience Center, University Magna Graecia, Catanzaro,
Italy
Introduction: Progressive supranuclear palsy (PSP), mul-
tiple system atrophy (MSA), and dementia with Lewy
bodies (DLB) are defined as atypical parkinsonisms. This
term describes a syndrome characterized by typical par-
kinsonian features, such as bradykinesia, rigidity, postural
instability and resting tremor, and other clinical signs aty-
pical for Parkinson’s disease (PD). The signs are different
for each disease, but they share the pathological
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mechanisms: they presented intracellular protein aggrega-
tion in the brain of tau or α-synuclein, which is thought to
be the cause of the development of the disease. Mutations in
genes encoding tau and α-synuclein have been identified as
risk factors for these diseases. DCTN1 encodes the largest
subunit of dynactin complex essential in the retrograde
axonal transport and cytoplasmic transport of vesicles;
mutations in DCTN1 have been reported predominantly in
individuals with Perry syndrome and, recently, in patients
with PSP. Here we performed a mutational screening of
DCTN1 in 207 patients with atypical parkinsonisms
from Italy.
Material and Methods: The cohort included 79 patients
with PSP, 100 patients with MSA and 28 patients with
DLB. A control group of 500 healthy subjects from the
same geographical area was also examined. All 32 exons
and intron-exon boundaries region of DCTN1 were
sequenced.
Results: Sequence analysis revealed only a synonymous
variant in one of PSP case, and two intronic variants with
the same frequency in patients with atypical parkinsonisms
and healthy subjects cohort.
Discussion: DCTN1 mutations have not a key role in the
development of atypical parkinsonisms in the Italian
population.
R. Procopio: None. M. Gagliardi: None. M. D’Amelio:
None. L. Brighina: None. G. Nicoletti: None. M. Morelli:
None. G. Bonapace: None. A. Quattrone: None. G.
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Genetic characterization of Hungarian patients with
early onset dementia
D. Csabán1, R. Bencsik1, A. Illés1, V. Molnár1, P. Balicza1,
A. Gézsi1, Z. Grosz1, Á. Palásti1, N. Á. Varga1, H. Zeke1, A.
Gál1, T. Kovács2, M. J. Molnár1
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Semmelweis University, Budapest, Hungary, 2Department
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Introduction: Dementia is one of the most common neu-
rodegenerative disorder with a previously suggested het-
erogeneous genetic background. In the recent years the
increasing availability of Next Generation Sequencing
(NGS) has made it possible to better understanding the
genetic background of this disease group.
Materials and Methods: In our study 111 Hungarian
patients with relatively early onset dementia (mean age of
onset was 56 ± 7.41 years) were pre-screened for the most
common AD or FTD associated genes by Sanger
sequencing and C9orf72 hexanucleotide repeat expansion.
In subjects without positive results (n = 56), targeted panel
sequencing was performed on the Illumina platform. The
common AD genetic risk factors, APOE and MTHFR
genotyping were performed too.
Results: In the most common dementia associated genes
(PSEN1, PSEN2, APP, GRN), mutations were detected in
8.1 % of the cases. Abnormal repeat number for C9orf72
gene was identified in 6 cases. Further heterozygous
possibly damaging alterations were detected by NGS in
other genes such as TREM2, ABCA7, PLA2G6, C19orf12,
PARK7. In some cases the coexistence of a genetic risk
factors and a rare variant indicating monogenic dementia
has additive effect on the phenotype.
Conclusions: In our study, variants with potential
association with the early onset dementia were identified
in 20.7% of the investigated cohort. With the application of
NGS both rare damaging variants and genetic risk factors
could be effectively identified, which could contribute to
understand the complex genetic architecture of dementias
and could be helpful for genetic counselling.
Disclosure: Hungarian Brain Research Program (KTIA_-
NAP_ 2017-1.2.1-NKP-2017-00002)
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Monogenic causes of developmental epileptic encepha-
lopathies in a large cohort from Latin America
H. T. Moraes1,2, H. Urquia-Osorio1,3, C. M. Cavalcante1,
E. Almendares-Bonilla1,2, M. M. Guerreiro1, M.
Montenegro1, B. Henning1,2, B. S. Carvalho4,2, A. Coan1,
M. T. Medina3, R. Caraballo5, I. Lopes-Cendes1,2
1School of Medical Sciences, State University of Campinas,
Campinas, Brazil, 2Brazilian Institute of Neuroscience and
Neurotechnology - BRAINN, Campinas, Brazil, 35Faculty
of Medical Sciences, National Autonomous University of
Honduras, Tegucigalpa, Honduras, 4Institute of Mathe-
matics, Statistics and Computer Science, University of
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Neurology, Buenos Aires, Argentina
Introduction: Recent molecular genetics techniques
improved mutations detection in patients with develop-
mental epileptic encephalopathies (DEEs). However, the
current studies are performed predominantly in European
populations, and information in more ethnically diverse
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groups is lacking. This study aims to search for the
monogenic causes of DEEs in Latin-America.
Materials and Methods: We ascertained 316 patients
from different countries: Brazil (223), Argentina (57), Chile
(15), Peru (14), Uruguay (4), and Honduras (3). To date, we
performed whole-exome sequencing in 100 patients. For
genetic variant selection, two filters were used: i) read depth
(RD≥10), allele frequency in control population (≤1%) and
exonic consequence; ii) 129 known genes related to DEEs.
For variants of interest selection, three criteria were used:
considered deleterious by variant effect predictors, impact
in the protein, presence on dbSNP and CLINVAR.
Results: The mean RD was 30X, and the mean
percentage of targets with at least 10x RD was 89%. The
mean number of genetic variants per patient was 19,5341
before the filters and 22 after the filters. We selected sixty-
three variants of interest in 41 genes from 49 individuals for
further studies. From the selected variants, 51 are missense,
5 nonsense, 4 frameshift indel, 2 in-frame indel, and one
affects a splicing site. According to the American College
of Medical Genetics classification 52 variants are of
uncertain significance, 9 likely pathogenic, one likely
benign, and one pathogenic.
Conclusions: The combined filters and selection criteria
used identified genetic variants of potential clinical interest
in 49% of Latin-American patients with DEE.
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Vitamin D3supplementation affects the morphology and
MTHFR and caspase 3 p12 expression in the olfactory
bulb of a mouse model for Down syndrome
F. Campos Gomes1, J. S. Melo-Neto2, M. F. Ramires
Ferrari3, O. Y. Galvis-Alonso4, E. M. Goloni-Bertollo1, É.
C. Pavarino1
1Genetics and Molecular Biology Research Unit (UPGEM),
São José do Rio Preto Medical School (FAMERP), São
José do Rio Preto, Brazil, 2Institute of Health Sciences,
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3Department of Genetics and Evolutionary Biology, Bios-
ciences Institute, University of São Paulo (USP), São
Paulo, Brazil, 4Laboratory of Experimental Physiology,
São José do Rio Preto Medical School (FAMERP), São
José do Rio Preto, Brazil
Introduction: Individuals with Down syndrome (DS) have
olfactory function impairment and are susceptible to
develop Alzheimer’s disease (AD). Olfactory dysfunction
may be an early clinical symptom of AD. Recent studies
show that vitamin D3 (VD3) has neuroprotective effects in
mouse models of AD. In this study, we evaluated the effects
of VD3 on the olfactory bulb (OB) in mouse model for DS.
Materials and Methods: Female mice with 14-week-old
of the lineage B6EiC3Sn-Rb(12.Ts171665Dn)2Cje/CjeDnJ
were distributed into experimental groups: with trisomy (Ts
(CO) or Ts(VD3)) and wild-type (Wt(CO) or Wt(VD3)), and
treated for 10-week with common diet (CO) or 12.500 IU/
Kg of VD3. At twenty-fourth week old the mice were
euthanized. The OB was processed for morphological/
stereological analysis; immunochemistry/Western blotting
for Aβ-42, Caspase-3 p12, MTHFR, NeuN and Pgp. Data
were analyzed statistically (P < 0.05). The F-(F) and H-
statistic (H) were used to analyze between-groups factors
(trisomy; vitamin D3; interaction).
Results: Trisomy reduced the volume of the external
plexiform layer (F = 4.313; P = 0.046), number of mitral
cells (F = 9.941; P = 0.006), increased Pgp expression (F =
9.802; P = 0.005), caspase-3 p12 in (P < 0.0001) and Aβ-42
(H=8.67; P= 0.003). VD3 reduced the expression of
caspase-3 p12 (F=107.729; P < 0.0001) and MTHFR
(F=13.191; P=0.002) and increased the volume of the
mitral cell layer (F = 5.398; P = 0.034).
Conclusions: Ts mice show morphological and molecu-
lar changes in the OB and VD3 can attenuate and reverse
these abnormalities indicating its neuroprotective function.
Grants: Capes (Code 001); CNPq (310806/2018-6) and
FAPESP (2018/09126-0).
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A clinical case of dystonia-28 childhood-onset with a
previously undescribed variant in the KMT2B gene.
D. Guseva, I. Sharkova, N. Semenova, E. Dadali
Research Centre for Medical Genetics, Moscow, Russian
Federation
Introduction: Dystonia-28 is a neurological disorder
characterized by onset of progressive dystonia in the first
decade of life. It is an autosomal dominant disease with
incomplete penetrance. The clinical symptoms of dystonia-
28 are development delayed, microcephaly, focal or gen-
eralized dystonia, gait difficulties and toe walking.
Materials and methods: We present a 7-year-old girl
with clinical symptoms of generalized dystonia. Motor
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development is delayed - keeps his head from a fore month,
sits from a ten month, walk from a year. At the age of 2
years, she started walking on "socks" and instability was
observed. At the age of 6 years, after infections, there was
tension in the muscles of the left leg, involuntary move-
ments, a turn of the left leg when walking, tiredness due to
walking. The dystonia was progressive and eventually
became generalized with involvement of the upper limbs,
hands, neck, face, tongue, and trunk. She had microcephaly
elongated face, dysarthria, generalized dystonia, and
spasticity. EEG and MRI of the brain were normal.
Results: Analysis of whole genome sequencing data
revealed a previously undescribed heterozygous variant
с.3626G>A in KMT2B gene. This variant was not detected
in either parent and was confirmed with Sanger sequencing.
Conclusions: We report clinical case with undescribed
heterozygous variant KMT2B in the girl with a clinically
recognizable form of dystonia. Verification of the genetic
etiology of dystonia allowed selection of appropriate
treatment strategies, determination of genetic risk and
discussion of the necessary of prenatal testing.
D. Guseva: None. I. Sharkova: None. N. Semenova:
None. E. Dadali: None.
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Understanding the mechanism of RNF216-mediated
neurodegeneration: genetic, proteomic, neuropathologi-
cal and cellular approach
S. Roy1,2, P. Ervilha Pereira1,2, N. Schuermans1,2, A.
Sieben3,4, F. Thery5,6, E. Mondragon Rezola7, E.
Debackere1,2, P. LeBlanc1,2, M. Galas8, P. Santens3,4, F.
Impens5,6, E. Bogaert1,2, B. Dermaut1,2
1Center for Medical Genetics, Ghent University Hospital,
Gent, Belgium, 2Department of Biomolecular Medicine,
Faculty of Medicine and Health Sciences, Ghent University,
Ghent, Belgium, 3Department of Neurology, Ghent Uni-
versity Hospital, Gent, Belgium, 4Department of Head and
Skin, Faculty of Medicine and Health Sciences, Ghent
University, Ghent, Belgium, 5Department of Biomolecular
Medicine, Faculty of Medicine and Health Sciences, Ghent
University, Gent, Belgium, 6Center for Medical Biotechnol-
ogy, VIB Ghent, Ghent, Belgium, 7Department of Neurol-
ogy, University Hospital Donostia, Basque Country
University, Donostia, Spain, 8Inserm, UMRS1172, JPARC,
Alzheimer & Tauopathies, Lille, France
Introduction: Neurodegenerative diseases frequently result
from mutations in ubiquitin-signaling genes. Our group was
among the first to report bi-allelic mutations in RNF216, an
E3 ubiquitin ligase, as the genetic cause of Gordon Holmes
syndrome (GHS), an adult-onset rare neurodegenerative
disorder characterized by ataxia, dementia and hypogona-
dotropic hypogonadism or Huntington-like disorder (HDL).
To date, >10 mutations in RNF216 have been reported not
only from the catalytic active site but also from N-terminal
part of the protein.
Objective: We intend to unravel the mechanisms by
which RNF216 mutations lead to GHS and HDL. We aim
to identify novel RNF216 mutations for genotype-
phenotype correlation studies, identify protein composition
of the pathological intranuclear inclusions, and understand
the cellular and biochemical function of the RNF216
protein.
Methods: Frozen and fixed brain material from patient
were used for generalized proteomics and neuropathological
studies and patient fibroblast and Hela cells were used for
cellular studies.
Results: We describe a Spanish patient with HDL having
2 novel compound heterozygous missense mutations in
RNF216. The study of brain material from one of the two
reported Belgian families demonstrated ubiquitin- and p62-
positive intranuclear inclusions, negative for Tau, α-
synuclein and TDP-43. Proteomics generated a list of
candidate genes whose histopathological examination is
currently ongoing. Hela cells transfected with wildtype and
mutant RNF216 constructs revealed RNF216 and ubiquitin
positive intranuclear speckle-like bodies.
Conclusions: The identity of intranuclear bodies should
be further analyzed hoping to reveal molecular intricacies
linked to this neurodegenerative disease.
Odysseus Type-I (G0H8318N) FWO grant, Starting grant
(01N10319) Ghent University
S. Roy: None. P. Ervilha Pereira: None. N. Schuer-
mans: None. A. Sieben: None. F. Thery: None. E.
Mondragon Rezola: None. E. Debackere: None. P.
LeBlanc: None. M. Galas: None. P. Santens: None. F.
Impens: None. E. Bogaert: None. B. Dermaut: None.
P09.049.B
Identification of genes for epileptic encephalopathy: the
impact of exome analysis in a pediatric cohort.
L. Musante1, C. Zanus2, P. Costa2, A. P. d’Adamo1, A. M.
Bianco1, G. Ragusa1, E. Athanasakis1, F. Faletra1, P.
Gasparini1, M. Carrozzi2
1SC Genetica Medica, Institute for Maternal and Child
Health IRCCS Burlo Garofolo, Trieste, Italy, 2SC Neurop-
sichiatria Infantile, Institute for Maternal and Child Health
IRCCS Burlo Garofolo, Trieste, Italy
Early onset infantile epileptic encephalopathies (EIEE) are
neurodevelopmental disorders, with persistent severe elec-
troencephalographic abnormalities, developmental delay or
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regression associated with ongoing epileptic activity and
often characterized by pharmaco-resistant epilepsy. By
Next-Generation Sequencing (NGS) great advances have
been made in gene discovery for EIEE and several studies
emphasized de novo variants as major underlying cause.
Current diagnostic pathways allow molecular diagnosis to
be made in about 20% of cases with EIEE and recent studies
have also highlighted extreme genetic heterogeneity.
Therefore, the current scenario indicates that most of the
genes responsible for EIEE are probably still unknown. To
this regard, our group recruited 21 patients (and their par-
ents) with EIEE or epilepsy of unknown origin, negative for
the presence of micro-arrangements, and investigated by
WES, in the frame of the multicentric project EPI-IDEA,
which is part of the RETE-IDEA network constituted by
eight Italian pediatric IRCCS. In our study, we identified a
pathogenic or very likely pathogenic variant/genotype in
about 48% of the patients. Only in 2 patients a de novo
mutation was identified, whereas 64% of diagnosed cases
were caused by recessive genes previously associated with a
seizure-related phenotype/s, including five compound het-
erozygosity for causative sequence and 2 homozygous. 27%
of the mutations were novel variants not described before.
10 patients are currently still under investigation. Our
results confirm a relevant role of mostly compound het-
erozygous recessive inheritance for EIEE with important
implication for genetic counselling.
L. Musante: None. C. Zanus: None. P. Costa: None. A.
P. d’Adamo: None. A.M. Bianco: None. G. Ragusa:
None. E. Athanasakis: None. F. Faletra: None. P.
Gasparini: None. M. Carrozzi: None.
P09.050.C
Clinical significance of submicroscopic copy number
variants (CNVs) in the etiopathogenesis of epilepsy
I. Plaskota, M. Bartnik-Głaska, M. Smyk, B. Wiśniowiecka-
Kowalnik, K. Kowalczyk, M. Paczkowska, M. Zbiciak, J.
Bernaciak, E. Szczepanik, H. Mierzewska, E. Obersztyn, B.
Nowakowska
Institute of Mother and Child, Warsaw, Poland
Epilepsy is one of the most common diseases of the central
nervous system affecting about 1% of the human popula-
tion. The etiology of epilepsy remains unknown in 40-50%
of cases, although it is well known that approximately 30%
causes is genetic. According to recent studies, the copy
number variants (CNVs) are important factors in this dis-
order (2-11%). We used array CGH method in a cohort of
90 patients with epilepsy, and neurodevelopmental
abnormalities with or without dysmorphic features. Array
CGH analysis was performed using genome-wide
microarray with average resolution of 30 kb (180K, OGT)
with specifically designed coverage for over 212 selected
genes, known or candidate to play an important role in the
pathogenesis of epilepsy. Chromosomal microarray analysis
revealed 33 CNVs (17 duplications, 15 deletions, 1 tripli-
cation) in 29 out of 90 (32.2%) patients with epilepsy. 2
pathogenic CNVs were detected in 2 patients from our
cohort. 9 potentially pathogenic CNVs, and 22 CNVs with
unknown clinical significance were detected in 27 indivi-
duals. All of the identified CNVs were submicroscopic in
size, ranging from 1.7 kb to 8.85 Mb, and therefore could
not have been detected by standard karyotype analysis.
Additionally, 17 CNVs (51%) could not have been detected
by our clinical microarray (60K). Our study highlights the
role of CNVs in the etiopathogenesis of epilepsy and
demonstrates that the array CGH is an effective tool in the
genetic diagnosis of this neurodevelopmental disorder. The
work was supported by projects 510-18-47, 510-18-57,
510-18-71 from the Ministry of National Education
I. Plaskota: None. M. Bartnik-Głaska: None. M.
Smyk: None. B. Wiśniowiecka-Kowalnik: None. K.
Kowalczyk: None. M. Paczkowska: None. M. Zbiciak:
None. J. Bernaciak: None. E. Szczepanik: None. H.
Mierzewska: None. E. Obersztyn: None. B.
Nowakowska: None.
P09.051.A
Two novel mutations in GRIN2A and LGI1 in multi-
generational Bulgarian families with different forms of
epilepsy
V. Peycheva1, K. Kamenarova1, R. Tzveova1, N. Ivanova1,
S. Zhelyazkova2, M. Radionova2, I. Pacheva3, I. Ivanov3, I.
Litvinenko4, V. Mitev1, I. Tournev2, A. Jordanova1,5, R.
Kaneva1
1Molecular Medicine Center, Department of Medical
Chemistry and Biochemistry, Medical University-Sofia,
Sofia, Bulgaria, 2Clinic of Neurology, University Hospital
“Alexandrovska”, Department of Neurology, Medical
University-Sofia, Sofia, Bulgaria, 3University Hospital “St.
George”, Department of Pediatrics and Medical Genetics,
Medical University- Plovdiv, Plovdiv, Bulgaria, 4University
Pediatrics Hospital, Clinic of Pediatric Neurology, Medical
University-Sofia, Sofia, Bulgaria, 5Molecular Neurogene-
nomics Group, VIB-Antwerp Center for Molecular Neurol-
ogy, University of Antwerp, Antwerp, Belgium
The aim of the study was to reveal the genetic causes of the
familial epilepsy in two four-generational clinically het-
erogeneous Bulgarian families. Both families were clini-
cally assessed in detail and mutation analysis was
performed using Clinical Exome Sequencing(CES) with
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Illumina platform. In the first family CES revealed a fra-
meshift deletion (c.194delT,p.Leu65ArgfsTer3) affecting
the GRIN2A gene. The proband presented unprovoked
myoclonic and Generalized Tonic-Clonic Seizures(GTCS),
motor aphasia and moderate intellectual disability (ID). In
his pedigree we diagnosed a total of seven additional
affected members all having GTCS with onset around 4-6
years of age. The GRIN2A gene encodes a subunit of N-
methyl-D-aspartate(NMDA) receptors found in excitatory
synapses with role in neural plasticity. GRIN2A mutations
are associated with focal epilepsy with speech disorder with
or without cognitive disability. In the second family CES
revealed a possibly pathogenic splice-acceptor variant
c.216-1G>A in exon 2 of the LGI1 gene. This family
consists of a total of eight affected members. The proband
presented a fever-provoked GTCS, while his first-degree
relatives have GTCS preceded by auditory aura and later
onset. LGI1 gene encodes brain leucine-rich protein reg-
ulating postnatal glutamatergic synapse development. Loss
of function LGI1 mutations are associated with partial epi-
lepsy with auditory features. Confirmation Sanger sequen-
cing showed that the variants segregate with disease
phenotype in all available affected members from each
family. Both variants are absent in public databases. Further
investigations are needed to elucidate the splice-site muta-
tion effect on RNA level. The study was supported by
Grants DTK/67/2009 and DUNK/01-2/2009 of NSF, MES,
Bulgaria.
V. Peycheva: None. K. Kamenarova: None. R.
Tzveova: None. N. Ivanova: None. S. Zhelyazkova:
None. M. Radionova: None. I. Pacheva: None. I. Ivanov:
None. I. Litvinenko: None. V. Mitev: None. I. Tournev:
None. A. Jordanova: None. R. Kaneva: None.
P09.053.C
ADGRV1 is a susceptibility gene for familial forms of
Genetic Generalized Epilepsy
M. Dahawi1,2, M. S Elmagzoub3, E. A Ahmed4, F. A
Elmugadam5, W. A Abdelgadir6, O. Abdalla7, J. Buratti8, E.
Noé9, M. Alzubeir5, R. Abubakr10, S. Baldassari9, S.
Baulac9, L. Elsayed11, A. E Ahmed5, E. Leguern9,12
1University of Khartoum, Faculty of medicine, department
of physiology, Khartoum, Sudan, 2niversity of Khartoum,
Faculty of medicine, department of physiology, Khartoum,
Sudan, 3National Ribat University Faculty of Medicine,
khartoum, Sudan, 4UNESCO Chair on Bioethics, University
of Khartoum, Faculty of Medicine, Sudan, khartoum,
Sudan, 5University of Khartoum, Faculty of medicine,
Sudan, khartoum, Sudan, 6Al-Neelain University, Faculty of
science and technology, department of biochemistry and
molecular biology, Khartoum, Sudan., khartoum, Sudan,
7University of Khartoum, Faculty of medicine, department
of physiology, Sudan, khartoum, Sudan, 8Department of
genetics, La Pitié-Salpêtrière Hospital, AP-HP Sorbonne
Université, paris, France, 9Institut du Cerveau et de la
Moelle épinière, INSERM U1127, CNRS UMR7225, paris,
France, 10University of Khartoum, Faculty of medicine,
Sudan, Khartoum, Sudan, 11University of Khartoum,
Faculty of medicine, department of biochemistry, Sudan,
khartoum, Sudan, 12Department of genetics, La Pitié-
Salpêtrière Hospital, AP-HP Sorbonne Université, Paris,
France
Objective:Genetic generalized epilepsies (GGE) including
childhood absence epilepsy (CAE), juvenile absence epi-
lepsy (JAE), juvenile myoclonic epilepsy (JME), and GGE
with tonic-clonic seizures (TCS) alone (GGE-TCS), are
mainly determined by genetic factors with a likely poly/
oligogenic mode of inheritance. Recent studies on large
American or European cohorts showed that susceptibility
genes for GGE are numerous and their variants rare, chal-
lenging their identification. In this study, we aimed to assess
the GGE genetic etiology in a Sudanese population.
Methods:We collected 13 large consanguineous families
with GGE from Sudan including 34 patients to search for
GGE susceptibility genes. We performed whole exome
sequencing (WES) in DNA samples of probands from 13
families. We filtered non-silent ultrarare/rare variants
identified in each family and compared them with publicly
available data and ethnicity-match controls.
Results:We identified in a family of 3 siblings with GGE-
TCS one ultra-rare missense variant in ADGRV1, a gene
recently involved in the pathogenesis of sporadic myoclonic
epilepsies. Five additional ADGRV1 ultra rare/rare missense
variants segregated with GGE in three of the remaining
families. The frequency of this class of ADGRV1 variants
was significantly higher in our cohort compared to gnomAD
African controls (P=0.0018). A homozygous patient for an
ADGRV1 variant presented a more severe phenotype than
her heterozygous brother, suggesting a dosage effect.
Significance:Our study showed for the first time the
segregation of ADGRV1 variants with familial GGE,
extending the phenotype spectrum of ADGRV1-related
epilepsies to CAE/JAE and GTC epilepsy. This work was
supported by INSERM (France), IHU-A-ICM (France), the
Sudanese Ministry of Higher Education.
M. Dahawi: None. M. S Elmagzoub: None. E. A
Ahmed: None. F. A Elmugadam: None. W. A Abdelga-
dir: None. O. Abdalla: None. J. Buratti: None. E. Noé:
None. M. Alzubeir: None. R. Abubakr: None. S.
Baldassari: None. S. Baulac: None. L. Elsayed: None.
A. E Ahmed: None. E. Leguern: None.
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P09.054.A
EFHC2 variants in juvenile myoclonic epilepsy
S. V. JOSHI1, P. Raju1, P. Satishchandra2, S. Sinha2, S.
Nayak1, A. Anand1
1Jawaharlal Nehru Centre for Advanced Scientific
Research, Bengaluru, India, 2National Institute of Mental
Health and Neurosciences, Bengaluru, India
Juvenile myoclonic epilepsy (JME) is a brain disorder
characterized by frequent myoclonic seizures often accom-
panied by generalized tonic-clonic seizures during adoles-
cence. Here, we present, our work on contribution of
EFHC2 in predisposition to JME. EFHC2 encodes a protein
containing three DM10 domains and a putative EF-hand
motif. EFHC2 is expressed in the mammalian brain regions:
cerebral cortex, hippocampus, hypothalamus and cere-
bellum. In cultured mammalian cells, it localizes to the
spindle poles and midbody. We have identified seven
potentially pathogenic EFHC2 variants present almost
exclusively among 500 JME patients examined. On over-
expression of EFHC2 carrying these variants, significant
levels of spindle abnormalities, multi-polarity and chro-
mosome segregation defects are observed. We analyze the
contribution of the DM10 domains to subcellular localiza-
tion and function of the protein. EFHC2 is a homolog of
EFHC1, a known JME causing gene. Cellular defects
caused by EFHC2 variants in cultured mammalian cells are
partially rescued by EFHC1, and vice versa. EFHC2 co-
precipitates with α-tubulin and γ-tubulin suggesting that
EFHC2 is a microtubule-associated protein. EFHC2’s role
in microtubule organization during cell cycle are being
currently studied.
We would like to acknowledge the grant BMS/TF/Trans-
Neuro-2014-3681/Jul-2015/47/KA/Govt.
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P09.055.B
Delineating the phenotypic spectrum of STX1B asso-
ciated epilepsy
M. Schlögl1, M. Krenn1,2, E. Pataraia2, S. Schröder3, J. A.
Mayr4, C. Rauscher4, D. Kotzot5, F. Zimprich2, T.
Meitinger1, M. Wagner1,6
1Institute of Human Genetics, Munich, Germany, 2Depart-
ment of Neurology, Medical University of Vienna, Vienna,
Austria, 3Dr. von Hauner Children’s Hospital, Ludwig-
Maximilians-University Munich, Munich, Germany, 4Uni-
versity Children’s Hospital, Salzburger Landeskliniken
(SALK), Salzburg, Austria, 5Unit of Clinical Genetics,
Salzburg, Austria, 6Institute for Neurogenomics, Helmholtz
Zentrum München, Neuherberg, Germany
Introduction: STX1B (Syntaxin 1B) encodes a presynaptic
protein which is part of the SNARE complex. De novo,
mostly loss of function variants cause a spectrum of epi-
leptic disorders. These have recently been divided into four
groups: (1) Genetic epilepsies with febrile seizures plus
(GEFS+), (2) Genetic generalized epilepsy (GGE), (3)
Developmental and epileptic encephalopathy (DEE) and (4)
Focal epilepsy. Most patients with STX1B-associated epi-
lepsy can be classified as GEFS+, whereas those with GGE
or focal epilepsy are less common.
Materials and Methods: We screened our diagnostic in-
house exome sequencing database comprising 4000 datasets
for cases with de novo and/or loss of function variants in
STX1B and reviewed the clinical information of the
respective patients.
Results: We identified four patients with pathogenic or
likely pathogenic variants in STX1B: c.293G>A, p.(Ser98-
Asn); c.165dup, p.(Gln56ThrfsTer3); p.(Phe215CysfsTer9)
and c.537+1G>A, p.(?). All patients had epilepsy and the
clinical spectrum ranged from febrile and afebrile seizures
to developmental and epileptic encephalopathy with
cerebral malformations.
Conclusions: Our findings confirm the broad clinical
spectrum of STX1B associated epilepsies. We identified
three loss of function variants in differently affected
individuals implying that a one-to-one genotype-
phenotype correlation cannot be established.
M. Schlögl: None. M. Krenn: None. E. Pataraia: None.
S. Schröder: None. J.A. Mayr: None. C. Rauscher: None.
D. Kotzot: None. F. Zimprich: None. T. Meitinger: None.
M. Wagner: None.
P09.057.A
Whole-exome sequencing is effective for clarification of
unsolved causes of epileptic encephalopathies
L. Sedlackova1, P. Lassuthova1, K. Sterbova2, M. Vlckova3,
D. Stanek1, P. Seeman1
1DNA laboratory, Department of Pediatric Neurology, 2nd
Faculty of Medicine, Charles University and University
Hospital Motol, Prague, Czech Republic, 2Department of
Pediatric Neurology, 2nd Faculty of Medicine, Charles
University and University Hospital Motol, Prague, Czech
Republic, 3Department of Biology and Medical Genetics,
2nd Faculty of Medicine, Charles University and University
Hospital Motol, Prague, Czech Republic
Introduction: Epileptic encephalopathies (EE) are severe
epilepsies of childhood with early onset of usually drug-
390 J. del Picchia
resistant seizures and developmental delay or regression.
Their etiology is extremely heterogeneous. Whole-exome
sequencing (WES) was used in patients previously unsolved
using standard diagnostic methods and clinical experience.
Patients and Methods: Here we present WES results of
48 EE patients. These patients were selected based on
previous experience by the expert in epilepsy genetics from
the cohort of patients unsolved after targeted NGS
gene panel.
Results: To date, causative variants were found in ten
patients (20.8%) in genes explaining the cause of EE
(HUWE1, UBTF, SERPINI1, SLC1A4, GABRB2, DHDDS,
PPP2R5D, NARS2, YWHAG, KMT2A). In other six patients
(12.5%), seven suspected variants of unknown causality
were found and wait to be validated and interpreted by
family segregation or phenotype confirmation by the
physician (CACNA1A, SNAP25, NLGN3, CBL, DONSON,
SPATA5, PAK3). In further three patients, we found variants
in genes not associated with EE or any other human disease
(KCNJ4, TULP4, PHYHIP). Five variants out of twenty
presented were already published before (by different
authors) and the rest of them are novel.
Conclusions: WES represents efficient tool for clarifica-
tion of various EE types. It has an important potential for
novel candidate genes detection, however, international
collaboration is required for searching other patients for
genotype-phenotype confirmation. WES may help in
selected patients to obtain genetic diagnosis in those who
remained unclarified after targeted NGS gene panel (up to
40% of patients). Supported by: MH CR AZV 15-33041
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P09.059.C
A novel Italian family with Familial Adult Myoclonic
Epilepsy (FAME) broadens the phenotypic and mole-
cular spectrum of FAME2 caused by a pentanucleotide
expansion in STARD7
L. Veneziano1, A. Coppola2, L. Fontana3, S. Rossi1, L.
Camerota4,3, E. Mantuano1, A. Suppa5,6, L. Bilo2, M.
Iacomino7,8, F. Zara7,8, G. Novelli3,6, G. Cestra9, P.
Striano7,8, A. Botta3, M. Cozzolino1, F. Brancati1,4,10
1Institute of Translational Pharmacology, National
Research Council, Rome, Italy, 2Department of Neu-
roscience, Reproductive and Odontostomatological
Sciences, Federico II University of Naples, Naples, Italy,
3Department of Biomedicine and Prevention, Tor Vergata
University of Rome, Rome, Italy, 4Institute of Medical
Genetics, Department of Life, Health and Environmental
Sciences, University of L’Aquila, L’Aquila, Italy,
5Department of Human Neurosciences, Sapienza University
of Rome, Rome, Italy, 6IRCCS Neuromed Institute, Pozzilli,
Italy, 7Pediatric Neurology and Muscular Diseases Unit,
IRCCS Giannina Gaslini, Genova, Italy, 8Department of
Neurosciences, Rehabilitation, Ophthalmology, Genetics,
Maternal and Child Health, University of Genoa, Genova,
Italy, 9Institute of Molecular Biology and Pathology,
National Research Council, Rome, Italy, 10Laboratory of
Molecular and Cell Biology, IRCCS Istituto Dermopatico
dell’Immacolata, Rome, Italy
Familial Adult Myoclonic Epilepsy (FAME; OMIM Phe-
notypic Series - PS601068) is an autosomal dominant adult-
onset disorder characterized by cortical myoclonic tremor
and epilepsy. FAME is genetically heterogeneous with 6
distinct disease-causative genes identified over the last two
years. Notably, all share an emerging common pathomole-
cular mechanism consisting in the expansion of non-coding
(intronic) pentanucleotide repeats at distinct loci. We report
a novel three generation FAME pedigree with 3 affected
subjects and a healthy carrier. Two sibs had full-blown
FAME phenotype, while a 32-year-old girl manifested only
myoclonus starting at age 25. Molecular genetics investi-
gation by means of repeat primed PCR (RP-PCR) detected
the pathogenic ATTTC pentanucleotide expansion in
STARD7, diagnostic of FAME2. The ATTTT repeat refer-
ence sequence was not identified in the expansion. Sanger
sequencing confirmed an apparent loss of heterozygosity in
affected members and, more interestingly, depicted a com-
plex structure of wild-type (not expanded) alleles. Of note,
ATTTC-STARD7 expansion was confirmed in the unaf-
fected 89-year-old mother of affected sibs. To our knowl-
edge this is the first report of reduced penetrance in a
molecularly confirmed STARD7 expansion carrier indivi-
dual. In addition, the identification of atypical wild-type
alleles broadens the repeat structure repertoire suggesting
further complexity at the STARD7/FAME2 locus.
L. Veneziano: None. A. Coppola: None. L. Fontana:
None. S. Rossi: None. L. Camerota: None. E. Mantuano:
None. A. Suppa: None. L. Bilo: None. M. Iacomino:
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P09.062.C
Mitochondrial dysfunction and oxidative stress contri-
bute to the phenotype of FOXP1 deficiency
J. Wang, H. Fröhlich, G. A. Rappold
Institut für Humangenetik, Heidelberg, Germany
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Patients with FOXP1 haploinsufficiency present intellectual
disability, autism spectrum disorder, severe speech and
language impairments as well as motor dysfunction. To
unravel the pathological mechanism underlying
FOXP1 syndrome, we analysed Foxp1+/- mice, which clo-
sely reflect FOXP1 haploinsufficiency. We can show that
Foxp1+/- animals exhibit behavioural deficits such as
reduced neonatal ultrasonic vocalization, hyperactivity,
anxiety and alterations in spatial navigation and memory.
Furthermore, they manifest decreased exercise capacity and
endurance. We also found that Foxp1+/- animals display a
reduced striatal expression of proteins involved in mito-
chondrial biogenesis and dynamics (Pgc-1α, Tfam, Opa1
and Drp1), suggesting that mitochondrial dysfunction may
contribute to the symptoms. To address this issue in more
detail, we investigated mitochondria in WT and Foxp1+/-
animals. We demonstrate that Foxp1+/- striatal neurons
display a disrupted mitochondrial membrane potential. In
addition, we detected an increased abundance of reactive
oxygen species, increased cytochrome C release as well as
lipid peroxidation in the Foxp1+/- striatum. In summary, our
results indicate mitochondrial dysfunction in murine Foxp1
deficiency, suggesting that mitochondrial dysfunction and
increased oxidative stress may also contribute to the deficits
in FOXP1 Syndrome.
J. Wang: None. H. Fröhlich: None. G.A.
Rappold: None.
P09.063.A
Fragile X premutation mouse embryonic stem cells as an
in vitro model for CGG repeat expansion and disease
pathology
I. Gazy1,2, C. Miller2, G. Kim2, K. Usdin2
1KwaZulu-Natal Research Innovation and Sequencing
Platform (KRISP), University of KwaZulu-Natal, Durban,
South Africa, 2Laboratory of Cell and Molecular Biology,
NIDDK, National Institutes of Health, Bethesda, MD,
United States
The Fragile-X related disorders (FXDs) are Repeat Expan-
sion Disorders (REDs) that result from expansion of a
CGG-repeat tract in the FMR1 gene. While expansion
affects both disease risk and severity in humans, the
underlying molecular mechanism responsible is unknown.
Despite a high frequency of expansions in vivo, existing
patient-derived cell models do not show significant repeat
instability. Here, we describe the generation of mouse
embryonic stem cells (mESCs) carrying an expanded CGG-
repeat tract in the endogenous murine Fmr1 gene. We show
that these cells show high frequency repeat expansions,
visible in a matter of days in culture. Moreover, using the
CRISPR-Cas9 gene editing system, we show that these
expansions are dependent on MSH2, a factor essential for
expansions in vivo. Altogether, our data has implications
for the timing of expansion and allows these cells to be
useful for modeling the expansion mutation. Additionally,
we demonstrate that these cells have abnormalities con-
sistent with human disease including elevated mitochondrial
copy numbers and Fmr1 hyperexpression, that we show is
O2-sensitive. Thus, this new stem cell model should facil-
itate studies of both expansion and the consequences of
expansion during early embryonic development.
I. Gazy: None. C. Miller: None. G. Kim: None. K.
Usdin: None.
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Autophagic alterations in skin fibroblasts from Fragile
X-associated tremor/ataxia syndrome patients
L. Rodriguez-Revenga1, M. Alvarez-Mora1, I. Gonzalez-
Casacuberta2, T. Barcos1, G. Garrabou2
1Hospital Cinic, Barcelona, Spain, 2CIBERER, Barcelona,
Spain
Introduction: Fragile X-associated tremor/ataxia syndrome
(FXTAS) is a late-onset neurodegenerative disorder with
reduced penetrance that appears in adult FMR1 premutation
carriers (55-200 CGGs). The neuropathological hallmark of
FXTAS consists of presence of ubiquitin-positive nuclear
inclusions that are broadly distributed throughout the brain.
Additionally, bioenergetic deficits and mitochondrial dys-
function have been also reported. Since autophagy promotes
cell survival by elimination of damaged organelles and
proteins aggregates, we aimed to study its potential role in
the pathogenesis of FXTAS.
Material and Methods: Skin fibroblasts cultures from
FXTAS patients (n = 4) were used to quantify autophagic
flux (time-course bafilomycin a1-mediated autophagic
inhibition) by measuring by western blot autophagic
substrates (p62 levels), autophagosome formation (LC3-
BII content) and mitochondrial amount (VDAC1
expression).
Results: The analysis of autophagic flux in skin
fibroblasts cultures evidenced enhanced autophagic path-
way activation and increased mitochondrial amount in
FXTAS patients compared to controls. Increased autopha-
gosome number was also confirmed by confocal
microscopy.
Conclusions: These findings suggest that despite the
increase in autophagic flux, abnormal cell waste may
contribute to the pathology of FXTAS fibroblasts by
causing the accumulation of incomplete degraded mito-
chondria, among other subtracts. As a result, we postulate
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that FXTAS fibroblasts suffer from a bioenergetic collapse,
leading to cell stress that triggers cell death.
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Introduction: Parkinson’s disease (PD) is the second most
common neurodegenerative disorder affecting more than
1% of the over-65 population. To date, mutations in the
GBA gene, coding for the lysosomal glucocerebrosidase,
represent the most frequent cause of genetic PD. Besides
GBA, other lysosomal genes have also been implicated in
PD pathogenesis, such as SMPD1, NPC1, and SCARB2.
The reason why patients with the same mutation may or
may not develop neurodegeneration and PD is still unclear.
To this end, we evaluated the impact of the burden of
deleterious mutations in lysosomal genes in patients het-
erozygous for pathogenic GBA mutations vs asymptomatic
GBA-mutation carriers.
Materials and Methods: This analysis was performed
using a custom NGS panel by exploiting a DNA pooling
strategy. The panel included 50 genes responsible for
lysosomal storage disorders (LSD) and all previously
reported PD-genes to evaluate if they contribute to PD
penetrance in GBA-mutation carriers.
Results and Conclusions: Statistical analysis revealed a
significantly increased burden of deleterious variants in
LSD genes in PD cases (P=0.003). In particular, the 36% of
patients was carrier of at least one mutation in an LDS gene
compared to the 23% of controls. Moreover, performing
single-gene analysis, we observed that a second mutation in
GBA represents the strongest modulator of GBA itself (5%
vs 1%, P=0.012). The identification of genetic lesions in
lysosomal genes increasing the risk to develop PD may
contribute to classify patients in subgroups most likely to
benefit from existing and upcoming targeted therapies.
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Modelling motor-neurons in a dish to study the effects of
a homozygous codon-stop mutation in GDAP1 respon-
sible for Charcot-Marie-Tooth disease
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Introduction: Charcot-Marie-Tooth (CMT) disease, the
most common inherited peripheral neuropathy in humans, is
caused by mutations in more than 90 genes. Among these,
GDAP1 encodes for a mitochondrial protein important for
mitochondrial dynamic and protection from ROS. However,
motor neurons (MNs), the mainly involved cells in this
neuropathy, cannot be obtained from patients. Our goal was
to generate MNs derived from iPSc (induced-pluripotent-
stem-cells) in order to investigate the effects of GDAP1-
mutations.
Materials and Methods: We created iPSc from fibro-
blasts of two unaffected subjects and a CMT-patient
carrying a GDAP1 homozygous codon-stop mutation. iPSc
were differentiated in neural progenitors (NP), then in motor
neurons (MN). To study GDAP1 expression, we realized
RNA-extraction, qRT-PCR and immunocytochemistry.
Electronic microscopy and functional tests were also
achieved.
Results: By studying GDAP1 mRNA expression in
Fibroblasts, iPSc, NPs and MNs, on controls’ cells, we
observed that GDAP1 is mostly expressed in neural cells
(NPs and MNs), showing the importance of generating
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MNs to study GDAP1 mutations effects. Interestingly, in all
patient’s cell types, GDAP1 expression was low, suggesting
that GDAP1 mRNA, containing a premature termination
codon (PTC), is probably degraded by the nonsense-
mediated-decay (NMD) system. These results have been
confirmed by immunocytochemistry. Then, we analyzed
morphological and functional properties of our cellular
models.
Conclusions: Cellular models are useful tools to
investigate the impact of genomic mutations on functional
level. Our study highlighted the importance of employing
the good cellular model (MNs), to study the altered
molecular mechanisms associated to GDAP1-mutations in
CMT disease.
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Telomere length and mitochondrial DNA copy number
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Molnár
Institute of Genomic Medicine and Rare Disorders,
Semmelweis University, Budapest, Hungary
Introduction: Telomere length was previously shown to be
decreased in several neurodegenerative disorders including
Huntington’s Disease (HD) while mitochondrial DNA copy
number changes were reported to show conflicting results.
Simultaneous measurements and detailed data on disease
severity is lacking.
Materials and methods: HD patients and preclinical
patients (pathologic CAG expansion carriers) were staged
(n = 142) based on the Shoulson-Fahn clinical staging
system (Stage I-V. and preclinical). A healthy control group
was used (n = 71). mtDNA copy number and telomere
lengths were measured with real-time PCR technique.
Results: For preclinical HD patients the average telomere
length is 133.8 (±88.2) (kb/cel) and mtDNA copy number is
387.5 (±167.4) (pcs/cel). Stage I HD patients have an
average telomere length of 138.7 (±101), mtDNA copy
number of 393.7 (± 117.4), while stage II telomere length is
124.5 (±74.8) and mtDNA copy number is 382.5 (±119.8)
and stage III telomer lengths is 94.1 (±65.8) while mtDNA
copy number is 326.5 (±127). We did not have any stage IV
and V HD patients. Average telomere length for the control
patients is 167.3 (±84.7) while mtDNA copy number is
201.5 (±103.7)
Conclusions: HD patients have a significantly (p < 0,05)
lower telomer length and higher mtDNA copy number than
healthy controls. Both telomere length and mitochondrial
copy number decreased with HD disease severity (with a
small spike in Stage I patients) but the changes were not
statistically significant in that regard with the given
sample sizes.
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Genetic disorders with central nervous system white matter
abnormalities, also referred to as leukodystrophies and/or
genetic leukoencephalopathies (LD/gLE), are a hetero-
geneous group of neurodegenerative conditions. Till date,
316 monogenic and 2 chromosomal disorders are desig-
nated as LD/gLE. Though neuroimaging was the key to
diagnosis over last two decades, broad-spectrum genetic
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testing has now taken a central role in diagnosis. Methods:
We reviewed literature to retract a list of genetic disorders
with white matter abnormalities. We also evaluated 109
individuals from 101 families with white matter abnormal-
ities. Exome sequencing (ES) was performed for genomic
evaluation. Results: Literature review rendered 445 condi-
tions with white matter abnormalities. One-hundred-and-
two conditions present with hypomyelination and 343
conditions have de/dysmyelination. Of the total, 129 dis-
orders have not yet been designated as LD/gLE but have
predominant white matter abnormalities. Diagnostic yield of
ES in heterogenous cohorts of individuals with white matter
abnormalities has been noted to be in the range of 40-50%.
ES has led to discovery of 63 novel conditions with white
matter abnormalities in the past decade. In our cohort of 109
families, 14 had hypomyelination and 95 had de/dysmye-
lination. Molecular diagnosis was established in 67 families
(66.33%). Thirty-eight (59.37%) of 64 disease-causing
variants were novel. Four novel conditions with patho-
genic variants in ISCA1, AIMP2, EXOSC1 and ANKRD17
were identified. Conclusions: The spectrum of genetic
disorders with white matter abnormalities is ever-increasing
and ES has emerged as a highly efficient modality for
diagnosis of known conditions as well as elucidation of
novel conditions.
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Introduction: Cerebral palsy (CP) is a clinical descriptive
term defining a heterogeneous group of non-progressive,
neurodevelopmental disorders of motor impairment, which
co-occur with a wide range of medical conditions, including
intellectual disability, speech and language deficits, autism,
epilepsy and visual and/or hearing impairment. Recent
studies demonstrate an important contribution of genetic
factors.
Materials and methods: We performed diagnostic
genetic studies in 100 CP-patients that are followed at the
Pediatric Neurology department using a whole exome
sequencing (WES) based gene panel consisting of 200
genes associated with CP and CP-mimics.
Results: Here, we report the presence of de novo KIF1A
variants in a relatively large proportion of our CP
population (7/100 patients tested, 7%). These variants were
located in the KIF1A motor domain, absent in control
databases, predicted pathogenic by in silico prediction
programs and reported as likely pathogenic (class 4/5) or
pathogenic (class 5/5). Patients presented with develop-
mental delay and mild to moderate ID (7/7), spastic
paraplegia (7/7), periventricular white matter abnormalities
(4/7), corpus callosum hypoplasia (2/7), cerebellar atrophy
(1/7), behavioural problems (ADHD/autism) (4/7) and
seizures (1/7). These findings were already reported in
KIF1A variants.
Conclusions: Variants in KIF1A, which encodes a
kinesin axonal motor protein, have been described to cause
variable neurological disorders. This is the first report in
which de novo KIF1A mutations are demonstrated to be an
important cause of CP associated with early onset spasticity
and a frequent finding of periventricular white matter
abnormalities.
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for Kleefstra Syndrome
I. M. van der Werf1,2, M. Negwer1, P. Decuzzi2, H. van
Bokhoven1, N. Nadif Kasri1
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Haploinsufficiency of the EHMT1 gene is the cause of
Kleefstra Syndrome (KS), a disorder characterized by
intellectual disability, autism spectrum disorders and spe-
cific facial features. EHMT1 encodes the Euchromatic
Histone Lysine Methyltransferase 1 (EHMT1) protein,
which in complex with EHMT2 can deposit methyl groups
on histone 3 lysine 9 (H3K9me1/H3K9me2), important
epigenetic marks for gene repression. The Ehmt1+/- mouse
model, with heterozygous knockout of Ehmt1, shows phe-
notypic resemblance of the human disorder with develop-
mental delay, learning and memory deficits, craniofacial
abnormalities and diminished response to social novelty. To
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evaluate social behaviour in the Ehmt1+/- mouse model in
more depth, we used the recently developed Live Mouse
Tracker system (de Chaumont et al. 2019). This system can
automatically track and score behaviour of a group of mice
in a home cage-like setting. We recorded Ehmt1+/- mice and
their wildtype littermates over time periods of 23 hours and
analyzed general activity, isolated behaviour, dyadic inter-
actions and group dynamics in familiar social contexts,
thereby excluding social novelty. Our results indicate that
Ehmt1+/- mice are generally hypoactive when compared to
wildtype littermates and display specific social behaviour
deficits, in particular in group dynamics. These phenotypes
will be further investigated as endpoint measures for phe-
notypic rescue in drug studies.
This work was supported by the K.I.D.S.IQ Project and
the IIT MINDED project (European Union’s Horizon 2020
research and innovation programme, Marie Skłodowska-
Curie grant agreement No 754490)
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Introduction: Wiedemann Steiner syndrome (WSS)
(605130 OMIM), is a rare autosomal dominant disorder
characterized by distinctive facial features, variable devel-
opmental delay, short stature, and hypertrichosis especially
of the elbows; related to heterozygous mutations in the
KMT2A gene. To date, more than 100 cases have been
described expanding the clinical phenotype. The aim of this
study is to improve the clinical description of patients
with WSS.
Materials and methods: This retrospective study
included patients followed in our center with confirmed
WSS. Data from the medical records were abstracted,
recorded in an Excel spreadsheet and analyzed using simple
frequency analysis. We compare these patients with
previously reported cases.
Results: We described 14 unrelated patients with
pathogenic mutations in KMT2A. All the mutation occurred
de novo. Age at diagnosis ranged from 2 to 19 years, sex
ratio 1. All patients presented with global developmental
delay with a wide range of severity, only 14% with severe
intellectual disability. 86% of the patients have language
disorders. Gastrointestinal findings were common (feeding
difficulties 100%, constipation 22%). 94% of the patients
had an hypertrichosis whose more than half with hairy
elbow. Abnormalities of craniocervical junction were
reported in 4 patients (29%). Two patients developed
conductive deafness.
Conclusions: This study improved the description of
natural history of WSS, especially about neurological
development. Moreover, our cohort emphases the impor-
tance of early detection of craniocervical junction abnorm-
alities and deafness.
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A. Martinelli1, M. Rice2, S. Smith3, J. Talcott4, J. Stein5, L.
Kent1, M. Hayiou-Thomas6, D. Newbury7, C. Hulme5, S.
Pitt1, S. Paracchini1
1University of St Andrews, St Andrews, United Kingdom,
2University of Kansas, Lawrence, KS, United States, 3Uni-
versity of Nebraska, Lincoln, NE, United States, 4Aston
University, Birmingham, United Kingdom, 5University of
Oxford, Oxford, United Kingdom, 6University of York,
York, United Kingdom, 7Oxford Brookes University,
Oxford, United Kingdom
Developmental Language Disorder (DLD) is a common
condition presenting unexpected difficulties in expressing
and understanding spoken language. DLD presents exten-
sive comorbidity with other disorders like dyslexia and
ADHD. DLD is highly heritable but few genes have been
identified so far. Through an exome sequencing analysis we
identified a rare missense mutation (chr16:84405221 G>A
(GRCh38.p12)) in the ATP2C2 gene. Exactly the same
variant was reported previously in a different exome
sequencing study for DLD, and ATP2C2 was previously
proposed as susceptibility gene for language disorders by
linkage and association studies. We followed this finding up
by genotyping the mutation in cohorts selected for DLD and
comorbid disorders. We found that the variant had a higher
frequency in DLD cases (1.8%, N=360) compared to
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cohorts selected for dyslexia (0.8%, N = 520) and ADHD
(0.7%, N = 150), which presented frequencies comparable
to reference databases (0.9%, N = 24,046 gnomAD con-
trols). Analysis of quantitative phenotypes in the ALSPAC
birth cohort showed that carriers (N=42) of the variant had,
as a group, lower mean scores on a range of reading and
language-related measures compared to controls (N=1825),
e.g. carriers had a mean score 0.4 SD lower than non-
carriers on a phoneme awareness task. We are currently
investigating the potential effects of this variant on protein
function with a range of biochemical and electrophysiology
assays. This work is supported by an Action Medical
Research Action/The Chief Scientist (CSO) Office, Scot-
land grant (GN2614) and a Cunningham Trust grant.
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Introduction: LIS1 is an ubiquitous protein of which loss
of function mutations lead to lissencephalies, whereas LIS1
overexpression causes microcephaly. This suggests cerebral
development is very sensitive to LIS1 dosage. The main
goal of this project is to evaluate the dose-effect impact of
LIS1 on the different degrees of lissencephalies’ severity.
Material and methods: Four lines of fibroblast from
patients with LIS1 de novo heterozygous mutations were
used. Two of them displaying a severe phenotype carry an
intronic mutation (c.1002+1G>T) or a missense
(c.445C>T) while the two other patients presenting a less
severe phenotype display a splice site mutation (c.569-
10T>C). LIS1 transcripts and proteins were quantified and
the subcellular distribution of the protein was visualized by
immunofluorescence.
Results: Analysis of LIS1 mRNA showed that the c.569-
10T>C mutant transcripts were degraded while both
c.445C>T et c.1002+1G>T mutant transcripts, associated
to the severe phenotypes, were not. Yet, no difference of
LIS1 protein level was detected between patient and control
lines, by Western Blot. But, immunofluorescence targeting
LIS1 after proteasome inhibition allowed the detection of
clusters in fibroblasts associated to the severe phenotypes
(c.1002+1G>T ; c.445C>T).
Conclusions: In LIS1 lissencephalies, our data suggest
that more severe forms would be associated to an abnormal
repartition of the LIS1 protein forming clusters after
proteasome inhibition, which might be toxic for the cell.
Recent studies indicate the clusters might be stress granules,
membraneless organelles involved in post-transcriptional
regulation and translational control, formed by RNA-RNA,
protein-protein and RNA-protein interactions, in which
LIS1 would bind RNA-binding proteins.
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The development of the cerebral cortex is a complex pro-
cess and pathogenic variants in >200 genes have been
associated with malformations of cortical development
(MCD). Yet, the etiology still remains to be elucidated in a
large group of MCD patients. The proband of this study, a
17-year old boy presented with a complex brain mal-
formation including severe cortical dysplasia, agenesis of
the corpus callosum, interhemispheric cysts and pontocer-
ebellar hypoplasia. Parents are non-consanguineous. The
father of the proband has a simple arachnoid cyst. Whole
exome sequencing showed a novel homozygous variant
(c.607G>A, p.(Gly203Arg)) in the MAN2C1
(NM_006715.3) gene. This variant was not reported earlier
and classified as variant of uncertain significance (VUS 3).
The MAN2C1 gene encodes a cytosolic mannosidase and is
involved in the degradation of misfolded glycoproteins.
Possibly, as a consequence of the accumulation of proteins,
the organization and maturation of neurons is altered during
fetogenesis. Preliminary RT-PCR results showed that the
expression level ofMAN2C1 is downregulated in fibroblasts
compared to controls, although this downregulation was not
significant. The variant in MAN2C1 causes a ± 50%
decrease in cytosolic alpha-mannosidase enzymatic activity
in the patient compared to controls. RNA sequencing ana-
lysis in patient and control fibroblasts showed up/down
regulation of multiple glycosylated proteins. The functional
consequences of the detected variant and the exact role of
the MAN2C gene in the development of MCD need further
investigation.
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Malformations of cortical development (MCD) represent a
major cause of developmental disabilities and severe
epilepsy. Some of the MCD causative genes have been
identified, but part remain unknown. Here, we describe a
patient with heterozygous variants in the C-terminal domain
phosphatase 1 (CTDP1) gene, a gene potentially involved in
MCD. CTDP1 functions as a phosphatase which depho-
sphorylates the C-terminus of RNA polymerase II, making
it available for initiation of gene expression.
A 2.5-year old girl presented with congenital arthrogry-
posis, periventricular gray matter heterotopia, optic atrophy,
absent optic chiasma and unilateral auditory neuropathy.
Trio exome analysis revealed that the index is compound
heterozygous for two novel variants in CTDP1: c.609G>C,
p. (Gln203His) and c.2665C>T, p. (Arg889Trp). To assess
the gene expression levels of CTDP1, real-time polymerase
chain reaction (RT-PCR) is performed. The phosphatase
activity of CTDP1 was assessed by performing western
blotting (WB) of its target RNA polymerase II.
RT-PCR data showed a non-significant downregulation of
CTDP1 expression in the patient versus controls. By
performing WB, more phosphorylated RNA polymerase II
was detected in patient cells.
Our preliminary analyses show that the phosphatase
activity of CTDP1 is altered in the patient compared to
controls, supporting its role in MCD. CTDP1 is involved in
the regulation of RNA polymerase II and forms a complex
with INTS1 and INTS8. Variants in the latter genes result in
a phenotype similar to that of in our index patient, further
suggesting a role for CTDP1 in brain development.
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Malformations of cortical development: international
consensus recommendations on diagnostic work-up
R. Oegema1, T. Barakat2, N. Bahi -Buisson3, E. Aronica4,5,
V. Conti6, M. Zaki7, W. Dobyns8,9, A. Fry10,11, T. Geis12, D.
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Introduction: Malformations of cortical development
(MCD) are a group of predominantly genetic disorders due
to abnormal formation of cerebral cortex during fetal brain
development. Main examples of MCD are lissencephaly,
heterotopia, and polymicrogyria. MCD place a significant
burden on affected individuals, their families and society, as
patients often suffer from lifelong symptoms including
drug-resistant epilepsy, cerebral palsy, and intellectual dis-
ability. Although next-generation sequencing has become
broadly available worldwide, marked differences in diag-
nostic yield remain due to broad genetic and clinical
heterogeneity and lack of guidelines in the recognition and
classification of these rare disorders.
Methods: The international network on brain malforma-
tions Neuro-MIG formed a multidisciplinary task force.
Through expert meetings, literature search, and the Delphi
consensus method a diagnostic strategy for individuals with
MCD was developed.
Results: We present consensus recommendations on the
optimal work flow applicable to any individual with MCD.
This includes a flow chart for the clinical work-up,
laboratory standards, and a curated MCD gene panel list.
In addition, we discuss the differential diagnosis, possible
diagnostic pitfalls and special recommendations for specific
MCD subtypes.
Conclusions: These recommendations will aid clinicians
in providing the optimal diagnostic strategy, which will
improve genetic and prognostic counseling and patient care.
Financial support: Neuro-MIG is supported by COST
Action CA16118 (https://www.neuro-mig.org/).
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Introduction: Primary microcephaly (MCPH) is a neuro-
developmental disorder manifesting as cerebral cortical
hypoplasia and intellectual disability. Biallelic mutations in
25 genes have been demonstrated to cause MCPH, and the
numbers are growing with more inclusive and cross dis-
ciplinary collaborative approaches.
Materials and Methods: This study analyzed two
consanguineous MCPH families (Pakistani and Syrian)
through homozygosity mapping and whole-exome sequen-
cing (WES). The functional consequences of the candidate
variants were studied by immunofluorescence, confocal
microscopy and Clariom™ S microarray analysis.
Results: In the Pakistani family, WES identified a
homozygous missense mutation, c.1449C>G;p.Asp483Glu,
of PCDHGC4 (NM_018928.2), residing within a linkage
interval afore identified on chromosome 5 (LOD score of
3.1). In the Syrian patient (identified through Gene-
Matcher), clinical WES revealed another missense mutation
in the same gene, NM_018928.2:c.1463C>T:p.Ala488Val.
Together with its isoforms, PCDHGC4 is expressed on the
surface of neuronal cells in different combinations, thereby
providing cells with a unique “barcode” for self/non self-
discrimination. PCDHGC4 is a highly conserved Ca+2
binding protein and in silico analyses predicted both
variants to decrease its Ca+2 affinity, which most likely
impairs its function. We also observed endogenous and
transiently overexpressed PCDHGC4 to localize within the
nucleus and cytoplasm. In patient-derived fibroblasts,
blebbing of the nuclear envelope, micronuclei, misshapen
nuclei and higher apoptotic rates were observed. Array
transcriptome analysis revealed altered expression of genes
involved in cadherin signaling.
Conclusions: Our findings indicate that PCDHGC4 is a
novel MCPH gene, and its optimal function seems to be an
indispensable requirement for the development of a proper
brain structure.
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Introduction: Thyroid hormone is crucial for brain and
other tissue development, and monocarboxylate transporter
8(MCT8) facilitates T3 uptake into cells. Mutations in
MCT8 (SLC16A2 gene on Xq13.2) cause Allan-Herndon-
Dudley syndrome(AHDS), characterized by severe neuro-
cognitive impairment and abnormal thyroid function (low
serum T4, high T3 levels).
Methods: Male subjects clinically suggestive of AHDS
underwent thyroid function testing(particularly T3),
SLC16A2 analysis, or WES.
Results: We report 7 individuals from 5 families,3 were
siblings. All boys startled easily and showed progressive
hypotonia by 3-6 months-old. Key unifying features
included severe motor and intellectual disability, axial
hypotonia, progressive spasticity, microcephaly, failure to
thrive. Limb dystonia was a dominant feature, and 3
demonstrated paroxysmal movements. Two had seizures/
abnormal EEG, one had sleep myoclonus. MRI brain
showed delayed myelination with progression in 4 boys.
TFT revealed high serum T3, low T4 and normal TSH in
all. Four novel hemizygous pathogenic variants in
SLC16A2 (3 frameshift,1 missense) were identified in
4unrelated families. The fifth variant(c.698G>T) was
classified VUS but in-silico analyses suggest it disease-
causing, and patient showed clinical and biochemical
correlation. Four mothers were carriers. Upon diagnosis,
L-thyroxine in 3 individuals was ceased as not to further
exacerbate the high T3 and resulting hypermetabolism.
Conclusions: We wish to highlight the combination of
clinical features and abnormal TFT unique to MCT8
deficiency in prompting early diagnosis, as disease
confirmation not only directs accurate genetic counselling
and reproductive options, but also offers therapeutic hope as
ongoing clinical trials suggest encouraging response to T3
analogue Triac as a potential therapy.
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Biallelic MFSD2 Avariants associated with congenital
microcephaly, developmental delay, and recognizable
neuroimaging features.
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Introduction: Major Facilitator Superfamily Domain con-
taining 2a (MFSD2A) is an essential endothelial lipid
transporter at the blood-brain barrier. Biallelic MFSD2A
pathogenic variants cause autosomal recessive primary
microcephaly 15 (MCPH15, OMIM# 616486). We sought
to expand our knowledge of the phenotypic spectrum of
MCPH15 and demonstrate the underlying mechanism of
inactivation of the MFSD2A transporter.
Materials and Methods:We carried out detailed analysis
of the clinical and neuroradiological features of eight
individuals from seven consanguineous families with severe
microcephaly. Genetic investigation was performed through
exome sequencing. Structural insights on the human
Mfsd2a model and in vitro biochemical assays were used
to investigate the functional impact of the identified
variants.
Results: All patients had primary microcephaly and
severe developmental delay. Brain MRI showed variable
degrees of white matter reduction, ventricular enlargement,
callosal hypodysgenesis, and pontine and vermian hypo-
plasia. ES led to the identification of the novel biallelic
MFSD2A variants p.(Pro493Leu), p.(Pro164Thr), p.
(Arg326His), p.(Val250Phe), p.(Gln462HisfsTer17) and p.
(Cys251SerFsTer3), and the recurrent variants p.
(Thr198Met) and p.(Thr159Met), all resulting in either
reduced MFSD2A expression and/or transport activity.
Conclusions: Our study further delineates the phenotypic
spectrum of MCPH15, refining its clinical and neuroradio-
logical characterization and supporting that MFSD2A
deficiency causes early prenatal brain developmental
disruption. We also show that poor MFSD2A expression
despite normal transporter activity is a relevant pathome-
chanism in MCPH15.
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Prevalence of Machado-Joseph disease (MJD/SCA3)
explained by migration and multiple founder effects
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Machado-Joseph disease (MJD/SCA3) is a neurological
disorder caused by an unstable (CAG)n in ATXN3, ranging
usually 61-87 repeats in patients. Although MJD is the most
frequent dominant ataxia worldwide, our previous studies
suggest that de novo expansions would not explain its
worldwide prevalence. To date, only two major MJD
mutational origins have been identified: the Machado line-
age, more recent, most frequent in parts of Portugal; and the
ancient Joseph lineage, of Asian origin, spread worldwide.
We extended our previous studies and tested the potential of
additional markers for higher-resolution MJD haplotypes.
We analysed a total of 370 families, from 30 world popu-
lations (5 continents); assessed a set of 30 SNPs in cis with
the (CAG)n expansion, to establish lineages; and genotyped
7 STRs flanking ATXN3, to construct phylogenetic net-
works. In addition to the Joseph (n = 210) and Machado (n
= 90 families) pure lineages, we observed 7 sublineages,
differing from those two main haplotype backgrounds at 1-3
variants. Based on extended STR-haplotypes, the highest
gene diversity was observed in Joseph-lineage families from
the USA (0.91 ± 0.05) and Asia (0.88 ± 0.03), followed by
central European populations (around 0.50), with Portu-
guese families showing the lowest diversity (0.18 ± 0.08).
Besides its epidemiological and historical interest, these
variants could be of great value to study phenotypic varia-
tion and genetic modifiers linked to these haplotypes; to
study genetic instability of the (CAG)n; and for ther-
apeutical interventions, including gene-based targeting,
namely in the best design for allele-specific ATXN3 silen-
cing, that might be applicable to most MJD patients. SM is
funded by FCT:CEECIND/00684/2017
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Conserved methyltransferase NSUN5: a novel genetic
modifier of Machado-Joseph disease (MJD/SCA3)?
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Machado-Joseph disease (MJD) or spinocerebellar ataxia
(SCA3) is caused by a coding CAG repeat expansion in
Ataxin-3 (ATXN3). The CAG repeat length is inversely
correlated with the age of onset (AO) but only explains up
to 60-70% of AO variation. Thus, additional modifiers of
AO need to be identified. Whole exome sequencing was
performed in 4 early AO and 5 late AO (±10 years devia-
tion) patients of a large Dutch MJD/SCA3 family (naffec-
ted_total=32) via Illumina HiSeq. Sequencing data were
analyzed via an in-house bioinformatics pipeline and Alissa
(Agilent). ATXN3 protein aggregates were quantified using
a filter-trap assay. We identified a rare non-synonymous
variant c.472G>C, p.Gly158Arg in the highly conserved
methyltransferase domain of NSUN5 in the late AO cases
but not in the cases with early AO. NSUN5 was previously
shown to regulate lifespan and stress resistance in yeast,
worms, and flies. Upon screening of all 32 affected family
members, we identified 8 cases carrying the p.Gly158Arg
variant, who showed an average delay in AO (7.9 ± 4.8
years) compared to non-carriers. Upon silencing of NSUN5
in HEK293T cells transiently expressing ATXN3-148Q
increased protein aggregates were observed compared to
control.
Our preliminary results point to NSUN5 as likely modifier
gene of AO in MJD/SCA3. Further studies are needed to
confirm if the p.Gly158Arg variant changes NSUN5’s
modifying role on ATXN3 protein aggregation and toxicity.
China Scholarship Council (CSC) #201608440359 and de
Jan Kornelis de Cock Stichting grant (MH), JPND eRARE
grant and Rosalind Franklin Fellowship of the University of
Groningen (DSV).
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Clinical and molecular characterization of a large
MPAN cohort
P. Sparber1, T. Krylova1, S. Repina1, N. Demina1, G.
Rudenskaya1, I. Sharkova1, A. Sharkov2,3,4, V. Kadishev1, I.
Kanivets3, S. Korostelev3, E. Pomerantseva5, M. Ivanova6,
S. Mikhailova7, E. Zaharova1, A. Filatova1, M. Skoblov1
1Research center of medical genetics, Moscow, Russia,
Moscow, Russian Federation, 2Veltischev Research and
Clinical Institute for Pediatrics Pirogov RNRMU, Moscow,
Russian Federation, 3Genomed ltd., Moscow, Russian
Federation, 4Institute of Gene Biology RAS, Moscow,
Russian Federation, 5Genetico ltd., Moscow, Russian
Federation, 6Oftalmic ltd., Moscow, Russian Federation,
7Russian Children’s Clinical Hospital, Moscow, Russian
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Introduction: Mitochondrial membrane protein-associated
neurodegeneration (MPAN) is a rare neurological disorder
with an autosomal recessive mode of inheritance and
characterized by spasticity, optic nerve atrophy, neu-
ropsychiatric abnormalities and most important iron accu-
mulation in the basal ganglia. MPAN is caused by biallelic
pathogenic variants in the C19orf12 gene and is considered
the third most common clinical form of neurodegeneration
with brain iron accumulation. Nevertheless, only few
patient cohorts were described and MPAN clinical and
genetic diversity is of great interest.
Material and methods: For cohort formation, we
analyzed the internal database in Research Centre for
Medical Genetics in Moscow and several commercial
genetic laboratories. Patients were examined by a clinical
geneticist and gave their inform consent to participate in the
study. Mutation analysis was performed by whole exome
sequencing or by Sanger sequencing of C19orf12 gene.
Functional analysis of c.193+5G>A variant was performed
using a minigene assay. Disease prevalence was calculated
with the Hardy-Weinberg equilibrium. Allelic imbalance
was detected using RT-PCR.
Results: We gathered a cohort of 17 confirmed MPAN
patients with detailed clinical information. The common
c.210_214del variant accounted for 73,5% of all the
pathogenic alleles. We detected four previously undescribed
variants and several patient with an unusual clinical
presentation. The estimated MPAN prevalence was
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1:600000. In one heterozygous carrier, a pronounced allelic
imbalance with lower expression levels of the wild-type
allele was detected.
Conclusion: We describe the third largest cohort of
MPAN patients to date with novel clinical findings. Our
work expand the clinical and mutational spectrum
of MPAN.
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A recurrent de novo CAPRIN1 mutation causes a novel
progressive early onset neurodegenerative disorder
A. Delle Vedove1,2,3, G. Zanni4, M. Eckenweiler5, M.
Storbeck1,2,3, S. Barresi6, S. Pizzi6, S. Hosseinibarkooie1,2,3,
N. Mendoza-Ferreira1,2,3, I. Hölker1,2,3, F. Körber7, M.
Kye1,2, E. Bertini4, J. Kirschner8, M. Tartaglia4, B.
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Introduction: Neurodegenerative disorders (NDs) repre-
sent increasingly prevalent and severely debilitating dis-
eases. In several cases, their molecular diagnosis remains
elusive.
Materials and methods: Trio-based WES and Sanger
sequencing led to the identification of the disease-causative
variant. Its functional impact is being investigated in
HEK293T cells and iPSCs.
Results: We describe two individuals from two unrelated
non-consanguineous families with an identical de novo
mutation in CAPRIN1 (Cell Cycle Associated Protein 1): an
8 year-old girl with progressive muscular atrophy, who
developed ataxia and cognitive decline at 11 years, and a 7
year-old boy with spinocerebellar ataxia and learning
difficulties. Both carry an identical de novo c.1535C>T
variant (p.Pro512Leu) which is not reported in gnomAD
and affects a highly conserved residue. CAPRIN1 is
abundant in the brain, where it regulates the transport and
translation of mRNAs of genes involved in synaptic
plasticity. As other ND-related proteins, it is a component
of stress granules and harbours a prion-like domain (PRD).
In accordance with the in silico predictions suggesting that
the p.P512L mutation increases its aggregation propensity,
CAPRIN1P512L overexpression causes the formation of
insoluble aggregates in transfected HEK293T cells. To
investigate the mutation effects in neurons, we successfully
introduced the missense mutation in human iPSCs using the
CRISPR/Cas9 system.
Conclusions: Our results suggest that CAPRIN1P512L is
prone to aggregation. As CAPRIN1 deficiency is linked to
autism-spectrum disorders (ASD) in humans, we identify
CAPRIN1 as a novel gene implicated in NDs, and a novel
class of mutations perturbing CAPRIN1 function in a
dominant manner.
A. Delle Vedove: None. G. Zanni: None. M. Eck-
enweiler: None. M. Storbeck: None. S. Barresi: None. S.
Pizzi: None. S. Hosseinibarkooie: None. N. Mendoza-
Ferreira: None. I. Hölker: None. F. Körber: None. M.
Kye: None. E. Bertini: None. J. Kirschner: None. M.
Tartaglia: None. B. Wirth: None.
P09.101.C
Implementation of WES-based gene panel testing in
patients with adult-onset neurological disorders at the
University Hospital of Ghent: a retrospective observa-
tional analysis of 176 patients
N. Schuermans1,2, E. Debackere1,2, S. Symoens1,2, B.
Poppe1,2, P. Santens3,4, J. De Bleecker3,4, D. Hemelsoet3,4,
B. Dermaut1,2
1Center for Medical Genetics, Ghent University Hospital,
Ghent, Belgium, 2Department of Biomolecular Medicine,
Faculty of Medicine and Health Sciences, Ghent University,
Ghent, Belgium, 3Department of Neurology, Ghent Uni-
versity Hospital, Ghent, Belgium, 4Department of Head and
Skin, Faculty of Medicine and Health Sciences, Ghent
University, Ghent, Belgium
Introduction: Neurodegenerative inherited diseases are an
important cause of morbidity and mortality. A molecular
diagnosis is elementary for genetic counseling and potential
therapeutic strategies. In January 2019 6 novel WES-based
gene panels were introduced at the Ghent University Hos-
pital to facilitate diagnostics in patients with neurodegen-
erative diseases. In this study we want to establish the added
value of these panels and define patient- and disease-
specific characteristics associated with a high
diagnostic yield.
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Methods: 6 novel gene panels were introduced in
diagnostic setting at the Centre for Medical Genetics Ghent:
1. Ataxia/spasticity 2. Leukodystrophy 3. Paroxysmal/
episodic disorders 4. Movement disorders 5. Neurodegen-
eration with brain iron accumulation 6. Progressive
myoclonic epilepsy
Results: From January the 1st up till December 31st 2019
176 cases have been analyzed. The mean age of the patients
was 50 years with a majority of the patients being adults
(98%). The leukodystrophy panel was most popular (43%),
followed by the ataxia/spasticity panel (26%) and the
movement disorders panel (20%). The overall diagnostic
yield was 15%. In another 15% variants of unknown
significance were found. The diagnostic yield was highest
among patients presenting with spinocerebellar ataxia
(30%). The causal mutations were missense (62%),
nonsense (25%), splice-site (10%) and deletion (3%)
mutations.
Conclusions: Gene panel testing is a successful tool to
diagnose inherited neurological diseases. The overall
diagnostic yield after analysis of 176 cases was 15%, with
another 15% of potential but unsure diagnoses. Patients
suffering from ataxia and/or spastic paraplegia were most
likely to obtain a molecular diagnosis (30%).
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NMIHBA causing PRUNE1 variants result in loss of
exopolyphosphatase activity.
H. Nistala1, J. Dronzek1, C. Gonzaga-Jauregui1, S. Chim1,
S. Rajamani2, S. Nuwayhid2, D. Delgado2, E. Burke3, E.
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Y. Tang2, M. G. Dominguez2, M. Withers5, R. A.
Deckelbaum2, C. J. Scheonherr1, W. A. Gahl3, M. C.
Malicdan3, B. Zambrowicz2, N. W. Gale2, R. A. Gibbs5, W.
K. Chung6, J. R. Lupski5, A. N. Economides1
1Regeneron Genetics Center, Tarrytown, NY, United States,
2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United
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versity of Alabama, Birmingham, AL, United States, 5Bay-
lor College of Medicine, Houston, TX, United States,
6Columbia University Medical Center, New York, NY,
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Neurodevelopmental disorder with microcephaly, hypoto-
nia, and variable brain anomalies (NMIHBA) is an auto-
somal recessive neurodevelopmental and neurodegenerative
disorder characterized by global developmental delay and
severe intellectual disability. Microcephaly, progressive
cortical atrophy, cerebellar hypoplasia and delayed myeli-
nation are neurological hallmarks in affected individuals.
NMIHBA is caused by biallelic variants in PRUNE1
encoding prune exopolyphosphatase 1. We provide in-depth
clinical description of two affected siblings harboring
compound heterozygous variant alleles, c.383G>A (p.
Arg128Gln), c.520G>T (p.Gly174*) in PRUNE1. To gain
insights into disease biology, we biochemically character-
ized missense variants within the conserved N-terminal
aspartic acid-histidine-histidine (DHH) motif and provide
evidence that they result in the destabilization of protein
structure and/or loss of exopolyphosphatase activity.
Genetic ablation of Prune1 results in midgestational leth-
ality in mice, associated with perturbations to embryonic
growth and vascular development. Our findings suggest that
NMIHBA results from hypomorphic variant alleles in
humans and underscore the potential key role of PRUNE1
exopolyphoshatase activity in neurodevelopment.
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Exome Sequencing in Bangladeshi families with neuro-
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Efthymiou1, R. Maaroofian1, A. Fragkouli1, T. Bourinaris1,
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Background: Neurodevelopmental disorders are char-
acterized by high clinical and genetic heterogeneity. Their
molecular basis had not been well characterized in
Bangladesh. Through the Synaptopathies and Paroxysmal
Syndromes (SYNaPS) Study Group, we aimed to elucidate
the genetic basis of neurodevelopmental disorders affecting
the Bangladeshi patients.
Methods:We applied whole exome sequencing (WES) in
a cohort of 50 Bangladeshi families with primarily
Mendelian neurodevelopmental diseases. In families with-
out likely pathogenic variants in known disease causing
genes; novel candidate genes were prioritized according to
functional impact, rarity in multiple databases especially in
Southeast Asia population, presence in multiple families
with overlapping phenotypes, mutational tolerance of the
gene, animal studies, predicted deleteriousness by several in
silico tools and expression of the protein in affected tissues.
Results:We found known pathogenic or novel variants in
known disease genes with phenotypic expansion in 18
families and 12 novel candidates in 10 families including
RTN4R, ITGB8 and ACBD6. Overall, molecular diagnosis
was provided by variants in known genes in 36 families
(72%) and by novel candidate genes in additional 10
families, resulting in a potential molecular diagnostic rate of
92%. Homozygous variants were causative in only 34.7%,
despite high rate of consanguinity in our cohort.
Conclusions: Our study shows the benefits of WES
analysis in neurodevelopmental disorders in non-European
populations and highlights ongoing difficulties in variant
interpretation. In our cohort, only six of identified variants
were previously reported, the remaining were novel variants
and hence interpretation of pathogenicity was challenging
especially in cases with atypical phenotypes.
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Update on a sponsored no-cost epilepsy gene panel for
seizure onset between 2-4 years of age: Results from 682
tests
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Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) disease
often presents with epilepsy at approximately three years of
age accompanied by a history of language delay. Behind the
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Seizure® (BTS) is a US-based, sponsored, no-cost, targeted,
next-generation sequencing epilepsy gene panel for children
suspected to have genetic epilepsy. The goal is to utilize
BTS to lower the age of CLN2 disease diagnosis.
Eligibility criteria were: age-at-test-order between 24-60
months and unprovoked seizure onset >24 months. BTS
uses an epilepsy gene panel of 180+ genes with the option
to include preliminarily associated genes.
Non-BTS epilepsy gene panel testing, which includes no
limitation for age-at-test-order and age-of-seizure-onset, has
shown a 15.5% (n = 1234/7939) molecular diagnostic yield
(MDx) overall and 0.05% specifically involving TPP1 gene
(CLN2 disease). Within the BTS program, the overall MDx
was 6.74% (n = 46/682). However, the yield of TPP1
positives was 0.88%, representing a 17.6-fold increase in
comparison to non-BTS cohort. Age of CLN2 disease
diagnosis was earlier than as described in the literature
(3.89-year versus 5-year). CLN2 disease was not a
suspected diagnosis for 5 out of 6 individuals tested using
BTS. Other genes that contributed to positive molecular
diagnoses in the BTS program included CACNA1A, CHD2,
EHMT1, FOXG1, FRRS1L, GRIN2A, IQSEC2, KANSL1,
KIAA2022, MECP2, PACS1, PCDH19, PPT1, PURA,
SCN1A, SCN2A, SLC6A1, STX1B, SYNGAP1, TSC1 and
ZEB2.
The BTS program has facilitated earlier CLN2 disease
identification. These findings indicate that broad epilepsy
gene panel tests can increase diagnostic yield for CLN2
disease and simultaneously identify other genetic causes of
epilepsy.
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‘Spit for Science’ is a cohort of over 17,000 youth (6-17
years of age) with associated psychiatric phenotype mea-
surements and saliva DNA collection. Quantitative pheno-
type data were collected for attention deficit hyperactivity
disorder (ADHD), obsessive compulsive disorder (OCD),
and response inhibition using Stop-Signal Reaction Time
(SSRT). We genotyped unrelated Caucasians (n = 4,817)
using Illumina HumanCoreExome beadchips. We per-
formed global and functional gene-set burden analyses, and
locus association test on rare CNVs using linear regression
against different traits.
We identified CNVs linked with neuropsychiatric dis-
orders in 191 (4.0%) participants with elevated standardized
z-scores for all traits. These CNVs included i) sex-
chromosome and autosomal aneuploidies in 12 (0.25%)
individuals, ii) 13 unique genomic loci previously impli-
cated in NDD in 52 (1.1%) different participants, and iii)
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CNVs affecting genes with known functions in the human
brain such as ASTN2, DLGAP2, MACROD2, NRXN1, and
others. ADHD traits were associated with increased deletion
burden (p = 0.014), whereas there was an increased burden
of duplication for SSRT (p = 0.034). We found no global
CNV burden for OCD traits. ADHD traits showed
significant enrichment for deletions in genes associated
with mouse neurophenotypes (p = 0.009) and with human
brain gene expression (p = 0.04). OCD and SSRT traits
showed enrichment for duplications in genes expressed in
human brain (p = 0.004 and 0.016, respectively). SSRT
traits showed enrichment for duplications in eight loci:
1q21.1, 1q42.3, 2q37.3, 9q22.2, 12q13.13, 18p11.21, and
22q11.21.
These results highlight the importance of mapping the
prevalence and impact of rare variants in community
samples to improve understanding of pediatric mental
health.
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versity, Department of Neurology, Budapest, Hungary,
3Albert Szent-Györgyi Clinical Center, University of
Szeged, Szeged, Hungary
Background: Cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy
(CADASIL) is a hereditary, small vessel disease associated
with resurrent stroke syndrome, migraine, progressive
cognitive decline, and psychiatric disturbances. The
worldwide prevalence of CADASIL has been estimated at
approximately 5:100,000.
Methods: Total coding region of the NOTCH3 gene was
analyzed with Sanger or NGS sequencing in 650 patients
(359 male, 291 female; mean age 45.27 ± 15.95 years) with
the MRI sign of small vessel disease. In our cohort non
genetic risk factors for cerebovascular disorders have been
excluded.
Results: Damaging variants has ben in found in 7.84% of
the cases, in 51 patiens 16 missense substitutions were
found in the NOTCH3 gene. Twelve have been previously
described as pathogenic variants (p. R90C, C146R, C208R,
C440R C448R, C75R, R110C R141C, R153C, R169C,
R182C, R1076C), while 4 were novel, likely pathogenic
alterations (p. C222S, G420C, R133C, R207C). These
variants were not present in controls and were predicted as
disease causing by in silico analysis.
Conclusions: In the Hungarian cohort the most common
rare variant was the R90C NOTCH3 gene, the mutation
frequency was, 2.5%. In the Caucasian population this
variant is the most frequent pathogenic variant. We detected
rare variants characteristic of Asian population as well
(R133C). We can conclude that the henetic epidemiological
data of the Hungarian pateints with CADASIL can be
explained by the Hungarian history. This study was
supported by the Hungarian Brain Research Program
(KTIA_NAP_ 2017-1.2.1-NKP-2017-00002).
F. Szabo: None. Z. Grosz: None. P. Balicza: None. A.
Gal: None. B. Gunda: None. K. Sas: None. M.
Molnár: None.
P09.107.C
Biallelic loss-of-function NRROS variants impairing
active TGF-β1 delivery cause a severe infantile onset
neurodegenerative condition with intracranial
calcification
X. Dong1,2, N. B. Tan1,2,3, K. B. Howell1,2,4, S. Barresi5, J.
L. Freeman1,4, D. Vecchio5, M. Piccione6, F. Clementina
Radio5, D. Calame7,8, S. Zong1, S. Eggers1,3, I. E.
Scheffer1,2,9, T. Y. Tan1,2,3, N. J. Van Bergen1,2, M.
Tartaglia5, J. Christodoulou1,2,3, S. M. White1,2,3
1Murdoch Children’s Research Institute, Parkville, Vic-
toria, Australia, 2Department of Paediatrics, University of
Melbourne, Parkville, Victoria, Australia, 3Victorian Clin-
ical Genetics Services, Parkville, Victoria, Australia,
4Department of Neurology, Royal Children’s Hospital,
Parkville, Victoria, Australia, 5Genetics and Rare Diseases
Research Division, Ospedale Pediatrico Bambino Gesù,
Rome, Italy, 6Department of Science for Health Promotion
and Mother and Child Care, Università degli Studi di
Palermo, Palermo, Italy, 7Baylor College of Medicine,
Houston, TX, United States, 8Texas Children’s Hospital,
Houston, TX, United States, 9Department of Medicine,
University of Melbourne, Austin Health, Heidelberg,
Victoria, Australia
Introduction: NRROS is a leucine-rich repeat-containing
protein that associates with latent TGF-β1 and anchors it on
the cell surface, a requirement for activation of TGF-β1 in
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microglia. We report six individuals from four families with
biallelic variants in NRROS. All affected individuals had
refractory epilepsy, developmental regression, and reduced
white matter volume with delayed myelination. Intracranial
calcification was detected in three individuals. These fea-
tures are consistent with those observed in the Nrros
knockout mouse.
Methods: Confocal microscopy in HEK293T cells was
used to investigate the localisation of wild-type and mutant
NRROS proteins. Flow cytometry was performed to analyse
the influence of mutant NRROS proteins in anchoring latent
TGF-β1 to the cell surface.
Results: Wild-type and mutant NRROS proteins were
found to co-localise with latent TGF-β1 intracellularly.
However, flow cytometry showed that the mutant NRROS
proteins failed to anchor latent TGF-β1 on the cell surface,
as compared to wild-type NRROS. Moreover, wild-type
NRROS rescued the defect of the disease-associated
mutants in presenting latent TGF-β1 to the cell surface.
Conclusion: Our findings suggest that loss of NRROS
function causes a severe childhood-onset neurodegenerative
condition with features suggestive of a disordered response
to inflammation.
Funding: Research at Murdoch Children’s Research
Institute is supported by the Victorian Government’s
Operational Infrastructure Support Program and the Harbig
Foundation. NBT acknowledges the Australian NHMRC
CRE in Neurocognitive Disorders for their support. KBH is
supported by funding from the Australian NHMRC. MT
acknowledges the Italian Ministry of Health (Ricerca
Corrente 2019) and Fondazione Bambino Gesù (Vite
Coraggiose).
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Barresi: None. J.L. Freeman: None. D. Vecchio: None.
M. Piccione: None. F. Clementina Radio: None. D.
Calame: None. S. Zong: None. S. Eggers: None. I.E.
Scheffer: None. T.Y. Tan: None. N.J. Van Bergen: None.
M. Tartaglia: None. J. Christodoulou: None. S.M.
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P09.108.A
De novo NSF mutations cause early infantile epileptic
encephalopathy
H. Suzuki1, T. Yoshida2, N. Morisada3, T. Uehara1, K.
Kosaki1, T. Takano-Shimizu4, T. Takenouchi1
1Keio University, Tokyo, Japan, 2Kyoto University, Kyoto,
Japan, 3Kobe Children’s Hospital, Hyogo, Japan, 4Kyoto
Institute of Technology, Kyoto, Japan
Introduction: N-ethylmaleimide-sensitive factor (NSF)
plays a critical role in intracellular vesicle transport, which
is essential for neurotransmitter release. Dysregulation of
neurotransmitter releasing process has been recognized as
the mechanistic basis for neurological disorders. Here, we
describe two patients with de novo pathogenic variants in
NSF with early infantile epileptic encephalopathy.
Clinical Report: Patient 1 was a girl with no significant
family medical history. She was born at 37 weeks of
gestation by uneventful delivery after an uneventful
pregnancy. Immediately after birth, she developed contin-
uous tonic seizures. Electroencephalography showed burst-
suppression patterns. Patient 2 was a 1-year-old girl with no
significant family medical history. In her prenatal period,
she exhibited failure to thrive, fetal hydrops, and anemia.
After birth, she had no spontaneous respiration, which
required mechanical ventilation, and had frequent myoclo-
nic seizures. Her electroencephalography showed burst-
suppression patterns.
Results: Trio-based exome sequencing revealed a de
novo heterozygous variant in the NSF gene (NM_006178.3)
in both the probands: c.1375G>A chr17:44782125G>A
(GRCh37) p.Ala459Thr in patient 1 and c.1688C>T
chr17:44791279C>T (GRCh37) p.Pro563Leu in patient 2.
Functional analysis: When ectopically expressed in the
developing eye of Drosophila in the presence of normal fly
protein, the mutant human NSF protein severely affected
eye development, while the wild-type human protein had no
detectable effect under the same conditions. This finding
suggested that the two variants had a dominant negative
effect.
Conclusions: De novo heterozygous mutations in the
NSF cause early infantile epileptic encephalopathy.
Research grant: The Japan Agency for Medical Research
and Development (JP18ek0109301, JP19gk0110038, and
JP18ek0109288h0002).
H. Suzuki: None. T. Yoshida: None. N. Morisada:
None. T. Uehara: None. K. Kosaki: None. T. Takano-
Shimizu: None. T. Takenouchi: None.
P09.109.B
Homozygous variants of PACS1cause an autosomal
recessive developmental and epileptic encephalopathy
N. Chatron1,2, A. Rad3, S. Efthymiou4, A. Labalme1, B.
Vona3, M. Carneiro5, K. Saeidi6,7, H. Houlden4, T. Sultan8,
R. Maroofian4, G. LESCA1,9
1Department of Medical Genetics, Hospices Civils de Lyon,
Lyon, France, 2Institut NeuroMyoGène, CNRS UMR 5310 -
INSERM U1217, Université de Lyon Université Claude
Bernard Lyon 1, Lyon, France, Lyon, France, 3Department
of Otorhinolaryngology, Head and Neck Surgery, Tuebin-
gen Hearing Research Centre (THRC), Eberhard Karls
University, Tuebingen, Germany, 4Department of
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Neuromuscular Disorders Institute of Neurology, Univer-
sity College London, Queen Square, London, United
Kingdom, 5Department of Pediatric Neurology, Hospices
Civils de Lyon, Lyon, France, 6Neuroscience Research
Center, Institute of Neuropharmacology, Kerman Univer-
sity of Medical Sciences, Kerman, Iran, Islamic Republic of,
7Department of Medical Genetics, Kerman University of
Medical Sciences, Kerman, Iran, Islamic Republic of,
8Department of Pediatric Neurology, Institute of Child
Health, The Children’s Hospital Lahore, Lahore, Pakistan,
9Institut NeuroMyoGène, CNRS UMR 5310 - INSERM
U1217, Université de Lyon Université Claude Bernard
Lyon 1, Lyon, France
PACS1 (OMIM 607492) encodes a trans-Golgi-membrane
traffic regulator that directs protein cargo and several viral
envelope proteins. It is upregulated during human
embryonic brain development and has low expression after
birth. Homozygous KO mice are lethal. A recurrent mis-
sense variant was reported in patients with Schuurs-
Hoeijmakers syndrome (OMIM 615009), an autosomal
dominant disorder characterized by intellectual disability,
distinct craniofacial features, and variable additional con-
genital abnormalities. Seizures of various types are frequent
and usually respond well to antiepileptic drugs. This variant
was suggested to act via a dominant-negative or a gain-of-
function mechanism. No other pathogenic variant has been
reported to date. We report on four patients from three
unrelated families, with homozygous variants of PACS1.
They presented with severe developmental delay, poor eye
contact, absent language. Seizures started in infancy. They
were of various types (focal seizures in one patient, spams
in another one and generalized seizures in three patients)
and drug resistant. EEG showed multifocal spikes or gen-
eralized sharp waves. Brain MRI showed variable patterns
in patients, including delayed myelination or cerebral atro-
phy. Patients did not show the dysmorphic features remi-
niscent of Schuurs-Hoeijmakers syndrome. One family
carried a homozygous stop variant and the two others dif-
ferent unreported homozygous missense variants, affecting
highly conserved amino acids. These variants were absent
or with a very low occurrence in the gnomAD v2.1 data-
base. These observations suggest that biallelic variants of
PACS1 can cause a phenotype of developmental epileptic
encephalopathy. Functional analyses will be performed to
characterize the consequences of these variants.
N. Chatron: None. A. Rad: None. S. Efthymiou: None.
A. Labalme: None. B. Vona: None. M. Carneiro: None.
K. Saeidi: None. H. Houlden: None. T. Sultan: None. R.
Maroofian: None. G. Lesca: None.
P09.117.A
Mitochondrial-specific polygenic risk score is associated
with increased Parkinson’s disease risk
Z. Landoulsi1, D. Bobbili1,2, S. Pachcheck1, G. Arena3,
NCER-PD Consortium, R. Krüger3,4,5, P. May1
1Bioinformatics Core, Luxembourg Centre for Systems
Biomedicine, University of Luxembourg, Belvaux, Luxem-
bourg, 2Megeno S.A., Esch-sur-Alzette, Luxembourg, 3Clin-
ical and Experimental Neuroscience, Luxembourg Centre
for Systems Biomedicine, University of Luxembourg,
Belvaux, Luxembourg, 4Parkinson Research Clinic, Centre
Hospitalier de Luxembourg, Luxembourg, Luxembourg,
5Transversal Translational Medicine, Luxembourg Institute
of Health, Strassen, Luxembourg
Introduction: Strong evidence indicates that mitochondrial
dysfunction is implicated in Parkinson’s disease (PD)
pathophysiology. The underlying mechanism of mitochon-
drial processes in the sporadic form of PD is still largely
unknown. Polygenic risk scores (PRS) gather the total risk
for disease in an individual based on common variants,
where the risk alleles and their effects are defined by pre-
vious genome-wide association studies (GWAS). Here we
evaluate whether an additive genetic risk of variants from
gene-sets is associated with increased PD risk.
Material and Methods: A Luxembourgish cohort of 656
controls and 633 PD patients were genotyped on the
Neurochip array. PRS for each individual were calculated
with PRSice-2, using the GWAS data from Nalls et al.,
2018. The PRS was tested for association with PD status
with mitochondrial and other pathway-related gene-sets.
The Parkinson’s Progression Markers Initiative (PPMI)
dataset included 363 PD cases and 165 controls genotyped
with NeuroX chip.
Results: The results show a significantly higher common
variant burden in PD cases compared to controls in
mitochondrial gene-sets (odds ratio: 1.31 [1.18, 1.48] per
one standard deviation; empirical-P = 8.9 e-04). The PRS
was also associated with PD status within the known PD
genes, lysosomal and autophagy gene-sets. The same result
was observed with the (PPMI) data.
Conclusions: Our study suggests that cumulative effect
of common variants in mitochondrial genes significantly
contribute to PD. Association tests targeting specific
mitochondrial pathways and functional studies could
determine the level of involvement of each mitochondrial
process in the disease onset and progression.
Z. Landoulsi: None. D. Bobbili: None. S. Pachcheck:
None. G. Arena: None. R. Krüger: None. P. May: None.
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Genetic and clinical report of ten additional patients
with PNKP-related ataxia (AOA4)
S. Sousa1,2, J. Oliveira1,2, J. Parente-Freixo1,2, I. Alonso1,2,
P. Silva1,2, A. Moreira3, L. Valdemar4, M. Pereira5, C.
Soares6, M. Rosas6, M. Leão7, L. Azurara8, S. Rocha9, J.
Ferreira8, J. Damásio1,2,10, J. Sequeiros1,2
1CGPP-IBMC, Universidade do Porto, Porto, Portugal,
2i3S - Instituto de Investigação e Inovação em Saúde,
Universidade do Porto, Porto, Portugal, 3Serviço de
Neurologia, Hospital de Dona Estefânia, Centro Hospitalar
de Lisboa Central, EPE, Lisboa, Portugal, 4Serviço de
Neurologia, Hospital do Divino Espírito Santo de Ponta
Delgada, EPE, Ponta Delgada, Portugal, 5Serviço de
Neurologia, Centro Hospitalar e Universitário de Coimbra,
EPE, Coimbra, Portugal, 6Consulta de Neurologia Geral,
Centro Hospitalar Universitário de São João, EPE, Porto,
Portugal, 7Serviço de Genética Médica, Centro Hospitalar
Universitário de São João / Faculdade de Medicina da
Universidade do Porto, Porto, Portugal, 8Serviço de
Neurologia Pediátrica, Hospital de São Francisco Xavier,
Centro Hospitalar de Lisboa Ocidental, EPE, Lisboa,
Portugal, 9Serviço de Neurologia, Hospital de Braga,
Braga, Portugal, 10Centro Hospitalar Universitário do
Porto, Hospital de Santo António, Porto, Portugal
Ataxia with oculomotor apraxia (AOA) is the second most
frequent recessive ataxia in Portugal. It is characterized by
childhood-onset cerebellar ataxia, sensorimotor axonal
neuropathy, oculomotor apraxia and dystonia; with a vari-
able degree of cognitive impairment. Diallelic variants in
the polynucleotide kinase 3’-phosphatase (PNKP) gene
were shown to be the cause of AOA4, by our group, in
2015. We now reviewed genetic and clinical data from a
sequential series with pathogenic variants in PNKP, 2015
through 2019, to update mutational spectrum and reassess
phenotypes; we report 10 additional AOA4 patients. We
used Sanger sequencing of PNKP or a NGS multigene
(whole-exome based) panel for recessive ataxias, according
to clinical request; 10 Portuguese AOA patients (7 families),
were found to be homozygotes (2 families) or compound
heterozygotes (5 families), bearing 4 known PNKP patho-
genic variants: c.1221_1223del (p.Thr408del) and
c.1123G>T (p.Gly375Trp) (each present in 4 families),
c.1315_1330delinsGGGGACG (p.Arg439_Pro444de-
linsGlyAspAla) and c.1029+2T>C (r.spl) (each present in 1
family); and 2 novel variants: c.1510del (p.Arg504Glyfs*)
and c.1282_1283insACAAACCCAGAC (p.Ala428de-
linsAspLysProArgPro), for which pathogenicity is being
confirmed. Incidentally, through multigene panels, six other
patients with ataxia (or other differential diagnoses) carried
a single pathogenic or likely- pathogenic variant in PNKP.
This study expands considerably the number of AOA4
patients genetically characterized by our group, from 11
reported in 2015 to a total of 21. Further, confirms AOA4 as
among the most frequent subtypes of recessive ataxia in
Portugal. Considering the limited number of patients
reported in the literature so far (n = 8), studies in other
populations are much needed.
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None. I. Alonso: None. P. Silva: None. A. Moreira: None.
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Genome-Wide Association Study of Postoperative Cog-
nitive Dysfunction in older surgical patients
N. Göttel1,2, M. Rickenbacher1, C. S. Reinbold3, S.
Herms3,4,5, P. Hoffmann3,4,5, S. Cichon3,4, A. U. Monsch6,
L. A. Steiner1,2
1Department of Anesthesia, Prehospital Emergency Medi-
cine and Pain Therapy, University Hospital Basel,
University of Basel, Basel, Switzerland, 2Department of
Clinical Research, University of Basel, Basel, Switzerland,
3Human Genomics Research Group, Department of Bio-
medicine, University of Basel, Basel, Switzerland, 4Institute
of Medical Genetics and Pathology, University Hospital
Basel, Basel, Switzerland, 5Institute of Human Genetics,
University of Bonn, School of Medicine & University
Hospital Bonn, Bonn, Germany, 6Memory Clinic, Univer-
sity Center for Medicine of Aging Basel, Felix Platter
Hospital, Basel, Switzerland
Introduction: Postoperative cognitive dysfunction (POCD)
is a common neurocognitive complication after surgery,
particularly in elderly patients. Various studies suggest
genetic risk factors for POCD. This prospective cohort
study aimed to detect genome-wide associations with
POCD in older patients.
Methods: Study participants aged ≥65 years completed a
battery of neuropsychological tests consisting of the
Consortium to Establish a Registry for Alzheimer’s
Disease-Neuropsychological Assessment Battery
(CERAD-NAB), Trail Making Tests A and B, and the
Phonemic Fluency Test (S-words) before, and at 1 week
and 3 months after major noncardiac surgery. Test variables
were converted into standard scores (z-scores) based on
demographic variables. POCD was diagnosed if the decline
was >1 standard deviation in 2 or more of the 15 variables
in the test battery. A genome-wide association study
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(GWAS) was performed to determine potential alleles that
are linked to the phenotype POCD.
Results: Sixty-three patients with blood samples were
included in the study. POCD was diagnosed in 47.6% of
patients at 1 week and in 34.2% of patients at 3 months after
surgery. Insufficient sample quality led to exclusion of 26
patients. In the remaining 37 patients, a GWAS was
performed, but no association with POCD was found. A
subsequent gene set analysis on 36 genes using VEGAS2
did not reveal any significant associations.
Conclusions: In this patient cohort, a GWAS did not
reveal an association between specific genetic alleles and
POCD at 1 week and 3 months after surgery. Future genetic
analysis should focus on specific candidate genes
for POCD.
N. Göttel: None. M. Rickenbacher: None. C.S.
Reinbold: None. S. Herms: None. P. Hoffmann: None.
S. Cichon: None. A.U. Monsch: None. L.A.
Steiner: None.
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Functional characterization of a novel variant in POLG2
shows disrupted mitochondrial integrity
M. Dulovic Mahlow1, M. Borsche1,2, H. Baumann1, S.
Tunc2, E. Knappe1, S. Özcakir1, J. Trinh1, N.
Brug̈gemann1,2, K. Lohmann1
1Institute of Neurogenetics, Luebeck, Germany, 2Depart-
ment of Neurology, UKSH, Luebeck, Germany
Introduction: Pathogenic variants in the DNA polymerase-
gamma2 (POLG2) cause a rare mitochondrial disease with
variable phenotypic presentations.
Material and methods: We performed exome sequen-
cing in a family with ataxia. To interpret pathogenicity of a
POLG2 variant, we used deep mitochondrial DNA
(mtDNA) sequencing, tested for mitochondrial deletions;
and established primary fibroblast lines from two mutation
carriers to investigate mitochondrial integrity by immuno-
cytochemistry, immunoblotting, and flow cytometry.
Results: The index patient, a 55-year-old woman,
presented with signs of vertigo at 30 years, followed by
the development of cerebellar ataxia and progressive
ophthalmoplegia. Her brother and mother had onset of
ataxia at ages of 40 and 50 years. By exome sequencing, we
identified a segregating, heterozygous, novel missense
variant (c.1270T>C [p.Ser424Pro], NM_007215.3) in
POLG2 in all three affected family members. Initially, this
was a variant of uncertain significance (VUS). We found a
higher number of mtDNA sequence changes in blood cells
from the mutation carriers compared to matched healthy
controls. However, large mtDNA deletions were not
detected in the blood samples. In POLG2-mutant fibro-
blasts, we demonstrated an impaired mitochondrial net-
work, a decreased mitochondrial membrane potential, and
decreased TOMM20 protein levels in comparison to healthy
controls. A muscular biopsy was not available.
Conclusions: We provide multiple lines of evidence that
this POLG2 variant is associated with impaired mitochon-
drial integrity suggesting its pathogenicity in respect to the
mitochondrial phenotype (ataxia and progressive external
ophthalmoplegia) in this family. Our work highlights the
importance of functional characterization of VUS to enable
meaningful genetic counselling.
M. Dulovic Mahlow: None. M. Borsche: None. H.
Baumann: None. S. Tunc: None. E. Knappe: None. S.
Özcakir: None. J. Trinh: None. N. Brüggemann: None.
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Extending the phenotypic spectrum of NEDHIB (neu-
rodevelopmental disorder with hypotonia and variable
intellectual and behavioral impairment) in a girl with
multiple anomalies and a de novo frameshift mutation in
POLR2A.
J. Behunova, F. Laccone
Institute of Medical Genetics, Medical University of Vienna,
Vienna, Austria
The gene POLR2A is coding polymerase II, RNA, subunit
A and its heterozygous mutations have been described to
cause global developmental delay with hypotonia, abnormal
behaviour, feeding and visual problems, strabismus, vari-
able craniofacial dysmorphic features, frequent infections,
and, eventually, structural brain anomalies. To date only 16
patients with POLR2A mutations have been described in a
single publication, three of them carrying a truncating
mutation. Many features in the published patients are
overlapping with those of our patient. However, none of the
patients reported presented a polydactyly (in our girl pre-
axial with a double thumb on the left), a thumb hypoplasia
(in our girl just a „soft tissue thumb“, which had been
removed, on the right), anal anteposition and stenosis, and a
heart defect (ASDII). There was significant neonatal
hypotonia. Unsupported walking was possible only at the
age of 4 years. Developmental delay now at the age of 14
years is severe. The girl does not speak at all. After the first
decade the tendon-reflexes of the legs decreased and bilat-
eral pes cavus developed, possibly manifesting a peripheral
neuropathy. There are craniofacial dysmorphic features, but
no microcephaly. Whole exome sequencing (incl. CNV)
identified a 2 bp deletion in POLR2A which is supposed to
cause a frameshift and a premature stop of protein synthesis.
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No other DNA variants were identified that could explain
the symptoms unusual for NEDHIB. The healthy unrelated
parents do not carry the mutation, two sisters are healthy.
J. Behunova: None. F. Laccone: None.
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Polygenic-wide analysis to predict genetic risk profiles
on brain morphometry over phenome-wide diseases
N. Vilor-Tejedor1,2,3,4, R. Guigo1,4, G. Operto2,5,6, M.
Crous-Bou2,5,6,7, R. Cacciaglia2,5,6, C. Falcón2,6,8, E. M.
Arenaza-Urquijo2,5,6, C. Minguillón2,5,6, K. Fauria2,5,6, J.
Molinuevo2,4,5,6, J. Gispert2,4,6,8
1Centre for Genomic Regulation (CRG), The Barcelona
Institute for Science and Technology., Barcelona, Spain,
2Barcelonaβeta Brain Research Center (BBRC), Pasqual
Maragall Foundation., Barcelona, Spain, 3Department of
Clinical Genetics, ERASMUS Medical Center., Rotterdam,
Netherlands, 4Universitat Pompeu Fabra, Barcelona,
Spain, 5Centro de Investigación Biomédica en Red de
Fragilidad y Envejecimiento Saludable (CIBERFES),
Madrid, Spain, 6IMIM (Hospital del Mar Medical Research
Institute), Barcelona, Spain, 7Department of Epidemiology,
Harvard TH Chan School of Public Health, Boston, MA,
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Neurodegenerative diseases are associated with progressive
neuronal damage along with an accelerated brain atrophy,
which is influenced by multiple genetic factors. Polygenic
risk scores (PRS) are used for identifying the genetic
architecture of complex diseases in order to predict disease
genetic risk, as well as testing their shared genetic archi-
tecture. In this study, we investigated the association
between PRS related to neurodegenerative and complex
diseases and brain morphometry. A total of 479 cognitively
unimpaired middle-age participants at increased risk of AD
(ALFA cohort) with available genotyping and neuroima-
ging data were included. PRS were calculated from the most
recent genome-wide association meta-analyses for Alzhei-
mer’s disease (AD), Parkinson disease, stroke, hyperten-
sion, hypercholesterolemia, diabetes, depression,
cerebrovascular disease, and CSF core AD biomarkers.
Association analyses included brain regional volumes as
outcomes. Associations were estimated using linear
regression models adjusted for age, sex, education, APOE-
ϵ4 status, and total intracranial volume. We found increased
PRS average of AD, p-tau and Aβ42 levels among ALFA
participants. Furthermore, results suggested evidence of an
association between increased risk of cholesterolemia and
reduced volumes of left accumbens area, increased risk of
cardiovascular disease and reduced volumes of thalamus
proper, as well as increased risk of having higher p-tau
levels and reduced volumes of right thalamus proper and
right cerebellum cortex. We provide strong evidence that
genetic liability of cardiovascular diseases and core AD
biomarkers influences brain morphology in ALFA partici-
pants. In addition, across all diseases, ALFA participants
showed increased genetic risk of AD and altered CSF
biomarker.
N. Vilor-Tejedor: None. R. Guigo: None. G. Operto:
None. M. Crous-Bou: None. R. Cacciaglia: None. C.
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Biallelic loss of function mutations in JAM2 cause
primary familial brain calcification
Z. Cen, Y. Chen, S. Chen, D. Yang, L. Wang, H. Wang, X.
Chen, P. Liu, B. Zhang, W. Luo
The Second Affiliated Hospital, Zhejiang University School
of Medicine, Hangzhou, China
Introduction: Primary familial brain calcificationis a
monogenic disease characterized by bilateral calcification in
the basal ganglia and other brain regions, and commonly
presents motor, psychiatric, and cognitive symptoms. Cur-
rently, four autosomal dominant (SLC20A2, PDGFRB,
PDGFB, XPR1) and one autosomal recessive (MYORG)
causative genes have been identified.
Materials and Methods: Homozygosity mapping and
whole genome sequencingwere performed in a consangui-
neous family with two affected siblings diagnosed with
primary familial brain calcificationto detect novel causative
gene. Further genetic screening was performed in a cohort
of 398 probands with primary familial brain calcification.
Results: A homozygous frameshiftmutation (c.140delT,
p.L48*) in the JAM2gene in theconsanguineous family.
Further more, a homozygous start codon mutation (c.1A>G,
p.M1?) and compound heterozygous mutations [c.504G>C,
p.W168C and c.(67+1_68-1)_(394+1_395-1), p.
Y23_V131delinsL], respectively, in two unrelated famil-
ieswere detected. In Chinese hamster ovary cells, truncated
His-tagged JAM2 proteins were detected by western blot
following transfection of p.Y23_V131delinsLmutant plas-
mid, while no protein was detected following transfection of
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p.L48* or p.1M? mutant plasmids. In immunofluorescence
experiments, the p.W168C mutant JAM2 protein failed to
translocate to the plasma membrane.
Conclusions: Our findings offer a novel causative gene
for primary familial brain calcification, whose vital function
and high expression in the neurovascular unitfurther
supports impairment of the neurovascular unit as the root
of primary familial brain calcificationpathogenesis.
Z. Cen: None. Y. Chen: None. S. Chen: None. D. Yang:
None. L. Wang: None. H. Wang: None. X. Chen: None.
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Novel progressive myoclonus epilepsy syndrome caused
by a recurrent homozygous variant of SLC7A6OS
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Joensuu3, C. Courage3, N. Chatron1, G. Borsani5, E. Alix1,
F. Ramond6, R. Touraine6, S. F. Berkovic7, N. Bebek4, A.
Lehesjoki3, G. Lesca1
1University Hospital of Lyon, Lyon, France, 2University
Hospital of Saint Etienne, Saint Etienne, France, 3Fol-
khälsan Research Center, Helsinki, Finland, 4Istanbul
Faculty of Medicine, Istanbul, Turkey, 5University of
Brescia, Brescia, Italy, 6University Hospital of Saint-
Etienne, Saint-Etienne, France, 7Epilepsy Research Centre,
University of Melbourne, Victoria, Australia
Purpose: Progressive myoclonus epilepsies are a geneti-
cally heterogeneous group of rare Mendelian disorders
defined by the combination of action and reflex myoclonus,
other types of epileptic seizures, and progressive neuro-
cognitive impairment. In addition to the classical diseases,
namely Unverricht-Lundborg and Lafora, several other
genetic forms have been identified during the past years.
Despite recent advances, a substantial proportion of cases
remain without a molecular diagnosis and additional genes
still remain to be identified.
Methods: Individuals from two families from different
ethnic backgrounds with several individuals affected with a
similar presentation of progressive myoclonus epilepsy
resembling Unverricht-Lundborg disease were analyzed by
exome sequencing.
Results: Affected individuals from both families were
homozygous for the same p.(Gln64Arg) variant affecting a
splice site in SLC7A6OS. It occurs 7 times in gnomAD as a
heterozygote, and is absent as a homozygote. Haplotype
analysis suggests the variant arose independently in the two
families. Analysis of cDNA from lymphoblastoid cells of a
patient showed a partial abolition of the splice site and the
creation of an abnormal isoform with the retention of intron
1 (NM_032178.2:r.191_193ins[ag;192+1_193-1]). RT-
qPCR and western blot showed a ≈80% reduction of cDNA
and 60% of protein. Gene knockdown experiments in
zebrafish indicate that slc7a6os plays a critical role in
defined areas of the developing CNS.
Conclusions: Our results suggest that SLC7A6OS may be
a novel gene causing progressive myoclonus epilepsy
phenotype resembling Unverricht-Lundborg disease.
A. Labalme: None. L. Mazzola: None. M. Muona:
None. B. Baykan: None. T.H. Joensuu: None. C.
Courage: None. N. Chatron: None. G. Borsani: None.
E. Alix: None. F. Ramond: None. R. Touraine: None. S.
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G. Lesca: None.
P09.128.C
The genotype-phenotype correlation of intragenic
RBFOX1 deletions.
M. A. Paczkowska, M. Geremek, B. Nowakowska
Institute of Mother and Child, Warsaw, Poland
The RBFOX1 gene encodes a protein that regulates pre-
mRNA splicing in developmental genes expressed in
muscle, heart and neuronal cells. Intragenic deletions of
RBFOX1 gene have been identified as susceptibility loci
and reported in patients with aggressive behavior, conduct
disorder, epilepsy and autism spectrum disorder. Despite of
the documented correlation with neurodevelopmental dis-
orders, the deletions of RBFOX1 gene are often inherited
from the healthy parents, therefore the clinical interpretation
of CNVs within this gene is still unclear. We applied oli-
gonucleotide microarrays (OGT) in a cohort of 9430
patients with neurodevelopment disorders and their healthy
relatives. The analyses of genomes were performed using
genome-wide array to accurate detection of copy number
variation at the exon level in RBFOX1 gene. Chromosomal
analysis revealed intragenic RBFOX1 deletions in 36
patients. The differential distribution across the gene
between patients with neurodevelopmental disorders and
the control group allowed to distinguished evidently
pathogenic areas within the gene. Deletions of exones 1-2
and 13-14 have high penetrance, and are mainly associated
with conduct disorder and autism spectrum disorder. While
the middle part of the gene and all intronic CNVS were
observed with higher frequency in the control group, sug-
gesting their benign impact on the phenotype.
The work was supported by MINDDS - CA COST Action
CA16210 - Maximising Impact of research in NeuroDeve-
lopmental DisorderS
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Deep targeted-NGS identifies RLS genes by differential
burden with low-frequency variants and differential
target sequencing depth
E. Tilch1, B. Schormair1, C. Zhao1, A. Salminen1, A. Antic
Nikolic1, E. Holzknecht2, B. Högl2, W. Poewe2, C.
Bachmann3, W. Paulus4, C. Trenkwalder5, W. Oertel1, M.
Hornyak6, I. Fietze7, K. Berger8, P. Lichtner9, C. Gieger10,
A. Peters10, B. Müller-Myhsok11,12, A. Hoischen13, J.
Winkelmann1,11,14, K. Oexle1
1Institute of Neurogenomics, Helmholtz Zentrum München
GmbH, German Research Center for Environmental
Health, Neuherberg, Germany, 2Department of Neurology,
Medical University of Innsbruck, Innsbruck, Austria,
3Department of Neurology, Paracelsus Clinic Osnabrück,
Osnabrück, Germany, 4Department of Clinical Neurophy-
siology, Georg August University, Göttingen, Germany,
5Center of Parkinsonism and Movement Disorders,
Paracelsus-Elena Hospital, Kassel, Germany, 6Neuropsy-
chiatry Center Erding/Munich, Erding, Germany, 7Depart-
ment of Cardiology and Angiology, Center of Sleep
Medicine, Charité-Universitätsmedizin Berlin, Berlin, Ger-
many, 8Institute of Epidemiology and Social Medicine,
University of Münster, Münster, Germany, 9Institute of
Human Genetics, Helmholtz Zentrum München GmbH,
German Research Center for Environmental Health,
Neuherberg, Germany, 10Institute of Epidemiology, Helm-
holtz Zentrum München GmbH, German Research Center
for Environmental Health, Neuherberg, Germany,
11MunichCluster for Systems Neurology, Munich, Germany,
12Max Planck Institute of Psychiatry, Munich, Germany,
13Department of Human Genetics, Radboud University
Medical Center, Nijmegen, Netherlands, 14Department of
Neurogenetics and Institute of Human Genetics, Technical
University of Munich, Munich, Germany
Introduction: Restless legs syndrome (RLS) is one of the
most common and burdensome neurological disorders.
Patients typically present with an urge to move the legs at
rest at night which severely impairs sleep and quality of
life. Based on previous GWAS results, we performed
mutational load analysis of putatively causal candidate
genes.
Materials and Methods: We sequenced exons and
promotors of 84 genes in 4,649 RLS patients and 4,982
population-based controls from Germany in a targeted NGS
approach with 11,214 molecular inversion probes (MIPs).
We compared the variant load (MAF < = 0.05) by gene
between cases and controls using standard burden testing.
As variants in a MIP’s binding regions affect its sequencing
yield, we also analyzed target sequencing depths as an
integrative and independent assessment of the differential
variant burden.
Results: Differential variant burden results of both types
of analysis overlapped significantly. Therefore, 14 genes
were significantly associated and validated. Both types of
analysis also converged significantly in fine-mapping
potentially causative domains within these genes.
Conclusions: By assessing differential burden with
intragenic low-frequency variants we identified at least 14
putatively causative genes in RLS. In keeping with other
polygenic diseases, the variant burden was higher in
patients. Methodologically, we demonstrate that target
depth analysis is useful for independent validation of
conventional variant-based burden tests.
Acknowledgements: DFG (project 310572679), RLS e.
V., and SRLS.
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Extension of the phenotypes caused by RNF13 variants
to include a choreo-dystonic movement disorder
E. Ranza1, X. Blanc1, F. Santoni1, F. Guerry1, S.
Antonarakis1, C. Korff2
1Medigenome, Swiss Institute of Genomic Medicine,
Geneva, Switzerland, 2Pediatric Neurology, Geneva Uni-
versity Hospitals, Geneva, Switzerland
The substantial recent advances in genetic diagnosis, have
identified numerous pathogenic variants on genes involved
in neurodevelopment in patients with developmental delay
and epilepsy. Among those, heterozygous missense gain-of-
function variants in RNF13 leading to altered signaling of
the endoplasmic reticulum stress response, have been
recently reported in three children with congenital micro-
cephaly, encephalopathy with epilepsy, blindness, and
failure to thrive (PMID 30595371). None of these patients
presented with movement disorders. We here report a child
with early-onset global developmental delay, acquired
microcephaly, failure-to-thrive, infantile spasms, focal sei-
zures and gastrointestinal dysfunction, who also presented
at 3 years with a choreo-dystonic movement disorder. An
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extended metabolic work-up was normal. Brain MRI did
not reveal significant abnormalities. A trio whole-exome
sequencing revealed a heterozygous de novo c.932delT:(p.
Leu311TyrfsTer2) variant in the RNF13 gene. The variant
results in a frameshift near the carboxyl terminus of the
predicted protein sequence (codon 311 of 380), producing
an abnormal protein with a postulated gain of function
effect. Interestingly the previously described pathogenic
variants were in the same location of the primary protein
sequence p.(Leu311Ser) and p.(Leu312Pro).To our knowl-
edge, our patient is the fourth described so far. In addition to
previously reported symptoms, the phenotype of this child
also included a choreo-dystonic movement disorder; thus
the phenotypes related to RNF13 pathogenic variants are
extended to include a movement disorder. The RNF13
should be added to the panel of candidate genes in patients
with abnormal movements, in addition to those involved in
encephalopathy and early-onset epilepsy.
E. Ranza: None. X. Blanc: None. F. Santoni: None. F.
Guerry: None. S. Antonarakis: None. C. Korff: None.
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DNMT1 overexpression results in dysregulation of
multiple genes associated with neurological disorders
and abnormal neurogenesis.
S. Saxena1, S. Choudhury2, A. Sampath1, K. Naga
Mohan1
1BITS PILANI HYDERABAD CAMPUS, hyderabad, India,
2BITS PILANI HYDERABAD CAMPUS, Hyderabad, India
In the context of DNMT1 overexpression as one of the
etiological factors for schizophrenia (SZ), and abnormal
neurogenesis associated with Dnmt1Tet/Tet (Tet/Tet) mouse
embryonic stem cells, we studied the effects of DNMT1
overexpression on neurogenesis. Transcriptome analysis of
Tet/Tet neurons showed dysregulation of a significant
number of genes associated with neurological disorders.
Downregulation of Shh was the main event associated with
dysregulation of genes involved in multiple pathways such
asWnt1 andWnt3a signaling, extracellular matrix synthesis,
homeobox family and other transcription factors required
for brain development. Transcriptome analysis of Tet/Tet
ES cells to understand earlier events also showed
dysregulation of a significant number of genes associated
with neurodevelopment and neurological disorders. Speci-
fically, Bmp4, an antagonistic molecule to Shh, emerged
with the highest number of interacting partners. In ES cells,
high Bmp4 transcript levels were associated with low
transcript levels of Lrp2, Htra1 and Bmper (negative
regulators of Bmp4) and Dpysl2 (negatively regulated by
BMP4). Consequently, as in case of some SZ-patient
derived iPS cells, Tet/Tet ES cells possessed a decreased
potential to produce neurons and oligodendrocytes but an
increased potential in forming glial cells. RRBS data on
ESCs and neurons did not reveal any significant difference
in the level of DNA methylation of the promoters of the
affected genes. DNMT1 affects on these genes therefore,
appear to be independent of catalytic activity. Taken
together, increased DNMT1 levels results in abnormal
neurogenesis by affecting multiple SZ-associated genes and
pathways in a DNA-methylation independent manner.
S. Saxena: None. S. Choudhury: None. A. Sampath:
None. K. Naga Mohan: None.
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Two intronic variants in cis in both alleles of the
POLR3A gene cause progressive spastic ataxia with
hypodontia
A. Felner1,2, A. Lossos3, E. Kogan2, Z. Argov3, C. Gonzaga-
Jauregui4, A. R. Shuldiner4, N. Lev-El Halabi1, I.
Lagovcky1, S. Naftaly Nathan1, L. Bazak1, G. Lidzbarsky1,
L. Basel-Salmon1,5,6, Y. GOLDBERG1
1Raphael Recanati Genetics Institute, Rabin Medical Center,
Petah Tikva, Israel, 22. Department of Neurology, Rabin
Medical Center, Beilinson Hospital, Petah Tikva, Israel,
3Department of Neurology, Hadassah-Hebrew University
Medical Center, Jerusalem, Israel, 4Regeneron Genetics
Center, Tarrytown, NY, United States, 5Sackler Faculty of
Medicine, Tel-Aviv University, Tel Aviv, Israel, 6Felsenstein
Medical Research Center, Petah Tikva, Israel
Background: POLR3A encodes the largest subunit of the
DNA-dependent RNA polymerase-III. Mutations in this gene
are associated with dysregulation of tRNA production and
other non-coding RNAs. Biallelic POLR3A pathogenic var-
iants are associated with several phenotypes, including
Hypomyelinating leukodystrophy, hypogonadism, hypo-
dontia, progressive spastic ataxia, and the progeroid disorder
Wiedemann-Rautenstrauch syndrome (WRS). Genotype-
phenotype correlation is unclear, though some variants have
been associated mainly with spastic ataxia and others
with WRS.
Methods: Phenotypic analysis and exome sequencing
were performed in 4 affected siblings, two healthy siblings
and their mother.
Results: All affected siblings (two men, two women; ages
45-58) had early childhood-onset hypodontia and
adolescent-onset progressive spastic ataxia. None had
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dysmorphism or hypogonadism. They all had biallelic
POLR3A pathogenic variants. The mother was heterozygo-
tous and both healthy siblings had wild-type alleles. Each
mutated allele had two intronic splicing-altering variants in
cis, leading to skipping of exons 14 and 26. This allele was
reported previously in compound heterozygous combina-
tions in patients with severe progeroid WRS.
Conclusions: This is the first report addressing the
clinical consequence associated with a unique homozygous
pathogenic allele in the POLR3A gene. Our findings
indicate that homozygosity for this pathogenic allele causes
spastic ataxia with hypodontia, rather than a progeroid
syndrome, dysmorphism or hypogonadism previously
attributed to this allele when found in a compound
heterozygous state with other alleles. Our findings con-
tribute to the characterization of genotype-phenotype
correlation in POLR3A-related disorders.
A. Felner: None. A. Lossos: None. E. Kogan: None. Z.
Argov: None. C. Gonzaga-Jauregui: A. Employment (full
or part-time); Modest; Regeneron. A.R. Shuldiner: A.
Employment (full or part-time); Modest; Regeneron. N.
Lev-El Halabi: None. I. Lagovcky: None. S. Naftaly
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Increased gene expression ofGINS2in patients with
Specific Language Impairment
I. G. Sotkova-Ivanova1, H. Ivanov1, A. Linev1, T. Vachev1,
N. Popov2, I. Ivanov1, I. Pacheva1, R. Yordanova1, V.
Stoyanova1
1Medical Univercity Plovdiv, Department of Pediatrics and
Medical Genetics, Medical University Plovdiv, Plovdiv,
Bulgaria, 2Psychiatric ward for active treatment, State
Phsychiatry Hospital Pazardzhik,, Plovdiv, Bulgaria
Introduction: Specific Language Impairment (SLI) is a
disorder characterized by slow, abnormal language devel-
opment, despite normal intelligence, adequate social
environment and in the absence of any explanatory medical
conditions. Most children with this disorder do not present
any other cognitive or neurological deficits and have normal
non-verbal IQ. This condition is highly heritable and affects
between 5% and 8% of pre-school children. Lately inves-
tigations have begun to uncover genetic factors that may
contribute to susceptibility to language impairment. In our
previous study we conducted a pool expression analysis and
GINS2 was the most up regulated gene.
Materials and Methods: The study aimed to examine the
individual expression profile of GINS2 gene by ddPCR in
the peripheral blood of 48 individuals divided into two
groups: children with SLI and healthy controls.
Results: Mean values of 15,4copies/20mcl was found in
the SLI group and 8,8 - in the control one. The difference
was statistically significant - P=0.03, proving that the
GINS2 gene is up regulated in the SLI group. GINS2,
located in 16q21 is part of the GINS complex which plays
an essential role in the initiation of DNA replication, and
progression of DNA replication forks. There are a couple of
case reports that report speech delay in patients with 16q21
duplications. A recent study found a connection with
GINS2 expression and neuroinflamation.
Conclusions: Comparative gene expression analysis is
useful in discovering novel genetic markers associated with
SLI. Elevated gene expression of GINS2 might contribute to
the elucidation of the pathogenesis of SLI.
I.G. Sotkova-Ivanova: None. H. Ivanov: None. A.
Linev: None. T. Vachev: None. N. Popov: None. I.
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A 357 kb duplication encompassing the ATP2B3 gene in
Xq28 is associated with X-linked spinocerebellar ataxia
(SCAX1) in two males within one family
Y. Stratis, F. Stock, C. Müller-Hofstede, S. Ledig, J.
Horvath, P. Wieacker, A. Bohring, A. Röpke
Institute of Human Genetics, Münster, Germany
X-linked transmission of spinocerebellar ataxia (SCAX) is
relatively rare. One missense mutation in ATP2B3
resulting in spinocerebellar ataxia 1 (SCAX1) is reported
twice in the literature as the cause of SCAX1 in two
families. The ATP2B3 gene encodes for a member of the
calmodulin-activated plasma membrane Ca2+ ATPase
family (PMCA3) which extrudes excess calcium from the
cell to maintain neuronal Ca2+-homeostasis, especially in
the cerebellum. The 46 year old index patient was referred
to our institute because of early onset cerebellar ataxia. He
showed a delayed motor development as an infant,
impaired gross and fine motor skills, dysarthria, and
hypoplasia of the cerebellum. Intellectual development
was normal. Kennedy’s disease was excluded and a NGS
panel for ataxia related genes showed no pathogenic
variants. Array-CGH revealed a duplication of 357 kb in
Xq28. This duplication spans eight genes, including
ATP2B3 and two more OMIM genes (BGN, FAM38A).
Further analysis of female family members confirmed this
duplication in the patient’s mother, her sister and the
sister’s daughter. Her three year old son also displayed
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ataxia and a delayed motor development. He was proved
to carry the duplication as well. Based on the family
constellation and the known literature for the ATP2B3
gene we highly assume that the duplication in Xq28
comprising ATP2B3 is causative for the spinocerebellar
ataxia within this family, implicating a dysregulation of
the calcium homeostasis in neuronal cells by the dupli-
cation of the ATP2B3 gene.
Y. Stratis: None. F. Stock: None. C. Müller-Hofstede:
None. S. Ledig: None. J. Horvath: None. P. Wieacker:
None. A. Bohring: None. A. Röpke: None.
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Genetic risk factors for tendency to suicide detected in a
cohort GWAS study
A. Haghighatfard1, F. Mohammadpour2
1Islamic Azad university-Tehran medical sciences branch,
Tehran, Iran, Islamic Republic of, 2University of Guilan,
Rasht, Iran, Rasht, Iran, Islamic Republic of
Suicide is a major public health problem, with almost one
million people victims’ world-wide each year. Psychologi-
cal risk factors for suicidal behaviors are including, psy-
chiatric and medical illness, impulsivity, aggression, alcohol
and drug abuse specially stimulants, and low stress resi-
lience. Genetic risk factors of suicide are not completely
clarified. Our study aimed to detect genetic risk factors that
increasing the vulnerability to committing suicide. DNA
was extracted from blood samples of 8240 saved suicide
victims with at least one attempt to suicide in last 12 months
that were suffering from psychosis and 5000 healthy sub-
jects. Genotyping for the subjects was performed using the
Affymetrix Genome-Wide Human SNP Array 6.0 (Affy-
metrix, Santa Clara, CA) according to the manufacturer’s
protocol. Several SNPs were detected with genome-wide
significance. The significant association found in 77 SNPs
involved in dopaminergic pathway and neurodevelopment
of CNS. 56 of significantly related SNPs were found as risk
factors of psychiatric disorders specially schizophrenia;
other 21 SNPs were related to the mitochondrial complexes,
transcription factors and growth factor genes. The study
showed strong genetic bases of suicidal thoughts and could
be used for providing genetic prognostic markers for pre-
diction of suicide risk especially in subjects with psychosis.
Also importance of mitochondrial complexes and growth
factors in neuorobilogical functions and decision making
processes of brain were showed.
A. Haghighatfard: None. F. Mohammadpour: None.
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Expanding phenotypic spectrum of TAF1 variants:
Report of two novel families
J. Pozojevic1, M. G. Pauly1, N. Schell1, H. Pawlack1, C.
Klein1, A. Westenberger1, N. Brüggemann1,2
1Institute of Neurogenetics, Lübeck, Germany, 2Department
of Neurology, Lübeck, Germany
Introduction: Pathogenic variants affecting the TAF1
(TATA-box binding protein associated factor 1) coding
region have been shown to cause a complex X-linked
neurodevelopmental syndrome that includes intellectual
disability, dysmorphic features, and neurological manifes-
tations. The changes described to date are predominantly
missense and distributed along the entire gene. A non-
coding TAF1 variant causes X-linked dystonia-parkinson-
ism (XDP), an adult-onset neurodegenerative movement
disorder.
Patients and Methods: By whole-exome sequencing, the
genetic cause of X-linked intellectual disability was
investigated in male patients from two families. In other
available family members, the presence of relevant TAF1
variants was investigated by targeted Sanger sequencing.
Where appropriate, a standard X-chromosome inactivation
assay was used.
Results: The proband from Family 1 clinically mani-
fested with global developmental delay including motor,
speech and cognitive abilities and carried the c.1606G>A
(p.(Asp536Asn)) TAF1 variant and the MT-CO1
m.6054G>A (p.(Asp51Asn)) mitochondrial variant in the
heteroplasmic state. In Family 2, the affected male patients
presented with early onset spastic paraplegia and mild
cognitive impairment, all carrying a missense (c.5418G>C;
p.(Glu1806Asp)) variant in TAF1. Their mother was a
heterozygous carrier of the same change and developed
adult-onset parkinsonism, spasticity, and dementia. Her X-
chromosome inactivation (XCI) was random.
Conclusions: Two novel TAF1 variants were identified as
the likely disease causes in our patients. The affected
members of Family 2 presented with pyramidal signs,
suggesting that the TAF1 variants other than those related to
XDP may cause an affection of additional neurological
systems.
J. Pozojevic: None.M.G. Pauly: None. N. Schell: None.
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Brain lipid profile of early onset Tay-Sachs disease
mouse model
418 J. del Picchia
T. Sengul1, M. Can1, S. Akyildiz Demir1, C. Klose2, M.
Surma2, V. Seyrantepe1
1Izmir Institute of Technology, Izmir, Turkey, 2Lipotype
GmbH, Dresden, Germany
Introduction: Tay-Sachs disease is one of the lysosomal
disorders caused by mutation in Hexa gene. HEXA gene
deficiency affects the central nervous system owing to GM2
accumulation in lysosomes resulting in progressive neuro-
degeneration in patient. Previoulsy generated Hexa-/-
Neu3-/- mice mimic neuropathological and clinical
abnormalities of early onset Tay-Sachs patients. Lipids are
important players in the central nervous system function-
ality. Several studies showed that neurodegenerative dis-
eases indicate alterations in lipid metabolism. Here, we
aimed to clarify the secondary accumulation of lipids and
presence of unregulated lipid metabolism in brain of early
onset Tay-Sachs disease mice model by lipidome profiling.
Materials and methods: Cortex and hippocampus of 5-
month-old of WT, Hexa-/-, Neu3-/- and Hexa-/-Neu3-/-
mice were analyzed by mass spectrometry and lipid levels
belongs to glycerolipids, glycerophospholipids, sphingoli-
pids, sterol lipids were evaluated by using shotgun
lipidomics approach.
Results: In glycerophospholipid class, high level of LPC,
LPE and PG lipids while low level of PC, PS lipids were
detected in cortex and hippocampus of Hexa-/-Neu3-/- mice
compared to age matched control group. Significantly high
levels ceramide and sterolipid were also measured in cortex.
Alterations in glycerolipid class was detected in both
regions.
Conclusion: Here we report that in addition to abnormal
GM2 accumulation in lysosomes, secondary but distinct
lipid alterations may also contribute to pathophysiology of
early onset Tay-Sachs disease suggesting the possible
dysfunctionality of cellular pathways such as autophagy.
Acknowledgement: Research was funded by TUBITAK
215Z083.
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Role of oxidative stress in the pathogenesis of Tay-Sachs
disease mouse model
N. Ates, H. Basirli, T. Caliskan, A. Nalbant, V. Seyrantepe
Izmir Institute of Technology, Izmir, Turkey
Introduction: Tay-Sachs disease is one of the lethal lyso-
somal storage disorders caused by mutations on the HEXA
gene leading to GM2 accumulation which causes neuro-
degeneration. Hexa-/-Neu3-/- mice mimic neuropathologic
phenotype of the disease. Oxidative stress has been
demonstrated to be involved in the pathogenesis of many
neurodegenerative diseases. In this research we investigated
whether the oxidative stress has an effect on the
neuropathology mice.
Material and Methods: Brain sections and fibroblasts
from WT, Hexa-/-, Neu3-/- and Hexa-/-Neu3-/- mice as well
as neuroglia were studied. Oxidative stress markers were
analysed by RT-PCR, western blot and protein carbonyla-
tion assay. The intracellular ROS level was measured by
using H2DCFDA and analysed by FACScan.
Results: Significant increase in protein carbonyl levels
was determined particularly in cerebellum of Hexa-/-
Neu3-/- mice. Similarly, we determined significant change
in neuroglia but not in Hexa-/-Neu3-/- fibroblast. However,
we found significantly high level of catalase and Ttase1
mRNA in Hexa-/-Neu3-/- fibroblasts. In addition, oxidized
DCFDA was also increased in Hexa-/-Neu3-/- fibroblast
indicating high level of ROS but surprisingly we detected
the low level of ROS in neuroglia. Significant increase in
the level of APE1/Ref-1 protein was observed in cerebellum
and thalamus of Hexa-/-Neu3-/-; however, in fibroblast
there was no significant difference among samples.
Significantly decreased level of catalase and increased
Ttase1 mRNA were detected in neuroglia compared to
control.
Conclusions: We suggest that abnormal GM2 accumula-
tion in lysosomes trigger oxidative stress leading alterations
in redox homeostasis in early-onset Tay-Sachs disease
pathology. The research was supported by TUBİTAK-
215Z083
N. Ates: None. H. Basirli: None. T. Caliskan: None. A.
Nalbant: None. V. Seyrantepe: None.
P09.149.C
Neurodegenerative-like phenotype of a TTR mutation
deciphered by bioinformatic tools
A. Lunati1, C. Delamarche2, P. Diraison3, I. Isabelle
Quintin-Roue4, B. Funalot1, P. Fanen1
1Département de génétique; CHU Henri Mondor, Créteil,
France, 2Professor - Retired from University of Rennes 1,
Rennes, France, 3Service de neurologie, CH de Cor-
nouaille, Quimper, France, 4Service d’anatomie et cytolo-
gie pathologiques, CHRU, Brest, France
Hereditary transthyretin amyloidosis (ATTR) leads to a
variable phenotype and involve many organs. Here we
report one patient presenting with central neurological and
ophthalmological signs, amyloid deposits on subarachnoid
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biopsy and a familial history of neurodegenerative disorder.
We identified a rare heterozygous TTR mutation c.149T>G,
p.(Val50Gly) at the same aminoacid position as the most
frequent mutation V50M. In order to understand this unu-
sual phenotype, we used bioinformatic tools including
structure prediction, estimation of thermodynamic para-
meters (ΔΔG) to compare models of V50M and V50G
mutants, in relation to WT-TTR and applied a molecular
modeling method to test the self-assembly capacity of a
TTR peptide located in the region of the mutated residue.
Our model predicted that the relative stability of tetramers
and dimers was not affected by both mutations, ΔΔG values
indicated a moderate instability of V50M monomers
whereas V50G showed a very high unfolding capacity. We
also investigated theorical models composed of 4 segments
P11-K35 with a methionine or glycine at position 50.
Although in both mutants the structure of each segment
consists of a β-arch, oligomers were very different. V50M
4 β-arches were stacked in a parallel β-sheet structure sta-
bilized by inter-strand interactions whereas 4 β-arches of
V50G associated in a β-barrel structure with intra and inter
strand interactions. Our data strongly suggest that V50G is
more cytotoxic than V50M due to its propensity to be more
unstable as a monomer and to aggregate as β-barrel struc-
tures similar to those observe in neurodegenerative dis-
orders such as Alzheimer disease.
A. Lunati: None. C. Delamarche: None. P. Diraison:
None. I. Isabelle Quintin-Roue: None. B. Funalot: None.
P. Fanen: None.
P09.150.A
Molecular screening of patients affected with tuberous
sclerosis complex
E. Bukowska-Olech1, D. Popiel2, A. Dawidziuk2, G.
Koczyk2,3, A. Sowinska-Seidler1, S. Jóźwiak4, K. Kotulska-
Jóźwiak5, J. Strzelecka4, J. Borkowska5, A. Jamsheer1,2
1Department of Medical Genetics, University o Medical
Sciences in Poznan, Poland, Poznan, Poland, 2Centers for
Medical Genetics GENESIS, Poznan, Poland, 3Institute of
Plant Genetics (PAS), Department of Biometry and
Bioinformatics, Poznan, Poland, 4Department of Child
Neurology, Medical University of Warsaw, Warsaw,
Poland, 5Department of Neurology and Epileptology,
Children’s Memorial Health Institute, Warsaw, Poland
Background: Tuberous sclerosis complex (TSC) represents
a rare genetic multisystem neurocutaneous disorder, that is
caused by pathogenic variants within TSC1 and TSC2
genes. The disorder is characterised by multiple hamarto-
mas in the brain, heart, skin, and kidney. Another common
feature of TSC is epilepsy, which is frequently drug-
resistant and constitutes the main cause of morbidity and
disability in affected individuals. The project EPIMARKER
is aimed to identify new biomarkers of epilepsy in a group
of patients affected with TSC. We believe, the results of this
research will become a starting point for further work on
new therapeutics and clinical solutions.
Materials and methods: The first step of the project was
intended to describe an exact molecular cause of TSC in a
group of 65 affected individuals. We screened TSC1 and
TSC2 genes with the use of targeted next-generation
sequencing (NGS) and quantitative PCR (qPCR) for all
exons of both genes.
Results: Testing with targeted next-generation sequen-
cing gene panel revealed pathogenic variants in 50 out of 65
patients, whereas qPCR performed in 15 remaining
individuals showed intragenic deletions in 5 additional
cases. Noteworthy, we have found 19 novel and 31 known
pathogenic variants.
Conclusions: The diagnostic algorithm presented here is
a suitable and helpful approach in the molecular analysis of
TSC. Furthermore, the data we have obtained will be used
in the further part of the project, which is focused on novel
therapeutic strategies. This work was supported by the grant
from the National Centre for Research and Development no.
STRATEGMED3/306306/4/NCBR/2017.
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Biallelic missense variant in SVBP causes impaired
detyrosination of tubulin leading to complex hereditary
spastic paraplegia without microcephaly
E. Verdura1,2, N. Launay1,2, G. Fernandez Garcia de
Eulate3,4,5, J. Ondaro4,5, A. Schlüter1,2, M. Ruiz1,2, S.
Fourcade1,2, A. López de Munain3,4,5, A. Pujol1,2
1Neurometabolic Disease Lab, Institute of Neuropathology,
IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain,
2Center for Biomedical Research on Rare Diseases
(CIBERER U759), Ministry of Science, Innovation and
University, Madrid, Spain, 3Department of Neurology,
Hospital Universitario Donostia, San Sebastián, Spain,
4Department of Neurosciences, Instituto Biodonostia, San
Sebastián, Spain, 5Department of Neurosciences, School of
Medicine and Nursery, University of the Basque Country,
UPV-EHU, San Sebastián, Spain
Introduction: Reversible C-Terminal detyrosination of
alpha-tubulin is crucial for microtubule organization, and is
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strongly linked to neuronal differentiation. VASH1 and
VASH2, in complex with SVBP, have recently been iden-
tified as responsible for intracellular tubulin detyrosination
activity. Biallelic loss-of-function mutations in SVBP have
much recently been described in patients showing intellec-
tual disability, microcephaly, ataxia and hypotonia.
Methods: All patients underwent accurate clinical
evaluation and provided informed consent. Whole-exome
sequencing (WES) was performed using patients’ DNA
samples, and segregation in relatives was confirmed by
Sanger sequencing. Primary fibroblasts were generated from
patients’ skin biopsies, and cultured cells were incubated
with paclitaxel to analyze detyrosinated tubulin levels by
immunofluorescence and western blot. cDNA of VASH1
and wild-type/mutated forms of SVBP were cloned into a
pCMV-Tag4A vector, and then cotransfected into HeLa
cells for Western Blot analysis.
Results: We report two families with multiple patients
harboring an homozygous missense variant in SVBP (p.
Leu49Pro). Affected individuals show spastic paraplegia,
peripheral neuropathy, verbal apraxia and intellectual
disability, in absence of microcephaly, broadening the
previously reported phenotype. In vitro experiments in
patients’ fibroblasts demonstrate a significant loss of
VASH1/2 detyrosination activity and decreased SVBP
levels. Cotransfection studies show that SVBP p.Leu49Pro
variant reduces both VASH1 and SVBP soluble quantities
or their stability.
Conclusions: Our results expand the phenotypic spec-
trum of SVBP mutations to complex spastic paraplegia
without microcephaly, and confirm for the first time that a
detyrosination defect is observed in patients’ cell lines,
enabling functional testing of SVBP variants and extended
pathogenetic studies.
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Another case with childhood-onset Neurodegeneration
due to a UBTF variant identified by whole-exome
sequencing (WES).
D. Zengeler1, H. Gabriel1, S. Biskup1, C. Schell-Apacik2
1Praxis für Humangenetik, Tuebingen, Germany, 2Medi-
cover Human Genetics Berlin-Westend MVZ, Berlin,
Germany
Recently, Edvardson and collegues identified the de novo
variant c.628G>A; p.Glu210Lys in the gene UBFT in cases
with childhood-onset Neurodegeneration. In these patients,
regression of skills occurred at 2.5-7 years. Initially motor
regression followed by language regression was found.
Brain MRI revealed diffuse cortical atrophy of the sub-
cortical white matter. UBFT encodes a transcription factor,
which facilitate the assembly of the transcription initiation
complex of the RNA polymerase I (PolI), which is crucial
for rRNA synthesis. Functional studies showed that the
UBTF variant leads to a stronger binding affinity to the
rDNA promotor and increased 18s rRNA expression. As a
result the chromatin structure at the rDNA locus was
decondensed. In rats enhanced PolI activity promotes
neurite outgrowth, which can lead to neurodegenerative
processes (Edvardson et al., 2017). Here we report on
another patient carrying the de novo p.Glu210Val UBTF
variant identified by WES. The psychomotoric development
of the boy was slightly delayed at first. He started walking
on his own with 1 ½ year, and ataxic gait was noted. At the
age of 5 years, he was unable to walk without assistance,
and was wheelchair-bound at the age of 7. Subsequently,
the boy developed tetraparesis, global retardation, and
severe scolio-kyphosis. Around the age of 1 ½ the boy
started to use identifiable words but his speech deteriorated
and by the age of 7 he presented with slurred speech, and
subsequently stopped using words. MRI of the brain per-
formed at the age of 14 years revealed supratentorial
atrophy.
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Expanding the spectrum of WDR62 mutations :
description of new cases
L. Ruaud1,2, S. Drunat3,2, A. Ernault1, Y. Capri1, L. Van
Maldergem4,5, C. Engel4,5, C. Altuzarra6, A. Bayat7, S.
Moortgart8, I. Maystadt8, M. Abramowicz9, C. Zweier10, I.
Lorenz11, D. Haye12, F. Giuliano12, S. Vaessen13, L.
Servais14, E. Di Maria15,16, F. Faravelli15, J. Kohlhase17, T.
Bast18, N. Miladi19,20, A. Agadr21,22, S. Auvin23, A.
Verloes1,2, S. Passemard1,2
1Service de génétique clinique, AP-HP, Hôpital Robert
Debré, Paris, France, 2Université de Paris, Neurodiderot,
Inserm, Paris, France, 3Service de génétique moléculaire,
AP-HP, Hôpital Robert Debré, Paris, France, 4Centre de
génétique humaine, CHRU de Besançon, Besançon,
France, 5Université de Bourgogne-Franche Comté, Besan-
çon, France, 6Service de pédiatrie, CHRU Besançon,
Besançon, France, 7Danish Epilepsy Centre, Filadelfia,
Denmark, 8Centre de Génétique Humaine, Institut de
Pathologie et Génétique, Charleroi, Belgium, 9Laboratoire
de Diagnostic Moléculaire et Génomique, Hôpitaux
universitaires de Genève HUG, Genève, Switzerland,
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sität Erlanger-Nürnberg, Erlangen, Germany, 11Depart-
ment of Pediatrics, Division of Neuropediatrics, Friedrich-
Alexander-Universität Erlangen-Nürnberg, Erlangen, Ger-
many, 12Service de génétique, CHRU Nice, Nice, France,
1312Centre de génétique humaine, Hôpital de La Citadelle,
CHU de Liège, Liège, Belgium, 14Neuromuscular Reference
Center, Hôpital de La Citadelle, CHU de Liège, Liège,
Belgium, 15Unit of Medical Genetics, Galliera Hospital,
Genova, Italy, 16Department of Health Sciences, University
of Genova, Genova, Italy, 17SYNLAB Center for Human
Genetics, Freiburg, Germany, 18Children’s Hospital, Epi-
lepsy Center Kork, Kehl, Germany, 19Service de neurologie
pédiatrique, Magreb Médical, Tunis, Tunisia, 20Université
de Tunis El Manar, Tunis, Tunisia, 21Service de pédiatrie,
Hopital militaire Mohamed V, Rabat, Morocco, 22Faculté
de médecine Mohamed V, Rabat, Morocco, 23Service de
neurologie pédiatrique, APHP, Hôpital Robert Debré,
Paris, France
MCPH2 (MicroCephaly Primary Hereditary 2), caused by
WDR62 mutations, is the second most common form of
MCPH. WDR62, located on chr19q13.12, encodes WD
repeat-containing protein 62, playing a role for mitotic
division, proliferation of neuronal progenitor and neuronal
migration. To date, more 100 patients with pathogenic
homozygous or compound heterozygous variants in
WDR62 were reported. They have developmental delay
with constant speech impairment, moderate to severe
intellectual disability (ID) and multiple brain malformations
including hypoplasia of corpus callosum and migration
disorders (polymicrogyria, pachygyria, lissencephaly and
schizencephaly). Nevertheless, no patient have been prop-
erly assessed by appropriated neuropsychological tests.
Using multi-gene panel or exome sequencing, we identified
18 cases with WDR62 variants and report clinical, neu-
ropsychological assessment and neuroradiological pheno-
type. Phenotypic spectrum of our patients is very large
ranging from severe antenatal presentation leading to pro-
found motor handicap, to mild-moderate ID, learning abil-
ities and autonomy in daily life. We were surprised to
discover that some patients had a VCI at 50 and able to read
and write, similar to what is described with ASPM. Some
patients had normal brain structure on MRI except micro-
cephaly. Interestingly, some patients develop ataxia with
age, which was never reported. Epilepsy is not constant but
pharmaco-sensitive for all patients unless one. We report
here the largest series of WDR62 patients with a very pre-
cise clinical, neuropsychological and neuroradiological
characterization. We demonstrate that WRD62 mutations do
not always cause severe ID/motor handicap and cortical
malformation. However, we have concerns regarding the
long term neurological outcome.
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Identification of new variants in amyotrophic lateral
sclerosis patients by whole genome sequencing data
L. Corrado1, R. Croce1, N. Barizzone1, A. Di Pierro1, L. M.
Genovese2, F. Geraci2, E. Mangano3, R. D’Aurizio2, R.
Bordoni3, D. Corà1, F. Favero1, F. De Marchi4, G. De
Bellis3, G. Manzini2,5, M. Severgnini3, M. Pellegrini2, L.
Mazzini4, S. D’Alfonso1
1University of Eastern Piedmont UPO, NOvara, Italy,
2Institute of Informatics and Telematics of CNR, Pisa, Italy,
3National Research Council of Italy, Institute for Biomedi-
cal Technologies, Segrate (MILANO), Italy, 4ALS Center
AOU Maggiore della Carità, NOvara, Italy, 5University of
eastern Piedmont, UPO, Alessandria, Italy
Amyotrophic lateral sclerosis (ALS) is a fatal motor
neuron disorder with adult onset. Mutation in over 30
genes account for less than 65% of ALS familial cases. To
explore ALS missing heritability, we performed WGS of
70 ALS/Frontotemporal Dementia (FTD) patients nega-
tive for mutations in main known causative genes,
focusing on a panel of 699 genes implicated in 5 neuro-
degenerative disorders (NDDs, ALS, Parkinson’s disease,
FTD, Ataxia and Spastic Paraparesis). We analysed and
prioritized mutations in the coding sequence, repeats
expansions, and structural variants by standard bioinfor-
matic tools and we implemented a novel pipeline to
prioritize non coding-variants with a possible pathoge-
netic effect. We identified 11 pathogenic variants. Four of
them map in genes causative of rare forms of ALS
(KIF5A, NEK1, TBK1 OPTN). The remaining 7 variants
map in genes associated with different NDDs and never
reported in ALS. Among them, ABCA7, TGM6 and
CCDC88C genes associated respectively to Alzheimer
disease and autosomal dominant spinocerebellar ataxia. In
addition, we found the most common causative mutation
of PD in LRRK2, in an ALS patient with a PD positive
family history. Among the non-coding variants, we
prioritized 5 deep intronic variants predicting an effect on
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splicing mechanism whose functional impact is under
investigation with in vitro studies. We found pathogenetic
variants in ALS patients in genes involved in other NDDs,
reinforcing the idea of a shared genetic cause and a pos-
sible overlapping condition between these disorders. We
identified for the first time non-coding variants with a
possible pathogenic role in ALS
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A novel bioinformatic approach for the family-based
genetic analysis of whole-genome sequencing data from
8 multigenerational Spanish families with bipolar
disorder
S. B. Fischer1,2, M. Fink3, C. K. Y. Ng4,5, C. S. Reinbold6,1,2,
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Oslo, Norway, Oslo, Norway, 7Institute of Human Genetics,
University of Bonn, School of Medicine & University
Hospital Bonn, Bonn, Germany, Bonn, Germany, 8Depart-
ment of Genetic Epidemiology in Psychiatry, Central
Institute of Mental Health, University Medical Center
Mannheim/University of Heidelberg, Mannheim, Germany,
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Institute of Biomedicine IBIMA, University Hospital of
Malaga, Malaga, Spain, Malaga, Spain, 10Unidad de
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Experimental Neurology, Division of Neurology, Goethe
University Hospital, Frankfurt, Germany, Frankfurt, Ger-
many, 12Isar Amper Klinikum München Ost, kbo, Haar,
Germany, Haar, Germany, 13Department of Mental Health,
University Hospital of Reina Sofia, Cordoba, Spain,
Cordoba, Spain, 14Department of Mental Health, University
Hospital of Jaen, Jaen, Spain, Jaen, Spain, 15Department of
Mental Health, University Hospital of Jerez de la Frontera,
La Frontera, Spain, La Frontera, Spain, 16Department of
Mental Health, University Hospital of Puerto Real,
Department of Mental Health, Cádiz, Spain, Cádiz, Spain,
17Department of Mental Health, Hospital Punta de Europa,
Algeciras, Spain, Algeciras, Spain, 18Department of Psy-
chiatry, Carlos Haya Regional University Hospital,
Malaga, Spain, Malaga, Spain, 19Centre for Human
Genetics, University of Marburg, Marburg, Germany,
Marburg, Germany, 20Institute of Neuroscience and
Medicine INM-1, Research Center Jülich, Jülich, Germany,
Jülich, Germany
Introduction: Bipolar Disorder (BD) is a complex neu-
ropsychiatric disorder, with an estimated heritability of 60-
80%. Common genetic risk factors identified by GWAS
explain 25-38% of the phenotypic variance. It is assumed
that rare variants may also play a substantial role and
explain part of the hidden heritability. One strategy to
identify such variants is Whole Genome Sequencing (WGS)
of large multiply affected families with BD. In the present
study we conducted WGS of 108 individuals in 8 multi-
generational affected families of Spanish origin.
Methods: Sequencing was performed with 30x mean
coverage on an Illumina HiSeq2500 and variant calling was
performed using the GATK best practice workflow. For
downstream analysis we developed a variant based scoring
model. We combined information on family structure and
the proportion of allele sharing amongst the affected
individuals plus the biological impact for each variant
based on different prediction classifiers such as CADD or
SNPeff.
Results: We focused on the identification of rare variants
following two analyses pathways for the WGS data: an
“extended exome” analysis, focusing on the high impact
and protein-coding variants only. Secondly we applied the
model to the full WGS dataset, including also the non-
coding part of the genome. On average we identified 4.4
million variants per individual. In two families, we
identified stop mutations as the top scored variants in the
genes TAS2R19 and PPEF2. Additional top scoring variants
were identified in the non-coding/intronic regions of the
genome.
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A case of fetal arthrogryposis due to ACTA1-associated
myopathy inherited from an affected mosaic mother
U. Grasshoff1, K. Schoner2, T. Haack1, K. Schaeferhoff1, P.
Mazzola1, S. Beck-Woedl1, D. Rating3, H. Goebel4, S.
Hentze5
1Medical Genetics and Applied Genomics, Tübingen,
Germany, 2Institute of Pathology, Philipps University
Marburg, Marburg, Germany, 3Pediatric Neurology, Uni-
versity Children’s Hospital, Heidelberg, Germany,
4Department of Neuropathology, Charitè University Hospi-
tal, Berlin, Germany, 5Human Genetical Practice, Heidel-
berg, Germany
Introduction: Pathogenic variants in ACTA1 (OMIM
*102610) have been associated with a spectrum of rare
myopathies. Inheritance is described as autosomal-recessive
as well as autosomal-dominant. The clinical phenotypes can
be highly variable regarding age at onset and severity. The
severe form of the disorder is characterized by the absence
of spontaneous movement, arthrogryposis, and respiratory
failure at birth.
Case report: We report on a young woman who
presented with a congenital non-progressive muscular
disease with unilateral paresis of N. facialis, muscular
hypotonia and non-symmetrical muscular atrophy. A
phenotype-based exome analysis showed no causative
mutation. During her first pregnancy a sonogram at
14 weeks of gestation diagnosed severe arthrogryposis of
the fetus with akinesia of the hips and ulnar deviation of the
hands. The pregnancy was terminated. Fetal autopsy
documented arthrogryposis multiplex as well as facial
dysmorphism, bilateral talipes equinovarus and extreme
atrophy of muscle fibres. Histological examination was
concordant with a severe structural (actin) myopathy. The
subsequent trio exome analysis prioritized an apparently de
novo heterozygous ACTA1 missense variant (c.226G>C,p.
Val118Met) in the fetus. A re-examination of the maternal
data revealed a low mosaicism (15%) in the maternal blood
sample for the same variant.
Conclusions: We postulate that the asymmetric maternal
myopathy is caused by a postzygotic mosaic mutation in
ACTA1. The fetus inherited the ACTA1 variant in a then
non-mosaic state and developed the severe lethal pheno-
type. An analysis of the ACTA1 variant in maternal muscle
tissue is intended.
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Whole exome sequencing reveals a novel homozygous
mutation in the ADAM22 gene, underpinning its
association with severe neurologic morbidity.
L. Sagi-Dain1, S. Sagi2, J. Haddad-Halloun1, V. Adir1, O.
Sadeh1, A. Peleg1
1Carmel Medical Center, Haifa, Israel, 2Bnei Zion Medical
Center, Haifa, Israel
Background: Numerous genes have been implicated in
congenital arthrogryposis and epilepsy. In this report we
describe a second reported case of ADAM22 mutations,
associated with severe neurologic manifestations.
Case presentation: We describe a female infant with
congenital arthrogryposis and severe hypotonia including
diaphragmatic weakness. Intractable seizures appeared in
the age of several days, and the patient passed away at the
age of one year. Family history evaluation revealed similar
symptoms in daughter of paternal cousin, who passed away
at the age of 6 months. This patient had hypotonia, seizures,
respiratory difficulty, and her brain MRI showed progres-
sive atrophy of the white matter. Consanguinity was noted
in parents of both patients.
Results: Whole exome sequencing of the patient revealed
a novel homozygous variant c.2077-2A>C in intron 23 of
ADAM22 gene. The variant was not found in large exome
databases, and several in-silico prediction programs classi-
fied the mutation as "pathogenic" vs no benign predictions.
Family segregation analysis demonstrated heterozygous
carrier state in both parents, their healthy daughter, as well
as in parents of additional familial case with similar
symptoms. Literature search yielded one description of
compound heterozygous mutations in ADAM22 gene,
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causing rapidly progressing cerebral atrophy, intractable
seizures, and intellectual disability. Previous research
showed that knockout mice for ADAM22 manifest with
lethal seizures during the first postnatal weeks.
Conclusions: Our case provides valuable information to
the scarce literature evidence describing the association
between mutations in ADAM22 gene to severe neurologic
morbidity.
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The genetic architecture of Amyotrophic lateral sclerosis
and the role of comorbidity in Italian population
I. Palmieri1,2, S. Conti3, O. Pansarasa1, L. Diamanti4, S.
Gagliardi1, M. Filosto5, C. Cereda1
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Introduction: Amyotrophic Lateral Sclerosis (ALS) is a
neurodegenerative disease (ND) characterized by hetero-
geneous clinical manifestations due to both genetic and
phenotypic overlapping with other NDs, such as Fronto-
temporal dementia (FTD), Parkinson’s disease (PD) and
Hereditary spastic paraplegia (HSP) (Elert-Dobkowska
et al., 2019; Abramzon et al., 2020). Here, we screened an
Italian population of 210 sporadic ALS patients for 95
genes related to ALS, FTD, PD and HSP to enlighten the
genetic burden in ALS clinical spectra.
Materials and Methods: Next Generation Sequencing
(NGS) was done using a customized panel of 175 genes
(SureSelect, Agilent). The eVai software (https://evai.
engenome.com) was used for variant calling and classifica-
tion. Pathogenic, likely pathogenic and uncertain variants
were retained and validated by Sanger sequencing. C9orf72
repeat expansion was assessed using the AmplideX® PCR/
CE C9orf72 Kit (Asuragen).
Results: 81 ALS patients carry one or more variants in
ALS/FTD associated genes. Interestingly, there are also
ALS patients that carry variants in PD (19) or in HSP (9)
linked genes and patients that carry variants in genes related
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Conclusions: Our study confirmed that the genetic
architecture of ALS is extremely complex, highlighting
the importance to screen also genes related to other NDs.
Considering a broader genetic spectrum will help in
understanding also atypical clinical presentations.
I. Palmieri: None. S. Conti: None. O. Pansarasa: None.
L. Diamanti: None. S. Gagliardi: None.M. Filosto: None.
C. Cereda: None.
P10.04.B
Different levels of soluble nuclear SOD1 activate specific
pathways in Peripheral Blood Mononuclear Cells of
ALS patients
S. Gagliardi1, M. Garofalo1,2, C. Pandini1,2, M. Bordoni1,
L. Diamanti3, D. Sproviero1, O. Pansarasa1, C. Cereda1
1Genomic and post-genomic Center, IRCCS Mondino
Foundation, Pavia, Italy, 2Department of Biology and
Biotechnology "L. Spallanzani", University of Pavia, Pavia,
Italy, 3General Neurology, IRCCS Mondino Foundation,
Pavia, Italy
Introduction: Amyotrophic Lateral Sclerosis (ALS) is a
fatal neurodegenerative disease caused by loss of motor-
neurons. SOD1 may have a toxic role in the pathogenesis
when the protein aggregates in the cytoplasm; increased
accumulation of nuclear SOD1 (nSOD1) represents a pro-
tective cellular reaction (Cereda et al., 2013; Bordoni et al.,
2019). We investigated pathways activated by nSOD1 in
Peripheral Blood Mononuclear Cells (PBMCs) of ALS
patients by dividing them depending on the “high” or “low”
concentration of nSOD1.
Methods: Subcellular fractionation from PBMCs of ALS
patients (18) and healthy controls (12) was performed and
proteins were quantified by Western blotting. RNA libraries
were prepared by Illumina TruSeq Stranded RNA Library
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and run on NextSeq (Illumina). Differential expression
analysis was performed using R package EBSeq.
Results: We obtained two gene expression patterns for
high and low nSOD patients. Differentially expressed genes
in patients with high nSOD1 form a cluster similar to
controls compared to low nSOD1 group. Pathways
activated in high nSOD1 patients are related to the up-
regulation of SEMA6B, a semaphorin involved in axon
guidance, and HSP70, molecular chaperones ensuring the
correct protein folding. In low nSOD1 group the up-
regulation of KDM4C and S100B may be responsible for
hyper-demethylation of histone H3 impaired in ALS.
Conclusions: Our findings highlight the importance of
subcellular localization of soluble nSOD1 in ALS patients.
We observed a different behavior of RNA regulation in the
two groups of patients, leading to pathways conferring
“protection” where nSOD1 was high, and a general
“perturbations” where nSOD1 was low.
S. Gagliardi: None. M. Garofalo: None. C. Pandini:
None. M. Bordoni: None. L. Diamanti: None. D.
Sproviero: None. O. Pansarasa: None. C. Cereda: None.
P10.06.A
Efficiency of high-throughput sequencing in the diag-
nosis of genetic causes of cerebral palsy
V. Udalova1, I. Kanivets1, D. Pyankov1, I. Komarkov1, K.
Gorgishely1, S. Korostelev1,2
1LLC GENOMED, Moscow, Russian Federation, 2Federal
State Autonomous Educational Institution of Higher
Education I.M. Sechenov First Moscow State Medical
University of the Ministry of Health of the Russian
Federation (Sechenov University), Moscow, Russian Fed-
eration
Introduction: Cerebral Palsy (CP) is a group of clinically
heterogeneous conditions, data on the genetic causes of
which are currently underrepresented. The aim of our work
is to determine the effectiveness of high-throughput
sequencing in patients with CP.
Materials and methods: 604 patients, in whose clinical
signs was CP, were examined using NGS-based tests (gene
panels, containing up to 2000 genes, whole exome and
genome sequencing). Data analysis was performed using in-
house pipeline.
Results: Among the provided clinical data, spastic
manifestations were described in 256 patients (39.07%),
atonic-astatic - in 111 patients (18.38%), mixed form - 45
patients (7.45%). Intellectual developmental disorder,
speech delay were observed in 380 patients (62.91%),
seizures - in 267 patients (44.21%). After testing definitive
diagnosis can be made in 31.8% cases, a possible cause was
detected in 17.5%, a negative result was obtained in 50.6%.
Mutations in the LAMA2, ATM, MECP2, CAPN3,
KCNQ2, RYR1, SPAST, SCO2, SLC16A2, SLC2A1,
SPG11, STXBP1 genes were most often found in the
investigated group. Copy number variations (CNVs) were
determined by coverage analysis in 31 patients (10.4%).
Conclusions: In our study NGS-based tests detected
31.8% clinically significant variants in patients with CP.
The results of our work show that CP should not be
considered as an independent nosology, but as a key
symptom in many hereditary diseases, including genetically
heterogeneous.
V. Udalova: None. I. Kanivets: None. D. Pyankov:
None. I. Komarkov: None. K. Gorgishely: None. S.
Korostelev: None.
P10.08.C
Unraveling the genetic architecture of autosomal reces-
sive Charcot-Marie-Tooth neuropathies
C. Armirola1, K. Peeters1, E. de Vriendt1, S. Amor-Barris1,
A. Jordanova1,2
1VIB-UAntwerp Center of Molecular Neurology, Antwerp,
Belgium, 2Department of Medical Chemistry and Biochem-
istry, Medical University-Sofia, Sofia, Bulgaria
Introduction: Even though autosomal recessive Charcot-
Marie-Tooth neuropathy (ARCMT) represents less than
10% of CMT patients in Europe, in endogamous popula-
tions it accounts for 30-50% of all CMT cases. The
pathogenesis of ARCMT is poorly understood. Over 30
ARCMT genes have been identified so far, yet they only
explain a small portion of cases. The aim of this project is to
identify novel causative ARCMT genes.
Methods: Based on whole exome sequencing data of a
cohort of 135 ARCMT families highly enriched with
consanguineous pedigrees, we perform homozygosity
mapping and focus on the resulting autozygous regions to
do variant filtering and prioritization. The functional effect
of the variants in candidate ARCMT genes is further
characterized in vitro and in vivo, using Drosophila
melanogaster as our main model of choice.
Results: In 2 siblings with severe axonal CMT we have
found a homozygous splice-site variant in a mitochondrial
nuclear-encoded gene, that works as an assembly factor for
cytochrome c oxidase. Screening for additional cases
identified 5 additional families with 9 different variants.
The splice variant leads to frame recovery and expression of
an alternative transcript which lacks one exon. Immuno-
blotting showed that the new isoform is effectively
translated into protein. The functional characterization of
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the mutant protein in patient-derived lymphoblasts and in
yeast models is currently ongoing.
Conclusions: We have established a gene discovery
pipeline for ARCMT that combines exome sequencing with
homozygosity mapping and functional experiments in
cellular or in vivo models. The characterization of the
latest candidate is underway.
C. Armirola: None. K. Peeters: None. E. de Vriendt:
None. S. Amor-Barris: None. A. Jordanova: None.
P10.10.B
CRISPR interference as therapy strategy for COL VI-
CMD
F. Haarich, Z. Aherrahrou, J. Erdmann
Institute for Cardiogenetics, University of Lübeck, Lübeck,
Germany
Introduction: The spectrum disorder Collagen VI con-
genital muscular dystrophy (COL VI-CMD) is caused by
mutations in COL6A1, COL6A2 and COL6A3. The phe-
notypic spectrum consists of the mildest and late onset form
Bethlem Myopathy (BM, OMIM #158810), intermediate
phenotypes and the most severe and early onset form Ull-
rich congenital muscular dystrophy (UCMD, OMIM
#254090). There is still no treatment for COL VI-CMD.
Considering that haploinsufficiency is tolerated for
COL6A2, specific knockdown of the allele including a
pathogenic dominant-negative variant is under investigation
as a treatment strategy for COL VI-CMD. The only
approach for COL6A2 so far targeted a variant in intron 9
(c.954+17_954+22del28). We focus on a group of patho-
genic variants that lead to substitutions of essential Glycines
in triple helical repeats (Gly-X-Y).
Materials and Methods: The aim is to utilize CRISPR
interference to repress the transcription of the mutated allele
and to use common variants to differentiate between alleles.
After the identification of common heterozygous variants in
potential target sites (promotors, enhancers) via Sanger
sequencing, the target region was enriched using Cas9
enrichment and sequenced with an Oxford Nanopore
MinION. The data analysis was performed with a script
containing several command line tools.
Results: A 48kb region including enhancers, promotors
and 24 exons of COL6A2 was successfully enriched,
sequenced and the found variants were phased with the
pathogenic variant.
Outlook: Allele-specific guideRNAs will be used to
repress the transfection of the pathogenic allele.
The project is supported by a grant of the German Society
of Muscular Diseases (DGM).
F. Haarich: None. Z. Aherrahrou: None. J.
Erdmann: None.
P10.12.A
Molecular diagnosis of merosin-deficient congenital
muscular dystrophy in Moroccan patients by NGS and
identification of a novel mutation
Y. El Kadiri1,2, I. Ratbi1, A. Zrhidri1,2, N. Birouk3, Y.
Kriouile4, A. Sefiani1,2, J. Lyahyai1
1Centre de Recherche en Génomique des Pathologies
Humaines (GENOPATH), Faculté de Médecine et de
pharmacie, Mohammed V University, Rabat, Morocco,
2Département de Génétique Médicale, Institut National
d’Hygiène, Rabat, Morocco, 3Service de Neurophysiologie
clinique, Hôpital des Spécialités, Rabat, Morocco, 4Unité
de Neuropédiatrie et maladies neurométaboliques, Service
de Pédiatrie PII- Hôpital d’enfant de Rabat, Faculté de
Médecine et de pharmacie, Mohammed V University,
Rabat, Morocco
Introduction: Congenital muscular dystrophies (CMDs)
are a clinically and genetically heterogeneous group of
neuromuscular disorders. The most common CMD subtype
is laminin-α2 or merosin deficient congenital muscular
dystrophy (also known as MDC1A), accounting for 30-40%
of CMD cases. It is characterized by muscle weakness at
birth or within the first months of life, delay in motor
milestones, elevated creatine kinase (CK) and white matter
abnormalities in brain MRI. MDC1A is an autosomal
recessive condition caused by LAMA2 gene mutations.
Patients and methods: We investigated six unrelated
Moroccan patients with clinical and paraclinical signs of
congenital muscular dystrophy. We performed a molecular
analysis of a customized panel of 24 genes involved in
different forms of muscular dystrophies by targeted next
generation sequencing. Mutations were confirmed by
Sanger sequencing.
Results: Five known homozygous mutations: c.32T>C
(p.Leu11Pro), c.1377delC (p.Tyr460ThrfsTer15), c.6993-
2A>C, c.8244+1G>A, c.8244+3_8244+6delAAGT, and a
novel homozygous nonsense variant c.2217G>A (p.
Trp739Ter) were identified in the LAMA2 gene.
Conclusions: Next generation sequencing has improved
genetic diagnosis pathway for heterogeneous diseases like
muscular dystrophies. Our results allowed to provide
appropriate management of patients and genetic counseling
to families, and to expand mutational spectrum of LAMA2
gene in Moroccans.
Y. El Kadiri was supported by an excellence research
grant from the National Center for Scientific and Technical
Research, Rabat-Morocco.
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Y. El Kadiri: None. I. Ratbi: None. A. Zrhidri: None.
N. Birouk: None. Y. Kriouile: None. A. Sefiani: None. J.
Lyahyai: None.
P10.13.B
The importance of targeted sequencing in the diagnosis
of congenital muscular dystrophy type 1A
V. Antsupova1, I. Lastivka2, L. Khlunovska2, M.
Ryznychuk2, L. Hodovaniuk3
1Bohomolets National medical university, Kyiv, Ukraine,
2HSEE of Ukraine, “Bukovinian State Medical University”,
Chernivtsi, Ukraine, 3Bukovynian Center for Rehabilitation
and Integrated Rehabilitation of Children, Chernivtsi,
Ukraine
Introduction: Type 1A Merosindeficient congenital mus-
cular dystrophy (CMD1A) is an autosomal recessive neu-
romuscular disease caused by a mutation of the LAMA2
gene encoding the laminin α2-chain (merosine). Although
CMD1A in the European population takes the first place
(50%) in the structure of all CMD, there are difficulties in
diagnosing this pathology.
Materials and Methods: Case CMD1A. Used clinical
and genealogical, molecular-genetic, laboratory and instru-
mental methods.
Results: A 3-year-old boy with a diagnosis of Werdnig-
Hoffmann spinal amyotrophy complicated by arthrogrypo-
sis was sent to consult a geneticist. At birth, the child had
diffuse hypotension with the involvement of facial muscles,
a weak cry, a decrease in reflexes. At the age of 5 months,
the child did not roll over; when verticalized, it did not rest
on its legs. In 1 year appeared flexion contracture of large
joints, a delay in motor development. Examination of
genetics: the child has severe diffuse muscular hypotension,
weakness of the axial muscles, proximal muscles of the
limbs, face. Keeled chest deformity, contracture of the knee
and ankle-foot joints. Blood CPK is 10 times higher than
normal; ENMG – signs of primary muscle damage; MRI:
damage to the white matter of the brain. Targeted
sequencing in the LAMA2 gene revealed mutations
2049_2050del(pArg683Serfs*21) and c.7732C>T(p.
Arg2578*) in a compound heterozygous state. Final
diagnosis: Merosindeficient congenital muscular dystrophy
type 1A.
Conclusions: The knowledge of the key sign CMD1A
allows you to immediately scrape the patient for molecular-
genetic diagnostics. Core diagnosis, more important in
predicting seizure; adequate therapy and rehabilitation of
the patient.
V. Antsupova: None. I. Lastivka: None. L. Khlu-
novska: None. M. Ryznychuk: None. L.
Hodovaniuk: None.
P10.14.C
Further delineation of clinical and molecular character-
istics of congenital myasthenic syndromes in Indian
families
S. Mishra, K. Girisha, A. Shukla
Kasturba Medical College, Manipal Academy of Higher
Education, Manipal, Karnataka, India
Introduction: Congenital myasthenic syndrome (CMS) is a
clinically and genetically heterogeneous group of disorders
characterized by a neuromuscular transmission defect. They
are rare and often treatable genetic disorders depending on
the underlying molecular defect. This study expands the
mutational spectrum of CMS in India.
Materials and Methods: We performed detailed clinical
evaluation in seven patients with CMS from five families
and singleton exome sequencing in five index patients.
Validation of the identified variant and segregation analysis
was done by Sanger sequencing.
Results: All patients had autosomal recessive pattern of
inheritance. Clinically significant variants were identified in
4 CMS disease-causing genes in five families: COLQ (2/5),
DOK7 (1/5), RAPSN (1/5) and CHRNE (1/5). We identified
2 novel variants (c.930_933delCATG in DOK7 and
c.1016_1032+2dup in CHRNE) and 2 known variants
(c.955-2A>C in COLQ and c.490C>T in RAPSN) in
homozygous state. COLQ variant c.955-2A>C was identi-
fied in two unrelated families. Patient with RAPSN variant
had a later onset of disease while all others had an early-
onset of disease. All patients with COLQ variant had
generalized muscle weakness, those with DOK7 and
RAPSN variants had limb-girdle weakness, and with
CHRNE variant had predominant ocular weakness. Patients
with COLQ and DOK7 variants showed improvement with
salbutamol and CHRNE with pyridostigmine therapy.
Conclusions: In CMS, genetic diagnosis is essential to
guide pharmacotherapy and avoid adverse reactions to
acetylcholinesterase inhibitors in COLQ, DOK7, and slow
channel CMS (AChR subunit genes). This study adds a
small but significant cohort of patients with CMS
from India.
S. Mishra: None. K. Girisha: None. A. Shukla: None.
P10.15.A
Rare heterozygous DHTKD1 variants in patients with
amyotrophic lateral sclerosis
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I. Gogol1,2, A. Osmanovic2, H. Martens1, M. Widjaja1,2, K.
Müller3, O. Schreiber-Katz2, G. Schmidt1, B. Auber1, P.
Andersen4, A. Ludolph3, J. Weishaupt3, F. Brand1, S. Petri2,
R. G. Weber1
1Department of Human Genetics, Hannover Medical
School, Hannover, Germany, 2Department of Neurology,
Hannover Medical School, Hannover, Germany, 3Depart-
ment of Neurology, Ulm University, Ulm, Germany,
4Department of Neurosciences, Umeå University, Umeå,
Sweden
Introduction: Amyotrophic lateral sclerosis (ALS) is a
neurodegenerative disorder characterized by upper and
lower motor neuron loss. Numerous genes regulating
mitochondrial function have been associated with neuro-
degeneration. In a pilot whole-exome sequencing study of
27 ALS patients, rare heterozygous variants in the DHTKD1
gene were recurrently identified, including one nonsense
variant. DHTKD1 encodes a dehydrogenase subunit acting
in L-lysine degradation in mitochondria. Pathogenic var-
iants in DHTKD1 have been described causative of auto-
somal recessive 2-aminoadipic and 2-oxoadipic aciduria
and autosomal dominant Charcot-Marie-Tooth disease type
2. Here, we aimed to investigate the frequency and clinical
implications of rare DHTKD1 variants in an ALS cohort.
Methods: We performed whole-exome (n = 46) and
targeted (n = 179) sequencing of 225 unrelated ALS
patients of central European ancestry. All patients were
diagnosed according to the El Escorial criteria by a
specialized neurologist. Clinical (e.g. age and region of
onset, ALS subtype, and disease progression) and diag-
nostic (e.g. electrophysiological, biochemical) characteris-
tics are being analyzed to discover genotype-phenotype
relations.
Results: Five missense and one nonsense variant, all rare
(MAF < 0.5%) or novel and predicted to be pathogenic,
were identified in 10 of 225 patients. Two of these variants
were previously described in patients with 2-aminoadipic
and 2-oxoadipic aciduria. Preliminary clinical correlations
indicate a slightly later ALS onset in DHTKD1 variant
carriers (median: 71 years) compared to non-carriers
(median: 63 years).
Conclusions: We identified rare heterozygous DHTKD1
variants in 4.4% of central European ALS patients. Potential
phenotype-genotype correlations and frequency of rare
DHTKD1 variants in other ALS cohorts are currently being
assessed.
I. Gogol: None. A. Osmanovic: None. H. Martens:
None.M. Widjaja: None. K. Müller: None. O. Schreiber-
Katz: None. G. Schmidt: None. B. Auber: None. P.
Andersen: None. A. Ludolph: None. J. Weishaupt: None.
F. Brand: None. S. Petri: None. R.G. Weber: None.
P10.16.B
Dystrophinopathy patients with non-contiguous mole-
cular alterations: diagnosis and characterization of the
genetic mechanisms involved
L. Luce1,2, M. Carcione1,2, C. Mazzanti1,2, I. Szijan1, S.
Menazzi3, L. Francipane3, J. Nevado4,5, P. Lapunzina4,5, L.
Rossetti6, P. Radic6, M. Abelleyro6, C. De Brasi6, F.
Giliberto1,2
1Universidad de Buenos Aires; Departamento de Micro-
biología, Inmunología, Biotecnología y Genética; Cátedra
de Genética; Laboratorio de Distrofinopatías, Buenos
Aires, Argentina, 2CONICET - Universidad de Buenos
Aires; Instituto de Inmunología, Genética y Metabolismo
(INIGEM), Buenos Aires, Argentina, 3Universidad de
Buenos Aires, Hospital de Clínicas "José de San Martín",
División de Genética, Buenos Aires, Argentina, 4Hospital
Universitario La Paz, IdiPAZ, Instituto de Genética Médica
y Molecular (INGEMM), Madrid, Spain, 5Centro de
Investigaciones Biomédicas en Red para Enfermedades
Raras (CIBERER), Madrid, Spain, 6CONICET - Academia
Nacional de Medicina, Instituto de Medicina Experimental
(IMEX), Buenos Aires, Argentina
Introduction: Dystrophinopathies are neuromuscular X-
linked recessive diseases caused by DMD mutations.
Molecular alterations in this gene are large deletions/
duplications in 80% of cases and small mutations in the
remaining. Several authors reported the occurrence of non-
contiguous rearrangements within the same DMD allele,
with frequencies up to 4%. The present work aims to
characterize the incidence of complex rearrangements in an
Argentinian dystrophinopathy cohort and unravel the
causing molecular mechanisms.
Materials and Methods: We analyzed 437 boys with
clinical diagnosis of Dystrophinopathy. The following
techniques were implemented: MLPA, WES, WGS, PCR-
Sanger Sequencing, CGH Array and HUMARA assay. In 2
cases, breakpoints were precisely determined, so we
performed a bioinformatic screening of microhomologies,
interspersed repeats, secondary structures and recombino-
genic motifs 50pb surrounding each breakpoint.
Results: We detected 6 patients carrying complex
rearrangements in DMD: 2 deletions-duplications, 3 non-
contiguous duplications and 1 large deletion plus a 20pb
insertion. These accounted for 1.4% of our cohort. In a
deletion-duplication case, familial segregation and bioinfor-
matics analysis suggested that the duplication was the first
mutagenic event caused by Fork Stalling and Template
Switching (FoSTeS), while the deletion occurred secondly
by Non-homologous end joining. Furthermore, bioinfor-
matic screening of the deletion plus insertion propose that
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the deletion was due to Microhomology-mediated end
joining, while the insertion arose by FoSTeS.
Conclusions: Our findings widen the understanding of
the molecular events that may take place in DMD and
characterize the occurrence of complex rearrangements in
our dystrophinopathy cohort. This study was supported by
PTC Therapeutics and University of Buenos Aires.
L. Luce: None. M. Carcione: None. C. Mazzanti:
None. I. Szijan: None. S. Menazzi: None. L. Francipane:
None. J. Nevado: None. P. Lapunzina: None. L. Rossetti:
None. P. Radic: None. M. Abelleyro: None. C. De Brasi:
None. F. Giliberto: None.
P10.17.C
Elucidating myopathies with high creatine-kinase- from
unsolved cases to common diagnosis
C. L. Serban1,2, N. Andreescu1,2, I. Jurca-Simina1,2, A.
Corches1,2, A. Chiriţă Emandi1,2, M. Puiu1,2
1Victor Babes University of Medicine and Pharmacy,
Timisoara, Romania, 2Louis Turcanu Clinical Emergency
Hospital for Children, Timişoara, Romania
Background: One of the most common causes for myo-
pathies are related to X-linked DMD gene, including
Duchene Muscular Dystrophy(DMD) and Becker Muscular
Dystrophy(BMD). Other autosomal recessive myopathies
affect males(M) and females(F) consisting of limb-girdle
myopathies.
Method: 42 patients with high levels of creatine-kinase
addressed the Regional Center of Medical Genetics Timis
County, Romania (October 2017-September 2019), either
having suggestive symptoms of myodystrophy (23M and
1F) or for verifying carrier (6M and 10F).
Results: DMD was diagnosed in 13M, with hemizygous
variants in DMD gene (using MPLA) with following exons
deletion: 10-11;13-17;22-41;39-43;46-53;51;58,exon 3-7
duplication and variants (using NGS): c.7174dupG;
c.8608C>T; c.8688_8689delAG; c.10738delG. BMD was
diagnosed by MLPA in 6M: deletions in exons 45-47 and
45-51. Two male cousins had a previously unreported splice
site NM_004009.3:c.175-1G>T pathogenic variant in DMD
gene. After negative testing for DMD gene, limb-girdle
muscular dystrophy was confirmed using NGS in com-
pound heterozygosity in FKRP gene in 3 patients, of which
2 were siblings(M/F): c.148A>G/c.985G>A, and one
unrelated (c.826C>A/c.935G>C). Pompe disease was
diagnosed in two brothers showing pathogenic variants in
GAA gene (exon 18 deletion) and in one unrelated patient
with c.784G>A/?. Carrier status for DMD was identified in
6 out of 10F. Using MLPA for DMD and a NGS panel of
4813 genes, no pathogenic variants were detected in 4M
and 1F (persistent extremely elevated CK levels).
Conclusions: This study shows a diagnostic yield of
almost 80% and lists the variants associated with myody-
strophies, underling the limitation in establishing the
diagnosis in patients with increased CK levels.
C.L. Serban: None. N. Andreescu: None. I. Jurca-
Simina: None. A. Corches: None. A. Chiriță Emandi:
None. M. Puiu: None.
P10.21.A
The floppy child syndrome is not only caused by
mutations in genes related to neuromuscular disorders.
M. Gos1, E. Dębek1, A. Madej-Pilarczyk2, A. Potulska-
Chromik3, J. Pilch4, R. Śmigiel5, J. Wierzba6,7, R. Posmyk8,
J. Fijak-Moskal9, A. Kutkowska-Kaźmierczak1, A. Jakubiuk-
Tomaszuk10, B. Wojtaś11, B. Gielniewski11, A. Kostera-
Pruszczyk3, J. Bal1, M. Jędrzejowska12,2
1Department of Medical Genetics, Institute of Mother and
Child, Warsaw, Poland, 2Department of Medical Genetics,
The Children’s Memorial Health Institute, Warsaw, Poland,
3Department of Neurology, Medical University of Warsaw,
Warsaw, Poland, 4Department of Pediatrics and Neurology
for Children and Adolescents, Medical University of Silesia,
Katowice, Poland, 5Department of Paediatrics and Rare
Disorders, Wroclaw Medical University, Wrocław, Poland,
6Department of General Nursery, Medical University of
Gdańsk, Gdańsk, Poland, 7Department of Pediatrics,
Hematology and Oncology, Medical University of Gdansk,
Gdańsk, Poland, 8Department of Clinical Genetics, Medical
University of Białystok, Białystok, Poland, 9Department of
Medical Genetics, Polish-Amercian Institute of Pediatrcs,
Jagiellonian University, Krakow, Poland, 10Department of
Pediatric Neurology and Rehabilitation, Medical University
of Białystok, Białystok, Poland, 11Laboratory of Molecular
Neurobiology, Neurobiology Center, Nencki Institute of
Experimental Biology, Polish Academy of Sciences, War-
saw, Poland, 12Neuromuscular Department, Mossakowski
Medical Research Centre, Polish Academy of Sciences,
Warsaw, Poland
Introduction: The, floppy child syndrome” is one of the
most unambiguous clinical manifestations. Neonatal or
childhood hypotonia can present with other symptoms, like
decreased muscle tone, arthrogryposis or developmental
delay making a definite clinical diagnosis challenging. We
aimed to assess the genetic causes of this condition, with
interest in neuromuscular disorders (NMD).
Patients and methods: For 124 patients with excluded
common genetic causes of early hypotonia (e.g. SMA,
PWS, MTM1 and ACTA1 mutations), an exome sequencing
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have been performed. The first-tier analysis of exome data
has been done towards the identification of pathogenic
variants in NMD-, arthrogryposis- or connective tissue
disorder-related genes.
Results: Mutations in genes related to neuromuscular
disorders (NMD) were identified in 42 patients. In 21 (32%)
and 18 (27%) probands, we have found mutations in genes
related to congenital myopathies or muscular dystrophies,
respectively. The commonly affected genes included
LMNA, RYR1 and TTN with 5, 4 and 3 patients with
pathogenic variants, respectively. In 13 patients, mutations
in non-NMD genes were found, including 2 cases with
mutation in FKBP14 (Ehlers-Danlos syndrome), PIEZO2
(distal arthrogryposis) and NALCN (hypotonia with psy-
chomotor delay). Mutations in DDX3X, COL9A3, NEXMIF,
PPP2R1A, CTBP1, SLC16A2 and GRIA3 were found in
single cases.
Conclusions: The genetic cause of floppy child syndrome
was identified in 55/124 (44.3%) patients. Although the
most commonly mutated genes are related to NMD, other
genes involved in etiology of connective tissue disorders
and syndromic hypotonia should be also considered.
The study was supported from National Science Centre
grant no. UMO-2015/17/B/NZ5/01368
M. Gos: None. E. Dębek: None. A. Madej-Pilarczyk:
None. A. Potulska-Chromik: None. J. Pilch: None. R.
Śmigiel: None. J. Wierzba: None. R. Posmyk: None. J.
Fijak-Moskal: None. A. Kutkowska-Kaźmierczak:
None. A. Jakubiuk-Tomaszuk: None. B. Wojtaś: None.
B. Gielniewski: None. A. Kostera-Pruszczyk: None. J.
Bal: None. M. Jędrzejowska: None.
P10.22.B
Diagnostic of facioscapulohumeral muscular dystrophy
in Russian patients based on newly developed qPCR
approach
N. Zernov, M. Skoblov, A. Guskova
Research centre for medical genetics, Moscow, Russian
Federation
Introduction: Facioscapulohumeral muscular dystrophy
(FSHD) is one of the most prevalent congenital myody-
strophies. FSHD molecular-genetic diagnostics requires
expensive and laborious methods. Here we present a newly
developed simplified qPCR-based diagnostic approach and
obtained results.
Materials and Methods: Blood-derived DNA samples
from 64 FSHD patients and 39 their phenotypically healthy
relatives were examined by Southern blotting, molecular
combing, and a newly developed qPCR-based approach.
Results: We validated the qPCR-based approach on 26
individuals with at least one allele of chromosome 4 D4Z4
array contracted up to 10-1 repeats, and on 19 individuals
without the contraction. In 96% of the cases, qPCR-based
results were concordant with the Southern blotting and
molecular combing references. Remaining 60 individuals
were analyzed only by qPCR-based approach. In a group of
64 affected individuals, FSHD diagnosis was confirmed for
36 (56.3%) patients. In 69% of the confirmed cases,
pathogenic alleles had number of D4Z4 repeats in range
between 3-6. We defined 13 carriers in a group of 39
healthy relatives (33.3%). Among them, 76.9% of cases had
the permissive allele with number of the D4Z4 repeats from
6 to 8. There were no significant prevalence between sex in
any observed groups.
Conclusions: In this work we present newly developed
FSHD diagnostics approach based on qPCR and first study
of the FSHD genotyping in Russian patients. We observed
enrichment of the permissive alleles in the range of 3-6
D4Z4 units among affected individuals, whereas among
carriers permissive alleles were enriched in the range 6-8
D4Z4 units.
N. Zernov: None. M. Skoblov: None. A.
Guskova: None.
P10.24.A
Molecular -genetic study of hereditary spastic para-
plegia in Russian patients
V. A. Kadnikova, O. P. Ryzhkova, G. E. Rudenskaya, A. V.
Polyakov
Research Centre for Medical Genetics, Moscow, Russian
Federation
Introduction: Hereditary spastic paraplegia (HSP) is
highly heterogeneous group of neurodegenerative dis-
eases that is characterized by progressive spasticity and
weakness of the lower limbs and mild sensory dysfunc-
tion, due to the axonal degeneration in the pyramidal tract.
Mutations in about 80 different loci and 60 genes have
been associated with HSP pathogenesis. Thus the appli-
cation of NGS technologies can enable the enhanced
molecular diagnosis of HSP because multiple loci can be
analyzed simultaneously. Herein we characterize a cohort
of Russian HSP patients using NGS techniques along with
the routine diagnostics.
Materials and Methods: We screened DNA samples
from 198 unrelated probands with HSP. Sanger sequencing
of SPAST gene was performed in 60 DNA samples, and
ATL1 was analyzed in 24 of partially overlapping samples.
DNA with unidentified mutations and non-tested samples
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were examined by MLPA-analysis and by target gene panel
containing 63 HSP related genes.
Results: We diagnosed the genetic type of HSP for 97
(49%) patients (SPG4 – 54.6%, SPG3A – 14.4%, SPG30 –
6.2%, SPG11 – 6.2%, SPG8 – 3.1%, SPG17 – 3.1%, and 9
more forms less than in 3% each). We find 88 mutations
across diagnosed patient, whereas 39 mutations were new.
Remarkably, 85.2% of mutations were discovered by NGS
and Sanger sequencing; and 14.8% of larger genomic
rearrangements - by MLPA-analysis.
Conclusions: Our data show that combination of NGS
and routine methods allows for effective HSP diagnostics.
This is the first overview of the HSP mutations frequencies
in Russian population that have to be further expanded.
V.A. Kadnikova: None. O.P. Ryzhkova: None. G.E.
Rudenskaya: None. A.V. Polyakov: None.
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Genetic analysis of 50 unrelated cases affected with
hereditary spastic paraplegia (HSP): a novel candidate
gene
R. Hajati1, A. Davarzani1, S. Hashemi1, M. Rahimi
Bidgoli1, L. Javan Parast1, M. Pashaei1, F. DanaeeFard1,
H. Najmabadi1, M. Rohani2, F. Fatehi3, S. Nafissi3, A.
Alavi1
1Genetics research center, University of Social Welfare and
Rehabilitation Sciences, Tehran, Iran, Islamic Republic of,
2Department of Neurology, Iran University of Medical
Sciences, Hazrat Rasool Hospital, Tehran, Iran, Islamic
Republic of, 3Department of Neurology, Tehran University
of Medical Sciences, Tehran, Iran, Islamic Republic of
Introduction: Hereditary spastic paraplegia (HSP) is a
genetically heterogeneous neurodegenerative disorder is
characterized by lower-limb spasticity and weakness. To
date, more than 70 genes have been identified that con-
tribute to the cause of HSP. Despite the use of next-
generation sequencing-based methods, genetic-analysis has
failed in the finding of causative-genes in ~50% of HSP
patients, indicating a significant genetic heterogeneity in the
disease and emphasizing that the majority of HSP-genes
have remained unknown.
Materials and Methods: To identification of HSP-
causing genes, whole-exome sequencing (WES) was
performed in 50 unrelated-Iranian probands. Candidate
variants were confirmed and co-segregated in the family
members. Functional studies including RNAseq for a family
harboring a variation in a novel candidate-gene are currently
in progress.
Results: Variations in 18 known HSP-causing genes
including SPEG, ERLIN1, ERLIN2, ATAD3A, SPAST (four
families), ENTPD1, SPG7 (two families), KIF5A, CYP7B1,
ZFYVE26, GJC2, CAPN1, ZFYVE26, KIF1B, SPG11 (four
families), ATL1 (two families), MFN2, C19orf12, and one
novel candidate-HSP gene were identified.
Discussion: HSP-causing genes were detected in 26
probands(52%). Also, a novel candidate-gene that is
exclusively expressed in the brain and directly involved in
axonogenesis was identified. Given that the HSP is a length-
dependent, “dying-back” axonopathy, the candidate-gene
can be an important HSP-causative gene. The research
presented the powers of WES for facilitating gene-
discovery and identification of causative genes for diseases
with genetic heterogeneity. The precise mechanisms under-
lying the HSP are unknown. Identification of novel genes
and molecular-pathways will enhance our knowledge of the
cellular pathways that are involved in the disease
pathogenesis.
Grant-Reference:no.963846(NIMAD)
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P10.26.C
GWAS on hand grip strength: new insights into the
genetics of muscular strength support a strong genetic
component at different ages.
F. Abbondanza, S. Paracchini
University of St Andrews, St Andrews, United Kingdom
Introduction: Hand grip strength (HGS) is a widespread
proxy for muscular strength and a predictor of cardiovas-
cular disease and poor health outcomes. Genetic studies in
adult cohorts (e.g. UK Biobank) found multiple genes
associated with HGS and showed a modest heritability
(h2~24%). However, the genetics of HGS remains largely
elusive and has never been explored in a cohort of young
individuals.
Materials and Methods: We performed GWAS analyses
on three measures of HGS in the ALSPAC dataset
(N~5,400, mean age = 11.8 years), namely HGS for the
right and left hand and grip strength maximal, i.e. best result
regardless of the hand used. Analyses were performed in
PLINK and functional mapping with FUMA. Genetic
correlations and SNP-heritability were computed with LD
Score Regression using summary statistics from UK
Biobank.
Results:We reported a novel genome-wide significant hit
for HGS (rs2968991, p < 1.75E-08) with the right hand and
we replicated a common association in UK Biobank for the
three traits (p < 1E-06). We reported a higher SNP-
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heritability than previous studies and highlighted a
moderate-to-high genetic correlation between HGS in the
current study and in the UK Biobank.
Conclusions: In addition to a novel association, our
analysis replicated some of the associations previously
reported both at pathway (skeletal muscle fibres and
neurological disorders pathways) and gene-specific
(HOXB3) level. This, together with the modest-to-high
genetic correlation with HGS in the UK Biobank suggests a
stable genetic component of HGS at different ages. This
work was funded by the Royal Society.
F. Abbondanza: None. S. Paracchini: None.
P10.27.A
new mutation causing hypokalemic periodic paralysis in
a young child, a practical example for helpfulness of
genotype first approach
M. Shariati, R. Jafarzadeh Esfehani, R. Boostani, M.
Soudyab, A. Sadr-Nabavi
Mashhad University of Medical Sciences, Mashhad, Iran,
Islamic Republic of
Introduction: Hypokalemic periodic paralysis(HOKPP) is
a rare disorder usually manifesting by episodes of muscle
weakness or paralysis. However in some cases, clinical
presentation may be atypical and may be misdiagnosed with
other possible progressive neurological diseases. The pre-
sent report describes a case of HOKPP which was first
misdiagnosed as a case of distal spinal muscular atrophy
(DSMA).
Material and methods: A 5 years old male child referred
because of variable distal limb weakness. The patient had a
history of hypotonia at birth, evidence of irritable myopathy
on electro-diagnostic study and elevated creatine-
phosphokinase. The whole exome sequencing(WES)
revealed a variant with unknown significant(VUS) in
IGHMBP2 gene(c.403A>G) causing DSMA. However,
the VUS was not confirmed in segregation analysis and
the patient’s WES data was reanalyzed with a genotype first
approach.
Results: The FASTQ files were reanalyzed by Seam-
lessTM software and the pathogenicity of 112 variants which
were pathogenic or likely pathogenic were checked in
VarsomeTM and Sixteen pathogen and likely pathogen
variants were remained checked in OMIMTM database.
Only 1 candidate variant in CACNA1S gene(c.3724A>G)
causing HOKPP was remained. After a brief history taking,
prolonged episodes of muscle weakness after exercises in
school was reported. Our segregation study on patient’s
family confirmed the diagnosis of HOKPP and the patient’s
father also reported milder and similar weakness in his
childhood and carried the same mutation.
Conclusions: The present experience demonstrates that a
genotype first approach can be helpful in discovering novel
mutation in rare diseases even with atypical clinical
presentations or negative WES results.
M. Shariati: None. R. Jafarzadeh Esfehani: None. R.
Boostani: None. M. Soudyab: None. A. Sadr-
Nabavi: None.
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A case of Neuromyotonia associated to a C9ORF72
CCCGG expansion
G. Bonapace1, R. Gullace1, R. Procopio2,3, M. Gaglardi3,
F. Fortunato2, A. Gambardella2,3, P. Valentino2, G. Annesi3
1University Magna Graecia, Faculty of Medicine, Pedia-
trics, Catanzaro, Italy, 2Institute of Neurology, University
"Magna Graecia" of Catanzaro, Department of Medical
Sciences, Catanzaro, Italy, 3Neuroimaging Research Unit,
IBFM/CNR; Institute of Neurology, Catanzaro, Italy
Introduction: Neuromyotonia is a peripheral nerve hyper-
excitability (PNH) syndrome that presents as continuous
motor activity. Mutations in the KCNA1 gene, which
encodes the voltage-gated potassium channel,
Kv1.1 subunit, have been found to be associated with this
syndrome.
Materials and Methods: The patient was a 56-year man
presenting cramps painful stiffness of calves, undulating
wave-like rippling of left thigh muscles. The neurological
examination showed visible myokymias of left thigh.
Electromyography revealed spontaneous continuous single
motor unit discharges firing at a high intraburst frequency
(>150 Hz)compatible with neuromyotonic discharges, on
vastus medialis of the left tight. Single needle electromyo-
graphy and nerve conduction studies were unremarkable.
Brain MRI and laboratory test excluded autoimmune or
paraneoplastic conditions. The Molecular analysis revealed
no point mutation on the KCANA1 gene. Based on the
recently identified role for C9ORF72 protein, in modulating
the membrane channel subunits maturation, an Amplicon-
length analysis on the C9ORF72 gene, was performed.
Results: Capillary electrophoresis analysis of the patient
amplicon revealed the presence of a 94 pathological
CCCGG expansion.
Conclusions: The Kv1.1 subunit recycling processes is
driven by specific Rab proteins and regulated by the
C9ORF72 protein acting both as Rab effector and
component of the GTP ase exchange factor GEF. We
hypothesize that the loss of function of the c9orf72 protein,
due to the CCCGG expansion can affect the trafficking of
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the Kv1.1 monomers leading to a reduction in the channel
subunits correctly allocated into the plasma membrane,
altering the normal flows of potassium during the action
potential generation.
G. Bonapace: None. R. Gullace: None. R. Procopio:
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Identification of two rare homozygous frameshift
variants in LBX1 and PAPD5/TENT4B genes in siblings
with chronic respiratory insufficiency
D. Musalkova1, L. Noskova1, V. Stranecky1, P.
Melenovska1, R. Dobrovolny1, H. Treslova1, K. Hodanova1,
H. Hartmannova1, A. Gregorova2, T. Honzik1, S. Kmoch1
1Research Unit for Rare Diseases, Department of Pedia-
trics and Adolescent Medicine, First Faculty of Medicine,
Charles University, Prague, Czech Republic, 2Department
of Medical Genetics, University Hospital Ostrava, Ostrava,
Czech Republic
We report a case of two siblings with chronic respiratory
insufficiency, psychomotor retardation, and suspected con-
genital myopathy. The children were born to con-
sanguineous parents of Roma ethnicity.
Exome sequencing identified two rare homozygous
frameshift variants in LBX1 and PAPD5 genes. These
variants were present in heterozygous state in the parents.
LBX1 is a transcription factor that affects migration of
muscle precursor cells and it has been associated with adult
idiopatic scoliosis. Identical frameshift variant (p.Val236A-
lafsTer59) was described in a recent publication (Hernan-
dez-Miranda et al., 2018) as a variant that interferes only
with a subset of Lbx1 functions, specifically, with the
ability to cooperate with Phox2b. This disturbance leads to
congenital central hypoventilation. The variant was present
in one individual of Roma ethnicity in our internal database
but is absent from GnomAD database. Ethnicity-specific
genomic databases would be useful tools to estimate
population frequency of candidate variants.
The effect of the homozygous frameshift variant in
PAPD5/TENT4B gene (p.Ser610ArgfsTer56) is not clear.
The gene is classified as intolerant to the loss of function
(pLI = 0,999) but it is not associated with any disorder. The
TENT4B enzyme was recently described as a noncanonical
poly(A) polymerase that generates mixed poly(A) tails with
intermittent guanyl residues that shield mRNA from
degradation (Lim et al., 2018).
Two homozygous candidate variants in siblings born to
consanguineous parents substantially complicate a potential
prenatal or preimplantation genetic testing in the family. At
the same time, it underscores the importance of whole-
exome sequencing.
D. Musalkova: None. L. Noskova: None. V. Stranecky:
None. P. Melenovska: None. R. Dobrovolny: None. H.
Treslova: None. K. Hodanova: None. H. Hartmannova:
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Investigating the pathogenicity of CAPN3 c.1746-20C>G
splicing variant and its association with LGMD R1
calpain3-related
M. Mroczek1, J. Hudson2, A. Töpf1, R. Barresi1, J. Duff1, E.
England3, K. Chao3, M. Sobalska-Kwapis4, D. Strapagiel4,
D. MacArthur3, V. Straub1
1Translational and Clinical Research Institute, Newcastle
upon Tyne, United Kingdom, 2Highly Specialized Service
(HSS) for LGMDs, Newcastle upon Tyne, United Kingdom,
3Analytic and Translational Genetics Unit, Massachusetts
General Hospital, Boston, MA, United States, 4The Biobank
Lab, Department of Molecular Biophysics, Lodz, Poland
Limb girdle muscular dystrophy (LGMD) R1 calpain3-
related is the most common autosomal recessive form of
LGMD. The CAPN3 c.1746-20C>G variant has a popula-
tion frequency of above >1% and there is conflicting
information regarding its pathogenicity in the literature. In
approximately 2.000 exome sequenced patients included in
the MYO-SEQ project we identified c.1746-20C>G 26
times in heterozygosity and 1 time in homozygosity. We
recruited further centres from Poland, Estonia, Latvia and
UK. We identified the c.1746-20C>G together with CAPN3
c.598_612del, c.550delA, p.Arg39Cys, p.Gly234Arg and
other pathogenic heterozygous CAPN3 variants. One indi-
vidual affected with LGMD was homozygous for c.1746-
20C>G. Most of the patients were of Polish or Eastern
European origins. In all these cases there was reduced cal-
pain3 expression on Western Blots and muscle MRI in
available cases was suggestive for LGMD R1 calpain3-
related. The phenotype of these patients was keeping up
with mild calpainopathy with characteristic hypertrophies.
Population studies suggest allele frequency of 0.017 in
Poland and 0.015 in Estonia. No homozygous healthy
individuals were identified so far in our populational studies
and according to gnomAD there are 3 homozygous indi-
viduals (out of 282.874). In some populations the variant
was rare or nearly absent. Functional studies are ongoing.
Population frequency data suggest that c.1746-20C>G may
be a hypomorphic variant. Preliminary haplotype analysis
of a patient homozygous for c.1746-20C>G revealed a
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haplotype block, indicating this might be a founder allele in
Polish population. CAPN3 c.1746-20C>G variant may be
often missed as many tests include only 10bp of flanking
intronic region.
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Genetic variability and clinical spectrum of limb-girdle
muscular dystrophy in a cohort of Turkish patients
D. Mortazavi1, E. Vanlı Yavuz2, E. Borklu Yucel3, S. Avcı3,
S. Eraslan3, P. Oflazer2, H. Kayserili3
1Koç University, Graduate School of Health Science,
Istanbul, Turkey, 2Department of Neurology, Koç Univer-
sity School of Medicine, Istanbul, Turkey, Istanbul, Turkey,
3Department of Medical Genetics, Koç University School of
Medicine, Genetic Diagnostics Center Istanbul, Turkey,
Istanbul, Turkey
Background: Limb-Girdle Muscular Dystrophies
(LGMDs) are clinically and genetically heterogeneous
group of neuromuscular disorders affecting hip and
shoulder muscles. Features include hypertrophy of calf
muscles and elevated level of serum CK. Age of onset,
progression and distribution of weakness vary according to
genetic subtypes which are related to more than 30 genes.
We aimed to correlate the clinical manifestations and clin-
ical exome sequencing results of 29 patients with LGMD
from Turkey.
Method: 29 patients with clinical diagnosis of LGMD
were recruited to NGS-based clinical exome screening of
4811 genes, we performed during 2017-2019, at tertiary
health center, Istanbul/Turkey.
Results: In 28 patients, 34 variants were identified, seven
of variants are novel. In 28 patients, the most common
subtypes were LGMD R1 calpain3-related in eleven
(39.28%), LGMD R2 dysferlin-related in nine (32.14%),
Sarcoglycanopathies in four [14.28%; LGMD R3 α-sarco-
glycan-related in three (10.71%), LGMD R5 γ -sarcogly-
can-related in one(3.57%)], LGMD R14 POMT2-related,
LGMD R20 ISPD-related, LGMD R7 telethonin-related
and LGMD R10 titin-related, each in one patient (3.57%)
and one patient with no variant related to the phenotype.
Rare clinical presentations were observed, one LGMD R10
titin-related patient with cognitive/psychomotor retardation
and a LGMD R14 POMT2-related patient with distal
weakness. Increased liver aminotransferases (ALT/AST) led
to diagnosis of neuromuscular diseases in seven patients.
Conclusions: The result of the cohort led to better
understanding of the relative prevalence of different LGMD
subtypes and genotype-phenotype correlation in Turkish
population.
D. Mortazavi: None. E. Vanlı Yavuz: None. E. Borklu
Yucel: None. S. Avcı: None. S. Eraslan: None. P.
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Expanding of mutation spectrum in Muscular Dystro-
phies: A Turkish Cohort
C. Alavanda1, H. Polat1, A. Ilker1, E. A. Ates2, M. A.
Soylemez1, B. B. Geckinli1, A. I. Guney1, P. Ata1, A. Arman1
1Marmara University School of Medicine, Medical Genetics
Department, Istanbul, Turkey, 2Marmara University Pendik
Research and Training Hospital, Medical Genetics Depart-
ment, Istanbul, Turkey
Muscular dystrophies are heterogeneous group of disorder.
More than 40 genes were identified and genotype-phenotype
correlation is not clear for most of cases. The aim of this study
is to improve the genotypic features of muscular dystrophies
other than Duchenne-Becker Muscular Dystrophy with novel
mutations. Thirty-three patients who were suffering from
muscular dystrophy were referred to our clinic. Sixteen
patients were male and seventeen patients were female. Mean
age was 22,06 years and mean age of disease onset was 11,48
years. Creatinine kinase levels were between 27.000 and 90
U/L(mean 2.964). Next-Generation Sequencing(NGS) panel
which has 33 muscular dystrophy related genes were
sequenced for all patients. Reported pathogenic mutations in
fourteen patients and novel mutations in twelve patients were
identified. One patient’s biopsy had shown megaconial
changes, NGS panel revealed homozygous c.1031G>A(p.
Arg344Gln) known mutation in CHKB gene. Another
mutation in CHKB gene which was novel homozygous
c.1130G>T(p.Arg377Leu) mutation was detected in eleven-
year-old patient. Novel homozygous c.195+3A>T mutation
in SGCG gene was identified in patient whose biopsy showed
pathogenic staining with gamma-sarcoglycan. In thirty-four-
year-old patient and her sibling who had same clinic novel
homozygous c.3666delA(p.Asp1223Thefs*24) mutation in
DYSF gene were identified. In CAPN3 gene two novel
homozygous mutations were detected, which were c.691T>C
(p.Phe231Leu) and c.632+2T>G. In one patient, CNV ana-
lyses revealed SYNE2 gene exon 65-66 deletion. Homo-
zygous SGCA c.850C>T(p.Arg284Cys) mutation in two
unrelated patients were detected, which indicates this muta-
tion may have founder effect. Herein we present 33 patients’
genetic test results with recurrent and novel mutations which
contribute the literature.
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Genetic analysis of 309 Iranian patients with muscular
dystrophy and congenital myopathy by next generation
sequencing
M. Asadollahi1, A. Karamzade1, M. Taghizadeh2, Z.
Golchehre1, P. Nourmohammadi2,3, N. Nourpour2,3, M.
Jamshidifar2,3, R. Taheri2,3, A. Keramatipour3, M.
Keramatipour1,2,3
1Department of Medical Genetics, School of Medicine,
Tehran University of Medical Sciences, Tehran, Iran,
Islamic Republic of, 2Watson Genetic Laboratory, North
Kargar Street, Tehran, Iran, Islamic Republic of, 3NGS
Department, Pishgam Biotech Company, North Kargar
Street, Tehran, Iran, Islamic Republic of
Muscular dystrophies and congenital myopathies are a large
group of heterogeneous muscle disorders. Here, next
generation sequencing (NGS) was used to investigate
genomic variants including copy number variants (CNV) to
determine causative variants behind clinical presentations in
patients. DNA samples were extracted from 309 patients with
presentation of muscular dystrophy and congenital myopathy
who were referred to our laboratory. NGS was performed to
investigate genes associated with muscular disorders. NGS
findings were validated using other molecular methods such
as MLPA, QPCR, long PCR, and PCR-Sanger sequencing. In
275 out of 309 patients, variants with pathogenic or likely
pathogenic classifications (88.9%) were detected. Based on
genetic finding and other clinical and para-clinical data,
diagnosis was confirmed in these 275 patients. Total number
of known or novel detected pathogenic and likely pathogenic
variants is 303 variants in 51 genes. The most frequent genes
causing the disease in this study were DMD (68/309, 22%),
LAMA2 (36/309, 11%), and SGCB (31/309, 10%). More-
over, the most common mutations detected in our patients
were gross deletion/duplication variants in DMD gene, SGCB
deletions and deletion of exon 7 in SMN1 gene. Detailed
analysis of data will be presented in the meeting. In addition
to obtaining valuable data regarding genetic epidemiology of
hereditary muscular diseases in Iran, this study showed great
value of NGS for defining causative variants in patients with
muscular diseases. High frequency of CNVs detected as the
causative variants in patients shows the necessity of
developing efficient tools for CNV analysis on NGS data.
M. Asadollahi: None. A. Karamzade: None. M.
Taghizadeh: None. Z. Golchehre: None. P. Nourmo-
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Usefulness of studying myopathies and muscular dys-
trophies through Exome Sequencing: an experience of
73 cases
Y. Moreno-Saez1, A. Romera-López1, A. Andújar1, A.
López2, T. Otero1, M. D. Ruíz1, S. Valverde1, C. Casañ-
Martínez1, N. Serrano1, J. L. Díaz1, J. García1, A. Gómez1,
C. Collado1, A. Arilla1, C. M. Moya1, A. Matilla-Dueñas3,
S. Santillán1
1Sistemas Genómicos, Paterna (Valencia), Spain, 2SIGEN-
Fundación Santa Fe de Bogotá, Bogotá (Colombia),
Colombia, 3Health Sciences Research Institute Germans
Trias i Pujol, Badalona (Barcelona), Spain
Muscle weakness and hypotonia usually suggest a clinical
diagnosis of myopathy or muscular dystrophy. However,
these pathologies include more than 50 subtypes and are
associated with more than 250 genes, making an accurate
diagnosis challenging.
Genetic testing through NGS has a huge impact on
diagnosis due to its ability to analyze, in parallel, large
number of genes and due to the possibility of reanalyzing
non-conclusive cases including new disease-causing genes.
Such potential has been proven to be even useful for the
diagnosis of families with a strong history of hereditary
disease when no affected members are available and healthy
relatives must be tested.
Here, we applied NGS to a cohort of 73 patients with
clinical or familial suspicion of myopathy or muscular
dystrophy. Samples were analyzed using SureSelect XT
Human All Exon kit (Agilent) and a HiSeq sequencer
(Illumina). An in-house pipeline was used for the bioinfor-
matic analysis. Fifty-four out of 73 individuals were
analyzed using a whole clinical exome approach while the
others were analyzed through virtual panels. Variant
filtering was performed based on variant effect, familial
pattern of inheritance, allele frequency and information
available in databases.
Genetic diagnosis was achieved in 23 out of 73 patients
(31,5%) including a patient with a complex phenotype of
tricuspid insufficiency with structural heart disease and
fibromyalgia. In 39 patients only VOUS were detected
(53,4%). In 11 out of 73 patients (15,1%) no candidate
variants were found. These results confirm exome sequen-
cing as an effective strategy to study myopathies and
muscular dystrophies.
Y. Moreno-Saez: None. A. Romera-López: None. A.
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NGS-based testing in diagnostics of hereditary neuro-
muscular disorders: observations on a large cohort from
a clinical bioinformatician’s perspective
M. Ampleeva1, E. Tolmacheva1, I. Komar’kov2, N.
Shcherbakova3, D. Khmelkova4, E. Surkova2, O. Ryzhkova5,
V. Kaimonov4, I. Mironova4, E. Pomerantseva4, A. Isaev4,
E. Dadali5, D. Pyankov2, A. Antonets2, I. Kanivets2, S.
Korostelev2, F. Konovalov1
1Independent Clinical Bioinformatics Laboratory, Moscow,
Russian Federation, 2Genomed Ltd., Moscow, Russian
Federation, 3Veltischev Research and Clinical Institute for
Pediatrics, Moscow, Russian Federation, 4Center for
Genetics and Reproductive Medicine “Genetico”, Moscow,
Russian Federation, 5Research Centre for Medical Genet-
ics, Moscow, Russian Federation
Next generation sequencing (NGS) is a powerful tool for
accurate diagnostics in genetically heterogenous hereditary
disorders. From 2015 till 2020 our variant analysis team
interpreted NGS data for 837 patients with myopathy or
myasthenia, mostly from Russia and other Russian-
speaking countries. The set included 271 clinical exomes,
176 WES, 16 WGS, and 374 custom panels of several
types comprising in most cases >2000 genes. After pro-
cessing via an automated pipeline, the variants were
uploaded into a custom database-driven software and
assessed by clinical bioinformaticians, with subsequent
review of the reports by medical geneticists, when possible.
As a result, 336 patients (40%) had definitive molecular
diagnostic findings explaining the phenotype (mostly
mutations in LAMA2, CAPN3, DMD, RYR1, NEB, SEPN1,
DYSF, CHRNE, TTN) and 123 patients (15%) had a pos-
sible diagnosis based on variants of unknown significance
with a need for additional evidence. Maximum success rate
was in infants who were less than 1 year old at the time of
test (59%; 53/90 cases) and minimum success rate was in
adults 18 years and older (33%; 56/170 cases). In 59 suc-
cessful cases (18% of 336; 7% of total) the result was due
to detection of CNVs, and this was not limited to DMD
deletions/duplications. The CNV ratio here is higher than
in our other patient cohorts, indicating high importance of
CNV analysis step in myopathy/myasthenia cases. Mole-
cular diagnostics of neuromuscular disorders is complex
due to their clinical variability and genetic heterogeneity,
requiring a combination of exome-scale NGS and thorough
data analysis.
M. Ampleeva: None. E. Tolmacheva: None. I.
Komar’kov: None. N. Shcherbakova: None. D. Khmelk-
ova: None. E. Surkova: None. O. Ryzhkova: None. V.
Kaimonov: None. I. Mironova: None. E. Pomerantseva:
None. A. Isaev: None. E. Dadali: None. D. Pyankov:
None. A. Antonets: None. I. Kanivets: None. S.
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P10.38.C
Myotonia congenita: a series of familial cases with
causative pathogenic variants in both CLCN1 and
SCN4A
K. Šiaurytė1,2, A. Matulevičienė3,2, L. Cimbalistienė3,2, A.
Morkūnienė3,2, A. Vaitkevičius4, A. Utkus3
1Faculty of Medicine, Vilnius University, Vilnius, Lithuania,
2Centre for Medical Genetics at Vilnius University Hospital
Santaros Klinikos, Vilnius, Lithuania, 3Department of
Human and Medical Genetics, Institute of Biomedical
Sciences, Faculty of Medicine, Vilnius University, Vilnius,
Lithuania, 4Clinic of Neurology and Neurosurgery, Institute
of Clinical Medicine, Faculty of Medicine, Vilnius Uni-
versity, Vilnius, Lithuania
Introduction: In cases of non-dystrophic myotonias
(NDM) phenotype-genotype correlations are difficult to
discern due to the overlap of nosologic entities caused by
mutations in CLCN1 (17q23.3) and SCN4A (7q34) genes.
Patients may exhibit phenotypes including dominant and
recessive myotonia congenita (MC), paramyotonia con-
genita (PC) and sodium channel myotonia (SCM). Here we
report on a familial case series where members with MC of
varying severity harbour different combinations of patho-
genic variants in these two genes.
Materials and methods: Five out of six family members
display the classical spectrum of MC features. Proband
(aged 57), her two daughters (aged 37 and 24), her grandson
(aged 17), and a cousin (aged 45) have similar complaints
of muscle rigidity in the extremities and face, provoked by
cold or potentially elicited by percussion of muscles. The
youngest grandson (aged 8) does not exhibit symptoms
representative of his age. EMG of three individuals (mother,
older daughter, cousin) showed classical excessive myo-
tonic discharges.
Results: Sanger sequencing revealed heterozygous pre-
viously reported missense mutation NM_000083.3:
c.2680C>T (NP_000074.3: p.(Arg894Ter)) in exon 23 of
the CLCN1 gene of every family member excluding the
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cousin. Another heterozygous previously reported missense
mutation NM_000334.4:c.4343G>A (NP_000325.4:p.
(Arg1448His)) in exon 24 of the SCN4A gene was found
in every family member except for the youngest grandson.
Conclusions: In cases when NDM phenotype severity is
varied in members of the same family, molecular genetic
analysis of both CLCN1 and SCN4A genes should be
considered.
K. Šiaurytė: None. A. Matulevičienė: None. L.
Cimbalistienė: None. A. Morkūnienė: None. A. Vaitke-
vičius: None. A. Utkus: None.
P10.41.C
Molecularly confirmed pontocerebellar hypoplasia in an
extensive family with four affected children
Z. Kubiritova1,2,3, E. Radvanska4, F. Bauer4, J. Barosova5,
M. Hyblova6,7, T. Szemes2,3,8, L. Kadasi1,2, J. Radvanszky1,3
1Slovak Academy of Sciences, Biomedical Research Center,
Bratislava, Slovakia, 2Department of Molecular Biology,
Faculty of Natural Sciences, Comenius University, Bra-
tislava, Slovakia, 3Geneton Ltd., Bratislava, Slovakia,
4Department of Neonatology, Faculty Hospital Nove
Zamky, Nove Zamky, Slovakia, 5Genet Ltd., Nitra, Slovakia,
6Trisomy Test Ltd., Bratislava, Slovakia, 7Medirex Inc.,
Bratislava, Slovakia, 8Comenius University Science Park,
Bratislava, Slovakia
Introduction: Pontocerebellar hypoplasia (PCH) is a rare
and heterogenous group of neurodegenerative disorders
having typically prenatal onset. Patients present with
hypotonia and severe atrophy of various parts of their brain,
resulting in slow development, movement problems and
intellectual disability, even death.
Material and Methods: In our family, we identified the
causative mutation by massively parallel sequencing, using
a clinical-exome kit (Illumina) in three affected patients
(post-mortem, from archived DNA samples). Following the
initial finding, we screened the respective genomic position
in the remaining family members using Sanger sequencing.
Results: In the affected family members we identified a
rare homozygous pathogenic variant c.92G>C in the
EXOSC3 gene, causing an autosomal recessive PCH type
1B. Unaffected parents and four siblings are heterozygous
carriers, one healthy sibling has a wild type genotype and
three affected siblings were homozygous and died soon
after birth (2-6 months of age). Two other siblings were not
analyzed, however, one of them also died soon after birth
and suffered most probably from the same disorder.
Conclusions: We report detailed clinical findings of the
largest PCH type 1B family published up to date, with four
affected children. The causative variant was reported to be
more frequent in the Roma population of the Czech
Republic (considered a founder mutation). Based on the
close connection of the populations of Slovakia and the
Czech Republic, we hypothesize, these two alleles may
have a common origin. Therefore, we are still investigating
their haplotype background. Funding: APVV-18-0319;
MZSR_2018/46-SAV-5; VEGA_2/0167/20.
Z. Kubiritova: None. E. Radvanska: None. F. Bauer:
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P10.42.A
Biallelic mutations in neurofascin cause neurodevelop-
mental impairment and peripheral demyelination
S. Efthymiou1, V. Salpietro1, N. Malintan1, M. Poncelet2, Y.
Kriouile3, S. Fortuna4, R. de Zorzi4, K. Payne5, L.
Henderson6, A. Cortese1, S. Maddirevula7, N. Alhashmi8, S.
Wiethoff1, M. Ryten1, J. Botia1, V. Provitera9, M.
Schuelke10, J. Vandrovcova1, L. Walsh5, E. Torti6, V.
Iodice1, M. Najafi11, E. Karimiani12, R. Maroofian1, K.
Siquier-Pernet13, N. Boddaert13, P. De Lonlay13, V.
Cantagrel13, M. Aguennouz14, M. El Khorassani3, M.
Schmidts11, F. S. Alkuraya15, S. Edvardson16, M. Nolano9,
J. Devaux2, H. Houlden1
1UCL Institute of Neurology, London, United Kingdom,
2INSERM U1051, Institut de Neurosciences de Montpellier
(INM), Montpellier, France, 3University Mohammed V of
Rabat, Rabat, Morocco, 4University of Trieste, Trieste,
Italy, 5Riley Hospital for Children, Indianapolis, IN, United
States, 6GeneDx, Gaithensburg, MD, United States, 7King
Faisal Specialist Hospital and Research Centre, Riyadh,
Saudi Arabia, 8College of Medicine, Sultan Qaboos
University, Oman, Oman, 9Istituti Clinici Scientifici Mau-
geri IRCCS, Naples, Italy, 10Charite´ Universita¨ tsmedizin,
Berlin, Germany, 11Radboud University Medical Center,
Nijmegen, Netherlands, 12St George’s University of Lon-
don, London, United Kingdom, 13Paris Descartes -
Sorbonne Paris, Paris, France, 14University of Messina,
Sicily, Italy, 15Alfaisal University, Riyadh, Saudi Arabia,
16Hadassah Medical Center, Jerusalem, Israel
Axon pathfinding and synapse formation are essential
processes for nervous system development and function.
The assembly of myelinated fibres and nodes of Ranvier is
mediated by a number of cell adhesion molecules of the
immunoglobulin superfamily including neurofascin,
encoded by the NFASC gene, and its alternative isoforms
Nfasc186, Nfasc140 and Nfasc155. We identified 10
individuals from six unrelated families, exhibiting a
neurodevelopmental disorder characterized with a
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spectrum of central and peripheral neurological involve-
ment, who were found by NGS to carry frameshift and
non-synonymous variants. Expression studies using
immunostaining-based techniques identified absent
expression of the Nfasc155 isoform as a consequence of
the frameshift variant and a significant reduction of
expression was also observed in association with two non-
synonymous variants affecting the fibronectin type III
domain. Cell aggregation studies revealed a severely
impaired Nfasc155-CNTN1/CASPR1 complex interaction
as a result of the identified variants. Immunofluorescence
staining of myelinated fibres from two affected indivi-
duals showed a severe loss of myelinated fibres and
abnormalities in the paranodal junction morphology. Our
results establish that recessive variants affecting the
Nfasc155 isoform can affect the formation of paranodal
axoglial junctions at the nodes of Ranvier. The genetic
disease caused by biallelic NFASC variants includes
neurodevelopmental impairment and a spectrum of central
and peripheral demyelination as part of its core clinical
phenotype. Our findings support possible overlapping
molecular mechanisms of paranodal damage at peripheral
nerves in both the immune-mediated and the genetic
disease. Wellcome Trust strategic award (Synaptopathies
WT093205 MA and WT104033AIA)
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P10.43.B
Detection and interpretation of variants in
dystroglycanopathy-causing genes in a cohort of 1,803
patients with unexplained limb-girdle muscle weakness
A. Topf1, A. B. Casasus1, R. Barresi1,2, K. Johnson1, M.
Mroczek1, J. Duff1, L. Phillips1, E. England3,4, L. Xu3,4, E.
Valkanas3,4, D. G. MacArthur3,4, V. Straub1
1John Walton Muscular Dystrophy Research Centre,
Translational and Clinical Research Institute, Newcastle
University, Newcastle, United Kingdom, 2Muscle Immu-
noanalysis Unit, Newcastle upon Tyne, United Kingdom,
3Analytic and Translational Genetics Unit, Massachusetts
General Hospital, Boston, MA, United States, 4Program in
Medical and Population Genetics, Broad Institute of MIT
and Harvard, Boston, MA, United States
Background: Dystroglycanopathies are a clinically and
genetically heterogeneous group of disorders characterised
by limb-girdle muscle weakness (LGMW) often in combi-
nation with brain abnormalities. To date, 18 disease-causing
genes have been identified, all encoding for proteins
involved in the glycosylation of α-dystroglycan and thus
affecting its binding to the extracellular matrix.
Methods: As part of the MYO-SEQ project, detailed
clinical and histological information was collected for 1,803
patients with unexplained LGMW. Whole-exome sequen-
cing was carried out and genes known to be associated with
dystroglycanopathies were analysed to identify likely
pathogenic variants.
Results: Suspected disease-causing variants in 8 genes
were detected in 47 patients: DPM3 and ISPD in one patient
each, FKTN, POMK and POMT1 in two patients, GMPPB
in four patients, POMT2 in 14 patients and FKRP in 21
patients. The overall frequency for the disease group was
2.6%. The phenotypes were highly variable, generally
presenting with progressive proximal muscle weakness and
high CK, yet cognitive impairment was not always
observed. Muscle biopsies were available for 21 cases;
reported results of α-dystroglycan labelling were incon-
sistent, indicating that standardised immunohistochemical
protocol and training in its interpretation are crucial. In
addition, we looked at undiagnosed patients carrying two or
more heterozygous pathogenic variants in two different
dystroglycanopathy genes, however we did not find
evidence of digenic inheritance in this pathway.
Conclusions: Given their genetic and phenotypic hetero-
geneity, here we highlight the advantage of using next-
generation sequencing in combination with traditional
histopathological analysis to improve the diagnosis of
dystroglycanopathies as a rare disease group.
A. Topf: None. A.B. Casasus: None. R. Barresi: None.
K. Johnson: None. M. Mroczek: None. J. Duff: None. L.
Phillips: None. E. England: None. L. Xu: None. E.
Valkanas: None. D.G. MacArthur: None. V.
Straub: None.
P10.44.C
A treatable hereditary polyneuropathy due to impaired
Vitamin B6 metabolism
P. N. Torbati1, E. G. Karimiani2,3, N. M. Ferreira4, R.
Maroofian2, V. Chelban5, Y. Khalil6, P. B. Mills6, R.
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Boostani7, H. Thiele8, H. Houlden2,5, B. Wirth4, M.
Karakaya4
1Department of Molecular Genetics, Next Generation
Genetic Polyclinic, Mashhad, Iran, Mashhad, Iran, Islamic
Republic of, 2Molecular and Clinical Sciences Institute, St.
George’s University of London, London, United Kingdom,
3Department of Molecular Genetics, Next Generation
Genetic Polyclinic, Mashhad, Iran, Islamic Republic of,
4Institute of Human Genetics, Center for Molecular
Medicine Cologne (CMMC), Institute of Genetics, and
Center for Rare Diseases Cologne, University of Cologne,
Cologne, Germany, 5Department of Neuromuscular Dis-
eases, UCL Queen Square Institute of Neurology, Uni-
versity College London, London, United Kingdom,
6Genetics and Genomic Medicine, Great Ormond Street
Institute of Child Health, University College London,
London, United Kingdom, 7Neurology Dept., Ghaem
Hospital, Medical School, Mashhad University of Medical
Sciences, Mashhad, Iran, Islamic Republic of, 8Cologne
Center for Genomics (CCG), University of Cologne,
Cologne, Cologne, Germany
Introduction: PDXK encodes for a pyridoxal kinase, which
converts inactive B6 vitamers to the active cofactor pyr-
idoxal 5’-phosphate (PLP), which is an essential co-factor
involved in vital metabolic pathways, including neuro-
transmitter production and amino acid biosynthesis.
Recently, biallelic pathogenic variants in PDXK were
shown to cause axonal Charcot-Marie-Tooth disease with
optic atrophy that responds to PLP supplementation.
Methods: We performed whole exome sequencing and
segregation analysis using Sanger sequencing in order to
uncover the pathogenic variant(s) in a family affected by an
undiagnosed autosomal recessive peripheral neuropathy.
Pathogenicity of the variant was confirmed via enzymatic
assays and mass spectroscopy on dried blood-spot samples,
derived from all members of the family.
Results: Here, we report two affected individuals, aged
17 and 14 years old, from a consanguineous Iranian family
presenting with a childhood-onset sensorimotor axonal
neuropathy and first signs of optic atrophy. Genetic analysis
identified a segregated novel homozygous missense variant
in PDXK, (NM_003681.4); c.225T>A, p.(Asn75Lys). We
show that the variant leads to reduced PDXK enzymatic
activity with low PLP. The relatively early diagnosis and
PLP replacement restored the PLP plasma levels with
observable clinical improvement.
Conclusions: We recommend that patients presenting
with autosomal recessive childhood-onset axonal neuro-
pathy and optic atrophy should be screened for PDXK
mutations, as this is a rare opportunity for treatment.
P.N. Torbati: None. E.G. Karimiani: None. N.M.
Ferreira: None. R. Maroofian: None. V. Chelban: None.
Y. Khalil: None. P. B. Mills: None. R. Boostani: None. H.
Thiele: None. H. Houlden: None. B. Wirth: None. M.
Karakaya: None.
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Novel HINT1 variant identified in Lithuanian patients
with autosomal recessive axonal neuropathy with
neuromyotonia
B. Burnyte1,2, A. Morkuniene1,2, K. Grigalioniene1,2,
L. Ambrozaityte1,2, R. Buneviciute3,2, A. Vaitkevicius3,2,
E. Preiksaitiene1,2, A. Matuleviciene1,2, L. Cimbalistiene1,2,
A. Utkus1,2
1Department of Human and Medical Genetics, Institute of
Biomedical Sciences, Faculty of Medicine, Vilnius Uni-
versity, Vilnius, Lithuania, 2Vilnius University Hospital
Santaros Klinikos, Vilnius, Lithuania, 3Institute of Clinical
Medicine, Faculty of Medicine, Vilnius University, Vilnius,
Lithuania
Aim: Autosomal recessive axonal neuropathy with neuro-
myotonia (ARAN-NM) is a rare subtype of hereditary
neuropathy. HINT1 gene c.110G>C, (p.Arg37Pro) variant
already reported in the literature as the most common
pathogenic variant [P. Laššuthová, 2016]. Here, we describe
genetic and phenotypic characteristics of patients with
ARAN-NM in Lithuania.
Materials and methods: By using multigene NGS panel,
we identified 8 patients with recessive variants in HINT1
gene from 2014 to 2019.
Results: Eight patients showed homozygous or com-
pound heterozygous variants in HINT1 gene, including
previously reported pathogenic variant c.110G>C p.(Arg37-
Pro) and a novel variant c.299A>G p.(Glu100Gly): i) five
patients harboured a homozygous pathogenic variant
c.110G>C, ii) two patients had compound heterozygous
variants (c.110G>C and c.299A>G), and iii) one patient had
a homozygous novel variant, which was also identified in
affected brother. Co-segregation of these variants in
affected sibs or healthy relatives confirmed a recessive
inheritance. Patients with homozygous novel and previously
reported HINT1 variants shared pure axonal motor
neuropathy.
Conclusions: Novel variant in HINT1 has been identified
from three unrelated patients. Our data expand the spectrum
of pathogenic variants in HINT1 and its significance in
molecular diagnosis. Additionally, our findings support that
previously reported variant c.110G>C may result from a
founder mutation in European populations.
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The result of NGS disease specific panel for practical
genetic diagnostics of neuromuscular disorders.
I. Haiboniuk1, H. Makukh1, O. Semeriak2, M. Dushar1, H.
Akopyan1
1Institute of Hereditary Pathology NAMS of Ukraine, Lviv,
Ukraine, 2Lviv Regional Clinical Hospital, Lviv, Ukraine
Introduction:The genetic determined neuromuscular dis-
ease are characterized by broad spectrum of clinical dis-
orders and clinical polymorphism.
Materials and Methods:We analyze the results of using
NGS for practical genetic diagnostics. Genetic testing was
performed among 65 person (55% male), 1 to 56 y.o with
clinicaly unexplained progressive neuromuscular pathol-
ogy. DNA samples was extracted from blood leucocytes
and common mutilations for DMD and SMA were excluded
by target testing. The Illumina technology for 289 genes
associated with muscular dystrophies, myopathies, neuro-
pathies was performed at INVITAE laboratory, USA. All
clinically significant observations were additionally
confirmed.
Results:The positive results - identification of at least one
pathogenic variant in the gene panel, were received for 35/
65 (54%) of cases. The conformation of CAPN3 autosomal
recessive limb-girdle muscular dystrophy was the most
frequent, 9.2%: three patients c.550del homozygous and
two compound with other mutations. Charcot-Marie-Tooth
disease was diagnosed in association with mutations in
PMP22, MFN2, GJB1, GDAP1 genes in 6.2%. The other
than deletion DMD genetic variants were identified in 4
males. The interesting finding of this study: TCF4 deletion
of entire coding sequence associated with Pitt-Hopkins
syndrome; copy number gains for X-chromosome genes
and after cytogenetic testing 47, XXY karyotype in boy
with SMA- like clinical phenotype. In 40% of patients the
diagnosis of monogenic disorder was confirmed with use of
NGS disease specific panel. The clinical treatment of VUS
is challenging.
Conclusions:The collaboration between molecular
geneticist, clinical geneticist and neurologist guarantee the
correct diagnosis for patients with orphan neuromuscular
disease.
I. Haiboniuk: None. H. Makukh: None. O. Semeriak:
None. M. Dushar: None. H. Akopyan: None.
P10.47.C
Identification of a novel PRUNE1 gene mutation in a
patient with severe neurodevelopmental disorder char-
acterized by hypotonia and epileptic encephalopathy
L. Lazaros1, D. Palaiologou1, A. Romito2, A. Pantou1, A.
Marais2, E. Kanavakis1
1Genesis Genoma Lab, Genetic Diagnosis, Clinical Genet-
ics & Research, Athens, Greece, 2Centogene AG, Rostock,
Germany
Introduction: The application of whole exome sequencing
(WES) has revealed the genetic basis of an autosomal
recessive neurodevelopmental disorder characterized by
microcephaly, hypotonia and variable brain anomalies
(NMIHBA). In the current study, we describe a severe case
of NMIHBA due to the compound heterozygosity of a
missense and a novel frameshift variant in the
PRUNE1 gene.
Materials and Methods: The affected proband is a 3.5-
year-old girl characterized by generalized muscular hypo-
tonia, drug-resistant epilepsy (10-15 myoclonic seizures
daily) and severe swallowing problems. Serious develop-
mental and speech delay is also present. The clinical
examination of the patient has detected scoliosis and
kyphosis, high myopia, frequent respiratory tract infections,
tooth enamel loss and severe constipation. WES was
performed in three family members (proband & parents)
using SureSelect Human All Exon V6 kit in a HiSeq4000
instrument. The detected variants were confirmed by Sanger
sequencing analysis.
Results: WES analysis detected two heterozygous
PRUNE1 gene variants in the affected proband,
c.316G>A (p.Asp106Asn) and c.181_185delTCTGA (p.
Ser61Thrfs*6), the first of paternal and the second of
maternal origin, confirming the compound heterozygosity in
the index patient.
Conclusions: Given that PRUNE1 gene has recently been
associated with neurodevelopmental disorders and conse-
quently it is not included in older custom NGS gene panels,
WES application constituted the most efficient approach for
the molecular investigation of the specific case. These
results highlight the utility of WES in order to reveal the
genetic etiology of complex phenotypes, allowing the better
classification of the patients and the design of personalized
therapeutic strategies.
L. Lazaros: None. D. Palaiologou: None. A. Romito:
None. A. Pantou: None. A. Marais: None. E.
Kanavakis: None.
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Variants causing mitochondrial dysfunction are not rare
in non-5q SMA: Re-evaluation of thirty families by
exome sequencing
M. Karakaya1, N. Keller1, J. Altmueller2, S. Motameny2, H.
Thiele2, G. Wunderlich3, J. Kirschner4, B. Schrank5, R.
Maroofian6, C. Paketci7, U. Yis7, P. Nuernberg2, B. Wirth1
1University Hospital Cologne, Institute of Human Genetics,
Cologne, Germany, 2Cologne Center for Genomics,
Cologne, Germany, 3University Hospital Cologne, Depart-
ment of Neurology, Cologne, Germany, 4University Hospi-
tal Bonn, Department of Neuropediatrics, Bonn, Germany,
5DKD HELIOS Kliniken, Department of Neurology,
Wiesbaden, Germany, 6Molecular and Clinical Sciences
Institute, St. George’s University of London, London,
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Introduction: Spinal muscular atrophy (SMA) without
deletions/mutations in SMN1 (non-5q-SMA) is genetically
very heterogeneous. Due to the strongly overlapping phe-
notypes, the differential diagnosis of non-5q-SMAs is
challenging.
Materials/Methods: 52 patients analysed by a large gene
panel with 479 neuromuscular disease-causing genes
received no conclusive results. We re-evaluated 21
unsolved cases by trio whole-exome sequencing (trio-
WES), in addition to nine families without previous panel
analysis.
Results: In 10/21 individuals with negative panel results,
trio-WES revealed the pathogenic variant (48%). Of these
ten identified genes, five (50%) were associated with genes
involved in mitochondrial function and stability (FDXR,
NDUFS6, ECHS1, MPV17, VPS13D). The remaining genes
encoded for proteins of diverse functions, with one variant
in the lysosomal enzyme-encoding gene ARSA, one in a
gene required for amino acid synthesis (SEPSECS) and one
in the muscle protein-coding TTN. Additionally, we
identified a variant in a gene relevant for cellular stress
response (ADPRS) and one encoding an enzyme essential
for vitamin B6 metabolism (PDXK). Among nine patients
with no prior gene panel testing, we diagnosed four patients
(4/9) with pathogenic variants in known neuromuscular
disease genes.
Discussion: Inborn errors of organelle metabolism might
primarily manifest with neuropathic features in childhood.
Our preliminary analysis shows that mutations in mitochon-
drial proteins are the leading cause in this spectrum. Due to
abundance and high number of the associated genes, and
high clinical variability, we recommend performing WES
instead of gene panels, in order to address the extreme
heterogeneity of the causal pathomechanisms.
Grant reference: Deutsche Forschungsgemeinschaft
(Wi945/19-1)
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Comparison of gene panel and alpha-glucosidase activ-
ity on dried blood spot in patients with suspected muscle
disease in order to screen and diagnose Pompe disease
F. Thuriot1,2, K. Hodson3, E. Gravel1,2, C. Buote2, S.
Gravel1,2, S. Lévesque1,2
1Université de Sherbrooke, Sherbrooke, QC, Canada,
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3Dynacare, Laval, QC, Canada
Pompe disease is an autosomal recessive disorder caused by
alpha-glucosidase (GAA) deficiency, leading to a pro-
gressive limb-girdle weakness and respiratory insufficiency.
Limb-girdle weakness is the most common form of muscle
weakness and Pompe disease is hard to differentiate,
delaying diagnosis and administration of treatment. Enzy-
matic activity of GAA is wildly used to screen patients but
sequencing of GAA is required to confirm the diagnosis. In
order to investigate if potential Pompe cases could be
missed by using a gene panel approach alone, we screened
876 patients with a suspected muscle disease, and compared
GAA enzymatic activity on dried blood spot with an 89-
gene panel. Eight patients were diagnosed with Pompe
disease; enzymatic activity and sequencing results were
concordant. Of the 36 patients carrying a single hetero-
zygous GAA variant, only one patient harboring a patho-
genic heterozygous variant had low enzyme activity
overlapping with levels seen in Pompe cases suggesting that
a second variant could have been missed. RNA studies are
pending. Finally, nine patients had low or borderline
enzyme activity, but no variant was detected. These patients
have a low risk of having Pompe disease since enzymatic
activity is close to the threshold and does not overlap with
confirmed Pompe cases. With gene panels being increas-
ingly performed as a first-tier test for patients with sus-
pected muscle disorders, our study emphasizes the need to
perform reflex enzymatic activity in patients with a single
GAA variant. RNA sequencing should be considered if it the
enzymatic result is compatible with Pompe. *Supported by
Sanofi-Genzyme.
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A homozygous frameshift mutation in PTRH2 gene
S. Seneca1,2, L. Régal3, M. Becker4, K. Stouffs1,2, A.
Gheldof1,2, E. Scalais5
1UZ Brussel, Center for Medical Genetics, Brussels,
Belgium, 2Neurogenetics Research Group, Reproduction –
Genetics and Regenerative Medicine Research Cluster,
Vrije Universiteit Brussel (VUB), Brussels, Belgium, 3Divi-
sion of Pediatric Neurology, UZ Brussel, Brussels, Belgium,
4Pediatric Department, Centre Hospitalier de Luxembourg,
Luxembourg City, Luxembourg, 5Division of Pediatric
Neurology, Centre Hospitalier de Luxembourg, Luxem-
bourg City, Luxembourg
The identification of the genetic defect of a neurological
disease is complex, and many patients are still without a
molecular diagnosis. With massive parallel sequencing and
a laboratory developed Mendeliome gene panel, we iden-
tified a truncation mutation in the PTRH2 gene in two
affected siblings. This multifunctional and evolutionary
well conserved enzyme encodes the mitochondrial peptidyl-
tRNA hydrolase 2 protein (Ptrh2), and prevents the accu-
mulation of peptidyl-tRNA. It is also a key determinant in
cell survival, growth and apoptosis processes. The precise
role of the protein in muscle disease has still to be deli-
neated. Our index patients are the 15- and 13-year-old son
and daughter of non-consanguineous healthy Nepalese
parents. Both patients had multiple neurological symptoms
including sensorineural deafness, psychomotor and lan-
guage delay, epilepsy and behavioral disturbances, subse-
quently motor regression with ataxia, peripheral neuropathy
and later, in one of them, diabetes mellitus. In both patients,
pancreatic echography disclosed hyper-echogenicity. A
homozygous pathogenic 1 base pair insertion c.127dupA
was revealed in the PTRH2 gene of both siblings, and
confirmed with Sanger sequencing. This frameshift causes a
premature translation stop p.(Ser43Lysfs*11), and is present
in heterozygosity in both parents. Originally, a homozygous
deletion variant in the PTRH2 gene was identified as the
molecular cause of global developmental delay, hearing loss
and ataxia. Since 2014, the identification of additional
patients has documented a clinical heterogeneity, and
expanded the clinical spectrum of pathogenic PTRH2 var-
iants. They are now known as the cause of infantile mul-
tisystem neurologic, endocrine and pancreatic disease
(IMNEPD).
S. Seneca: None. L. Régal: None. M. Becker: None. K.
Stouffs: None. A. Gheldof: None. E. Scalais: None.
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Genetic analysis of recessive rhabdomyolysis - mutations
in LPIN1 (Lipin-1)
Y. Jelting1, A. Zaum1, S. Spranger2, S. Rost1
1University of Würzburg, Institute for Human Genetics,
Würzburg, Germany, 2Praxis für Humangenetik, Bremen,
Germany
Lipin-1, a protein coded by the LPIN1 gene, plays an
important role in the human triglyceride synthesis. Mutations
in LPIN1 lead to recurrent rhabdomyolysis with myoglobi-
nuria, myalgia and generalized weakness in childhood. We
investigated two independent cases with rhabdomyolysis.
Patient 1 is a six-year-old Turkish boy with healthy con-
sanguineous parents. His sister died of a respiratory infection
at the age of 3. He showed massively increased creatinine
kinase (CK) levels (up to 400.000 U/l) and myoglobinuria.
Patient 2 is a German 36-year-old women with myalgia,
increased CK values and a history of kidney failure after
gastrointestinal infection in early childhood. The DNA was
processed by next-generation sequencing (NGS) after
enrichment of a custom-made myopathy panel (65 genes).
Data analysis was done by GensearchNGS. Three different
variants in LPIN1 could be identified, a large recurrent dele-
tion including exon 18, a nonsense variant and a single base
pair duplication. Patient 1 carries the deletion and the dupli-
cation, each in homozygous state. The duplication has not
been described before, is not present in gnomAD and leads to
a frameshift with a premature stop codon at position 769.
Patient 2 carries the same deletion of exon 18 and a known
nonsense variant leading to a stop codon at position 19. The
breaking points of the deletion could be identified exactly by
NGS. Our findings revealed a novel and already known
mutations in LPIN1 and verified the breakpoints of the
recurrent deletion. This confirms the causative role of LPIN1
mutations in patients with muscular disorders.
Y. Jelting: None. A. Zaum: None. S. Spranger: None.
S. Rost: None.
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Autosomal recessive spinocerebellar ataxia 20: a novel
insertion in the SNX14 gene
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A. Harari-shaham1, L. Shemer1, V. Adir1, O. Sadeh1, H.
Baris-Feldman2, A. Mory3, L. Sagi-Dain1, A. Peleg1
1Carmel medical center, Haifa, Israel, 2Rambam medical
center, Haifa, Israel, 3Rambam Medical Center, Haifa,
Israel
Background: Autosomal recessive spinocerebellar ataxia
20 (SCAR20) is a rare disorder, mainly characterized by
intellectual disability, ataxia, coarse facial features, pro-
gressive loss of Purkinje cells in the cerebellum and often
hearing loss and skeletal abnormalities.
Case report: We describe a 3.5 years old boy, fourth
child to consanguineous parents, double first cousins from
Druze origin.
Prenatal sonographic examination demonstrated periven-
tricular pseudo-cyst, mild unilateral ventriculomegaly, small
and dysmorphic corpus callosum, dysmorphic small cave of
septum pellucidum and shortened long bones of the legs (5th
percentile). Amniocentesis for chromosomal microarray
analysis yielded normal results. Magnetic resonance
imaging (MRI) demonstrated hypogenesis of corpus
callosum and delayed myelination of the white matter.
Examination of the 3.5 year old boy at our genetics clinic
demonstrated global severe developmental delay, vision
impairment, severe hypotonia, lower motor neuron lesion
characteristics and some dysmorphic signs.
Results: Two bioinformatics analyses of exome sequen-
cing did not reveal any pathogenic findings. However, the
third exome re-evaluation raised suspicion of about 200bp
deletion in the SNX14 gene, including part of exon 13 and
intron 14. The approximated boundaries were Chr6
(GRCh37) g.86252986_86253202del.
Sanger sequencing and a PCR fragment analysis revealed
a homozygote 142bp insertion. Chr6 (GRCh37)
g.86252986_86252987ins[142], the insertion interrupted
the coding region of the SNX14 gene, NM_153816.5;
c.1320_1321ins[142].
Conclusions: We report a novel SNX14 gene mutation,
causing a severe phenotype of a recently described
SCAR20. Our findings emphasize the limitation of the
exome analysis and the importance of the use of different
analysis platforms.
A. Harari-shaham: None. L. Shemer: None. V. Adir:
None. O. Sadeh: None. H. Baris-Feldman: None. A.
Mory: None. L. Sagi-Dain: None. A. Peleg: None.
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SMN2genes study by NGS in spinal muscular atrophy:
towards identification of new SMA modifiers
L. Blasco-Pérez1, I. Paramonov1, L. Iranzo1, D. Martinez-
Cruz1, L. Alias2, S. Bernal2, C. Castiglioni3, S.
Kapetanovic4, C. Høi-Hansen5, E. García-Arumí1, I.
Cuscó1, E. F. Tizzano1
1Department of Clinical and Molecular Genetics and
Medicine Genetics Group, VHIR, University Hospital Vall
d’Hebron, Barcelona, Spain, 2Servei de Genètica, Hospital
de la Santa Creu i Sant Pau, Barcelona, Spain, 3Clínica Las
Condes, Santiago de Chile, Chile, 4Hospital Universitario
de Basurto, Bilbao, Spain, 5Copenhagen University Hospi-
tal, Copenhagen, Denmark
Introduction: Spinal muscular atrophy (SMA) is a neuro-
muscular disorder caused by loss of function of both copies
of SMN1. SMA patients are classified into different clinical
groups. Copy number of SMN2, the highly homologous copy
of SMN1, is considered the most important phenotypic
modifier of the disease but this correlation is not absolute. In
the present therapeutic scenario with SMN2 splicing modi-
fiers patients receive expensive treatments and there are dif-
ferent degrees of responses (responders, slow responders,
non-responders). All SMN2 copies are not always equivalent.
Thus, in deep analysis of the SMN2 genotype could provide
useful information to further characterize SMA patients.
Materials and Methods: We study 53 SMA patients
with homozygous SMN1-deletion to determine their SMN2
sequences. DNA samples were sequenced by Long-PCR
and NGS. The amplified region includes the complete
SMN2 gene (promoter, 5’UTR and 3’UTR regions). Variant
analysis was performed using a bioinformatic pipeline
adapted to the complexity of the region.
Results:We found previously described modifier variants
c.859G>C, c.835-44A>G, c.835-1897C>T in 5 patients,
and 10 new candidates, being two of them recurrent.
Additionally we have detected SMN1-SMN2 hybrid in two
patients.
Conclusions: our technique was useful to accurately
characterize the SMN2 copies, identifying described and
new modifier variants. Further functional analysis of those
candidates should be essential for categorization. In the
current framework of new therapies it is extremely
important to characterize historical and new patients that
receive further advanced treatments. Funded by Biogen and
FIS PI18/00687
L. Blasco-Pérez: None. I. Paramonov: None. L.
Iranzo: None. D. Martinez-Cruz: None. L. Alias: None.
S. Bernal: None. C. Castiglioni: None. S. Kapetanovic:
None. C. Høi-Hansen: None. E. García-Arumí: None. I.
Cuscó: None. E.F. Tizzano: None.
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Distinguishing SMN1 and SMN2: nanopore sequencing
as a powerful tool to assign variants
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K. Eggermann, T. Pfister, I. Kurth, F. Kraft
Institute of Human Genetics RWTH University Hospital,
Aachen, Germany
Spinal Muscular Atrophy (SMA)-5q is an autosomal-
recessive neuromuscular disorder with a frequency of app.
1:4,900 in the European population. Mutations in the Sur-
vival Motor Neuron (SMN) 1 gene are responsible for the
disease while the copy number of SMN2 modifies the
patient’s phenotype. Both genes are located in a highly
homologous, duplicated and inverted region on chromo-
some 5q. The majority of patients carry a homozygous
deletion of SMN1 but 3-4% of patients are compound
heterozygous for the deletion on one and single nucleotide
variants (SNV) on the other allele. There are not more than
five unique sequence differences between SMN1 and
SMN2, only one of those, c.840C/T, in the coding sequence
and the others in intronic or non-coding regions. When a
patient suspected of having SMA carries a heterozygous
deletion of SMN1, direct sequencing of the SMN1 gene to
detect a second pathogenic SNV is necessary. Due to the
nearly 100 % sequence identity it is almost impossible to
distinguish SMN1 and SMN2 sequences with standard
sequencing approaches and a SNV cannot be assigned
unequivocally to one of the genes. Several sequencing
strategies to overcome this problem have been introduced,
all of them being rather laborious. We have established a
long-range Nanopore sequencing protocol that allows
unequivocal assignment of variants to SMN1 or SMN2, and
thereby improves the diagnostics for the patient and genetic
counselling for the family. In times of promising therapeutic
approaches for SMA-5q, it is crucial to make a fast and
unambiguous diagnosis of the disease.
K. Eggermann: None. T. Pfister: None. I. Kurth: None.
F. Kraft: None.
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Update on SMN1 mutations in Spanish SMA patients:
description of new rare missense, nonsense and splicing
mutations
L. Alías1, S. Bernal1, F. March2, I. Cuscó3, L. Blasco3, S.
Quero2, M. Simón2, E. Martínez-Sánchez2, P. Fuentes-
Prior4, P. Gallano1, E. Tizzano5
1Genetics Department. Hospital Sant Pau, CIBERER U-
705, Barcelona, Spain, 2Genetics Department. Hospital
Sant Pau, Barcelona, Spain, 3Medical Genetics Group,
VHIR, Barcelona, Spain, 4Molecular Bases of Disease, IIB-
Sant Pau, Barcelona, Spain, 5Dept. Of Clinical and
Molecular Genetics and Rare Diseases Unit, Hospital Vall
d’Hebrón, Barcelona, Spain
Background: Homozygous absence of SMN1 is the major
genetic cause of SMA (90%), the remaining cases are
hybrid SMN2-SMN1 genes (4.6%) and rare point mutations
(5%). When a patient has no homozygous deletion, SMA
molecular diagnostic is of utmost importance to include him
in a specific advanced treatment considering the current
SMA landscape.
Materials and Methods: The SMN genes were quantified
by MLPA in 931 unrelated Spanish SMA patients. Sanger
sequencing was usefully to detect point mutations in the
SMN1 gene. C212 and C272 molecular markers were
analysed to establish the familial haplotype.
Results: From our SMA cohort: 834 (89.6%) showed
homozygous absence of the SMN1; 42 (4.5%) showed
homozygous absence of only exon 7, harbouring at least
one SMN2-SMN1 hybrid gene; 46 (4.9%) showed a point
mutation in the SMN1 gene, being the c.399_402delAGAG
in exon 3 and the c.770_780dup11 in exon 6 responsible of
the 65.2% of the cases (20 and 10 respectively), other 11
known and 3 novel (missense:c.808A>C, nonsense:
c.188C>A and splicing:c.724-1G>C) point mutations were
detected. Interestingly, just one SMN1 deleted allele was
found in 9 symptomatic patients but any other pathogenic
variant in the other allele has been currently identified.
Conclusions: Although the vast majority of Spanish
SMA cases present an homozygous deletion of the SMN1
gene, a minority of cases can be explained due to other rare
mutations that are necessary to discover by Sanger or Next
Generation Sequencing. Genetic confirmation of these
patients is crucial in order to include them in therapeutic
protocols. FIS-PI18/00687
L. Alías: None. S. Bernal: None. F. March: None. I.
Cuscó: None. L. Blasco: None. S. Quero: None. M.
Simón: None. E. Martínez-Sánchez: None. P. Fuentes-
Prior: None. P. Gallano: None. E. Tizzano: None.
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Analytical validation of a multiplex PCR/CE assay for
simultaneous determination of SMN1/SMN2 exon 7
copy number and variant status
W. Laosinchai-Wolf, J. L. Larson, J. Janovsky, K. Jefferson,
D. Patel, M. Church, H. Zhu, G. J. Latham, J. N. Milligan
Asuragen, Austin, TX, United States
Introduction: Spinal Muscular Atrophy (SMA) is an
autosomal recessive neuromuscular disease commonly
caused by homozygous loss of function deletions in SMN1
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exon7, frequently resulting in infant mortality. SMN2, a
paralog of SMN1, modulates SMA severity. Recent break-
through therapies rely on quantification of SMN1 and SMN2
copies to inform treatment, and early detection is critical.
Additionally, detection of c.859G>C in SMN2 is linked to
reduced disease severity and prognosis while gene dupli-
cation variants c.*3+80T>G and c.*211_*212del in SMN1
can inform carrier risk in several populations.
Methods: We validated the AmplideX® PCR/CE SMA
Plus Kit, which quantifies 0 to ≥4 SMN1 and SMN2 exon7
copy numbers and the three informative variants. Auto-
mated analysis with AmplideX PCR/CE Reporter software
incorporates batch and sample QC checks to qualify results.
We assessed single-site precision and accuracy of SMN1
and SMN2 copy number and variant detection against
reference methods using DNA samples isolated from whole
blood with over five purification methods. We also assessed
analytical specificity, reagent stability, and other perfor-
mance factors.
Results and Conclusion: SMN1 and SMN2 copy number
and variant measurements were concordant with reference
methods for all isolation methods. Further, results were
precise across 200 sample measurements generated with
three reagent lots and two operators over multiple runs/
days. The assay was specific for all genes and variants. The
AmplideX PCR/CE SMA Plus Kit is in development for
in vitro diagnostic use for carrier screening and disease
diagnosis, and provides accurate and reliable results in
under four hours.
W. Laosinchai-Wolf: A. Employment (full or part-time);
Significant; Asuragen. J.L. Larson: A. Employment (full
or part-time); Significant; Asuragen. J. Janovsky: A.
Employment (full or part-time); Significant; Asuragen. K.
Jefferson: A. Employment (full or part-time); Significant;
Asuragen. D. Patel: A. Employment (full or part-time);
Significant; Asuragen. M. Church: A. Employment (full or
part-time); Significant; Asuragen. H. Zhu: A. Employment
(full or part-time); Significant; Asuragen. G.J. Latham: A.
Employment (full or part-time); Significant; Asuragen. J.N.
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Bruce Rappaport Faculty of Medicine, Technion - Israel
Institute of Technology, Hifa, Israel
Introduction: Spinal Muscular Atrophy (SMA) is an
autosomal recessive neuromuscular disorder caused by loss
of lower motor neurons. All types of SMA are caused by
homozygous loss of the SMN1 gene, resulting in low levels
of the survival motor neuron protein, insufficient to protect
motor neurons. Homozygous deletions of exon 7 in SMN1
gene in clinically asymptomatic individuals are extremely
rare, involving less than 30 described cases. These patients
usually have several copies of the SMN2 gene, which
compensates for the loss of SMN1 product.
Case presentation: An asymptomatic 31-years old woman
was referred for pregestational genetic testing within the Israeli
national genetic carrier-screening program for reproductive
purposes. Carrier screening was performed using Multiplex
ligase-dependent probe amplification (MLPA) Probemix P060.
Results: The patient was diagnosed with homozygous
absence of exon 7 in the SMN1 gene. The deletion was
validated using MLPA Probemix P021 and Real Time-
Polymerase Chain Reaction. MLPA testing revealed three
copies of SMN2 exon 7 and 8. Genetic testing of the spouse
revealed three copies of exon 7 in SMN1.
Discussion: Carrier testing for reproductive partner of
SMA requires SMN1 dosage analysis. If an individual is
found to have at least two SMN1 copies, the probability of
being a carrier is approximately 1/670 (mainly taking into
consideration the 2% frequency of two SMN1 copies on the
same chromosome). However, in our unique and pretty
fortunate couple the risk for SMA disease in the progeny is
very low due to the spouses’ extra copy.
M. Echar: None. L. Sagi-Dain: None. V. Adir: None.
O. Sadeh: None. A. Peleg: None.
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Profiling of the oculomotor nucleus and spinal cord in
amyotrophic lateral sclerosis using single-nuclei RNA
sequencing (snRNA-seq)
P. Alipour1,2, J. P. Ross1,2, D. Spiegelman1,3, D.
Rochefort1,3, P. A. Dion1,3, G. A. Rouleau1,2,3
1Montreal Neurological Institute, and Hospital, McGill
University, Montréal, QC, Canada, Montreal, QC, Canada,
2Department of Human Genetics, McGill University,
Montréal, QC, Canada, Montreal, QC, Canada, 3Depart-
ment of Neurology and Neurosurgery, McGill University,
Montréal, QC, Canada, Montreal, QC, Canada
Introduction: Amyotrophic lateral sclerosis (ALS) is a
progressive neurodegenerative disorder which involves loss
of upper and lower motor neurons (MNs) in the central
nervous system (CNS). While both upper and lower MNs
are affected, some subtypes of lower MNs are resistant to
degeneration such as oculomotor nuclei located in the
midbrain. The molecular mechanism underlying this dif-
ferential vulnerability among MNs is currently unknown.
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Using snRNA-seq to profile expression in ALS tissues will
explain the changes in cell type proportions associated with
neurodegeneration.
Materials & Methods: Postmortem brain tissues have
been collected from 30 tissue samples from oculomotor
nucleus, medulla, and spinal cord of ALS cases and healthy
controls. Nuclei isolation and library preparation using the
Chromium Single Cell 3′ Reagent Kits v2 (10X Genomics)
has been performed aiming for 6,000 nuclei per sample. The
average sequencing depth per sample was 360M reads using
the NovaSeq 6000 (Illumina). Cellranger software was used
for alignment and generation of feature-barcode matrices.
The R package Seurat was applied for downstream analysis
such as differential gene expression and cell clustering.
Preliminary Results: We have identified differences in
surviving cell types between severely affected and spared
regions of the CNS. Further, we identified cell population
differences and cell-specific dysregulation of genes between
ALS patients and controls, as well as between different
regions of the CNS.
Conclusions: Knowing the mechanisms underlying tissue-
specific neurodegeneration could help understand why some
cell types are resistant to degeneration and how it could be
possible to simulate this resistance in vulnerable regions.
P. Alipour: None. J. P. Ross: None. D. Spiegelman:
None. D. Rochefort: None. P. A. Dion: None. G. A.
Rouleau: None.
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New splice site mutation in SPG7
A. Zaum, F. Zimmer, N. Pluta, E. Kunstmann, S. Rost
Institute of Human Genetics, Wuerzburg, Germany
Introduction: SPG7 encodes paraplegin, a protein that is
part of a metalloprotease of the inner mitochondrial mem-
brane. Mutations in SPG7 cause an autosomal recessive
form of hereditary spastic paraplegia (SPG), a clinically and
genetically heterogeneous group of neurological diseases.
Due to the heterogeneity of SPGs and other neuropathies,
genetic diagnostics by whole exome sequencing (WES) is
beneficial and performed successfully in our laboratory for
different (virtual) gene panels.
Methods: We present the case of a patient with clinical
suspicion of SPG. For molecular diagnosis, we used WES
and analysed a (virtual) SPG-panel consistent of 13 genes.
To validate one variant’s effect on splicing, we isolated
RNA from whole blood and retranscriped it into cDNA,
followed by Sanger sequencing.
Results: We identified two heterozygous variants in SPG7:
one recurrent pathogenic variant (p.(Ala510Val)) and a
variant of uncertain significance (c.1779+5G>C). Prediction
tools calculated a decreased probability for the usage of the
donor splice site adjacent to the second variant. However,
RNA analysis confirmed the usage of a cryptic splice site
(c.1779+42) that leads to the inclusion of 14 amino acids in
the protein. The insertion is in frame, but occurs in a
functionally important peptidase domain of the protein.
Conclusions: In summary, we present the case of a new
SPG7 splice site variant, with confirmed effect on RNA
splicing. Together with the second variant, it confirms and
specifies the clinical diagnosis. Therefore, WES is a powerful
tool to diagnose heterogeneous neurological disorders.
A. Zaum: None. F. Zimmer: None. N. Pluta: None. E.
Kunstmann: None. S. Rost: None.
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Detection of cis duplication of SMN1 in healthy carrier,
a droplet digital PCR method to improve genetic
counselling
C. VEREBI, C. Vignal, S. Drunat
Robert Debre University Hospital, Paris, France
Introduction: The c.*3+80T>G and c.*211_*212del
SMN1 variants had been initially associated with SMN1 cis
duplication in the Ashkenazi population (Luo et al. Genet
Med. 2014). Our study falls within improvement of genetic
counseling for carriers of SMA as already done for Spanish
population (Alías et al. EJHG. 2018).
Materials and methods: We used a previously published
ddPCR design for the variant c.*3+80T>G detection
(Vidal-Folch et al. Clin Chem. 2018) and a custom made
design for the variant c.*211_*212del. Carrier status was
established after familial studies around SMA cases.
Results: See Table ; SMA for Spinal Muscular Atrophy ;
*Corresponding to the same individuals ; &27 individuals
carried the two variants, the last individual only carried the
c.*3+80T>G variant.
Conclusions: The variants were absent in 1/0 healthy
carriers which corroborate the high association with multi-
ple and furthermore cis duplicate SMN1 genes. We can
assume that the percentage of variants carriers in 2/0 carriers
individual is about 43% in our population which place itself
between the average 20% and 46% in Spanish and
Ashkenazi population respectively(Luo et al. Genet Med.
2014, Alías et al. EJHG. 2018). The variant study leaded to
the estimation of 11.48% of cis duplication carrier in our
general population, allowing us to increase the sensitivity of
our SMA carrier detection test.
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Long-read amplicon sequencing detects a bi-allelic
SMN1>SMN2 gene conversion allele that does not
guarantee a spinal muscular atrophy (SMA) phenotype
H. Muallem1, J. Harting2, C. Heiner2, S. Y. Scher3, J.
Ekstein3, D. A. Zeevi1
1Dor Yeshorim Committee for Prevention of Jewish Genetic
Diseases, Jerusalem, Israel, 2Pacific Biosciences, Menlo
Park, CA, United States, 3Dor Yeshorim Committee for
Prevention of Jewish Genetic Diseases, New York, NY,
United States
Introduction: Spinal muscular atrophy (SMA) is caused
primarily by bi-allelic loss of SMN1 exon 7 via deletion
and/or gene conversion to SMN2. Here we show that bi-
allelic SMN1>SMN2 gene conversion presents with mild, or
completely absent, disease phenotype.
Materials and Methods: A consanguineous couple and 4
children were selected for investigation. Two children were
asymptomatic and the other two children were diagnosed
with mild Type 3 SMA (at ages 13 and 28, respectively).
For each sample, SMN1 exon7 dosage was measured by
qPCR and SMN1/2 alleles were determined by long read
amplicon Single Molecule, Real-Time (SMRT) sequencing
on the Sequel System (Pacific Biosciences) followed by
segregation analysis.
Results: The qPCR assay identified a carrier state in
both parents, non-carrier state in one unaffected child, and
complete absence of SMN1 exon 7 in 2 affected children
and 1 unaffected child. Long-read amplicon analysis
identified identical genotypes in the parents, including one
normal SMN chromosome (bearing 1 copy of SMN1 and 1
copy of SMN2) and one gene conversion SMN chromo-
some (bearing one normal copy of SMN2 and one
SMN1>SMN2 gene converted copy). The non-carrier
unaffected child was homozygous for the normal SMN
chromosome, while the 2 affected children and 1
unaffected child were each homozygous for the gene
conversion SMN chromosome.
Conclusions: SMN1>SMN2 gene conversion, which is
fairly common in the general population, was readily
detected with qPCR and long amplicon sequencing. Our
results suggest that bi-allelic loss of SMN1 by gene
conversion is not necessarily indicative of disease.
H. Muallem: None. J. Harting: A. Employment (full or
part-time); Significant; Pacific Biosciences. C. Heiner:
None. S.Y. Scher: None. J. Ekstein: None. D.A. Zeevi:
None.
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Possible X-linked genetic and epigenetic modifiers of
proximal spinal muscular atrophy
A. Yurchenko1, E. Patskun2, S. Kravchenko3, N.
Hryshchenko3
1Educational and Scientific Center “Institute of Biology and
Medicine” of Taras Shevchenko National University of
Kyiv, Kyiv, Ukraine, 2Municipal Non-Profit Enterprise
"Transkarpathian Clinical Regional Hospital named after
Andrii Novak", Uzhgorod, Ukraine, 3Institute of Molecular
Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
Introduction: Proximal spinal muscular atrophy (SMA) is
a neuromuscular autosomal recessive disease, mostly
caused by a homozygous deletion in SMN1 gene. Despite
SMA is a classic monogenic disease, the clinical phenotype
of patients varies from the most acute infantile type to a
relatively mild chronic juvenile type. Some genetic modi-
fiers of SMA are already known, such as a type of SMN1
mutation and SMN2 copy number variation. It was shown
that the female SMA phenotype was significantly differing
from the phenotype of the male patients. The aim of our
investigation is to study an association of SMA phenotype
with X-linked genetic and epigenetic factors.
Materials and Methods: The study groups consisted of
female (n = 103) and male (n = 75) patients with
determined SMN1 and SMN2 genotypes. The analysis of
X-chromosome inactivation (XCI) was done by methyl-
specific CAG-genotyping of AR gene. The rs2070169 and
rs4339766 of UBA1 were analyzed by RFLP-method.
Spearman’s correlation, regression analysis and Mann-
Whitney test were used for the statistical analysis.
Results: The correlation between the patients’ SMN1 and
SMN2 genotypes and SMA phenotypes was stronger in the
male group. Skewed XCI was detected in 45.5% of females,
these patients significantly more often (p <0.05) had differ
phenotype than expected. It was demonstrated that
rs2070169 and rs4339766 had no significant effect on
SMA phenotype.
Conclusions: It was confirmed that a XCI skewing may
influence on SMA phenotype. The skewed XCI in SMA
patients lead both to milder and severer phenotypes.
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Introduction: Archvillin, the muscle specific isoform of
supervillin encoded by the SVIL gene, is a large sarco-
lemmal protein. Despite an important role of supervillin in
muscle cell physiology has been suggested, no muscular
disease associated with SVIL mutations has been described.
We here report a new structural myopathy in four
individuals of two unrelated, consanguineous families
caused by biallelic loss-of-function mutations in SVIL.
Material and Methods: Patients were comprehensively
investigated clinically, and whole exome sequencing on
genomic DNA was performed in all affected individuals.
Skeletal muscle biopsies were morphological analyzed by
enzyme and immunohistochemical techniques and electron
microscopy.
Results: Affected patients share a distinctive phenotype
that includes a wide neck, anteverted shoulders, and a
prominent trapezius muscle together with variable contrac-
tures besides further skeletal and mild heart muscle
involvement. Muscle biopsies of both families demon-
strated complete loss of supervillin in muscle tissue by
western blot and immunohistochemical analyses. Compre-
hensive light and electron microscopical investigations of
muscle biopsies showed striking similarities between
patients and revealed a structural myopathy with prominent
lobulated type 1 fibers, myofibrillar disintegration and signs
of altered proteostasis and impaired autophagy.
Conclusions: The results underline the importance of
supervillin for the structural integrity of muscle fibers in
humans and show that recessive loss-of-function mutations
in SVIL cause a novel myopathy with distinct histological,
ultrastructural and clinical findings. Funding: This study
was supported by the Swedish Research Council to AO
(grant number 2018-02821) and by the German Research
Foundation (DFG) to IK (KU1587/4-1).
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Background: In Amyotrophic Lateral Sclerosis (ALS) and
Frontotemporal Dementia (FTD), TDP-43 proteinopathy
occurs in 97% of ALS cases and 45% of FTD patients.
Furthermore, missense mutations in the C-terminus of TDP-
43 are a genetic cause of ALS, emphasizing the crucial role
of this protein in the disease’s pathogenesis.
Objective: To identify and characterize the genetic cause
of an autosomal dominant slowly progressive neurogenic
myopathy in a large Belgian family.
Methods: Whole exome sequencing and segregation
analysis of candidate causal variants.
Results:We identified a novel causal 11bp deletion in the
TARDBP gene (c.1152_1162del) segregating with the
disease (2-point LOD-score of 2.4). The disease presented
as a slowly progressive neurogenic myopathy with an
average age-of-onset of 32 years (range: 18-40) and a
disease duration of >45 years. No family members showed
classical ALS or FTD pathology. Unlike previously
described classical ALS-causing mutations in TARDBP,
this mutation causes a frameshift that leads to an entirely
novel C-terminus. This region of the protein is key for the
formation of TDP-43 aggregates, therefore this novel
mutation provides a unique opportunity to dissect the
pathogenic role of TDP-43.
Conclusions: Since the molecular mechanisms respon-
sible for TDP-43 pathology remain fairly unknown,
unravelling the biophysical properties of TDP-43 aggrega-
tion is of utmost importance. Functional analysis this novel
and unusual TARDBP 11 bp deletion (c.1152_1162del)
using patient iPSC-derived neurons and Drosophila models
are ongoing.
Funding was obtained through following grants:
Odysseus Type I grant (G0H8318N), Research Foundation
Flanders (FWO) and Starting grant (01N10319), Ghent
University Special Research Fund
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Recessive TTN gene variants cause congenital myopathy
(CM) with variable presentation, progression and patholo-
gical features. Implementation of Next generation sequen-
cing (NGS) has enabled screening of the TTN gene in
routine diagnostic testing and is highlighting the consider-
able prevalence of this myopathy. The UK Highly Specia-
lised Service for CM started TTN analysis in 2016 as part of
a panel of genes associated with congenital myopathy. We
present results from 99 patients with TTN sequence variants.
In most cases other potentially relevant CM genes had been
excluded either prior to or at the same time as TTN analysis.
23 patient have homozygous/compound heterozygous
(likely) pathogenic variants which were confirmed to be in
trans in 13 patients. 21 patients had one or more missense
variants of uncertain significance in addition to a (likely)
pathogenic TTN variant, confirmed to be in trans in 16
patients. A further 13 patients had a heterozygous patho-
genic variant but a second causative variant was not iden-
tified. The remaining 42 patients had one (n = 18), two
(12), or more than three (4) variants of uncertain sig-
nificance. The high number of missense variants with
insufficient evidence to classify as likely pathogenic, even
in patients with strong clinical, pathological and MRI fea-
tures, means that functional characterisation of missense
variants is required and further investigation such as tran-
scriptome analysis is necessary to identify additional
pathogenic variants in in those patients with a single het-
erozygous pathogenic variant.
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Introduction: Myasthenia gravis (MG) is an autoimmune
disease characterised by female prevalence (3:1). Several
mechanisms were proposed as explanation of gender bias in
autoimmune diseases, including skewed X chromosome
inactivation (XCI) and X chromosome dosage, sex hor-
mones, and variants of genes involved in autoimmunity
development. Normally, XCI is a biological event that
occurs randomly, and females are thus functional mosaics
for the X-linked genes. A skewed XCI pattern can lead to an
unbalanced expression of certain X-linked alleles, for this
reason it has been hypothesized that females may be more
prone to certain diseases. Indeed, a high frequency of
skewed XCI pattern has been observed in several auto-
immune disorders characterized by female predominance.
No data are yet available concerning myasthenia gravis, so
that we investigated the XCI pattern in MG females with
this autoimmune disease.
Materials and Methods: XCI analysis was performed on
blood samples of 84 myasthenic women and 111 healthy
age-matched female controls. XCI was analysed by human
androgen receptor (HUMARA) assay.
Results: In 72 MG informative patients the frequency of
skewed XCI pattern (≥75%) was 35,0 %, which was higher
than in healthy controls (14,4%; p =0.002). Furthermore,
the prevalence of skewed pattern was observed mostly in
youngest patients (<50 years; p = 0.008), suggesting an
age-independent effect.
Conclusions: In this study, we observed preferential XCI
in MG female patients, this could suggest a potential role of
this mechanism in the disease etiology, and in the increased
prevalence of autoimmune disorders in females.
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YIF1B, an intracellular transmembrane protein, involves in
trafficking of molecules from the endoplasmic reticulum to
the Golgi apparatus in eukaryotic cells. Errors in such
transportation between the organelles can lead to human
diseases and implicated in nervous system disorders. Here,
we describe 6 patients from 5 unrelated families presenting
with progressive encephalopathy with various degrees of
mixed movement disorder, dysphagia, hypotonia, micro-
cephaly, and epilepsy. Common genetic errors found in all
these patients are homozygous truncating variants
(c.186dupT:p.Ala64fs; c.360_361insACAT:p.Gly121fs;
c.598G>T:p.Glu200*) in YIF1B. The genetic analysis was
carried out using whole exome sequencing. All affected
individuals shared a similar phenotypic features. The resi-
dues in the variants are highly conserved among different
species and were absent in publicly available databases such
as GnomAD. YIF1B is ubiquitously expressed molecule in
various tissues including neuronal cells and specifically in
raphe neurons. We performed computational structural
analysis of the variants. The modeling predicted that the
variants lead to unstructured molecules with loss of func-
tion. Our network and functional analyses revealed co-
regulation of 171 genes with YIF1B in over 46,000 human
RNAseq samples (r≥0.9). Our data indicates that disease
causing variants in YIF1B in humans lead to a novel neu-
rogenetic disorder. Additional studies are required to dis-
entangle the precise pathobiological mechanisms of this
autosomal recessive novel disease entity.
We are grateful to the patient families for their
participation. This research received intramural funds from
KFSHRC, grants from NSTIP/KACST (NK, DC), KSCDR
(NK), KAUST (STA), NARSAD (TSB). We extend our
special thanks to the funding agencies.
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P11 Multiple Malformation/Anomalies Syndromes
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Introduction: The 1q21.1 deletion/duplication syndrome is
associated to a variable clinical phenotype, characterized by
neurodevelopmental disorder, craniofacial dysmorphisms
and heart defects. The Thrombocytopenia Absent Radius
(TAR) syndrome is characterized by hypo-megakaryocytic
thrombocytopenia, radius agenesis with thumbs. This study
describes ten patients with 1q21.1 CNV including one
clinical TAR syndrome.
Material and Methods: An array-CGH (Agilent
4x180K) was performed in 1508 patients with different
indications.
Results: Ten CNVs in 1q21.1 region were identified, 6
pathogenic and 4 probably pathogenic. Nine patients
showed a variable clinical phenotype, autism spectrum
disorders (ASD), intellectual disability (ID), developmental
delay and craniofacial dysmorphisms, and a fetus with
radius agenesis; three CNVs included the deletion of
RBM8A gene, but only the fetus had clinical TAR.
Discussion/Conclusion: The presence of a CNV in the
1q21.1 region could represent a contiguous gene deletion/
duplication syndrome (autosomal dominant inheritance) or
TAR syndrome (autosomal recessive inheritance).In the
fetus with absent radius, the RBM8A gene sequencing
revealed no pathogenic coding variants, so further studies
will be performed to identify a second variant (intronic or
promotor regions) that could explain the TAR phenotype.In
1q21.1deletion patients the most common psychiatric
manifestation includes internalizing disorders. In 1q21.1-
duplications, ASD, attention deficit-hyperactivity disorder
and ID are the most common features. Our patients´ clinical
characterization and a comparison of the deletion versus
duplication phenotypes will be done in detail. This study
highlights the clinical usefulness of aCGH as a first-tier test
for evaluation of patients with neurodevelopmental dis-
orders and malformation syndromes.
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Introduction: The clinical heterogeneity in 22q11.2
deletion syndrome (22q11.2DS) might be caused by
complex mechanisms including variants in other regions
of the genome, known as genetic modifiers. Congenital
heart disease (CHD) is one of the most relevant phenotypes
and previous studies have shown that copy number variants
(CNVs) outside the 22q11.2 region could play a role in its
variable expressivity. However, those described loci
account for a small proportion of the variability. Therefore,
CNV analysis in new cohorts from different ancestry-based
population are a valuable resource to identify a wider range
of modifiers.
Materials and Methods: We performed SNP-array
(CytoScanHD) in 77 Brazilian patients with 22q11.2DS
(55 with CHD and 22 with normal cardiac phenotype).
Genome-wide CNV analysis was performed by two
algorithms (PennCNV and Rawcopy) and the overlapping
CNVs were considered for downstream analysis. The CNVs
content was annotated using AnnotSV and compared
between patients with and without CHD using Gene Set
Enrichment Analysis (GSEA).
Results: We identified 407 CNVs (308 deletions and 99
duplications). CNV-affected genes in patients with CHD
were enriched for pathways related to transition metal ion
binding, cytoskeleton and stabilization of membrane
potential. Some of these genes have been previously
associated to cardiac alterations (OTUD7A, DNAH5,
KIF6, EVC, KCNK17).
Conclusions: Further exploration of the genes in these
pathways could reveal new modifiers to the cardiac
phenotype in 22q11.2DS patients. This study will leverage
new insights to the understanding of genetic modifiers
involved in the expressivity of cardiac alterations in
22q11.2DS. Financial support: CAPES, FAPESP, Brazil.
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Introduction: Adams-Oliver syndrome (AOS) is a debili-
tating disorder of limb, scalp and vascular birth defects,
providing a unique window into the regulation of human
embryogenesis. AOS is considered to be a disorder of
vasculogenesis; however, this remains to be determined. We
have previously identified pathogenic mutations of the Rho
GTPase regulators ARHGAP31 and DOCK6, implicating
Rho dysregulation in AOS aetiology. Gain-of-function
ARHGAP31 mutations and DOCK6 loss-of-function
impact cytoskeletal dynamics through abnormal inactiva-
tion of Cdc42 and Rac1. Nonetheless, their role in human
blood vessel formation requires further exploration. Here,
we sought to generate in vitro and in vivo models of Rho
dysregulation to investigate the mechanism of vascular
disruption in AOS.
Materials and Methods: Rho GTPase dysregulation was
modelled in zebrafish embryos (Danio rerio) and human
vascular smooth muscle cells. Gene expression patterns
were assessed by quantitative PCR and whole-mount in situ
hybridisation. Gene knockdown was conducted using
splice-blocking morpholino oligonucleotides.
Results: Both genes were expressed in human vascular
smooth muscle cells and early stages of vascular develop-
ment in zebrafish. Whole-mount in situ hybridisation in
zebrafish embryos indicated arhgap31 and dock6 are
localised to the vasculature, ocular and cranial regions,
highlighting a correlation with the human phenotype.
Furthermore, dock6 morphant embryos displayed vascular
defects and microphthalmia, analogous to the clinical
features observed in DOCK6-related AOS.
Conclusions: Our preliminary results support a role for
ARHGAP31 and DOCK6 during vascular development.
Further interrogation of these models will broaden our
understanding of Rho GTPase biology in the vasculature
and the mechanisms driving AOS pathogenesis.
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Alkuraya-Kucinskas syndrome (ALKKUCS, OMIM
#617822) is a recently described, ultra-rare autosomal
recessive neurodevelopmental disorder characterized by
structural, cortical and parenchymal brain abnormalities,
global developmental delay/intellectual deficit and joint
contractures. The phenotypic spectrum of 15 previously
reported cases range from mild-to-moderate intellectual
deficit with microcephaly to a phenotype characterized by
severe ventriculomegaly and/or brainstem dysgenesis with
intrauterine or neonatal death. Only three children survived
till childhood. We here report two new ALKKUCS cases
from two unrelated consanguineous families. The first
patient was presented with antenatal ultrasound findings of
severe hydrocephaly, interhemispheric cyst, hydropic
changes with cystic hygroma and joint contractures. Pedi-
gree analysis showed two similarly affected siblings and
four affected cousins. Postmortem examination was com-
patible with a lethal contracture phenotype. Whole exome
sequencing (WES) revealed a ‘likely pathogenic’ homo-
zygous variant in the KIAA1109 gene. The second patient
was consulted at 9 years of age. She had a history of NICU
care due to poor sucking/weak swallowing reflex and car-
diac arrest in early neonatal period. Clinical findings
included mild myopathy of the neck muscles, pes equino-
varus, scapula alata and camptodactyly. Identification of a
homozygous variant in the KIAA1109 gene, segregating
with the phenotype, made the diagnosis of ALKKUCS
possible, placing the case to the mildest end of the pheno-
typic spectrum. Cases we here report highlights the power
of WES in identifying genetic etiopathogenesis of rare
disorders; and expand the phenotypic spectrum of
ALKKUCS.
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Severe scoliosis in the patient with a novel variant p.
Pro237ArgfsTer7 in the WDR45 gene
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Introduction: Mutations in the WDR45 gene have been
described as the cause of beta-propeller protein-associated
neurodegeneration (BPAN), an X-linked dominant disorder
with brain iron accumulation. It typically presents in early
childhood with global developmental delay, seizures and
autistic-like behavior. Following an initial static phase,
these symptoms progress to dystonia, parkinsonism and
dementia in early adulthood. We report a case with a novel
pathogenic variant in the WDR45 gene that exhibited an
early progression of symptoms and severe scoliosis which,
to our knowledge, has not been previously reported
in BPAN.
Case report: A 10-year-old girl is the second child of
healthy unrelated parents. At 14 months, developmental
delay was noted. She had autistic-like behavior, didn’t walk
until the age of 3-year and was mute. Seizures were never
noticed but EEG was abnormal. Her condition was stable
until the age of 7-year when her cognitive skills further
declined. In that time, scoliosis was noted together with
bradykinesia, rigidity and postural instability. Scoliosis was
severely progressive and needed surgical treatment. At the
age of 9-year she lost the ability to walk. Whole exome
sequencing revealed a novel heterozygous frameshift
pathogenic variant in the WDR45 gene p.Pro237ArgfsTer7,
verified by Sanger sequencing, that wasn’t present in either
parent. No other variants of studied genes associated with
scoliosis were identified.
Conclusions: Our case is a very rare example of BPAN
with severe scoliosis that might be due to a novel variant in
the WDR45 gene and thus expands the knowledge of the
phenotype-genotype correlation of BPAN.
N. Maric: None. J. Luna: None. M. Codina: None. L.
Armengol: None.
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4Abdullah Gul Universitesi, Doga Bilimleri Fakultesi,
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protrude from the apical aspect of the cells. They can be
either motile or immotile-sensory and play many distinct
roles in human development. Defective cilia lead to a group
of inherited, monogenic disorders referred as ciliopathies,
including disorders such as Bardet-Biedl syndrome, poly-
cystic kidney disease, Joubert syndrome, and nephro-
nophthisis. Here, we present homozygous CC2D1A
c.1186C>T (p.Arg396*) variant identified in our proband
with left renal cysts, autistic features and Mental Motor
Retardation (MMR), his sibling has also austictic features,
obesity and MMR, as a candidate ciliopathy gene. To
analyze the effect of CC2D1A in ciliogenesis, we utilized
the frog Xenopus and C.Elegans model systems. Xenopus
tadpole epidermis harbor numerous multiciliated cells that
generate head-to-tail polarized fluid flow. When we
knocked down CC2D1A in frog Xenopus tropicalis using
CRISPR/CAS9 system, and analyzed epidermal flow using
Optical Coherence Tomography Imaging, we observed loss
of epidermal flow in F0 mutant tadpoles. When we further
examined the epidermal surface in these tadpoles using
immunofluorescence, we detected the loss of multiciliated
cells. In parallel, we also showed the loss of cilia in C.
Elegans CC2D1A knock-out model utilizing the CRISPR/
Cas9 system. Together, this work demonstrates that
CC2D1A is required for proper ciliogenesis in multiciliated
cells, providing a plausible mechanism for its role in our
patient phenotype. <!--EndFragment-->
I. Sakin: None. G. Tuncel: None. S. Ozemri sag: None.
O.I. Kaplan: None. M.K. Khokha: None. M.C. Ergoren:
None. E. Deniz: None. S.G. Temel: None.
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Chitayat syndrome: a rare but potentially underdiag-
nosed condition ?
C. Mueller-Hofstede1, A. Tewes1, J. Horvath1, F. Rutsch2,
A. Bohring1
1Institut für Humangenetik, University Hospital, Muenster,
Germany, 2Klinik für Kinder- und Jugendmedizin, Allge-
meine Pädiatrie, University Hospital, Muenster, Germany
We report on a ten months old boy, third child of non-
consanguineous parents. The pregnancy was uncomplicated
without ultrasound abnormalities. Body measurements were
in the normal range. Bowed hands and feet with bilateral
shortened and ulnar deviated index fingers, additional bone
nuclei of digits II / III of both hands and clinodactyly of
digiti II, III, IV were noticed. The feet showed bilateral
hallux valgus. Neonatal respiratory distress required initi-
ally high-flow oxygen therapy.
At presentation the boy showed a pectus excavatum and
mild facial dysmorphism (hypertelorism, broad nasal
bridge, short columella) in addition to the above-
mentioned abnormalities. The general development was
age-appropriate.
Due to the combination of the symptoms Chitayat
syndrome has been considered. Sequence analysis identified
the de novo heterozygous variant c.266A>G (p.(Tyr89Cys))
in the ERF-gene.
Chitayat et al. first described 1993 a patient with
hyperphalangism, brachydactyly, bronchomalacia and facial
anomalies. Since then, only 6 other patients have been
described in literature. In 2016 the recurrent variant
c.266A>G (p.(Tyr89Cys)) in the ERF-gene was identified
as the underlying molecular cause.
Heterozygous mutations (predominantely loss-of-func-
tion) in the ERF-gene are described in syndromal
craniosynostosis 4. The above-mentioned variant has not
yet been described in this context. This could indicate, that
the variant may have a different influence on protein
function and potentially leads to a gain-of-function.
We suggest that the rare condition of Chitayat syndrome
should always be considered in children with the combina-
tion of characteristic skeletal abnormalities of the hands and
feet especially hyperphalangism with respiratory distress.
C. Mueller-Hofstede: None. A. Tewes: None. J.
Horvath: None. F. Rutsch: None. A. Bohring: None.
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Isolated familial choanal atresia: a new entity in the
phenotypic spectrum of KMT2D gene
A. Garde1,2, F. Tran Mau-Them2, S. Nambot1,2, M. Fradin3,
S. Odent3, Y. Duffour2, S. Banka4, C. Philippe2, C. Thauvin-
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Anomalies du Développement, Université de Bourgogne,
Dijon, France, 3Service de Génétique Clinique, IGDR
(Institut de Génétique et développement de Rennes) (S.O.),
CHU de Rennes, Rennes, France, 4Division of Evolution
and Genomic Sciences, School of Biological Sciences,
Faculty of Biology, Medicine, and Health, The University of
Manchester, Manchester, United Kingdom
Introduction: Loss of function variants in KMT2D can be
responsible of Kabuki syndrome type 1 (KS1). Recently,
missense variants in exon 38 or 39 in KMT2D have been
found in patients presenting a new phenotype with multiple
malformations distinct from KS1, including choanal atresia
and absence of intellectual disability. Choanal atresia (CA)
is a congenital disorder characterized by a bony or mem-
branous septum between the nose and nasopharynx. CA can
occur as an isolated form or in syndromic presentations.
Patients and Method: A newborn girl was referred to
our medical department because of choanal atresia. Given
the fact that 8 members of the family spreading across 3
generations had non-syndromic choanal atresia, we decided
to perform exome sequencing (ES) in our patient and one
cousin, the most distant affected relative.
Results: In 2014, ES was first concluded as negative.
Following the publication entitled “A restricted spectrum of
missense KMT2D variants cause a multiple malformations
disorder distinct from Kabuki syndrome” (Cuvertino et al.,
2020), we interrogated our database for missense variants in
exons 38-39 of KMT2D. We identified a p.Glu3569Gly, in
exon 38, segregating with choanal atresia in the family. One
obligate carrier did not present choanal atresia, suggesting
incomplete penetrance. Prediction scores are in favor of the
pathogenicity and functional analyses have been proposed.
Conclusions: Considering these results and the recent
literature, we suggest that missense variants in exon 38 of
KMT2D can be responsible of even milder phenotypes such
as isolated choanal atresia.
A. Garde: None. F. Tran Mau-Them: None. S.
Nambot: None. M. Fradin: None. S. Odent: None. Y.
Duffour: None. S. Banka: None. C. Philippe: None. C.
Thauvin-Robinet: None. L. Faivre: None.
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Chromatinopathies: clinical hypothesis versus molecular
diagnosis
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Sinibaldi, M. Dentici, M. Digilio, A. Novelli
Laboratory of Medical Genetics, Medical Genetics, Bam-
bino Gesù Pediatric Hospital, Rome, Italy
Introduction: Defects of the structural or regulatory com-
ponents of cohesin lead to various multisystem malforma-
tion syndromes described as “cohesinopathies”, that share
clinical findings such as distinctive facial features, growth
retardation, intellectual disability and limb abnormalities.
Moreover, in patients presenting classical and non-classical
features of cohesinopathies were identified pathogenic
variations in key chromatin-associated factors, genetically
different from cohesin, but with overlapping functions, such
as transcriptional regulation, chromatin remodeling and
epigenetic modifications; these conditions could be con-
sidered part of a larger disease family categorized as
“chromatinopathies”.
Materials and Methods: Between 2017 and 2018, 40
cohesinopathies/chromatinopathies patients carrying hetero-
zygous pathogenic variants have been diagnosed at the
Bambino Gesù Children Hospital, with initial clinical
hypothesis of KBG syndrome, CHARGE association,
Kabuki syndrome, Cornelia de Lange syndrome and
Coffin-Siris syndrome. A custom Chromatinopathies NGS
panel was used to analyze genes associated with these
syndromes.
Results: In 22.5% of cases molecular defects causing
phenotypic conditions different from the initial clinical
hypothesis were identified in other genes coding for
cohesin, transcriptional regulators, chromatin-associated
protein complex and its interactors, such as MBD5
(OMIM:611472), BRD4 (OMIM:608749), SOX11
(OMIM:600898), SMARCA2 (OMIM:600014), KDM5C
(OMIM:314690), KMT2A (OMIM:159555) and MECP2
(OMIM:300005).
Conclusions: Because of phenotypic overlap among
chromatin disorders, clinical diagnosis of these patients is
often challenging or rather impossible without genetic
evidence. In our cohort, the high rate of positive cases not
matching with the first clinical suspect suggests that broad
spectrum molecular analysis is crucial to reach accurate
diagnosis and will probably led to the identification of
additional genotype-phenotype associations.
C. Cesario: None. M. Gnazzo: None. E. Pisaneschi:
None. R. Capolino: None. L. Sinibaldi: None.M. Dentici:
None. M. Digilio: None. A. Novelli: None.
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Phenotype-genotype analysis in a large cohort of 250
individuals with a chromosome 6q deletion
A. Engwerda1, S. E. Meijer1, P. Bouman2, N. F. Simoes de
Souza1, B. Frentz3, B. C. T. Flapper4, N. Corsten-Janssen1,
E. H. Gerkes1, M. A. Swertz1, M. Plantinga1, T. Dijkhuizen1,
W. S. Kerstjens-Frederikse1, C. M. A. van Ravenswaaij-
Arts1
1University of Groningen, University Medical Centre
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lands, 2Facebook contact parent, Chromosome 6 Facebook
group, Utrecht, Netherlands, 3Vanboeijen, Assen, Nether-
lands, 4University of Groningen, University Medical Centre
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Chromosome 6q deletions are rare and little is known about
their phenotypical consequences. Parents of children with
such a deletion search the internet and unite in international
social media platforms. A successful collaboration with the
Chromosome 6 Facebook group allowed us to collect data
of 109 newly identified individuals.
Families can sign up for the study via the secured
project’s website by uploading the proband’s array report.
Phenotype data is collected directly from the individuals or
parents via an online multilingual questionnaire. Literature
case reports are added to the database using the same
questionnaire. Up till January 2020 this resulted in a total of
250 individuals.
Subgroups are made based on the predicted haploinsuffi-
ciency genes within the deletions, leading to detailed
phenotype descriptions for 18 subgroups thus far.
Gastroesophageal reflux, trachea/laryngo/bronchomala-
cia, congenital heart defects, cerebral defects, seizures and
vision and respiratory problems are predominant in
6q14.2q15 deletions. In contrast, 6q11q14.1 deletions
present less severe clinical characteristics.
Deletions including the gene TAB2 (6q25.1) are char-
acterized by facial dysmorphisms, short stature, heart
defects and connective tissue problems and resemble a
Noonan-like syndrome.
Within the 6q25.2q25.3 region ARID1B plays a promi-
nent role, resulting in a Coffin-Siris syndrome phenotype
when deleted.
Terminal 6q26q27 deletions are characterised by micro-
cephaly, hypotonia, balance problems, vision problems,
seizures and brain abnormalities. Deletions including
PARK2 presented with more severe developmental delay.
In conclusion, social media are instrumental in collecting
large numbers of detailed data on rare chromosome
aberrations, resulting in a more precise description of the
phenotypic spectrum.
A. Engwerda: None. S.E. Meijer: None. P. Bouman:
None. N.F. Simoes de Souza: None. B. Frentz: None. B.
C.T. Flapper: None. N. Corsten-Janssen: None. E.H.
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Cilium Phenotyping using patient-derived cells to
accurately diagnose ciliopathies
M. M. Oud1,2, R. van Beek1,2, C. van Manen1,3, D.
Lugtenberg1, E. M. H. F. Bongers1, R. Roepman1,3, H.
Yntema1, L. E. L. M. Vissers1,2
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Introduction: Cilia are small signaling organelles pro-
truding from the cell membrane of nearly every vertebrate
cell. Ciliary dysfunction leads to rare recessive multiorgan
disorders, collectively termed ciliopathies, which have
overlapping genotype-phenotype correlations, making
accurate diagnosis challenging. Our aim is to develop a
novel cell-based functional assay to improve accurate
diagnosis of ciliopathies on the basis of the underlying
mechanism of disease.
Materials and Methods: Skin-fibroblasts from 10
ciliopathy patients (from 3 different subgroups) and 8
controls were cultured in vitro and immunofluorescence was
applied to determine cilium phenotype parameters; 1)
ciliogenesis, based on presence or absence of cilium
markers, 2) cilium length, measured by the combined
signal of an axonemal and a cilium membrane marker, and
3) intraflagellar transport (IFT), quantified by the area of the
ciliary tip using the IFT88 signal.
Results: Cilium phenotypic data from skin-fibroblasts of
eight controls yielded comparable and reproducible results:
88% cells were ciliated, the cilium length was
3.30 ± 0.251μm, and the IFT88 ciliary tip area was
0.13 ± 0.02μm2. Analysis of the cilium phenotype in the 10
patients for three clinical subgroups not only showed
significant differences in cilium length and IFT results, but
also allowed to distinguish the three ciliopathy subgroups
from one another.
Conclusions: In summary, standardized analysis of the
cilium phenotype can lead to identifiable clusters for
different ciliopathies. Therefore, we believe that standar-
dized tests based on cilium phenotypic data can provide
additional proof for conclusive diagnosis of ciliopathies,
which is essential in routine diagnostic care.
M.M. Oud: None. R. van Beek: None. C. van Manen:
None. D. Lugtenberg: None. E.M.H.F. Bongers: None. R.
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Clinical and diagnostic implications of whole-genome
sequencing (WGS) of 42 patients affected by rare
diseases: the first Italian experience on a diagnostic
basis.
F. Sirchia1, D. Carli2, E. Giorgio2, L. Sorasio3, F. Faletra1,
A. Fabretto1, F. Guidolin4, V. Antona5, J. Belmont6, J.
Ortega6, R. Taft6, A. Scocchia6, G. Ferrero2, P. Gasparini1,
A. Brusco2
1IRCCS Burlo Garofalo di Trieste, Trieste, Italy, 2Univer-
sity of Turin, Torino, Italy, 3Santa Croce e Carle Hospital,
Cuneo, Italy, 4University of Padova, Padova, Italy, 5Uni-
versity of Palermo, Palermo, Italy, 6Illumina Inc., San
Diego, CA, United States
We report the collaboration between the Medical Genetics
Units in Torino and Trieste with the Illumina Company in a
diagnostic setting by trio-WGS. We selected 42 complex
pediatric patients <16 years with normal CGH/SNP-arrays
without recognizable genetic disorders. We found a certain
molecular diagnosis in 26 (62%; ultrarare genes in the lit-
erature were ASXL1, ASXL3, CSNK2A1, DDX3X, DYRK1A,
FLNA, HIPEV2, LMNA, NFIX, PACS1, PDE4D, PDHA1,
PIGA, PIEZO2, PIGO, RRM2B, SATB2, SETBP1, SRCAP
and TUBB3). Three cases (3/26, 11.5%) had two diseases,
and 3 further could potentially be double diagnoses. A
mosaic chr 9 trisomy (not previously identified by array-
CGH) and a mat-UPD1 were also identified. In 21/26 (81%)
the disease was associated with a de novo, highlighting the
importance of trio analysis; in 1 patient the disease was
inherited from the affected mother (ANKRD11, KBG syn-
drome). One or more VUSs were found in 5/43 (11.5%)
patients. SNVs were in the coding region/nearby intron
suggesting our high diagnostic rate may be related to a more
complete coverage of WGS versus exome, and/or our
intertwined bioinformatics and clinical prioritization of
variants. The diagnosis changed the management of all
positive cases, including referral to palliative cures
(RRM2B; mtDNA depletion syndrome), referral for a spe-
cific follow-up, or cancer surveillance program (ASXL1).
We provided a correct recurrence risk for future pregnancies
for parents, including a consanguineous couple with a de
novo causative variant in their child. In conclusion, we
show how WGS can dramatically increase our ability to
reach a genetic diagnosis in undiagnosed cases.
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A case with complex small supernumerary marker
chromosome consisting 19p and 22q
S. Altiner, N. Yürür Kutlay
Ankara University School of Medicine, Department of
Medical Genetics, Ankara, Turkey
Introduction: Complex small supernumerary marker
chromosomes (sSMC) consist of chromosomal material
derived from more than one chromosome (Liehr et al.,
2013). Here, we describe a complex sSMC derived from a
maternal translocation between chromosomes 19p and 22q
in a patient with intellectual disability and short stature.
Materials and Methods: G-banding, FISH, and micro-
array were performed in order to define sSMC.
Results: The patient presented with a complex sSMC
derived from a 3:1 segregation of a maternal balanced t
(19;22)(p13;q11) reciprocal translocation and resulting in
tertiary trisomy of 19p13.3 and 22q11.1q11.21.
Conclusions: Genotype-phenotype correlation and
assigning a specific feature to an aberration are often
difficult in cases with combined partial trisomies. Besides,
numerical and structural abnormalities involving chromo-
some 19 is relatively rare compared to other chromosomes.
In comparison to patients with similar aberrations, our
patient showed a phenotype similar to 19p13.3 duplication,
regarding intellectual disability and growth retardation
(Orellana et al., 2015). This is the first complex sSMC
originating from chromosome 19 and 22. Functional
analysis of the genes in these regions may provide a better
explanation about the gene-dosage effects on the phenotype.
References Liehr, T., Cirkovic, S., Lalic, T., Guc-Scekic,
M., de Almeida, C., Weimer, J., et al. (2013). Complex
small supernumerary marker chromosomes - an update.
Mol. Cytogenet. 6, 46. Orellana C, Roselló M, Monfort S,
Mayo S, Oltra S, Martínez F. (2015). Pure duplication of
19p13.3 in three members of a familyintellectual disability
and literature review. Definition of a new microduplication
syndrome. Am J Med Genet A. 167:1614-20.
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Clinical and molecular description of 202 cases of
Cornelia de Lange Syndrome and differential diagnoses
G. VERA, A. Goldenberg, F. Lecoquierre, N. Drouot, K.
Cassinari, F. Charbonnier, S. Coutant, O. Quenez, T.
Frebourg, G. Nicolas, P. Saugier-Veber
Rouen University Hospital, Department of Genetics, F
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France
Introduction: Cornelia de Lange Syndrome (CdLS) is a
multisystem disorder characterised by growth retardation,
microcephaly, dysmorphism, hypertrichosis, limb and organ
malformations, feeding difficulties, and neurodevelop-
mental disorder. Clinical heterogeneity is illustrated by
variable severity and atypical cases overlapping with some
other syndromes. Mutations in 6 genes from the cohesin
complex can cause CdLS: NIPBL, SMC1A, HDAC8, SMC3,
RAD21 and BRD4. We present results from a retrospective
study of 202 cases referred between 2011 and 2019.
Methods: Clinical data were reviewed by an expert
clinician before molecular testing. Phenotypes were classi-
fied as typical/mild/atypical CdLS or another diagnosis. We
applied a clinical score for all suspected CdLS cases, and
compared values per molecular outcome and phenotype. A
gene panel sequencing assessed 5/6 CdLS and 17
differential diagnoses genes (~700x depth of coverage on
average).
Results: Differential diagnoses were suspected for 23
individuals. CdLS was suspected for 179 individuals: 66
typical, 40 mild and 73 atypical. Molecular testing
identified a (likely) pathogenic variant for 47/66 typical
(71%), 18/40 mild (45%), and 14/73 atypical (19%)
individuals confirming CdLS for 73 of them. A differential
diagnosis was identified for 6 atypical individuals. We
identified 11 mosaic mutations with variable phenotypes; 9
were detected in saliva and were undetectable in blood.
Clinical scores were significantly higher for typical
individuals and for pathogenic variants carriers.
Conclusions: Applying deep gene panel sequencing from
other tissues than blood is an effective strategy for typical
CdLS given the number of mosaics, while atypical
phenotypes could be resolved by first-tier exome/genome
sequencing.
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Identifying Cornelia de Lange Syndrome by facial
phenotypes using Face2Gene
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Introduction: DeepGestalt technology, and its app Face2-
Gene, is having a growing impact on the diagnosis and
management of genetic diseases by analysing the features of
affected individuals. This is of particular interest for Cor-
nelia de Lange syndrome (CdLS), in which heterogeneity in
clinical presentation and phenotype overlap with different
syndromes, and the still widely unknown molecular
pathomechanisms makes its diagnosis challenging for pae-
diatricians. Here, we performed a phenotypic study on a
cohort of 49 individuals harbouring causative variants in
known CdLS genes in order to evaluate Face2Gene utility
and sensitivity in the clinical diagnosis of CdLS.
Material and Methods: We analysed the frontal images
of all individuals using Face2Gene technology. All
individuals with CdLS were subjected to molecular analysis
by next generation sequencing. The CdLS clinical score was
computed by trained physicians according to the interna-
tional consensus criteria of CdLS.
Results: Based on the profile images of patients, a
diagnosis of CdLS was within the top five predicted
syndromes for 97.9% of our cases and even listed as first
prediction for 83.7%. The age of patients did not seem to
affect the prediction accuracy, whereas our results indicate a
correlation between the clinical score and affected genes.
Furthermore, each gene presents a different pattern
recognition that may be used to develop new neural
networks with the goal of separating different genetic
subtypes in CdLS.
Conclusions: Overall, we conclude that computer-
assisted image analysis based on deep learning could
support the clinical diagnosis of CdLS.
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Almeida1, S. Maia1,3, C. F. Reis4, J. Sá1,3
1Medical Genetics Unit, Centro Hospitalar e Universitário
de Coimbra, Coimbra, Portugal, 2Medical Genetics Unit -
Hospital de Braga (former worker of Medical Genetics
Unit, Centro Hospitalar e Universitário de Coimbra),
Braga, Portugal, 3University Clinic of Genetics, Faculty of
Medicine - Universidade de Coimbra, Coimbra, Portugal,
4Medical Genetics Unit, Centro Hospitalar e Universitário
do Porto (former worker of Medical Genetics Unit, Centro
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Introduction: Cornelia de Lange Syndrome (CdLS) is a
heterogeneous genetic disorder best known for its dis-
tinctive craniofacial features of microbrachycephaly,
highly-arched eyebrows, synophrys and anteverted nares, as
well as upper-limb defects, growth retardation, intellectual
disability and hirsutism. Five genes have been identified but
only 4% of cases are associated with HDAC8, in contrast to
60% associated with NIPBL gene. Variants in HDAC8
present themselves with phenotypical differences from the
classical-CdLS, therefore having no evident clinical diag-
nose. In the past 3 years, with whole exome sequencing
(WES), we identified three cases of HDAC8 CdLS,
including a long-term accompanied, yet undiagnosed, 20
year old girl.
Cases report: Three girls were studied due to develop-
ment disorder and multiple dysmorphologies not resem-
bling of any particular syndrome. After initial inconclusive
analysis, further testing with WES found that each one
presented a variant in the HDAC8 gene, one already known
and classified as pathogenic, and two unknown classified as
likely pathogenic. The next table lists some alterations
usually linked to HDCA8-CdLS and found in our patients.
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Patient 1 Patient 2 Patient 3
Age of first
evaluation
10 years 5 months 3 years
Age of diagnosis 20 years 35 months 10 years
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30 months 18 months 24 months
Hirsutism Yes No No
Conclusions: These cases enlighten the heterogeneity of
phenotypes and the clinical diagnostic challenge regarding
syndromes in the spectrum of a very well-known pathology.
It also shows how the evolution of genetical tests now
allows us to finally attribute a “name” and a better follow-
up to some of our long-term undiagnosed patients.
M.S. Santos: A. Employment (full or part-time);
Significant; Centro Hospitalar e Universitário de Coimbra.
S. Fernandes: A. Employment (full or part-time); Sig-
nificant; Centro Hospitalar e Universitário de Coimbra. M.
Lopes-de-Almeida: A. Employment (full or part-time);
Significant; Hospital de Braga. P.M. Almeida: A. Employ-
ment (full or part-time); Significant; Centro Hospitalar e
Universitário de Coimbra. S. Maia: A. Employment (full or
part-time); Significant; Centro Hospitalar e Universitário de
Coimbra. C.F. Reis: A. Employment (full or part-time);
Significant; Centro Hospitalar e Universitário do Porto. J.
Sá: A. Employment (full or part-time); Significant; Centro
Hospitalar e Universitário de Coimbra.
P11.26.B
A homozygous missense variant inTUBGCP2alter the g-
tubulin ring complex leading to abnormal cortical
development, pontocerebellar atrophy and altered
myelination
Y. Oktay1,2,3, S. Gungor4, S. Hiz5, A. Yaramis6, Á.
Aranguren-Ibáñez7, U. Yis5, E. Sonmezler2, E. Yilmaz2, B.
Ekinci2, M. Aslan4, S. Balaraju8, N. Szabo9, S. Laurie10, S.
Beltran10, D. Hathazi9, D. MacArthur11, A. Roos12, H.
Lochmuller13, I. Vernos14, R. Horvath9
1Izmir Biomedicine and Genome Center (IBG), Izmir,
Turkey, 2Izmir International Biomedicine and Genome
Institute, IBG-izmir, Dokuz Eylul University, Izmir, Turkey,
3Dept. of Medical Biology, Faculty of Medicine, Dokuz
Eylul University, Izmir, Turkey, 4Inonu University, Faculty
of Medicine, Turgut Ozal Research Center, Department of
Paediatric Neurology, Malatya, Turkey, 5Dokuz Eylul
University, Faculty of Medicine, Department of Pediatric
Neurology, Izmir, Turkey, 6Pediatric Neurology Clinic,
Diyarbakir Memorial Hospital, Diyarbakir, Turkey, 7Cen-
tre for Genomic Regulation (CRG), The Barcelona Institute
of Science and Technolog, Barcelona, Spain, 8John Walton
Muscular Dystrophy Research Centre, Institute of Transla-
tional and Clinical Research, Newcastle University, New-
castle upon Tyne, United Kingdom, 9Department of Clinical
Neurosciences, John Van Geest Cambridge Centre for
Brain Repair, University of Cambridge School of Clinical
Medicine, Cambridge, United Kingdom, 10CNAG-CRG,
Centre for Genomic Regulation, Barcelona Institute of
Science and Technology, Barcelona, Spain, 11Analytic and
Translational Genetics Unit, Massachusetts General Hos-
pital, Boston, MA, United States, 12Leibniz Institut für
Analytische Wissenschaften, ISAS, Dortmund, Germany &
Pediatric Neurology, University Hospital, University of
Duisburg-Essen, Faculty of Medicine, Essen, Germany,
13Children’s Hospital of Eastern Ontario Research Insti-
tute; Division of Neurology, Department of Medicine, The
Ottawa Hospital; and Brain and Mind Research Institute,
University of Ottawa, Ottawa, ON, Canada, 14Centre for
Genomic Regulation (CRG), The Barcelona Institute of
Science and Technology, Barcelona, Spain
Microtubules are long fibers made of protofilaments of α-
and β-tubulin heterodimers. Microtubule organizing centers
are protein complexes composed of several proteins form-
ing the γ-tubulin ring complex or γ-TuRC that directly
drives MT nucleation. By whole exome sequencing we
identified a novel homozygous variant in exon 8 of
TUBGCP2(NM_001256617.1:c.1015G>A, p.Glu339Lys),
which encodes γ-TuRC component GCP2 protein, in two
siblings (10 yo female and 8 yo male) from a con-
sanguineous Turkish family. Although TUBGCP2 muta-
tions were recently reported in families with developmental
delay, dysmorphic features, hypotonia, epilepsy,
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microcephaly and lissencephaly spectrum changes, we for
the first time investigated the cellular defects caused by
GCP2 mutations in patient fibroblasts by immunocyto-
chemical, proteomic and in silico analyses. We studied the
localization of some γ-TuRC components and associated
proteins in control and patient fibroblasts in interphase and
in mitosis by immunofluorescence, and the levels of the
GCP2 protein along the cell cycle. Our data suggested that
the localization of γ-TuRC complex was perturbed in
mitosis but not in interphase. Label-free LC-MS/MS ana-
lysis of patient-derived fibroblasts identified 26 upregulated
and 24 down-regulated proteins, which were enriched for
tubulin and cytoskeletal proteins that play role in neurode-
velopment. In summary, we describe two siblings carrying a
novel homozygous TUBGCP2 variant with dysmorphic
signs, severe developmental delay and epilepsy, and show
that, in addition to a neuronal migration defect, brainstem
atrophy and disturbed myelination are also associated with
TUBGCP2 mutations, explaining the variable clinical and
imaging findings. *TUBITAK research grant 216S771,
Newton Fund (UK/Turkey, MR/N027302/1), AFM #21644.
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Yaramis: None. Á. Aranguren-Ibáñez: None. U. Yis:
None. E. Sonmezler: None. E. Yilmaz: None. B. Ekinci:
None. M. Aslan: None. S. Balaraju: None. N. Szabo:
None. S. Laurie: None. S. Beltran: None. D. Hathazi:
None. D. MacArthur: None. A. Roos: None. H.
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P11.28.A
Clinical & genetic characteristics of syndromes asso-
ciated with craniosynostosis
M. Danila1, M. Tonu1, M. Panzaru2,3, L. Butnariu2,3, R.
Popescu2,3, C. Banescu4, I. Resmerita3, E. Gavril3, E. V.
Gorduza1,3, C. Rusu2,3
11. "Cuza-Voda" Obstetrics and Gynecology Hospital, Iasi,
Romania, 22. “Saint Mary” Emergency Children’s Hospital
- Regional Medical Genetics Centre, Iasi, Romania, 33.
“Grigore T. Popa” University of Medicine and Pharmacy -
Department of Medical Genetics, Iasi, Romania, 44.
Clinical County Emergency Hospital, Targu Mures,
Romania
Craniosynostosis represents a premature fusion of one or
more cranial sutures leading to secondary distortion of skull
shape resulting in skull deformities with a variable pre-
sentation. Craniosynostosis may occur in an isolated setting
or as part of a syndrome. FGFR2, FGFR3, FGFR1, TWIST1
and EFNB genes are major causative genes of genetic
syndromes with craniosynostosis. Our aim was to investi-
gate the clinical and genetic aspects for the patients
recorded with craniosynostosis in the files of the Iasi
Regional Medical Genetics Center for the last 15 years. For
each case we have studied clinical features to highlight the
evocative signs for diagnosis and to establish the correlation
with the laboratory results. In all patients we applied ima-
gistic investigations (RX or CT) that was concordant with
craniosynostosis types. We identified 99 patients suspected
for craniosynostosis. From these, 84 presented an isolated
form of craniosynostosis, while 15 patients had a syndromic
form (Apert, Saethre-Chotzen, Crouzon, Carpenter syn-
dromes). We investigated 15 patients with syndromic forms
of craniosynostosis by MLPA analysis using kit P064 and
P080 (MRC Holland®). We identified the mutation in
TWIST1 gene associated with Saethre-Chotzen syndrome in
4 patients. Another mutation was detected in FGFR2 gene,
being discovered in a case of Apert syndrome. In familial
cases we accorded genetic counselling in concordance with
results of molecular analyses and we discussed the possi-
bility of surgical therapy. Our cases illustrate the genetic
heterogeneity among cranyosinostosis syndromes. Mole-
cular diagnosis is very important for an adequate genetic
counseling and guidance for patients with syndromic
craniosynostosis.
M. Danila: None. M. Tonu: None. M. Panzaru: None.
L. Butnariu: None. R. Popescu: None. C. Banescu: None.
I. Resmerita: None. E. Gavril: None. E.V. Gorduza:
None. C. Rusu: None.
P11.29.B
The clinical features of individuals of Menke-Hennekam
syndrome
E. Nishi1, K. Ueda1, F. Miya2, K. Yanagi3, S. Mizuno4, T.
Kaname3, K. Kosaki5, N. Okamoto1
1Department of Medical Genetics, Osaka Women’s and
Children’s Hospital, Osaka, Japan, 2Department of Med-
ical Science Mathematics, Medical Research Institute,
Tokyo Medical and Dental University, Tokyo, Japan,
3Department of Genome Medicine, National Research
Institute for Child Health and Development, Tokyo, Japan,
4Department of Clinical Genetics, Aichi Developmental
Disability Center Central Hospital, Kasugai, Japan, 5Cen-
ter for Medical Genetics, Keio University School of
Medicine, Tokyo, Japan
Menke-Hennekam syndrome-1 (MKHK1) is a congenital
disorder characterized by variable impairment of intellectual
development, feeding difficulties, autistic behavior, hearing
impairment, short stature, microcephaly, and facial dys-
morphisms [Menke et al., 2016; Menke et al., 2018].
MKHK1 is caused by heterozygous mutation in exon 30 or
31 of CREBBP (OMIM 600140). CREBBP mapped
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16p13.3 encodes CREB-binding protein, the heterozygous
loss of function variants are well-known causes of
Rubinstein-Taybi syndrome Type 1 (RSTS1, OMIM
180849) which is characterized by developmental delay,
mild to moderate intellectual disability, short stature,
microcephaly, broad thumbs, broad halluces, and facial
dysmorphism including highly arched eyebrows, long eye-
lashes, downslanting palpebral fissures, broad nasal bridge,
beaked nose with the nasal septum, highly arched palate,
mild micrognathia [Hennekam, 2006; Petrij et al., 1995].
The clinical features included facial characteristics of indi-
viduals of MKHK1 are developmental delay or intellectual
disability, short stature, microcephaly, short palpebral fis-
sures, telecanthus, depressed nasal bridge, short nose,
anteverted nares, short columella, and long philtrum.
Although both syndromes have variants in the same gene,
CREBBP, the phenotype of individuals with MKHK1 are
differed substantially from phenotype of RSTS1[Menke
et al., 2016; Menke et al., 2018]. Here we report four further
individuals with de novo pathogenic variants, affecting the
last amino acids of exon 31 of CREBBP. One has a
recurrent variant, and the othes have novel variants
including two nonsense variants. All of them did not
recognize the characteristics of RSTS like broad thumbs,
but rather shared the clinical features of MKHK1.
E. Nishi: None. K. Ueda: None. F. Miya: None. K.
Yanagi: None. S. Mizuno: None. T. Kaname: None. K.
Kosaki: None. N. Okamoto: None.
P11.31.A
Two different de novo mutations causing syndromic
developmental delay in two patients from a consangui-
neous Turkish family
L. Castilla-Vallmanya1, S. Acar2, Ö. Giray-Bozkaya3, A.
Prat1, M. Centeno1, A. Carbonell-Roqué1, R. Martínez-
Cabrera1, R. Rabionet1, D. Grinberg1, S. Balcells1, R.
Urreizti1
1Department of Genetics, Microbiology and Statistics,
Faculty of Biology, University of Barcelona, IBUB, IRSJD,
CIBERER, Barcelona, Spain, 2Department of Pediatric
Genetics, Dr. Behcet Uz Children’s Hospital, Izmir, Turkey,
3Department of Pediatric Genetics, Dokuz Eylül University,
Izmir, Turkey
Introduction: We present a Turkish family with two cou-
sins (OC15 and OC15b) affected with syndromic develop-
mental delay, microcephaly and trigonocephaly but with
some phenotypical traits distinct between them.
OC15 showed asymmetrical skeletal defects and syndac-
tyly, while OC15b presented with a more severe micro-
cephaly and semilobal holoprosencephaly. All four
progenitors were related (the two mothers being sisters and
the two fathers being cousins once removed). Additionally,
OC15 parents were consanguineous (again cousins once
removed).
Material and Methods: WES analysis of patient OC15
was performed as a singleton inside the URD-Cat project.
The OC15b trio was sequenced at the National Center of
Genomic Analyses (CNAG; Barcelona, Spain). Selected
variants were validated by Sanger sequencing.
Results:We did not identify any shared variant that could
be associated with the disease. Instead, each patient
presented a de novo heterozygous variant in a different
gene. OC15 carried a nonsense mutation in PORCN (p.
Arg95*), a gene responsible for Goltz-Gorlin syndrome,
while OC15b carried an indel mutation in ZIC2 leading to
the substitution of 3 residues by a proline (p.His404_-
Ser406delinsPro). Autosomal dominant mutations in ZIC2
have been associated with holoprosencephaly 5. Both
variants are absent in the general population and are
predicted to be pathogenic.
Conclusions: These two de novo heterozygous variants
identified in the two patients seem to explain the major
phenotypic alterations of each particular case, instead of a
homozygous variant that would be expected by the
underlying consanguinity.
Funding: Associació Síndrome Opitz C, Spain; Spanish
MINECO (SAF2016-75948-R, FECYT-PRECIPITA); Cat-
alan Government (PERIS SLT002/16/00174); CIBERER
(U720).
L. Castilla-Vallmanya: None. S. Acar: None. Ö. Giray-
Bozkaya: None. A. Prat: None. M. Centeno: None. A.
Carbonell-Roqué: None. R. Martínez-Cabrera: None. R.
Rabionet: None. D. Grinberg: None. S. Balcells: None. R.
Urreizti: None.
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Non-mosaic germline cancer hotspot mutation p.
Ser1344Leu in the RNase IIIa domain of DICER1
causes a GLOW syndrome-like phenotype
S. A. Frisk1,2, E. Pontén1, K. Lagerstedt-Robinson1,2, R.
Vaz1, F. Taylan1, A. Nordgren1,2
1Karolinska Institutet, Solna, Sweden, 2Karolinska Uni-
versity Hospital, Stockholm, Sweden
DICER1 is an endoribonuclease central to the generation of
microRNAs (miRNAs), important for embryogenesis and
early somatic development. Germline DICER1 mutations
cause DICER1 syndrome - a cancer predisposition syn-
drome with an increased risk of a variety of tumors, most
commonly pleuropulmonary blastomas, cystic nephromas,
Sertoli-Leydig cell tumors and multinodular goiter.
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Recently, biallelic mutations of DICER1 involving the
RNase III domain were reported in 1% of Wilms
tumor (WT).
Here, we present an 18-year old male with macrocephaly,
lung and renal cysts, polydactyly, autism, intellectual
disability, scoliosis, multiple nevi, ear pits and WT. Whole
genome sequencing identified a de novo heterozygous
c.4031C>T, p.Ser1344Leu variant located in the RNase IIIa
domain of DICER1. The phenotype in our patient resembles
two previously reported patients with GLOW (Global
developmental delay, Lung cysts, Overgrowth and Wilms
tumor)syndrome harboring mosaic hotspot mutations in the
RNase IIIb domain. His symptoms support novel results
from integrated genetic analysis and in vitro cell experi-
ments where RNase IIIa p.Ser1344 site mutations cause
miRNA-strain imbalance, analogous to RNase IIIb muta-
tions involving the catalytic core, causing phenotype
commonalities with tissue specific tumors. In addition, his
symptoms with macrocephaly, polydactyly, multiple nevi,
and intellectual disability resemble phenotypes seen in other
overgrowth syndromes that activate PI3K/AKT/mTOR
signaling.
In conclusion, we show that non-mosaic germline
mutation p.Ser1344Leu in the RNase IIIa domain of
DICER1 is compatible with life and causes a GLOW
syndrome-like phenotype through a novel pathogenic
mechanism in the RNase IIIa domain.
Grant references: Swedish Childhood Cancer Foundation
S.A. Frisk: None. E. Pontén: None. K. Lagerstedt-
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Whole Exome Sequencing in Brazilian individuals with
intellectual disability, Neurodevelopmental Delay and
(or) Multiple Congenital Anomalies with Copy Number
Variants of Uncertain Clinical Significance detected by
Chromosomal Microarray Analysis
S. Spineli-Silva1, N. de Leeuw2, A. P. dos Santos1, N.
Leijsten2, M. H. A. Ruiterkamp-Versteeg2, J. R. M. Prota1,
A. T. Maciel-Guerra1, A. Marques-de-Faria1, C. E.
Steiner1, V. L. Gil-da-Silva-Lopes1, T. P. Vieira1
1Department of Medical Genetics and Genomic Medicine,
School of Medical Sciences, State University of Campinas,
Campinas, São Paulo, Brazil, 2Department of Human
Genetics, Radboud University Medical Center, Nijmegen,
Netherlands
Introduction: The identification of variants of unknown
clinical significance (VOUS) is a constant challenge during
the interpretation of copy number variants (CNVs) detected
in individuals with multiple congenital anomalies (MCA)
and (or) intellectual disability (ID)/ developmental delay
(DD). The aim of this study is to perform whole exome
sequencing (WES) in these individuals to search for single
nucleotide variants (SNVs) related to the phenotype.
Methods: We selected 36 individuals with CNVs
classified as VOUS, from a group of 228 individuals
presenting MCA and (or) ID/DD previously investigated by
Chromosomal Micorarray Analysis. To date, WES was
performed for 18 individuals using the Agilent SureSelect
Target Enrichment V5 (Agilent Technologies, Santa Clara,
CA, USA) sequenced on the Illumina HiSeq platform
(Illumina, San Diego, CA, USA).
Results: WES revealed pathogenic nucleotide variants in
4/18 (22,2%) individuals (ANKRD11; JAG1; KMTD2;
EBF3). In all of them the clinical phenotype was compatible
with the mutations found. In addition, a class IV, likely
pathogenic SNV was found in one individual (FOXL2), and
SNVs classified as VOUS were found in an additional five
individuals (ARID2; GNAS; SOX11 and NSDHL; ASXL2;
TGFBR1), one of them also with a pathogenic variant in
another gene. None of the SNVs found matched the CNVs
classified as VOUS.
Conclusions: Since the (likely) pathogenic SNVs found
in 5/18 (28%) individuals explain the clinical phenotype, we
conclude that the CNVs classified as VOUS were rare
findings, with no clinical relevance.
Financial support: CAPES, FAPESP (#2018/08890-9)
and FAEPEX-Unicamp.
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Santos: None. N. Leijsten: None. M.H.A. Ruiterkamp-
Versteeg: None. J.R.M. Prota: None. A.T. Maciel-
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ner: None. V.L. Gil-da-Silva-Lopes: None. T.P.
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EFTUD2 and Mandibulofacial Dysostosis with Micro-
cephaly - An Australian case series
S. O’Sullivan1, J. McGaughran1, L. McGregor2
1Genetic Health Queensland, Royal Brisbane and Women’s
Hospital, Brisbane, QLD, Australia, 2SA Clinical Genetics
Service, Women and Children’s Hospital, Adelaide, Aus-
tralia
Introduction: Mandibulofacial dysostosis with micro-
cephaly (MFDM) was recognised as a distinct clinical entity
in 2006, with the genetic basis later attributed to hap-
loinsufficiency of the EFTUD2 gene. EFTUD2 pathogenic
variants cause mis-splicing of pre mRNAs, disrupted gene
expression and cell apoptosis. MFDM is characterised by
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first and second pharyngeal arch anomalies, hearing loss,
microcephaly, developmental delay, intellectual impair-
ment, dysmorphism and systemic malformations. The pre-
valence is currently unknown, with 110 affected individuals
reported in the literature. MFDM is an important differential
for other multiple congenital malformation syndromes such
as CHARGE syndrome.
Materials and methods: A systematic review of the
literature was undertaken using Pubmed. A proforma was
devised to capture the demographic, clinical and genetic
variables of identified patients. Other clinical genetic
services in Australia were contacted to contribute.
Results: Four patients with EFTUD2 related MFDM
were identified at two Australian centres. Two patients were
monochorionic monoamniotic (MCMA) twins. One twin
died secondary to complications of MFDM in the first year
of life, his surviving twin was recently reviewed at age 7
years. Two patients were last reviewed aged 15 and 30
years respectively.
Conclusions: This case series contributes further to the
literature, allowing for greater expansion of the known
phenotype for this rare congenital multiple malformation
syndrome. In particular, our report of MCMA twins of
varying clinical manifestations, supports the view that while
MFDM is highly penetrant, it is variably expressive. Our
case series may further guide surveillance and management
of this small, but highly diverse, patient group.
S. O’Sullivan: None. J. McGaughran: None. L.
McGregor: None.
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Genome wide methylation profiling, EpiSign, as a
diagnostic test
M. Alders1, P. Henneman1, E. Aref-Eshghi2, A. Venema1, J.
Kerkhof2, B. Sadikovic2,3, M. Mannens1
1Amsterdam UMC, Amsterdam, Netherlands, 2London
Health Sciences Centre, London, ON, Canada, 3Western
University, London, ON, Canada
A growing number of neurodevelopmental syndromes are
shown to have unique genomic DNA methylation profiles.
These episignatures can be used to diagnose patients with
such syndromes. We have recently implemented genome
wide methylation profiling as a diagnostic test in our
laboratory. This test, named EpiSign(v1), is able to recog-
nize 22 syndromes, 14 of which are syndromes with specific
episignatures, (for example for Kabuki syndrome, BAFo-
pathies and Cornelia de Lange syndrome), 6 are imprinting
disorders and 2 are repeat expansion disorders. Validation
of the test was based on 38 positive samples (with known
pathogenic variant) and 24 negative controls. All samples
were called correctly provided that the DNA was extracted
from peripheral blood and there was no low mosaicism for
the pathogenic variant. Reasons for requesting an EpiSign
clinical test were: the presence of a variant of unknown
clinical significance, clinical diagnosis without molecular
confirmation, or as a test complementary to WES/WGS,
without a prior (suspected) diagnosis. In approximately
40% of cases with a suspected (VUS present) or clinical
diagnosis, EpiSign was able to confirm this diagnosis. This
shows that EpiSign is a powerful new diagnostic tool, in
particular for patients for whom conventional genetic test-
ing was inconclusive. In March 2020 an updated version of
EpiSign will be available (EpiSignv2), allowing diagnosis
of an additional 23 syndromes (45 in total). For a current list
of syndromes detected by EpiSign see https://genomedia
gnostics.amsterdamumc.nl/
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FOXG1 variants can be associated with milder pheno-
types than congenital Rett syndrome
B. Mazel1,2, A. Garde1,2, A. Bruel3,2, Y. Duffourd3,2, D.
Lopergolo4,5, A. M. Pinto5, M. A. Mencarelli5, R. Canitano6,
F. Valentino4, C. Fallerini4, F. Papa4, F. Mari4,5, N. Bahi-
Buisson7,8, A. Munnich9, R. Pfundt10, D. Fitzpatrick11, C.
Thauvin1,3,2, A. Renieri4,5, C. Philippe1,3,2, L. Faivre1,3
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Innovation en diagnostic génomique des maladies rares,
Centre Hospitalier Universitaire de Dijon, Dijon, France,
3Inserm UMR1231 GAD, Génétique des Anomalies du
Développement, Université de Bourgogne, Dijon, France,
4Medical Genetics, University of Siena, Siena, Italy,
5Genetica Medica, Azienda Ospedaliera Universitaria
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Neuropsychiatry, University Hospital of Siena, Siena, Italy,
7Service de Neurologie Pédiatrique, Hôpital Necker Enfants
Malades, Paris, France, 8Inserm, Equipe "Embryologie et
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Maladies Génétiques, Institut Imagine, Paris, France,
9Service de Génétique Médicale et Clinique, Hôpital Necker
Enfants Malades, Paris, France, 10Department of Human
Genetics, Radboud University Medical Center, Nijmegen,
Netherlands, 11MRC Human Genetics Unit, MRC Institute
of Genetics and Molecular Medicine at the University of
Edinburgh, Edinburgh, United Kingdom
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Introduction : Forkhead box G1 (FOXG1) haploinsuffi-
ciency has been associated in 2008 with a severe neurode-
velopmental phenotype with features of Rett syndrome, but
earlier onset in the first months of life. Most patients did not
achieve unassisted sitting or walking, had no speech and
were not able to use their hands purposefully. For years,
targeted sequencing of FOXG1 gene has only been pre-
scribed in such severe cases and did not permit to describe
the full clinical spectrum associated with FOXG1 variants.
The advent of exome/genome sequencing now permits to
diagnose unbiased clinical presentations.
Methods : A collaborative call was sent through the
ERN-ITHACA, in order to gather detailed clinical cases
with a heterozygous FOXG1 variant associated with a mild
phenotype, defined as a patients who could walk unassisted
and/or acquire speech.
Results : Eight patients were collected from different
European countries, all carrying a pathogenic or likely
pathogenic de novo missense FOXG1 variant, the majority
being located in the forkhead conserved site 1. Patients
usually presented with non-specific ID, distinct from the
congenital Rett variant, microcephaly and epilepsy being
rarely associated.
Conclusion : These findings corroborate with the recent
genotype-phenotype analysis (Mitter et al., 2017) proposing
to delineate 5 different FOXG1 genotype groups. Milder
phenotypes were associated with FOXG1 missense variants
in the forkhead conserved site. This information is valuable
for better prognosis after the identification of a FOXG1
variant in young children but also for the interpretation of
new FOXG1 variants identified after exome/genome
sequencing.
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Trio genome sequencing reveals a high proportion of
ultra-rare genetic disorders due to de novo mutations in
children with medical complexity
G. Costain1, R. Z. Hayeems1,2, S. Walker1, M. Marano1, D.
Veenma1, M. Snell1, M. Curtis1, S. Luca1, j. Buera1, D.
Arje1, M. Reuter1, B. Thiruvahindrapuram1, B. Trost1, W.
Sung1, R. Yuen1, D. Chitayat3,2, R. Mendo-Londono1,2, D.
Stavropoulos1,2, S. W. Scherer1,2, C. W. Marshall1,2, R. R.
Cohen1,2, E. Cohen1,2, J. Orkin1,2, S. Meyn4,1,2
1The Hospital for Sick Children, Toronto, ON, Canada,
2The University of Toronto, Toronto, ON, Canada, 3Mount
Sinai Hospital, Toronto, ON, Canada, 4University of
Wisconsin - Madison, Madison, WI, United States
Children with medical complexity have ≥1 chronic condi-
tion(s), multiple subspecialist involvement, and high
healthcare utilization. We hypothesized that genome
sequencing (GS) has high potential to diagnose children
with medical complexity, and that cohorts of these children
are enriched for novel genetic disorders.
Screening 545 children with medical complexity from a
Complex Care Program yielded 143 children suspected of
an undiagnosed genetic condition, despite having under-
gone an average of four genetic tests per proband. 49/143
were evaluated through clinical genetic assessments and
found to be phenotypically complex, with a median of 24
Human Phenotype Ontology terms/patient. Short read GS
was performed on these 49 probands, including 2 quartets,
40 trios, and 3 dyads.
Despite prior genetic testing, GS yielded a new molecular
diagnosis for 15/49 probands (31%). The majority of
diagnostic variants were sequence level variants, although
an exonic duplication causing Kabuki syndrome found by
GS escaped detection by CMA, ES, or MLPA analysis. Of
note, only three autosomal recessive disorders were
identified and >90% (11/12) of the dominant and X-
linked disorders identified by GS were caused by de novo
mutations. The majority of disorders (9/15) were ultra rare
(<25 reported cases), including three associated with novel
disease genes FBXW7, H3F3B, and RAC3. Importantly,
using DECIPHER, Matchmaker Exchange, and ClinVar,
similarly affected individuals were rapidly identified around
the globe.
Our results suggest that trio-based genome sequencing is
a high yield testing strategy for this patient population,
which appears to be enriched for de novo mutations, ultra-
rare disorders and novel genetic syndromes.
G. Costain: None. R.Z. Hayeems: None. S. Walker:
None. M. Marano: None. D. Veenma: None. M. Snell:
None. M. Curtis: None. S. Luca: None. J. Buera: None.
D. Arje: None. M. Reuter: None. B. Thiruvahindra-
puram: None. B. Trost: None. W. Sung: None. R. Yuen:
None. D. Chitayat: None. R. Mendo-Londono: None. D.
Stavropoulos: None. S.W. Scherer: None. C.W. Mar-
shall: None. R.R. Cohen: None. E. Cohen: None. J.
Orkin: None. S. Meyn: E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
Gene42.
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P11.42.C
The first patient with mesomelic dysplasia and urogen-
ital abnormalities associated with a de novo hetero-
zygous variant in HOXA11 gene
A. Sezer1, F. E. Perçin1, H. H. Kazan2, G. Kayhan1, M.
Aktürk3
1Gazi University, Faculty of Medicine, Department of
Medical Genetics, Ankara, Turkey, 2Middle East Technical
University, Department of Biological Sciences, Ankara,
Turkey, 3Gazi University, Faculty of Medicine, Department
of Endocrinology and Metabolism, Ankara, Turkey
Introduction: Hox genes encode transcription factors
playing critical roles during animal embryonic development
and many of these genes have been shown to related to
developmental disorders in animal models and patients.
Hoxa11 mutant mice exhibit homeotic transformations in
thoracic and sacral vertebrae, zeugopodal phenotype in
forelimb and hindlimb, and urogenital abnormalities. A
certain heterozygous variant in HOXA11 gene has been
associated with radioulnar synostosis and amegakaryocytic
thrombocytopenia 1 (RUSAT1, OMIM #605432). Here we
present the first patient with mesomelic dysplasia and uro-
genital abnormalities putatively related to a de novo variant
in HOXA11 gene.
Materials and Methods: An 18-year-old female patient
with normal intelligence was presented with dispropor-
tionate short stature, scoliosis, mesomelic limb shortening,
radial and ulnar bowing, fusions in carpal bones, operated
pes equinovarus, short 4th-5th metatarsals, primary amenor-
rhea due to hypoplasia of uterus, and vesicoureteral reflux.
Whole-exome sequencing (WES) analysis was applied to
investigate the genetic etiology.
Results: WES analysis revealed heterozygous c.881T>G
(p.Met294Arg) variant in HOXA11 (NM_005523.6) gene.
The variant was determined as de novo by family study.
Conclusions: To date, only a heterozygous premature
stop-codon variant in HOXA11 gene has been associated
with RUSAT1 in two families. Some skeletal problems
without mesomelic dysplasia and urogenital abnormalities
have been reported in this condition. However, our patient
did not have RUSAT. This may be due to the different
functional effects of these variants, although they are
located in the same protein domain (homeodomain). In vitro
functional studies are ongoing to evaluate the effect of the
variant, c.881T>G.
A. Sezer: None. F.E. Perçin: None. H.H. Kazan: None.
G. Kayhan: None. M. Aktürk: None.
P11.44.B
SEVERE RESPIRATORY DISTURBANCE IN NEO-
NATAL INTENSIVE CARE UNIT WITH A RECUR-
RENT NONSENSE VARIANT IN MAGEL2 GENE
Y. SAHIN1, T. CELIK2, N. NARLI3, H. OZGUR1
1Genoks Genetic Diseases Diagnostic Center, Ankara,
Turkey, 2Department of Child Neurology, Private Practice,
Adana, Turkey, 3Department of Pediatrics, Division of
Neonatology, Cukurova University Faculty of Medicine,,
Adana, Turkey
Schaaf-Yang syndrome (SYS) is characterized by neonatal
hypotonia, feeding difficulties, developmental delay/intel-
lectual disability, hypogonadism and short stature. SYS is
caused by pathogenic mutations in the paternal allele of the
MAGEL2 gene located in the maternally imprinted region
of Prader-Willi syndrome. A 4-months-old male was
referred to our genetic laboratory because of respiratory
distress, hypotonia and small hands, camptodactyly of the
third and fourth fingers. And the other sibling of the family
died after 90 days of aggravated apnea. Whole exome
sequencing (WES) performed on DNBSEQ-G400 sequen-
cer and Sanger sequencing were used to validate the find-
ings. WES was revealed a novel truncating pathogenic
variant in MAGEL2 gene inherited from the unaffected
father and confirmed by Sanger sequencing. We report 2
newborns affected with SYS in one family with severe
respiratory distress one of them died. Considering neonatal
intensive care conditions where time is overvalued, WES is
an important diagnostic method in rare cases with atypical
courses.
Y. Sahin: None. T. Celik: None. N. Narli: None. H.
Ozgur: None.
P11.46.A
The genetic landscape of Joubert syndrome in Italy
V. Serpieri1, S. Nuovo2, A. Micalizzi3, F. D’Abrusco1, P.
Accorsi4, R. Battini5,6, F. Benedicenti7, E. Bertini8, S.
Bigoni9, M. Bonati10, R. Borgatti11, M. Briguglio12, A.
Casella1, R. Ciccone1, S. D’Arrigo13, M. Dotti14, F.
Emma15, E. Fazzi16,17, M. Ginevrino18, L. Giordano16, I.
Moroni19, M. Romani20, R. Romaniello21, S. Signorini11, F.
Stanzial7, N. Vanacore22, G. Zanni8, E. Valente1,23
1Dept. of Molecular Medicine, University of Pavia, Pavia,
Italy, 2Dept. of Paediatrics, Child Neurology ad Psychiatry,
Sapienza University of Rome, Rome, Italy, 3Lab. of Medical
Genetics, IRCCS Bambin Gesù Children’s Hospital, Rome,
Italy, 4Child Neuropsychiatry Unit, Spedali Civili di
Brescia, Brescia, Italy, 5Dept. of Developmental
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Neuroscience, IRCCS Stella Maris Foundation, Pisa, Italy,
6Dept. of Clinical and Experimental Medicine, University of
Pisa, Pisa, Italy, 7Genetic Counseling Service, Dept. of
Pediatrics, Regional Hospital of Bolzano, Bolzano, Italy,
8Lab. of Molecular Medicine, Unit of Neuromuscolar and
Neurodegenerative Disorders, Dept. of Neurosciences,
IRCCS Bambin Gesù Children’s Hospital, Rome, Italy,
9Medical Genetics Unit, Ospedale Universitario S. Anna,
Ferrara, Italy, 10Clinic of Medical Genetics, IRCCS Istituto
Auxologico Italiano, Milan, Italy, 11Child and Adolescent
Neuropsychiatry Unit, IRCCS Mondino Foundation, Pavia,
Italy, 12Child and Adolescent Neuropsychiatry, University
of Messina, Messina, Italy, 13Dept. of Developmental
Neurology, IRCCS Foundation, Istituto Neurologico C.
Besta, Milan, Italy, 14Dept. of Medicine, Surgery and
Neuroscience, University of Siena, Siena, Italy, 15Dept. of
Nephrology and Urology, Unit of Nephrology and Dialysis,
IRCCS Bambin Gesù Children’s Hospital, Rome, Italy,
16Child and Adolescent Neurology and Psychiatry Unit,
Children’s Hospital, Spedali Civili di Brescia, Brescia,
Italy, 17Dept. of Human Neuroscience, SapienzaUniversity
of Rome, Rome, Italy, 18Unit of Genetics, Università
Cattolica del Sacro Cuore, Rome, Italy, 19Dept. of
Paediatric Neuroscience, IRCCS Foundation, Istituto
Neurologico C. Besta, Milan, Italy, 20Molecular Genetics
Laboratory, Eurofins GENOMA Group, Rome, Italy,
21Neuropsychiatry and Neurorehabilitation Unit, Scientific
Institute IRCCS Eugenio Medea, Bosisio Parini, Lecco,
Italy, 22National Center for Disease Prevention and Health
Promotion, National Institute of Health, Rome, Italy,
23IRCCS Mondino Foundation, Pavia, Italy
Joubert syndrome (JS) is a rare genetically heterogeneous
disorder, with recessive inheritance, characterized by a
unique cerebellar and brainstem malformation (the “molar
tooth sign”) and variable organ involvement, mainly eyes,
kidneys and liver. JS is related to dysfunction of the primary
cilium and, up to now, about 40 causative genes are known,
overall responsible for about 60% cases. Over 15 years, we
recruited 595 JS families (mostly Italian), of whom 507
underwent genetic screening either by Sanger sequencing of
selected JS genes, targeted sequencing or WES. With these
strategies, we identified biallelic pathogenic variants in 284
probands (56%). Six major genes accounted for two-thirds
of mutated cases (CEP290 14.8%; CPLANE1 14.4%;
CC2D2A 12.3%; TMEM67 10.9%; AHI1 9.5%;
KIAA0586 5.3%). Additional 86 probands (17%) carried a
single pathogenetic variant in a JS gene: to date, 42 of them
underwent high-resolution custom array, which disclosed
large heterozygous deletions in 5 probands (1 AHI1, 2
CPLANE1, 2 KIAA0586). Array-negative single hetero-
zygous carriers are currently undergoing RNA analysis to
investigate the presence of cryptic variants affecting
splicing. In 137 probands, no pathogenic variants were
identified. Yet, most of them have been tested only for a
subset of known genes, and WES is in progress. Clinical
evaluation of JS-mutated cases confirmed strong gene-
phenotype correlates for some major genes (CEP290 with
JS+retina+kidney; CPLANE1 with pure JS or OFDVI
syndrome; TMEM67 with JS+liver; AHI1 with JS+retina),
while no obvious correlates emerge for CC2D2A and
KIAA0586. These findings have major implications for
prognosis and counselling of JS families.
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P11.47.B
Description of the molecular and phenotypic spectrum
of Kabuki syndrome in 73 Chinese patients
Y. Wang, Y. Shen, J. Wang, X. Wang
Shanghai Children’s Medical Center, Shanghai,
China, China.
<META NAME="author" CONTENT="月巴月半小夜
曲"> Introduction: To retrospective analysis the clinical
phenotypes and genotypes of Kabuki syndrome patients
diagnosed in a single center. Meanwhile, the clinical dataof
Chinese KS patients reported in the previous literature were
summarized. To explore the characteristics of phenotype
and genotype of Chinese KS patients. Materials and
Method: The objects who were referred to Shanghai
Children’s Medical Center from July 2017 to December
2019 diagnosed with KS were included, and Chinese KS
patients reported in the database were collected. The clinical
phenotypes Chinese KS patients were compared with non-
Chinese KS patients to further analyze and summarize the
characteristics of their phenotype and genotype. Results: A
total of Chinese KS patients include 32 cases diagnosed by
our hospital and 41 reported cases in the database. By
comparing the clinical phenotypes of Chinese KS patients
with non-Chinese KS patients, we found that the incidence
of some facial features was higher in Chinese KS patients,
but congenital heart disease, cleft palate, infant finger pad
and vision abnormality was lower. The difference of the
above phenotypic incidence was statistically significant.
Sixty-five pathogenic mutations of KMT2D gene, 7
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pathogenic mutations of KDM6A gene and 1 copy number
mutation of KDM6A gene were found. Conclusions:
Through this study, we found that the incidence of several
phenotypes in Chinese KS patients vs non-Chinese KS
patients was statistically significant. This study expanded
the phenotype and genotype of KS in China, and provided a
theoretical basis for its diagnosis, treatment and prognosis.
Y. Wang: None. Y. Shen: None. J. Wang: None. X.
Wang: None.
P11.49.A
Clinical features and identification of mutation spectrum
in 23 Turkish children with Kabuki syndrome
E. Usluer1, G. Yeşil2, N. Güneş1, D. Uludag Alkaya1, B.
Tüysüz1
1Istanbul University, Cerrahpasa Medical Faculty, Istan-
bul, Turkey, 2Bezmialem Vakif University, Medical Faculty,
Department of Medical Genetics, Istanbul, Turkey
Introduction: Kabuki syndrome (KS) is a rare genetic
disorder characterized by distinct facies (long palpebral
fissures with eversion of the lateral portion of the lower
eyelid and large ears), persistent fetal finger pads and
intellectual disability (ID). It is caused by heterozygous
mutations in KMT2D (56-75%) or KDM6A (3-8%) genes.
We investigated clinical and molecular findings of 23
patients diagnosed with KS.
Methods: Twenty-three patients clinically were enrolled.
Exons and exon-intron boundaries of KMT2D and KDM6A
were studied by Sanger sequencing method.
Results: We detected different pathogenic mutations (five
missense, four nonsense, five small deletion, one small
insertion, one splicing) in KMT2D gene in 16 patients
(69.6%), seven of them were novel. None of patients had a
mutation in KDM6A gene. All of the patients had typical facial
features, fetal finger pads and ID (6 severe, 17 mild). The
patients also had short stature (11/23), renal anomalies (11/23),
congenital heart defects (CHD) (11/23), cleft palate (5/23),
epilepsy (8/23), abnormal brain MRI findings (6/23), con-
genital hypothyroidism (6/23) and premature thelarche (2/23).
Conclusions: Up to date 829 different mutations in
KMT2D gene have been reported. This study also revealed
that novel mutations are common in KMT2D gene. The
absence of mutations in 30.4% of patients points genetic
heterogeneity and the need to investigate indels and new
candidate genes. In addition, while patients with KMT2D
gene mutations have CHD and renal abnormalities, the
absence of those without mutations supports the effect of
KMT2D gene on heart and kidney development.
E. Usluer: None. G. Yeşil: None. N. Güneş: None. D.
Uludag Alkaya: None. B. Tüysüz: None.
P11.50.B
KBG syndrome: common and uncommon clinical
features based on 31 new patients
M. Gnazzo1, F. Lepri1, M. Dentici1, R. Capolino1, E.
Pisaneschi1, E. Agolini1, M. Rinelli1, V. Alesi1, P. Versacci2,
S. Genovese1, C. Cesario1, L. Sinibaldi1, A. Baban1, A.
Bartuli1, B. Marino2, M. Cappa1, B. Dallapiccola1, A.
Novelli1, M. Digilio1
1Laboratory of Medical Genetics, Medical Genetics, Rare
Diseases, Pediatric Cardiology, Endocrinology Units and
Scientific Rectorate, Bambino Gesù Pediatric Hospital,
Rome, Italy, 2Pediatric Cardiology, Department of Pedia-
trics, Sapienza University, Rome, Italy
Introduction: KBG syndrome (MIM #148050) is an
autosomal dominant disorder characterized by develop-
mental delay, intellectual disability, distinct craniofacial
anomalies, macrodontia of permanent upper central inci-
sors, skeletal abnormalities and short stature. Molecular
defect results from loss of function mutations or deletions of
the ANKRD11 gene, encoding for an inhibitor of ligand-
dependent transcriptional activation.
Materials and Methods: KBG patients were analized
with NGS Cohesinopathies gene panel while clinical exome
sequencing was performed to study patients with a likely
association of neurofibromatosis. Common clinical features
have been reviewed together with unusual findings, clinical
expression in the first years of life and distinctive
associations.
Results: This single-center study reports the clinical
features of 31 KBG patients of Bambino Gesù Children
Hospital: 28 with ANKRD11 pathogenic variants and 3 with
16q24 deletions. In addition to ANKRD11 causative
mutation, pathogenic NF1 variants have been found in
two patients. Unusual manifestations emerging from present
series include juvenile idiopathic arthritis, dysfunctional
dysphonia, multiple dental agenesis, idiopathic precocious
telarche, oral frenula, motor tics, lipoma of corpus callosum,
pilomatrixoma and endothelial corneal polymorphic dystro-
phy. Facial clinical markers suggesting KBG syndrome
before 6 years of age include ocular and mouth conforma-
tion, wide eyebrows, synophrys, long black eyelashes, long
philtrum and thin upper lip.
Conclusions: The spectrum of clinical features in KBG is
wide. It is likely that uncommon clinical presentation and
overlapping features in patients with multiple variants are
responsible for underdiagnosis in KBG syndrome.
Improved knowledge about typical and atypical symptoms
is useful for clinical management of this disorder.
M. Gnazzo: None. F. Lepri: None. M. Dentici: None.
R. Capolino: None. E. Pisaneschi: None. E. Agolini:
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Pathogenic variant in KLHL11 in six individuals from a
family with lichen planus, ungueal hypoplasia and
cancer. ¿A new entity with novel gene?
J. Tenorio1, J. Nevado1, J. Fort2, M. Feito3, V. Martínez-
Glez1, R. De Lucas3, A. Fernández4, V. Ruíz-Pérez5, L.
Montoliú4, M. Palacín2, P. Lapunzina1
1INGEMM, Madrid, Spain, 2Institute for Research in
Biomedicine, Barcelona, Spain, 3Dermatology Department
- Hospital Universitario La Paz, Madrid, Spain, 4Centro
Nacional de Biotecnología, Madrid, Spain, 5Instituto de
Investigaciones Biomédicas Alberto Sols, Madrid, Spain
Lichen planus (LP) is a chronic inflammatory disorder that
affects the skin, oral mucosa and hair. The lesions of the LP
tend to chronify and sometimes can lead to malignancy
neoplasias. LP can be associated with several systemic
disorders such as metabolic syndrome, diabetes mellitus,
hypertension, etc. We here present a 2-generation family
with six affected members with LP, nail dystrophy and in
two of them, carcinoma of the tongue and other localiza-
tions, with several members of the families developing
cancer. Clinical features segregates along the family, sug-
gesting an autosomal dominant pattern of inheritance. Thus,
whole exome sequencing was performed in all available
members of the family (including healthy and affected
members), allowing to identify a heterozygous missense
variant in KLHL11 that segregates with the phenotype. This
variant is not present in the control population databases. In
addition, there is no disease associated with KLHL11 yet.
KLHL11 belongs to the KELCH superfamily -42 genes
described -, and encoded for a protein that have a BTB/
POZ, BACK five KELCH domains. The BTB/POZ domain
is involved in protein-protein binding and dimerization. The
BACK domain does not have a known function and the
KELCH motifs create a tertiary structure of β –helix which
is involved in extracellular functions, cellular integrity and
protein binding. Kelch proteins acts as homodimer, and the
variant detected it is suspected to impair this dimerization.
It’s the first time that a KLHL11 is associated with lichen
planus and neoplasia. Functional assays are necessary to
confirm the pathogenic mechanism.
J. Tenorio: None. J. Nevado: None. J. Fort: None. M.
Feito: None. V. Martínez-Glez: None. R. De Lucas:
None. A. Fernández: None. V. Ruíz-Pérez: None. L.
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Mabry syndrome: A novel recurrent PGAP3 variant in
an African population
H. Bezuidenhout1, S. Bayley1, K. Fieggan2, N. Makubalo3,
C. Spencer2, S. Moosa1, L. Smit1, C. Uren1, M. Moller1, C.
Kinnear1, M. Urban1
1Division of Molecular Biology and Human Genetics,
University of Stellenbosch and Tygerberg Hospital, Cape
Town, South Africa, 2Division of Medical Genetics, Groote
Schuur Hospital and University of Cape Town, Cape Town,
South Africa, 3Dora Nginza Hospital, Port Elizabeth, South
Africa
Background: Mabry syndrome (MS) is a rare autosomal
recessive disorder caused by pathogenic variants in one of
several genes involved in glycosylphosphatidylinositol
metabolism. The phenotype includes severe intellectual
disability, distinctive but subtle facial features, hypotonia,
variable congenital malformations and persistently elevated
alkaline phosphatase (ALP).
Methods: The search for an unidentified syndrome
causing the above clinical features led to the clinical
identification of a case of MS at Tygerberg Academic
Hospital. This was assisted by Face2Gene phenotype
matching and confirmed by elevated ALP. Whole exome
sequencing detected a homozygous candidate variant
(PGAP3:c.557G>C, p.Arg186Thr). A case series was
assembled by retrospective and prospective case finding at
three South African sites using database searches, Face2-
Gene phenotype matching, and/or ALP levels and Sanger
sequencing for the candidate variant.
Results: Nine clinical cases were identified and Sanger
sequencing could be performed on 7, all proved homo-
zygous for the candidate variant. The likely pathogenic
variant is absent from population databases, affects a highly
conserved amino acid and is predicted damaging/deleter-
ious. Observed clinical features in all included severe
intellectual disability, absent speech, hypotonia and cleft
palate in (5/9) (56%). ALP levels were significantly raised.
Most discriminating facial features include hypertelorism,
long palpebral fissures, broad nasal tip and tented upper lip.
Conclusion: A previously undiagnosed syndrome was
identified in an indigenous South African population, with
computer-assisted syndromology being instrumental. We
describe 9 cases of MS and their genetic basis. The common
homozygous variant in PGAP3, in the absence of
consanguinity, suggests genetic drift and investigation is
ongoing.
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De novo variants in MCF2L are associated with
congenital blindness, hearing loss, microcephaly, ID
and autism
D. J. Smits, L. Donker Kaat, R. Schot, M. Wilke, M. van
Slegtenhorst, G. M. S. Mancini
Erasmus University Medical Centre, Rotterdam, Nether-
lands
Introduction: MCF2L encodes for the Dbs protein which is
a Rho-specific guanine nucleotide exchange factor (Rho-
GEF). Rho-GEFs accelerate the exchange activity of Rho
GTPases and thereby regulate several growth related pro-
cesses. MCF2L interacts with RAC1 via its plekstrin
homology domain, and thereby in turn activates RHOA.
RAC1 activating mutations have been associated with
megalencephaly and RHOA mosaic postzygotic inactivat-
ing variants have been recently associated with a neu-
roectodermal syndrome with asymptomatic
leukoencephalopathy, microphthalmia or other ocular,
dental and skeletal anomalies. Previously, GWAS studies
pointed to MCF2L as locus for osteoarthritis.
Results: We identified heterozygous de novo missense
variants in the spectrin-like repeat domain of MCF2L in
two unrelated boys. They presented with nearly identical
and recognizable phenotypic features including mild
facial dysmorphisms, microphthalmia with persistent
hyperplastic primary vitreous, congenital retinal detach-
ment, mild hearing loss, microcephaly, cognitive impair-
ment, autism, epilepsy, pyramidal signs and congenital
thyroid insufficiency. Brain MRI in one child (10 years of
age) showed focal cortical dysplasia of the insula, one
periventricular nodular heterotopia and calcifications. In
the other child, the MRI showed neonatal cerebellar
subdural hygroma, modest intraparenchymal parietal and
vitreous bleeding.
Conclusions: These phenotypic similarities suggest a
causal implication for the MCF2L variants, which enlarge
the broad clinical spectrum of mutations in proteins
involved in regulation of Rho-protein signalling and
emphasize the importance of this pathway in neurodevelop-
mental disorders.
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The Qatari Mendelian program - A premium resource
for gene discovery and data sharing for rare diseases
from the greater Middle East
W. Aamer1, A. Almaraghi1, A. Al-Kurbi1,2, S. Padmajeya1,
A. Al-Shakaki3, the Qatari Mendelian Program, A. Robay3,
M. Kamal1,4, A. Akil1, T. Ben Omran1,4,3, K. A. Fakhro1,3,2
1Sidra Medicine, Doha, Qatar, 2Hamad Bin Khalifa
University, Doha, Qatar, 3Weill Cornell Medical College,
Doha, Qatar, 4Hamad Medical Corporation, Doha,
Qatar
The recent investment in biomedical research and the
launch of a large-scale national genome program for Qatar
have motivated the establishment of the Qatari Mendelian
Program - a multi-stakeholder initiative offering WGS to
patients with idiopathic disorders in an area of the world
where consanguinity levels are high (>50%) and clinical
care is largely centralized. Following our recent pilot of 30
families (PMID:31625567), we have now sequenced the
whole genomes of a further 336 individuals (including 115
patients) from 87 families with various conditions, includ-
ing: Autism (n = 23), neurodevelopmental and neuromus-
cular (n = 16), metabolic and endocrine (n = 14),
craniofacial (n = 10), sensory (n = 7), immune (n = 7) and
other (n = 10) disorders. We identified novel causative
mutations in known disease genes in 34 families (40.2%),
including 29 SNVs/indels and 5 structural variants. Nota-
bly, we discovered a complex rearrangement (tandem
duplication and deletion) affecting exons 1-6 of IRF6 in
three siblings with Popliteal pterygium syndrome, con-
firmed by de novo local re-assembly of WGS reads and
PCR. For another 15 families, we identified putatively
damaging variants in novel candidate genes, e.g. a missense
variant in the CPSG4 shared by two siblings with severe
hypotonia, dysmorphic features and myoclonic encephalo-
pathy with seizures. Homozygous zebrafish we generated
by CRISPR displayed highly similar phenotypes, prompting
deeper functional studies to elucidate gene mechanism. The
Qatari Mendelian program continues to enroll 2-4 families
per week, consented for sample/data sharing, thus creating
an international genomic and phenotypic resource for
mutation matching and gene discovery from the globally
under-represented greater Middle Eastern populations.
W. Aamer: None. A. Almaraghi: None. A. Al-Kurbi:
None. S. Padmajeya: None. A. Al-Shakaki: None. A.
Robay: None. M. Kamal: None. A. Akil: None. T. Ben
Omran: None. K.A. Fakhro: None.
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Menke-Hennekam syndrome subtypes caused by var-
iants in the Zinc finger domains ZZ and TAZ2 and the
fourth intrinsically disordered linker of CBP and p300
L. A. Menke1,2, Z. A. Jenkins2, E. Williams2, G. Gimenez3,
A. C. O’Neill2, R. C. Hennekam1, S. P. Robertson2
1Department of Paediatrics, Amsterdam UMC, University
of Amsterdam, Amsterdam, Netherlands, 2Department of
Women’s and Children’s Health, Dunedin School of
Medicine, University of Otago, Dunedin, New Zealand,
3Department of Pathology, Dunedin School of Medicine,
University of Otago, Dunedin, New Zealand
Introduction: CREB-binding protein (CBP, encoded by
CREBBP) and its paralog E1A-associated protein p300
(EP300) are histone acetylators and important cofactors for
transcription. Variants that produce a null allele or destroy
their catalytic function cause Rubinstein-Taybi syndrome,
while clustered pathogenic variants in exon 30/31 cause
phenotypes now bundled under the umbrella term Menke-
Hennekam syndrome (MKHK, OMIM 618332 and
618333).
Materials and Methods: To distinguish MKHK sub-
types and define their characteristics, molecular and
extended clinical data on 53 individuals (25 unpublished)
with a variant in CBP/p300 (hg19; residues 1710-1872 and
1673-1835, respectively) were systematically gathered.
Morphological characteristics were assessed by an expert
(RCH) blinded to the molecular data. Variants were plotted
on 3D protein domains using iCn3D software.
Results: Variants clustered closely around the Zinc
binding residues of two Zinc finger domains (ZZ and
TAZ2) and within the first α-helix of the fourth intrinsically
disordered linker (ID4) of CBP/p300. All variants were
predicted to disturb local protein structure and therefore
likely the function of CBP/p300. By evaluating morpholo-
gical and physical features, we discerned one clearly
delineated and three likely subtypes.
Conclusions: Variants in the first α-helix of ID4 cause a
separate, recognisable MKHK subtype. Although numbers
are still small, three other possible subtypes can be
discerned in ZZ and two regions within TAZ2. LAM was
funded by the Janivo Foundation and Emma Children’s
Hospital Foundation.
L.A. Menke: None. Z.A. Jenkins: None. E. Williams:
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P11.60.C
Microcephalic osteodysplastic primordial dwarfism type
II and pachygyria: morphometric analysis in a 2 years-
old girl
M. Dentici, M. Rossi-Espagnet, L. Pasquini, C. Carducci,
M. Lucignani, D. Longo, E. Agolini, A. Novelli, M. V.
Gonfiantini, M. Digilio, A. Bartuli
Bambino Gesú Pediatric Hospital, IRCCS, Rome, Italy.,
Rome, Italy
Microcephalic osteodysplastic primordial dwarfism
(MOPD) type II is a rare disorder characterized by skeletal
dysplasia, severe proportionate short stature, insulin resis-
tance and cerebrovascular abnormalities including cerebral
aneurysms and moyamoya disease. MOPD type II is caused
by mutations in the pericentrin (PCNT) gene, which
encodes a protein involved in centrosomes function.
We report a 2 year old girl affected by MOPD type II
caused by two compound heterozygous loss of-function
variants in PCNT gene, of which one is a novel variant
(c.5304delT; p.Gly1769AlafsTer34). The patient presented
atypical brain MRI findings consistent with pachygyria.
This was confirmed by morphometric analysis of cortical
thickness and gyrification index by comparing MRI data of
the patient with a group of 8 age-matched healthy controls.
The statistical analysis revealed a significant and diffuse
increase of cortical thickness with an anterior predominant
pattern and diffuse reduced gyrification (p< 0.05).
These findings provide new evidences to the emergent
concept that malformations of cortical development are
complex disorders and that new genetic findings contribute
to the fading of classification borders.
M. Dentici: None. M. Rossi-Espagnet: None. L.
Pasquini: None. C. Carducci: None. M. Lucignani:
None. D. Longo: None. E. Agolini: None. A. Novelli:
None. M.V. Gonfiantini: None. M. Digilio: None. A.
Bartuli: None.
P11.61.A
Mowat-Wilson syndrome: growth charts
I. Ivanovski1, O. Djuric2, S. Broccoli2, S. Caraffi1, P.
Accorsi3, M. P. Adam4, K. Avela5, M. Badura-Stronka6, A.
Bayat7,8, J. Clayton-Smith9,10, D. Cordelli11, G. Cuturilo12,
V. Di Pisa13, J. Dupont Garcia14, R. Gastaldi15, L.
Giordano3, A. Guala16, C. Hoei-Hansen17, M. Inaba18, A.
Iodice19, J. Nielsen20, V. Kuburovic21, B. Lazalde-Medina22,
B. Malbora23, S. Mizuno18, O. Moldovan14, R. Møller24,25,
P. Muschke26, C. Pantaleoni27, C. Piscopo28, M. Poch-
Olive29, I. Prpic30, M. Purificacìon31, F. Raviglione32, E.
Ricci11, E. Scarano33, R. Smigiel34, G. Tanteles35, L.
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Tarani36, A. Trimouille37,38, E. Valera39, S. Vergano40,41, K.
Writzl42, B. Callewaert43, S. Savasta44, M. Street45, L.
Iughetti46,47, S. Bernasconi48, P. Giorgi Rossi49, L.
Garavelli1
1Medical Genetics Unit AUSL IRCCS RE, Reggio Emilia,
Italy, 2Epidemiology Unit, Azienda Unità Sanitaria Locale
– IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy,
3Neuropsychiatric Department, Spedali Civili Brescia,
Brescia, Italy, 4Division of Genetic Medicine, University
of Washington School of Medicine, Seattle, WA, United
States, 5Department of Clinical Genetics, Helsinki Uni-
versity Hospital, Helsinki, Finland, 6Department of Medical
Genetics, Poznan University of Medical Sciences, Poznań,
Poznan’, Poland, 7Department of Pediatrics, University
Hospital of Copenhagen/Hvidovre, Copenhagen, Denmark,
8Department of Clinical Genetics, Rigshospitalet, Univer-
sity Hospital of Copenhagen, Copenhagen, Denmark,
9Manchester Centre for Genomic Medicine, University of
Manchester, St Mary’s Hospital, Manchester, United
Kingdom, 10Division of Evolution and Genomic Sciences,
School of Biological Sciences, Faculty of Biology, Medicine
and Health, University of Manchester, Manchester, United
Kingdom, 11Child Neurology and Psychiatry Unit, Pediatric
Department, S. Orsola Hospital in Bologna, University of
Bologna, Bologna, Italy, 12Faculty of Medicine, University
of Belgrade, Belgrade, Serbia, 13Manchester Centre for
Genomic Medicine, St Mary’s Hospital, Manchester Uni-
versity NHS Foundation Trust, Health Innovation Manche-
ster, Manchester, United Kingdom, 14Serviço de Genética
Médica, Departamento de Pediatria, Hospital de Santa
Maria, Centro Hospitalar Lisboa Norte, Centro Académico
de Medicina de Lisboa, Lisbon, Portugal, 15UOC Clinica
Pediatrica, Istituto Giannina Gaslini, Genova, Italy, 16SOC
Pediatria, Ospedale Castelli, Verbania, Italy, 17Department
of Paediatrics, Copenhagen University Hospital, Rigshos-
pitalet, Copenhagen, Denmark, 18Department of Pediatrics,
Central Hospital, Aichi Human Service Center, Kasugai,
Japan, 19Child Neurology and Psychiatry Unit, AUSL-
IRCCS, Reggio Emilia, Italy, 20Department of Pediatrics,
Zealand University Hospital Roskilde, Roskilde, Denmark,
21Department of Cardiology, Mother and Child Health
Care Institute, Belgrade, Serbia, 22Biomedical Research
Unit, Mexican Institute of Social Security, Durango,
Mexico, 23Department of Pediatric Hematology & Oncol-
ogy, Tepecik Training and Research Hospital, Izmir,
Turkey, 24Danish Epilepsy Centre, Dianalund, Denmark,
25Institute for Regional Health Services, University of
Southern Denmark, Odense, Denmark, 26Institute for
Human Genetics, University Hospital Magdeburg, Magde-
burg, Germany, 27Developmental Neurology Unit, Fonda-
zione IRCCS Istituto Neurologico Carlo Besta, Milano,
Italy, 28U.O.S.C. Medical Genetics, A.O.R.N. "A.
Cardarelli", Naples, Italy, 29Department of Pediatrics, H.
San Pedro, La Rioja, Logrono, Spain, 30Department of
Pediatrics–Child Neurology Service, University Hospital
Rijeka, Medical Faculty, University of Rijeka, Rijeka,
Croatia, 31Dismorphology and Reproductive Genetics,
Neonatal Research Group, Health Research Institute
Hospital La Fe, University & Polytechnic Hospital La Fe,
Valencia, Spain, 32Child Neuropsychiatry Unit, U.O.N.P.I.
A ASST–Rhodense, Rho, Milano, Italy, 33Unit of Pediatrics,
Department of Medical and Surgical Sciences, Policlinico
St. Orsola-Malpighi Hospital, University of Bologna,
Bologna, Italy, 34Department of Genetics, Wroclaw Medical
University, Wroclaw, Wroclaw, Poland, 35Clinical Genetics
Clinic, Cyprus Institute of Neurology and Genetics,
Nicosia, Cyprus, 36Department of Pediatrics, University
“La Sapienza”, Rome, Italy, 37CHU de Bordeaux, Service
de Génétique Médicale, Bordeaux, France, 38INSERM
U1211, Univ. Bordeaux, Bordeaux, France, 39Department
of Pediatrics, Ribeirão Preto Medical School, University of
São Paulo, São Paulo, Brazil, 40Department of Pediatrics,
Eastern Virginia Medical School, Norfolk, VA, United
States, 41Division of Medical Genetics and Metabolism,
Children’s Hospital of The King’s Daughters, Norfolk, VA,
United States, 42Clinical Institute of Medical Genetics,
University Medical Centre Ljubljana, Ljubljana, Slovenia,
43Ghent University, 26656, Center for Medical Genetics
Ghent, Ghent, Belgium, 44Pediatric Clinic, IRCCS Policli-
nico "S. Matteo" Foundation, University of Pavia, Pavia,
Italy, 45Division of Pediatric Endocrinology and Diabetol-
ogy, Department of Mother and Child, Azienda Unità
Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia,
Italy, 46Post-graduate School of Pediatrics, University of
Modena and Reggio Emilia, Modena, Italy, 47Department
of Medical and Surgical Sciences of Mother, Children and
Adults, Pediatric Unit, University of Modena and Reggio
Emilia, Modena, Italy, 48Microbiome Research Hub,
University of Parma, Parma, Italy, 49Epidemiology Unit,
Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia,
Reggio Emilia, Italy
Mowat-Wilson syndrome (MWS) is a genetic condition
caused by heterozygous mutations or deletions of the ZEB2
gene, and characterized by typical face, intellectual dis-
ability, epilepsy, Hirschsprung disease, and congenital
anomalies. The charts for males and females aged from 0 to
16 years were constructed using a total of 2,865 measure-
ments of 99 MWS patients, of different ancestries. The data
were collected through collaboration with the Italian MWS
association (AIMW) and the MWS Foundation. To model
the growth charts, the GAMLSS package for the R statis-
tical program was used. Height, weight, body mass index
(BMI) and occipito-frontal circumference (OFC) were
compared to healthy children using CDC growth charts. In
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newborns, weight and length were distributed as in the
general population, while head circumference was slighlty
smaller. Weight and height distribution was slightly shifted
to lower values than the general population until the age of
7, when the difference increased. BMI distribution was
almost similar to that of the non- affected children until the
age of 7, then values in the general population increase
rapidly and in MWS children increase with a less steep
slope. Microcephaly develops gradually in infancy, not all
children were microcephalic and the head circumference
was often between the 3rd and the 10th centile. These charts
contribute to the understanding of the natural history of
MWS and should assist pediatricians and other caregivers in
providing optimal care to MWS individuals with problems
related to physical growth. This is the first study on growth
in patients with MWS.
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J. Clayton-Smith: None. D. Cordelli: None. G. Cuturilo:
None. V. Di Pisa: None. J. Dupont Garcia: None. R.
Gastaldi: None. L. Giordano: None. A. Guala: None. C.
Hoei-Hansen: None. M. Inaba: None. A. Iodice: None. J.
Nielsen: None. V. Kuburovic: None. B. Lazalde-Medina:
None. B. Malbora: None. S. Mizuno: None. O. Moldo-
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P11.62.B
A novel GREB1L c.705G>T missense variant identified
by whole-exome sequencing in a three-generation family
with Müllerian and renal agenesis: a new candidate gene
in Mayer-Rokitansky-Küster-Hauser (MRKH)
syndrome
M. K. Herlin1,2, A. T. Højland1,3, V. Q. Le1, A. Ernst1, H.
Okkels1, A. C. Petersen1, M. B. Petersen1,3, I. S. Pedersen1,3
1Aalborg University Hospital, Aalborg, Denmark, 2Aarhus
University Hospital, Aarhus, Denmark, 3Aalborg Univer-
sity, Aalborg, Denmark
Introduction: Mayer-Rokitansky-Küster-Hauser (MRKH)
syndrome, also referred to as Müllerian aplasia, is a con-
genital anomaly characterised by uterovaginal agenesis in
females with a normal 46,XX karyotype. Prevalence is 1 in
5,000 females. MRKH syndrome is often associated with
extragenital malformations (type 2), predominantly kidney
anomalies such as renal agenesis. The aetiology remains
unknown, however rare reports of familial occurrence
suggest a genetic cause following autosomal dominant
inheritance with incomplete penetrance.
Material and Methods: We investigated a unique three-
generation family with two female cousins with type 2
MRKH syndrome including unilateral renal agenesis and
two deceased male relatives with renal agenesis. We
performed whole-exome sequencing (WES) of genomic
DNA from eight family members.
Results: We identified a novel likely pathogenic (CADD
= 33) c.705G>T missense variant in GREB1L - a gene
recently identified as a novel cause of bilateral renal
agenesis. Previous literature include several cases of
bilateral renal agenesis in female foetuses also having
uterus agenesis, which supports GREB1L as an important
gene in both kidney and female genital tract development.
The missense variant was confirmed in all affected family
members, however, the variant was vertically transmitted
through two unaffected women suggesting incomplete
penetrance following a parent-origin-specific manner.
Conclusions: We suggest GREB1L as a novel and
promising candidate gene in MRKH syndrome aetiology,
especially in patients with type 2 MRKH syndrome also
having kidney abnormalities. The incomplete penetrance
observed in our family could be explained by genomic
imprinting and is currently subject to further investigation.
M.K. Herlin: None. A.T. Højland: None. V.Q. Le:
None. A. Ernst: None. H. Okkels: None. A.C. Petersen:
None. M.B. Petersen: None. I.S. Pedersen: None.
P11.64.A
Singleton clinical exom sequencing in fetuses with
multiple anomalies
K. Gahle, M. Shoukier, C. Daumer-Haas, C. Bagowski, N.
Hirschberger, S. Minderer, T. Schramm, K. P. Gloning
Prenatal Medicine Munich, Munich, Germany
Introduction: Identifying the genetic cause of fetal struc-
tural anomalies is a diagnostic challenge. We present here
the results of singleton clinical exome sequencing (SCES)
of 60 fetuses with complex malformations.
Materials and Methods: From January 2019 to January
2020, in total 60 prenatal cases with complex structural
anomalies, not fitting any specific syndrome, were inves-
tigated by targeted NGS of the coding regions of
5230 selected genes (Custom Constitutional Panel 17 Mb,
Agilent, Santa Clara, CA, USA). Variant pathogenicity
assessment by familial co-segregation analysis for was
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carried out when necessary. According to the ACMG-AMP
guidelines (2015), variants were classified as classes 1 to 5.
Fetal karyotypes were normal.
Results: Likely pathogenic (class 4) and pathogenic
(class 5) variants were identified in 14 (23%) out of the 60
cases. The variants were found in 13 different genes:
DHCR7 (2 cases), AFF4, ARSE, CNTNAP1, ERCC5,
FAT4, KIF7, MAGED2, MYH3, NIPBL, RAF1, SHH and
TSEN54. In addition variants of uncertain significance
(class 3) were detected in 6 cases (10%). No variants (class
3-5) were identified in a total of 40 fetuses (67%). Our
findings show a strong correlation between the detection
rate of causative mutations and the complexity of the fetal
phenotype.
Conclusions: SCES facilitates the identification of
genetic causes with high diagnostic yield and should be
considered for molecular genetic diagnosis in cases of
complex fetal malformations. This unique challenge of
exome-based prenatal diagnostics requires a team of
prenatal and human genetic specialists.
K. Gahle: None.M. Shoukier: None. C. Daumer-Haas:
None. C. Bagowski: None. N. Hirschberger: None. S.
Minderer: None. T. Schramm: None. K.P.
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P11.67.A
Spectrum of Noonan Syndrome: Is genotype predicted
by phenotype?
E. Tsoutsou, N. Marinakis, K. Kosma, S. Psoni, J. Traeger-
Synodinos
National & Kapodistrian University of Athens, Athens,
Greece
Introduction: Noonan syndrome (NS) is an autosomal
dominant disorder belonging to a group of developmental
disorders called RASopathies with overlapping features and
multiple causative genes. The variable clinical phenotype
associated with NS and Noonan-like disorders is partly due
to genetic heterogeneity, whereby mutations in many genes
may result in different phenotypic expression. In this study
we present the genotypic and phenotypic spectrum of NS
illustrated by the analysis of 15 patients.
Materials and Methods: Fifteen patients with pheno-
typic characteristics of NS were referred to the Laboratory
of Medical Genetics, following clinical evaluation, pre-test
counselling and signed consent. Clinicians requested whole
exome sequencing (WES, ~19,000 genes). Library prepara-
tion used Sophia Genetics kits and Nextera Rapid Capture
Exome (Illumina), run on a NextSeq-500 (Illumina).
Bioinformatics analysis used SOPHiA DDM® and VarAFT.
Variants were categorised according to ACMG guidelines;
only “Pathogenic” or “Likely pathogenic” variants were
reported.
Results: Heterozygous missense variants were identified
in 10/15 patients, achieving a diagnostic yield of 67%.
Causative alterations included known pathogenic variants in
the PTPN11 gene (5 variants), 2 in RIT1 gene, 1 in KRAS
gene, 1 in SOS1 gene and 1 in SHOC2 gene.
Discussion: In most cases, the NS genotype cannot be
predicted by phenotype. Even typical cases with character-
istic morphological features, pulmonary valve stenosis and
short stature, as well as atypical cases, were positive for
pathogenic variants in any currently known Noonan
causative genes. WES supports marked improvement in
diagnostic-yield for NS, including unusual phenotypes and
sometimes revealing unusual genotypes.
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P11.68.B
MEK inhibitor treatment in a newborn with Noonan
syndrome and severe obstructive hypertrophic
cardiomyopathy
A. Mussa1, D. Carli1, E. Giorgio2, A. M. Villar3, C.
Carbonara4, G. Paolo4, G. Botta5, G. Andelfinger6, M.
Tartaglia7, E. Medico8,9, A. Brusco2,10, G. B. Ferrero1
1Department of Public Health and Pediatric Sciences,
University of Torino, Torino, Italy, 2Department of Medical
Sciences, University of Torino, Torino, Italy, 3Pediatric
Cardiology, Regina Margherita Children Hospital, Città
della Salute e della Scienza, Torino, Italy, 4Neonatal
Intensive Care Unit, S.Anna Hospital, Città della Salute e
della Scienza, Torino, Italy, 5Department of Pathology, S.
Anna Hospital, Città della Salute e della Scienza, Torino,
Italy, 6Cardiovascular Genetics, CHU Sainte Justine,
Department of Pediatrics, Université de Montréal, 3175,
Chemin Côte Sainte Catherine,, Montréal, QC, Canada,
7Genetics and Rare Diseases Research Division, Ospedale
Pediatrico Bambino Gesù, IRCCS, Roma, Italy, 8Labora-
tory of Oncogenomics, Candiolo Cancer Institute, FPO-
IRCCS, Candiolo, Italy, 9Department of Oncology, Uni-
versity of Torino, Torino, Italy, 10Medical Genetics Unit,
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We report a preterm female newborn, with a gestation
characterized by polyhydramnios and fetal hypertrophic
cardiomyopathy (HCM), presenting facial dysmorphisms
consistent with Noonan syndrome (NS), who required
resuscitation and mechanical ventilation at birth. Echo-
cardiography confirmed severe obstructive HCM and dys-
plastic pulmonary valve. At the 2nd day of life, she
developed a cerebral ventricular haemorrhage. A
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heterozygous de novo c.770C>T p.Ser257Leu variant in
RAF1 (NM_002880), typically associated with severe HCM
and pulmonary hypertension, confirmed the clinical diag-
nosis. She developed severe congestive heart failure (CHF)
requiring amine administration and mechanical ventilation.
Given the near-terminal CHF, Trametinib - a selective
inhibitor of MEK1/2 approved for the treatment of cancers
with RAS/MAPK hypersignaling - was introduced (0.022
mg/kg/day). There was prompt improvement in clinical
condition, allowing inotropes and mechanical ventilation
withdrawal; consistent with HCM stabilization, nt-pro-BNP
decreased from 30,805 to 2,355 pg/ml. During the next
month, treatment was continued without side effects,
allowing a progressive reduction of respiratory support.
Cardiac ultrasound showed a tendency to HCM improve-
ment but revealed the sudden appearance of pulmonary
artery dilation. At 3 months of age, she underwent ven-
triculoperitoneal shunt device placement for post haemor-
rhagic hydrocephalus: after surgery she showed a rapidly
worsening of CHF and died at 3½ months of age from
untreatable CHF. Autopsy showed an obstructive HCM,
severe dilation of pulmonary artery trunk and branches with
complete disarray of both gross and fine pulmonary vas-
cular anatomy. Whole RNA sequencing from white blood
cells before and during treatment was performed to define
transcriptional effects of MEK inhibition.
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P11.69.C
Research on a pathogenesis of cognitive and neurofunc-
tioning impairments in patients with Noonan syndrome.
A role of RAS/MAPK signaling pathway gene
disturbances
N. Braun-Walicka1, A. Pluta2,3, T. Wolak2, E. Maj2, A.
Maryniak3, M. Gos1, A. Abramowicz1, A. Landowska1, E.
Obersztyn1, J. Bal1
1Department of Medical Genetics, Institute of Mother and
Child, Warsaw, Poland, 2Bioimaging Research Center,
World Hearing Center at the Institute of Physiology and
Pathology of Hearing, Kajetany, Poland, 3Department of
Child and Family Clinical Psychology of the University of
Warsaw, Warsaw, Poland
Introduction: Noonan syndrome (NS) is one of the most
common genetic conditions caused by mutations in parti-
cular genes of the RAS/MAPK signaling pathway. Patients
with NS might have cognitive problems in language skills,
memory, attention, executive functioning and decreased
overall intelligence level. The resting-state functional con-
nectivity (rsFC) analysis could be particularly useful for
characterizing functional brain network differences in
populations with intellectual disabilities.
Materials and Methods: According to our knowledge
this is first study on functional connectivity in Noonan
syndrome. 28 subjects with Noonan syndrome and 23
healthy took part in rs-fMRI data acquisition using a 3 T
Siemens PRISMA scanner. All subsequent analysis of rs-
fMRI findings was performed in CONN-fMRI Functional
Connectivity (FC) toolbox ver. 18b. We tested for group
differences in between- and within-network rsFC connec-
tivity for key seeds of salience and default mode network. In
addition,, subjects underwent a complex assessment of
cognitive abilities with the use of Stanford-Binet Intelli-
gence Scales.
Results: Overall, both hypo- and hyper- connectivity
within salience and DMN networks were revealed in
subjects with Noonan syndrome. For example, patients
exhibit increased connectivity between DMN network
MPFC seed and superior frontal gyrus bilaterally and
PCC and cerebellum. Simultaneously, they demonstrated
decreased connectivity within precuneus which is a key
region of DMN. In respect of IQ, subjects with Noonan
syndrome showed decreased Verbal and Nonverbal IQ
compared to healthy controls.
Conclusions: These findings imply that the functional
architecture of rsFC might be altered in subjects with
Noonan syndrome.
Supported from NCN research projects no. 2016/21/N/
HS6/02891
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Genotype and phenotype in patients with Noonan
syndrome caused by SOS2 variants
C. Lissewski1, V. Chune2, F. Pantaleoni3, A. De Luca4, Y.
Capri2, J. Brinkmann1, F. Lepri3, P. Daniele4, E. Leenders5,
L. Mazzanti6, K. Kutsche7, A. Küchler8, M. Gérard2, J.
Amiel2, Y. Vial2, I. van der Burgt5, E. Andreucci9, G.
Mastromoro10, M. C. Digilio3, H. Cavé2,11, M. Tartaglia3,
M. Zenker1
1Institute of Human Genetics, University Hospital Magde-
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Introduction: RASopathies are caused by pathogenic var-
iants in genes encoding members or modulators of the RAS/
MAPK signalling pathway. Noonan syndrome is the most
common entity among this group of disorders and is char-
acterized by heart defects, short stature, variable develop-
mental delay and typical facial features. Pathogenic variants
in SOS2, encoding a guanine nucleotide exchange factor for
RAS, have recently been identified in patients with Noonan
syndrome. The number of published cases with pathogenic
SOS2 variants is still limited and little is known about
genotype-phenotype correlation.
Materials and Methods: We collected clinical and
genotype data from 17 previously unpublished individuals
carrying a disease-causing SOS2 variant. Results: Most
individuals had one of the previously reported pathogenic
variants; only three had novel changes at the established
mutation hotspots, which were classified as likely patho-
genic. The phenotype of the 17 patients fits well into the
spectrum of Noonan syndrome and is most similar to the
phenotype observed in patients with SOS1-related Noonan
syndrome, with ectodermal anomalies as common and short
stature and learning disabilities as infrequent findings. The
spectrum of heart defects in SOS2-related Noonan syn-
drome was consistent with the known spectrum of cardiac
anomalies in RASopathies, but no specific heart defect was
particularly predominating. Notably, lymphatic anomalies
were extraordinarily frequent in our cohort, affecting more
than half of the patients.
Conclusions: SOS2-related Noonan syndrome is pheno-
typically similar to SOS1-related Noonan syndrome and
associated with a particularly high risk of lymphatic
complications that may have a significant impact on
morbidity and quality of life.
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Investigating the genetic intersection of orofacial clefting
and normal facial variation
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Eller4, S. Walsh4, M. D. Shriver3, S. Richmond5, H.
Peeters1, M. L. Marazita2, J. R. Shaffer2, S. M. Weinberg2,
G. Hens1, P. Claes1
1KULeuven, Leuven, Belgium, 2University of Pittsburgh,
Pittsburgh, PA, United States, 3Pennsylvania State Uni-
versity, State College, PA, United States, 4Indiana Uni-
versity Purdue University Indianapolis, Indianapolis, IN,
United States, 5Cardiff University, Cardiff, United King-
dom
Orofacial clefting is the most common craniofacial mal-
formation in humans. Previous research has demonstrated
that unaffected relatives of patients with non-syndromic
cleft lip with/without cleft palate (NSCL/P) show distinctive
facial features, which can be considered an endophenotype.
The presence of this facial endophenotype is potentially an
expression of underlying genetic susceptibility to NSCL/P.
To investigate this, we applied partial least squares regres-
sion (PLSR) to define a set of endophenotypic traits in a
dataset of 3D facial images from 264 unaffected parents of
patients with NSCL/P and 3,171 controls. The PLSR pro-
vides a p-value and direction of effect (or trait) for each
endophenotype. We observed nominally significant (p <
0.05) differences between parents and controls involving 59
endophenotypic traits. Next, we quantified these discovered
endophenotypic traits in another dataset of 8,246 unaffected
European individuals and then subjected these traits to
GWAS. We identified 29 independent lead SNPs that were
associated with at least one of the tested endophenotypic
risk phenotypes at the genome-wide level (p < 5e-8). Of the
29 lead SNPs, 22 are in the proximity of SNPs previously
associated with normal facial variation and 15 are near
genes that show evidence of roles in orofacial clefting. This
study supports the existence of an overlap between the
genetic pathways involved in normal facial development
and orofacial clefting.
Grants: National Institutes of Health (1-RO1-
DE027023), the Research Fund KU Leuven (BOF-C1,
C14/15/081) and the Research Program of the The
Research Foundation-Flanders (Belgium) (FWO,
G078518N)
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Further definition of the proximal 19p13.3 microdele-
tion/microduplication syndrome and implication of
PIAS4 as the major contributor
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Meneses2, P. Arias1, I. Dapía1, C. Venegas-Vega3, M.
Calvente4, A. Hernández1, L. Landera5, S. Ramos-Sorigué1,
T. Consortium1, J. Cigudosa4, L. Pérez-Jurado6
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formations laboratory, Federal University of Rio de
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tal, South Australian Health and Medical Research Institute
(SAHMRI), Adelaide, Australia
The proximal 19p13.3 microdeletion/microduplication
(prox19p13.3del/dup) syndrome is a recently described
disorder with common clinical features including develop-
mental delay, intellectual disability, speech delay, facial
dysmorphic features with ear defects, anomalies of the
hands and feet, umbilical hernia and hypotonia. While
deletions are associated with macrocephaly, patients with
duplications have microcephaly. The SRO in multiple
patients (113.5Kb) included three genes and one pseudo-
gene, with a suggested major role of PIAS4 in determination
of the phenotype and head size in these patients. Here we
refine the prox19p13.3del/dup with four additional patients;
two with microdeletions, one with microduplication and for
the first time as far as we know one family with single-
nucleotide nonsense variant in PIAS4:NM_015897.4:
exon9:c.1063C>T:p.Gln355* and concordant phenotype.
The variant was detected by NGS and is not present in her
healthy parents. PIAS4 is an E3 ubiquitin ligase encoded by
PIAS4 and acts as a small ubiquitin-like modifier (SUMO)
ligase that regulates the interaction between E2 enzymes
such as UBE2I and the substrateThe patient with the PIAS4
LoF variant displayed a phenotype quite similar to deletion
patients -including the macrocephaly and many other core
features of the syndrome. Patient’s SNV was inherited from
her mother who is similarly affected. Thus, our data indicate
that PIAS4 is a major contributor to the proximal
19p13.3del/dup syndrome phenotype. In summary, we
report the first patient with a pathogenic variant in PIAS4-
and three additional rearrangements at the proximal 19p13.3
locus. These observations add further evidence about the
molecular basis of this microdeletion/microduplication
syndrome.
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Expanding the spectrum of PPP2R3C-related syndromic
phenotypes to XX gonadal dysgenesis without ocular or
muscular involvement
U. Altunoglu1, E. Börklü-Yücel1, A. Shukla2, N. Escande-
Beillard3, S. Ledig4, H. Azaklı1, S. Nayak2, S. Eraslan1, K.
Girisha2, I. Kennerknecht4, H. Kayserili1
1Koc University School of Medicine, Medical Genetics
Department, Istanbul, Turkey, 2Department of Medical
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Higher Education, Manipal, India, 3Institute of Medical
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Homozygous mutations in PPP2R3C have been reported to
cause a syndromic 46,XY complete gonadal dysgenesis
phenotype with extragonadal manifestations (Gonadal dys-
genesis, dysmorphic facies, retinal dystrophy and myo-
pathy, GDRM, MIM# 615902) in patients from four
unrelated families, whereas heterozygous mutations have
been linked to reduced fertility with teratozoospermia
(SPGF36, MIM# 618420) in male carriers. We present eight
patients from four unrelated families of Turkish and Indian
descent with three different germline homozygous
PPP2R3C mutations including a novel in-frame duplication
(c.639_647dupTTTCTACTC, p.Ser213_Tyr215dup). All
patients exhibited recognizable facial dysmorphisms with
broad eyebrows, underdeveloped alae nasi, thin vermilion
of the lips and low-set ears, allowing for gestalt diagnosis.
46,XX patients had hypergonadotropic hypogonadism and
nonvisualized gonads, and were diagnosed due to primary
amenorrhea along with absence of secondary sexual char-
acteristics and/or unique facial gestalt. 46,XY affected
individuals displayed a spectrum of genital phenotype from
ambiguous to complete female, with Müllerian remnants
confirmed by imaging and/or histopathology. Four of eight
patients were evaluated by fundoscopy, optical coherence
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tomography, and electromyogram, and had no evidence of
retinal dystrophy or a myopathy. We expand the spectrum
of PPP2R3C-related syndromic phenotypes to XX and
incomplete XY gonadal dysgenesis without ocular invol-
vement or myopathy. We speculate a possible role for
PPP2R3C in the early signalling cascade controlling sex
determination in humans, since it causes gonadal dysgenesis
in both sexes.
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The diverse pleiotropic effects of spliceosomal protein
PUF60: a case series of Verheij syndrome
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Poke5, C. McKeown5, M. F. Hunter1,2
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bourne, Melbourne, Australia, 5Genetic Health Service New
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Introduction: Verheij syndrome (VRJS) is a neurodeve-
lopmental and multiple congenital anomaly syndrome
caused by heterozygous SNVs in PUF60 or interstitial
deletions of the 8q24.3 region, where PUF60 is located.
PUF60 encodes a splicing factor which facilitates assembly
of the spliceosome and preferentially activates specific
exons enriched for uridine upstream of their 3’ splice sites.
We undertook a literature review of VRJS caused by
PUF60 SNVs to ascertain the known mutational and phe-
notypic spectrum. This identified 25 individuals exhibiting
marked phenotypic heterogeneity.
Case reports: We report four additional patients,
including the first described patients of Khmer and Indian
ethnicities, with previously unreported heterozygous
PUF60 variants (3 confirmed de novo, 1 undetermined)
identified through clinical exome sequencing. These
included two novel frameshift variants (p.(Pro385Leufs*12)
and p.(Gly268Alafs*18)), a novel missense change (p.
(Arg146Cys)) and one inframe deletion variant (p.
(Ala150_Phe152del)). All four patients had global devel-
opmental delay (GDD) and underwent thorough phenotypic
assessment identifying variable dysmorphism, growth
delay, and congenital anomalies. Features unique to our
Khmer and Indian patients were talon cusps and proximal
insertion of the right hallux, and craniosynostosis,
respectively.
Discussion: In combining this detailed phenotypic data
with the previously reported, and variably phenotyped,
individuals we further refine the known frequencies of
features associated with VRJS. These include GDD (100%),
short stature (68%), limb anomalies (64%), axial skeletal
anomalies (57%), cardiac anomalies (62%), auditory
impairment (50%), colobomata (31%) and other ocular
anomalies (61%). This case series, incorporating two
patients from previously unreported ethnicities, further
delineates the mutational spectrum and pleiotropy of
PUF60 variants.
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Perinatal mortality in Rasopathies
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Bessiere3, J. Martinovic4, P. Letard5, L. Loeuillet6, S.
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Rasopathies are a group of multiple congenital anomalies
syndromes clinically and biologically similar including
Noonan, Cardio-Facio-Cutaneous and Costello syndromes.
Rasopathies occur in a dominant or sporadic manner and are
caused by abnormality of ubiquitous proteins belonging to
the cell signalling pathway RAS-MAPKinase. Prenatal
symptoms including abnormal nuchal translucency, serosis
effusion or polyhydramnios lead to suspect Rasopathies
during pregnancy but little is known about the prognosis of
foetuses with prenatal symptoms. By studying the clinical
presentation and the distribution of molecular anomalies in
affected subjects who died in perinatal period, we aimed to
find prognostic elements which could help in counseling.
Among more than 1500 positives patients for a mutation in
one of the 18 known genes involved in Rasopathies from
the French cohort, we selected subjects who died in peri-
natale period (during pregnancy or within the 28 days after
birth). We collected 65 subjects with severe clinical pre-
sentation leading to pregnancy termination (34), stillbirth
(15) or death within the 28 days after birth (16). Mutations
occurred de novo in 43, was inherited in 14. PTPN11 was
involved in 33 cases (50,7%), RAF1 in 12 (18,5%), RIT1 in
10 (15,4%), SOS1 in 3 (4,6%), BRAF in 3, and HRAS,
NRAS, LZTR1 and NF1 in 1 for each gene. If PTPN11
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remains the major gene, RIT1 and RAF1 are more repre-
sented in this lethal population compared to the post natal
distribution of Rasopathie genes. Whereas SOS1, which is
usually the 2nd gene in Noonan syndrome, is under-
represented.
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The role of A2ML1 variants in Noonan syndrome
remains unverified
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Introduction: The RASopathies are a group of clinically
and genetically heterogeneous developmental disorders
caused by dysregulation of the RAS/MAPK signalling
pathway. Mutations in several components and regulators of
this pathway have been identified as pathogenetic cause. In
2015, missense variants in A2ML1 were reported in three
unrelated families with clinically suspected Noonan syn-
drome (NS). Two subsequent publications reported three
additional A2ML1 variants in NS patients. However, an
association of A2ML1 variants with NS has not been
replicated since. Herein, we report our experience with
A2ML1 mutational screening in a large cohort of patients
with clinically suspected NS or another RASopathy.
Materials and Methods: Individuals included in this
study belong to a cohort of 1029 patients with clinically
suspected NS/RASopathy that underwent multigene panel
sequencing of RASopathy-related genes including A2ML1.
Results: We report on 15 individuals carrying rare
variants in A2ML1, including previously published variants.
The respective A2ML1 variant was inherited in all cases
where parental DNA was available. Seven individuals had
an alternate disease-causing genetic aberration. In cases
with A2ML1 mutations only, careful re-analysis of the
phenotype indicated that clinical features were insufficient
to meet criteria for definite clinical diagnosis of NS in most.
None of the A2ML1 variants evaluated herein reach a
classification above class 3 (VUS) with strict application of
published classification criteria.
Conclusions: Our findings underscore that current
evidence is insufficient to support a causal relation of
variants in A2ML1 and NS. Inclusion of A2ML1 mutation
screening in diagnostic RASopathy testing cannot be
recommended.
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Characterization of a unique karyotype resulting from a
complex rearrangement involving the chromosomes 3
and 4 using chromosome analysis, FISH and array-
CGH in a girl with facial dysmorphism
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Genomic rearrangements can result in losses, gains, trans-
locations and insertions of DNA fragments thereby mod-
ifying genome architecture, and potentially having clinical
consequences. We report on a four-month-old girl with
facial dysmorphism. Physical and motoric development was
normal. Karyotype analysis presented mosaicism, showing
one partially deleted chromosome 4 in all analysed cells and
an additional ring chromosome of unknown origin in only
part of the cells. Array CGH detected different gains
4p15.33p15.31, 4p15.1p12 and 4p12q12 and one deletion
in 4q13.3q22.1. Two gains showed mosaicism of 76%. The
deletion was detected in a mosaic level of 35%. Therefore,
we suggested that the additional ring chromosome consisted
of the detected aberrations showing mosaicism. To prove
this presumption, we performed FISH. The results con-
firmed our hypothesis concerning the ring chromosome and
surprisingly identified an insertion of material of chromo-
some 4 in the short arm of one chromosome 3 in all of the
analysed metaphase spreads. In relation to the array result,
this insertion might represent the gain of 4p15.33p15.31,
detected without mosaicism. As well as for the gains as for
the deletion, different severe clinical effects were described
including developmental delay, behavioural problems, epi-
leptic seizures and facial dysmorphisms. The clinical fea-
tures could differ due to size of the copy number changes as
well as to mosaic level and distribution in different tissues.
Our results suggest that the mosaicism of the 4q deletion
could explain the mild clinical features of the little girl.
Analysis of the parents showed that the chromosome
abnormalities occurred de novo.
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Fetal phenotype of Rubinstein-Taybi syndrome caused
by CREBBP mutations
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Rubinstein-Taybi syndrome (RSTS; OMIM 180849) is an
autosomal dominant developmental disorder characterized
by facial dysmorphism, broad thumbs and halluces asso-
ciated with intellectual disability. RSTS is caused by
alterations in CREBBP (about 60%) and EP300 genes (8%).
RSTS is often diagnosed at birth or during early childhood
but generally not suspected during antenatal period. We
report nine cases of well-documented fetal RSTS. Two
cases were examined after death in utero at 18 and 35 weeks
of gestation and seven cases after identification of ultra-
sound abnormalities and termination of pregnancy. On
prenatal sonography, a large gallbladder was detected in
two cases, and brain malformations were noted in four
cases, especially cerebellar hypoplasia. However, the diag-
nosis of RSTS has not been suggested during pregnancy.
Fetal autopsy showed that all fetuses had large thumbs and/
or suggestive facial dysmorphism. A CREBBP gene
anomaly was identified in all cases. Alterations were similar
to those found in typical RSTS children. This report will
contribute to a better knowledge of the fetal phenotype to
consider the hypothesis of RSTS during pregnancy. Geno-
typing allows reassuring genetic counseling.
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SETBP1 gene variants: from Schinzel-Giedion syn-
drome to mild neurodevelopmental disorder, a challenge
for the clinician.
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Introduction: Genotype-phenotype correlations for
SETBP1 gene are extremely complex and clinically rele-
vant. Nonsense variants and whole gene deletions cause
intellectual disability with marked speech delay, seizures
and facial dysmorphisms. Recurrent missense variants at
codons 868-871, forming the critical consensus sequence of
the degradation signal, have been associated with classic
Schinzel-Giedion syndrome (SGS; MIM269150) which is
characterized by severe developmental delay, facial dys-
morphisms, epilepsy, hydronephrosis, cardiac and brain
anomalies and progressive neurodegeneration, malignancies
and frequent early death. Patients with missense mutation
near the degradation sequence (codons 862, 867, and 873)
exhibit a milder SGS phenotype. Here we report two
patients with novel de novo missense heterozygous SETBP1
variants, presenting with mild and atypical phenotypes.
Case report: Patient 1 is a 3 years old female with
developmental delay, stunted growth, typical SGS facial
dysmorphisms, neutropenia, and joint hypermobility, carry-
ing a p.Ser854Tyr variant. Patient 2 is a 15 years old male,
with speech delay and borderline intellectual disability with
autistic traits, carrying the p.Pro995Leu variant, not
associated with other sign of SGS.
Conclusions: Phenotype severity in patients carrying
SETBP1 missense variants depends on localization and
biological effect of the variants, providing a likely
explanation to the mild phenotypes we have observed in
these patients. Clinical evaluation and prognosis definition
in SETBP1 patients are challenging. Further functional and
genotype-phenotype correlation studies are essential to
establish their natural history and management indications.
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Maternal uniparental disomy of chromosome 20 (UPD
(20)mat) and advanced maternal age in Silver Russell
Syndrome: identification of three new cases.
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Silver Russell Syndrome (SRS, MIM #180860) is a rare
(1:30,000-1:100,000) growth retardation disorder, whose
clinical diagnosis is based on the Netchine-Harbison clinical
scoring system (NH-CSS), combining six features: pre- and
postnatal growth failure, relative macrocephaly, prominent
forehead, body asymmetry and feeding difficulties. The
molecular mechanisms underlying SRS are highly hetero-
geneous, including (epi)genetic deregulation at multiple
loci. Over 50% of SRS show loss of methylation (LOM) at
the paternal H19/IGF2:IG-DMR (chr11p15.5), about 10%
maternal uniparental disomy of chromosome 7 (UPD(7)
mat), while pathogenic CNVs, 14q32 abnormalities, rare
CDKN1C and IGF2 mutations, UPD(16)mat and UPD(20)
mat have been reported in a minority of cases. Our study
was aimed to evaluate the frequency of the rarest known
molecular defects in a cohort of SRS patients with a NH-
CSS≥3. Within a selected cohort of 176 SRS, 55 patients
had LoM at H19/IGF2:IG-DMR (31.3%) and 17 cases
showed UPD(7)mat (9.7%). Further investigations on the
104 remaining patients identified 3 cases sharing
UPD20mat (1,7%), the most frequent out of the rare
alterations. The patients, with a clinical score >3, shared
prominent forehead, feeding difficulties and postnatal
growth delay, while one case had relative macrocephaly,
and another body asymmetry. Interestingly maternal age in
these three UPD(20)mat cases is >40 years and literature
survey pointed out on a total of 16 cases a mean of 38 years,
likely due to its origin by trisomy rescue. Our study iden-
tifies UPD(20)mat as a subclass among patients with NH-
CSS≥3 and elevated maternal age suggesting to introduce
this pathomechanism in the SRS diagnostic flow-chart.
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First record of homozygous loss of function variants in
the SLF2 gene in patients with chromosome instability
syndromes
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N. Nahavandi1, Z. Yüksel1, M. Drasdo1, A. Kron1, P. Vogt1,
A. Jonasson1, S. Ahmed Seth2, M. Tareg Mustafa2, K.
Danish2
1Bioscientia Institute for Medical Diagnostics, Human
Genetics, Ingelheim, Germany, 2King Fahad Military
Medical Complex, Dhahran, Saudi Arabia
The chromosome instability syndromes are a group of
predominantly recessively inherited conditions associated
with defects in DNA repair mechanisms that lead to chro-
mosomal instability and chromosomal breakage. The so far
known Double Strand Break Repair (DSBR) associated
inherited genetic disorders share cancer predisposition,
immunodeficiency, neurological disease and aplastic ane-
mia as main clinical phenotypes. Here we present two
patients with the shared clinical symptoms of severe
intrauterine growth restriction, short stature, hypotonia,
respiratory insufficiency and dysmorphic features. Chro-
mosomal analysis for both patients revealed increased
amount of numerical and structural chromosome aberra-
tions, indicative for a genetic instability syndrome. Whole
exome sequencing analysis revealed novel homozygous
loss of function variants in SLF2 [p.(Arg190*) and p.
(Asp783Serfs*53)]. SLF2 (SMC5-SMC6 complex locali-
zation factor 2) plays a role in the DNA damage response
(DDR) pathway by regulating post-replication repair of UV-
damaged DNA and genomic stability maintenance. The
SLF1-SLF2 complex acts to link RAD18 with the SMC5-
SMC6 complex at replication-coupled interstrand cross-
links (ICL) and DNA double-strand breaks (DSBs) sites on
chromatin during DNA repair. To the best of our knowledge
we are presenting here the first human phenotype of a
chromosome instability syndrome in association with SLF2.
Our findings underline the importance of SLF2 in the DDR
pathway and introduce the first human chromosomal and
phenotypic presentation associated with a defect in this
gene. In addition to diagnostic analysis, reporting scientific
findings in disease candidate genes seems to be a crucial
task of the diagnostic laboratory settings.
N. Nahavandi: None. Z. Yüksel: None. M. Drasdo:
None. A. Kron: None. P. Vogt: None. A. Jonasson: None.
S. Ahmed Seth: None. M. Tareg Mustafa: None. K.
Danish: None.
P11.90.C
Prevalence of NF1 missense mutations and candidate
modifier genes in 12 familial and 15 sporadic spinal
neurofibromatosis patients
P. Riva1, E. Mangano2, C. Cesaretti3, P. Bettinaglio1, R.
Bordoni2, V. Tritto1, C. Battaglia1, V. Saletti4, D.
Bianchessi4, M. Marina Melone5, C. Schettino5, F.
Natacci3, M. Eoli4
1Univrsità degli Studi di Milano, Milano, Italy, 2CNR,
Milano, Italy, 3Fondazione IRCCS Cà Granda Ospedale
Maggiore Policlinico, Milano, Italy, 4Fondazione IRCCS
Istituto Neurologico Carlo Besta, Milano, Italy, 5Università
della Campania Luigi Vanvitelli, Napoli, Italy
Spinal Neurofibromatosis (SNF) is a specific form of
Neurofibromatosis type 1 (NF1) characterized by bilateral
neurofibromas involving all spinal roots. This feature allows
to specifically distinguish SNF from Neurofibromatosis type
1 (NF1), and Multiple Neurofibromas Few Spinal Root
(MNFSR), presenting single/few isolated spinal neurofi-
bromas. While the clinical phenotype of SNF, MNSFR and
classical NF1 can be revealed by spinal MRI, little is known
on the molecular basis underlying these conditions. We
investigated 12 NF1 families with at least one SNF patient,
15 sporadic SNF/MNSFR patients, diagnosed by Spinal
MRI. We applied Targeted NGS using a panel consisting of
139 genes encoding RAS pathway effectors, neurofibromin
interactors and genes mapping at 17q11.2 region. On
identified 26 NF1 variants, 36,6% were missense mutations,
indicating an increased prevalence in our cohort versus
27,7% missense/nonsense mutations reported in Italian
(PMID: 26740943) and in a British (PMID:28637487) NF1
population. Furthermore, we evaluated rare variants with
damaging predictors in genes of RAS pathway and neuro-
fibromin interactors. In more than one sporadic case pos-
sible pathogenic variants were found in LIMK2, RASAL1,
RASAL3, SOS1, A2ML1, MAP3K1, while in more than
one SNF family were detected RASAL1, RASAL3,
MAP3K1 genes variations. Our results confirm the high
frequency of missense mutations in SNF as reported
(PMID: 26740943, PMID:25211147), indicating neurofi-
bromin gain-of-function variants as associated to SNF. In
some patients, the co-occurrence of potential pathogenic
variants in NF1 related genes are detected with severe
phenotypes, suggesting that they might be modifier genes
and promising pharmacological targets. Italian Ministry of
Health RF-2016-02361293.
P. Riva: None. E. Mangano: None. C. Cesaretti: None.
P. Bettinaglio: None. R. Bordoni: None. V. Tritto: None.
C. Battaglia: None. V. Saletti: None. D. Bianchessi:
None. M. Marina Melone: None. C. Schettino: None. F.
Natacci: None. M. Eoli: None.
P11.91.A
New cohort of patients with CEDNIK syndrome
expands the phenotypic and genotypic spectra
482 J. del Picchia
A. Y. Mah-Som1, C. Skrypnyk2, R. Hamad3, V. Nivrutti3, A.
Guerin4, M. Shinawi1
1Washington University School of Medicine, Saint Louis,
MO, United States, 2Department of Molecular Medicine, Al
Jawhara Center for Molecular Medicine, Genetics and
Inherited Diseases, College of Medicine and Medical
Sciences, Manama, Bahrain, 3Division of Medical Genetics,
Department of Pediatrics, Bahrain Defense Force Hospital,
Manama, Bahrain, 4Department of Pediatrics, Queen’s
University, Kingston, ON, Canada
Introduction: CEDNIK (cerebral dysgenesis, neuropathy,
ichthyosis, and keratoderma) syndrome (MIM# 609528) is a
rare condition (15 published cases) caused by biallelic loss-
of-function variants in SNAP29, which encodes a protein
involved in membrane trafficking processes. Clinical man-
ifestations include developmental delay (DD)/ intellectual
disability (ID), brain malformations including cortical
migration and corpus callosum (CC) defects, failure to
thrive, and skin abnormalities.
Materials and Methods: Clinical trio exome or targeted
sequencing was performed for each case to elucidate the
cause of DD/ID and of other specific findings.
Results: We report five patients with homozygous
predicted loss-of-function variants in SNAP29, four of
which are from consanguineous marriages. All patients
exhibit DD/ID, ichthyosis and/or palmoplantar keratoderma,
and hypotonia with spasticity. 3/5 subjects had seizures and
4/5 had ophthalmological findings. Other phenotypes were
variable between cases, including facial features, poor
growth and feeding difficulties, and recurrent respiratory
infections. The cohort includes 2 siblings with a c.2T>C
variant who have a milder neurological phenotype, a patient
with the most C-terminal variant yet described (c.622G>T)
with a more severe phenotype, and two patients with
previously described variants (c.354dupG, c.487dupA).
Conclusions: We describe five additional patients with
CEDNIK syndrome, including novel SNAP29 variants and
the oldest known surviving individual. Our cohort expands
the genotypic and phenotypic (seizures and strabismus)
spectrum of CEDNIK syndrome.
Table 1. Phenotypic and genotypic data of patients with
CEDNIK syndrome
Patient 1&2 3 4 5
Age (yrs) 19, 12 8 4 7
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A.Y. Mah-Som: None. C. Skrypnyk: None. R. Hamad:
None. V. Nivrutti: None. A. Guerin: None. M.
Shinawi: None.
P11.93.C
Loss-of-function mutations of TMEM260 cause auto-
somal recessive polycystic kidney, cerebral atrophy and
cardiac malformation
T. M. Keszthelyi1,2, M. Varga3, D. Czimer3, D. Ralbovszki3,
L. Ablonczy4, C. Bole5, C. Antignac5, K. Tory1,2
1Semmelweis University, Ist Department of Pediatrics,
Budapest, Hungary, 2MTA-SE Lendület Nephrogenetic
Laboratory, Budapest, Hungary, 3Department of Genetics,
Eötvös Loránd University, Budapest, Hungary, 4Gottsegen
György National Institute of Cardiology, Budapest, Hun-
gary, 5INSERM, UMR 1163, Imagine Institute, Paris,
France
Introduction: Association of polycystic kidney, cerebral
atrophy and truncus arteriosus had not been reported in the
medical literature until recently. We aimed to identify the
causal gene and to explore the function of the encoded
protein.
Materials and methods: Exome sequencing was per-
formed in a 5-year-old male. The localization of the protein
was studied by immunofluorescence staining in transiently
transfected IMCD3 cells after the induction of ciliogenesis.
Mutant zebrafish lines were generated by the CRISPR/
Cas9 system.
Results: We identified compound heterozygous truncat-
ing mutations in the TMEM260 gene: c.592_593delTT, p.
Leu198Valfs44* (paternal) and c.1854C>A (p.Tyr618*)
(maternal). Out of the two isoforms
(ENST00000261556.11, long”; ENST00000538838.5,
short”), only the long is affected by the p.Tyr618* mutation,
allowing the short isoform to be properly translated. We
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successfully generated tmem260 biallelic loss-of-function
mutant zebra danio lines. Homozygous mutants with
different LOF mutations show no obvious phenotype.
Interestingly, in contrast to the proteins implicated in ciliary
kidney disorders, TMEM260 long isoform showed a
moderate cytoplasmic and a strong nuclear membrane
localization. The short isoform located in the cytoplasm and
strongly in the nucleus. Neither isoforms were detectable in
the primary cilium. Mutations of TMEM260 cause auto-
somal recessive polycystic kidney, cerebral atrophy and
truncus arteriosus.
Conclusions: Our results are strongly supported by one
publication indicating the role of TMEM260 in this
syndrome. The preserved translation of the short isoform
in all three affected families strongly suggest that the
dysfunction of the short isoform is intrauterine lethal.
T.M. Keszthelyi: None. M. Varga: None. D. Czimer:
None. D. Ralbovszki: None. L. Ablonczy: None. C. Bole:
None. C. Antignac: None. K. Tory: None.
P11.96.C
Possible improvement in phenotype definition of
Weidemann-Steiner syndrome by Whole Exome
Sequencing
E. Fiorentini, G. Traficante, R. Artuso, G. Gori, G.
Forzano, S. Giglio
Medical Genetics Unit, Department of Clinical and
Experimental Biomedical Sciences ‘Mario Serio’, Univer-
sity of Florence, I-50139 Florence, Italy., Florence, Italy
We report the case of a boy evaluated mainly for trigono-
cephaly and generalized seizures. His critical events were
poorly controlled by antiepileptic multi-drug therapy. His
phenotype with some facial features (thick eyebrows, epi-
canthus, long filtering, thin upper lip), growth and psy-
chomotor development delay, renal ectopia, complete hip
dislocation, thin corpus callosum with scarcity of white
matter, did not suggest any specific condition. Karyotype
and CGH-array analysis were normal. Whole exome
sequencing (WES) revealed a heterozygous frameshift
variant in KMT2A, resulting in a premature stop codon.
Variants in KMT2A have been already described in patients
with Wiedeman-Steiner Syndrome (WSS). This gene
encodes a histone methyltransferase involved in the reg-
ulation of chromatin-mediated transcription and it is widely
expressed in most human tissues. The majority of WSS-
associated variants reported so far are de novo loss-of-
function, predicted to result in premature termination of
translation and nonsense-mediated decay of the corre-
sponding transcripts. WSS is a rare autosomal dominant
disorder, characterized by short stature, developmental
delay and intellectual disability, hypertrichosis (cubiti-hairy
elbow-or generalized) and facial dysmorphism. Concerning
the incidence of bone anomalies, to date trigonocephaly (a
feature at our first evaluation) has been reported only in one
case, while craniovertebral junction anomalies have been
described in two other patients; both of these signs were not
included in the features associated with WSS. Further data
will be needed to evaluate the exact incidence of these
features in subjects with WSS associated with hap-
loinsufficiency of a gene involved in histone-mediated
chromatin remodeling.
E. Fiorentini: None. G. Traficante: None. R. Artuso:
None. G. Gori: None. G. Forzano: None. S. Giglio: None.
P11.97.A
Phenotypic spectrum of Xp22 duplication; A tertiary
center experience
N. Alsaleh1, I. Ben Abdallah2, A. Al Hashem1,3, H. El
Ghezal2
1Division of Genetic and Metabolic Medicine, Department
of Pediatrics, Prince Sultan Military Medical City, Riyadh,
Saudi Arabia, 2Cytogenetics and Molecular Genetics
Division, Prince Sultan Military Medical City, Riyadh,
Saudi Arabia, 3Department of Pediatrics, College of
Medicine, AlFaisal University, Riyadh, Saudi Arabia
Introduction: Evidence strongly supports the use of chro-
mosomal microarray analysis as a first-tier cytogenetic
diagnostic tool in patients with developmental delay/intel-
lectual disability and multiple congenital anomalies. Copy
number variants (CNV) involving the X chromosome has
been previously described, mainly deletions (e.g. Leri-Weill
dyschondrostsosis). However, little is known about pheno-
types arising from duplications. In this study, we reviewed
CNVs involving the short arm of the X chromosome, spe-
cifically duplications involving band P22. This region
contains 194 genes, only 107 have an OMIM description
(e.g. SHOX and STS).
Materials and Methods: Cases that underwent array
comparative genomic hybridization between years (2016-
2019) were reviewed. Indication for testing was variable,
ranging from developmental delay, seizures to multiple
congenital anomalies. We focused on cases with duplication
involving Xp22
Results: 69 cases reported with CNVs involving the X
chromosome. (33/69) with Xp22 duplication. (17/33)
Females and (16/33) males. (1/33) involving Xp22.2, (1/
33) involving Xp22.3, (1/33) involving Xp22.32, (12/33)
involving Xp22.31 and (18/33) involving Xp22.33. The
size of the duplication ranged from 147 Kb to 2.3 Mb. The
detected CNVs ranged from benign or likely benign (12/
484 J. del Picchia
33), pathogenic or likely pathogenic (9/33) and variants of
unknown significance (12/33). Some cases were de novo,
others were inherited from a healthy parent. Variable
expressivity and low penetrance were observed in this
cohort.
Conclusions: Deletions affecting the X chromosome is
usually associated with a known clinical syndrome that
could be male lethal. However, duplications tend to be
milder, showing variable expressivity and penetrance,
which makes it hard to confirm pathogenicity.
N. Alsaleh: None. I. Ben Abdallah: None. A. Al
Hashem: None. H. El Ghezal: None.
P11.98.B
Deleterious de novo variants of X-linked ZC4H2 in
females cause a variable phenotype with neurogenic
arthrogryposis multiplex congenita
S. G. M. Frints1,2, F. Hennig3, R. Colombo4,5, S.
Jacquemont6, P. Terhal7, H. H. Zimmerman8, D. Hunt9, B.
A. Mendelsohn10, U. Kordaß11, R. Webster12, M.
Sinnema1,2, O. Abdul-Rahman13, V. Suckow3, A. Fernández-
Jaén14, Deciphering Developmental Disorders (DDD)
Study, S. J. C. Stevens1,2, M. V. E. Macville1,2, K. van
Roozendaal1, S. Al-Nasiry15, K. van Gassen7, N. Utzig16, S.
M. Koudijs17, L. McGregor18, S. M. Maas19, D. Baralle9,20,
A. Dixit21, P. Wieacker22, M. Lee23, A. S. Lee24,25, E. C.
Engle24,25,26, G. Houge27, A. G. L. Douglas9,28, C.
Longman29, S. Joss29, G. A. Gradek27, D. Velasco30, R. C.
Hennekam31, H. Hirata32, V. M. Kalscheuer33
1Department of Clinical Genetics, Maastricht University
Medical Center+, azM, Maastricht, Netherlands, 2Depart-
ment of Genetics and Cell Biology, Faculty of Health
Medicine Life Sciences, Maastricht University Medical
Center+, Maastricht University, Maastricht, Netherlands,
3Max-Planck-Institute for Molecular Genetics, Berlin,
Germany, 4Catholic University of the Sacred Heart, Rome,
Italy, 5Center for the Study of Rare Inherited Diseases
(CeSMER), Niguarda Ca’ Granda Metropolitan Hospital,
Milan, Italy, 6Service de Génétique Médicale, CHUV,
Lausanne, Switzerland, 7Laboratories, Pharmacy and
Biomedical Genetics Division, University Medical Centre
Utrecht, Utrecht, Netherlands, 8Department of Pediatrics,
Division of Medical Genetics, University of Mississippi
Medical Center, Mississippi, MS, United States, 9Wessex
Clinical Genetics Service, University Hospital Southampton
NHS Foundation Trust, Southampton, United Kingdom,
10Division of Genetics, Department of Pediatrics, Univer-
sity of California, San Francisco, CA, United States, 11MVZ
für Humangenetik und Molekularpathologie GmbH, Zweig-
stelle Greifswald, Greifswald, Germany, 12The Department
of Neurology and Neurosurgery, The Children’s Hospital at
Westmead, Westmead, Australia, 13Munroe-Meyer Institute
for Genetics & Rehabilitation, University of Nebraska
Medical Center, Omaha, NE, United States, 14Hospital
Universitario Quirón de Madrid, Madrid, Spain, 15Depart-
ment of Obstetrics and Gynecology, Prenatal Diagnostics
& Therapy, Maastricht University Medical Center+, azM,
Maastricht, Netherlands, 16Universitätsmedizin Greifswald,
Klinik für Kinder- und Jugendmedizin, Greifswald, Ger-
many, 17Department of Neurology, Maastricht University
Medical Center+, azM, Maastricht, Netherlands, 18SA
Clinical Genetics Service, Women’s and Children’s Hospi-
tal, Adelaide, Australia, 19Department of Clinical Genetics,
Amsterdam UMC location AMC, Amsterdam, Netherlands,
20Faculty of Medicine, University of Southampton, South-
ampton, United Kingdom, 21Nottingham University Hospi-
tals NHS Trust, City Hospital Campus,, Nottingham, United
Kingdom, 22Institute of Human Genetics, Westfälische
Wilhelms Universität Münster, Münster, Germany,
23Department of Pediatrics, Division of Pediatric Neurol-
ogy, University of Mississippi Medical Center, Mississippi,
MS, United States, 24Department of Neurology, Boston
Children’s Hospital and Harvard Medical School, Boston,
MA, United States, 25Broad Institute of MIT and Harvard,
Cambridge, MA, United States, 26Department of Ophthal-
mology, Boston Children’s Hospital and Harvard Medical
School, Boston, MA, United States, 27Department of
Medical Genetics, Haukeland University Hospital, Bergen,
Norway, 28Human Development and Health, Faculty of
Medicine, University of Southampton, Southampton, United
Kingdom, 29West of Scotland Regional Genetic Centre,
Queen Elizabeth University Hospital, Glasgow, United
Kingdom, 30Department of Pediatrics, Munroe-Meyer
Institute for Genetics & Rehabilitation, University of
Nebraska Medical Center, Omaha, NE, United States,
31Department of Pediatrics, Amsterdam UMC, Amsterdam,
Netherlands, 32Department of Chemistry and Biological
Science, College of Science and Engineering, Aoyama
Gakuin University, Sagamihara, Japan, 33Research Group
Development and Disease, Max-Planck-Institute for Mole-
cular Genetics, Berlin, Germany
Introduction: Pathogenic variants in the X-linked gene
ZC4H2 cause an infrequently described syndromic form of
arthrogryposis multiplex congenita (AMC) with central and
peripheral nervous system involvement (ZC4H2-Associated
Rare Disorders, ZARD).
Materials and Methods: We performed exome sequen-
cing and array-CGH and tested ZC4H2 missense variants
identified in affected patients in zebrafish.
Results: We present genetic and detailed phenotypic
information on 23 newly identified families and simplex
cases that include 19 affected females from 18 families and
14 affected males from nine families. The genetic spectrum
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of ZC4H2 defects comprises novel and recurrent mostly
inherited missense variants in affected males, and de novo
splicing, frameshift, nonsense, and partial ZC4H2 deletions
in affected females. Two newly identified missense variants
were investigated by studies in zebrafish and the results
supported pathogenicity. Of note, the 15 females with
deleterious de novo ZC4H2 variants presented with
phenotypes ranging from mild to severe, and their clinical
features overlapped with those seen in affected males. By
contrast, of the nine carrier females with inherited ZC4H2
missense variants that were deleterious in affected male
relatives, four were symptomatic. We also compared
clinical phenotypes with previously published cases of both
sexes and provide an overview on 48 males and 57 females
from 42 families.
Conclusions:We propose ZC4H2 as a good candidate for
early genetic testing of males and females with a clinical
suspicion of fetal hypo-/akinesia and/or (neurogenic) AMC.
Grants: DDD study HICF-1009-003 and WT098051, Dutch
NWO VENI OND1312421 (to SGM), NEI R01EY027421
and NHLBI X01HL132377 (to ECE).
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None. U. Kordaß: None. R. Webster: None.M. Sinnema:
None. O. Abdul-Rahman: None. V. Suckow: None. A.
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Functional annotation of 5p15 risk locus for Barrett’s
esophagus and esophageal adenocarcinoma
J. Schröder1, R. Hollstein1, I. Gockel2, R. Thieme2, K. U.
Ludiwg1, J. Schumacher3, A. C. Böhmer1
1Institute of Human Genetics, University of Bonn, School of
Medicine & University Hospital Bonn, Bonn, Germany,
2Department of Visceral, Transplant, Thoracic and Vas-
cular Surgery, University Hospital of Leipzig, Leipzig,
Germany, 3Center for Human Genetics, University Hospital
of Marburg, Marburg, Germany
Esophageal adenocarcinoma (EA) and its precancerous
condition Barrett’s esophagus (BE) are multifactorial dis-
eases with rising prevalence rates in Western populations.
Our recent integrative analysis of GWAS and GTEx eQTL
data showed that the risk allele of the sentinel SNP
(rs147462972) at the genome-wide significant locus 5p15 is
associated with increased SLC9A3 expression in esophageal
mucosa tissue. Interestingly, upregulation of this gene has
been linked to gastro-esophageal reflux disorder, a major
risk factor for BE development. Therefore, we hypothesize
that rs147462972 maps to a regulatory element influencing
SLC9A3 expression. To study the regulatory mechanisms at
5p15, chromatin interactions are analyzed using circular
chromosome conformation capture (4C) technology from
two distinct viewpoints, the promoter of SLC9A3 and the
region around rs147462972. The method was first estab-
lished in induced pluripotent stem cells (iPSC), where
numerous interactions at the locus and beyond were
observed. Further analyses will be performed in different
cell lines representative of the course of BE/EA develop-
ment: healthy epithelium (EPC1), Barrett’s esophagus (CP-
A), intraepithelial neoplasia (CP-B), and EA (OE19).
No interaction between the SLC9A3 promoter and the
sentinel SNP was detected at 5p15 in iPSC. A lack of this
interaction was assumed, since these cells do not express
SLC9A3. Based on these results, the experiments in
esophageal cell lines are currently ongoing and the results
will be presented at the conference. Our work will help to
understand the contribution of the risk locus 5p15 to the
etiology of BE and EA, and the role of SLC9A3 in their
pathogenesis.
J. Schröder: None. R. Hollstein: None. I. Gockel:
None. R. Thieme: None. K.U. Ludiwg: None. J.
Schumacher: None. A.C. Böhmer: None.
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Discovery of novel tumor-associated exonic incertions of
polymorphic retroelements in human genome
A. Y. Komkov1,2, M. Saliutina1,3, M. Kulikov3, E. Volchkov2,
S. Urazbakhtin1,3, A. Popov2, M. Maschan2, Y. Lebedev1, Y.
Olshanskaya2, I. Mamedov1,2
1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry
of the Russian Academy of Sciences, Moscow, Russian
Federation, 2Dmitry Rogachev National Medical Research
Center Of Pediatric Hematology, Oncology and Immunol-
ogy, Moscow, Russian Federation, 3Lomonosov Moscow
State University, Moscow, Russian Federation
Introduction: Retroelements (RE) make a significant con-
tribution to many mono- and polygenic disorders, including
different types of cancer. New RE insertion can lead to exon
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deletion, exon disruption and alternative splicing, including
formation of RE-containing exon. Most tumor-related
insertions are individual-specific owing to germline or
somatic retroposition events. Here we investigate exonic
polymorphic RE insertions (PREI) distributed in
population.
Materials and methods: Two cohorts of 200 healthy
donors and 120 pediatric lymphoblastic leukemia patients
were used for this study. Whole genome identification of
RE insertions was conducted using target high-throughput
sequencing of genome fragments adjusted to insertions of
active RE. Novel detected PREIs were validated using
capillary sequencing. PREI allele status in donors was
identified using locus-specific PCR.
Results: We identified five exonic PREIs among all
detected polymorphic insertions. Frequency of bi-allelic
PREI (AluYa5) in PRAMEF4 gene exon was significantly
higher in healthy female cohort compared to healthy males
(p-value=0.05, two-tailed Fisher’s exact test) and in T-
lineage leukemia male cohort compared to healthy male
donors (p-value=0.01). Leukemia samples with bi-allelic
PREI in PRAMEF4 had specific (p-value=0.008) immu-
nophenotype: CD33-CD13-CD34-CD117-CD56-CD1a
+CD3+CD4+CD8+CD10+ inherent to more mature
lymphoblasts.
Discussion: The results demonstrate that PREI in
PRAMEF4 exon could participate in leukemogenesis in
gender-dependent manner affecting male patients despite
AluYa5-containing exons present in population. We
hypothesize that bi-allelic insertion in PRAMEF4 exon is
insufficient for leukemogenesis and requires additional
mutations in sex chromosomes because of gender-specific
nature of the observed phenomenon. The study was
supported by RFBR grant 18-315-20038 and RSF grant
18-14-00244.
A.Y. Komkov: None. M. Saliutina: None. M. Kulikov:
None. E. Volchkov: None. S. Urazbakhtin: None. A.
Popov: None. M. Maschan: None. Y. Lebedev: None. Y.
Olshanskaya: None. I. Mamedov: None.
P12.003.B
Driver mutations in pediatric core binding factor acute
myeloid leukemia
T. Nasedkina1, L. Ghukasyan1, G. Krasnov1, L. Baidun2, S.
Ibragimova3
1Engelhardt Institute of Molecular Biology of the Russian
Academy of Sciences, Moscow, Russian Federation, 2Rus-
sian Children’s Clinical Hospital, Moscow, Russian
Federation, 3Scientific Research Institute of Hematology
and Blood Transfusion, Tashkent, Uzbekistan
Introduction: Core binding factor acute myeloid leukemia
(CBF-AML) combines two entities, which differ sig-
nificantly in their clinical and biological features, AML with
t(8;21) and AML with inv(16). High-throughput sequencing
methods reveal characteristic mutation spectra in two leu-
kemia subtypes; however, the role of different mutation
events in tumorigenesis remains unclear.
Patients and methods: In total, 9 patients with t(8;21)
and 16 patients with inv(16) were investigated (13 boys and
12 girls, mean age 7.2 years). For 18 patients, paired
samples at diagnosis and remission were analyzed. Coding
regions of 84 genes, involved in the pathogenesis of AML,
were captured with SeqCap EZ Target Enrichment System
(NimbleGen, Roche) and sequenced using NextSeq500
Illumina platform.
Results: In both AML subtypes, somatic mutations in the
genes KIT (40%), NRAS (24%), KRAS (16%), FLT3 (12%)
were found. The KIT mutations were more common for inv
(16) compared to t(8;21) (56% vs. 11%, p = 0.04). In the
group with inv(16), KIT mutations in exon 8 (66%)
prevailed comparing with exon 17 (33%); two patients
(12.5%) had biallelic KIT mutations. In group with t(8;21),
mutations in the SMC1A (cohesin complex), CBL, CBLB,
ASXL1, TET1, EZH2 genes were revealed. In patients with
inv(16), mutations in the KDM6A and KMT2A genes,
involved in chromatin modification, were found.
Conclusions: Mutational profiling revealed characteristic
differences in spectrum and frequency of somatic mutations
in patients with t(8;21) and inv(16). Novel mutations, which
may be involved in leukemia development, were identified.
The work was supported by the Russian Science Founda-
tion (grant # 18−15-00398).
T. Nasedkina: None. L. Ghukasyan: None. G. Kras-
nov: None. L. Baidun: None. S. Ibragimova: None.
P12.004.C
Molecular studies for gain of cytarabine-resistance in
AML cells with FLT3-ITD mutations
P. Chen1, Z. Chen2, L. Lin3, J. Yen2
1Center of Medical Genetics, Hualien Tzu Chi Hospital,
Hualien, Taiwan, 2Department of Molecular Biology and
Human Genetics, Tzu Chi University, Hualien, Taiwan,
3Department of Clinical Laboratory Sciences and Medical
Biotechnology, National Taiwan University, Taipei, Tai-
wan
Introduction: Although cytarabine (ara-C) has remained an
important cornerstone for treatment of acute myeloid leu-
kemia (AML) for decades, chemo-resistance is common
and the overall survival of adult AML patients is less than
40%. Internal tandem duplication mutations in the FLT3
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tyrosine kinase receptor (FLT3-ITD) account for up to 30%
of cases and are associated with a poor outcome. To
understand the role of FLT3-ITD in the development of
drug resistance. An ara-C resistant cell line (MV-4-11-CR)
was established from parent MV-4-11 cells which harbors
FLT3-ITD. Here, we compared MV-4-11-CR with MV-4-
11 cells, and explored the underling mechanisms for
developing resistance in FLT3-ITD AML cells.
Materials and Methods: MV-4-11-CR and MV-4-11
cells were performed tests including MTT assay, RTqPCR,
Western blot, G-banding and SKY.
Results:MV-4-11-CR cells were highly resistant to ara-C
by their high IC50 value, and enhanced cell growth rate.
This cell line was confirmed to retain the homologous
FLT3-ITD mutations. However, a significant increase of
FLT3-ITD mRNA and protein was observed. To test
whether FLT3-ITD activation is crucial for resistance, we
measured the effects of combined treatment of cells with
ara-C and FLT3 inhibitors. Inhibition of FLT3 was notably
effective in cell viability, but not effective in drug
sensitivity. We further compared genomic alterations and
found multiple chromosomal changes and complex karyo-
types. Moreover, down-regulation of deoxycytidine kinase
(DCK), a cytarabine metabolic enzyme, was observed in
MV-4-11-CR.
Conclusions:We suggest that gain the resistance to ara-C
may be associated with chromosomal aberrations and DCK
deficiency in FLT3-ITD+ AML cells.




ing of AML patients
F. Kraft1, P. Krüger1, S. Koschmieder2, E. Jost2, M.
Crysandt2, I. Kurth1
1Institute of Human Genetics, University Hospital RWTH
Aachen, Aachen, Germany, 2Department of Medicine
(Hematology Oncology, Hemostaseology, and Stem Cell
Transplantation), University Hospital RWTH Aachen,
Aachen, Germany
Introduction: The current diagnostic scheme for classifi-
cation of acute myeloid leukemia (AML) patients is usually
based on cytogenetic and molecular biology methods. The
turnaround time for karyotype analysis is up to two weeks,
due to the indispensable cultivation of hematopoietic cells.
Although initial PCR or FISH-based testing for recurrent
structural variations (SV) can be carried out within few
hours, the AML classification is demanding and requires
accurate karyotyping.
Methods: We utilized nanopore-sequencing to overcome
the time-consuming karyotyping and further increase
resolution and accelerate SV analysis for AML classifica-
tion. In detail, low-coverage whole genome sequencing
(LC-WGS) was carried out in combination with a modified
SMURFseq protocol on AML bone marrow or blood
samples (≥20% blasts). LC-WGS data was used to identify
classification-relevant SV in AML. Genome-wide CNV
analysis was done from SMURFSeq data.
Results: For all 16 samples the results from nanopore-
sequencing confirmed the SV identified by conventional
cytogenetic and FISH analyses. Translocations, inversions,
tandem duplications and CNVs were identified at single
base resolution. We could detect additional small CNVs in
growth regulating genes which may modify the aggressive-
ness of the leukemia. Moreover, the procedure from DNA
isolation to obtaining results requires less than 48h and is
not operator dependent. The method can also generate
karyotype data from samples for which the cell cultivation
failed.
Conclusions: We show that nanopore-sequencing can
speed-up and potentially improve the comprehensive
analysis of SV in AML. Rapid classification according to
ELN risk stratification will immediately impact on targeted
and risk adapted treatment of AML patients.
F. Kraft: None. P. Krüger: None. S. Koschmieder:
None. E. Jost: None.M. Crysandt: None. I. Kurth: None.
P12.008.A
Classification of ATM variants identified in Spanish
patients with suspicion of hereditary cancer
L. Feliubadaló1,2,3, M. Santamariña Peña4,5,6, L. Porras7,8,
A. Moles-Fernández9, A. Sánchez10,11, A. Blanco12,13,5, O.
Diez9,14, S. Gutiérrez-Enríquez9, M. de la Hoya15,16, A.
Lopez-Novo17, A. Osorio18,5, M. Pineda1,2,3, D. Rueda19,20,
C. Ruiz-Ponte21,5, A. Vega12,13,5, I. J. Molina22, X. de la
Cruz7,8,23, C. Lázaro1,2,3
1Hereditary Cancer Program, Catalan Institute of Oncol-
ogy, IDIBELL, Hospitalet de Llobregat, Spain, 2Program in
Molecular Mechanisms and Experimental Therapy in
Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat,
Spain, 3Centro de Investigación Biomédica en Red de
Cáncer (CIBERONC), Madrid, Spain, 4Grupo de Medicina
Xenómica. Instituto de Investigación Sanitaria de Santiago
de Compostela, Santiago de Compostela, Spain,
5CIBERER, Madrid, Spain, 6Universidad de Santiago de
Compostela, Santiago de Compostela, Spain, 7Research
Unit in Clinical and Translational Bioinformatics, Vall
d’Hebron Institute of Research (VHIR), Barcelona, Spain,
8Universitat Autònoma de Barcelona, Barcelona, Spain,
9Hereditary Cancer Genetics Group, Vall d’Hebron
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Institute of Oncology (VHIO), Barcelona, Spain, 10Heredi-
tary Cancer Program, Catalan Institute of Oncology,
Barcelona, Spain, 11Aberystwyth University, Aberystwyth,
United Kingdom, 12Fundación Pública Galega Medicina
Xenómica-SERGAS, Santiago de Compostela, Spain,
13Instituto de Investigación Sanitaria de Santiago de
Compostela (IDIS), Santiago de Compostela, Spain, 14Area
of Clinical and Molecular Genetics, University Hospital of
Vall d’Hebron, Barcelona, Spain, 15CIBER-ONC, Instituto
de Salud Carlos III, Madrid, Spain, 16Molecular Oncology
Laboratory, Hospital Clinico San Carlos, IdISSC (Instituto
de Investigación Sanitaria del Hospital Clínico San
Carlos), Madrid, Spain, 17Fundacion Publica Galega de
Medicina Xenómica, Grupo de Medicina Xenomica-
Universidade de Santiago de Compostela, Instituto de
Investigacion Santiago de Compostela (E035), Santiago de
Compostela, Spain, 18Human Genetics Group, Spanish
National Cancer Research Centre (CNIO), Madrid, Spain,
19Digestive Cancer Research Group, 12 de Octubre
Research Institute, Madrid, Spain, 20Molecular Biology
Laboratory, 12 de Octubre University Hospital, Madrid,
Spain, 21Fundacion Publica Galega de Medicina Xenomica,
Grupo de Medicina Xenomica-Universidade de Santiago de
Compostela, Instituto de Investigacion Sanitaria de San-
tiago de Compostela (E035), Santiago de Compostela,
Spain, 22Institute of Biopathology and Regenerative Med-
icine, University of Granada, Granada, Spain, 23Institució
Catalana de Recerca i Estudis Avançats (ICREA), Barce-
lona, Spain
The use of NGS gene panels for clinical testing has
increased the diagnostic yield, but also the frequency of
variants of unknown significance (VUS) per patient. With
the aim of improving and standardizing variant classifica-
tion, we’ll create a national registry of genetic variants in
cancer predisposing-genes. To that end, seven Spanish
molecular laboratory groups currently using NGS panels for
hereditary cancer diagnostics created a variant database.
Our current database gathers all variants with less than 1%
allele frequency in all GnomAD outbred populations,
starting with the ATM gene, study because of its moderate
increase in breast cancer risk and its remarkable number of
VUSes. The methodology consisted of: 1) selection and
curation of 50 representative variants from our cohort; 2)
evaluation of each by three members; and 3) discussion of
evidences for classification in monthly teleconferences. As
ATM-specific guidelines have not been published, we have
previously carried out our own ACMG/AMP criterion
adjustment. So far, 842 variants belonging to 730 tested
patients with different hereditary cancer conditions. Among
the 265 unique variants, 97 appeared more than once, and
35 had differences in classification among groups. Our new
ATM-specific criteria have allowed us to improve and
standardize the classification of the 50 pilot variants. We’ll
next submit our classifications to international databases
and extend our database to other Spanish participants and
hereditary cancer genes. Grant support: Carlos III National
Health Institute - FEDER funds [PI19/00553; PI16/00563;
PI16/01898; SAF2015-68016-R and CIBERONC]; the
Government of Catalonia [PERIS_MedPerCan and URD-
Cat projects, 2017SGR1282 and 2017SGR496].
L. Feliubadaló: None. M. Santamariña Peña: None. L.
Porras: None. A. Moles-Fernández: None. A. Sánchez:
None. A. Blanco: None. O. Diez: None. S. Gutiérrez-
Enríquez: None. M. de la Hoya: None. A. Lopez-Novo:
None. A. Osorio: None. M. Pineda: None. D. Rueda:
None. C. Ruiz-Ponte: None. A. Vega: None. I. J. Molina:
None. X. de la Cruz: None. C. Lázaro: None.
P12.009.B
Establishing a scalable automation approach with the
epMotion and Ampliseq for Illumina
M. Hahn1, V. Montel2, N. Mouttham2, E. Gancarek3, S.
Hamels3, U. Wilkening1, J. Tsai2
1Eppendorf AG, Hamburg, Germany, 2Illumina Inc, San
Diego, CA, United States, 3Eppendorf Application Tech-
nologies SA, Namur, Belgium
Due to the growing number of relevant genes and variants,
next generation sequencing (NGS) has become a standard
technique in the field of cancer research and molecular
pathology. AmpliSeqTM panels for Illumina® have been
introduced to study the growing number of interesting var-
iants in an increasing number of relevant genes. In theory,
library preparation with such panels promise the ability query
many interesting loci in DNA or RNA isolated from a broad
range of specimen, including blood, cell culture, and
formalin-fixed paraffin-embedded (FFPE) tissue at low
efforts. However, especially working with the latter materials
can represent practical challenges that require robust and
established workflows for analytical studies. Here we sought
to establish a workflow for this purpose using automated
liquid handling for library preparation on the epMotion sys-
tem that can accommodate both RNA and DNA samples. We
show exemplary NGS sequencing data achieved with the
AmpliSeq for Illumina Focus panel assembled from indivi-
dual DNA and RNA reference sample sets with known
mutations and quality generated in a single automated setup.
We found high run-to-run reproducibility and repeatability
(R²>0.98) with 100% success rate for library preparation
(DNA n = ; RNA n = preparations). Call rates of known
variants (R²>0.99) and fusion transcripts were consistent over
several independent experimental replicates. Furthermore
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variant calling and index representation were comparable to
manual preparations performed on the same samples. The
flexibility and scalability of this approach may aid in the
routine study of different samples and throughputs, while
reducing the hands-on time.
M. Hahn: A. Employment (full or part-time); Significant;
Eppendorf AG. V. Montel: A. Employment (full or part-
time); Significant; Illumina Inc. N. Mouttham: A. Employ-
ment (full or part-time); Significant; Illumina Inc. E.
Gancarek: A. Employment (full or part-time); Significant;
Eppendorf Application Technologies SA. S. Hamels: A.
Employment (full or part-time); Significant; Eppendorf
Application Technologies SA. U. Wilkening: A. Employ-
ment (full or part-time); Significant; Eppendorf AG. J.
Tsai: A. Employment (full or part-time); Significant;
Illumina Inc.
P12.010.C
Family with mesothelioma and variant of unknown
significance in the BAP1 gene
B. W. van Paassen, N. M. van Poppelen, R. Cornelissen, J.
von der Thüsen, A. de Klein, E. Kilic
Erasmus MC, Rotterdam, Netherlands
The BAP1 tumor predisposition syndrome (BAP1-TPDS) is
a hereditary tumor syndrome caused by germline patho-
genic variants in BAP1. It is associated with increased risks
for uveal melanoma, mesothelioma, cutaneous melanoma,
renal cell carcinoma, and cutaneous BAP1-inactivated nevi.
A 50 year old female patient presented with pneumothorax,
caused by bilateral mesothelioma, with no history of
asbestos exposure. Molecular analysis of the tumor showed
a pathogenic variant and a variant of unknown significance
(the c.535C>T, p.(Arg179Trp) variant) in the right tumor.
The left tumor showed the same variant of unknown sig-
nificance (VUS) as found in the other tumor, but no second
mutation. Both tumors showed no staining for BAP1 by
immunohistochemistry. DNA analysis of a blood sample
confirmed that the VUS is present in the germline. RNA
analysis showed expression of both the wild type and the
variant allele in the same amount. Clinical work up of the
patient showed no signs of uveal melanoma. Testing of
healthy parents showed the VUS is present in the 80 year
old mother of the proband. In the meantime the mother also
developed mesothelioma, with no history of asbestos
exposure. Molecular analysis of the tumor of the mother
showed the VUS that is present in germline and another
somatic VUS in the other BAP1 allele. The tumor was
positive for staining of the BAP1 protein. Family history is
positive for basal cell carcinoma, leiomyosarcoma of the
kidney and lung cancer. At the moment further testing of
affected family members is conducted.
B.W. van Paassen: None. N.M. van Poppelen: None. R.
Cornelissen: None. J. von der Thüsen: None. A. de
Klein: None. E. Kilic: None.
P12.012.B
Clinically important variants in Slovene bilateral breast
cancer patients tested between 2014 and 2019
G. Klancar1, P. Skrel1, V. Setrajcic Dragos1, V. Stegel1, A.
Blatnik2, K. Strojnik2, M. Banjac2, M. Krajc2, S. Novaković1
1Institute of Oncology, Division of Diagnostics, Department
of Molecular Diagnostics, SI-1000 Ljubljana, Slovenia,
2Cancer Genetics Clinic, Institute of Oncology Ljubljana,
Ljubljana, Slovenia, SI-1000 Ljubljana, Slovenia
Introduction: Bilateral breast cancer accounts for 2-11% of
all breast cancer cases. By the literature, 5-30% of patients
with bilateral breast cancer carry a pathogenic variant in the
high-penetrant BRCA genes. Our aim was to determine the
spectrum of pathogenic variants in HBOC genes among
Slovene bilateral breast cancer patients.
Materials and Methods: Among 2483 HBOC patients
tested between years 2014 and 2019, 205 patients with
bilateral breast cancer were included in the study. gDNA
was extracted from peripheral blood and NGS sequencing
was performed using Nextera_DNA_Library_Preparation_-
Kit in combination with Illumina’s TruSight_Cancer_Panel
or TruSight_Hereditary_Panel. All variants were classified
according to ACMG_guidelines.
Results: Among 205 patients with bilateral breast cancer,
124 (60.5%) had positive HBOC family history and 81
(39.5%) had no HBOC family history. A pathogenic variant
in one of HBOC genes listed in the NCCN guidelines was
detected in 58 patients, which represents 28.3% of all
patients. Most of them (67.2 %) were patients with positive
HBOC family history. Majority of patients with pathogenic
variant harbored variant in BRCA genes: 50.0% in BRCA1
and 27.6% in BRCA2. Other pathogenic variants were
discovered also in other genes CHEK2 (6.9%), PALB2
(5.2%), TP53 (3.4%), CDKN2A (3.4%), PTEN (1.7%) and
PMS2 (1.7%).
Conclusions: Majority of bilateral breast cancer patients
with positive family history had pathogenic variant in
HBOC genes: 68.9% of cases in BRCA genes and 61.5%
cases in other genes. The frequency of BRCA pathogenic
variants in Slovene patients with bilateral breast cancer is
similar to frequencies reported in the literature.
G. Klancar: None. P. Skrel: None. V. Setrajcic Dragos:
None. V. Stegel: None. A. Blatnik: None. K. Strojnik:
490 J. del Picchia
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Novaković: None.
P12.013.C
Comprehensive analysis of prominent molecular bio-
markers for TGCT diagnostics
J. Krasic1,2,3, D. Raos1,2,3, A. Katusic Bojanac1,2, S.
Masic2,4, M. Ulamec2,3,4, F. Bulic-Jakus1,2, D. Jezek2,5, N.
Sincic1,2,3
1Department of Medical Biology, School of Medicine
University of Zagreb, Zagreb, Croatia, 2Centre of Excel-
lence for Reproductive and Regenerative Medicine, School
of Medicine University of Zagreb, Zagreb, Croatia, 3Epi-
Mark, Group for Research on Epigenetic Biomarkers,
Zagreb, Croatia, 4University Clinical Hospital Center
Sestre milosrdnice, Ljudevit Jurak Clinical Department of
Pathology and Cytology, Zagreb, Croatia, 5Department of
Histology and Embryology, School of Medicine University
of Zagreb, Zagreb, Croatia
Introduction: Testicular germ cell tumours (TGCTs) are
classified into seminoma (SE) and non-seminoma (NSE) of
various types. They originate from germ cell neoplasia
in situ (GCNIS) caused by genetic and epigenetic incidents.
With currently used TGCT biomarkers lacking specificity
and sensitivity, stronger discriminatory biomarkers for
various forms of TGCTs are needed. Our goal was to
evaluate the diagnostic potential of POU5F1, NANOG,
KIT, SALL4, HOXA9 and MGMT assessed at the protein
level (current clinical use) alongside mRNA expression,
DNA alteration and DNA methylation using prominent
databases.
Materials and Methods: For immunohistochemical
detection, 108 FFPE TGCTs and 48 tumour-free testes
were analysed semi-quantitatively. TGCT patient’s data
were retrieved from TCGA while healthy adult testis data
from GTEx datasets, and analysed using XENA, UALCAN
and cBioPortal platforms.
Results: Our results suggest that TGCT could be
discriminated from healthy tissue by difference in mRNA
levels (all investigated genes), while SE from NSE by
increased mRNA level (KIT) and DNA hypomethylation
(MGMT and HOXA9). Identification of individual NSE
types and GCNIS was possible only by analysing gene
expression at the protein level (HOXA9, KIT, SALL4 and
POU5F1), since databases present NSE as a single entity
and no data on GCNIS.
Conclusions: There is discriminatory value in gene
expression at the mRNA level and DNA methylation of
analysed genes in TGCT diagnostics. Promoting the
inclusion of further molecular analyses, rather than just at
the protein level, enhances the development of TGCT
diagnostics as has recently been done for other types of
tumours.
J. Krasic: None. D. Raos: None. A. Katusic Bojanac:
None. S. Masic: None. M. Ulamec: None. F. Bulic-Jakus:
None. D. Jezek: None. N. Sincic: None.
P12.014.A
BIRC5 gene polymorphisms and gene expression of eight
different isoforms in breast cancer
V. Musani1, M. Vincetić1, I. Sušac2, M. Sabol1, D. Trnski1,
P. Ozretić1
1Rudjer Boškovic Institute, 10000 Zagreb, Croatia, 2Eljuga
Polyclinic, 10000 Zagreb, Croatia
Introduction: Survivin (encoded by BIRC5 - baculoviral
IAP repeat containing 5) gene is the smallest member od the
family of inhibitors of apoptosis (IAP) proteins. Breast
cancer (BC) is one of the most common cancers and is one
of the leading causes of cancer related deaths in women in
the world.
Materials and Methods: The whole coding region,
including alternate exons S-2α, S-2B and S-3B, as well as
5’ and 3’UTR regions of BIRC5 gene was genotyped in
eighteen BC patients. Eight different BIRC5 gene isoforms
(S-WT, S-2α, S-2B, S-3α, S-3B, S-Δex3, S-3γM and S-
3γV) were analyzed at the mRNA expression level in BC
samples and matching healthy tissues. TBP gene was used
as housekeeping control.
Results: Eleven different polymorphisms were found in
the breast cancer samples. All eight isoforms were detected
in BC samples, but isoforms S-3γM and S-3γV were not
expressed in any of the healthy matching tissues. S-WT and
S-2α isoforms had the highest expression, followed by S-
Δex3, S-3B, S-2B, S-3α, and S-3γM and S-3γV had the
lowest. All isoforms, except for S-2B, S-3γM and S-3γV,
had significantly higher expression in cancer tissue in
comparison to healthy tissue. Expression of three isoforms,
S-3α, S-3γM and S-3γV showed significant association with
polymorphisms c.-644T>C, c.9386T>C, c.9809T>C and
c.10611C>A.
Conclusions: At least eight different BIRC5 isoforms are
expressed in breast cancer. The isoforms showed significant
positive association in BC tissues, and less so in healthy
tissue. The isoforms showed significant association with
different polymorphisms.
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P12.016.C
Rare congenital disease: Bloom syndrome. Complex
cytogenetic and molecular genetic analysis
R. Michalovská1, V. Krulišová1, T. Píš1, L. Hrušková1, H.
Paszeková1, M. Gančarčíková2, Z. Vlčková1
1GHC Genetics, Praha, Czech Republic, 2LLG, Pardubice,
Czech Republic
Introduction: Bloom syndrome (BS) is a very rare auto-
somal recessive disease characterized by prenatal and
postnatal growth retardation, photosensitive skin changes,
immune deficiency, insulin resistance, and significantly
increased risk of cancer in very young age. BS is caused by
pathogenic variants in the BLM gene. Absence of functional
BLM protein causes chromosome instability, excessive
homologous recombination, and increased numbers of sister
chromatids exchanges.
Materials and Methods: We performed massive parallel
sequencing on NextSeq (Illumina) using Sequence Capture
(ROCHE) panel of 55 genes. Examination of spontaneous
chromosome aberrations (ZCA) and classical conventional
cytogenetic analysis (G band) were used as standard
cytogenetic procedures.
Results: The 12 year old boy born from second
physiological pregnancy (sp2760 g, PD 46 cm) was
genetically examined for a number of non-specific clinical
problems and due to the occurrence of cancer in the family,
respectively. We detected variants in BLM gene in the
compound heterozygous state c.1642C>T (p.Gln548Ter,
rs200389141, inherited maternally, class 5) and c.2015A>G
(p.Gln672Arg, rs747281324, inherited paternally, class 4),
which confirmed clinical diagnosis of Bloom syndrome.
Subsequent cytogenetic analysis of SCE and ZCA supports
the outcome of molecular genetic testing and presents
complex examination in the rare chromosome instability
syndrome of the genome
Conclusions: Given the anamnestic data, a very rare
disease called Bloom syndrome was predicted as a possible
genetic background of the patient’s phenotype.
R. Michalovská: None. V. Krulišová: None. T. Píš:
None. L. Hrušková: None. H. Paszeková: None. M.
Gančarčíková: None. Z. Vlčková: None.
P12.017.A
Differential expressed genes in BRAF-positive versus
BRAF-negative papillary thyroid carcinomas
S. Schipor, D. Manda, C. Poalelungi, I. Nedelcu, A.
Muresan
"C. I. Parhon" National Institute of Endocrinology,
Bucharest, Romania
Introduction: BRAFV600E is the most prevalent mutation
in patients with papillary thyroid carcinoma (PTC). The
successful targeted therapies against this mutation explain
the importance of the analysis of concomitant molecular
transformations in this pathology.
Materials and methods: In order to evaluate the differential
gene expression profile between BRAF-positive and BRAF-
negative samples in PTC patients we used DNA Agilent
microarray. There were included 24 patients (8 classical PTC,
14 follicular variant of PTC, 2 insular and/or sclerosing variant
of PTC), with 2 samples per patient (tumor and normal
samples) obtained shortly after surgery. Patients gave their
informed consent for study before surgery. Microarray analysis
was performed following Agilent One-Color Microarray-Based
Gene Expression protocol, ver 6.6, using SurePrint G3 Human
Gene Expression arrays 8x60Kv2. BRAF status was deter-
mined by Sanger sequencing.
Results: The list of differential expressed genes (DEGs)
between BRAF(+) and BRAF(-) samples was obtained by
statistical analysis using GeneSpring GX-PA 14.5 software.
Moderated T-Test with p < 0.05 identified 541 DEGs.
Applying a fold-change >2 the list restricted to 536 DEGs
(366 up-regulated, 170 down-regulated). A subsequent analysis
(one-way ANOVA, p-value with Benjamini-Hochberg correc-
tion) gave a final list of 125 DEGs, 91 genes upregulated and
34 down-regulated between cPTC and the other types of
tumors. The Kegg pathway analysis suggested “pathways in
cancer” as the most significant signal pathway, followed by N-
glycan biosynthesis and glycolysis/gluconeogenesis.
Conclusions: Differential gene expression analysis could
be a valuable source of information regarding the molecular
changes and pathways involved in BRAF-related papillary
thyroid carcinomas (CNCS-UEFISCDI grant PCCA-2011-
3.2-1337)
S. Schipor: None. D. Manda: None. C. Poalelungi:
None. I. Nedelcu: None. A. Muresan: None.
P12.018.B
Identification of BRCA1/2 large deletions in DNA
isolated from FFPE tumor tissues and blood.
A. Podgorska1, A. Stachurska1, E. Kwiatkowska1, A. Janiec-
Jankowska1, A. Grzelak1, D. Nowakowska2, M. Prochorec-
Sobieszek1, A. Tysarowski1
1Department of Pathology and Laboratory Diagnostics,
Maria Sklodowska-Curie National Research Institute of
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Oncology, Warsaw, Poland, 2Genetic Outpatient Clinic,
Maria Sklodowska-Curie National Research Institute of
Oncology, Warsaw, Poland
Introduction: Pathogenic germline mutations in BRCA1 and
BRCA2 can be identified in more than 10% of hereditary breast
and ovarian cancers. With the introduction of targeted therapy
for BRCA-deficient recurrrent ovarian cancer and breast can-
cer, testing for somatic/germline mutations in BRCA1/2 genes
in tumor tissue became essential for treatment decisions.
Identification of pathogenic BRCA1/2 variants, especially large
rearrangements in DNA isolated form FFPE, is challenging due
to the high fragmentation grade of formalin-treated DNA and
chemical modifications that lower the DNA quality. Therefore,
the aim of the study was to verify the usefulness of NGS
analysis of BRCA1/2 large rearrangements detection in DNA
isolated from blood and FFPE samples.
Materials and Methods: 920 blood samples from
patients with ovarian/breast cancer and 233 FFPE tissue
samples from ovarian cancer patients were enrolled. FFPE
tumor cell content was determined by a pathologist and
tumor tissue was micro-dissected prior to DNA isolation.
The NGS technology was used to detect BRCA1/2 large
rearrangements in all the samples. All detected BRCA1/2-
deletions were confirmed by MLPA method.
Results: In total we detected 18 large deletions: 12 in 920
blood-derived DNA and 6 in 233 FFPE isolated DNA. In 15
cases deletions were detected in BRCA1 gene and 3 in BRCA2.
Conclusions: The detection rate of large rearrangements was
similar in both FFPE samples and blood derived DNA reaching
1% and 3%, respectively. The results show that BRCA1/2 large
rearrangements can be reliably detected in both FFPE and
blood derived DNA by next-generation sequencing (NGS).
A. Podgorska: None. A. Stachurska: None. E. Kwiat-
kowska: None. A. Janiec-Jankowska: None. A. Grzelak:
None. D. Nowakowska: None. M. Prochorec-Sobieszek:
None. A. Tysarowski: None.
P12.019.C
Identification and characterization of regulatory var-
iants in BRCA1/2 causing hereditary breast and ovarian
cancer
J. Bublitz, J. L. van Luttikhuizen, S. Schubert, W. Hofmann,
G. Schmidt, B. Schlegelberger, D. Steinemann
Department of Human Genetics, Hannover, Germany
Introduction: The genetic predisposition causing heredi-
tary breast and ovarian cancer (HBOC) remains in the
majority of patients unknown. We hypothesize that a subset
of HBOC is caused by regulatory variants located outside of
coding regions of the highly penetrant genes BRCA1 and
BRCA2 (BRCA1/2).
Materials and Methods: We selected 96 high-risk
HBOC patients tested negative for (likely) pathogenic
variants in 94 cancer-associated genes using the TruSight
Cancer panel and high resolution CGH-arrays. Their
genomic BRCA1/2 loci including introns and flanking
intergenic regions, comprising ̴140 kb each, were first
enriched using a SureSelect custom panel and subsequently
sequenced on Illumina NextSeq 500.
Results: Of 629 and 663 detected variants in BRCA1 and
BRCA2, respectively, 1̴00 variants per gene had a MAF
≤0.1% in the general population (gnomAD) and <5% in our
cohort. Using in silico analyses, such as CADD, ncER, and
Alamut, remaining variants were further prioritized. Among
others, one BRCA1 variant (c.5333-469T>A, intron 21 of
23) is predicted to create a novel acceptor splice site, which
appears stronger than the canonical site. The variant might
lead to intron retention, which is currently tested on
transcription level to prove the predicted splicing effect.
Conclusions: As the field of genomic sequencing and
variant interpretation rapidly progresses, regulatory variants
should be included in the search for cancer predisposing
variants. The identification and characterization of genetic
predispositions outside the coding genome cannot only
provide HBOC patients with superior treatment and
prevention plans, but may also offer new insights into
transcriptional regulation of BRCA1/2.
J. Bublitz: None. J.L. van Luttikhuizen: None. S.
Schubert: None. W. Hofmann: None. G. Schmidt: None.
B. Schlegelberger: None. D. Steinemann: None.
P12.020.A
Is HRT safe for BRCA mutation carriers after risk
reduction salpingo-oophorectomy? A 7.5 year cohort
study
S. Gabizon-Peretz1, S. Paluch-Shimon1,2, S. Armon1,3, E.
Levy-Lahad1,4, R. Michaelson-Cohen1,3,4
1Hebrew University of Jerusalem, Jerusalem, Israel, 2Divi-
sion of Oncology, Shaare Zedek Medical Centre, Jerusa-
lem, Israel, 3Department of Obstetrics & Gynecology,
Shaare Zedek Medical Center, Jerusalem, Israel, 4Medical
Genetics Institute, Shaare Zedek Medical Center, Jerusa-
lem, Israel
Introduction: Hormonal replacement treatment (HRT)
after Risk-Reducing-Salpingo-oophorectomy (RRSO) in
BRCA1/2 mutation carriers is controversial. In the general
population, HRT slightly raises breast cancer (BC) risk
(HR=1.34). However, it is unclear whether this applies to
mutation carriers. Our hypothesis was that short-term use of
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HRT from RRSO till age 50 would not elevate BC risk
significantly more than baseline risk of healthy carriers.
Methods: A retrospective cohort of 306 healthy BRCA1/
2 mutation carriers who had undergone RRSO was
followed-up for a mean duration of 7.26 years. We
compared BC incidence over time in carriers who received
HRT vs. those who didn’t.
Results: During follow-up, BC incidence was 22/150
(14.7%) in HRT group vs. 16/156 women (10.2%) in non-
HRT group (OR= 1.371, NS), when controlled for age, the
association appeared stronger (OR=1.996, NS). However,
survival analysis didn’t demonstrate a significant difference in
BC incidence (HR=1.777, NS), possibly due to shorter follow-
up in HRT group (6.2 vs. 8.3 years, p < 0.001). Median age at
BC diagnosis appeared earlier (43.5 vs. 49 years, respectively),
and latency period to BC diagnosis seemed shorter in HRT
group vs. non-HRT group (invasive BC 1.58 vs. 3.45 years,
respectively, DCIS 1.92 vs. 6.52 years, respectively), however,
neither of these differences was significant.
Conclusions: In our BRCA carrier cohort, followed for
~7.5 years post-RRSO, there is no evidence that HRT
elevates breast cancer incidence, or significantly shortens
the latency period between RRSO and cancer diagnosis.
However, caution in HRT administration is warranted until
larger, prospective studies show similar results.
S. Gabizon-Peretz: None. S. Paluch-Shimon: None. S.
Armon: None. E. Levy-Lahad: None. R. Michaelson-
Cohen: None.
P12.021.B
Recurrent BRCA2 Pathogenic Exon 5-11 Duplication in
the Christian Arab Population in Northern Israel
N. Ekhilevitch
rambam, HAIFA, Israel
Most of the genetic research of BRCA1/2 genes germline
mutations in Israel have been focused on the Jewish Israeli
Population. The Christian Arab population in Israel
accounts for about 2% of the population. Unlike in the
Jewish population founder BRCA1/2 mutations have not yet
been reported in the Christian Arab population.
Here we describe a recurrent BRCA2 pathogenic rearran-
gement in four patients from different families with a
personal and/ or familial history of Hereditary Breast and
Ovarian Cancer (HBOC). During the years 2015-2019, 20
Christian Arab patients with a personal or familial history of
breast (BC) and/ or ovarian (OC) cancer were referred to
BRCA1/2 testing (Sequencing and Copy Number Variants
(CNV’s) analysis). A recurrent gross duplication of the
genomic region encompassing exons 5-10 and the 5’ portion
of exon 11 of the BRCA2 gene was found in 4 out of 20
(20%) patients from different Christian Arab families. This
duplicated is expected to result in an absent or disrupted
protein product. A similar duplication has been reported in
the literature in two individuals affected with BC. The Exon
5-11 BRCA2 Duplication is a recurrent rearrangement,
possibly founder in the Christian Arab population in
Northern Israel. It is important to include CNV’s analysis
in all Christian Arab patients suspected for HBOC.
Farther research is needed to evaluate the carrier
frequency of this rearrangement in the Christian Arab
population and the degree of its penetrance. These results




Hereditary breast and ovarian cancer: two cases of
double heterozigosity for pathogenic variants in the
BRCA1 or BRCA2 and ATM genes
P. Theisen1, P. Rodrigues1, C. Silva2,3, D. Carpinteiro2, L.
Ribeiro4, H. Carreiro5, H. Gervásio6, J. Leal da Silva7, L.
Vieira2,3, J. Gonçalves3
1Molecular Genetics Unit, Human Genetics Department,
National Institute of Health Dr. Ricardo Jorge, Lisbon,
Portugal, 2Technology and Innovation Unit, Human
Genetics Department, National Institute of Health Dr.
Ricardo Jorge, Lisbon, Portugal, 3Centre for Toxicoge-
nomics and Human Health (ToxOmics) Nova Medical
School, Faculty of Medical Sciences, New University of
Lisbon, Lisbon, Portugal, 4Hematology-Oncology Service,
CUF Infante Santo Hospital, Lisbon, Portugal, Lisbon,
Portugal, 5Oncological Risk Consultation, CUF Infante
Santo Hospital, Lisbon, Portugal, Lisbon, Portugal,
6Hematology-Oncology Service, CUF Viseu Hospital,
Viseu, Portugal, 7Medical Oncology Service, Luz Arrábida
Hospital, Vila Nova de Gaia, Portugal
Introduction: Hereditary breast and ovarian cancer
(HBOC) is estimated to represent 5-10% of all breast and
ovarian cancer cases. Pathogenic germline variants in
BRCA1 and BRCA2 account for 25% of familial cases. The
identification of genetic defects in HBOC patients allows
detection of carriers that can benefit from cancer risk
management protocols, and predictive genetic testing to at-
risk family members, after appropriate genetic counseling.
Two female patients with a personal and family history of
cancer were studied by next-generation sequencing (NGS).
Methods: NGS using TruSight Cancer Panel (Illumina)
followed by bioinformatic analysis of 18 genes associated
with HBOC was performed. Pathogenic variants were
confirmed by Sanger sequencing.
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Results: A rare event of double heterozigosity for
pathogenic variants was identified in both patients: patient
A was heterozygous for BRCA1:c.2037delinsCC, p.
(Lys679Asn*4) and ATM:c.3802delG, p.(Val1268*) and
patient B carried both BRCA2:c.6001dupT, p.(Ser2001-
Phefs*2) and ATM:3435_3436delTGinsA, p.
(Asp1145Glufs*11). After genetic counseling, three rela-
tives of patient A were analyzed: while one of her two
healthy sons was heterozygous for the ATM variant, the
other was a double heterozygote for BRCA1:
c.2037delinsCC and ATM:c.3802delG; a female cousin,
recently diagnosed with breast cancer, was a carrier of
ATM:c.3802delG only.
Conclusions: The identification of these two rare cases of
double heterozigosity for pathogenic variants in BRCA1/
BRCA2 and ATM genes, highlights the importance of using
NGS-gene panel testing in HBOC. If molecular analysis had
been restricted to BRCA genes only, the pathogenic ATM
variants would have been missed in both families, depriving
them of appropriate genetic counseling and cancer risk
management.
P. Theisen: None. P. Rodrigues: None. C. Silva: None.
D. Carpinteiro: None. L. Ribeiro: None. H. Carreiro:
None. H. Gervásio: None. J. Leal da Silva: None. L.
Vieira: None. J. Gonçalves: None.
P12.023.A
The landscape of BRCA1 and BRCA2 variants from
300,000 individuals in the UK Biobank population
sampling
Z. Ghazoui
AstraZeneca, Cambridge, United Kingdom.
Prior prevalence estimates of BRCA1 and BRCA2 protein-
truncating variants (PTVs) have been generally limited to
studies that have ascertained for cancer patients or individuals
with a family history of cancer. The aim of this study is to
utilise one of the largest sequenced Biobank populations to
investigate the prevalence of BRCA1 and BRCA2 PTVs and
ClinVar pathogenic/likely pathogenic classified missense
variants. We analysed whole-exome sequence data from
300,000 UK Biobank participants (https://www.ukbiobank.
ac.uk/), which is a prospective cohort study linked to deep
phenotypic data. Among the 300,000 exomes, we identified
1332 carriers of high confidence rare PTVs in BRCA1/2 and
another set of 62 carriers of rare ClinVar pathogenic/likely
pathogenic classified missense variants in BRCA1/2. Of the
1394 BRCA1/2 putatively pathogenic variant carriers, 529
(38.0%) have been diagnosed with cancer, 455 (32.6%) have
a reported family history of cancer but are not diagnosed with
cancer and 410 (29.4%) have no reported history (or family
history) of cancer. For the 529 individuals with a cancer
diagnosis we further evaluated the contribution that they have
to 100 distinct ICD10 primary cancer phenotypes and iden-
tified that ovarian (5.3% of reported), breast (2% of reported),
prostate (1% of reported), pancreas (1.5% of reported) and
lung (1.1% of reported) cancers are amongst the cancers that
are significantly enriched for these BRCA1/2 putatively
pathogenic variants. This study provides an unbiased sum-
mary of germline BRCA1/2 contribution to various primary
cancers and highlights the value of careful variant
interpretation.
Z. Ghazoui: A. Employment (full or part-time); Sig-
nificant; AstraZeneca.
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Mutational spectrum of tumor susceptibility genes in
Bulgarian BRCA1/2 negative patients with ovarian
cancer
M. Atanasoska1,2, R. Vazharova1,3, L. Balabanski1, S.
Ivanov1, S. Yaneva-Staykova1, D. Toncheva1,4
1Gynecology and assisted reproduction hospital “Malinov
MD”, Sofia, Bulgaria, 2Sofia University St. Kliment
Ohridski, Faculty of Biology, Department of Genetics,
Sofia, Bulgaria, 3Sofia University St. Kliment Ohridski,
Faculty of Medicine, Department of Biology, Medical
genetics and Microbiology, Sofia, Bulgaria, 4Department
of Medical Genetics, Medical University of Sofia, Sofia,
Bulgaria
Introduction: There are more than 840 ovarian cancer
cases in Bulgaria and more than 240 000 worldwide, every
year. OC represents 3.7% of all female cancers and it is the
main cause for cancer deaths with gynecologic malignancy.
Fifteen to thirty five percent of the familial cases are carriers
of pathogenic variants in tumor suppressor genes. There are
more than 16 known genes associated with hereditary
ovarian carcinogenesis. Here we present a retrospective
review of rare genetic variants in different tumor suppressor
genes in BRCA1/2 negative Bulgarian patients with diag-
nosed ovarian cancer.
Materials and Methods: Our cohort includes 91 patients
diagnosed with ovarian cancer. Their DNA samples were
investigated for the presence of pathogenic variants in 94
cancer-predisposing genes. Sequence analysis was per-
formed on an Illumina platform.
Results: We identified germline pathogenic variants in
24% (21/91) of the patients. The pathogenic variants in the
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BRCA1/2 genes were detected in 17% (16/91) of the
patients. In 6.6% (5/75) of BRCA1/2 negative patients
pathogenic loss-of-function variants were observed in ATM,
CHEK2, FANCA, FANCL and BLM genes.
Conclusions: The risk of ovarian cancer increases
parallel with the modernization and the social economic
development. The precise and fast identification of
pathogenic variants in the ovarian cancer-predisposing
genes is a key in the decision-making process for therapy
strategies. Our results gain a better understanding of the
genetic complexity of the disease and may result in a more
personalized approach for cancer risk management in a
preventive settings, early diagnosis, prognosis and treatment
of ovarian cancer.
M. Atanasoska: None. R. Vazharova: None. L.
Balabanski: None. S. Ivanov: None. S. Yaneva-Stay-
kova: None. D. Toncheva: None.
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Relevance of RNA analysis for the classification of
BRCA1 intronic variants and clinical management of
family members
S. Sousa1,2, M. Ferreira1,2, S. Maia3,4, F. Ramos3, M.
Baixia1,2, M. S. Quental1,2, D. Pinho1,2, S. Castedo1,2,5
1Institute of Molecular Pathology and Immunology of the
University of Porto (Ipatimup), Porto, Portugal, 2Institute for
Research and Innovation in Health (i3S), University of Porto,
Porto, Portugal, 3Medical Genetics Unit, Hospital Pediat́rico,
Centro Hospitalar e Universitaŕio de Coimbra, Coimbra,
Portugal, 4University Clinic of Genetics, Faculty of Medicine,
University of Coimbra, Coimbra, Portugal, 5Faculty of
Medicine, University of Porto, Porto, Portugal
Introduction: Carriers of BRCA1 or BRCA2 pathogenic
variants have a high lifetime risk of developing breast and/or
ovarian cancer. The most common pathogenic variants in
BRCA1 gene are nonsense and frameshift variants, however
there are well documented pathogenic missense and splice site
variants. Classification of intronic variants can be challenging
and frequently demands further molecular studies. We iden-
tified a breast cancer (BC) family with six family members
affected with BC. In the proband c.4675+3A>C BRCA1
variant was identified, which was later found to be present in
two more affected relatives (of the remaining patients, two
were deceased and one awaits genetic counselling). Due to
lack of further evidence, this variant was classified as variant
of unknown significance, according to the ACMG guidelines.
To clarify the clinical significance of this variant, we decided
to evaluate its splicing impact.
Material and Methods: We performed RT-PCR in
cDNA synthetized from a RNA sample of the proband,
followed by Sanger sequencing, to evaluate the splicing
impact of the c.4675+3A>C BRCA1.
Results: We were able to identify an aberrant transcript,
as a result of the creation of a new splice site, located 5`-
upstream from the canonical site that is translated into a
truncated protein, p.Gln1556Glyfs*14.
Conclusions: Based on these findings and the absence of
this variant in the population, we were able to reclassify the
c.4675+3A>C BRCA1 variant as pathogenic, thereby
warranting the genetic study of at risk relatives, and making
carriers eligible for surveillance and, when clinically
applicable, treatment with PARPi.
S. Sousa: None. M. Ferreira: None. S. Maia: None. F.
Ramos: None. M. Baixia: None. M.S. Quental: None. D.
Pinho: None. S. Castedo: None.
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Investigating of genetic variants, associated with breast
cancer in Russian women
T. Lisitsa1, A. Danishevich1, M. Litvinova1, N. Bodunova1,
E. Shagimardanova2, L. Shigapova2, O. Gusev2,3
1Moscow Clinical Scientific Center n.a. Loginov, Moscow
Healthcare Department, Moscow, Russian Federation,
2Institute of Fundamental Medicine and Biology, Kazan
(Volga Region) Federal University, Kazan, Russian Fed-
eration, 3Cluster for Science, Technology and Innovation
Hub, RIKEN, Wako, Japan
Introduction: Breast cancer is the most common cancer in
women. Genetic testing is used to identify hereditary breast
cancer. Hereditary breast cancer is a polygenic disease, and
next-generation sequencing allows the most comprehensive
genetic examination of patients.
Materials and Methods: We performed the analysis of
the genomic DNA of 62 patients with a diagnosis of breast
cancer, who were treated in Moscow Clinical Scientific
Center n.a. Loginov. The average age at diagnosis were
43 ± 6.5 years. Three patients were diagnosed with bilateral
breast cancer, and another 4 had a combination of breast
cancer and other malignancy. A family history of 31
patients was burdened with malignant tumors. All patients
had negative test results for 8 frequent mutations in the
BRCA1/2 genes. DNA was isolated from leukocytes of
peripheral blood. For sample preparation, enrichment by
hybridization with NimbleGen probes (Roche) was used.
Results: We identified 140 variants in 49 genes in 48
patients with a minor allele frequency <1%. 57 variants
were annotated as variants with uncertain clinical signifi-
cance. In 12 patients, pathogenic and likely pathogenic
variants were found in the genes BRCA1, BRCA2, MSH6,
PALB2, TP53, CTNNA1, FANCE.
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Conclusions: It is necessary to conduct prospective
monitoring of patients, as well as segregation analysis in
families, to estimate clinical significance of the identified
genetic variants. Investigation the effect of cancer-
associated genes variants can help to understand the
processes of carcinogenesis and individualize the treatment
and further observation and provide genetic counseling for
patients and their relatives.
T. Lisitsa: None. A. Danishevich: None. M. Litvinova:
None. N. Bodunova: None. E. Shagimardanova: None.
L. Shigapova: None. O. Gusev: None.
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Study of relative mRNA expression of TRAIL-induced
apoptotic pathway components in breast carcinogenesis
E. Roupou1, M. Michelli1, I. Chatziandreou1, N.
Michalopoulos2, P. Karathanasis3, A. Lazaris1, A. Saetta1
11st Department of Pathology, School of Medicine,
National and Kapodistrian University of Athens, Athens,
Greece, 2Department of Surgery Attikon Hospital, School of
Medicine, National and Kapodistrian University of Athens,
Athens, Greece, 31st Department of Propaedeutic Surgery
Hippokrateion Hospital, School of Medicine, National and
Kapodistrian University of Athens, Athens, Greece
Introduction: Exploitation of TRAIL apoptotic pathway as
a therapeutic target led in promising results in vivo, and
although the efficacy of such monotherapies/combination
therapies in clinical trials did not meet the expectations,
TRAIL pathway still remains a promising target due to its
high selectivity towards cancer cells. TRAIL pathway
components’ expression patterns could possibly serve as
future predictive biomarkers for patient assortment regard-
ing TRAIL targeting therapies.
Materials and Methods: Relative mRNA expression of
TRAIL pathway genes (TRAIL, DR4, DR5, DcR1, DcR2,
cFLIP, BCL2) was evaluated in 90 breast cancer tissues,
using the RT-PCR/ΔΔCt method. The SPSSv22 package
was used for statistical analysis.
Results: The aforementioned genes presented elevated
mRNA levels ranging from 8% to 17% of the cases and
reduced mRNA levels between 31%-65% of the cases.
Linear correlations were observed, indicating the simulta-
neous gene expression, with the strongest found between
cFLIP/DR4 (R=0,709, p < 0,001) and cFLIP/DR5
(R=0,793, p < 0,001). Several significant statistical
correlations with clinicopathological characteristics
emerged: a) T-category with TRAIL, DcR1, cFLIP mRNA
expression, b) N metastasis status with DR4, DcR1, cFLIP,
c) p-Stage category with cFLIP, receptors’ genes, and d) p-
Prognostic stage with cFLIP, BCL2, receptors’ genes.
Conclusions: In our study of different components of
TRAIL apoptotic pathway, relative mRNA levels correlated
with clinicopathological characteristics and multiple simul-
taneous expression patterns emerged. Taking into consid-
eration these findings, it is of significant importance to
stratify breast cancer patients using predictive biomarkers in
order to maximize the efficacy of TRAIL targeting
therapies.
E. Roupou: None. M. Michelli: None. I. Chatzian-
dreou: None. N. Michalopoulos: None. P. Karathanasis:
None. A. Lazaris: None. A. Saetta: None.
P12.031.C
Elucidating the role of microRNAs in cholesterol
mediated drug resistance in breast cancer
B. A. Monchusi, G. Palma, M. Kaur
University of the Witwatersrand, Braamfontein, Johannes-
burg, South Africa
Introduction: Breast cancer is the most commonly diag-
nosed and leading cause of cancer-related deaths amongst
women globally. TAM resistance is the major challenge
faced during endocrine therapy in ER+ breast cancer.
Several TAM resistance mechanisms have been proposed.
Recently lipid reprogramming was reported to be involved
in TAM resistance. It has emerged that certain miRNAs are
involved in cholesterol metabolism and cancer drug resis-
tance pathways. We hypothesise that miRNAs controlling
cholesterol metabolism and homeostasis are potential tar-
gets to be investigated in cholesterol-mediated drug resis-
tance in breast cancer.
Materials and methods: To investigate the role of
miRNAs in cholesterol-mediated drug resistance, bioinfor-
matic tools and in vitro cell based assays were utilised.
Estrogen positive (ER+) breast cancer was of interest as
drug resistance is a major problem in patients with ER+
breast cancer.
Results: We find that inhibition of hsa-miR-128-3p with
AP + TAM treatment induced cell death and decreased
cholesterol levels in MCF7 cells. Through focused pathway
study using the RT2 profiler microarray, we find that genes
that were differentially expressed promoted cholesterol
efflux and drug metabolism while genes that mediate drug
resistance were reduced. The work also highlights another
potential mechanism of AP in ER+ breast cancer, where it
acts as a negative regulator of hsa-miR-128.
Conclusions: The findings demonstrate that targeting
these miRNAs presents an opportunity for developing new
strategies to combat anticancer drug resistance.
Acknowledgements: This research has been funded by
grant #113442 from the NRF. BM has been funded by
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Comparative analysis of MLPA and “CNV by NGS” for
detecting copy number variations in hereditary cancer
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Unal1,2, J. Yildiz2,3, G. Dinler-Doganay2,3, L. Doganay2,4
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Copy number variations (CNVs) are the dosage difference
of the genes and are among disease-causing mutations in
hereditary cancer syndrome. MLPA (Multiplex Ligation-
dependent Probe Amplification) is widely used to detect
CNVs. Recent advancements in bioinformatics made dele-
tion/duplication analysis possible within the NGS data
without any further experimentation. Here, with this study,
we compared the results of MLPA with CNV detection
algorithm (CNV by NGS) in colorectal and breast cancer
patients.
Our study included 755 (683 breast-ovarian and 72
colorectal cancer) patients. MLPA test was performed using
exon specific primers for BRCA1/2, MLH1, MSH2, MSH6,
PMS2 and EPCAM. NGS libraries were prepared by using
targeted multi-gene capture panel (coding regions and splice
junctions of aforementioned genes) and sequenced by
NextSeq using paired-end reads. CNV by NGS analysis
was performed with Sophia DDM bioinformatics software.
In 724 patients (96%) no deletion/duplication was
detected in CNV by NGS, consistent with the results of
MLPA. In 21 patients (2.8%), the same germline pathogenic
variation was detected in both CNV by NGS and MLPA
analyses. CNV by NGS gave a false positive result in 12
patients (1.6%) and a false negative result in only 1 patient
(0.13%), in which MSH6 e1 deletion was only detected
with MLPA.
Our experience reveals that the sensitivity of CNV by
NGS is comparable to MLPA. Yet its considerably high
false positive rates necessitate confirmation of the positive
findings with an alternative method.
N.B. Agaoglu: None. G. Alkurt: None. E. Celik: None.
I.M. Akcay: None. B. Unal: None. J. Yildiz: None. G.
Dinler-Doganay: None. L. Doganay: None.
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RGS7 is recurrently mutated in melanoma and pro-
motes migration and invasion of human cancer cells
n. qutob1, I. Masuho2, r. emmanuel3, M. Alon3, i. cohen1, A.
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Haifa, Israel, 10University of Sydney, Sydney, Australia,
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Analysis of 501 melanoma exomes revealed RGS7, which
encodes a GTPase-accelerating protein (GAP), to be a tumor-
suppressor gene. RGS7was mutated in 11% of melanomas
and was found to harbor three recurrent mutations (p.R44C, p.
E383K and p.R416Q). Structural modeling of the most
common recurrent mutation of the three (p.R44C) predicted
that it destabilizes the protein due to the loss of an H-bond and
salt bridge network between the mutated position and the
serine and aspartic acid residues at positions 58 as 61,
respectively. We experimentally confirmed this prediction
showing that the p.R44C mutant protein is indeed destabi-
lized. We further show RGS7 p.R44C has weaker catalytic
activity for its substrate Gαo, thus providing a dual mechan-
ism for its loss of function. Both of these effects are expected
to contribute to loss of function of RGS7 resulting in
increased anchorage-independent growth, migration and
invasion of melanoma cells. By mutating position 56 in the
R44C mutant from valine to cysteine, thereby enabling the
formation of a disulfide bridge between the two mutated
positions, we slightly increased the catalytic activity and
reinstated protein stability, leading to the rescue of RGS7′s
function as a tumor suppressor. Our findings identify RGS7 as
a novel melanoma driver and point to the clinical relevance of
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using strategies to stabilize the protein and, thereby, restore its
function.
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Levi: None. J. Gartner: None. V. Hill: None. J. Lin:
None. Y. Hevroni: None. P. Greenberg: None. A.
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Unsettling NGS findings related to 94 cancer genes in
pediatric patients- is there benefit or harm in reporting?
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Large panels of genes - also called the “clinical exome” -
are increasingly used in medical practice, where “inci-
dental” or “unsolicited” findings are common. There is a
lack of consistency regarding protocols for addressing such
findings between different laboratories. The benefit of
reporting secondary findings in NGS related to cancer genes
in children may have implications for family members,
nevertheless, could also cause distress.
Aim: to retrospectively investigate germline variants in
94 genes implicated in oncogenesis, in patients referred to
NGS testing for various rare genetic diseases and reevaluate
the utility of reporting different classes of pathogenicity.
Methods: We used in silico prediction software to
classify variants and conducted manual review to further
examine secondary findings frequencies in 229 children
with rare diseases, that underwent sequencing using a 4813
gene panel.
Results: The reanalysis revealed 27907 variants, of which
176 were considered after filtering. Nine pathogenic
expected variants (in BRCA1, BMPR1A, FANCA, FANCB,
FANCC, NBN, STK11, MSH6) and four unexpected variants
(in BRCA2, PALB2, PMS2, RAD50) were reported to
patients. Five secondary, probably pathogenic variants in
ATM, ATR, BLM (in two patients), SUFU and SDHB genes,
presented potential cancer susceptibility, raised ethical
debate in reporting them.
Conclusions: In retrospect, 4.4% (10/229) of individuals
in our cohort had unexpected NGS findings related to
cancer. More efforts are needed to create an updatable
consensus in reporting variants in cancer predisposing
genes, especially for children. Strategies are required to
ensure that consent process informs of both value and risk
of additional genetic information.
A. Chirita Emandi: None. N. Andreescu: None. C.G.
Zimbru: None. M. Puiu: None.
P12.040.C
Somatic mutation analysis of cell-free DNA in the
plasma of gastric cancer patients
G. Streleckiene1, M. Forster2, L. Kupcinskas1, J.
Skieceviciene1
1Lithuanian University of Health Sciences, Kaunas, Lithua-
nia, 2Institute of Clinical Molecular Biology, Kiel, Ger-
many
Introduction: Since the discovery of the circulating plasma
cell-free DNA (cfDNA) the origin and characteristics of
cfDNA were extensively studied. It was shown that cfDNA
could harbor genetic aberrations from malignant tissue.
However, there is a lack of comprehensive studies con-
ducted in gastric cancer (GC) comparing tumor tissue DNA
and plasma cfDNA mutational profiles. The aim of this
study was to analyze cfDNA yield and to compare tumor
tissue DNA and cfDNA mutational profiles for GC patients.
Materials and Methods: GC tissue and blood were
collected from 30 patients who were recruited at the
Department of Gastroenterology, LUHS Hospital. Tumor
tissue was obtained from the primary lesion and peripheral
blood was drawn before the surgery. cfDNA amount was
quantified by laser-induced fluorescence-based microcapil-
lary electrophoresis. Whole exome sequencing was per-
formed for the tissue samples and targeted sequencing for
the plasma cfDNA samples.
Results: Significantly higher yield of cfDNA was
determined for GC patients. Mutations in GC related genes
were detected for 76.7 % of the patients. Top 10 mutated
genes: KMT2C, TP53, TTN, FAT4, SYNE1, EPHB1, GLI3,
PIK3CA, TRRAP, and APC. A custom gene panel was
created for plasma cfDNA sequencing and analysis. Finally,
correlation of mutant allele frequencies between tissue and
plasma cfDNA samples was determined.
Conclusions: Our results demonstrated that cfDNA yield
is significantly higher in GC patients and reflects mutation
profile in GC tissue, therefore may enable cfDNA analysis
for monitoring of the GC patients’ disease state. Supported
by the grant from Research Council of Lithuania No. LMT-
K-712-01-0130_MULTIOMICS.
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P12.041.A
BCR-ABL1 fusion gene acquisition of endothelial cells
from K562 spent serum
C. Ç. Koçana, S. F. Toprak, S. Sözer
Aziz Sancar Institute of Experimental Medicine, Istanbul,
Turkey
Introduction: Chronic Myeloid Leukaemia(CML) is a
hematopoietic stem cell originated slow-growing myelo-
proliferative neoplasm. CML is associated with BCR-ABL1
located on Philadelphia chromosome[t(9;22)(q34;q11)].
Recent studies revealed that some leukemic cells might
release BCR-ABL1. Our hypothesis is; the cell-free BCR-
ABL1 might transfect the susceptible cells and may trans-
form them into leukemic cells. This study aims to under-
stand whether endothelial cells EC could acquire cell-free
BCR-ABL1 in vitro.
Materials-Methods: BCR-ABL1 positive CML cell line
(K562) is cultivated and the spent media was collected
every 96 hours, some saved for DNA isolation and rest was
aliquot and stored in -80oC. BCR-ABL1- EC line(HUVEC)
was cultured with 1x105/ml density in 96-well plates for
transfection. HUVEC culture media was mixed with 40μl of
K562 spent media without any nucleases and incubated for
48h at 37oC. After 48h, HUVEC was washed and detached
from the plate. Following gDNA isolation, PCR analysis
were performed for BCR-ABL1. BCR-ABL1 product of
418bp was analysed by electrophoresis in 2% gel.
Results: BCR-ABL1- HUVEC was transfected easily with
BCR-ABL1+ K562 spent media. BCR-ABL1 insertion into
the HUVEC genome was confirmed by PCR analysis.
Conclusions: Metastasis of the haematological malig-
nancies usually referred to the cancer cells migration and
insertion into the different distant organs. Some studies
revealed the theory of genometastasis; transfection of
healthy cells by cell-free DNA without any induction. This
study provides evidence for BCR-ABL1 insertion into the
different type of cells from their origin including EC. This
process might also provide some answers to other cancer
prognosis as well. Project No:TDB-2019-28744
C.Ç. Koçana: None. S.F. Toprak: None. S.
Sözer: None.
P12.042.B
EGFR mutation testing in cf-DNA from NSCLC patients
using Cobas® EGFR mutation test v2
M. Michelli, I. Giannopoulou, I. Chatziandreou, A.
Zougros, E. Roupou, A. A. Saetta
1st Department of Pathology, School of Medicine, National
and Kapodistrian University of Athens, Athens, Greece
Introduction: EGFR mutation analysis in circulating cell-
free tumor DNA (cf-DNA) from plasma constitutes a con-
venient and less invasive alternative method for NSCLC
patients without adequate tumor material and for disease
monitoring.
Materials and Methods: We examined 420 blood
samples from patients with NSCLC of which 102 had also
FFPE tissue tested. Circulating cell-free tumor DNA (cf-
DNA) isolation from plasma and detection of EGFR
mutations was performed using Cobas ® EGFR
mutation v2.
Results: EGFR mutations in cf-DNA were detected in
26% of the samples. The most common mutations were
deletions in exon 19 (62%), followed by point mutations in
exon 21 (31%). A resistance mutation, p.Thr790Met was
displayed in 24% of the mutant cases. The presence of
mutations in primary samples reached 12% whereas for
follow up samples the percentage of mutations was 40%.
Three out of fifteen tissue samples with Invalid cobas result,
showed presence of EGFR mutation in cfDNA. The
presence of EGFR mutations in plasma and tumor tissues
was correlated with gender (p < 0.001, p=0.031) as were
more common in female patients. The overall concordance
of EGFR mutation status in plasma and tumor was 80%,
specificity 100%, PPV 100%, NPV 72%.
Conclusions: The above analysis adds to current data
indicating that cf-DNA EGFR mutation testing has a very
high PPV. The PPV indicates that EGFR mutations could
be reported with certainty, whereas the sensitivity of the test
indicates that a biopsy should be obtained for patients with
an EGFR mutation-negative cfDNA test.
M. Michelli: None. I. Giannopoulou: None. I. Chat-
ziandreou: None. A. Zougros: None. E. Roupou: None.
A.A. Saetta: None.
P12.043.C
Selection criteria for assembling a pediatric cancer
predisposition gene panel for use in routine diagnostics
A. Byrjalsen1, I. J. Diets2, J. Bakhuizen3,4, T. van Overeem
Hansen1, K. Schmiegelow5, A. Gerdes1, R. P. Kuiper3, H.
Merks3, K. Wadt1, M. C. J. Jongmans3,4
1Department of Clinical Genetics, Rigshospitalet, Copenha-
gen, Denmark, 2Department of Human Genetics, Radboud
university medical center, Nijmegen, Netherlands, 3Prin-
cess Máxima Center for pediatric oncology, Utrecht,
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Netherlands, 4Department of Genetics, University Medical
Center Utrecht, Utrecht, Netherlands, 5Department of
Paediatrics and Adolescent Medicine, Rigshospitalet,
Copenhagen, Denmark
Introduction: Genomic sequencing technologies are used
increasingly in childhood cancer diagnostics and research.
This provides opportunities for standardized screening of
both known and putative cancer predisposition syndromes
(CPS) in children with cancer. This confers a challenge
regarding what gene panel to use in a diagnostic setting.
Methods: Criteria were developed to select genes eligible
for a childhood CPS gene panel. Genes were divided into
two categories: 1) genes associated with conditions that can
only be caused by this specific gene, and 2) grouped genes
that give rise to the same CPS. The criteria were applied to
multiple sources of in total 392 candidate genes.
Results: Single genes were included in the panel when a
minimum of five children with cancer and a pathogenic
variant in the gene were reported in literature. In addition,
evidence must be present supporting a causal relation with
the malignancy (i.e. studies describing somatic second hits
in the tumor or segregation in families). Genes were
grouped if they are associated with a heterogenous CPS and
if they share the same cellular pathway or mechanism. At
least two genes in the group must fulfill the criteria for
individual genes for the group to be included in the panel. In
total, we included 139 genes in the childhood cancer
gene panel.
Conclusions: We have made criteria for the development
of a childhood cancer gene panel. Currently, 139 genes are
included in the gene panel. Regular updates in the future are
necessary for novel genes.
A. Byrjalsen: None. I.J. Diets: None. J. Bakhuizen:
None. T. van Overeem Hansen: None. K. Schmiegelow:
None. A. Gerdes: None. R.P. Kuiper: None. H. Merks:
None. K. Wadt: None. M.C.J. Jongmans: None.
P12.044.A
Combination of Panobinostat and Chloroquine as a
therapeutic strategy against ovarian cancer
M. Ovejero-Sánchez1,2,3, D. Iglesias-Corral2,1,3, P. Martín-
Bejarano Soto4,2, M. A. Pérez-Nieto1,2, P. García-Vallés2,
R. González-Sarmiento1,2,3, A. B. Herrero1,2,3
1Institute of Biomedical Research of Salamanca (IBSAL),
Salamanca, Spain, 2Molecular Medicine Unit, Department
of Medicine, University of Salamanca, Salamanca, Spain,
3Institute of Molecular and Cellular Biology of Cancer
(IBMCC), Salamanca, Spain, 4Institute of Molecular and
Cellular Biology of Cancer (IBMCC), University of
Salamanca-CSIC, Salamanca, Spain
Introduction: Ovarian cancer (OC) is the most lethal
gynecologic malignancy, therefore new and potent treat-
ments are needed. Chloroquine is known to generate reac-
tive oxygen species (ROS) causing DNA double strand
breaks (DSBs). Some HDACi have been reported to inhibit
DNA repair by homologous recombination (HR). This
study aims to investigate the effect of Chloroquine, Pano-
binostat and their combination in the survival of different
OC cell lines.
Material and methods: OC cell lines OVCAR-8, SK-
OV-3, IGROV-1 and A2780 were used. MTT, cell cycle
and apoptosis assays were performed to test chloroquine
and Panobinostat anticancer activity. Synergistic interaction
between these two drugs was assessed using the median
dose effect analysis of Chou and Talalay, and combination
indexes were calculated. DCFH-DA staining was used to
determine ROS generation. γ-H2AX and Rad51 foci were
detected by immunofluorescence. To analyze HR, a reporter
GFP cassette was integrated into the genome of SK-OV-3
and a unique DSB was introduced by transfection with an
endonuclease encoding plasmid. HR-efficiency in the
presence or absence of Panobinostat was calculated by
quantifying the number of GFP+ cells by flow cytometry.
Results: Chloroquine and Panobinostat decreased cell
viability and induced G0/G1 and G2/M cell cycle arrest,
respectively. The combination of both drugs caused a
synergistic effect in all cell lines that was reverted by the
addition of an antioxidant. Treatment with Panobinostat
decreased the efficiency of HR due to the inhibition of
Rad51 recruitment to DSBs.
Conclusion: Our study suggests that the Chloroquine-
Panobinostat combination could be a therapeutic strategy
against OC.
M. Ovejero-Sánchez: None. D. Iglesias-Corral: None.
P. Martín-Bejarano Soto: None. M.A. Pérez-Nieto:
None. P. García-Vallés: None. R. González-Sarmiento:
None. A.B. Herrero: None.
P12.045.B
Tumorsphere derived chordoma cancer stem cells have
low migration and invasion capacities
N. EKIMCI GURCAN1,2, U. OZBEY1,2, M. BAYINDIR
BILGIC1,2, D. TECIMEL1,2, N. IMAMOVA1,2, A.
KUSKUCU1, O. F. BAYRAK1
1Yeditepe University, School of Medicine, Department of
Medical Genetics, Istanbul, Turkey, 2Yeditepe University,
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Institute of Natural and Applied Sciences, Department of
Biotechnology, Istanbul, Turkey
Introduction: Tumorsphere formation is a widely used
cancer stem cell (CSC) enrichment method. The protocol is
based on cultivating cancer cells on a non-attachment sur-
face with specific growth factors and absence of serum for
enrichment of cancer cells with higher stem-like properties.
Studies suggest that invasion and metastasis capabilities of
cancer cells are driven by increased epithelial mesenchymal
transition (EMT) status and associated with CSC pheno-
type. However, EMT characteristics of tumorsphere-
derived CSCs are poorly defined. In this study, migration/
invasion capabilities of tumorsphere-derived chordoma
CSCs, and their EMT related gene expression levels are
investigated.
Materials and Methods: U-CH1 and MUG-Chor 1
Chordoma cell line derived tumorspheres were cultured on
ultra-low attachment plate in serum free culture medium
with specific supplements. Pluripotency and EMT related
gene expression profiles were evaluated using qPCR.
Migration capacity and invasiveness were assessed via
Boyden chamber assay.
Results: Elevated SOX2, KLF4 and NANOG expres-
sions in chordoma tumorspheres comparing parental cell
lines indicates an enriched population with high pluripo-
tency. Additionally, downregulation of CK19 and upregula-
tion of Twist, Snail and ZEB1 in tumorspheres offers an
epithelial-mesenchymal transition phenotype. In contrast
migration/invasion capacities of tumorsphere derived cells
are decreased, a signature EMT marker, CDH1 expression
is increased.
Conclusions: Our results demonstrates that tumorsphere
formation assay may enrich cancer stem-like cell popula-
tions with high stemness potential, but these tumorsphere-
derived cells are losing their capacity to migrate, probably
due to the high CDH1 expression. Suggesting, CDH1 has a
therapeutic potential for chordomas with high migrative
capacity.(TUBITAK project number: 118S691)
N. Ekimci gurcan: None. U. Ozbey: None.M. Bayindir
bilgic: None. D. Tecimel: None. N. Imamova: None. A.
Kuskucu: None. O.F. Bayrak: None.
P12.046.C
Genetic profiling of chronic lymphocytic leukemia
patients in Estonia during 2018-2019
M. Tooming1, P. Tammur1, A. Auser1, Ü. Murumets1, U.
Šamarina1, T. Kahre1,2
1Tartu University Hospital United Laboratories Depart-
ment of Clinical Genetics, Tartu, Estonia, 2University of
Tartu, Institute of Clinical Medicine, Department of
Clinical Genetics, Tartu, Estonia
Introduction: Chronic lymphocytic leukemia (CLL) is the
most common type of leukemia in adults. Laboratory
methods such as next-generation sequencing (NGS), fluor-
escence in situ hybridization (FISH) and chromosomal
microarray (CMA) are used to investigate CLL patients.
The aim of this study was to genetically profile and to get an
overview of genetic alterations of the CLL patients in
Estonia.
Patients and methods: 378 patient samples were referred
to the Tartu University Hospital Clinical Genetics Center
during 2018-2019 from 3 major tertiary referral hospitals.
Patients were tested with Illumina TruSight Myeloid panel
(NGS-54 genes), FISH (TP53, trisomy12, ATM deletion,
DLEU1 deletion) and CMA (HumanCytoSNP-12). FISH or
CMA was carried out on 343 patients. NGS was performed
in 210 patients. Both NGS and FISH or CMA was
performed in 175 patients.
Results: Altogether 50/378 patients (13,2%) tested
positive for TP53 mutations or del17p. TP53 pathogenic
mutations were detected in 40 (19%) patients. FISH/CMA
revealed 23 (6,7%) patients with del17p. 13 (3,4%) patients
harboured both TP53 mutations and del17p. Additionally,
pathogenic mutations were found in ABL1, ASXL1, BCOR,
BRAF, DNMT3A, GATA2, IDH2, KRAS, MYD88,
NOTCH1, NRAS, RAD21, SF3B1, SRSF2 genes by NGS
panel and by FISH trisomy12, ATM and DLEU1 deletions.
Unfortunately, in 160 FISH/CMA-negative cases NGS was
not performed and in 22 TP53-negative NGS cases FISH/
CMA was not analysed.
Conclusions: Both NGS and FISH/CMA testing should
be considered to establish a status of TP53 mutation/del17p
to improve patient stratification and optimize therapeutic
decisions. Funding: Estonian Research Council grant
PRG471.
M. Tooming: None. P. Tammur: None. A. Auser:
None. Ü. Murumets: None. U. Šamarina: None. T.
Kahre: None.
P12.047.A
Variants in the ASXL1 and &gt; for DMNT3A genes
may provide a personalized approach to targeted CML
therapy
E. P. Adilgereeva1, A. G. Nikitin2, D. G. Zheglo1, O. A.
Shukhov3, S. A. Smirnikhina1, E. Y. Chelysheva3, A. V.
Lavrov1, A. G. Turkina3, S. I. Kutsev1
1Research Centre for Medical Genetics, Moscow, Russian
Federation, 2Pulmonology Research Institute, Federal
Medical-Biological Agancy of Russia, Moscow, Russian
Federation, 3National Research Center for Hematology,
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Moscow, Russian Federation
Introduction: Chronic myeloid leukemia (CML) accounts
for about 15% of all leukemias in adults. Great success has
been achieved in the treatment of CML due to the devel-
opment of tyrosine kinase inhibitors (TKI), but 20-40% of
patients are resistant to targeted therapy. The aim of the
study is to detect exome variants predicting effectiveness of
CML therapy.
Materials and methods: Blood was sampled from 60
CML patients at the time of diagnosis, before starting the
TKI therapy. Later, 30 of the patients matched the
ELN2013 criteria of optimal response, 18 were included
in warning group, and 12 were resistant to therapy. Exome
sequencing was performed on the Illumina NextSeq 550
Sequencing System. Bioinformatic analysis included
SnpEff (analysis of all transcripts), ANNOVAR (analysis
of allele frequencies in gnomAD, 1000G, and ESP6500,
algorithms in silico prediction of pathogenity of SIFT,
PolyPhen2, MutationTaster, FATMM, CADD, DANN,
REVEL, M-CAP), and Alamut Batch (influence on
splicing, dbsnp, ClinVar, COSMIC, and HGMD).
Results: Loss-of-function variants were revealed in the
ASXL1 and DNMT3A genes in 33% of patients in the group
of resistant to therapy TKI, but not in other groups. 25% of
patients in the treatment-resistant group had variants only in
ASXL1, while 8% had variants in both ASXL1 and
DNMT3A.
Conclusions: The identified variants in ASXL1 and
DNMT3A may be associated with resistance to TKI therapy
and serve as prognostic markers of the TKI therapy
effectiveness at the stage of CML diagnosis, and thus
provide a personalized approach to the targeted CML
therapy.
E.P. Adilgereeva: None. A.G. Nikitin: None. D.G.
Zheglo: None. O.A. Shukhov: None. S.A. Smirnikhina:
None. E.Y. Chelysheva: None. A.V. Lavrov: None. A.G.
Turkina: None. S.I. Kutsev: None.
P12.049.C
Detection of Androgen Receptor in plasma circular
RNAs in Prostate Cancer
P. Vázquez-Cárdenas1,2,3, A. Martel-Martel1,2,4, M. A.
Pérez-Nieto1, J. L. García-Hernández1,3, I. Misiewicz-
Krzeminska1,3, Á. J. Virseda-Rodríguez5, S. Marcos-
Asensio5, F. Gómez-Veiga5, J. J. Cruz-Hernández1,2,4, A. B.
Herrero2,3, R. González-Sarmiento1,2,3
1Biomedical Research Institute of Salamanca (IBSAL),
Salamanca, Spain, 2Molecular Medicine Unit, Department
of Medicine, University of Salamanca, Salamanca, Spain,
3Institute of Molecular and Cellular Biology of Cancer
(IBMCC), University of Salamanca-CSIC, Salamanca,
Spain, 4Medical Oncology Service, University Hospital of
Salamanca, Salamanca, Spain, 5Translational Research
Group of Urology GITUR-IBSAL, University Hospital of
Salamanca, Salamanca, Spain
Introduction: Androgen receptor (AR) plays a crucial role
in prostate cancer (PCa) and the presence of the receptor in
blood cancer is being used as a biomarker. Circular RNAs
(circRNAs) are a newly discovered type of endogenous
non-coding RNAs, characterized by a closed continuous
loop, which can regulate gene expression by acting as
microRNA or RNA-binding protein sponges. In this work
we wanted to test whether circRNAs derived from the AR
gene (circ-AR) could also be detected in blood samples and
used as PCa biomarker.
Methods: Peripheral blood was drawn from 35 patients
with diagnostic of metastasic PCa. Whole blood (10mL)
was collected in EDTA tubes. Plasma was isolated from the
supernatant by centrifugation at RT, 20 minutes and 1500
rpm. Total RNA was extracted from patient serum/plasma
and VCAP cell line using the miRNeasy and miRNeasy
Mini kits respectively. RNA samples were treated with
RNase R for 30 minutes at 37ºC to digest linear RNA and
circRNAs were isolated again. Circ-AR expression was
analysed by qPCR using GAPDH mRNA for normalization.
Divergent primers for circ-AR were designed using the
CircInteractome webtool and the convergent primers of
GAPDH were designed by Primer-BLAST.
Results: Circ-AR was detected by RT-qPCR in plasma
PCa patients and in VCAP cell line. To validate the
existence of a circ-AR, Sanger sequencing was performed
on the PCR product amplified with the divergent primers.
Conclusions: Circ-AR was detected by RT-qPCR in all
plasma samples, indicating that these molecules could be
used as novel biomarkers in PCa.
P. Vázquez-Cárdenas: None. A. Martel-Martel: None.
M.A. Pérez-Nieto: None. J.L. García-Hernández: None.
I. Misiewicz-Krzeminska: None. Á.J. Virseda-Rodrí-
guez: None. S. Marcos-Asensio: None. F. Gómez-Veiga:
None. J.J. Cruz-Hernández: None. A.B. Herrero: None.
R. González-Sarmiento: None.
P12.050.A
Analytical validation of the Droplet Digital PCR system
for the detection of the most frequent clinically relevant
EGFR, BRAF and KRAS hotspot tumor variants
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A. Hallermayr1, J. Romic-Pickl1, A. Benet-Pagès1,2, V.
Steinke-Lange1, E. Holinski-Feder1
1MGZ - Medical Genetics Center, Munich, Germany,
2Genomics Institute, University of California Santa Cruz,
Santa Cruz, CA, United States
Introduction: Precision medicine targeting specific genetic
variants in cancer can be used for prediction and prognosis
of disease progression and outcome. This requires accurate
molecular profiling of the tumor, which is traditionally
performed using DNA extracted from tumor tissue. Liquid
biopsies can overcome some of the challenges regarding
tissue biopsies and offer several advantages like real-time
monitoring of driver hotspot variants, although highly
sensitive methods are required to identify these variants
in ctDNA.
Materials and Methods: The Droplet Digital™ PCR
(ddPCR) technology requires low amounts of input DNA
and enables quantification of low variant allele frequencies
(VAF) of targeted variants, yet accuracy varies between
assays and laboratory protocols.
Results: We conducted the analytical validation of five
ddPCR assays, for the detection of the most frequent
clinically relevant EGFR, BRAF and KRAS hotspot tumor
variants and established precise thresholds between negative
and positive results as well as VAF quantification. All assays
showed very low limits of blank and detection ranging from
0% to 0.11% fractional abundance and 0.08% to 0.4% VAF
of the targeted variants, respectively. However, striking
differences were observed between ddPCR assays for the
detection of low VAFs of the targeted variants.
Conclusions: In particular, the observed difference in
performance in low VAF variant detection and quantification
demonstrates the importance of specific analytical validation
for each assay to obtain reliable results of ctDNA analysis.
A. Hallermayr: None. J. Romic-Pickl: None. A. Benet-
Pagès: None. V. Steinke-Lange: None. E. Holinski-
Feder: None.
P12.052.C
A case of MSH2-related constitutional mismatch repair
deficiency syndrome
E. M. Leter1, M. J. L. Ligtenberg2,3, R. S. van der Post3, N.
Hoogerbrugge2, A. R. Mensenkamp2
1Department of Clinical Genetics, Maastricht University
Medical Center, Maastricht, Netherlands, 2Department of
Human Genetics, Radboud University Medical Center,
Nijmegen, Netherlands, 3Department of Pathology, Rad-
boud University Medical Center, Nijmegen, Netherlands
Constitutional mismatch repair deficiency (CMMRD)
syndrome is a rare autosomal recessive hereditary cancer
condition, characterized by early onset colorectal cancer,
leukemia and lymphoma, brain tumors and other malig-
nancies. We report a 24-year-old man referred to our
outpatient genetic clinic because of rectal cancer. His
sister had died of an astrocytoma at age 14. Their father
was diagnosed with prostate, bladder and renal cancer at
age 47 and 58. A paternal uncle died of esophageal cancer
at age 50, a paternal aunt was diagnosed with breast
cancer at age 70 and the paternal grandfather died of liver
cancer at age 70. The maternal grandfather died of bladder
cancer at age 77. The family history did not include
additional cancer cases amongst first or second degree
relatives. Immunohistochemistry of the rectal cancer
showed mismatch repair deficiency with loss of MSH2,
atypical diminished staining of MSH6 and presence of
MLH1 and PMS2. Genetic analyses revealed two patho-
genic heterozygous germline variants in MSH2, c.1759
+3A>G (p.(Ser554fs)) and a deletion of the first exon, c.
(?_-1)_(211+1_212-1)del. RNA analyses showed that the
splice site variant results in a loss of exon 11 from the
transcript. Parental testing showed that both variants were
inherited from a different parent. The latter finding con-
firmed CMMRD due to bi-allelic pathogenic MSH2 var-
iants in our patient. Formalin-fixed paraffin-embedded
tissue analysis revealed that his deceased sister also car-
ried both MSH2 variants. This case again highlights how
an index case of CMMRD may lack a clear family history
of Lynch syndrome associated tumors.
E.M. Leter: None. M.J.L. Ligtenberg: None. R.S. van
der Post: None. N. Hoogerbrugge: None. A.R.
Mensenkamp: None.
P12.053.A
Colorectal Cancer in Adolescents and Young Adults:
Comprehensive Analyses of the Clinical and Molecular
Features
R. M. de Voer, I. Diets, R. van der Post, R. Weren, E.
Kamping, T. de Bitter, L. Elze, R. Verhoeven, E. Vink-
Börger, A. Eijkelenboom, A. Mensenkamp, I. Nagtegaal, M.
Jongmans, M. Ligtenberg
Radboudumc, Nijmegen, Netherlands
Colorectal cancer (CRC) at adolescent and young adult age
(AYA; ≤25 years) is a rare condition. Here we analyzed the
clinicopathological and molecular features of CRC at AYA
age to improve genetic counselling, surveillance and, ulti-
mately, treatment and disease outcome. We retrospectively
collected clinical information and tumor tissues from AYAs
with CRC between 2000 and 2017 in the Netherlands.
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Tumor DNAs were analyzed for microsatellite instability,
mutations in 56 hotspot regions and/or driver genes, and
genome-wide somatic copy number aberrations. A total of
139 patients (58% male) were diagnosed with CRC ≤25
years of age (mean age 22) between 2000 and 2017.
Mucinous and/or signet-ring-cell components were
observed in 33% of cancers. A genetic tumor risk syndrome
was confirmed in 39% of cases. Negative predictors of
outcome were a younger age at diagnosis, signet-ring-cell
carcinoma, the absence of a genetic tumor risk syndrome,
and a diagnosis at advanced stage of disease. Compared to
CRCs ≥60 years of age from The Cancer Genome Atlas,
microsatellite stable (MSS) CRCs at AYA age more fre-
quently harbor somatic mutations in TP53 and POLE, less
frequently have APC mutations and are enriched for nearly-
diploid MSS tumor genomes. Our data suggest that CRCs at
AYA age have a biology and etiology different from
sporadic CRCs at older age. Therefore, treatment of AYAs
with CRC should be optimized based on their molecular
genetic phenotypes. Performing comprehensive sequencing
of germline and tumor DNA in every individual diagnosed
with CRC ≤25 years of age would aid in this optimization.
R.M. de Voer: None. I. Diets: None. R. van der Post:
None. R. Weren: None. E. Kamping: None. T. de Bitter:
None. L. Elze: None. R. Verhoeven: None. E. Vink-
Börger: None. A. Eijkelenboom: None. A. Mensenkamp:
None. I. Nagtegaal: None. M. Jongmans: None. M.
Ligtenberg: None.
P12.054.B
Detection of germline genetic variants in hereditary
colorectal cancer
F. Eiengård1,2, A. Rohlin1,2, E. Mårtensson1, T.
Olausson1,2, T. Zagoras1,2, U. Lundstam3, S. Gebre-
Medhin4,5, M. Nordling1,2
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Lund, Sweden, 5Department of Clinical Genetics and
Pathology, Skåne University Hospital, Lund, Sweden
Introduction: Germline pathogenic variants in genes
established to be associated with hereditary colorectal can-
cer (CRC) explain the disease in approximately 5-6%
patients. Due to technical limitations and variant
interpretation challenges, high penetrant pathogenic variants
are frequently reported only in the exonic regions of
the genes.
Materials and methods: The study included 206 patients
with suspected hereditary CRC referred to the Cancer
Genetics Counselling Clinic at Sahlgrenska University
Hospital in Gothenburg, Sweden. Variant screening was
performed using a comprehensive genomic panel including
established and also putative CRC predisposition genes
(covering 50 kb upstream and downstream of the genes and
intron regions). Variants, including CNVs (copy-number
variants), were evaluated regarding pathogenicity. In
addition, 40 out of the 206 patients were further investigated
through whole-genome sequencing (WGS).
Results: The spectrum of pathogenic variants was
determined. The findings include identification of pre-
viously unreported variants and putative causative variants
in genetically unexplained patients with hereditary CRC.
Conclusions: The combination of high-throughput panel-
sequencing and WGS identifies a broader set of pathogenic
variants in patients with hereditary CRC, which is crucial
for clinical follow up of patients and predictive testing of
relatives. The study was supported by grants from the
Swedish state under the agreement between the Swedish
government and the county councils, the ALF-agreement
(ALF-725011) and the Swedish Cancer Society (Grant no
18 0357).
F. Eiengård: None. A. Rohlin: None. E. Mårtensson:
None. T. Olausson: None. T. Zagoras: None. U.
Lundstam: None. S. Gebre-Medhin: None. M.
Nordling: None.
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A new approach for the identification of novel candidate
genes of susceptibility to colorectal cancer
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vicio de Digestivo, Complexo Hospitalario de Pontevedra,
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 505
Pontevedra, Spain, 5Servicio de Digestivo, Complexo
Hospitalario Universitario de Santiago de Compostela,
Santiago de Compostela, Spain, 6Servicio de Anatomia
Patologica, Complexo Hospitalario Universitario de San-
tiago de Compostela, Santiago de Compostela, Spain,
7Servicio de Anatomia Patologica, Institut D’Investigacions
Biomediques August Pi i Sunyer, Centro de Investigacion
Biomedica en Red de Enfermedades Hepaticas y Digestivas
(CIBERehd) and Tumor Bank-Biobank, Hospital Clinic,
Barcelona, Spain, 8Servicio de Digestivo, Institut D’Inves-
tigacions Biomediques August Pi i Sunyer, Centro de
Investigacion Biomedica en Red de Enfermedades Hepati-
cas y Digestivas (CIBERehd), Hospital Clinic, Universitat
de Barcelona, Barcelona, Spain, 9Grupo de Oncologia
Gastrointestinal y Pancreatica, Institut D’Investigacions
Biomediques August Pi i Sunyer, Centro de Investigacion
Biomedica en Red de Enfermedades Hepaticas y Digestivas
(CIBERehd), Hospital Clinic, Universitat de Barcelona,
Barcelona, Spain, 10Centro de Investigacion Biomedica en
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Introduction: Whole-exome sequencing (WES) was
expected to identify genetic variation that explained the
missing heritability in colorectal cancer (CRC). The strate-
gies mainly relied on prioritization of recurrent loss-of-
function rare germline variants in genes previously involved
in cancer pathways. However, not only a very small number
of candidate genes with strong scientific evidence were
identified, but a large number were proposed whose role in
colorectal tumorigenesis is not yet established. The failure
to identify the real causative genes could be due to the
genetic heterogeneity underlying CRC. Our aim is to
molecular characterize early-onset MMR-proficient CRC at
somatic level to further identify novel candidate genes by
integrating germline and tumor omic data.
Materials and Methods: WES and RNA-seq were
performed on paired normal-tumor tissues from a phenoty-
pically homogeneous cohort of 20 early-onset (<50y)
MMR-proficient CRC patients. Differential expression
analysis (DESeq2), functional enrichment analysis (G:
Profiler), consensus molecular subtyping (CMSCaller) and
signature profile (MuSiCa) were carried out.
Results: According to consensus molecular subtyping,
colorectal tumors were classified as: CMS1 (3), CMS2 (2),
CMS3 (4), CMS4 (6), the remaining were still not
classified.
Conclusions: These data show the molecular hetero-
geneity underlying this phenotypically homogeneous cohort
of early onset MMR-proficient CRC. Thus, a more
comprehensive prioritization of germline variants according
to the molecular subtype of each tumor will be followed
increasing the probabilities to identify the causative
germline CRC risk variants. As a result a more personalized
genetic diagnostic could be achieved.
Grant support: ISCIII and FEDER funds PI17/00509;
Predoctoral Fellowship (GAIN, Xunta de Galicia)
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GNMTpolymorphisms are associated with perineural
invasion and age of disease onset among colorectal
cancer patients
W. Chang1,2, M. Misbah2, K. Chen3,4, J. Wang5,6,W. Wang7
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Medical University, Taipei, Taiwan, 5Graduate Institute of
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ical University, Kaohsiung, Taiwan, 6Center for Biomar-
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Introduction: Glycine N-methyl transferase (GNMT) is
known to play an important role in the pathogenesis of
cancer. However, the effects of GNMT polymorphisms on
colorectal cancer (CRC) are still unclear. Herein, we
investigated the role of GNMT in CRC.
Materials and Methods: The study sample consists of
352 CRC patients. Clinical variables including parameters
of staging, vascular invasion, perineural invasion, and age
of CRC onset were collected. Five single nucleotide
polymorphisms (SNPs) including rs9471976, rs9462856,
rs11752813, rs10948059, and rs2274517 were genotyped.
The associations of SNPs with clinical variables were
examined by a two-stage approach: chi-square test and
logistic regression were used for categorical variables;
Kaplan-Meier method and Cox proportional hazard model
were used for age of onset.
Results: The minor alleles of three SNPs were associated
with a higher risk of perineural invasion: T of rs9471976
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(OR = 1.70, 95%CI = (1.13-2.55)), C of rs9462856 (OR =
1.66, 95%CI = (1.11-2.49)), and T of rs2274517 (OR =
1.64, 95%CI = (1.10-2.45)). Furthermore, subjects carrying
GG genotype of rs11752813 have a younger age of onset
compared with other subjects (HR = 3.02, 95%CI = (1.09,
8.36)). According to GTEx database, these four SNPs may
influence expression levels of PEX6 and GNMT in
transverse and sigmoid colon tissues.
Conclusions: GNMT is associated with risk of perineural
invasion and age of disease onset among CRC patients.
This study was supported by the Ministry of Science and
Technology, Taiwan (MOST105-2628-B-038-001-MY4
and MOST 106-2314-B-038-052-MY3) and the Interna-
tional Office of Taipei Medical University (TMU105-5803-
003-111 and TMU105-5803-010-111).
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Microsatellite instability (MSI) and Lynch syndrome (LS)
prevalence in colorectal cancer (CRC) patients is estimated
to be 15% and 3% in European populations. However,
prevalence estimates from India are not available. We aim
to systematically assess the prevalence of MSI and LS in
CRC patient population from India. Venous blood and
primary tumour biopsies were prospectively collected and
analysed for MSI using Promega fragment length analysis
assay and BRAF V600E using Q-PCR. Patients with MSI-
high BRAF-negative tumour biopsies were assessed for LS
using germline DNA sequencing of the mismatch repair
genes (MLH1, MSH2, MSH6, PMS2 and EPCAM). Within
9 months of a 3 year study, 38 patients have been recruited
with CRC. MSI testing in these patients showed MSI-high
phenotype in 10 patients (26.3%). Of these, 9 patients
(90%) were negative for BRAF V600E mutation. Germline
testing in 6 of these patients have shown known and novel
mutations in the MLH1 gene. Ad hoc analysis of the pro-
spective study cohort suggests higher prevalence of MSI
and LS in CRC patient population in India. Analysis of the
entire patient cohort (n = 0) in 2022 will provide a robust
estimate of the prevalence of MSI and LS in CRC patients
in India. These estimates would help in formulation of
national guidelines for MSI testing, LS diagnosis and che-
moprevention strategies of CRC in India. Study is funded
by Gujarat State Biotech Mission (GSBTM/JDR&D/604/
2019/297).
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Introduction: Colorectal cancer (CRC) is one of the most
prevalent cancers worldwide and is the second leading
cause of cancer-related mortality. CRC detection rates have
improved; however, disease-related mortality remains very
high. Comprehensive miRNA analysis showed deregulated
miRNA profiles in CRC. In order to understand functional
relevance of miRNA deregulation, studies analyzing their
target genes are of major importance.
Materials and methods: MTT, colonogenic, wound
healing, dual-light luciferase reporter gene, gene and protein
expression assays were performed in SW620, HCT-116 and
Caco-2 cell lines after cell transfection with hsa-miR-1246
mimic and inhibitor to determine miR-1246 impact in cell
function changes and to confirm its target genes.
Results: Reduced cell viability was observed in Caco-2
and SW620 cell lines 72 hours after transfection with miR-
1246 inhibitor. Colonogenic test results demonstrated that
inhibition of miR-1246 decreased colony number only in
Caco-2 cell line. Inhibition of miR-1246 decreased covered
gap area in wound healing assay in Caco-2 and HCT-116
cells. CFTR, AXIN2 CRC-associated putative target genes
of miR-1246 were confirmed by dual light luciferase assay.
Overexpression of miR-1246 decreased the expression of
CFTR and AXIN2 genes in SW620 cell line 48 hours after
transfection. Tendency of higher CFTR and AXIN2
expression in protein level was observed after inhibition
of miR-1246 in Caco-2 and SW620 cell lines.
Conclusions: AXIN2 and CFTR are direct targets of miR-
1246. Overexpression or inhibition of miR-1246 affected
cell viability, colony formation and migration in CRC
cell lines.
Funding: Funded by the Research Council of Lithuania
(grant. no. S-MIP-17-22)
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Introduction: Colorectal cancer (CRC) is one of the most
common malignant tumors. Patients with CRC have an
increased risk for developing metachronous CRC (MCRC)
during follow-up evaluation. It is still unknown which
patients are prone to this condition, despite genomics stu-
dies have enhanced our ability to identify molecular chan-
ges associated with CRC. The clinician´s challenge is to
propose a tight follow-up and control the possible return of
cancer. This study is focusing on the characterization of
mutational profile of MCRC that could inform in regards to
prognosis and therapy decision.
Materials and Methods: A total of 90 formalin-fixed,
paraffin-embedded (FFPE) tumor DNA from 45 patients
diagnosed with MCRC were selected to perform next
generation sequencing (NGS) using Ion Torrent platform
and Ampliseq cancer hotspot panel v2 (Thermofisher). Data
analysis was performed using Torrent Suite and Ion
Reporter software (Thermofisher). The annotated variants
were visualized using IGV (Broad Institute).
Results: The most frequent mutations in initial tumors
were located in APC (48,9%), KRAS (42,2%), TP53
(28,3%) and PIK3CA (8,9%), while in metachronous
tumors the most common mutations were identified in
KRAS (50,0%), APC (42,2%), TP53 (15,6%), FBXW7
(13,3%) and CTNNB1 (8,9%). Remarkably, three (6,7%)
patients showed the same mutations in both tumors.
Moreover, those patients with APC mutation in their inicial
tumor showed a tendency to develop later their metachro-
nous tumors (p=0,05).
Conclusions: These results highlight the genetic features
of MCRC that could influence for tailored surveillance
programs. Additionally, data showed the mutational profile
differences between both tumors in MCRC patients.
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None. N. Carrizo: None. Y. Rodríguez-Gil: None. I. Rey:
None. J. Perea: None.
P12.062.A
Constitutional mismatch repair deficiency is the differ-
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Introduction: Biallelic germline mismatch repair (MMR)
gene mutations cause constitutional MMR deficiency
(CMMRD), a highly penetrant childhood cancer syndrome
phenotypically overlapping with neurofibromatosis type 1
(NF1). CMMRD testing in suspected NF1 children without
NF1/SPRED1 mutations enables inclusion of CMMRD
positives into monitoring programs prior to tumor onset.
However, testing is associated with potential harms. The
prevalence of CMMRD among these children, although
unknown, is estimated to be as low as 0.39%.
Methods: We have previously developed a simple and
scalable microsatellite instability (MSI) assay of non-
neoplastic leukocyte DNA to reliably detect CMMRD.
Here we used this assay to retrospectively screen a cohort of
>700 children suspected of sporadic NF1, but lacking NF1/
SPRED1 germline mutations after highly sensitive mutation
analysis.
Results: For three MSI-positive patients, identification of
MMR gene germline mutations confirmed the diagnosis of
CMMRD. Founder mutations NM_000535.5(PMS2):
c.736_741delinsTGTGTGTGAAG, prevalent in Europe
and North America, and NM_000179.2(MSH6):c.10C>G,
affecting 1:400 French Canadians, represented two of five
mutations. CMMRD prevalence was 3/735 (0.41%, 95%
CI: 0.08-1.19%).
Conclusions: Our empirical data provide reliable num-
bers urgently needed for genetic counseling, and confirm
previous prevalence estimations on which the Care for
CMMRD (C4CMMRD) consortium guidelines are based.
These advocate CMMRD testing of preselected patients
rather than offering reflex testing to all suspected sporadic
NF1 children lacking NF1/SPRED1 mutations. The MMR
mutations in the CMMRD patients identified here suggest
that the possibility of founder effects should be considered,
in addition to C4CMMRD guidelines, when counseling
NF1/SPRED1 mutation negative children.
This work was funded by Austrian Science Funds.
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Introduction: Colorectal cancers (CRC) are the third most
common cancers and leading causes of death in Turkey. Up
to 10% of all CRC cases are considered hereditary. Here,
we aimed to characterize the spectrum of pathogenic var-
iants in Turkish CRC patients and investigated the
phenotype-genotype relationships of these variants.
Materials and Methods: We sequenced the coding
regions and splice junctions of 25 cancer susceptibility
genes in 174 unrelated CRC patients and 457 elderly
controls with no personal and familial cancer history using
multi-gene panel testing. We also performed MLPA
analyses for mismatch repair genes (MLH1, MSH2,
MSH6, PMS2) and EPCAM 3’UTR to detect gross
deletions.
Results: We detected pathogenic germline variants in
24.1% (19/79) of high-risk CRC patients, 6.3% (6/95) of
low-risk CRC patients, and 2.6% (12/457) of healthy
controls. 54.2% (n = 24) of all pathogenic variants were in
mismatch repair genes MLH1 (n = 7), MSH2 (n = 4) and
MSH6 (n = 2). 2 of these variants were gross deletions.
MUTYH c.1437_1439delGGA variant was the most pre-
valent pathogenic variant. Monoallelic MUTYH mutations
were not significantly associated with colorectal cancers
(p=0.2849). 47% of patients with MMR gene defects had
loss of MMR gene expression in their tumors. 4% (7/174)
of all patients had mutations in well-known breast cancer
genes and other cancer susceptibility genes. Variants of
uncertain significance (VUS) were detected in more than
34% of all subjects.
Conclusions: This study provides important information
to estimate the contribution of cancer susceptibility genes to
CRC in Turkish population, and to improve the interpreta-
tion of VUS.
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Introduction: The interstitial deletion del(5q) is a recurrent
cytogenetic aberration in bone marrow of patients with
myelodysplastic syndromes (MDS). The extent of the del
(5q) varies in individual cases. Two different commonly
deleted regions (CDRs) have been published: the proximal
5q31.2 region associated with a high-risk MDS, and the
distal CDR 5q32-5q33 involved in the pathogenesis of
MDS with isolated del(5q). However, rare cases of atypical
deletions not including defined CDRs have also been
reported.
Materials and methods: During 1993-2019 we exam-
ined bone marrow cells of 3714 MDS patients by
conventional G-banding and I-FISH (Abbott). Extent of
del(5q) was analyzed using multicolor banding (mBAND;
MetaSystems) and/or aCGH (Illumina, Agilent).
Results: del(5q) was detected in 920/3714 patients
(24,8%). Most of them had large deletion spanning both
defined CDRs. Atypical deletions with retained CDRs were
identified in 9/920 cases (1%; 4M/5F; median age, 73
years). In five of them del(5q) was a sole aberration, in four
cases it was detected together with other chromosomal
rearrangements. In all cases, deletion was localized
proximally to the 5q31 region. The size of the deleted
segment ranged from 25.46 to 53.19 Mb (median
38.51 Mb).
Conclusions: Our results suggest that del(5q) may occur
outside of defined CDRs. Although these findings are
extremely rare, they show that also genes located outside
known CDRs may contribute to the malignant progression
of MDS. The identification of these genes will lead to better
understanding of the MDS pathogenesis and may contribute
to identify new therapeutic targets. Supported by RVO-
VFN64165, IHBT-00023736.
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Introduction: Diffuse gliomas are highly heterogenous
tumors with occurrence of recurrent lesions in majority of
patients. During disease progression gliomas undergo cel-
lular and genomic evolution. However, the mechanism of
this complicated process associated with treatment failure is
poorly understood.
Materials and Methods: We compared genomic profiles
of 28 primary and recurrent gliomas. To assess copy
number variations, IDH1/IDH2 mutation status and hyper-
methylation of MGMT and MLH3 promoters we used array
CGH/SNP (Illumina, Agilent), I-FISH (Abbott Molecular,
MetaSystems) and MLPA/MS-MLPA (MRC Holland).
Results: In 27/28 cases, the genomic profiles of recurrent
tumors were different from their primaries and shared the
genetic/epigenetic alterations depending on the evolutionary
pattern, i.e. linear or divergent. Except typical aberrations,
recurrent lesions in all these patients included additional
gains/losses of various parts of different chromosomes
resulting in complex rearrangements. Repeatedly affected
regions were detected in bands 2q36.3, 3p11.1, 8q24.13,
13q14, and 22q11.1. Besides copy number variations,
cnLOH were proved in 25/28 cases, predominantly located
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at 7p, 9p, 12p, and 17p. In one case, newly acquired
chromothripsis of chromosomes 1, 9, 11 and 17 was
observed. Hypermethylation of MGMT and/or MLH3
promoter was detectedin 10/28 recurrent tumors.
Conclusions: Our study proved heterogenous pattern of
clonal evolution in gliomas which is characterized by
acquisition of new genomic aberrations and leads to high
genome instability. We proved, that recurrences are
genetically/epigenetically different from their primaries
and may arise from one major tumor clone or by one or
more subclones presented within primary tumors. Sup-
ported by RVO-VFN64165
L. Lizcova: None. D. Vesela: None. K. Svobodova:
None. H. Cechova: None. H. Lhotska: None. L.
Pavlistova: None. L. Hodanova: None. Z. Krejcik: None.
S. Ransdorfova: None. F. Kramar: None. D. Netuka:
None. P. Hrabal: None. K. Michalova: None. Z.
Zemanova: None.
P12.067.C
Development of a novel, online training platform for
genomics education in cancer care; preparing health-
care professionals for "Generation Genome"
V. Tripathi1, A. E. Coulson1, E. Cox2, Z. Beydoun3, V.
Reeve3, J. Malawana2, A. Kulkarni1
1South East Thames Regional Genetics Service, Guy’s and
St Thomas’ NHS Foundation Trust, London, United King-
dom, 2Medics.Academy, London, United Kingdom, 3Guy’s
and St Thomas’ NHS Foundation Trust, London, United
Kingdom
Introduction: Genomic testing in the UK is changing, with
more clinicians ordering genomic tests for patient care. The
UK Government has called for improved education to
appropriately order and interpret tests. Existing evidence
highlights the benefits of online learning, as well as those of
blended delivery approaches, and initiatives need to be
scalable to the wider workforce. We developed an online
platform (Nucleus) to address this need across for cancer
healthcare professionals in our region.
Materials and Methods: Collaborating with healthcare
technology company, Medics.Academy, Nucleus was
developed based on face-to-face education delivered by
Guy’s Hospital. Scoping exercises, literature reviews and
recommendations from national healthcare and govern-
mental bodies identified target audiences, training needs and
the utility of online training. Content was developed and
reviewed by genetics clinicians. User testing data of an
initial Nucleus module was collected.
Results: Modules in basics of cancer genomics, cancer
genomics susceptibility, and precision oncology (technolo-
gical and clinical applications) have been developed.
Podcasts and blogs are currently in development. Initial
user testing has been very positive with users rating the
platform as relevant to practice (x̄=4.57/5), with appro-
priate length (x̄=4.29/5) and pace (x̄=4.14/5).
Conclusions: Nucleus can facilitate scalable cancer
genomics education and is well-received by clinicians.
Modules will be combined with face-to-face teaching in a
blended learning course to be piloted in June 2020.
Subsequent expansion of further modules is planned over
the next 18 months.
V. Tripathi: None. A.E. Coulson: None. E. Cox: None.
Z. Beydoun: None. V. Reeve: None. J. Malawana: None.
A. Kulkarni: None.
P12.068.A
Using genetics to understand the relationship between
non-cancerous gynaecological diseases and endometrial
cancer risk
T. A. O’Mara1, P. Kho1, S. Mortlock2, G. W. Montgomery2,
A. B. Spurdle1, D. M. Glubb1
1QIMR Berghofer Medical Research Institute, Brisbane,
Australia, 2The Institute for Molecular Bioscience, Uni-
versity of Queensland, Brisbane, Australia
Endometriosis, polycystic ovary syndrome (PCOS) and
uterine fibroids are three prevalent non-cancerous gynae-
cological diseases, affecting women of reproductive age,
with unclear effects on endometrial cancer risk. Using
GWAS summary statistics for each of these diseases (n
cases: 14,949 endometriosis; 4,890 PCOS; 20,101 uterine
fibroid; 12,906 endometrial cancer), we performed genetic
correlation, genetic causal inference (latent causal variable
and Mendelian randomization analysis) and gene-based
analyses (fastBAT analysis) to understand the relationship
between these three non-cancerous gynaecological diseases
and risk of endometrial cancer. We found positive genetic
correlation between endometrial cancer and PCOS
(rg=0.37, P=2×10−3) and endometrial cancer and uterine
fibroids (rg=0.24, P=7×10−3). There was no evidence of
genetic correlation between endometrial cancer and endo-
metriosis. As body mass index (BMI) is a shared risk factor
for PCOS, uterine fibroids and endometrial cancer we
adjusted genetic correlation results for BMI. Upon this
adjustment, the significant correlation between uterine
fibroids and endometrial cancer remained; however, the
genetic correlation between PCOS and endometrial cancer
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was attenuated. Despite the significant genetic correlation
observed, we did not find evidence supporting a causal
relationship between any of the three non-cancerous
gynaecological diseases and endometrial cancer develop-
ment. Gene-based analyses prioritized seven endometriosis
and five uterine fibroids-associated genes that overlapped
with endometrial cancer-associated genes, highlighting
potential shared pathways affecting risk of these diseases.
No PCOS-associated genes overlapped with endometrial
cancer-associated genes. Our study provides insights into
the shared relationship between PCOS, uterine fibroids and
endometrial cancer, and avenues for future research. Funded
by NHMRC grants to TOM, ABS, GWM
T.A. O’Mara: None. P. Kho: None. S. Mortlock: None.
G.W. Montgomery: None. A.B. Spurdle: None. D.M.
Glubb: None.
P12.074.A
Proofing the concept of a circulating tumor DNA-based
clinically scalable workflow focused on ESR1 epigenetic
modification in hormone receptor positive Metastatic
Breast Cancer
A. Franzoni1, D. Basile2, L. Allegri3, D. Viotto4, C.
Corvaja2, L. Bortot2, E. Bertoli5, S. Buriolla2, G. Targato5,
L. Da Ros6, S. Russo7, M. Bonotto7, L. Gerratana2, B.
Belletti4, G. Baldassarre4, F. Puglisi2, G. Damante8
1Institute of Human Genetics-ASUFC Udine, Udine, Italy,
2DAME-University of Udine, Department of Medical
Oncology-IRCCS CRO Aviano, Udine/Aviano, Italy,
3DAME-University of Udine, Udine, Italy, 4Department of
Cancer Research and Advanced Diagnostics-IRCCS CRO
Aviano, Aviano, Italy, 5DAME-University of Udine, Depart-
ment of Oncology-ASUFC Udine, Udine, Italy, 6Depart-
ment of Medical Oncology-IRCCS CRO Aviano, Aviano,
Italy, 7Department of Oncology-ASUFC Udine, Udine,
Italy, 8Institute of Human Genetics-ASUFC Udine; DAME-
University of Udine, Udine, Italy
Background: ESR1 genomic alterations have been largely
explored in Metastatic Breast Cancer (MBC) but little is
known about their epigenetics. Aim of the study was to test
the feasibility of a circulating tumor DNA (ctDNA)-based
workflow focused on ESR1 mutations and promoter
methylation in MBC patients (pts) treated with endocrine
therapy (ET).
Methods: overall, 49 pts eligible for first line ET were
prospectively enrolled. Mutations were evaluated through
NGS, while the methylation of ESR1 promoter A and B
(met_promA/B) was assessed through methylation-specific
ddPCR. Associations between prom A/B, pathological
characteristics and mutations were explored through Fish-
er’s exact test and Mann–Whitney test.
Results: Aromatase inhibitors were the main ET back-
bone (70.83%). Median met_promA was 38.5%, met_-
promB was 33%. Lower met_promA was observed in pts
with liver metastases (P=0.0211) while for met_promB no
differences were observed among sites, with the exception
of numerically higher levels in pts with soft tissue
involvement. Met_promA was significantly lower in pts
with ESR1 mutations (median 41 vs 25 for ESR1 wild-type
and mutated; P=0.0091) and numerically lower in pts with
a PIK3CA mutation (median 40.5 vs 24 for PIK3CA wild-
type and mutated). Three clusters were defined by
combining met_promA and B, with a significant association
between PIK3CA mutations and Cluster1 (P=0.0025).
Conclusions: The study showed the feasibility of a
ctDNA-based epigenetic evaluation. Intriguingly, differen-
tial methylation levels were observed across baseline
features, suggesting a broader impact of epigenetic
modulation of ESR1 in breast cancer biology.
A. Franzoni: None. D. Basile: None. L. Allegri: None.
D. Viotto: None. C. Corvaja: None. L. Bortot: None. E.
Bertoli: None. S. Buriolla: None. G. Targato: None. L.
Da Ros: None. S. Russo: None. M. Bonotto: None. L.
Gerratana: None. B. Belletti: None. G. Baldassarre:
None. F. Puglisi: None. G. Damante: None.
P12.075.B
Identification of modifier and dependency genes for
human hereditary cancer syndromes using CRISPR/
Cas9 mediated genome editing in Xenopus tropicalis
T. Naert1, D. Dimitrakopoulou1, D. Tulkens1, S.
Demuynck1, K. Vleminckx1,2,3
1Department of Biomedical Molecular Biology, Ghent,
Belgium, 2Department of Biomolecular Medicine, Ghent,
Belgium, 3Cancer Research Institute Ghent, Ghent, Bel-
gium
CRISPR/Cas9 mediated genome editing allows gene dis-
ruption experiments in a multitude of organisms. Xenopus
tropicalis shares with zebrafish an aquatic habitat and easy
manipulations associated with its external development.
However, unique features make it a favorable and powerful
organism for human disease modeling. Unlike zebrafish,
Xenopus tropicalis has a true diploid genome. Hence, gene
disruption studies are not suffering from redundancy. Its
genome shows high synteny with humans, assisting iden-
tification orthologs of human genes. Targeted injection of
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individual blastomeres allows manipulations of specific
tissues and organs. We generated the first genetic cancer
models in Xenopus tropicalis. Upon mosaic targeting of the
tumor suppressor gene Apc using CRISPR/Cas9, tadpoles
rapidly (< 1.5 months) and efficiently developed a range of
neoplasia characterizing Familial Adenomatous Polyposis
(FAP), including intestinal neoplasia, desmoid tumors and
medulloblastomas. Similarly, Rb1/Rbl1 double mosaic
mutant tadpoles rapidly develop retinoblastoma. Most
recently we documented the generation of Tp53 hetero-
zygous and homozygous mutant animals that develop sev-
eral neoplasms characterizing Li-Fraumeni Syndrome,
including leukemia and sarcoma. The rapid kinetics of
tumor development in the tadpoles/froglets pave the way for
their use as pre-clinical models. These cancer models pro-
vide unique possibilities for identification of modifier and
dependency genes using multiplexed CRISPR/Cas9 gRNA
injections (e.g. tumor suppressor gene + candidate depen-
dency gene). We present our results with multiplexed gene
targeting in a FAP associated desmoid tumor model iden-
tifying EZH2 as a druggable dependency factor. These
genetic Xenopus tropicalis models offer a unique experi-
mental platform in the field of human cancer research and
medical genetics.
T. Naert: None. D. Dimitrakopoulou: None. D.
Tulkens: None. S. Demuynck: None. K.
Vleminckx: None.
P12.077.A
Diagnostic yield of a comprehensive panel for cancer
predisposition genes
K. De Leeneer1,2, T. Rosseel1, R. De Putter1,2, I.
Vandernoot3, D. t’Kint de Roodenbeke4, L. Wilderoo-Van
Wouwe1, C. Kumps1, B. Poppe1,2, K. B. M. Claes1,2
1CMGG Ghent University Hospital, Ghent, Belgium, 2Can-
cer Research Institute Ghent (CRIG), Ghent, Belgium,
3Centre de génétique humaine - ULB, Brussels, Belgium,
4Jules Bordet Institute, Brussels, Belgium
We validated and implemented a custom panel of 66 genes
associated with familial cancer syndromes. Target enrich-
ment was done by SeQCap EZ Hypercap (Roche) followed
by sequencing on a Miseq or a Novaseq (Illumina) instru-
ment. Data analysis was performed with an in house
developed pipeline, allowing to limit the analysis to sub-
panels specified by the clinician. In total, 1522 patients
referred to our hospital for clinical testing were investigated.
We analyzed the following subpanels: melanoma (n = 113),
colon cancer (n = 437), HBOC (n = 1026). Combinations
of panels were analyzed for some patients, depending on
personal and/or family history. In 270 patients (18%) a
variant (Class V, Class IV) was detected in the requested
panel. Our diagnostic yield increased with 3% (n = 47)
compared to what we would have obtained if we had
applied our previous panels for these indications. This
increase is mainly attributable to the expansion of the panels
with moderate risk genes, like ATM (19 pathogenic variants
detected), BRIP1 (7 pathogenic variants) and CHEK2 (6
mutations other than c. 1100delC) in our HBOC panel.
Interestingly, we also identified several variants in genes
associated with rare syndromes - like NTHL1 (homo-
zygous), BAP1, POT1, MITF, RAD51D, CDH1, HOXB13,
STK11 and BMPR1A. The technique also allowed to detect
several mosaic patients (TP53) or patients displaying clonal
hematopoiesis in their lymphocytes (TP53, ATM). Further
validations include CNV detection and expansion with
additional genes allowing to analyze all patients with a
presumed predisposition for cancer in a uniform workflow.
K. De Leeneer: None. T. Rosseel: None. R. De Putter:
None. I. Vandernoot: None. D. t’Kint de Roodenbeke:
None. L. Wilderoo-Van Wouwe: None. C. Kumps: None.
B. Poppe: None. K.B.M. Claes: None.
P12.078.B
Family HealthLink:A web-based family history triage
tool
K. M. Sweet
Ohio State University, Columbus, OH, United States
Although family history remains an essential tool for
assessment of risk, diagnostics and prevention, it is often
not systematically collected or assessed in clinical settings.
Thus, individuals at increased risk for common diseases
such as cancer and/or coronary heart disease (CHD) might
not be identified or referred appropriately. A web-based tool
known as Family HealthLink which assesses familial cancer
and CHD risk was made available for the general public
(2010-2018) and as part of patient registration (2014-2018)
with over 200,000 users. A one-page anonymous user sur-
vey was made available on the website during a one-month
period (Jan-Feb 2018). Of 502 survey participants, 460
(91.6%) found FHL easy to use; 476 (94.8%) felt the
assessment was easy to understand; and 365 (72.7%) found
the assessment accurate and complete. 337 (67.1%) felt the
program helped the user to learn more about cancer and
CHD disease risk; 421 (83.8%) would encourage a family
member to use the program, and 377 (75.1%) planned to
talk to their healthcare provider about their risk. Qualitative
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research on patient users showed that certain aspects of FHL
could be executed more effectively, to include increased
opportunity for personalization of the web interface and risk
messaging. FHL version 3.0 is under development and will
allow for 1) automatic integration and updating of profes-
sional guidelines (e.g. NCCN guidelines for hereditary
cancer); 2) expansion as a mobile application and for EPIC
electronic health record integration; and 3) capacity to
deliver tailored, evidence-based risk messages.
K.M. Sweet: None.
P12.080.A
Two novel APC deletions resulting in a hybrid APC-
SRP19 transcript with high sequence homology to
U2AF35 splicing factor
M. Staninova Stojovska1, N. Matevska Geshkovska1, B.
Angelovska2, N. Mitreski2, M. Panovski3, A. J. Dimovski1
1Faculty of Pharmacy, Skopje, Macedonia, The Former
Yugoslav Republic of, 2University Clinic for Radiotherapy
and Oncology, UKIM-Faculty of Medicine, Skopje, Mace-
donia, The Former Yugoslav Republic of, 3University Clinic
for Digestive Surgery, UKIM-Faculty of Medicine, Uni-
verstity "Ss Cyril and Methodius, Skopje, Macedonia, The
Former Yugoslav Republic of
Germline mutations in the APC gene are the underlying
cause of familial adenomatous polyposis (FAP), an auto-
somal dominant syndrome characterized by the presence of
multiple colorectal (CRC) adenomatous polyps. Although
truncating mutations in the APC gene are the most common
defects in FAP patients, recent papers indicate that in a
significant number of cases the disease develops due to
large deletions that cannot be detected with routine testing.
Here we describe two novel germline large deletions of the
APC gene detected in 4 unrelated families presenting a
severe FAP phenotype. The deletions were characterized
using MLPA, high-resolution array-CGH and bridging-PCR
followed by Sanger sequencing methodologies. Both dele-
tions (123.466bp and 139.889bp) had a 5’ breakpoint in
intron 4 of the APC gene and a 3’ breakpoint in intron 4 of
the SRP19 gene, indicating that these regions are prone to
recombination errors and might also be frequently affected
by somatic rearrangements in sporadic CRC. RT-PCR
analysis showed that the deletions resulted in the production
of a hybrid APC-SRP19 transcript with an ORF of 550 AA,
with ~92% sequence homology with the ZRSR2 gene. The
ZRSR2 gene codes for the U2 small nuclear ribonucleo-
protein auxiliary factor 35kD subunit-related protein-2,
which plays an important role in RNA splicing. Mutations
in this gene have been found in various hematological
malignancies associated with poor overall survival. We
describe the detection of a potentially novel biomarker that
can be used both as a marker for early detection and a target
for individualized therapy in CRC patients.
M. Staninova Stojovska: None. N. Matevska Gesh-
kovska: None. B. Angelovska: None. N. Mitreski: None.
M. Panovski: None. A.J. Dimovski: None.
P12.084.B
Investigating the role of CD44v6 in Gastric Cancer:
development of exon-v6 skipping models by CRISPR/
Cas9
S. Lobo1,2, C. Pereira1,2,3, C. Oliveira1,2,3, G. Almeida1,2,3
1Instituto de Investigação e Inovação em Saúde (I3s),
Porto, Portugal, 2Instituto de Patologia e Imunologia da
Universidade do Porto (IPATIMUP), Porto, Portugal,
3Faculdade de Medicina da Universidade do Porto
(FMUP), Porto, Portugal
Introduction: Gastric cancer (GC) is the 5th most common
cancer and 3rd with highest mortality. Standard of care for
advanced disease is conventional chemotherapy. CD44v6-
containing isoforms are de novo expressed in GC, are often
correlated with cancer aggressiveness, and may predict
chemotherapy response in vitro. Whether expression of
CD44v6-containing variants, or presence of exon-v6 per se
in these isoforms, determine tumor behavior and therapy
response is unknown. This is relevant for therapeutic design
and constitutes our main aim.
Materials and Methods: Using CRISPR/Cas9, we
specifically deleted exon-v6, whilst maintaining the reading
frame, from two GC cell lines endogenously expressing
CD44v6. Edited cell lines were characterized and treated
with cisplatin and 5-fluorouracil. Cell survival was
compared to wt controls.
Results: We obtained homozygous edited cell lines
lacking exon-v6 that maintained expression of remaining
CD44 variant portions. Edited cells’ transcripts resulted in
frame v5-v7 splicing, mimicking complete exon-v6 skip-
ping. Drug treatments’ results demonstrate that removing
specifically exon-v6 does not affects GC cells chemother-
apy response, however, skipping exon-v6 is sufficient to
impair GC cells self-renewing and decrease proliferation
levels. Moreover, CD44v6-containing isoforms knockdown
modulates cell survival in GC cells.
Conclusions: We successfully designed exon-v6 skip-
ping models in GC cells lines. These exon skipping models
are extremely important to disclose exon-v6 specific role in
GC chemotherapy response. We conclude that CD44v6-
containing isoforms modulate cell survival in GC cells and,
furthermore, exon-v6 is capable of, by itself, altering one of
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S. Lobo: None. C. Pereira: None. C. Oliveira: None. G.
Almeida: None.
P12.085.C
ARID1A and FAT4 genes are frequently mutated and
deleted ina cohort of Omani patients with gastric
adenocarcinoma
Y. Tamimi1, A. Al-Abri1, F. A-Kindi1, M. Al-Riyami2, M. Al-
Moundhri2
1SQU, Muscat, Oman, 2SQUH, Muscat, Oman
Background: Gastric cancer (GC) is one of the most
common diseases worldwide. The composition of the
molecular profiles of this disease is still not fully under-
stood. ARID1A and FAT4 were identified as novel driving
genes with a pivotal role in GC pathogenesis. In this study,
we used Sanger and gene panel exome sequencing (GPES)
to assess the incidence rate of somatic mutations in FAT4
and ARID1A in a cohort of Omani patients with GC and
compared results to the TCGA and GEPIA databases.
Methods: DNA from 75 samples were subjected to GPES
as well as Sanger sequencing to screen for alterations in
ARID1A and FAT4. In addition, we used different
bioinformatics tools to retrieve TCGA data for 117 and
119 cases mutated in FAT4 and ARID1A, respectively.
Mutations and deletions were subsequently correlated with
clinical-pathological features and survival data.
Results: GPES data revealed that 44.2% of patients
displayed deletions within the ARID1A gene, and 27.9%
carried mutations. Samples from 20.9% of patients were
found to have deletions in FAT4, and 37.2% displayed
variations. Sanger sequencing analysis of FAT4 identified
novel missense mutations in 8% of cases and genomic
deletions in exon-17 in 21.3% of samples. In silico analysis
of tertiary protein structures, predicted alterations in two
domains that contained mutations.
Conclusions: A markedly higher frequency of mutations/
deletions in ARID1A and FAT4 genes were found in GC
patients from the Middle East region, reflecting the
importance of genetic background component variation
among different ethnic groups.
Y. Tamimi: None. A. Al-Abri: None. F. A-Kindi: None.
M. Al-Riyami: None. M. Al-Moundhri: None.
P12.087.B
Microsatellite instability and Epstein-Barr Virus status
in Russian gastric cancer patients.
A. Danishevich1,2, N. Pospekhova1, A. Stroganova1, D.
Golovina1
1Federal State Budgetary Institution «N.N. Blokhin
National Medical Research Center of Oncology», Moscow,
Russian Federation, 2Moscow Clinical Research center n.a.
A.S. Loginova, Moskow Helthcare Department, Moscow,
Russian Federation
Introduction: According to the The Cancer Genome Atlas
(TCGA) Research Network classification the Epstein-Barr
Virus-associated (EBV +) and Microsatellite instability-
associated (MSI) tumors are the molecular subtypes of
gastric cancer. These markers are used as prognostic factors
and prediction of chemotherapy and immunotherapy
efficacy.
Materials and Methods: FFPE tumor samples and
clinical information from 150 gastric cancer patients treated
in N.N. Blokhin NMRCO in 2010-2019 have been
investigated. Five quasimonomorphic mononucleotide mar-
kers were used for the detection of MSI status. EBV status
has been determined by the quantitative Real-time-PCR.
Results:The clinicopathological characteristics of the
gastric cancer patients and their association with the
presence of EBV and MSI status are shown in Table 1.
The majority of EBV-positive (n = 12, 92,31%, p < 0,05)
and MSI-High tumor samples (n = 6, 54,55%, p>0,05)
were detected in males. EBV-associated (61,54%) and MSI-
High (63,64%) gastric cancer cases were more often
diagnosed among patients over 55 years old. Half of
malignancies (n = 7, 53,85% of EBV+ and n = 5, 45,45%
of MSI-High) were located in the gastric body. Diffuse or
mixed subtypes were frequently (61,54%) revealed in EBV
+ samples, whereas 77,00% MSI-High were intestinal.










n (%) 13 (8,67) 137 (91,33) 11 (7,33) 139
(92,67)
Gender
Male 74(49,33) 12(92,31) 62 (45,26) 6 (54,55) 68 (48,92)
Female 76
(50,67)




8 (61,54) 85 (62,04) 7 (63,64) 88 (63,31)
< 55 56
(37,33)
5 (38,46) 52 (37,96) 4 (36,36) 51 (36,69)
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5(38,46) 37 (27,00) 2 (18,18) 40 (28,78)
Body 58
(38,67)
7(53,85) 51 (37,23) 5 (45,45) 53 (38,13)
Pylorus/antrum 20
(13,33)









5 (38,46) 65 (47,45) 7 (77,00) 67 (48,20)




2 (15,38) 18 (13,14) 0 20 (14,38)
II 28
(18,67)
4 (14,28) 24 (17,52) 2 (18,18) 26 (18,70)
III 55
(36,67)
5 (38,46) 50 (36,49) 6 (54,54) 49 (35,25)
IV 47
(31,33)
2 (15,38) 45 (32,84) 3 (27,27) 44 (31,65)
Conclusions: The received results correspond to the
worldwide data and provide new possibilities for the
treatment of Russian patients with gastric cancer.
A. Danishevich: None. N. Pospekhova: None. A.
Stroganova: None. D. Golovina: None.
P12.089.A
Oncology research applications on the GenapSys high
accuracy sequencing platform
M. Fallahi, S. Paliwal, A. Nabi, S. Bagchi, M. Jouzi, A.
Thomas, M. Barmi, S. Sankar, H. Esfandyarpour
GenapSys Inc, Redwood City, CA, United States
Next Generation Sequencing (NGS) technologies have
revolutionized basic biological and clinical research, espe-
cially in oncology. NGS cancer assays are used to determine
cancer predisposition, identify tumor mutations, monitor
treatment response and develop personalized therapies.
Here, GenapSys presents a scalable, low cost, and high
accuracy sequencing platform based on electrical impe-
dance detection. We demonstrate that Chips with 1M, 16M
and 144M sensors can be run on the same GenapSys
instrument, with greater than 99% raw accuracy and an
average read length of about 150bp. We highlight its
applications for oncology research, using diverse cancer
panels on reference and clinical samples.
We tested hybrid-capture and multiplex PCR-based
cancer panels on a range of DNA sources, including
oncology reference standards derived from cell line DNA,
cfDNA standards, clinical samples: FFPE, fresh frozen
tumor tissue, and blood. For hybrid-capture libraries, we
used the IDT xGen Pan Cancer and Exome Research
panels. We detected low frequency mutations in the range
of 1%-24.5% across multiple reference standards with the
cancer panel, and observed high correlation in allele
frequency with expected values (R2 > 0.99). Similar results
were obtained with the Ion AmpliSeq Cancer Hotspot Panel
v2. Whole exome sequencing and pan cancer sequencing of
clinical FFPE, fresh frozen and blood samples showed high
concordance (F1-score 95% - 99%) of SNV mutation
calling with industry standard technology. Thus, we
demonstrate that the GenapSys Sequencing Platform is an
accurate, scalable, and low cost solution for oncology
research on a wide range of sample types and NGS assays.
M. Fallahi: A. Employment (full or part-time); Sig-
nificant; GenapSys. S. Paliwal: A. Employment (full or
part-time); Significant; GenapSys Inc. A. Nabi: A. Employ-
ment (full or part-time); Significant; GenapSys Inc. S.
Bagchi: A. Employment (full or part-time); Significant;
GenapSys Inc. M. Jouzi: A. Employment (full or part-
time); Significant; GenapSys Inc. A. Thomas: A. Employ-
ment (full or part-time); Significant; GenapSys Inc. M.
Barmi: A. Employment (full or part-time); Significant;
GenapSys Inc. S. Sankar: A. Employment (full or part-
time); Significant; GenapSys Inc. H. Esfandyarpour: A.
Employment (full or part-time); Significant; GenapSys Inc.
P12.091.C
The role of miR-375 in the pathogenesis of gastrointest-
inal stromal tumors
U. Gyvyte1, J. Bekampyte2, G. Gudoityte2, S. Juzėnas1,3, G.
Streleckiene1, R. Lukosevicius1, R. Inciuraite1, P. Ruzgys4,
L. Kupcinskas1, J. Skieceviciene1
1Institute for Digestive Research, Lithuanian University of
Health Sciences, Kaunas, Lithuania, 2Institute of Oncology,
Lithuanian University of Health Sciences, Kaunas, Lithua-
nia, 3Institute of Clinical Molecular Biology, Christian-
Albrechts University, Kiel, Germany, 4Biophysical
Research Group, Vytautas Magnus University, Kaunas,
Lithuania
Introduction: Deregulated miRNA profiles and their con-
tribution to carcinogenesis have been observed in virtually
all types of cancer. However, their contribution to the
pathogenesis of rare gastrointestinal stromal tumors (GISTs)
is not well defined yet. In this study, we aimed to investigate
the role of miR-375 - a well-known tumor-suppressive
miRNA - in the pathogenesis of GIST.
Materials and Methods: MirVana miRNA mimic and
negative control were transfected to the GIST-T1 cell line
using the lipofection technique. Target gene and protein
expression were detected by RT-qPCR and Western Blot,
respectively. Alterations in cell viability, migration rate and
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apoptotic cell counts, as well as miRNA-target gene
interaction, were evaluated by MTT, Wound Healing,
Annexin V FITC and Dual-Light Luciferase assays,
respectively. Statistical analysis was performed using the
computing environment R.
Results: Overexpression of miR-375 reduced levels of
KIT gene mRNA (1.9-fold, p < 0.05) and protein (1.4-fold,
p < 0.05) in GIST-T1 cell line. Further functional analysis
revealed a significant effect of miR-375 on cell viability
(reduced by 47%, p < 0.05) and migration rates (reduced by
up to 28% in different time points, p < 0.05). GIST-T1 cells
with KIT 3’UTR construct (pos855-861) showed decreased
luciferase activity down to 76% when miR-375 was
overexpressed.
Conclusions: Our findings indicate that miR-375 could
suppress GIST by targeting KIT and contribute to the
pathogenesis of GIST. This study was funded by the
Research Council of Lithuania (Grant No: MIP-006/2014).
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Massive GIST as first manifestation of neurofibroma-
tosis type I
B. S. Küchler1, W. Heinritz2, A. Bier2, S. Reif2, C. Jänecke2,
M. Großmann2, J. Plaschke1, S. Krüger2
1MEWIGEN, Dresden, Germany, 2ÜBAG für Humangenetik
Oberelbe/Spree, Dresden/Cottbus, Germany
Gastrointestinal stromal tumours (GISTs) are the most
common mesenchymal tumours in the gastrointestinal tract.
The incidence is estimated at 4.3 - 22 cases per million.
GISTs are primarily sporadic (85 - 90%) caused by somatic
activating mutations in the KIT or PDGFRA genes, or less
commonly BRAF or RAS. SDH gene inactivation is
involved in about 2%. Mutations in the Neurofibromin gene
(NF1) were found in 6 - 9%. Clinicians should always
consider a germline condition, as our illustrative case
demonstrates.
Here we report a patient (55y) who suffered from weight
loss, intermittent sweating at night and postprandial
abdominal pain. Computer tomography revealed a massive
duodenal tumour (14x9x9 cm). The excised GIST was
tested negative for mutations in KIT, PDGFRA and BRAF.
No pathogenic germline mutations were revealed in SDHB,
SDHC, SDHD, FLCN and PRKARA1A. However, the
pathogenic mutation c.6006+1G>T (NM_001042492.2)
was identified in the NF1 gene. Subsequent clinical
examinations revealed multiple nodular skin alterations
most likely representing neurofibromas and several pale
café-au-lait spots.
It is remarkable that the syndromic condition of this
patient was missed until the genetic diagnosis was made.
The diagnosis in such patients is complicated by the high de
novo mutation rate of about 50%. Therefore it is important,
to consider neurofibromatosis type I also upon the
apparently sole appearance of rare manifestations. Finally,
patients with a subtle cutaneous phenotype are still at high
risk of developing severe tumours.
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Introduction: Although gliomas are generally sporadic,
there are families with several members affected by these
tumors. With exception of Li-Fraumeni syndrome, little is
known about predisposing factors underlying familial
aggregation of glioma cases. In this study, we aim to
identify rare glioma predisposing variants for familial
glioma.
Materials and methods: We performed exome sequen-
cing of 13 individuals (8 affected and 5 unaffected family
members) from four Finnish glioma families with 50X
coverage using blood-derived DNA. We called germline
variants by using an in-house developed and GATK
pipeline. Variants were filtered based on population allele
frequency and functional annotation. Variants, which were
shared by all genotyped affected members in at least one
family, were validated by targeted sequencing in 15
additional glioma families. A total of 115 known glioma-
related variants were also covered with targeted sequencing.
We are currently analysing targeted sequencing data.
Results: A total of 470 variants were identified in four
glioma families after exome sequencing. Majority of
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variants were private mutations within one family (86%). A
total of 8 variants were shared between affected cases and
present in two to four families. No familial glioma-
associated DNA copy number variants were detected.
Preliminary analysis of targeted sequencing revealed that
24% of variants were shared between two or more families
and 41% were not detected in any family.
Conclusions: Our results indicate that Finnish glioma
families carry both private mutations and mutations which
are shared between families. The role of variants as
predisposing factors of glioma will be further evaluated.
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Meta-GWAS of multiple myeloma patients fromthe
Nordic Region identifies a new risk locus in chromosome
13
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Portilla1, E. Johnsson1, I. Turesson3, N. Abildgaard4, U.
Mellqvist5, N. Andersen6, A. Waage7, A. Vangsted8, M.
Hansson3,9, U. Thorsteinsdóttir2, T. Rafnar2, K.
Stefánsson2, B. Nilsson1,10
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Olavs Hospital and Norwegian University of Science,
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Introduction: Multiple myeloma (MM) is a common
hematological malignancy, characterized by an uncontrolled
expansion of plasma cells in the bone marrow. First-degree
relatives of MM patients have 2 to 4 times higher risk of
MM. Previous studies have identified 24 genomic loci
associated with MM risk. However, these loci only explain
15 to 20% of the heritability, indicating that the molecular
basis of MM predisposition is incompletely understood.
Materials and Methods: To identify MM risk loci, we
performed a genome-wide association study in the Nordic
region totalling 5,320 cases and 422,289 controls from
Denmark, Iceland, Norway and Sweden.
Results and conclusions: We found a new MM risk
associated locus at chromosome 13. Further analysis using
blood and plasma cell eQTL data identified several potential
candidate genes at the locus, as well as a likely causal
variant mapping to a regulatory element that is selectively
open in plasma cells. Our study increases the number of
known MM risk loci to 25.
Grants and fellowships: Swedish Research Council
(2018-00424), Swedish Cancer Society (2017/265), Nordic
Cancer Union (R217-A13329), Canfaster (EU-H2020-
MSCA-COFUND-2016-754299).
L. Duran-Lozano: None. G. Thorleifsson: A. Employ-
ment (full or part-time); Modest; Amgen Genetics. A.
Lopez de Lapuente Portilla: None. E. Johnsson: None. I.
Turesson: None. N. Abildgaard: None. U. Mellqvist:
None. N. Andersen: None. A. Waage: None. A.
Vangsted: None. M. Hansson: None. U. Thorsteinsdót-
tir: A. Employment (full or part-time); Modest; Amgen
Genetics. T. Rafnar: A. Employment (full or part-time);
Modest; Amgen Genetics. K. Stefánsson: A. Employment
(full or part-time); Modest; Amgen Genetics. B.
Nilsson: None.
P12.097.C
Impact of NGS in management of haematological
malignancies: experience after one year of routine in
Eurofins-Biomnis laboratory
V. Geromel1, P. Mouty1, C. Chal1, J. delaunay2, S. Sadot
Labouvier2, R. Kaphan3, B. Rossignol4, K. Le Dû5, J.
Vigvari6, J. Coadic7, E. Marin La Meslee7, R. Boutault8, O.
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France, 5Haematological department, Jean Bernard Le
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8Labm, Labomaine Laboratory,, Le Mans, France, 9Cellu-
lar haematology/cytogenetics department, Eurofins-
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The biological management of haematological malignancies
requires close collaboration between cellular hematology,
cytogenetics and molecular biology. In contrast to traditional
single-gene methods, next-generation sequencing (NGS) is a
molecular diagnostic methodology that can study multiple
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regions of genomic tumor DNA in a single assay. Since 2019,
over 500 analyses were routinely performed with a com-
mercial panel allowing the analysis of 30 genes (Myeloid
solution™ by SOPHiA GENETICS). Our experience is pre-
sented here. Some clinical cases were selected, for which the
results of the NGS analysis have contributed either to an
improvement in patient management, or to call into question
the diagnostic or prognostic value of the molecular anomalies
observed. In particular, the diagnostic value of CHIPs (Clonal
Hematopoiesis of Indeterminate Potential) and the impact of
double mutations JAK2/CALR and JAK2/MPL in the pro-
gression of myeloproliferative neoplasia are reviewed. In
addition, the CNV information provided by NGS is useful for
the characterization of these diseases and complements the
cytogenetic result. In chronic myeloid malignancies, the latest
WHO classification includes only mutations of the JAK2,
CALR, MPL, CSF3R and SF3B1 genes in strict diagnostic
criteria. However, the current OMS classification of these
haematological malignancies will certainly be redefined by a
more exhaustive molecular approach based on recent NGS
contributions.
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Epigenetically regulated miR-129-5p functions as tumor
suppressor in liver cancer by directly targeting HDGF
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Introduction: In hepatocellular carcinoma (HCC) an
overexpression of histone deacetylases (HDACs) has
become evident. This results in chromatin compaction and
silencing of microRNAs (miRNAs). To identify epigeneti-
cally regulated miRNAs we analyzed global miRNA
expression after HDAC inhibition in HCC cell lines.
Amongst others, we identified miR-129-5p to be re-
expressed after histone acetylation. MiR-129-5p has been
shown to act tumor suppressive in several tumor entities and
we aimed to investigate its role in HCC tumorigenesis.
Materials and Methods: After transfection of HCC cell
lines (HLE, HLF, Huh7, HepG2) with miR-129-5p, tumor-
relevant functional effects were analyzed using in vitro
assays and a xenograft mouse model. Luciferase reporter
assays were performed to validate hepatoma-derived
growth factor (HDGF) as a direct target of miR-129-5p.
HDGF expression and survival data of public HCC datasets
were analyzed. Cancer-related functions of HDGF were
examined after siRNA-mediated knockdown.
Results: MiR-129-5p increased apoptosis and decreased
proliferation and migration in vitro and tumor growth
in vivo. Direct binding of miR-129-5p to the HDGF-3’UTR
via a noncanonical binding site was validated. HDGF
knockdown increased apoptosis and attenuated cell viabi-
lity, migration, and Wnt/β-catenin signaling activity of HCC
cells. Overexpression of HDGF correlated with poor overall
survival, especially in Wnt-inactive HCCs.
Conclusions: HDAC inhibition induces expression of the
tumor suppressor miR-129-5p which plays an important
role in hepatocarcinogenesis by regulating HDGF. In the
future, direct transfer of miR-129-5p or inhibition of its
target genes may be considered for HCC therapy. In this
context, inhibition of HDGF may be particularly beneficial
in Wnt-inactive HCCs.
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Characterization of somatic copy number variations in
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Background: Most Head and Neck Squamous Cell Carci-
nomas (HNSCC) are diagnosed in locally advanced stages
and, despite advances in treatment, survival rates are still
very low. The aim of this study was to identify recurrent
somatic alterations in HNSCC that could be relevant in
cancer initiation, progression or stratification.
Patients and methods: Tumour samples from 98 patients
included in clinical trial TTCC-2007-01 were used. All
patients presented locally advanced epidermoid carcinomas
(non-metastatic stages III and IV) at different locations; oral
cavity, oropharynx, hypopharynx and larynx. Tumours
were analysed by OncoScan® assay and bioinformatic tools
(Bioconductor package, GISTIC and WebGestalt software),
to detect genome-wide copy number variations and loss of
heterozygosity.
Results and discussion: We identified genomic regions
recurrently amplified (1q, 3q, 5p, 8q and 12p) and deleted
(3p, 9p and 11q) in HNSCC. We considered the amplifica-
tion in 1q21.3, identified in 58% of the samples to be
particularly interesting. Gene enrichment analysis in this
region revealed a significant association with processes
related to epithelial development. Region 1q21.3 contains
FLG, IVL and LOR genes, that codify proteins highly
expressed in the epithelium. Germinal mutations in these
genes have been associated with genodermatosis suggesting
that their somatic alteration could also be involved in the
pathogenesis of HNSCC.
Conclusion: The chromosomic region 1q21.3, that
contains FLG, IVL and LOR genes, is recurrently amplified
in HNSCC. The present study brings new data to HNSCC
research widening the spectrum of changes that could help
to identify critical regions for tumorigenesis.
Funded by FIS-FEDER:PI18/01476.
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Identification of a novel regulator of the hepatic
leukemia factor HLF ortholog
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Introduction: HLF is associated with precursor B-cell
acute lymphoblastic leukemia as part of a fusion gene. The
functional regulation of HLF is poorly understood. From
previous studies, we were led to hypothesize that taranis
(tara) regulates HLF ortholog. tara has four orthologs:
CDCA4 (Cell Division Cycle Associated 4), SERTAD2
(SERTA Domain Containing 2), SERTAD3 (SERTA
Domain Containing 3), and SERTAD1 (SERTA Domain
Containing 1). The first three tara orthologs are associated
with diseases.
Materials and Methods: Genomic editing with CRISPR/
Cas9, protein quantification through western blotting,
protein co-immunoprecipitation, transcriptional activity
assays in heterologous cell lines, and statistical analysis.
Results: TARA enhances the transcriptional activity of
HLF ortholog. In the nucleus, HLF ortholog levels are
affected by tara. TARA forms a physical complex with
HLF ortholog. More specifically, of the four conserved
domains present in all four tara orthologs, the SERTA
domain is the only domain required for the transcriptional
activity of HLF ortholog.
Conclusions: In this work, we shed new light into the
molecular mechanisms that regulate the transcriptional
activity of HLF ortholog. Plausibly, CDCA4, SERTAD2,
SERTAD3, and/or SERTAD 1 may regulate HLF trough an
identical molecular mechanism.
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Argonaute-RIP-Sequencing identifies new microRNA-
449a target genes in hepatocellular carcinoma
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Breiholz2, B. Schlegelberger1, T. Illig1, B. Skawran1
1Department of Human Genetics, Hannover Medical
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Introduction: MicroRNAs are important transcriptional
regulators that target multiple molecules affecting disease
development. The regulatory potential of tumor suppressor
miRNAs represents an interesting option for cancer ther-
apeutics. It has been shown that overexpression of miR-
449a reduces tumor growth of hepatocellular carcinoma
in vivo and in vitro. However, only few direct target genes
of miR-449a have been validated to date. Therefore, we
analyzed the targetome of miR-449a to decipher the large
network of target genes and involved signaling pathways in
order to understand its role in hepatocellular carcinoma.
Methods: HLE cells transfected with miR-449a were
used for Argonaute-RNA immunoprecipitation (RIP) and
subsequent high-throughput sequencing. Luciferase reporter
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assays were performed to validate PEA15, PPP1CA and
TUFT1 as direct targets of miR-449a. Expression of these
genes in correlation with survival data in public HCC
datasets was analyzed. Cancer-related functional effects
were examined after siRNA-mediated knockdown of
PEA15.
Results: Ago-RIP-Seq identified 183 genes as direct
targets of miR-449a. Seven genes were selected for further
investigation, as they are potential tumor suppressors
according to manual literature search. Reduced mRNA
expression following miR-449a overexpression was con-
firmed in all of these genes. Direct binding of miR-449a to
the 3’UTR of PEA15, PPP1CA and TUFT was validated. In
HCC datasets overexpression of PEA15, PPP1CA or
TUFT1 correlated with poor overall survival.
Conclusions: Ago-RIP-Seq is a promising method to
decipher the network of micro-RNA target genes. Here, we
identified several new miR-449a targets providing potential
targets for cancer therapy.
This project is supported by the German Cancer Aid
funding.
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gene test requesting risk-reducing mastectomy
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Introduction: Making an evidence based decision about
risk-reducing mastectomy (RRM) is complex. We devel-
oped and audited an algorithm for women with a diagnosis
of breast cancer, a negative breast cancer susceptibility gene
test and a high-risk breast cancer family history requesting
RRM. This incorporates current National Institute for
Health and Care Excellence (NICE) Familial Breast Cancer
Clinical guideline [CG164] (2013) and the findings from
Reiner et al. (2013 and 2018) who found that women
diagnosed <45 years had a high risk of developing a second
primary breast cancer when they had a first degree relative
(FDR) with breast cancer.
Methods and materials: 39 women with breast cancer
diagnosed <45 years old, a negative breast cancer suscept-
ibility gene test and a FDR with breast cancer were
identified out of 213 women who had genetic testing
between 2017-2019. A BOADICEA risk score was
calculated to determine the risk of a second breast cancer
in these women.
Results: We present findings that highlight a lack of
correlation between the used risk stratification sources,
including BOADICEA and Reiner et al. (2013 and 2018).
Conclusions: We conclude that clinicians can utilise
scenario-based guidance to assist in making decisions about
RRM in affected individuals for specific high-risk family
histories, which is derived from the use of validated tools
such as BOADICEA and also prospective data from the
literature.
Outcome: We propose using an audited categorised
approach to surgical RRM decision-making in women with
unilateral breast cancer, which incorporates personal and
family history based guidance.
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CanVaS: A national registry of Greek cancer patient
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Introduction: Recent advances in sequencing technologies
have allowed the integration of large genetic variation
datasets in public resources, providing the foundation for
precision medicine. They have also introduced the necessity
for inter- and intra-population genetic/genomic data
recording, in order to capture variation between and within
populations. National genetic variation registries could
serve both ends by vastly increasing the level of detail for
the relevant population, while directly affecting local patient
management.
Methods: We report CanVaS, a Cancer Variation reSource
aiming to document the genetic variation of cancer patients in
Greece. Currently, CanVaS comprises germline genetic data
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from ~11,000 Greek cancer patients, analyzed for the
presence of variants in 1-94 cancer susceptibility genes.
Results: The dataset incorporates ~3,700 functionally
annotated coding variants and ~3,000 variants in non-
coding loci. For each variant, allele frequency for the Greek
population, clinical significance interpretation and anon-
ymized family, segregation information, and phenotypic
traits of the carriers are included. Moreover, it provides
information on the geographic distribution of the variants
across the country, enabling the study of Greek population
isolates. Direct comparisons between Greek (sub)popula-
tions with relevant genetic resources is supported, allowing
fine-grain localized adjustment of guidelines and clinical
decision-making. Most importantly, anonymized data are
available for download, while our first priority is integra-
tion/interconnection with other resources, such as the
Leiden Open Variation Database.
Conclusions: CanVaS can become a stepping-stone for a
countrywide effort to characterize the cancer mutation
landscape, concurrently supporting national and interna-
tional cancer research.
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Introduction: Much of the genetic predisposition to col-
orectal cancer (CRC) cannot be explained by pathogenic
variants in known high/moderate-penetrance cancer-
predisposing genes. Here we aim to investigate whether
part of the genetically unexplained familial/early-onset
CRC cases may be attributed to the accumulation of low
risk alleles for CRC.
Material and methods: A weighted polygenic risk score
(wPRS) based on 95 CRC risk alleles identified and
validated through genome-wide association studies
(Huyghe et al. Nature genetics 2018), was determined in
421 familial/early-onset unrelated CRC patients (fCRC),
1,077 sporadic CRC patients, and 1,642 cancer-free
controls. Logistic regression was used to model the risk.
Two-sided t-test was applied to compare means among
cohorts. Additionally, we grouped individuals (fCRC and
controls) into 20 quantiles. Odds ratios (OR) were estimated
taking the quantile 10 as reference.
Results: The average wPRS was statistically higher in
fCRC patients compared to either controls (Pt-test=2.2e-16),
with an OR of 22.8, or sporadic CRC patients (Pt-test=0.004).
Familial CRC patients in the highest (20th) wPRS quantile
were at a four-fold increased CRC risk than those in the
middle (10th) quantile. The frequency of high-wPRS fCRC
patients who had developed multiple (synchronous or
metachronous) colorectal tumors and that had familial CRC
history was higher than in low-wPRS patients. The heritability
explained by the studied alleles was of 37.48% for fCRC.
Conclusions: The accumulation of low risk CRC alleles
may explain a relevant proportion of familial/early-onset
CRC cases without germline pathogenic variants in known
hereditary cancer genes.
L. Valle: None. P. Mur: None. N. Bonifaci: None. A.
Díez-Villanueva: None. E. Munté: None. M. Alonso:
None. G. Aiza: None. M. Navarro: None. J. Brunet:
None. V. Moreno: None. G. Capellá: None.
P12.106.C
Assessment of the causal association of recently pro-
posed candidate genes with colorectal cancer and
polyposis predisposition
I. Quintana1, P. Mur1,2, E. Munté1, M. Terradas1,2, G. Aiza1,
M. Navarro1,2, J. Brunet1,2,3, G. Capellá1,2, L. Valle1,2
1Hereditary Cancer Program, Catalan Institute of Oncol-
ogy; Oncobell Program, IDIBELL, Hospitalet de Llobregat,
Barcelona, Spain, 2CIBERONC, Madrid, Spain, 3IDIBGi,
Girona, Spain
Introduction: A previous in silico study identified 49 genes
as the most-frequently enriched in rare damaging germline
variants in samples with putative somatic loss of hetero-
zygosity (LOH) in cancer patients, thus presenting as good
candidates for cancer predisposition. Based on their func-
tion, involvement in CRC carcinogenesis and expression in
colonic mucosa, we selected six of those genes: NSD1,
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HDAC10, KRT24, BBS1, ACACA and TP63, to evaluate
their actual involvement in colorectal cancer predisposition.
Materials and methods: Germline mutational screening
of the six genes was performed in 738 patients (465
familial/early onset CRC patients, 177 (attenuated) familial
adenomatous polyposis and 96 serrated polyposis patients)
by using pooled DNA amplification followed by targeted
next generation sequencing. The impact of the identified
missense variants was analyzed by using 13 pathogenicity
prediction tools. Co-segregation studies and second hit
analysis in tumors or polyps are currently being performed.
Results and conclusions: Twenty-four carriers of
disruptive or predicted deleterious variants in the studied
genes were identified. Assessment of allele frequencies in
controls compared to familial/early-onset CRC patients
showed an association of NSD1 disruptive variants with
increased CRC risk, and no association was detected for
ACACA. No conclusive evidence was found for HDAC10,
KRT24, BBS1 and TP63. Results from co-segregation and
second hit analyses will provide further evidence in favor or
against the association of those genes with CRC
predisposition.
Grant: BES-2017-079701 (Co-funded by European Social
Fund. ESF investing in your future)
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Clinical audit of multigene panel testing at the Royal
Melbourne Hospital
R. Sheridan1,2, M. Bogwitz2, P. James3, I. Winship1,2
1University of Melbourne, Parkville, Australia, 2Royal
Melbourne Hospital, Parkville, Australia, 3Peter MacCal-
lum Cancer Centre, Parkville, Australia
Introduction: In 2016 the Parkville Familial Cancer Centre
at the Royal Melbourne Hospital introduced panel based
genetic testing to screen for hereditary cancer syndromes.
Multigene panel tests allow simultaneous screening for
pathogenic variants in multiple cancer predisposition genes
and replaced iterative single gene tests, which proved to be
slow, inefficient and expensive. This study seeks to validate
the clinical testing criteria used by the Familial Cancer
Centre and to identify areas of improvement to increase
overall clinical utility.
Materials and Methods: This study used a tailored
database extraction to collate panel testing results over a 28-
month period, and these results were analysed in conjunc-
tion with relevant patient data, such as primary cancer type,
age of diagnosis, family history, and relevant phenotypic
features.
Results: A total of 757 patients met testing criteria for
state funding, and were offered panel testing relevant to
their cancer diagnosis and/or family history. Pathogenic
variants were detected in 13% (n = 101). Individual panel
yield varied, with a trend suggesting that clear concomi-
tant phenotypic features, such as skin signs with renal
cancer, increased the likelihood of a panel yielding a
positive result. Positive results also varied by specific
cancer pathology. Of patients presenting with a primary
breast cancer (n = 335), 12% had a pathogenic mutation.
The mutation pickup rate for a triple hormone-receptor
negative breast cancer n = was 18%, but only 10% for
breast cancers with at least one hormone-receptor positive
pathology result (n = 237).
Conclusions: This project demonstrates that ongoing
review of publicly funded testing is warranted.
R. Sheridan: None.M. Bogwitz: None. P. James: None.
I. Winship: None.
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Oncopanel screening for hereditary cancers: a retro-
spective review of a hospital-based experience
E. Yilmaz1,2, E. Borklu Yucel2, S. Avci2, H. Azakli2, P.
Saracoglu2, S. Eraslan2, H. Kayserili2
1Research Center for Translational Medicine (KUTTAM),
Koç University, Istanbul, Turkey, 2Department of Medical
Genetics, School of Medicine, Koç University, Istanbul,
Turkey
In the last decade, cancer, as a large group of diseases
described as an uncontrollable abnormal cell growth that
can start in almost any organ or tissue of the body, becomes
the major health problem and the second leading cause of
death globally. The leading types are lung, breast, color-
ectal, prostate and stomach cancers. 18.1 million new cases
were diagnosed globally in 2019 and only 5-10% of them
are attributed to hereditary factors. Genetic testing can be
offered not only to identify the individuals’ cancer risk, but
also to enable the possibility of molecular targeted thera-
pies. Here, we report the retrospective analysis of a single
institution’s 3-year experience of oncopanel sequencing,
which targets 94 genes and 284 SNPs, carried out by using
peripheral blood samples. 125 unrelated patients with a
male:female ratio of 1:4 (mean age 40(sd 6,51)) were
screened. Our studies showed that 72% of the cases have at
least one variant classified as pathogenic, possibly patho-
genic or of unknown significance in targeted regions.
Pathogenic variants were detected in 12%, and possible
pathogenic variants were detected in 18% of the cases.
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CHEK2 and ATM were detected as most common genes in
patients with pathogenic mutations. Although pathogenic
variant detection rate is relatively high, variants of unknown
significance (VUS), which were found in 42% of the cases,
are also needed to be evaluated carefully, especially in
hereditary forms of cancer. It is obvious that more research
on VUS and assessment of their effect on cancer develop-
ment is essential to shed light to underlying pathogenicity
and medical management.
E. Yilmaz: None. E. Borklu Yucel: None. S. Avci:
None. H. Azakli: None. P. Saracoglu: None. S. Eraslan:
None. H. Kayserili: None.
P12.111.B
TP53 pathogenic variants in colorectal cancer patients in
absence of Li-Fraumeni-associated phenotypes
M. Terradas1,2, P. Mur1,2, S. Belhadj1, E. R. Woodward3,4,
G. J. Burghel3, P. M. Munoz-Torres1, I. Quintana1, M.
Navarro1, J. Brunet1,5, C. Lázaro1, M. Pineda1, V.
Moreno6,7, G. Capellá1, G. R. Evans3,4, L. Valle1,2
1Hereditary Cancer Program, Catalan Institute of Oncol-
ogy; Oncobell Program, IDIBELL, Hospitalet de Llobregat,
Spain, 2CIBERONC, Madrid, Spain, 3Manchester Centre
for Genomic Medicine, St Mary’s Hospital, Manchester
University NHS Foundation Trust, Manchester, United
Kingdom, 4Division of Evolution and Genomic Sciences,
Faculty of Biology, Medicine and Health, University of
Manchester, Manchester, United Kingdom, 5Catalan Insti-
tute of Oncology, IDIBGi, Girona, Spain, 6Unit of
Biomarkers and Susceptibility, Cancer Prevention and
Control Program, Catalan Institute of Oncology, IDIBELL,
Hospitalet de Llobregat, Spain, 7CIBERESP, Madrid,
Spain
Introduction: Germline TP53 pathogenic variants cause
Li-Fraumeni syndrome (LFS), an aggressive multi-tumor-
predisposing condition. Due to the implementation of multi-
gene panel testing, TP53 variants have been detected in
individuals without LFS suspicion, e.g. colorectal cancer
(CRC) patients. We aim to decipher whether these findings
are the result of detecting background population pre-
valence or the etiologic basis of CRC.
Materials and Methods: TP53 mutational screening was
performed in 473 familial/early-onset CRC cases. Our
findings were analyzed together with results from five
additional studies that evaluated the prevalence of TP53
germline variants in CRC patients (total n=6,200). Data
from control population and LFS cases were obtained from
gnomAD and the IARC TP53 database, respectively. All
variants were reclassified according to ACMG/AMP
guidelines (both applying the TP53 rule specifications
(v.1) provided by the ClinGen TP53 Expert Panel, and
automatically using PathoMan).
Results: (Likely) pathogenic variants were identified in
0.03% of controls and ~0.21% of CRC patients
(p < 0.0001), none of whom fulfilled the clinical criteria
established for TP53 testing. Loss-of-function/splice-site
variants were significantly associated with CRC as
compared with controls (OR=19; p <0.001). Compared to
LFS, enrichment of this type of variants and of variants with
no dominant negative effect was observed in CRC patients.
Conclusions: TP53 pathogenic variants should not be
unequivocally associated with LFS. The association with
CRC risk may be explained by the absence of dominant
negative effects and/or the loss-of-function nature of the
variants.
M. Terradas: None. P. Mur: None. S. Belhadj: None.
E.R. Woodward: None. G.J. Burghel: None. P.M.
Munoz-Torres: None. I. Quintana: None. M. Navarro:
None. J. Brunet: None. C. Lázaro: None. M. Pineda:
None. V. Moreno: None. G. Capellá: None. G.R. Evans:
None. L. Valle: None.
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Clinical significance of gene mutations and polymorphic
variants and their association with prostate cancer risk
in Polish men.
M. Heise1, P. Jarzemski2, A. Junkiert-Czarnecka1, A. Bąk1,
M. Pilarska-Deltow1, M. Borysiak2, O. Haus1
1Department of Clinical Genetics, Faculty of Medicine,
Collegium Medicum, Nicolaus Copernicus University,
Bydgoszcz, Poland, 2Department of Urology, Jan Biziel
University Hospital, Bydgoszcz, Poland
Introduction: We tested the association of BRCA1,
BRCA2, CHEK2, CDKN2A, HOXB13, MLH1, NBS1,
NOD2, PALB2, CYP1B1, PON1, 8q24 mutations and
polymorphisms with prostate cancer (PC) risk and analyzed
the impact changes on disease clinical course, including
overall survival time.
Material: DNA from 110 men with PC from all over
Poland and from 110 men - healthy volunteers.
Methods: Sequencing, AS-PCR, RFLP-PCR, multiplex-
PCR.
Results: The percentage of men with ≥1 change was
higher in PC group (61,8%) than in healthy men (52,3%) (p
= 0,15). The presence of at least two changes was
associated with shorter patient survival than the presence
of one or no change (p = 0,14). The G84E of HOXB13
was detected in 2,9% of PC men and in no healthy man
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(p = 0,19, trend, OR=7,21). The average age at PC onset of
men with CYP1B1 432GG and PON1 55AA originated
from Hereditary Prostate Cancer Families (HPC) was
significantly younger than the age of men with
these variants from families without HPC (respectively:
p = 0,0077, p = 0,0350).
Conclusions: The presence of at least one genetic change
is an unfavorable factor in PC. The presence of ≥2 changes
may be associated with shorter survival. The HOXB13
(G84E) are probably associated with PC development and
with hereditary form of the disease. The CYP1B1 (432GG)
and PON1 (55AA) are associated with younger age at PC
onset in men from HPC families. The HOXB13 (G84E),
NOD2 (3020insC) and PON1 (55AA) are assiciated with
shorter overall survival.
This study was supported by the found of the Collegium
Medicum.
M. Heise: None. P. Jarzemski: None. A. Junkiert-
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P12.113.A
Evaluation of the clinical impact of a questionnaire-
based self-assessment family history of colorectal cancer
compared to a professional pedigree survey
S. I. Steiner1,2, B. Denecke2, U. Berger2, V. J. Scheble3, A.
Dufke1
1Institute of Medical Genetics and Applied Genomics,
University Hospital Tübingen, Tübingen, Germany, 2Com-
prehensive Cancer Center Tübingen-Stuttgart, University
Hospital Tübingen, Tübingen, Germany, 3Department of
Internal Medicine I, University Hospital Tübingen, Tübin-
gen, Germany
Introduction: The “German Cancer Society” is providing a
questionnaire-based risk-score to delineate persons at risk
for familial colorectal cancer, intended for easy use by non-
geneticists in daily routine with colon cancer patients. The
intention is to support therapists in detecting patients that
should undergo a genetic counselling regarding hereditary
tumour predisposition syndrome. The monocentric study
aimed to analyse and evaluate the value of this score
compared with a standard three-generation pedigree
analysis.
Material and Methods: Starting in June 2018, 100
colorectal cancer patients treated at the University Tübingen
were randomly picked over a 14 months period. After
patients completed the questionnaire, a pedigree and a
survey on the comprehensibility of the questionnaire were
conducted. Pedigrees and available histopathological data
were then evaluated according to the Bethesda and
Amsterdam guidelines and analysed for other familial
tumour syndromes. The results were compared to the self-
assessment risk-score.
Results: In 41/100 patients the questionary screening
approach indicated a familial colorectal cancer risk
compared to 22 patients by pedigree analysis. Into the
positive questionary group fell 16/22 of these patients. In 9
cases the family trees identified criteria for other familial
cancer syndromes.
Conclusions: The questionnaire is a valuable screening
tool for identifying family risk of colorectal cancer. In order
to exploit the full potential of the questionnaire, it is
advisable to use it with a medical or professional
perspective and assistance, because sensitivity and specifi-
city is significantly lower compared to pedigree analysis.
S.I. Steiner: None. B. Denecke: None. U. Berger: None.
V.J. Scheble: None. A. Dufke: None.
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Immune checkpoint genes expression vary among
paediatric an adult glioblastoma models
R. Mehrian-Shai1, D. Rogachevsky1, P. A. Stempor2,3, A.
Toren4,1, P. Dobosz5,1
1Paediatric Haemato-Oncology, Oncology Department,
Cancer Research Centre, Sheba Medical Centre Hospital,
Tel Hashomer,, Ramat Gan, Israel, 2School of Life
Sciences, Gurdon Institute, Department of Genetics, Tennis
Court Rd, Cambridge CB2 1QN, Cambridge, United
Kingdom, 3The Wellcome Trust/CRUK Gurdon Institute,
University of Cambridge, Tennis Court Rd,, Cambridge,
United Kingdom, 4Oncology Department, Sackler Faculty
of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel,
5Department of Haematology, Oncology and Internal
Diseases, Medical University of Warsaw, Warsaw,
Poland
Introduction: Glioblastoma (GB) is the most aggressive
malignant primary brain tumour in both children and adults.
Regardless of age, GB is incurable and associated with poor
prognosis. Because of its highly invasive nature, it is
impossible to remove all tumour cells during surgical
resection, making relapse inevitable, thus, GB treatment
presents one of the greatest challenges. Molecular data
reveal significant differences between the paediatric and
adult GBs, e.g. recurrent somatic mutations in some histone
variants. The aim of the study was to determine differences
in gene expression among paediatric and adult GB, sug-
gesting the possible reason for failures of immunotherapy
in GB.
Materials and methods: GB cell lines: paediatric
(KNS42, SF188, SF8628), adult (U87, U251, T98G), and
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normal human astrocytes were used as a reference. RNA
was harvested and the gene expression level was deter-
mined using RT-PCR. Selected genes with proven involve-
ment for immunotherapy response have been analysed.
Results: Of all 27 analysed genes, only a small fraction
seems to be expressed in GB, some of which were not
analysed in GB literature so far. Expression of those seem to
be higher in paediatric GB, e.g. BACH2 and IL-6R.
Conclusions:Most of the genes involved in the formation
of immunological synapse are significantly down-regulated
or not expressed at all in GB, providing the potential
explanation for many failures of checkpoint inhibitors
immunotherapy in GB. However, differences in gene
expression might favour paediatric GB over adult GB as a
candidate for future research leading to the successful
immunotherapy.
R. Mehrian-Shai: None. D. Rogachevsky: None. P.A.
Stempor: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Smart
Immune Ltd.. A. Toren: None. P. Dobosz: E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Modest; Smart Immune Ltd.
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TP53 with in cis RAD51C pathogenic variants modulates
the TP53-dependent tumorigenesis to sebaceous gland
carcinomas
J. Hentschel1, D. Le Duc1, S. Neuser1, M. Stiller1,2, C.
Meier1, E. Jäger3, R. Abou Jamra1, K. Platzer1, A.
Monecke2, M. Ziemer4, A. Markovic4, H. Bläker2, J. R.
Lemke1
1Institute of Human Genetics, University Medical Center
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versity Medical Center Leipzig, Leipzig, Germany,
3Department of Endocrinology, Nephrology, and Rheuma-
tology, University Medical Center Leipzig, Leipzig, Ger-
many, 4Department of Dermatology, Venereology and
Allergology, University of Leipzig Medical Center, Leipzig,
Germany
Introduction: Pathogenic variants in the tumor suppressor
TP53 cause Li-Fraumeni syndrome, a cancer predisposition
syndrome with high risks for childhood- and adult-onset
malignancies e.g. breast cancer, soft tissue or bone sarcoma,
brain tumors and adrenocortical carcinoma.
Case description: We describe a 43-year-old male with
germline pathogenic variants in TP53 and RAD51C located
in cis on chromosome 17, who has so far not developed any
tumors of the LFS-spectrum. Instead, he developed a
sebaceous gland carcinoma (SGC), without detection of
mismatch repair deficiency, which is the only known cause
of SGC to date. These findings are replicated by a Trp53-
Rad51c-double-mutant cis mouse-model, which develops
SGCs, but suppresses the characteristic Trp53-associated
tumor spectrum.
Methods: Variants were identified using tumor panel
next generation sequencing. Phasing of the two variants was
done using short tandem repeat analysis.
Conclusions: In line with the observations in Trp53-
Rad51c-double mutant cis mice, we propose that the human
in cis co-occurrence of pathogenic TP53 and RAD51C
variants substantially transforms the Li-Fraumeni phenotype
to a predisposition to SGC.
J. Hentschel: None. D. Le Duc: None. S. Neuser: None.
M. Stiller: None. C. Meier: None. E. Jäger: None. R.
Abou Jamra: None. K. Platzer: None. A. Monecke:
None. M. Ziemer: None. A. Markovic: None. H. Bläker:
None. J.R. Lemke: None.
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Cellfree tumour DNA analysis detects copy number
alterations in gastrooesophageal cancer patients.
K. Wallander1,2, J. Eisfeldt1, M. Lindblad1,2, D. Nilsson1,2,
K. Billiau1, H. Foroughi1, M. Nordenskjöld1, A. Leiden1,2,
E. Tham1,2
1Karolinska Institutet, Stockholm, Sweden, 2Karolinska
University Hospital, Stockholm, Sweden
Background:Analysis of cell-free tumour DNA, a liquid
biopsy, is a promising biomarker for cancer. We have
performed a proof-of principle study to test the applicability
in the clinical setting, analysing copy number alterations
(CNAs) in plasma and tumour tissue from 44 patients with
gastro-oesophageal cancer.
Methods:DNA was isolated from blood plasma and a
tissue sample from each patient. Array-CGH was applied to
the tissue DNA. The cell-free plasma DNA was sequenced
by low-coverage whole-genome sequencing using a clinical
pipeline for non-invasive prenatal testing. WISECONDOR
and ichorCNA, two bioinformatic tools, were used to
process the output data and were compared to each other.
Results:Cancer-associated CNAs could be seen in 59%
(26/44) of the tissue biopsies. In the plasma samples, a
targeted approach analysing 61 regions of special interest in
gastro-oesophageal cancer detected cancer-associated
CNAs with a z-score >5 in 11 patients. Broadening the
analysis to a whole-genome view, 17/44 patients (39%) had
cancer-associated CNAs using WISECONDOR and 13
(30%) using ichorCNA. Of the 26 patients with tissue-
verified cancer-associated CNAs, 14 (54%) had correspond-
ing CNAs in plasma. Potentially clinically actionable
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amplifications overlapping the genes VEGFA, EGFR and
FGFR2 were detected in the plasma from three patients.
Conclusions:We conclude that low-coverage whole-
genome sequencing without prior knowledge of the tumour
alterations could become a useful tool for cell-free tumour
DNA analysis of total CNAs in plasma from patients with
gastro-oesophageal cancer.
K. Wallander: None. J. Eisfeldt: None. M. Lindblad:
None. D. Nilsson: None. K. Billiau: None. H. Foroughi:
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A novel long non coding RNA FGF10AS and sense
transcript are correlated with poor prognosis in color-
ectal cancer
L. Rejali1,2, M. Hashemi3, H. Asadzadeh Aghdaei4, E.
Nazemalhosseini2, S. Seyedna1
1Department of Biology, Faculty of Biological Sciences,
Islamic Azad University, North Tehran Branch, Tehran,
Iran, Islamic Republic of, 2Gastroenterology and Liver
Diseases Research Center, Research Institute for Gastro-
enterology and Liver Diseases, Shahid Beheshti University
of Medical Sciences, Tehran, Iran, Islamic Republic of,
3Department of New Sciences, Tehran Medical Branch,
Islamic Azad University, Tehran, Iran, Islamic Republic of,
4Basic and Molecular Epidemiology of Gastrointestinal
Disorders Research Center, Research Institute for Gastro-
enterology and Liver Diseases, Shahid Beheshti University
of Medical Sciences, Tehran, Iran, Islamic Republic of
Introduction: Natural antisense transcripts (NATs) are
inclusively predicted to play a leading role in cancer pro-
gression. Growth factors contribute to cell growth, differ-
entiation, angiogenesis, and most significantly tumor
formation in many types of cancers. The present study
aimed to evaluate the relationship of fibroblast growth
factor 10 (FGF10) and FGF10AS expression with clin-
icopathological features in CRC advancement.
Methods & Materials: This study was navigated on 100
CRC tumoral and parallel adjacent normal tissues. The
expression levels of FGF10 and FGF10AS were evaluated
by the q-RT PCR method. For findings validation,
expression levels were measured in HCT116 and SW480
cell lines. Immunohistochemistry analysis was performed
systematically for FGF10 expression appraisal.
Results: A substantial increase and decrease in expression
levels were perceived in FGF10 (P < 0.001) and FGF10AS
(P > 0.02) in tumoral tissues, in comparison with the adjacent
normal tissues. Besides, upregulation of sense and down-
regulation of antisense were strongly correlated with
the TNM stage (P < 0.007 and P < 0.004), vascular invasion
(P < 0.03 and P < 0.01), lymph invasion (P < 0.02 and P <
0.04) and differentiation (P < 0.01 and P < 0.02) respectively.
The area under the ROC curve for the prognostic value of
FGF10 was about 0.84 (95% confidence interval, 0.771-
0.912). The results of linear regression analysis confirmed a
negative correlation between FGF10AS expression and sense
transcript. (r = −0.02)
Conclusion: The relationship between the expression
levels of FGF10 and FGF10AS in tumoral and adjacent
normal tissues indicated that sense and antisense FGF
RNAs could be remarkable prognostic biomarkers for
achieving effective treatment and higher survival rates.
L. Rejali: None. M. Hashemi: None. H. Asadzadeh
Aghdaei: None. E. Nazemalhosseini: None. S.
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Intragenic deletions within the putative tumor suppres-
sor LSAMP are rare in primary neuroblastomas but
common in cancer cell lines from diverse origin
L. Mösle1, H. Christiansen2, S. Ackermann3, A. Weber1
1Institute of Human Genetics, Justus-Liebig-Universität,
Giessen, Germany, 2Department of Pediatric Oncology,
Hematology and Hemostaseology, University Children´s
Hospital, Leipzig, Germany, 3Experimental Pediatric
Oncology University Children’s Hospital, Cologne, Ger-
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Introduction: Intragenic deletions within the LSAMP-Gene
on human chromosome 3 have been described in osteo-
sarcomas and osteosarcoma cell lines before. We asked for
the frequency of intragenic LSAMP copy number variations
(CNVs) in primary neuroblastomas, neuroblastoma cell
lines and cell lines from other cancer origin.
Materials and Methods: Specific real time PCRs were
established for genomic regions of the seven exons of the
LSAMP-gene (NM_002338.4) and six genomic control
regions. Genomic copy number of the seven LSAMP-exons
was calculated according to the 2−ΔΔCt method, using n =
20 control DNAs for calibration. LSAMP-exon CNVs were
defined with a 2−ΔΔCt value below (deletion) or above
(duplication) the 2nd standard deviation (SD) of the mean of
the controls. In total we investigated genomic DNA from n
= 54 primary neuroblastomas, n = 12 neuroblastoma cell
lines and n = 17 cell lines of other malignancies.
Results: We found CNVs in LSAMP in n = 14 (26%)
primary neuroblastomas. The findings did not correlate with
tumor stage, age at diagnosis or survival. Furthermore, we
found distinct CNVs of one or multiple LSAMP-exons in n
= 16 out of the n = 29 cell lines investigated (55%).
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Conclusions: In primary neuroblastomas LSAMP CNVs
were found only in a minority of cases. The clinical
relevance for primary neuroblastoma development remains
unclear. The common finding of LSAMP intragenic CNVs
in cell lines of neuroblastoma and other cancer origin gives
further evidence of a tumor suppressor function of LSAMP
and makes us assume, that a loss of LSAMP function might
be relevant for growth progression of tumor cells.
L. Mösle: None. H. Christiansen: None. S. Acker-
mann: None. A. Weber: None.
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Distinct Landscapes of Genomic Alterations between
Lung Carcinoids and Non-Small Cell Lung Cancers
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ment of Human Genetics, McGill University-Génome
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Introduction: Genomic profiling of tumours has become a
crucial component of precision cancer medicine. A com-
parison of the molecular alterations between Non-Small
Cell Lung Cancer (NSCLC) and Lung Carcinoid (LC)
subtypes however is missing and might further improve
patient stratification.
Methods: We sequenced 216 paired tumour-normal
samples using a combination of whole-exome and targeted
capture sequencing. Additionally, all samples underwent
Illumina OmniExpressExome (v1.6) SNP genotyping.
Results: Out of 108 lung cancer patients, 22 had LC and
86 NSCLC. Those with NSCLCs showed lower survival
time compared to LCs (P = 0.0148). Recurrent mutations
were found in TP53 (81%), KRAS (34%), STK11 (23%) and
KEAP1 (21%) in NSCLC but none of these genes were
mutated in the LC subtype. Similarly, Copy Number (CN)
burden was also higher in NSCLC than in LCs, with 10%
and 5% of genome respectively harbouring CN alterations.
Recurrent amplifications in MYC (35%), SOX2 (20%) and
MDM2 (11%) were found in NSCLC but only 18% of LC
patients showed MYC amplifications and none were
detected in SOX2 and MDM2. Furthermore, MTAP and
CDKN2A were co-deleted at frequencies of ~30% in
NSCLC but at 4.5% only in LCs.
Conclusions: Molecular profiles in NSCLC and LC are
substantially different and this may have direct conse-
quences in the therapy decision process. For example,
preferential loss of the CDKN2A locus in NSCLC could
impact the response to immunotherapy drugs. In contrast, as
MDM2 is a negative regulator of TP53, MDM2 amplifica-
tion in NSCLC could indicate therapeutic efficacy of
MDM2 inhibitors in p53 mutant tumours.
C. Domingo-Sabugo: None. E. Starren: None. A.
Mandal: None. A. Nastase: None. L. Hoang: None. M.
Edwards: None. D. Morris-Rosendahl: None. E. Lim:
None. A. G. Nicholson: None. M. Lathrop: None. W.
Cookson: None. M. Moffatt: None.
P12.127.C
A Novel High Multiplex and ddPCRTM Based Technol-
ogy for Lung Cancer MutationScreening
Z. Yang1, Y. Wang1, P. Jagiello2, V. Ruiz3
1Atila BioSystems, Inc, Mountain View, CA, United States,
2Fujirebio Europe N.V., Zwijnaarde, Belgium, 3Fujirebio
Europe NV, Ghent, Belgium
Introduction: Genetic mutations have been found in many
different genes, including EGFR, KRAS, HER2, MET and
BRAF in the cancer cells of NSCLC patients. Testing for
these mutations and tailoring therapy accordingly are
widely accepted as standard practice. Recently a novel
technology that enables high multiplex amplification reac-
tions was developed by Atila Biosystems. With the droplet
digital (ddPCRTM) technology, the Atila iCARE (RUO)
Lung cancer mutation screening kit identifies and quantifies
99 possible mutation sites in two reaction wells in a rapid
and cost-effective manner.
Materials and Methods: Artificially prepared DNA
samples were used to evaluate analytical sensitivity and
specificity. We used enzymatically digested normal human
genomic DNA as negative DNA samples and mutation
bearing plasmid DNA as spike in positive DNA. A serial
dilution of mutations at 0%, 0.1%, 0.2%, 0.5%, 1%, and
10% were used to evaluate assay sensitivity.
Results: The iCARE Lung cancer screening assay targets
42 mutations in EGFR, 41 mutations in KRAS, 1 mutation
in BRAF, 13 mutations in HER2, and 1 mutation in MET.
The assay differentiates mutations from wildtype targets
based on cluster locations in the ddPCRTM two-dimensional
graphs. All mutations were successfully detected in serially
diluted samples containing from 8% to 0.1% spiked
mutations.
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Conclusions: The iCARE Lung Cancer Mutation Screen-
ing Assay kit allows quantification and screening for 99
NSCLC mutations of multiple samples in a rapid and cost-
effective manner. The assay has reached 0.1% sensitivity
for mutation detection in all 5 genes and showed no false
positive in wildtype DNA samples.
Z. Yang: A. Employment (full or part-time); Significant;
Atila BioSystems, Inc. Y. Wang: A. Employment (full or
part-time); Significant; Atila BioSystems, Inc. P. Jagiello:
A. Employment (full or part-time); Significant; Fujirebio
Europe N.V.. V. Ruiz: None.
P12.130.C
Design and implementation of the first one-stop multi-
disciplinary clinic for Lynch syndrome in the United
Kingdom (UK)
B. DeSouza, V. Tripathi, A. Shaw, L. Izatt, S. Demartino, G.
Tritto, P. Ross, G. Mehra, A. Schizas, M. George, C. Firth,
K. Hilario, C. Reinholtz, A. Kulkarni
Guy’s and St Thomas’ NHS Foundation Trust, London,
United Kingdom
Introduction: The clinical benefit of a multidisciplinary
clinic (MDC) model has been well documented for a variety
of medical conditions. We designed and implemented a
novel MDC for Lynch syndrome (LS) patients, which aims
to improve treatment outcomes, participation in research
trials, and patient satisfaction.
Methods: From January 2019, LS patients in our region
were invited to attend a bimonthly MDC offering gene-
specific evidence-based cancer risk management. Patients
could choose to see the gastroenterology, colorectal,
gynaecology, medical oncology, research, and clinical
psychology teams. Clinical outcomes and patient satisfac-
tion were evaluated over 12 months.
Results: Thirty-eight LS patients were seen (8 MLH1, 18
MSH2, 8 MSH6, 4 PMS2); mean age was 46y (range: 20-
69y); 15 patients had colorectal cancer (39.5%). Twenty-six
(68.4%) patients were female; 6 (23.1%) had undergone
prior risk-reducing gynaecological surgery, 7 (27%) under-
went surgery at our institution (n = 4) or locally (n = 3),
and 13 (50%) were too young for surgery. Eight patients
(30.8%) transferred their colonoscopic surveillance to our
care due to concerns about local provision. Nineteen
patients (73.1%) accessed psychological support and 10
patients (38.5%) were recruited to research studies. Twenty-
six patients (68.4%) completed a post-clinic satisfaction
questionnaire; 96.2% (n = 25) rated their clinic experience
as excellent or very good.
Conclusions: We have designed and implemented an
effective multidisciplinary model of care for LS, which
addresses unmet needs in this patient group. Other
institutions are encouraged to adopt a coordinated MDC
service for LS. We will continue to evaluate the MDC’s
impact on disease-specific outcomes in future reports.
B. DeSouza: None. V. Tripathi: None. A. Shaw: None.
L. Izatt: None. S. Demartino: None. G. Tritto: None. P.
Ross: None. G. Mehra: None. A. Schizas: None. M.
George: None. C. Firth: None. K. Hilario: None. C.
Reinholtz: None. A. Kulkarni: None.
P12.131.A
Lynch syndrome: gene variants in 35 patients and
cascade screening of individuals at-risk
H. P. Saraçoğlu1, E. Börklü Yücel2, S. Eraslan2, E.
Yılmaz3,4, U. Altunoğlu2,3, H. Kayserili2,3
1Cellular and Molecular Medicine, Institute of Health
Sciences, Koç University, İstanbul, Turkey, 2Diagnostic
Center for Genetic Diseases, Koç University Hospital,
İstanbul, Turkey, 3Medical Genetics Department, Koç
University School of Medicine (KUSOM), İstanbul, Turkey,
4Research Center for Translational Medicine (KUTTAM),
Koç University, İstanbul, Turkey
Lynch syndrome (LS), or hereditary nonpolyposis color-
ectal cancer (HNPCC), is a disorder caused by heterozygous
mutations in mismatch repair (MMR) genes; which are
MLH1, MSH2, MSH6, PMS2, and EPCAM. Pathogenic
variants in MLH1 and MSH2 are linked to 50% and 40% of
the cases, respectively. It is estimated that 1 in 300-440
individuals have LS. Besides colon cancer, patients have
increased risks of rectum, endometrium and ovarian can-
cers. Genetic diagnosis relies on panel screening and MLPA
of MMR genes. The aim of the study is to identify LS
causal variants in a small cohort of 35 patients from Turkey.
In 35 patients tested for LS by sequence panel comprising
94 genes associated with hereditary cancers/cancer sus-
ceptibility, 24 (68.6%) had a variant. Out of 24, nine var-
iants (37.5%) were pathogenic or likely pathogenic. While
4/9 (44.4%) of the variants resided in MLH1, two (22.2%)
in MSH2; and one each MSH2, MSH6 and PMS2. VUS
distribution of the cohort was, four (26.7%) in MLH1, one
(6.7%) in MSH2, five (33.3%) in MSH6, four (26.7%) in
PMS2 and one (6.7%) in EPCAM. The results of germline
panel screening for LS prompted genetic counselling.
Screening at-risk individuals in LS families, cascade
screening, provides opportunity for cancer prevention and
early detection, through follow-up protocols, intensive
surveillance, and/or prophylactic surgeries.
H.P. Saraçoğlu: None. E. Börklü Yücel: None. S.
Eraslan: None. E. Yılmaz: None. U. Altunoğlu: None. H.
Kayserili: None.
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P12.132.B
The prevalence of MMR gene mutations in Estonian
general population
L. Roht1,2, S. Pajusalu2,3, U. Šamarina3, T. Kahre2,3, K.
Õunap2,3
1Tartu University Hospital, United Laboratories, Depart-
ment of Clinical Genetics, Tallinn, Estonia, 2University of
Tartu, Institute of Clinical Medicine, Department of
Clinical Genetics, Tartu, Estonia, 3Tartu University Hospi-
tal, United Laboratories, Department of Clinical Genetics,
Tartu, Estonia
Introduction: Lynch syndrome is an autosomal-dominant
cancer predisposition syndrome caused by germline muta-
tions of mismatch-repair (MMR) genes (MLH1, MSH2,
MSH6, PMS2) and EPCAM gene. At the moment, there are
76 Lynch syndrome patients in Estonia.
Aim: To determine the prevalence of MMR gene
mutations in Estonian general population.
Material and methods: Data from Estonian Genome
Center, 2420 genomes and 2356 exomes, was analyzed to
calculate the estimated prevalence of MMR and EPCAM
gene variants.
Results: Genome sequencing detected disease-causing
variants in following genes: one in MSH2, two in PMS2,
three in MSH6 and none in MLH1 and EPCAM genes.
Exome sequencing revealed one disease-causing variant in
MLH1, MSH6 and EPCAM genes and none in MSH2 and
PMS2 genes. Altogether eight mutations were found and
based on that the estimated prevalence of MMR gene
mutations in Estonian general population is 1:597 (Poisson
95% CI: 1:1384 - 1:303). In Estonian patient cohort MLH1
was the most prevalent gene mutated (34 patients) followed
by MSH2 (24), MSH6 (10), PMS2 (3) and EPCAM (2)
genes. From MMR genes MSH6 gene variants were
detected most frequently in our general population. The
prevalence of MSH6 mutations was also higher than
described in the literature in our patient cohort.
Conclusions: We present Estonian general population
prevalence of Lynch syndrome associated MMR gene
variants based on Estonian Genome Center data. According
to literature, MMR gene variants prevalence in the world is
1:370-450, which compared to Estonian data is ~1.5 times
higher.
Funding: Estonian Research Council grants PRG471,
PUTJD827.
L. Roht: None. S. Pajusalu: None. U. Šamarina: None.
T. Kahre: None. K. Õunap: None.
P12.133.C
Whole Exome Sequencing approach identified candidate
genetic modifiers of Lynch syndrome penetrance
E. Dámaso1, A. Castillejo1, A. Sánchez-Heras2, M.
Castillejo1, J. Soto2
1Elche University Hospital - FISABIO, Elche, Spain, 2Elche
University Hospital, Elche, Spain
-Introduction:Lynch syndrome (LS) is an autosomal-
dominant cancer-predisposing syndrome caused by muta-
tions in mismatch repair genes (MMR). Germline altera-
tions in MMR genes shows a substantial level of cancer risk
heterogeneity. Identifying genetic modifiers of risk could
help to achieve a more precise cancer risk prediction and
more efficient personalized surveillance programs. We
aimed to identify new potential genetic modifiers of LS
penetrance using Whole Exome Sequencing (WES).
-Materials and Methods: Twenty-three individuals from
15 families carrying MMR pathogenic variants in MLH1 or
MSH2 were sequenced by WES. Fifteen patients were
diagnosed of LS-spectrum cancers before age 45 and 8 were
healthy carrier individuals aged over 55. WES was
performed using SureSelect-Human-AllExonV6+UTR
(AgilentTechnologies) libraries and sequencing on
Illumina-NovaSeq6000 at 100X. Alignment and variant
calling was performed by SureCall and variant filtering by a
custom pipeline for cohort analyses on AlissaInterpret
software (AgilentTechnologies).
-Results: Among 254.316 total called variants, we only
considered those present in over 80% of cancer patients and
less than 20% of healthy carriers, and found 20 genetic
variants in 18 genes [RR=2.571; 95%CI: 1.05-6.15;
p = 0.023]. Four variants were located in coding regions
and 16 in UTRs or intronic sequences. Population
frequency of all variants is over 20% (GnomAD).
Intriguingly, 17 of these have been also reported as somatic
mutations in tumors, 9 of them in colorectal adenocarci-
noma (ICGC).
-Conclusions: We identified 20 new variants as possible
risk modifier for LS. Further studies in larger cohorts of LS
patients are needed to confirm their cancer risk impact.
-Grant_ID: PI17/01082(ISCIII_AES)
E. Dámaso: None. A. Castillejo: None. A. Sánchez-
Heras: None. M. Castillejo: None. J. Soto: None.
P12.134.A
GERMLINE BIALLELIC MUTATIONS IN MCM8
ARE ASSOCIATED WITH EARLY-ONSET LYNCH-
LIKE SYNDROME
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M. Golubicki1, L. Bonjoch2, J. G. Acuña-Ochoa2, M. Díaz-
Gay2, J. Muñoz2, M. Cuatrecasas2, T. Ocaña2, S. Iseas1, G.
Mendez1, D. Cisterna1, S. A. Schubert3, M. Nielsen3, T. van
Wezel3, Y. Goldberg4, E. Pikarsky5, J. Robbio1, E. Roca1, A.
Castells2, F. Balaguer2, M. Antelo1, S. Castellvi-Bel2
1Hospital of Gastroenterology "Dr. C. B. Udaondo",
Buenos Aires, Argentina, 2IDIBAPS, Barcelona, Spain,
3Leiden University Medical Center, Leiden, Netherlands,
4Rabin Medical Center, Petah Tikva, Israel, 5Hebrew
University-Hadassah Medical School, Jerusalem, Israel
Introduction: Lynch-like syndrome (LLS) refers to indi-
viduals with mismatch repair (MMR)-deficient tumors, with
no pathogenic germline mutation identified in a MMR gene.
Biallelic somatic inactivation or cryptic MMR germline
mutations not detected during genetic testing have been
proposed to be involved, although germline pathogenic
genetic variants in highly penetrant genes other than MMR
genes could also be causing this phenotype.
Material and Methods: Sixteen patients with non-
polyposis LLS colorectal cancer (CRC) diagnosed before
the age of 40 were selected for germline and tumor whole-
exome sequencing. A knockout cellular model for a
candidate recessive gene was generated by CRISPR/Cas9
and genetic variants were produced by mutagenesis and
ectopically expressed. Subsequently, DNA damage, micro-
satellite instability and mutational signatures were monitored.
Results: Two potentially pathogenic recessive MCM8
germline variants were detected in an early-onset CRC LLS
male patient with infertility problems. Two somatic MLH1
pathogenic genetic variants were also detected. DNA
damage was evident for MCM8KO cells and the analyzed
genetic variants. Microsatellite instability and mutational
signatures in MCM8KO cells were compatible with an
involvement of MCM8 in MMR.
Conclusions:Some LLS CRC cases may be caused by
underlying germline mutations in genes different than
MMR genes, especially in patients with an early onset.
We suggest MCM8 as a new gene involved in germline
CRC predisposition and infertility with a recessive
inheritance pattern.
Funding: Foundation Nelia et Amadeo Barletta, FJCI-
2017-32593, CIBEREHD, 2019FI_B2_00203, Argentinian
Cancer Institute, FIS/FEDER (17/00878), CERCA Pro-
gram, GRPRE 2017SGR21, GRC 2017SGR653, Dutch
Digestive Foundation (MLDS FP13-13), COST Action
CA17118.
M. Golubicki: None. L. Bonjoch: None. J.G. Acuña-
Ochoa: None. M. Díaz-Gay: None. J. Muñoz: None. M.
Cuatrecasas: None. T. Ocaña: None. S. Iseas: None. G.
Mendez: None. D. Cisterna: None. S.A. Schubert: None.
M. Nielsen: None. T. van Wezel: None. Y. Goldberg:
None. E. Pikarsky: None. J. Robbio: None. E. Roca:
None. A. Castells: None. F. Balaguer: None. M. Antelo:
None. S. Castellvi-Bel: None.
P12.135.B
Implementing mainstreaming genetic testing of BRCA1/
2 for cancer patients in a Portuguese tertiary hospital:
preliminary results
M. Soeiro e Sá, J. Dupont, A. B. Sousa
Serviço de Genética Médica, Hospital de Santa Maria,
Centro Hospitalar e Universitário Lisboa Norte, Centro
Académico de Medicina de Lisboa, Lisboa, Portugal,
Lisbon, Portugal
Aim: To implement a similar programme to the original
“Mainstreaming Cancer Genetics” of BRCA1/2 testing in
our Hospital, extending the criteria to include prostate
cancer.
Methods: We defined patient selection criteria and
designed a protocol for patient referral, informed consent,
sample collection, and genetic testing. We centralized the
process through Genetics, making sure we had knowledge
of all patients included and their results. We promoted
educational sessions for oncologists, prepared informative
brochures for patients, and produced standard clinical
reports to accompany laboratory test results. Statistical
analysis was done after codification.
Results: Since September 2018, 106 patients were referred,
of whom 94 were included. The most frequent inclusion
criteria was breast cancer (BC) <40 years (n = 32), followed
by ovarian cancer (n = 18), and triple negative BC (n = 15).
Of 86 available results, we identified 9 (10.5%) pathogenic
variants (8 germinal/1 somatic) and 6 VUS (5 germinal/
1 somatic). All patients in whom a variant was identified had
a genetics appointment within a mean time of 17.9 ± 15.8 days.
The mean response time of genetic testing was 51.7 ± 9.8 days.
The mean time from patient referral to final results (sent to the
oncologist) was 67.7 ± 18.8 days.
Conclusions: We decreased our waiting time for urgent
patients and lessened the burden of extra appointments in
our clinic, while providing faster results that might
influence patients’ treatment. In the future we will assess
impact on patients and their families, degree of satisfaction
with the protocol (both from patients and oncologists), and
review the classification of previously identified VUS.
M. Soeiro e Sá: None. J. Dupont: None. A.B.
Sousa: None.
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P12.137.A
The single nucleotide polymorphism rs2235503 C>A
leads to increased MSLN gene transcription and it is
strongly associated with the levels of SMRP in vivo
R. Silvestri1, P. Pucci2, C. De Santi3, I. Dell’Anno1, S.
Miglietta4, A. Corrado5, V. Nicolì6, D. Marolda1, M.
Cipollini1, E. Pellegrino1, F. Morani1, M. Evangelista7, A.
Bonotti8, R. Foddis6, A. Cristaudo6, F. Gemignani1, S.
Landi1
1University of Pisa, Department of Biology, Pisa, Italy,
2The Open University, School of Life Health and Chemical
Sciences, Milton Keynes, United Kingdom, 3Royal College
of Surgeons in Ireland, Department of Molecular and
Cellular Therapeutics, Dublin, Ireland, 4IRCCS San
Raffaele Scientific Institute, San Raffaele Telethon Institute
for Gene Therapy (SR-Tiget), Milano, Italy, 5University of
Milan, Department of Bioscience, Milano, Italy, 6University
of Pisa, Department of Translational Research and of New
Surgical and Medical Technologies, Pisa, Italy, 7CNR,
Institute of Clinical Physiology (IFC), Pisa, Italy, 8Uni-
versity Hospital of Pisa, Preventive and Occupational
Medicine, Pisa, Italy
Introduction: The “soluble mesothelin-related peptide”
(SMRP) is one of the most promising diagnostic biomarkers
for malignant pleural mesothelioma (MPM). However,
several factors can affect SMRP levels, hampering its
accuracy and limiting its usage in the clinical practice. In
the present work, we explored the hypothesis that genetic
variants within the MSLN promoter could represent a con-
founding factor able to affect SMRP levels.
Methods: Blood samples from a cohort of 70 MPM and
689 non-MPM subjects were analyzed to assess the
association between the SMRP levels and four haplotypic
variants of MSLN promoter: haplotype #1 (reference), #2,
#3, #4. Functional studies were carried out in Met-5A and
Mero14 cell lines using a fluorescence reporter assay to
assess the differences between the activity of the four
variants of the MSLN promoter and to identify the SNPs
responsible for the observed differences.
Results: Carriers of haplotype #2 showed a significantly
higher level of SMRP when compared with the reference
group (p-value < 10−5). The functional study confirmed the
role of haplotype #2, which caused a 41% increase in the
reporter fluorescence intensity (p-value=6x10−4). The in vitro
analysis also led to the identification of rs2235503 C>A as the
SNP responsible for the increased activity of haplotype #2
(35% increase in the reporter intensity; p < 10−5).
Conclusions: The rare variant of rs2235503 C>A leads to
an increase of SMRP levels through the enhancement of
MSLN expression. The establishment of a personalized cut-
off value based on this SNP could increase the accuracy of
SMRP in the diagnosis of MPM.
R. Silvestri: None. P. Pucci: None. C. De Santi: None.
I. Dell’Anno: None. S. Miglietta: None. A. Corrado:
None. V. Nicolì: None. D. Marolda: None. M. Cipollini:
None. E. Pellegrino: None. F. Morani: None. M.
Evangelista: None. A. Bonotti: None. R. Foddis: None.
A. Cristaudo: None. F. Gemignani: None. S.
Landi: None.
P12.138.B
Pathogenic variants in cancer predisposition genes in
patients with stage II melanoma
S. Armeanu-Ebinger1, T. Amaral2, T. Sinnberg2, C.
Roggia1, F. Hilke1,3, H. Niessner2, I. Bonzheim4, T. Haack1,
O. Rieß1, C. Garbe2, C. Schroeder1
1Institute of Medical Genetics and Applied Genomics,
Tübingen, Germany, 2Department of Dermatology, Tübin-
gen, Germany, 3Department of Dermatology, Venereology
and Allergology, Berlin, Germany, 4Institute of Pathology
and Neuropathology, Tübingen, Germany
Introduction: Melanoma is an aggressive cutaneous tumor
with an increasing incidence. Sun exposure is one of the
major risk factors. Recent studies indicate that 6-7 % of all
melanoma patients carry a pathogenic germline variant in a
cancer predisposition gene (CPG) while the association with
melanoma is often unknown. We screened a large cohort of
stage II melanoma patients for pathogenic germline variants
in CPGs.
Materials and Methods: DNA from paired tumor and
normal FFPE tissue of 196 patients with stage II melanoma
was sequenced with a NGS custom enrichment panel
covering 693 genes, selected promotor and intronic regions.
We used megSAP (https://github.com/imgag/megSAP) for
NGS data analysis and germline variants in 152 CPGs were
filtered for population allele frequency (AF < 1 %) and
classified according to ACMG guidelines.
Results: We detected pathogenic or likely pathogenic
variants in recessive and dominant CPGs in 18 out of 196
patients (9.2 %, including ATM, BRCA1, CHEK2, MSH2,
PALB2, SDHA). A second hit in tumor tissue was detected
in one patient carrying an ATM mutation. Tumors with
germline pathogenic variants in MSH2 did not reveal
microsatellite instability. Besides relevance for surveillance
and families, five pathogenic variants affected DNA repair
genes with potential relevance for therapy.
Conclusions: Pathogenic germline variants in CPGs in
stage II melanoma patients are frequent and of relevance for
surveillance, families and potentially therapy. Further
studies are needed to investigate whether pathogenic
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variants in CPGs that are not known to be related to
melanoma contribute to melanoma development.
S. Armeanu-Ebinger: None. T. Amaral: B. Research
Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received); Significant;
Novartis. T. Sinnberg: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Significant; Novartis. C.
Roggia: None. F. Hilke: None. H. Niessner: None. I.
Bonzheim: None. T. Haack: None. O. Rieß: B. Research
Grant (principal investigator, collaborator or consultant and
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Novartis. C. Garbe: B. Research Grant (principal investi-
gator, collaborator or consultant and pending grants as well as
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B. Research Grant (principal investigator, collaborator or
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P12.139.C
Whole exome sequencing of patients with early onset
melanoma (age < 40 years)
E. Chatziioannou1, K. Kypraiou2, G. Vatsellas1, M. Plaka2,
T. Loupis1, D. M. Vrachnos1, D. Polydorou2, D.
Chatzopoulos1, V. Chasapi2, G. Champsas2, D. Thanos1, A.
Stratigos2, P. Makrythanasis1,3
1Biomedical Research Foundation of the Academy of
Athens, Athens, Greece, 2First Department of Dermatology
and Venereology, National and Kapodistrian University of
Athens, Medical School, Andreas Syggros Hospital for Skin
and Venereal Diseases, Athens, Greece, 3Department of
Genetic Medicine and Development, Medical School,
University of Geneva, Geneva, Switzerland
Introduction: Cutaneous melanoma develops frequently in
people over the age of 50 and can arise sporadically or in
the setting of a germline predisposition in approximately
10% of cases. During the last years high penetrance genes
have been discovered and genes related to nevus count and
pigmentation have been linked to melanoma. However only
50% of the patients that demonstrate positive family history
carry germline mutation in the above-mentioned genes,
suggesting that other genes or an interplay of genes may be
implicated in its carcinogenesis. Additionally, the pre-
valence of pathogenic variants in these genes in cases of
early onset of melanoma is poorly studied.
Materials and Methods: We performwhole exome
sequencing of DNA extracted from blood of 80 patients with
early onset melanoma (diagnosis occurring before 40 years of
age). We first assess a panel of genes containing genes
hitherto associated with familial melanoma, genodermatoses,
DNA repair, telomere maintenance, pigmentation, nevus
count and hereditary predisposition to other cancers and
subsequently expand our analysis to the whole exome. The
family history isre-examined according to results.
Results: We have analyzed data from 10 patients. In 1
patient we have identified one novel pathogenic variant in
CDKN2A. Aggregate data per gene, family of genes and
pathways are catalogued and studied.
Conclusions: The present study is ongoing, and we aim
to define the prevalence of known high penetrance genes
and to identify potential candidate variants/genes implicated
in cases of early onset of melanoma.
E. Chatziioannou: None. K. Kypraiou: None. G.
Vatsellas: None. M. Plaka: None. T. Loupis: None. D.M.
Vrachnos: None. D. Polydorou: None. D. Chatzopoulos:
None. V. Chasapi: None. G. Champsas: None. D. Thanos:
None. A. Stratigos: None. P. Makrythanasis: None.
P12.140.A
Patients with germline pathogenic variants in DNA
repair genes show increased susceptibility to asbestos-
induced malignant pleural mesothelioma
M. Sculco1, M. La Vecchia1, E. Casalone2, D. Ferrante3, A.
Aspesi1, S. Brossa1, M. Clavenna1, A. Allione2, F. Grosso4,
R. Libener5, A. Muzio6, O. Rena7, C. Casadio7, G. Baietto7,
S. Parini7, D. Mirabelli8,9, C. Magnani3, G. Matullo2,9,10, I.
Dianzani1,9
1Department of Health Sciences, Università del Piemonte
Orientale, Novara, Italy, 2Department of Medical Sciences,
Università di Torino, Torino, Italy, 3CPO-Piemonte e Unit
of Medical Statistics and Epidemiology, Università del
Piemonte Orientale, Novara, Italy, 4Mesothelioma Unit, AO
SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy,
5Pathology Unit, AO SS Antonio e Biagio e Cesare Arrigo,
Alessandria, Italy, 6Division of Medical Oncology, Ospe-
dale Santo Spirito, Casale Monferrato (AL), Italy, 7Thor-
acic Surgery Unit, AOU Maggiore della Carità, Novara,
Italy, 8Unit of Cancer Epidemiology, CPO-Piemonte e
Università di Torino, Torino, Italy, 9Interdepartmental
Center for Studies on Asbestos and other Toxic Particulates
“G. Scansetti”, Università di Torino, Torino, Italy, 10Med-
ical Genetics Unit, AOU Città della Salute e della Scienza
di Torino, Torino, Italy
Introduction: Malignant pleural mesothelioma (MPM) is a
rare and aggressive cancer caused by exposure to asbestos. A
role for inherited predisposition was hypothesized since the 10-
17% of individuals exposed to high levels of asbestos develop
MPM and some families present multiple MPM cases.
Materials and Methods: We investigated 107 cancer-
predisposing genes in 144 MPM patients (16 familiar,
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128 sporadic) by NGS. Lifelong asbestos exposure was
quantified in 131 patients. Moreover, we performed WES in
two families, each with three MPM cases.
Results: We identified 17 pathogenic truncating variants
(PTVs, in PALB2, BRCA1, FANCI, ATM, SLX4, BRCA2,
FANCC, FANCF, PMS1, XPC, SBDS, CDKN2A, VHL,
BRIP1) and 27 rare missense variants (evaluated as
pathogenic by 6 in silico prediction tools), mostly in genes
involved in homologous recombination repair that repairs
double strand breaks in DNA caused by asbestos. PTVs
carriers represent 11% of the patients and show a
statistically significant lower asbestos exposure in compar-
ison to non-mutated patients (p = 0.0003). Only one of the
six patients analyzed by WES, showed a PTV in PMS2, a
gene involved in mismatch repair, suggesting that asbestos
exposure may have a predominant role in some families.
Conclusions: Overall, these data suggest that patients
with germline variants in DNA repair genes are less
proficient to repair the DNA damage induced by asbestos
and show increased susceptibility to asbestos-induced
MPM. These patients carrying predisposing variants may
respond to drugs that induce synthetic lethality.
Grants: HeRMes project (compensation to MPM patients
of Casale Monferrato) (ID, CM); AIRC2018-
IG21390 (GM)
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Functional variants of the Methylenetetrahydrofolate
reductase in childhood acute lymphoblastic leukemia
R. Frikha
Medical Genetic department, Hedi Chaker Hospital and
Faculty of Medicine, Sfax, Tunisia
Introduction: Functional variants of the Methylenete-
trahydrofolate reductase (MTHFR) gene result in dis-
turbance in folate metabolism and may affect susceptibility
to childhood acute lymphoblastic leukemia (ALL) [1]. In
addition, a potential impact of such variants in the efficacy
of methotrexate has been reported but the results are con-
flicting [2]. The aim of this study was to investigate the
possible role of MTHFR C677T (rs1801133; C>T) and
A1298C (rs1801131; A>C) polymorphism as a risk factor
for the development of ALL in a cohort of Tunisian
children.
Methods: This study was conducted in 28 children with
ALL treated with the EORTC 58951. Clinical and
biological data were recorded. Genomic DNA was extracted
from whole venous blood and genotyping were carried out
with restriction fragment length polymorphism (RFLP).
Results: The allelic frequency of MTHFR 677T and
A1298C was 14.3% and 42.8% respectively. A particular
history of relapse and toxicity during methotrexate therapy
was reported in ALL patients with the MTHFR 677T
variant.
Conclusions: Despite the limit of this study; our finding
highlights the impact of functional variants of MTHFR on
leukemogenesis. Awareness of folate metabolism is man-
datory to prevent childhood leukemia. 1. Yang, M.,
Association between MTHFR C677T Polymorphism and
Risk of Acute Lymphoblastic Leukemia: A Meta-Analysis
Based on 51 Case-Control Studies. Medical Science
Monitor, 2015. 21: p. 740-748. 2.Lopez-Lopez, E., et al.,
A systematic review and meta-analysis of MTHFR poly-
morphisms in methotrexate toxicity prediction in pediatric
acute lymphoblastic leukemia. The Pharmacogenomics
Journal, 2012. 13(6): p. 498-506.
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miR-20b and miR-451a Are Involved in Gastric
Carcinogenesis through the PI3K/AKT/mTOR Signal-
ing Pathway: Data from Gastric Cancer Patients, Cell
Lines and INS-GAS Mouse Model
G. Streleckiene1, R. Inciuraite1, S. Juzenas1,2, V.
Salteniene1, R. Steponaitiene1, U. Gyvyte1, P. Ruzgys3, A.
Link4, J. Kupcinskas1,5, J. Skieceviciene1
1Institute for Digestive Research, Lithuanian University of
Health Sciences, Kaunas, Lithuania, 2Institute of Clinical
Molecular Biology, Christian-Albrechts-University of Kiel,
Kiel, Germany, 3Biophysical Research Group, Vytautas
Magnus University, Kaunas, Lithuania, 4Department of
Gastroenterology, Hepatology and Infectious Diseases,
Otto-von-Guericke University, Magdeburg, Germany,
5Department of Gastroenterology, Lithuanian University
of Health Sciences, Kaunas, Lithuania
Introduction: Gastric cancer (GC) is one of the most pre-
valent and lethal cancer worldwide. Many studies have
shown that development of malignancies is mainly driven
by alterations of cellular signaling pathways. MicroRNAs
are small noncoding molecules playing an essential role in
various biological processes. The aim of this study was to
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evaluate the functional role of miR-20b and miR-451a and
their target genes in GC.
Materials and methods: To determine the expression
level of miR-20b and miR-451a in vivo and in vitro, biopsy
samples of GC patients, healthy controls, INS-GAS mice,
AGS and MKN28 cell lines samples were analysed using
qRT-PCR. To confirm putative microRNA target-genes and
determine miR-20b and miR-451a impact on cell function,
luciferase reporter, protein expression, MTT, clonogenic,
apoptosis, wound healing assays were performed in GC cell
cultures.
Results: Deregulated expression of miR-20b and miR-
451a was determined in GC cell lines and the INS-GAS
mouse model. Western blot and luciferase reporter assay
have also confirmed that miR-20b directly regulates
expression of PTEN and TXNIP, and miR-451a - CAV1
and TSC1. Loss-of-function experiments revealed that
down-regulation of miR-20b and upregulation of miR-
451a expression exhibits an anti-tumor effect in vitro (miR-
20b: reduced viability, colony formation, increased apop-
tosis rate, and miR-451a: reduced colony forming ability).
Conclusions: This study identified that expression of
miR-20b and miR-451a are deregulated in vitro and in vivo
and have a tumor suppressive role in GC through regulation
of the PI3K/AKT/mTOR signaling pathway. Funding: This
research was funded by Research Council of Lithuania
(Grant number MIP-007/2014).
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The importance of diagnostic and prognostic utility of
miRNAs analysis in bladder cancer.
E. M. Borkowska1, T. Konecki2, M. Pietrusinski1, M.
Borowiec1, Z. Jablonowski2
1Medical University of Lodz Department of Clinical
Genetics, Lodz, Poland, 2Medical University of Lodz I
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Introduction: Bladder cancer (BC) is still characterized by
a very high death rate in patients with this disease. One of
the reasons for this is the lack of adequate markers which
could help determine the biological potential of the tumor to
develop into its invasive stage. Some microRNAs (miR-
NAs) correlate with disease progression. The purpose of
this study was to identify which miRNAs can accurately
predict the presence of BC and can differentiate low grade
(LG) tumors from high grade (HG) tumors.
Materials and methods:The study included 55 patients
with diagnosed bladder cancer and 30 persons belonging to
the control group. The expression of seven selected
miRNAs was estimated with the real-time PCR technique
according to miR-103-5p (for the normalization of the
results). Receiver operating characteristics (ROC) curves
and the area under the curve (AUC) were used to evaluate
the feasibility of using selected markers as biomarkers for
detecting BC and discriminating non-muscle invasive BC
(NMIBC) from muscle invasive BC (MIBC).
Results: For HG tumors, the relevant classifiers are miR-
205-5p and miR-20a-5p, whereas miR-205-5p and miR-
182-5p are for LG (AUC = 0.964 and AUC = 0.992,
respectively). NMIBC patients with LG disease are
characterized by significantly higher miR-130b-3p expres-
sion values compared to patients in HG tumors.
Conclusions: Our findings could be of clinical impor-
tance. The implementation of miR-205-5p, miR-20a-5p and
miR-130b-3p into routine practice can be an alternative to
screening or the follow up of treatment effects. This work
was supported by Medical University Grant 502-03/5-138-
02/502-54-146, Grant 502-03/5-138-02/502-54-133.
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Evidence of cancer predisposition gene pathogenic
variant mosaicism identified through concurrent
sequencing of tumour samples and blood from indivi-
duals with multiple primary tumours
J. Whitworth, J. Martin, O. Giger, F. Nice, G. Clark, M.
Maranian, F. Rodger, NIHR BioResource Rare Diseases
Consortium, E. Maher
University of Cambridge, Cambridge, United Kingdom
Tumours are often conceptualised as occurring due to
germline variants in cancer predisposition genes (CPGs) or
solely somatic mutations but mosaicism for a CPG variant
has also been widely described. Mosaic individuals are at
increased risk of neoplasms and are not readily detected
clinically. Multiple primary tumours in the same individual
(MPT) represent an opportunity to detect mosaicism as
variants may be present in both tumours but not blood. We
sequenced separate primaries from three MPT individuals
with a panel assay incorporating 350 cancer genes on DNA
from FFPE tissue, and corresponding blood samples with
whole-genome sequencing. Variants in tumour samples
were filtered to include non-synonymous or splice variants
present in both tumours from each individual and exclude
likely false positives. 2/3 individuals had truncating CPG
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variants in both of their tumours that were undetected in
their blood sample or in other tumours in the same
sequencing run (n = 23). One had a VHL frameshift variant
detected in bilateral clear cell renal cell carcinomas diag-
nosed at age 40 and 47 years. Variant allele fractions (VAF)
were 41% and 49% respectively and 0/37 germline reads
showed evidence of the variant. Another case had a TP53
nonsense variant in bilateral breast carcinomas diagnosed at
age 48 and 52 years. VAFs were 22% and 15% and 0/34
germline reads showed variant base calls. Neither individual
had a family history of tumours in first degree relatives.
These results suggest appreciable frequency of CPG
pathogenic variant mosaicism in MPT cases without a
prominent family history cancer.
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ISUL”, Sofia, Bulgaria, 4Endoscopy Ward, Clinic of ENT
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Introduction: Multiple primary neoplasia (MPN) has been
defined as more than one primary malignancy found in one
and the same individual. The main factors implicated in MPN
development are genetic factors (hereditary predisposition to
cancer); hormonal factors; lifestyle (smoking, alcohol con-
sumption), unhealthy diet and obesity; environmental factors
etc. The aim of the current study was to explore the role of
genetic predisposition for MPN development.
Materials and Methods: The study included 36 MPN
patients, selected according to recognized IACR/IARC
guidelines, of which 20 females (56%) and 16 males (44%).
Fifty five % of the patients had family history of cancer and
30.5% had an early onset (<50y). The analysis of germline
mutations was performed by NGS of a panel of 94 tumor-
associated genes on a MiSeq platform (Illumina).
Results: Around 18% of the total variants were evaluated
as clinically significant. Among selected variants 33.4%
were pathogenic, 13.3% likely pathogenic and 53.3%
variants of uncertain significance (VUSs). Pathogenic/
likely pathogenic variants were detected mainly in the
genes BRCA1, BRCA2, MMR genes and CDH1 while VUSs
in GPC3, DIS3L2, PRF1, STK11, DICER1, RET etc.
Conclusions: Overall, the genetic cause of MPN was
found in 42.7% of the patients. Further research is needed to
evaluate the functional effect of all VUSs. Thus clinical
multi-gene panel testing is recommended for detection of
germline mutations in high-risk MPN individuals.
Acknowledgments: Grants KP-06-OPR03/17/
19.12.2018, National Science Fond; D01-285/17.12.2019,
Ministry of Education and Science, Bulgaria
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A substantial proportion of adults with multiple primary
tumors carry pathogenic variants in cancer-
predisposition genes
F. Brugnoletti1,2, J. Vos3, J. Schuurs-Hoeijmakers1, B.
Hilhorst1, A. Mensenkamp1, M. Ligtenberg1,4, L.
Remondini5, M. Pomponi5, E. Lucci Cordisco2,5, M.
Genuardi2,5, R. de Voer1, N. Hoogerbrugge1
1Department of Human Genetics, Radboud Institute for
Molecular Life Sciences, Radboud university medical
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Genomica, Università Cattolica del Sacro Cuore, Fonda-
zione Policlinico Universitario A. Gemelli, Rome, Italy,
3Department of Human Genetics, Radboud Institute for
Health Sciences, Radboud university medical center,
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Genetica Medica, Fondazione Policlinico Universitario A.
Gemelli IRCCS, Rome, Italy
Multiple primary tumors and young age at diagnosis are
hallmarks of inherited cancer predisposition. However, the
identification of a genetic cause in individuals with multiple
primary malignancies is still challenging due to phenotypic
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variability, presence of phenocopies and mostly used can-
didate gene approaches. To unravel the presence of an
inherited cancer predisposition, we performed whole-exome
sequencing (WES) on germline DNA from 44 individuals
selected for the presence of either: i) ≥2 primary tumors <65
years; ii) one tumor and one additional feature (e.g. mac-
rocephaly, benign tumors) <65; or, iii) an adult type of
cancer <25. We analyzed sequencing data for germline
variants in 211 known cancer predisposition genes (CPGs)
and classified each variant based on the AMCG/AMP
guidelines. Pathogenic or likely pathogenic variants in
CPGs were identified in 10/44 individuals (23%). Two
individuals carried one pathogenic variant that explains
their tumor phenotype (PTEN; NF1). In five individuals
pathogenic/likely pathogenic variants in CHEK2 (n = 3),
HOXB13 (n = 1) and FANCM (n = 1) that may have
contributed to their malignancies were identified. In three
individuals, the analysis revealed heterozygous pathogenic
variants in genes associated with recessive disorders
(POLH, n = 2; RAD50, n = 1). In our highly selected
cohort of adults with multiple primary tumors we identified
pathogenic/likely pathogenic variants in CPGs in 23% of
patients. This analysis resulted in a molecular diagnosis for
two individuals and for eight individuals we identified
alterations that may have cooperated in cancer develop-
ment, giving cues for further genome-wide analysis on the
germline and tumor tissues that are now ongoing.
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MYD88 p.L265P mutation in DLBCL cases with CNS
relapse
E. Voropaeva1, T. Pospelova2, M. Voevoda1, V. Maximov1,
V. Stupak3, I. Avzalov3
1Institute of Therapy and Preventive Medicine - branch of
ICG SB RAS, Novosibirsk, Russian Federation, 2Novosi-
birsk State Medical University, Novosibirsk, Russian
Federation, 3Research Institute of Traumatology and
Orthopedics, Novosibirsk, Russian Federation
Previously reported about detection of the MYD88 p.L265P
mutation in the cerebrospinal fluid of a patient with sec-
ondary CNS lymphomas.The aim of the study was to
identify the mutational features associated with high risk of
secondary CNS involvement in DLBCL.
Methods: Diagnostic FFPE tissue blocks of patients with
DLBCL, who subsequently developed a CNS relapse, were
taken. Whole exome sequencing of 7 tumor samples was
performed. Additionally DLBСL whole-exome sequencing
of dates presented in the cBioPortal for Cancer Genomics
were analyzed: cases with (n = 48) and without (n = 355)
proven CNS relapse were selected.
Results: In the tumor tissue of patients with DLBCL the
pathogenic aberrations in the MYD88, TP53, PIM1,
CD79B, MSH2, CARD11, NOTCH1, SMARCA4,
KMT2D and EP300 genes were detected. The MYD88 p.
L265P recurrent mutation was detected in 3/7 of samples.
According to the cBioPortal for Cancer Genomics database,
in DLBCL patients with CNS relapses mutations in the
MYD88 gene were detected in 14/48, 29.2% of cases. In the
sample of patients without secondary CNS lesions, the
central nervous system mutations in the MYD88 gene were
54/355, 15.2% (p = 0.016). The mutation p.L265P
compose 12/14 (85.7%) and 32/54 (59.3%) cases of
MYD88 aberrations, accordingly. Thus, CNS relapse
developed in 12/44 (27.3%) MYD88 p.L265P carriers and
only in 36/359 (10.0%) patients without this mutation
(p < 0.001). The CNS relapse risk in mutation MYD88 p.
L265P carriers was OR=3.365, 95% CI (1.59; 7.11).
Conclusions: It is shown that testing DLBCL for
MYD88 mutations is a potentially approach to diagnosing
patients with high CNS relapse risk.
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Quantification of JAK2V617F mutation burden by
droplet digital PCR in patients with myeloproliferative
neoplasms
H. Y. Ivanov1, A. Linev1, I. Zheliazkov1, V. Graklanov2, E.
Beleva3, V. Goranova-Marinova2, Z. Grudeva-Popova3, V.
Stoyanova1
1Medical University Plovdiv, Departament of Pediatrics
and Medical Genetics, Plovdiv, Bulgaria, 2Medical Uni-
versity Plovdiv, First Department of Internal Medicine,
Clinic of Hematology,, Plovdiv, Bulgaria, 3Medical Uni-
versity Plovdiv, Department of Clinical Oncology, Plovdiv,
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Philadelphia-negative chronic myeloproliferative neoplasms
(MPNs) are characterized by excessive production of
terminally differentiated blood cells that are fully func-
tional. Classical MPNs have been classified into 3 entities:
polycythemia vera (PV), essential thrombocythemia (ET),
and primary myelofibrosis (PMF). The JAK2 V617F
mutation is detected in nearly 90% of PV patients, and in
around a half of all ET and MF patients The aim of this
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study was to verify the effectiveness of digital droplet PCR
(ddPCR) in the diagnosis of JAK2 V617F-mutated MPN
and to investigate how the mutated allele burden correlate
with the clinic.
Materials and methods: the JAK2 V617F mutation have
been evaluated/quantified by ddPCR in 21 patients with
MPN of whom 15 had the mutation.
Results: an increase of mutant allele burden from ET to
PV and PMF was observed. A moderate negative correla-
tion between the mutation burden and the platelet counts
was found. A correlation between splenomegaly and the
mutation burden was also observed. In conclusion, our
study showed that quantification of the JAK2 V617F
mutational burden by ddPCR could represent a new and
promising technology for detection of JAK2 mutation in
MPNs and the follow up of the patients may reflect the
clinical response to treatment.
The study was funded by Project BG05M2OP001-1.002-
0005-C 01, Center for Competence "Personalized Innova-
tive Medicine (PERIMED)", funded by the Operational
Program "Science and Education for Intelligent Growth"
2014-2020, co-funded by the European Union for regional
development.
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Three novel splicing mutations in the NF1 gene cause
exon skipping
I. Kyprianou1, V. Anastasiadou2, P. Gerasimou1, A.
Miltiadous1, J. Chi1, I. Savvidou2, P. Costeas1
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Introduction: Neurofibromatosis type 1 is a condition
characterized by changes in skin coloring (café-au-lait
spots) and the growth of tumors (neurofibromas) along
nerves in the skin, brain, and other parts of the body. The
signs and symptoms of this condition vary widely among
affected people.
Case Description: Three patients with clinical diagnosis
of Neurofibromatosis type 1 were investigated for molecular
evidence to support.
Methodology: A custom Haloplex/ Sureselect (Agilent)
NGS panel was used to investigate mutations in Neurofi-
bromatosis associated genes as per manufacturer’s instruc-
tions. RNA investigation for exon skipping was employed.
Interpretation: Three heterozygous novel splice-site
mutations in the NF1 gene were detected. The c.1642-
2A>G, c.1722-1G>A, c.6085-3C>A variants are all classi-
fied as pathogenic according to ACMG recommendations
and Bioinformatics tools predicted that this novel mutations
have pathogenic effects on splicing machinery. RNA
investigation revealed that these variants lead in exon 15,
exon 16, and exon 41 skipping of the NF1 gene,
respectively.
Conclusions: To date, more than 1,000 NF1 mutations
that cause neurofibromatosis type 1 have been identified.
Most of these mutations are unique within families. Many
NF1 mutations result in the production of an extremely
short or abnormal version of the protein neurofibromin. This
study highlights the presence of three novel splicing
mutations in the NF1 gene that lead in exon skipping,
causing the production of aberrant protein isoforms.
I. Kyprianou: None. V. Anastasiadou: None. P.
Gerasimou: None. A. Miltiadous: None. J. Chi: None.
I. Savvidou: None. P. Costeas: None.
P12.158.A
Splicing variants in hereditary cancer genes: clinical
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Introduction: Next generation sequencing (NGS) approa-
ches have simplified multi-gene testing; yet the interpreta-
tion of variants remains a challenge. Most splicing variants
(SVs) in genes associated with hereditary cancer are often
classified as variants of uncertain significance (VUS) due to
the lack of functional RNA analysis. The aim of this study
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was to investigate the occurrence of SVs in hereditary
cancer genes the clinical utility of RNA analysis.
Material and Methods: We performed a retrospective
analysis of 887 individuals referred to our laboratory for
genetic testing using a NGS panel of 36 hereditary cancer
genes. Functional RNA analysis for SVs was performed
with RNA extracted from peripheral blood lymphocytes
following RT-PCR and Sanger Sequencing.
Results: A SV was identified in 22/ 887 individuals
(2.5%) and 7/22 (31.8%) were classified as pathogenic and
5/22 (22.7%) as likely pathogenic. The remaining 10
variants were initially classified as VUS (45.5%) and RNA
analysis could be performed for 2 variants. RNA analysis of
a variant in ATM (c.2125-1G>T) revealed the deletion of 11
bases (r.2125del), thus resulting in a frameshift (p.
(Ile709Phefs*22)). Moreover, for a MSH2 variant (c.1510
+1_1510+2dupGT), it was shown that the insertion of 2
bases (r.1510dup) causes a frameshift, p.(Gly5040-
Glyfs*39). The two novel variants were reclassified from
VUS to Pathogenic.
Conclusions: In our cohort, SVs accounted for 8.6% of
pathogenic and 2.5% of VUS results. RNA analysis assisted
in the reclassification of 20.0% of splicing VUS. RNA
analysis is essential in the case of uncharacterized SVs, for
proper classification and personalized management of
patients.
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Evaluating the performance of the NF2 Genetic Severity
Score and the potential impact of using functional assays
to improve prognosis prediction in a cohort of Spanish
patients
N. Catasus1, B. Garcia2, A. Plana3, A. Negro4,5, I. Rosas4,5,
I. Galván6, A. Ros2, C. Hostalot7, F. Roca-Ribas8, E.
Amilibia8, R. de Cid6, I. Bielsa3, E. Serra5, I. Blanco2, E.
Castellanos4,5
1Hereditary Cancer Group, Germans Trias i Pujol
Research Institute (IGTP-PMPPC);, Badalona, Spain,
2Clinical Genetics and Genetic Counseling Program,
Germans Trias i Pujol University Hospital (HUGTiP),
Badalona, Spain, 3Dermatology Department, Germans
Trias i Pujol University Hospital (HUGTiP), Badalona,
Spain, 4Clinical Genomics Unit, Germans Trias i Pujol
University Hospital (HUGTiP), Badalona, Spain, 5Heredi-
tary Cancer Group, Germans Trias i Pujol Research
Institute (IGTP-PMPPC), Badalona, Spain, 6Genomes for
Life-GCAT Lab Group, Germans Trias i Pujol Research
Institute (IGTP-PMPPC), Badalona, Spain, 7Neurosurgery
Department, Germans Trias i Pujol University Hospital
(HUGTiP), Badalona, Spain, 8Otorhinolaryngology
Department, Germans Trias i Pujol University Hospital
(HUGTiP), Badalona, Spain
Introduction: Neurofibromatosis Type 2 (NF2) is an
autosomal dominant disorder characterized by the devel-
opment of multiple schwannomas, particularly at vestibular
nerves, and meningiomas1. A genotype-phenotype asso-
ciation is well established in NF2. A Genetic Severity Score
(GSS) for NF2 mutations was developed to help predicting
the disease course2. In the present study, we evaluated the
performance of the GSS in our Spanish NF2 cohort and
analyzed the potential added value of including functional
molecular information.
Methods: Patients: GSS was validated using the NF2
Spanish Reference Center HUGTiP-ICO cohort. Functional
assays: Merlin, ERK and their phosphorylated forms were
measured by Western Blot using patient-derived fibroblasts.
Association analysis: Mann-Whitney U test and regression
model analysis.
Results: The application of the GSS to the Spanish NF2
cohort confirmed the identification of significant correla-
tions across patient’s phenotype and NF2 mutation: Spanish
patients that harbor a truncating mutation in the NF2 gene
were associated with a most severe disease. However, for
mutations in mosaicism and mutations associated to
moderate phenotypes, GSS did not predict their clinical
outcome as expected. We identified a correlation between
the phenotype and the degree of activation of ERK
pathway. We developed a lineal regression model to predict
NF2 prognosis from functional and molecular data.
Conclusions: We validated the GSS in our cohort
although a significant phenotypic variability intragroup
was identified. To improve the performance of GSS, we
evaluated the additional use of functional assays that
allowed a better classification patients with mild and
moderated phenotypes by applying a new statistical model.
N. Catasus: None. B. Garcia: None. A. Plana: None. A.
Negro: None. I. Rosas: None. I. Galván: None. A. Ros:
None. C. Hostalot: None. F. Roca-Ribas: None. E.
Amilibia: None. R. de Cid: None. I. Bielsa: None. E.
Serra: None. I. Blanco: None. E. Castellanos: None.
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P12.161.A
NF2 low grade mosaicism detected by deep sequencing
of multiple tumor and normal tissue samples - a case
report
C. Roggia1, M. Schadeck2,1, U. Faust1, S. Armeanu-
Ebinger1, A. Dufke1, G. Tabatabai3, O. Riess1, C.
Schroeder1
1Institute of Medical Genetics and Applied Genomics,
University Hospital Tübingen, Tübingen, Germany, 2SYN-
LAB Humangenetik Freiburg GmbH, Freiburg i. Br.,
Germany, 3Department of Neurosurgery, University Hospi-
tal Tübingen, Tübingen, Germany
Neurofibromatosis 2 (NF2, MIM#101000) is a rare auto-
somal dominant disorder characterized by multiple
schwannomas and mostly bilateral vestibular schwannoma
(VS). Mutation carriers may develop meningiomas, epen-
dymomas and retinal hamartomas. Mosaicism is a known
phenomenon which is difficult to detect by conventional
sequencing and is therefore impeding cascade screening and
adequate surveillance for offspring-carriers. We describe a
27-year-old woman reaching out for preconception advice
while presenting with singular VS, a facial nerve schwan-
noma, multiple cerebral bilateral meningiomas and medullar
schwannomas, first diagnosed at the age of 26 years. Her
parents or other family members were not affected, sug-
gesting a de novo mutation in the NF2-gene. Previously
external performed Sanger sequencing did not detect any
pathogenic mutation in NF2 in the patient´s blood. We
analyzed two different tumors of the patient (facial nerve
schwannoma and medullar schwannoma) by next-
generation sequencing (NGS) and found the same patho-
genic clonal NF2 variant (c. 362dup:p.Val122Glyfs*8)
together with a second hit (LOH) in both tumors. The same
pathogenic frameshift NF2-Variant was subsequently con-
firmed by NGS in blood and in skin (with an allele fre-
quency of 0.5 % and 1 %, respectively), while no mutation
was detected in genes associated with schwannomatosis
(LZTR1, SMARCB1 and PRKAR1A), ruling out the main
differential diagnosis of NF2. Deep sequencing of blood
through modern sequencing techniques such as NGS can
improve the sensitivity of detection of mosaicism compared
to traditional sequencing allowing therefore adequate
genetic counseling concerning the risk for offsprings to
inherit NF2 and specific surveillance for children carrying
the mutation.
C. Roggia: None. M. Schadeck: None. U. Faust: None.
S. Armeanu-Ebinger: None. A. Dufke: None. G.
Tabatabai: None. O. Riess: None. C. Schroeder: None.
P12.163.C
Hematological phenotypes. Validation of a custom NGS
panel including telomere and other leukemia-
predisposing genes
C. Matteucci, F. Pellanera, V. Nofrini, M. Quintini, P.
Gorello, S. Arniani, C. Camerini, E. Mavridou, M. Moretti,
T. Pierini, C. Nardelli, A. G. Lema Fernandez, V. Bardelli,
D. Di Giacomo, C. Mecucci
University of Perugia, Perugia, Italy
A growing number of hereditary hematological malig-
nancies have been reported since the extended use of NGS
that greatly improved our knowledge on germline mutations
underlying myeloid neoplasms. We developed a customized
diagnostic NGS panel (CHHD_A_v1 NGS panel, SOPHiA
Genetics) including 21 established leukemia predisposing
and 35 telomere biology genes. Cases with an hematolo-
gical phenotype (cytopenia(s), myelodysplastic syndromes,
acute myeloid leukemia) were selected on personal and/or
familial history. Libraries were pooled and sequenced on
Illumina MiSeq. Fastq files were analyzed with SOPHiA
DDM software. Coding variants with variant fraction
between 40 and 60 or >90, and minor allele frequency
<0.01 in most common databases (g1000, ExAC, Gno-
mAD, esp5400) were classified according to the ACMG
guidelines. From 46 diagnostic samples 209 rare variants
emerged; 47 were non-coding, 160 coding (84 missense, 4
frameshift, 3 inframe indel, 3 nonsense, 1 splice site,
65 synonymous) and 2 involved TERC gene; 78/160 were
benign/likely benign, 73 VUS, 3 likely pathogenic and 6
pathogenic. In this group two novel variants affected
RAD50 gene. Undescribed, likely pathogenetic variant
affected CEBPA in one familial leukemia and RUNX1 in
one post-transplant donor leukemia. A novel TERC VUS
g.303G>A was associated with frank telomere pathology.
Moreover, the DDX41 G92D missense VUS
(rs371460149), very rare in GnomAD genome database
(frequency=0.000021,) was found in 3/46 cases (6.5%) of
this highly selected series, suggesting it plays a role in
MDS/AML. Sharing of NGS results will deeply improve
our knowledge on the occurrence and role of rare variants at
candidate genes in hematological phenotypes.
C. Matteucci: None. F. Pellanera: None. V. Nofrini:
None. M. Quintini: None. P. Gorello: None. S. Arniani:
None. C. Camerini: None. E. Mavridou: None. M.
Moretti: None. T. Pierini: None. C. Nardelli: None. A.G.
Lema Fernandez: None. V. Bardelli: None. D. Di
Giacomo: None. C. Mecucci: None.
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P12.164.A
Functional characterization of non-coding regulatory
drivers in Chronic Lymphocytic Leukemia
A. Réal, H. Ongen, N. M. R. Lykoskoufis, C. Borel, G. Puga
Yung, J. D. Seebach, E. T. Dermitzakis
University of Geneva, Geneva, Switzerland
Most cancers are associated with coding mutations. How-
ever, the effects of non-coding regulatory drivers in cancer
development remains poorly understood. In a previous
study (BioRxiv 174219), we identified 32 local modules of
coordinated non-coding regulatory elements (CRDs, FDR
5%) that accumulated an excess of somatic mutations in 150
patients with chronic lymphocytic leukemia (CLL). We
hypothesized that CRDs with excess of somatic mutations
(after controlling for mutational confounders) can have a
driver role in CLL development. We aimed to functionally
characterize the effect of significant CRDs on their candi-
date target genes.
We developed an in vitro model in which 317 genetically-
different lymphoblastoid cell lines (LCLs) are evaluated for
variations in cancer-like phenotypes such as cell migration
(chemotaxis), proliferation (mitotic index) and apoptosis
(Fas-induced). In a preliminary screening on 42 LCLs, we
found 50 significant genome-wide SNPs associated with
these phenotypes (P<=1e−06). Among them, we identified a
SNP correlating with proliferation (p < = 4.762e−07) that is
an eQTL (expression quantitative trait loci) associated with
the GSDMB (gasdermin B) gene (P < =0.0001), which has
been linked with apoptosis and cancer regulation.
We are currently in the process to investigate the
expression profile of all 317 LCLs. These data together
with phenotypic data will allow us to functionally
characterize LCLs with differential expression of candidate
driver genes. This could provide an experimental frame-
work to explore and dissect the contribution of the non-
coding cancer genome in CLL, helping to understand the
biological complexity of these effects. Experiments are
ongoing and updated results will be presented.
A. Réal: None. H. Ongen: None. N.M.R. Lykoskoufis:
None. C. Borel: None. G. Puga Yung: None. J.D.
Seebach: None. E.T. Dermitzakis: None.
P12.165.B
Molecular predictors of non-muscle invasive bladder
cancer progression
M. Smal1, A. Rolevich2, N. Nikitchenko1, S. Krasny2, R.
Goncharova1
1Institute of Genetics and Cytology NASB, Minsk, Belarus,
2N.N. Alexandrov National Cancer Center of Belarus,
Lesnoy, Minsk District, Belarus
Non-muscle invasive bladder cancer (NMIBC) comprises
approximately 75-85% of primary bladder cancer cases, has
low mortality rate, but is burdened by high rates of recur-
rence and progression. The risk of the latter is defined by
the complex of clinicopathologic features which, however,
provide low accuracy in predicting clinical outcomes. The
aim of our study was to determine the prognostic value of
FGFR3, HRAS, KRAS, PIK3CA, ТР53 gene mutations,
RUNX3, p16 abnormal methylation, as well as CDKN2A
and RB1 loss of heterozygosity (LOH) with regard to pro-
gression in a prospective cohort of 249 NMIBC patients.
The multivariate Cox regression analysis, after adjusting for
clinical parameters, revealed an independent effect of pre-
vious recurrence episodes (HR 25.1; 95%CI 4.6-135.3; р <
0.001), TP53 mutation (HR 135.4; 95%CI 11.6-1558.3; р <
0.001), RUNX3 (HR 20.7; 95%CI 2.8-152.9; р=0.003) and
p16 methylation (HR 19.1; 95%CI 2.9-127.1; р=0.002), as
well as RB1 LOH (HR 20.5; 95%CI 3.7-114.5; р=0.001) on
NMIBC progression. Simultaneous presence of at least 3
established predictors resulted in significantly decreased 5-
year progression-free survival (14.3 ± 13.2%) as compared
with a lesser number of indicated molecular alterations
(91.9 ± 2.8%) (p < 0.001, log-rank test). Using logistic
regression, we built a prediction model, comprising all five
prognostic factors. The 5-marker panel was able to dis-
criminate between patients with and without progression
with 84.6% sensitivity, 91.7% specificity, and 0.88 AUC (р
< 0.001). The data obtained demonstrate that the use of
molecular markers in addition to clinicopathologic ones
may help in stratifying NMIBC patients into groups with
different prognosis for the selection of optimal treatment
regimens.
M. Smal: None. A. Rolevich: None. N. Nikitchenko:
None. S. Krasny: None. R. Goncharova: None.
P12.166.C
Prevalence and clinical outcomes of non-small cell lung
cancer (NSCLC) patients (pts) with potential pathogenic
germline variants (pPGVs) in British Columbia (BC),
Canada
S. Kuang, A. Karsan, S. Yip, I. Bosdet, S. Young, T. Tucker,
K. A. Schrader, S. Sun
BC Cancer, Vancouver, BC, Canada
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Background: Multi-gene panel tumour testing (TT) has
been available in BC since 2016 for pts with metastatic
NSCLC. BRCA+ and mismatch repair deficient cancers
may respond favourably to platinum chemotherapy and
immunotherapy, respectively. We performed a review of
NSCLC pts with potential pathogenic germline variants
(pPGVs) identified by TT.
Methods: NSCLC pts with pPGVs from 2016-2019 were







TP53 added Dec 2018. Clinical and treatment data were
obtained.
Results: Of 2074 pts, pPGVs were found in 83(4%),
commonly BRCA1(n = 23), BRCA2(n = 29),MSH6(n = 8),
MSH2(n = 5). 2 pts had pPGVs in both BRCA1 and
BRCA2. 33/83 pts(40%) were referred to genetics, 10
confirmed germline and 16 somatic. 23/83(28%) pts had
other driver mutations: 19 EGFR, 2 ALK and 2 BRAF
V600E. 16/38 BRCA+ pts received platinum therapy with
median time to progression of 29 weeks(range 6-64 weeks).
1 pt with MSH2 and KRAS G12C variants received
immunotherapy with progression at 4 months.
Conclusions: pPGVs were identified in 4% of NSCLCs,
commonly BRCA1/BRCA2 and MSH2/MSH6, with other
targetable driver mutations present in 28%. Concomitant
KRAS variant may be a mechanism of resistance to
immunotherapy. These pts may benefit from clinical trials
with combined targeted therapy +/- immunotherapy.
Referral rates for germline testing were low, and future
directions include reflex genetics referral and testing for pts
with pPGVs.
Patient Demographics and Disease Characteristics
Characteristic pPGVs (n = 83)














Driver mutations, n (%)
EGFR 19 (23%)
ALK 2 (2%)
BRAF V600E 2 (2%)
Multiple primaries, n (%)
Yes 16 (19%)
No 63 (76%)
Site of metastasis, n (%)
Visceral 43 (52%)
Brain 11 (13%)
S. Kuang: None. A. Karsan: None. S. Yip: None. I.
Bosdet: None. S. Young: None. T. Tucker: None. K.A.
Schrader: None. S. Sun: F. Consultant/Advisory Board;
Modest; Pfizer, AstraZeneca, BMS, Novartis.
P12.167.A
Mutation analysis in liquid biopsy from Lithuanian non-
small cell lung cancer patients
S. Jarmalaite1,2, A. Sestokaite1,2, V. Gedvilaite1, R.
Sabaliauskaite1, S. Cicenas1
1National Cancer Institute, Vilnius, Lithuania, 2Institute of
Biosciences, Life Sciences Center, Vilniu University,
Vilnius, Lithuania
Introduction & Objectives: Non-small cell lung cancer
(NSCLC) is a common and rapidly progressing cancer with
poor survival rates. Blood cell-free DNA (cfDNA) has been
proven to have prognostic potential as well as being useful
for molecular profiling and monitoring disease burden.
Next-generation sequencing (NGS) is the most efficient and
sensitive method to detect mutations from cfDNA. The aim
of this study was to screen Lithuanian NSCLC samples for
common lung cancer-related mutations by targeted NGS
and to determine their associations with clinical features.
Materials & Methods: Analysis was conducted in
NSCLC patient plasma samples before treatment and after
clinical progression. Sequencing libraries were prepared
from cfDNA using Oncomine Lung panel targeting 11 gene
180 hotspot mutation regions.
Results: Out of all 39 analysed plasma samples, in
24 samples taken before treatment largely from patients
with advanced NSCLC, we identified 34 protein-coding
mutations. Of them - 2 mutations were INDELS. Most
common pathogenic variants in Lithuanian population were
KRAS and PIK3CA. Moreover, higher mutation load was
detected in patient samples after clinical progression vs
samples before treatment. Specifically, in a group of
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patient’s overall mutation count was found 4-fold higher in
samples after immediate progression diagnosed during
routine check-up at end of the treatment as compared to
patient samples before treatment. In conclusion, plasma
cfDNA is useful for molecular profiling of NSCLC patients
to capture clinically relevant somatic alterations in advanced
stage patients and could be used as prognostic biomarker.
S. Jarmalaite: None. A. Sestokaite: None. V. Gedvi-
laite: None. R. Sabaliauskaite: None. S. Cicenas: None.
P12.168.B
Further delineation of the NTHL1 associated syndrome:
a report from the French oncogenetic consortium
F. Boulouard1,2, E. Kasper1, M. Buisine3, G. Lienard1, S.
Vasseur1, S. Manase1, M. Bahuau4, V. Bubien5, F. Coulet6,
V. Cusin7, M. Dhooge8, L. Golmard9, V. Goussot10, N.
Hamzaoui11, E. Lacaze12, S. Lejeune13, J. Mauillon1, S.
Pinson14, C. Tlemsani15, C. Toulas16, J. Rey17, N.
Uhrhammer18, G. Bougeard-Denoyelle1, T. Frebourg1, C.
Houdayer1, S. Baert-Desurmont1
1Département de Génétique et Inserm U1245, UNIROUEN,
Normandie Univ, CHU de Rouen, Centre Normand de
Génomique et de Médecine Personnalisée, Rouen, France,
2Laboratoire de génétique moléculaire Centre François
Baclesse, Caen, France, 3Institut de Biochimie et Biologie
Moléculaire, Oncogénétique Moléculaire, CHU de Lille,
Inserm UMR-S 1172, Université de Lille, Lille, France,
4Departement de Biochimie-biologie moléculaire, Pharma-
cologie, génétique médicale CHU Henri Mondor, Créteil,
France, 5Département de BioPathologie, Unité d’Onco-
génétique - Laboratoire de génétique moléculaire CLCC
Institut Bergonié, Bordeaux, France, 6Département de
Génétique, UF d’oncogénétique et d’angiogénétique molé-
culaire CHU Paris-GH La Pitié Salpêtrière-Charles Foix -
Hôpital Pitié-Salpêtrière, Paris, France, 7Département de
Génétique - CHU Paris-GH La Pitié Salpêtrière-Charles
Foix - Hôpital Pitié-Salpêtrière, Paris, France, 8Service de
gastro-entérologie CHU Paris Centre - Hôpital Cochin,
Site Cochin, Paris, France, 9Service de Génétique - Unité
de Génétique constitutionnelle - CLCC Institut Curie, PSL
Research University, Paris, France, 10Département de
biologie et pathologie des tumeurs - CLCC Georges-
François Leclerc, Dijon, France, 11Laboratoire d’onco-
génétique, CHU Paris Centre - Hôpital Cochin, Site
Cochin, Paris, France, 12Service de génétique médicale -
GH du Havre - Hôpital Jacques Monod, Le Havre, France,
13Clinique de Génétique "Guy Fontaine" - Pôle de Biologie
Pathologie Génétique - CHU de Lille - Hôpital Jeanne de
Flandre, Lille, France, 14Service de Génétique Moléculaire
et Clinique – Unité Médicale de Génétique des Cancers et
des Maladies Multifactorielles - CHU de Lyon HCL - GH
Est, Lyon, France, 15Service de cancérologie - CHU Paris
Centre - Hôpital Cochin, Site Cochin, Paris, France,
16Laboratoire d’oncogénétique - Institut Universitaire du
Cancer Toulouse - Oncopole, Toulouse, France, 17Labor-
atoire de Biologie des Tumeurs Solides - CHU de
Montpellier - Hôpital Arnaud de Villeneuve, Montpellier,
France, 18Laboratoire de Biologie Médicale OncoGènAu-
vergne - CLCC Jean Perrin, Clermont-Ferrand, France
Biallelic mutations in the NTHL1 (Nth Like DNA Glyco-
sylase 1) gene cause a novel autosomal recessive hereditary
cancer syndrome predisposing to adenomatous polyposis
and colorectal cancer. Half of the biallelic carriers also
display multiple colonic or extra-colonic primary tumors,
mainly breast, endometrium, urothelium and brain tumors.
Published data designates NTHL1 as an important con-
tributor to hereditary cancers but also underlines the scarcity
of available information. Thanks to the French oncogenetic
consortium (Groupe Génétique et Cancer), a well-organized
network of laboratories and family cancer clinics, we col-
lected NTHL1 variants from 6432 patients attending a visit
for hereditary colon cancer (n = 3529) or other hereditary
cancers (n = 2903). We found 7 patients with pathogenic,
loss of function, biallelic NTHL1 germline variations. All
carriers were from the “colorectal cancer or polyposis”
collection and no variant was identified in the “extra
digestive” collection of patients. Among the 7 biallelic
carriers, 6 underwent colonoscopy and all of them presented
adenomatous polyps. For digestive cancers, average age at
diagnosis was 59 and we reported colorectal, duodenal,
caecal and pancreatic cancer. None of these tumors showed
microsatellite instability. Extra-digestive malignancies
included sarcoma, basal cell carcinoma, breast cancer,
urothelial carcinoma, and scalp melanoma. We reported the
second largest NTHL1 collection. NTHL1 is not yet con-
sidered for diagnostic purposes in France. Despite tumor
risks to be precisely defined, these novel data may favor
NTHL1 inclusion in diagnostic panel testing. Colonic sur-
veillance should be based on MUTYH recommendations
and extra-colonic surveillance has to be defined.
F. Boulouard: None. E. Kasper: None. M. Buisine:
None. G. Lienard: None. S. Vasseur: None. S. Manase:
None. M. Bahuau: None. V. Bubien: None. F. Coulet:
None. V. Cusin: None. M. Dhooge: None. L. Golmard:
None. V. Goussot: None. N. Hamzaoui: None. E. Lacaze:
None. S. Lejeune: None. J. Mauillon: None. S. Pinson:
None. C. Tlemsani: None. C. Toulas: None. J. Rey: None.
N. Uhrhammer: None. G. Bougeard-Denoyelle: None. T.
Frebourg: None. C. Houdayer: None. S. Baert-
Desurmont: None.
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P12.169.C
Characterization of BRCA deficiency in ovarian cancer:
implications for treatment and outcome
G. Barbero1, R. Zuntini2, A. Perrone3, D. Rubino4, M.
Grippa1, G. Innella1, A. De Leo5, C. Ceccarelli5, L.
Godino1, S. Miccoli1, S. Ferrari1, D. Santini5, P. De Iaco3,
C. Zamagni4, D. Turchetti2,1
1Unit of Medical Genetics, Academic Hospital S.Orsola-
Malpighi, Bologna, Italy, 2Unit of Medical Genetics,
Department of Medical and Surgical Sciences, University
of Bologna, Bologna, Italy, 3Unit of Oncological Gynecol-
ogy, Department of Medical and Surgical Sciences,
University of Bologna, Bologna, Italy, 4Unit of Medical
Oncology, Academic Hospital S.Orsola-Malpighi, Bologna,
Italy, 5Unit of Pathology, Academic Hospital S.Orsola-
Malpighi, Bologna, Italy
Impairment of BRCA function in Ovarian Cancer (OC) has
proven to predict response to platinum-based chemotherapy
and PARP-inhibitors; consequently, BRCA1/2 sequencing is
being routinely used to inform medical treatment of OC
patients. A comprehensive assessment of BRCA defects was
performed in 30 clinically characterized OC patients to obtain
a picture of BRCA alterations and to test the accuracy of
standard diagnostic approaches. BRCA1/2 sequence, copy
number, and promoter methylation were analyzed in fresh-
frozen OC tissue. Twelve patients (40%) showed clear evi-
dence of BRCA deficit (BD): 6 (20%) carried germline
pathogenic variants (3 in BRCA1, 3 in BRCA2) and one
(3.3%) a somatic BRCA2 mutation, all displaying Loss-Of-
Heterozygosity; 5 (16.7%) had one BRCA1 copy deleted and
the other methylated; in the remaining 18 cases, BRCA deficit
was undetected/unclear (BU). 29 patients received platinum-
based chemotherapy, with baseline clinical features not sig-
nificantly differing by BRCA status: after a median follow-up
of 44.2 months, 15 had experienced progression: mean PFS
was 43.5 months (95%CI: 35.6-51.3) in the BD and
28 months (95%CI: 21.1-35.0) in the BU group (p = 0.018).
BRCA sequence analysis in respective Formalin-Fixed-
Paraffin-Embedded (FPPE) samples detected all the variants
found in fresh-frozen tissue, but also multiple additional
somatic variants, including pathogenic variants (allelic load
20-40%) in 2 tumours previously classified as BU. Our
findings suggest that BRCA sequencing in FFPE OC tissue
may involve a risk of false positive results, while missing a
substantial fraction of BRCA defective (methylated) tumours.
Supported by LOTO Onlus, AstraZeneca, Fondazione
Del Monte
G. Barbero: None. R. Zuntini: None. A. Perrone:
None. D. Rubino: None. M. Grippa: None. G. Innella:
None. A. De Leo: None. C. Ceccarelli: None. L. Godino:
None. S. Miccoli: None. S. Ferrari: None. D. Santini:
None. P. De Iaco: None. C. Zamagni: None. D.
Turchetti: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; AstraZeneca. D. Speakers
Bureau/Honoraria (speakers bureau, symposia, and expert
witness); Modest; MSD.
P12.173.A
Mutation analysis of uterine lavage fluid from Lithua-
nian ovarian cancer patients
R. Sabaliauskaite1, I. Vaicekauskaite1,2, D. Zilovic1,2, R.
Ciurliene1, S. Jarmalaite1,2
1National Cancer Institute, Vilnius, Lithuania, 2Institute of
Biosciences, Life Sciences Center, Vilniu University,
Vilnius, Lithuania
Introduction & Objectives: Ovarian cancer (OC) is a
leading cause of death in gynecological cancers with more
than 250 000 new cases diagnosed each year, 60% of these
at an advanced stage. OC has only 29% 5-year survival,
causing high mortality rates. However, currently there is no
effective screening methodology or accurate early diag-
nostic test for OC. A few proof-of-principle studies
demonstrated the use of next-generation sequencing (NGS)
of DNA of uterine lavage, to identify mutations in patients
with known gynecologic cancers. The aim of this study was
to screen uterine lavage and ovarian tissue samples form
Lithuanian OC patients for common cancer-related muta-
tions by targeted NGS and to determine their associations
with clinical features.
Materials & Methods: Cell-free DNA from 36 uterine
lavage fluid and DNA from 18 ovarian tissue samples were
analysed using NGS. The sequencing libraries were
prepared using Ion AmpliSeq™ On-Demand Panel target-
ing 10 most common OC related genes.
Results: DNA mutations were detected in: 13 of 36
(36%) uterine lavage samples (21 of 36 mutations known as
pathogenic) and 10 of 18 (55.56%) tissue samples (18 of 30
mutations known to be pathogenic). 19 mutations (11
pathogenic) were detected in both cell-free and tissue
samples from the same patients in 11 of 17 (64.71%)
sample pairs. The most often mutated genes were TP53,
BRAC1 and ARID1A. In conclusion, cell-free DNA
samples obtained from uterine lavage could be useful for
molecular profiling of OC patients.
R. Sabaliauskaite: None. I. Vaicekauskaite: None.
D. Zilovic: None. R. Ciurliene: None. S. Jarmalaite:
None.
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P12.174.B
Mutations in the ATM gene are a frequent cause of
apparently sporadic pancreatic carcinoma
E. Kunstmann, S. Rost, A. Gehrig
Department of Human Genetics, Würzburg, Germany
Introduction: Pancreatic cancer is an either inherited or
acquired rare type of abdominal cancer. Smoking, alcohol
consumption as well as diet and obesity are well known risk
factors of this acquired disease. Germline mutations in
BRCA2 are the most common cause of familial pancreatic
cancer. In addition, the prevalence of ATM mutations has
been found to be significantly higher in familial pancreatic
cancer cases than in controls. Here we present data that
mutations in the ATM gene may be a frequent cause of
apparently sporadic pancreatic cancer.
Materials and Methods: We analyzed pedigree informa-
tion and genes associated with pancreatic cancer (BRCA1/
2, ATM, CDKN2A, CHEK2, NBN and PALB2) in 8
families.
Results: Three families showed a pathogenic mutation in
BRCA2, four families had pathogenic mutations in ATM.
The index patients were all men and diagnosed with
pancreatic carcinoma at the age < 60 years. One patient had
no further family member with a history of cancer. The
father of one index patient was diagnosed with tongue
cancer. Two families showed several family members
suffering from cancer like breast cancer, sarcoma, colorectal
cancer and brain tumours. No mutation was detected in one
patient.
Conclusions: None of these presented pedigrees fulfilled
the criteria of any hereditary tumor syndrome. Nevertheless,
pathogenic germline mutations in the ATM gene were
detected in half of patients leading to the possibility of
predictive testing in healthy family members. Therefore,
genetic testing including ATM should be offered to patients
with pancreatic carcinoma despite a negative family history
of cancer.
E. Kunstmann: None. S. Rost: None. A. Gehrig: None.
P12.180.B
Molecular characterization of metastatic eccrine
porocarcinoma
D. Westphal1,2, M. Garzarolli1, M. Sergon3, B. Hutter4,5, M.
Wiegel1, J. Bauer6, S. Redler7, A. Rütten8, S. Blum9, M.
Laniado9, S. Ugurel10, J. Maschke1, S. Beissert1,2, S.
Fröhling5,11,12, P. Horak5,11,12, F. Meier1,2, H. Surowy7
1Department of Dermatology, Faculty of Medicine and
University Hospital Carl Gustav Carus, Technische
Universität Dresden, Dresden, Germany, 2National Center
for Tumor Diseases (NCT) Dresden, Dresden, Germany,
3Department of Pathology, Faculty of Medicine and
University Hospital Carl Gustav Carus, Technische Uni-
versität Dresden, Dresden, Germany, 4Division of Applied
Bioinformatics, National Center for Tumor Diseases (NCT)
Heidelberg, Heidelberg, Germany, 5German Cancer Con-
sortium (DKTK) Heidelberg, Heidelberg, Germany,
6Department of Dermatology, University Medical Center
Tübingen, Tübingen, Germany, 7Institute of Human Genet-
ics, University Clinic Düsseldorf (UKD), Heinirch-Heine
University, Düsseldorf, Germany, 8Institute of Dermato-
pathology, Friedrichshafen, Germany, 9Department of
Radiology, Faculty of Medicine and University Hospital
Carl Gustav Carus, Technische Universität Dresden,
Dresden, Germany, 10Department of Dermatology, Uni-
versity of Essen, Essen, Germany, 11Department of
Translational Medical Oncology, National Center for
Tumor Diseases (NCT) Heidelberg and German Cancer
Research Center (DKFZ) Heidelberg, Heidelberg, Ger-
many, 12DKFZ-Heidelberg Center for Personalized Oncol-
ogy (HIPO), Heidelberg, Germany
Background: Eccrine Porocarcinoma (EPC) arise from
distal portions of sweat ducts and constitute one of the rarest
forms of malignant skin neoplasias, with high recurrence
and metastasis rates. Due to their largely unknown etiology
and molecular pathology, no effective therapeutic recom-
mendations exist, especially in metastatic EPC.
Methods: We performed whole exome sequencing
(WES) in normal and metastatic tissue of an EPC case,
supplemented by RNA-Sequencing, array-CGH and immu-
nohistochemistry, and functional analyses.
Results: The metastatic EPC tissue exhibits a high
somatic point mutation burden of 21 tumor-specific
alterations per MB. The dominance of C>T transitions
and double-substitutions point towards the UV-light
exposure related tumor mutation signatures (Cosmic-Ver-
sion3) 7a/7b. Known cancer driver mutations are present in
APC, PTEN and TP53. In addition, multiple gene families
related to cell proliferation, migration, adhesion and
connectivity are notably enriched among genes harbouring
missense or truncating mutations or exhibiting dysregulated
gene expression, for example PI3K subunits and protein
kinases. In addition, wide-spread copy-number changes are
present throughout the genome, including gain of chr7p
(EGFR) and loss of chr9p (CDK2NA). A strongly CNV-
altered region on chr11q contains a highly expressed
CTNND1:PAK1 in-frame fusion gene that likely retains
Wnt-signalling as well as p21-binding and protein kinase
properties. Presence of the altered region in an early
metastasis suggests this fusion as a potentially dominant
driver in tumor development.
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Conclusions: Our results demonstrate the involvement of
multiple cellular signalling pathways in EPC tumor
development, many of which are involved in other cancer
types, and point towards potential treatment targets.
D. Westphal: None. M. Garzarolli: None. M. Sergon:
None. B. Hutter: None. M. Wiegel: None. J. Bauer:
None. S. Redler: None. A. Rütten: None. S. Blum: None.
M. Laniado: None. S. Ugurel: None. J. Maschke: None.
S. Beissert: None. S. Fröhling: None. P. Horak: None. F.
Meier: None. H. Surowy: None.
P12.181.C
Genetic and in vitro analysis in a large family with a
PRDM10 variant and a phenotype partly resembling
Birt-Hogg-Dubé syndrome
I. van de Beek1, I. E. Glykofridis1, Q. Waisfisz1, H. Meijers-
Heijboer1, M. A. M. van Steensel2,3, R. M. F. Wolthuis1, A.
C. Houweling1
1AmsterdamUMC, Vrije Universiteit Amsterdam, Amster-
dam, Netherlands, 2Lee Kong Chian School of Medicine,
Nanyang Technological University, Singapore, Singapore,
3Skin Research Institute of Singapore, Agency for Science,
Technology and Research, Singapore, Singapore
Introduction: Birt-Hogg-Dubé syndrome (BHD) is char-
acterized by fibrofolliculomas, lung cysts, pneumothorax
and renal cell carcinoma (RCC), and is caused by hetero-
zygous germline mutations in the FLCN gene. Fibrofolli-
culomas are considered pathognomonic for BHD. We here
present a family of which the proband has a histologically
confirmed fibrofolliculoma, more extensive skin lesions not
completely consistent with BHD and over 50 lipomas. He
has no identifiable lung cysts on chest CT. At least 15
family members were reported to be affected by multiple
lipomas, skin lesions and/or RCC. No mutation was
detected in FLCN.
Materials and Methods: We performed whole exome
sequencing (WES) and segregation analysis in four affected
family members.
Results: The Cys677Tyr missense variant in PRDM10
was the only potentially causative variant present in the
DNA of all four affected relatives. We hypothesized a gain-
of- function effect based on limited data of PRDM10
knockout mice and the absence of LOH of PRDM10 in both
lipoma and RCC tissues derived from the family. To assess
the effect of the variant, we overexpressed PRDM10 wild-
type and mutant protein in Renal Proximal Tubule
Epithelial Cells (RPTEC). Preliminary data show that
overexpression of PRDM10 in RPTEC results in decreased
expression of FLCN. GPMNB expression increased upon
both FLCN deficiency and PRDM10 overexpression.
Conclusions: We identified a PRDM10 variant as the
most likely cause in a family with multiple lipomas, RCC
and skin lesions partly resembling BHD.
I. van de Beek: None. I.E. Glykofridis: None. Q.
Waisfisz: None. H. Meijers-Heijboer: None. M.A.M. van
Steensel: None. R.M.F. Wolthuis: None. A.C.
Houweling: None.
P12.182.A
Prevalence of pathogenic variants in cancer predisposi-
tion genes in patients with pancreatic cancer: A multi-
centre clinical study
A. Eliades1, E. Fountzila2, C. Loizides1, A. Achilleos1, C.
Marinou1, C. Kkoufou1, L. Constantinou1, K. Tsangaras1,
E. Kypri1, M. Ioannides1, G. Fountzilas3, G. Koumbaris1, P.
C. Patsalis1
1NIPD Genetics Public Company Ltd, Nicosia, Cyprus,
2Euromedica General Clinic of Thessaloniki, Thessaloniki,
Greece, 3Laboratory of Molecular Oncology, Hellenic
Foundation for Cancer Research/Aristotle University of
Thessaloniki, Thessaloniki, Greece
Introduction: Pancreatic cancer is one of the top leading
causes of cancer-related deaths with more than 432,000
patients were predicted to die worldwide from the disease in
2018 according to the World Health Organisation. Most
patients have a one-year survival rate of 20% and a five-
year survival rate of 7%. These low survival rates are
mainly because in most cases at the time of diagnosis
malignancy has already progressed to advanced stages. It is
estimated that Identification of high-risk individuals via
genetic screening can improve survival rates.
Materials and methods: This multicentre retrospective
study enrolled 572 patients diagnosed with pancreatic
adenocarcinoma (PDAC). Germline DNA was extracted
from these patients and subjected to targeted in solution
hybridisation-based next generation sequencing using the
PreSENTIA pan-cancer panel covering 62 genes associated
with cancer predisposition. Results were validated by an
orthogonal method. Clinical and family history data were
collected from the participants.
Results: We have identified pathogenic variants in 18
genes associated with hereditary cancer predisposition
including genes that were previously associated with
increased risk for pancreatic cancer including PALB2,
ATM, BRCA1, BRCA2, MSH6 and APC. We have
additionally identified pathogenic variants in genes not
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previously associated with pancreatic adenocarcinoma such
as SDHB, FANCM and RET.
Conclusions: The results suggest that a substantial
proportion of patients with PDAC are carriers of pathogenic
germline variants in predisposition genes and highlight the
clinical utility of germline multigene testing. Importantly
relatives of patients that are carriers of pathogenic variants
could benefit from germline testing.
A. Eliades: A. Employment (full or part-time); Significant;
NIPD Genetics Public Company Ltd. E. Fountzila: None. C.
Loizides: A. Employment (full or part-time); Significant;
NIPD Genetics Public Company Ltd. A. Achilleos: A.
Employment (full or part-time); Significant; NIPD Genetics
Public Company Ltd. C. Marinou: A. Employment (full or
part-time); Significant; NIPD Genetics Public Company Ltd.
C. Kkoufou: A. Employment (full or part-time); Significant;
NIPD Genetics Public Company Ltd. L. Constantinou: A.
Employment (full or part-time); Significant; NIPD Genetics
Public Company Ltd. K. Tsangaras: A. Employment (full or
part-time); Significant; NIPD Genetics Public Company Ltd.
E. Kypri: A. Employment (full or part-time); Significant;
NIPD Genetics Public Company Ltd. M. Ioannides: A.
Employment (full or part-time); Significant; NIPD Genetics
Public Company Ltd. G. Fountzilas: None. G. Koumbaris:
A. Employment (full or part-time); Significant; NIPD
Genetics Public Company Ltd. P.C. Patsalis: A. Employment
(full or part-time); Significant; NIPD Genetics Public
Company Ltd.
P12.183.B
Post-biopsy cell-free DNA in blood: an open window on
primary prostate cancer genetics and biology
M. Corbetta1, M. Lazzeri2, C. Chiereghin1, I. De Simone1,
M. Zuradelli1, G. Soldà1, R. Asselta1, N. M. Buffi1, P.
Casale2, R. Hurle2, G. Lughezzani1, A. Saita2, G.
Guazzoni1, S. Duga1
1Humanitas University, Pieve Emanuele - Milan, Italy,
2Humanitas Clinical and Research Center, IRCCS, Rozzano
- Milan, Italy
Introduction: The analysis of circulating cell-free DNA
(ccfDNA) represents a promising strategy for non-invasive
cancer diagnosis. However, the fraction of cancer-derived
ccfDNA (ctDNA) is variable, and particularly low in pri-
mary disease in capsulated organs like prostate. Most stu-
dies explored ctDNA in advanced metastatic prostate cancer
(PCa), conversely, detection of ctDNA in localized disease
is challenging. Inflammation, exercise, or tissue injury,
substantially increase ccfDNA; we therefore hypothesized
that prostate biopsies (each typically picking 14-18 samples
from the gland) might release prostate-derived ccfDNA/
ctDNA, which could be exploited for molecular tests.
Materials and Methods: We collected tissue/blood
samples (before and after biopsy at different timepoints)
from 34 patients undergoing prostate biopsy: 26 with PCa, 8
negative. ccfDNA was extracted with the Maxwell-RSC
ccfDNA Plasma Kit, quantified by Qubit; size-distribution
analysis was performed by Tape-station. Somatic mutations,
identified by RNAseq on biopsies using the TruSight RNA
Pan-Cancer Panel, were searched in ccfDNA (before/after
biopsy) by targeted NGS (NEBNext Ultra II DNA Library
Prep; mean depth 280,000x).
Results: We demonstrated a significant transient increase
in plasma ccfDNA after biopsy (4.23.6 ± 3.39ng vs.
2.72 ± 1.02ng per mL plasma; P-value=0.0098 after 1h;
9.32 ± 5.08ng vs. 6.74 ± 4.35ng, P=0.0052 after 2h).
ccfDNA molecules extracted after biopsy were also
significantly longer. Finally, targeted NGS on pre/post-
biopsy ccfDNA confirmed a significant enrichment (2.15-
164 fold) in the ctDNA fraction.
Conclusions: Plasma post-biopsy ccfDNA represents a
source of pan-prostate DNA, a major advantage over the
analysis of single biopsies. This opens the possibility to
analyze somatic mutations/epigenetics markers with prog-
nostic value in primary PCa.
M. Corbetta: None. M. Lazzeri: None. C. Chiereghin:
None. I. De Simone: None.M. Zuradelli: None. G. Soldà:
None. R. Asselta: None. N.M. Buffi: None. P. Casale:
None. R. Hurle: None. G. Lughezzani: None. A. Saita:
None. G. Guazzoni: None. S. Duga: None.
P12.184.C
Study of Androgen Receptor and variant 7 in Tumor-
Educated Platelets in Metastasic Prostate Cancer
P. Vázquez-Cárdenas1,2,3, M. C. Moreno-Samaniego1, J. L.
García-Hernández2,3, I. Misiewicz-Krzeminska2,3, Á. J.
Virseda-Rodríguez4, S. Marcos-Asensio4, A. B. Herrero1,2,
F. Gómez-Veiga4, J. J. Cruz-Hernández1,3,5, R. González-
Sarmiento1,2,3
1Molecular Medicine Unit, Department of Medicine, University
of Salamanca, Salamanca, Spain, 2Institute of Molecular and
Cellular Biology of Cancer (IBMCC), University-CSIC,
Salamanca, Spain, 3Institute of Biomedical Research of
Salamanca (IBSAL), Salamanca, Spain, 4Translational
Research Group of Urology GITUR-IBSAL, University
Hospital of Salamanca, Salamanca, Spain, 5Oncology Service,
University Hospital of Salamanca, Salamanca, Spain
Introduction: Liquid biopsies is a non-invasive method to
detect tumor-associated biomarkers. This study aimed to detect
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the presence of androgen receptor (AR) and the androgen
receptor variant 7 (AR-V7) a biomarker associated with worse
prognosis, in blood samples of prostate cancer (PCa) patients
by two methods: RT-qPCR from platelet-isolated RNA and
determination of AR and AR-V7 protein levels in plasma using
capillary nano-immunoassay.
Methods: The study included 35 patients with PCa and
16 healthy donors. Whole blood (10mL) was collected and
platelets were isolated from the supernatant by centrifuga-
tion at room temperature for 20 minutes at 1500 rpm. RNA
was extracted and RT-qPCR for GAPDH, ITGA2B, AR
and AR-V7 was performed. Proteins were extracted to
detect AR and AR-V7 using Simple West Protein analysis.
Results: Both AR and AR-V7 expression were detected
by RT-qPCR. Five patients exhibited a high expression of
the 2 receptors, 8 showed low levels and 22 patients showed
expression levels similar to those of the VCAP PCa cell
line, that was used as a positive control. These biomarkers
were absent in the 16 healthy donors, as expected. AR
protein was detected by Simple West in all plasma patients.
However, AR-V7 protein was only detected in 11 patients.
Conclusions: The results demonstrate that platelets
contain tumor-associated RNA and could be used for
detection of AR and AR-V7 expression in blood samples in
PCa patients. Moreover, determination of AR-V7 protein by
nano-immunoassay represents a novel methodology and
may serve to detect this biomarker associated with bad
prognosis.
P. Vázquez-Cárdenas: None. M.C. Moreno-Sama-
niego: None. J.L. García-Hernández: None. I. Misie-
wicz-Krzeminska: None. Á.J. Virseda-Rodríguez: None.
S. Marcos-Asensio: None. A.B. Herrero: None. F.
Gómez-Veiga: None. J.J. Cruz-Hernández: None. R.
González-Sarmiento: None.
P12.185.A
First results of germline genetic testing in Slovenian
patients with prostate cancer
K. Strojnik1, M. Krajc1, M. Banjac1, V. Stegel2, P. Skerl2, V.
Setrajcic Dragos2, G. Klancar2, S. Novakovic2, A. Blatnik1
1Cancer Genetics Clinic, Institute of Oncology, Ljubljana,
Slovenia, 2Department of Molecular Diagnostics, Institute
of Oncology, Ljubljana, Slovenia
Introduction: Metastatic prostate cancer (PC) has recently
been introduced as an independent criterion for germline
BRCA1/2 genetic testing. Clinical studies indicate that
variants in other DNA-repair genes might also have ther-
apeutic implications. The prevalence of germline patho-
genic variants/likely pathogenic variants (PV/LPVs) in
BRCA1/2 and other DNA-repair genes in the Slovenian
population of PC patients is unknown.
Methods: We performed a retrospective analysis of all
PC patients referred to our institution for germline genetic
testing since 2015. In 2018, we implemented genetic testing
for systemic therapy decision making in metastatic PC
patients. The majority (53/57) were tested using a multi-
gene panel. In four cases Sanger sequencing was performed
for known familial variants.
Results: Overall, we identified 40 patients with metastatic
and 17 patients with localized PC. We detected a significant
increase in referral rates with 8 patients (14.0%) referred
between 2015 and 2017, 11 (19.3%) in 2018 and 38
(66.7%) in 2019. PV/LPVs in 4 different DNA-repair genes
were found in 17.5% (7/40) of metastatic PC patients (three
in BRCA2, two in CHEK2, one in RAD51C, one in ATM).
Two (11.8%) patients with localized PC had PV/LPVs in
two DNA-repair genes (one in BRCA1, one in MSH2).
Conclusions: Our preliminary results show a high
prevalence of germline PV/LPVs in DNA-repair genes in
Slovenian metastatic PC patients. Although not all detected
variants are in known prostate-susceptibility genes, they
might prove important in the future as new targeted therapy
options become available, as well as for identifying other
family members at risk.
K. Strojnik: None. M. Krajc: None. M. Banjac: None.
V. Stegel: None. P. Skerl: None. V. Setrajcic Dragos:
None. G. Klancar: None. S. Novakovic: None. A.
Blatnik: None.
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Wide range of phenotypes in a family with PTEN
germline mutation
C. Henke, F. Stock, A. Bohring, U. Siebers-Renelt
Institut für Humangenetik, Universitätsklinikum Münster,
Münster, Germany
We report on a family with clustering of premenopausal
breast cancer and other tumors. The first woman appearing
in our outpatient clinic was diagnosed with breast cancer
(bilateral DCIS) at the age of 26. Five more family members
displaying breast cancer were identified (age spectrum 27 to
75 years at diagnosis). Criteria for hereditary breast and
ovarian cancer were therefore fulfilled. A complete record
of family history revealed several other diseases (clear cell
renal cell carcinoma, melanoma, bilateral thyroid cancer,
mucoepidermoid carcinoma of trachea, ovarian cancer,
endometrium cancer, benign lesion of glandula parotis,
gastrointestinal polyps (including hamartomas), polypoid
lesion of pancreas, benign thyroid lesions and vascular
malformations). Therefore, we included PTEN in the
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genetic testing in addition to the core genes associated with
hereditary breast and ovarian cancer (e.g. BRCA1, BRCA2,
PALB2, CHEK2, RAD51C, RAD51D, ATM; true risk
panel®). Sequencing detected a germline deleterious variant
(c.1003C>T, p.(Arg335*)) in PTEN which could also be
found in three other family members. Molecular analysis in
four further individuals is pending. Germline mutations in
the PTEN tumor suppressor gene cause PTEN hamartoma
tumor syndrome (PHTS) which is characterised by frequent
occurrence of benign and malign lesions, especially an
elevated lifetime risk for developing breast and thyroid
cancer. This case underlines the variability of phenotypes
associated with PHTS even within one family. It highlights
the importance of a detailed family history and stresses the
necessity of profound knowledge about rare tumor predis-
position syndromes in breast cancer families.
C. Henke: None. F. Stock: None. A. Bohring: None. U.
Siebers-Renelt: None.
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Recognizing PTEN Hamartoma Tumour Syndrome by
only 3 simple criteria.
N. Hoogerbrugge, J. Meek, J. Schieving, J. Schuurs, J. R.
Vos
Radboud university Medical Center, Nijmegen, Nether-
lands
Introduction: Patients with PTEN Hamartoma Tumour
Syndrome (PHTS) have 80-100% risk to develop cancer,
often in multiple organs and at early age. The majority
(80%) of PHTS patients is not yet identified as such and
does not receive proper cancer risk management. We aim
for easy-to-apply criteria - usable for almost every health-
care professional - to identify those at high risk of carrying a
PTEN mutation in a phase prior to cancer development.
Methods: In a cohort of 176 paediatric and adult PHTS
patients phenotypical characteristics were assessed by one
of two expert clinicians. Prevalence of early-onset char-
acteristics and their (combined) sensitivity to identify PHTS
was determined for all patients and by age group (0-12, 12-
25, 25+ years)
Results: Macrocephaly is an early-onset characteristic
that was present in 82% of all patients and in 100% of those
below age 12 (n = 58). Multinodular Struma (MNS)
development was detected in 97% of patients age 25+.
Multiple oral features (gingival hypertrophy, tongue and/or
mucosal papillomas, or high palate) were detected in 94%
of patients above age 25.
Simplified criteria were formulated as the presence of two
out of three of the following features: macrocephaly; MNS;
and multiple oral features. In adult patients this has a
sensitivity of 95% (95% CI: 90-98%).
Conclusions: Our simplified criteria, specifically the oral
phenotype, could serve as an early trigger initiating the
more elaborate assessment of patients suspected of a PTEN
mutation. They can be assessed by most clinical specialists
that see complex patients unknowingly presenting
with PHTS.
N. Hoogerbrugge: None. J. Meek: None. J. Schieving:
None. J. Schuurs: None. J.R. Vos: None.
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Renal cell carcinoma (RCC) predisposition genes: Who
should be tested?
A. Andreou1,2, B. Yngvadottir1, L. Bassaganyas1, P. S.
Smith1, R. Barber3, K. Ong3, D. H. Lim3, Genomics
England Research Consortium, RCC GeCIP Domain
members, D. R. Mole4, S. Turajilic5, K. Litchfield5, A. J.
Cornish6, R. S. Houlston6, Y. Wallis3, E. R. Woodward7, E.
R. Maher1
1Department of Medical Genetics, University of Cambridge,
Cambridge, United Kingdom, 2Cancer Research UK Cam-
bridge Institute, Cambridge, United Kingdom, 3West Mid-
lands Regional Genetics service, Birmingham Women’s and
Children’s NHS Trust, Birmingham, United Kingdom,
4University of Oxford, Oxford, United Kingdom, 5Francis
Crick Institute, London, United Kingdom, 6Institute of
Cancer Research, London, United Kingdom, 7Manchester
Centre for Genomic Medicine, St Mary’s Hospital,
Manchester University NHS Foundation Trust, Manchester,
United Kingdom
Approximately 3% of renal cell carcinoma (RCC) is thought
to be inherited. Syndromic and non-syndromic forms have
been described. It has been recommended that RCC patients
with young age at onset (≤45 years), multicentric/bilateral
tumours, family history or with presence of syndromic
clinical features should be referred for genetic assessment
and testing (1).
Our aim was to determine the detection rate of a clinical 5
gene panel (FLCN, FH, VHL, MET, SDHB) of RCC
predisposition genes. We retrospectively evaluated a
referral-based cohort of non-syndromic RCC patients (n =
262) and found a diagnostic yield of 2.7% [7/262
pathogenic/likely pathogenic variants (P/LP)]. We then
interrogated the unselected RCC cohort (n = 862) recruited
to the 100,000 Genomes Project for germline P/LP variants
in these genes and found a detection rate of 0.9% (8 P/LP
variants). Five out of the 8 P/LP variants were seen in
participants with early onset disease (<45 years).
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We then investigated whether P/LP variants might be
detected in cancer predisposition genes (CPGs) less
frequently tested using a virtual panel of 137 CPGs.
Analysis is ongoing but to date additional P/LP variants
have been identified in SDHA, MITF and CHEK2. The
availability of comprehensive genomic analysis can better
inform the genetic architecture of inherited RCC and refine
clinical recommendations for diagnostic testing.
Reference:1. Reaume MN, Graham GE, Tomiak E,
Kamel-Reid S, Jewett MA, Bjarnason GA, et al. Canadian
guideline on genetic screening for hereditary renal cell
cancers. Can Urol Assoc J. 2013;7(9-10):319-23.
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The influence of the type of predisposing RB1 variants
on the incidence of malignancies
P. Ketteler1,2, I. Hülsenbeck1, M. Frank3, B. Schmidt3, K.
Jöckel3, D. R. Lohmann2
1Department of Pediatrics 3, Essen, Germany, 2Institute of
Human Genetics, Essen, Germany, 3Institute of Medical
Informatics, Biometry and Epidemiology, Essen, Ger-
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Survivors of heritable retinoblastoma have a high risk to
develop other malignancies later in life. The incidence of
these second malignancies (SPMs) is significantly higher
after external beam radiotherapy. We have tested if the
incidence of SPM with and without previous irradiation is
distinct depending on the type of the predisposing RB1 gene
variant as indicated by retinoblastoma penetrance. From
1940 to 2008, 655 national patients were treated for heri-
table retinoblastoma at the German referral center. Com-
plete information on SPMs until 2012 and data on
constitutional RB1 variant was available for 317 patients
(48.3%). With respect to the type, predisposing RB1 gene
variants were classified by observed penetrance for retino-
blastoma (incomplete and complete penetrance type var-
iants). SPMs occurred in 51 of 317 survivors of heritable
retinoblastoma. In non-irradiated retinoblastoma survivors,
the incidence rate per 1,000 person years (IR) of SPMs was
lower compared to the irradiated patients (IR 11.1 [95%
confidence interval 7.9-15.1] vs. IR 4.3 [2.1 -7.9]; p < 0.01).
The IR of SPMs was higher in patients with complete
penetrance type variants compared to incomplete type var-
iants (p < 0.05). Without previous irradiation, SPM were
only observed in patients with complete penetrance type
RB1 variants. The association between the type of RB1
variant and penetrance of retinoblastoma in childhood is
also present with respect to the risk for SPMs later in life.
This finding will help to develop screening programs tai-
lored to the individual risk of survivors with heritable reti-
noblastoma. The Deutsche Kinderkrebsstiftung and the
Wilhelm-Sander Stiftung financed this study.
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Comprehensive investigation of factors defining retro-
element activity in colorectal cancer.
M. V. Saliutina, A. Y. Komkov, S. Z. Urazbakhtin, A. O.
Smirnova, G. A. Nurmanov, Y. B. Lebedev, I. Z. Mamedov
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry
of Russian Academy of Science, Moscow, Russian Federa-
tion
Introduction: Retroelement (RE) activity is one of the most
important causes of human genome instability. Somatic
insertions of L1 and Alu were detected in some cancer types
(colorectal, lung, breast). Despite the abundance of data
about the regulation of RE activity, the exact mechanisms of
RE activation in particular cancer types are still unclear. In
this study we investigate the correlation between RE
insertional activity in colorectal cancer and other factors,
such as gene expression, L1 transcription and methylation
profiles of young L1 copies.
Materials and Methods: sequencing libraries of L1 and
Alu flanking sequences were prepared from DNA isolated
from paired normal and tumor tissue samples. Digested
DNA was ligated to adapters containing unique molecular
identifiers (UMI) and amplified with primers, specific to
young RE subfamilies. The same DNA samples were used
for investigation of methylation profile of young L1-copies
by enzymatic based conversion of 5-mC with subsequent
amplification and sequencing of L1Hs promoters. Total
RNA was extracted from the same tissue samples and used
for RNA-seq library preparation.
Results: Tumor-specific insertions were identified in 18
tumors from 55 analyzed normal/tumor paired samples. In
these paired samples we also identified L1HS-copies with
demethylated promoters. We characterized the differential
expression of genes that influence RE activity and
transcription activity of individual L1 copies.
Conclusions: In this work, we conducted a first
systematic study of multiple factors that can influence RE
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transpositional activity in colorectal cancer. Funding: this
work was supported by RSF18-14-00244 grant.
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Sporadic vestibular schwannoma: a molecular testing
summary
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Objectives: Cases of sporadic vestibular schwannoma
(sVS) have a low rate of association with germline patho-
genic variants. However, some individuals with sVS can
represent undetected cases of neurofibromatosis type 2
(NF2) or schwannomatosis. Earlier identification of patients
with these syndromes can facilitate more accurate familial
risk prediction and prognosis.
Methods: Cases of sVS were ascertained from a local
register at the Manchester Centre for Genomic Medicine.
Genetic analysis was conducted in NF2 on blood samples
for all patients, and tumour DNA samples when available.
LZTR1 and SMARCB1 screening was also performed in
patient subgroups.
Results: Age at genetic testing for VS presentation was
young in comparison to previous literature, a bias resulting
from updated genetic testing recommendations. Mosaic or
constitutional germline NF2 variants were confirmed in 2%
of patients. Pathogenic germline variants in LZTR1 were
found in 3% of all tested patients, with a higher rate of 5%
in patients <30 years. No pathogenic SMARCB1 variants
were identified within the cohort. Considering all indivi-
duals who received tumour DNA analysis, 69% of patients
were found to possess two somatic pathogenic NF2
variants, including those with germline LZTR1 pathogenic
variants, supporting the multi-hit mechanism of LZTR1-
associated VS tumourigenesis.
Conclusions: Undiagnosed schwannoma predisposition
may account for a significant proportion of apparently sVS
cases, especially at lower presentation ages. Loss of NF2
function is a common event in VS tumours and may
represent a targetable common pathway in VS
tumourigenesis.
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POLE, POLD1 and RNF43 screening in serrated
polyposis syndrome
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1Gastroenterology Department, Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de
Investigación Biomédica en Red de Enfermedades Hepáti-
cas y Digestivas (CIBERehd), Hospital Clínic, Barcelona,
Spain, 2Bioinformatics Platform, Centro de Investigación
Biomédica en Red de Enfermedades Hepáticas y Digestivas
(CIBERehd), Barcelona, Spain, 3Pathology Department,
Institut d’Investigacions Biomèdiques August Pi i Sunyer
(IDIBAPS), Centro de Investigación Biomédica en Red de
Enfermedades Hepáticas y Digestivas (CIBERehd) and
Tumor Bank-Biobank, Hospital Clínic, Barcelona, Spain,
4Genetics Unit, Hospital Universitario de Móstoles,
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Introduction: Serrated polyposis syndrome (SPS) is a
condition characterized by large and multiple polyps and
colorectal cancer (CRC) predisposition. RNF43 has been
recently related to SPS, and POLE and POLD1 to multiple
polyposis predisposition. We aimed at screening for
potentially pathogenic mutations in these genes in a SPS
cohort.
Materials and methods: Initially, 39 SPS cases under-
went whole-exome sequencing. Subsequently, a replication
cohort of 211 SPS patients were analyzed in a custom panel
containing POLE, POLD1 and RNF43. Rare, potentially
pathogenic missense and truncation variants were prior-
itized with an in-house bioinformatics pipeline.
Results: Ten missense variants were identified in POLE.
Truncation variants were identified in POLE and POLD1
and RNF43. To date, all variants are considered as of
uncertain significance except for the one in RNF43 (p.
Arg132*). We have started functional studies using
CRISPR/Cas9 gene editing in cellular models for the
frameshift POLD1 candidate variant (p.Lys648fs).
Conclusions: RNF43 variants seem to be a very rare
contributor to germline SPS predisposition. POLE and
POLD1 variants may predispose in some cases to SPS
although further functional assessment of truncating
variants and missense variants outside the exonuclease
domain of POLE and POLD1 is compulsory to evaluate
their impact in germline SPS predisposition.
Grant support: LCF/BQ/DI18/11660058(ID100010434)
funded by Marie Skłodowska-Curie grant agreement no.
713673, FJCI-2017-32593, 2019FI_B2_00203, Fondo de
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(SAF2016-80888-R, BIO2017-89754-C2-2R), PERIS
(SLT002/16/00398, SLT002/16/0037), Generalitat de Cat-
alunya (GRPRE 2017SGR21, GRC 2017SGR653,
2017SGR723, 2017SGR861, 2017SGR1282), COST
Action CA17118, CIBEREHD, CIBERONC and
CIBERER.
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Colorectal cancer genetic variants are also associated
with Serrated polyposis syndrome susceptibility
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Biomédica en Red de Enfermedades Raras (CIBERER),
552 J. del Picchia
Santiago de Compostela, Spain, 10Unit of Biomarkers and
Susceptibility, Oncology Data Analytics Program, Catalan
Institute of Oncology (ICO); Colorectal Cancer Group,
ONCOBELL Program, Bellvitge Biomedical Research
Institute (IDIBELL); CIBERESP, Barcelona, Spain
Background: Serrated polyposis syndrome (SPS) is a
clinical entity characterized by multiple serrated polyps
throughout the colon and increased risk for colorectal can-
cer (CRC). The basis for SPS genetic predisposition is
largely unknown. Common, low-penetrance genetic var-
iants have been consistently associated with CRC suscept-
ibility, however, their role in SPS genetic predisposition has
not been yet explored.
Objective: The aim of this study was to evaluate if
common low-penetrance genetic variants for CRC risk are
also implicated in SPS genetic susceptibility.
Methods: A case-control study was performed in 219
SPS patients and 548 asymptomatic controls analyzing 65
CRC susceptibility variants. A risk prediction model for
SPS predisposition was developed.
Results: Statistically significant associations with SPS
were found for 7 genetic variants (rs4779584-GREM1,
rs16892766-EIF3H, rs3217810-CCND2, rs992157-
PNKD1/TMBIM1, rs704017-ZMIZ1, rs11196172-TCF7L2,
rs6061231-LAMA5). The GREM1 risk allele was remark-
ably overrepresented in SPS cases compared to controls
(OR=1.573, 1.21-2.04, P-value = 0.0006). A 4-fold
increase in SPS risk was observed when comparing subjects
within the highest decile of variants (≥ 65) with those in the
first decile (≤ 50).
Conclusions: Genetic variants for CRC risk are also
involved in SPS susceptibility, being the most relevant ones
rs4779584-GREM1, rs16892766-EIF3H and rs3217810-
CCND2.
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sity Hospital, Fez, Morocco, 3Radiology department,
Hassan II University Hospital, Fez, Morocco, 4Trauma-
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Introduction: Soft tissue sarcomas (STS) are hetero-
geneous group of tumors. Pathological diagnosis relies on
morphology and immunohistochemistry. It should be
complemented by molecular technique, when the diagnosis
is doubtful, and when it may have prognostic and/or pre-
dictive relevance. This study aims to assess the clinical
effect of implementation of FISH to improve sarcoma
misdiagnosis.
Materials and Methods: It is a retrospective study
conducted in the pathology department of Hassan II
university hospital between 2010 and 2018. 110 cases of
mesenchymal tumors were included. HES coloration was
performed in all cases followed by immunohistochemistry.
FISH was performed in all cases. Probes used were Vysis
break apart; EWSR1, MDM2, and SS18.
Results: The median age is 38 years [1-82]. On the
basis of histology and immunohistochemical stains. There
were 33 ewing sarcoma, 21 synovial sarcomas, 28
lipomas, 5 liposarcomas, and 23 unclassified sarcomas.
FISH was successful in 97%. EWSR1 gene was rear-
ranged in 72% of cases. For synovial sarcomas the
rearrangement of SS18 was detected in 71%. MDM2 was
amplified in 40% of atypical lipomatous tumors and
dedifferentiated liposarcomas, whereas 93% of lipomas
were negative, with 2 cases labelled as liposarcomas after
FISH MDM2.
Conclusions: This is the first and largest moroccan series
for molecular diagnosis of STS by FISH. It is important to
implement this technique in a local laboratory to make it
available at routine for moroccan patients. Our study shows
that FISH improves sarcomas misdiagnosis, and it is very
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useful when histology and immunohistochemistry can’t
accurately classify tumors.
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hereditary cancer genes: tools to prioritize RNA studies
and challenges in applying ACMG guidelines
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Gómez2, G. Vargas1, E. Montes2, M. Salinas1, A. Solanes2,
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Purpose: RNA analyses are a potent tool to identify spli-
ceogenic effects of DNA variants, although they are time-
consuming and cannot always be performed. Here, we
present splicing assays of 20 variants representing a variety
of mutation types in ten hereditary cancer genes, together
with an attempt to incorporate these results into ACMG
classification guidelines.
Methods: We selected 16 point mutations, 3 exon
duplications and one single-exon deletion prioritized by in
silico algorithms. RNA was extracted from short-term
lymphocyte cultures to perform RT-PCR and Sanger
sequencing. Whenever possible, allele-specific expression
was assessed by SNaPshot.
Results: We detected aberrant transcripts in 14 variants
(70%). We faced the difficulty of variant interpretation
comparing old classification standards to generic ACMG
guidelines and devised a proposal to weight functional
analyses at RNA level. According to ACMG guidelines
only 12 were reclassified as pathogenic/likely pathogenic,
since the remaining two did not gather enough evidence.
Conclusions: Our study highlights the importance of
RNA studies to improve variant classification. However, it
also evidences the challenge of incorporating these results
into generic ACMG guidelines and the need to refine these
criteria gene-specifically. Nevertheless, 60% of variants
were reclassified, thus improving genetic counseling and
surveillance for carriers of these variants.
Grant support Contract grant sponsor: Supported by the
Carlos III National Health Institute funded by FEDER funds
– a way to build Europe – [PI19/00553; PI16/00563; PI16/
01898; SAF2015-68016-R and CIBERONC]; the
Government of Catalonia [Pla estratègic de recerca i
innovació en salut (PERIS_MedPerCan and URDCat
projects), 2017SGR1282 and 2017SGR496].
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Introduction: Genetic testing has a pivotal role in the
diagnosis of hereditary cancer predisposition syndromes.
However, variant interpretation is still a challenging step
and often the lack of functional studies leads clinicians to
classify them as variants of uncertain significance (VUS).
RNA functional studies can improve the characterization of
variants thus allowing the implementation of personalized
strategies in cancer patient care.
Materials and Methods: VUSs were analysed using the
Human Splicing Finder (HSF) software, to predict the effect
of intronic and exonic variants on splicing. Thereafter, RNA
was extracted from short-term lymphocyte cultures (96h)
from peripheral blood and /or from lymphoblastoid lines,
both in presence and absence of puromycin to inhibit
Nonsense Mediated Decay. cDNA was obtained and
amplification products were analyzed by gel electrophoresis
and Sanger sequencing to detect any abnormal splicing
patterns.
Results and Discussion: A total of fourteen VUS, twelve
intronic and two exonic, in the following genes have been
analyzed: MSH2, MLH1, MSH6, APC, PMS2, MUTYH,
PTEN, TP53, NF1, SPRED1. Ten of them affected exon
incorporation as a consequence of intronic sequence
changes. In the remaining four no differences were
observed in transcript sequences in both untreated and
puromycin-treated cultures.
Conclusions: Our study shows that 71% of the splicing
variants analyzed by RNA sequencing can be reclassified as
pathogenetic or likely pathogenetic. These preliminary data
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suggest that RNA analysis should be a part of the diagnostic
workflow in patients with VUS in hereditary cancer
predisposition genes in order to improve genetic testing
accuracy and patients managment.
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Facile genome-wide detection of genomic fusions and
other somatic abnormalities through Bionano Genome
Imaging
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Genome instability is a key hallmark of cancer as it allows
the genome to acquire growth advantage by amplifying or
creating oncogenes by creating gene fusions and by delet-
ing/inactivating tumor suppressor genes. Several gene
fusions have been discovered and exploited for therapies as
they produce fusion proteins that can be targeted by che-
motherapeutics such as tyrosine-kinase inhibitors targeting
BCR-ABL used to treat CML. In addition, other genomic
fusions serve as diagnostic or prognostic indicators impor-
tant for cancer management. Whole genome approaches to
detect fusions have innate limitations, for example, kar-
yotyping is low resolution and whole genome sequencing is
blind in the ~66% of the genome containing repeats. Bio-
nano genome imaging is able fill the gap, it provides high
resolution and ability to span genomic repeats.
Here we demonstrate an easy, fluid, largely automated
workflow for whole genome detection of fusions and other
somatic variants. The Bionano workflow involves a novel
rapid isolation protocol for extremely high molecular
weight DNA, labeling the DNA to create a barcode across
the genome and automated data collection using the
Bionano Saphyr instrument. This complete assay can be
conducted within 4 days from tissue to variant calls. We
detected numerous fusions that have not previously been
detected. In a standard assay, whole genome imaging can
detect variants at 5% allele fraction and with increased
coverage fusions down to 1% allele fraction can be
efficiently detected! Whole genome optical mapping for
fusion detection is surely going to play an increasing role in
cancer research going forward.
A. Hastie: A. Employment (full or part-time); Significant;
Bionano Genomics.
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Targeted RNA sequencing enables detection of relevant
translocations, single nucleotide variants and automatic
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Background: Leukemia patients carry a wide range of
chromosomal and molecular abnormalities which affect
their prognosis and treatment options. Since no simple
technique is available that detects all relevant abnormalities,
the choice of techniques is depending on the referral reason.
Therefore, we tested targeted transcriptome sequencing as a
single platform to detect all relevant variants compared to
current techniques.
Material and Methods: In a cohort of 136 primary
diagnosed leukemia patients we performed RNA sequen-
cing of 1,385 genes (TruSight RNA Pan-Cancer, Illumina).
We used a decision tree based on principle component
analysis of expression profiles to guide leukemia classifica-
tion. Gene fusions were detected, and overexpression for
the genes EVI1, CCND1 and BCL2 was quantified. SNV/
indels were analyzed in a virtual myeloid and lymphoid
panel of 54 and 72 genes, respectively. Results were
compared to current techniques.
Results: Compared to current techniques specificity for
detecting relevant variants was 100%. Two variants were
missed:c.2447A>T in KIT [qPCR at 10−4], and BCL2
overexpression with t(14;18)(q32;q21) in 5% of the cells.
With RNA sequencing six additional fusion genes and in
two samples overexpression of CCND1, due to a t(11;14)
(q13;q32), were detected. We predicted leukemia classifica-
tion correctly in 81% of patients and improved classification
in three patients.
Conclusions: Targeted RNA sequencing combined with
our workflow for data analysis is feasible and improves
detection of relevant variants. Expression patterns can assist
to establish the leukemia subtype. The diagnostic value of
our novel approach will be tested in a large prognostic
cohort.
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Introduction: Oxidative stress disrupts telomere home-
ostasis triggering genome instability. The most common
oxidative DNA lesion at the telomeres is 8-oxoguanine
which is mainly removed by OGG1, initiating base excision
repair pathway. Given that telomere maintenance is crucial
for cancer progression, OGG1 inhibition could represent an
attractive and unexplored opportunity for compromising
telomere integrity in cancer cells.
Materials and Methods: We characterized OGG1 repair
dynamics at telomeres in the U20S cancer cell line and we
investigated the consequences at telomeres of either
CRISPR-Cas9 mediated OGG1 depletion or pharmacologi-
cal OGG1 inactivation with the recently developed OGG1
inhibitor TH5487.
Results: we found that OGG1 is recruited to the
telomeres in response to oxidative stress. Besides, Upon
induction of oxidative DNA damage, lack of OGG1 activity
impairs BER at telomeres causing accumulation of
oxidative DNA damage, telomere losses and consequently
inducing mitotic and proliferation defects.
Conclusions: Our findings demonstrate that OGG1 is
required to preserve telomere homeostasis under oxidative
stress conditions in cancer cells and, present OGG1
inhibitors as a tool to induce oxidative DNA damage at
telomeres, with potential implications in cancer and aging
research.
Grants: J.M.B. is supported by grant FPU15/01978 from
the Spanish Ministry of Education, Culture and Sport. A.O.
is supported by grant FIS PI19/00640 supported by FEDER
funds. JB’s laboratory is partially funded by FIS PI16/
00440 supported by FEDER funds, H2020 BRIDGES
project and the Spanish Network on Rare Diseases
(CIBERER).
J.M. Baquero: None. C. Benítez-Buelga: None. R.
Torres-Ruiz: None. S. Rodríguez-Perales: None. T.
Helleday: None. J. Benítez: None. A. Osorio: None.
P12.211.C
Identification of genetic events that cooperated with RAS
or PAX8-PPARG in the genesis of thyroid carcinoma
T. N. R. Carneiro1, L. Bim1, V. C. Buzzato2, V. Galdeno2, E.
A. Lee3, P. Galante2, J. Cerutti1
1Federal University of São Paulo, Department of Morphol-
ogy and Genetics, São Paulo, Brazil, 2Centro de Oncologia
Molecular, Hospital Sírio-Libanês, São Paulo, Brazil,
3Division of Genetics and Genomics, Boston Children’s
Hospital and Harvard Medical School, Boston, MA, United
States
Introduction: RAS point mutations and PAX8/PPARG
fusion are the most frequent genetic alterations in benign
and malignant thyroid tumours. The presence of these
genetic alterations across a large spectrum of thyroid lesions
suggests that they might be an early mutational event in a
subset of indolent thyroid lesions that are prone to develop
metastases and dedifferentiate. However, it is still not clear
whether additional genetic events are needed to progress
from a benign in situ to an invasive and more aggressive
tumor phenotype.
Material and Methods: To identify new point mutations,
fusions or alteration of gene expression that could cooperate
with RAS or PAX8/PPARG, we performed and analyzed
RNA-seq from 14 thyroid tumors samples harboring RAS
point mutation or PAX8/PPARG fusion. GRCh38 was used
as reference genome. We additionally analyzed RNA-seq
from 65 thyroid carcinomas positive for RAS or PAX8/
PPARG rearrangement available through The Cancer
Genome Atlas Program (TCGA).
Results: Forty five percent of RAS positive thyroid
carcinomas showed exclusive mutations in genes that
belong to the same pathway, which regulates important
cellular processes as growth and division and recently has
been associated with tumor progression. Additionally, the
expression levels of coding genes that belong to this
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pathway were also altered in both our own and TCGA
carcinoma samples evaluated in this study.
Conclusions: We here identified somatic mutations in
genes that belong to the same pathway in a large fraction of
RAS positive cancer samples suggesting that they may
cooperate with RAS to drive thyroid tumor progression.
T.N.R. Carneiro: None. L. Bim: None. V.C. Buzzato:
None. V. Galdeno: None. E.A. Lee: None. P. Galante:
None. J. Cerutti: None.
P12.212.A
Germline truncating variants in TINF2 cause cancer
through telomere length elongation
I. Schmutz1, A. Mensenkamp2, M. Haadsma2, L. Spruijt2, R.
de Voer2, T. de Lange1, M. Jongmans2,3,4
1Rockefeller University, New York, NY, United States,
2Radboud UMC, Nijmegen, Netherlands, 3UMC Utrecht,
Utrecht, Netherlands, 4Princess Máxima Center for Pedia-
tric oncology, Utrecht, Netherlands
Shelterin protects chromosome ends from the DNA damage
response and controls telomere length homeostasis. Shel-
terin is composed of TRF1, TRF2, TIN2, Rap1, TPP1 and
POT1. Within shelterin, TIN2 interacts with TRF1, TRF2,
and TPP1. TIN2 contributes to telomere protection and is
critical for limiting telomerase-mediated telomere elonga-
tion. We identified novel germline variants in exon 5 of
TINF2 (encoding TIN2) in four probands affected by mul-
tiple malignancies. Three probands shared c.604G>C,
which results in alternative splicing causing early truncation
of the protein. This variant was maternally inherited in two
probands. The second variant, c.557del (p.(Ser186fs), cau-
ses a premature stop codon. These six individuals in this
study developed 13 malignancies, including three papillary
thyroid cancers and three breast cancers. No LOH or second
hits in TINF2 were observed in three tumors tested. The
truncated TIN2 proteins encoded by c.604G>C and
c.557del do not interact with TRF1, a main factor in telo-
mere length control. Consistent with loss of TRF1 binding,
three patients had lymphocyte telomere lengths in the 99th
percentile. CRISPR/Cas9 edited RPE1 cells heterozygous
for the TINF2 variants showed that the truncated TIN2
proteins do not cause telomere damage or genome
instability but result in telomere elongation. The data
establish that the TINF2 variants predispose to cancer
through inappropriate telomere elongation and suggest that
telomere shortening is a potent tumor suppressor pathway in
multiple cancer types. We suggest that previously described
cancer-predisposing POT1 variants also act through indu-
cing telomere elongation rather than by generating genome
instability.
I. Schmutz: None. A. Mensenkamp: None. M.
Haadsma: None. L. Spruijt: None. R. de Voer: None.
T. de Lange: None. M. Jongmans: None.
P12.214.C
ERN GENTURIS guidelines for the Li-Fraumeni and
Heritable TP53-Related Cancer syndromes
T. Frebourg1, S. B. Lagercrantz2, C. Oliveira3, R.
Magenheim4, D. Evans5, the European Reference Network
GENTURIS
1Department of Genetics, Rouen University Hospital and
Inserm U1245, Normandie University, UNIROUEN, Nor-
mandy Centre for Genomic and Personalized Medicine,
Rouen, France, 2Hereditary Cancer Unit, Department of
Clinical Genetics, Karolinska University Hospital, Stock-
holm, Sweden, 3i3S Instituto de Investigação e Inovação em
Saúde & Institute of Molecular Pathology and Immunology
of the University of Porto, and Porto Comprehensive
Cancer Center, Porto, Portugal, 4Community Representa-
tive, Berlin, Germany, 5Manchester Centre for Genomic
Medicine, Division of Evolution and Genomic Sciences,
University of Manchester, MAHSC, St Mary’s Hospital,
Manchester University Hospitals NHS Foundation Trust,
Manchester, United Kingdom
Fifty years after the recognition of the Li-Fraumeni syn-
drome (LFS), our perception of cancers related to germline
alterations of TP53 has drastically changed: (i) germline
TP53 alterations are often identified among children with
cancers, in particular soft-tissue sarcomas, adrenocortical
carcinomas, central nervous system tumours or among adult
females with early breast cancers, without familial history.
This justifies the expansion of the LFS concept to a wider
cancer predisposition syndrome designated heritable TP53-
related cancer (hTP53rc) syndrome; (ii) the interpretation of
germline TP53 variants remains challenging and should
integrate epidemiological, phenotypical, bioinformatics
prediction and functional data; (iii) the penetrance of
germline disease-causing TP53 variants is variable,
depending both on the type of variant (dominant-negative
variants being associated with a higher cancer risk) and on
modifying factors; (iv) whole-body MRI (WBMRI) allows
early detection of tumours in variant carriers and (v) in
cancer patients with germline disease-causing TP53 var-
iants, radiotherapy and conventional genotoxic chemother-
apy contribute to the development of subsequent primary
tumours. It is critical to perform TP53 testing before the
initiation of treatment in order to avoid in carriers, if pos-
sible, radiotherapy and genotoxic chemotherapies. In chil-
dren, the recommendations are to perform clinical
examination and abdominal ultrasound every 6 months,
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annual WBMRI and brain MRI from the first year of life, if
the TP53 variant is known to be associated with childhood
cancers. In adults, the surveillance should include every
year clinical examination, WBMRI, breast MRI in females
from 20 until 65 years and brain MRI until 50 years.
T. Frebourg: None. S.B. Lagercrantz: None. C.
Oliveira: None. R. Magenheim: None. D. Evans: None.
P12.215.A
Higher TP53 somatic mutation prevalence from liquid
biopsy analysis in smoker non-small-cell lung cancer
patients
H. Erdem, T. Bahsi
Department of Medical Genetics, University of Health
Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology
Training and Research Hospital, Ankara, Turkey
Introduction: Non-small-cell lung cancer constitutes 80%
part of all lung cancers. TP53 is a tumor suppressor gene in
the DNA damage pathway, and also is the most frequently
mutated gene in various malignancies. According to the
AACR Project GENIE Consortium, TP53 mutations present
in 41.88% of all non-small-cell lung carcinoma patients.
Due to the many carcinogens in tobacco smoke, smoking-
related cancers have a high genome-wide burden of muta-
tions. To support this theory, TP53 mutation prevalence of
smoker and non-smoker non-small-cell lung cancer patients
were compared with liquid biopsy.
Materials and Methods: Totally, circulating tumor DNA
of 82 smoker non-small-cell lung cancer patients and 51
never-smoker non-small-cell lung cancer patients were
performed using commercially available liquid biopsy
platforms. TP53 gene hotspot regions were analyzed.
Variants were evaluated according to AMP/ASCO/CAP
classification guidelines. Only Tier I and Tier II variants
were reported.
Results: TP53 mutations were described in 41/133
(30.8%) of the samples. In never-smokers 12/51 (23.5%)
patients and in smokers, 30/82 (36.5%) patients carry a
TP53 mutation. Moreover, the prevalence of truncating
mutations was higher in smokers 8/30 (26.6%) compared to
non-smokers 2/16 (16.6%).
Conclusions: Tobacco exposure causes a heavy burden
of genomic alterations in TP53 at somatic level in non-
small-cell lung cancer. The higher incidence of truncating
mutations in smokers shows that the damaging effect of the
resulting mutations is higher in smokers than never-
smokers. In future research, clinical outcomes and detection
of drug sensitivity/resistance status of this study group in
different histological subtypes will contribute to persona-
lized therapy studies.
H. Erdem: None. T. Bahsi: None.
P12.216.B
PTEN transcript analysis in 10 unrelated patients with
suspected but unexplained Cowden syndrome
A. K. Sommer1, F. Kratz1, J. Kionke1, I. Spier1,2, S. Aretz1,2
1Institute of Human Genetics, University Hospital Bonn,
Bonn, Germany, 2Center for Hereditary Tumor Syndromes,
University Hospital Bonn, Bonn, Germany
Introduction: Cowden syndrome (CS) is the adult onset
subtype of the PTEN hamartoma tumor syndrome and a
cancer predisposition syndrome, primarily linked to germ-
line PTEN mutations. However, in 30-40% of patients with
suspected CS, no causative PTEN mutation can be identi-
fied in routine diagnostics. In particular, pathogenic variants
located outside the coding regions remain undetected.
Material and Methods: To uncover deep intronic PTEN
mutations, ten clinically well characterized, unrelated
patients with suspected CS and missing PTEN mutation
were tested for aberrant splicing by cDNA analysis. In
addition, three patients with suspected splice variants
(PTEN:c.209+5G>A, PTEN:c.634+5G>A, PTEN:c.210-
12C>G) found in routine diagnostic were analyzed. The
coding exons 1-9 of PTEN were amplified in three
overlapping fragments using specific primers. Amplification
products were separated by gel-electrophoresis and
sequenced in both directions. Deviant patterns were excised,
eluted, reamplified, and sequenced.
Results: In the three patients with an intronic variant, the
pathogenicity could be confirmed: In two patients, an exon
deletion was found, and in one patient an insertion of 11bp
could be revealed. All unexplained patients did not show
aberrant patterns on the gel-image. Currently, sequencing of
the PCR products is being performed to uncover cryptic
splice variants resulting in short aberrations.
Conclusions: Rare, pathogenic deep intronic germline
mutations have already been described in several hereditary
tumor syndromes. However, systematic screening of a small
cohort of unexplained CS patients did not detect aberrant
splicing so far. In contrast, suspected splice variants in three
patients could be confirmed by the transcript analysis.
A.K. Sommer: None. F. Kratz: None. J. Kionke: None.
I. Spier: None. S. Aretz: None.
P12.217.C
Translocation t(14;16)(q32;q23) in patients with multi-
ple myeloma (MM)
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L. Pavlistova1, A. Berkova1, K. Svobodova1, S. Izakova1, I.
Spicka2, J. Straub2, K. Michalova1, Z. Zemanova1
1Center of Oncocytogenomics, General University Hospital
and First Faculty of Medicine, Charles University in
Prague, Prague 2, Czech Republic, 21st Medical
Department-Department of Hematology, General Univer-
sity Hospital and First Faculty of Medicine, Charles
University in Prague, Prague 2, Czech Republic
Introduction: Translocation t(14;16)(q32;q23) is rare
chromosomal aberration (CA) detected in 2-4% patients
with multiple myeloma (MM). Currently, it is included in
prognostic scoring system as high-risk aberration. However,
the prognostic value of t(14;16) remains controversial as it
was not confirmed in several MM series. Thus, further
studies are needed to verify its true clinical relevance. The
aim of this study was to assess the frequency and prognostic
impact of t(14;16) in our cohort of patients.
Material and Methods: During 2004-2019 we examined
bone marrow samples of 1100 MM patients using FISH on
immunofluorescently labeled plasma cells (cIg FISH). t
(14;16) was verified with dual fusion probe (Abbott).
Kaplan-Maier analysis was performed to evaluate the overal
(OS) and event-free (EFS) survival of IGH/MAF
positive cases.
Results: t(14;16) was detected in 26/1100 patients
(2,4%). The atypical FISH pattern of fusion signals and
numerical changes of 14q32 and 16q23 regions were
detected in 8 and 10 cases, respectively. In 17 patients
(65%), two or more additional CA were observed. t(14;16)
with another high-risk CA - deletion of TP53 - was found in
four patients, three of them died within the short period
from the diagnosis (9-15 months). We proved the
significantly shorter OS in t(14;16) positive cases
(p = 0,1), for EFS the difference was not significant.
Conclusions: In this study, the frequency of t(14;16) was
consistent with published data and our results support its
negative prognostic impact. Combination with other CA
and variability of FISH pattern will be discussed. Supported
by RVO-64165 and Progres Q28.
L. Pavlistova: None. A. Berkova: None. K. Svobodova:
None. S. Izakova: None. I. Spicka: None. J. Straub:
None. K. Michalova: None. Z. Zemanova: None.
P12.218.A
Multigene panel testing of triple negative breast cancer
patients from Russia
I. Abramov1, A. Ikonnikova1, Y. Korneva2, O. Shisterova3,
M. Emelyanova1, T. Nasedkina1
1Engelhardt Institute of Molecular Biology RAS, Moscow,
Russian Federation, 2Smolensk State Medical University,
Smolensk, Russian Federation, 3Smolensk regional clinical
oncologic dispensary, Smolensk, Russian Federation
Introduction: Triple-negative breast cancer is characterized
by lack of expression of estrogen, progesterone, and HER2
receptors. It is highly aggressive disease, more common
occurring in younger women and is associated with her-
editary forms of breast cancer caused by pathogenic muta-
tions, mostly in the BRCA1/2 genes.
Methods: In the present study, we used next-generation
sequencing (NGS) to analyze mutations in FFPE (formalin
fixed embedded) tissues samples of 12 patients with triple-
negative breast cancer (mean agewas 50,8 years). Target
enrichment with coding sequences of APC, ATM, BRCA1,
BRCA2, CDH1, CDH3, CDK4, CHEK2, MET, MLH1,
MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN,
RET, STK11, TP53, VHL genes was done using Nimble-
gen (Roche) custom panel of oligonucleotide probes. The
sequencing was performed on MiSeq Illumina platform
with coverage up to1000x.
Results: Both germline and somatic mutations in tumor
cells have been identified comparing sequencing results
from paired tumor and normal tissue samples. Two
pathogenic germline mutations were found in the BRCA1
gene (185delAG,3347delAG), mutations in the BRCA2
(886delGT) and TP53(c.733G>A) genes. Pathogenic
somatic mutations were found in the MUTYH (c.734G >
A), PTEN (c.640C>T) and TP53 (c.637C > T) genes. The
genotyping results were compared with clinical data.
Conclusion: Triple-negative breast cancer is a hetero-
geneous group of diseases. Knowledge of genetic profiles
and identification of predictive biomarkersis important for
further improvement of therapy results. The work was
supported by the Russian Ministry of Science and High
Education (grant# 05.604.21.0234, unique number
RFMEFI60419X0234).
I. Abramov: None. A. Ikonnikova: None. Y. Korneva:
None. O. Shisterova: None. M. Emelyanova: None. T.
Nasedkina: None.
P12.219.B
Rapid isolation of high quality ultra-high molecular
weight (UHMW) genomic DNA (gDNA) from blood,
bone marrow aspirates (BMAs)and fresh frozen tumors
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H. B. Sadowski, Y. Zhang, K. Pham, H. Way, M.
Oldakowski
Bionano Genomics, San Diego, CA, United States
Optical mapping with Bionano Genome imaging is a pow-
erful tool for comprehensive detection of structural variations
(SVs) in cancer genomes. A crucial step in this workflow is
isolating intact UHMW gDNA. For routine study of leu-
kemic samples, we developed Bionano Prep SP kits for rapid,
solution phase, isolation of UHMW gDNA from blood and
BMAs. We also developed a rare variant bioinformatic
pipeline that detects SVs at 5 % allele fraction. Together,
these can potentially replace a suite of “classical” cytogenetic
tests for leukemia analysis (karyotyping, FISH, CNV
microarrays) with a single Bionano Genome Imaging ana-
lysis. For solid tumors, we developed a novel protocol to
isolate UHMW gDNA from small amounts (≤ 10 mg) of
fresh frozen tissues. Homogenized tissues are processed with
the Bionano Prep SP kit, where lysis is coupled with pur-
ification steps to bind, wash and elute UHMW gDNA. With
this protocol, a batch of 8 samples can be processed in <6h.
Eluted UHMW gDNA (3-19 μg DNA/10 mg) is compatible
with Direct Label and Stain protocol. When run on a Saphyr
Chip, the purified gDNA gives high throughputs (>1.3 Tbp/
sample in 24h) with excellent single molecule metrics of
DNA size (N50>150 kbp of 260-300 kbp) and mapping rate
(80-92%), sufficient for use in SV analysis of cancer gen-
omes from solid tumors. This protocol has been tested on
fresh frozen human tumors including liver, lung, kidney,
bladder, brain, colon, thyroid, prostate, breast, and ovary. A
comprehensive analysis of SVs in these tumors will be
presented.
H.B. Sadowski: A. Employment (full or part-time);
Significant; BioNano Genomics. Y. Zhang: A. Employ-
ment (full or part-time); Significant; BioNano Genomics. K.
Pham: A. Employment (full or part-time); Significant;
BioNano Genomics. H. Way: A. Employment (full or part-
time); Significant; BioNano Genomics. M. Oldakowski: A.
Employment (full or part-time); Significant; BioNano
Genomics.
P12.221.A
Germline loss-of-function variants in MBD4 are rare in
Finnish patients with uveal melanoma
P. E. Repo1,2, J. E. Jäntti1, R. Järvinen1,2, M. Täll2, V.
Raivio2, T. T. Kivelä2, J. A. Turunen2,1
1Folkhälsan Research Center, Helsinki, Finland, 2Depart-
ment of Ophthalmology, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland
Introduction: Uveal melanoma (UM) is the most common
primary intraocular cancer in adults. Metastases develop in
approximately 50% of patients with poor prognosis regardless
of treatment. UM tumors generally acquire unusually few
somatic mutations. Eight genes are recognized as drivers of its
tumorigenesis, typically consisting of one mutually exclusive
mutation in GNAQ, GNA11, PLCB4 or CYSLTR2 followed
by one mutually exclusive mutation in EIF1AX, SF3B1,
SRSF2 or BAP1. Germline variants that predispose to UM
have been described in BAP1. Recently, germline loss-of-
function (LOF) variants in the methyl-CpG binding domain-4
(MBD4) gene were found in four patients with UM. Loss of
functional MBD4 induces a hypermutated profile, making
tumors susceptible to immune checkpoint inhibitors. We
conducted a population based screening of MBD4 in Finnish
patients with UM to identify pathogenic variants.
Materials and Methods: Sanger sequencing of MBD4 in
440 Finnish patients with UM.
Results: We identified eight exonic missense variants in 51
(12%) patients. Only one is likely to alter MBD4 function.
We found no LOF variants (95% confidence interval [CI],
0.0-0.8%). Frequency of LOF variants in the general Finnish
population is 0.052% in gnomAD, suggesting one might
occur by chance in one in 2000 patients with UM.
Conclusions: Germline variants altering MBD4 function
do not seem to predispose to UM in Finland. Somatic
biallelic loss of MBD4 might modify the mutational burden
in UM and change its response to immune checkpoint
inhibitors.
Funding: The Helsinki University Hospital Research
Fund; the Cancer Foundation; the Sigrid Jusélius Founda-
tion; the Eye Foundation.
P.E. Repo: None. J.E. Jäntti: None. R. Järvinen: None.
M. Täll: None. V. Raivio: None. T.T. Kivelä: D. Speakers
Bureau/Honoraria (speakers bureau, symposia, and expert
witness); Modest; Santen Finland. J.A. Turunen: D.
Speakers Bureau/Honoraria (speakers bureau, symposia,
and expert witness); Modest; Thea, Finland, Blueprint
Genetics, Finland. F. Consultant/Advisory Board; Modest;
Novartis, Finland.
P12.223.C
Ocular phenotype of retinal haemangioblastomas corre-
lated to von Hippel-Lindau tumor suppressor genotype:
mutations and functional domains
A. Hajjaj1, K. A. van Overdam2, R. A. Oldenburg1, E.
Brosens1, A. M. W. van den Ouweland1, A. de Klein1, E.
Kilic1
1Erasmus MC, Rotterdam, Netherlands, 2The Rotterdam
Eye Hospital, Rotterdam, Netherlands
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Introduction: von Hippel-Lindau (VHL) disease is a
familial disorder characterized by a predisposition to
develop retinal haemangioblastomas (RH) among other
tumours. Phenotypic heterogeneity of this ocular tumours
has led to a difficulty in the management of RH. We aimed
to correlate the different ocular phenotypes in VHL patients
with structural VHL variants in different functional
domains.
Materials and Methods: Retrospective analysis of a
longitudinal cohort of 33 VHL germline mutation carriers
and RH. Clinical and genetic data was obtained to analyse
the correlation of genotype with phenotype.
Results: VHL patients were categorised in genotypic
categories, based on the presumed effect on the VHL
protein. Interface A is important for VCB-complex forma-
tion, interface B forms the HIF-α binding site, and interface
C plays a role in the Cullin-2 interaction. Twelve patients
had a mutation that corresponds with interface C, 11
patients in interface A, and 9 patients in interface B. One
patient had a whole gene deletion. An aggressive ocular
phenotype was most observed in patients with mutations in
interface C (75%), followed by interface B (44.4%) and
interface A (18.2%). The highest number of amino acid
substitutions were present in the interface C domain, where
50% of the variants were missense mutations.
Conclusions: Variants in the domain that corresponds
with the interaction with Cullin-2 are more often missense
mutations and had a higher prevalence of an aggressive
ocular phenotype of RH in this study. The scaffold protein
Cullin-2 seems to play a more important role in the
progression of RH.
A. Hajjaj: None. K.A. van Overdam: None. R.A.
Oldenburg: None. E. Brosens: None. A.M.W. van den
Ouweland: None. A. de Klein: None. E. Kilic: None.
P12.225.B
Whole genome sequencing reveals high variability of
genetic risk variants associated with hereditary cancer
N. Danial-Farran, M. Khayat, C. Gafni, L. Peretz Peled, E.
Mamlook, E. Chervinsky, S. A. Shalev
Genetics, Ha’Emek Medical Center, Afula, Israel
While germ-line mutations in BRCA1 and BRCA2 genes
account for the major risk factors for breast cancer in the
Israeli populations due to high frequencies of founder var-
iants in the Ashkenazi families, many Ashkenazi and non-
Ashkenazi families from Northern Israel with strong family
history remain undiagnosed. We used Whole genome
sequencing (WGS) data generated from 15 blood samples to
analyze 15 such families. The genetic variants were detected
and analyzed using Variantyx Genomic Intelligence
platform, version 2.8.0.0. We identified the first CNV in
HMMR gene (chr5:163,475,593-163,476,336) that includes
a partial deletion of exon and intron 11. In addition, we
identified an SNV located in mir-153 seed side of the 3’
UTR region of AKT1 gene, c.*437c>T, which was pre-
viously found to associate with lung cancer. In other four
families, we detected novel nonsynonymous variants with
high potential of pathogenicity due to their low frequencies
in the general population and conserved residue in the
protein levels: c.1205 A>G in CHEK2 gene, c.1283C>G in
STK11 gene, c.3683A>G in BRCA1 gene and c.128G>A in
PHB gene. In other 9 families, no suspected variants were
found. Further studies are needed to confirm the patho-
genicity of the detected variants, but our study demonstrates
the vast variability of genetic causes for hereditary cancer in
our population, the complexity of the mechanisms in
familial cancer, and the challenge of detecting those muta-
tions for better clinical approach and genetic counseling
purposes. Li Ka Shing Foundation Grant for Joint
Research Program between Shantou University and
2023476Technion-Israel Institute of Technology
N. Danial-Farran: None. M. Khayat: None. C. Gafni:
None. L. Peretz Peled: None. E. Mamlook: None. E.
Chervinsky: None. S. A. Shalev: None.
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"Mapping of Wnt-Frizzled interactions through mRNA
coexpression patterns in breast and colorectal cancer"
A. Zougros1, M. Michelli1, I. Chatziandreou1, N.
Michalopoulos2, A. C. Lazaris1, A. A. Saetta1
11st Department of Pathology, School of Medicine,
National and Kapodistrian University of Athens, Athens,
Greece, 2Department of Surgery, Attikon Hospital, School
of Medicine, National and Kapodistrian University of
Athens, Athens, Greece
Introduction: Wnt pathway regulates important cell func-
tions and is frequently deregulated in breast and colorectal
cancer. Wnt signaling is mediated through the interaction of
19 Wnt ligands and 10 Frizzled receptors; however the
specificity of their interaction and their clinical significance
remains largely unknown.
Materials and Methods: WNT2, WNT3, WNT5A, FZD4,
FZD6 and FZD7 mRNA expression levels in 102 colorectal
and 82 breast tumours were determined by RT-PCR and the
ΔΔCt method. Possible correlations of Wnt pathway
components’ expression levels with clinicopathological
data were investigated.
Results: In breast carcinomas, decreased relative mRNA
expression levels of WNT2, WNT5A, FZD4, FZD6 and
FZD7 were found in 54%, 57%, 80%, 48% and 82% of
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carcinomas, respectively. Furthermore, increased relative
mRNA expression levels were observed in WNT3 in 54% of
the cases. Expression levels of WNT3 and FZD6 were
significantly correlated with tumour grade (p = 0,035) and
pT category of tumours (p = 0,011), respectively.
Regarding colorectal carcinomas, increased relative mRNA
expression levels of FZD7, WNT5A, FZD4 and FZD6
ranged from 25-40% of the samples and WNT2, WNT3
levels were determined at 59% and 60% respectively. No
clinicopathological correlation was found in colorectal
cancer. Positive linear correlations were established among
several of the investigated genes in both types of cancer.
Conclusions: Deregulated expression of the investigated
genes was found in both breast and colorectal cancer. The
linear correlations determined among Wnts and Frizzleds
are indicative of their functional interaction and could point
out the complexity that characterizes the Wnt-Frizzled
interactions in breast and colon carcinogenesis.
A. Zougros: None. M. Michelli: None. I. Chatzian-
dreou: None. N. Michalopoulos: None. A.C. Lazaris:
None. A.A. Saetta: None.
P13 Genome Variation and Architecture
P13.02.A
22q11.2 copy number variations in patients with oro-
facial cleft defects with or without congenital heart
disease
D. M. Cardenas-Nieto1, J. Martinez-Lozano2, I. Briceño2,
M. Forero-Castro1
1Escuela de Ciencias Biológicas, Grupo de investigación en
Ciencias Biomédicas (GICBUPTC), Universidad Pedagó-
gica y Tecnológica de Colombia, Tunja, Colombia, Tunja,
Colombia, 2Facultad de Medicina, Grupo de investigación
en Genética Humana, Universidad de La Sabana, Chía,
Colombia, Bogota, Colombia
Introduction: Cleft lip and/or palate (CL/P) and congenital
heart disease (CHD) are the most common malformations
observed in newborns. 15-20% of patients with CL/P and
CHD can carry some type of chromosome abnormality.
Between 5 to 8% of CL/P cases and 75 to 80% of CHD
cases present the cryptic chromosomal microdeletion
22q11.2. Herein, we identified the genetic abnormalities in
patients with CL/P and CHD using cytogenetic and MLPA
analysis.
Materials and Methods: 14 patients with CL/P and
CHD from Operation Smile Foundation (Bogotá-Colombia)
were included in this study. G-banded chromosome analysis
and 22q11 region was studied using MLPA (Kit P250-B2)
and/or FISH (TUPLE1-HIRA LSR ARSA) techniques.
Clinical parameters were evaluated in all patients.
Results: Patients’ age ranged 2-20 years (median 7
years). 28.6% of the patients showed CP and 71.4% CLP,
the main CHD observed were: tricuspid valve insufficiency
(42.9%), atrial septum defects (42.9%) and ventricular
septum defects (35.7%). Other phenotypic traits included
abnormalities in male genital organs (66.6%), alterations in
bone tissue (57.2%), abnormalities in the teeth (50%),
delayed language development (42.9%), and mental
disorders (100%). All patients had normal karyotype. One
male patient (20 years) carried the 22q11.2 microdeletion,
and another female patient (19 years) carried the micro-
duplication of TOP3B gene located on 22q11.2 region. Both
cases had CL/P and CHD including persistent arterial
ductus, and congenital mitral valve abnormalities and
bivalve aorta, respectively.
Conclusions: Screening of 22q11.2 alterations in patients
with CL/P and CHD would be very helpful in their early
diagnosis, treatment, and genetic counseling.
D.M. Cardenas-Nieto: None. J. Martinez-Lozano:
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Investigation of indel variants in candidate-gene panel
for 22q11.2 deletion syndrome
N. Nunes1, A. G. Dantas1, M. Zamariolli1, D. C. Q.
Soares2, L. C. dos Santos1, V. A. Meloni1, S. I. Belangero1,3,
V. L. Gil-Da-Silva-Lopes4, C. A. Kim2, M. I. Melaragno1
1Universidade Federal de São Paulo - UNIFESP, São
Paulo, Brazil, 2Instituto da Criança, Universidade de São
Paulo - USP, São Paulo, Brazil, 3Laboratory of Integrative
Neuroscience, UNIFESP, São Paulo, Brazil, 4Faculdade de
Ciências Médicas, Universidade Estadual de Campinas,
Campinas, Brazil
Introduction: The 22q11.2 deletion syndrome
(22q11.2DS) results from hemizygous deletions of chro-
mosome 22 segments and is the most frequent microdele-
tion syndrome observed in humans. The 22q11.2 region
involved in the deletion is quite complex and contains
highly repetitive low copy repeats (LCR), DNA sequences
that make the region susceptible to recurrent genomic
rearrangements. Our studies, as well as others in the lit-
erature, indicate that 22q11.2 deletion syndrome results in a
wide variety of heterogeneous clinical signs, such as con-
genital cardiac malformations, characteristic facial features,
immune deficiency, and psychiatric disorders. One of the
hypotheses lies in the fact that allelic variation, such as
indels, within the non-deleted 22q11.2 allele or in other
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genes outside the 22q11.2 region could influence the phe-
notype outcome of the 22q11.2DS.
Materials and Methods: We performed Ion Ampliseq in
peripheral blood from 60 22q11.2DS patients to sequence
seven candidate genes (CRKL, MAPK1, HIRA, TANGO2,
PI4KA, ZFPM2, and JAM3), located in and outside the
22q11.2 hemizygous region. To predict indels that may
have a role as modifiers, we used genomic variants filtering
by deep learning models in NGS (GARFIELD-NGS),
which rely on machine learning models to efficiently
distinguish clinically pathogenic from neutral indels.
Results: We identified indel variants that may have a role
as modifiers in the 22q11.2DS.
Conclusions: These results show how the application of
new methodologies for predicting variants can guide to new
findings with great exploration potential. Financial support:
CAPES, FAPESP, Brazil.
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LCR22q11.2 hypervariability is human specific
L. Vervoort1, W. Demaerel1, Z. Pereboom2, M. Rocchi3, J.
R. Vermeesch1
1Laboratory for Cytogenetics and Genome Research, KU
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Conservation, Royal Zoological Society of Antwerp,
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Introduction: Low copy repeats (LCRs) are amongst the
most complex regions in the human genome. Scrutinizing
these structures unraveled their importance during evolu-
tion. LCRs play an important role in the disease mechanism
of genomic disorders as well. Non-allelic homologous
recombination between chromosome 22 LCRs (LCR22s)
cause the 22q11.2 deletion syndrome. LCR22-A hyper-
variability was uncovered in human. However, it remains
unknown whether such variability is human specific or is
also a feature of other primates.
Materials and Methods: The LCR22 variability in the
Great Apes was charted using an LCR22-specific fiber-
FISH. The structures of five chimpanzees, one bonobo, two
gorillas, and six orangutans were de novo assembled to
assess the level of inter- and intraspecies variation. In
addition, we used Bionano optical mapping to chart the
overall 22q11.2 structure of the orangutans.
Results: The chimpanzee and bonobo harbored the
smallest LCR22-A allele observed in humans, containing
core duplicons, without intra-species variation. The gorilla
haplotype had small expansions compared to the chimpan-
zee. In contrast, the overall 22q11.2 region is different in the
orangutan, including rearrangements in the sequence
between the LCR22s, intra-individual structural variation,
and LCR22-A haplotypes not resembling the human ones.
Conclusions: For the first time, the LCR22s subunits
were evolutionary charted and uncovered lineage-specific
differences. The LCR22-A hypervariability is human
specific, since no structural variation was observed in
chimpanzee or bonobo. This suggests an important role of
the locus in human adaptation and evolution.
Funding: FWO GOE1117N, Jerome Lejeune
Project 1665
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Extensive (epi)genetic profiling of pre- and post-natal
tissues from female monozygotic twins discordant for
Beckwith-Wiedemann syndrome
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Background: Beckwith-Wiedemann syndrome (BWS) is
an overgrowth disorder caused by defects at the 11p15.5
imprinted region. Many cases of female monozygotic (MZ)
twins discordant for BWS have been reported, but no
definitive conclusions have been drawn regarding the link
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between epigenetic defects, twinning process, and gender.
Here, we report a comprehensive characterization and
follow-up of female MZ twins discordant for BWS.
Methods: 11p15.5 methylation pattern and multilocus
methylation defects (MLID) profiling were performed by
pyrosequencing and MassARRAY in pre- and post-natal
tissues. Whole-exome sequencing (WES) was carried out to
identify MLID causative mutations. X-chromosome inacti-
vation (XCI) status was defined by HUMARA test.
Results: Both twins share ICR2 LOM and MLID in
blood and the epigenetic defect in the healthy twin remained
stable over time. ICR2 LOM appeared non-homogenously
distributed in the placental samples. Twins shared the same
severe XCI skewing pattern. No MLID causative mutations
were identified by WES.
Conclusion: This is the first reported case in which
methylation analyses was extended to extraembryonic
tissues, and results suggest that caution is required when
attempting prenatal diagnosis in similar cases. Although the
causative mechanism of LOM remains unsolved, the XCI
pattern, along with mosaic LOM, suggests that both
twinning and LOM/MLID occurred after XCI commitment.
This study was supported by the Italian Ministry of Health
(Grant RF-2013-02359454) and Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico (Grant 5X1000-519
02 and Ricerca Corrente-519 03 to MM).
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New loci associated with carotenoid blood concentra-
tions in the Lithuanian population cohort
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Introduction: Variation in carotenoid bioavailability at an
individual and population levels might depend on host-
related factors where genetic variation has a part. It man-
ifests through the proteins involved in carotenoid intestinal
absorption and metabolism, blood lipoprotein transport or
tissue uptake. This study aims to identify novel SNPs which
could be associated with carotenoid serum concentrations.
Materials and Methods: 265 self-reported healthy
individuals of Lithuanian ethnicity were genotyped (Illu-
mina HumanOmniExpress-12v1.0 or v1.1 and Infinium
OmniExpress-24v1.2 arrays) and blood serum concentra-
tions of β- and α-carotene, β-cryptoxanthin, lycopene, lutein
and zeaxanthin were measured (Shimadzu Prominence
HPLC system). According to the carotenoid concentrations
individuals were subdivided in to the quartiles. Q1 and Q4
were used for the following association analysis. The set of
2868 SNPs in 150 potential candidate genes (assumed for
direct or indirect role in the carotenoid bioavailability) was
analysed using PLINK v1.90b software (α=0.05/n).
Results: SNPs rs2279238 (p = 2.129×10−5) and
rs11039155 (p = 2.984×10−5) in NR1H3 and rs550619
(p = 4.844×10−5) in APOB genes were associated with
higher zeaxanthin concentration. SNP rs756473 (p =
7.422×10−5) in RDH12 gene was associated with higher
lycopene concentration. Twenty-one SNPs in locus
10q23.33 including CYP2C9, CYP2C18 and CYP2C19
genes were significantly associated with higher β-carotene
concentration.
Conclusions: Four novel genomic loci were found to be
associated with carotenoid serum levels. Zeaxanthin,
lycopene and β-carotene serum concentrations might
depend on genetic variation in NR1H3, APOB, RDH12
and CYP2C9 genes.
This research is part of the LITGEN project (VP1-3.1-
ŠMM-07-K-01-013) and was funded by the European
Social Fund under the Global Grant measure.
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Transriptome analysis reveals distinct responses to
structural variations at theCDH1gene
R. Barbosa-Matos1, M. Ferreira1, A. Ferro1, B. Mesquita1,
H. Pinheiro1, S. Valente1, P. Oliveira1, C. Oliveira1,2
1Instituto de Investigação e Inovação em Saúde, Porto,
Portugal, 2Department of Pathology, Faculty of Medicine
of the University of Porto, Porto, Portugal
Introduction: CDH1 encodes E-Cadherin which is critical
for epithelial tissue architecture and cell-cell adhesion.
CDH1 impairment is associated with metastatic spread in
most epithelial cancers (somatic), early-onset of gastric and
breast cancer and cleft-lip/palate (germline), however the
germline and somatic mechanisms described so far can’t
justify all CDH1-associated phenotypes. We explored
expression profile changes induced by structural variations
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across the CDH1 gene body to infer the role of coding and
non-coding sequences.
Material and Methods: We CRISPR/Cas9 deleted an
out-of-frame exon (Exon_deletion), an intronic cis-regula-
tory element (iCRE) and an intronic portion not assigned to
regulatory function (Partial_intron). Obtained clones were
characterized by qRT-PCR, western-blotting and immuno-
cytochemistry and further studied through RNA-Seq
followed by Differential Expression (DE) analysis using
the DESeq2 package.
Conclusions: Compared to parental cells, Exon_deletion
triggers CDH1 loss, with 19-downregulated and 34-
upregulated genes, being the Top-5 pathways associated
with inflammatory-responses; iCRE deletion also triggers
CDH1 loss, having 1106-downregulated and 1238-
upregulated genes and its Top-5 pathways are associated
with shifting from cadherin- to protocadherin-mediated
adhesion, cell motility and migration; Partial_intron dele-
tion didn’t impact CDH1 expression and showed 153-
downregulated and 220-upregulated genes, the Top-5
pathways are associated with vasoconstriction and blood-
vessel size. Both clones harbouring CDH1 LoF share 35 DE
genes, and only 10 genes are DE in all clones. Our CRISPR/
Cas9 assay reveals unanticipated transcriptomic conse-
quences of CDH1-locus associated structural variation and
demonstrates that different portions of the locus play
different regulatory functions.
Funding: Solve-RD project received funding from
European Union’s Horizon2020 research and innovation
programme, grant agreement Nº:779257;2)FEDER/COM-
PETE,“POCI-01-0145-FEDER-030164”.
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New pathogenic structural variants responsible for
Charcot-Marie-Tooth disease
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Introduction: Charcot-Marie-Tooth (CMT) is the most
common hereditary neuropathy characterized by damages
of both motor and sensory peripheral nerves. CMT trans-
mission modes can be various (dominant, recessive, auto-
somal or X-linked) and there are more than 90 genes
involved. PMP22 duplication was the first described
mutation in this disease, explaining around 15% of CMT
patients. However, to date, the majority of the reported
mutations in CMT patients are single nucleotide variants
detected by targeted Next Generation Sequencing (NGS)
and Structural Variants (SVs) have rarely been described.
The aim of our study was to identify new SVs involved in
CMT disease.
Materials and Methods: DNA from 695 CMT patients
were analysed by NGS using an amplicon targeted
sequencing panel and we performed a specific bioinformatic
analysis of NGS data by Cov’Cop and CovCopCan
softwares looking for new pathogenic SVs involved
in CMT.
Results: Thank to this approach, we found new SVs in
107 CMT patients, highlighting the importance of SVs
analysis during CMT patients’ examination. 28 were small
deletions (3-6 amplicons), 10 were large deletions, 49 were
small duplications and 20 were large duplications. We will
focus here on two of these large deletions, we proved then
to be responsible for our patients’ disease.
Conclusions: These SVs would not have been detected
using the typical NGS analyses. We believe our strategy
using Cov’Cop and CovCopCan could increase the
diagnosis rate of patients suffering from neuropathies and
could be used by molecular biologists and geneticists to
improve diagnosis of all inherited diseases.
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Chromosome conformation capture (4C-seq and UMI-
4C) in human retina combined with whole genome
sequencing for the detection and functional interpreta-
tion of noncoding genetic defects in North Carolina
Macular Dystrophy, a regulatory disease
S. Van de Sompele1, E. D’haene1, T. Van der Snickt1, P.
Liskova2, S. Vergult1, J. van den Ende3, A. A. Bergen4, I.
Balikova5, J. De Zaeytijd6, F. S. Shaya7, C. Rivolta8, K. W.
Small7, E. De Baere1
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Introduction: Integrated -omics increasingly reveal non-
coding mutations in Mendelian disorders, mostly deep-
intronic splicing mutations, while noncoding mutations in
cis-regulatory elements (CREs) are more scarce. An
example of these are regulatory changes near PRDM13 or
IRX1 in autosomal dominant North Carolina Macular
Dystrophy (NCMD). NCMD has a recognizable phenotype
of the central retina, making it interesting for regulatory
variants. We aimed at dissecting the regulatory landscapes
of PRDM13 and IRX1 to find novel causes of NCMD and to
understand disease mechanisms.
Methods: Chromosome conformation capture (4C-seq
and UMI-4C) was applied on postmortem adult human
retinas to fine-map interactions of retinal CREs with the
PRDM13 and IRX1 promoters. Interaction profiles were
integrated with additional retinal epigenomic data in UCSC.
Twenty-five NCMD families underwent assessment of
known defects followed by whole genome sequencing.
Results: 4C-seq and UMI-4C profiles, together with other
retinal epigenomic profiles, revealed noncoding putative
CREs interacting with the PRDM13 and IRX1 promoters.
One of them overlaps with a novel noncoding sequence
variant located upstream of PRDM13, and is active in
developmental central retina. Interestingly, another novel
and known noncoding variant at the same position and a
novel duplication overlap with a noncoding putative CRE
upstream of PRDM13 containing a DNase
hypersensitive site.
Conclusions: Retinal interaction profiles of the PRDM13
and IRX1 regions advance the interpretation of noncoding
variants and provide insight into the cis-regulatory mechan-
isms underlying NCMD. The genetic architecture of NCMD
was expanded with novel noncoding variants with a likely
effect on PRDM13 regulation.
Funding: FWO/1145719N; FWO/1802220N; EJPRD19-
234 Solve-RET.
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Identification of Structural Variants on Whole Genome
Sequencing data for clinical purposes
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Gimelli, E. Stathaki, A. Vannier, L. Lemmens, V. Kremer, S.
Fokstuen, A. Giacobino, T. Ait Mouhoub, M. Carminho
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While WGS is being largely used in scientific research, its
application in the diagnostic routine is still lagging behind.
In order to develop a pipeline for the identification of SVs
from short-reads WGS data that can be translated into
transferred to clinical purposes we tested 7 previously
published (publically available) algorithms for SV identifi-
cation and evaluated their Sensitivity and False-Discovery-
Rate. We observed variable level of sensitivity (36-87%)
depending on the tool and SV type and size. Read-depth
approaches worked better for large deletions (79-86%),
while combined paired/split-reads approaches gave better
identification of small deletions (81-94%). High sensitivity
was found for insertions (93%) and inversions (96-100%).
As described by others, we report a high number of False
Positives (FP) (102-103) as main issue. To reduce FP, we
decided to use one to two tools for each SV type and
selected the one with highest sensitivity. After filtering
based on quality parameters, SVs were annotated using
annotSV and candidate SVs were selected based on fre-
quency, involved genes and inheritance pattern. We applied
the approach to a first set of 8 patients for whom no genetic
cause was identified using aCGH and panel targeted whole
exome sequencing a few years ago. The first results include
identification of an homozygous 22.6 kb deletion encom-
passing 5’UTR and exon 1 of ERGIC1 in a patient with
arthrogryposis. Biallelic mutations of ERGIC1 were pre-
viously associated to arthrogryposis in a single family. Of
note, this gene was initially not included in our WES gene
panel for this pathology.
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Germline chromothripsis: Integration of Hi-C and long-
read sequencing reveals the structure of highly rear-
ranged chromosomes
R. Schöpflin1,2, U. Souto Melo1,2, D. Heller3, J.
Jungnitsch1,2, M. Klever1,2, M. Holtgrewe4,5, E. Comak3, V.
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Chromothripsis is characterized by the shattering of one or a
few chromosomal segments followed by a chaotic reas-
sembly of the chromosomal fragments. Commonly
observed in cancer, chromothripsis-like rearrangements also
occur as a rare event in the germline. We investigated 10
cases with congenital complex or even chromothripsis-like
rearrangements and surprisingly mild phenotypes, despite
massive large-scale rearrangements. To understand and
predict the pathogenic effects of rearrangements, a recon-
struction of the shattered chromosomes with precise map-
ping of the breakpoints is needed. However, due to the high
error rate in breakpoint detection by short-read whole-gen-
ome sequencing this remains challenging.
Here, we address these issues by combining Hi-C with
PacBio long-read sequencing for the reconstruction of
patient genomes. Hi-C was very efficient and sensitive in
detecting large scale rearrangements and provided a global
coarse-grained atlas of the fusion events and information on
their layout. In contrast, PacBio reads provided fine-grained
local information of breakpoints, due to long (10-50 kb)
reads and the reduced sensitivity to repetitive regions. Hi-C
was used to evaluate the breakpoint calls obtained from
PacBio sequencing thereby reducing the candidate list to 5-
50 rearrangements > 5 Mb per individual. In a next step, the
derivative chromosomes were reconstructed using both
technologies jointly. The potentially pathogenic effects of
these highly rearranged genomes were assessed by mapping
the breakpoints in the context of 3D chromatin structure and
topologically associated domains (TADs). Thus, we present
an efficient method for the reconstruction and evaluation of
shattered chromosomes in a cohort of individuals with
chromothripsis-like rearrangements.
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Radiation-induced alterations in the genome and exome
of human gingiva fibroblasts
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Jensen2, L. Kaderali1, M. Port3, H. Scherthan3, A. W. Kuss2
1Institute of Bioinformatics, University Medicine Greifs-
wald, Greifswald, Germany, 2Department of Functional
Genomics, Interfaculty Institute for Genetics and Func-
tional Genomics, University Medicine Greifswald, Greifs-
wald, Germany, 3Bundeswehr Institute for Radiobiology
affil. to the University of Ulm, München, Germany
Little is known about the mutational impact of ionizing
radiation (IR) exposure on a genome-wide level. Recent
advancements in sequencing technology, however, have
opened up new avenues for studying and characterizing
global genomic IR-induced effects. Here, we present our
investigation of putative IR-induced mutation signatures in
whole genome and exome sequencing datasets of human
gingiva fibroblasts (HGFs), which were exposed to
increasing doses of X-radiation in combination with dif-
ferent post-exposure repair intervals. For our analyses we
developed a bioinformatics workflow incorporating three
stringent filtering steps for the removal of non-IR induced
variants, to eliminate sequencing errors and to remove
variants with low sequencing coverage. We studied the
accumulation of single nucleotide variants (SNVs) as well
as insertions and deletions (Indels) and statistically analyzed
the accumulation of variants with respect to different
genomic features such as cytogenetic bands and topologi-
cally associating domains (TAD). SNVs showed low tran-
sition/transversion (Ti/Tv) mutation ratios, while the
number of deletions exceeded the number of insertions.
SNVs in gene sets related to stress response and DNA-
repair, were situated mostly in intronic, up- or downstream
regions and sequence ontology analyses showed that they
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were mostly neutral without effects on protein function.
Taken together, our results provide evidence for a char-
acteristic genomic meta-signature of variants after IR
exposure. Furthermore, effects related to structural and/or
functional chromatin domains of particular chromosomal
areas were noted, which may reflect DNA repair pathway
choice.
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Current Human Reference Genome and Missing
Information
J. Kim1,2, J. Sung1,3, K. Han4, W. Lee4, S. Mun4, J. Lee1,3, K.
Bahk1, I. Yang5, Y. Bae5, C. Kim6, J. Kim7, J. Seo8
1Genome & Health Big Data Branch, Department of Health
Science, School of Public Health, Seoul National Uni-
versity, Seoul, Korea, Republic of, 2Interdisciplinary
program in Bioinformatics, Seoul National University,
Seoul, Korea, Republic of, 3Institute of Health & Environ-
ment, Seoul National University, Seoul, Korea, Republic of,
4Department of Nanobiomedical Science, BK21 PLUS NBM
Global Research Center for Regenerative Medicine,
Dankook University, Cheonan, Korea, Republic of, 5Korea
Research Institute of Standards and Science, Daejeon,
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Institute, Medical Research Center, Seoul National Uni-
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Center, Seoul National University Bundang Hospital,
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The human reference genome (GRCh38) serves as a tem-
plate for sequencing analysis, but it might lack some ethnic-
specific sequences particularly for Asians. To understand
the extent and characteristics of missing information, we
juxtaposed GRCh38 with high-contiguity genome assembly
(AK1) of a Korean, to show that ~53.4 Mbp of
AK1 sequences (~1.8% of genome) were missing in
GRCh38, which harbors ~1,390 putative coding elements.
To validate the possible information loss, we analyzed the
“unmapped” (to GRCh38) reads of fourteen individuals’
deep sequencing data (5 East-Asians, 4 Europeans, and 5
Africans), to find that ~5.3 Mbp of previously deserted
unmapped sequences were recovered by using AK1 as
reference. The recovered regions included 38 globally
shared (≥7 individuals out of 14) regions with >25 candidate
coding elements. We also verified that many of these
common missing regions in GRCh38 existed in multiple
populations and a chimpanzee by PCR analysis. Our study
illuminates the usefulness of precise ethnic genomes, and
supports the rationale for building a pan-genome reference.
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Genetic aetiology of early onset severe obesity revealed
in half of the affected cases from a consanguineous
population of Pakistan
S. Saeed1, M. Arslan2, J. Manzoor3, Q. M. Janjua4, H.
Ayesha5, E. Durand6, W. I. Khan7, T. A. Butt8, A.
Bonnefond6, P. Froguel1
1Faculty of Medicine, Imperial College London, London,
United Kingdom, 2School of Life Sciences, Forman
Christian College (A Chartered University), Lahore,
Pakistan, 3Department of Paediatric Endocrinology, Chil-
dren’s Hospital, Lahore, Pakistan, 4Department of Physiol-
ogy, University College of Medicine and Dentistry,
University of Lahore, Lahore, Pakistan, 5Department of
Paediatrics, Punjab Medical College, Faisalabad, Paki-
stan, 6EGID - UMR 1283 - 8199, Lille, France, 7Children
Hospital and Institute of Child Health, Multan, Multan,
Pakistan, 8Department of Pediatrics, Fatima Memorial
Hospital, Lahore, Pakistan
Introduction: Single gene pathogenic mutations account
for only 5-7% of obese cases in European populations. No
assessment of their prevalence has yet been made in con-
sanguineous populations.
Materials and Methods: DNA from 225 severely obese
probands (BMI-SDS>3.5), were first screened for the
mutations in LEP and MC4R genes by Sanger sequencing.
This was then followed by an in-house developed
augmented whole-exome sequencing (CoDE-seq) enabling
direct and simultaneous detection of CNVs and point
mutations in coding regions. The variants associated with
obesity were graded according to ACMG criteria to predict
pathogenicity.
Results: We report 110 cases (49%) with 55 different
pathogenic variations (49 point mutations; 6 CNVs), in
known monogenic obesity genes: Point mutations were
identified in LEP, LEPR, MC4R and ADCY3 (47%, 14%,
11% and 3.5% of cases, respectively). Mutations causing
syndromic obesity were identified in BBSs and ALMS1
(15.5% and 3.5% of cases, respectively). CNVs affecting
obesity associated genes (LEPR, PWS, 16p11.2) accounted
for 5.5% of patients. In addition, CoDE-seq also identified
28 rare or novel CNVs in 22 (10%) obese subjects, in
regions associated with intellectual disability. Lastly we
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highlighted variants in 4 potential candidate genes for
obesity warranting further investigation.
Conclusions: Here, we demonstrate a remarkably high
frequency (49% plus potentially 10%) of monogenic
obesity in a consanguineous population. Large inbred
populations provide a genetically enriched material to
elucidate the missing heritability of obesity and for the
discovery of novel mechanisms influencing energy balance.
Acknowledgements: The study was funded by French
National Research Agency (ANR-10-LABX-46, ANR-10-
EQPX-07-01).
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Molecular characterisation of NF1 in Cypriot neurofi-
bromatosis type 1 patients
A. Miltiadous1, P. Gerasimou1, I. Kyprianou1, J. Chi1, P.
Costeas1, V. Anastasiadou2
1Karaiskakio Foundation, Nicosia, Cyprus, 22Department
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Introduction: NF1 is a large gene containing at least 57
exons and encoding a protein sized 2818 aminoacids. NF1
mutations are generally associated to Neurofibromatosis
type 1, an autosomal dominant disease characterised by
café-au-lait spots and neurofibromas. Studying the NF1
gene has been challenging over the years due to its large
size and the similarity it shares with over seven NF1
pseudogenes.
Materials and Methods: Forty patients with suspected or
confirmed clinical diagnosis of neurofibromatosis type 1,
were screened with NGS (Haloplex and Sureselect panels
from Agilent), Sanger sequencing and MLPA (MRC-
Holland) for NF1 copy number detection.
Results: Twenty-nine patients (73%) harboured patho-
genic or likely pathogenic variants in NF1, of which 11
(37%) variants were novel. Eight (28%) of all variants were
nonsense, 8 (28%) were missense, 6 (21%) were located on
splice sites (3 were investigated and resulted in exon
skipping), 1 (3%) was an Indel and 6 (21%) were all novel
frameshift variants. Two (5% of all patients), harboured an
NF1 multi-exon deletion, and a whole NF1 gene deletion,
respectively. More than half of all variants detected, lie in
exons that share >90% similarity with NF1 pseudogenes.
The identified variants were equally distributed along
the gene.
Conclusions: We present the first study done in
neurofibromatosis type 1 Cypriot patients, in which
nonsense and missense changes are the most common type
of variants observed. We highlight the importance of copy
number testing in neurofibromatosis patients as well as
distinguishing true pathogenic variants from variants
occurring in NF1 pseudogenes.
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Unraveling genomic interactions at nsCL/P associated
GWAS loci using Circular Chromosome Conformation
Capture (4C)
R. Hollstein1, J. Schröder1, J. Welzenbach1, M. Bartusel2,
A. Rada-Iglesias2,3, K. U. Ludwig1
1Institute of Human Genetics, University of Bonn, School of
Medicine & University Hospital Bonn, Bonn, Germany,
2Center for Molecular Medicine Cologne (CMMC), Uni-
versity of Cologne, Cologne, Germany, 3Institute of
Biomedicine and Biotechnology of Cantabria (IBBTEC),
University of Cantabria, Cantabria, Spain
Non-syndromic cleft lip with or without cleft palate (nsCL/
P) is among the most common birth defects worldwide. Its
etiology is multifactorial with a strong genetic component,
which is supported by previous identification of 45 risk loci
through GWAS. As the majority of risk loci map to non-
coding regions, molecular effects on gene regulation or
chromatin organization have been suggested. However, the
translation of genetic findings into pathomechanisms is
challenging, due to the early embryonic time point of facial
development and thus, the lack of accessible relevant
human tissues for functional analyses. Our group has pre-
viously shown that associated risk variants for nsCL/P are
strongly enriched in active regulatory elements of human
neural crest cells (hNCCs). To unravel genomic interactions
and possible target genes of associated variants, we are
performing circular chromosome conformation capture (4C)
in hNCCs. We selected one novel risk locus on chr.20q13 to
establish the method. According to GTEx, the lead SNP is
an eQTL for EYA2 in multiple tissues. Notably, EYA2 is a
developmental gene expressed in hNCCs that is involved in
cellular mechanisms such as migration and apoptosis. Our
preliminary data based on the viewpoint around the sentinel
SNP suggest an interaction between its region and the
promoter region of EYA2. Analyses using the promoter
region of EYA2 as a second viewpoint and allele-specific
investigations are currently on the way, to validate the
interaction. Overall, our approach will help to identify target
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genes that are involved in the molecular pathology of nsCL/
P at GWAS loci.
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A new genetic variants in DNAI2 detected by target
sequencing in a newborn with Primary Ciliary
Dyskinesia
M. Rocca1, C. Vinanzi1, A. Michelucci2, M. Caligo2, A.
Valetto3, M. De Santi4, V. Bertini3, G. Piatti5, C. Foresta1
1University of Padova, Padova, Italy, 2University Hospital
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Introduction: Primary Ciliary Dyskinesia (PCD) is a rare
recessive disease characterized by motile cilia dysfunction.
Clinical manifestations of this disease include upper and
lower respiratory tract infections, laterality defects and
infertility. To date, mutations in approximately 40 different
genes have been found to be causative of PCD. Here, we
report the case of a new-born with PCD carrying a new
homozygous deletion in DNAI2 gene.
Materials and Methods: Transmission electron micro-
scopy was carried out for diagnosis of PCD. To identify
genetic cause of disorder, DNA sequencing by a custom
multigene next generation sequencing panel and aCGH
were performed.
Results: Transmission electron microscopy showed the
absence of outer dynein arms in all analysed axonemes and
abnormal inner dynein arm in more than 90% of axonemes.
Target sequencing and microarray analysis detected a
homozygous 6.9Kb deletion including exons 7-8-9 of
DNAI2 gene.
Conclusions: In this study, we describe a novel
homozygous deletion of exons 7-9 of DNAI2 found in a
4-month old girl with respiratory distress, ventriculomegaly,
situs inversus, patent foramen ovale, absent outer dynein
arms and abnormal inner dynein arms. Although most of the
PCD cases are the result of mutations in gene encoding
axonemal proteins or protein related to dynein arm
assembly, variants in DNAI2 gene are rarely found in
PCD patients. The application of high-throughput technol-
ogies allowed us, hence, to identify a new intragenic
deletion of DNAI2 gene that could likely cause the loss of
function of the protein resulting in a severe PCD phenotype.
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Haploinsufficiency of the Primary Familial Brain
Calcification gene SLC20A2 mediated by disruption of
a regulatory element
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Institut de Biologie François Jacob, CEA, Université Paris-
Saclay, F-91057, Evry, France, 4Department of internal
medicine and systemic diseases, Dijon University Hospital,
Dijon, France, 5Normandie Univ, UNIROUEN, Inserm
U1245 and Rouen University Hospital, Department of
Neurology and CNR-MAJ, F 76000, Normandy Center for
Genomic and Personalized Medicine, Rouen, France,
6Inserm UMR 1231 GAD, Genetics of Developmental
disorders, Université de Bourgogne-Franche Comté, FHU
TRANSLAD, Dijon, France, 7Institut de Recherche en
Infectiologie de Montpellier (IRIM), Université de Mon-
tpellier, CNRS, Montpellier, France
Objective: Primary Familial Brain Calcification (PFBC) is
a rare cerebral microvascular calcifying disorder with
diverse neuropsychiatric expression. Four autosomal-
dominant PFBC genes have been reported. Haploinsuffi-
ciency of SLC20A2, which encodes an inorganic phosphate
(Pi) importer, is a major cause of PFBC. During the analysis
of exome sequencing data of 71 genetically unexplained
unrelated PFBC patients, we detected an 8p11.21 deletion,
mapping 35 kb upstream of SLC20A2 and segregating with
PFBC in 3 patients, and assessed its consequences on gene
function.
Methods: We explored SLC20A2 blood expression by
RT-ddPCR, performed an ex vivo Pi uptake assay and we
deleted a putative SLC20A2 enhancer mapping to this
region in HEK293 cells by CRISPR/Cas9.
Results: The deletion carriers/normal controls ratio of
relative SLC20A2 mRNA levels was 60.2% (p < 0.001).
This was comparable to that of patients carrying an
SLC20A2 premature stop codon (63.4%, p < 0.001). The
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proband exhibited a 39.3% decreased Pi uptake in blood (p
= 0.015). In HEK293 cells, we observed a 39.8% decrease
in relative SLC20A2 mRNA levels after normalization on
DNA copy number (p < 0.001) in a bulk analysis.
Discussion: We identified a deletion encompassing an
enhancer of SLC20A2 expression, with carriers showing
haploinsufficiency in similar ranges than loss-of-function
allele carriers. Deleting this element in a cellular model was
associated with similarly reduced mRNA levels. Here, we
used a simplified CRISPR/Cas9 assay associated to (RT-)
ddPCR which allows a rapid study of DNA/RNA extracted
from the cellular bulk. We propose a 3-step strategy to
identify and easily assess the effect of such non-coding
events.
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Cleft palate and left hydronephrosis in a fetus with a
non-contiguous 6,7 Mb gain and 2,1 Mb loss in
chromosome 22: unfolding an atypical ring chromosome
from array to karyotype
S. Serafim1, B. Marques1, S. Pedro1, C. Alves1, A. R.
Tarelho1, L. Simao1, J. Furtado1, S. Rangel1, R. Peliano1,
C. Ferreira1, N. Silva1, M. Silva1, F. Brito1, A. Bernardo2, I.
Carvalho1, A. Cohen2, H. Correia1
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mento de Genética, Unidade de Citogenética, Lisboa,
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Chromosomal microarray analysis (CMA) is the recom-
mended genetic test in pregnancies with ultrasound
abnormalities allowing the identification of small patho-
genic copy number variations (CNV). Nevertheless kar-
yotype may be needed to clarify the underlying mechanism
of complex rearrangements. Here we report a fetus referred
for prenatal diagnosis due to cleft palate and left hydrone-
phrosis uncovered during second trimester ultrasound.
Affymetrix Cytoscan 750 CMA revealed a 6,7 Mb inter-
stitial gain at 22q12.2q13.1 and a 2,1 Mb terminal loss at
22q13.32q13.33, in a male fetus. The deletion includes
SHANK3 whose haploinsufficiency causes Phelan-
McDermid syndrome (PMS) and hence considered as a
pathogenic CNV. Patients with PMS mainly exhibit neu-
rological and behavioural symptoms, not detectable in a
prenatal ultrasound, although hydronephrosis, as described
in the fetus, is one of the few congenital abnormalities
occasionally reported. To exclude a complex rearrangement
and evaluate recurrence risk karyotype was performed both
in the fetus and the parents revealing a de novo ring chro-
mosome 22 in all cells analyzed. While terminal deletions in
ring chromosomes are expected, the non-contiguous gain/
loss identified here questions whether this ring could have
been generated by a mechanism of chromothripsis/chro-
moanagenesis, as recently described in a child with PMS
and a complex ring 22. Although the duplicated region was
considered of unknown clinical significance, the cleft palate
observed in the fetus has not been described in PMS
patients and may be a consequence of this more complex
rearrangement. After genetic counseling the parents opted to
terminate the pregnancy.
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The intronic pathogenic variant in SCN2A associated
with neurodevelopmental disorder and epileptic
encephalopathy.
A. A. Sharkov1,2, P. Sparber3, A. Filatova3, M. Skoblov3, I.
Kanivets2,4, D. Pyankov2, S. Korostelev2
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We present a clinical case of 4-year-old girl with epileptic
encephalopathy related to de novo intronic variant in
SCN2A gene. The pregnancy, delivery and family history
were unremarkable. Psychomotor development was con-
sidered normal until 2 y.o., but slightly autistic features
were recognised at 1 y.o. Seizures onset was at 18 months
like as clusters of generalised tonic-clonic seizures, she had
also daily generalised tonic seizures, myoclonic and
myoclonic-atonic seizures, sometimes febrile provoked.
Multiple antiepileptic drugs (AEDs) and hormonal treat-
ment were not effective, the best effect was on the combi-
nation Carbamazepine with Levetiracetam. Severe
developmental and motor regress, autistic traits, muscle
hypotonia with high tendon reflexes, ataxia were reported at
2 y.o. EEG at 4 y.o. showed slow background, a bifrontal
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and generalized discharges, low-average index in the sleep.
MRI was unremarkable. Gene panel showed a variant in
SCN2A gene (chr2:166170123A>G), confirmed de novo by
Sanger. To investigate the potential impact of the
NG_008143.1 (NM_021007.2): c.1035-7A>G variant on
splicing and due to the fact that SCN2A gene expression is
brain restricted, splicing minigene assay was performed.
Wild-type and mutant alleles containing 9 and 10 exons
with the corresponding intronic sequences were cloned into
pSpl3-Flu2 plasmid. Minigene assay showed that c.1035-
7A variant activate a cryptic intronic acceptor site which
leads to 6 nucleotide extension of exon 9 (NP_066287.2:p.
(Gly345_Gln346insTyrSer). This insertion affects the
extracellular domain of SCN2A protein where several
pathogenic missense variants were previously described. To
our knowledge, this is the first functional analysis of a
splicing variant in SCN2A gene.
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Cis-acting variants modify the behavior of PiS allele
from moderately deficient to null phenotype in Alpha-1
Antitrypsin Deficiency
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Introduction: Alpha-1 Antitrypsin deficiency (AATD) is
an inherited condition characterized by reduced levels of
serum AAT due to mutations in SERPINA1 gene. The PiS
(Glu264Val) is one of the most frequent deficient alleles of
AATD which reduce by 40% the protein level. This allele is
the most frequent in Caucasians.
Material and Methods: After genotyping the most
frequent variants PiZ and PiS in AATD patients, there are
deficient individuals with lower serum levels of AAT than
expected for the initial genotype that should be further
analyzed by sequencing coding exons of SERPINA1 gene,
and protein phenotyped by isoelectric focusing. Novel
variants were found and were functionally characterized by
expressing them in a cellular model.
Results: We identify and characterize two new alleles
carrying S mutation, but producing null phenotype. We
describe two previously unknown missense variants con-
firmed to be in-cis configuration each of them with the S
mutation, and demonstrated that they modify the properties
of the PiS allele in terms of higher AAT intracellular
retention and no extracellular secretion. Plasma samples
from patients carrying these combinations confirmed null-
phenotype behavior. These represent a novel type of AATD
alleles that we named ‘PiS-plus’ alleles, as they have more
pathogenic properties comparing to typical deficient PiS
alleles, and modify clinical consequences.
Conclusions: This finding highlights that phasing genetic
variants in AATD is an important issue to establish a
definitive diagnosis. The discovery of different PiS-plus
alleles could contribute to explain the phenotypical
variability observed among patients. (Grant: AESI
PI17CIII/00042).
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Combined involvement of the human-specific duplica-
tions at 16p11.2 in iron metabolism and immune defense
G. Giannuzzi1, G. Willemin1, E. Porcu1, J. Chrast1, K.
Hoekzema2, 16p11.2 Consortium, Z. Kutalik1, E. Eichler2,
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Human-specific duplications at chromosome 16p11.2
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mediate recurrent pathogenic copy-number variations
through non-allelic homologous recombination. These
copy-number polymorphic duplications (3-8 copies) are
under positive selection and include BOLA2, whose
expansion might have an adaptive role in protecting against
iron deficiency. It is unknown whether other genes mapping
to this duplicate segment, like SLX1 that takes part in the
SLX1-SLX4 complex involved in the control of genome
stability, might have a role too.
As SLX4 mutations are associated with the inability to
produce blood cells, we assessed leukocyte differential counts
in 379,385 controls and individuals who have lost or gained
copies of BOLA2-SLX1: 89 chromosome 16p11.2 deletion and
56 reciprocal duplication carriers from the UK Biobank. We
found that the deletion is associated with higher neutrophil
(P = 7e-6) and lower lymphocyte (P = 3e-3) counts. Upon
stratification of the deletion carriers of our clinical cohort by
BOLA2-SLX1 copy number, we found an association between
low BOLA2-SLX1 dosage and lymphocyte count < 1.5 M/ml
of blood, as 4/7 carriers with three copies had this phenotype
compared to 0/12 carriers with more than three copies
(P = 9e-3). We are currently measuring leucocyte differential
counts in Slx1b-knockout mice.
Our results show that the BOLA2-SLX1 copy number
in humans is positively associated with lymphocyte
counts and its increase might improve our immune
system. They pinpoint one locus potentially involved in
the lymphocyte count difference between humans and
apes and highlight a potential dual adaptive role of
BOLA2-SLX1 expansion in improving both iron meta-
bolism and immune defense.
G. Giannuzzi: None. G. Willemin: None. E. Porcu:
None. J. Chrast: None. K. Hoekzema: None. Z. Kutalik:
None. E. Eichler: None. A. Reymond: None.
P13.35.A
A new family with spastic paraplegia type 51 and novel
mutations in AP4E1
I. Winkler1, P. Miotla2, M. Lejman3, A. Pietrzyk4, M.
Kacprzak4, M. Kubiak1, M. Sobczyńska-Tomaszewska4, I.
Jaszczuk3,5
1St’Johns Center Oncology, Lublin, Poland, 2II Department
of Gynecology, Medical University of Lublin, Lublin,
Poland, 3Department of Paediatric Haematology, Oncology
and Transplantology, Children Clinical Hospital, II Dept.
of Paediatrics, Lublin, Poland, 4MedGen Medical Centre,
Warszawa, Poland, 5Departament of Cancer Genetics with
Cytogenetic Laboratory, Medical University of Lublin,
Lublin, Poland
Autosomal recessive mutations in AP-4 complex subunit ϵ-
1 (AP-4E1) gene on chromosome 15q21.2 are known to
cause spastic paraplegia 51 (SPG51). However, since only a
few families affected by this mutation have been reported,
the exact phenotype of SPG51 remains poorly character-
ized. In addition, a previous study identified an autosomal
dominant mutation in AP4E1 gene to be associated with
persistent stuttering. The aim of the present study was to
characterize the phenotype of a pediatric patient displaying
significant psychomotor retardation, intellectual disability
and paraplegia. This phenotype was identified to be asso-
ciated with a novel mutation in the AP4E1 gene, c.942_943
+3delinsCC. The pediatric patient showed severe delayed
psychomotor development, impaired global physical
development and general illness. Movement disorders were
evident during the neonatal period. Moreover, magnetic
resonance imaging identified hypoplasia of the corpus cal-
losum. The proband DNA was tested by multiplex ligation-
dependent probe amplification and array comparative
genomic hybridization. Subsequently, next generating
sequencing (NGS) was performed in the patient, and Sanger
sequencing was performed in his family members. The
present study identified a previously unknown disease-
inducing AP4E1 gene mutation via NGS.






























































Clinical features of proband and his family
Proband Brother Father
Intelligence Severe intellectual disability Deep intellectual disability Normal
Speech
development
A few words (He understands
simple commands)




Heigh Short stature (<3 pc) Short stature (<3 pc) Medium
stature (10 pc)
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spastic
paraplegia
Movement Crawling, standing only with
suport. He doesn’t walk.
Crawling, standing and
walking only with support
Total
Others Contractures. Abduction
contracture of the fingers.
Knee valgus. Hypoplasia of
the corpus callosum. Several
episodes of increased
drowsiness, increased ptosis,











I. Winkler: None. P. Miotla: None. M. Lejman: None.
A. Pietrzyk: None. M. Kacprzak: None. M. Kubiak:
None. M. Sobczyńska-Tomaszewska: None. I.
Jaszczuk: None.
P13.37.C
Genetic effects on splicing and expression in normal
colon tissue gives insights into the genetic architecture of
complex traits and diseases
V. Diez-Obrero1,2,3,4, M. Devall5,6, F. Moratalla-
Navarro1,2,3,4, C. H. Dampier5,6,7, S. J. Plummer5,6, R.
Carreras-Torres1,2,3, G. Casey5,6, V. Moreno1,2,3,4
1Oncology Data Analytics Program, Catalan Institute of
Oncology, L’Hospitalet de Llobregat (Barcelona), Spain,
2ONCOBELL Program, Bellvitge Biomedical Research
Institute (IDIBELL), L’Hospitalet de Llobregat (Barcelona),
Spain, 3Consortium for Biomedical Research in Epidemiol-
ogy and Public Health (CIBERESP), Madrid, Spain,
4Department of Clinical Sciences, Faculty of Medicine,
University of Barcelona, Barcelona, Spain, 5Center for
Public Health Genomics, University of Virginia, Charlot-
tesville, VA, United States, 6Department of Public Health
Sciences, University of Virginia, Charlottesville, VA, United
States, 7Department of Surgery, University of Virginia,
Charlottesville, VA, United States
Associations of genetic variation with tissue-specific alter-
native splicing and gene expression can help characterize
the molecular basis of gene regulation, complex trait risk
loci, and disease mechanisms. Therefore, cataloguing
quantitative trait loci (QTLs) across tissues is a priority in
complex disease genetics.
In this study, we profiled alternative splicing and gene
expression with bulk RNA sequencing (RNA-seq) in colon
tissue biopsies from a novel dataset of 445 healthy
individuals.
We found transcriptomic differences between colon
anatomic locations and identified 1,817 splicing QTLs
(sQTLs) and 9,831 expression QTLs (eQTLs). These QTLs
were enriched at regulatory elements and explained a
proportion of genetic heritability not only for colorectal
cancer and inflammatory bowel disease risk, but also for
cognitive traits and psychiatric and neurodegenerative
disease risk. We replicated the results using GTEx
transverse colon data and made an interactive web resource
to explore the results (http://barcuvaseq.org/).
Overall, our findings provide evidence of genetic
regulation of alternative splicing and gene expression in
colon tissue at risk loci for complex traits and diseases.
Grant references: NIH/NCI CA143237; NIH/NCI
CA204279; NIH/NCI CA201407; ISC III - FEDER PI14-
00613; CIBERESP CB07/02/2005; Catalan Government
DURSI 2014SGR647; EU H2020 - MSC grant No 796216;
FPU16/00599.
V. Diez-Obrero: None. M. Devall: None. F. Moratalla-
Navarro: None. C.H. Dampier: None. S.J. Plummer:
None. R. Carreras-Torres: None. G. Casey: None. V.
Moreno: None.
P13.38.A
PopDel identifies medium to large deletions jointly in
tens of thousands of genomes
S. Niehus1,2, J. Schönberger1,2, H. Jónsson3, E. Björnsson3,
D. Beyter3, H. P. Eggertsson3, P. Sulem3, K. Stefánsson3,4,
B. V. Halldórsson3,5, B. Kehr1,2
1Berlin Institute of Health (BIH), Berlin, Germany, 2Charité
– Universitätsmedizin Berlin, corporate member of Freie
Universität Berlin, Humboldt-Universität zu Berlin, and
Berlin Institute of Health, Berlin, Germany, 3deCODE
genetics/Amgen Inc, Reykjavik, Iceland, 4Faculty of Med-
icine, School of Heath Sciences, University of Iceland,
Reykjavik, Iceland, 5School of Science and Engineering,
Reykjavik University, Reykjavik, Iceland
Catalogs of genetic variation for large numbers of indivi-
duals are a foundation for modern research on human
diversity and disease. Creating such catalogs for small
variants from whole-genome sequencing (WGS) data is
now commonly done for thousands of individuals collec-
tively. We have transferred this joint calling idea from SNPs
and indels to larger deletions and developed the first joint
calling tool, PopDel, that can detect and genotype deletions
in WGS data of tens of thousands of individuals simulta-
neously as demonstrated by our evaluation on data of up to
49,962 human genomes. Good sensitivity, precision and the
correctness of genotypes are demonstrated by extensive
tests on simulated and real data and comparison to other
state-of-the-art SV-callers. PopDel detects deletions in
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HG002 and NA12878 with high sensitivity as shown by the
large overlap with different high-confidence reference call
sets while maintaining a low false positive rate. On data of
up to 6,794 trios, inheritance patterns are in concordance
with Mendelian inheritance rules and exhibit a close to ideal
transmission rate of 49.6%. PopDel reliably reports com-
mon, rare as well as de novo deletions and the deletions
reflect reported population structure. Meaningful quality
measures and metrics of the variants like genotype quality,
variant likelihood ratio and allele frequency within the
cohort are reported along with the variants, enabling further
downstream analysis. Therefore, PopDel enables routine
scans for deletions in large-scale sequencing studies and we
are currently in the process of implementing the detection of
other SV-types. BMBF Grant #031L0180
S. Niehus: None. J. Schönberger: None. H. Jónsson:
None. E. Björnsson: None. D. Beyter: None. H.P.
Eggertsson: None. P. Sulem: None. K. Stefánsson: None.
B.V. Halldórsson: None. B. Kehr: None.
P13.42.B
The chromatin 3D structure reorganization in Trisomy
21
I. Kolpakov1, C. Borel1, F. Bezrukov1, B. Ren2,3, S. E.
Antonarakis1
1University of Geneva, Geneva, Switzerland, 2Ludwig
Cancer Research Institute, San Diego, CA, United States,
3School of Medicine, University of California, San Diego,
CA, United States
The pathogenetic mechanisms of human trisomy 21 (T21)
include the dosage effect of functional genomic elements on
chr21, global dysregulation of gene expression and the
individual genomic variability. In this study, we hypothe-
size that the extra-copy of chr21 may change the chromatin
3D structure, which in turn may affect gene expression. We
have used HiC experiments in 3 primary fibroblast cell lines
from a pair of monozygotic twins discordant for T21 (to
eliminate the noise of the genome sequence variation). We
have also used transcriptome, Lamin-associated domains
(LAD from PMID, and 24740065) H3K4me3 datasets from
fibroblasts. No differences between T21 and euploid cis-
chromatin interactions (TADs) were detected. We have,
however, observed significant differences in higher-order
chromatin contacts, largely explained by differences in A/B
compartmentalization. Remarkably, we have detected 83
genomic regions (>1Mb) that change the compartment in
T21 (from B to A, or A to B). These reorganized regions
(ΔABt21) comprise a total of ~250 Mb of the genome.
Genes within ΔABt21 regions display a dysregulated
expression in T21: upregulated in the A, and downregulated
in the B compartment. A substantial number of the ΔABt21
regions are constitutive annotated as LADs suggesting a
partial repositioning of sequences at the nuclear envelope
components to the transcriptionally active compartment in
T21. A fraction of the observed differences were also
observed in comparisons between unrelated T21 and
euploid fibroblasts. In conclusion, we have identified mea-
surable chromatin structure differences in T21 versus an
euploid nucleus, that likely result in gene expression dif-
ferences in T21.
I. Kolpakov: None. C. Borel: None. F. Bezrukov:
None. B. Ren: None. S.E. Antonarakis: None.
P13.43.C
Topological Assessment of the KCNQ1 variants: a gene-
specific approach for variant interpretation
V. Novelli1, M. Cerrone2, M. Care3, A. C. Sturm4, J.
Garcia5, A. Wilde6, J. Ware7, M. Gollob8, M. Genuardi1
1Fondazione Policlinico A. Gemelli, IRCCS; Catholic
University of the Sacred Heart, Rome, Italy, 2New York
University, NYC, NY, United States, 3Toronto General
Hospital and University of Toronto, Toronto, ON, Canada,
4Geisinger Genomic Medicine Institute, Danville, CA,
United States, 5Invitae Corp., San Francisco, CA, United
States, 6Heart Center, Department of Clinical and Experi-
mental Cardiology,, Amsterdam, Italy, 7National Heart and
Lung Institute and Medical Research Council London
Institute of Medical Sciences, Imperial College London,
London, United Kingdom, 8Division of Cardiology, Toronto
General Hospital and University of Toronto,, Toronto, ON,
Canada
Background: Variant interpretation is becoming the most
challenging step of genetic testing. The introduction of the
ACMG guidelines set more stringent criteria, trying to
standardize variant assessment in the clinical settings.
However, this approach has universal applicability and
therefore requires significant expertise to be applied cor-
rectly for specific genes and diseases.
Purpose: we highlight the potential role of the location of
variants within the protein topology for ion channels genes,
supporting variant interpretation process.
Methods and Results: Data from 3580 probands,
referred for LQTS genetic testing, was analyzed for KCNQ1
gene variants. In particular, the N-Terminal,
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Transmembrane linker pore region (TLP) and C-Terminal
regions were used to assess the variant position. Subse-
quently, four conservative helical regions, within the C-
terminal, were incorporated in the analysis. The GnomAD
population was used as a control. Our analysis revealed that
missense variants localized in the TLP have the highest
probability for pathogenicity (expected predictive value
(EPV)=98,4. Within the TLP, the pore and interlink
domains showed the highest EPV, 100%, and 99.8 %
respectively. Hence results confirmed the critical role of the
four helical regions within the C- terminal. In particular,
helix B and helix C provide an EPV of 100%, identifying a
critical conserved region between 509-562 aa.
Conclusions: Topological location of variants in the
KCNQ1 gene can be used as a gene-specific criterion for
variant interpretation. Further studies stratifying the risk
based on the variant location also in other ion channel genes
could open new frontiers for the clinical application of
genetic testing results.
V. Novelli: None. M. Cerrone: None. M. Care: None.
A.C. Sturm: None. J. Garcia: None. A. Wilde: None. J.
Ware: None. M. Gollob: None. M. Genuardi: None.
P13.44.A
ENIGMA - Etalon of National Interpreted Genome Map
of the Czech population
P. Brož1,2, K. Kvapilová1,3, P. Pavliš4, P. Vojta4, M.
Bendová4, J. Drábek4, J. Srovnal4, L. Daniel1, P. Kvapil1,
M. Hajdúch4
1Institute of Applied Biotechnologies a.s., Prague, Czech
Republic, 2Second Faculty of Medicine Charles University,
Prague, Czech Republic, 3Faculty of Science Charles
University, Prague, Czech Republic, 4Institute of Molecular
and Translational Medicine, Faculty of Medicine and
Dentistry, Palacky University, Olomouc, Czech Republic
Introduction: Due to the variability of the human genome
the proper interpretation of genomic data is fundamentally
dependent on the appropriate bioinformatics pipeline and
reference database. Local human genome standards serve as
a reference, furthermore, the general ones help clinical
geneticists to discern pathogenic mutations from benign
polymorphisms.
Materials and Methods: Samples were selected follow-
ing strict criteria from Czech healthy blood donors. Next-
generation sequencing was performed using the PCR-free
whole genome kit followed by sequencing on Illumina
NovaSeq 6000 (WGS). The genome variant calling format
was generated by the Dragen Bio-IT platform. Variants
were annotated using the Variant Effect Predictor version
99 and the bioinformatic pipeline was validated using the
Genome in a Bottle standard. RSIDs were obtained from
dbSNP build 153. Clinical relevance annotations were
generated using ClinVar version 20200210.
Results: 100 samples were sequenced with average read
depth > 30X. The median of the total number of variants
was 4,736,609, the median number of: heterozygous
2,904,376, homozygous 1,930,728, SNPs 3,823,298,
INDELs 902,433 and MNPs 11,187, biallelic 4,236,049
and multiallelic 501,887. The median number of transitions
3,568,436 and transversions 1,841,354 with Ti/Tv ratio 1.9.
Conclusions: WGS protocol including the bioinformatics
analysis was created and validated to abide the EN ISO
15189 requirements. The variant analysis pipeline has been
verified and validated using the genome standard. The draft
of the digital genome of the Czech population was created
and will be expanded to up to 1,000 samples. CZ.01.1.02/
0.0/0.0/16_084/0010360, LM2015064
P. Brož: None. K. Kvapilová: None. P. Pavliš: None. P.
Vojta: None. M. Bendová: None. J. Drábek: None. J.
Srovnal: None. L. Daniel: None. P. Kvapil: None. M.
Hajdúch: None.
P13.46.C
Costitutional chromoanasynthesis: a familiar chromo-
some explosion
P. Reho1, N. Kurtas2, L. Tiberi1, D. Vergani2, D.
Formicola2, F. Vanderwert1, A. Provenzano1, A. Pagliazzi2,
S. Guarducci2, O. Zuffardi3, S. Giglio1,2
1Dpt. of Biomedical Experimental and Clinical Sciences
"Mario Serio", University of Florence, Florence, Italy,
2Medical Genetics Unit, Meyer Children’s University
Hospital, Florence, Italy, 3Dpt. of Molecular Medicine,
University of Pavia, Pavia, Italy
Chromoanasynthesis is characterized by extensive genomic
rearrangements including variable DNA copy-number
changes and several breakpoints, clustered into one or few
chromosomes. Here, we studied a family case with a mul-
tiple abortion history and four affected members showing
neurological defects. The index case is a three-year-old girl
characterized by corpus callosum hypoplasia, bilateral cleft
palate, speech delay and facial dysmorphisms. The father,
paternal aunt and grandmother showed partial corpus cal-
losum hypoplasia, psychiatric disorder and short stature,
respectively. By conventional cytogenetics, we detected an
unbalanced reciprocal translocation t(4;8)(p15.2;q12) seg-
regating in the four individuals through three-generation.
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Array-CGH showed a 5,8 Mb duplication at 4p15.32-p15.2
in all the translocation carriers. In order to better char-
acterize the chromosomal rearrangement, we performed a
whole genome sequencing (WGS) 50x of the proband,
father and grandmother. As a result, we revealed the hidden
complexity of the translocation event classified as chro-
moanasynthesis. Taking advantage from discordant reads
and coverage depth, we detected six breakpoints clustered
within 12,6Mb on 4p and 8q arms, duplications, deletions
and inversions, defining the intricate genomic architecture
of the translocation. All the breakpoints were confirmed by
sanger sequencing, showing that only NKAIN3 is disrupted
in its intron. NKAIN3 has not been associated with any
known human disease, but its high expression in corpus
callosum highlights the gene as a potential candidate for the
neurological findings. Our data call for WGS as first tier
genomic analysis in order to properly delineate the com-
plexity of chromosomal rearrangements and shed light on
the genotype-phenotype association.
P. Reho: None. N. Kurtas: None. L. Tiberi: None. D.
Vergani: None. D. Formicola: None. F. Vanderwert:
None. A. Provenzano: None. A. Pagliazzi: None. S.
Guarducci: None. O. Zuffardi: None. S. Giglio: None.
P13.47.A
Whole genome sequencing of unexplained inherited
retinal disease cases
Z. Fadaie1, L. Whelan2, A. Dockery2, T. Ben-Yosef3, J.
Farrar2, F. P. M. Cremers1, S. Roosing1
1Radboud University Medical Center, Nijmegen, Nether-
lands, 2The School of Genetics & Microbiology, Smurfit
Institute of Genetics, Trinity College Dublin, Dublin,
Ireland, 3The Rappaport Faculty of Medicine, Technion-
Israel Institute of Technology, Haifa, Israel
Purpose: Inherited retinal diseases are a major cause of
visual impairment. This clinically heterogeneous disorders
are caused by mutations in many genes. Nevertheless, 30-
40% of cases remain genetically unexplained. Therefore, we
aimed to identify the genetic cause in unresolved cases
through whole genome sequencing (WGS).
Methods: After gene-panel or exome sequencing pre-
screening methods, we performed WGS to identify the
causative variants in 100 unresolved cases. After initial
prioritization, a focused in-depth prioritization took place of
all deep-intronic variants and structural variants in genes
with candidate variants. In addition, functional analysis of
the putative splice-site altering variants was performed
using a midigene-based in-vitro splice assay.
Results: We identified a genetic cause in 21 patients.
Among others, causative coding variants were observed in
genes such ATXN7, CEP78, EYS, FAM161A, PEX5, and
RPGRIP1, . Gene disrupting structural variants were also
observed in PDE6B and EYS. Moreover, in 49 monoallelic
cases, we identified candidate variants based on the possible
introduction of a cryptic splice site leading to a pseudoexon.
For variants with a good genotype-phenotype correlation in-
vitro splice assays were performed.
Conclusions: We confirmed that WGS is a powerful tool
to identify causative variants, when pre-screening methods
remain negative. This was most efficient in cases with a
distinct clinical diagnosis. We highlight the importance of
the analysis of non-coding regions beyond the non-
canonical splice-sites. We suggest that WGS provides the
optimal detection method to enable a genetic diagnosis for
unresolved cases.
Funding: Foundation Fighting Blindness USA Project
Program Award, Uitzicht, Fighting Blindness Ireland.
Z. Fadaie: None. L. Whelan: None. A. Dockery: None.
T. Ben-Yosef: None. J. Farrar: None. F.P.M. Cremers:
None. S. Roosing: None.
P14 Cytogenetics
P14.01.C
1p36 deletion syndrome - Iasi Regional Medical
Genetics Centre’s Experience
C. Rusu1,2, R. Popescu1,2, M. Panzaru1,2, L. Butnariu1,2, I.
Resmerita1, E. Gavril1
1"Grigore T Popa" University of Medicine and Pharmacy,
Iasi, Romania, 2"Sf Maria" Children’s Hospital, Regional
Medical Genetics Centre, Iasi, Romania
1p36 deletion syndrome is a common subtelomeric micro-
deletion (1/5,000 newborns), characterized by distinctive
facial features, hypotonia, intellectual disability, seizures,
heart defects, hearing impairment, and prenatal onset
growth deficiency. Although usually clinically recogniz-
able, the syndrome has a considerable phenotypic variation.
We present six cases identified using MLPA and/or Array-
CGH in our center in order to illustrate particularities found
in our patients and correlate them with genotype. We
identified 3 de novo interstitial 1p36 microdeletions of
different sizes (2.48 Mb to 5.90 Mb) and 3 with reciprocal
duplication (one patient with 4q35.1dup and two brothers
with 14q32.33dup). All cases had a wide phenotypic
spectrum. Most cases had perinatal distress and hypotonia.
Constant features were severe intellectual disability and
seizures. Even if straight eyebrows, deep-set eyes and
pointed chin are considered highly suggestive for the
diagnosis, they are present only in some of the cases. The
particularities found in the ”pure” 1p36 microdeletions
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include: familial hypocalciuric hypercalcemia, pilonidal
sinus, tall stature, obesity, rare eyebrows in external 1/3 (2
cases). The additional chromosomal anomalies present in 3
of the patients contribute to the phenotype severity, and
additionally modify the clinical manifestations of 1p36
deletion. Analyzing the familial cases, we noticed that the
same chromosomal anomaly generates distinct phenotypes
in the two brothers. In conclusion, we are presenting six
cases with 1p36 microdeletion to discuss the frequency of
definitory features and illustrate particularities.
C. Rusu: None. R. Popescu: None. M. Panzaru: None.
L. Butnariu: None. I. Resmerita: None. E. Gavril: None.
P14.03.B
The utility of FISH for post-array CGH investigations
S. Bint1, A. F. Davies1, C. Lee1, C. Mackie Ogilvie2
1Genetics Laboratories, Guy’s Hospital, London, United
Kingdom, 2King’s College London, London, United King-
dom
Array CGH is widely used for the detection of chromosome
imbalance in patients with congenital anomalies or neuro-
developmental disorders. The significance of unique inter-
stitial copy number imbalances detected by this technique is
largely informed by the carrier status of the parents, who are
generally tested by targeted array CGH. If neither parent
carries the imbalance, further studies may be carried out
using fluorescence in situ hybridisation (FISH) to establish
if either parent carries a balanced chromosome rearrange-
ment. In the absence of such a rearrangement, their recur-
rence risk approaches zero; however, a balanced
rearrangement results in a 50% risk of imbalance in future
pregnancies. Since 2008, our centre has tested approxi-
mately 50,000 patients, with imbalances detected in ~22%;
after parental array CGH testing 1,083 imbalances were not
detected in either parent. Parents and probands of 203 non-
LCR-mediated cases were tested using FISH probes tar-
geted at the regions of imbalance. Deletions represented 175
of these cases, one of which was inherited from a parent
with a balanced rearrangement (ins(1;11)). There were 28
duplications, 27 of which were tandem, and the other
inherited from a parent with a balanced rearrangement (ins
(6;4)). The overall prevalence of parental balanced rear-
rangements in these cases is therefore 2/203 (~1%). This
figure is lower than that previously published, and may
indicate that testing for these rearrangements may not be
financially justified. Interestingly, we found no cases of de
novo duplications caused by insertion of the duplicated
region into a distant locus, indicating that this mutational
event is rare.
S. Bint: None. A.F. Davies: None. C. Lee: None. C.
Mackie Ogilvie: None.
P14.04.C
Retrospective investigation of array-CGH prenatal
diagnosis at Geneva Hospital: a cohort of 626
pregnancies
S. Gimelli1, E. Stathaki1, V. Kremer1, B. Martinez de Tejada
Weber1, P. Extermann2, J. Pellegrinelli1, M. Billieux1, I.
Eperon1, V. Mirlesse1, B. Heggel-Hort3, B. Plaschy4, T. Von
Kanel4, S. Fokstuen1, R. Robyr5, E. Ranza6,1, S.
Antonarakis6,7, M. Abramowicz1, F. Sloan-Béna1
1HUG, Geneva, Switzerland, 2Dianecho, Geneva, Switzer-
land, 3Valais Hospital, Sion, Switzerland, 4Valais Hospi-
tals, Sion, Switzerland, 5Echofemme, Geneva, Switzerland,
6Medigenome, Geneva, Switzerland, 7University of Geneva,
Geneva, Switzerland
Chromosomal microarray (CMA) is recommended pre-
natally as a first-tier investigation in case of abnormal fœtal
ultrasound. Following the identification of fœtal anomalies,
molecular diagnostic investigations using CMA will diag-
nose a clinically significant subchromosomal copy number
variation (CNV) in approximately 6% of pregnancies. We
performed a retrospective study including 626 fetuses
referred to Genetic Medicine in Geneva Hospitals, Swit-
zerland, between 2013 and 2019. The cohort consisted of
458 amniotic fluids and 168 chorionic villi. Referrals for
abnormal ultrasound findings were the most frequent indi-
cation. Other indications were: high risk for trisomy in
maternal serum screening or NIPT, advanced maternal age
and family history of chromosomal abnormalities. Cytoge-
netic investigations included Agilent 44K oligonucleotide
array-CGH and karyotyping analysis. Array-CGH identified
pathological numerical or large structural rearrangements in
a total of 32 cases (5%) and microdeletions/duplications
associated to known syndromes in 16 foetuses (2,5%).
Variants of unknown significance were identified in 10
pregnancies (1,5%).Conventional karyotyping identified 2
additional aberrations with one de novo balanced translo-
cation and one case of low trisomy 16 mosaicism. After
years of experience, our center has developed a strong
technical and clinical experience of CMA testing in prenatal
diagnosis. This approach improves the yield of chromosome
aberration detection for fetuses with abnormal ultrasound
scans. In addition, karyotyping remains useful for the
mechanistic explanation of chromosome rearrangement and
prevention of recurrence in some cases.
S. Gimelli: None. E. Stathaki: None. V. Kremer: None.
B. Martinez de Tejada Weber: None. P. Extermann:
None. J. Pellegrinelli: None. M. Billieux: None. I.
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None. R. Robyr: None. E. Ranza: None. S. Antonarakis:
None. M. Abramowicz: None. F. Sloan-Béna: None.
P14.06.B
De novo deletion of the BCL11A gene in 2p16.1
A. Röpke, Y. Stratis, C. Müller-Hofstede, A. Bohring, F.
Tüttelmann
University Hospital Münster, Münster, Germany
We report on a 17-month-old girl of nonconsanguineous
parents. The pregnancy had occurred after intracytoplasmic
sperm injection. The girl presented with difficulties of
feeding, speech and motor delay, microcephaly, brachyce-
phaly, and unspecific craniofacial dysmorphism. The cranial
MRI was unremarkable. Array analysis discovered a het-
erozygous deletion of approximately 156kb in 2p16.1,
confirmed in the child and excluded in parents by
quantitative PCR. This deletion encompasses exclusively
the entire BCL11A gene. Sequence variations in BCL11A
(MIM 606557) are associated with the autosomal-dominant
Dias-Logan syndrome (MIM 617101). Larger deletions
including the BCL11A and neighboring genes were found in
patients with the 2p16.1-p15 deletion syndrome (MIM
612513). Both syndromes are characterized by develop-
mental delay, intellectual disability, microcephaly, dys-
morphic features and persistent fetal hemoglobin. Deletions
in 2p16.1 comprising only the BCL11A gene are rarely
reported. Until now, only two patients with a BCL11A
deletion were described. The patient described by Balci
et al. (2015) showed brain malformations, developmental
delay and distinctive facial features. Peter at al. (2014)
reported a patient with hypotonia, delays in gross motor
skills and a severe speech disorder. However, this patient
had no cranial and skeletal anomalies, microcephaly or
growth retardation. In summary, this is the third patient
described with entire but exclusively deletions of BCL11A.
These patients demonstrate features of Dias-Logan syn-
drome which broadly overlap with 2p16.1-p15 deletion
syndrome and support the assumption that BCL11A is the
candidate gene of most findings seen in patients with
2p16.1-p15 deletion.
A. Röpke: None. Y. Stratis: None. C. Müller-Hofstede:
None. A. Bohring: None. F. Tüttelmann: None.
P14.07.C
A high detection rate for chromosomal microarray
testing in 837 microcephaly cases.
R. Sukenik-Halevy, L. Basel-Salmon, R. Tomashov Matar,
S. Kahanaa, S. Yacobson, I. Agmon-Fishman, I. Maya
Recanati Genetic Institute, Rabin Medical Center, Petah
Tikva,, Israel
Introduction: Microcephaly is a deviation from normal
head growth that may be the first indication of an under-
lying genetic syndrome. We aimed to assess the yield of
chromosomal microarray (CMA) testing for prenatally
detected microcephaly as well as for postnatal cases.
Materials and Methods: CMA testing was performed
for 88 prenatally detected microcephaly cases and for 749
postnatal cases at a single lab. We assessed the yield of
CMA in relation to specific clinical characteristics.
Results: Pathogenic and likely pathogenic (LP) results
were detected in 4.6% of prenatal cases, significantly higher
than the rate reported in low risk pregnancies (1.4%). The
male to female ratio in this cohort was 3. The yield was not
affected by gender nor by any other clinical parameter. The
yield for postnatal cases was 15% with a significantly
higher detection rate for cases in which dysmorphism,
hypotonia, epilepsy, congenital heart defects (CHD),
learning disabilities (LD) and a history of intrauterine
growth restriction (IUGR) were reported. There were no
specific recurrent copy number variations (CNVs). The rate
of variants of unknown significance was 3.94%.
Conclusions: The yield of CMA testing is significant
both for prenatal as well as for postnatal microcephaly
cases. Microcephaly combined with dysmorphism, hypoto-
nia, epilepsy, CHD, LD and IUGR significantly increases













Prenatal (88) 4.6% 25% 75% 0% 25%
Postnatal (749) 15% 17.9% 60.1% 18.75% 17%
Total (837) 13.9% 18.1% 61.2% 18.1% 17.2%
R. Sukenik-Halevy: None. L. Basel-Salmon: None. R.
Tomashov Matar: None. S. Kahanaa: None. S. Yacob-
son: None. I. Agmon-Fishman: None. I. Maya: None.
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The chromosomal microarray analysis of products of
conception in pregnancy loss.
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E. G. Panchenko1, I. V. Kanivets1,2, I. I. Romanova1,3, Y. K.
Kievskaya1, E. V. Kudryavtseva1,4, D. V. Pyankov1, S. A.
Korostelev1
1Genetic Center «Genomed», Moscow, Russian Federation,
2Russian medical Academy of continuing professional
education of the Ministry of health of the Russian
Federation, Moscow, Russian Federation, 3Federal Uni-
versity of Kazan, Kazan, Russian Federation, 4Ural State
Medical University, Yekaterinburg, Russian Federation
Introduction: The miscarriage is an actual problem, that
frequency is from 15-25% to 55%, reaching 80% in the first
trimester. The reccurent pregnancy loss (RPL) is observed
in 2-5% of cases. Chromosomal abnormalities (CAs) are a
common cause of miscarriages and RPL. In 2014-2019 we
performed 2201 analyses of POC to evaluate the prevalence
and structure of chromosomal abnormalities.
Materials and Methods: 2201 samples of DNA from
POC were studied by the chromosomal microarray analysis
(CMA), using CytoScan Optima array (ThermoFisher
Scientific, USA).
Results: CAs were detected in 49.57% of cases, of which
aneuploidy of one chromosome, including mosaic forms, were
detected in 72.69%, aneuploidy more, then one chromosome,
including mosaic forms - 6.97%, triploidy - 10.72%, other CAs
with possible clinical significance - 8.62% (of these - 15.95%
were terminal deletions and duplications of non-homologous
chromosomes, indicating a high probability of unbalanced
translocation), tetraploidy - 1.01%. In 5.7% samples the size of
CAs was less, than the theoretical resolution of the karyotype
analysis (10Mb), of which in 48.48% of cases, such CAs were
found as part of complex CAs.
Conclusions: Chromosomal abnormalities in POC can be
cause of miscarriages and RPL and some complex
rearrangements may present an increased risk for next
pregnancies. In our study CAs were detected in 49,57%
POC samples.
E.G. Panchenko: None. I.V. Kanivets: None. I.I.
Romanova: None. Y.K. Kievskaya: None. E.V.
Kudryavtseva: None. D.V. Pyankov: None. S.A.
Korostelev: None.
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Incidence of constitutional chromosome aberrations in
patients with hematological diseases
M. Valerianova1, S. Ransdorfova1,2, I. Sarova1,2, Z.
Zemanova1,2, M. Onderkova1, S. Izakova2, A. Jonasova3, J.
Cermak1, J. Brezinova1
1Institute of Hematology and Blood Transfusion, Prague,
Czech Republic, 2Center of Oncocytogenomics, Institute of
Medical Biochemistry and Laboratory Diagnostics, Gen-
eral University Hospital and First Faculty of Medicine,
Charles University, Prague, Czech Republic, 31st Medical
Department, General University Hospital and First Faculty
of Medicine, Charles University, Prague, Czech Republic
Introduction: Constitutional chromosome aberrations are
usually a random finding (except of trisomy 21) in cyto-
genetics examination of patients with hematological dis-
eases. In retrospective study over the last 21 years, we
followed the incidence of constitutional chromosome
aberrations detected in connection with the diagnosis of
hematological malignancy and/or other hematological dis-
order. We compared our data with the incidence of specific
chromosome aberrations in previously published studies.
Materials and Methods: We analyzed karyotypes of
bone marrow or peripheral blood cells in 23201 patients
with myeloid or lymphoid disorders diagnosed in 1998-
2019. Subsequently, we verified suspected constitutional
chromosome abnormalities by examination of PHA stimu-
lated peripheral blood lymphocytes. For karyotyping, we
used conventional G-banding completed with molecular
cytogenomics techniques. Patients with Down syndrome
were evaluated as a special group.
Results: In our cohort, we established constitutional
chromosome aberrations in 92/23201 patients (0.4%). Auto-
somal aberrations were more frequent than sex chromosomal
abnormalities. Trisomy 21 (n = 18), balanced reciprocal
translocations (n = 18) and Robertsonian translocations (n =
17) occurred most often in a group of patients with autosomal
anomalies. Sex chromosome aneuploidies were more frequent
in patients with male phenotype (n = 23) than female
phenotype (n = 12), mosaic variants of karyotype (n = 10)
were present in both phenotypes.
Conclusions: The incidence of constitutional chromo-
some aberrations in our cohort of patients with hematolo-
gical diseases is corresponding to their frequency in
population. Our results, similarly as other studies, indicate
that the connection of hematological disorders and con-
stitutional chromosome aberrations seems to be random,
except of acute leukemia and constitutional trisomy 21.
Supported by MH-DRO(IHBT,00023736), RVO-
VFN64165.
M. Valerianova: None. S. Ransdorfova: None. I.
Sarova: None. Z. Zemanova: None. M. Onderkova:
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Detailed cytogenetic analysis of a preconception adult
male sample revealed clonal evolution and (probably)
changed his life
580 J. del Picchia
N. Oliva-Teles1,2, S. Pires1, M. Mota-Freitas1,2, C.
Candeias1,2, E. Lopes1, P. Oliveira1, A. Gavina1, C.
Azevedo Soares3,2, A. Fortuna3,2, N. Tkachenko3
1Centro Hospitalar Universitário do Porto/Centro de
Genética Médica Jacinto Magalhães, Unidade de Citogen-
ética, Porto, Portugal, Porto, Portugal, 2Unit for Multi-
disciplinary Research in Biomedicine/Institute of
Biomedical Sciences Abel Salazar of University of Porto
(UMIB/ICBAS, UP), Porto, Portugal, Porto, Portugal,
3Centro Hospitalar Universitário do Porto/Centro de
Genética Médica Jacinto Magalhães, Serviço de Genética
Médica, Porto, Portugal, Porto, Portugal
Genetic services that specialise in preconception analysis
have traditionally included karyotyping among their routine
genetic studies. If there is any particular clinical suspicion
of a specific disorder, other cytogenomic analyses may be
offered. The authors present the case of an asymptomatic 32
year-old male with non-consanguineous parents from Eur-
opean and African ancestry, who received preconception
genetic counselling at a medical genetics appointment. After
having given his written informed consent for genetic
testing, the patient was screened for carrier status for the
most common variants of cystic fibrosis (CF) and spinal
muscular atrophy (SMA), sickle cell anemia (SCA) and
thalassemia, and balanced chromosomal anomalies by kar-
yotype. No pathogenic variants were found on the CF and
SMA screening and no anomalous results were found for
SCA and thalassemia. However, in three independent cul-
tures, the patient’s blood karyotype revealed a 46, XY line
and another line with a translocation between the long arms
of chromosomes 9 and 22, designated as Philadelphia
chromosome, well-known to be associated with hematolo-
gic malignancy. The karyotype was thus: 46,XY,t(9;22)
(q34;q11.2)[6]/46,XY[33]. He was counselled for the test
results and a complete blood count was performed imme-
diately showing an elevated white blood count with 2%
blasts, thrombocytosis, and hemoglobin values on the lower
limit of normal. He was diagnosed with Chronic Myeloid
Leukemia and initiated treatment with imatinib with a good
clinical evolution. The authors enhance the fact that dis-
closure of incidental findings related with cancer in pre-
conception genetic counselling was very relevant to clinical
care in the case described.
N. Oliva-Teles: None. S. Pires: None. M. Mota-Freitas:
None. C. Candeias: None. E. Lopes: None. P. Oliveira:
None. A. Gavina: None. C. Azevedo Soares: None. A.
Fortuna: None. N. Tkachenko: None.
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When one CNV is not enough and array needs
karyotype and to go FISHing
B. Marques1, S. Serafim1, S. Pedro1, C. Alves1, C.
Ferreira1, A. R. Tarelho1, R. Peliano1, L. Simão1, M. Silva1,
N. Silva1, M. Viegas1, F. Brito1, A. Medeira2, H. Correia1
1Instituto Nacional Saúde Doutor Ricardo Jorge, Lisboa,
Portugal, 2Diferenças - Centro de Desenvolvimento Infan-
til, Lisboa, Portugal
Chromosomal microarray analysis (CMA) allows the
detection of microdeletions/microduplications at a higher
resolution but nonetheless karyotype and FISH studies may
be required to clarify the underlying mechanism and
recurrence risk of complex rearrangements. Here we present
a 3-year-old girl with attention deficit/hyperactivity disorder
(ADHD), speech disorder (SD), developmental delay (DD),
and strabismus with a 3.6 Mb terminal loss at 9p24.3p24.2,
a 433 Kb interstitial gain at 15q13.3, and a 3.3 Mb terminal
gain at Xp22.33, uncovered by Affymetrix Cytoscan HD
CMA. The 15q13.3 gain, inherited from the unaffected
father, includes part of CHRNA7 and it´s a known region
with incomplete penetrance and variable expressivity
associated to DD, SD, and ADHD, apparently fitting to the
patient phenotype. However, to assess a predicted unba-
lanced t(X;9) karyotype and FISH were performed, both in
the patient and the parents, revealing a de novo submicro-




x3. The few reported patients with 9p deletion show a
variable phenotype which may include DD, SD, and stra-
bismus, among others, features also described in our patient.
The Xp gain has an unknown contribution for the overall
phenotype. Trio SNP-array showed the der(9) to be of
maternal origin and therefore a balanced t(X;9) with low
level/gonadal mosaicism in the mother may exist and thus
recurrence risk is not completely excluded. This case shows
of how CNVs may contribute cumulative to a phenotype
and the importance of keeping both cytogenetics and
cytogenomics present in a diagnostic setting as CMA may
need clarification by karyotype/FISH.
B. Marques: None. S. Serafim: None. S. Pedro: None.
C. Alves: None. C. Ferreira: None. A. R. Tarelho: None.
R. Peliano: None. L. Simão: None. M. Silva: None. N.
Silva: None. M. Viegas: None. F. Brito: None. A.
Medeira: None. H. Correia: None.
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Diploid/triploid mosaicism in a child with normal
development
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Engelund1, C. Fagerberg1
1Department of Clinical Genetics, Odense University
Hospital, Odense, Denmark, 2Department of Dermatology
and Allergy Centre, Odense University Hospital, Odense,
Denmark, 3H.C. Andersen Children’s Hospital, Odense
University Hospital, Odense, Denmark
Introduction: Diploid/triploid mosaicism is a rare entity,
where a triploid cell line is present with varying tissue
distribution. Cognitive deficit of varying degree is reported
in most published cases. Other frequently reported features
are growth retardation, syndactyly or clinodactyly, hypo-
tonia, truncal obesity, body or facial asymmetry and pig-
mentary changes of the skin in the distribution of
Blaschko’s lines. We present a case with diploid/triploid
mosaicism in a girl with normal development and review
reported cases of diploid/triploid mosaicism.
Materials and Methods: Affymetrix Cytoscan HD
chromosomal micro array (CMA), and G-band karyotyping.
Results: A 3,5-year old girl was referred for evaluation of
irregular skin pigmentation following Blaschko’s lines. She
was otherwise healthy with normal development. Karyotyp-
ing of fibroblasts from hyperpigmented and normal skin,
revealed mosaicism with a triploid cell line (69,XXX) in
39% and 24% respectively. CMA verified mosaicism in the
hyperpigmented skin biopsy but failed to detect the low-
grade mosaic in normal skin. A normal karyotype 46,XX
was seen in blood.
Conclusions: This case confirms, that diploid/triploid
mosaicism can be seen in persons with normal develop-
ment, representing one end of a broad phenotypic spectrum.
Genetic testing is biased towards individuals with cognitive
deficit, and it is therefore likely that diploid/triploid
mosaicism is underdiagnosed in patients with normal
development. While triploid mosaicism was seen by
karyotyping in hyperpigmented as well as normal skin,
CMA failed to detect the triploid cell line in normal skin,
confirming that karyotyping is still a valid and useful
diagnostic method for pigmentary anomalies.
M.S. Andersen: None. K. Pallesen: None. M.A. Kabel:
None. M.B. Engelund: None. C. Fagerberg: None.
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Genotoxicity induced in vitro by water soluble indoor
ΡΜ2.5 fractions in relation to eight heavy metals
concentrations
E. Kogianni1, C. Samara1, T. S. Lialiaris2
1Aristotle University of Thessaloniki, Dept of Chemistry,
Thessaloniki, Greece, 2Dekokritus University of Thrace,
Medical School, Dept of Genetics, Alexandroupolis,
Greece
Introduction: Airborne particulate matter (PM) generally
contains a large number of genotoxic substances. Heavy
metals concentrations in water-soluble outdoor PM frac-
tions have been found consistent with genotoxicity to a
significant degree, when no sufficient evidence exists for the
indoor PM corresponding fractions.
Materials and Methods: The genotoxicity induced by
water extractable particulate matter PM2.5 selected from
indoor air of 20 workplaces in Alexandroupolis (North-
eastern Greece) was examined in relation to the concentra-
tions of the heavy metals Cu, Pb, Mn, Ni, Co, Zn, Cr and
Cd. For the determination of genotoxicity, the Sister
Chromatid Exchange (SCE) induction assay was applied
in human peripheral lymphocytes from healthy volunteer
donors, whereas metals concentrations were determined
using atomic absorption spectroscopy. Measurements took
place in three water-soluble fractions: the total fraction WSA
(filtered through 0.45 μm), the dissolved fraction WSB
(filtered through 0.22 μm) and the non-chelexed dissolved
fraction WSC (filtered through Chelex-100 resin).
Results: Statistically significant genotoxicity has been
induced by all three fractions in relation to the control.
When the results have been air volume- and ΡΜ2.5 mass-
normalized, the number of SCE’s decreases from WSA to
WSC, while the difference of SCE’s between WSA and WSC
is statistically significant in the air volume- normalized
approach. Also, significant correlations between a number
of metals and the induced genotoxicity resulted in all three
fractions, which are weaker in the air volume- normalized
approach.
Conclusions: Heavy metal concentrations seem to play
an important role to genotoxicity induced by water-soluble
indoor ΡΜ2.5 fractions.
E. Kogianni: None. C. Samara: None. T.S.
Lialiaris: None.
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Assessment of genotoxicity at low Doxorubicin doses in
mice using chromosomal aberration assay
R. M. Sionel1, L. Berca2, S. Spandole Dinu1, P. Apostol3,
M. Toma4, D. Cimponeriu1, R. I. Nica4
1Faculty of Biology, University of Bucharest, Bucharest,
Romania, 2National Institute of Research and Development
for Food Bioresources – IBA Bucharest, Bucharest,
Romania, 3Clinica Sante, Bucharest, Romania, 4Central
Military Emergency Clinical Hospital, Bucharest, Roma-
nia
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Our aim is to investigate if high fat diet can interfere with
genotoxicity of low doxorubicin (DOX) doses on bone
marrow cells. We investigated four groups of adult BALBc
mice that received normal diet (groups NFI, NFII) or pork
greaves (groups PGI, PGII) for 7 days. At the beginning of
the 8th day mice from each group received a single intra-
peritoneal injection with DOX (doses range: 1.7-7.7 mg/kg
body weight) or isotonic saline solution. All doses were
tested in quadruplicate. In the 10th (groups NFI, PGI) and in
the 14th (groups NFII, PGII) days from the beginning of the
experiment the mice were euthanized and the chromosome
aberrations were tested in bone marrow cells. We initialy
assumed that the brutal shift of diet from normal food to
pork greaves will have a big impact on mice weight, but the
results have shown that DOX had a stronger impact cousing
ambrupt weight loss. After 3- or 7-days post-injection with
low DOX doses the number of chromosomal aberrations
was significantly increased when compared to control group
(p < 0.05). From observed aberrations the frequencies of
polyploidy and deletion were significantly higher in mice
who received 5.7-7.1 mg/kg when compared to those trea-
ted with lower doses. The clastogenic impact of DOX in
bone marrow cells seem to not be influenced by
alternative diet.
R.M. Sionel: None. L. Berca: A. Employment (full or
part-time); Modest; National Institute of Research and
Development for Food Bioresources – IBA Bucharest. S.
Spandole Dinu: None. P. Apostol: None. M. Toma: A.
Employment (full or part-time); Modest; Central Military
Emergency Clinical Hospital. D. Cimponeriu: A. Employ-
ment (full or part-time); Modest; Faculty of Biology,
University of Bucharest. R.I. Nica: A. Employment (full
or part-time); Modest; Central Military Emergency Clinical
Hospital.
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Environmental impact on genotoxicity measured with
the micronucleus test
O. Alexandru1, M. Alexandra2, P. Laura1, C. Adela1,2, A.
Nicoleta1,2, P. Maria1,2
1Clinical Emergency Hospital for Children "Louis Tur-
canu", Timisoara, Romania, 2Genetics Department, Geno-
mic Medicine Timisoara University of Medicine and
Pharmacy “Victor Babes”, Timisoara, Romania
Introduction: Genotoxicity represents the damage done to
DNA by ionizing radiation. This damage can lead to the
formation of random mutations in somatic cells and sub-
sequently to the formation of different types of neoplasia.
We aim to: Study the association of environmental factors
with the genotoxic effect of ionizing radiation.
Material and Methods: We tested 64 doctors and nurses
working in the Radiology and Radiotherapy departments
using the micronucleus test. Along with the test, the medical
personnel received a questionnaire regarding personal
lifestyle choices as well as additional sources of exposure
to genotoxic agents. Using the data received from the
questionnaire we attempted to establish correlations
between specific lifestyle choices and the results of the
micronucleus test.
Results: We looked at correlations between age, overall
number of risk factors, individual risk factors, employment
length and the number of micronuclei per 1000 lympho-
cytes. Our results showed no significant correlation between
the variables measured. Participants with risk factors such
as smoking (40%), alcohol consumption (19%) and X-ray
exposure in the last 5 years (58%) showed no measurable
increase in the average number of micronuclei. Only
participants that had undergone CT-scans in the last 5
years (26%) showed an increased average of their
micronucleus test (8.375‰ compared to the overall average
of 5.7‰).
Conclusions: The environment seems to play a negligible
role in number of micronuclei, as a proxy for genotoxicity,
however increased number of participants could bring
additional information. Exposure to CT scans was shown to
be associated with genotoxicity.
O. Alexandru: None. M. Alexandra: None. P. Laura:
None. C. Adela: None. A. Nicoleta: None. P.
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Interstitial 11q12.1q13.1 duplication in patients with
intellectual disability
B. Gläser1, K. Komlosi1, T. Haack2, S. Waldmüller2, A.
Gazou2, A. Müller2, T. Liehr3, J. Fischer1, A. Tzschach1
1Institute of Human Genetics, Freiburg, Germany, 2Institute
of Medical Genetics and Applied Genomics, Tübingen,
Germany, 3Institute of Human Genetics, Jena, Germany
Interstitial duplications of chromosome region
11q12.1q13.1 are rare. We report on two siblings with
intellectual disability in whom an interstitial de-novo-
duplication of chromosome region 11q12.1q13.1 was
detected. The 35-year-old female index patient had mild
intellectual disability, but no malformations or other major
health problems. Her 28-year-brother had moderate intel-
lectual disability. Array-CGH analyses revealed an identical
7.83 Mb duplication in chromosome region 11q12.1q13.1
(genomic position according to hg19: chr11:57453530-
65234091) in both patients. The duplication was confirmed
by FISH analyses and whole-exome sequencing. The
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duplication was present neither in the healthy parents nor in
the healthy sister, suggesting germline mosaicism in one of
the parents. The findings in the family reported here indicate
that duplications of chromosome region 11q12.1q13.1 are
associated with mild to moderate intellectual disability, but
not with major malformations or other severe health pro-
blems. Reports of additional patients with overlapping
duplications will be needed to elucidate the contribution of
individual genes to the clinical phenotype.
B. Gläser: None. K. Komlosi: None. T. Haack: None.
S. Waldmüller: None. A. Gazou: None. A. Müller: None.
T. Liehr: None. J. Fischer: None. A. Tzschach: None.
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A case report of a possible novel deletion syndrome
involving the KCTD16 gene
G. Gori1, F. Di Giovanni1, A. Pagliazzi1, S. Bargiacchi2, S.
Guarducci2, F. Pochiero3, S. Giglio1
1Department of Biomedical Experimental and Clinical
Sciences "Mario Serio", University of Florenc, Florence,
Italy, 2Medical Genetics Unit, Meyer Children’s University
Hospital,, Florence, Italy, 3Metabolic and Muscular Unit,
Neuroscience Department, Meyer Children’s Hospital,
Florence, Italy
Here we describe the case of a male newborn of non con-
sanguineous parents, born by cesarean section for intrau-
terine growth retardation. In occasion of genetic evaluation,
performed at age two years, we have ascertained hypospa-
dias, microcephaly, dysmorphic facial features and devel-
opmental delay, in association with hyperCK-emia and high
levels of transaminases. Array-CGH analysis showed a de
novo interstitial deletion of approximately 194 kilobases in
the 5q31.3 region, which includes part of the KCTD16
gene, to date not associated with any specific human dis-
ease. KCTD16 is one of the auxillary subunits of the
GABA-B receptor and has been demonstrated to influence
neuronal excitability by regulating GABA-B receptor-
mediated gating of postsynaptic ion channels. This subunit
is highly expressed in many brain regions, including
amygdala and hippocampus, and regulates GABA-B
receptors’ action on postsynaptic ion channels. KCTD16,
essentially, influences GABA-B modulation of neuronal
excitability, oscillatory network activity and cognitive
functions. Our report is the first finding of an intragenic
deletion of KCTD16 and we could speculate that hap-
loinsufficiency of this gene may have played a role in
determining our patient’s neurodevelopmental phenotype.
We plan to perform further molecular analyses (whole
exome sequencing) since we cannot rule out the neurolo-
gical phenotype may be determined by biallelic variants of
this gene. Furthermore, our patient’s phenotype could also
be caused by other known disease-genes. We will then
proceed with functional studies to verify the real association
of this gene with a new syndrome.
G. Gori: None. F. Di Giovanni: None. A. Pagliazzi:
None. S. Bargiacchi: None. S. Guarducci: None. F.
Pochiero: None. S. Giglio: None.
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Mosaic loss of chromosome Y is more prevalent in
patients with prostate cancer
T. Kobayashi1, T. Hachiya2, K. Hino3, T. Ando3, M.
Terashima3, I. B. Sato3, M. Nagata1, H. Kawano1, S. Horie1
1Department of Urology, Juntendo University, Graduate
School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan,
2Department of Advanced Informatics for Genetic Disease,
Juntendo University, Graduate School of Medicine, Hongo,
Bunkyo-ku, Tokyo, Japan, 3Genesis Healthcare Co., Ebisu,
Shibuya-ku, Tokyo, Japan
Introduction: Clinical utility of mosaic loss of chromo-
some Y (mLOY) for cancer screening or for predicting
cancer prognosis is controversial. We examined the pre-
valence of mLOY in patients with prostate cancer.
Materials and Methods: DNA microarray analysis was
performed on saliva samples from 176 prostate cancer
patients and 5402 control subjects. From the fluorescence
intensity data of 2464 probes located at male-specific region
of chromosome Y, the median of log R ratio (mLRR-Y)
was calculated, and subjects with mLRR-Y ≤ -0.15 was
classified into the mLOY group. Age distribution was
matched in prostate cancer and control groups, and the
frequency of mLOY was compared. Furthermore, we
investigated the association of mLOY with age at diagnosis,
PSA value at diagnosis (iPSA), progression to castration-
resistant prostate cancer (CRPC), and treatment methods
among prostate cancer patients.
Results: Of the 165 cases in each of the age-matched
groups, the number of subjects with mLOY was signifi-
cantly higher in prostate cancer compared to control (9 in
prostate cancer and 0 in control; P-value = 0.003). Among
the prostate cancer patients, there were no significant
differences in age at diagnosis, iPSA, and the proportion of
the cases that progressed to CRPC. Regarding treatment
methods, mLOY was not associated with surgery, but was
significantly associated with radiotherapy (P-value =
0.021).
Conclusions: mLOY occurs more frequently in patients
with prostate cancer than in the control group. Among
prostate cancer patients, mLOY is more likely to occur in
cases who have been treated with radiation.
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Mosaic Turner syndrome of maternal origin in a child
resulting from a consanguineous marriage: evaluation of
the folate metabolism
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FAMERP, São José do Rio Preto, Brazil, 2União das
Faculdades dos Grandes Lagos- UNILAGO, São José do
Rio Preto, SP, São José do Rio Preto, Brazil, 3Universidade
Estadual do Norte Fluminense Darcy Ribeiro – UENF,
Campos dos Goytacazes, Brazil
Introduction: Turner syndrome affects approximately
1:2000 female live births. 45,X/47,XXX mosaicism is seen
in only 1% of cases; often caused by early post-zygotic
chromosomal non-disjunction in disomic cells. Abnormal
folate metabolism, as a result of genetic polymorphisms,
can result in chromosomal non-disjunction. The present
study evaluated the parental origin of non-disjunction and
polymorphisms in genes involved in the folate metabolism
in 45,X/47,XXX mosaic patient and their parents.
Materials and Methods: Allelic segregation analysis for
the STR marker located in the Retinitis pigmentosa 2 (RP2)
gene was performed using quantitative fluorescent poly-
merase chain reaction (QF-PCR). The RFC1A80G,
MTRA66G, MTHFRC667T, MTHFRA1298C,
CBS844ins68 and DHFRdel19pb polymorphisms were
investigated by PCR and enzymes restriction.
Results: The amniocentesis karyotype, revealed 45,X/47,
XXX mosaicism. Postnatal karyotype confirmed mosaicism
and the genealogy revealed consanguineous union, first
cousins. The patient’s DNA sample exhibited a triallelic
profile which two are of maternal origin (alleles 315bp and
319bp) and one of paternal origin (309bp allele). The
analysis also indicated that 45,X cells maintain maternal X
represented by the 319bp allele. In the patient, the allelic
variants RFC1A80G, MTRA66G, MTHFRC667T,
MTHFRA1298C and DHFRdel19pb were observed in
heterozygosity. The presence of heterozygosity also was
observed in her mother (MTHFRC667T, DHFRdel19pb
and MTHFRA1298C) and in her father (MTRA66G,
RFC1A80G and MTHFRA1298C). CBS844ins68 alleles
were homozygous in the family trio.
Conclusions: It is possible that the presence of allelic
variants involved in the folate metabolism might have
favored errors in chromosomal disjunction during maternal
gametogenesis, resulting in Turner syndrome mosaic.
Grants: FAPESP(2018/09126-0), CNPq(310806/2018-
6), CAPES(001), FAMERP/FUNFARME.
O. Borghi Nascimento: None. B. Pavarino Bertelli:
None. M. Fraga Mattos: None. A.L. Galbiatti Dias da
Silva: None. E.M. Goloni-Bertollo: None. E. Medina-
Acosta: None. T. Louvain de Souza: None. É.C.
Pavarino: None.
P14.26.A
A Case With Turner-Down Syndrome
S. Canbek1, H. C. Emeksiz2, A. Ozturk Kaymak3, A. Tukun3
1Medical Genetics Department, Umraniye Training and
Research Hospital, Istanbul, Turkey, 2Pediatric Endocri-
nology Department, Medeniyet University Goztepe Training
and Research Hospital, Istanbul, Turkey, 3Medical Genetics
Department, Duzen Laboratories, Ankara, Turkey
Introduction: We reported a patient with the mosaic form
of Turner Syndrome and Down Syndrome, which is extre-
mely rare. A 16-year-old girl was evaluated for her short
stature and minor dysmorphic features. She has mild mental
retardation, short stature and minor dysmorphic features
with mild hypotelorism, mild epicanthic folds, long phil-
trum, micrognathy, retrognathy, mild low set ears, mild low
posterior hairline, short neck, short fifth fingers, increased
distance between the first and second toes, skin syndactyly
of second to third toes, bilateral proximal outlet of fourth
toe. She has no gonadal dysgenesia and has regular men-
strual periods. The patient’s pelvic and renal ultrasound and
echocardiographic examinations were normal. She is the
seventh child of 53 years old mother and 55 years old
father.
Materials and Methods: Cytogenetic analysis of per-
ipheral blood samples by using G-banding revealed
mosaicism with 2 cell lines (47,XX+21[16]/45,X[14]).
FISH analysis revealed that 78.5% of the cells had
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monosomy X karyotype and 21.5% of the cells had XX
karyotype; trisomy 21 was detected in 7.4 % of the cells.
Results: The cytogenetic analysis of the patient revealed
mosaicism of Turner and Down syndrome. Her FISH
analyses from urine and buccal swab confirmed that result.
Her parental chromosome analyses were normal.
Conclusions: The incidence of Turner / Down Syndrome
is very rare. To date, less than 100 patients have been
identified. We present this case to emphasize that classical
cytogenetic analysis is still very important for the diagnosis
of chromosomal abnormalities
S. Canbek: None. H.C. Emeksiz: None. A. Ozturk
Kaymak: None. A. Tukun: None.
P14.30.B
Verification of balanced and unbalanced structural
variants by optical genome mapping
J. Schiller1, U. Heinrich1, E. Krimmel1, E. Vibe1, S. Bauer2,
D. Wahl3, F. Maier3, M. Cohen1, H. Klein1
1MVZ Martinsried, Martinsried, Germany, 2Bionano Geno-
mics, San Diego, CA, United States, 3Medical Practice for
Genetic Counseling and Psychotherapy, Augsburg, Ger-
many
Conventional chromosome analysis is capable of detecting
both copy number (CNV’s) and balanced structural variants
(SV’s), but only at a low resolution. Microarray analysis
can detect CNV’s at a high resolution level, but is unable to
detect copy neutral SV’s. To get a deeper insight in such
variants and to narrow down the breakpoint regions, we
started a verification study using 20 samples with known
chromosome and microarray analysis results using Bionano
Genomics’ optical mapping technology. Bionano Genomics
offers a complete workflow solution from sample prepara-
tion, DNA imaging and genomic data analysis enabling the
identification of balanced and unbalanced SV’s. Ultrahigh-
molecular-weight DNA (size 50kb to ≥ 1 Mb) was extracted
from fresh human blood followed by a single direct-labeling
enzymatic reaction to incorporate fluorophores at a specific
6-basepair sequence motif, yielding approximately 15 labels
per 100 kb. The SAPHYR-Instrument loads samples into
nanochannels linearizing the labeled sample DNA and
visualizing the label pattern. An algorithm converts the
images into molecules and aligns molecules ‘de novo’ to
construct consensus genome maps. Cross-Mapping to a
reference sequence enables an automated SV detection.
In a runtime of about 24h, an effective coverage of approx.
318-381x (minimum required 80x for non-mosaic samples)
was achieved with a total DNA (>=150 kb) output of 1300
Gb and a map rate of 78-89%. We will discuss our results
and demonstrate that this technology can be applied in a
clinical diagnostic setting having the potential to replace
conventional cytogenetics and microarray analysis.
J. Schiller: None. U. Heinrich: None. E. Krimmel:
None. E. Vibe: None. S. Bauer: A. Employment (full or
part-time); Modest; Bionano Genomics. D. Wahl: None. F.
Maier: None. M. Cohen: None. H. Klein: None.
P14.32.A
Molecular manifestations of Phelan-McDermid syn-
drome. Assotiation to ring chromosome
M. Bellido1, T. De Haro1, C. García2, M. Perez1
1Hospital Universitario Virgen de las Nieves, Granada,
Spain, 2Hospital Universitario Juan Ramon Jjimenez,
Huelva, Spain
Background Phelan-McDermid syndrome (PHMDS) is
typically characterized by autism spectrum disorder, absent
to severely delayed speech, and neonatal hypotonia. The
PHMDS wide phenotypic variation is attributed partly to
the type and size of 22q13 genomic deletion, partly to
additional undefined factors. This deletion encompasses the
SHANK3 gene which is thought to be the critical gene for
the neurodevelopmental features. We report the cytogenetic
and molecular characterization of a constitutional de novo
ring chromosome 22 (r(22)) in a patient with autism and
language disorders Methods GTG-banding karyotype was
performed according to standard protocols. Twenty meta-
phases chromosomes were examined with a 400-550 bands
of resolution. Array-CGH analysis was performed by a
CGXTM HD v1,1 4-plex array 180 k (PerkinElmer), with an
average resolution of 40 kb in the backbone and 20kb in the
regions of interest. Results Karyotype results were 46,XY,r
(22)(p13q13.33). Array-CGH revealed a terminal deletion
on the long arm of chromosome 22, involving region
22q13.33 with an estimated size of 734.84 Kb, including
SHANK3 gene; arr (GRCh19) 22q13.33(50,443,314-
51,178,149)x1. Conclusion The determination of the size of
the deletion by aCGH is very useful for the association with
described syndromes associated with deletions or duplica-
tions. However, the possibility that this deletion leads the
formation of a ring chromosome can only be evaluated by
performing a karyotype which is also necessary to analyse
the presence or absence of mosaicism respect to ring
chromosome, and therefore, the clinical symptoms and
evolution of the patient could have implications for genetic
counselling.
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P14.33.B
De novo microdeletions at 6q14.1 encompassing the
PHIP gene in two girls with developmental delay,
intellectual disability, behavioral problems obesity, and
dysmorphic features
A. Boughalem1, D. Trost1, A. Bazin2, C. Allioux3, A.
Lantres2, P. Kleinfinger1, S. Zimmer1, L. Lohmann1, A.
Luscan1, M. Valduga1, J. Costa1
1Laboratoire Cerba, Saint Ouen l’Aumone, France,
2Hôpital René Dubos, Pontoise, France, 3Hôpital De Saint
Denis, Saint Denis, France
Heterozygous deleterious variants in the pleckstrin homol-
ogy domain-interacting protein (PHIP) located on chro-
mosome 6q14.1, have been associated with Chung-Jansen
syndrome MIM # 617991. Only 9 patients with micro-
deletions spanning the 6q14.1 region including the PHIP
gene have been reported with a phenotype similar to Chung-
Jansen syndrome. However, these patients have a number of
additional clinical findings, likely due to the deletion of
adjacent genes in 6q14. Here, we report two interstitial
deletions at 6q14.1 involving the PHIP gene, in two unre-
lated patients with a common phenotype of developmental
delay, intellectual disability, behavioral problems, obesity
and dysmorphic features. Methods and results: SNP-CGH
analysis using Affymetrix Cytoscan HD microarray has
been performed. A 642kb microdeletion at 6q14.1
(79,326,616_79,968,863 hg19) has been detected in the first
female patient presenting with obesity, developmental
delay, behavioral and facial abnormalities. A smaller 54 kb
intragenic microdeletion at 6q14.1, spanning part of exon 8-
exon 24 of the PHIP gene (79687488_79741515 hg19) has
been detected in the second female patient presenting with
behavioral problems, developmental delay, dysmorphic
features. Her endocrine problems (other than obesity)
included hypothyroidism, generalized hirsutism and pre-
cocious puberty. Conclusions: To our knowledge the 54 kb
deletion is the smallest microdeletion described in this
region by the use of SNP-CGH analysis. The patients we
report here show clinical overlap with the phenotypic
spectrum of previously reported in individuals with PHIP
variants, which confirms that haploinsufficiency of PHIP is
sufficient to cause Chung-Jansen syndrome. This is the first
report of endocrine problems eg. Hirsutism, in Chung-
Jansen syndrome.
A. Boughalem: None. D. Trost: None. A. Bazin: None.
C. Allioux: None. A. Lantres: None. P. Kleinfinger:
None. S. Zimmer: None. L. Lohmann: None. A. Luscan:
None. M. Valduga: None. J. Costa: None.
P14.35.A
Rescue of the karyotype with ring chromosome 8 in
human induced pluripotent stem cells
T. V. Nikitina1, M. M. Gridina2, Y. M. Minina2, A. A.
Kashevarova1, Y. S. Yakovleva1,3, D. A. Fedotov3, M. E.
Lopatkina1, S. A. Vasilyev1, O. L. Serov2,4, I. N. Lebedev1
1Research Institute of Medical Genetics, Tomsk NRMC,
Tomsk, Russian Federation, 2Institute of Cytology and
Genetics SB RAS, Novosibirsk, Russian Federation, 3Siber-
ian State Medical University, Tomsk, Russian Federation,
4Novosibirsk State University, Novosibirsk, Russian Fed-
eration
Introduction: Ring chromosomes are usually found as a
part of mosaic karyotype and dynamic mosaicism is a fre-
quent event in the patient’s cells. Induced pluripotent stem
cells (iPSCs) proved to be a valuable tool for the modelling
of the dynamics of ring chromosome mosaicism through
multiple cell divisions.
Materials and Methods: We obtained 6 iPSC lines from
skin fibroblasts of patient with 46,XY,r(8) and compared
karyotypes of fibroblasts and iPSCs at different passages
using G-banding, FISH and SNP-arrays.
Results: Molecular karyotyping revealed that ring
chromosome originated from an inverted duplication
8p23.1-p11.22 with a terminal deletion at 8p23.3-p23.1.
We found 85% fibroblasts with r(8) and 15% with
monosomy 8, but later a clone of the cells with t(7;8)
arose, that have gained a proliferative advantage with more
than 80% of the cells after P20. iPSC karyotypes were
similar with the initial fibroblasts in the early passages (90%
of the cells had r(8) at P4), but later changes occurred in the
line iTAF11-4: only 2% of the cells had the ring at P11 (100
cells were counted per passage). SNP-arrays revealed signs
of chromothripsis in early passage and 46,XY karyotype at
P11 with an UPD(8)pat.
Conclusions: Molecular and cytogenetic analyses allow
to track the mitotic behavior of the ring chromosome in
iPSCs culture. Spontaneous correction of the 46,XY,r(8)
karyotype via uniparental disomy origin has been registered
in one of the 6 iPSC lines. This study was supported by
Russian Science Foundation, grant 16-15-10231.
T.V. Nikitina: None. M.M. Gridina: None. Y.M.
Minina: None. A.A. Kashevarova: None. Y.S. Yakov-
leva: None. D.A. Fedotov: None. M.E. Lopatkina: None.
S.A. Vasilyev: None. O.L. Serov: None. I.N.
Lebedev: None.
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P14.36.B
A case of ring chromosome 21 with hemifacial micro-
somia, developmental and speech delay analysed with
WGS and patient-derived iPS
J. Schuy1, J. Eisfeldt1,2,3, M. Pettersson1,2, N.
Shahrokhshahi2, M. Shahsavani1, D. Nilsson1,2,3, A. Falk4,
A. Lindstrand1,2
1Department of Molecular Medicine and Surgery and
Center for Molecular Medicine, Karolinska Institutet,
Stockholm, Sweden, 2Department of Clinical Genetics,
Karolinska University Hospital, Stockholm, Sweden,
3Science for Life Laboratory, Karolinska Institutet Science
Park, Stockholm, Sweden, 4Department of Neuroscience,
Karolinska Institutet, Stockholm, Sweden
Introduction: Ring chromosomes are rarely occurring cir-
cularized chromatin which can arise during mitosis if the
telomeric sequences are lost. Structural variants (e.g. dele-
tions) often accompany the formation of ring chromosomes,
leading to neurodevelopmental disorders which severity
strongly depends on the affected genes. However, the exact
mechanism and biological effect of ring chromosomes is
still unknown. Here, we present RD_P26, a 6-year old girl
presenting hemifacial microsomia, developmental and
speech delay, and a ring chromosome 21, 46,XX,r(21)
(p11.2q22.3).
Methods: Characterization with chromosomal microar-
ray, whole genome sequencing and breakpoint junction
(BPJ) PCR unravelled three alternating deletions and two
inversions with templated and non-templated insertions in
the BPJs. Remarkably, this loss of genetic material,
affecting 29% (70/242) of the protein-coding genes on
chromosome 21, is not lethal. Moreover, the ring chromo-
some is stable through multiple passages of neuroepithelial
stem cells (NES), differentiated from patient-derived
induced pluripotent stem cells. Furthermore, we analysed
the transcriptome of NES from RD-P26 and compared the
expression profile to two trisomy 21 patients and three
healthy controls.
Results: 11.6% genes (2080/17831) were differentially
expressed. Of the 171 genes located on chromosome 21,
24% (41/171) were differentially expressed. Within the
three deleted segments, 19 genes were significantly down-
regulated and there were no significant upregulations,
consistent with haploinsufficiency. Moreover, the down-
regulated gene expression was mirrored by an elevated gene
dosage in the trisomy 21 patients.
Conclusions: The hemizygous genes located within the
deletions are considered as likely causing the patient’s
phenotype, also other chromosomal rearrangements
were found. Funding: Swedish science council 2017-
02936.
J. Schuy: None. J. Eisfeldt: None.M. Pettersson: None.
N. Shahrokhshahi: None. M. Shahsavani: None. D.
Nilsson: None. A. Falk: None. A. Lindstrand: None.
P14.38.A
Tetrasomy of SCN2A associated with refractory neona-
tal epileptic encephalopathy
M. Krumbiegel1, R. Trollmann2, D. Mammadova2, A.
Schnell2, C. Kraus1, A. B. Ekici1, A. Reis1, C. Zweier1
1Institute of Human Genetics, Friedrich-Alexander-Univer-
sität Erlangen-Nürnberg, Erlangen, Germany, 2Department
of Pediatrics, University Hospital for Children and
Adolescents, Friedrich-Alexander-Universität Erlangen-
Nürnberg, Erlangen, Germany
Autosomal dominant missense or truncating mutations or
deletions of sodium channel genes such as SCN1A, SCN2A
or SCN9A cause a broad spectrum of neonatal epileptic
encephalopathies with variable clinical phenotypes. The
sodium channel gene family clusters in 2q24.3, and dupli-
cations of this region have been rarely described. All
reported patients presented with severe, early-onset seizures
and variable developmental and behavioral anomalies.
We now report on a female newborn who presented from
first day of life with severe muscular hypotonia and
prolonged focal cerebral seizures. Seizures were initially
therapy refractory, but a high dose parenteral therapy with
Phenytoin suppressed seizures almost completely, indicat-
ing a mutation in SCN2A gene as possible cause. Trio
exome sequencing, however, did not reveal a causative
variant in SCN2A or other epilepsy-related genes. Chro-
mosomal microarray analysis with an Affymetrix CytoScan
HD Array revealed a copy number gain of 5,516 kb in
2q24.3q31.1 affecting 34 genes including the sodium
channel gene cluster on 2q24.3. The proximal part of 0.5
Mb containing SCN2A was present in four copies and the
distal part of 5 Mb (containing SCN1A and SCN9A) in
three copies. The aberration was confirmed, and a parental
cryptic translocation was excluded by FISH analyses.
We therefore consider this copy number gain in
2q24.3q31.1 to be disease-causing in our patient. To our
knowledge, this is the first copy number gain in this region
that includes a triplication of SCN2A. Tetrasomy of SCN2A
might therefore contribute to the particularly severe
phenotype.
M. Krumbiegel: None. R. Trollmann: None. D.
Mammadova: None. A. Schnell: None. C. Kraus: None.
A.B. Ekici: None. A. Reis: None. C. Zweier: None.
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Profound body asymmetry in a girl with a develop-
mental delay carrying germline partial trisomy 15q and
somatic duplication 11p15
K. Bilska1, U. Heinrich1, E. Krimmel1, D. Wahl2, I. Rost1, T.
Eggermann3, F. Maier2
1MVZ Martinsried, Martinsried, Germany, 2Medical Prac-
tice for Genetic Counseling and Psychotherapy, Augsburg,
Germany, 3Institute of Human Genetics, Medical Faculty,
RWTH Aachen University, Aachen, Germany
We present a 3 1/2 year old Chechen girl with severe body
asymmetry, developmental delay and dysmorphic features.
Chromosome analysis from cultured peripheral lymphocytes
was performed, which showed an additional chromosomal
material on the short arm of one chromosomes 22. For further
characterization of the chromosomal aberration, we performed
array CGH analysis and detected an almost 25 Mb large
terminal duplication 15q24.3q26.3. The combination of these
two methods showed a de-novo pure partial trisomy 15q with
the karyotype 46,XX,der(22)t(15;22)(q24.3;p12). The Region
15q24.3-qter contains 151 proteins and is associated with
overgrowth and developmental delay. In order to clarify the
cause of the asymmetry, methylation-sensitive MLPA and
qPCR was performed on mucosal cells of the left and right side.
Triplicated copy number variation of 11p15.5 with unsuspicious
methylation status was found in mucosal cells of the left side
and is known for the growth retardation syndrome Silver-Russel
and IMAGe. Subsequent quantitative PCR showed at least 20.8
Mb de-novo duplication 11p15.5p15.1. No mosaicism was
found in mucosal cells of the right side. This case shows a
complex phenotype-genotype-correlation with coexistence of a
germline and a somatic variant leading to hemihypertrophy and
hemihypotrophy and may provide new insights of the precise
human embryonic and fetal growth network.
K. Bilska: None. U. Heinrich: None. E. Krimmel:
None. D. Wahl: None. I. Rost: None. T. Eggermann:
None. F. Maier: None.
P14.42.B
Hi-C enables the 3D characterization of small super-
numerary marker chromosomes
J. Jungnitsch1,2, M. Klever1,2, U. Melo2,1, R. Schöpflin2,1,
C. A. Prada-Medina2, T. Liehr3, S. Mundlos1,2, M.
Spielmann1,2
1Institute for Medical Genetics and Human Genetics,
Charité – University Medicine Berlin, Berlin, Germany,
2Max Planck Institute for Molecular Genetics, Research
Group Development and Disease, Berlin, Germany,
3Institute of Human Genetics, Jena University Hospital,
Friedrich Schiller University, Jena, Germany
For the last five decades, small supernumerary marker
chromosomes (sSMCs) have been known to exist and are
estimated to be present in ~3.3 million human individuals,
while approximately a third of them are clinically affected.
sSMCs comprise chromosomal parts, which occur addi-
tionally to the physiological 46 chromosomes. These extra
chromosomes appear in various morphological shapes, e.g.
ring, inverted duplicated or centric minute chromosomes.
Chromosome conformation capture technologies have the
potential to detect structural variants and advanced the
interpretation of altered gene expression caused by them.
Applying these novel technologies could give new insights
into the emergence of sSMCs and their genotype-phenotype
correlation. In this study we applied Hi-C in lymphoblastoid
cell lines from four samples of individuals presenting
developmental delay carrying different sSMCs (1 ring, 1
inverted duplicated, 2 centric minute chromosomes). These
samples were previously screened by FISH and aCGH. In
addition we also performed RNA-seq to investigate dysre-
gulation of genes included in the sSMC sequence, which
when combined with Hi-C could uncover yet undiscovered
mechanisms (e.g. enhancer adoption). Strikingly, Hi-C was
able to detect the sSMCs and the breakpoints at a higher
resolution compared to karyotype and aCGH. Furthermore,
Hi-C helped to reconstruct the 3D genome architecture of
sSMCs compared to their physiological counterparts. We
show that the Hi-C technology is able to contribute sub-
stantially to the detailed characterization of sSMCs. Future
studies will elaborate the cytogenetic and morphological
characteristics further and eventually be able to explain and
hopefully treat syndromes and phenotypes resulting from
these chromosomal aberrations.
J. Jungnitsch: None. M. Klever: None. U. Melo: None.
R. Schöpflin: None. C.A. Prada-Medina: None. T. Liehr:
None. S. Mundlos: None. M. Spielmann: None.
P14.43.C
Complex small supernumerary marker chromosome
sSMC originates from 6 different parts of 5
chromosomes
A. Weber1, T. Liehr2, S. Bilgen3, M. Stumm1
1Medicover Genetics GmbH, Berlin, Germany, 2Zentrum
für ambulante Medizin, Praxis für Humangenetik, Jena,
Germany, 3Medicover Bochum MVZ, Bochum, Germany
Introduction: The risk for phenotypic abnormalities of
patients carrying an sSMC depends on several factors as
tissue specific mosaicism, the number of additional dosage
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sensitive genes, and/or the possibility of impaired imprint-
ing due to the origin of the supernumerary chromosomal
material. Especially, a valid genotype/phenotype correlation
is very difficult in patients with sSMCs originating from
different parts of multiple chromosomes, because complex
sSMCs can multiply all these effects. We report on a 39-
year-old patient with hypogonadotropic hypogonadism,
infertility, small testicles, obesity, gynecomastia, hyper-
thyroidism, rheumatism and psychiatric problems, carrying
a unique highly complex sSMC.
Methods: The patient´s lymphocytes and DNA from
peripheral blood cells were analyzed by conventional
chromosome analysis (GTG banding) and array compara-
tive genomic hybridization (aCGH). Additionally, the
sSMC was microdissected, amplified, labeled and hybri-
dized as fluorescence in situ hybridization (FISH) probe.
Results: aCGH detected copy number gains in chromo-
somal regions 8q22.3q23.1, 9q33.3q34.11, 14q21.1,
14q21.1q21.2, 15q21.2 and 21q21.1 with evidence of
mosaicism. Therefore, the sSMC originates at least from 6
different parts of 5 chromosomes. After microdissection of
the sSMC and reverse FISH, the localization of the DNA
gains on the respective chromosomes could be confirmed.
Around 50% of peripheral blood (mesoderm) and buccal
mucosa cells (ectoderm) contained the sSMC.
Conclusions: Complex sSMCs are very rare and the
formation mechanisms of such complex structural con-
stellations are still unclear, but chromothripsis-like pro-
cesses could be considered. To best of our knowledge, our
patient is the first one reported, carrying a sSMC with such
a high complexity.
A. Weber: None. T. Liehr: None. S. Bilgen: None. M.
Stumm: None.
P14.44.A
An unusual case of CLL with cytogenetical t(11;14) but
two different IGH/CCND1 rearrangements
C. Senwitz1, S. Anders1, B. Opitz2, M. Klaus1
1Mitteldeutscher Praxisverbund Humangenetik, Dresden,
Germany, 2Onkologisches Zentrum St. Elisabeth und St.
Barbara, Halle, Germany
The translocation t(11;14)(q13;q32) occurs mainly in MCL,
but is also found in a wide range of other B-cell lymphoma.
We report about a case of a 58 year old male patient with
suspected CLL and t(11;14)(q13;q32), detected by chro-
mosome banding analysis (CBA). Additional fluorescence
in situ hybridization (FISH) of the IGH and CCND1 loci
(dual fusion probe) unexpectedly revealed two independent
clones: One clone (1; 60%) harbored the fusion signal
constellation for the standard translocation t(11;14)(q13;
q32) with corresponding IGH/CCND1 colocalization on
derivative chromosomes (der) 11 and 14, respectively. The
other clone (2; 40%) showed a variant translocation t
(11;14), including the pathognomonically relevant IGH/
CCND1 colocalization on der(11), but no fusion signal on
der(14). Instead, the 3’CCND1 signal was found on an F-
group-chromosome. Further FISH-analysis revealed the
involvement of one chromosome 19 with isolated translo-
cation of the 3’CCND1 region from 11q to 19p. Both clones
1 and 2 cannot be distinguished by CBA at 300 band levels.
We suspect that the variant IGH/CCND1 rearrangement led
to a fusion of 3’CCND1 and FSTL3 (follistatin-like-3) on
chromosome 19, but due to the lack of commercially
available FISH probes for this region this assumption could
not be verified. The respective translocation t(11;19)(q13;
p13) [CCND1/FSTL3] constitutes a very rare event with to
date only one CLL case described. Impact on prognosis is
unclear. As a conclusion, we recommend additional FISH
analysis of the IGH and CCND1 loci in every case of
cytogenetically assured t(11;14), in order to preclude cryptic
variant rearrangements and to ensure proper disease
monitoring.
C. Senwitz: None. S. Anders: None. B. Opitz: None.M.
Klaus: None.
P14.47.A
A case of maternal UPD20 detected by routine SNP
array diagnostics
E. Blom, J. J. Saris, L. J. C. M. van Zutven, L. H. Hoefsloot
Erasmus Medical Center, Rotterdam, Netherlands
In our laboratory we perform routine SNP array analysis for
several clinical phenotypes, including intellectual disability,
congenital abnormalities, and prenatal indications.
Although this technique is not primarily aimed for UPD
(Uniparental Disomy) diagnostics, a patient with a maternal
UPD of chromosome 20 was discovered. UPD as a con-
sequence of heterodisomy is not detectable by SNP array
analysis. However, the presence of (large) homozygous
regions on a single chromosome can be suggestive for an
isodisomy UPD, which can be further tested for with
another technique. Here, we present a case of an infant with
severe feeding difficulties needing gastric-tube feeding.
Routine SNP array analysis did not show any particularities,
except two terminal regions of homozygosity, at 20p and
20q, which is suggestive for UPD. To confirm the possible
presence of UPD, we requested parental samples and
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performed a SNP trio-analysis. SNP trio-analysis indeed
confirmed the presence of UPD20, which showed of a
maternal origin. Maternal UPD20, or upd(20)mat syn-
drome, is a very rare condition for which only a very limited
number of cases are described in literature. The main
symptoms of this disorder are prenatal and postnatal growth
retardation and (severe) feeding difficulties requiring
gastric-tube feeding in the first years of life. Literature of the
upd(20)mat syndrome and mechanisms leading to UPD
formation are reviewed.
E. Blom: None. J.J. Saris: None. L.J.C.M. van Zutven:
None. L.H. Hoefsloot: None.
P14.50.A
Trisomy 14 Mosaicism in form of an Robertson
Translocation der(14;14) in a child with skeletal
abnormalities
M. Wenzel1, I. Dietze-Armana1, W. Hütter2, K. Mehnert1
1genetikum, Neu-Ulm, Germany, 2Praxisklinik
Frauenstraße, Ulm, Germany
Introduction: Mosaic trisomy 14 is a rare chromosomal
disorder. Full trisomy 14 is often reported in abortion.
Features in affected individuals with mosaic trisomy 14 can
vary. Symptoms that have been most commonly reported
include intrauterine growth restriction, failure to thrive,
developmental delay, asymmetric growth, abnormal skin
pigmentation, distinctive facial characteristics and structural
malformations.
Case Report: A 6-month-old female was referred for
genetic counselling because of short femora and humeri.
The girl showed additionally a prominent forehead but no
developmental delay and a normal skin at this point. In
pregnancy intrauterine growth retardation was noted. Non-
invasive prenatal testing for chromosome 13, 18, 21 and
gonosomes showed no abnormalities. No further examina-
tions from parents were desired.
Results: Because of described skeletal anomalies and
facial dysmorphism molecular diagnostic of FGFR3 was
performed and no mutation was found. Chromosome
analysis of peripheral blood revealed a mosaic trisomy 14
in form of a Robertson translocation 46,XX,+14,der(14;14)
in 12% of cells. Fluorescence in situ hybridization of 37
nuclei from buccal mucosa showed three copies in 5% of
cells. To exclude an uniparental disomy 14 we performed
an STR marker analysis. No upd(14) was detected.
Chromosome analysis of both parents were normal.
Conclusions: To our knowledge, this is the first report of
trisomy 14 mosaicism in form of a Robertson translocation.
Our patient with intrauterine growth retardation matched
with many patients described in literature.
M. Wenzel: None. I. Dietze-Armana: None.W. Hütter:
None. K. Mehnert: None.
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Creating artificial human genomes using generative
neural networks
B. Yelmen1,2, A. Decelle3, L. Ongaro1,2, D. Marnetto1, C.
Tallec3, F. Montinaro1, C. Furtlehner3, L. Pagani1,4, F. Jay3
1Institute of Genomics, University of Tartu, Tartu, Estonia,
2Institute of Molecular and Cell Biology, University of
Tartu, Tartu, Estonia, 3Laboratoire de Recherche en
Informatique, Paris, France, 4APE Lab, Department of
Biology, University of Padova, Padua, Italy
Generative models have shown breakthroughs in a wide
spectrum of domains due to recent advancements in
machine learning algorithms and increased computational
power. Despite these impressive achievements, ability of
generative models to create realistic synthetic data is still
under-exploited in genetics and absent from population
genetics. Yet a known limitation of this field is the reduced
access to many genetic databases due to concerns about
violations of individual privacy, although they would pro-
vide a rich resource for data mining and integration towards
advancing genetic studies. In this study, we demonstrated
that deep generative adversarial networks (GANs) and
restricted Boltzmann machines (RBMs) can be trained to
learn the high dimensional distributions of real genomic
datasets and generate novel high-quality artificial genomes
(AGs) with none to little privacy loss.
We show that our generated AGs replicate characteristics
of the source dataset such as allele frequencies, linkage
disequilibrium, pairwise haplotype distances and population
structure. Moreover, they can also inherit complex features
such as signals of selection and genotype-phenotype
associations. To illustrate the promising outcomes of our
method, we showed that imputation quality for low
frequency alleles can be improved by augmenting reference
panels with AGs and that the RBM latent space provides a
relevant encoding of the data, hence allowing further
exploration of the reference dataset and features for solving
supervised tasks.
Generative models and AGs have the potential to become
valuable assets in genetic studies by providing a rich yet
compact representation of existing genomes and high-
quality anonymous substitutes for private databases.
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D. Marnetto: None. C. Tallec: None. F. Montinaro:
None. C. Furtlehner: None. L. Pagani: None. F.
Jay: None.
P15.06.A
Reconstruction of complex genomic rearrangements
with 3rd generation sequencing in rare diseases: two
chromothripsis cases
S. verdez1,2, Y. Duffourd1,3, E. Tisserant1,3, A. Plagos1,3, A.
Bruel1,3, F. Tran Mau-Them1,2,3, C. Philippe1,2,3, C.
Thauvin1,2,3,4, L. Faivre1,2,3,4, N. Chatron5,6, C. Schluth-
Bolard5,6, P. Callier1,2,3, D. Sanlaville5,6, A. Vitobello1,3
1UMR1231 GAD, Inserm – University of Burgundy-
Franche Comté, Dijon, France, 2UF Innovation en
diagnostic génomique des maladies rares, Dijon, France,
3Unité Fonctionnelle Innovation en Diagnostic génomique
des maladies rares, FHU-TRANSLAD, Dijon, France,
4Centre de Référence maladies rares « Anomalies du
développement et syndromes malformatifs », centre de
génétique, FHU-TRANSLAD, Dijon University Hospital,
Dijon, France, 5Hospices Civils de Lyon, Service de
Génétique, CHU de Lyon, Lyon, France, 6Equipe GENDEV
INSERM U1028, CNRS, UMR5292, Lyon, France
Long-read genome sequencing (LRGS) is revealing its
utility to identify complex chromosomal rearrangement
involving multiple breakpoints or low-complexity regions.
Chromothripsis, as an example, results from rearrangement
of multiple chromosomal double-stand breaks, obtained
from a single catastrophic event, giving rise to complex
derivative chromosomes. In 2 chromothripsis patients pre-
senting with syndromic intellectual disability, and without
candidate gene accounting for their clinical presentation
after short-read genome sequencing (30X srGS) analysis,
we performed de novo assembly using 20X SMRT (Sequel
1 system - Pacific Bioscience) with the aim to reconstruct
the map of derivative chromosomes.
We utilized two assembly tools (Falcon, Canu) and took
advantage of available short-read Illumina reads to correct
sequencing errors originated from long reads (polishing
steps). Contigs containing at least one breakpoint were
mapped against the Genome Reference Consortium Human
Build 37 (GRCh37/hg19) using Blast in order to calculate
the percentage of identity.
On average, Falcon allowed to obtain 111 contigs with
98,84% (SD 0.070) identity whereas 81 contigs with
98,92% (SD 0.001) identity were obtained with Canu.
The average size of the chromosomal blocks contained in
these contigs were 206kb (SD 104kb) for Falcon and 185kb
(SD 11kb) for Canu.
In conclusion our bioinformatic method allowed us to
precisely reconstruct the sequence of their derived chromo-
somes, highlighting genomic events concerning chromo-
somes 4, 11, 13, 14, 15, 21 for the first patient and 3, 10, 12
for the second patient. Overall the combination of srGS and
lrGS permitted to resolve complex chromosomal rearrange-
ments, not otherwise achievable by srGS alone.
S. verdez: None. Y. Duffourd: None. E. Tisserant:
None. A. Plagos: None. A. Bruel: None. F. Tran Mau-
Them: None. C. Philippe: None. C. Thauvin: None. L.
Faivre: None. N. Chatron: None. C. Schluth-Bolard:
None. P. Callier: None. D. Sanlaville: None. A.
Vitobello: None.
P15.07.B
Targeted and genome-wide discovery of genomic inter-
actions, structural variants, and gene regulatory
mechanisms using the Arima-HiC platform
J. Belton, D. Reid, X. Zhou, S. Mac, S. Tin, C. Caneda, J.
Kirkland, A. Schmitt
Arima Genomics, Inc., San Diego, CA, United States
Three-dimensional genome organization is critical for gen-
ome function. Hi-C technology has enabled high throughput
analyses of chromatin conformation, providing valuable
insights into the mechanisms of chromatin folding and gene
regulation. However, conventional Hi-C methods can suffer
from laborious workflows, sub-optimal analytical sensitivity
and reproducibility, and prohibitively expensive sequencing
requirements. Realizing these challenges, Arima developed
a 6-hour Hi-C protocol that improves analytical sensitivity
through rapid, reproducible, multiple restriction enzyme Hi-
C chemistry. This improved Hi-C chemistry detects more
loops from significantly reduced sequencing depth. For
example, Arima-HiC identified >12,500 loops in GM12878
cells from just 600 million raw reads.
New technologies are being built on the Arima-HiC
platform. For instance, Arima developed an optimized low-
input protocol proven to detect >10,000 loops from 50,000
cells. Additionally, targeted genome conformation assays
such as HiChIP and Capture-HiC have emerged. Our
H3K27ac and H3K4me3 HiChIP data demonstrate repro-
ducible detection of long-range gene regulatory interactions
at a fraction of the cost as genome-wide Hi-C. Moreover,
Capture-HiC enables discovery of chromatin loops around
oncogenes and tumor suppressors at 500bp resolution, from
only ~10M reads per genetic locus. Lastly, Arima-HiC data
is emerging as powerful tool for genome-wide discovery of
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structural variants (SVs) in cancer genomes. Analysis of a
human GIST revealed >70 SVs, with several of these
forming “neo-TADs”, bringing genes (or fusion genes) into
new regulatory environments potentiating mis-regulation
and enhancer hijacking. Overall, Arima-HiC aims to be a
flexible protocol for multiple “C” assays (Hi-C, HiChIP,
Capture-HiC) that will accelerate research across human
genetics and epigenetics.
J. Belton: A. Employment (full or part-time); Significant;
Arima Genomics, Inc. D. Reid: A. Employment (full or
part-time); Significant; Arima Genomics, Inc. X. Zhou: A.
Employment (full or part-time); Significant; Arima Geno-
mics, Inc. S. Mac: A. Employment (full or part-time);
Significant; Arima Genomics, Inc. S. Tin: A. Employment
(full or part-time); Significant; Arima Genomics, Inc. C.
Caneda: A. Employment (full or part-time); Significant;
Arima Genomics, Inc. J. Kirkland: A. Employment (full or
part-time); Significant; Arima Genomics, Inc. A. Schmitt:
A. Employment (full or part-time); Significant; Arima
Genomics, Inc.. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Significant; Arima
Genomics, Inc..
P15.08.C
Comprehensive characterization of cell-free coding and
non-coding RNAs using polyadenylation ligation-
mediated sequencing (PALM-Seq)
X. Yang1, T. Wang1, S. Zhu2, J. Zeng2, Y. Xing1, Q. Zhou1,
Z. Liu1, H. Chen1, J. Sun1, L. Li1, J. Xu1, C. Geng1, X. Xu1,
J. Wang1, H. Yang1, S. Zhu1, F. Chen1, W. Wang1
1BGI-Shenzhen, Shenzhen, China, 2Shenzhen Maternity and
Child Healthcare Hospital, Shenzhen, China
Introduction: Both cell-free coding and non-coding RNAs
serve as promising biomarkers for disease prediction,
diagnosis and prognosis, but it remains challenging to
characterize cell-free RNAs (cfRNAs) comprehensively.
Methods: We developed polyadenylation ligation-
mediated sequencing (PALM-Seq) to sequence cell-free
mRNA, long non-coding RNA (lncRNA), and small RNAs
simultaneously, and validated it by applying it to plasma
and amniotic fluid samples.
Results: By comparing the involvement and non-
involvement of the steps of T4 PNK treatment and targeted
RNA depletion, we showed that PALM-Seq could simulta-
neously capture cell-free coding RNA, lncRNA and various
small RNAs, and efficiently deplete redundant RNAs, with
comparable performances of existing cell-free mRNA or
small RNA sequencing methods. Describing cfRNAs in
plasma and amniotic fluid with PALM-Seq revealed distinct
RNA composition and similarly featured 3’ ends of mRNA
and lncRNA. Furthermore, we identified a group of
mRNAs, lncRNAs and microRNAs (miRNAs) in plasma
that could perfectly distinguish pregnant and non-
pregnant women.
Conclusions: Altogether, PALM-Seq enables compre-
hensive characterization of cell-free coding and non-coding
RNAs, which could stimulate further progress in biomarker
discovery, health status monitoring, and intercellular
communication research.
Grant: Shenzhen Municipal Government of China (No.
JCYJ20170412152854656).
X. Yang: None. T. Wang: None. S. Zhu: None. J.
Zeng: None. Y. Xing: None. Q. Zhou: None. Z. Liu:
None. H. Chen: None. J. Sun: None. L. Li: None. J. Xu:
None. C. Geng: None. X. Xu: None. J. Wang: None. H.
Yang: None. S. Zhu: None. F. Chen: None. W.
Wang: None.
P15.09.A
Integration of genome-wide methylation analysis with
transcription analysis and genome sequencing enables
molecular confirmation in a patient with CHARGE
syndrome
J. L. Granadillo, D. J. Wegner, M. Willing, K. Sisco, J.
Wambach, D. Baldridge, F. S. Cole
Washington University School of Medicine, Saint Louis,
MO, United States
Introduction: CHD7 pathogenic variants cause more than
90% of CHARGE syndrome cases, an autosomal dominant
condition characterized by coloboma of the iris, retina, and/
or optic disk; choanal atresia, cranial nerve dysfunction,
characteristic CHARGE syndrome ear malformations,
developmental delay, congenital cardiac defects, and poor
growth. Approximately 10% of cases have no known
genetic cause.
Materials and Methods: We report the case of a patient
with clinical features of CHARGE syndrome and non-
diagnostic genetic testing, including chromosome micro-
array, CHD7 sequencing and deletion/duplication analysis,
SEMA3E sequencing, and trio Whole Exome Sequencing.
After enrollment in the NIH-funded Undiagnosed Diseases
Network (UDN), a comprehensive clinical assessment,
genome-wide methylation analysis (GMA), Whole Genome
Sequencing (WGS), and CHD7 RNA studies were
performed.
Results: The proband is a Hispanic 5-year-old male with
global developmental delay, bilateral optic nerve coloboma,
strabismus, nystagmus, bilateral hearing loss, repaired
persistent ductus arteriosus, bicuspid aortic valve, micro-
penis, and cryptorchidism. Physical exam was notable for a
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squared face and CHARGE-like ears. CT scan of the
temporal bones revealed cochlear and vestibular malforma-
tions, hypoplastic facial nerves, and hypoplastic left internal
auditory canal. GMA revealed a CHD7-associated epige-
netic signature. WGS with focused bioinformatic analysis
of CHD7 and removal of all variant filters detected a de
novo 15 bp deletion in intron 4 of CHD7, denoted c.2239-
20_2239-6delGTCTTGGGTTTTTGT (NM_017780.3).
RNA studies confirmed that this deletion causes disruption
of the canonical 3’ splice site, and introduction of a
premature stop codon.
Conclusions: Integrating genomic, epigenomic, and
transcriptomic methods may increase the diagnostic yield
for CHARGE and other genetic syndromes.
J.L. Granadillo: None. D.J. Wegner: None. M. Will-
ing: None. K. Sisco: None. J. Wambach: None. D.
Baldridge: None. F.S. Cole: None.
P15.10.B
A novel generation of digital PCR allows fast, convenient
and accurate chimerism monitoring after hematopoietic
stem cell transplantation
E. Gourri, B. M. Frey, S. Meyer
Department of Molecular Diagnostics and Cytometry,
Blood Transfusion Service Zurich, Swiss Red Cross,
Schlieren, Switzerland
Introduction: Monitoring of chimerism in patients after
stem-cell transplantation is part of the surveillance of
impending clinical relapse. We previously established a
method for monitoring based on detection of SNVs by
Taqman™ assays on a chip-digital PCR (chdPCR) platform
(Thermofisher). This method enabled reliable monitoring on
nearly 2,000 samples. However, substantial hands-on-time
renders this platform less suitable for high sample
throughput. We aimed to establish an alternative system to
our approved chdPCR platform providing higher sample
throughput and minimal hands-on-time.
Material and Methods: The Opal™ dPCR chip
represents the larger unit of the Naica™ crystal dPCR
system (Stilla) and allows SNV detection in approximately
20,000 droplets. Crystal dPCR combines automated droplet
formation and thermocycling on a single device (Naica™
Geode). Fluorescence signal of each droplet is measured in
the Naica™ Prism instrument. With 48 reactions per run,
the system represents a fast and economical alternative to
other platforms.
Results: Artificial DNA mixes provided reproducible
quantification of the minor allele, even below 0.25%.
Notably, the clinically required 0.5% minor allele sensitiv-
ity was achieved with only 5ng of input DNA. Additionally,
the reliability of the crystal dPCR platform was confirmed
on previously monitored patient’s samples and numerous
EQA samples.
Conclusions: This new generation of dPCR is fully
compatible with our established SNV-based chimerism
monitoring and has been proven to be fast, convenient and
highly accurate. In addition to minimal hands-on-time, and
consumable use, the low amount of input DNA per reaction
should be emphasized, opening the option of lineage
specific chimerism monitoring.
E. Gourri: None. B.M. Frey: None. S. Meyer: None.
P15.13.B
CNV analysis based on whole genome sequencing for
distant relatedness determination
M. Korabecna1, A. Zinkova1, I. Brynychova1, E.
Pazourkova1, H. Simkova1, J. Geryk1,2
1First Faculty of Medicine, Charles University, Prague,
Czech Republic, 2Second Faculty of Medicine, Charles
University, Prague, Czech Republic
The samples from 100 healthy non-related individuals from
Czech population were used for whole genome sequencing
(WGS) on NovaSeq 6000 (Illumina) to prepare the database
of biallelic structural variants (CNV, SVs) existing in this
population. After careful data filtering, the sets of well
characterized individual variants were used for, finger-
printing“ and relatedness determination. 35 000 SVs were
detected in the Czech population, 8969 structural variants
(SVs) per individual on average (median 9389). The num-
ber of detected SVs per individual is highly dependent on
the mean coverage value. The sufficient coverage to capture
all SVs in the sample should be significantly higher than the
conventionally used value equal to 30. To test the genome
wide analysis of SVs for relatedness determination, we used
WGS data from 10 individuals belonging to a three-
generation family. For the relationship category prediction,
the following coefficients were computed by using package
Demerelate in R: Bxy, Sxy, Mxy, rxy, Lxy, Li, Ioiselle,
wang, wang.fin. The distributions of values of all these
coefficients for different relationships were computed first
using all detected variants as markers. Then the variants not
having exactly identical genomic positions within all sam-
ples were removed. We demonstrated that WGS in asso-
ciation with appropriate bioinformatic tools is highly
effective for SVs detection, the determination of their extent
and population frequency. Our approach may lead to the
successful determination of coefficients of relationships also
for pairs with r=0.125. Supported by the Ministry of
Interior of the Czech Republic grant no. VI20172020102.
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Practical applications of CRISPR knock in: generation
of cacna1c mutant zebrafish
E. Sieliwonczyk, B. Vandendriessche, M. Alaerts, D.
Knapen, L. Vergauwen, C. Moers, D. Snyders, B. Loeys, D.
Schepers
University of Antwerp, Antwerpen, Belgium
Introduction: The similarity between the human and the
zebrafish cardiac action potentials makes zebrafish an
attractive model for cardiogenetic disorders. However,
introducing base pair substitutions (knock in, KI) by the
CRISPR/Cas9 technique in zebrafish remains challenging.
In our efforts to generate a KI zebrafish model of the human
CACNA1c c.2570C>G long QT syndrome mutation, we
have combined early genotyping with next-generation
sequencing (NGS) to improve the KI efficiency.
Methods: Zebrafish eggs were injected with Cas9 mRNA
or protein, 1-2 gRNA and four conformations of ssODN:
identical (“target”) or complementary (“non-target”) to the
gRNA binding sequence, symmetric or asymmetric. KI
detection was performed by NGS on a MiSeq instrument
(Illumina). To select embryos for breeding, DNA was
extracted from live embryos with the Zebrafish Embryo
Genotyping device.
Results: Variable KI rates were observed, ranging from
0.1 to 1.58%. The highest KI rate was observed with Cas9
mRNA with 1 gRNA and the right asymmetric target
ssODN. Embryos from the Cas9 mRNA injection group
containing >0.2% KI reads were raised to maturity and
crossed out to assess germline transmission. One out of 10
fish passed the edited allele on to 25% of its offspring.
Conclusions: KI experiments in zebrafish show a high
degree of variability. The KI efficiency tends to be lower in
disease modeling than in methodological studies as the
experiments are more restrictive. We intend to overcome
these limitations by combining early genotyping with an
NGS detection technique.
Grants: This research is supported by the Fund for
Scientific Research, Flanders.
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Validation of INNO-LiPA CFTRiage for prenatal
diagnostic
P. Reichgelt1, R. van de Graaf1, W. Deelen1, J. Vanden
Broecke2, L. Tremmerie3, M. Wilke1
1Department of Clinical Genetics, Rotterdam, Netherlands,
2Fujirebio Europe NV, Ghent, Belgium, 3Fujirebio Eurpe
NV, Ghent, Belgium
Cystic fibrosis (CF) is a genetic disorder caused by aberrant
variants in the CF transmembrane conductance regulator
(CFTR) gene. For a full diagnosis of CF multiple tests are
needed, among which genetic testing is one of the most
important. During the first round of genetic testing different
tests are performed covering most frequent pathogenic
variants (>1 %). Fujirebio Europe N.V.’s newly available
commercial test INNO-LiPA CFTRiage was launched for
identification of 88 known pathogenic variants in the CFTR
gene in whole blood, dried blood spots and buccal brushes.
Here we describe the validation of the INNO-LiPA
CFTRiage for prenatal samples. Earlier INNO-LiPA
CFTR19/CFTR17+Tn Update/CFTR Deletions + 6/CFTR
Italian Regional tests were used for detection of variants in a
prenatal setting. 34 (prenatal) samples were investigated for
the validation of INNO-LiPA CFTRiage. The test set con-
sisted of earlier identified pathogenic variants derived from
four chorionic villi samples (CVS, one normal, three
mutated), 28 amniotic fluid samples (AF, 25 normal, 3
mutated), one Intra Uterine Foetal Death (IUFD) sample
(normal) and one non-prenatal control. The experiments
were performed at the department of Clinical Genetics
(Erasmus MC, Rotterdam, NL). The automatic read out was
performed by Fujirebio Europe N.V. Results were com-
pared with earlier obtained data. 34/34 were identical (one
sample needed to be diluted 1/10).We tested a limited
number of prenatal samples. All gave the expected result.
Therefore we think that INNO-LiPA CFTRiage is suitable
for detection of pathogenic variants in a prenatal setting
using DNA derived from CVS and AF.
P. Reichgelt: None. R. van de Graaf: None. W. Deelen:
None. J. Vanden Broecke: C. Other Research Support
(supplies, equipment, receipt of drugs or other in-kind
support); Modest; Fujirebio Europe NV. L. Tremmerie: C.
Other Research Support (supplies, equipment, receipt of
drugs or other in-kind support); Modest; Fujirebio Europe
NV. M. Wilke: None.
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An analytical comparison of commonly used arrays vs.
shallow whole genome sequencing for cytogenetic testing
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S. Verma, R. Keshavan, S. Shams
BioDiscovery, El Segundo, CA, United States
High-density SNP array, with its ability to detect regions of
homozygosity and copy number variants (CNVs), is now the
most commonly used platform for cytogenetic testing. Next-
generation sequencing (NGS), traditionally used for detection
of small base-level genomic changes, is now gaining wider
acceptance as a platform for detecting CNVs in addition to
single nucleotide variants (SNVs). With the reduction in cost
of whole-genome sequencing (WGS), many labs are con-
sidering using “shallow” WGS to replace microarrays for
cytogenetic testing. To assess content and design of micro-
arrays, we performed analytical analyses on ten commonly
used SNP array platforms for cytogenetic testing offered by
Illumina and Thermo Fisher/Affymetrix. The set of arrays
included the Global Screening Array (GSA) and the Global
Diversity Array (GDA) platforms from Illumina since they
offer a very low-cost option. The analyses included number
and coverage statistics on heterozygous probe distribution for
detection of AOH events, probes spanning exons/genes, and
distribution of probes genome-wide covering regions with
clinical significance from sources such as ClinGen, OMIM,
DDG2P, and including a number of additional genes strongly
associated with constitutional and oncology testing. Here we
will share the results of the array comparison project as they
compare with each other and with shallow WGS, both in
terms of coverage as well as cost.
S. Verma: A. Employment (full or part-time); Significant;
BioDiscovery. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; BioDiscovery. R.
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Enabling variant calling in challenging FFPE samples
by coupling a novel library preparation chemistry with
exome sequencing
M. Hong1, E. Star1, H. Huang1, T. Barnes1, T. Chen1, K.
Datta1, K. Dilger1, N. Roseman2, T. Rusch2, R. Lopez2, K.
Scott2, L. A. Lewis2, S. Groenewold2, L. Ren2, J. Zhou1, K.
Lai1, J. Sheu1, X. Wang1, Y. Wang1, A. Wang1, N. Downey2,
A. Potts1, U. Das Chakravarty1, B. Min1, P. J. Lau1, S.
Henck1
1Integrated DNA Technologies, Inc., Redwood City, CA,
United States, 2Integrated DNA Technologies, Inc.,
Coralville, IA, United States
Comprehensive tumor profiling using NGS is fundamen-
tally transforming oncology research. However, converting
archival tissue samples into libraries is often challenging
due to the low quantity and quality of DNA. Here we
present accurate detection of variants in the human exome
using the novel chemistry of the xGen Prism DNA library
preparation kit, optimized for low-input and degraded
samples, with xGen Research Exome v2.0 hybrid-capture
enrichment. The IDT Exome v2 panel was used to carry out
targeted sequencing of Prism DNA libraries generated from
archival FFPE samples. The unique library preparation is
enabled by an engineered mutant ligase and proprietary
adapters that prevent chimeras and suppress dimer-forma-
tion, thereby maximizing the conversion of input DNA to
sequencing libraries. We achieved high yields of library
(300-400 ng) from input amounts as low as 25 ng for
severely damaged FFPE samples (DIN 1-3), >90% on-
target rates and uniform depth of coverage (>96% bases
covered at >20X and >98% bases covered at >10X) for
FFPE samples across a wide range in quality. We also
observed minimal exon drop-outs in difficult-to-target genes
for severely damaged FFPE material. To validate the variant
calling performance of the Prism-Exome workflow, we used
the Horizon OncoSpan FFPE reference control which con-
tains 1-92% AF SNVs and Indels and achieved >98%
sensitivity across ~250 SNVs and Indels. This study
demonstrates that the xGen Exome Research v2, when
combined with xGen Prism DNA library preparation, pro-
vides researchers with a complete human exome FFPE-
sequencing solution with robust performance across FFPE
samples of varying quality.
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IDT. L.A. Lewis: A. Employment (full or part-time);
Significant; IDT. S. Groenewold: A. Employment (full or
part-time); Significant; IDT. L. Ren: A. Employment (full
or part-time); Significant; IDT. J. Zhou: A. Employment
(full or part-time); Significant; IDT. K. Lai: A. Employ-
ment (full or part-time); Significant; IDT. J. Sheu: A.
Employment (full or part-time); Significant; IDT. X. Wang:
A. Employment (full or part-time); Significant; IDT. Y.
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Wang: A. Employment (full or part-time); Significant; IDT.
A. Wang: A. Employment (full or part-time); Significant;
IDT. N. Downey: A. Employment (full or part-time);
Significant; IDT. A. Potts: A. Employment (full or part-
time); Significant; IDT. U. Das Chakravarty: A. Employ-
ment (full or part-time); Significant; IDT. B. Min: None. P.
J. Lau: A. Employment (full or part-time); Significant;
IDT. S. Henck: A. Employment (full or part-time);
Significant; IDT.
P15.21.A
Quantitative facial phenotyping for Koolen-de Vries and
22q11.2 deletion syndrome
A. J. M. Dingemans1, D. E. Stremmelaar1, R. Van der
Donk1, L. E. L. M. Vissers1, D. A. Koolen1, P. Rump2, J. Y.
Hehir-Kwa3, B. B. A. De Vries1
1Radboudumc, Nijmegen, Netherlands, 2UMCG, Gronin-
gen, Netherlands, 3Princess Máxima Center for Pediatric
Oncology, Bilthoven, Netherlands
Abstract
Introduction: The Koolen-de Vries syndrome (KdVS)
is a multisystem syndrome with variable facial features
caused by a 17q21.31 microdeletion or KANSL1 truncat-
ing mutation. As the facial gestalt of KdVS is similar to
the gestalt of the 22q11.2 deletion syndrome
(22q11.2DS), we assessed whether our previously
described hybrid quantitative facial phenotyping algo-
rithm could distinguish between these two syndromes,
and, in addition, whether there is a facial difference
between the molecular KdVS subtypes.
Materials and Methods:We applied our algorithm to 2D
photographs of 97 patients with KdVS (78 microdeletions,
19 truncating mutations) and 48 patients with 22q11.2DS as
well as age, gender and ethnicity matched controls with
intellectual disability (n = 145).
Results: The facial gestalts of KdVS and 22q11.2DS
are both recognizable, yet different from one another (p =










22q11.2DS 48 25 23 15.0 33.0 0.00522
KdVS 97 90 7 66.0 31.0 7.5-10
Furthermore, the facial gestalts of KdVS caused by a
17q21.31 microdeletion and KANSL1 truncating mutation
are indistinguishable (p = 0.981 and p = 0.130). Further
application to 3 patients with a variant of unknown clinical
significance in KANSL1 showed that these do not match a
clinical diagnosis of KdVS.
Conclusions: Our data highlight quantitative facial
phenotyping not only as a powerful tool to distinguish
syndromes with overlapping facial dysmorphisms but also
to establish pathogenicity of variants of unknown clinical
significance.
A.J.M. Dingemans: None. D.E. Stremmelaar: None. R.
Van der Donk: None. L.E.L.M. Vissers: None. D.A.
Koolen: None. P. Rump: None. J.Y. Hehir-Kwa: None.
B.B.A. De Vries: None.
P15.22.B
High throughput analysis of disease repeat expansions
and contractions by optical mapping
E. T. Lam, J. Wang, D. Zhang, T. Wang, A. W. C. Pang, H.
B. Sadowski, A. R. Hastie, M. Oldakowski
Bionano Genomics, San Diego, CA, United States
Repeat expansions and contractions are associated with
degenerative disorders such as facioscapulohumeral mus-
cular dystrophy (FSHD). The phenotype severity is often
correlated with the extent of pathogenic expansion or con-
traction. Inherently, these repeats are unstable. The repeat
size in somatic cells can vary over time and be hetero-
geneous, which impacts the age of onset in both the current
and successive generations. Most repeat disorders have no
direct treatments.
Southern blotting is the current gold standard for
analyzing pathogenic repeats. While sequencing-based
methods are being developed, these efforts are hampered
by limitations in read lengths and the repetitive and
polymorphic nature of these regions. Optical mapping with
Bionano Genome Imaging enables analysis of ultra-high
molecular weight DNA molecules that can span large
repeats. In addition, a comprehensive streamlined workflow
inclusive of sample preparation, DNA imaging, and
genomic data analysis has been developed for high-
throughput analysis of repeats of interest.
We recently demonstrated the utility of the platform by
focusing on the D4Z4 repeat contraction on chromosome
4q35, which is a marker of FSHD when present on a
permissive haplotype. The analysis had high sensitivity,
specificity, and reproducibility. We analyzed 30 FSHD-
positive samples. 28 of them had repeat contractions on the
4qA haplotype. The two samples that did not show repeat
contractions were run twice; the results were consistent. We
a-
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lso analyzed 58 FSHD-negative samples; none had repeat
counts in the clear pathogenic range. With the method
described above, we have analyzed other repeat expansions
with high sensitivity.
E.T. Lam: A. Employment (full or part-time); Signifi-
cant; Bionano Genomics. E. Ownership Interest (stock,
stock options, patent or other intellectual property); Modest;
Bionano Genomics. J. Wang: A. Employment (full or part-
time); Significant; Bionano Genomics. E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Modest; Bionano Genomics. D. Zhang: A.
Employment (full or part-time); Significant; Bionano
Genomics. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Bionano
Genomics. T. Wang: A. Employment (full or part-time);
Significant; Bionano Genomics. E. Ownership Interest
(stock, stock options, patent or other intellectual property);
Modest; Bionano Genomics. A.W.C. Pang: A. Employ-
ment (full or part-time); Significant; Bionano Genomics. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Modest; Bionano Genomics. H.B.
Sadowski: A. Employment (full or part-time); Significant;
Bionano Genomics. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
Bionano Genomics. A.R. Hastie: A. Employment (full or
part-time); Significant; Bionano Genomics. E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Modest; Bionano Genomics.M. Oldakowski: A.
Employment (full or part-time); Significant; Bionano
Genomics. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; Bionano
Genomics.
P15.23.C
Global Screening Array as a First Line Test for
Mutation Detection in Familial Hypercholesterolaemia
F. Anderson1, J. Berg2, S. Srinivasan2, C. Palmer2
1Dundee School of Medical, Dundee, United Kingdom,
2Dundee School of Medicine, Dundee, United Kingdom
Background: Familial Hypercholesterolaemia (FH) is a
common autosomal dominant disorder caused by mutations
in LDLR, PCSK9 or APOB. Mutation analysis allows early
detection and treatment of at risk individuals, preventing
cardiovascular morbidity. In Scotland, despite availability
of testing to anyone fulfilling Simon Broome Criteria, it is
estimated that 80% of individuals remain undiagnosed. Use
of a screening array of known mutations has the potential to
detect actionable mutations more cheaply, allowing testing
of many more individuals and improving detection of
pathogenic variants in the population.
Method and Results: We evaluated the potential clinical
utility of an array based approach to mutation analysis for
FH. In NHS Tayside, between 2010 and 2018, 37
pathogenic variants and 8 variants of uncertain significance
were identified in LDLR in 75 individuals. We compared
these to the manifest of the 2016 Illumina Infinium Global
Screening Array-24 V2.0, containing 1077 mutations
implicated in FH. All 26 of the pathogenic point mutations
were present on the array, and 10/11 of the deletions had
overlapping SNVs present- giving a potential coverage of
actionable variants of 97%. 6/8 (75%) of variants of
uncertain significance were also represented.
Conclusions: We conclude that array technology for
DNA mutation analysis has potential for screening for FH
mutations in clinical practice. with the possibility of
designing different clinical models for case identification.
With careful optimisation of this low cost test option, a
much greater proportion of mutation carriers could be
identified and treated, with significant impact on cardiovas-
cular disease in the population.
F. Anderson: None. J. Berg: None. S. Srinivasan:
None. C. Palmer: None.
P15.24.A
A flexible workflow solution including error correction
by molecular barcoding for low inputffpe tissue biopsy
and circulating tumor DNA samples
B. Arezi1, S. Lee1, B. Hsue1, K. Chen1, B. Rogers1, B.
Novak1, X. Zhang1, J. Ghosh2, G. Amparo2, N. Mehendale2,
C. Pabon2, J. Ku2
1Agilent Technologies, la jolla, CA, United States, 2Agilent
Technologies, Santa Clara, CA, United States
Accurate low allele frequency variant calling by next gen-
eration sequencing (NGS) can be challenging with FFPE
specimens and circulating tumor DNA due to limited DNA
availability, poor DNA quality, and variation in tumor
fraction from sample to sample. Other practical considera-
tions such as turnaround time, multiplexing capability and
workflow simplicity or technological limitations such as
index cross-contamination and index hopping with newer
Illumina sequencing chemistries can also influence how
readily NGS is applied to clinical tumor samples. Here we
address these challenges by developing a complete but
flexible workflow solution which is optimized for a wide
range of DNA input (10-200 ng), various sample types
(intact or FFPE samples), different shearing methods
(mechanical vs. enzymatic), sequencing chemistries (2 ×
100 bp or 2 × 150 bp), 90-minute or overnight bait hybri-
dization, and up to 384 unique dual sample indices to
eliminate index hopping. Furthermore, we incorporate
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duplex molecular barcodes at the ligation step to filter out
PCR errors by making consensus calls using MBC infor-
mation from both strands (duplex MBC), hybrid (duplex
MBC where info is available), single strand (single MBC)
or discard MBC information (no MBC), based on the
application. While both duplex and single MBC improve
the accuracy of low VAF detection compared to no MBC,
duplex MBC enables the most effective error correction. As
we will demonstrate, the number of false positive calls of
low VAF (≤4%) for duplex MBC were reduced significantly
by 74% and 93% compared to single MBC and no MBC,
respectively.
B. Arezi: A. Employment (full or part-time); Significant;
Agilent Technologies. S. Lee: A. Employment (full or part-
time); Significant; Agilent Technologies. B. Hsue: A.
Employment (full or part-time); Significant; Agilent
Technologies. K. Chen: A. Employment (full or part-time);
Significant; Agilent Technologies. B. Rogers: A. Employ-
ment (full or part-time); Significant; Agilent Technologies.
B. Novak: A. Employment (full or part-time); Significant;
Agilent Technologies. X. Zhang: A. Employment (full or
part-time); Significant; Agilent Technologies. J. Ghosh: A.
Employment (full or part-time); Significant; Agilent
Technologies. G. Amparo: A. Employment (full or part-
time); Significant; Agilent Technologies. N. Mehendale: A.
Employment (full or part-time); Significant; Agilent
Technologies. C. Pabon: A. Employment (full or part-
time); Significant; Agilent Technologies. J. Ku: A.
Employment (full or part-time); Significant; Agilent
Technologies.
P15.26.C
An NGS-based approach for the detection of GBA
variants including recombinations with the pseudogene
GBAP
N. Ameziane1, M. Horovitz2, F. Vogel1, P. Bauer1, A.
Rolfs1, C. Beetz1
1Centogene AG, Rostock, Germany, 2Tel Aviv University,
Tel Aviv, Israel
Pathogenic biallelic alterations in GBA cause Gaucher dis-
ease, while monoallelic alterations represent a risk factor for
Parkinson’s disease. The mutational spectrum consists of
single nucleotide variants and small insertions/deletions as
well as of recombination-mediated rearrangements with the
nearby pseudogene GBAP. The latter type of alteration has
been difficult to detect and characterize by the standard
GBA diagnostic approaches due to the application of an
initial GBA-specific long-range PCR. We developed a
capture-based NGS protocol and a dedicated bioinformatics
pipeline that exploits the relative number of aligned reads to
GBA and GBAP to detect recombinational events. We
applied our tool to a set of samples with known and sus-
pected GBA alterations, which had been comprehensively
analyzed by various methods including Southern blotting
and cDNA cloning. We detected all known SNVs and small
insertions/deletions. For cases with suspected rearrange-
ments, we observed altered relative GBA and GBAP read
ratios. The findings were of two kinds: 1) suggestive of
recombination-mediated conversions, 2) suggestive of
recombination-mediated large deletions. Our observations
are consistent with theoretical considerations put forward
previously. In conclusion, we have developed a method that
can reliably detect all types of disease-relevant alterations in
GBA. This will allow for accurate molecular classification
of Gaucher patients and of individuals at higher risk for
Parkinson’s disease.
N. Ameziane: A. Employment (full or part-time);
Significant; Centogene AG. M. Horovitz: None. F. Vogel:
A. Employment (full or part-time); Significant; Centogene
AG. P. Bauer: A. Employment (full or part-time);
Significant; Centogene AG. A. Rolfs: A. Employment (full
or part-time); Significant; Centogene AG. C. Beetz: A.
Employment (full or part-time); Significant; Centogene AG.
P15.34.B
Genetic aberration detection through whole exome
sequencing in comparison with microarray-based meth-
ods in children with global developmental delay and
intellectual disability
P. Chen1, T. Liu2, Y. Jong3, Y. Chen1,4,5
1Department of Life Sciences and Institute of Genome
Sciences, Taipei, Taiwan, 2Genome Research Center,
National Yang-Ming University, Taipei, Taiwan, 3Kaoh-
siung Medical University, Kaohsiung, Taiwan, 4Division of
Genetics and Metabolism, Department of Pediatrics, Taipei
Veterans General Hospital, Taipei, Taiwan, 5Department of
Education and Research, Taipei City Hospital, Taipei,
Taiwan
Developmental delay (DD) is a common pediatric condi-
tion, with copy number variations (CNVs) considered one
of its major causes. This study aims to determine the effi-
ciency of whole exome sequencing (WES) as a first-tier
diagnostic test to detect aberrations including CNVs and
single nucleotide variants (SNVs) in comparison with array
comparative genomic hybridization (aCGH) for DD. Sub-
jects (541) diagnosed with global developmental delay
(GDD) or intellectual disability (ID) of unknown cause have
been enrolled, and aCGH tests have a positive rate of 23.7%
(111/468). Fragile X syndrome or Rett-like syndrome tests
and treatable targeted NGS-based panel were also utilized
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for assessment. Furthermore, WES was performed on 34
cases with Agilent SureSelect target enrichment system
using Illumina HiSeq2000. WES data were analyzed using
Varseq v2.1.0 and Illumina BaseSpace Variant Interpreter.
Trio analyses were performed on 24 aCGH-negative cases,
thus far revealing 4 known rare pathogenic variants asso-
ciated with GDD/ID. To determine the consistency in CNV
detection between aCGH and WES tests, 10 aCGH-positive
singletons were included. CNVs were detected in 11 out of
13 regions using WES. On average, 115 CNVs with p-
values < 0.01 were called per case. These CNVs ranged
from 119bp to 15Mbp in span, with duplications accounting
for 65.0% of total calls. Approximately 1% (30/2764) of
CNVs were drawn for qPCR validation, and 40% (12/30) of
the tested CNVs have relative quantities suggestive or
indicative of their CNV types. WES provides comprehen-
sive and high-throughput information with the potential to
cut medical expenditures, elevate diagnostic yield, and
reduce diagnostic odyssey.
P. Chen: None. T. Liu: None. Y. Jong: None. Y.
Chen: None.
P15.35.C
Comprehensive single-nucleotide, indel, structural, and
copy-number variant detection in human genomes with
PacBio HiFi reads
A. M. Wenger, W. J. Rowell, A. Töpfer, L. Hickey
Pacific Biosciences, Menlo Park, CA, United States
Introduction: Long-read sequencing has revealed more
than 20,000 structural variants spanning over 12 Mb in a
healthy human genome. Short-read sequencing fails to
detect most structural variants but has remained the more
effective approach for small variants, due to 10-15% error
rates in long reads, and copy-number variants (CNVs), due
to lack of effective long-read variant callers. The develop-
ment of PacBio highly accurate long reads (HiFi reads) with
read lengths of 10-25 kb and quality >99% presents the
opportunity to capture all classes of variation with one
approach.
Methods: We sequence the Genome in a Bottle bench-
mark sample HG002 and an individual with a presumed
Mendelian disease with HiFi reads. We call SNVs and
indels with DeepVariant and extend the structural variant
caller pbsv to call CNVs using read depth and clipping
signatures.
Results: For 18-fold coverage with 13 kb HiFi reads,
variant calling in HG002 achieves an F1 score of 99.7% for
SNVs, 96.6% for indels, and 96.4% for structural variants.
Additionally, we detect more than 300 CNVs spanning
around 10 Mb. For the Mendelian disease case, HiFi reads
reveal thousands of variants that were overlooked by short-
read sequencing, including a candidate causative structural
variant.
Conclusions: These results illustrate the ability of HiFi
reads to comprehensively detect variants, including those
associated with human disease.
A.M. Wenger: A. Employment (full or part-time);
Significant; Pacific Biosciences. W.J. Rowell: A. Employ-
ment (full or part-time); Significant; Pacific Biosciences. A.
Töpfer: A. Employment (full or part-time); Significant;
Pacific Biosciences. L. Hickey: A. Employment (full or
part-time); Significant; Pacific Biosciences.
P15.37.B
Targeting clinically significant dark regions of the
human genome with high accuracy long read sequencing
L. A. Aro, C. Heiner, Y. Tsai, J. Harding, J. Ziegle
Pacific Biosciences, Menlo Park, CA, United States
Introduction: There are many clinically important genes in
“dark” regions of the human genome, with poor coverage
due to low amplification or difficulty mapping with other
technologies. These dark regions often contain highly
homologous genes and pseudo genes, repeat expansions,
and areas of biased base composition. Ambiguous mapping
due to the limitations of short-read sequencing prevents
accurate assessment of structural rearrangements and
importantly, short-reads limit the ability to phase across
gene regions.
Materials and Methods: We investigated several
important dark region genes using PacBio SMRT Sequen-
cing using long-range PCR and/or direct sequencing using a
CRISPR/cas9 mediated No-Amp for target enrichment
approach. Genes included HTT, FMR1, CYP21A2 and
HBB. Sample prep and sequencing methods are described in
detail.
Results: Here we show results from successfully
sequencing a key portion of the HTT gene using both No-
Amp and long-range PCR. This comparison includes a set
of samples with moderate to extensive repeat expansions,
demonstrating highly accurate sequencing of the repeat
region with both approaches. General advantages and
disadvantages of each method are discussed.
Conclusion: We demonstrate that accurate, long read
sequencing provides new opportunities for sequencing
clinically relevant but difficult regions of the human
genome that are underrepresented in short-read sequencing.
The preferred method of targeting depends on the gene of
interest and project goals. SMRT Sequencing of these
regions enables a better understanding of the relationship
between genetic factors and personal health.
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Genetic profiling and early cancer detection using NGS-
based Liquid Biopsy
A. Wąsowska1,2, E. Matczyńska1,2, M. Krawczyk1, P.
Łyszkiewicz1, A. Kowalik3, M. Chłopek3, J. Kosakowski1, M.
Jurkowska1, A. Boguszewska-Chachulska1
1Genomed SA, Warsaw, Poland, 2Medical University of
Silesia, Katowice, Poland, 3Holy Cross Cancer Centre,
Kielce, Poland
There is an urgent need for early and efficient cancer
detection, risk stratification, and therapy monitoring. Cir-
culating cell-free tumor DNA (ctDNA) may provide sensi-
tive and representative marker for that purpose. The project
aimed at developing non-invasive genetic diagnostics and
cancer monitoring, based on the liquid biopsy (LB) for
cancer patients and people at risk. Cell-free DNA (cfDNA)
of 82 breast, colorectal or lung cancer cases was isolated
from plasma. Additionally, breast and colorectal frozen
tumours from 12 patients were collected together with the
corresponding 9 blood samples. A deep coverage WGS of
the tumour DNA and a standard coverage WGS for the
corresponding germline DNA were performed to assess
mutational burden and somatic CNVs in 10 patients. A
shallow WGS (sWGS) and targeted breast cancer-related
gene panel sequencing was performed for 80 LB samples.
For 6 tumour samples most common PIK3CA somatic
variants in breast cancer were identified (H1047R and
E545K). None of these variants was uncovered in the LB
samples, while somatic variants identified in ctDNA were
missing in the tumour DNA. As expected, the CNV analysis
performed for tumour samples allowed to distinguish
subclonal tumour variations for the same patient. A method
allowing breast cancer detection at a relatively early stage,
based on sWGS and CNV analysis, was developed. Dis-
crepancies observed between the tumour and the LB results
may be partially due to clonal variants in the heterogenous
tumour tissues, but it also suggests the need for a further
improvement regarding sensitivity of liquid biopsy
methods.
Funding: RPMA.01.02.00-14-6209/16.
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Utilize of liquid biopsy in monitoring circulating tumor
DNA in a patent with colorectal cancer
C. C. Hung1, T. K. Lin1,2, Y. L. Lin3, C. W. Huang4, C. W.
Yeh4, H. M. Wang5, Y. N. Su1,6
1Sofiva Genomics Co., Ltd., Taipei, Taiwan, 2Graduate
Institute of Clinical Medicine, College of Medicine,
National Taiwan University, Taipei, Taiwan, 3Division of
Hematology and Oncology, Department of Internal Medi-
cine, Cardinal Tien Hospital, Taipei, Taiwan, 4National
Center for High Performance Computing, National Applied
Research Laboratories, Hsinchu, Taiwan, 5Division of
Colorectal Surgery, China Medical University Hospital,
Taichung, Taiwan, 6Dianthus Maternal Fetal Medicine
Clinic, Taipei, Taiwan
Background: Liquid biopsy is a minimal invasive exam-
ining circulating tumor DNA (ctDNA) in the blood, com-
pared with invasive tissue biopsy. Frequency detecting of
molecular alterations in ctDNA should be an alternative tool
for monitoring disease progression.
Method:We used next-generation sequencing (NGS) based
ctDNA panel assay containing 197 targeted genes and
sequenced on an Illumina NextSeq 550. A 41-year old patient
with stage IV colorectal cancer was examined in this study.
Results: We found 8 mutations in this patient in 2018
when he found the cancer and the mutation sites were APC
c.3189 delT (50.81%), TP53 c.339 delC (55.46%), KRAS
c.38 G>A (39.38%), EYS c.157 T>G (0.38%), KIT c.147
C>T (0.31%), PHACTR1 c.760 C>G (0.20%), CSMD3
c.837 T>G (0.08%) and SLITRK4 c.329 A>C (0.05%).
Physician chose neoadjuvant therapy, CCRT (concurrent
chemoradiotherapy) and Avastin for this patient. Two
months later, we focused on monitoring APC c.3189 delT,
TP53 c.339 delC and KRAS c.38 G>A mutation sites, and
the mutation rates were 0.69%, 0.72% and 0.34%,
respectively. After given the same treatment, the mutation
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rates were increased to 16.08%, 14.02% and 10.25%,
respectively. The cancer therapist decided to change to
immunotherapy combined with targeted therapy, and the
mutation rates decreased to 5.92%, 5.59% and 4.35%,
respectively.
Conclusions: The earlier determination of ctDNA can
help track tumor response and resistance to therapy, and
may also help prevent recurrence. The more clinical
validation and utility of liquid biopsy would improvet of
quality of life in cancer patients.
C.C. Hung: A. Employment (full or part-time); Sig-
nificant; Sofiva Genomics Co., Ltd. T.K. Lin: A. Employ-
ment (full or part-time); Significant; Sofiva Genomics Co.,
Ltd.. Y.L. Lin: None. C.W. Huang: None. C.W. Yeh:
None. H.M. Wang: None. Y.N. Su: A. Employment (full
or part-time); Significant; Sofiva Genomics Co., Ltd..
P15.40.B
New revolutionary approach for Klippel-Trenaunay
Syndrome: cfDNA NGS Liquid Biopsy
M. Palmieri1, L. Di Blasio2,3, A. Currò1,4, V. Monica2,3, L.
Di Sarno1, G. Doddato1,4, E. Frullanti1, G. Chaiverina2,3,
A. Giliberti1,4, B. Mussolin2, C. Fallerini1,4, F. Molinaro5,
M. Vaghi6, L. Primo2,3, A. Renieri1,4, A. Pinto4
1Medical Genetics, University of Siena, Siena, Italy, 2Can-
diolo Cancer Institute FPO-IRCCS, Candiolo, Italy,
3Deparment of Oncology, University of Turin, Turin, Italy,
4Genetica Medica, Azienda Ospedaliera Universitaria
Senese, Siena, Italy, 5Chirurgia Pediatrica, Azienda
Ospedaliera Universitaria Senese, Siena, Italy, 6Chirurgia
Vascolare, Ospedale Maggiore di Crema, Largo Ugo
Dossena, Crema, Italy
NGS-liquid biopsy using cell-free DNA (cfDNA) has
emerged as an innovative non-invasive approach for early
detection and monitoring of cancer. This approach over-
coming the space-time profile constraint of tissue biopsies
opens a new scenario also for vascular malformations due to
somatic mosaicism. We propose here this approach as a fast
non-invasive reliable tool for Klippel-Trenaunay syndrome
(KTS) diagnosis. Six patients group suffering from KTS
were selected. Blood samples from both peripheral and
efferent vein from vascular malformation were collected
and cfDNA extracted. Tissue biopsies from vascular lesions
were also collected. CfDNA libraries were performed using
Oncomine™ Pan-Cancer Cell-Free Assay. Ion Proton for
sequencing and Ion Reporter Software for analysis were
used. Different mutations on PIK3CA gene were detected in
all patients including p.Glu542Lys and p.Glu545Gly. The
same mutation detected in tissue was detected in liquid
biopsy with a variant allele frequency (VAF) ranging from
0,1-0,2% in cfDNA from peripheral vein to 1-2% in cfDNA
from efferent vein. We demonstrate that cfDNA-NGS-
Liquid Biopsy is able to identify the PIK3CA mutation
detected in affected tissues. Moreover, we have shown that
blood sample withdrawal at the lesion site increases VAF
rate with an order of magnitude above the limit of detection
(usually 0,05%) lowering the risk of false negative. Finally,
the non-invasiveness of the method avoids any risk of
bleeding, being easily performed also in children. We pro-
pose this method as method of choice for KTS diagnosis
and subsequent therapy tailored to the genetic defect. We
acknowledge ILA association.
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Optimising long-range PCR methodology and long-read
DNA sequencing
L. E. Batty1, B. Alobaidi1, G. S. Holt1, M. S. Oud2, H. E.
Smith1, P. F. de Vries2, R. M. Smits3, L. E. L. M. Vissers2, L.
Ramos3, M. J. Xavier1, J. A. Veltman1
1Biosciences Institute, Newcastle University, Newcastle
upon Tyne, United Kingdom, 2Department of Human
Genetics, Donders Institute for Brain, Cognition and
Behaviour, Radboudumc, Nijmegen, Netherlands, 3Depart-
ment of Obstetrics and Gynaecology, Radboudumc, Nijme-
gen, Netherlands
Long range PCR for targeted long-read sequencing has
many practical uses, however the inherent sequencing error
(~10%) of Oxford Nanopore Technologies (ONT) necessi-
tates significant sequencing depths to achieve acceptable
levels of confidence. Several methods exist for target cap-
turing, most can be broadly categorised under PCR and
CRISPR-Cas enrichment approaches. Here we report on the
usage of long-range PCR to target capture large regions
spanning rare de novo mutations linked to male infertility
for sequencing with ONT for phasing analysis. Long-range
PCR was used on 5-10kb regions to achieve minimum
sequencing depths of >2,000x coverage, >10 fold that of
CRISPR enrichments and >90% less off-target sequencing.
Individually unique target regions removed the necessity for
barcodes, saving time, cost and yield. This approach
allowed bringing costs to as little as €15 per sample in runs
of 100 samples. The optimised method involved specialised
primer design with our bespoke primer tool and improved
PCR conditions, followed by sequencing on ONT MinION
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with adapted library preparation. Using input concentrations
twice the standard recommendation achieved >2-fold
increased to previous yields. “Refuelling” flowcells mid-run
with ATP-containing sequencing buffer restored nanopores
from <1% to >80%, a further 6.8 fold increase in yield.
More than 30 billion base calls are consistently obtained
following this procedure, matching best-in field flowcell
performance. Currently available methods for long-read
sequencing and target capture can be expensive, time con-
suming and overly off target. Our proposed methodology
provides a combination of common approaches that have
been optimised to achieve greater results more efficiently.
L.E. Batty: None. B. Alobaidi: None. G.S. Holt: None.
M.S. Oud: None. H.E. Smith: None. P.F. de Vries: None.
R.M. Smits: None. L.E.L.M. Vissers: None. L. Ramos:
None. M.J. Xavier: None. J.A. Veltman: None.
P15.42.A
Challenges in identifying a large complex chromosomal
rearrangement by long reads sequencing
B. Jenko Bizjan1, T. Katsila2, T. Tesovnik1, R. Šket1, M.
Debeljak1, J. Kovač1
1University Children’s Hospital Ljubljana, Ljubljana,
Slovenia, 2Institute of Chemical Biology, National Hellenic
Research Centre, Athens, Greece
Background: The success in the identification of genomic
structural variations (SVs) in routine clinical protocols
mainly depends on the complexity and size of SVs. Short
and/or simple SV are being successfully identified by
cytogenetic techniques or short read sequencing, while large
nested and complex rearrangements demand case-specific
investigation via the application of novel emerging tech-
nologies. For a clinical case with developmental delay
cytogenetic analysis revealed a large complex de novo
chromosomal rearrangement. We aimed to evaluate the
potential of whole genome long-reads sequencing to resolve
the precise variant configuration and its underlying
mechanism.
Methods: Long-reads sequencing was performed by
MinION Oxford Nanopore Technologies. Bioinformatic
pipeline of reference-based alignment with SVs calling in
combination with De novo assembly was applied. Reads
were aligned to the reference using NGMLR or minimap2,
following by detection of SVs with SVIM and Sniffles.
Canu was used for De novo assembly.
Results: We have performed 6 effective runs using
MinION long-read sequencing and reached 13,2x theore-
tical coverage of the human genome. Median read quality
was 12.44, with an average N50 read length of 10.2 kb.
Read-depth analysis identified the gain for triplication and
duplication, yet the precise breakpoints cannot be defined
(reads coverage variation). NGMLR alignment in combina-
tion with Canu-trimming, followed by SVIM variant
calling, resulted in a few probable inversions and one
tandem duplication.
Conclusions: For determination of precise breakpoints of
a large nested SV, which is much larger than the average
read, long-reads sequencing needs to be combined with
additional long-range technologies.
B. Jenko Bizjan: None. T. Katsila: None. T. Tesovnik:
None. R. Šket: None. M. Debeljak: None. J.
Kovač: None.
P15.43.B





Zhao)">Introduction: Systematic errors can be introduced
from DNA amplification during massively parallel
sequencing library preparation and sequencing array for-
mation. PCR-free genomic library preparation methods
were previously shown to improve whole genome sequen-
cing (WGS) quality on the Illumina platform, especially in
calling InDels. We hypothesized that substantial InDel
errors continue to be introduced by the remaining PCR step
of DNA cluster generation.
Materials and Methods: Here, we sequenced PCR-free
libraries as paired-end 150-base reads on MGI’s PCR-free
DNBSEQTM arrays to accomplish the first true PCR-free
WGS. We used MGI’s PCR-free WGS library preparation
kits as recommended or with some modifications to prepare
several NA12878 libraries. We also assessed the process
data performances with three variant calling pipelines.
Conclusions: Reproducibly high-quality libraries were
obtained with low coverage bias and less than 1% read
duplication. Using machine learning (ML) methods (Deep-
Variant or DNAscope), variant calling performance (SNPs
F-measure>99.94%, InDels F-measure>99.6%) exceeded
widely accepted standards. Furthermore, PCR-free WGS
libraries sequenced on the PCR-free DNBSEQTM platform
have up to 55% less InDel errors compared to the NovaSeq
platform, confirming that DNA clusters contain PCR-
generated errors. We also found some clinical relevant
gene locis can only be detected by PCR-free DNBSEQTM.
Therefore, true PCR-free DNBSEQTM WGS provides a
powerful solution for improving WGS accuracy while
reducing cost and analysis time, thus facilitating future
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Nanopore sequencing of differentiating murine neuronal
precursor cells
C. Hewel, C. Vennin, B. Lutz, S. Gerber
Johannes Gutenberg University of Mainz, Mainz, Ger-
many
Nanopore sequencing has emerged as a promising approach
to overcome some of the limitations of classical Next-
Generation-Sequencing. Among the benefits of this tech-
nique are direct and PCR-free sequencing of RNA or DNA,
native detection of basepair-modifications and full-length
read sequencing. This has led to a number of interesting
applications, also for clinical purposes. Here, we were
especially interested in the detection of transcript isoforms
during neuronal differentiation, thus making use of the
capability of a nanopore sequencer to provide full-length
transcript sequences. Previous studies have shown that
during neuronal differentiation the 3’ends of transcripts can
extend by several kilo-basepairs and the presence or
absence of this feature conveys critical function. Moreover,
key players in neuronal differentiation, such as the BDNF-
gene have been shown to have several distinct isoforms,
that specifically trigger different receptors, evoking varying
signalling cascades. To investigate transcript isoforms dur-
ing neuronal differentiation, we employed a differentiation
protocol in a cell line of murine neuronal precursor cells.
During differentiation, the cells were harvested on 4 time-
points. The RNA was converted to cDNA and library pre-
paration for a nanopore sequencing device was done as per
manufacturers specifications. Subsequently sequencing on a
nanopore device and basecalling using the MinKNOW
software followed. Conclusively, we were able to test the
feasibility of nanopore sequencing in our lab and to inves-
tigate complex splice isoforms during neuronal differentia-
tion. Results will be presented and discussed.
C. Hewel: None. C. Vennin: None. B. Lutz: None. S.
Gerber: None.
P15.46.B
High-throughput genome sequencing facility: Imple-
menting NovaSeq(s)
Z. Gerber, J. Tassin, F. Jobard, F. Sandron, D. Delafoy, S.
Meslage, G. Septier, C. Baulard, J. Perrier, D. Derbala, E.
Menard, C. Besse, D. Lechner, J. Garnier, B. Fin, E.
Jakoby, F. Gavory, D. Bacq-Daian, V. Meyer, A. Boland, J.
Deleuze, R. Olaso
CEA / National Center for Research in Human Genomics,
Evry, France
We have optimised next-generation sequencing on the
NovaSeq 6000 platform for our major sequencing applica-
tions: whole genome (PCR free), whole exome, and
RNAseq. Our optimal loading concentration for each
application is 2.0 nM, 1.5 nM and 2.25 nM in standard
workflow, respectively, resulting in 77 – 85% of clusters
passing filter and low level of optical duplicates. We
observed index-dependent differences in sequencing per-
formance in the NovaSeq: libraries with certain indexes are
consistently under- or overrepresented (27% less or 32%
more than the average number of reads per library, calcu-
lated across 68 runs). In contrast, we observed little effect of
insert size on clustering efficiency (for insert sizes ranging
265 – 476 bp in the same flowcell). The end-of-read quality
scores are higher in the NovaSeq compared to HiSeq X
Five, resulting in less sequencing errors. In contrast, we
observed slightly increased systematic bias in C > A and G
> T errors at the end of NovaSeq reads, possibly due to the
dual channel technology. The reduction in run time is an
important advantage over the HiSeq platform, for example
in our emergency neonatal genome sequencing for Fastge-
nomics. In conclusion, NovaSeq produces more output in
shorter time, with sequencing quality similar to previous
generation of sequencers. However, the unprecedented
plexity allowed by the large sequencing capacity of Nova-
Seq presents new challenges in pooling certain indexes.
Z. Gerber: None. J. Tassin: None. F. Jobard: None. F.
Sandron: None. D. Delafoy: None. S. Meslage: None. G.
Septier: None. C. Baulard: None. J. Perrier: None. D.
Derbala: None. E. Menard: None. C. Besse: None. D.
Lechner: None. J. Garnier: None. B. Fin: None. E.
Jakoby: None. F. Gavory: None. D. Bacq-Daian: None.
V. Meyer: None. A. Boland: None. J. Deleuze: None. R.
Olaso: None.
P15.47.C
High-throughput NGS Library Normalization Method
P. Mielinis, A. Stašytė, A. Lubys
Thermo Fisher Scientific, Vilnius, Lithuania
Introduction: With the advances in the next-generation
sequencing and capacity of sequencers growing, more and
more sample can be analyzed in a single run. To achieve
efficient, well balanced run, all libraries must be carefully
quantified and pooled. Current strategies rely on qPCR,
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ddPCR, fluorometry (Qubit) or capillary electrophoresis,
however, they are either time consuming, costly or inac-
curate, leading to unbalanced ratios between pooled librar-
ies, especially when handling many samples.
Underrepresented libraries may require re-sequencing, fur-
ther increasing the cost of the experiment.
Materials and Methods: Here we describe a
quantification-free NGS library normalization method,
based on library tagging via PCR. Tagged libraries are
then bound by a capturing reagent and purified using
magnetic beads. Multiple libraries can be pooled early in the
normalization procedure yielding excellent sample distribu-
tion within a pool and significantly shortening the whole
normalization procedure.
Results: We show that the normalization method
produces well balanced library pool with coefficient of
variation (CV) being controlled under <10 % with no
observed effect on GC bias or genomic content, making it
very convenient to use with samples within an extreme
range of GC content.
Conclusions: Although the technology is compatible
with diverse library types, including whole human genome,
exome or small genome, the method is going to be the most
beneficial when working with plentiful of samples and
various inputs of genomic material. Due to the simplicity of
materials and a workflow, the normalization has a potential
to be automated, simplifying the normalization and pooling
procedures even further.
P. Mielinis: A. Employment (full or part-time); Modest;
Thermo Fisher Scientific. A. Stašytė: None. A. Lubys: A.
Employment (full or part-time); Modest; Thermo Fisher
Scientific.
P15.48.A
When Whole Exome Sequencing fails: Lessons learned
from Whole Genome Sequencing
A. Eliyahu1,2,3, D. Marek-Yagel1,3, B. Pode-Shakked1,4,3, A.
Veber1, A. Philosoph1, N. Shalva1, B. Ortal5, I. Bar-
Joseph5, O. Nayshool5, B. Ben-Zeev6,3, G. Heimer6,7, O.
Staretz-Chacham8, D. Oz-Levi9, N. Pode-Shakked10,11,3, Y.
Anikster1,3,12
1Metabolic Disease Unit, Edmond and Lily Safra Chil-
dren’s Hospital, Sheba Medical Center, Tel-Hashomer,
Israel, 2The Danek Gertner Institute of Human Genetics,
Sheba Medical Center, Tel-Hashomer, Israel, 3Sackler
Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel,
4The Talpiot Medical Leadership Program, Sheba Medical
Center, Tel Hashomer, Israel, 5The Genomic Unit, Sheba
Cancer Research Center, Sheba Medical Center, Tel-
Hashomer, Israel, 6Pediatric Neurology Unit, Edmond
and Lily Safra Childrens Hospital, Tel-Hashomer, Israel,
7Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv,
Italy, 8Metabolic Clinic, Pediatric Division, Soroka Medical
Center, Ben-Gurion University, Beer Sheva, Israel,
9Department of Molecular Genetics, Weizmann Institute of
Science, Rehovot, Israel, 10The Talpiot Medical Leadership
Program, Sheba Medical Center, Tel-Hashomer, Israel,
11Pediatric Stem Cell Institute, Edmond and Lily Safra
Childrens Hospital, Sheba Medical Center, Tel-Hashomer,
Israel, 12Wohl Institute for Translational Medicine, Sheba
Medical Center, Tel-Hashomer, Israel
Exome sequencing is an extremely efficient way to to
identify disease-causing variations and increasingly used in
healthcare and research. However, in certain cases, either
due to the complexity or the location of the aberration,
whole exome sequencing (WES) might not yield a patho-
genic variant, and whole genome sequencing (WGS) may
be required. We report herein four recent cases diagnosed in
our lab, which were all initially missed by WES and later
resolved only by sequencing the entire genome:1-Promoter
mutation: Four patients of two unrelated families, with
portal vein thrombosis and macrocephaly. WGS revealed
the –270C>G homozygous mutation, located in the pro-
moter of the PIGM gene.2-Large deletions: Eight patients
from 7 different families of Iraqi-Jewish origin with auto-
somal recessive intractable diarrhea of infancy. Linkage
analysis with WGS enabled the detection of two over-
lapping deletions on chromosome 16.3-Intronic mutation:
Two siblings with PS6 syndrome without mutation in the
coding sequence of the candidate gene, ARSB. WGS,
revealed deep intronic mutation in the gene, which leads to
insertion of a pseudo-exon.4-Large duplication: Three
female siblings of Iraqi-Jewish descent, presented with
cerebellar ataxia, encephalopathy, seizures and cognitive
disability. WGS with Bam file analysis identified a novel
biallelic duplications in the COQ5 gene. It is clear that
WGS is a powerful tool, which can improve the rate of
discovery of disease-causing mutations, especially in such
challenging cases. With the falling cost of WGS, more
individuals are pursuing this option, which enable to enrich
the databases, and lead to better diagnosis.
A. Eliyahu: None. D. Marek-Yagel: None. B. Pode-
Shakked: None. A. Veber: None. A. Philosoph: None. N.
Shalva: None. B. Ortal: None. I. Bar-Joseph: None. O.
Nayshool: None. B. Ben-Zeev: None. G. Heimer: None.
O. Staretz-Chacham: None. D. Oz-Levi: None. N. Pode-
Shakked: None. Y. Anikster: None.
P15.51.A
Phased WGS by direct library preparation from 240
FACS sorted cells for comprehensive genetics in multi-
ple myeloma
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C. Gran1,2, L. Peña-Pérez1, J. Eisfeldt1, C. Gustafsson1, J.
Borg Bruchfeld1,2, J. Hauenstein1, N. Frengen1, F.
Taborsak-Lines3, R. Olsen4, P. Ewels4, A. Lindstrand1,2, H.
Nahi1,2, R. Månsson1
1Karolinska Institutet, Stockholm, Sweden, 2Karolinska
University Hospital, Stockholm, Sweden, 3Royal Institute
of Technology, Stockholm, Sweden, 4Stockholm University,
Stockholm, Sweden
Introduction: multiple myeloma (MM) is an incurable and
aggressive plasma cell malignancy characterized by genetic
heterogeneity and complexity. In addition to single
nucleotide variants (SNV), tumor cells often carry multiple
complex structural variants (SV) and copy number varia-
tions (CNV). Nonetheless, only limited genetic character-
ization is performed by fluorescence in situ hybridization
(FISH) in standard care. Linked reads whole genome
sequencing (WGS) - or phased WGS - has shown great
promise for providing improved calling of structural aber-
rations. However, its implementation has been hampered by
the difficulty of high molecular weight (HMW) DNA
preparation.
Materials and Methods: here we demonstrate that DNA
preparation can be circumvented by direct loading of 240
FACS sorted cells into the linked read library preparation.
Besides providing a simplified workflow, this procedure
results in longer DNA molecules (median 190kbp) and
longer phase blocks (median N50 length 16.9Mbp)
compared to standard methods.
Results: in the ongoing initial benchmarking, all CNVs
and SVs previously found by FISH were identified through
linked read sequencing. Additionally, several aberrations
not detected by an expanded FISH panel were identified.
The latter remain to be verified by FISH.
Conclusions: the use of linked read technologies
combined with our direct cell loading protocol and
diagnostic flow cytometry can feasibly establish a more
comprehensive genetic characterization for MM - and other
diseases - in clinical routine. This will contribute to
improved diagnostics and risk stratification in MM.
C. Gran: None. L. Peña-Pérez: None. J. Eisfeldt: None.
C. Gustafsson: None. J. Borg Bruchfeld: None. J.
Hauenstein: None. N. Frengen: None. F. Taborsak-
Lines: None. R. Olsen: None. P. Ewels: None. A.
Lindstrand: None. H. Nahi: None. R. Månsson: None.
P15.52.B
Precise correction of heterozygous SHOX2 mutations in
iPSCs derived from patients with atrial fibrillation via
genome editing and sib-selection
S. A. Sumer1,2, S. Hoffmann1,2, S. Laue3,4, B. Campbell3, K.
Raedecke1,2, V. Frajs1, S. Clauss5,4, S. Kääb5,4, H. Janssen6,
A. Jauch6, T. Dorn3,4, K. L. Laugwitz3,4, A. Moretti3,4, G. A.
Rappold1,2
1Department of Human Molecular Genetics, Institute of
Human Genetics, University of Heidelberg, Heidelberg,
Germany, 2DZHK (German Center for Cardiovascular
Research), Partner Site Heidelberg/Mannheim, Heidelberg,
Germany, 3First Department of Medicine, Cardiology,
Klinikum rechts der Isar – Technical University of Munich,
Munich, Germany, 4DZHK (German Center for Cardiovas-
cular Research), Partner Site Munich, Munich, Germany,
5Department of Medicine I, Klinikum Grosshadern, Uni-
versity of Munich (LMU), Munich, Germany, 6Department
of Human Genetics, Institute of Human Genetics, University
of Heidelberg, Heidelberg, Germany
Patient-specific iPSCs offer unprecedented opportunities for
the investigation of multigenic disease, personalized medi-
cine and stem cell therapy. For complex diseases, such as
atrial fibrillation (AF), precise correction of the associated
mutation is crucial. Here, we generated and corrected iPSC
lines from two AF patients carrying different heterozygous
SHOX2 mutations. In this context, we developed a novel
strategy for the scarless correction of heterozygous muta-
tions. It is based on a stochastic enrichment by sib-selection
(subdivision of edited cells into small cell pools), followed
by allele quantification via digital PCR and next generation
sequencing to detect isogenic subpopulations. This method
does not require the use of antibiotic selection or cell sorting
and can be easily combined with existing improvements for
gene editing such as modified Cas9 enzymes and base
editors. By avoiding the insertion of silent mutations that
are used to prevent re-cutting by Cas9, this method is suited
for the correction of intronic or intergenic variants. The
presented strategy helps to overcome the low efficiency of
homology-dependent repair in iPSCs and therefore facil-
itates the generation of isogenic control lines that represent
the gold standard for modeling complex cardiac diseases
in vitro. In summary, we generated the first AF model using
patient-specific and gene-corrected iPSCs and developed a
novel method for the correction of heterozygous mutations.
This work has been funded by DFG RA380/14-4 (to GA.R),
DZHK 81X2500133 and 81X2500113 (to S.H.),
81X2600603 and 81X2600607 (to A.M.) and German
Research Foundation Transregio (to A.M., K-L.L.).
S.A. Sumer: None. S. Hoffmann: None. S. Laue: None.
B. Campbell: None. K. Raedecke: None. V. Frajs: None.
S. Clauss: None. S. Kääb: None. H. Janssen: None. A.
Jauch: None. T. Dorn: None. K.L. Laugwitz: None. A.
Moretti: None. G.A. Rappold: None.
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Fast genome sequencing in less than 40 days for
newborn patients in intensive care unit: a feasibility
study allowing diagnosis in 56% of cases in a French
hospital network
A. Denommé-Pichon1,2,3, A. Vitobello1,2,3, R. Olaso4, A.
Ziegler5, B. Isidor6,7, M. Jeanne8,9, C. Racine1,2,3, F. Tran
Mau-Them1,2,3, V. Couturier1, C. Poë1, T. Jouan1, A.
Boland4, B. Fin4, A. Garde1,2,3, A. Prost1,2, P. Garret2, É.
Tisserant1,2, J. Delanne2,3, M. Gorce5, M. Nizon6, M.
Vincent6, S. Moutton2,3, S. Nambot2,3, Y. Capri10, J. Van
Gils11, T. Busa12, S. Sigaudy12, M. Fradin13,14, A.
Lavillaureix13, P. Rollier13, L. Pasquier13, M. Barth5, A.
Bruel1,2,3, D. Bonneau5, A. Toutain8,9, C. Philippe1,2,3, Y.
Duffourd1,2,3, P. Callier2,15, J. Deleuze4, L. Faivre1,2,3, C.
Thauvin-Robinet1,2,3, A. Sorlin1,2,3
1Unité Fonctionnelle Innovation en Diagnostic génomique
des maladies rares, FHU-TRANSLAD, CHU Dijon Bour-
gogne, Dijon, France, 2UMR1231 GAD, Inserm - Uni-
versité Bourgogne-Franche Comté, Dijon, France, 3Centre
de Référence Maladies Rares « Anomalies du développe-
ment et syndromes malformatifs », centre de génétique,
FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France,
4Centre National de Recherche en Génomique Humaine
(CNRGH), Institut de Biologie François Jacob, CEA,
Université Paris-Saclay and LabEx GENMED, Évry,
France, 5Department of Biochemistry and Genetics, Angers
University Hospital and UMR CNRS 6015-INSERM 1083,
Angers, France, 6Service de génétique médicale, CHU de
Nantes, Nantes, France, 7Inserm, CNRS, Université de
Nantes, l’institut du thorax, Nantes, France, 8Service de
Génétique, Centre Hospitalier Universitaire de Tours,
Tours, France, 9UMR 1253, iBrain, Université de Tours,
Inserm, Tours, France, 10Service de Génétique Clinique,
CHU Robert Debré, Paris, France, 11Service de Génétique
Médicale, CHU de Bordeaux, Bordeaux, France,
12Département de génétique médicale, CHU Timone
enfants, AP-HM, Marseille, France, 13Service de Génétique
Médicale, Centre Référence Anomalies du Développement,
CHU Rennes, Rennes, France, 14Service de Génétique
Médicale, CH Saint Brieuc, Saint Brieuc, France, 15Labor-
atoire de génétique chromosomique et moléculaire, FHU-
TRANSLAD, CHU Dijon Bourgogne, Dijon, France
Introduction: Fast etiological diagnosis for infants in
intensive care unit (ICU) remains a major challenge for rare
diseases with early onset and rapid evolution, whose genetic
causes are very heterogeneous. We tried to assess the fea-
sibility of fast genetic diagnosis by trio-GS (genome
sequencing) in newborns and children requiring an urgent
diagnosis for their care in a French hospital network. This
study was designed to identify pitfalls and evaluate our
capacity to deliver GS in emergency.
Materials and Methods: A French prospective multi-
centric pilot study included newborns or infants in neonatal
or pediatric ICU, affected with severe phenotype that made
suspect a genetic disease without obvious clinical diagnosis
and required etiological diagnosis in emergency for guiding
medical care. Pitfalls and duration of each biological step
were noted. Every time the duration was above the expected
limit, the causes were analysed and blockers handled.
Results: For the 34 newborns and infant included, the
positive molecular diagnosis rate (IV and V classes
variations) was 56% (19/34) and suggested care manage-
ment changes for 47% (9/19) of the positive cases. The
rapid trio-GS strategy allowed to obtain a median
duration of 45 days (27 to 92) from blood sampling to
results communication to the clinician. Especially during
the first three months, we identified several pitfalls,
causing steps longer than planned. Corrective measures
or protocol adaptations enabled a clear decrease of such
difficulties.
Conclusions: Usefulness of rapid trio-GS is undeniable
for patients in ICU, but requires adapting all stages of the
classic circuit.
A. Denommé-Pichon: None. A. Vitobello: None. R.
Olaso: None. A. Ziegler: None. B. Isidor: None. M.
Jeanne: None. C. Racine: None. F. Tran Mau-Them:
None. V. Couturier: None. C. Poë: None. T. Jouan:
None. A. Boland: None. B. Fin: None. A. Garde: None.
A. Prost: None. P. Garret: None. É. Tisserant: None. J.
Delanne: None. M. Gorce: None. M. Nizon: None. M.
Vincent: None. S. Moutton: None. S. Nambot: None. Y.
Capri: None. J. Van Gils: None. T. Busa: None. S.
Sigaudy: None. M. Fradin: None. A. Lavillaureix: None.
P. Rollier: None. L. Pasquier: None. M. Barth: None. A.
Bruel: None. D. Bonneau: None. A. Toutain: None. C.
Philippe: None. Y. Duffourd: None. P. Callier: None. J.
Deleuze: None. L. Faivre: None. C. Thauvin-Robinet:
None. A. Sorlin: None.
P15.54.A
A three-year follow up study on 104 exome-sequenced
patients with paediatric-onset diseases: Exome reana-
lysis and the impacts on clinical management and
outcome
J. L. F. Fung1, S. Huang2, M. H. C. Yu1, C. C. Y. Chung1,
M. C. Y. Chan1, S. Pajusalu2, C. C. Y. Mak1, M. Lek2, B. H.
Y. Chung1
1Department of Paediatrics and Adolescent Medicine, LKS
Faculty of Medicine, University of Hong Kong, Hong Kong,
Hong Kong, 2Department of Genetics, Yale School of
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Introduction: Whole exome sequencing (WES) has
become one of the important diagnostic tools in clinical
genetics with mean diagnostic rate of 36%. Many studies
have illustrated the diagnostic and immediate clinical
impact of WES. However, a vast majority of patients remain
undiagnosed and there is little documentation of the long-
term(>1year) clinical utility.
Methods: This is a three-year follow-up analysis to our
previous publication(PMID:30109123). The diagnostic yield
was 41% (43/104). 46 non-diagnosed patients consented for the
reanalysis. Depending on the availability, either raw sequen-
cing data were reanalyzed, or stored DNA were re-sequenced.
The long-term outcome of 36 diagnosed patients were
measured by clinical follow-up and review of medical records.
Results: WES reanalysis gave rise to twelve additional
diagnoses (table), boosting the overall diagnostic yield from
41% to 53%. The reanalysis of one patient had lead the
discovery of MN1 C-Terminal Truncation (MCTT) syn-
drome caused by mutations in MN1(PMID:31834374).
Currently, we are prospectively collecting and sharing more
clinical information on the disease. If you have a patient
with MCTT syndrome or would like to learn more, please
visit https://humandiseasegenes.nl/mn1/. After three years
of follow-up, change in clinical management was observed
in 72.2% of the families(26/36), leading to positive change
in outcome in four patients(11%).
Conclusions: WES reanalysis provides promising addi-
tional diagnoses to patients. Longitudinal follow-up showed
that a genetic diagnosis gave rise to positive management
and outcomes for patients.
ID Sample Type Gene Variant(s) Segregation Diagnosis (OMIM) Inheritance
U018 DNA ATP1A3 c.954C>G,
(p.Ile318Met)









U036 DNA MN1 c.3870_3879dup
TGACGCCAAG,
p.(Ala1294Ter)




U043 DNA PTPN11 c.5C>T,
p.(Thr2Ile)
De novo Noonan Syndrome (163950) AD













U066 DNA MFN2 c.707C>T,
p.(Thr236Met)
Unknown Charcot-Marie-Tooth disease,
axonal, type 2A2A (609260);
Hereditary motor and sensory
neuropathy VIA(601152)
AD
U071 DNA COL11A1 c.3115G>A,
p.(Gly1039Ser)




U075 DNA SPTAN1 exon10-12
deletion
Unknown Epileptic encephalopathy, early
infantile, 5 (613477)
AD
U077 Data SPTAN1 c.4828C>T,
p.(Arg1610Trp)
De novo Epileptic encephalopathy, early
infantile, 5 (613477)
AD
U086 Data GNB1 c.239T>C,
p.(Ile80Thr)
Unknown Mental retardation, autosomal
dominant 42 (616973)
AD










J.L.F. Fung: None. S. Huang: None.M.H.C. Yu: None.
C.C.Y. Chung: None. M.C.Y. Chan: None. S. Pajusalu:
None. C.C.Y. Mak: None. M. Lek: None. B.H.Y.
Chung: None.
P15.55.B
Sequencing the previously unsequencable using
Amplification-free Targeted Enrichment powered by
CRSIPR/Cas9
J. Ekholm, N. Piganeau, Y. Tsai, I. McLaughlin, J. Ziegle
Pacbio, Menlo Park,, CA, United States
Genomic regions with extreme base composition bias and
repetitive sequences have long proven challenging for tar-
geted enrichment methods, as they rely upon some form of
amplification. Similarly, most DNA sequencing technolo-
gies struggle to faithfully sequence regions of low com-
plexity. This has especially been trying for repeat expansion
disorders such as Fragile X disease, Huntington disease and
various Ataxias, where the repetitive elements range from
several hundreds of bases to tens of kilobases. We have
developed a robust, amplification-free targeted enrichment
technique, called No-Amp Targeted Sequencing, that
employs the CRISPR/Cas9 system. In conjunction with
SMRT Sequencing, which delivers long reads spanning the
entire repeat expansion, high consensus accuracy, and uni-
form coverage, these previously inaccessible regions are
now accessible. This method is completely amplification-
free, therefore removing any PCR errors and biases from the
experiment. Furthermore, this technique also preserves
native DNA molecules, allowing for direct detection and
characterization of epigenetic signatures. The No-Amp
method is a two-day protocol that is compatible with mul-
tiplexing of multiple targets and multiple samples in a single
reaction, using as little as 1 μg of genomic DNA input per
sample. We have successfully targeted a number of repeat
expansion disorder loci (HTT, FMR1, ATXN10, TCF4,
C9orf72) with alleles as long as >2700 repeat unites (>13
kb). Using the No-Amp method we have isolated hundreds
of individual on-target molecules, allowing for reliable
repeat size estimation, mosaicism detection and identifica-
tion of interruption sequences - all aspects of repeat
expansion disorders important for better understanding the
underlying disease mechanisms.
J. Ekholm: None. N. Piganeau: None. Y. Tsai: None. I.
McLaughlin: None. J. Ziegle: None.
P15.56.C
Innovative approach for digital gene expression and
alternative polyadenylation profiling
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Z. Kapustina1,2, J. Sulgaite1,2, S. Zeimyte2, A. Lubys2
1Vilnius University, Vilnius, Lithuania, 2Thermo Fisher
Scientific Baltics UAB, Vilnius, Lithuania
Introduction: High-throughput RNA sequencing offers a
comprehensive analysis of transcriptome complexity origi-
nated from regulatory events such as differential gene
expression, alternative polyadenylation and others, and
allows the increase in diagnostic capacity and precision.
Here, we report TAS-seq (Terminator-Assisted Synthesis-
based sequencing) - a novel RNA-seq library preparation
method directed towards mRNA 3’ termini. We demon-
strate specific enrichment for 3’UTR/polyA tail junctions by
a simplest possible one-step protocol which takes under
2 hours to complete. To achieve that, we synthesized
modified terminators which allow to generate cDNA
fragments labeled by sequencing adapters at both termini
at the reverse transcription step.
Results: To demonstrate proof-of-principle and evaluate
dose-response in resulting libraries, we have utilized
Universal Human Reference RNA, Human Brain Reference
RNA and ERCC spike-in controls. We obtained high-
quality stranded libraries from 20 pg - 1 ug of total RNA
which implies the utility of our approach for single-cell
sequencing. This notion was confirmed upon successful
integration of TAS-seq into the droplet-based scRNA-seq
protocol. Moreover, modified terminators allow for easy
introduction of unique molecular identifiers to correct for
PCR bias.
Conclusions: We conclude that for high-throughput gene
expression profiling applications which do not specifically
require information on alternative splicing events, 3’
mRNA termini counting approach is a cost-effective
alternative to whole transcriptome sequencing. TAS-seq
workflow proposed in this work makes it one of the
simplest RNA-seq library preparation methods reported in
the field.
Z. Kapustina: None. J. Sulgaite: None. S. Zeimyte:
None. A. Lubys: None.
P15.57.A
The RNA-sequencing approach recapitulates the mole-
cular pathogenesis of PHOX2B polyalanine expansion
mutations in Congenital Central Hypoventilation
Syndrome
T. Bachetti1, E. Di Zanni2, F. Giacopelli2, R. Cusano3, P.
Uva3, I. Ceccherini2
1Laboratory of Developmental Neurobiology, DISTAV,
University of Genova, Genova, Italy, 2UOSD Laboratory
of Genetics and Genomics of Rare Diseases, Istituto
Giannina Gaslini, Genova, Italy, 3Centre for Advanced
Studies, Research and Development in Sardinia (CRS4),
Science and Technology Park Polaris, Pula, CA, Italy
Introduction: Autonomic control of breathing is defective
in congenital central hypoventilation syndrome (CCHS)
patients, who thus require lifelong ventilatory supports.
Heterozygous +4 to +13 residue expansions of a poly-Ala
stretch in the PHOX2B gene do cause CCHS. In vitro stu-
dies have shown formation of toxic intracytoplasmic
aggregates and impaired PHOX2B mediated transactivation
of target genes, that can be reversed by treatments inducing
heat shock response and autophagy (i.e. 17AAG).
Material and Methods: RNA-sequencing analysis was
performed in SK-N-BE cells transfected with WT and
+13Ala PHOX2B and relative controls, with/without
17AAG treatment. Data were analyzed through a standard
pipeline and lists of differentially expressed genes subjected
to Gene Set Enrichment Analysis (GSEA).
Results: Gene expression profiles of transfectant cell
lines allowed us to 1) rank genes and pathways resulting to
drive the most deleterious effects of the +13Ala PHOX2B
mutation (i.e. apoptosis, proteasome, autophagy, etc); 2)
confirm the effect of 17AAG in stimulating pathways
already reported to be beneficial to CCHS (i.e. rapamycin,
progesterone); 3) validate a number of differentially
expressed genes and verified the effect of newly identified
pathogenic mechanisms.
Conclusions: we have recapitulated i) the presence of
pathways-hallmarks-perturbations already known to play a
role in polyAla dependent CCHS pathogenesis and ii) the
beneficial effect of drugs like 17AAG, in reverting
deleterious polyAla consequences, thus providing a “proof
of concept” of the feasibility of the RNA-seq approach to
disclose molecular mechanisms of orphan diseases.
Major Funding: This study was supported by The CCHS
Network and the Italian CCHS association (AISICC).
T. Bachetti: None. E. Di Zanni: None. F. Giacopelli:
None. R. Cusano: None. P. Uva: None. I.
Ceccherini: None.
P15.62.C
Understanding the inconsistencies of the smallRNAseq
results by exploring different library preparation
technologies
M. González-López1, E. Aparicio-Puerta2, N. Macias-
Cámara1, L. Bárcena1, J. L. Lavín1, D. Fernández-
Ramos1,3, P. Fernández-Tussy1, M. Reig4, L. Boix4, J.
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Bruix4,3, M. L. Martinez-Chantar1,3, M. Hackenberg2, A. M.
Aransay1,3
1CIC bioGUNE, Derio, Spain, 2Department of Genetics,
University of Granada, Granada, Spain, 3CIBERehd,
Madrid, Spain, 4Fundació Clínic per a la Recerca
Biomédica (FCRB), IDIBAPS, University of Barcelona,
Barcelona, Spain
ABSTRACT The discovery of an important role of
microRNAs in the disease pathogenesis along with the
finding of these molecules in bodily fluids, has positioned
microRNAs as one of the most promising biomarkers
categories. However, despite the considerable amount of
research conducted in this field, the medical use of micro-
RNAs as biomarkers and the translation of microRNA
profiling into meaningful clinical data remain a work in
progress. This scenario might be caused by the low repro-
ducibility among studies and the low disease-specificity of
the microRNAs reported as biomarkers. Here, we aimed to
demonstrate that the selection of kit and protocol for
smallRNAseq library preparation, the method of choice for
microRNA profiling, can have a great impact in the
inconsistency of the results. Starting from the same samples,
we prepared smallRNAseq libraries using: three commer-
cially available kits based on fixed adapter ligation, two
based on degenerated adapters ligation, one based on tem-
plate switch technology, and one based on monoadapter
ligation and circularization, exploiting all current smallR-
NAseq library preparation methods. We identified strengths
and weaknesses of each protocol regarding sensitivity,
accuracy and reproducibility. In addition, we evaluated the
use of unique molecular identifier sequences in two of these
kits. Remarkably, Illumina’s kit seemed to be the outlier
when compared to the rest of protocols in spite of being the
most widespread library preparation kit.
FINANCIAL SUPPORTElkartek-Programs 2017-2020,
Bizkaia-County and Severo-Ochoa (SEV-2016-0644), to
MG, NM-C, LB, JLL and AMA; Spanish-Government
(AGL2017-88702-C2-2-R) to M.H; MINECO (IFI16/
00041) to E.A-P; MINECO to D.F-R., P.F-T. and M.L.M-
C.
M. González-López: None. E. Aparicio-Puerta: None.
N. Macias-Cámara: None. L. Bárcena: None. J.L. Lavín:
None. D. Fernández-Ramos: None. P. Fernández-Tussy:
None. M. Reig: None. L. Boix: None. J. Bruix: None. M.
L. Martinez-Chantar: None. M. Hackenberg: None. A.
M. Aransay: None.
P15.65.C
A simple next generation sequencing method to detect
sequence variants causing alpha and beta thalassemia
B. Vanherberghen, A. Hedrum
Devyser, Hägersten, Sweden
Background: Thalassemia’s are inherited blood disorders
characterized by abnormal hemoglobin production. Today,
several methods are used sequentially for variant analysis of
thalassemia patients, adding costs and increasing turn-
around times. These methods include, but are not limited to,
GAP-PCR, Sanger sequencing and MLPA. Often, if a
variant or deletion is found in one gene, analysis of the
other gene is not performed.
Method: We developed an amplicon-based NGS method
on the Illumina sequencers using a single oligo-mix to
detect virtually all known variants for alpha and beta
thalassemia. The method includes sequencing of HBB,
HBA1 and HBA2 genes as well as direct detection of the
most common deletions in alpha and beta thalassemia
(GAP-PCR). Regions upstream and downstream of the
above genes are sequenced to detect deletions by CNV
analysis. The protocol is rapid and user-friendly, requiring
less than one hour of hands-on time.
Results: Evaluation of 125 clinical samples revealed that
all expected single nucleotide variants (SNVs) and deletions
were detected. Additional variants were found in 15% (19/
125) of samples and occurred primarily in the other gene (i.
e. if the original variant was in the alpha gene, the additional
variant was found in the beta gene and vice-versa).
Conclusions: We report the successful development of a
rapid, NGS-based assay to detect variants involved in both
alpha and beta thalassemia which identified all confirmed
variants, and picked up previously undetected variants.
These findings demonstrate the need for a single method
that can simultaneously detect variants in both alpha and
beta thalassemia’s.
B. Vanherberghen: A. Employment (full or part-time);
Significant; Devyser. A. Hedrum: A. Employment (full or
part-time); Significant; Devyser.
P15.66.A
Knockdown of TIRR and MAD2L2 for enhancing of
genome editing efficacy
A. Anuchina, M. Zaynitdinova, L. Belova, A. Lavrov, S.
Smirnikhina
Research Centre for Medical Genetics(RCMG), Moscow,
Russian Federation
Introduction: Enhancing of genome editing method
through manipulation with repair key factors is a wide-
spread technique nowadays. Here we performed a knock-
down of two factors involved in homology directed repair
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process - TIRR and MAD2L2. These proteins are linked
with non-homologous end joining pathway, which inhibi-
tion is considered to improve target-editing efficacy by
homology-directed repair (HDR).
Materials and Methods: siRNA was designed with
siRNAfit program. Transfection of HEK-293T cells was
performed with the use of Turbofect transfection reagent.
Transfection efficacy was measured with flow cytometer
Flomax. Expression analysis was performed with real-time
PCR; expression was normalized on TFRC, TBP, GAPDH
housekeeping genes.
Results: It was shown that one of two designed siRNAs
for TIRR and all three designed siRNAs for
MAD2L2 significantly suppress the expression of corre-
sponding genes. Knockdown for siTIRR was 52% (p~0,03),
maximal knockdown for siMAD2L2 was 93.8% (p = 0,02).
Additionally, enhancing of TIRR expression as a response
on three non-targeting siRNA was described in comparison
with non-transfected cells and cells with transfection
reagent only (maximal enhancing was in 2,4 times,
p~0,02). We are running now experiments to estimate the
impact of developed knockdown on the HDR efficacy and
anticipate to finalize them for ESHG’20 presentation.
Conclusions: we developed efficient knockdown of two
key factors involved in DNA repair pathways - TIRR and
MAD2L2. We also discovered a unique reaction of TIRR
transcript expression in response to any targeted and non-
targeted artificial siRNA, which should be discovered in
more details and can possibly used to further control DNA
repair process.
A. Anuchina: None. M. Zaynitdinova: None. L.
Belova: None. A. Lavrov: None. S. Smirnikhina: None.
P15.67.B
Effectiveness and sustainability of a multidimensional
approach based on tele-health and multi-OMIC testing:
the Italian Undiagnosed Patients Network.
F. Radio, A. Bartuli, A. Novelli, Italian Undiagnosed
Patients Network, M. Tartaglia, B. Dallapiccola
Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
Introduction: Recent advances in genomic sequencing and
its implementation in clinical practice are widely recognised
as cost-effective diagnostic milestones. However, avail-
ability of these technologies in the clinical setting is still
limited and not widely accessible. The diagnostic odyssey
of undiagnosed subjects and their families is still a major
constrain preventing appropriate management and care. We
report on a two-year experience of the Italian Undiagnosed
Patients Network of experts based on an e-health approach
combined with a multi-OMIC workflow.
Materials and Methods: Since January 2018, 312
patients from 24 Italian rare diseases reference centers have
been evaluated in the frame of 35 multidisciplinary sessions
involving 20 experienced clinicians selected on a case-to-
case basis. About 40% of patients underwent a multi-OMIC
analysis directed by clinical presentation.
Results: The effectiveness (evidence-based) and sustain-
ability (cost-effectiveness) of this multidimensional
approach was proven by a significant reduction of
diagnostic costs (>25%) and an incremental rate of
diagnoses (> 60%).
Conclusions: The proposed approach has produced a
multiplying effect, allowing the improvement of care of
undiagnosed patients greater than it would be expected by
simply adding the single experts’ abilities. Sharing
competence among network members fosters the develop-
ment of new knowledge and creates a critical mass of
patients. In the case of ultra-rare and unknown disorders,
pooling of a few patients only triggers new opportunities for
research.
F. Radio: None. A. Bartuli: None. A. Novelli: None. M.
Tartaglia: None. B. Dallapiccola: None.
P15.68.C
Improving transcriptome analysis by incorporating
unique molecular identifiers into RNA-sequencing
D. Posfai, K. Krishnan, C. Song, P. Liu, G. Naishadham, B.
W. Langhorst, E. T. Dimalanta, T. B. Davis
New England Biolabs, Ipswich, MA, United States
RNA-sequencing is a powerful tool for the study of gene
regulation and function. Applications of RNA-sequencing
have vastly expanded with improvements to low RNA input
library preparation methods. Although analyzing low-input
samples is necessary to answer certain biological questions,
generating these libraries introduces greater biases with
additional PCR cycles that amplify transcripts dis-
proportionately. To better gauge true transcript abundance
levels, unique molecular identifiers (UMIs) can be used to
distinguish PCR duplicates from distinct original molecules.
Accurate identification of such artifacts can significantly
impact quantification of transcript abundance. To address
this need in RNA-seq, we have developed barcoded adap-
tors incorporating UMIs.
We have developed 96 UMI-containing barcoded adap-
tors optimized across various RNA inputs (10 ng to 1 μg).
Ligation of barcoded adaptors followed by PCR enrichment
produced high-quality library and sequencing metrics (e.g.
yields and coverage across transcript length). However,
duplication rates significantly differed when utilizing
traditional computational approaches to identify duplicates
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based on mapping position compared to analysis incorpor-
ating UMIs. As many as 90% of reads identified as
duplicates using read position alone were determined to in
fact originate from unique molecules, increasing the total
number of reads available for further analysis.
In this study we show that incorporation of UMIs into
RNA-sequencing analysis allows for a more accurate
calculation of transcript abundance. Use of UMIs allows
for identification of true read duplicates in RNA-seq,
thereby increasing transcript detection accuracy and
improving sensitivity of differential expression analysis.
Furthermore, our adaptors incorporate barcodes during
adaptor ligation allowing for PCR-free library pooling.
D. Posfai: A. Employment (full or part-time); Significant;
New England Biolabs. K. Krishnan: A. Employment (full
or part-time); Significant; New England Biolabs. C. Song:
A. Employment (full or part-time); Significant; New
England Biolabs. P. Liu: A. Employment (full or part-
time); Significant; New England Biolabs. G. Naishadham:
A. Employment (full or part-time); Significant; New
England Biolabs. B.W. Langhorst: A. Employment (full
or part-time); Significant; New England Biolabs. E.T.
Dimalanta: A. Employment (full or part-time); Significant;
New England Biolabs. T.B. Davis: A. Employment (full or
part-time); Significant; New England Biolabs.
P15.70.B
Next-Generation Sequencing approach for a wide range
of genetic disorders: the experience of a Portuguese
Academic Hospital
R. Quental1, A. Grangeia1,2, I. Alonso3,4, S. Fernandes2,5, I.
Miguel3, C. Moura1,2,5, J. P. Freixo4, M. Amorim3, J. P.
Oliveira1,2,5, R. Oliveira1, M. Leão1,5, *The first two authors
contributed equally to thework
1Medical Genetics Service, São João University Hospital
Centre, Porto, Portugal, 2i3S - Institute for Research and
Innovation in Health, University of Porto, Porto, Portugal,
3Genetyca-ICM Laboratory, Porto, Portugal, 4CGPP -
Centre for Predictive and Preventive Genetics, IBMC -
Institute for Molecular and Cell Biology, i3S - Institute for
Research and Innovation in Health, University of Porto,
Porto, Portugal, 5Department of Genetics, Faculty of
Medicine of the University of Porto, Porto, Portugal
Next-generation sequencing (NGS) has been increasingly
used in clinical practice for the diagnosis of genetic dis-
orders. Clinical exome (CE) and whole-exome sequencing
(WES) have improved the diagnostic yield in neurodeve-
lopmental disorders (NDD), with diagnostic rates of around
36%.We evaluated the diagnostic yield of CE and in trio
WES in 324 and 117 patients, respectively, referred to our
Medical Genetics outpatient clinic for diagnostic assess-
ment. Patients have been grouped based on their clinical
features: isolated NDD (developmental delay, intellectual
disability, autism spectrum disorder and epilepsy); NDD
plus (any of the previous plus an additional neurological,
systemic or dysmorphic manifestation); NMD (neuromus-
cular disorders); NDG (neurodegenerative disorders); MCA
(multiple congenital anomalies); and “others”.A definite
diagnosis was achieved in 27,8% (90/324) and 26,5% (31/
117) patients by CE and WES, respectively. The NDD and
NDD plus groups represented 55% (243/441) of our
patients, with a diagnostic yield ranging from 28.2% to
31.1% (WES and CE, respectively). Among the different
clinical categories, diagnostic yield was highest in the NDG
(15/38, 39.5% by CE) and MCA (6/18, 33.3% by WES) and
lowest in the “others” (1/14, 7.1% by WES). Achieving a
diagnosis is important for patients and their families, as it
can alter clinical management and the provision of accurate
genetic counseling. Our results are globally consistent with
those of comparable studies, highlighting CE and WES as
efficient strategies for the diagnosis of a wide range of
suspected genetic disorders, particularly of patients with
NDG, NDD and MCA.
R. Quental: None. A. Grangeia: None. I. Alonso: None.
S. Fernandes: None. I. Miguel: None. C. Moura: None. J.
P. Freixo: None. M. Amorim: None. J.P. Oliveira: None.
R. Oliveira: None. M. Leão: None.
P15.72.A
Whole exome sequencing reduce diagnostic odyssey of
patients with epilepsy and intellectual disability
R. Minardi1, L. Laura1,2, T. Pippucci3, M. C. Baroni4, C.
Stipa1, B. Mostacci1, G. Severi5, V. Carelli1,2, M. Seri5, P.
Tinuper1,2, F. Bisulli1,2
1IRCCS, Istituto delle Scienze Neurologiche di Bologna,
UOC Neurological Clinic, Bologna, Italy, 2Department of
Biomedical and Neuromotor Sciences, University of
Bologna, Bologna, Italy, 3Medical Genetics Unit, Polyclinic
Sant’Orsola-Malpighi University Hospital, Bologna, Italy,
4Department of Biomedical and Surgical Sciences (DIMEC)
University of Bologna, Bologna, Italy, 5Medical Genetics
Unit Polyclinic Sant’Orsola-Malpighi University Hospital,
Bologna, Italy
Introduction: Patients with epileptic encephalopathy (EE)
and developmental encephalopathy (DE) usually undergo
multiple clinical evaluations and several genetics test before
reaching the final diagnosis. The purpose of this study was
to assess the utility of Whole-Exome Sequencing (WES) in
patients with EE/DE with unknown aetiology.
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Material and Methods: We analysed the exomes of a
cohort of 71 adult unrelated patients with EE/DE, which
had already undergone single or multiple prior genetic tests
(array-CGH, single gene or gene-panel screening) resulted
negative. Variants were classified according to the Amer-
ican College of Medical Genetics and Genomics (ACMG)
guidelines. Significant variants were validated and verified
for inheritance by Sanger sequencing, when possible.
Results: In 18 patients WES analysis disclosed a total of
24 causative variants in epilepsy associated genes with
either autosomal dominant (DYNC1H1; ZBTB20; CAC-
NA1E; DYRK1A; ANKRD11; GABRG2; KCNB1; KCNH5;
SCN1A; GABRB2; YWHAG; STXBP1), recessive (PRODH;
LAMB1; PNKP; APC2; RARS2) or X-linked (KIAA2022;
SMC1A) inheritance. Eleven out of 24 variants were novel.
In 4 (22%) patients the new genetic diagnosis had
therapeutic implications. We estimated a diagnostic delay
of 38.5 years (18-64.9).
Conclusions: In our cohort of undiagnosed adult EE/DE
patients, WES analysis allowed us to obtain a diagnostic
yield of 25.3%. Despite the considerable diagnostic delay,
genetic diagnosis had a significant impact on patients’
management, allowing in selected cases for a targeted
therapy. Concluding, early WES analysis in EE/DE patients
would prevent “diagnostic odyssey” and unnecessary costs.
R. Minardi: None. L. Laura: None. T. Pippucci: None.
M.C. Baroni: None. C. Stipa: None. B. Mostacci: None.
G. Severi: None. V. Carelli: None. M. Seri: None. P.
Tinuper: None. F. Bisulli: None.
P15.73.B
Validation of a new technology for whole genome
amplification (WGA) and NGS sequencing in preim-
plantation genetic testing (PGT)
S. Popov1, S. Ladygin2, V. Zavarin1, S. Avdeychik1, M.
Tofilo1, D. Fomin2, A. Belyaev3
1Medical Genomics, Tver, Russian Federation, 2The Net-
work of Medical Centers «Fomin Clinic», Moscow, Russian
Federation, 3LLC AB-Vector, San Diego, CA, United
States
We have validated new WGA technology, AB-WGA (AB
Vector, USA) for aneuploidy detection (PGT-A). The
advantage of this technology is exhaustive random priming
of the template DNA, which is crucial for minimizing
amplification bias and improving genome coverage. Unlike
most other WGA methods that either sacrifice specificity of
copy number variation (CNV) detection for high genome
coverage, or genome coverage for increased accuracy of
CNV detection, AB-WGA provides nearly complete gen-
ome coverage while maintaining high accuracy of CNV
detection. Genomic DNA from the biopsy material (3-10
cells) was extracted and amplified using AB-WGA kit.
Libraries were sequenced using either Miseq reagent kit V3
(150 cycles) or NextSeq 500 reagent kit v2.5 (75 cycles).
CNV-charts generation was performed using software
developed by AB Vector. For comparison, we sequenced
several trophectoderm biopsies (TE) samples using Illumina
VeriSeq-PGS kit. CNV-charts showed 100% karyotype
matching between Illumina VeriSeq-PGS and AB-WGA
kits. We also analyzed CNV-charts of TE and the inner cell
mass of embryos (ICM). We have observed high con-
cordance between TE and ICM samples using the AB
Vector technology. About 10% of samples have shown
different karyotypes between TE and ICM, similar to the
recent study (Victor et al. 2018). Performance of the new kit
was quite satisfactory, featuring a simplified protocol, better
throughput and improved CNV resolution. Further studies
are required for validation of this technology in PGD for
detection of monogenic disorders as well as for registration
of the kit as an IVD medical product for use in reproductive
genetics.
S. Popov: None. S. Ladygin: None. V. Zavarin: None.
S. Avdeychik: None. M. Tofilo: None. D. Fomin: None.
A. Belyaev: None.
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Partner independent fusion gene detection by multi-
plexed CRISPR Cas9 enrichment and long read
Nanopore sequencing
C. Stangl1,2,3, S. de Blank1, I. Renkens1, L. Westera4,5, T.
Verbeek1, J. Espejo Valle-Inclan1,3, R. Chamorro
González6,7, A. Henssen6,7,8,9, M. van Roosmalen4, R. Stam4,
E. Voest2,3, W. Kloosterman1,10,11, G. van Haaften1, G.
Monroe1
1UMC Utrecht, Utrecht, Netherlands, 2Netherlands Cancer
Institute, Amsterdam, Netherlands, 3Oncode Institute,
Amsterdam, Netherlands, 4Princess Máxima Center for
Pediatric Oncology, Utrecht, Netherlands, 5Dutch Child-
hood Oncology Group, Utrecht, Netherlands, 6Charité-
Universitätsmedizin Berlin, Berlin, Germany, 7Experimen-
tal and Clinical Research Center (ECRC) of the MDC and
Charité Berlin, Berlin, Germany, 8German Cancer Con-
sortium (DKTK), Partner Site Berlin, and German Cancer
Research Center (DKFZ), Heidelberg, Germany, 9Berlin
Institute of Health, Berlin, Germany, 10Cyclomics, Utrecht,
Netherlands, 11Frame Cancer Therapeutics, Amsterdam,
Netherlands
Fusion genes are hallmarks of various cancer types and
important determinants for diagnosis, prognosis and treat-
ment. Fusion gene partner choice and breakpoint-position
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promiscuity restricts diagnostic detection, even for known
and recurrent configurations. To accurately and impartially
identify fusions, we here developed FUDGE: FUsion
Detection from Gene Enrichment. FUDGE couples target-
selected and strand-specific CRISPR/Cas9 activity for
fusion gene driver enrichment - without prior knowledge of
fusion partner or breakpoint-location - to long-read Nano-
pore sequencing with the bioinformatics pipeline NanoFG.
FUDGE has flexible target-loci choices and enables multi-
plexed enrichment for simultaneous analysis of several
genes in multiple samples in one sequencing run. We
observe on-average 665 fold breakpoint-site enrichment and
identify nucleotide resolution fusion breakpoints - within
two days. The assay identifies cancer cell line and tumor
sample fusions irrespective of partner gene or breakpoint-
position. FUDGE is a rapid and versatile fusion detection
assay, providing unparalleled opportunity for diagnostic
pan-cancer fusion detection. Furthermore, this method
paves the way for other applications of targeted long-read
sequencing studies in genetics.
C. Stangl: None. S. de Blank: None. I. Renkens: None.
L. Westera: None. T. Verbeek: None. J. Espejo Valle-
Inclan: None. R. Chamorro González: None. A. Hens-
sen: None. M. van Roosmalen: None. R. Stam: None. E.
Voest: None. W. Kloosterman: None. G. van Haaften:
None. G. Monroe: None.
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P16.01.A
Evaluation of SpliceAI in predicting abnormal splicing
in a cohort of 964 patients with rare and undiagnosed
diseases
M. Yamada, T. Uehara, H. Suzuki, K. Kosaki
Center for medical genetics, Keio University School of
Medicine, Tokyo, Japan
Background: Prediction of variants associated with
abnormal splicing from exome or whole genome sequen-
cing data without transcriptome data is difficult and unre-
liable for non-canonical splicing variants that occur outside
of the canonical donor/ acceptor consensus sites (gt/ag).
Recently, an algorithm SpliceAI based on machine learning
theory was developed to quantify variant’s potential to
cause abnormal splicing as the delta score that ranges from
zero to one. Clinical utility of SpliceAI has not been
established.
Methods: Using SpliceAI, we scored all the de novo
variants obtained from 964 trio exome data which derived
from Japan’s national clinical sequencing project Initiative
on Rare and Undiagnosed diseases (IRUD). The delta score
above 0.2 was considered positive.
Results: Among 964 patients, 255 patients had one or
more de novo variants with positive delta score (>=0.2). A
total of 332 variants was detected including 264 non-
canonical variants. The list of genes to which these 264
variants belonged included 63 known disease causative
genes. Thirty seven of the 63 genes could account for de
novo autosomal dominant or X-linked conditions. Among
37 patients with de novo non-canonical variants in these
genes, 15 patients had phenotype compatible with the
genotype (41%). Analysis of 964 patients unraveled de
novo non-canonical splicing variants with positive delta
score among 31 loss-of-function-intolerant genes of which
loss-of-function mutations are likely to be pathogenic.
Discussions: Positive predictive value of Splice AI at
non-canonical sites exceeded 40% and 31 loss-of-function-
intolerant genes were demonstrated to be fair candidates of
novel disease-causative genes. (grant number JP19K17342)
M. Yamada: None. T. Uehara: None. H. Suzuki: None.
K. Kosaki: None.
P16.03.C
B-allele frequency distribution in PCR-free Whole
Genome Sequencing
E. Souche, L. Dehaspe, J. Allemeersch, J. Van Bouwel, S.
Deman, W. Bossuyt
Department of Human Genetics, KU Leuven, Leuven,
Belgium
Whole Genome Sequencing (WGS) analysis provides
information on Single Nucleotide Variants (SNVs), indels
and Copy Number Variants (CNVs). As such, WGS may
replace SNP arrays and (clinical) Whole Exome Sequencing
(WES) for the detection of CNVs and SNVs respectively.
WGS is thought to outperform WES as it suffers from
limited biases due to the PCR-free library preparation and
the absence of capture. However, the B-allele frequency
distribution (BAF) of WGS heterozygous variants deviates
from the expected binomial normal distribution. An asym-
metric enrichment of variants with low BAF (<0.25) is
observed in both Genome In A Bottle (GIAB) cell lines and
patients, excluding cell culture artefacts as a source. No
similar enrichment is observed for heterozygous variants
with a high BAF (>0.75). Applying more stringent quality
thresholds to the data, such as extracting GIAB confident
regions or increasing depth, diminishes the width of the
distribution but does not remove it. GIAB data shows that
filtering out variants with low BAF successfully diminishes
the number of false positives but at the price of removing
true positives. Such classical filtering strategies should thus
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be applied cautiously on real data sets. These findings also
have implications in the use of B-allele frequencies for
CNV calling and haplotyping.
E. Souche: None. L. Dehaspe: None. J. Allemeersch:
None. J. Van Bouwel: None. S. Deman: None. W.
Bossuyt: None.
P16.04.A
Shallow whole-genome sequencing of cell-free DNA for
B-cell lymphoma diagnosis and disease monitoring: a
standardized approach with underappreciated potential
L. Raman
Ghent University, 9000, Belgium
B-cell lymphoma (BCL) tumors are physically related to the
cardiovascular system and generally have a large cell
turnover. As a collective, they are therefore excellent can-
didates for liquid biopsy (LB)-based research. The omni-
present, cheap and standardized shallow whole-genome
sequencing (sWGS) of cell-free DNA for copy number
profiling, is not sufficiently explored. To resolve this, a
prospective cohort of 38 Hodgkin (HL) and 86 non-
Hodgkin lymphoma (nHL) patients has been recruited,
following sWGS of 255 samples.
At diagnosis, LBs had detectable abnormalities in 84.2%
of HL and 74.4% of nHL patients. Profiles from paired
tissue biopsies showed high correlation within nHL
(r = 0.815 ± 0.043); and, compared to tissue, LBs had
alterations with mostly higher amplitudes for both HL
(P = .005) and nHL (P = .026), implying tumor DNA is
more abundant in blood samples. In addition, sequencing
reads were mapped to viral reference genomes, which
indicated that 15 HL and 13 nHL cases had significantly
elevated titers of Epstein-Barr virus (EBV) at diagnosis. All
patients that tested positive during routine EBV testing, had
increased plasmatic viral read fractions.
Longitudinal analysis indicated that, when detectable,
copy number patterns were similar across restaging
moments in refractory/relapsed patients. Moreover, the
overall anomaly of copy number profiles correlated with
disease status.
Finally, predictive modeling demonstrates that LBs might
aid in case of doubt between, e.g., HL versus nHL: receiver
operating characteristic analysis produced an area under the
curve of 0.972. This could be helpfull when the disease is
located in sites that are difficult to reach.
L. Raman: None.
P16.06.C
Blended phenotypes: an unusual expression of genetic
heterogeneity
J. Parente-Freixo1,2, J. Oliveira1,2, R. Quental3, P. Silva1,2,
S. Sousa1,2, D. Gonçalves4, C. Moura2,3, M. Leão3, J.
Sequeiros1,2
1CGPP-IBMC, Universidade do Porto, Porto, Portugal,
2i3S - Instituto de Investigação e Inovação em Saúde,
Universidade do Porto, Porto, Portugal, 3Serviço de
Genética Médica, Centro Hospitalar Universitário de São
João, Universidade do Porto, Porto, Portugal, 4Serviço de
Pediatria, Centro Hospitalar Universitário de São João,
Universidade do Porto, Porto, Portugal
During recent years, DNA sequencing capacity has con-
siderably improved genetic diagnostic rate, contributed to
identification of new genetic causes of rare monogenic
diseases, and challenged our perception about the extension
and complexity of some phenotypes. Comprehensive
genomic approaches, clinical exome and whole-exome
sequencing (WES) have shown that, in a small subset, the
presented phenotype is the product of concomitant mono-
genic disorders in a single patient, giving rise to so-called
"blended phenotypes". We used a WES approach in 4,027
individuals referred for genetic diagnostic study at CGPP
(2016-2019), for targeted disease-specific multigene panels
(n = 3,284); or for clinical exome or analysis of WES in a
trio (n = 743), in clinically heterogeneous presentations.
We systematically reviewed the genetic data of these 743
cases, either (singleton) clinical exome (n = 629) or WES in
trio (patient and both parents) (n = 114). Patients showing
variants classified as pathogenic or likely pathogenic, in at
least two different genes, and data (at least partly) compa-
tible with phenotype and known inheritance pattern for their
disease, were reassessed. Five patients had two genetic
conditions: two dominant diseases were found in 3 cases; 2
patients had an autosomal recessive and a dominant disease.
Though parental studies were not possible for all cases, of
note is that 2 patients had de novo variants occurring in two
different gene-pairs: HUWE1 and CHAMP1, and SETD5
and KIF21A. Frequency of the blended (overlapping or
combined) phenotypes was ~0.67% in our cohort (n = 743).
This work further expands knowledge and need for
awareness about such conditions in a diagnostic setting.
J. Parente-Freixo: None. J. Oliveira: None. R.
Quental: None. P. Silva: None. S. Sousa: None. D.
Gonçalves: None. C. Moura: None. M. Leão: None. J.
Sequeiros: None.
P16.08.B
Transcriptomic changes of cell-free RNA in plasma with
different blood storage times and temperatures
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 615
J. Sun1,2, X. Yang2, T. Wang2,1, Y. Xing1,2, H. Chen2, S.
Zhu3, J. Zeng3, F. Chen2, H. Jiang2, W. Wang2
1BGI Education Center, University of Chinese Academy of
Sciences, Shenzhen 518083, China, 2BGI-Shenzhen, Shenzhen
518083, China, 3Obstetrics Department, Shenzhen Maternity
and Child Healthcare Hospital, Shenzhen, China
Introduction: Cell-free RNA (cfRNA) in plasma can serve as
potential biomarkers for detecting and monitoring diseases.
However, the transcriptomic profile of cfRNA is impacted by
the delay before blood fractionation. Yet no study has eval-
uated systematically the influence of blood storage condition
on the expression of cfRNA in plasma.
Materials and Methods: We collected fresh blood
samples from four healthy subjects. After allowing blood
samples to stand at room temperature (RT) and 4°C for
various times (0h, 2h, 6h and 24h), plasma was separated
and cfRNA was extracted and sequenced by PALM-seq, an
integrated sequencing method for cell-free long and small
RNA. Then, the expressions of cfRNA were quantitated and
compared with the expression at 0h.
Results: Differential expression analysis reveals that the
storage time influenced the transcriptomic profile with
increasing significantly changed genes. The effects were
noted after blood stored for 24h at 4°C and for 6h at RT.
Moreover, blood stored at RT has a greater impact on the
expression of cfRNA than stored at 4°C. Most of the up-
regulated genes of 24h are monotonically increasing over
time, while down-regulated genes of 24h are fluctuating.
Compared with lncRNA and mRNA, miRNA is more stable
and has a higher Pearson correlation with the
expression at 0h.
Conclusions: Our study depicts the changes of cfRNA
transcriptomic profile in different blood storage times and
storage temperatures, and provides relevant research with a
list of genes whose expressions are sensitive to blood
storage conditions.
Grant: Shenzhen Municipal Government of China (No.
JCYJ20170412152854656).
J. Sun: None. X. Yang: None. T. Wang: None. Y. Xing:
None. H. Chen: None. S. Zhu: None. J. Zeng: None. F.
Chen: None. H. Jiang: None. W. Wang: None.
P16.09.C
Monitoring the impact of extraction methods on cfDNA
quality
E. Graf1, C. Pocernich2
1Agilent Technologies, Waldbronn, Germany, 2Agilent
Technologies, Ankeny, IA, United States
Introduction: Cell-free DNA (cfDNA) plays an emerging
role as source for potential new biomarkers. However,
cfDNA still represents a demanding sample type due to
restricted abundance and complex fragment size distribu-
tion. Standardizing and monitoring pre-analytical para-
meters, including cfDNA extraction, is inevitable to achieve
best possible sample quality and yield.
Materials and Methods: CfDNA was extracted with
nine different kits and then analyzed with an electrophoretic
assay tailored for cfDNA analysis. The assay provides
quantitative results for total DNA as well as cfDNA
separated from high molecular weight (HMW) DNA. The
quality score %cfDNA is provided as additional quality
parameter, determining the percent cfDNA of total DNA in
presence of HWM DNA. This set of quality parameters
adjusted to the needs of cfDNA characterization was
applied to compare the extraction kits.
Results: The nine cfDNA extraction kits varied in rate of
yield and their size selection capacity to remove HMW
DNA. In general, each kit afforded either superior yield or
high selectivity towards cfDNA.
Conclusions: High yield may be crucial for plasma with
low cfDNA content, yet if the plasma is expected to
contain considerable amounts of HMW DNA, the
selectivity towards cfDNA might be favored. Even if no
preference for a single kit could be established, the results
present a straightforward way to monitor the impact of
pre-analytical parameters on cfDNA yield and quality.
Automatic evaluation of a quality score for cfDNA allows
to define a threshold for objective sample quality
assessment.
E. Graf: A. Employment (full or part-time); Significant;
Agilent Technologies. C. Pocernich: A. Employment (full
or part-time); Significant; Agilent Technologies.
P16.13.A
Comparative evaluation of Exome-CNV calling with
Chromosomal Microarray Analysis for the identification
of large copy number variations
S. Tzur1, S. Kahana2, R. Attali1, T. Zinger1, T. Talmy1, P.
Smirin-Yosef1, R. Matar2, L. Bazak2,3, N. Ruhrman-Shahar2,
L. Basel-Salmon2,3,4,5
1Emedgene Technologies, Tel Aviv, Israel, 2Recanati
Genetics Institute, Beilinson Hospital, Rabin Medical
Center, Petach Tikva, Israel, 3Sackler Faculty of Medicine,
Tel Aviv University, Tel Aviv, Israel, 4Pediatric Genetics
Clinic, Schneider Children’s Medical Center of Israel,
Petach Tikva, Israel, 5Felsenstein Medical Research
Center, Petach Tikva, Israel
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In this study, we evaluated the potential use of Exome Copy-
Number Variations calling (Exome-CNV) with that of
chromosomal microarray analysis (CMA) for the identifi-
cation of large structural variations. For that aim, we com-
pared exome CNV calling results of 45 individuals with
results of CMA analysis. The samples belong to the patients
with developmental delay/intellectual disability with or
without additional abnormalities for whom no pathogenic or
likely pathogenic CNVs were reported by CMA and hence,
they underwent exome trio testing. The CMA analysis
identified 64 regions overlapping with coding regions, but
27 of them were designated as CMA artifacts. The remain-
ing 37 CMA regions (in 27 samples), included 11 deletions
(average 537Kbp), and 26 duplications (average size
665Kbp). Exome sequencing was performed following
enrichment with TWIST Human Core Exome plus kits
(average coverage >250x). Exome-CNV calling was exe-
cuted using default parameters of DRAGEN Ver. 3.4.14
based on read-depth method. In the current methodology, 33
out of 37 (89%) regions reported by CMA were successfully
identified by the Exome-CNV calling. The remaining 4
regions were duplications in size ranging between 256Kbp-
890Kbp. In addition, Exome-CNV calling identified at least
150 more high-quality CNV regions not reported by CMA,
and also encountered a large number of false positives. We
concluded that default parameters of DRAGEN CNV calling
for exome samples should be optimized to increase the
accuracy and reduce the number of false positives in order to
make it comparable with CMA analysis.
S. Tzur: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Significant;
Emedgene. S. Kahana: None. R. Attali: None. T. Zinger:
None. T. Talmy: None. P. Smirin-Yosef: None. R. Matar:
None. L. Bazak: None. N. Ruhrman-Shahar: None. L.
Basel-Salmon: None.
P16.14.B
New genomic rearrangements identified in genes asso-
ciated to inborn errors of metabolism
N. Castejon-Fernandez, I. Bravo-Alonso, R. Navarrete, F.
Leal, M. Ugarte, P. Rodríguez-Pombo, B. Pérez
Centro de Diagnóstico de Enfermedades Moleculares.
Universidad Autónoma de Madrid, Madrid, Spain
Recent developments in high-throughput sequence capture
have made next generation sequencing (NGS) of routine use
when making genetic diagnoses. Improvement of the depth
of coverage allows for the detection of large genomic
deletions in addition to single nucleotide variations (SNVs),
although further validations are needed for an accurate
diagnosis. The present study proposes a bioinformatic
pipeline to exploit the potential use of the NGS to detect
CNV in addition to SNVs.
This work includes genetic analysis of 21 unsolved cases
with suspicion of metabolic disorders. We have used two
NGS panels for genetic studies: a targeted exome panel
(panel1) and the Clinical-Exome Sequencing TruSightTM
One [Illumina] (panel2). Bioinformatic pipeline consist on a
first step of annotation of SNVs and a second step -if
necessary- of CNVs analysis using an algorithm based on
the DeCON R package modified in-house, combined with
post-computational filter-selection to reduce false positives.
The bioinformatic pipeline allowed the identification of
eighteen large deletions in 16 different genes, 7 of which
were novel. The results of the SNPs arrays studies and/or
long range PCR analysis showed that a high number of
genomic rearrangements detected involved Alu sequences.
Two cases showed Alu insertion that was not detected by
either panel due to the incorrect alignment.
These results show that the NGS can detect genomic
rearrangements plus SNVs with a well-defined pipeline
what reduces the response time in the genetic diagnosis, but
other molecular assays are needed for the correct character-
ization of them.
N. Castejon-Fernandez: None. I. Bravo-Alonso: None.
R. Navarrete: None. F. Leal: None. M. Ugarte: None. P.
Rodríguez-Pombo: None. B. Pérez: None.
P16.15.C
Fast, scalable validation of NGS diagnostics using
hundreds of clinical samples
T. Medina, M. Beukers, P. B. T. Neerincx, K. M. Abbott, B.
Sikkema-Raddatz, M. A. Swertz
University Medical Center Groningen, Groningen, Nether-
lands
Introduction: High-confidence variant call sets, such as
those offered by the Genome in a Bottle Consortium, are the
current gold standard for evaluating NGS analysis pipelines.
Individual samples do not, however, include significant
numbers of rare or clinically relevant variants. Reanalysis of
in-house samples known to contain such variants comple-
ments this deficiency, but is limited by its lack of scal-
ability. We present a method for incorporating variant-
relevant NGS reads from a multitude of clinical samples
into a single hybrid control for efficient pipeline validation.
Materials and Methods: NIST reference sample
NA24385 was whole-exome sequenced using a custom
GATK-based clinical diagnostic pipeline. Using our devel-
oped VaSeBuilder tool (https://github.com/molgenis/Va
SeBuilder), sequencing reads aligning in a continuous
region around patient variant loci were added to the
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NA24385 read set. NA24385 reads in the same alignment
window were removed. The resulting hybrid set of reads
was then routinely added to diagnostic analysis batches as
an in silico spike-in control for continuous validation.
Results: NA24385 sequencing reads were exchanged
with reads representing 1283 clinically relevant autosomal
variant calls from 656 patient WES samples. Of the 1081
SNVs and 202 indels added, 98.8% are recalled in
concordance with their original samples.
Conclusions: The compilation of an artificial genome
enriched with clinically relevant variants allows for much
more efficient and relevant validation of NGS pipelines than
by using high-confidence call sets alone. In addition, this
method can be automated and used continuously for routine
diagnostic validation with every analysis run.
Grant: Work supported by NWO Vidi Grant 917.16.455
T. Medina: None. M. Beukers: None. P.B.T. Neerincx:
None. K.M. Abbott: None. B. Sikkema-Raddatz: None.
M.A. Swertz: None.
P16.17.B
A rapid multiplex PCR assay and software system with
broad coverage of pathogenic CFTR mutations for
diverse populations
G. Latham, P. Rao, S. Gokul, E. Hallmark, C. Parker, D.
Patel, B. Hall
Asuragen, Inc., Austin, TX, United States
Introduction: ECFS practice guidelines recommend
detection of at least one abnormal CFTR mutation in >96%
Cystic Fibrosis (CF) patients. ACMG and ACOG guide-
lines in the US recommend a targeted CFTR panel of 23
variants. We addressed both European and US recommen-
dations with a panel derived from common mutations
indexed in CFTR2 and reflected in the US population using
an integrated system of PCR reagents and analysis software.
Methods: We developed a prototype, two-tube panel
using AmplideX® PCR that genotypes 65 mutations,
including SNPs, INDELs, CNVs and the IVS8 poly-T/TG
modifier, within five hours. Amplicons were resolved by
capillary electrophoresis (CE) on a 3500 Genetic Analyzer
(Thermo Fisher). Evaluated samples included synthetic
DNA (n = 43) and genomic DNA from cell lines (n = 79),
whole blood (n = 300), and residual clinical samples with
known pathogenic variants (n = 35). Genotypes were
assigned using a prototype AmplideX Reporter software
module. Sanger sequencing confirmed all variants.
Results: The CFTR mutation panel targeted at least one
pathogenic mutation in >99% of CF patients, and
represented 92.6% of variant alleles in the US population.
Mutations and zygosity agreed with reference calls for
>98% of variants across different samples. Automated
software calls agreed with manual calls yet required <100-
fold analysis time. Carrier rates for presumed healthy blood
donors were compared with published values for the
relevant groups.
Conclusions: We developed and evaluated a prototype
multiplex, allele-specific PCR/CE system with up-to-date,
evidence-based mutation content, a streamlined workflow,
and automated software. This system can genotype diverse
populations for CF carrier screening and diagnostics.
G. Latham: A. Employment (full or part-time); Sig-
nificant; Asuragen, Inc.. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Significant;
Asuragen, Inc. P. Rao: A. Employment (full or part-time);
Significant; Asuragen, Inc.. S. Gokul: None. E. Hallmark:
A. Employment (full or part-time); Significant; Asuragen,
Inc. C. Parker: A. Employment (full or part-time);
Significant; Asuragen, Inc. D. Patel: A. Employment (full
or part-time); Significant; Asuragen, Inc. B. Hall: A.
Employment (full or part-time); Significant; Asuragen,
Inc.. E. Ownership Interest (stock, stock options, patent or
other intellectual property); Significant; Asuragen, Inc.
P16.18.C
A cost-effective solution for the genetic analysis of cystic
fibrosis combining next generation sequencing and
fragment analysis methods
C. Zaouter
Devyser AB, Stockholm, Sweden
Introduction: Cystic fibrosis (CF) is a severe genetic
disease caused by mutations in the CFTR gene. The
identification of mutations is a key step in the process of
diagnosis and carrier screening. However, the high mutation
variability between different geographical and ethnic
populations makes the analysis of the CFTR gene
challenging and has a direct bearing on the strategy of
molecular analysis of CF.
Methods: We developed two assays for a multi-level
testing strategy that maximizes mutation detection while
minimizing costs. A first multiplex allele-specific PCR
assay followed by fragment analysis was used to allow the
simultaneous detection of the 68 most common European
mutations in only two PCR reactions per sample. A second,
amplicon-based NGS assay was employed to detect all
mutations in exons and flanking intronic sequences of
CFTR using one single PCR mix per sample. The
performance of these two assays was evaluated by
analyzing samples carrying pathogenic mutations that were
previously characterized using commercially available kits.
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Preliminary results: The allele-specific PCR analysis of
41 samples from Spain carrying a total of 60 mutations
revealed that 57 of these mutations were included in our
mutation panel and identified, providing a high detection
rate of 95%. The NGS analysis of 32 samples carrying 116
mutations showed a sensitivity and specificity of >99%,
combined with an excellent coverage uniformity of >99.8%.
Conclusions: The combination of a fragment analysis
assay enabling high mutation detection rate with a
comprehensive NGS assay is a cost-effective strategy that
is well suited for routine laboratories.
C. Zaouter: A. Employment (full or part-time); Sig-
nificant; Devyser AB.
P16.19.A
ISCN 2020: What’s new and how can we use it?
J. McGowan-Jordan1, R. J. Hastings2, J. T. den Dunnen3
1CHEO/University of Ottawa, Ottawa, ON, Canada, 2John
Radcliffe Hospital, Oxford University Hospitals NHS
Foundation Trust, Oxford, United Kingdom, 3Leiden
University Medical Center, Leiden, Netherlands
Clear descriptions of clinical and experimental findings are
essential for consistent communication amongst individual
scientists, clinicians, and groups. In laboratory genetic stu-
dies this has happened through the International System for
Human Cytogenomic Nomenclature (ISCN) and Human
Genome Variation Society (HVGS). The Standing Com-
mittee of the ISCN has established a standard system for the
description of numerical and structural chromosome
abnormalities characterized by various methods. The next
revision of these standards will be released in 2020, and will
address issues raised from members of the cytogenomics
community and vetted through the Standing Committee.
These include clarity on general principles with more spe-
cific definitions of terms. Improvements to oncology, FISH,
microarray and region specific assay nomenclatures will be
emphasized. ISCN 2020 will align the rules governing the
description of all chromosome abnormalities regardless of
technology used. The “view” of chromosomes will move
from centromere-focused to one based on genomic
sequence from pter to qter; sex chromosomes abnormalities
will be presented first followed by those affecting auto-
somes for all techniques. Continued improvements and
refinements to guidelines first released in 2016 in colla-
boration with HGVS will also be included. This new stan-
dard combines aspects of both HGVS and ISCN and will
meet the needs of both the cytogenomic and molecular
communities, making information on both the chromosomal
and base-pair level readily evident and providing a con-
sistent description of large intra- and inter-chromosomal
rearrangements. Elements and examples of these improve-
ments to ISCN and the combined standard will be presented
to illustrate their utility.
J. McGowan-Jordan: None. R.J. Hastings: None. J.T.
den Dunnen: None.
P16.21.C
Exome sequencing as the first-line investigation for
developmental disorders in South Africa: an evaluation
of current practice, the patient cohort and potential
challenges
E. K. Wiener, Z. Lombard, A. Krause, the DDD-Africa
Study
Division of Human Genetics, National Health Laboratory
Service and School of Pathology, Faculty of Health
Sciences, University of the Witwatersrand, Johannesburg,
South Africa
Introduction: Latest guidelines for the diagnosis of
developmental disorders (DD) suggests exome sequencing
as the first-line investigation, however, the applicability of
such guidelines in an African setting is uncertain. Due to the
dearth of research into DD in Africa, there is little knowl-
edge of the characteristics of the patient cohort with DD and
current diagnostic processes. This knowledge is essential
before considering implementation of such guidelines.
Methods: A clinical file audit was performed on 934
patients presenting to Medical Genetics clinics in Johannes-
burg South Africa in 2017.
Results: 83% of the patient cohort presented with features
of DD with 37% having global developmental delay. Three
main groups of patients were identified within the cohort
according to their different diagnostic processes. The first
group (18%) with genetically confirmed aneuploidies were
often diagnosed by general clinicians before referral. The
second group (25%) presented with conditions that were
clinically recognisable, by medical geneticists, and so
received clinical diagnoses with 39% confirmed genetically.
The third and largest group (57%) presented with non-
specific, unrecognisable conditions. Of these, 92% remain
undiagnosed, even after all appropriate available testing.
Conclusions: Patients with DD are the largest group of
patients seen at this Medical Genetics clinic. Current
diagnostic testing approaches are limited, so where condi-
tions are unclear or unrecognisable, diagnostic yield is very
low. Therefore, there is a large cohort of patients who
would benefit from implementation of first-line exome
sequencing, from a time, diagnosis and cost perspective.
NIH funding award: U01MH115483.
E.K. Wiener: None. Z. Lombard: None. A.
Krause: None.
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Genomic testing in more than 1,000 individuals from
Pakistani families results in high diagnostic yield and
remarkable clinical impact
A. Bertoli-Avella1, H. Cheema2, V. Skrahina1, M. Nadeem
Anjum2, N. Salman2, A. Saeed2, C. Beetz1, J. Perez-Lopez1,
M. Rocha1, S. Alawbathani1, C. Pereira1, M. Hovakimyan1,
I. Patric1, O. Paknia1, N. Ameziane1, C. Cozma1, P. Bauer1,
A. Rolfs1,3
1CENTOGENE AG, Rostock, Germany, 2Pediatric Depart-
ment of Gastroenterology. Children’s Hospital of Lahore
Hospital, Lahore, Pakistan, 3University of Rostock,
Rostock, Germany
To establish the genetic diagnosis, and to asses diagnostic
yield and clinical impact in patients with no previous access
to genetic testing.
We implemented a collaborative diagnostic program in
Lahore, Pakistan. Local physicians carefully ascertained
pediatric patients at their departments. More than 1,586
genetic tests were performed in 1,019 individuals consisting
of 349 index cases and 670 relatives. Most performed tests
were exome/genome sequencing (ES/GS) and specific gene
panels.
In 61.3% of the patients (n = 214) a genetic diagnosis
was established based on pathogenic and likely pathogenic
variants. In 19.8% (69 cases), variants of unknown clinical
significance were reported. Diagnostic yield was higher in
consanguineous families. Most identified disorders were
metabolic diseases corresponding to the main referral
clinical department. Furthermore, in 28 patients, genetic
diagnosis relied on additional biochemical testing, which
allowed for rapid assessment of the functional effect of the
relevant variants. Remarkably, the genetic diagnosis had a
direct impact on clinical management in 79.4% of the
patients (170/ 214). Most relevant consequences were
therapy related decisions such as initiation of the appro-
priated treatment in a timely manner (e.g. biotin). Others
included referral to other medical specialties and possibility
of prenatal/predictive testing. Finally, we report 12
candidate genes among 66 cases with no clear genetic
diagnosis.
Our results emphasize the importance of careful clinical
assessment, patient selection and physician-to-lab commu-
nication as crucial steps of the diagnostic process. The high
diagnostic yield, clinical impact, and relevant research
findings demonstrate the utility of genomic testing,
especially when used as first-line genetic test.
A. Bertoli-Avella: A. Employment (full or part-time);
Significant; CENTOGENE AG. H. Cheema: None.
V. Skrahina: A. Employment (full or part-time); Signifi-
cant; CENTOGENE AG. M. Nadeem Anjum: None. N.
Salman: None. A. Saeed: None. C. Beetz: A. Employment
(full or part-time); Significant; CENTOGENE AG. J.
Perez-Lopez: A. Employment (full or part-time); Signifi-
cant; CENTOGENE AG. M. Rocha: A. Employment (full
or part-time); Significant; CENTOGENE AG. S. Alaw-
bathani: A. Employment (full or part-time); Significant;
CENTOGENE AG. C. Pereira: A. Employment (full or
part-time); Significant; CENTOGENE AG. M. Hovakim-
yan: A. Employment (full or part-time); Significant;
CENTOGENE AG. I. Patric: A. Employment (full or
part-time); Significant; CENTOGENE AG. O. Paknia: A.
Employment (full or part-time); Significant; CENTOGENE
AG. N. Ameziane: None. C. Cozma: A. Employment (full
or part-time); Significant; CENTOGENE AG. P. Bauer: A.
Employment (full or part-time); Significant; CENTOGENE
AG. A. Rolfs: A. Employment (full or part-time);
Significant; CENTOGENE AG.
P16.24.C
A simple and cost-effective method for CNV confirma-
tion and segregation analysis by EvaGreen digital PCR
E. Sanchez1, A. Fabre1, M. Rama2, A. Schneider1, V.
Gatinois1, F. Pellestor1, J. B. Gaillard1
1Génétique Chromosomique, CHU, Montpellier, France,
2Cytogénomique des déficiences intellectuelles et anomalies
du développement, CHU, Lille, France
Introduction: The use of array comparative genomic
hybridization (aCGH) as a diagnostic tool in molecular
genetics has facilitated the identification of copy number
variations (CNVs). In this study, we present a simple and
highly accurate method for CNV confirmation and segre-
gation analysis using an EvaGreen single colour, digital
PCR (dPCR).
Methods: In an EvaGreen multiplex assay (Biorad), the
fluorescence amplitude varies with amplicon size, PCR
efficiency and primer concentrations allowing amplicon
separation. A gene ratio can then be calculated by absolute
quantification of events for the target and reference genes
with no need of standard curves. For each CNV, we
developed a duplex assay with RPP30 as reference gene and
designed primers for the target gene with an amplicon size
between 100 and 250 bp. In order to more easily separate
amplicons, we used 50nM and 150nM for target and
reference primers respectively. We compared results
obtained from dPCR (DQ) to aCGH (log2ratio) and qPCR
(normalized ratio) from 137 samples (blood, amniotic fluid,
chorionic villi).
620 J. del Picchia
Results: Our experiments showed that dPCR is a
reproducible method with a low variation coefficient
(5%). Correlations are equivalent between both molecular
method, i.e. dPCR and qPCR, compared to results obtained
by aCGH (r²= 0.964, p = 1). Same analytical sensitivity
was obtained for experiments from 1.25 to 10 ng DNA by
well, thus allowing sample saving in particular for prenatal
diagnosis.
Conclusions:This dPCR assay in a single well is a
simple, reliable and cost-efficient method which could be an
interesting alternative to relative quantification assay
as qPCR.
E. Sanchez: None. A. Fabre: None.M. Rama: None. A.
Schneider: None. V. Gatinois: None. F. Pellestor: None.
J.B. Gaillard: None.
P16.25.A
Best practice guidelines for genetic testing in
dystrophinopathies
C. Fratter1,2, R. Dalgleish3, S. K. Allen4, R. Santos5, S.
Abbs6, S. Tuffery-Giraud7, A. Ferlini8,9
1Oxford Genetics Laboratories, Oxford, United Kingdom,
2Genomics Quality Assessment (GenQA), Edinburgh, Uni-
ted Kingdom, 3Department of Genetics and Genome
Biology, Leicester, United Kingdom, 4West Midlands
Regional Genetics Laboratory, Birmingham, United King-
dom, 5Centro Hospitalar Universitário do Porto, Porto,
Portugal, 6Cambridge University Hospitals NHS Founda-
tion Trust, Cambridge, United Kingdom, 7Laboratory of
Genetics of Rare Diseases (LGMR), University of Mon-
tpellier, Montpellier, France, 8Department of Medical
Sciences, Ferrara, Italy, 9Dubowitz Neuromuscular Unit,
University College London, London, United Kingdom
Dystrophinopathies are X-linked genetic diseases resulting
from dystrophin gene (DMD) sequence variants. Genetic
testing is recommended as part of routine clinical practice
since a genetic diagnosis allows confirmation of the clinical
diagnosis, ensuring appropriate care and follow up access to
personalised treatments, carrier identification, and family
planning. The advent of next generation sequencing-based
diagnostics has prompted the update of testing guidelines,
previously published in 2010. The compilation of these
revised guidelines was facilitated by the European Mole-
cular Genetics Quality Network (EMQN).We have con-
sidered several issues. Technical aspects include variant
detection (including small variants and copy number var-
iations); RNA analysis and its use in DMD genetic testing;
genotype-phenotype correlation as an implication of genetic
testing. Male and female carrier diagnostic flowcharts have
been revised with specific recommendation about known or
unknown familial pathogenic variant identification. The
entire cohort of prenatal diagnostic workflows, including
non-invasive foetal sexing and diagnosis (NIPD) and pre-
implantation genetic diagnosis are discussed. A section is
dedicated to variant annotation, which is of paramount
importance for accurate variant reporting. We also provide
recommendations on results reporting (in males and car-
riers), and interpretation of atypical variants or genomic
configurations. We discuss and delineate possible mod-
alities of reporting incidental findings related to the DMD
gene analysis. The impact of genetic testing in personalized
therapies and clinical trials enrollment procedures is also
discussed. Finally we provide recommendations on
laboratory settings, including accreditation, ERN network
(Euro-NMD) participation, Orphanet platform registration
and participation in quality-assessment schemes.
C. Fratter: None. R. Dalgleish: None. S.K. Allen:
None. R. Santos: None. S. Abbs: None. S. Tuffery-
Giraud: None. A. Ferlini: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Significant; Sarepta
Ther, PTC Therapeutics. D. Speakers Bureau/Honoraria
(speakers bureau, symposia, and expert witness); Modest;
Sarepta, PTC. F. Consultant/Advisory Board; Modest;
Sarepta, PTC.
P16.26.B
Targeted next-generation-sequencing analysis of 93
patients with suspected Ellis Van Creveld syndrome: a
clinically relevant approach with improved diagnostic
yield
F. Piceci-Sparascio1, I. Torrente1, M. D’Asdia1, V. Guida1,
F. Consoli1, B. Torres1, L. Bernardini1, T. Mazza2, M.
DiGilio3, P. Versacci4, B. Marino4, A. De Luca1
1Medical Genetics Unit, Fondazione Casa Sollievo della
Sofferenza, IRCCS, San Giovanni Rotondo, Italy, 2Labora-
tory of Bioinformatics, Fondazione Casa Sollievo della
Sofferenza, IRCCS, San Giovanni Rotondo, Italy, 3Medical
Genetics Unit, Bambino Gesù Children’s Hospital and
Research Institute, IRCCS, Rome, Italy, 4Department of
Pediatrics, Sapienza University, Rome, Italy
Ellis-Van Creveld (EvC) syndrome is a rare autosomal
recessive skeletal ciliopathy presenting with postaxial
polydactyly, ectodermal dysplasia and congenital heart
disease. EvC is caused by mutations in EVC or EVC2 genes
in approximately 85% of cases. From year 2003 to 2019 we
collected and analyzed for mutations by DHPLC and/or
Sanger sequencing the EVC and EVC2 genes in a cohort of
93 patients suspected of having EvC syndrome. After this
screening, 42 patients remained mutation-negative. In this
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study, we used a targeted next-generation-sequencing
(NGS) skeletal ciliopathy panel to reanalyze this EVC/
EVC2 mutation-negative cohort. NGS analysis identified
compound heterozygous or homozygous genotypes in 15
out of the 42 cases analyzed (36%). Of these, 5 subjects
harbored mutations in either EVC or EVC2, and 10 were
found to be mutated in other ciliary genes. Of these, 6/10
carried mutations in the DYNC2H1 gene associated with
Jeune syndrome, comprising one compound heterozygous
for a DYNC2H1 splice site change and a 3.6 Mb de novo
deletion encompassing the entire DYNC2H1 gene, 3/12
were mutated in DYNC2LI1, a gene associated with a wider
clinical spectrum including EvC-like phenotypes, and a
fetus was mutated in NEK1, a gene associated with type II
short rib-polydactyly syndrome (Majewski type). In con-
clusion, NGS technology represents a powerful approach in
the field of skeletal ciliopaties, where the application of a
small NGS targeted panel can be successfully applied to
revaluate based on molecular findings, the diagnosis of
individuals with clinically-overlapping phenotypes.
F. Piceci-Sparascio: None. I. Torrente: None. M.
D’Asdia: None. V. Guida: None. F. Consoli: None. B.
Torres: None. L. Bernardini: None. T. Mazza: None. M.
DiGilio: None. P. Versacci: None. B. Marino: None. A.
De Luca: None.
P16.27.C
Chromosomes in the DNA world - preserving cytoge-
nomic competence of diagnostic medical genetic
laboratories
R. Hochstenbach1, T. Liehr2, R. Hastings3
1Department of Clinical Genetics, Amsterdam UMC,
Amsterdam, Netherlands, 2Institute of Human Genetics,
University Clinic Jena, Jena, Germany, 3GenQA, Oxford
University Hospitals Foundation Trust, Oxford, United
Kingdom
Introduction: In a future where Whole Genome Sequen-
cing (WGS) will predominate, clinical laboratory geneticists
(CLGs) with knowledge about chromosomes will be needed
because not all clinically relevant chromosomal aberrations
can be revealed by WGS. CLGs who specialize in cytoge-
nomics are able to recognize when there is a need for
cytogenetic follow-up studies after WGS. Here, we present
evidence from recent External Quality Assessments (EQAs)
that competence in clinical cytogenomics is at risk.
Methods: Recent EQAs organized by GenQA were
evaluated in which identical critical errors had been made
by at least five participants. We also used public sources
about age distributions of CLGs, job opportunities and
training programs.
Results:We identified critical errors at both the analytical
and interpretative level that would adversely affect patient
management, revealing that, in many laboratories, there is a
deficit in CLGs with cytogenomic expertise. This may
deteriorate further as 25-30% of EBMG-registered CLGs
with experience in cytogenetics will retire in the next
decade. At the same time, trainees entering the field have a
preference for molecular genetics. We show that job
opportunities in molecular genetics are in excess over those
in cytogenomics, and that current CLG training programs
tend to accommodate less time for cytogenomics.
Discussions: Here, we define the minimal knowledge a
CLG should have about cytogenomics in a world
predominated by WGS. We argue that laboratory directors
and boards of professional organizations in clinical genetics
can preserve cytogenomic competence by providing
adequate CLG training programs and attracting sufficient
numbers of capable trainees.
R. Hochstenbach: None. T. Liehr: None. R.
Hastings: None.
P16.28.A
Testing and improving DeepGestalt’s discriminatory
power on photographs of individuals with and without a
genetic syndrome
J. T. Pantel1,2, N. Hajjir1,3, M. Danyel1,4, J. Elsner1, A.
Abad-Perez1, P. Hansen1,5, M. Spielmann1,6, D. Horn1, C.
E. Ott1, M. A. Mensah1,7
1Institute of Medical Genetics and Human Genetics,
Charité - Universitätsmedizin Berlin, corporate member
of Freie Universität Berlin, Humboldt-Universität zu Berlin
and Berlin Institute of Health, Berlin, Germany, 2Institute
for Genomic Statistics and Bioinformatics, University
Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität
Bonn, Bonn, Germany, 3Klinik für Pädiatrie mit Schwer-
punkt Gastroenterologie, Nephrologie und Stoffwechselme-
dizin, Charité - Universitätsmedizin Berlin, corporate
member of Freie Universität Berlin, Humboldt-Universität
zu Berlin and Berlin Institute of Health, Berlin, Germany,
4Berlin Center for Rare Diseases, Charité - Universitäts-
medizin Berlin, corporate member of Freie Universität
Berlin, Humboldt-Universität zu Berlin and Berlin Institute
of Health, Berlin, Germany, 5The Jackson Laboratory for
Genomic Medicine, Farmington, CT, United States, 6Max
Planck Institute for Molecular Genetics, RG Development
& Disease, Berlin, Germany, 7Berlin Institute of Health
(BIH), Berlin, Germany
Introduction: Facial recognition methodologies such as
DeepGestalt (Face2Gene) are increasingly used in the
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diagnostic process in clinical genetics. Previous studies on
DeepGestalt’s quality focused on its sensitivity in patients
with facial dysmorphisms. However, any diagnostic pro-
cedure also requires negative testing to determine its accu-
racy. We present these systematic tests of DeepGestalt on
photographs of healthy individuals and suggest a machine-
learning driven approach to infer presence/absence of a
syndromic facies from DeepGestalt’s results.
Materials and Methods: We collected 19 images for
each of 17 distinct syndromes. 323 images of healthy
individuals were matched to these regarding age, sex and
ethnicity. Altogether, we analyzed 646 frontal photographs.
We accessed DeepGestalt (v. 19.1.7) using Face2Gene
CLINIC and evaluated results for the suggested diagnoses’
frequencies, ranks and scores. We trained and tested a linear
support vector machine (SVM) using a leave-one-out
scheme to distinguish the two classes of images based on
DeepGestalt’s output.
Results:We confirm DeepGestalt’s high true positive rate
(top-10-sensitivity 91%). Furthermore, false positives
showed an interesting distribution. DeepGestalt suggested
171 distinct differential diagnoses in the top-10-results lists
of the healthy control cohort. Frequencies differed: For
example - although known to the system - it never falsely
suggested Apert syndrome, while it proposed Fragile X
syndrome in 50% of healthy controls.
DeepGestalt’s top-1-scores do fairly predict presence/
absence of a syndromic facies (AUROC: 0.71). Using a
linear SVM on DeepGestalt’s output enhances this predic-
tion (AUROC: 0.89).
Conclusions: Our data facilitate the interpretation of
DeepGestalt’s results and may help improve it and similar
systems.
J.T. Pantel: None. N. Hajjir: None. M. Danyel: None.
J. Elsner: None. A. Abad-Perez: None. P. Hansen: None.
M. Spielmann: None. D. Horn: None. C.E. Ott: None. M.
A. Mensah: None.
P16.29.B
Benchmarking SNP microarray analysis of compro-
mised DNA and impact on forensic genetic genealogy
J. H. de Vries1, D. Kling2, A. Vidaki3, P. Arp1, P. Kalamara3,
M. M. P. J. Verbiest1, A. G. Uitterlinden1, M. Kayser3
1Department of Internal Medicine, Erasmus MC University
Medical Center, Rotterdam, Netherlands, 2National Board
of Forensic Medicine, Linköping, Sweden, 3Department of
Genetic Identification, Erasmus MC University Medical
Center, Rotterdam, Netherlands
Introduction: SNP microarrays have recently demonstrated
its first successes in forensic genetic genealogy and more
forensic applications are foreseen. However, array tech-
nology was not developed for low quantity and quality
forensic DNA. Here we systematically tested how DNA
quantity and quality impacts array-based genotyping accu-
racy and consequent success in identification of relatives.
Methods: We used the Illumina GSA-v2 array for blood
DNA with varying degrees of DNA concentration and
degradation. We established high-quality reference data,
which allowed quantifying genotyping error rate and
investigating its impact on the success of identifying
relatives, simulated from these reference data.
Results: Stepwise decrease of DNA quantity from 200
nanogram down to 6.25 picogram led to a gradual decrease
in the SNP call rate from 100% to 43%, an increase in
heterozygote discordance from 0% to 73% while the
homozygote discordance remained zero down to 250
picogram and then increased to 21%. However, the
identification rate for relatives remained stable at 100%
down to 250 picogram for siblings and 1st cousins and down
to 1 nanogram for 2nd cousins and 3rd cousins, before the
identification rate decreased to zero at 25 picogram and
below. Analyses on artificially degraded DNA are ongoing
and not yet completed.
Conclusions: Our study provides the first empirical
evidence on SNP microarray genotyping accuracy in
compromised DNA samples and illustrates the consequence
of genotyping errors for genetic genealogy. Our results are
relevant for forensic genetic genealogy and any other
forensic microarray applications such as appearance
prediction and biogeographic ancestry inference.
J.H. de Vries: None. D. Kling: None. A. Vidaki: None.
P. Arp: None. P. Kalamara: None. M.M.P.J. Verbiest:
None. A.G. Uitterlinden: None. M. Kayser: None.
P16.30.C
CADA: network-based gene prioritization with pheno-
typic features
C. Peng1, T. Hiseh1, G. Nadav2, J. T. Pantel3, P. Krawitz1
1Institute for Genomic Statistics and Bioinformatics -
University Hospital Bonn, Bonn, Germany, 2FDNA Inc.,
Boston, MA, United States, 3Charité - Universitätsmedizin
Berlin, Berlin, Germany
Introduction: Human Phenotype Ontology (HPO) is
widely used for deep phenotyping of patients with Men-
delian disorders. Lots of existing tools have been developed
to search the semantic similarity in the ontology and
achieved high accuracy in the task of gene prioritization by
patients’ phenotypic features. However, since the similarity
search is biased among diseases of varying prevalences,
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these tools usually perform poorly on patients with rare
diseases. Therefore, we propose Case-Annotation plus
Disease-Annotation (CADA), a network-based gene prior-
itization method to improve the gene prioritization for rare
diseases patients.
Materials and Methods: The diagnosed disease, disease-
causing gene and phenotypic features of 11,000 patients
from the Clinvar and our hospitals are collected. Along with
the phenotypic features and their annotated diseases and
genes from HPO, A knowledge graph, incorporating nodes
of diseases, genes, patients and phenotypic features as well
as their relationships as edges, is prepared. Then node2vec
is used for node embeddings generation. With node
embeddings, the gene prioritization is achieved by
similarity-based node link prediction.
Results: The patients with the same disease and disease-
causing gene were located in close proximity in node
embeddings. Clustering visualization shows that diseases
with similar phenotypic features tend to cluster together as
well. The prioritization of disease-causing gene improved
on more than 60% of rare disease patients.
Conclusions: By integrating real-world case annotations
and existing disease annotations from HPO, CADA
provides a new way to address the semantic search bias
problem in existing tools for the gene prioritization of rare
disease patients with phenotypic features.
C. Peng: None. T. Hiseh: None. G. Nadav: None. J.T.
Pantel: None. P. Krawitz: None.
P16.31.A
Need for a precise molecular diagnosis in Beckwith-
Wiedemann and Silver-Russell syndrome. What has to
be considered and why it is important
T. Eggermann, J. Brück, K. Eggermann, I. Kurth, M.
Begemann, M. Elbracht
Institute of Human Genetics, Aachen, Germany
Molecular diagnostic testing of imprinting disorders
(ImpDis) is challenging due to the broad spectrum of
molecular defects and their mosaic occurrence. Clinically,
these entities are heterogeneous as well, and they show a
notable phenotypic overlap. However, the precise identifi-
cation of the type of defect is a prerequisite for the clinical
management and genetic counselling. In fact, the con-
tribution of the four major alterations (UPDs, CNVs SNVs,
epimutations) varies considerably in the currently known
ImpDis. Due to their formation mechanism, epimutations
are particular prone to mosaicism, as well as upd(11)pat in
Beckwith-Wiedemann syndrome (BWS). It is therefore not
surprising that ImpDis are un- and misdiagnosed. We will
report on our experience of testing in >1000 patients
referred for diagnostic testing of BWS and Silver-Russell
syndrome (SRS). Though the majority of patients carried
the expected molecular results, we identified a considerable
number of unexpected alterations, new changes as well as
undiagnosed epimutations / UPDs due to extremely dis-
crepant mosaic distributions. Additionally, the rate of
multilocus imprinting disturbances (MLID) and genome-
wide uniparental disomies is further specified. Altogether,
these cases show that comprehensive tests targeting differ-
ent tissues and including different methods have to be
applied, combined with a thorough clinical examination.
The precise molecular diagnosis is required as the basis for
a targeted management (e.g. ECG and tumor surveillance in
BWS, growth treatment in SRS). For genetic counselling it
is needed for recurrence risk estimation which is hindered
by the impact of the spatial arrangements of imprinting
elements and their interactions on the phenotype.
T. Eggermann: None. J. Brück: None. K. Eggermann:
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Elbracht: None.
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A cost-effective model for the pathway of care of CDH1-
related hereditary diffuse gastric cancer syndrome
(HDGC)
L. Garrido*1,2, L. Sousa*2,3,4, T. Nércio1, L. Castro1, R.
Leal3, S. Costa1,5, A. Magalhães1,5, A. F. Pereira1, R.
Guimarães1, L. Ferro1, L. Vilarinho1, I. Gullo1,3,5, H.
Pinheiro3, S. Sousa2,3, A. P. Neto3,5, L. Capela3,5, C.
Caeiro1, I. Augusto1, D. Almeida1, G. Pinto1, C. Teixeira1,
V. Devezas1,5, G. Macedo1, J. L. Fougo1,5, J. Preto1,5, J.
Barbosa1,5, J. Costa-Maia1, M. Baptista1,5, S.
Fernandes2,3,5, F. Carneiro1,2,3, S. Castedo1,2,3, C.
Oliveira2,3,5
1Centro Hospitalar e Universitário São João (CHUSJ),
Porto, Portugal, 2European Reference Network on Genetic
Tumour Risk Syndromes (GENTURIS) & SolveRD, Solving
the unsolved in rare diseases, Grant No 779257 & Porto.
Comprehensive Cancer Centre (P.CCC), Porto, Portugal,
3Instituto de Investigação e Inovação em Saúde (i3s) &
Institute of Molecular Pathology and Immunology of the
University of Porto (Ipatimup), Porto, Portugal, 4Depart-
ment of Economics and Economic Policies Research Unit
(NIPE), University of Minho, Braga, Portugal, 5Faculty of
Medicine of the University of Porto (FMUP), Porto,
Portugal
Introduction: CDH1-germline mutations cause Hereditary-
Diffuse-Gastric-Cancer(HDGC) syndrome. Penetrance is
60%-80% in both genders for diffuse-gastric-cancer(DGC),
and 40% in females for lobular-breast-cancer(LBC). In
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asymptomatic-carriers, risk-reduction gastrectomy (RRG)
and mastectomy (RRM), complemented by intensive sur-
veillance, prevents disease. We present a cost-model spe-
cific for HDGC care-pathway demonstrating that enrolment
in disease-specific care-pathways at Expert Centres and
adoption of risk-reduction measures is cost-effective and
life-saving.
Material and Methods: We calculated costs for optimal
HDGC care-pathway in the public Portuguese Health
System(PHS); and analysed clinical and financial records
(2008-2018) from structured oncogenetics/high-risk con-
sultations from 115 at risk individuals from 7 HDGC-CDH1
families, at a GENTURIS Healthcare Provider Centre.
Results: This model predicts that a non-carrier costs 350
€, being discharged from further follow-up. An
asymptomatic-carrier (male/female) undergoing RRG costs
14K€ the 1st year, 160€/year the 2 following years and 125
€/year thereafter. Hospital expenses with female-carriers
undergoing RRM is 9K€ the 1st year, 200€ the following
year and 100€/year thereafter. Asymptomatic-carriers
deciding for surveillance cost 700€/year. However, if
developing disease (early-detected) during surveillance,
cost increases to 15K€ for DGC and 10K€ for LBC in the
1st year, with overall good prognosis. If late-detected during
surveillance, prognosis is poor and cost raises the 1st year to
32K€ if DGC, 28K€ if LBC and 60K€ if both.
Conclusions: This study, the first on cost impact of
preventive multidisciplinary-care applied to rare-cancer-
syndromes performed at a European Reference Centre,
shows that prevention/early diagnosis in CDH1-mutation-
carriers is life-saving and considerably less-costly for the
PHS than treating patients with expressed disease. *Equal
contribution
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Identifying the genetic causes of hereditary angioedema
through whole exome sequencing in the Canary Islands,
Spain.
A. Mendoza-Alvarez1, A. Muñoz-Barrera2, I. Marcelino-
Rodriguez1, L. Rubio-Rodríguez2, E. Tosco-Herrera1, B.
Guillen-Guio1, A. Corrales1, A. Iñigo-Campos2, A.
Callero3, J. Garcia-Robaina3, R. González-Montelongo2, J.
Lorenzo-Salazar2, C. Flores1,2,4
1Research Unit, Hospital Universitario Nuestra Señora de
Candelaria, Santa Cruz de Tenerife, Canary Islands, Spain,
2Genomics Division, Instituto Tecnológico y de Energías
Renovables (ITER), Granadilla de Abona, Canary Islands,
Spain, 3Deparment of Allergy, Hospital Universitario
Nuestra Señora de Candelaria, Santa Cruz de Tenerife,
Canary Islands, Spain, 4CIBER de Enfermedades Respir-
atorias, Instituto de Salud Carlos III, Madrid, Spain
Introduction: Hereditary angioedema (HAE) is a rare dis-
ease caused by C1 inhibitor dysfunction and the dysregu-
lation of the kinin cascade. The updated HAE management
guidelines recommend performing genetic tests to reach a
precise diagnosis. Unfortunately, genetic tests are still
uncommon in the diagnosis routine. Here we characterized
for the first time the genetic causes of HAE in individuals
from Canary Islands (Spain).
Material and Methods: Whole-exome sequencing data
was obtained from 35 enrolled patients (21 families) and the
results were analyzed with the Hereditary Angioedema
Database Annotation (HADA) tool for ACMG pathogeni-
city classification and causal variant prioritization. Manual
reclassification of prioritized variants according to ACMG
guidelines was assessed in those families without known
causal variants.
Results: Three known causal variants were detected in 4
families: rs38940870, classified as likely pathogenic, and
rs35788383 and rs118204456, classified as of uncertain
significance. In two unrelated patients without any
described causal variant within SERPING1 or F12, we
detected two novel variants in SERPING1 of uncertain
significance that were manually reclassified as likely
pathogenic. A total of 17 families (81%) remained without
a genetic diagnosis of HAE based on the current
knowledge.
Conclusions: All described or novel causal variants
found affected SERPING1 and F12 genes. However, further
in-depth sequence analysis is required to fully describe the
genetic variation causing HAE.
Funding: Ministerio de Ciencia, Innovación y Universi-
dades (RTC-2017-6471-1; AEI/FEDER, UE); ITER agree-
ment OA17/008; SEAIC Foundation (18_A01); Fundación
Canaria Instituto de Investigación Sanitaria de Canarias
(FPIFIIS19/48); CajaSiete-ULL (AMA); Instituto de Salud
Carlos III (CD19/00231; IMR).
A. Mendoza-Alvarez: D. Speakers Bureau/Honoraria
(speakers bureau, symposia, and expert witness); Modest;
Takeda Pharmaceutical Company. A. Muñoz-Barrera:
None. I. Marcelino-Rodriguez: None. L. Rubio-Rodrí-
guez: None. E. Tosco-Herrera: None. B. Guillen-Guio:
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Thrombophilic gene mutations as risk factors for
recurrent pregnancy loss
M. Samfireag1,2, C. Potre1,2, O. Potre1,2, M. Pescaru1,3, R.
Tudor1,4, I. Ionita1,2, H. Ionita1,2, A. Anghel1
1University of Medicine and Pharmacy “Victor Babes”,
Timisoara, Romania, 2Hematology Clinic, Municipality
Emergency Hospital, Timisoara, Romania, 3Hematology
Clinic, Varnamo, Sweden, 4Neurology Clinic, Timisoara
County Emergency Clinical Hospital, Timisoara, Roma-
nia
Introduction: Hereditary thrombophilia is a genetic dis-
position related to hypercoagulable states generated by
acquired conditions of haemostasis; pregnancy changes the
haemostatic system into a hypercoagulable state, which
increases throughout pregnancy and is utmost around
delivery [1]. Genetic testing for thrombophilia mutations
implies the study through different methodologies of real-
time polymerase chain reaction and DNA microarrays of
specific genes: the polymorphic methylenetetrahydrofolate
reductase (MTHFR) mutations - C677T and A1298C,
Factor V Leiden (FVL), and two polymorphisms - the
coagulation factor XIII (FXIII) Val34Leu and plasminogen
activator inhibitor- 1 (PAI-1) 4G/5G.
Materials and Methods: We performed a retrospective
study on a group of 40 pregnant caucasian women,
diagnosed with hereditary thrombophilia during 2017-
2019, in the west part of Romania, investigated by
analyzing the main thrombofilic gene mutations involved
as risk factors in the process of coagulation and of the
nucleic acids metabolism.
Resuls: The overall relative risk for early pregnancy loss
was significant increased for the homozygosity of PAI-1
and for the MTHFR mutations (p < 0, 05). We noticed no
statistically relevant association of any of the other tested
mutations with early pregnancy loss.
Conclusions: The genetic testing for thrombophilic gene
mutations as risk factors for recurrent pregnancy loss
revealed that the main genes involved in mechanism of
hereditary thrombophilia were PAI-1 and MTHFR.
M. Samfireag: None. C. Potre: None. O. Potre: None.
M. Pescaru: None. R. Tudor: None. I. Ionita: None. H.
Ionita: None. A. Anghel: None.
P16.38.B
Assessing performance of pathogenicity predictors using
clinically-relevant variant datasets.
A. C. Gunning, V. Fryer, J. Fasham, A. H. Crosby, S.
Ellard, E. Baple, C. F. Wright
University of Exeter, Exeter, United Kingdom
Purpose: Pathogenicity predictors are integral to genomic
variant interpretation but, despite their widespread usage, an
independent validation of performance using a clinically-
relevant dataset has not been undertaken.
Methods: We derive two validation datasets: an “open”
dataset containing variants extracted from publicly-
available databases, similar to those commonly applied in
previous benchmarking exercises, and a “clinically-repre-
sentative” dataset containing variants identified through
research/diagnostic exome and panel sequencing. Using
these datasets, we evaluate the performance of three recent
meta-predictors, REVEL, GAVIN and ClinPred, and
compare their performance against two commonly used in
silico tools, SIFT and PolyPhen-2.
Results: Although the newer meta-predictors outperform
the older tools, the performance of all pathogenicity
predictors is substantially lower in the clinically-
representative dataset. Using our clinically-relevant dataset,
REVEL performed best with an area under the ROC of
0.81. Using a concordance-based approach based on a
consensus of multiple tools reduces the performance due to
both discordance between tools and false concordance
where tools make common misclassification. Analysis of
tool feature usage may give an insight into the tool
performance and misclassification.
Conclusions: Our results support the adoption of meta-
predictors over traditional in silico tools, but do not support
a consensus-based approach as recommended by current
variant classification guidelines. We acknowledge funding
from Wellcome [200990].
A.C. Gunning: None. V. Fryer: None. J. Fasham:
None. A.H. Crosby: None. S. Ellard: None. E. Baple:
None. C.F. Wright: None.
P16.40.A
NGS custom panel assessment for sequencing circulating
tumor DNA samples in patients with colorectal cancer
R. Tebar-Martinez1,2, J. Martín-Arana2,3,4, E. Seda1, S.
Blesa1, A. Ferrer-Martínez2,4, S. Zuñiga1,3, N. Tarazona2,4,
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S. Roselló2, D. Roda2, M. Huerta2, P. Rentero-Garrido1, A.
Cervantes2,4
1Personalize Medicine Unit, Biomedical Research Institute
INCLIVA, Valencia, Spain, 2Department of Medical
Oncology, Biomedical Research Institute INCLIVA, Valen-
cia, Spain, 3Bioinformatics and Biostatistics Unit, Biome-
dical Research Institute INCLIVA, Valencia, Spain,
4CIBERONC, ISCIII Institute of Health Carlos III, Madrid,
Spain
Introduction: In colorectal cancer (CRC), liquid biopsies
suppose a non-invasive alternative for biomarker identifi-
cation and minimal residual disease detection. Our aim is to
evaluate the potential of a custom gene panel that includes
unique molecular identifier technology (UMI) for analysis
of plasma cell-free DNA (cfDNA).
Materials and Methods: Horizon Discovery’s standards
HD780 and HD816 simulating cfDNA and plasma patient
samples, respectively, were selected for evaluation of 8
mutations at different variant allele frequencies (VAF). 2ml
of each HD816 standards were purified using QIAamp
Circulating Nucleic Acid Kit (QIAgen). A custom gene
panel of 29 frequently mutated CRC genes was designed for
QIAseq technology (QIAgen). cfDNA library preparation
input was 10ng, 20ng, 40ng and 80ng from
HD780 standards and 40ng of purified HD816. HD780
libraries were generated according manufacturer’s instruc-
tions, whereas HD816 included modifications. All libraries
were sequenced on the NextSeq platform at >30,000X and
processed with an in-house pipeline for UMI processing.
Results: Coverage with non-duplicated reads (NDR)
were proportional to the cfDNA input, up to 80ng. Panel
sensitivity at 1% VAF was 87.5% with 20ng input and
100% with 40ng or higher input. 3 out of 8 mutations were
lost at 10ng. Sensitivity at 0.1% was 25% in 20ng and 40ng
cfDNA inputs. Similar sensitivity and non-significant
variations (P=0.35) in NDR coverage were found between
HD816 and HD780.
Conclusions: Our panel reaches 100% sensitivity at 1%
VAF with cfDNA expected input. Adjustments are needed
to reach higher sensitivity.
Tébar-Martínez’s PhD contract is funded by Spanish
Association Against Cancer (AECC).
R. Tebar-Martinez: None. J. Martín-Arana: None. E.
Seda: None. S. Blesa: None. A. Ferrer-Martínez: None.
S. Zuñiga: None. N. Tarazona: None. S. Roselló: None.
D. Roda: None. M. Huerta: None. P. Rentero-Garrido:
None. A. Cervantes: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Modest; Roche, Merck
Serono, SERVIER, Novartis, Lilly, Tesaro, Johnson &
Johnson, MedImmune, Theradex, Astellas Pharma, Array
BioPharma. D. Speakers Bureau/Honoraria (speakers
bureau, symposia, and expert witness); Modest; Merck
Serono, Roche, SERVIER. F. Consultant/Advisory Board;
Modest; Bayer, Pierre Fabre.
P16.41.B
detecting down & fragile X syndromes by using deep
machine learning from facial images
R. Jafarzadeh-Esfehani1, M. Mirzaei Fard2, F. Habibi-
Hatam-Ghale2, M. Beiraghi-Toosi1, S. Eslami1, A. Sadr-
Nabavi1
1Mashhad University of Medical Sciences, Mashhad, Iran,
Islamic Republic of, 2Ferdowsi University of Mashhad,
Mashhad, Iran, Islamic Republic of
Introduction: Delayed diagnosis of genetic syndromes is
an important challenge for health care providers. Among
various attempts towards reducing the rate of delayed
diagnosis, using machine learning is considered as a new
and rapidly developing solution. In the present study,
validation of a new diagnostic algorithm for diagnosis of
two common genetic syndromes with unique facial phe-
notype is discussed.
Material and methods: The frontal and lateral picture
datasets were gathered from Iranian patients who were
diagnosed to have down or fragile X syndromes as well as
healthy patients without any genetic syndrome with
prominent facial appearance. After processing the pictures,
landmark detection, feature extraction, feature selection,
and classification were performed. Five support vector
machine(SVM) Classifier designed for the present study.
Each classifier took features of frontal and side view images
as input and presented its decision from one of the states as
output. After implementing all of the classifiers on the input
data, true parameters for each category were considered and
the input image matched with the category with higher
count of true statements.
Results: Among 100 syndromic and 200 healthy patients,
the accuracy, sensitivity and specificity of the software was
calculated as 0.986, 1.000 and 0.961 respectively which
was greater than human inelegance for similar pictures.
Conclusion: We have demonstrated that our proposed
algorithm using both frontal and lateral picture of
syndromic patients can achieve considerable accuracy and
can be used as a screening program helping the physicians
in order to detect the genetic syndrome with facial features.
R. Jafarzadeh-Esfehani: None. M. Mirzaei Fard:
None. F. Habibi-Hatam-Ghale: None. M. Beiraghi-
Toosi: None. S. Eslami: None. A. Sadr-Nabavi: None.
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P16.43.A
A standardized framework for the control and estima-
tion of measurement uncertainty for clinical genomic
tests
I. Delon1, A. S. Devonshire2, C. Mattocks3, R. Hawkins4, S.
Tobi5, S. Patton5, S. L. R. Ellison2
1East Midlands and East of England Genomic Laboratory
Hub, Cambridge, United Kingdom, 2National Measurement
Laboratory at LGC, Teddington, United Kingdom, 3West
Midlands, Oxford and Wessex Genomic Laboratory Hub,
Salisbury, United Kingdom, 4NIBSC, Ridge, United King-
dom, 5EMQN, Manchester, United Kingdom
The quality and comparability of laboratory medicine
results underpins accurate diagnosis and disease monitoring
in patient care pathways. Measurement uncertainty is the
quality metric that informs the testing laboratory and its
users about test fitness for purpose, whether a result is above
or below a treatment threshold and its degree of compar-
ability with other laboratories. An ISO15189 laboratory
medicine accreditation requirement, the measurement
uncertainty of a test is intended to encompass all random
and systematic effects on a measurement result. However
current models to assess measurement uncertainty have
been developed in the field of physical measurement or
analytical chemistry and do not apply well to clinical
genomic tests. Here we describe two new principles to
standardise measurement uncertainty evaluation for geno-
mic tests: 1) the ‘examinand’ -a general concept that applies
to both qualitative and quantitative properties- is defined by
the genomic target sequence and the source of the sample,
2) the combination of type of data output and reported
result, which may be qualitative or quantitative, defines the
requirement for the type of analysis. We propose the use of
a structured cause-effect diagram for mapping sources of
measurement uncertainty in the pre-analytical, analytical
and post-analytical phases, along with standard templates
for recording sources of uncertainty and their mitigation, in
addition to measurement uncertainty calculation when
applicable. We propose that using this standardised frame-
work to guide laboratories through measurement uncer-
tainty evaluation will contribute to improving the quality of
genomic results and increasing patient’s safety and equity.
I. Delon: None. A.S. Devonshire: None. C. Mattocks:
None. R. Hawkins: None. S. Tobi: None. S. Patton: None.
S.L.R. Ellison: None.
P16.44.B
Clinical utility of Mendeliome sequencing with respect to
whole exome sequencing
M. Zollino1, S. Frangella1, P. N. Doronzio1, S. Maietta1, D.
Orteschi1, S. Amenta1, S. Ricciardi1, L. Masini2, M. De
Santis2, G. Vento3, R. Manfredi4, V. Nigro5, M. Pinelli5,
TUDP Consortium, G. Marangi1
1Institute of Genomic Medicine, Università Cattolica del
Sacro Cuore, Fondazione Policlinico A. Gemelli IRCCS,
Roma, Italy, 2Department of Obstetrics and Gynecology,
Università Cattolica del Sacro Cuore, Fondazione Policli-
nico A. Gemelli IRCCS, Roma, Italy, 3Department of
Pediatrics, Università Cattolica del Sacro Cuore, Fonda-
zione Policlinico A. Gemelli IRCCS, Roma, Italy, 4Depart-
ment of Radiological Sciences, Università Cattolica del
Sacro Cuore, Fondazione Policlinico A. Gemelli IRCCS,
Roma, Italy, 5TIGEM (Telethon Institute of Genetics and
Medicine), Napoli, Italy
Whole exome sequencing (WES) can be considered the
test of choice to search for intragenic variants in unex-
plained monogenic diseases not caused by CNVs. To
verify whether mendeliome (or clinical exome) sequen-
cing can be still proven to be useful, we critically eval-
uated our experience with 64 patients affected by
syndromic conditions that were likely monogenic in ori-
gin. Relevant for this analysis were also the following
aspects: 1) planning of new pregnancies; 2) early use of
mendeliome sequencing in the diagnostic procedure; 3)
parental consent. By mendeliome sequencing, we were
able to reach the genetic diagnosis in 15 (23,4 %) cases, of
which 8 (53.3 %) had a de novo autosomal heterozygous
variant; 5 (33.3 %) were compound heterozygous or
homozygous for an autosomal recessive condition; 2 (13.3
%) had an X-linked condition. Variants were mostly in
classes IV and V. Clinical re-evaluation of patients was
crucial for result validation. We could expand the phe-
notypic spectrum of known conditions in 30% of cases.
Prenatal diagnosis in subsequent pregnancies was con-
sistently performed in several occasions. By WES, pre-
cision diagnosis was expanded to three genes not included
in the mendeliome. By contrast, a high number of VUS
was observed, for which additional research activities
were required and planned. The use of mendeliome
sequencing as an early step of the diagnostic workflow,
critically oriented on the basis of the clinical phenotype,
has proven efficient also in terms of cost/benefit. Strate-
gies for the use of mendeliome sequencing, mainly in
silico, are here suggested.
M. Zollino: None. S. Frangella: None. P.N. Doronzio:
None. S. Maietta: None. D. Orteschi: None. S. Amenta:
None. S. Ricciardi: None. L. Masini: None.M. De Santis:
None. G. Vento: None. R. Manfredi: None. V. Nigro:
None. M. Pinelli: None. G. Marangi: None.
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P16.47.B
Clinical utility of the functional mRNA evaluation of
rare genetic variants in diagnostic practice
C. R. A. Duff-Farrier1, R. Whittington1, J. Honeychurch1,
J. Evans1, K. Low2, J. Kennedy2, S. Smithson2, M. Williams1
1Bristol Genetics Laboratory, Bristol, United Kingdom,
2Clinical Genetics, University Hospitals Bristol, Bristol,
United Kingdom
High throughput sequencing in clinical diagnostics gen-
erates many genetic variants that require interpretation. A
proportion of these affect mRNA splicing, and a range of in
silico tools are employed to predict their effect, however
these are limited in scope and may be unreliable. Evaluation
of splicing variants using targeted RT-PCR is useful to
demonstrate functionality. The implementation of a func-
tional splicing service at Bristol Genetic Laboratory has
demonstrated high clinical utility as complementary
approach to support ACMG classification (code PS3), to
deliver additional positive diagnoses, and to provide further
information into underlying disease mechanisms. RT-PCR
investigation was utilised in a cohort of ten index patients
from different disease backgrounds, using peripheral blood
or skin fibroblasts. In eight patients (80%) the investigated
variant demonstrated a splicing effect. Notable examples
include: (i) ANKRD11 c.744G>A, p.(Trp202Glyfs*99)
resulting in exon 7 skipping and causing loss of a critical D-
box sequence, compatible with a diagnosis of KBG syn-
drome. (ii) KAT6A c.1364-2A>T, p.(Asp455Glyfs*10) at a
dinucleotide consensus splice site resulting in activation of a
cryptic acceptor site in exon 8, causing KAT6A syndrome
and demonstrating a novel disease mechanism. (iii) TAZ
c.646+1del, p.(Ile196_Gly216del) at a dinucleotide con-
sensus splice site resulting in exon 8 skipping and pre-
mature protein truncation. The first report of Barth
syndrome in a heterozygous female. (iv) WDR45 c.236-
18A>G, p.(Asp44Alafs*9) resulting in activation of a
cryptic acceptor site in intron 5, intron inclusion, and a
frameshift. The first report of a ‘deep intronic’ WDR45
variant casual in Neurodegeneration with Brain Iron
Accumulation.
C.R.A. Duff-Farrier: None. R. Whittington: None. J.
Honeychurch: None. J. Evans: None. K. Low: None. J.
Kennedy: None. S. Smithson: None. M. Williams: None.
P16.48.C
How SMRT sequencing can improve the prognosis and
genetic counseling in DM1 patients
S. Tomé1, J. Ziegle2, Y. Tsai2, J. Harting2, J. Bonnefont3, G.
Bassez1, L. Aro2, C. Heiner2, G. Gourdon1
1INSERM UMR974, Sorbonne Université, Centre de
Recherche en Myologie, Paris, France, 2Pacific Bios-
ciences, Menlo Park, CA, United States, 3Molecular genetic
laboratory, Necker Hospital, Paris, France
Myotonic dystrophy type 1 (DM1) results from the expansion
of an unstable CTG repeat that usually increases across
generations and over time in somatic tissues. CTG repeat
instability and DM1 clinical manifestations depend on the
length of the repeat itself and the purity of the repeated
sequence. The genetic counseling in DM1 is very complex,
due to the highly variable clinical presentation and technical
difficulties in determining the size and purity of the CTG
expansion. We used Single Molecule Real-Time sequencing
(SMRT) developed by Pacific Biosciences (PacBio) to pre-
cisely measure large CTG repeat size and identify sequence
interruptions of expanded allele to understand clinical and
genetic variability in DM1 patients. We sequenced 10 DM1
patients with CTG repeat expansion ranging from 130 to >
1000 CTG repeats on the Sequel System. We amplified
expanded alleles by PCR and pooled samples equi-mass for
library construction, using 10 ng per sample. Selective
AMPure purification was done to enrich for expanded alleles.
We obtained more than 77% full DM1 reads per sample, with
>70% of the reads from expanded alleles. The data includes
long reads in the expected size range for all samples,
including DM1 patients with more than 1000 CTG repeats.
SMRT sequencing is very promising to sequence large triplet
repeat expansions and also to identify CTG repeat interrup-
tions and estimate somatic mosaicism in DM1 patients. This
method can improve the prognosis and counseling offered to
patients. This work was supported by Pac bio and the Asso-
ciation Institut de Myologie.
S. Tomé: None. J. Ziegle: None. Y. Tsai: None. J.
Harting: None. J. Bonnefont: None. G. Bassez: None. L.
Aro: None. C. Heiner: None. G. Gourdon: None.
P16.50.B
Pathogenic Neurofibromatosis type 1 (NF1) RNA-
splicing resolved by targeted RNAseq
R. Koster1, D. Tserpelis1, K. B. M. Claes2, A. D. C.
Paulussen1, M. Sinnema1, R. Szklarczyk1, K. Derks1, M. van
Geel1, M. J. Blok1
1Department of Clinical Genetics, Maastricht University
Medical Center+, Maastricht, Netherlands, 2Centre for
Medical Genetics, Ghent University Hospital, Ghent,
Belgium
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Introduction: Neurofibromatosis type 1 (NF1) is caused by
loss-of-function variants in the NF1 gene, about 30% effect
RNA-splicing. Approximately 10% are missed by conven-
tional DNA-diagnostics, because they are located outside
the region of interest, or are misinterpreted by in silico
splicing predictions. We designed a targeted RNAseq-based
approach to detect pathogenic RNA-splicing and thereby
causative DNA-variants.
Methods: RNA was extracted from lymphocytes fol-
lowed by targeted NF1 RNA-seq. An in-house developed
tool (QURNAS) was used to calculate an enrichment score
(ERS) for each splicing event. A high enrichment score
indicates high abundance of a potentially pathogenic
splicing event.
Results: A validation was first performed with nine
known pathogenic NF1 splice-variants and two wildtype
NF1 samples. All normal reference exon-exon splice
junctions, several novel and 16 out of 17 previously reported
naturally occurring splice events were detected. Further-
more, all expected pathogenic splice events were detected
based on high ERS. Next, we blindly replicated the
molecular diagnosis (based on RT-PCR) of ten patients
from Ghent. Since using our approach all pathogenic
splicing events and corresponding splice-variants were
detected. Additionally, using RNAseq we identified a de
novo deep intronic pathogenic splice variant in a patient with
a clear NF1 phenotype, whom lacked a molecular diagnosis.
Conclusions: Targeted NF1 RNAseq can be successfully
used to characterize variants of unknown significance
(VUS) and identify undetected pathogenic RNA-splicing
variants, additionally to DNA-based diagnostics.
R. Koster: None. D. Tserpelis: None. K.B.M. Claes:
None. A.D.C. Paulussen: None. M. Sinnema: None. R.
Szklarczyk: None. K. Derks: None. M. van Geel: None.
M.J. Blok: None.
P16.51.C
Sample identity quality control in Next Generation
Sequencing (NGS) routine diagnostics using KASP
F. Scharf, J. Romic-Pickl, T. Wohlfrom, A. Benet-Pagès, B.
Neitzel, A. Abicht, E. Holinski-Feder
Medical Genetics Center MGZ, Munich, Germany
The parallel processing of multiple samples in NGS appli-
cations requires the exclusion of possible sample swaps. We
present a QC approach based on the genotyping of single
nucleotide polymorphisms (SNPs) with Kompetitive Allele
Specific PCR (KASP) technology and the comparison to
NGS data for the verification of sample identities. 16 SNPs
covered in our NGS capture kit (Agilent SureSelectXT)
were selected. To reliably detect sample swaps, 1) haplo-
type overlaps between samples need to be excluded, i.e. no
sample has been pooled twice (uniqueness) and 2) the
identity of each sample needs to be confirmed by comparing
KASP and NGS data. Due to possible dropouts or erroneous
KASP results, some comparisons might not always be
possible. The minimal number of successful comparisons
and maximum number of mismatches for reliable conclu-
sions was calculated. Concerning uniqueness, the prob-
ability of encountering two samples with the same
haplotype over a certain number of SNPs in a certain
number of samples was calculated; the cutoffs for identity
confirmation are based on the probability of a sample
showing one specific haplotype over a certain number of
SNPs. Results showed that at least two differing SNPs in all
pairwise comparisons of the samples exclude overlaps with
>99% certainty. With a cutoff of maximally four dropouts
or three dropouts and one mismatch the correct sample
assignment can be verified with a probability of >99%. The
identity confirmation is integrated in our NGS analysis
pipeline. Samples failing the criteria are automatically
identified and held back from further processing.
F. Scharf: None. J. Romic-Pickl: None. T. Wohlfrom:
None. A. Benet-Pagès: None. B. Neitzel: None. A. Abicht:
None. E. Holinski-Feder: None.
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Evaluation and comparison of novel amplicon-based
NGS library preparation protocols across multiple
sequencing platforms
H. Wang1, E. Petrilli2, Y. Jiao1, Y. Ke2, G. Richman2, Z.
Wang2
1Pillar Shanghai Zhengu Biotech Co. Ltd, Shanghai, China,
2Pillar Biosciences, Natick, MA, United States
Introduction: SLIMamp allows multiplex-PCR of tiled
amplicons in a single tube, which enables targeting of large
exons for NGS analysis with a streamlined process. This
technology was previously demonstrated to be a sensitive
and robust NGS library prep method for Illumina instru-
ments. To benefit the largest number of patients and
researchers, SLIMamp library prep was made compatible
with multiple sequencing platforms that are common
worldwide including the MGISEQ.
Materials and Methods: Five ONCO/Reveal assays for
MGI were evaluated (multi-cancer, multi-cancer with CNV,
multi-cancer cfDNA, lung fusions, and lung and colon
cancer) on the MGISEQ-2000. Libraries were prepared and
sequenced by two laboratories (Zhengu and MGI). 14 CRC
samples were tested and compared on the MGISEQ-2000
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and NextSeq CN500 platforms. Automated library prepara-
tion by the MGISP-100 was also evaluated.
Results: Across the five assays, mapping and on-target
rates and coverage uniformity at 0.2x of the mean
demonstrated high performance (generally >95%). Variant
calls from 14 CRC samples for the ONCO/Reveal Multi-
Cancer Panel sequenced on the MGISEQ-2000 and
NextSeq CN500 demonstrated an R2 value of 97%. Variants
were concordantly called from 2% to 65% VAF. The
MGISP-100 reduced hands-on-time to 30 minutes.
Conclusions: All ONCO/Reveal assays demonstrated
high performance when sequenced on MGISEQ-2000 and
Illumina platforms. Automated library preparation utilizing
the MGISP-100 reduced hands-on time while providing
sensitive and robust performance. Concordance was
demonstrated across platforms, specifically the NextSeq
CN500 and MGISEQ-2000. ONCO/Reveal assays are
sensitive and robust solutions across multiple sequencing
platforms that can be used by researchers across the globe.
H. Wang: A. Employment (full or part-time); Significant;
Pillar Shanghai Zhengu Biotech Co. Ltd. E. Petrilli: A.
Employment (full or part-time); Significant; Pillar Bios-
ciences. E. Ownership Interest (stock, stock options, patent
or other intellectual property); Significant; Pillar Bios-
ciences. Y. Jiao: A. Employment (full or part-time);
Significant; Pillar Shanghai Zhengu Biotech Co. Ltd. Y.
Ke: A. Employment (full or part-time); Significant; Pillar
Biosciences. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Significant; Pillar
Biosciences. G. Richman: A. Employment (full or part-
time); Significant; Pillar Biosciecnes. E. Ownership Interest
(stock, stock options, patent or other intellectual property);
Significant; Pillar Biosciences. Z. Wang: A. Employment
(full or part-time); Significant; Pillar Biosciences. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Pillar Biosciences.
P16.54.C
Robustness and accuracy validation of fetal fraction
estimates in NIPT
I. Miceikaite, C. Brasch-Andersen, C. Fagerberg, M. J.
Larsen
Department of Clinical Genetics, Odense University
Hospital, Odense, Denmark
Introduction: Fetal fraction (FF) is the proportion of total
cell-free DNA present in the maternal plasma that is of fetal
origin. Sufficient amount of fetal DNA is crucial to avoid
false negative NIPT results. Accurate and robust methods to
estimate fetal fraction are therefore essential to ensure a
valid NIPT result. To what extent the total number of
sequencing reads influence the fetal fraction estimate is
unexplored. In this study, we tested the robustness of the
widely used SeqFF method to provide recommendations on
the optimal number of reads needed to obtain accurate fetal
fraction estimates.
Materials and Methods: Retrospective data from WGS
NIPT samples (n = 516) obtained as a part of our local
prenatal screening program (Department of Clinical Genet-
ics, OUH, Denmark) were included. For all samples >30M
(million) reads had been obtained. Data were randomly
down-sampled before estimating the fetal fraction and
results were compared with SNP-based and chrY-based FF
estimates.
Results: Overall, SeqFF estimates highly correlated with
both the SNP-based (R-squared=0.88) and chrY-based (R-
squared=0.92) methods. By down-sampling, we observed
that the SeqFF estimates were highly affected by the total
number of reads used. Accurate SeqFF estimates were
achieved using >10M reads. By increasing the number of
reads further, additional gain in accuracy was observed.
Including more than 20M reads did not result in further
significant improvement.
Conclusions: FF estimation is highly affected by the total
number of reads used. It is recommended to use no less than
10M reads to obtain accurate FF estimates for NIPT.
I. Miceikaite: None. C. Brasch-Andersen: None. C.
Fagerberg: None. M.J. Larsen: None.
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Repeatability assessment of a prenatal cell-free DNA test
S. Lee1, G. Zhang2, Z. Li1, C. Hacker1, J. Han1, J. Doshi1,
K. Kirkconnell1, R. Stokowski1, E. Martin1
1Roche Sequencing Solutions, Inc., San Jose, CA, United
States, 2Roche Sequencing Solutions, Inc., Pleasanton, CA,
United States
Introduction: Clinical implementation of a complex
molecular test such as cell-free DNA (cfDNA) testing for
fetal trisomy requires extensive validation; however, for
most commercially available cfDNA tests there is little
published performance data beyond the establishment of
sensitivity and specificity. The objective of this study was to
assess the repeatability of results for a prenatal cfDNA test.
Materials and Methods: The Harmony® prenatal test on
the Ariosa Cell-Free DNA System (CE-IVD) was assessed
across multiple lots of reagents and operators. Panels were
contrived from genomic DNA to generate sufficient
replicates to assess repeatability across multiple factors.
This resulted in a robust sample size of 1,710 samples with
fetal fractions reflecting those observed in a general
pregnancy population.
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Results: Overall 97% of samples met the test’s quality
control thresholds. Sensitivity was 100% for trisomy 21 (142/
142), 100% for trisomy 18 (122/122), 100% for trisomy 13
(114/114), 97.6% for the 22q11.2 deletion (120/123), and
100% for monosomy X (123/123). Specificity was 100%
(1,034/1,034). Sensitivity (100%) was in complete agreement
between the lots for trisomy 21, trisomy 18, trisomy 13, and
monosomy X. Sensitivity for 22q11.2 deletion in the 3 lots
[100% (41/41), 95%(40/41), and 97.5%(39/40)] was not
significantly different (p = 0.25).
Conclusions: The study demonstrated high sensitivity
and specificity with repeatable results over different lots,
with operators, runs, and days. There was no significant lot-
to-lot or inter-operator variability in sensitivity and
specificity.
S. Lee: A. Employment (full or part-time); Significant;
Roche Sequencing Solutions, Inc. G. Zhang: A. Employ-
ment (full or part-time); Significant; Roche Sequencing
Solutions, Inc. Z. Li: A. Employment (full or part-time);
Significant; Roche Sequencing Solutions, Inc. C. Hacker:
A. Employment (full or part-time); Significant; Roche
Sequencing Solutions, Inc. J. Han: A. Employment (full or
part-time); Significant; Roche Sequencing Solutions, Inc. J.
Doshi: A. Employment (full or part-time); Significant;
Roche Sequencing Solutions, Inc. K. Kirkconnell: A.
Employment (full or part-time); Significant; Roche Sequen-
cing Solutions, Inc. R. Stokowski: A. Employment (full or
part-time); Significant; Roche Sequencing Solutions, Inc. E.
Martin: A. Employment (full or part-time); Significant;
Roche Sequencing Solutions, Inc..
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Development of matched maternal-fetal non-invasive
prenatal testing (NIPT) reference materials compatible
with a broad range of assay methods
A. M. Caruso1, F. L. Tomson2, Y. Konigshofer2, R.
Santhanam1, R. Garlick1, B. Anekella2
1SeraCare LifeSciences, Milford, MA, United States, 2Ser-
aCare LifeSciences, Gaithersburg, MA, United States
Introduction: The availability of appropriate reference
materials that mimic the characteristics of clinical samples
for proficiency testing, assay validations, and run controls is
very limited. Seracare has developed a new technology and
formulation to provide a sustainable source of patient-like
NIPT reference materials. These materials are compatible
with a broad range of NIPT assay methods and should
enable clinical labs to validate and monitor NIPT assays.
Methods: Antepartum and postpartum samples were
obtained from patients with high-risk pregnancies
under IRB approved protocols. ccfDNA was isolated from
ante- and post-partum samples. This isolated ccfDNA was
amplified, encapsulated by a proprietary lipophilic proce-
dure and blended into a synthetic plasma to create patient-
like samples.
Results: These new NIPT reference materials demon-
strated patient-like fragment distribution (for both maternal
and fetal sizing) with a major peak of around 160-170 bp
and minor peaks above 250 bp. The materials have been
extensively tested by multiple commercial NIPT assays,
such as Harmony (Ariosa), VeriSeq (Illumina) or Panorama
(Natera). The trisomy 21 and 18 were called accurately as
male or female trisomy 21 and female trisomy 18 at fetal
fractions of 11%, 13%, and 18% respectively. We also
created an aneuploidy negative control - female and male
euploid material with fetal fractions at 16.6% and 9.4%.
Conclusions: The SeraCare portfolio of NIPT materials
with patient-like sample attributes are suitable for a broad
range of currently available NIPT methods. The availability
of matched fetal-maternal reference materials is particularly
important for the transition of NIPT into mainstream clinical
practice.
A.M. Caruso: A. Employment (full or part-time);
Significant; SeraCare LifeSciences. F.L. Tomson: A.
Employment (full or part-time); Significant; Seracare. Y.
Konigshofer: A. Employment (full or part-time); Signifi-
cant; Seracare. R. Santhanam: A. Employment (full or
part-time); Significant; Seracare. R. Garlick: A. Employ-
ment (full or part-time); Significant; Seracare. B. Anekella:
A. Employment (full or part-time); Significant; Seracare.
P16.57.C
a novel NIR spectroscopic qualitative method to monitor
the diet compliance in PKU patients
M. F. M. Vismara1, A. Valentini2, G. Bonapace3, O.
Marasco4, G. Scozzafava4, M. Ashour5, M. Pittelli4, T.
Greto4, M. T. Moricca3, S. A. Vismara6, D. Concolino3, N.
Perrotti7
1Department of Histology, University “Magna Græcia”,
Catanzaro, Italy, 2CARAVAGGIO medical center, Roma,
Italy, 3Department of Medical and Surgical Science,
Pediatric Unit, University “Magna Graecia”, Catanzaro,
Italy, 4Centro Regionale di Screening Neonatale, A.O.U.
“Mater Domini”, Catanzaro, Italy, 5Department of Health
Sciences, Nephrology Unit, “Magna Graecia” University,
Catanzaro, Italy, 6Ente Ospedaliero Cantonale del Ticino,
Istituto pediatrico della Svizzera italiana,, Lugano, Switzer-
land, 7Department of Health Sciences, University “Magna
Graecia”, Catanzaro, Italy
Introduction: Phenylketonuria (PKU MIM 261600) is a
human metabolic disease, caused by mutations in the
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phenylalanine hydroxylase gene. Children born with PKU,
thanks to the newborn screening and early dietary inter-
ventions, can have relatively normal lives. The diet allows
them to keep Phe level in range. The best indicator of
dietary compliance is regular monitoring of Phe con-
centrations by using a Liquid Chromatography (LC) based
procedure. We developed a qualitative chemometric model
able to separate PKU patients based on their response to the
diet in three different categories: Low (<2 mg/dl), Com-
pensate (2,5-6 mg/dl) and High (6,5- 20 mg/dl) with NIR
spectroscopy.
Methods and Results: A qualitative chemometric model
was elaborated using 3000 NIR spectra, from 562 DBS
PKU samples from the three different groups, based on their
Phe levels assessed by LC. Using a sensor calibrated in the
Near infra-Red spectrum, 20 scans per sample in duplicate
were acquired. Principal component analysis (PCA) was
conducted. The chemometric model was validated by blind
external procedure. Our model is able to correctly assign
unknown sample to the Low, Compensate, or High group
with a linearity of 0,91 and a σ=0,078, showing a
sensitivity ratio between the number of the correctly
classified samples (CCS) and the number of the known
samples belonging to each class (KS): Sn = CCS⋅100KS
close to 100%.
Conclusions:We demonstrated that it is possible to use
NIR spectroscopy to quickly monitor the diet compliance in
PKU patients.
M.F.M. Vismara: None. A. Valentini: None. G.
Bonapace: None. O. Marasco: None. G. Scozzafava:
None. M. Ashour: None. M. Pittelli: None. T. Greto:
None. M.T. Moricca: None. S.A. Vismara: None. D.
Concolino: None. N. Perrotti: None.
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Analysis of 15q11.2-q13 locus reorganizations
S. Chernushyn1, N. Hryshchenko1, S. Kravchenko1, E.
Patskun2
1Institute of Molecular Biology and Genetics, Kiev,
Ukraine, 2Municipal Non-Profit Enterprise "Transkar-
pathian Clinical Regional Hospital named after Andrii
Novak", Uzhgorod, Ukraine
Introduction: 15q11-q13 is a region harboring several
genes regulated by genomic imprinting, as a result, genes
subject to regulation by genomic imprinting are functionally
haploid, having only a single functional copy. Prader-Willi
syndrome (PWS), Angelman syndromes (AS) and 15q11-
q13.1 duplication syndrome (dup15q) are 3 clinically dis-
tinct disorders associated with multiple anomalies and
intellectual disability typically resulting from CNV of
imprinted genes.
Materials and Methods: Analysis of CNVs in 15q11-
q13 and UPD15 was performed using STR markers
D15S817, D15S1513, D15S822, D15S1002 genotyping.
The STR markers were selected according to their high
heterozygosity and location in the region adjacent of PWS
and AS loci.
Results: The STR markers genotyping in the analyzed
groups revealed 4 PWS patients with maternal UPD15 (iso-
and heterodisomic). Three PWS and one AS had the 15q11-
q13 deletions: paternal del 15q in PWS and maternal del15q
in AS patients. The maternal age of UPD15 patients was
significantly higher (40,3years) than in mothers of del15q
patients (28,4 years). In two AS-like patients with seizures
15q11-q13 duplication was detected, one dup15q was
inherited from the effected mother and another one was a
de novo maternal mutation.
Conclusion: The selected set of STR markers allows
detecting all types of molecular genetic disorders of 15q11-
q13 chromosomal region as well as to differentiate the
mutation type and its origin.
S. Chernushyn: None. N. Hryshchenko: None. S.
Kravchenko: None. E. Patskun: None.
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Update of the EMQN / ACGS best practice Guidelines
for Molecular Analysis of Prader-Willi and Angelman
Syndromes
J. Beygo1, K. Buiting1, S. Ramsden2, R. Ellis3, J. Clayton-
Smith2,4, D. Kanber1
1Institut für Humangenetik, Universitätsklinikum Essen,
Universität Duisburg-Essen, Essen, Germany, 2Manchester
Centre for Genomic Medicine, Manchester University
Hospitals NHS Foundation Trust, Manchester Academic
Health Sciences Centre, Manchester, United Kingdom,
3Department of Medical Genetics, Yorkhill NHS Trust,
Yorkhill Hospital Glasgow, Glasgow, United Kingdom,
4Division of Evolution and Genomic Sciences School of
Biological Sciences University of Manchester, Manchester,
United Kingdom
Prader-Willi (PWS, #176270) and Angelman syndrome
(AS, #105830) are rare neurogenetic imprinting disorders
caused by genetic and epigenetic disturbances affecting the
chromosomal region 15q11q13 which harbours a cluster of
imprinted genes. The parent-of-origin specific expression of
these genes is regulated by an imprinting centre. The
molecular defects include large deletions of 5-7 Mb, uni-
parental disomies, imprinting defects (ID) with or without
imprinting centre deletions, mosaic IDs, point mutations
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 633
and deletions of the UBE3A gene as well as rare chromo-
somal rearrangements. Given the broad nature of the
underlying molecular causes and the different techniques
needed to establish the molecular genetic diagnosis and
hence the recurrence risk, diagnostic of PWS and AS is
challenging. Furthermore, there is increasing need for
proper, universally understandable and standardised diag-
nostic reports. In the light of improvements and new
developments regarding techniques and differential diag-
noses together with reporting standards we updated the best
practice guidelines for the PWS and AS diagnostics. The
guidelines were open for consultation and amendment by
the broad community of labs participating in the annual
European Molecular Genetics Quality Network (EMQN)
schemes for PWS and AS diagnostic and were approved by
the EMQN and the Association for Clinical Genomic Sci-
ence (ASCG).
J. Beygo: None. K. Buiting: None. S. Ramsden: None.
R. Ellis: None. J. Clayton-Smith: None. D.
Kanber: None.
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Mainstreaming genomic reporting in Australia- recom-
mendations from an Australian Genomics working
group
J. M. Fletcher1, K. Bloggs2, L. Gilkes3, J. Harraway4, S.
Mead5, C. Meldrum6, M. Moy7, C. Patel8, D. Tang9, D.
Walsh10
1Genetics and Molecular Pathology,, North Adelaide,
Australia, 2Australian Genomics Health Alliance, Murdoch
Children’s Research Institute, Melbourne, Australia, 3Uni-
versity of Notre Dame, Fremantle, Australia, 4Sullivan
Nicolaides Pathology, Brisbane, Australia, 5NSW Health
Pathology, Sydney, Australia, 6New South Wales Health
Pathology, Newcastle, Australia, 7Partridge General Prac-
tice, Adelaide, Australia, 8Genetic Health Queensland,
Brisbane, Australia, 9Murdoch Children’s Research Insti-
tute, Melbourne, Australia, 10Queen Elizabeth Hospital,
Adelaide, Australia
Introduction: A recent national audit of genetic testing
dispelled the myth that most tests are ordered by genetic
health professionals. Genetic pathology reports can be dif-
ficult to understand, and need to be easily understood by
healthcare providers so they can be used to improve patient
outcomes. Additionally, a new, national health e-resource
now allows patients to independently access their own
pathology results, including genetic results in some
jurisdictions.
Methods: A multi-disciplinary working party was
convened. Example reports and literature were reviewed
through different lenses. Membership comprised general
practitioners, a surgeon, clinical geneticist, genetic coun-
sellor, genomic scientist and genetic pathologists. Flesh-
Kincaid and SMOG were used to analyse report readability.
The Australian Genomics Community Advisory Group
reviewed the model factsheet and recommendations.
Results: The level of information that requestors wanted
in reports was different, with more detail requested by
genetic professionals. All wanted a clear summary of the
findings, with a standardised, consistent order of report
elements. Readability was identified as a major issue. Plain
language is important, but accuracy of genetic information
must be retained in line with accreditation guidelines.
Recommendations were formulated and included a model
laboratory report template and model report interpretation
fact sheet for primary referrers.
Conclusions: Laboratories reporting genomic tests
should simplify their reports as much as possible. Synoptic
reporting for genomic tests should be encouraged. The
matter has been referred to the Royal College of
Pathologists of Australasia for implementation. Australian
Genomics Health Alliance is funded by NHMRC grant
1113531 and the Medical Research Future Fund
J.M. Fletcher: None. K. Bloggs: None. L. Gilkes: None.
J. Harraway: None. S. Mead: None. C. Meldrum: None.
M. Moy: None. C. Patel: None. D. Tang: None. D.
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Sample identity confirmation in MPS workflows using
pxlence’s Human Sample ID Kit
V. Dunon1, F. Coppieters2,1, J. Vandesompele2,1, S.
Lefever2,1
1pxlence bvba, Dendermonde, Belgium, 2Ghent University,
Gent, Belgium
Background: Gene panel, whole exome (WES) and gen-
ome sequencing (WGS) are routinely performed. However,
library preparations are complex and laborious, and prone to
sample mix-ups. Here, we developed and validated an easy
and cost-effective sample identity test for independent
genotyping of 44 SNPs and 6 gender markers.
Methods: Target SNPs were selected based on their
minor allele frequency, exonic location and overlap with the
capture region of various WES enrichment kits. For
compatibility with FFPE DNA and cfDNA samples, short
60-100 bp amplicons were designed. Library preparation is
achieved by a limited-cycle indexing PCR step on universal
tails incorporated in the target-specific primers. We applied
this novel Human Sample ID Kit on 3 FFPE samples, 1 cell-
free reference DNA and 6 GiB reference DNA samples with
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input amounts ranging from 1 upto 20 ng. Performance was
evaluated by paired-end sequencing on a MiSeq instrument.
Results: Excellent homogeneous coverage and on-target
specificity was achieved. For all DNA samples, all SNPs
displayed a coverage higher than 20% of the mean and a
mean on-target rate of 94.3%. More impressively, 93.2% of
the SNPs had a uniform coverage within 2-fold of the mean.
Based on the resulting genotypes, DNA samples could be
unambiguously discriminated and linked to the correspond-
ing exomes.
Conclusions: We developed and validated a novel
sample tracking test for WES and WGS, involving a
ready-to-sequence 2-step multiplex PCR reaction. The
Human Sample ID Kit has a discrimination power of over
1:85,000 and enabled unambiguous discrimination of each
DNA sample.
V. Dunon: A. Employment (full or part-time); Signifi-
cant; pxlence bvba. F. Coppieters: E. Ownership Interest
(stock, stock options, patent or other intellectual property);
Significant; pxlence bvba. J. Vandesompele: E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Significant; pxlence bvba. S. Lefever: E. Own-
ership Interest (stock, stock options, patent or other
intellectual property); Significant; pxlence bvba.
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Sanger validation of NGS variants: is still always
necessary?
A. Arteche-López1, A. Ávila Fernández2, R. Riveiro
Álvarez2, M. López Martínez2, A. Giménez Pardo2, C.
Vélez2, J. Gallego Merlo2, I. García Vara1, B. Almoguera2,
A. Bustamante Aragonés2, F. Blanco Kelly2, S. Tahsin
Swafiri2, E. Rodríguez Pinilla2, I. Lorda Sánchez2, M.
Trujillo Tiebas1, C. Ayuso García2
1University Hospital 12 de Octubre. Fundación Jiménez
Díaz University Hospital, Madrid, Spain, MADRID, Spain,
2Fundación Jiménez Díaz University Hospital, Madrid,
Spain, MADRID, Spain
Introduction: As it has already been reported, Sanger
sequencing validation appears to have limited utility for
good quality single nucleotide variants (SNVs) NGS-
detected. However, more studies are needed for indels
variants and/or copy number variations (CNVs).We present
the largest single-center Sanger validation study, with a
subset data of clinical exomes in 825 characterized cases, in
order to confirm the high concordance expected of our
clinical exome diagnostic tool. We also aim to expand the
validations of our small deletion/duplication variants and
CNVs detected by NGS.
Materials and Methods: Clinical exomes were analysed
from peripheral blood samples using the TruSight One
Sequencing panel (Illumina) or the Clinical Exome Solution
(Sophia Genetics). A total of 1099 good quality NGS-
detected variants (>20X coverage, >20% heterozygosity
and Quality=PASS) and 30 CNVs were further confirmed
by Sanger sequencing and MLPA or array-CGH according
to convenience, respectively. Sequencing primers were
designed manually or with the ExonPrimer tool, and
checked in the SNPchecker program.
Results: Though 11 Sanger discrepancies that required
new primers designs were found, we had 100% con-
cordance for the 858 SNVs (80.16%) and 321 (19.64%)
indel variants analysed (n = 1099). However, we only had a
concordance of 96% for CNVs (n = 30), as we had a false
positive deletion in homozygosis.
Conclusions: NGS is a robust technique for the detection
for good quality SNVs/Indel variants, but validation for
CNVs is still necessary. Limitations of Sanger sequencing
should always be considered. Each laboratory might
stablish their own thresholds before deciding to discontinue
Sanger confirmation studies.
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R. Riveiro Álvarez: None. M. López Martínez: None. A.
Giménez Pardo: None. C. Vélez: None. J. Gallego Merlo:
None. I. García Vara: None. B. Almoguera: None. A.
Bustamante Aragonés: None. F. Blanco Kelly: None. S.
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Lorda Sánchez: None. M. Trujillo Tiebas: None. C.
Ayuso García: None.
P16.68.B
Multisite evaluation of a single-tube SMN1/2 PCR/CE
assay system that assesses copy number and expanded
content for spinal muscular atrophy
K. M. Abbott1, K. A. Kooi1, E. Huisman1, J. N. Milligan2,
H. Zhu2, J. L. Larson2, G. J. Latham2, H. H. Lemmink1
1University Medical Center Groningen, Groningen, Nether-
lands, 2Asuragen, Inc., Austin, TX, United States
Spinal Muscular Atrophy (SMA) is an autosomal recessive
neuromuscular disease that is often fatal before age two.
Approximately 95% of cases are caused by homozygous
deletion of SMN1 exon7. SMN2 is a homolog of SMN1
whose copy number is inversely correlated with disease
severity, making quantification of both genes relevant to
recent breakthrough treatments. Additionally, detection of
three variants - c.*3+80T>G, c.*211_*212del in SMN1
associated with gene duplication, and c.859G>C in SMN2
linked to reduced disease severity - can improve carrier
detection and inform therapy decisions. We evaluated an
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assay that quantifies SMN1 and SMN2 exon7 copy numbers
and the three variants in a single PCR reaction. We used the
AmplideX® PCR/CE SMN1/2 Plus kit to test over 100
whole blood or cell-line DNA samples. PCR products were
separated using Applied Biosystems™ 3730/3730xl Genetic
Analyzers and analyzed with AmplideX Reporter software.
We also compared the included kit calibrator to calibration
using samples from each purification method. Copy number
calls for SMN1 and SMN2 were over 95% concordant with
reference method results over multiple runs. Variant calls
were 100% concordant for all samples with known geno-
types. Performance was similar regardless of calibration
method although calibration with purified samples reduced
variability. The assay accurately and precisely quantified
exon7 for both SMN1 and SMN2 at or above four copies and
detected the three clinically-significant variants in under
four hours from DNA to genotype. The expanded content of
the assay may provide an all-in-one option for laboratories
interested in SMA carrier screening and diagnostics.
K.M. Abbott: None. K.A. Kooi: None. E. Huisman:
None. J.N. Milligan: A. Employment (full or part-time);
Significant; Asuragen, Inc. H. Zhu: A. Employment (full or
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Towards the integration of RNA-seq into diagnostic
pipelines for the identification of pathogenic splicing
variants in Mendelian disorders
C. F. Rowlands1, D. Baralle2, A. G. L. Douglas2, R.
O’Keefe1, S. Hubbard1, T. A. Briggs1, J. M. Ellingford1
1University of Manchester, Manchester, United Kingdom,
2University of Southampton, Southampton, United King-
dom
Background: RNA-seq shows promise as a diagnostic tool
to elucidate the effects of genomic variants impacting pre-
mRNA splicing. However, it remains difficult to speculate
in which disease and tissue types it may be most beneficial
in improving diagnostic yield. We thus aimed to develop a
bioinformatics approach for predicting cross-tissue RNA-
seq suitability for given disease genes of interest.
Methods: To identify characteristics of pathogenic
variation, we compared RNA-seq data from patients with
known splicing defects with control individuals from the
GTEx dataset across whole blood, lymphoblastoid cell line
(LCL) and skeletal muscle. We then devised a gene-specific
approach to predict the RNA sequencing depth required to
achieve sufficient coverage of transcripts for given disease
genes. This was applied to all 285 gene panels listed in the
Genomics England PanelApp repository.
Results: Between 22 and 84 panels were predicted to be
amenable to RNA-seq analysis dependent on tissue choice.
Diseases such as mucopolysaccharidosis showed particular
promise as candidates for RNA-seq-based diagnostics, as 37
M sequencing reads in LCL-based RNA-seq was predicted
sufficient to cover 90% of splice junctions with at least 8
reads in 16 of the 17 panel genes.
Conclusions: We present here a bioinformatics frame-
work for the prediction of RNA-seq suitability across
disease and tissue contexts, which may ultimately facilitate
the appropriate integration of RNA-seq into clinical
diagnostic pipelines.
Funding: Medical Research Council (MRC; 1926882)
CASE PhD studentship with QIAGEN
C.F. Rowlands: B. Research Grant (principal investiga-
tor, collaborator or consultant and pending grants as well as
grants already received); Modest; QIAGEN. D. Baralle:
None. A.G.L. Douglas: None. R. O’Keefe: None. S.
Hubbard: None. T.A. Briggs: None. J.M.
Ellingford: None.
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Splicing analysis of blood RNA can increase diagnostic
rate and resolve variants of uncertain significance
H. A. Wai1, J. Lord1, M. Lyon2, A. Gunning3, H. Kelly1, P.
Cibin1, E. G. Seaby1,4, K. Spiers-Fitzgerald1, J. Lye1, S.
Ellard3, N. S. Thomas1,2, D. J. Bunyan1,2, A. G. L.
Douglas1,5, D. Baralle1,5
1University of Southampton, Southampton, United King-
dom, 2Wessex Regional Genetics Laboratory, Salisbury,
United Kingdom, 3Exeter Genomics Laboratory, Exeter,
United Kingdom, 4Broad Institute of MIT and Harvard,
Cambridge, MA, United States, 5Wessex Clinical Genetics
Service, Southampton, United Kingdom
Introduction: In the setting of single-gene disorders, the
high prevalence of variants of uncertain significance limits
the clinical diagnostic rate of DNA-based sequencing
methodologies. A significant proportion of such variants
may cause disease through disruption of RNA splicing. We
examined the effects on splicing of a large set of variants of
uncertain significance clinically ascertained through diag-
nostic genetic testing. We also compared the experimentally
determined RNA splicing data to bioinformatic predictions
made by several commonly used splicing tools.
Materials and Methods: 257 variants of uncertain
significance were analysed from across three separate
laboratories. Blood RNA was collected in PAXgene tubes
and targeted RT-PCR was undertaken with agarose gel
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electrophoresis and Sanger sequencing analysis of products.
17 samples also underwent RNA sequencing of total RNA
with depletion of globin mRNA and rRNA. Targeted
analysis of splicing was performed on RNA-seq data using
Sashimi plot visualisation. Alamut, HSF 3.1 and SpliceAI
software were used for splicing predictions.
Results: 85/257 (33%) of analysed variants were found to
affect splicing. Skipping of the upstream exon was the most
frequent abnormality (39/85) and this was most often seen
in association with variants within the splice donor region.
SpliceAI had an accuracy of 0.91 and outperformed other
prediction tools in terms of sensitivity and specificity.
Conclusions: Analysis of splicing from blood RNA is
useful in identifying splicing abnormalities that cannot
reliably be predicted from DNA sequence alone. This
provides functional evidence of effect in a significant
proportion of uncertain variants, helping in classification of
pathogenicity. NIHR_RP-2016-07-011.
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Apparently isolated trigonocephaly: diagnostic yield
thanks to Whole Exome Sequencing
F. Di Giovanni1, G. Gori1, G. Traficante2, L. Dosa3, G.
Forzano1, E. Fiorentini1, D. Vergani1, S. Giglio1
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The recent availability of whole exome/whole genome
sequencing has led to the characterization of the molecular
basis of an increasing number of craniosynostosis, although
there is still little information about isolated trigonocephaly.
It usually occurs sporadically and results from the pre-
mature closure of the metopic sutures with consequent
deformation of the anterior calvarium. We describe two
patients (a female and a male) with isolated trigonocephaly.
WES disclosed in both cases a mutation in the PTCH1
gene: a de novo heterozygous frameshift variant in the
female and a heterozygous stop (inherited from the father
later discovered to be affected) in the male. Mutations in
PTCH1 have been found to cause Gorlin syndrome, an
autosomal dominant condition characterized by multiple
basal cell carcinomas, odontogenic keratocysts, skeletal
anomalies, macrocephaly, dysmorphisms and an increased
risk of tumors in early infancy. Skeletal anomalies with
defects in the shape of the skull, ribs and spine are often
described, but clinical data do not refer specifically to the
presence of trigonocephaly which instead is frequently
reported in patients with 9q22.3 deletion. PTCH1, included
in the region, is the only gene for which the deletion is
known to represent most of the features of patients with this
rearrangement. Our report reinforces the clinical utility of
WES even in apparently non-syndromic trigonocephaly: in
fact, the early diagnosis of PTCH1 variants allowed us the
early diagnosis of Gorlin syndrome with consequent prompt
surveillance, since approximately 5% of all children with
variants in this gene develop medulloblastoma.
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Genome-wide association study on glycation and its
implication on the diagnosis of type II diabetes mellitus
S. Ko1, I. Kim1, H. Ahn2, T. Park3, H. Won1, W. Park1, J.
Kim4
1Samsung Advanced Institute for Health Sciences &
Technology, Sungkyunkwan University, Seoul, Korea,
Republic of, 2Department of Life Sciences, Pohang
University of Science and Technology, Pohang, Korea,
Republic of, 3Division of Cardiology, Department of
Medicine, Heart, Stroke and Vascular Institute, Samsung
Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea, Republic of, 4Samsung Genome
Institute, Biomedical Research Institute, Samsung Medical
Center, Sungkyunkwan University School of Medicine,
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For the detection of diabetes, screening for the level of
glucose and glycated hemoglobin (HbA1c) in blood had
been widely used. Several reports showed that HbA1c was
more stable indicator of diabetes than blood glucose, since
HbA1c level depicts the average of blood glucose in 2-3
months. However, it has not been critically tested whether
genetic predisposition to glycation differs among indivi-
duals, which would alter the HbA1c levels given the same
glucose levels. To answer this question, we here investi-
gated ~270K individuals with 1,892 cases of type 2 diabetes
(T2D) in UK Biobank for the blood glucose and HbA1c,
and their associated single nucleotide polymorphisms
(SNPs). We discovered that 2,349 SNPs were associated
only with HbA1c level (dubbed as glycation SNPs), while
2,407 and 720 lead SNPs were associated with HbA1c and
glucose, respectively. These glycation SNPs were related to
genes such as SPTA1, SPTB, and ANK1, indicating their
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functional implication on glycation. We further built poly-
genic risk score (PRS) from the glycation SNPs, which
performed as an indicator of the deviated HbA1c levels
given the same glucose level across different individuals. In
addition, we categorized individuals into several groups
along with the PRS, and showed that those groups should
have different criteria of HbA1c level to maintain equiva-
lent sensitivity and precision of diabetes diagnosis. We
believe that our approach provides insights into persona-
lized diagnosis of complex diseases.
S. Ko: None. I. Kim: None. H. Ahn: None. T. Park:
None. H. Won: None. W. Park: None. J. Kim: None.
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Applying PP1 to variants where internal cosegregation
data exists at CHEOGenetics Diagnostic Laboratory
L. Little, L. Bronicki, O. Jarinova, A. Smith, L. Huang, J.
McGowan-Jordan
CHEO, Ottawa, ON, Canada
Introduction: The “PP1” variant classification criteria
created by the American College of Medical Genetics and
Genomics (ACMG) and Association of Molecular Pathol-
ogy (AMP) can be used as supporting, moderate or strong
level of evidence towards pathogenicity if a variant cose-
gregates with disease in multiple affected family members
in a gene definitively known to cause the disease. Appli-
cation of PP1 has improved the quality of variant inter-
pretation if evidence towards cosegregation exists in the
literature. However, the CHEO Genetics Diagnostic
Laboratory does not currently apply PP1 when cosegrega-
tion of a variant is observed in a family tested internally.
Several obstacles were identified in implementing the use of
PP1 for internal data, including the statistical evaluation of
cosegregation, which is not easily computable by most
laboratory personnel. Therefore, a protocol was designed to
address these obstacles and create a standardized process.
Materials and Methods: Specific cutoffs for pathogeni-
city were chosen, as informed by Jarvik et al. (2016). A
retroactive chart review was performed on variants where
≥2 family members were tested internally. PP1 was applied
when appropriate.
Preliminary Results: PP1 was applied to 3/3 likely
pathogenic (LP) variants and 7/11 variants of uncertain
clinical significance (VUS). Of these, all LP variants were
upgraded to pathogenic and 5 VUS’s were upgraded to
likely pathogenic.
Conclusions: Using a standardized protocol for applying
PP1 when evidence of cosegregation exists internally has
improved the overall quality of variant interpretation at
CHEO Genetics Diagnostic Laboratory, and can alter
clinical management for patients and their families.
L. Little: None. L. Bronicki: None. O. Jarinova: None.
A. Smith: None. L. Huang: None. J. McGowan-
Jordan: None.
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PanelApp: accelerating international consensus on
virtual gene panels through collaboration on a federated
open platform
Z. Stark1,2,3, R. E. Foulger4,5, E. Williams4,5, B. Thompson6,
C. Patel7, I. U. S. Leong4, L. C. Daugherty4,5, S. Leigh4, C.
Snow4,5, C. Boustred4, O. Niblock4, A. Rueda-Martin4, O.
Gerasimenko4, E. Ivanov4, K. Savage4, W. Bellamy4, V. San
Kho Lin8, R. Valls8, L. Gordon8, H. Brittain4, R. H. Scott4,
E. R. A. Thomas4, A. de Burca4, A. L. T. Tavares4, Z.
Hyder4, M. McEntagart4, C. Turnbull4, S. M. White1,3, T. Y.
Tan1,3, A. Yeung1, L. Downie1,3, S. Lunke1,3, J. Deller9, Z. C.
Deans9,10, S. L. Hill9, M. J. Caulfield4, K. N. North11,2,3, A.
Rendon4,5, O. Hofmann8,2, E. M. McDonagh4
1Victorian Clinical Genetics Services, Melbourne, Austra-
lia, 2Australian Genomics Health Alliance, Melbourne,
Australia, 3University of Melbourne, Melbourne, Australia,
4Genomics England, London, United Kingdom, 5Genomics
England Biodata Innovation Centre, Cambridge, United
Kingdom, 6Royal Melbourne Hospital, Melbourne, Austra-
lia, 7Genetic Health Queensland, Brisbane, Australia,
8Centre for Cancer Research, University of Melbourne,
Victorian Comprehensive Cancer Centre, Melbourne,
Australia, 9National Health Service England, London,
United Kingdom, 10National Health Service Improvement,
London, United Kingdom, 11Murdoch Children’s Research
Institute, Melbourne, Australia
Introduction: Robust gene-disease validity assessments are
the foundation of accurate variant interpretation in diag-
nostic genomics. Virtual gene panels for specific clinical
indications improve the efficiency of genomic analysis, yet
there is wide variability in the processes for panel creation
and maintenance, and in panel content.
Methods: PanelApp is an open platform for virtual gene
panel curation that captures structured gene-disease validity
assessments, with evidence thresholds governing gene
inclusion in panels. Developed by Genomics England for
the 100,000 Genomes Project, it is now used by the NHS
Genomic Medicine Service, and has been deployed by
Australian Genomics for use by Australian diagnostic
laboratories. We have established a collaboration to enable
technical co-development and systematic comparison of
virtual panels between the two PanelApps, sharing expert
reviews to accelerate discordance resolution.
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Results: Of the 511 virtual gene panels in the two
PanelApps, 79 panel pairs cover directly comparable
clinical indications; 182 panels are partially comparable;
171 panels are unique. Of the first 20 panels compared, 709
discrepant genes were identified. Sharing expert reviews has
resulted in inclusion of 285 new genes for diagnostic use,
and removal of 186, with curation ongoing. Common
reasons for discrepant gene ratings include differences in
panel scope definition; differential weighting of functional
evidence; and challenges in systematic timely identification
of new evidence establishing or refuting gene-disease
associations.
Conclusions: We have accelerated improvements in
evidence-based diagnostic genomics in two healthcare
systems through a federated open platform that supports
shared expert curation of virtual gene panels, while
retaining separate governance.
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The influence of storage conditions on WBCs transcrip-
tome profiles
X. Yanru1,2, Y. Xi2, C. Haixiao2, Z. Sujun3, X. Jinjin2, C.
Yuan2, Z. Juan3, C. Fang2, J. Hui2, W. Wen-Jing2
1School of Future Technology, University of Chinese
Academy of Sciences, Beijing, China, 2BGI-Shenzhen,
Shenzhen, China, 3Obstetrics Department, Shenzhen Mater-
nity and Child Healthcare Hospital, Shenzhen, China
Introduction: Transcriptome levels of white blood cells
(WBCs) play an important role in disease diagnosis, prog-
nosis and biomarker discovery research. Peripheral blood is
usually collected and treated for further experiments, but the
effect of storage conditions on WBCs transcriptome
remains largely unknown.
Methods: Blood samples from healthy donors were drawn
into EDTA tubes and stored at both 4°C and room temperature
(RT, 18-22°C) for 0h, 2h, 6h and 24h. Total cellular RNA was
extracted from WBCs after red blood cells lysis, and
transcriptome profiles were assessed by RNA sequencing.
Results: Compared with samples treated immediately, the
proportion of neutrophils decreased, but that of T cells
increased in the samples stored at RT for 24h. Samples
maintained at 4°C were less influenced than that at RT
within 24h. We identified 1428 up-regulated and 86 down-
regulated genes at 4°C, while there were 4493 genes up-
regulated and 5982 genes down-regulated at RT. Up-
regulated genes at 4°C were mostly related to HDACs
deacetylate histones, and that at RT were mostly related to
mRNA processing. Genes down-regulated at RT were
mostly due to leukocyte activation involved in immune
response. Reference genes such as CHMP2A and PSMB4
were relatively stable, while the expression of IL1RN,
which was similar in both men and women, increased more
in women than men after 24h stored at RT.
Conclusions: We provide a full-scale ex vivo change of
WBCs expression profiles, and suggest that these influences
should not be ignored in relative studies.
Funding: Shenzhen Municipal Government of China
(No.JCYJ20170412152854656).
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Modelling diagnostic yield in the 100,000 Genomes Rare
Disease Project using panel-based analysis and comple-
mentary approaches
E. R. A. Thomas1,2,3, D. Pasko1, C. Boustred1, D.
Kasperaviciute1,2, M. Bleda1, A. Rueda Martin1, D.
Smedley1,2, E. McDonagh1, H. Brittain1,4, A. Tucci1,5, Z.
Deans6, S. L. Hill6, T. Fowler1,2, A. Rendon1,7, M. J.
Caulfield1,2, R. H. Scott1,2,8, Genomics England Research
Consortium
1Genomics England, London, United Kingdom, 2Queen
Mary University of London, London, United Kingdom,
3Imperial College Healthcare NHS Trust, London, United
Kingdom, 4Birmingham Women’s and Children’s Hospital,
Birmingham, United Kingdom, 5University College London,
London, United Kingdom, 6NHS England Genomics Unit,
London, United Kingdom, 7University of Cambridge,
Cambridge, United Kingdom, 8Great Ormond Street
Hospital, London, United Kingdom
Background: The 100,000 Genomes Project Rare Disease
programme developed a gene panel-based analysis strategy
aiming to maximise specificity and sensitivity of automated
variant prioritisation before manual review by NHS clinical
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scientists. HPO terms were collected prior to analysis. Over
35,000 families have been analysed using this approach.
Methods: Using >950 confirmed genetic diagnoses in
patients with intellectual disability, we modelled the
outcome of different strategies for automated prioritisation
and manual review, focused on diagnostic sensitivity.
Results: 87% of genetic diagnoses were prioritised using
a single gene panel selected for the original diagnostic
hypothesis. The primary reason for non-prioritisation was
that the causative gene was in a different panel; sensitivity
increased to 92% using automated HPO-based rules to
apply additional panels.
Neuromuscular disorders (analysed with smaller
phenotype-specific panels) gave a panel-based yield of
38%, increasing to 71% with one broad panel.
Diagnoses of metabolic and mitochondrial conditions,
some treatable, were made where these conditions were
compatible with the phenotype data but outside the gene
panel for the primary diagnostic hypothesis.
Of the 13% with non-prioritised diagnoses, 72% were
trios or larger family structures; we will discuss the impact
of family structure on diagnostic yield.
For families where trio testing is not possible, phenotype-
based variant ranking algorithms such as Exomiser
contribute.
Conclusions: No single analysis strategy can identify all
diagnoses. Collecting detailed phenotype data at the time of
test initiation permits a multi-faceted strategy combining
broad gene panels, bespoke panel assignment, phenotype-
based prioritisation, and gene agnostic analysis, to max-
imise diagnostic yield.
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Validation of Clinically Relevant Variant Detection from
Whole Genome Sequencing for NHS England’s Geno-
mic Medicine Service
D. Kasperaviciute1,2, K. R. Smith1,2, K. Ibanez1,2, D. Pasko1,
M. Bleda1, S. Walker1, D. Polychronopoulos1, A. Rueda
Martin1, M. Kayikci1, J. Lopez1, E. Thomas1,2,3, E. Baple1,
A. Tucci1,2, R. H. Scott1,4, J. Polke5, R. Labrum5, L. Santos5,
K. Eggleton5, D. Mcmullan6, D. Morrogh7, J. W. Ahn8, Z.
Deans9, S. Hill9, M. J. Caulfield1,2, A. Rendon1,10, Genomics
England Research Consortium
1Genomics England, London, United Kingdom, 2Queen
Mary University of London, London, United Kingdom,
3Imperial College Healthcare NHS Trust, London, United
Kingdom, 4Great Ormond Street Hospital, London, United
Kingdom, 5Neurogenetics Unit UCL Institute of Neurology,
London, United Kingdom, 6West Midlands Regional
Genetics Laboratory, Birmingham Women’s and Children’s
Foundation Trust, Birmingham, United Kingdom, 7North
East Thames Regional Genetics Service, Great Ormond
Street Hospital for Children, NHS Foundation Trust,
London, United Kingdom, 8East Midlands and East of
England NHS Genomic Laboratory Hub, Cambridge
University Hospitals NHS Foundation Trust, Cambridge,
United Kingdom, 9NHS England, London, United Kingdom,
10Department of Haematology, University of Cambridge,
Cambridge, United Kingdom
Introduction: Standard benchmarking approaches for
whole genome sequencing (WGS) variant detection are not
sufficiently informative for rare pathogenic variants that fall
outside “high confidence” regions or represent classes of
variation absent from the truth sets. While developing the
new WGS pipeline as part of a new genomic medicine
service for England’s National Health Service, we validated
the variant detection of other diagnostically important
classes of variants.
Materials and Methods: The detection of diagnostic
variants was assessed using genome data from 100,000
Genomes project participants with diagnostic variants
detected and/or confirmed by orthogonal methods.
Results: The sensitivity of diagnostic variants detection
was as following: de novo small variants 99.4% (CI 98.43-
99.96%, N = 354), mitochondrial small variants 100% (CI,
82.92-100%, N = 10), pathogenic CNVs >10kb size 97.1%
(CI 93.71-99.28%, N = 136). The STR detection of full
expansions in 13 loci reached sensitivity and precision of
100% (CI 88.8-100%, 16 positive and 428 negative
controls), however, the sensitivity was tested in controls
identified by the earlier version of the WGS pipeline and
confirmed by orthogonal methods, and therefore may be
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overestimated. We further show high reproducibility of
CNV and STR calling using 80 monozygotic twin pairs.
Conclusions: We show high sensitivity, and, where
possible, precision, of our rare disease pipeline to identify
clinically relevant variants in families with rare disease. We
also present a framework for validation of WGS pipelines
for clinical service, and highlight the challenges posed by
the lack of unbiased truth sets of diagnostically relevant
variants.
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The contribution of whole genome sequencing in
establishment of genetic diagnosis in undiagnosed
patients with rare genetic disorders
A. Maver, G. Bergant, B. Peterlin
Clinical institute for Medical Genomics, Ljubljana, Slove-
nia
A significant proportion of patients with rare genetic dis-
orders remain undiagnosed despite comprehensive genetic
testing using exome sequencing (ES). It is known that
pathogenic genetic variants may reside in non-coding
regions or may arise due to mutational mechanisms not
detectable using ES. We therefore aimed to characterize the
utility of whole genome sequencing (WGS) in diagnosing
exome-negative patients. We performed WGS in a 30
patients with negative ES result and high suspicion of
genetic etiology based on one of the following inclusion
criterions: (1) observation of multiple affected family
members, (2) a specific diagnosis with high probability of
genetic etiology, (3) presence of significant blocks of
homozygosity, or (4) observation a single pathogenic var-
iant in a gene associated with recessive inheritance. We
developed an in-house pipeline for analysis of sequence
variation in WGS and have extended it with approaches for
analysing structural variation (including translocations and
retrotransposition events), polynucleotide expansions,
mitochondrial variation and artificial intelligence-based
splice variant effect prediction approaches. Among
30 selected patients, we identified the molecular cause in 9
(30.0%) using WGS. We detected deep intronic pathogenic
variants in 2 patients, a pathogenic promoter variant in 1
patient, a small structural variant in 1 patient, a complex
rearrangement in 1 patient, a translocation in 1 patient,
polynucleotide expansions in 2 patients and a retro-
transposition event in 1 patient. The results of our study
indicate that WGS may represent a valuable approach to
establish a diagnosis in a carefully selected subset of
patients with a negative ES result.
A. Maver: None. G. Bergant: None. B. Peterlin: None.
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A convolutional neural network based model to predict
allele-specific expression by regulatory sequence
Z. Zhang1,2, J. van der Velde1,2, GoNL consortium, BIOS
consortium, R. Sinke1, M. Swterz1,2
1University Medical Center Groningen, Groningen, Nether-
lands, 2Genomics Coordination Centre, Groningen, Nether-
lands
Allele-specific expression (ASE) refers to the imbalanced
abundance of allelic copies from one transcript. It is the
consequence of many regulation events such as cis-
regulatory variants. Recent studies imply its potential
roles in diseases and practical value in genome diagnostics.
However, routine genome diagnostics heavily depend on
DNA sequencing and usually ignore the regulation of gene
expression which can be indicated by ASE. Therefore, a
well-developed prediction model is capable to attribute the
value of ASE to the successful genome diagnosis.
We here report on a deep learning model built to
understand how the ASE effects of a transcript associated
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with the adjacent regulatory elements using NGS DNA
haplotypes obtained from the Genome of the Netherlands
project and RNA sequencing results from Biobank-based
Integrative Omics Studies. Then, given a transcript, for
paternal and maternal alleles, the ASE effects are quantified
from the RNA sequencing results and potential regulatory
sequences are acquired from whole-genome sequencing
results. Finally, we are piloting a convolutional neural
network, which values the objects in an image-like two-
dimension matrix (in our case, it is the regulatory sequence)
to distinguish one from the other. We also plan to apply the
model on diseases-related genes or transcripts to evaluate its
added value to the diagnosis. Ideally, the model can
contribute to the genome diagnostics and general biological
studies by supplying functional interpretation that exploits
expression evidence. This study is supported by the Chinese
Scholarship Consortium and NWO-VIDI grant.
Z. Zhang: None. J. van der Velde: None. R. Sinke:
None. M. Swterz: None.
P17.005.C
Conditional estimation of the contribution of genomic
annotations to common complex diseases
M. Patxot1, A. Kousathanas1, S. E. Ojavee1, D. Trejo
Banos1, M. R. Robinson2
1University of Lausanne, Lausanne, Switzerland, 2Institute
of Science and Techonology Austria, Vienna, Austria
Despite efforts to estimate the contribution of genomic
regions to common complex trait variation, the distribution
of effect sizes across functional annotations remains
unknown. Previous studies estimate enrichment across
annotations in a series of follow-up analyses rather than
utilizing functional information to assess enrichment con-
ditional on the rest of the genome.
Here, we introduce a scalable Bayesian model that utilizes
genomic annotations and individual-level data to jointly
estimate marker effects while accounting for LD. SNP
effects for each annotation group are modelled as a series of
normal distributions providing inference on the genetic
architecture of genomic enrichment. Effect size distribu-
tions can be compared across annotations and the genetic
variance for each group simultaneously quantified.
In simulations we demonstrate our method gives unbiased
estimates of annotation enrichment under extreme LD
scenarios. We apply the model to height, body mass index
(BMI), type-2-diabetes (T2D) and coronary artery disease
(CAD) in the UK Biobank. We find a stark contrast between
BMI and height: BMI being highly polygenic with tiny
effect sizes located 10 to 1000 kb from exons whereas
height shows a variety of effect sizes in coding and non-
coding regions. T2D and CAD are highly polygenic and we
also observe that promoter regions contribute less than 5%
to the phenotypic variance of all four traits.
This method provides a full quantification of genetic
architectures underlying complex traits and determines
which genomic regions are influential, improving disease
risk prediction.
This work was funded by an SNSF Eccellenza Grant
(PCEGP3_181181) to M.R.R.
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Automated re-analysis of over 7,500 exomes and
genomes within Solve-RD demonstrates its power to
deliver diagnosis for rare disease patients
L. Matalonga1, D. Danis2, S. Li3, D. Piscia1, C.
Hernandez1, R. Tonda1, S. Laurie1, I. Gut4, K. van der
Velde3, A. Topf5, R. Schüle6, M. Synofzik6, L. Vissers7, R. de
Voer8, P. Robinson2, H. Graessner9, A. Hoischen10, S.
Beltran4
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Barcelona Institute of Science and Technology (BIST),
Barcelona, Spain. Universitat Pompeu Fabra (UPF),
Barcelona, Spain, Barcelona, Spain, 5John Walton Muscu-
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Research Institute, Newcastle University, Newcastle upon
Tyne, UK, Newcastle, United Kingdom, 6Department of
Neurodegenerative Diseases, Hertie-Institute for Clinical
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Tübingen, Tübingen, Germany; German Center for Neuro-
degenerative Diseases (DZNE), University of Tübingen,
Tübingen, Germany, Tübingen, Germany, 7Department of
Human Genetics, Donders Centre for Neuroscience, Rad-
boud University Medical Center, Nijmegen, The Nether-
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Genetics, Radboud Institute for Molecular Life Sciences,
Radboud University Medical Center, Nijmegen, The Nether-
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ics and Applied Genomics, University of Tübingen,
Tübingen, Germany; Centre for Rare Diseases, University
Hospital of Tübingen, Tübingen, Germany; European
Reference Network for Rare Neurological Diseases,
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Tübingen, Germany, 10Department of Human Genetics,
Radboud University Medical Center, Nijmegen, The Nether-
lands. Radboud Expertise Center for Immunodeficiency and
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boud University Medical Center, Nijmegen, The Nether-
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Exome and genome sequencing is a cost-effective approach to
shorten the time to diagnosis for rare disease patients. Data
analysis and interpretation is one of the main challenges and
still many cases remain unsolved. However, scientific knowl-
edge evolves rapidly and periodic data reanalysis has been
shown to increase the diagnostic yield by up to 5-10%.We
have reanalysed 7,495 genomic datasets from unsolved rare
disease patients and relatives submitted in the context of the
"Solve-RD - solving the unsolved rare diseases" project. Data
was processed through the RD-Connect Genome-Phenome
Analysis platform (GPAP: https://platform.rd-connect.eu/), and
reanalysed using different innovative bioinformatics approa-
ches that enable variant filtering and prioritisation combining
genomic and clinical data: i) VFPS, a programmatic approach
integrated with the GPAP ii) Exomiser, a tool for phenotype-
driven prioritisation of disease-causing variants and iii)
CAPICE, a computational method for consequence-agnostic
pathogenicity estimation. A consensus output with a minimal
set of variant annotations has been defined for all approaches to
further facilitate data interpretation and results feedback. Can-
didate variants are made available in a secured cloud to clinical
researchers of the four participating European Reference Net-
works (euro-NMD, ITHACA, RND and GENTURIS) for data
interpretation. Preliminary results on the VFPS approach,
where more than 2500 candidate variants from 1700 patients
have been returned, already provided diagnosis for 3-8% of
patients. Solved cases are being used to train and improve the
tools’ algorithms. Solve-RD (H2020-779257)
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GenerAVI: Variant Interpreter and Genetic Analysis
Summary Generator
B. Salman1, C. Holyankin1, G. Haryanyan1, M. Say1, E.
Celik1, D. Bozkulak1, S. A. U. Iseri2
1Gen Era Diagnostics, Bioinformatics Department, Istan-
bul, Turkey, 2Istanbul University, Aziz Sancar DETAE,
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One of the most challenging tasks in the area of clinical
genetics is to determine the pathogenicity of genetic varia-
tions and provide standardized clinical evaluation for the
genetic data. Therefore, we have developed the GenerAVI.
v2 tool for the automatic interpretation of bulk variants by
American College of Genetics and Genomics (ACMG)
criteria. The GeneraAVI.v2 also allows users to make their
own interpretation and stores them in a disease-specific
manner. The GenerAVI.v2 is developed using C++ and
Python. The platform uses vcf files as the file input. After
preliminary filtering based on quality and previously known
false-positive calls, all variants are annotated using Ensembl
Variant Effect Predictor. Disease-specific allele frequency,
relative position on the gene, in silico pathogenicity tool
metrics, ClinVar records, and more parameters are used for
automated ACMG classifications. GeneraAVI.v2 tool can
automatically evaluate and report all variants detected in
terms of 15 known ACMG criteria. It also analyzes by
modified PVS1 criteria which are based on the non-
mediated-decay pathway and alternative splicing events. It
also allows users to make their own assessments for criteria
that cannot be automated. The tool keeps track of each
curation made and uses these evaluations in future analysis.
The GenerAVI.v2 tool helps researchers and clinicians to
easily create genetic analysis reports with automated
ACMG classifications and generate dynamic internal fre-
quency and clinical interpretation database.
B. Salman: None. C. Holyankin: None. G. Haryanyan:
None. M. Say: None. E. Celik: None. D. Bozkulak: None.
S.A.U. Iseri: None.
P17.010.B
Mobile elements identification in genes from exome
sequencing data of patients affected with developmental
and/or neurological abnormalities
P. Garret1,2, E. Tisserant1,3, P. Vabres1,4,5, O. Prevel1,5, C.
Philippe1,3, A. Boughalem2, J. Costa2, D. Trost2, A.
Vitobello1,3, L. Faivre1,6, C. Thauvin-Robinet1,3,7, Y.
Duffourd1,3
1UMR1231 GAD, Inserm, 21070 Dijon, France, 2Labor-
atoire CERBA, Saint-Ouen l’Aumône, France, 3Unité
Fonctionnelle Innovation en Diagnostic génomique des
maladies rares – FHU-TRANSLAD – Dijon University
Hospital, Dijon, France, 4Centre de Référence maladies
rares « maladies dermatologiques en mosaïque » – service
de dermatologie – FHU-TRANSLAD – Dijon University
Hospital, Dijon, France, 5Service Dermatologie – Dijon
University Hospital, Dijon, France, 6Centre de Référence
maladies rares « Anomalies du développement et syn-
dromes malformatifs » – centre de génétique – FHU-
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TRANSLAD – Dijon University Hospital, Dijon, France,
7Centre de Référence maladies rares « déficiences intellec-
tuelles de cause rare » – centre de génétique – FHU-
TRANSLAD – Dijon University Hospital, Dijon, France
Introduction: About 27% of the human genome is com-
posed of mobile elements (MEs), which can create genomic
instability leading to genetics diseases. The mechanism of
LINE1, Alu or SVA insertion has been described in several
pathologies. It has been estimated that about 0.3% of all
mutations are due to de novo insertion. Nowadays, the mas-
sive development of high-throughput sequencing provides the
opportunity to identify new MEs insertions on large scale.
Methodology: Exome sequencing (ES) data from
patients affected with developmental and/or neurological
abnormalities has been analyzed by MELT, a tool
identifying MEs insertions. The results were filtered by
frequency, impacted region and gene function.
Results: ES data from 3,322 individuals (2,500 probands)
were analyzed. 496,312 possible MEs were detected. After
filtering, 516 probands with 1,070 rare MEs in non-intronic
regions were obtained. Following phenotype comparison and
PCR validation, 3 candidates were kept. The most convincing
was found in a suspected consanguineous patient referred for
poikilodermia. An homozygous insertion was identified in
FERMT1 gene involved in Kindler syndrome, a condition
belonging to the class of poikilodermia. In two other patients,
an exonic and a 3’UTR insertions were identified in 2 genes
involved respectively in mental retardation/epileptic encepha-
lopathy and epilepsy. RNA-Seq analyzes are ongoing to study
transcriptional consequences.
Conclusions: This project aims to identify new insertions
in genes and highlight the interest to include MEs detection
in ES pipeline to reduce diagnostic wavering. This work on
preexisting ES data represents an additional argument in
favor of ES suitability as an unique exam.
P. Garret: None. E. Tisserant: None. P. Vabres: None.
O. Prevel: None. C. Philippe: None. A. Boughalem:
None. J. Costa: None. D. Trost: None. A. Vitobello:
None. L. Faivre: None. C. Thauvin-Robinet: None. Y.
Duffourd: None.
P17.011.C
Whole-genome sequencing and bioinformatics analysis
of M.tuberculosis multi-drug resistant strains from
Kazakhstan
U. Kairov
Lab of Bioinformatics and Systems Biology, CLS, NLA,
Nur-Sultan, Kazakhstan
1 Laboratory of Bioinformatics and Systems Biology, CLS,
NLA, Nazarbayev University, Nur-Sultan, Kazakhstan.2
Laboratory of Plants Genomics and Bioinformatics, NCB,
Nur-Sultan, Kazakhstan.3 Laboratory of Genomic and
Personalized Medicine, CLS, NLA, Nazarbayev University,
Nur-Sultan, Kazakhstan
Introduction: Tuberculosis (TB) is an infectious disease of
bacterial etiology, remains a significant public health
problem worldwide. Drug-resistant TB is a public health
problem in the Kazakhstan and drug susceptibility testing
and genotyping methods of M.tuberculosis (MTB) play
important role in tuberculosis treatment and control for TB
transmission. It is extremely important to determinate
susceptible and resistant strains with different mutations in
genes encoding drug metabolism of MTB strains in
Kazakhstan.
Materials and Methods: The whole genome sequencing
data from 8 multidrug-resistant (MDR) clinical isolates of
MTB were examined.
Results: Known pathogenic and novel variants were
found. Genomic variants (SNPs and InDels) in de novo
assembled and annotated whole-genomes and specific/novel
variants in drug-resistant genes of MDR strains from
Kazakhstan were observed. MDR clinical isolates of the
Beijing family and their complete genomes were studied for
the first time in Kazakhstan.
Conclusions: These findings may provide a basis for
expansion of the reference MTB database, and further
investigation of virulence and transmissibility patterns in
MDR strains. This study may provide a basis for creation of
the reference database, the subsequent study, and compar-
ison with the different drug-resistant isolates circulating in
Kazakhstan. This work highlights the importance of
expanded targets for drug resistance detection in MTB
isolates.




Multi-dimensional biomarker machine learning tool for
immune-oncology: combinatorial gene expression pre-
dict patient’s survivability
P. Stempor1,2, P. Dobosz3,4,2
1The Gurdon Institute, University of Cambridge, Cam-
bridge, United Kingdom, 2SmartImmune LTD, Cambridge,
United Kingdom, 3Department of Haematology, Oncology
and Internal Diseases, Medical University of Warsaw,
Warsaw, Poland, 4Paediatric Haemato-Oncology, Oncol-
ogy Department, Cancer Research Centre, Sheba Medical
Centre Hospital, Ramat Gan, Israel
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Introduction: Checkpoint blockade immunotherapy, which
utilizes immune system to selectively destroy tumour cells,
becomes an effective treatment for cancer. However, suc-
cess rate is low: many patients do not respond, whereas
others suffer from adverse effects. Immune response is
mediated by immunological synapse - checkpoint proteins
interface between lymphocytes and antigen presenting cells.
Understanding complex interactions within immunological
synapse will yield new biomarkers, with application to
clinical trials optimization, companion diagnostics to
existing drugs and better combination therapies.
Materials and Methods: We developed a computational
method that infers gene interaction networks from expres-
sion profiles in large cohorts of patients using unsupervised
Bayesian machine learning model. Our method also reduces
the dimensionality of data producing factors that represent
differences between cancer sub-types and individual
patients. We apply this method to bladder and kidney
carcinoma TCGA cohorts.
Results and Conclusions:We used the panel of 21 genes
expressed on cancer side of immunological synapse and 3
transcription factors that regulate them. We found that a
combinatorial markers have significantly better predictive
power for patient survivability rate in comparison to single
gene expression: p-value of 0.0002 for KIRC and 0.0076
BLCA cohorts. Further, we build de-novo gene interactions
networks from expression data and analysed influence
(loadings) of genes on our combinatorial model in context
of other co-expressed genes. Combinations containing
NFE2L2, ICOSLG and PD-L1 are particularly predictive
in KIRC, and NFE2L2 and VISTA in BLCA. Hence, we
show utility of machine learning tools to generate
combinatorial, multi-dimensional biomarkers from gene
expression measurements.
GrantRefs: https://orcid.org/0000-0002-9464-7475
P. Stempor: E. Ownership Interest (stock, stock options,
patent or other intellectual property); Modest; SmartIm-
mune LTD. P. Dobosz: E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
SmartImmune LTD.
P17.013.B
Softclipping of gene specific primers after primer
extension enrichment to remove artificial sequences
from downstream analysis
J. Rehker, M. Ball, C. Heydt, R. Büttner, S. Merkelbach-
Bruse
University Hospital Cologne, Cologne, Germany
Primer based amplification of genomic target regions suf-
fers from the fact that the primer sequence is initially
indistinguishable from amplified captured sequence of the
specimen. This might result in artifacts and undetected
variants when amplicons overlap each other as variant
callers take both into account, thereby reporting either
incorrect allelic fractions or not calling the variant at all.
Multiplex PCR as well as primer extension enrichment
suffer from this drawback. Multiple tools are available that
trim adapters from raw sequence. However there is an
advantage to soft clip primers after alignment as it allows
for more accurate indel detection at the ends of a captured
fragment. Multiple open source tools are available for soft
clipping of PCR primers based on the alignment start/end
position, but they do not seem applicable for primer
extension enrichment. We therefore developed PESC (Pri-
mer Extension Soft Clipper). It matches the starting position
and length of the primer to the alignment of read one. The
primer is softclipped. The tool then continues to check the
end of read two of the same readpair for overlap with the
identified primer and soft clips it as well. PESC is written in
Python and can remove primers at a speed of ~1.2 million
reads / minute on a regular desktop computer given a primer
file for detection of tumor mutational burden with ~19000
entries. With a memory footprint of 13.7 MB in this setup it
should integrate well into sequencing pipelines.
J. Rehker: None. M. Ball: None. C. Heydt: None. R.
Büttner: None. S. Merkelbach-Bruse: None.
P17.014.C
Biological constraints on GWAS SNPs at suggestive
significance thresholds reveals additional BMI loci
R. Hammond, A. D. Wells, S. F. A. Grant
Children’s Hospital of Philadelphia, Philadelphia, PA,
United States
GWAS requires increasingly larger sample sizes to over-
come extensive correction for multiple testing in order to
uncover additional signals. As an alternative, we aimed at
salvaging suggestive association signals in a series of
increasingly powered BMI GWAS efforts by intersecting
our ATAC-seq and high-resolution promoter-focused Cap-
ture C datasets. The biological constraint of insisting each
SNP both coincide with open chromatin and be contacted
directly by a gene promoter at sub-1kb resolution triaged
the vast majority of SNPs, leaving a manageable residual
number for further interpretation. Conducting retrospective
analyses utilizing three published GIANT BMI GWAS
efforts of increasing sample size from 2010, 2015 and 2018,
we characterized promoter contacts with open SNPs at
varying suggestive sub-threshold P-values from 5 × 10−7 to
5 × 10−4 in cell types relevant to neuronal, endocrine and
immune function. We identified sub-threshold signals in the
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2010 dataset corresponding to 14 BMI loci that only
achieved genome-wide significance in 2015, including
NAV1, SCG3, PRKD1 and NLRC3. Similarly, extending our
2010-based observations to the 2018 dataset we observed
64 loci. Furthermore, analyzing the 2015 dataset, we iden-
tified 160 sub-threshold loci that went on to achieve
genome-wide significance in 2018. The proportion of
implicated SNPs, of course, varied with the given thresh-
olds, with the most notable outcome being 90% of 2010
biologically-constrained independent P < 5 × 10−5 signals
going on to be genome-wide significant in 2018. Finally,
applying this approach to the latest 2018 dataset implicated
multiple independent novel loci. In conclusion, placing
biological constraints on sub-threshold signals revealed
additional loci in existing GWAS datasets.
R. Hammond: None. A.D. Wells: None. S.F.A.
Grant: None.
P17.015.A
Genomics analyses on the cloud versus on-premise:
comparison of performance, costs and accessibility
T. Bleazard1, P. Raposo2, L. Perfect2, G. Amos3, M.
Fritzsche1, R. Mate1, M. Bailey1, F. Lescai1
1Division of Analytical Biological Sciences, National
Institute of Biological Standards and Control (NIBSC),
Medicines and Healthcare products Regulatory Agency
(MHRA), South Mimms, London, UK, Potters Bar, United
Kingdom, 2UK Stem Cell Bank, National Institute of
Biological Standards and Control (NIBSC), Medicines
and Healthcare products Regulatory Agency (MHRA),
South Mimms, London, UK, Potters Bar, United Kingdom,
3Division of Bacteriology, National Institute of Biological
Standards and Control (NIBSC), Medicines and Healthcare
products Regulatory Agency (MHRA), South Mimms,
London, UK, Potters Bar, United Kingdom
When planning future infrastructure for genomics analyses,
most institutions face the difficult choice of whether to
expand an on-premise cluster, switch entirely to the cloud or
build a hybrid setup. Despite data in the literature about the
performance of cloud solutions, and the portability of
individual applications, we could not identify an exhaustive,
use case based comparison between the available options,
which was specific for genomics and providing metrics
useful for decision making at institutional level. We have
therefore designed three use cases, representing some of the
most demanding applications in terms of computing and
storage footprint: Human Whole Genome Sequencing,
Single Cell RNA Sequencing, Shotgun Metagenome
Sequencing. The use of large-sized datasets, for a total of
7.5TB, also allowed us to evaluate the effect of data
compression solutions. We have designed the analysis
pipelines using Nextflow on a Slurm scheduler, with Sin-
gularity containers to maximise portability and reproduci-
bility. By employing widely used applications, like GATK,
Cell Ranger and Seurat, Metaphlan and Humann2, we
ensured the relevance of our results for the community. This
allowed us to collect and compare metrics in six dimensions
consistently across different environments: performance,
scheduling, cost, running features, data transfer as well as
risk/benefit. We performed the comparison on a high-
performance computing (HPC) cluster on-premise and on a
similarly designed Cyclecloud HPC on Azure. Our results
will help life science organisations to map their computing
needs to the use cases and develop their computing infra-
structure roadmaps.
T. Bleazard: None. P. Raposo: None. L. Perfect: None.
G. Amos: None. M. Fritzsche: None. R. Mate: None. M.
Bailey: None. F. Lescai: None.
P17.021.A
TAD-aware prioritization of putative pathogenic copy
number variants
J. Hertzberg1,2, M. Vingron1, S. Mundlos1,2, G. Gallone1
1Max Planck Institute for Molecular Genetics, Berlin,
Germany, 2Institute for Medical and Human Genetics,
Charité Universitätsmedizin, Berlin, Germany
Introduction: The prioritization of genetic mutations is of
fundamental importance for the genomics, genetics and
clinical communities. Current methods prioritizing larger
chromosomal alterations such as Copy Number Variants
(CNVs) based on their pathogenicity are limited by the lack
of publicly available variant calls. We combined pathogenic
and non-pathogenic CNVs from multiple data sources to
analyze the utility of functional annotation, such as reg-
ulatory domains defined by TAD boundaries, in the prior-
itization of pathogenic CNVs.
Methods: We matched pathogenic and non-pathogenic
sets by size and variant count and conducted a series of
enrichment tests to investigate any correlations between
pathogenicity and overlap with genomic annotations.
Finally, we implemented a novel method to annotate CNVs
for manual and automated prioritization.
Results: We confirm a correlation between the patho-
genicity of a CNV and its tendency to overlap with gene-
centric and regulatory elements. Additionally, we present
the TAD annotation (TADA) tool, a method to annotate
CNVs with respect to their regulatory environment and a
proof-of-concept classification of pathogenic variants with
high accuracy (AUC = 0.8911).
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Conclusions: Considering recent advances in sequencing
and variant calling, the focus on larger genomic alterations
in diagnostics will likely increase, raising the need for
manual and automated prioritization methods. Our results
show that the prioritization of pathogenic CNVs based on
functional annotation is a promising approach. With an
increasing number of publicly available variant catalogues
we aim to improve the classifier’s predictive power and
adapt our approach to all types of structural variants.
J. Hertzberg: None. M. Vingron: None. S. Mundlos:
None. G. Gallone: None.
P17.023.C
Critical comparison of colocalization algorithms on
large datasets
V. Rallo1,2, A. Angius2,1, M. Steri2, C. Sidore2, F. Cucca1,2
1University of Sassari, Sassari, Italy, 2Institute for Genetic
and Biomedical Research (IRGB - CNR), Monserrato (CA),
Italy
Introduction: Great efforts have focused on identifying
causal genetic variants shared between quantitative traits
(QTs) and diseases. Several algorithms integrate association
data and provide insights on the role of QTs in disease
predisposition, such as Mendelian randomization, coin-
cident associations and colocalization, all of them having
benefits and drawbacks. Among these three, the colocali-
zation aims at identifying shared haplotypes influencing
both QTs and disease to find common molecular mechan-
isms. Here, we carry out a comparison of three colocaliza-
tion algorithms (coloc, eCAVIAR and gwas-pw) reviewing
their strengths and weaknesses.
Materials and Methods: We tested three colocalization
software using GWAS summary statistics of 272 immune
QTs measured in up to 2,870 individuals from SardiNIA
cohort and public data GWAS from a case-control meta-
analysis on rheumatoid arthritis (RA) (>100,000 indivi-
duals). The three tools use different approaches based on
Bayes factors to evaluate colocalization signals.
Results: We considered as true positive the 270 trait-
locus associations colocalizing (YC) or not-colocalizing
(NC) with RA for at least 2 of the 3 tools, resulting in a total
of 14 YC and 256 NC. Coloc and gwas-pw showed the
highest concordance (100%), followed by
eCAVIAR (98%).
Conclusions: The comparison showed a high concor-
dance among the colocalization algorithms. This suggests
that the choice of tool does not have a strong impact on the
colocalization results and the identification of links between
QTs or diseases. We can assert that the colocalization is a
robust approach to investigate connections between QTs
and to advance understanding of biological mechanisms
behind disease predisposition.
V. Rallo: None. A. Angius: None. M. Steri: None. C.
Sidore: None. F. Cucca: None.
P17.024.A
Allelic heterogeneity and complex patterns of genetic
effects across traits and cell types
K. Tayeb, M. Arvanitis, B. J. Strober, A. Battle
Johns Hopkins University, Baltimore, MD, United States
Association studies have identified thousands of genetic
variants associated with phenotypes ranging from molecular
traits to disease. These data offer the opportunity to com-
pare genetic effects across traits and tissues. For example,
by intersecting disease loci with expression quantitative trait
loci (eQTL) we can help identify the regulatory mechanisms
and target genes influencing disease. However, it remains
challenging to identify which associations observed in
multiple traits are driven by shared causal variants as
opposed to distinct mechanisms confounded by linkage
disequilibrium (LD). The problem is particularly challen-
ging in the presence of allelic heterogeneity, where multiple
causal alleles occur in the same genomic region. In fact, the
same region may harbor some shared and some distinct
causal effects across different tissues, conditions, or traits.
We introduce a probabilistic model, CAFEH, which
leverages multiple association studies to perform colocali-
zation and fine-mapping across studies in the presence of
allelic heterogeneity. CAFEH jointly models summary
statistics from each study, using a factor analysis approach
to identify patterns of association driven by shared and
distinct causal variants. CAFEH outperforms competing
colocalization methods, specifically when multiple studies
are provided. We apply CAFEH to eQTLs from 49 GTEx
tissues, demonstrating much more extensive tissue-
specificity than previously reported, and numerous cases
of allelic heterogeneity with different causal components
affecting different tissues. Applying CAFEH to UK
Biobank data along with GTEx, we connect these patterns
to shared causal factors with disease. Overall, our method
improves understanding of allelic heterogeneity and shared
genetic effects across traits and tissues.
K. Tayeb: None. M. Arvanitis: None. B.J. Strober:
None. A. Battle: None.
P17.027.A
Comprehensive CNV re-analysis of over 5,000 exomes
from undiagnosed Rare Disease patients collated by
Solve-RD
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S. Laurie1,2, G. Bullich1,2, G. Demidov3, L. Johansson4, F.
Musacchia5, M. Pauper6, K. Sablauskas6, L. Matalonga1, I.
Gut1,2,7, S. Ossowski3, M. Swertz4, C. Gilissen6, A.
Hoischen8,9, H. Graessner3,10, S. Beltran1,2,7
1Centro Nacional de Análisis Genómico (CNAG-CRG),
Center for Genomic Regulation, Barcelona, Spain, 2Barce-
lona Institute of Science and Technology (BIST), Barcelona,
Spain, 3Institute of Medical Genetics and Applied Geno-
mics, University of Tübingen, Tübingen, Germany, 4Uni-
versity Medical Center Groningen (UMCG), Groningen,
Netherlands, 5Telethon Institute of Genetics and Medicine
(TIGEM), Pozzuoli, Italy, 6Department of Human Genetics,
Radboud Institute for Molecular Life Sciences, Radboud
University Medical Center, Nijmegen, Netherlands, 7Uni-
versitat Pompeu Fabra (UPF), Barcelona, Spain, 8Radboud
Expertise Center for Immunodeficiency and Autoinflamma-
tion, Department of Internal Medicine, Radboud University
Medical Center, Nijmegen, Spain, 9Department of Human
Genetics and Department of Internal Medicine, Radboud
University Medical Center,, Nijmegen, Netherlands, 10Cen-
tre for Rare Diseases, University of Tübingen, Tübingen,
Germany
One of the key objectives of the H2020 Solve-RD project
(http://solve-rd.eu/) is the detailed reanalysis of 19,000
unsolved exome sequencing datasets from rare disease
cases, through the application of state-of-the-art tools and
methods, in order to attempt to solve them. Raw sequencing
data is processed, and genetic variants uploaded to the RD-
Connect Genome-Phenome Analysis Platform (https://pla
tform.rd-connect.eu/). While a percentage of cases are being
solved by automated reanalysis of short variants and
examination by domain experts, many datasets remain
unsolved. For an important proportion of these, the detec-
tion of copy number variants may help resolve the case, as it
may not have been attempted previously or our approach is
more comprehensive.
The accurate detection of CNVs from exome sequencing
data is known to be a very challenging task due to the
inherent stochasticity in the capture enrichment process.
The challenge within SolveRD is amplified due to the
submitted data being extremely heterogeneous in nature,
having been sequenced in different places, at different
times, using different machines and protocols. Of note, the
data submitted includes samples from more than 20
different commercial exome sequencing kits.
To date we have generated CNV calls from over 5,000
exomes, using three CNV calling algorithms, ExomeDepth,
Conifer, and ClinCNV, with tailored settings, and a
clustering algorithm, ClusterWES to define which samples
should be batched together. Here we detail our workflow,
report on the outcome of these analyses, and provide some
recommendations for others who wish to undertake similar
analyses.
S. Laurie: None. G. Bullich: None. G. Demidov: None.
L. Johansson: None. F. Musacchia: None. M. Pauper:
None. K. Sablauskas: None. L. Matalonga: None. I. Gut:
None. S. Ossowski: None. M. Swertz: None. C. Gilissen:
None. A. Hoischen: None. H. Graessner: None. S.
Beltran: None.
P17.029.C
Optimized strategy for copy-number calling in targeted
next-generation sequencing panels
M. Vyverman, R. De Smet, G. Vinterhalter, B. Slabbinck, J.
Deceukeleire, K. Bettens, J. Crappe
Agilent Technologies, Gent, Belgium
Introduction: Copy number variations (CNVs) represent a
significant fraction of pathogenic germline mutations found
in human conditions. Reliable identification of CNVs from
next-generation sequencing (NGS) data is challenging as it
is impacted by many different factors, such as sample
quality, sequencing depth, library preparation, ... Here we
present a CNV calling algorithm developed and optimized
for Agilent’s SureMASTR (amplicon based) NGS panels.
Materials and methods: The algorithm is developed for
the specific needs of the enrichment strategies of Agilent’s
SureMASTR panels and consists of the following: (1)
Normalization by using a pooled reference from the same
sequencing run, eliminating the need for matched normal
samples. (2)Bias correction to control for GC-, length- and
other technology-specific biases in the sequencing data. (3)
Quality filtering to remove low-quality samples, PCR
plexes or genomic regions. (4)Hidden Markov Models for
calling. We also optimized the algorithm for dosage
quotient (DQ) calculation and DQ-visualization of FFPE
and FFT samples. This algorithm is incorporated in the
MASTR Reporter, the analysis and quality control software
for (Sure)MASTR assays. MASTR Reporter CNV calling is
for Research Use Only.
Results: We tested the germline CNV calling algorithm
on >500 clinical samples analyzed with 5 different
SureMASTR panels and sequenced on Illumina MiSeq,
MiniSeq and NextSeq platforms. Analyzed samples
included 28 experimentally confirmed exon- and gene-
level CNVs. Across the different panels we observed a
specificity >= 98% and sensitivity of 100%.
Conclusions: We present an algorithm for reliable CNV
detection, that is specifically optimized for NGS targeted
sequencing panels.
M. Vyverman: A. Employment (full or part-time);
Significant; Agilent Technologies. R. De Smet: A.
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Technologies. G. Vinterhalter: A. Employment (full or
part-time); Significant; Agilent Technologies. B. Slab-
binck: A. Employment (full or part-time); Significant;
Agilent Technologies. J. Deceukeleire: A. Employment
(full or part-time); Significant; Agilent Technologies. K.
Bettens: A. Employment (full or part-time); Significant;
Agilent Technologies. J. Crappe: A. Employment (full or
part-time); Significant; Agilent Technologies.
P17.033.A
FlowCat: Automated classification of B-cell lymphoma
subtypes
N. Mallesh1, M. Zhao1, A. Höllein,2, R. Schabath2, T.
Haferlach2, C. Haferlach2, P. Krawitz1, W. Kern2, F.
Elsner3, H. Lüling3
1Institute for Genomics Statistics and Bioinformatics, Bonn,
Germany, 2Munich Leukemia Laboratory, Munich, Ger-
many, 3Res Mechanica GmbH, Munich, Germany
Leukemia and lymphoma are hematological disorders
involving malignant neoplasms of leukocytes. Multi-
channel flow cytometry (MFC) is an integral diagnostic
method for diagnosis and monitoring of those disorders.
MFC data analysis includes manual gating to interpret cell
populations. Although several computational approaches
are available to automate the process of gating, these
methods require expert supervision to adjust the gate defi-
nitions. We created an automated tool to directly classify
MFC data to diagnosis labels without any human proces-
sing. MFC data (FCS files) were obtained from routine
diagnostic of 20,622 patients. The dataset includes 8 B-cell
lymphoma subtypes and healthy controls. Three 9-color
MFC tubes were used to measure up to 50,000 cells per
case. Compensated and transformed flow cytometry data
from a single case is used to train a self-organizing map,
which is used as input to a convolutional neural network
generating class predictions. We achieved an overall
weighted F1 score of 0.92.We use transfer learning to
classify data acquired with a different flow cytometry panel.
We were able to increase the unweighted F1 score from
0.33 to 0.42 of a second network trained with 10,079 sam-
ples from a 5-color panel by transferring the knowledge
from our base network described above. We demonstrate an
automated classification of FCS data into multiclass labels
with high accuracy. We also show that the transfer of
knowledge between networks trained with data from dif-
ferent flow cytometry protocols can improve the classifi-
cation performance of such networks, especially for the rare
subtypes with very little data available.
N. Mallesh: None. M. Zhao: None. A. Höllein,: None.
R. Schabath: None. T. Haferlach: None. C. Haferlach:
None. P. Krawitz: None. W. Kern: None. F. Elsner:
None. H. Lüling: None.
P17.034.B
Genetic intolerance across homologous protein domains
identifies TTN missense variants with a role in dilated
cardiomyopathy
X. Zhang1,2, P. Theotokis1,2, N. Whiffin1,2, J. Ware1,2
1National Heart and Lung Institute, Imperial College
London, London, United Kingdom, 2Cardiovascular
Research Centre, Royal Brompton and Harefield NHS,
Foundation Trust London, London, United Kingdom
Introduction: The interpretation of TTN missense variants
in dilated cardiomyopathy (DCM) presents a profound
challenge in variant interpretation since rare missense var-
iants in TTN are prevalent in the population, and indis-
tinguishable from those in patients with DCM. Previous
studies assessing the relevance of TTN missense variants,
using sequence conservation across species or structural
features of proteins have been inconclusive.
Methods: Since ~70% of the titin protein sequence is
composed of ~300 Fibronectin type-III (fn3) and Immu-
noglobin I-set (I-set) domains, we quantified and aggregated
the degree of depletion of neutral missense variation within
the human genome at each domain position of the two
domain families over homologous amino acids, by
comparing the number of neutral variations based on a
sequence-context model and variations observed among
141,456 humans from the Genome Aggregation Database
(gnomAD).
Results: Six domain positions from fn3 and I-set domains
are significantly depleted of missense variants within
gnomAD populations (z-test P < 0.01). These constrained
domain sites are enriched for ClinVar pathogenic variants in
TTN and other proteins containing fn3 or I-set domains. We
combined our constraint scores with existing variant effect
prediction tools to prioritise TTN missense variants. The
predicted pathogenic TTN missense variants have shown
with an increased association with DCM (n = 1,343)
compared with health controls (n = 2,313) in a meta-
analysis across three populations of different ancestries.
Conclusions: The aggregation of constraint within the
human population across homologous domains represents a
complementary and effective approach to prioritize mis-
sense TTN variants with single amino acid resolution of
large deleterious impact.
X. Zhang: None. P. Theotokis: None. N. Whiffin:
None. J. Ware: None.
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The Gasdermin E Gene Has Potential as a Pan-Cancer
Biomarker, While Discriminating between Different
Tumor Types
J. Ibrahim1,2, K. Op de Beeck1,2, E. Fransen1,3, M.
Peeters2,4, G. Van Camp1,2
1Center of Medical Genetics, University of Antwerp and
Antwerp University Hospital, Antwerp, Belgium, 2Center
for Oncological Research, University of Antwerp and
Antwerp University Hospital, Antwerp, Belgium, 3StatUa
Centre for Statistics, University of Antwerp, Antwerp,
Belgium, 4Department of Medical Oncology, Antwerp
University Hospital, Antwerp, Belgium
Introduction: Due to the elevated rates of incidence and
mortality of cancer, early and accurate detection is crucial
for achieving optimal treatment. Molecular biomarkers
remain important screening and detection tools, especially
in light of novel blood-based assays. DNA methylation in
cancer has been linked to tumorigenesis, but its value as a
biomarker has not been fully explored. In this study, we
have investigated the methylation patterns of the Gas-
dermin E gene across 14 different tumor types using The
Cancer Genome Atlas (TCGA) methylation dataset
(N = 6502).
Methods: Differential methylation was tested through
linear mixed models. Binary logistic regression and
partial-least squares discriminant analysis prediction
models were used for identifying pan-caner and tumor-
specific markers. We were able to identify six CpG sites
that could effectively distinguish tumors from normal
samples in a pan-cancer setting (AUC = 0.86). This
combination of pan-cancer biomarkers was validated in
six independent datasets (AUC = 0.84-0.97). Moreover,
we tested 74,613 different combinations of six CpG
probes, where we identified tumor-specific signatures that
could differentiate one tumor type versus all the others
(AUC = 0.79-0.98). In all, methylation patterns exhibited
great variation between cancer and normal tissues, but
were also tumor specific.
Conclusions: Our analyses highlight that a Gasdermin E
methylation biomarker assay, not only has the potential for
being a methylation-specific pan-cancer detection marker,
but can also discriminate between different tumor types.
Funding: Research Foundation Flanders (FWO), Kom op
tegen Kanker (KOTK) and the Research Fund of the
University of Antwerp (GEOMED).
J. Ibrahim: None. K. Op de Beeck: None. E. Fransen:
None. M. Peeters: None. G. Van Camp: None.
P17.036.A
Longitudinal changes in blood metabolite levels from
young- to middle adulthood are related to epigenetic
variability genome-wide
I. Pupko1, H. Draisma1, L. Zudina1, Z. Balkhiyarova1, M.
Wielscher2, M. Ala-Korpela3, S. Sebert3, M. Järvelin2,3, M.
Kaakinen1, I. Prokopenko1
1University of Surrey, Guildford, United Kingdom, 2Imper-
ial College London, London, United Kingdom, 3University
of Oulu, Oulu, Finland
Associations between metabolite levels and DNA methy-
lation (DNAm) have been reported. However, the rela-
tionship between longitudinal changes in metabolite levels
and differential DNAm is underexplored. We assessed
associations between epigenome-wide blood DNAm and
changes in the levels of blood proton nuclear magnetic
resonance (1H-NMR) metabolomics-based traits. For 595
non-diabetic individuals from the Northern Finland Birth
Cohort 1966 with metabolomics data at ages 31 (T1) and 46
years (T2) as well as concurrent DNAm data (T2), we
calculated the average change in level per year between T1
and T2 for each of the 228 metabolomics-based variables.
We used our methylSCOPA software for fast single-
predictor longitudinal epigenome-wide association study
(EWAS). We regressed out participant sex from the change
in metabolomic variable level and used the resulting resi-
duals as predictors of DNAm in EWAS for 832,569 mar-
kers on the Illumina (San Diego, CA, USA)
MethylationEPIC BeadChip. We quality-controlled, resi-
dualized, and normalized the DNAm data, mapped genomic
locations to CGCh37/hg19, and adopted the Bonferroni-
corrected P-value = 4.4 × 10−10 threshold to denote epi-
genome- and metabolome-wide statistical significance of
association between predictor and epigenetic mark. We
detected an epigenome- and metabolome-wide significant
association between DNAm at cg16904859 (chr1:206,
849,995; β = 2.31; SE = 0.36; P = 3.2 × 10−10) and change
over time in the level of triglycerides in extremely large
very low-density lipoprotein particles and potentially also
chylomicrons. Additionally, we identified 67 epigenome-
wide significant (P < 1 × 10−7) predictor-epigenetic mark
associations, involving 28 unique epigenetic markers and
53 unique metabolomics-based variables. Using methylS-
COPA, we detected associations between longitudinal
changes in blood metabolite levels and DNAm.
Funding: H2020-SC1-2019-874739, WCRF-2017/1641.
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P17.037.B
Towards a more efficient genetic diagnosis of epilepsy:
switching between a mendelian genes space and a
clinical phenotypes space
A. Cisterna1, A. Sabater1, D. Zhang2, J. A. Hardy2, M.
Ryten2,3, I. Díez4, P. Maietta4, S. Álvarez4, J. A. Botía1,2
1Departamento de Ingeniería de la Información y las
Comunicaciones, Universidad de Murcia, Murcia, Spain,
2Department of Molecular Neuroscience, UCL Institute of
Neurology, London, United Kingdom, 3Department of Medical
and Molecular Genetics, King’s College London School of
Medicine, Guy’s Hospital, London, United Kingdom, 4NIM-
Genetics Genómica y Medicina S.L, Madrid, Spain
Introduction: Epilepsy is a group of neurological disorders
characterized by recurrent epileptic seizures. 35% of cases have
a genetic basis. For those, roughly the failed differential diag-
noses are about 15%. It is difficult to diagnose epilepsy, in
many cases, a genetic study of the patient is required, and these
may lead to false negatives. For those cases, we estimate
similarity between epilepsy and other close disorders by
transforming gene sets into phenotype sets to provide a clinical
similarity between genetic diseases. The tool is called
PhenoExam.
Methods: PhenoExam uses a score that evaluates how
many relevant phenotypes the reference panel shares with
the test panel and how similar is the representation of the
shared phenotypes in relative terms. It works on HPO and
MGI ontologies.
Results: We have created a phenotypic space for 120
diseases whose gene-based definitions where obtained from
Genomics England PanelApp. Panels closest to epilepsy are
hereditary ataxia, inherited white matter disease and
hereditary neuropathy. Through PhenoExam we have
refined the epilepsy panel predicting new epilepsy genes.
They have a higher PhenoExam score of phenotype
similarity than random genes (P < 10−5). Amongst those
genes are KIF1A, NFASC, RYR2, CELF2.
Conclusions: PhenoExam allows us to situate diseases,
defined by a set of genes into a metric space based on
phenotypical descriptions emerging from individual genes. We
confirmed that new genes likely to cause epilepsy recapitulate
and correlate with relevant phenotypes extracted from
NIMGenetics epilepsy panel. PhenoExam is an R package
available at https://github.com/alexcis95/PhenoExam.
Fundación Séneca and NIMGenetics.
A. Cisterna: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Modest; NIMGenetics. A. Saba-
ter: None. D. Zhang: None. J.A. Hardy: None.M. Ryten:
None. I. Díez: A. Employment (full or part-time);
Significant; NIMGenetics. P. Maietta: A. Employment
(full or part-time); Significant; NIMGenetics. S. Álvarez:
A. Employment (full or part-time); Significant; NIMGe-
netics. J.A. Botía: None.
P17.038.C
Differentially expressed gene analysis from whole-
transcriptome sequencing of patients with esophageal
squamous cell carcinoma from Kazakhstan
A. Sharip1, S. Rakhimova1, A. Molkenov1, U.
Kozhamkulov1, Y. Zhukov2, M. Omarov2, A. Akilzhanova1,
U. Kairov1
1National Laboratory Astana, Nur-Sultan, Kazakhstan,
2Oncology Center, Nur-Sultan, Kazakhstan
Introduction: Esophageal cancer is the eighth most com-
mon cancer worldwide and sixth in Kazakhstan. Esophageal
squamous cell carcinoma (ESCC) is the predominant his-
tological subtype of esophageal cancer and diagnosed at late
stage. The aim of the project was to identify genetic basis of
ESCC by analysing differentially expressed genes (DEGs)
from whole-transcriptome sequencing of Kazakhstani
patients.
Materials and Methods: Tissue samples were obtained
from 25 ESCC-affected individuals immediately after Ivor-
Lewis esophagectomy from Oncology Center in Nur-
Sultan. Whole transcriptome sequencing was performed
following the TruSeq RNA Protocol. STAR software and
DESeq2 package have been used for mapping and defining
differentially expressed genes. Functional analysis of DEGs
was performed using various R packages.
Results: The study sized 14 men and 11 women, average
age of patient 65.5 ± 7.7 years 88% of the patients were
diagnosed with advanced stages T3-T4. Analysis of tumor
and normal esophageal tissues identified 1197 DEGs,
comprising 883 upregulated and 314 downregulated genes
(with adjusted p-value <0.05). We found significant 4 up-
regulated and 6 down-regulated KEGG pathways (p-
value<0.05). Top 300 DEGs were mapped to PPI network
and functional enrichment analysis was performed on
identified three modules of closely connected nodes (genes).
Conclusions: ESCC with moderate dysplasia is the most
common histologic subtype of esophageal cancer in our
patients and is characterized by a poor prognosis. High-
throughput sequencing approach allows identifying
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molecular pathways involved in esophageal carcinogenesis
that could improve diagnosis and treatment strategies.
Acknowledgments: Work was supported by grant of the
Ministry of education and science #AP05134722,
#AP05135430 and #AP05136106.
A. Sharip: None. S. Rakhimova: None. A. Molkenov:
None. U. Kozhamkulov: None. Y. Zhukov: None. M.
Omarov: None. A. Akilzhanova: None. U. Kairov: None.
P17.039.A
MLI-score: a machine learning tool generating an
integrated score for pathogenic variant prediction
E. Benetti1, D. Rosati1, C. Fallerini2, F. Mari2,3, A.
Renieri2,3, S. Furini1
1Department of Medical Biotechnologies, University of
Siena, Siena, Italy, 2Medical Genetics, University of Siena,
Siena, Italy, 3Medical Genetics, University of Siena, Siena,
Italy Genetica Medica, Azienda Ospedaliera Universitaria
Senese, Siena, Italy
Exome sequencing is gaining importance in the clinical
practice thanks to its high accuracy and the decreasing
costs. However, a great challenge in the analysis of exome
sequencing experiments is how to identify variants that
are clinically relevant among an overwhelming number of
variants with no functional consequences. Many bioin-
formatic scores exist for predicting the pathogenicity of
genetic variants. In this work, we compared their perfor-
mances, and we tested if it was possible to improve the
accuracy of pathogenicity predictions by combining the
available bioinformatic scores into a unified Machine
Learning model using Logistic Regression. This inte-
grated strategy improves the performance by almost 5%
with respect to the best algorithm available in the litera-
ture and interestingly reduces by 7% the rate of benign
variants that are wrongly classified as pathogenic. By
integrating additional features, among which Minor Allele
Frequency (MAF) and the number of Pubmed articles
related to the rs code (pubmed_rss), the Machine Learning
model further improves the performance of almost 10%
with respect to the best single algorithm alone and further
decreases the rate of false positive up to 11%. This novel
integrated score for pathogenic variant prediction, that
incorporates multiple sources of information into a single
score, can therefore facilitate the analysis of exome
sequencing experiments and speed up the identification of
pathogenic variants by performing a more stringent and
accurate selection of variants.
E. Benetti: None. D. Rosati: None. C. Fallerini: None.
F. Mari: None. A. Renieri: None. S. Furini: None.
P17.041.C
Refining reference human protein-coding gene
annotation
A. Frankish, The GENCODE Consortium
EMBL-EBI, Hinxton, United Kingdom
The GENCODE consortium continues to produce founda-
tional genome annotation for the human and mouse refer-
ence genomes. GENCODE identify and classify, with high
accuracy, all protein-coding genes, pseudogenes, long non-
coding RNAs and small RNAs based on defined biological
evidence and make this annotation freely available for the
benefit of biomedical research and genome interpretation.
We will describe the ongoing extension of annotation
workflows to use long transcriptomic data from PacBio and
ONT in combination with RNAseq data to produce accurate
full-length transcript structures, CAGE, RAMPAGE and 3′-
enriched RNAseq to identify transcript ends, and targeted
proteogenomics and phylogenetic assessment to support
decisions regarding protein-coding potential. Alongside the
efforts to identify genes and alternatively-spliced (AS)
transcripts we continue to work closely with our colleagues
at other resources to resolve conflicts. We have undertaken
an extensive exercise to compare GENCODE and Uniprot
annotation. The GIFTS (Genome Integration with FuncTion
and Sequence) project has created a common framework for
UniProtKB-Ensembl/GENCODE mapping. Using GIFTS,
GENCODE annotators have investigated 716 Uniprot
entries that do not map to a protein-coding gene in the
Ensembl/GENCODE human geneset. The review process
has led to updates to Ensembl/GENCODE gene annotation,
discussions with Uniprot curators regarding entries that do
not display high protein-coding potential in the genomic
context, and identification of a set of loci where resource-
specific criteria preclude agreement.
This work was supported in part by the National Human
Genome Research Institute (NHGRI) (2U41HG007234),




Deciphering non-coding variants with GeneHancer
regulatory regions
S. Fishilevich, R. Barshir, T. Iny Stein, M. Safran, D.
Lancet
Weizmann Institute of Science, Rehovot, Israel
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Whole genome sequencing (WGS) variant analysis and
interpretation requires an exploration of non-genic func-
tional genomic elements such as promoters and enhancers,
involved in development and implicated in disease. The
comprehensive identification of regulatory elements and
their gene targets is a significant challenge. We created
GeneHancer (PMID:28605766), a regulatory element
database within the GeneCards Suite (https://www.geneca
rds.org/), with 400,000 enhancers and promoters. Infor-
mation is amalgamated from ENCODE, Ensembl, FAN-
TOM5, VISTA, dbSUPER, EPDnew, UCNEbase,
CraniofacialAtlas and GTEx. GeneHancer creates a
unique non-redundant and comprehensive view of reg-
ulatory elements, including their target gene associations,
transcription factor binding sites, tissue specificity and
super-enhancer mapping. We recently focus on pheno-
type/disease annotation of such elements, based on
variant-trait mappings from the GWAS Catalog, and
literature-curated evidence from DiseaseEnhancer and
NCBI Entrez Gene. GeneHancer is now used by a con-
siderable fraction of GeneCards’ 4 million user base to
annotate non-coding variants, and is included as a native
regulation track at the UCSC genome browser, where it is
the only source for explicit regulatory regions and gene
associations. GeneHancer provides an indispensable
augmentation for the GeneCards’ NGS disease inter-
pretation tools: VarElect, a phenotype interpreter
(PMID:27357693), and TGex, a VCF-to-report analyzer
(PMID:31888639), used by major clinical sequencing
centers. Non-coding variants are mapped to regulatory
regions, and then prioritized with respect to diseases and
phenotype keywords via direct and target gene-mediated
links. Such capacities provide a comprehensive route to
deciphering the clinical significance of non-coding single
nucleotide and structural variations, thus helping to elu-
cidate unsolved disease cases. Support: LifeMap
Sciences grant
S. Fishilevich: None. R. Barshir: None. T. Iny Stein:
None. M. Safran: None. D. Lancet: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received);
Significant; LifeMap Sciences.
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Towards a joint standardised “default” transcript set:
Matched Annotation from the NCBI and EMBL-EBI
(MANE)
J. Morales1, J. Loveland1, S. Pujar2, A. Astashyn2, R.
Bennett1, C. Davidson1, O. Ermolaeva2, C. Farrell2, L. Gil1,
J. M. Gonzalez1, V. Joardar2, M. Kay1, V. Kodali2, K.
McGarvey2, A. McMahon1, S. Rangwala2, G. Threadgold1,
F. Cunningham1, A. Frankish1, T. Murphy2
1European Bioinformatics Institute (EMBL-EBI), Hinxton,
United Kingdom, 2National Center for Biotechnology
Information, National Library of Medicine, Bethesda,
MD, United States
The accurate description of transcripts is foundational for
clinical genomics. GENCODE (annotation produced by
EMBL-EBI) and RefSeq (NCBI) produce comprehensive and
complementary human gene annotation. The large number of
alternatively spliced transcripts, together with unstandardised
use of canonical transcripts across resources, can present
challenges, especially in the clinical context. To address this,
EMBL-EBI and NCBI are working together on the Matched
Annotation from the NCBI and EMBL-EBI (MANE) initia-
tive. The aim is to generate a genome-wide transcript set that:
1) aligns to GRCh38, 2) includes pairs of 100% identical
Ensembl/GENCODE (ENST) and RefSeq (NM) transcripts
and 3) is well-supported. The output, the MANE Select set,
will include one transcript that is representative of biology at
each protein-coding locus across the genome. Select tran-
scripts are identified using independent computational pipe-
lines complemented by manual review and discussion. The
pipelines utilise evidence of functional potential such as
expression levels, evolutionary conservation, and clinical
significance. Currently, we have released MANE Select
transcripts for 75% of protein-coding loci across the genome,
including 83% of validated clinical genes and 90% of
ACMG59 genes. We aim to achieve genome-wide coverage
in 2020 and are working closely with partners to encourage
adoption of the MANE set on browsers and in clinical
workflows. We envision this dataset serving as a unified high-
value reference set for use in comparative genomics, clinical
reporting and basic research. Released transcripts are avail-
able on all genome browsers and on the NCBI’s FTP site.
This work is supported by: Wellcome Trust-WT200990/Z/16/
Z; EMBL-Core-Funds; NIH-U41HG007234 and NIH-
Intramural-Research-program.
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P17.051.A
Leveraging correlated risks to increase power in
Genome-Wide Association Studies
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N. Mounier1,2, Z. Kutalik1,2
1University Center for Primary Care and Public Health,
Lausanne, Switzerland, 2Swiss Institute of Bioinformatics,
Lausanne, Switzerland
Introduction: Genome-Wide Association Studies (GWASs)
are nowadays often conducted in more than 1 million sam-
ples. Improved discovery, by further increasing study sizes is
not the only strategy. Leveraging information from published
studies of related traits can improve inference. To this end, we
developed a Bayesian GWAS approach that builds informa-
tive priors for each single nucleotide variant (SNV) using
GWASs of related risk factors (RFs).
Methods: Mendelian Randomisation (MR) is used to
derive multivariate causal effects of a set of iteratively
selected RFs on the target outcome. These causal effects of
the RFs on the outcome are then combined with the SNV’s
effect on the identified RFs to build a Bayesian prior. Bayes
Factors (BFs) are used to quantify the evidence in favour of
the prior. P-values are assigned to these BFs to allow the
identification of associated SNVs.
Results: We found a set of universally optimal
parameters (instrument strength, clumping stringency and
shrinkage intensity) that maximises the out-of-sample
squared correlation between prior and observed effects
(up to ~40%). We also derived an analytical formula for the
null BFs distribution, leading to a 6-fold reduced runtime
and a more accurate estimation of BFs P-values, compared
to permutation-based approaches. The method now also
provides posterior and direct (part of observed effect not
mediated through the RFs) effect estimates that can be used
for downstream analyses.
Conclusions: The method, as well as functions facilitat-
ing results visualisation, have been implemented in an R
package (https://github.com/n-mounier/bGWAS) and can
be applied to any GWAS summary statistics.
N. Mounier: None. Z. Kutalik: None.
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An online platform for GWAS/EWAS summary statis-
tics harmonisation and data imputation
A. Demirkan1,2,3, K. Rudometkin1, L. Zudina1, Z.
Balkhiyarova3,1, M. Kaakinen1,3, I. Prokopenko1
1Department of Clinical & Experimental Medicine, Uni-
versity of Surrey, Guildford, United Kingdom, 2Department
of Genetics, University Medical Center Groningen, Gronin-
gen, Netherlands, 3Department of Medicine, Section
Genomics of Common Disease, Imperial College London,
London, United Kingdom
With the increasing utility of data driven methods in sci-
ence, ownership of complete datasets enabling use of
multivariate statistical methods has turned out to be of
major value. As an outcome of this trend, approaches that
tackle missingness in epidemiological and omic datasets are
of increasing demand. We developed a user-friendly web-
based portal and an analytical platform ANGLIA: “An
online platform for imputing and aNalyzinG epidemioLo-
gical -omIcs dAta” for the users with (epi)genomic and
other omic data, to address the issues raising from data
missingness and to enable data harmonisation at the sum-
mary statistics level. With ANGLIA we aim to address the
challenges by integrating approaches to imputation and
multi-variable analysis of omics data both at the individual
and summary statistics levels by implementing a framework
of existing and novel analytical tools. These include refining
existing and developing new high-performance tools for
missing data imputation, performing multi-phenotype (epi)
genome-wide association studies (EWAS/GWAS) and
performing EWAS/GWAS of composite measurements, as
well as upcycling GWAS summary statistics to more recent
genotype imputation panels. The showcase of the developed
platform is located at http://www.anglia.prokopenkogroup.
org/ and will serve for the very immediate needs of the
scientists working in the fields of genetics, epidemiology
and statistical omics, and eventually to different branches of
medicine through more accurate research of the omics data.
Our proposed framework has potential to enhance statistical
omics association studies of any kind, and enable new in-
silico discoveries to advance further our understating of
complex human conditions. Funding: H2020-SC1-2019-
874739, WCRF-2017/1641.
A. Demirkan: None. K. Rudometkin: None. L. Zudina:
None. Z. Balkhiyarova: None. M. Kaakinen: None. I.
Prokopenko: None.
P17.053.C
Accounting for age-of-onset, disease prevalence, and
family information in Genome-wide Association Studies.
E. M. Pedersen, J. W. Dreier, K. Musliner, ISPYCH-Broad
Consortium, A. Børglum, J. McGrath, S. Dalsgaard, J.
Christensen, P. B. Mortensen, E. Agerbo, F. Privé, B. J.
Vilhjalmsson
Aarhus University, Aarhus, Denmark
Most genome-wide association studies (GWAS) account
only for information from the genotyped individuals.
However, in epidemiological studies additional family
and temporal information, e.g. family history, disease pre-
valence and age-of-onset, are routinely accounted for.
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The recently proposed methods; GWAX: genome-wide
association study by proxy (Liu et al., Nat Genet 2017), LT-
FH: liability threshold model, conditional on family history
(Hujoel et al., BioRxiv 2019) and Cox regression GWAS
(Staley et al., EJHG 2017) incorporate either family history
or temporal information, but not both. Here we present a
new method that extends LT-FH to account for both family
and temporal information.
We compared our approach to both standard GWAS,
GWAX, and LT-FH using simulated polygenic liabilities
and case-control phenotypes. When only accounting for sex
of family members, we observed a modest improvement
(3% increased power) over LT-FH and large improvement
over GWAX (53% increased power) in simulations
assuming a disease prevalence of 4% in males and 1% in
females. Accounting for changes in disease prevalence over
time, age-of-onset, and oversampling cases (a common
strategy in genetic studies) further increases statistical
power. We applied our approach to several psychiatric
and neurological disorders in the iPSYCH study of five
serious mental disorders: ADHD, Autism, Bipolar disorder,
Depression, and Schizophrenia with more than 80,000
psychiatric cases and 50,000 controls.
In summary, the liability-threshold model is a promising
approach to increase power in GWAS when family history,
disease prevalence over time, and temporal information is
available.
E.M. Pedersen: None. J.W. Dreier: None. K. Musliner:
None. A. Børglum: None. J. McGrath: None. S.
Dalsgaard: None. J. Christensen: None. P.B. Mortensen:
None. E. Agerbo: None. F. Privé: None. B.J.
Vilhjalmsson: None.
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Engaging the GWAS community to increase Summary
Statistics data sharing in the GWAS Catalog
M. Cerezo1, J. A. L. MacArthur1, A. Buniello1,2, J.
Hayhurst1,2, P. Hall3, L. W. Harris1, L. A. Hindorff3, S.
Jupp1, E. Lewis1, C. Malangone1, A. McMahon1, J.
Morales1, E. Sollis1, J. Stewart1, D. Suveges1, P. L.
Whetzel1, T. Burdett1, F. Cunningham1, P. Flicek1, H.
Parkinson1
1EMBL-EBI, Cambridge, United Kingdom, 2Open Targets,
Cambridge, United Kingdom, 3Division of Genomic
Medicine, National Human Genome Research Institute,
National Institutes of Health, Bethesda, MD, United
States
In recent years, summary statistics (SumStats) from
genome-wide association studies (GWAS) have been
increasingly used to provide insights into the mechanisms
of complex disease, predict disease risk, prioritise candidate
loci, and discover drug targets. The availability of SumStats
has also proven beneficial for the development of new
statistical methods, conditional associations, and integration
with other omics. The NHGRI-EBI GWAS Catalog (www.
ebi.ac.uk/gwas) expanded its scope to include SumStats in
2017 and is now the largest and most updated freely
available SumStats resource. Thanks to the increase of
SumStats links in research articles, along with direct sub-
mission to the Catalog, the percentage of new publications
with available SumStats in the Catalog has increased from
6% in 2017 to 44% in 2019 and now includes over 10,000
datasets. Despite an increase in author submissions, the
percentage of publications with available SumStats remains
relatively low, with 86% of Catalog publications not having
available SumStats. In an aim to facilitate the data sharing,
we have developed a web-based deposition interface to
support author submission of SumStats and meta-data from
publications. We are also planning a workshop to address
the standards, infrastructure and incentives required to
promote and enable sharing of SumStats. The workshop
will bring together participants from the diverse stakeholder
space, including researchers, journal editors, funding bod-
ies, and biobank representatives. The aim is to reach a
consensus and publish an agreed action plan for SumStats
sharing and standardization which will have a positive
impact on the GWAS community.
M. Cerezo: None. J.A.L. MacArthur: None. A.
Buniello: None. J. Hayhurst: None. P. Hall: None. L.
W. Harris: None. L.A. Hindorff: None. S. Jupp: None. E.
Lewis: None. C. Malangone: None. A. McMahon: None.
J. Morales: None. E. Sollis: None. J. Stewart: None. D.
Suveges: None. P.L. Whetzel: None. T. Burdett: None. F.
Cunningham: None. P. Flicek: None. H.
Parkinson: None.
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ITHANET: An information and database community
portal for haemoglobinopathies
C. Stephanou, A. Minaidou, S. Tamana, M. Xenophontos,
C. W. Lederer, P. Kountouris, M. Kleanthous
The Cyprus Institute of Neurology and Genetics, Nicosia,
Cyprus
Introduction: The ITHANET portal (www.ithanet.eu) is an
expanding, publicly available biomedical resource dedi-
cated to haemoglobinopathies. It provides a manually
curated, literature-derived collection of published genetic
and epidemiological data, also integrating the latest updates
on news, events, publications, clinical trials, funding
opportunities, and many more.
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Materials and Methods: A team of expert biocurators is
involved in the collection, validation and annotation of
information with weekly updates on scientific literature
collected from PubMed, also incorporating new and
updated information from existing public databases. Con-
tributions are welcome and clearly acknowledged.
Results: ITHANET offers a range of curated databases;
IthaGenes currently stores information on over 2900 fully
annotated variations in more than 350 globin-related loci
and genes. Most variations are assigned at least one of 60
phenotypic annotations in IthaGenes, taken from the Human
Phenotype Ontology. IthaMaps stores epidemiological
information as documented in published literature for a
total of over 185 countries and illustrates this information
on a dynamic global to regional map. IthaChrom provides
digitised reports (as kindly provided by Bio-Rad Labora-
tories Inc.) of standard diagnostic HPLC analyses on more
than 600 haemoglobin variants.
Conclusions: ITHANET is the most comprehensive
knowledgebase on haemoglobinopathies and the official
partner of the Human Variome Project’s Global Globin
Network for data storing, curation and sharing within and
between countries. Also, this partnership fosters the
development of a genotype-phenotype database for better
health care delivery and forms the basis of an Expert Panel
application for haemoglobinopathy-related variant classifi-
cation under the Clinical Genome Resource.
Funded project: EXCELLENCE/1216/0256.
C. Stephanou: None. A. Minaidou: None. S. Tamana:
None. M. Xenophontos: None. C.W. Lederer: None. P.
Kountouris: None. M. Kleanthous: None.
P17.056.C
Inter-omics analysis in hepatocellular carcinoma
M. Jihad, I. Yet
Department of Bioinformatics, Graduate School of Health
Sciences, Hacettepe University, Ankara, Turkey
Introduction: The main aim of this study is to understand
the biological mechanisms involved in disease susceptibility
and progression, by linking CNV, DNA methylation and
gene expression to Hepatocellular carcinoma (HCC) using
Bayesian networks (BN).
Methods and Results: To infer causality in HCC by
fitting BN we used HCC single-cell sequencing dataset
contained 25 samples. We built three BN structures
representing the alternative hypotheses of the causal
relations between CNV, gene expression and methylation.
The parameters of these networks were estimated by using
MLE. Afterwards, we examined the compatibility of these
structures with the data by using the AIC score. After fitting
all the models, there were 17 models where the best model
was at least ten times more likely than the second
best model.
Discussion and Conclusion: The availability of different
levels of “-omics” data allowed us to explore the relation-
ship between disease-associated “-omics” profiles, specifi-
cally for genetic variation, methylation and gene expression.
We build three BN structure for the alternative causal
relations and detected several cases of three-way associa-
tions where either genetically driven DNA methylation
levels impact gene expression profiles, or genetically driven
gene expression traits impact DNA methylation levels.
Overall, these results suggest that the effects of DNA
methylation can be both active on gene expression levels,
and passive, by being a consequence for gene expression
levels. This study shows the potential of integrating other
“-omics” data for complex diseases.
M. Jihad: None. I. Yet: None.
P17.057.A
A novel machine learning-based approach for screening
Individuals at risk of hereditary haemochromatosis
P. Martins Conde1,2, T. Sauter1, T. P. Nguyen1,2
1University of Luxembourg, LSRU, Esch-sur-Alzette, Lux-
embourg, 2Megeno S.A., Esch-sur-Alzette, Luxembourg
Hereditary haemochromatosis (HH) is an autosomal reces-
sive disease, where homozygosity for C282Y in the HFE
gene accounts for 80%-85% of clinical cases among the
Caucasian population. HH is characterised by the accumu-
lation of iron, which, if untreated, can lead to the devel-
opment of liver cirrhosis and liver cancer. An iron overload
screening tool (IRON), employing traditional statistical
methods on self-reported and non-laboratory data, has been
proposed. This tool obtained an area under the curve (AUC)
of 68.5%, demonstrating great potential of integrating dif-
ferent types of self-reported and clinical data into compu-
tational screening tools. However, the utility of such tools is
limited by challenges associated with efficiently handling
and combining large amounts of structured and unstructured
data from different sources. We have developed a novel
computational model to identify individuals at risk of HH,
using the family study data of the HEIRS cohort. This
dataset, consisting of 254 cases and 701 controls, contains
variables extracted from questionnaires and biomarker
values. These variables were ranked using statistical and
recursive feature elimination methods. The model was
trained on an XGBoost classifier using the most significant
risk factors: HFE C282Y homozygosity, age, mean cor-
puscular volume, iron level, serum ferritin level, transferrin
saturation, and unsaturated iron-binding capacity. Parameter
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optimisation was carried out with multiple runs, resulting in
an AUC of 87.03% ± 5.43 for 10-fold stratified cross-
validation. Since iron overload is preventable and treatable
if diagnosed early, individuals at high risk can benefit from
efficient screening strategies employing artificial
intelligence-based approaches.
P. Martins Conde: A. Employment (full or part-time);
Significant; Megeno S.A.. T. Sauter: None. T.P. Nguyen:
A. Employment (full or part-time); Significant;
Megeno S.A.
P17.059.C
AutoMap: High performance homozygosity mapping
using sequencing data
M. Quinodoz1,2,3, V. Peter1,3,4, N. Bedoni2, B. Royer
Bertrand5, K. Cisarova3,2, A. Salmaninejad6, N. Sepahi7, R.
Rodrigues8, M. Piran9, M. Mojarrad6, A. Pasdar6,10, A.
Asad7, A. Sousa8,11, L. Coutinho-Santos12, A. Superti-
Furga5, C. Rivolta1,3,13
1Insitute of Molecular and Clinical Ophtalmology Basel,
Basel, Switzerland, 2Department of Computational Biology,
Unit of Medical Genetics, University of Lausanne, Lau-
sanne, Switzerland, 3Department of Genetics and Genome
Biology, University of Leicester, Leicester, United King-
dom, 4Institute of Experimental Pathology, Lausanne
University Hospital (CHUV), Lausanne, Switzerland, 5Ser-
vice of Medical Genetics, Lausanne University Hospital
(CHUV), Lausanne, Switzerland, 6Department of Medical
Genetics, Faculty of Medicine, Mashhad University of
Medical Sciences, Masshad, Iran, Islamic Republic of,
7Noncommunicable Diseases Research Center, Fasa Uni-
versity of Sciences, Fasa, Iran, Islamic Republic of,
8Department of Medical Genetics, Hospital Santa Maria,
Centro Hospitalar Universitário Lisboa Norte (CHULN),
Lisbon Academic Medical Center (CAML), Lisbon, Portu-
gal, 9Bioinformatics and Computational Biology Research
Center, Shiraz University of Medical Sciences, Shiran, Iran,
Islamic Republic of, 10Division of Applied Medicine,
Medical School, University of Aberdeen, Aberdeen, United
Kingdom, 11Medical Faculty, Lisbon University, Lisbon,
Portugal, 12Instituto de Oftalmologia Dr Gama Pinto,
Lisbon, Portugal, 13University of Basel, Basel, Switzer-
land
Through the identification of genomic runs of homo-
zygosity (ROHs), homozygosity (autozygosity) mapping is
a powerful approach to find autosomal recessive mutations,
especially in consanguineous families. Many tools exists for
ROH discovery that rely on data from genotyping arrays or
exome sequencing (ES). Since most of these tools had bad
performances or were difficult to use, we have developed a
new tool: AutoMap (Autozygosity Mapper). AutoMap
directly uses standard VCF files as primary source of data.
A careful variant filtering step is implemented prior to the
identification of ROHs by a sliding-window approach and
subsequent filtering. The tool was first trained on ES data
from 26 samples from consanguineous families, and further
validated in 26 additional samples. AutoMap displayed
similar performance for both training and validation
cohorts, with sensitivity of 90.5% and 92.4% respectively
and showed the best sensitivity/specificity combination with
respect to 8 existing tools. When applied to unpublished ES
data, AutoMap allowed the discovery of ROHs containing
homozygous non-coding variants that led to the identifica-
tion of disease genes for five novel conditions including the
Liberfarb syndrome. AutoMap is a reliable tool that can
predict, in less than a minute, ROHs with high specificity
and sensitivity by using a single VCF file. Our tool is
available both via a web-based interface, for a quick ana-
lysis with default parameters, as well as a command-line
package, allowing assessment of a large numbers of sam-
ples, the customization of many parameters and analysis of
VCFs from whole-genome sequencing (WGS) experiments.
M. Quinodoz: None. V. Peter: None. N. Bedoni: None.
B. Royer Bertrand: None. K. Cisarova: None. A.
Salmaninejad: None. N. Sepahi: None. R. Rodrigues:
None. M. Piran: None. M. Mojarrad: None. A. Pasdar:
None. A. Asad: None. A. Sousa: None. L. Coutinho-
Santos: None. A. Superti-Furga: None. C. Rivolta: None.
P17.060.A
How reliable is HPO-based phenotyping?
F. Boschann1, M. Schuelke1, E. Seelow1, R. Steinhaus2,1, D.
Hombach2,1, P. N. Robinson3, D. Seelow2,1
1Charité – Universitätsmedizin Berlin, Berlin, Germany,
2Berliner Institut für Gesundheitsforschung, Berlin, Ger-
many, 3The Jackson Laboratory for Genomic Medicine,
Farmington, CT, United States
The Human Phenotype Ontology has become a widely used
tool for the precise ‘deep’ phenotyping of patients. How-
ever, it remains unclear how accurate and reproducible
HPO-based phenotyping is. Different physicians put
emphasis on different features, provide different detail
levels, and have different opinions on the inclusion of non-
cardinal symptoms. The complex structure of the ontology
and the sheer amount of terms may also add some uncer-
tainty, especially for novel users.
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With The Reliable HPO, we strive to address these issues.
We encourage physicians and biomedical researchers to
‘phenotype’ simulated patients according to their health
records. By comparing different HPO phenotype profiles of
the same patient, we aim to determine the normal
divergence in the HPO-based description of a patient’s
symptoms and to identify missing or misleading terms.
This knowledge will help us and other groups to better
estimate a realistic ‘fuzziness’ of symptoms when develop-
ing software that utilises the HPO, for instance for the
prioritisation of mutations in clearly described diseases. In
addition, the results can and will be used for an optimisation
of the names, synonyms, and descriptions of HPO terms.
We include functions to suggest more appropriate names of
the symptoms and new synonyms and to point out missing
symptoms.
We will of course share all our findings with the
community.
Please contribute to The Reliable HPO project at
http://www.human-phenotype-ontology.org/reliableHPO/
F. Boschann: None. M. Schuelke: None. E. Seelow:
None. R. Steinhaus: None. D. Hombach: None. P.N.
Robinson: None. D. Seelow: None.
P17.062.C
Phenotypic data architecture in peer-reviewed literature
relating to genetically-determined developmental
disorders
T. M. Yates1, J. Campbell1, T. I. Simpson2, D. R.
FitzPatrick1
1Institute of Genetic and Molecular Medicine, University of
Edinburgh, Edinburgh, United Kingdom, 2Institute for
Adaptive and Neural Computation, School of Informatics,
University of Edinburgh, Edinburgh, United Kingdom
Introduction: Informatic approaches to phenotypic data
extraction from the peer-reviewed literature are needed, to
maximise speed and accuracy of diagnosis in genetically-
determined developmental disorders (GDD). We present
analysis of phenotypic data in full-text papers published
over one year in the American Journal of Human Genetics
(AJHG). This will form the basis for development of an
automated extraction pipeline.
Materials and Methods: AJHG abstracts from 2017-
2018 describing childhood onset disease were selected.
Phenotypic descriptors were annotated in full-text manu-
scripts and supplemental files (if these contained case
reports) using hypothes.is (https://hypothes.is). Annotations
were mapped to HPO (Human Phenotype Ontology) terms
by computing term frequency (TF) and inverse document
frequency (IDF), splitting spans into character trigrams, and












































Table 1. Proportion of phenotype terms in corpus,
mapped back to HPO using tf-idf and cosine similarity.
Conclusions: We demonstrate a significant volume of
extractable phenotypic data contained within full-text
papers describing GDD, most of which can be mapped to
HPO terms using closest string match methods. The design
of an automated system to extract phenotypes from the
scientific literature will be informed by the data architecture
presented here, with substantially more information in
supplementary files. Ultimately, genotype-phenotype corre-
lation using literature-derived disease models derived from
this system will significantly increase the rapidity and
accuracy of diagnosis in GDD.
Grant reference: Wellcome Strategic Award 200990/Z/
16/Z
T.M. Yates: None. J. Campbell: None. T.I. Simpson:
None. D.R. FitzPatrick: None.
P17.064.B
Efficient phasing and imputation of low-coverage
sequencing data using large reference panels
S. Rubinacci, D. Ribeiro, R. Hofmeister, O. Delaneau
University of Lausanne, Lausanne, Switzerland
Low-coverage whole genome sequencing followed by
imputation has been proposed as a cost-effective genotyp-
ing approach. However, its competitiveness against SNP
arrays is undermined as imputation methods are computa-
tionally expensive.
Here we describe a method for imputation of low-
coverage sequencing datasets called GLIMPSE. The
efficiency our method is achieved by combining advanced
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data structures (PBWT) with a new powerful linear-time
sampling algorithm. As a consequence, the computational
time to impute a single variant decreases as the size of the
reference panel increases, which is an important property
since larger panels are constantly made available.
We compared the performance of GLIMPSE to other low-
coverage imputation methods: BEAGLE, GENEIMP and
STITCH. GLIMPSE is more accurate for the full allele-
frequency range and for rare variants the difference is more
pronounced, as GLIMPSE gets an increased accuracy of more
than 20%. Notably, these improvements are obtained in running
times that are several orders of magnitude shorter of other
methods, archiving imputation of a full genome for less than 1$.
Our results show that 1x coverage enables effective
association studies in standard eQTL settings and is better
suited than SNP arrays to access the impact of rare
variations. We also show that this increased accuracy is
more evident for populations not well-represented on SNP
arrays. Finally, we demonstrate the potential of 4x coverage
outperforming every other setting tested.
Overall, we demonstrate the potential of low-coverage
imputation and suggest a paradigm shift in the design of
future genomic studies.
Swiss National Science Foundation project grant
(PP00P3_176977).
S. Rubinacci: None. D. Ribeiro: None. R. Hofmeister:
None. O. Delaneau: None.
P17.065.C
Machine learning to distinguish true somatic variants
from noise in tumour only next generation sequencing
data
C. Jaramillo Oquendo, H. Parker, J. C. Strefford, J.
Gibson, S. Ennis
University of Southampton, Southampton, United King-
dom
Introduction: Discovery of driver mutations in cancer play
a key role in developing staging systems and targeted drugs
to fight this disease. Identification of somatic mutations is
complex, often aided by concurrent analysis of germline
tissue, which is not always available. However, detecting
true somatic mutations without germline tissue may leave
numerous false positives in the data, requiring validation or
time-consuming manual curation. Our aim was to develop
an unsupervised machine learning model to distinguish true
somatic variants from noise in tumour-only data.
Methods: HaloplexHS libraries were prepared from splenic
marginal zone lymphoma tumour samples (n = 62),
sequenced, and variants were called with an in-house pipeline
that populated numerous quality metrics. Variants were filtered
to enrich for somatic mutations and manually curated by two
independent investigators, labelling each variant true or false.
Ten features were selected after evaluation of all quality metrics
for their value in the model. Clustering was performed using k-
means.
Results: Variants (n = 873) clustered into five groups, true
variants in one group and false into four, with 92% agreement
to manual curation labels. Our approach accurately predicted
210/217 (97%) and 637/656 (97%) of the variants labelled true
and false respectively. Principal component analysis identified
mutant allele frequency and quality as the features with the
greatest effect on variance between true and false clusters.
Conclusions: This approach successfully identified the
majority of true variants with high sensitivity and
specificity, allowing for a faster and more accurate method
of filtering out noise in tumour-only samples.
Acknowledgements: C.J.O. funded by COLCIENCAS.
C. Jaramillo Oquendo: None. H. Parker: None. J.C.
Strefford: None. J. Gibson: None. S. Ennis: None.
P17.066.A
GenNet framework: interpretable neural networks for
predicting phenotype from genotype
A. van Hilten1, S. A. Kushner1, H. H. H. Adams1, M. A.
Ikram1, W. J. Niessen1,2, G. V. Roshchupkin1
1Erasmus MC, Rotterdam, Netherlands, 2TU Delft, Delft,
Netherlands
Introduction: Neural networks are currently the state of the
art in many domains but seldom applied for genetic risk
prediction. Reliable genetic risk prediction demands a net-
work that is able to handle a large number of genetic var-
iants, as well as produce interpretable results that provide
insights into the underlying biological mechanisms.
Methods: We propose GenNet, a framework with novel
interpretable genetic neural network architectures. Prior
biological knowledge (such as DNA annotations, pathways,
and gene expression) is used to create layers limited to
functionally meaningful connections, thereby constructing
computational feasible and interpretable network architec-
tures. Each node represents a biological entity (e.g. gene,
pathway). Learned weights represent the contribution of
these entities to the overall prediction providing the
important entities without any secondary analysis.
Results: The framework’s effectiveness is demonstrated
by predicting various diseases or traits across a wide
spectrum of polygenicity. Table 1 shows the performance
and the genes with the largest predictive contributions per
phenotype. The framework is not limited to gene-based
results. It also includes architectures based on genomic,
tissue, cell type, and other functional annotations.
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Conclusion: We developed GenNet, a framework for
interpretable neural networks to predict phenotype from
genotype data by incorporating prior biological knowledge.
Given the interpretability of the network, we anticipate this
approach as having the potential for uncovering novel
insights into the genetic architecture of complex diseases.
Overview of the results on the held-out test set
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A. van Hilten: None. S.A. Kushner: None. H.H.H.
Adams: None. M.A. Ikram: None. W.J. Niessen: A.
Employment (full or part-time); Significant; Quantib BV..
G.V. Roshchupkin: None.
P17.067.B
The added value of RNA sequencing on top of WES for
variant interpretation and diagnosis of patients with
Mendelian disorders
V. A. Yepez1, M. Gusic2, R. Kopajtich2, C. Mertes1, H.
Prokisch2, J. Gagneur1
1Technical University of Munich, Garching, Germany,
2Helmholtz Zentrum Munich, Munich, Germany
Introduction: RNA sequencing (RNA-seq) is a promising
technology to complement Whole Exome Sequencing (WES)
for pinpointing the genetic cause of Mendelian diseases.
However, with ever-growing and improving databases of
WES samples, and better variant effect predictors, the relative
advantage of RNA-seq may be questioned.
Materials and Methods: We performed RNA-seq on
fibroblasts from 245 individuals affected with a mitochondrial
disease who had previously undergone WES, which represents
the largest RNA-seq compendium for rare disease diagnostics.
We built a computational pipeline to prioritize genes
harbouring either mono-allelic expression of a rare allele,
aberrant expression level using OUTRIDER, or aberrant
splicing using a novel algorithm called FRASER. Moreover,
we pinpointed rare variants associated with the prioritized
genes either by re-annotating WES variants in the light of the
RNA-seq results or by calling variants from the RNA-seq data.
Results: We provided a diagnosis for 15% (24 out of
165) of WES unsolved cases. We also showed that the
majority of OMIM diseases genes are expressed in each of
the following clinically accessible tissues: whole blood,
muscle, and fibroblasts, suggesting that RNA-seq of
accessible, yet not affected, tissues may be suitable for a
broad range of rare diseases. We share our computational
workflow, called DROP (Detection of RNA Outliers
Pipeline), that integrates all analysis steps, can leverage
parallel computing infrastructures, and generates browsable
web page reports.
Conclusions: Collectively, these results further establish
RNA-seq as an effective strategy for validating or
invalidating variants of unknown significance and for the
discovery of pathogenic gene regulatory events.
V.A. Yepez: None. M. Gusic: None. R. Kopajtich:
None. C. Mertes: None. H. Prokisch: None. J.
Gagneur: None.
P17.068.C
Genotyping rare variants with high accuracy using
microarray technology
O. Mizrahi Man, M. H. Woehrmann, T. Webster, J. Gollub,
A. Roter, J. Schmidt
Thermo Fisher Scientific, Santa Clara, CA, United States
Introduction: UK Biobank is a health resource that follows
the health and well-being of 500,000 participants, all gen-
otyped with very high accuracy on Thermo Fisher Scien-
tific’s Applied BiosystemsTM AxiomTM microarrays. A
recent pre-publication based on this data set claimed that
microarrays may not be the technology of choice for calling
very rare variants, defined as having minor allele frequency
below 0.01%. We show that a genotyping algorithm mod-
ification tailored to very rare variants achieves excellent
accuracy for these variants.
Materials and Methods: We have optimized the
genotyping algorithms for very rare variants. For common
variants the location of the heterozygous cluster provides
powerful evidence for heterozygous calls. Rare variants
usually have a single sample in the het cluster, making the
call less robust. An in-depth analysis of the distribution of
replicate probe signal on Axiom microarrays revealed this
distribution can be used to significantly improve the
accuracy of heterozygous calls.
Results: Eight separate data sets with 1000 Genomes
Project truth originally achieved positive predictive values
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(PPVs) ranging from 60% to 93% for very rare variant calls.
The new algorithms increased all PPVs to near 90% while
losing on average only 0.5% of correct calls. We will report
the results of applying the new algorithms to rare variant
genotyping in the UK Biobank cohort.
Conclusions: Improved algorithms for genotype calls for
Axiom microarrays improve the PPV of very rare variants
while minimally affecting sensitivity.
Analysis of UK Biobank data is conducted using UK
Biobank Resource under Application Number 55681.
O. Mizrahi Man: None. M.H. Woehrmann: A.
Employment (full or part-time); Significant; Thermo Fisher
Scientific. T. Webster: A. Employment (full or part-time);
Significant; Thermo Fisher Scientific. J. Gollub: A.
Employment (full or part-time); Significant; Thermo Fisher
Scientific. A. Roter: A. Employment (full or part-time);
Significant; Thermo Fisher Scientific. J. Schmidt: A.
Employment (full or part-time); Significant; Thermo Fisher
Scientific.
P17.070.B
AdapMiR: a new tool for trimming adapters and counts
calculation in miRNA sequencing
A. Zarubin, A. Markov, M. Nazarenko
Research Institute of Medical Genetics, Tomsk National
Research Medical Center, Tomsk, Russian Federation
Introduction: Trimming of adapter sequences from
miRNA-seq data is a common preprocessing step during
NGS data analysis. Overtrimmed reads and adapter con-
tamination can be challenging for downstream analysis. We
have proposed an algorithm called AdapMiR for the trim-
ming adapters and further analysis of miRNA expression
that turns these drawbacks into advantages. Our algorithm
can achieve high accuracy of adapter trimming and discard
non-miRNA reads.
Material and Methods: AdapMiR was implemented in
R language. miRNA-seq data of atherosclerotic plaques
(n = 5) and healthy vessels (n = 5) was used as a test
dataset. Mature miRNAs sequences were obtained from
miRBase and used for construction of artificial reference
including adapter sequences. BWA and edgeR were used
for read alignment and differential expression analysis. We
compared developed algorithm with miARma-Seq and
Trimmomatic in high sensitivity mode. AdapMiR is freely
available (https://github.com/alekseizarubin/AdapMiR).
Results and discussion: Results of adapMiR and
Trimmomatic differed for 55% of miRNA reads. Moreover,
we noticed a peculiarity in Trimmomatic output: the lesser
read length the more probable was overtrimming, but longer
read sequences (≥20 bp) could contain adapter fragments. In
contrast, AdapMiR did not produced excessively trimmed
reads while filtered out erroneously read nucleotides. Only
2% of total counts per sample differed between algorithms.
The number of differentially expressed miRNAs between
atherosclerotic plaques and healthy vessels were equal (n =
151), but resulting lists of both algorithms was different by
18 miRNA.
Conclusions: AdapMiR is comparable to miARma-Seq
approach. Our algorithm improves the accuracy of single-
end read trimming by adding adapter sequences to the
reference.
A. Zarubin: None. A. Markov: None. M.
Nazarenko: None.
P17.073.B
Multisite de novo mutations after paternal exposure to
ionizing radiation
F. Brand1, M. Holtgrewe2, A. Knaus1, D. Beule2, P. M.
Krawitz1
1Institut for genomics statistics and bioinformatics, Bonn,
Germany, 2Berlin Institute of Health, Berlin, Germany
In our ongoing study we evaluate the effects of ionizing
radiation on the offspring of exposed soldiers.
We sequenced the entire genomes of 56 families with 87
children on an Illumina NovaSeq 6000. Eighteen offspring
of twelve families have earlier been sequenced on a HiSeq
X, three of which have now been resequenced. In our
comparison we found a sequencing pattern with an
increased rate of A > C and T > G transversions on the
NovaSeq, most probably due to its novel two-color
chemistry.
Our focus lies on specific mutational patterns such as
MSDNs (at least two de novo mutations within 20 bp), SVs
and CNVs, which could be a result of DNA damage from
exposure to ionizing radiation before conception of the
children.
From our large cohort we are able to reliably estimate age
effects and compare the performance of different variant
calling applications. We confirmed the origin of all MSDNs
using long-read and Sanger sequencing and validated all
complex de novo variants. We found that MSDNs occurred
only on the paternal allele. Since only fathers were exposed
to ionizing radiation, this finding strengthens our hypothesis
that MSDNs could serve as a biomarker to identify previous
exposure for exposure to ionizing radiation.
In our cohort we detected 1.125 MSDNs/offspring of
exposed fathers compared to 0.3 MSDNs/offspring in
unexposed controls. These numbers are corrected for age
effects and platform specific mutational signatures. The
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increased rate of MSDNs could serve as a biomarker for
DNA damage caused by prolonged exposure to irradiation.
F. Brand: None.M. Holtgrewe: None. A. Knaus: None.
D. Beule: None. P.M. Krawitz: None.
P17.077.C
unCOVERApp: an interactive graphical web-
application for clinical assessment of sequence coverage
at the base-pair level
E. Iovino1, T. Pippucci2
1University of Bologna, Department of Medical and
Surgical Sciences, Bologna, Italy, 2Medical Genetics Unit,
Sant’Orsola-Malpighi University Hospital, Bologna, Italy
Introduction: The rapid spread of Next Generation
Sequencing technology has been coupled since its begin-
ning with development of bioinformatic tools for data
analysis and interpretation. However, despite increasing
accuracy of available approaches, the need to assess
sequencing quality of the analysis targets at the base-pair
resolution poses growing challenges, especially in the
clinical settings. In diagnostics indeed, meticulous investi-
gation of every single target base is often required to
exclude that pathogenic events across the gene of interest
may be missed due to uneven sequence coverage. We
present unCOVERApp an application both for graphical
inspection both dbNSFP-based annotations of sequence
coverage at base-pairs levels.
Method: unCOVERApp is a freely available application
written in R and developed with Shiny packages (https://
github.com/Manuelaio/unCOVERApp).
Results: unCOVERApp is a suite of graphical and
statistical tools to support the clinical assessment and
annotation of low-sequence coverage positions in genomic
data, providing interactive plots displaying gene sequence
coverage, functional and clinical annotations of base-pair
positions within user-defined coverage thresholds to support
user’s judgement about their possible clinical relevance.
Importantly, the binomial calculator expresses the prob-
ability that a variant is missed given its expected allelic
fraction and sequence coverage. The maximum credible
allele frequency calculator allows to label existing variants
within low coverage regions based on allele frequency
calculated according to the disease model instead of using
general cut-offs (e.g. 0.05).
Conclusions: uncoverApp is a graphical interface tool
designed to help especially clinically-oriented users in easy
inspection of coverage profiles of the gene of interest at the
base-pair level.
E. Iovino: None. T. Pippucci: None.
P17.079.B
Prioritisation of non-coding regions based on human
genomic constraint and primary sequence context with
deep learning
D. Vitsios, S. Petrovski
AstraZeneca, Cambridge, United Kingdom
Elucidating functionality in human non-coding sequence is
a key genomics challenge. It has been shown that intoler-
ance to variation of coding and proximal non-coding
sequence is a strong predictor of human disease relevance.
Here, we expand on published methods by applying a tiled
genome-wide Residual Variation Intolerance Score
(gwRVIS) to Whole Genome Sequencing (WGS) data from
62,784 individuals with lower gwRVIS corresponding to
greater intolerance to genetic variation. We verified
that gwRVIS distinguishes sequence occupied by
human Mendelian disease genes from intergenic sequence
(median gwRVIS −0.54 versus −0.011; p= 2.4 × 10−195).
Remarkably, despite being focused solely on human lineage
purifying selection, gwRVIS identified sequence occupied
by known ultra-conserved non-coding elements as the
most intolerant category (median gwRVIS=−0.85; p <
1 × 10−320). gwRVIS also boosts predictive performance in
pathogenic variant detection from ClinVar in intergenic
regions, lincRNAs and UTRs. We then employ gwRVIS
along with functional genomic annotation (including
methylation and chromatin accessibility) and primary
genomic sequence to build “Junk Annotation” RVIS
(JARVIS): a comprehensive deep learning model to prior-
itise non-coding variants using only human lineage-specific
information. Despite not incorporating any conservation
information, JARVIS outperforms every comparable score
on pathogenicity inference of non-coding variants and
performs comparably or better in some cases over current
state-of-the-art methods that do employ conservation
information. Both gwRVIS and JARVIS capture previously
inaccessible human-lineage constraint information as
derived from 62,784 WGS to help prioritise genetic variants
found in the human non-coding regulatory sequence and
further enable the pursuit of novel drug targets and bio-
markers in the non-coding genome.
D. Vitsios: A. Employment (full or part-time); Signifi-
cant; AstraZeneca. S. Petrovski: A. Employment (full or
part-time); Significant; AstraZeneca.
P17.080.C
Analysis of mutation burden in Parkinson’s disease
using machine learning, a case-control study
662 J. del Picchia
G. Bergant, A. Maver, A. Kovanda, B. Peterlin
Clinical Institute of Genomic Medicine, Ljubljana, Slove-
nia
Introduction: Despite known risk factors and monogenic
causes most sporadic and familial cases of Parkinson’s
disease (PD) remain idiopathic. In our study we hypothesize
that polygenic causes explain a proportion of idiopathic
cases and use machine learning on exome sequencing data
to identify individuals at risk for PD.
Materials and Methods: We analyzed genetic variants
detected by clinical exome sequencing of 68 early onset or
familial PD patients with no discovered monogenic cause
and 323 control individuals. All single nucleotide coding
variants with genotype quality ≥100 have been selected and
the number of germline variants per gene has been
calculated for all individuals. A single dataset containing
the calculations, information on all analyzed genes and the
individual’s disease status has been prepared as an input to
the ML analysis. We employed a supervised ML algorithm,
gradient boosted trees with regularization (eXtreme Gra-
dient Boosting), which used the observed patterns to
determine, first, the possibility to predict the disease status
on the test group and, second, the subset of genes with the
highest contribution to the prediction.
Results: ML approach yielded the accuracy of 80.5%,
and area under the receiver-operator characteristic curve of
74.3% (sensitivity: 30.8%, specificity: 90.6%). The genes
contributing highly to the algorithms prediction were
analyzed and a pathway enrichment analysis was
performed.
Conclusions: The results show that the argument for a
significant polygenic risk on the development of PD is
promising, however, larger studies are necessary to further
determine its impact.
G. Bergant: None. A. Maver: None. A. Kovanda:
None. B. Peterlin: None.
P17.082.B
Phenotype-based search using free online databases is
ineffective in diagnostics of mendelian disorders
A. Fellner1,2, N. Ruhrman-Shahar1,3, N. Orenstein3,4, G.
Lidzbarsky1, O. Hagari1, H. Brown-Shalev1, L. Bazak1, L.
Basel-Salmon1,3,5
1Raphael Recanati Genetics Institute, Rabin Medical
Center, Beilinson Hospital, Petah Tikva, Israel, 2Depart-
ment of Neurology, Rabin Medical Center, Beilinson
Hospital, Petah Tikva, Israel, 3Sackler Faculty of Medicine,
Tel-Aviv University, Tel-Aviv, Israel, 4Pediatric Genetics
Clinic, Schneider Children’s Medical Center of Israel,
Petah Tikva, Israel, 5Laboratory of Immunology and
Genetics, Felsenstein Medical Research Center, Petah
Tikva, Israel
Introduction: Searching online databases for a genetic
diagnosis that fits a clinical phenotype is used routinely in
clinical genetics. We investigated the diagnostic yield of
phenotype-based search using free online databases.
Materials and methods: We included consecutive
solved cases from our whole-exome database. For each
case, the combination of Human Phenotype Ontology
(HPO) terms reported by the clinician was used to search
three commonly used databases: Online Mendelian Inheri-
tance in Man (OMIM), Phenolyzer and Mendelian. We
examined whether the actual molecular diagnosis (AMD)
found by whole-exome sequencing was included in the
search results (First 300 in OMIM and Phenolyzer; All 100
in Mendelian).
Results: One hundred consecutive cases were included
(43 females; mean age: 10 years). Search results included
the AMD in none of the databases in 33.0% of cases, and in
one, two or three databases in 30.0%, 20.0% and 17.0% of
cases, respectively. The first 5 search results included the
AMD in only 9.0%, 6.0% and 7.0%, in OMIM, Phenolyzer
and Mendelian, respectively. When included, the AMD’s
mean rank in the results’ list was 97 (range: 1-295), 56 (1-
270) and 37 (1-92) in these databases, respectively.
Conclusions: This study demonstrates that phenotype-
based search using free online databases is ineffective in
finding a probable diagnosis of mendelian conditions. It
emphasizes the need for better search tools and for a more
structured approach in HPO terms selection, and may
suggest that, at least in some cases, a genotype-first
approach with backward phenotyping may be more
appropriate.
A. Fellner: None. N. Ruhrman-Shahar: None. N.
Orenstein: None. G. Lidzbarsky: None. O. Hagari:
None. H. Brown-Shalev: None. L. Bazak: None. L.
Basel-Salmon: None.
P17.084.A
Developing genetic risk model for quantitative traits
considering epistasis
J. Park1, I. Kim1, J. Chae1, G. Kim1, H. Won1, W. Park2, J.
Kim2
1Samsung Advanced Institute for Health Sciences and
Technology, Sungkyunkwan University, Samsung Medical
Center, Seoul, Korea, Republic of, 2Samsung Genome Institute,
Samsung Medical Center, Seoul, Korea, Republic of
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As massive resources of genotype and phenotype data become
available, genetic risk score holds great potential to improve
precision medicine. Unfortunately, the problem of missing
heritability still prevails, despite several previous studies had
improved the conventional polygenic risk score, for which risk
alleles were weighted by the effect size of their association with
given trait and summed up. To alleviate the problem here we
systematically explore epistasis between genes that may mod-
ulate polygenic risk score for greater accuracy. Specifically, we
developed a model assuming multiplicative interactions
between different loci and applied the model to blood assay
quantitative traits in UK Biobank. To avoid overfitting emerged
from enumerated variables depicting many interactions
between loci, we employed a shrinkage method. We found that
the epistasis model indeed improved polygenic risk score for
several traits, including total bilirubin and Lipoprotein A. We
further investigated the functional relationships between genes
that may contribute to the discovered epistatic effects.
J. Park: None. I. Kim: None. J. Chae: None. G. Kim:
None. H. Won: None. W. Park: None. J. Kim: None.
P17.085.B
Differential positive selection in complex traits: inter-
population study of local adaptation in loci associated
with hair colour
F. Ganau1, C. S. Haley2, O. Lao3, P. Navarro2, S. Knott1
1Institute of Evolutionary Biology, University of Edinburgh,
Edinburgh, United Kingdom, 2MRC Human Genetics Unit,
University of Edinburgh, Edinburgh, United Kingdom,
3CNAG-CRG, Barcelona, Spain
When humans left Africa and dispersed around the world,
they met novel environments to which their phenotypes
were not adapted. The resulting local selective pressures in
each of these geographically distinct populations varied in
direction and strength, and led to a plethora of divergent
phenotypic adaptations. This research studies the genomic
fingerprint left by these processes for hair colour, a trait
with substantial inter and intra-population phenotypic var-
iation, that we use as a proof-of-concept for differential
adaptation. Genomic regions strongly associated with hair
colour are defined based on a published GWAS of the white
British population. Evidence for positive selection in these
regions is evaluated with a single, composite statistic. This
statistic is produced by merging five different tests of
positive selection with the De-correlated Composite of
Multiple Signals method, used for multivariate analyses. By
applying conservative P-rank transformations, we integrate
signal information from both of haplotype homozygosity
and Site-Frequency Spectrum (SFS) into a single, normally
distributed parameter of adaptation. Association between
hair colour and selection is tested using permutation-based
methodologies. Significant regions from the British hair-
colour GWAS are tested for selection across all 26 popu-
lations present in the 1000 Genomes database (https://www.
internationalgenome.org/), comparing how positive selec-
tion shaped each of them. As selective sweeps often lead to
extreme allele frequencies (MAF, it is possible that inter-
mediate size alleles undergoing recent adaptation are nearly
fixed and thus undetectable by GWAS. To evaluate this
effect the analysis is repeated selecting GWAS regions
based on effect sizes instead of p-values.
F. Ganau: None. C.S. Haley: None. O. Lao: None. P.
Navarro: None. S. Knott: None.
P17.086.C
GenomeMixer and NiPTUNE: novel bioinformatics
tools to improve Non-Invasive Prenatal Testing for fetal
aneuploidies
V. Duboc1, D. Pratella2, M. Milanesio2,3, J. Boudjarane4, S.
Descombes2, V. Paquis-Flucklinger1,2, S. Bottini2
1Université Côte d’Azur, CHU, Inserm U1081, CNRS
UMR7284, IRCAN, Nice, France, 2MDLab - MSI -
Université Cote d’Azur, Nice, France, 3Inria Sophia
Antipolis, Epione Research Project, Sophia Antipolis,
France, 4Département de génétique médicale, CHU la
Timone, Marseille, France
Introduction: The discovery of free circulating fetal DNA
in maternal blood has led to the development of Non-
Invasive Prenatal Testing (NIPT) techniques for detection
of fetal aberrations such as trisomy 21. NIPT is based on the
analysis of small fragments of DNA, circulating freely in
the maternal blood, by massively parallel sequencing. Its
reliability relies heavily on both the presence in the maternal
blood of a sufficient amount of fetal DNA (ff for fetal
fraction) and a sufficient sequencing depth (sd). Bioinfor-
matics tools have been developed to determine the ff but
there is currently no reference method in clinical practice.
Materials and Methods: We developed GenomeMixer,
an approach to estimate confidence intervals for aneuploi-
dies prediction, usable by all diagnostic laboratories and
NiPTUNE, a package to automate NIPT analysis. Geno-
meMixer creates synthetic sequencing data mixing reads
from pregnant women with fetal aneuploidies and from
non-pregnant women in order to determine the threshold of
both minimum ff and sd necessary to detect aneuploidies
reliably. Niptune pipeline is composed by several modules
including quality control, ff estimation by different methods
and aneuploidies prediction.
Results: We tested our tools on 2 different cohorts
composed by 377 and 1055 samples including respectively
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10 and 24 aneuploidies. GenomeMixer allowed to deter-
mine minimal threshold of both ff and sd. NiPTUNE was
validated thanks to the retrospective study performed on the
cohorts.
Conclusions: We have developed bioinformatics tools to
empower each diagnostic laboratory to determine the
confidence intervals of both ff and sd necessary to a
reliable NIPT.
V. Duboc: None. D. Pratella: None. M. Milanesio:
None. J. Boudjarane: None. S. Descombes: None. V.
Paquis-Flucklinger: None. S. Bottini: None.
P17.087.A
Classifying Rare Genetic Variants by Enriching and
Clustering on 3D Protein Structure Domains
J. D. Stephenson1, R. A. Laskowski1, M. E. Hurles2, J. M.
Thornton1
1EMBL-EBI, Hinxton, United Kingdom, 2Wellcome Sanger
Institute, Hinxton, United Kingdom
Introduction: Variant classification is an important step in
reducing the diagnostic odyssey for patients with rare
genetic disorders. For missense variants their direct effect is
largely determined by their local environment as dictated by
their position in the protein structure. This means that other
variants in the local environment may lead to a similar
protein consequence. Our method classifies variants of
unknown significance by considering their positions in
structure relative to known pathogenic or neutral variants.
Materials and Methods: We map neutral and known
pathogenic variants to the most relevant protein 3D
structures and then enrich the data to aid pattern detection
by combining variant data across structurally conserved
regions of proteins. Following this we discover clusters of
known pathogenic and neutral variants on the protein
structure domain assemblage with parameters optimised
using machine learning to capture variant effects common
across proteins with shared structure. Single VUS or entire
cohorts are then compared with our pre-calculated clusters
across all conserved structural domains containing over
100,000 protein structures.
Results: Our method classifies individual VUS based on
their proximity to pre-calculated neutral/pathogenic regions
with confidence values based on domain specific model
classification precision. Using this method we have
analyzed a set of 30,000 missense VUS from patients with
rare developmental disorders and uncovered several pre-
viously unreported gene associations.
Conclusions: Our method offers a complementary
approach to other pathogenicity predictors by combining
evolutionary structure conservation with previously anno-
tated variant locations.
J.D. Stephenson: None. R.A. Laskowski: None. M.E.
Hurles: None. J.M. Thornton: None.
P17.089.C
Making the most of Clumping and Thresholding for
polygenic scores
F. Privé1,2, B. J. Vilhjálmsson1, H. Aschard3, M. G. B.
Blum2
1Aarhus University, Aarhus, Denmark, 2Univ. Grenoble
Alpes, Grenoble, France, 3Institut Pasteur, Paris, France
Polygenic prediction has the potential to contribute to pre-
cision medicine. Clumping and Thresholding (C+T) is a
widely used method to derive polygenic scores. We
implement an efficient way to derive thousands of different
C+T polygenic scores corresponding to a grid over several
hyper-parameters. We find that optimizing over the pro-
posed four hyper-parameters improves the predictive per-
formance of C+T in both simulations and real data
applications, as compared to tuning only the p-value
threshold of C+T. A particularly large increase can be
noted when predicting depression status, from an AUC of
0.557 (95% CI: [0.544-0.569]) when tuning only the p-
value threshold in C+T to an AUC of 0.592 (95% CI:
[0.580-0.604]) when tuning all four hyper-parameters of C
+T. Overall, by optimizing C+T polygenic scores, one can
achieve prediction accuracies on par with more sophisti-
cated approaches such as LDpred and lassosum (Vilh-
jálmsson 2015, Mak 2017).
We further propose Stacked Clumping and Thresholding
(SCT). Instead of choosing one set of hyper-parameters that
maximizes prediction in some training set, SCT learns an
optimal linear combination of all C+T scores (stacking).
We apply SCT to 8 different case-control diseases in the
UK biobank data and find that SCT significantly improves
prediction accuracy compared to C+T, resulting in an
average AUC increase of 0.035 over standard C+T. We
conclude with extensions of SCT.
F. Privé: None. B.J. Vilhjálmsson: None. H. Aschard:
None. M.G.B. Blum: None.
P17.090.A
Identifying single nucleotide polymorphisms modulating
gene expression by transcription factors. A novel
approach for regulatory QTLs.
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F. Moratalla-Navarro1,2,3, V. Diez-Obrero1,2,3, R.
Carreras-Torres1,2,3, M. Devall4, G. Casey4, V. Moreno1,2,3
1Oncology Data Analytitcs Program, Catalan Institute of
Oncology (ICO), L’Hospitalet de Llobregat, Spain, 2Color-
ectal Cancer Group, ONCOBELL program, Bellvitge
Biomedical Research Institute (IDIBELL), L’Hospitalet de
Llobregat, Spain, 3Consortium for Biomedical Research in
Epidemiology and Public Health (CIBERESP), Madrid,
Spain, 4Public Health Sciences, University of Virginia,
Charlottesville, VA, United States
Introduction: The functional role of expression quantita-
tive trait loci (eQTLs) often remains to be explained. Most
of the single nucleotide polymorphisms (SNPs) involved in
are located in regulatory regions such as promoters or
enhancers, and could interact with transcription factors
(TFs) to regulate gene expression (regQTLs). We hypo-
thesize a main role of TFs mediating the association
between SNPs and gene expression.
Materials and Methods: Colon tissue biopsies and blood
samples were obtained from 191 healthy donors, from
which both gene expression and genotype data were
generated. Using expression data, a consensus Gene
Regulatory Network (GRN) was constructed by merging
three different GRN inference methods (ARACNE-ap,
BC3, and GENIE3), to get only robust interactions. Finally,
regression models were applied to detect regQTLs, using
co-expression of TF – gene pairs learned by GRN and SNPs
located in regulatory sites.
Results: We found a total of 1,427 different interactions
between regQTLs, TFs and target genes, comprising 73
unique target genes of 109 TFs and 1,212 unique regQTLs
(FDR < 0,01). We plan to enlarge the existing dataset to
nearly 500 samples during the next months.
Conclusions: In this study, we present a novel in-silico
method that identified 1,212 unique regQTLs, and could help
to explain regulatory interactions and genome-wide disease
associations. Preliminary results still need to be validated.
Grant references:NIH/NCI CA143237; NIH/NCI
CA204279; NIH/NCI CA201407
F. Moratalla-Navarro: None. V. Diez-Obrero: None.
R. Carreras-Torres: None. M. Devall: None. G. Casey:
None. V. Moreno: None.
P17.092.C
INFRAFRONTIER services for rare disease research
A. Ali Khan, R. Michna, M. Raess, S. Fessele, M. Hrabĕ de
Angelis, INFRAFRONTIER Consortium
INFRAFRONTIER GmbH, Munich, Germany
According to the EU, a rare disease is defined as a disease
afflicting fewer than 1 in 2000 individuals. It is estimated
that 30 million people in Europe suffer from a rare disease.
There are currently about 7000 rare diseases known with
more being discovered continually. The field of rare dis-
eases suffers from a deficit of medical and scientific
knowledge. These diseases reside in the ‘unchartered space’
of biomedical research with their treatment marred by a
dearth of medical and biochemical knowledge. This has led
to development and implementation of several strategies to
tackle the treatment of rare and debilitating diseases. For
example, the EU supports research into rare diseases
through Horizon 2020, the EU Framework Programme for
Research and Innovation. Via Horizon 2020, about €900
million is available to more than 160 collaborative projects
related to rare diseases. The core services of INFRA-
FRONTIER (the European Research Infrastructure for
Mouse Models) comprise of the systemic phenotyping of
mouse mutants in the participating mouse clinics, and the
archiving and distribution of mouse mutant lines by the
European Mouse Mutant Archive (EMMA) which also
include lines important for rare disease research. To con-
solidate and present the INFRAFRONTIER / EMMA
resources related to rare diseases in an easily accessible
location, the INFRAFRONTIER and Rare Diseases web
page was created, providing access to a) EMMA strains
related to rare diseases b) EMMA publications related to
rare diseases and c) information on INFRAFRONTIER
activities at rare disease conferences. This webpage can be
found at: https://www.infrafrontier.eu/infrafrontier-and-ra
re-diseases.
A. Ali Khan: None. R. Michna: None. M. Raess: None.
S. Fessele: None. M. Hrabĕ de Angelis: None.
P17.093.A
Exome-wide identification of pathogenic missense var-
iants by Paralogue Annotation
N. Li, E. Mazaika, R. Walsh, P. Theotokis, M. Ahmed, M.
Jang, X. Zhang, N. Whiffin, P. Barton, J. Ware
Imperial College London, London, United Kingdom
Introduction: Distinguishing novel pathogenic from rare
but benign variants is a key challenge in clinical genetics.
Machine learning tools that predict the consequence of
missense variants typically perform unreliably on novel
variants since there is little information to be used in
training sets. We previously developed Paralogue Annota-
tion (PA); a method that does not require training, but
instead exploits an under-utilised source of information. We
look for functionally equivalent variants of known con-
sequence at equivalent positions across paralogous protein
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families and use their information to predict pathogenicity.
This method was validated in a restricted set of arrhythmia
syndrome genes. Here, we extend it exome-wide.
Materials and Methods: Paralogue relationships as
defined by Ensembl were examined in 7,016 protein-
coding genes associated with human diseases, that harbor
48,258 (Likely) Pathogenic/Benign missense variants from
ClinVar. PA and current established prediction tools were
applied to this and multiple independent test sets.
Results: We identify 3,621 genes that have at least 1
paralogue and show that equivalent pathogenic variants
from other related proteins provides strong supporting
evidence for pathogenicity at 98% precision for ClinVar
variants. Other tools have a lower precision (mean 57.3%
less) and higher false-positive rate (mean 98.4% more)
across all variants tested. With current variants in ClinVar,
we identify 178,378 potentially informative annotations
exome-wide.
Conclusions: PA represents an under-used source of
information with an extremely high positive predictive
value for identifying novel and rare disease-causing
variants. As more variants arise, the utility and power of
PA will increase over time.
N. Li: None. E. Mazaika: None. R. Walsh: None. P.
Theotokis: None. M. Ahmed: None. M. Jang: None. X.
Zhang: None. N. Whiffin: None. P. Barton: None. J.
Ware: None.
P17.094.B
A population-specific reference genome built by inte-
grating three de novo Japanese genome assemblies
J. Takayama1,2,3, S. Tadaka2, K. Yano2,3, F. Katsuoka1, C.
Gocho2, T. Funayama2, S. Makino2, Y. Okamura1,2, A.
Kikuchi4, J. Kawashima2, A. Otsuki2, J. Yasuda2, S. Kure2,4,
K. Kinoshita1,2,5, M. Yamamoto1,2, G. Tamiya1,2,3
1Advanced Research Center for Innovations in Next-
Generation Medicine, Tohoku University, Sendai, Japan,
2Tohoku Medical Megabank Organization, Tohoku Uni-
versity, Sendai, Japan, 3RIKEN Center for Advanced
Intelligence Project, Tokyo, Japan, 4Department of Pedia-
trics, Tohoku University School of Medicine, Sendai, Japan,
5Graduate School of Information Sciences, Tohoku Uni-
versity, Sendai, Japan
The human reference genome is an invaluable resource both
for basic and clinical genetic research. However, the reference
genome lacks some population-specific sequences, is mainly
composed of genomes from African or European origins, and
has > 90,000 rare reference alleles. Here we report JG1, a
population-specific reference genome built by integrating
three de novo Japanese genome assemblies. We performed
three de novo hybrid assemblies of >100X PacBio long reads
and >100X Bionano optical maps per individual. After error-
correction with the long and >50X short reads, the three
assemblies were meta-assembled by using mate-pair infor-
mation. We then replaced minor alleles in the meta-assembled
genome by major alleles defined among the three individual
assemblies. Finally, we built pseudo-chromosomes by
anchoring each scaffold to each chromosome on the basis of
marker positional information from genetic and radiation
hybrid maps. The resulting genome JG1 was highly con-
tiguous (Scaffold NG50 = 141 Mb), concordant with
GRCh38 (only 1,654 mis-assemblies), and replaced minor
reference allele in 96% of 650,718 SNV sites (non-reference
allele frequency > 90% in Japanese population). Moreover,
we performed confirmatory exome re-analysis of rare diseases
using JG1 as a reference, and found that the number of total
variant calls was smaller in JG1 than in the reference hs37d5,
while the variant call set retained the causal variants. These
results suggest that integration of multiple assemblies is an
effective way to build a high-quality population-specific
reference genome. JG1 is publicly available and can be
browsed in the jMorp website (https://jmorp.megabank.
tohoku.ac.jp/).
J. Takayama: None. S. Tadaka: None. K. Yano: None.
F. Katsuoka: None. C. Gocho: None. T. Funayama:
None. S. Makino: None. Y. Okamura: None. A. Kikuchi:
None. J. Kawashima: None. A. Otsuki: None. J. Yasuda:
None. S. Kure: None. K. Kinoshita: None. M. Yama-
moto: None. G. Tamiya: None.
P17.095.C
Accurate and simultaneous identification of differential
expression and splicing using hierarchical Bayesian
analysis
P. N. Robinson1, G. Karlebach1, P. Hansen1, D. F. T.
Veiga1, R. Steinhaus2, D. Danis1, S. Li1, O. Anczukow1
1The Jackson Laboratory for Genomic Medicine, Farm-
ington, CT, United States, 2Charité Universitätsmedizin,
Berlin, Germany
The regulation of mRNA controls both overall gene
expression as well as the distribution of mRNA isoforms
encoded by the gene. Current algorithmic approaches focus
on characterization of significant differential expression or
alternative splicing without integrating both events. Here,
we present Hierarchical Bayesian Analysis of Differential
Expression and ALternative Splicing (HBA-DEALS),
which simultaneously characterizes differential expression
and splicing in cohorts. The statistical model of HBA-
DEALS characterizes genes as having differential gene
expression (DGE), differential alternative splicing (DAST),
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both, or neither. We analyzed 50 simulated datasets for
DGE with HBA-DEALS and five other top-performing
DGE analysis tools: voom, DESeq2, edgeR, baySeq, and
NOISeq. We analyzed the same datasets for DAST with
rMATS. HBA-DEALS displayed a larger area under the
precision-recall curve than the other approaches did for both
DGE and DAST. To assess the accuracy of HBA-DEALS
using real data, we ran HBA-DEALS on estimated isoform
levels from the Genotype-Tissue Expression (GTEx) pro-
ject. We used HBA-DEALS to identify differentially
expressed and differentially spliced genes in 20 different
pairs of tissues and found a high degree of overlap of genes
identified as differentially expressed or spliced (p < 2.23 ×
10−308 for all comparisons, hypergeometric test). Based on
an analysis of the GTEx data, we demonstrate the existence
of sets of genes that show predominant DGE or DAST
across a comparison of 20 tissue pairs, and show that these
sets have pervasive differences with respect to gene struc-
ture, function, membership in protein complexes, and pro-
moter architecture.
P.N. Robinson: None. G. Karlebach: None. P. Hansen:
None. D.F.T. Veiga: None. R. Steinhaus: None. D. Danis:
None. S. Li: None. O. Anczukow: None.
P17.096.A
ROHMM, a flexible HMM approach for detecting
homozygosity using next generation sequencing data
G. Çelik1, T. Tuncalı2
1Health Sciences Institute, Ankara Yildirim Beyazit Uni-
versity, Ankara, Turkey, 2Department of Medical Genetics,
Ankara University School of Medicine, Ankara, Turkey
Introduction: Runs of long homozygous stretches (ROH)
are considered to be the result of consanguinity and usually
contain recessive deleterious disease causing mutations.
Several algorithms have been developed to detect ROHs.
Here, we developed a simple, alternative strategy by
examining X chromosome non-pseudoautosomal region
(Non-PAR) to detect the ROHs from NGS data utilizing the
genotype probabilities and the hidden Markov model
(HMM) algorithm as a tool, namely ROHMM. It is
implemented purely in java and contains both command
line and GUI. ROHMM can operate in a range from single
sample to population scale data alike.
Materials and Methods: NGS genotype data is from
1000G phase3. 25 deep sequenced whole genome data (10
males, 15 females) were processed to collect genotyping
results from the X chromosome Non-PAR. Genotype
probabilities were integrated into HMM algorithm along
with dynamic transition probabilities calculated from
distances between each locus.
Results: Simulation results demonstrated that ROHMM
can detect ROHs of varying lengths with great precision and
accuracy compared to PLINK, BCFtools, and H3M2. On
real population data, ROHMM proved to be as robust as
using allele frequencies or sliding window methods.
Comparisons between heterozygosity ratio and ROHMM’s
inferences have shown a significant correlation which
supports the integrity of the ROHMM for the population
studies.
Conclusions: We present a novel approach for the
detection of ROHs. ROHMM’s strength comes from the
emission parameters deduced from NGS genotype topology
rather than allele frequencies that may contain potential
sampling bias, and flexibility for application to any size
of data.
G. Çelik: None. T. Tuncalı: None.
P17.098.C
‘Deep dive’ disease gene re-annotation in GENCODE:
identifying and reporting new variant interpretations of
likely clinical relevance.
J. M. Mudge, T. Hunt, J. M. Gonzalez, A. Frankish
European Molecular Biology Laboratory, Hinxton, United
Kingdom
The accuracy of variant interpretation directly relates to the
‘trueness’ of gene annotation. However, current annotations
are limited in scope and quality, and these deficiencies
foster an opaque view of disease biology. We present a
drive by Ensembl-GENCODE to radically improve our
understanding of disease gene structure and function,
deploying a fully integrated, manually supervised workflow
incorporating state-of-the-art transcriptomics datasets with
enormous tissue coverage alongside targeted proteoge-
nomics and in-depth phylogenetic assessment. Crucially,
we can specifically identify ‘missing’ gene features that
appear most likely to be biologically relevant, and thus of
potential clinical importance. Previously, our re-annotation
of 191 epilepsy genes led to the identification of 3 novel de
novo SCN1A mutations within a panel of 122 patients with
Dravet’s syndrome. We are expanding this work in colla-
boration with clinical partners to query additional genes and
experimental datasets, and our efforts have now progressed
into gene panels for other diseases. We will present
potentially crucial new understandings of genes such as
POLG, which is linked to mitochondrial disease. None-
theless, genic insights provided by Ensembl-GENCODE do
not efficiently propagate into the clinic, for two major rea-
sons: firstly, genomics projects - both small and large scale -
typically utilise older annotations; secondly, investigative
work and diagnostics often incorporate a single transcript
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model per gene. We will therefore outline our proposed
strategy for the targeted dissemination of new annotation
information into different parts of the scientific community
and would welcome feedback on these ideas. Supported by
NHGRI Award U41HG007234.
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P17.099.A
Determining the role of gene expression on human
sexual dimorphism
E. Porcu1,2, A. Claringbould3, K. Lepik4,5, BIOS
Consortium, L. Franke3, F. A. Santoni6, A. Reymond1, Z.
Kutalik5,2
1Center for Integrative Genomics, University of Lausanne,
Lausanne, Switzerland, 2Swiss Institute of Bioinformatics,
Lausanne, Switzerland, 3University Medical Centre Gro-
ningen, Groningen, Netherlands, 4Institute of Computer
Science, University of Tartu, Tartu, Estonia, 5University
Center for Primary Care and Public Health, Lausanne,
Switzerland, 6Endocrine, Diabetes, and Metabolism Ser-
vice, Centre Hospitalier Universitaire Vaudois (CHUV),
Lausanne, Switzerland
Despite the prevalence of many diseases differs between
women and men, only few published genome-wide asso-
ciation studies (GWAS) have been performed in a sex-
stratified manner. Nowadays the molecular bases of sex
associated differences in complex traits remain poorly
understood. We hypothesized that given the marked causal
involvement of gene expression levels in complex traits,
sex-biased trait associations might be driven by sex-biased
eQTLs.To challenge this assumption, we performed a
genome-wide analysis of sex-specific whole blood RNA-
seq eQTLs from 3,447 individuals. Amongst the pre-
selected 9 million SNP-gene pairs (based on sex-combined
association), we identified 18 genes with significantly (FDR
5%) different eQTL effects in men and women. PheWAS
analyses for these 18 eGenes on >700 traits revealed that
sex-biased eQTLs in CDIP1 and PSMD5 translate into sex-
specific trait-associations for trunk predicted mass. How-
ever, such examples are sporadic and sex-specific expres-
sion regulation does not systematically propagate to high-
level traits. Next, we applied a sex-specific transcriptome-
wide Mendelian Randomization approach (TWMR) by
combining sex-specific summary statistics for both eQTLs
and complex traits and observed the presence of a com-
pensatory effect downstream of gene expression, e.g. genes
with stronger eQTLs in women have weaker woman-
specific causal effects on complex traits. Finally, we show
that the sex-specific GWAS associations are not driven by
sex-biased eQTLs. Our findings suggest that sex-specific
trait associations can rarely occur as a consequence of sex-
specific gene expression regulation in whole blood, hence
other omics data are necessary to better understand the
genetic basis of sexual dimorphism.
E. Porcu: None. A. Claringbould: None. K. Lepik:
None. L. Franke: None. F.A. Santoni: None. A.
Reymond: None. Z. Kutalik: None.
P17.100.B
SCelVis: exploratory single cell data analysis on the
desktop and in the cloud
B. Obermayer1,2, M. Holtgrewe1,2, M. Nieminen1,3, C.
Messerschmidt1,2, D. Beule1,3
1Berlin Institute of Health, Berlin, Germany, 2Charite -
Universitaetsmedizin, Berlin, Germany, 3Max-Delbrueck-
Center for Molecular Medicine in the Helmholtz Associa-
tion, Berlin, Germany
Introduction: Single cell omics technologies present
unique opportunities for biomedical and life sciences from
lab to clinic, but the high dimensional nature of such data
poses challenges for computational analysis and inter-
pretation. Furthermore, FAIR data management as well as
data privacy and security become crucial when working
with clinical data, especially in cross-institutional and
translational settings. To facilitate analysis and interpreta-
tion of single-cell data by users without bioinformatics
expertise, we present SCelVis, a flexible, interactive and
user-friendly app for web-based visualization of pre-
processed single-cell data.
Methods: SCelVis is implemented in Python using Dash
by Plotly and available as a Python package, via Conda/
Bioconda and as a Docker image under the permissive MIT
license. All components are based on open standards and
interfaces, enabling further development and integration
with third party pipelines and analysis components. The
GitHub repository is https://github.com/bihealth/scelvis.
Results: In SCelVis, users can survey multiple interactive
visualizations of their single cell expression data and cell
annotation, define cell groups by filtering or manual
selection and perform differential gene expression, and
download raw or processed data for further offline analysis.
SCelVis can be run both on the desktop and cloud systems
and accepts input from local and various remote/cloud
sources using open protocols. We use SCelVis in connec-
tion with an iRODS based omics data management system
for interdisciplinary single cell data analysis in translational
research and clinical applications. Other users found it
useful to easily create standalone websites that allow
efficient exploration of their published data sets.
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P17.102.A
Unveiling Early Differentiation induced by Histone
Deacetylase inhibitors in Neuroblastoma cell lines: a
Single-Cell Transcriptomics Approach
G. Milazzo1, D. Mercatelli1, E. Aleo2, G. Perini1, F. M.
Giorgi1
1University of Bologna, Bologna, Italy, 2IGA Technology
Services, Udine, Italy
The process of tumorigenesis cannot be fully explained
solely by genetic alterations. Epigenetic regulation is an
underinvestigated basal cause initiating and sustaining
cancer cells development. In this context, Histone deace-
tylases (HDACs) play a fundamental role in remodeling
chromatin and thus regulating gene expression towards cell
proliferation and de-differentiation (PMID 21416059).
Currently, there are more than 20 HDAC inhibitor drugs
approved for cancer treatment or in clinical trials. These
inhibitors can promote cell differentiation and apoptosis and
ultimately reduce cancer cell growth, infiltration and
angiogenesis. However, little is known on the early tran-
scriptional response induced by HDAC inhibitors, particu-
larly in Neuroblastoma. Current transcriptomics techniques
(microarrays and bulk RNA-Seq) lack the ability to
understand short-term transcriptional responses at a single
cell resolution. Here, we measure transcript expression from
2000 single cells from Neuroblastoma cell lines treated with
an HDAC pan-inhibitor using 10x Genomics with Cell
Hashing and Illumina sequencing. Our analysis of single-
cell gene expression profiles detected an increased propor-
tion of cells in G1 phase in inhibitor-treated Neuroblastoma
cells. Amongst these we were able to identify progressively
differentiated and apoptotic cell populations. We also detect
a high heterogeneity in individual cells transcriptional
response upon drug delivery, linked with short-term rewir-
ing and/or the insurgence of resistance mechanisms. This
can help understanding how HDAC inhibitors can benefit
from the combination with other drugs, in order to further
guide the tumor’s molecular machinery towards differ-
entiation and apoptosis.
G. Milazzo: None. D. Mercatelli: None. E. Aleo: None.
G. Perini: None. F.M. Giorgi: None.
P17.104.C
Integrative somatic variant calling in paired FFPE
tumor and peripheral blood samples to identify candi-
date mutations to follow-up in circulating tumor DNA
for tracking minimal residual disease in localized
colorectal cancer patients
J. Martín Arana1,2,3, R. Tébar-Martínez1,4, N. Tarazona1,2,
P. Rentero-Garrido4, J. Carbonell-Asins3, C. Martínez-
Ciarpaglini5, C. Alfaro-Cervello5, M. Huerta1, S. Roselló1,2,
A. Ferrer-Martínez1,2, D. Roda1,2, S. Zúñiga3,4, A.
Cervantes1,2
1Department of Medical Oncology, INCLIVA Biomedical
Research Institute, Valencia, Spain, 2CIBERONC, Instituto
de Salud Carlos III, Madrid, Spain, 3Bioinformatics and
Biostatistics Unit, INCLIVA Biomedical Research Institute,
Valencia, Spain, 4Precision Medicine Unit, INCLIVA
Biomedical Research Institute, Valencia, Spain, 5Depart-
ment of Pathology, INCLIVA Biomedical Research Institute,
Valencia, Spain
Introduction: Mutation tracking in circulating tumour
DNA (ctDNA) is used to detect minimal residual disease
(MRD) in localized colorectal cancer (CRC) patients.
Sequencing of tumor-only samples restricts the selection of
tracking somatic mutations to those already known to be
pathogenic. To increase the number of candidate mutations
to monitor patients, sequencing of paired tumor-normal
samples is required.
Validation and optimization of different variant calling
tools are essential to maximize sensitivity scores. The aim
of this work is developing an integrative bioinformatics
pipeline to compare the use of only-tumor versus paired
normal-tumor samples to identify candidate somatic muta-
tions to follow-up in ctDNA to detect MRD.
Materials and Methods: Tumor Formalin Fixed Paraf-
fin Embedded (FFPE) and peripheral blood samples of 150
CRC patients were sequenced using a 29-gene custom panel
including Unique Molecular Identifiers technology. For
pipeline development, five different algorithms were tested
on a mixture of HapMap cell lines and 2 commercial
standards.
Results: Smcounter2, LoFreq and Mutect2 reported best
sensitivity values. 11% of patients could not be monitored
because no pathogenic variants were detected using tumor-
only samples, whereas all 150 patients presented at least
two somatic variants when adding normal sample data. In
addition, paired samples analysis identified somatic variants
in 16 genes where no pathogenic variants had been
previously detected using tumor-only samples.
Conclusions: A combination of different variant calling
tools is necessary to achieve best sensitivity ranges. Paired
tumor-normal sample analysis increases the percentage of
patients to be monitored to detect MRD.
J.MA contract is founded by CIBERONC.
670 J. del Picchia
J. Martín Arana: None. R. Tébar-Martínez: None. N.
Tarazona: None. P. Rentero-Garrido: None. J. Carbo-
nell-Asins: None. C. Martínez-Ciarpaglini: None. C.
Alfaro-Cervello: None. M. Huerta: None. S. Roselló:
None. A. Ferrer-Martínez: None. D. Roda: None. S.
Zúñiga: None. A. Cervantes: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Modest; Roche, Merk
Serono, SERVIER, Novartis, Lilly, Tesaro, Johnson &
Johnson, Medlmmune, Theradex, Astellas Pharma, Array
BioPharma. D. Speakers Bureau/Honoraria (speakers
bureau, symposia, and expert witness); Modest; Merk
Serono, Roche, SERVIER. F. Consultant/Advisory Board;
Modest; Bayer, Pierre Fabre.
P17.105.A
Performance evaluation of deleteriousness prediction
methods for intronic SNVs in next generation sequences
R. Quintas-Rey1, J. Amigo2, A. Carracedo2, F. Barros2
1Grupo de Medicina Xenómica, USC, Santiago de Com-
postela, Spain, 2Fundacion Publica Galega de Medicina
Xenomica - Sergas, Grupo de Medicina Xenomica -
CIBERER, Universidad de Santiago de Compostela,
Santiago de Compostela, Spain
Introduction: Alterations in splicing sites (ss) are estimated
to explain approximately 10% of human disease causal
variants. Mutations outside the ss but affecting “regulatory
elements” can be up to 25%. Accurate deleteriousness
prediction for intronic variants is crucial for diagnostic
purposes. Many deleteriousness prediction methods have
been developed, but their relative values are still unclear in
practical applications. We comprehensively evaluated the
predictive performance of two complementary
deleteriousness-scoring methods using information from
real patients.
Material and Methods: We selected the dbscSNV (both
ADA and RF scores) and SPIDEX algorithms, that study
variants in splicing consensus regions or in regulatory
regions respectively. The tools, either alone or in combina-
tion, were tested on 29294 gene intronic SNVs that have
previously been characterised by ClinVar as either “patho-
genic” (430) or “benign” (28864). The sensitivity, specifi-
city and positive and negative predictive values were
calculated. Moreover, we applied the algorithms to WES
data from undiagnosed patients, and we analysed the
mRNA sequence from genes that fitted the patient’s
phenotype.
Results: The highest sensitivity corresponds to dbscSNV
with 96.55% while the best specificity is for SPIDEX with
95.78%. When considering the 3 scores (SPIDEX,
dbscSNV ADA and RF Score), the sensitivity and
specificity values were 60.7% and 94.6%. The Positive
and Negative Predictive Value were 14.45% and 99.39%.
The results for 20 undiagnosed cases are presented.
Conclusions: Besides the low positive predictive value,
the combination of both algorithms leads less than 1% of
false negatives, so their routine use can be recommended for
diagnostic purposes.
R. Quintas-Rey: None. J. Amigo: None. A. Carracedo:
None. F. Barros: None.
P17.106.B
Functional and in-silico interrogation of rare genomic
variants impacting RNA splicing for the diagnosis of
genomic disorders
J. M. Ellingford1, H. B. Thomas1, C. Rowlands1, G. Arno2,
G. Beaman1, B. Gomes-Silva1, C. Campbell3, N. Gossan3,
C. Hardcastle3, K. Webb1, C. O’Callaghan4, R. A. Hirst4, S.
Ramsden3, E. Jones3, J. Clayton-Smith1, A. R. Webster2,
Genomics England Research Consortium, R. T. O’Keefe1,
W. G. Newman1, G. C. M. Black1
1University of Manchester, Manchester, United Kingdom,
2University College London, London, United Kingdom,
3Manchester Universities NHS Foundation Trust, Manche-
ster, United Kingdom, 4University of Leicester, Leicester,
United Kingdom
Purpose: To develop a comprehensive analysis framework
to identify pre-messenger RNA splicing pathogenic variants
in the context of rare disease.
Methods: We ascertained variants of uncertain signifi-
cance (VUS) through clinical multi-disciplinary team
meetings, and defined an accurate in-silico strategy for the
prioritization of variants impacting splicing through com-
parison to functional analyses. We retrospectively applied
these prioritization strategies to a large cohort of 2783
individuals who had previously received genomic testing
for rare genomic disorders, and assessed clinical impact.
Results: We identified 21 VUS that potentially impacted
splicing, and used cell based splicing assays to identify
those variants which disrupted normal splicing. We
established the comparative utility of 9 in-silico strategies
for variant prioritization. We analysed 1,346,744 variants
identified through diagnostic testing for 2783 individuals,
and observed that clinical impact is highly dependent on the
specific incorporated in-silico prioritization strategy. We
show that incorporation of one of these strategies into
diagnostic testing would improve clarity in clinical analysis
for 15% of the individuals surveyed. Prioritized variants
could provide new molecular diagnoses or provide
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additional support for molecular diagnosis for up to 81
individuals within our cohort.
Conclusions: Incorporation of an in-silico and functional
analysis framework for splicing pathogenic variants
improves clarity in diagnostic reporting, increases diagnos-
tic yield and, with the advent of targeted treatment
strategies, can directly alter patient clinical management.
J.M. Ellingford: None. H.B. Thomas: None. C. Row-
lands: None. G. Arno: None. G. Beaman: None. B.
Gomes-Silva: None. C. Campbell: None. N. Gossan:
None. C. Hardcastle: None. K. Webb: None. C.
O’Callaghan: None. R.A. Hirst: None. S. Ramsden:
None. E. Jones: None. J. Clayton-Smith: None. A.R.
Webster: None. R.T. O’Keefe: None. W.G. Newman:
None. G.C.M. Black: None.
P17.107.C
A comprehensive in silico analysis of the functional,
structural and stability impact of the PALB2 p.
Leu1143His variant of uncertain clinical significance.
M. Zanti, M. A. Loizidou, K. Michailidou, C. Machattou, P.
Pirpa, G. M. Spyrou, K. Kyriacou, A. Hadjisavvas
The Cyprus Institute of Neurology and Genetics, Nicosia,
Cyprus
Introduction: Germline genetic testing can identify women
with pathogenic mutations who are at increased risk of BC.
However, genetic testing may reveal a variant of uncertain
clinical significance (VUS). These variants pose significant
challenges for clinicians since, their ambiguous association
with disease interferes with effective genetic counseling.
Although, in-vitro characterization of these variants should
be performed, it is often not feasible to carry out functional
interpretation for every single VUS. To this end, we con-
ducted a comprehensive in silico analysis of the structural,
functional and stability impact of the PALB2 p.Leu1143His
VUS which was identified in 9 Cypriot BC patients with
extensive family history of the disease.
Materials and Methods: A combination of structural
bioinformatics tools were used for the in silico classification
of the PALB2 p.Leu1143His VUS.
Results: Stability analyses based on ΔΔG calculations
(10 prediction tools) predicted a destabilization of the
mutant PALB2 protein. The substitution from the non-
polar, hydrophobic Leucine to the positively charged,
hydrophilic Histidine, results in a minor change of the
surface charge and conformation. Both amino acids are
exposed to the surface (cut-off value: Relative Solvent
Accessibility -RSA > 25%) since RSA demonstrated similar
values (71.3% and 83.1%) upon mutagenesis. Results on
protein stability and structure end up being contradicting.
Conclusions: Although in silico tools are valuable for the
interpretation of VUS, functional studies are needed to draw
more definite conclusions on variant classification.
Grant: EU H2020; 669026; Establishment of the
Bioinformatics Chair at the CING (BIORISE).
M. Zanti: None.M.A. Loizidou: None. K. Michailidou:
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P17.108.A
Towards a better understanding of the low discovery
rate of short-read based insertion variant callers
W. Delage1, J. Thevenon2, C. Lemaitre1
1Univ Rennes, CNRS, Inria, IRISA - UMR 6074, F-35000,
Rennes, France, 2Unité de Génétique Clinique, Pôle Couple
Enfant, CHU de Grenoble Site Nord-Hôpital Couple-
Enfant, 38043, Grenoble, France
Since 2009, numerous tools have been developed to detect
structural variants using short read technologies. Insertions
are one of the hardest type to discover and are drastically
underrepresented in gold standard variant call sets. The
advent of long read technologies has completely changed
the situation. In 2019, two independent cross technologies
studies have published the most complete variant call sets
with sequence resolved insertions in human individuals.
Among the reported insertions, only 15% could be dis-
covered with short-read based tools. In this work, we per-
formed an in-depth analysis of these unprecedented
insertion call sets, in order to investigate the causes of such
failures. We have first established a precise classification of
insertion variants according to three different layers of
characterization: the nature of the inserted sequence, the
genomics context of the insertion site and the breakpoints
junction complexity. Because these levels are intertwined,
we used simulations to characterize the impact of each
complexity factor. Most reported insertions exhibited
characteristics that may interfere with their discovery: 50%
were tandem repeat expansions, 40% contained homologies
larger than 20 bp within their breakpoints junctions and
70% were located in simple repeats. Consequently, the
recall of short-read based variant callers was significantly
lower for such insertions (7% vs 54% for mobile element
and novel insertions). Simulations showed that the most
impacting factor on the discovery rate was the insertion type
rather than the genomics context, and that the different
factors of insertion complexities were handled differently
depending on the chosen tool.
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Vaquita-LR: A new bioinformatics tool for identifying
structural variants using long and short reads
J. J. Kim1, J. Kim1, K. Reinert1,2
1Max Planck Institute for Molecular Genetics, Berlin,
Germany, 2Freie Universität Berlin, Berlin, Germany
Introduction: The identification of structural variation in
the genome is difficult due to the lack of a “perfect”
sequencing technology. By combining short and long read
sequencing data, Vaquita-LR is a novel bioinformatics
approach to identify more variants with higher accuracy by
utilizing the strengths of one method to overcome the
weaknesses of the other.
Materials and Methods: Vaquita-LR is an extension of
Vaquita, a short read variant caller, which has been
modified to identify potential variants in long reads in
addition to short reads and merge them to provide a final set
of variants. Vaquita-LR takes into consideration the read
depth, read length, and other characteristics of the
sequencing data to add weight to more confident calls.
Additionally, it adapts techniques from Pilon to improve the
accuracy of the long read data using relevant short read
information.
Results: By combining short and long reads, Vaquita-LR
is able to outperform other structural variant callers,
including meta callers which combine results from other
callers. Importantly, supplying long reads is effective at
sequencing depths as shallow as 1x. Using this combination
allows Vaquita-LR to better filter out false positives while
retaining true positives, providing a better list of possible
causal variants for further investigation.
Conclusions: With the abundance of data available
today, it is important to consider how the data can be
effectively merged to better serve our needs. Vaquita-LR is
an initial step in showing the usefulness of integrating
different sequencing data types when identifying structural
variants.
J.J. Kim: None. J. Kim: None. K. Reinert: None.
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Identification of subnetwork markers for diagnosis and
prognosis of Middle-Eastern patients with colorectal
cancer using integrative genomic and network-based
analysis
O. Al-Harazi1,2, I. H. Kaya1,3, A. El Allali2, N. Kaya4, D.
Colak1
1Department of Biostatistics, Epidemiology and Scientific
Computing, King Faisal Specialist Hospital and Research
Centre, Riyadh, Saudi Arabia, 2College of Computer and
Information Sciences, Computer Science Department, King
Saud University, Riyadh, Saudi Arabia, 3College of
Medicine, Alfaisal University, Riyadh, Saudi Arabia,
4Department of Genetics, King Faisal Specialist Hospital
and Research Centre, Riyadh, Saudi Arabia
Introduction: The identification of gene signatures for
disease prognosis and diagnosis is considered a major step.
Artificial intelligence and machine learning methodologies
have been used to investigate the molecular characteristics
of diseases. It has been reported that subnetwork markers
are reliable with high accuracy in disease classification.
Materials and Methods: We developed and used a
subnetwork-based method to identify network markers for
Saudi colorectal cancer (CRC) patients. Whole-genome
gene expression and copy number alterations (CNAs)
datasets were gathered from publically available databases.
We then performed an integrated analysis of mRNA and
CNA datasets followed by a gene interaction network
analysis using several publically available databases. We
clustered the identified gene network into subnetworks and
calculated an activity score for each significant subnetwork.
The scores were then used as feature values to build a
support vector machine (SVM) classification model.
Results: The integrated genomic analysis revealed 24
differentially expressed genes with CNAs. Network analy-
sis revealed 15 significant subnetwork markers associated
with CRC. The SVM classifier using individual marker
genes showed 94.7% accuracy, whereas the classifier with
the subnetwork markers achieved 98.4% accuracy in
identifying CRC patients. Furthermore, we validated the
prognostic potential of our subnetwork markers on
independent CRC datasets with detailed clinical data.
Conclusions: Subnetwork markers that are based on
integrated genomic and network analyses yield more robust
and accurate classification results compared to gene
markers.
Acknowledgement: This study is funded by the Research
Grant (RAC#2110006 to DC). We would like to thank Ms.
Sukina Qanbar for her administrative support.
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ePOSSUM2: A web app for predicting the impact of
DNA variants on transcription factor binding
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1Charité, Berlin, Germany, 2The Jackson Laboratory,
Farmington, CT, United States
Modelling gene regulation is a major challenge in biome-
dical research. Mutations in transcription factor binding
sites (TFBS) may cause the misregulation of genes, even-
tually leading to disease.
In 2016, we published a study that compared the ability of
179 binding models for 82 human transcription factors to
identify experimentally verified “real” in vivo binding sites
derived from ENCODE ChIP-seq data. Our results showed
that several models do not reliably detect TFBSs. Using
these results, we created ePOSSUM, a web application for
predicting the impact of DNA variants on transcription
factor binding.
Here we present an update of the application. ePOSSUM2
has been rebuild from the ground up with a modern C++
back-end that runs many computations in milliseconds.
In ePOSSUM2, web users can easily upload VCF files to
identify and rank variants that most likely affect gene
expression. ePOSSUM2 supports more than 4,000 different
binding models, including transcription factor flexible
models. It features an improved log-weighted matching
algorithm that takes into account the wild-type dinucleotide
distribution surrounding matching sites. For each variant,
ePOSSUM2 predicts the effect on transcription factor
binding. To account for the poor performance of several
binding models, it also reports a negative or positive
predictive value.
ePOSSUM2 is freely available at: http://www.muta
tiondistiller.org/ePOSSUM2
S. Proft: None. R. Steinhaus: None. P.N. Robinson:
None. D. Seelow: None.
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TaPAS db: A centralised storage solution for case-
management and variant interpretation for diagnostic
targeted next generation sequencing data
J. Adams1,2, M. Owens1, M. Sloman1, A. Moleirinho1, K.
Colclough1, C. Bowles1, R. van Heugten1, A. Davies2, A.
Parrish1
1Exeter Genomics Laboratory, Royal Devon and Exeter
NHS Foundation Trust, Exeter, United Kingdom, 2Univer-
sity of Manchester, Manchester, United Kingdom
Analysis of panels of genes associated with particular
clinical indications by targeted Next Generation Sequencing
(tNGS) is offered routinely in diagnostic laboratories to
maximise the likelihood of finding a genetic diagnosis. In
2019, Exeter Genomics Laboratory (EGL) performed tNGS
testing for approximately 2000 patients, generating hun-
dreds of variants per patient requiring secure storage and
interpretation. Efficient variant prioritisation and inter-
pretation is essential for delivering a timely diagnosis which
can be facilitated by cross-referencing results from previous
patients and applying filtering strategies based on ACMG
variant classification guidelines. Historically, data for each
patient has been stored independently, limiting the ability to
detect trends across patients and utilise information from
previous analyses.
Here we present TaPAS, a variant interpretation interface
and centralised data store for variants identified using
EGL’s in-house tNGS bioinformatics pipeline. Built using
the Django framework based around an SQL database,
TaPAS dynamically filters and displays variants based on
the intrinsic characteristics of the variants and ACMG
variant classification criteria, with JavaScript elements used
to access external databases and manipulate local programs
such as Alamut® Visual and IGV to visualise variants. It
maintains a historical record of previous analyses, display-
ing variant frequency in the patient cohort, previous variant
classifications and allows the application of additional
panels to the data as required. TaPAS streamlines the
process of variant classification and genomic diagnosis,
optimises interpretation and reanalysis of tNGS data and
reduces turnaround times.
J. Adams: None. M. Owens: None. M. Sloman: None.
A. Moleirinho: None. K. Colclough: None. C. Bowles:
None. R. van Heugten: None. A. Davies: None. A.
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Using transcription factor sequence information to
interpret rare variants in non-coding regions
H. K. Zieger, F. Thieme, A. Schmidt, J. Fazaal, E.
Mangold, J. Welzenbach, K. Ludwig
Institute of Human Genetics, University of Bonn, School of
Medicine & University Hospital Bonn, Bonn, Germany
Common diseases are characterized by variants from dif-
ferent parts of the allelic spectrum. While common risk
variants are identified by GWAS, the conclusive identifi-
cation of causal private/rare variants remains challenging.
Collapsing rare variants into groups, as performed in gene
burden analyses, is difficult for non-coding regions, due to
the lack of functional annotations. Here we combine rese-
quencing data of non-coding regions with information of
transcription factor binding sites (TFBS), to identify novel
etiological variants and molecular players in non-syndromic
cleft lip with/without cleft palate (nsCL/P). We used data of
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691 European cases and 854 European controls, in which
functional candidate regions at three GWAS risk loci (total
56.7 kb) had been resequenced using molecular inversion
probes. Based on 624 rare variants (MAF<1%) and position
weight matrix information, we predicted TFBS for 810
human transcription factors from JASPAR2020. Of the 370
motifs that were hit by at least one rare variant (total
number: 4,013), 21 motifs were hit significantly more often
in cases compared to controls. When integrating the pre-
dicted allelic effect on TF binding capacity, we identified an
additional set of nine TFs where in aggregate the variants’
effects on the motif were stronger in cases. Across both
approaches, consistent effects were observed for TF motifs
of FOXO6 and ZEB1, suggesting them as molecular players
in nsCL/P at these loci. This analysis framework will
improve systematic evaluation of rare variant data and can
be extended to large data sets, such as from whole genome
sequencing studies.
H.K. Zieger: None. F. Thieme: None. A. Schmidt:
None. J. Fazaal: None. E. Mangold: None. J. Welzen-
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Meta-analysis of cancer transcriptomes using Indepen-
dent Component Analysis
A. Seisenova, A. Sharip, A. Molkenov, D. Karabayev, U.
Kairov
Laboratory of Bioinformatics and Systems Biology, Center
for Life Sciences, National Laboratory Astana, Nazarbayev
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Introduction: Independent Component Analysis (ICA) is a
matrix factorization method for data dimension reduction.
ICA has been widely applied for the analysis of tran-
scriptomic data for blind separation of biological, environ-
mental and technical factors affecting gene expression. This
study aimed to analyze cancer data using the ICA for
identification and comprehensive analysis of reproducible
signaling pathways and molecular signatures in cancer.
Materials and Methods: In this study, four independent
cancer transcriptomic datasets GSE26886, GSE69925,
GSE32701 and GSE21293 (Affymetrix) from GEO data-
bases were used. R Bioconductor and Matlab have been
used for normalization. A bioinformatics tool «BiODICA -
Independent Component Analysis of Big Omics Data» was
applied to compute independent components (ICs). Gene
Set Enrichment Analysis (GSEA) and ToppGene uncovered
the most significantly enriched pathways. Construction and
visualization of gene networks and graphs were performed
using the OFTEN method, Cytoscape and HPRD database.
Results: The correlation graph between decompositions
into 30 ICs was built with absolute correlation values
exceeding 0.15. Clusters of components - pseudocliques
were observed in the structure of the correlation graph. Top
500 most contributing genes of each ICs in pseudocliques
were mapped to the PPI network to construct signaling
pathways for gene interaction. Some cliques were com-
posed of densely interconnected nodes and included
components common to most cancer types, while others
were common to some of them.
Conclusions: The results of this investigation may reveal
potential biomarkers of carcinogenesis, functional subsys-
tems in the tumor cells, and helpful in predicting the early
development of a tumor.
A. Seisenova: None. A. Sharip: None. A. Molkenov:
None. D. Karabayev: None. U. Kairov: None.
P17.116.C
Single and cross-tissue conditional transcriptome wide
analyses reveal independent and shared susceptibility
genes for psychiatric traits and inflammatory bowel
diseases
C. Maj1, F. Uellendahl-Werth2, O. Borisov1, S. Mucha2, S.
Bej3, M. Wolfien4, A. Weiß5, T. H. Karlsen6, A. Franke2, P.
Hoffmann5, F. Degenhardt5, P. Krawitz1, O. Wolkenhauer4,
M. Nöthen5, D. Ellinghaus1
1Institute for Genomic Statistics and Bioinformatics (IGSB),
Bonn, Germany, 2Institute of Clinical Molecular Biology,
Christian Albrechts University of Kiel, Kiel, Germany,
3Institute of Computer Science, Department of Systems
Biology and Bioinformatics, University of Rostock, Kiel,
Germany, 4Institute of Computer Science, Department of
Systems Biology and Bioinformatics, University of Rostock,
Germany, Rostock, Germany, 5Institute of Human Genetics,
University of Bonn, School of Medicine & University
Hospital, Bonn, Germany, 6Norwegian PSC Research
Center, Department of Transplantation Medicine, Division
of Cancer Medicine, Surgery and Transplantation, Oslo
University Hospital, Rikshospitalet, Oslo, Norway
Introduction: Genome-wide association studies (GWAS)
have identified hundreds of significantly associated loci for
different psychiatric and inflammatory phenotypes. Note-
worthy, genetic correlations have been reported for these
traits indicating the presence of potential shared molecular
mechanisms.
Materials and Methods: We performed transcriptome-
wide association study (TWAS) based on the largest
available GWAS results for a number of psychiatric and
inflammatory traits using the unified test for molecular
signature (UTMOST). We conducted multi-phenotype
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TWASs by considering single and cross-tissue expression
signals based on cis-eQTL. We selected 23 relevant tissues
for brain and gut traits from GTEx, STARNET, and
BLUEPRINT databases. Single tissue associations were
combined by means of the Generalized Berk-Jones (GBJ)
test and we performed genome-wide conditional analysis to
detect independent TWAS signals at loci with multiple
TWAS hits.
Results:A relatively high number of genes were found to
be associated with the analyzed traits. We observed strong
inflation of TWAS signals most likely due to correlated
predicted expression among same-locus genes. Gene
prioritization based on genome-wide conditional analyses
strongly reduced the number of associated genes and
highlighted specific associations including known risk
genes (e.g., SMAD3 for inflammatory bowel disease).
Interestingly some genes are associated both with brain and
gut related phenotypes suggesting common regulation
mechanisms of the gut-brain axis.
Conclusions: TWAS was able to prioritize gene-
associations in multiple psychiatric and inflammatory traits
supporting commonly regulated genes of the gut-brain axis.
Noteworthy, Conditional analysis at loci with multiple
TWAS hits can discriminate between spurious associations
due to correlation and true-association signals.
C. Maj: None. F. Uellendahl-Werth: None. O. Borisov:
None. S. Mucha: None. S. Bej: None. M. Wolfien: None.
A. Weiß: None. T.H. Karlsen: None. A. Franke: None. P.
Hoffmann: None. F. Degenhardt: None. P. Krawitz:
None. O. Wolkenhauer: None. M. Nöthen: None. D.
Ellinghaus: None.
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VarFish - Collaborative Fishing for Causative Variants
M. Holtgrewe1, O. Stolpe1, M. Nieminen1, S. Mundlos2, A.
Knaus3, U. Kornak2, D. Seelow4, L. Segebrecht4, M.
Spielmann4, B. Fischer-Zirnsak4, F. Boschann4, U. Scholl4,
N. Ehmke4, D. Beule1
1CUBI - Core Unit Bioinformatics, Berlin Institute of
Health, Berlin, Germany, 2Charité – Universitätsmedizin
Berlin, Berlin, Germany, 3Institute for Genomic Statistics
and Bioinformatics, University of Bonn, Bonn, Germany,
4Charité - Universitätsmedizin Berlin, Berlin, Germany
VarFish is an easy-to-use web-based database system
designed for empowering geneticists in the analysis of
clinical and whole exome sequencing variant data sets for
individuals and families. It provides a set of tools for sup-
porting the full workflow from (i) variant data quality
control, (ii) variant filtration and (iii) efficient assessment of
variants based on visual alignment inspection and
annotation data such as functional and frequency annota-
tion. The system allows to organize data into a folder
structure of projects with access control. Variant quality
metrics can be displayed project- (and thus cohort-) wise or
for single cases/families. The variants themselves can be
filtered based on genotype, population frequency, variant
effect, quality metrics, and annotation such as membership
in ClinVar or HGMD Public. A special ClinVar-centric
view allows for the easy screening of variants based on
pathogenicity annotation in ClinVar. After filtration of the
variants, their quick and efficient assessment is supported
by various tools: color flags and commenting allows for
simple yet effective note-taking, remote-controlling the
genome viewer IGV to display a variant’s locus, and some
important database excerpts are available directly within the
system. Assessment documentation according to ACMG-
AMP is also supported. Further, link-out to external data-
bases (e.g., ENSEMBL or NCBI), allow the assessment of
variants using MutationTaster, SIFT, or various splice site
assessment tools. Filtered data sets can be downloaded as
VCF or Excel files (including comments and flags) or
submitted to external tools such as MutationDistiller. Var-
Fish also allows for querying the GA4GH beacon network
for individual variants.
M. Holtgrewe: None. O. Stolpe: None. M. Nieminen:
None. S. Mundlos: None. A. Knaus: None. U. Kornak:
None. D. Seelow: None. L. Segebrecht: None. M.
Spielmann: None. B. Fischer-Zirnsak: None. F.
Boschann: None. U. Scholl: None. N. Ehmke: None. D.
Beule: None.
P17.120.A
Variant Record Fusion: a bioinformatics pipeline for
Tumor-only NGS testing in clinical routine
S. Lehnert1, H. Vranckx2, S. Vander Borght2, C.
Helsmoortel2, I. Vanden Bempt1, W. Bossuyt1
1KULeuven, Leuven, Belgium, 2UZ Leuven, Leuven,
Belgium
Here we present a novel approach for the detection and
filtering of variants for NGS cancer diagnostic tests without
tumor matched normal samples. A combination of different
variant callers allows a wider set of variant types to be
detected. Current approaches that make use of different
variant callers rely on merging or concatenating individual
sets of variant calls that have high confidence for a specific
caller. This approach however, needs to tradeoff between
low sensitivity or specificity for variants that have lower
confidence calls in individual variant callers, but are still
true variants. Our approach obviates this problem by fusing
normalized and decomposed variant-records of all different
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callers to allow filtering of individual variants based on the
information from all different callers. Variants in the fused
dataset are subsequently filtered using parameters specific to
the individual caller, to a combination of different callers
and to the combined variant calls of the entire run. The
pooled likelihood matrixes of different callers in fused
variant entries proved to be especially useful for categor-
izing low frequent variant calls (AF <=5%). This pipeline
was brought in clinical routine for a solid tumor gene panel
and a hematological malignancy gene panel. We used 3
variant callers (unified genotyper (2x) and MuTect) and
defined over 20 filter rules. Only 2 from 25 cutoffs required
a slight adaptation between the two different sample tests
with different sample types, FF and FFPE, indicating a
general applicability of this approach.
S. Lehnert: None. H. Vranckx: None. S. Vander
Borght: None. C. Helsmoortel: None. I. Vanden Bempt:
None. W. Bossuyt: None.
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CADD-Splice - Improving genome-wide variant effect
prediction using deep learning derived splice scores
P. Rentzsch1,2, M. Schubach1,2, J. Shendure3,4, M.
Kircher1,2
1Berlin Institute of Health, Berlin, Germany, 2Charité -
Universitätsmedizin Berlin, Berlin, Germany, 3Brotman
Baty Institute for Precision Medicine, Seattle, WA, United
States, 4Department of Genome Sciences, Seattle, WA,
United States
The assembly of genomic exons into mRNAs via splicing is
of critical importance for the correct synthesis of proteins.
As such, genomic variants in splicing regions have been
linked to various genetic diseases. In order to assist the
identification of splice altering variants from genetic data, a
number of methods aim to predict splicing effects. Recently,
deep neural networks (DNNs) have been shown to achieve
better results on predicting splice variants genome-wide.
However, these methods have been barely adopted in
genome-wide variant effect prediction.
We use the Multiplexed Functional Assay of Splicing
using Sort-seq (MFASS) dataset to assess several new
machine learning methods that score variant splicing
effects. To build a general variant effect model, we integrate
two of those approaches into our genome-wide variant
prioritization tool Combined Annotation Dependent Deple-
tion (CADD, cadd.gs.washington.edu), that weights and
integrates a diverse collection of other annotations.
We show that the new DNN scores improve prediction
across multiple variant categories. While splice effect scores
show superior performance on splice variants, the
specialized predictors cannot compete with other variant
scores in general variant interpretation, as these also account
for nonsense and missense effects that do not alter splicing.
This suggests that by integrating domain-specific informa-
tion from for example splice scores, variant prioritization
can generally be improved. We believe that this effect is
universal and outlines the importance of developing domain
specific scores for regulatory sequences, UTRs or non-
coding RNA species.
P. Rentzsch: None. M. Schubach: None. J. Shendure:
E. Ownership Interest (stock, stock options, patent or other
intellectual property); Modest; Patent application on basis
of CADD. M. Kircher: E. Ownership Interest (stock, stock
options, patent or other intellectual property); Modest;
Patent application on basis of CADD.
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Quantifying sequencing performance for clinical WGS
T. U. Dincer1, N. Johnson2, C. Colombo3, M. A. Bekritsky2,
M. A. Eberle2, D. R. Bentley3
1UCLA, Biological chemistry, Los Angeles, CA, United
States, 2Illumina, Inc, San Diego, CA, United States,
3Illumina UK, Cambridge, United Kingdom
Clinical whole genome sequencing (WGS) pipelines must
deliver quantifiably accurate and reproducible variant calls.
Publicly available truthsets allow labs to measure variant
calling performance in curated sets of samples. Truthset
generation methods seek to exclude any problematic
genomic regions that may contain both stochastic and sys-
tematic errors from the source samples. In clinical variant
calling, complementary standards to identify high- and low-
confidence sites are needed in order to detect systematic
effects that generalize to any sample.
With increased sequencing throughput, we can query
population-level sequence data to obtain 1000s of indepen-
dent per-site measures. To test this approach, we collected
metrics (e.g. base quality, depth and mapping quality) from
>30 samples and trained a logistic regression model to learn
the relationship of quality metrics to small variant calling
accuracy.
When applying the model to independent samples, we
found that it can effectively discriminate regions of high,
medium and low predicted accuracy, as well as identify
common deletions regions. Of the non-N autosomal
genome, we predict ~91%, ~2%, and ~5.4% has high,
medium, and low accuracy, while ~1.6% contains common
deletions. SNP concordance is >99.95%, >86.5%, >62.1%
and >80.5% respectively, demonstrating the validity of the
approach, which is further supported by performance
assessment using the Platinum Genomes truthset.
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Profiling systematic error proves a promising approach to
predict per-site variant calling accuracy and annotate variant
and invariant bases. This will reduce the need for
orthogonal validation of calls and the curation burden,
making clinical WGS quicker, less expensive, and more
reliable.
T.U. Dincer: A. Employment (full or part-time);
Significant; Illumina, Inc. N. Johnson: A. Employment
(full or part-time); Significant; Illumina, Inc. E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Significant; Illumina, Inc. C. Colombo: A.
Employment (full or part-time); Significant; Illumina UK.
E. Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Illumina, Inc. M.A.
Bekritsky: A. Employment (full or part-time); Significant;
Illumina, Inc. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Significant; Illumina,
Inc. M.A. Eberle: A. Employment (full or part-time);
Significant; Illumina, Inc. E. Ownership Interest (stock,
stock options, patent or other intellectual property);
Significant; Illumina, Inc. D.R. Bentley: A. Employment
(full or part-time); Significant; Illumina UK. E. Ownership
Interest (stock, stock options, patent or other intellectual
property); Significant; Illumina, Inc.
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Reproduce easily: analysis of matching tumor-normal
NGS data with the Sarek workflow
S. Juhos1, M. Garcia1, T. Díaz De Ståhl1, M. Mayrhofer2, J.
Sandgren1, M. Nistér1
1Karolinska Institutet, Solna, Sweden, 2NBIS, Science for
Life Laboratory, Uppsala, Sweden
Introduction: High throughput sequencing for precision
medicine is now a routine method. Numerous tools have to
be used, and analysis is time consuming. We propose Sarek,
an open-source container based bioinformatics workflow for
germline or matching tumor-normal pairs, written in Next-
flow, to process WGS, whole-exome or gene-panel samples.
Materials and methods: Sarek is part of nf-core, a
collection of peer-reviewed workflows; supported environ-
ments are Conda, Docker and Singularity. It is system-
agnostic: can be used on single machines, clusters (HPC) or
in a cloud such as AWS, with little difference between
setups. Additional software can be included as new
modules. Several model organism references are
available (including Human GRCh37 and GRCh38). The
pipeline reports germline and somatic SNVs and SVs (by
HaplotypeCaller, Strelka, Mutect2, Manta and TIDDIT).
CNVs, purity and ploidy is estimated by ASCAT and
Control-FREEC. Furthermore, a broad set of QC metrics is
reported at the end of the workflow with MultiQC.
Results: From FASTQs to annotated VCFs it takes three
days for a 90X/90X sample on a 48 cores node. Sarek is
used in production at the National Genomics Infrastructure
Sweden for germline and cancer samples for the Swedish
Childhood Tumor Biobank and other research groups.
Conclusions: Sarek is an easy-to-use tool for germline or
cancer NGS samples, to be downloaded from https://nf-co.
re/sarek under MIT license.
Supporting grants: Swedish Research Council (2017-
00630, 2017-00656), the Swedish Childhood Cancer Fund
(BTB: BB2017-0001; BB2018-0001; BB2019-0001), and
the Knut and Alice Wallenberg Foundation (KAW
2014.0278).
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Reduced penetrance of pathogenic ACMG variants in a
deeply phenotyped cohort study and evaluation of
ClinVar classification over time
J. G. J. van Rooij, L. Broer, J. Verlouw, F. J. A. van Rooij,
R. Kraaij, A. G. Uitterlinden, A. J. M. H. Verkerk
Erasmus MC, Rotterdam, Netherlands
Introduction: We studied the penetrance of pathogenic
classified variants in an elderly Dutch population from the
Rotterdam study for which deep phenotyping is available.
We screened the 59 actionable genes for which reporting of
“known” pathogenic variants was recommended by the
ACMG, and demonstrate that determining what constitutes
as a “known” pathogenic variant can be quite challenging.
Methods: We defined known pathogenic as classified
pathogenic by both ClinVar and HGMD. In 2,628
individuals, we performed exome sequencing and identified
known pathogenic variants. We investigated the clinical
records of carriers and evaluated clinical events during 25
years of follow-up for evidence of variant pathogenicity.
Results: Out of 3,815 variants detected in the 59 ACMG
genes, 17 variants were considered known pathogenic by
both ClinVar and HGMD. For 14/17 variants the ClinVar
classification had changed over time. We identified 24
carriers of these variants, which were confirmed by Sanger
sequencing. In only three participants (13%) we could
observe at least one clinical event possibly caused by the
variant.
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Conclusions: We show that the definition of “known
pathogenic” is often unclear and should be approached
carefully. Additionally variants marked as known patho-
genic do not always have clinical impact on their carriers.
Definition and classification of true (individual) expected
pathogenic impact should be defined carefully.
J.G.J. van Rooij: None. L. Broer: None. J. Verlouw:
None. F.J.A. van Rooij: None. R. Kraaij: None. A.G.
Uitterlinden: None. A.J.M.H. Verkerk: None.
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A complex pharmacogenomic landscape of ADME genes
in sub-Saharan Africa, revealed by genetic character-
isation of high coverage whole-genome data
H. Othman1, J. da Rocha1, G. Botha2, D. Twesigomwe1, S.
Ahmed3, L. Cottino1, B. Drögemöller4, F. M. Faisal3, P.
Machanick5, M. Mbiyavanga2, S. Panji2, G. Wright4, M. C.
Simuunza6, S. Baldwin7, M. Chiano7, C. Cox7, A. Gross8, P.
Thomas7, F. J. Gamo9, S. Hazelhurst1, as members of the
H3A Consortium
1Sydney Brenner Institute for Molecular Bioscience, Wits
University, Johannesburg, South Africa, 2Computational
Biology Division and H3ABioNet, Department of Integra-
tive Biomedical Sciences, University of Cape Town, Cape
Town, South Africa, 3Centre for Bioinformatics and Systems
Biology, Faculty of Science, University of Khartoum,
Khartoum, Sudan, 4University of British Columbia, Van-
couver, BC, Canada, 5Department of Computer Science,
Rhodes University, Grahamstown, South Africa, 6Depart-
ment of Disease Control, School of Veterinary Medicine,
University of Zambia, Lusaka, Zambia, 7GlaxoSmithKline,
Stevenage, United Kingdom, 8GlaxoSmithKline, Sydney,
Australia, 9Diseases of the Developing World, Tres Cantos
Medicines Development Campus, GlaxoSmithKline, Tres
Cantos, Spain
Introduction: Investigating the pharmacogenomics land-
scape of ADME (Absorption, Distribution, Metabolism, and
Excretion) genes is important to understand their implica-
tions on drug response. ADME variation has been char-
acterised across European and Asian populations, but data
relative to African populations are available only for a few
ADME genes.
Materials and Methods: We present the first study
aiming to characterise the pharmacogenomics landscape of
all ADME genes in sub-Saharan Africa using 458 high
coverage whole genomes and other publicly accessible
datasets.
Results: Our study shows a significant level of variability
in ADME genes. We identified 930 potential high impact
coding variants, most of which are rare and discrete to a
single African subgroup. Significant frequency differences
(i.e. >10%) are seen in common high impact variants
between subgroups. For some of the novel variants, we
show that their impact could be deleterious at the protein
structure level. Copy number variation was detected in 116
ADME genes, with equal ratios of duplications/deletions.
For variants of known clinical outcome, we note that most
of these are rare in Africa compared to European
populations, potentially reflecting the underrepresentation
of these groups in past research.
Conclusions: Our work highlights that the ADME
landscape in African populations is diverse and shows the
importance of rare variation held within individual popula-
tion clusters. The "genetic diversity bottleneck" in precision
medicine might increase the burden in developing targeted
therapies at sub-population levels. Moreover, current array-
based genotyping technologies have severe limitations to be
applied as the main method in precision medicine
applications.
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None. G. Wright: None. M.C. Simuunza: None. S.
Baldwin: A. Employment (full or part-time); Significant;
GlaxoSmithKline. M. Chiano: A. Employment (full or
part-time); Significant; GlaxoSmithKline. C. Cox: A.
Employment (full or part-time); Significant; GlaxoSmithK-
line. A. Gross: A. Employment (full or part-time);
Significant; GlaxoSmithKline. P. Thomas: A. Employment
(full or part-time); Significant; GlaxoSmithKline. F.J.
Gamo: A. Employment (full or part-time); Significant;
GlaxoSmithKline. S. Hazelhurst: B. Research Grant
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Significant; GlaxoSmithKline.
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GLCCI1, ORMDL-GSDMB and GNGT2 variants
increase exacerbation risk in adults with asthma
A. Edris1,2, E. W. De Roos2, M. J. McGeachie3, K. M. C.
Verhamme2, M. Ikram2, G. G. Brusselle4, K. G. Tantisira3,
C. Iribarren5, M. Lu6, A. C. Wu7, B. H. Stricker2, L.
Lahousse1,2
1Ghent University, Ghent, Belgium, 2Erasmus MC, Rotter-
dam, Netherlands, 3Channing Division of Network Medi-
cine, Brigham and Women’s Hospital, Boston, MA, United
States, 4Ghent University Hospital, Ghent, Belgium, 5Divi-
sion of Research, Kaiser Permanente Northern California,
Oakland, CA, United States, 6Division of Research, Kaiser
Permanente Northern California,, Oakland, CA, United
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Harvard Pilgrim Health Care Institute and Harvard
Medical School, Boston, MA, United States
Introduction: Asthma exacerbations may be associated
with genetic variants affecting the disease’s underlying
inflammatory pathways. We investigated the association of
single nucleotide polymorphisms (SNPs) on the risk of
exacerbations in adult patients with asthma, adjusted for
anti-inflammatory treatment effects.
Methods: Ten SNPs which previously associated with
asthma, change in lung function or exacerbations in
children, were investigated within adults with asthma from
the population-based Dutch Rotterdam study (n = 588) with
replication in the American GERA cohort (n = 9,842).
Hurdle regression models were used in the analysis to
account for both the incidence and the frequency of
exacerbations. All models were adjusted for age, sex,
BMI, inhaled corticosteroid (ICS) use, smoking, treatment
step according to GINA guidelines and the interaction
between ICS use and the genotypes. The Logarithm of the
follow-up time was used as an offset variable. P values less
than 0.005 were considered Bonferroni significant.
Results: Rs7216389 (ORMDL-GSDMB, previously asso-
ciated with risk of exacerbations in children) and rs37973
(GLCCI1, previously associated with FEV1 change) were
significantly associated with an increased subsequent
exacerbation risk in count models in both adult asthmatic
cohorts.(rs7216389 Discovery Rate Ratio(RR): 1.67;
p < 0.005, Replication: 1.10; p < 0.005, rs37973 Discovery
RR: 1.31; p < 0.005, Replication: 1.08; p < 0.005)
Additionally, rs17637472 (GNGT2) was nominally asso-
ciated with exacerbations in the Dutch cohort, and
significantly in the American cohort.
Conclusions: GLCCI1, ORMDL-GSDMB and GNGT2
variants may affect exacerbation risk in adults with asthma
regardless of ICS treatment.
A. Edris: None. E.W. De Roos: None. M.J. McGea-
chie: None. K.M.C. Verhamme: None. M. Ikram: None.
G.G. Brusselle: None. K.G. Tantisira: None. C. Iribar-
ren: None. M. Lu: None. A.C. Wu: None. B.H. Stricker:
None. L. Lahousse: None.
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Genetic and epigenetic factors of glucocorticoid sensi-
tivity in asthma patients
O. Savelieva1, A. Karunas1,2, Y. Fedorova2, R. Murzina3, R.
Gatiyatullin3, E. Etkina3, E. Khusnutdinova2,3
1Bashkir state university, Ufa, Russian Federation, 2Insti-
tute of Biochemistry and Genetics - Subdivision of Ufa
Federal Research Centre, Russian Academy of Sciences,
Ufa, Russian Federation, 3Bashkir State Medical Univer-
sity, Ufa, Russian Federation
Glucocorticoids are the most effective drugs for asthma. Up
to 50-60% of differences in sensitivity to therapy in asthma
patients is due to genetics. We studied polymorphisms in
genes involved in the metabolism of glucocorticoids
(GLCCI1, TBXT, ALLC, FBXL7, MAGI2) and the methy-
lation status of GLCCI1 gene in asthma patients and healthy
individuals. The study was conducted in 350 children with
asthma and 363 non-atopic children of different ethnicity
from the Volga-Ural region of Russia. Genotyping was
carried out by RT-PCR. The methylation status of the
promoter region of the GLCCI1 gene was determined based
on bisulfite conversion of DNA, the methylation-sensitive
melt curve analysis and sequencing of samples with dif-
ferent levels of methylation. The association of the
GLCCI1*rs37973G allele with uncontrolled asthma (p =
0,02, OR=1,74) in Tatars was defined. We found the
association of the TBXT*rs2305089T allele with asthma in
Bashkirs (p = 0,02, OR=2,16). The association of the
FBXL7*rs10044254AA genotype with significantly reduced
MEF25 in Russians (p = 0,03, OR=2,75) and association
of the MAGI2*rs2691529TC genotype with normal spiro-
metry values in Tatars were established (p < 0,05).
Hypermethylation of the promoter region of the GLCCI1
gene was detected only in asthma patients (p = 0,02,
OR=15,1). Patients with an increased level of the GLCCI1
gene methylation showed reduced FEV1 (p = 0,04),
MEF25 (p = 0,006), MEF50 (p = 0,04) compared with
asthma patients with low level of the GLCCI1 gene
methylation. These results suggest that GLCCI1, TBXT,
FBXL7, MAGI2 genes play an important role in the glu-
cocorticoids pathway and pathogenesis of asthma. The
study supported by the RFBR grants №17-04-02195 and
№19-31-590055.
O. Savelieva: None. A. Karunas: None. Y. Fedorova:
None. R. Murzina: None. R. Gatiyatullin: None. E.
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An admixture mapping analysis of asthma exacerba-
tions in African Americans identifies the association of
local ancestry at 3q27.3-28
E. Herrera-Luis1, F. Lorenzo-Diaz1, A. Mak2, E. G.
Burchard2,3, M. Pino-Yanes4,5,6
1Genomics and Health Group, Department of Biochemistry,
Microbiology, Cell Biology and Genetics, Universidad de
La Laguna, San Cristobal de La Laguna, Spain, 2Depart-
ment of Medicine, University of California San Francisco,
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neering and Therapeutic Sciences, University of California
San Francisco, San Francisco, CA, United States, 4Geno-
mics and Health Group, Department of Biochemistry,
Microbiology, Cell Biology and Genetics, Universidad de
La Laguna, San Cristobal de La Laguna, Spain, 5CIBER de
Enfermedades Respiratorias, Instituto de Salud Carlos III,
Madrid, Spain, 6Instituto de Tecnologías Biomédicas (ITB),
Universidad de La Laguna, San Cristobal de La Laguna,
Spain
Introduction: African ancestry has been consistently
associated with asthma risk and exacerbations in African
Americans. However, the genetic variation involved in
severe asthma exacerbations in this population remains
scarcely explored.
Aim: To perform an admixture mapping and fine
mapping of severe asthma exacerbations in African
Americans.
Methods: A total of 970 African American asthma patients
(448 exacerbators and 522 non-exacerbators) genotyped with
the Axiom LAT1 array (Affymetrix) were analyzed. Local
ancestry was assessed with ELAI for 412,603 SNPs using
data from Yorubans as reference panel. Association of local
ancestry with asthma exacerbations was assessed with logistic
regression models. A p≤1.63 x 10−4 was used to declare
significance based on the number of independent ancestry
blocks. Fine mapping was performed with data imputed to
the, 1000 Genome Project reference panel. Association of
polymorphisms and exacerbation status in the last 12 months
was assessed by binary logistic regression with correction for
age, sex, asthma severity and global African ancestry.
Results: African ancestry at chromosome 3q27.3-28 was
associated with exacerbations. The strongest association
(p = 3.79 x 10−6, odds ratio: 1.84, 95% confidence interval:
1.42-2.39) was located in the region containing the LPP
gene, which has been previously associated with asthma.
Additionally, fine mapping identified three common poly-
morphisms that remained significant after multilocus
correction for the number of effective tests.
Conclusions: African ancestry and three polymorphisms
at 3q27.3-q28 are associated with asthma exacerbations.
Future work will include evaluation of rare variants and
replication in independent studies.
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Genetic variability of antioxidant mechanisms and late
adverse events of breast cancer radiotherapy
K. Goricar1, J. T. Stojanov Konda2, V. Dolzan1, T.
Marinko3,2
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Introduction: Radiotherapy enables good long-term local
control and survival in early breast cancer patients. How-
ever, some patients experience acute or late adverse events
that can affect treatment protocol and decrease patient’s
quality of life. Genetic factors can contribute to the inter-
individual variability in occurrence of adverse events. As
radiation leads to increased production of reactive oxygen
species, contributing to oxidative stress, our aim was to
evaluate the association of common polymorphisms in
antioxidant genes with late adverse events of radiotherapy
in breast cancer patients.
Materials and Methods: Our study included 101 HER2-
positive early breast cancer patients treated with adjuvant
radiotherapy. We isolated DNA from buccal swabs and
genotyped all patients for CAT rs1001179, GSTP1
rs1138272, GSTP1 rs1695, SOD2 rs4880, PON1
rs854560 and PON1 rs662 polymorphisms using competi-
tive allele-specific PCR. Association of polymorphisms
with adverse events was evaluated using logistic regression.
Results: Median follow-up after radiotherapy was 4.0
(2.6-5.4) years. In total, 33 (32.7%) patients reported grade
≥2 late adverse events according to LENT-SOMA criteria,
and 12 (11.9%) experienced grade 2 skin toxicity according
to CTC criteria. Late adverse events were significantly more
common in carriers of at least one polymorphic PON1
rs854560 allele (OR = 3.03; 95% CI = 1.07-8.53, P =
0.036) and carriers of at least one polymorphic CAT
rs1001179 allele (OR = 2.71; 95% CI = 1.00-7.33, P =
0.049) after adjustment for clinical variables.
Conclusions: Polymorphisms in antioxidant genes were
associated with adverse events of radiotherapy and could
serve as biomarkers contributing to the personalization of
radiotherapy in breast cancer patients.
Research grants: ARRS J3-1753, P1-0170 and P3-0321.
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Development of a Point of Care Test for CYP2C19Al-
lowing Genotype Guided Antiplatelet Prescribing to
Prevent Recurrent Ischaemic Strokes
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Background: Clopidogrel is an antiplatelet medication
recommended for secondary prevention of ischemic strokes
and transient ischemic attacks in the UK. Activation is
required via the P450 cytochrome system, of which
CYP2C19 is a major component. CYP2C19 is highly
polymorphic, with over 30 loss of function (LOF) alleles.
Evidence suggests that outcomes could be improved if
individuals with LOF alleles were prescribed alternative
antiplatelets. We aimed to develop a point of care test
(POCT) to identify CYP2C19 status in a clinically relevant
timeframe, model the effect of implementation and capture
patient views on acceptability.
Methods: An asymmetric PCR was designed to amplify
CYP2C19 alleles prior to melt curve analysis using
fluorescent hybridisation probes. The assay was developed
on the Genedrive® rapid thermocycler using synthetic DNA
target templates before validation with genomic DNA. A
model-based cost-effectiveness analysis was used to assess
the indicative incremental costs and consequences of
genotype-guided prescribing, compared with current prac-
tice. A focus-group composed of stroke survivors explored
acceptability of genotype-guided prescribing.
Results: The assay detects *1,*2,*3,*4,*4b,*10 and *17
CYP2C19 alleles in diplotype, accounting for over 96% of
global variation. This POCT identifies metaboliser status in
<60 minutes via buccal swab. Qualitative evidence
suggested genotype-guided prescribing was acceptable to
patients. Indicative economic analysis suggested genotype-
guided prescribing has the potential to improve health
outcomes and save resource, but a definitive trial is
required.
Conclusions: This assay identifies CYP2C19 metaboliser
status in a clinically relevant timeframe. The assay is
portable, non-invasive and facilitates tailored antiplatelet
prescribing in the acute care setting.
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CYP2D6 predicted phenotype frequencies and major
ethnic differences among 8457 cases.
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Sevlie, M. Donaldson, B. Metzger, B. Hartung
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Introduction: Throughout world populations, different
allelic frequencies of CYP2D6 have been observed.
CYP2D6 is a prominent phase I metabolizing pathway that
mediates up to 25% of clinically used drugs. The goal of
this study was to identify CYP2D6 allelic frequencies in an
ethnically diverse patient population.
Materials and Methods: DNA samples were collected
from 8457 participants who consented to receive the
RightMed Comprehensive test (OneOme, USA). The
RightMed Comprehensive test report provides pharmaco-
genomic interpretation for 27 genes (111 alleles) and
guidance on 300+ medications. CYP2D6 genotypes and
their respective predictive phenotype interpretation were
analyzed.
Results: Out of a total of 8457 participants, 68.9% self-
identified as White or Caucasian, 4.4% as Hispanic or
Latino, 3.4% as Asian, and 2.6% as Black or African
American. The remaining 19.1% of participants selected
Unknown or did not provide ethnicity. Poor metabolizers
(PMs) with an activity score (AS) of 0 were identified in 7%
of individuals identifying as White, 5% of those identified
as Hispanic or Latino, 1% of Asian individuals, and 1% of
Black or African Americans. Overall, 6% of the total
participants were classified as PMs.
Conclusions: Pharmacogenomics has become a valuable
clinical tool for more effective prescribing by diminishing
the risk of adverse drug reactions for several medications
resulting in increased success. CYP2D6 plays an essential
role, and with more than 110 allele variants, the frequencies
fluctuate among populations. Ultimately, for a better
understanding and proper implementation, broader allele
coverage and accurate collection of sub-ethnicities is
needed.
B. Esquivel: A. Employment (full or part-time); Sig-
nificant; OneOme. E. Ownership Interest (stock, stock
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Imputation of CYP2D6 copy-number variation and
frequency of key pharmacogenetic variants in Finnish
population
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Introduction: Pharmacogenetic studies have been limited
by small sample size mainly through complexity of
CYP2D6-locus. Here, we demonstrate that CYP2D6 gene
duplication can be imputed accurately using existing
imputation algorithms and report the frequencies of phar-
macogenetic variants in a population isolate of Finland.
Materials and Methods: Genotyping of 10,075 psycho-
sis cases from SUPER-Finland was performed with
Illumina Global Screening Array. 9,381 samples have been
whole-exome sequenced and 897 whole-genome
sequenced. We used Finnish BrePainGen sample (n =
926 with GWAS-chip and CNV data) to construct the
imputation panel for CYP2D6 CNV. To validate the
imputation approach, we masked the CNV in a subset of
BrePainGen samples and imputed it back and correlated
against genotyped CNV.
Results: In the imputation of CNV duplication 20 out of
22 duplications (90.9%) in validation data set were imputed
correctly. CYP2D6 metabolizer statuses were distributed as
follows: Ultrarapid (UM) 5.4%, intermediate (IM) 0.9%,
poor (PM) 2.8% and normal (NM) 90.9 %. Correspond-
ingly, for CYP2C19 UM 28.1%, IM 28.7%, PM 3.5%, and
NM 39.7%.
Conclusions: The CYP2D6 can be imputed with high
accuracy allowing large pharmacogenetic studies. We
hereby confirm the 2-3 fold enrichment of CYP2D6 UMs
in Finland compared to other European populations.
Funding: The Stanley Center for Psychiatric Research at
the Broad Institute of MIT and Harvard, Academy of
Finland, Governmental Research Funds to the Helsinki
University Hospital, The Finnish Cultural Foundation,
The Finnish Foundation for Psychiatric Research, The
Ministry of Social Affairs and Health Finland, through the
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Finland
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Monogenic diabetes gene screening in a transnational
multicenter study from eleven countries of the Medi-
terranean area
M. Vaxillaire1, A. Bonnefond1,2, S. Liatis3, L. Ben Salem
Hachmi4, A. Jotic5, M. Boissel1, S. Gaget1, E. Durand1, E.
Vaillant1, M. Derhourhi1, N. Larcher1, F. Allegaert1, R.
Medlej6, A. Chadli7, Z. Arbouche8, A. Belhadj9, M.
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Introduction: Diagnosis of monogenic diabetes has
important implications for diabetes precision medicine and
health expenditure. Its prevalence in many countries
remains unclear, although young-adult non-autoimmune
diabetes is increasing. Here, we conducted a transnational
multicenter study to identify rare pathogenic mutations
causing monogenic diabetes in young-adults, and to assess
the diagnosis rates, genetic subtypes and specificities
between countries.
Materials and Methods: We performed exome sequen-
cing in 204 unrelated diabetic cases (age-at-diagnosis:
26.1 ± 9.1 years) clinically selected by 30 medical centers in
eleven Mediterranean countries. Rare coding variants in 35
targeted genes were evaluated for mutation pathogenicity
using American College of Medical Genetics and Genomics
guidelines. One-way ANOVA, chi-squared test, principal
component analysis and factor analysis of mixed data were
used for data analyses.
Results: Fourty pathogenic (P) or likely pathogenic (LP)
mutations were identified in 36 patients yielding an overall
genetic diagnosis in 17.6% of the participants. GCK
(37.5%), HNF1A (27.5%), ABCC8 (12.5%) and HNF4A
(7.5%) mutations accounted for the majority of cases. We
found country wise highly variable diagnosis rates (up to
40% in Greece) and interestingly a higher mutation rate in
European ancestry participants. Lower body mass index and
HbA1c level at study inclusion, and less insulin treatment at
diagnosis and inclusion are hallmarks of the mutation
carriers.
Conclusions: In practice, our findings impacted patient
long-term monitoring and therapeutic regimen. They also
highlight broad clinical and genetic spectrum of young-
onset diabetes in Mediterranean countries.
Funded by the French National Research Agency and the
Mediterranean Group for Study of Diabetes.
M. Vaxillaire: None. A. Bonnefond: None. S. Liatis:
None. L. Ben Salem Hachmi: None. A. Jotic: None. M.
Boissel: None. S. Gaget: None. E. Durand: None. E.
Vaillant: None. M. Derhourhi: None. N. Larcher: None.
F. Allegaert: None. R. Medlej: None. A. Chadli: None. Z.
Arbouche: None. A. Belhadj: None. M. Chaieb: None. J.
Raposo: None. H. Ilkova: None. D. Loizou: None. N.
Lalic: None. J. Vassallo: None. M. Marre: None. P.
Froguel: None.
P18.19.B
Comparison of EGFR mutation detection among
FFPET, bronchoalveolar lavage (BAL) and blood
samples in patients with non-small cell lung Cancer
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Savov1
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Background: FFPET samples remain the golden standard
for EGFR genotyping. In many cases the initial material is
insufficient. In those cases EGFR genotyping could be done
on BAL or blood samples. In the last few years liquid
biopsies prove to be reliable method for EGFR character-
ization, on the other hand cytology samples are not used
that often. In this study we compare the detection rate of
EGFR mutations in BAL and blood samples compared to
FFPET samples.
Materials and Method: For a period of 9 months 10
patients with EGFR activating mutations have been
selected. DNA extraction was performed with QiaAmp
Circulating Nucleic Acid kit for plasma and BAL samples.
For FFPET samples we used QIAamp DNA FFPE Tissue
Kit. EGFR genotyping was performed with therascreen
EGFR Plasma or tissue RGQ PCR Kits.
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Results and Discussion: Activating mutations were
confirmed based on EGFR genotyping in FFPET samples.
6 patients had deletions in exon 19, 3 had L858R
substitution in exon 21 and one patient had G719x in exon
18. In 9 cases mutations were confirmed in corresponding
BAL samples and they were detected in only 4 plasma
samples. In 1 case, in both liquid biopsy samples- BAL and
plasma, we found T790M mutation along with deletion in
exon 19, but not in the corresponding FFPET sample.
Conclusions: This study shows that BAL samples are
superior to plasma samples and almost equal to FFPET
samples in detecting EGFR mutations, therefore cytology
samples should be preferred before blood samples when
possible.
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Genetic test utilization in a large US healthcare database
of patients with indications of rare genetic disease
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Introduction: Our understanding of the genetic etiology of
many rare diseases has grown substantially in recent years.
However, there has been little real-world evidence pub-
lished regarding the epidemiology and care delivery of
patients with suspected rare genetic diseases at the popu-
lation level. The objective of this analysis was to char-
acterize the population of patients with indications of rare
genetic diseases in a large US healthcare claims database,
with a focus on utilization of genetic testing.
Materials and Methods: This retrospective administra-
tive claims analysis used the Optum Clinformatics database.
A total of 12,023,329 patients met inclusion criteria,
including continuous enrollment. Curated lists of ICD-9
and ICD-10, CPT codes, and other billing codes were
generated to identify patients with indications of suspected
genetic diseases. Combinations of variables were used to
define patient cohorts for analysis, with different levels of
stringency used to define wider vs more conservative
cohorts. Separate analyses were completed on critically-ill
infants and other pediatric patients.
Results: Up to 12% of pediatric patients (1,450,702) and
up to 53% of critically ill infants (26,322) had indicators of
genetic disease. Across all cohorts, only a small minority of
patients received any genetic testing—between 3 to 9%
based on different cohort criteria. Mean time to first genetic
test was >350 days for pediatric patients and >140 days for
critically-ill infants.
Conclusions: The results of this study highlight the
substantial patient population with indicators of suspected
genetic diseases, but notably, a significant underutilization
of genetic testing.
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Polygenic risk score improves the prediction ability in
knee and hip osteoarthritis
B. Sedaghati-khayat1, J. G. J. van Rooij1, C. G. Boer1, L.
Broer1, A. J. M. H. Verkerk1, E. Zeggini2, .. GO
consortium1,2, A. G. Uitterlinden1,3, J. B. J. van Meurs1,3
1Department of Internal medicine, Erasmus MC, Rotter-
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Helmholtz Zentrum München, German Research Center for
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of Epidemiology, Erasmus MC, Rotterdam, Netherlands
Introduction: Osteoarthritis (OA) is the most common
joint disorder worldwide, with mostly unknown etiology
but with substantial heritability. We estimated an indivi-
dual’s genetic risk of OA using a polygenic risk score (PRS)
calculated from the latest GWAS of the Genetics of
Osteoarthritis (GO)-consortium. This project is part of
“Genotyping On All Patients(GOALL)” of Erasmus MC to
return genetic information to the patient and clinician.
Methods: We analyzed all 6,291 Rotterdam Study (RS-I
base line cohort) Caucasian participants with 25 years
follow-up, containing 1,177 knee and 561 incident hip OA
cases. PRS were constructed for HipOA (43-SNPs) and
KneeOA (23-SNPs) with 11-SNPs shared. Standardized
PRSs (zPRS) were constructed to estimate the odds ratios
per standard deviation (SD) of zPRS for each subject,
weighted by effect sizes and adjusted for age/sex. External
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validation was performed in the clinical Cohort Hip and
Cohort Knee (CHECK), and RS-II and RS-III cohorts.
Results: The zPRS for HipOA predicted prevalent
HipOA (p = 6.7×10−4;OR=1.1). Moreover, the incident
HipOA was predicted (p = 6.2×10−4;OR=1.4) with the
area under the curve (AUC) of 0.59. When the zPRS were
added to the predictive AUC of 0.68 for age/sex, it
increased to 0.70. The zPRS for KneeOA only predicted
prevalent KneeOA (p = 1.5×10−6;OR=1.2). The top 10%
of the zPRS compared to the rest of the population had a 2
times higher risk for HipOA incidence (p = 7.7×10−4) and
50% higher risk for KneeOA incidence (p = 3.7×10−2).
Conclusions: Our work shows the potential of PRS as a
clinical prediction tool for prevalent and incident knee and
hip OA.
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International mapping of national genomics initiatives
T. Leonardo Alves1, M. E. Jansen1, B. Hoebee2, W.
Rodenburg1
1National Institute for Public Health and the Environment,
Centre for Health Protection, Bilthoven, Netherlands,
2National Institute for Public Health and the Environment,
Centre for Population Screening, Bilthoven, Netherlands
Introduction: The potential benefits of population-based
genomics are considered substantial, but little is known
about the type, nature and scale of national genomic plans.
We aimed to describe ongoing genomics initiatives identi-
fied in middle and high-income settings.
Methods: A convenience sample of countries was
selected based on expert referral and google searches. Data
was extracted and collated covering diverse items of
interest: country, type and scope of the initiative, funding,
participants, aims, activities, inception and conclusion date,
drivers and actors involved.
Results: A sample of 25 countries was included and a
total of 30 initiatives were found. Most have a national
scope (N = 27) and focus on Prevention and Screening as
well as on Diagnostics and Treatment (N = 10). If the
initiative is national, then it is often population-based.
Models are varied, from funding platforms to government-
lead initiatives, as well as individual research projects. In
some countries, there is full public funding while others opt
for public-private-partnerships. The scale of financing
varies largely, depending on the span of activities: research,
infrastructure, development of genomic testing and analysis,
as well as capacity-building and education. Drivers and
actors involved also differ depending on the nature of the
initiative, but universities and health research centres often
have a leading role within consortia or networks.
Conclusions: There is not a one-size fits all approach to
genomic plans. Countries seem to design initiatives
according to their priorities. However, lessons learned and
arguments for a certain model can hold valuable informa-
tion for individual countries and international
genomic plans.
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No relationship was found between IL28B rs12979860
polymorphism and spontaneous clearance of HDV in
Mongolian population
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Introduction: Host genetic factors play an important role
for viral infection. Numerous studies showed that the SNP
rs12979860 of IL28B gene is clearly associated with
spontaneous clearance of HCV, but not that of HBV.
However, only few studies were done in very small number
of people to reveal the possible effect of SNP rs12979860
genotypes in case of HDV infection. In this study, we did
comprehensive statistical analysis to show whether there is
a relationship between SNP rs12979860 and spontaneous
clearance of HDV using relatively large number of people.
Methods: Total of 820 participants including of 3 groups
(HDV spontaneously cleared n = 215, HDV chronic n =
304 and healthy n = 301) were participated in this study
according to their serological and molecular biological
diagnostic results. For each participant, SNP rs12979860
was genotyped by RFLP and Sanger sequencing. Pearson’s
chi square test and odds ratios were applied for assessing
the association between SNP rs12979860 and spontaneous
clearance of HDV.
Results: Our results are shown as following table.
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CT+TT 31 47 32
Conclusions: Our analysis showed that spontaneous
clearance of HDV is not dependent on the genotypes of
rs12979860 polymorphism. This project was funded by
CRDF Global (agreement number: DAA2-17-62984-1).
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Research Support (supplies, equipment, receipt of drugs or
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Identification of novel genetic risk factors in the
conserved haplotype region surrounding the LCT locus
on chromosome 2q21.
A. Cairo1, S. Spena2, E. Pappalardo2, M. Mancuso1, F.
Peyvandi1,2
1Angelo Bianchi Bonomi Haemophilia and Thrombosis
center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico and Fondazione Luigi Villa, Milan, Italy, 2Uni-
versità degli studi di Milano, Department of Pathophysiol-
ogy and Trasplantation, Milan, Italy
Introduction: Inhibitors development affects about 30% of
patients with severe hemophilia A (HA). Different envir-
onmental and genetic risk factors are involved in this pro-
cess.[1,2] Recently, we identified a SNV (rs3754689) in the
LCT gene potentially linked with this predisposition.[3]
Since this variant is benign [4] and is located in a conserved
haplotype block, we hypothesized that the association signal
captured by this variant is probably located in coinherited,
neighboring genes like R3HDM1, UBXN4 and miRNA-128-
1, previously linked with autoimmune disorders and there-
fore potential clinically relevant targets. The aim of this
study is to identify novel genetic risk factors associated with
inhibitor development in R3HDM1, UBXN4, CXCR4,
MCM6, miRNA-128-1 genes in patients with severe HA.
Materials and Methods: 246 Italian patients with severe
HA with (72) or without (174) inhibitor was sequenced by
TruSeq Custom Amplicon (Illumina). Data were analyzed
according to the guidelines reported by the Broadinstitute
(https://software.broadinstitute.org/gatk/best-practices/).
Statistical analysis was performed by Plink, PlikSeq.
Results: 228 variants passed the quality controls: 56
common (MAF≥1%) and 172 rare (MAF<1%). Logistic
regression of common variants confirmed the protective role
of the rs3754689 missense variant. Other 4 variants resulted
significantly associated. Two are localized in LCT, a
genomic region involved in the regulation of the UBXN4
expression. Rare variants resulted not associated.
Conclusions: This study confirmed the association of the
chromosomal region around the LCT locus with inhibitor
development in patients with severe HA. Further investiga-
tions are necessary to evaluate the expression of target
genes and miR-128-1.
A. Cairo: None. S. Spena: None. E. Pappalardo: None.
M. Mancuso: None. F. Peyvandi: D. Speakers Bureau/
Honoraria (speakers bureau, symposia, and expert witness);
Modest; Alnylam, Grifols, Roche, Takeda. D. Speakers
Bureau/Honoraria (speakers bureau, symposia, and expert
witness); Significant; Kedrion. F. Consultant/Advisory
Board; Modest; Bioverativ, Roche, Sanofi, Takeda.
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Identification of genomic signature as diagnostic and
prognostic blood biomarker for early hepatocellular
carcinoma using integrated cross-species genomic and
network analyses
I. H. Kaya1, O. Al-Harazi2, M. Al-Eid2, L. Alfantoukh2, M.
Al-Sabayel2,3, N. Kaya2, D. Colak2
1AlFaisal University, Riyadh, Saudi Arabia, 2King Faisal
Specialist Hospital and Research Centre, Riyadh, Saudi
Arabia, 3AlMaarefa University, College of Medicine,
Riyadh, Saudi Arabia
Introduction: Hepatocellular carcinoma (HCC) is the most
common primary cancer originating in the liver and third-
leading cause of cancer-related deaths worldwide. The
disease is mostly diagnosed at advanced stages, hence has
poor prognosis. Robust biomarkers are therefore urgently
needed for early diagnosis and prognostic estimation.
Materials and Methods: We performed integrated
genomic and network-based analyses of early HCC (eHCC)
using genome-wide gene expression profiling datasets from
human eHCC samples and eHCC rat model. The validation
of diagnostic and prognostic value of the identified gene
signature was done using independent datasets of gene
expression profiling of tissue samples as well as peripheral
blood mononuclear cells from patients with eHCC.
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Results: We identified 41-gene signature that is con-
served across species and expressed in blood. We validated
the diagnostic and prognostic potential of the gene signature
on independent datasets with detailed clinical data. We
developed a prognostic model based on our gene signature
that demonstrated that the high expression was significantly
associated with poor disease outcome. Multivariate regres-
sion analysis revealed that our gene set predicted the disease
outcome independent of other clinical factors.
Conclusions: Our results suggest that integrated cross-
species genomic and network analysis may provide a robust
methodology to identify key biological programs associated
with eHCC and may lead to improved diagnosis, prognosis,
and therapeutic options.
Acknowledgement: This study is funded by the Research
Grant (RAC#2110006, 2180030 to DC). We thank our
individual sponsors who generously donated to this
research. We also would like thank Ms. Sukina Qanbar
for her administrative support.
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Reports of incidental findings in a cohort of 500 exomes
of Brazilian patients were common and show potential
impact in life-expectancy
C. R. D. C. Quaio1,2, C. M. Moreira1, P. R. Sacramento-
Bobotis1, G. M. Novo-Filho1, M. G. Penna1, R. R. F.
Sousa1, A. C. G. Trindade1, C. R. Furuzawa1, D. P.
Pereira1, C. Olivati1, G. M. Spolador1, V. C. Pereira1, R. A.
Silva1, M. N. P. Santos1, W. A. R. Baratela1
1Fleury Medicina e Saúde, Sao Paulo - SP, Brazil, 2Facul-
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Incidental findings in next-generation sequencing-based
exams correspond to deleterious variants in clinically-
actionable conditions discovered unintentionally in genes
that were not the primary objective of analysis. American
College of Medical Genetics and Genomics (ACMG) has
published recommendations for reporting incidental find-
ings in selective genes.
We report incidental findings from 500 whole exomes
performed for clinical/diagnostic purposes at a private
laboratory in Brazil and discuss potential impact in life
expectancy. Information about potential life expectancy
impact of early diagnosis of genetic conditions was
reviewed from cost-effectiveness studies available in the
literature: we considered a potential increase of 21 years in
life expectancy for variants in congenital cardiomyopathy
genes, 7.6 years for long QT and 6.0 years in highly
penetrant breast cancer genes.
Incidental findings in genes enlisted by ACMG were
found in eight patients (1.6%), including four variants in
genes associated with cardiac conditions (KCNH2,
MYBPC3, DSC2, MYH7) and four variants in cancer-
predisposing genes (TP53, BRCA1, PMS2, BRCA2). We
additionally reported findings whose impact in life-
expectancy was not calculated: 15 (3%) pathogenic
heterozygous variants in autosomal recessive conditions of
ACMG list (LDLR, MUTYH, ATP7B, APOB genes) and
three variants (0.6%) for autosomal dominant cancer-
predisposing conditions not in ACMG list (CHEK2,
RAD51C, BRIP1).
We estimate that the reports of incidental findings may
have increased life expectancy in our cohort by 88.6 years,
or 0.18 year per cohort patient. Since general accessibility to
genomic testing is increasing, analysis of clinically-
actionable conditions show potential benefit for public
health policies in the future.
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inflammation status modulates the effect of host genetic
variation on intestinal gene expression in inflammatory
bowel disease
S. Hu1, W. T. Uniken Venema1, H. Westra1, A. Vich Vila1,
R. Barbieri1, M. D. Voskuil1, T. Blokzijl1, B. H. Jansen1, Y.
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Li1, M. J. Daly2, R. J. Xavier2, E. A. Festen1, G. Dijkstra1,
R. K. Weersma1
1UMCG, Groningen, Netherlands, 2Broad Institute of
Harvard and MIT, Boston, MA, United States
Introduction: More than 240 genetic loci have been asso-
ciated with Inflammatory bowel disease (IBD), but little is
known about how they contribute to disease development in
involved tissue. We hypothesized that host genetic variation
affects gene expression in an inflammation-dependent way.
Materials and Methods: We investigated 299 snap-
frozen intestinal biopsies from inflamed and non-inflamed
mucosa from 171 IBD patients. RNA-sequencing was
performed, and genotypes were determined using whole
exome sequencing and genome wide genotyping. In total,
28,746 genes and 6,894,979 SNPs were included. Linear
mixed models identified 7,667 independent intestinal cis-
expression quantitative trait loci (cis-eQTLs) (FDR<0.05)
and interaction analysis revealed 122 inflammation-
dependent intestinal cis-eQTLs (FDR<0.05), including
several for known IBD-risk genes and genes encoding
immune-cell receptors and antibodies. The inflammation-
dependent cis-eQTL SNPs mainly interact with prevalence
of immune cell types.
Conclusions: Inflammation-dependent intestinal cis-
eQTLs reveal genetic susceptibility under inflammatory
conditions that can help identify the cell types involved and
the underlying pathways, knowledge that may guide future
drug development and profile patients for precision
medicine in IBD.
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Integrated analysis of transcriptomic and genomic data
reveals blood markers with diagnostic and prognostic
potential in non-small cell lung cancer
M. T. Kaya1, O. Al-Harazi2, M. Aldosary2, A. Al-Bakheet3,
Y. Attaar1, M. Omar1, D. Colak3
1King Faisal School, Riyadh, Saudi Arabia, 2King Faisal
Specialist Hospital and Research Centre, Riyadh, Saudi
Arabia, 3King Faisal Specialist Hospital and Research
Center, Riyadh, Saudi Arabia
Introduction: Lung cancer is the second most common
cancer and the main leading cause of cancer-associated death
worldwide. Non-small cell lung cancer (NSCLC) accounts for
about 85% of lung cancer diagnoses, which enforces the
importance of diagnosing NSCLC patients reliably and as
early as possible in order to reduce the risk of mortality.
Materials and Methods: We identified blood-based gene
markers for NSCLC by utilizing an integrated analysis of
global gene expression and copy number alterations of
NSCLC patients using array-based techniques. The gene
signature was then validated using independent datasets of
gene expression profiling of over 1000 NSCLC patients.
We also validated the classification performance and the
prognostic potential of the gene signature using independent
datasets with detailed clinical information.
Results: The high expression of our gene signature is
associated with a poor disease outcome. Significantly
altered functions, pathways, and gene networks in
NSCLC-associated genes revealed alterations in several
cancer-related pathways that may have importance for
NSCLC transformation, further validating our gene signa-
ture’s diagnostic and prognostic potential.
Conclusions: Our findings suggest that integrated
genomic and network analysis is likely to provide a reliable
approach to identify genes that are associated with NSCLC
and may lead to improved diagnosis and therapeutic
options, without any invasive procedures required.
Acknowledgement: This study is funded by the Research
Grant (RAC#2110006 to DC). We would like to thank Ms.
Sukina Qanbar for her administrative support.
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Decomposing the genetic burden of chronic diseases into
multitrait signatures to support drug development
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Only a small fraction of molecules entering the drug
development process will actually be approved for market
use. Leveraging genetic information could improve the
success rate of drug clinical trial. Previous work showed
that molecules with genetic evidence of association with the
disease have greater chance of being eventually approved,
and that adverse effects can be partially predicted from
genetic associations. Here, we argue that multitrait genome-
wide association studies (GWAS) is a powerful framework
for harnessing genetics to inform drug targeting by: 1)
increasing power to identify new drug targets; 2) associating
drug targets with biological pathways through clustering;
and 3) suggesting drug targets with no indication of likely
adverse effects. We conducted a multitrait GWAS of
metabolic (lipid and glycemic) traits using our recently
developed JASS package (http://jass.pasteur.fr/index.html).
We identified 405 significant associations, detected six
multitrait association signatures (i.e. clusters of genetic
variants with similar association pattern) and associated
each signature with metabolic pathways. We investigated
the links between the identified multitrait association sig-
natures and coronary heart diseases (CHD). Signatures
associated with an increased risk of type 2 diabetes, low
density lipoprotein or triglycerides were also significantly
associated to CHD. Conversely, signatures associated to
high density lipoprotein did not exhibit protective effect on
CHD. These conclusions were concordant with past or
ongoing random control trials on the following molecules:
probucol, cetrapid, alirocumab, ezetimibe, and volane-
sorsen. We provide a list, for signatures associated with
CHD, of druggable genes with their associated metabolic
pathways that have not been investigated yet.
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Comprehensive Genomic analysis of Parkinson ’s
disease Cases of an Arab Descent
B. R. Mubarak
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Despite over 2 decades of Parkinson’s disease (PD)
research, the genetic picture remains unclear. Until now, no
universal risk variant(s) have been found. At least 40 dif-
ferent loci have been implicated in PD from genome-wide
association studies and an equal number of candidate genes
have been revealed by whole exome sequencing-based
studies. Thus, highlighting the genetic heterogeneity of PD.
Moreover, most of the large scale studies have been con-
ducted in European or Asian cohorts and their findings
rarely replicated across populations. Therefore, inclusion of
non-European data sets is necessary not only for validating
previous findings but also for variant/gene discovery.
Genetic studies on complex neurodegenerative disorders in
Arabs are lacking. Here we report on the first comprehen-
sive genomic study on 60 PD cases of Arab descent. A
three-stage analysis strategy was tailored to detect rare
variants in PD. By applying this strategy, 125 new variants
affecting 117 genes were identified in 85% of the cases. All
of the genes have not be previously linked to PD except two
(EIF4G1 and ATP13A2). Further prioritization of our data
generated a list of high confidence variants in 20 genes




How can we capture clinical variation and progression
in deeply phenotyped patient cohorts?
C. Sandor1, S. Millin2, A. Dahl2, M. Lawton3, L. Hubbard1,
B. Bojovic2, M. Peyret-Guzzon2, H. Matten2, C. Blancher2,
N. Williams1, Y. Ben-Shlomo3, M. Hu2, D. Grosset4, J.
Marchini2, C. Webber1
1Cardiff University, Cardiff, United Kingdom, 2University
of Oxford, Oxford, United Kingdom, 3University of Bristol,
Bristol, United Kingdom, 4Queen Elizabeth University
Hospital, Glasgow, United Kingdom
Introduction: There is large variation in the clinical pre-
sentations and progression between patients with the same
disorder. The generation of deeply and longitudinally phe-
notyped patient cohorts offers an enormous potential to
identify disease subtypes with prognostic and therapeutic
utility.
Material and Methods: Using three large cohorts of
Parkinson’s disease (PD) patients with extensive clinical
observational data repeatedly collected over many years, we
developed a Bayesian multiple phenotype mixed model
incorporating the genetic relationships between individuals
that was able to reduce a large number of diverse clinical
measurements into a smaller number of continuous under-
lying factors (“phenotypic axes”). This approach overcomes
many limitations associated with clustering methods and
better reflects the more continuous phenotypic variation
observed amongst patients.
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Results: We identify three principal axes of PD patient
phenotypic variation which are reproducibly found across
three independent, deeply and diversely phenotyped
cohorts. Together they explain over 75% of the observed
clinical variation and remain robustly captured with a
fraction of the clinically-recorded features. The most
influential axis was associated with the genetic risk of
Alzheimer’s disease (AD) suggesting PD patients with a
high genetic risk for Alzheimer’s disease are more likely to
develop a more aggressive form of PD including dementia
symptoms.
Conclusions: Our approach has the potential to accelerate
our understanding of how disease manifests and progresses.
This approach provides universal disease benchmarks
through which patients may be appropriately compared,
through which the underlying disease-modifying mechan-
isms can be understood and appropriately stratified, and
personalised therapeutic strategies and treatments can be
developed.
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Post-operative toxic reaction reversed through pharma-
cogenetics screening: a case report
C. Wick1, F. Cro’2, C. Lapucci2, M. Morris3
1Praxis am Lindspitz, Winterthur, Switzerland, 2Synlab
Italia Srl, Castenedolo, Italy, 3Synlab Switzerland, Lau-
sanne, Switzerland
We report the case of 78-year-old woman with a 3rd episode
of a toxic icteric hepatitis (liver parameters 4-7x). Each
occurrence was after surgical intervention and post-
operative infections, necessitating antibiotics and analge-
sics (paracetamol, amoxicillin-clavulanic acid).
Personal history: coronary heart disease with coronary
stent 3 years previously. Drug history: atorvastatin,
acetylsalicylic-acid and valsartan. Stopping atorvastatin, a
“commonly poorly-tolerated” drug, led to no improvement;
the patient continued to feel weak and remained icteric even
after 4 weeks.
She was screened for variants in 33 pharmacologically-
relevant genes (MyPGx). Results predicted Poor Metabo-
lizer/Low Function phenotypes in some PharmGKB Very
Important Pharmacogenes including CYP3A5, NAT2 and
SLC- and ABC-Transporters, plus Intermediate Metabolizer
phenotypes in CYP2C9, CYP2D6, UGT1A1 and others.
Based on the patient’s haplotypes, the MyPGx algorithm
predicted possible increased toxicity/risk of side effects for
both valsartan and atorvastatin. Valsartan is principally
excreted unchanged (80%) but is also metabolized by
CYP2C9, which showed a decreased function in the patient
(*1/*2).
Taking into account these results, valsartan was replaced
by olmesartan and atorvastatin by rosuvastatin; in both
cases the alternative drug belonged to the same class but the
key pharmacogene is SLCO1B1 (normal function, *1A/
*1B). After only two days the patient felt “as good as
before”; within 4 weeks, liver transaminases sank to quasi-
normal values. The complex genetic findings suggest
several interactions initially caused by post-operative drugs
but knowing the predicted activity of key pharmacogenes
facilitates selection of the best treatment leading, in this
patient, to reversing the toxic reaction she was experiencing.
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Quantifying Known and Novel Clinically Actionable
Pharmacogenetic Variations in Whole-exome Sequen-
cing(WES) Data of 1,132 Chinese Subjects
H. C. Yu1, C. Y. Chan1, K. S. Yeung1, C. C. Y. Mak1, J. F. T.
Chau1, M. Lee1, J. Yang1, W. L. Yang1, C. S. M. Tang2, M.
Garcia-Barcelo2, Y. L. Lau1, B. H. Y. Chung1
1Department of Paediatrics & Adolescent Medicine, LKS
Faculty of Medicine, The University of Hong Kong,
Pokfulam, Hong Kong, 2Department of Surgery, LKS
Faculty of Medicine, The University of Hong Kong,
Pokfulam, Hong Kong
Introduction: Pharmacogenetics (PGx) is an important area
of precision medicine. Currently, lack of large-scale exome/
genome-wide data precludes clinical application of pre-
emptive PGx testing in Chinese. In this study, we analyze
known and novel variants in clinically actionable pharma-
cogenes on the HKU Pediatric Exome Cohort in
Hong Kong.
Methods: WES data of 1,132 unrelated Chinese subjects
were analyzed using a two-tiered approach. The 1st-tier
analysis targeted known PGx variants based on a list of 135
curated actionable variants. The 2nd-tier analysis focused
on discovery of rare, predicted deleterious variants in 108
genes with PharmGKB Level 1/2 evidence based on 4
bioinformatic tools on missense (CADD, REVEL and
PREDICT) and loss-of-function (CADD and LOFTEE)
variants.
Results:We identified 29 known PGx variants (21.5%) in
the curated variant list, comprising of 57 drug-gene
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combinations. The most prevalent variants are rs1065852 in
CYP2D6 (60.7%), followed by rs12777823 in CYP2C8-
CYP2C9 region (31.5%) and rs4244285 in CYP2C19
(30.6%). Of the 1,132 Chinese subjects, 98.9% harbored
at least 1 known actionable PGx variant (median = 3).
Additionally, we discovered 561 rare variants in 108
PharmGKB Level 1/2 genes with diversified functional
effects such as non-synonymous nucleotide substitution (n
= 520), premature gain of stop codon (n = 33) and
disruption of reading frame (n = 8).
Conclusions: We have shown the abundance of known
and novel functional PGx variants that are potentially
clinically actionable. This study addresses the research gap
of inadequate Chinese samples by large-scale PGx studies
and also demonstrates the feasibility of secondary usage of
WES data on PGx.
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Aripiprazole and olanzapine may induce dysregulation
of the glucose utilization through the alteration of the
Myc signalling as detected by RNA-seq expression
analysis of treated healthy volunteers
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Universitario de la Princesa, Plataforma SCReN (Spanish
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Introduction: Aripiprazole and olanzapine are atypical
antipsychotics used mainly for schizophrenia treatment.
Being schizophrenia a chronic disorder, it requires lifelong
medication, that subsequently triggers metabolic Adverse
Drug Reactions (ADRs).
Objective: Identify biomarkers that may contribute to the
short-term prediction of metabolic dysfunctions associated
with antipsychotic treatment.
Materials and Methods: An open, controlled, rando-
mised, crossover clinical trial in healthy volunteers was
carried out to evaluate the short-term effects (5 days) of
olanzapine and aripiprazole in healthy volunteers. Blood
samples were collected before and after each treatment. A
total of 48 samples were analysed with Illumina total RNA-
Seq technology, followed by differential expression
analyses.
Results: A euclidean distance heatmap grouped the
4 samples from 4 volunteers, suggesting a lack of effect
due to the treatments while separating the samples of the
other 8 volunteers. A Gene Set Enrichment Analysis
(GSEA) showed the opposite effect of aripiprazole and
olanzapine on the expression of Oxidative phosphorylation
and Myc targets gene sets (p <0.001). While aripiprazole
produced a Normalized Enrichment Score (NES) of -2.9
and -2.4 respectively, olanzapine produced a NES of 4.9
and 5.7 respectively. The Myc network coordinates the
cellular utilization of glucose by regulating the mitochon-
drial mass and activity.
Conclusions: Our results suggest that the volunteers
could be stratified according to their response to the
treatments. Both aripiprazole and olanzapine may induce
dysregulation of the glucose utilization due to the alteration
of the Myc signalling. Further validation is ongoing. This
project was funded by the EU Framework Horizon 2020
under GA 721236.
M. Ruiz Rosario: None. R. Yildiz: None. D. Koller:
None. M. Monsalve: None. F. Abad-Santos: None. J.C.
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Polygenic risk score utilization in bone transcriptome
differential expression analyses
V. Prijatelj1, S. Reppe2, C. M. Medina-Gomez1, M. Dietz3,
J. A. M. Verlouw1, C. G. Boer1, J. B. J. van Meurs1, A. J.
van Wijnen3, K. M. Gautvik2, E. B. Wolvius1, F.
Rivadeneira1
1Erasmus MC, University Medical Center Rotterdam,
Rotterdam, Netherlands, 2Institute of Basic Medical
Sciences, University of Oslo, Oslo, Norway, 3Department
of Orthopedic Surgery, Mayo Clinic, Rochester, MA, United
States
Introduction: Clinically defined phenotypes are prone to
confounding which may obscure classification of cases and
controls. We aimed at using recall-by-genotype (RbG) to
leverage polygenic risk scores (PRS) for low bone mineral
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density (BMD) and osteoarthritis (OA) seeking to enhance
transcriptome differential expression analyses (DEA).
Materials: Whole-tissue bone samples were obtained
from either trans-iliacal biopsies or femoral head fragments
as part of hip replacement surgery in 121 participants. BMD
was measured at the Total Hip (TH-BMD) and Total Body
(TB-BMD) using DXA. Transcriptome profiling was done
on all samples using RNA-sequencing. Iliac samples (n =
71) were genome-wide genotyped. DEA was done by
grouping participants into cases and controls based on either
on TH-BMD T-values (<-2.5 and >-1.0 respectively) or OA
status. Weighted PRS were constructed for TB-BMD and
OA. DEA was repeated on transcriptome profiles using
RbG targeting the upper and lower PRS quintiles.
Results: Higher expression of SOST and DKK1 was
observed in patients with higher BMD replicated by both
approaches (phenotypic and recall-by-genotype grouping).
The latter approach also identified differential expression of
TPBG and MEPE. Differential expression of OA identified
known (SLC39A8, CTSK, MTF1) and novel OA genes.
Conclusions: Our findings illustrate PRS can enhance
transcriptome DEA when used in a RbG framework.
Further, the approach allows triangulation of functional
genomics evidence implicating shared and independent
pathways underlying osteoporosis and osteoarthritis.
Transcripts associated with higher TB-BMD (positive) and lower TB-BMD (negative effect
direction)
Name Effect Size Standard Error P-value FDR
SYT 0.084 0.017 2.02E-06 7.05E-05
WIF1 0.053 0.014 2.66E-04 2.34E-03
ANGPT4 0.055 0.015 2.67E-04 2.34E-03
DKK1 0.048 0.013 4.37E-04 2.78E-03
SCIN 0.059 0.017 7.03E-04 3.51E-03
ARMH1 0.108 0.032 1.16E-03 4.52E-03
COL8A2 0.095 0.028 1.08E-03 4.52E-03
MMP14 0.101 0.032 2.13E-03 6.79E-03
PLCD1 0.132 0.043 2.86E-03 8.35E-03
SPACA9 0.103 0.035 4.13E-03 1.08E-02
FGF1 0.040 0.014 4.31E-03 1.08E-02
SOST 0.024 0.009 1.18E-02 2.44E-02
SFRP4 0.041 0.016 1.19E-02 2.44E-02
CHIT1 0.029 0.013 2.19E-02 4.03E-02
IRX5 0.047 0.021 2.80E-02 4.46E-02
KLK4 0.038 0.017 2.62E-02 4.46E-02
TPBG 0.068 0.030 2.80E-02 4.46E-02
COL11A1 0.028 0.013 3.15E-02 4.59E-02
MEPE 0.027 0.012 3.28E-02 4.60E-02
NEXN -0.103 0.025 2.34E-05 4.10E-04
PDE5A -0.112 0.031 4.77E-04 2.78E-03
PRKG1 -0.085 0.026 1.30E-03 4.55E-03
RAB27B -0.055 0.021 9.28E-03 2.17E-02
ATP13A4 -0.041 0.017 1.98E-02 3.84E-02
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C.G. Boer: None. J.B.J. van Meurs: None. A.J. van
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Biobank-based genotype-first model for return of
actionable findings: follow-up and extended impact by
cascade screening of BRCA1/2 carriers
M. Palover1,2, L. Leitsalu1, T. Sikka1,2, A. Reigo1, T.
Nikopensius1, T. Esko1, A. Metspalu1,2, P. Padrik3,4, N.
Tõnisson1,5
1Estonian Genome Centre, Institute of Genomics, Tartu,
Estonia, 2Institute of Molecular and Cell Biology, Uni-
versity of Tartu, Tartu, Estonia, 3Hematology and Oncology
Clinic, Tartu University Hospital, Tartu, Estonia, 4Institute
of Clinical Medicine, University of Tartu, Tartu, Estonia,
5Dept. of Clinical Genetics, United Laboratories, Tartu
University Hospital, Tartu, Estonia
Introduction: accumulating data from population studies
intensifies the need to update best practices on how clini-
cally significant genetic findings are handled in research
cohorts and clinical practice.
Objective: We propose a model on how to distinguish,
contact and return high-risk genetic findings to biobank
participants.
Methods: Genotype-first approach was applied to
identify carriers of pathogenic variants in BRCA1/2 genes
and offer return of results with genetic counselling to the
Estonian biobank participants. We evaluated the long-term
effect of reporting actionable genetic findings.
Results: 22 of 40 carriers contacted opted for receiving
results. 18 of 21 appreciated being contacted; three were
unsure. 10 had relatives attending cascade screening. Within
one year, five of 16 female carriers opted for risk-reducing
surgery. Over follow-up of 30 months, 10 adhered to
surveillance recommendations. Only eight of 21 qualified
for high-risk assessment based on clinical criteria.
Discussion: This study highlights the significance of
population genomic studies for personal early risk evalua-
tion. It provides evidence for the genotype-first approach to
improve long-term outcomes for individuals, unaware of
their high genetic risk. We demonstrate that biobank
participants as well as their family members appreciate
receiving results that exemplifies how individuals from
general population would respond. Our results indicate that
age and family history are poor discriminators of risk alone.
Our study is a basis of ongoing national pilot study on
genetics of female breast cancer. This research was
supported by the PUT PRG555, IUT20-60 and RITA1/01-
42-01 grants from the Estonian Research Council and
European Regional Development Fund.
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 693
M. Palover: None. L. Leitsalu: None. T. Sikka: None.
A. Reigo: None. T. Nikopensius: None. T. Esko: None. A.
Metspalu: None. P. Padrik: None. N. Tõnisson: None.
P18.57.A
Treatabolome: a rare diseases treatment awareness
project
A. Atalaia1, R. Thompson2, A. Corvo3, L. Carmody4, D.
Piscia3, L. Matalonga3, A. Macaya5, A. Lochmuller6, B.
Fontaine7, B. Zurek8, C. Hernandez-Ferrer3, C. Reinhard9,
D. Gómez-Andrés5, J. F. Desaphy10, K. Schon6, K.
Lohmann11, M. Jennings6, M. Synofzik12,13, O. Riess9, R.
Ben Yaou14, T. Evangelista15, T. Ratnaike16, V. Bros-
Facer17, G. Gumus17, R. Horvath6, P. Chinnery18, S.
Laurie3, H. Graessner19, P. Robinson20, H.
Lochmuller21,22,23, S. Beltran3, G. Bonne24
1Soborne Universite, Inserm U974, institut de Myologie,
Hopital Pitie-Salpetriere, Paris, Paris, France, 2Children’s
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(CRG), Barcelona Institute of Science and Technology
(BIST), Barcelona, Spain, 4The Jackson Laboratory For
Genomic Medicine, Farmington, CT, United States, 5Pae-
diatric Neurology, Vall d’Hebron University Hospital and
VHIR (Euro-NMD, ERN-RND), Barcelona, Spain, 6Depart-
ment of Clinical Neurosciences, University of Cambridge
School of Clinical Medicine, Cambridge Biomedical
Campus, Cambridge, United Kingdom, 7Soborne Univer-
site, Inserm U974, Hopital Pitie-Salpetriere, Paris, Paris,
France, 87 Institute of Medical Genetics and Applied
Genomics, University of Tuebingen, Tuebingen, Germany,
9Institute of Medical Genetics and Applied Genomics,
University of Tuebingen, Tuebingen, Germany, 10Depart-
ment of Biomedical Sciences and Human Oncology, School
of Medicine, University of Bari Aldo Moro, Bari, Italy,
11Institute of Neurogenetics, University of Lübeck, Lübeck,
Germany, 12Department of Neurodegenerative Diseases,
Hertie-Institute for Clinical Brain Research and Center of
Neurology, University of Tübingen, Tübingen, Germany,
13German Center for Neurodegenerative Diseases (DZNE),
University of Tübingen, Tübingen, Germany, 14Soborne
Universite, Inserm U974, Institut de Myologie, Hopital
Pitie-Salpetriere, Paris, Paris, France, 15Unité de Morpho-
logie Neuromusculaire, Institut de Myologie, GHU Pitié-
Salpêtrière; Sorbonne Université, AP-HP, INSERM, Centre
de référence Des Maladies Neuromusculaires Nord/Est, Ile
de France, Paris, France, 16Department of Paediatrics,
Cambridge University Hospitals NHS Foundation Trust;
Department of Clinical Neurosciences, University of Cam-
bridge, Cambridge, United Kingdom, 17EURORDIS – Rare
Diseases Europe, Paris, France, 18Department of Clinical
Neurosciences, School of Clinical Medicine, University of
Cambridge and MRC Mitochondrial Biology Unit, Cam-
bridge Biomedical Campus, Cambridge, United Kingdom,
19Institute of Medical Genetics and Applied Genomics,
University of Tuebingen, Germany, Tuebingen, Germany,
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Farmington, CT, United States, 21Department of Neurope-
diatrics and Muscle Disorders, Medical Center - University
of Freiburg, Faculty of Medicine, University of Freiburg,
Freiburg, Germany, 22Children’s Hospital of Eastern
Ontario Research Institute; Division of Neurology, Depart-
ment of Medicine, The Ottawa Hospital, Ottawa, ON,
Canada, 23Brain and Mind Research Institute, University of
Ottawa, Ottawa, ON, Canada, 24Sorbonne Université -
Inserm UMRS 974, Center of Research in Myology, Institut
de Myologie, G.H. Pitié-Salpêtrière, Paris, France
Rare diseases are individually rare but globally affect about
6%% of the population according to the latest calculations.
Recent estimates point to over 10000 rare diseases, of which
6172 disorders are listed in Orphanet, 71.9% of which being
genetic and 69.9% having paediatric-onset. These diseases’
rarity is contextual, varying with the population considered
and also geographically. Nonetheless, disease rarity uni-
formly translates into a delayed diagnosis, with 25% of
patients having to wait for 5 to 30 years to have one. It is
essential, at the time of diagnosis, to be able to relay
information about potential gene and variant-specific
therapies to patients. “Solve-RD - solving the unsolved
rare diseases” is a research project funded by the European
Commission for five years(2018-2022) aiming at improving
the diagnostic and therapeutic management of rare diseases.
It will deliver seven implementation steps, including one
dedicated to treatment as part of the“genetic knowledge
web”. With this in mind, we propose a method of allowing
clinicians to access this information promptly to benefit
patients affected by rare disease and their families. The“-
Treatabolome” is an evidence-appraised database of rare
diseases treatments for specific genes and variants to be
made available through genetic diagnosis and support tools,
for example, the RD Connect Genome-Phenome Analysis
Platform. The Treatabolome aims at contributing to raising
awareness and increasing the visibility of existing rare
diseases’ treatments to clinicians.
Grants: European Reference Networks ERN Euro-NMD
and ERN-RND (project ID 739510), Solve-RD project -
EU’s Horizon 2020 grant 779257.
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C3435T ABCB1 polymorphism predicts therapeutic
response to cyclosporine in psoriasis patients.
D. Kilina1, A. Chernov1, O. Karnishkina1, T. Smirnova2, E.
Galimova1,3
1Center for Preclinical and Translational Research of
Federal State Budgetary Institution “Almazov National
Medical Research Centre” of the Ministry of Health of the
Russian Federation, St. Petersburg, Russian Federation,
2City dispensary of Dermatology and Venerology, St.
Petersburg, Russian Federation, 3Sechenov Institute of
Evolutionary Physiology and Biochemistry Russian Acad-
emy of Sciences, St. Petersburg, Russian Federation
Introduction: Psoriasis is a chronic immune-mediated skin
disease affecting 2-3% of the Caucasian population.
Cyclosporine, a potent calcineurin inhibitor acting selec-
tively on T-cells, is used for the treatment of severe psor-
iasis, show significant variability in efficacy, which
associated with varying degrees of toxicity. The detection of
pharmacogenetic markers of treatment response may be
useful in predicting clinical response to psoriasis therapies
and would help in the improvement of personalized therapy.
The aim of the present study was to assess the association
rs3213619, rs2229109, rs1128503, rs2032582 single-
nucleotide polymorphisms (SNPs) in the ABCB1 gene
with response to cyclosporine treatment in Russian psoriasis
patients.
Materials and Methods: DNA samples were collected
from 168 patients with psoriasis. Genotyping of SNPs was
performed by real-time polymerase chain reaction using the
CFX 96™ Real-Time Cycler (BioRad, USA). For case-
control association study we used χ² tests with Pearson
contingency tables were implemented in PLINK version
1.06 to compute the P-values and corresponding odds ratios
(OR) with 95% confidential intervals (CI) for allelic
association.
Results: The variant rs1045642 in the ABCB1 gene
showed an association with a negative response to
cyclosporine therapy (OR=2.58, 95% CI = 1.64-4.06) in
Russians. Carriers of the dominant model (TT+CTvsCC)
have 1.6-fold higher risk (OR = 4.01, 95% CI = 1.82-8.98)
of no response to cyclosporine treatment than recessive
(TTvsCC+CT) model (OR = 2.50, 95% CI = 1.14-5.50).
Conclusions: Further, larger studies are required to
confirm our findings and replicate them in various
populations before implementation in the clinical practice.
D. Kilina: None. A. Chernov: None. O. Karnishkina:
None. T. Smirnova: None. E. Galimova: None.
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Prevalence of actionable germline variants within a 53-
gene inherited cancer risk gene panel in a cohort of
2,642 cancer patients classified by an AI inference
engine
F. M. De La Vega1, T. Friedrich1, S. Nohzadeh-
Malakshah1, M. G. Reese1, C. D. Bustamante2, E. Frise1
1Fabric Genomics, Oakland, CA, United States, 2Stanford
University School of Medicine, Stanford, CA, United
States
Implementation of cancer risk gene tests continues to grow
driven by new reimbursement pathways and technological
advances. However, disagreement exists on what genes and
populations should be screened, their clinical utility and the
cost/benefit of such tests. This debate should be informed
by an understanding of the prevalence of cancer risk var-
iants in different population cohorts. Here we analyzed
germline variants from a cohort of 2,658 patients with 38
different types of cancer, whose tumor and matching normal
genomes were sequenced as part of the ICGC PanCancer
Analysis of Whole Genomes project. We identified 377,025
non-synonymous germline variants within the regions of an
expanded 53-gene hereditary cancer risk panel, which
includes genes associated with breast, ovarian, colon,
prostate, lung, and other cancers. For expedited and con-
sistent assessment of variant pathogenicity, we utilized a
recently developed artificial intelligence-based forward-
chaining inference engine, ACE, which implements the
ACMG-AMP criteria leveraging variant annotations and
codified gene-condition curations. ACE classified auto-
matically 97% of variants, leaving only 1,085 unique var-
iants annotated with a subset of the ACMG criteria for
manual review. Overall 5% of cancer patients were carriers
of pathogenic/likely pathogenic (P/LP) variants, with pre-
valence higher in patients of renal cell, pancreas adeno-
carcinoma, ovarian, breast, and liver cancers. A higher
frequency of the P/LP variants was observed in the genes
ATM, KCHN2, BRCA1/2, and PMS2. As population
screening for cancer risk is being actively discussed by
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healthcare stakeholders, our results illustrate that previously
established guidelines could miss people with potentially
actionable variants.
F.M. De La Vega: A. Employment (full or part-time);
Significant; Fabric Genomics, Inc.. E. Ownership Interest
(stock, stock options, patent or other intellectual property);
Significant; Fabric Genomics, Inc. T. Friedrich: A.
Employment (full or part-time); Significant; Fabric Geno-
mics, Inc. S. Nohzadeh-Malakshah: A. Employment (full
or part-time); Modest; Fabric Genomics, Inc. M.G. Reese:
A. Employment (full or part-time); Significant; Fabric
Genomics. E. Ownership Interest (stock, stock options,
patent or other intellectual property); Significant; Fabric
Genomics. C.D. Bustamante: None. E. Frise: A. Employ-
ment (full or part-time); Significant; Fabric Genomics. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Fabric Genomics.
P18.60.A
Exploring secondary findings in a Spanish cohort of 641
patients undergoing whole exome sequencing
M. Codina Solà, E. Rovira Moreno, A. Abulí Vidal, I.
Valenzuela Palafoll, A. Cueto Gonzalez, F. López
Grondona, I. Paramonov, S. Ourani, C. Serra Juhé, E.
García Arumí, I. Cuscó Martí, E. Tizzano Ferrari
Hospital Vall Hebron, Barcelona, Spain
Introduction: Exome-sequencing is being used across
diverse clinical settings allowing primary diagnosis but also
screening for unrelated disorders. The ACMG (2017)
recommends offering the analysis of 59 medically action-
able genes (secondary findings, SFs). However, little is
known about acceptance rates and penetrance of SFs in
patients without family history.
Materials and Methods: We retrospectively reviewed
patients (n = 641) who underwent exome-sequencing in a
Spanish tertiary center from May 2017 to September 2019.
During pretest genetic counseling all patients were offered
to know SFs or to opt out. We analyzed acceptance and
detection rate. In addition, we reviewed type of findings and
family history.
Results: The great majority of patients opted to receive
SFs. A secondary finding was identified in 11 patients
(1,7%). Pathogenic variants were found in genes related to
cancer (SDHB, BRCA2, PMS2, STK11), cardiomyopathies
(MYBPC3, BAG3, TNNT2, DSC2, DSP) and channelopa-
thies (RYR2, SCN5A). Segregation studies indicated that all
variants were inherited with exception of one de novo
variant in RYR2. Only one family (BAG3) met criteria for an
a priori genetic testing. In the rest of cases, carriers
evaluated so far had no personal/family history and showed
no signs of the disease.
Conclusions: Our results show a high acceptance for the
return of SFs. Virtually none of the variants would have
been a priori identified, since most patients did not have
family history to justify specific genetic testing. Further
clinical evaluation is being performed to assess penetrance
of SFs in the absence of family history.
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Impairments of smell perception: the role of sex, age and
genes
M. Concas1, T. Battistuzzi2, M. Cocca1, B. Spedicati3, G.
Pelliccione1, P. Gasparini1,3, G. Girotto1,3
1Institute for Maternal and Child Health – IRCCS ‘‘Burlo
Garofolo”, Trieste, Italy, 2Department of Life Sciences,
University of Trieste, Trieste, Italy, 3Department of
Medicine, Surgery and Health Sciences, University of
Trieste, Trieste, Italy
Smell deficits affect quality of life leading to loneliness and
depression and represent an early symptom of neurode-
generative diseases. Here, we investigated the role of age,
sex and genetics factors in smell perception in a large Italian
cohort (1155 individuals). Smell ability was assessed using
the SNIFFIN’ sticks test. Number of errors (NoE) was
counted and a linear mixed model applied to evaluate the
influence of age and sex. A mean NoE of 1.76 ± 1.65 was
detected. Male sex and increased age were associated with a
greater NoE (p < 0.05). A subset of subjects (802 out of
1155) was analysed by WGS to detect human Loss of
Function variants (LoF). The number of biallelic LoF
mutations (NoM) on 35 olfactory receptors (OR) genes (27
of which clearly expressed in the olfactory epithelium) was
counted and subjects (228) grouped accordingly. The NoM
was 4.19 ± 1.99, while NoE was 2.54 ± 1.95. Age accounts
for 22% of the variability in NoE, while NoM has no
impact. Excluding elderly people (≥70 y, n = 75) from the
analysis, we found that NoE increases with NoM, sug-
gesting a strong role of genetics factors. NoM explains 6%
of NoE variability, while age only 4.9% (p < 0.05).
Our findings confirm age as a strong factor influencing
smell deficits, and, for the first time, highlight the role of
genetics factors (i.e. mutations in OR genes) in predisposing
to smell deficits in the general population. Moreover, we
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showed that at a given time, the aging process has such
strong impact that exceeds the individual’s genetic
predispositions.
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Pharmacogenomics of varenicline using linked primary
care data in the UK
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Batini1
1Department of Health Sciences, University of Leicester,
Leicester, United Kingdom, 2Leicester NIHR BRC, Institute
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Background: Varenicline is a partial agonist to the α4β2
nicotinic acetylcholine receptors (nAChRs), which are
involved in nicotine-induced reward pathways, dependence
and withdrawal. Varenicline is the second most commonly
prescribed smoking cessation medication after nicotine
replacement therapy, and has the greatest therapeutic effi-
cacy. We present the first case-control candidate gene study
of varenicline effectiveness using EXCEED, a cohort of
~10,000 individuals based in the UK.
Methods: An electronic phenotyping algorithm using
prescription Read Codes in primary care data linked to
EXCEED participants was used to identify individuals with
varenicline prescriptions (N = 185). Cases and controls
were defined as smokers at ≥1 year follow up and non-
smokers at ≥1 year follow up, respectively. We tested 198
tag SNPs, spanning 12 biologically relevant candidate genes
encoding proteins involved in varenicline activity and
metabolism.
Results: Seven SNPs were associated with varenicline
effectiveness at nominal significance (P < 0.05), but none
passed the Bonferroni corrected threshold. These SNPs
were located in nAChR subunit genes CHRNA4, CHRNB4
and CHRNA7, and have not been previously reported as
associated with varenicline effectiveness or smoking
behaviour traits.
Future work: This study was limited by statistical power
due to low sample size. Therefore, we intend to use the
same approach to ascertain case-control status for indivi-
duals with varenicline prescriptions using primary care data
linked to ~230,000 UK Biobank participants. This will form
the foundations for a genome-wide association study to
identify unbiased genetic associations with varenicline
effectiveness.
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Impact of BRCA1 mutation status on the therapeutic
efficacy of CDK4/6 inhibitors in triple negative breast
cancer
G. Guney Eskiler1, Z. Ozman2
1Sakarya University, Faculty of Medicine, Department of
Medical Biology, Sakarya, Turkey, 2Sakarya University,
Institute of Health Science, Department of Medical
Biochemistry, Sakarya, Turkey
Introduction: The cyclin-dependent kinases (CDK)-reti-
noblastoma (RB) pathway plays a vital role in the pro-
gression of breast cancer (BC). Therefore, CDK4/6
inhibitors have great attention as a new therapeutic strategy
for the treatment of BC. On the basis of genetic feature,
there is a strong associations between TN phenotype and
BRCA1 mutation status. However, the effectiveness of
CDK4/6 inhibitors in triple negative breast cancer (TNBC)
has not been fully examined in terms of BRCA1 mutation
status. Therefore, we explored the therapeutic effects of
abemaciclib on two different TNBC cells and identified the
underlying mechanisms of apoptotic cell death.
Materials and Methods: The cytotoxicity, Annexin V,
cell cycle and RT-PCR analysis were performed to
determine anti-cancer effects of abemaciclib on HCC1937
(BRCA1 mutant) and MDA-MB-231 cells (BRCA1 wild-
type).
Results: Abemaciclib significantly inhibited the prolif-
eration of TNBC cells in a dose and time dependent manner
(p < 0.05). However, HCC1937 cells were more sensitive to
abemaciclib than MDA-MB-231 cells. After 24 hours
treatment with 1.5 μM abemaciclib, the percentage of total
apoptotic cells was 63.5% and 11.7% in HCC1937 and
MDA-MB-231 cells, respectively. We observed that more
cells accumulated in G0/G1 phase through down-regulation
of CCDN1 (1.7-fold; p = 0.001) and RB1 (0.7-fold; p =
0.015) in HCC1937 cells.
Conclusions: Abemaciclib exerted potential anti-cancer
effects on TNBC cells and BRCA1 mutation status increased
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therapeutic efficacy of abemaciclib. Our results suggest a
greater benefit for the future clinical trials of abemaciclib in
the treatment of BRCA1 mutation carriers with TNBC.
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Polygenic risk scores could improve venous trombosis
risk estimation in Factor V Leiden mutation carriers
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1Finnish Institute for Health and Welfare, Helsinki, Fin-
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of Medicine, University of Helsinki, Helsinki, Finland
Introduction: In P5 FinHealth study we have 3449 parti-
cipants from a biobanked population-based study cohort
FinHealth. We estimated participants’ polygenic risk scores
(PRSes) and ten years total risks for venous thromboem-
bolism (VTE) and returned the information to participants
via internet portal. In the process we studied how the known
VTE predisposing variant Factor V Leiden affects the risk
of VTE in the presence of PRS.
Materials and Methods: Our VTE PRS, containing 6.5
million genomic variants, was based on UK Biobank
GWAS summary statistics and adjusted for the effects of
linkage disequilibrium (LD) with Python package LDpred.
We generated PRSes also separately for Factor V Leiden
carriers and non-carriers. We used Cox regression to
estimate the effects of genetic (PRS) and traditional (e.g.
gender, age, smoking, BMI, prevalent CHD or T2D) risk
factors on future risk of VTE event in a large Finnish
follow-up cohort (N = 28.000).
Results: PRS associates significantly with a 10-year VTE
risk (Factor V Leiden carriers: HR=1.8, p = 7*104 and
non-carriers: HR=1.4, p = 2*106). Moreover, Net reclassi-
fication improvement (NRI) analysis showed that the model
with PRS correctly re-classifies cases in both groups: Factor
V Leiden carriers (p = 0.009) and non-carriers (p = 0.013),
compared to a model without PRS.
Conclusions: In our study we show that VTE PRS offers
additional value to VTE risk estimation even in the presence
of the known VTE predisposing variant Factor V Leiden.
We have returned personal genetic and absolute 10-year risk
estimates and instructions for their health care for the P5
participants in February 2020.
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Added value of clinical whole-genome sequencing: Co-
occurring rare diseases and pharmacogenetic profiling
S. M. Caspar1,2, A. Najafi1, J. Meienberg1, T. Schneider1, C.
Henggeler1, G. Matyas1
1Center for Cardiovascular Genetics and Gene Diagnos-
tics, Schlieren-Zurich, Switzerland, 2Laboratory of Transla-
tional Nutrition Biology, ETH Zurich, Schwerzenbach,
Zurich, Switzerland
Introduction: In the current genomics era, interpretation of
high-throughput sequencing data constitutes the main bot-
tleneck on the path to accurate diagnosis of Mendelian
disorders. Large-scale reference cohorts such as ExAC/
gnomAD are valuable for the population-frequency-based
filtering of the myriad of detected sequence variants. Using
the example of fibrillinopathies, such as FBN1-related
Marfan syndrome (MFS) and FBN2-related congenital
contractural arachnodactyly (CCA), we assessed the fre-
quency and co-occurrence of pathogenic FBN1/
FBN2 sequence variants in ExAC/gnomAD and the largest
Swiss database of Marfan genomes, respectively.
Methods: By focusing on a priori (likely) pathogenic
sequence variants in ExAC/gnomAD, we calculated
prevalence estimates for MFS and CCA. Furthermore, we
screened whole genomes (60× WGS) of ~550 patients with
rare (aortic) disorders for (likely) pathogenic and functional
sequence variants in FBN1/FBN2, and 12 pharmacogenes,
respectively.
Results: We show the presence of pathogenic FBN1/2
variants in the apparently healthy reference cohort ExAC/
gnomAD, providing prevalence estimates for MFS and
CCA. In our Swiss cohort, we identified two families with
dual FBN1/FBN2 mutations, explaining the variable
phenotype within these families including clinical features
of MFS and CCA (PMID:31506931). In one family, we
also detected a pharmacogenetically actionable variant in a
drug metabolizing enzyme.
Conclusions: Our results not only demonstrate that
apparently healthy reference data sets may include indivi-
duals with late-onset or unrecognized disease, but also show
that fibrillinopathies occur more frequently than expected
and may co-occur. Furthermore, we emphasize the
importance and increasing possibility of detecting digenic
and, as an added value, pharmacogenetically relevant
sequence variants using WGS.
S.M. Caspar: None. A. Najafi: None. J. Meienberg:
None. T. Schneider: None. C. Henggeler: None. G.
Matyas: None.
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Effectual delivery of Nef-MPER-V3 fusion protein using
LDP12 cell penetrating peptide as a HIV-1 vaccine
candidate
S. Sabaghzadeh1, S. Sadat2, A. Bolhassani2
1Islamic azad university of tehran medical branch, faculty
of advanced sciences & technology, Tehran, Iran, Islamic
Republic of, 2Pasteur institute of iran, department of
hepatitis and AIDS, Tehran, Iran, Islamic Republic of
Introduction: Human immunodeficiency virus (HIV)
which causing acquired immune deficiency syndrome
(AIDS) is one of the main universal health concern. In spite
of using antiretroviral treatments, there are no authorized
HIV vaccines. The development in using therapeutic pro-
teins is affected by the limitation on permeability and
selectivity of cell membranes. Thus, utilizing cell-
penetrating peptides (CPPs) as protein transfection
reagents or protein transduction domains (PTDs) has been
expanded. In addition, heat shock proteins suchlike Hsp27
as intracellular chaperones motivate efficient immune
responses.
Material and Methods: Following by the confirmation
of the plasmid construct HIV-1 Nef-MPER-V3-LDP12-
pET-28a by NdeI/XhoI restriction enzymes digestion,
applying prokaryotic expression, SDS-PAGE and western-
blotting were utilized. Next, the target protein was purified
on Ni-NTA agarose column, dialyzed and evaluated by
spectrophotometry. For transfection, 4 × 104 HEK-293T
cells/well were used and supplied by complete DMEM
medium. Then LDP12-Nef-MPER-V3, Nef-MPER-V3,
Hsp27-GFP-turbofect and GFP-turbofect were applied to
each well and assessed by western-blotting.
Results: The gene’s presence was confirmed by digestion
as 825 bp band and sequencing. Moreover, western-blot
analysis indicated a desired expression of Hsp27-GFP,
GFP, LDP12-Nef-MPER-V3, and Nef-MPER-V3 as ~54,
~27, ~37, and ~35 kDa bands, respectively. Our data
showed the significantly expression of fusion constructs in
Rosetta strain and also, was accurately purified under
denaturing condition.
Conclusions: Briefly, this stable construct (LDP12-Nef-
MPER-V3) with high cellular penetrance and low toxicity
could be used as a favorable procedure in HIV-1 vaccine
strategy, that is sufficiently capable of inducing specific
strong immune responses.
Grant: Seyed mehdi sadat, Pasteur institute of Iran
S. Sabaghzadeh: None. S. Sadat: None. A.
Bolhassani: None.
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12q24 locus affects BMI through alcohol drinking and
dietary behaviors
M. Igarashi1, S. Nogawa2, K. Kawafune2, T. Hachiya2,3, H.
Jia1, K. Furukawa1, S. Takahashi2, K. Saito1,2, H. Kato1
1The University of Tokyo, Tokyo, Japan, 2Genequest Inc,
Tokyo, Japan, 3Genome Analytics Japan Inc, Tokyo, Japan
Introduction: The 12q24 locus, East Asian-specific linkage
disequilibrium (LD) region, includes ALDH2 gene which
involves in alcohol metabolism. It has been reported that a
single nucleotide polymorphism (SNP) in ALDH2, rs671, is
associated with various dietary behaviors (DBs), susceptibility
to diseases and clinical measurements including BMI. The
purpose of this study was to investigate how the pleiotropic
effects of 12q24 affect human health through DBs.
Materials and Methods: Genomic DNA was extracted
from saliva samples of 12,315 Japanese subjects and
genotyped by SNP array. We collected data about
residential area, sex, age, and 56 DBs by Web questionnaire
survey. The sex-stratified phenome-wide association study
(PheWAS) for rs671 was performed by PLINK with
multiple testing correction (P < 0.05/56).
Results: The PheWAS analysis revealed that 11 and 7
DBs were significantly associated with rs671 in male and
female, respectively. After adjusting for alcohol intake
frequency, 6 DBs in male and 2 DBs in female were
significantly associated with rs671. Almost all associations
with DBs, except for coffee intake, were attenuated by
adjustment of alcohol intake frequency. The mediation
analysis revealed that 5 DBs in male and 3 DBs in female
were mediated between alcohol drinking and BMI.
Conclusions: This study showed that the 12q24 locus
affects BMI through complicated pathways with and
without the mediation of alcohol drinking. Furthermore, it
was suggested that sex-specific DBs was involved in the
pathway. Our findings can contribute to personalized
nutrition using rs671 in East Asians. This work was
supported by Grants-in-Aid (19K11709) from JSPS.
M. Igarashi: None. S. Nogawa: A. Employment (full or
part-time); Modest; Genequest Inc. K. Kawafune: A.
Employment (full or part-time); Modest; Genequest Inc.
T. Hachiya: A. Employment (full or part-time); Modest;
Genequest Inc. H. Jia: None. K. Furukawa: None. S.
Takahashi: A. Employment (full or part-time); Modest;
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Variants associated with Alzheimer’s disease develop-
ment revealed by analyzing genome data of healthy
individuals and Bulgarian supercentenarians
D. N. Nikolova1, D. Serbezov1, L. Balabanski1,2, S.
Karachanak-Yankova1,3, M. Mihailova1, V. Damyanova1, R.
Staneva1, D. Nesheva1, Z. Hammoudeh1, S. Hadjidekova1,
D. Toncheva1,2
1Medical University Sofia, Sofia, Bulgaria, 2Hospital
"Malinov", Sofia, Bulgaria, 3Sofia University “St. Kliment
Ohridski”, Sofia, Bulgaria
Introduction: Alzheimer’s disease (AD) is predominantly a
disease of the elderly and is a major cause of dementia,
slowly progressing towards disability and death. Genetic
studies are mainly related to the search for single mutations
with a pathogenic effect, as well as separate variants of
genes that would modify the risk of developing symptoms
earlier or later in life.
Materials and methods: DNAs from 32 centenarians
(100 to 106 years) and 61 healthy individuals aged 18-30
years have been exome sequenced in two separate pools.
1930 variants from DisGeNet database known to be
associated with AD have been searched.
Results: Five pathogenic variants have been found in
young healthy control group: rs63750264 in APP gene is
associated with early onset AD, while rs145999145 in
PLD3, rs72470545 in HTRA2, rs2070045 in SORL1,
rs429358 in APOE are associated with late onset AD.
Conclusion: Centenarians are a model of a “good quality
of life” and most of them do not show any manifestations of
dementia. They are "gold standard" for revealing protective
genetic variants or absence of pathogenic/risky ones, the
latter considered a triggering mechanism to unlock AD. Our
analysis shows that young healthy individuals carry risk
variants for predisposition to AD. This suggests that the
exome screening is useful for early diagnosis and preven-
tion of neurodegenerative disorders.
Acknowledgements: Contract DN 03/7 from 18.12.2016
and KP-06-N33/5 from 13.12.2019 of the National Science
Fund of Bulgaria.
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The first Y-STR haplotype of the Medieval Russia
Individual from the Tver Region.
G. D. Stepanov1, I. Alborova2, R. A. Zinchenko1, K. K.
Mustafin2
1Research Centre for Medical Genetics, Moscow, Russian
Federation, 2Moscow Institute of Physics and Technology,
Moscow, Russian Federation
Introduction: The study of ancient human DNA is rapidly
developing, although research on ancient samples at the
level of paleo-populations is almost not conducted. One of
the difficult regions of Eastern Europe’s ethnogenesis is
medieval Russia. The aim of this research is to obtain the Y-
chromosomal STR-haplotype of an individual buried in the
XII century on the territory of the Tver Kremlin and com-
pare it with the haplotypes of modern populations.
Materials and Methods: We used bone fragments and
teeth from individual found in the burial of the early
necropolis, wherein 1285 the construction of the Transfig-
uration Cathedral in the Tver Kremlin took place. The burial
was formed before the construction of the cathedral, which
is confirmed by radiocarbon analysis: date from the 12th-
13th centuries. The methods were used in the work: DNA
was extracted on a Silica Spin column; capillary electro-
phoresis and the Yfiler® Plus kit were used to determine the
lengths of polymorphic STR-loci of Y-chromosome.
Results: A Y-chromosomal STR-haplotype was obtained.
Of the 25 loci included in the Yfiler® Plus kit, 23 loci are
identified. Analysis using predictors shows that this
haplotype belongs to the haplogroup R1a1a1b1a1a
(M458). An analysis of publications revealed 3 identical
haplotypes by 16 common loci in populations: the Russian
of Ivanovo and Penza regions, the southern Germans.
Conclusions: This study confirms the possibility of
studying Medieval Russia samples. The haplotype is
widespread in the modern Russian population. Further
expansion of the sample will allow making a complete
picture of medieval Tver.
G.D. Stepanov: None. I. Alborova: None. R.A.
Zinchenko: None. K.K. Mustafin: None.
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Genome-wide association study meta-analysis identifies
three novel loci for circulating anti-Müllerian hormone
levels in women
R. M. G. Verdiesen1, Y. T. van der Schouw1, C. H. van
Gils1, W. M. M. Verschuren1,2, F. J. M. Broekmans3, M. C.
Borges4,5, A. L. G. Soares4,5, D. A. Lawlor4,5,6, A. H.
Eliassen7,8, D. P. Sandler9, S. D. Harlow10, J. A. Smith10, N.
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Utrecht, Utrecht, Netherlands, 4MRC Integrative Epide-
miology Unit at the University of Bristol, Bristol, United
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Introduction: Anti-Müllerian hormone (AMH) is expres-
sed by primary ovarian follicles in premenopausal women;
circulating AMH levels can be measured until menopause.
Variation in age-specific AMH levels has been associated
with breast cancer and polycystic ovary syndrome (PCOS),
amongst other diseases. Identification of genetic variants
underlying variation in AMH levels could elucidate these
AMH-disease associations.
Methods:We performed a meta-analysis of genome-wide
association studies including data from 7,049 premenopau-
sal female participants of European ancestry, to identify
SNPs associated with circulating AMH levels. Study-
specific analyses were adjusted for age at blood collection
and population stratification, and summary statistics were
meta-analysed using a standard error-weighted approach.
Results: We identified four loci for circulating AMH. We
confirmed the previously reported association with the
MCM8 locus and identified three novel signals in or near
AMH, TEX41, and CDCA7. The strongest signal was a
nonsynonymous missense variant located in exon 5 of the
AMH gene (rs10417628, β(SE)=-0.34 (0.05), p = 1.2 x
10−11). LD score regression analyses indicated a strong
positive genetic correlation among SNPs for AMH levels
and for age at menopause (rg=0.82, FDR=0.003). Two-
sample Mendelian Randomization analyses did not support
a causal effect of circulating AMH on breast cancer
or PCOS.
Conclusions: We identified three novel loci for AMH
levels in premenopausal women. Whilst this study almost
doubled the sample size of the most recent GWAS, we may
still lack power to determine causal effects of AMH on for
example breast cancer. RMGV was supported by The
Netherlands Organization for Scientific Research (Grant
number: 022.005.021).
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Founder effect in the French-Canadian population of the
Saguenay-Lac-St-Jean region in Quebec: screening
strategies for rare diseases and local initiatives under
development
T. Cruz Marino, M. Desmeules, J. Leblanc, A. Pratte, J.
Tardif, R. Guerin, L. Bouchard
CIUSSS Saguenay-Lac-St-Jean, Chicoutimi, QC, Canada
Introduction: French-Canadian settlers arriving from the
17th century onward provided the genetic background of
Saguenay-Lac-St-Jean’s population. A founder effect has
been well described in this Quebec region. A pilot program
started in 2010 for carrier screening of ARSACS, tyr-
osinemia type I, Leigh syndrome French-Canadian type,
and hereditary sensory-motor neuropathy with/without
agenesis of the corpus callosum. In 2018, this program
became province-wide through a web-based strategy that
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reached previously underserved regions. Simultaneously,
new founder conditions have been identified.
Methods: We review the particularities and the results of
the web-based test; we present a new group of founder
conditions, as well as the strategies under development for
their accurate diagnosis.
Results: During the first two years, more than 3000
individuals from 17 regions of Quebec province opted for
taking the web-based carrier test, the majority of them were
females, and preconceptional predominated over prenatal
requests. A project for neonatal screening of vitamin D-
dependent rickets is about to begin on a research basis as an
initial step. Other initiatives are being discussed for the
screening or early diagnosis of mucolipidoses type II,
Zellweger disease, junctional epidermolysis bullosa, MPI-
CDG, Naxos disease, APECED, autosomal recessive deaf-
ness type 57, and familial hypertrophic cardiomyopathy
type 1.
Conclusions: The web-based carrier testing allows
equitable access to all individuals coming from Saguenay-
Lac-St-Jean and living in any region of Quebec province.
This data highlights the importance of developing local
strategies that suit the needs of founder populations.
T. Cruz Marino: None. M. Desmeules: None. J.
Leblanc: None. A. Pratte: None. J. Tardif: None. R.
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Arsenic efficient metabolism in Mexican Indigenous
reinforces the arsenical hypothesis
R. I. Montero-Delgado1, M. López-González1, G. Noris2, C.
Santana2, N. A. Burguete-Argueta3, R. Gomez1
1Toxicology Department - CINVESTAV-IPN, Ciudad de
Mexico, Mexico, 2BIMODI, Santiago de Queretaro, Quer-
etaro, Mexico, 3Instituto de Ciencias Biológicas, Universi-
dad de Ciencias y Artes de Chiapas, Tuxtla Gutiérrez,
Chiapas, Mexico
Introduction: Mexico is an arsenic-endemic country with
more than two million individuals exposed, chronically, to
elevated concentrations of this metalloid via drinking water.
Arsenic-3-methyltransferase, encoded by AS3MT gene, is a
key enzyme in the metabolism of inorganic arsenic,
methylating it and eliminating in the urine. Dimethylarsinic
acid (DMA) has been associated with more efficiently
arsenic metabolism a reduced sensitivity to this metalloid;
monomethylarsonic acid (MMA) with elevated toxicity.
Varying MMA and DMA proportions present inter-
population and inter-ethnic variations. Native Americans
groups, whose ancestors arrived at the Americas >12,000
ybp seem to metabolize arsenic more efficiently than
European-derived populations who have exhibited high
toxicity risk. Thus, arsenic tolerance could be related to
long-term exposition. The contemporary Native Americans,
descendants of the ancient Mesoamerican cultures, along
with a prominent admixed population between European
and Indigenous (Mestizos), constitute a suitable scenario to
delineate the genetic variation of AS3MT polymorphisms,
which have been hardly studied.
Methods and Results: Using 28 Ancestry Informative
Markers and genotyping four AS3MT polymorphism
(rs11191439, rs3740400, rs7085104 and rs10748835) we
found that individuals with predominant Native American
ancestry exhibited higher frequencies of the “efficient”
haplotype TGGA (0.47) than Mestizos (0.31). C-
rs11191439 allele related to higher toxicity risk was also
absent in the tested Native Americans samples; the
frequencies in Mestizos and European derived populations
were 5% and 12%, respectively.
Conclusions: Our findings could reinforce the arsenical
hypothesis about genetic adaptation related to long-term
exposition. This study was financed by Conacyt, grants
261268, 178239 (to RG) and 728535 (to RM).
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Novel asthma risks within loci enriched in African
ancestry in Southwestern Europeans
C. Díaz-García1, E. Suarez-Pajes1, H. Rodríguez-Pérez1, J.
M. Lorenzo-Salazar2, I. Marcelino-Rodríguez1, A.
Corrales1,3, X. Zheng4, A. Callero5, E. Perez-Rodriguez5, J.
C. Garcia-Robaina5, R. González-Montelongo2, C.
Flores1,2,3, B. Guillen-Guio1
1Research Unit, Hospital Universitario N.S. de Candelaria,
Universidad de La Laguna, Santa Cruz de Tenerife, Spain,
2Genomics Division, Instituto Tecnológico y de Energías
Renovables (ITER), Santa Cruz de Tenerife, Spain, 3CIBER
de Enfermedades Respiratorias, Instituto de Salud Carlos
III, Madrid, Spain, 4Department of Biostatistics, University
of Washington, Seattle, WA, United States, 5Allergy Unit,
Hospital Universitario N.S. de Candelaria, Universidad de
La Laguna, Santa Cruz de Tenerife, Spain
Introduction: An important proportion of asthma genetic
risks remain unknown, especially in populations with
African genetic influences, which associate with greater
burden of asthma. Since the population of the Canary
Islands has a high North African genetic ancestry among
Southwestern Europeans and presents the highest asthma
prevalence in Spain, here we examined asthma associations
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in six loci showing an excess of African ancestry in this
population.
Methods: A two-stage study was conducted in 564
asthma cases and 923 controls from the Canary Islands
genotyped on the Axiom Genome-Wide CEU1 array
(Affymetrix). Imputation was performed using the HRC
reference panel and logistic regressions were used to test
association. Classic alleles from seven HLA genes were
imputed and association testing was assessed with HIBAG.
Results: Statistical significance was reached for a 3’ UTR
variant of HLA-DQB1 (meta-analysis OR=1.74; 95%
CI:1.42-2.14; p = 1.30e-7) that colocalizes with an eQTL
for several HLA and complement genes. This was
associated with asthma, lung traits and peanut allergy.
The most prominent classic HLA allele associations were
HLA-DQB1*02:01 and HLA-DQA1*05:01. These cluster
in the DQ2.5 haplotype that is frequent in North Africa and
associates with a high-risk of celiac disease and type-1
diabetes.
Conclusions: Targeted analyses of six regions enriched
in African ancestry in the Canary Islanders revealed novel
asthma risks linked to classic HLA alleles known to confer
a high-risk for autoimmune diseases.
Funding: Instituto de Salud Carlos III (PI14/00844, PI17/
00610, FI18/00230, CD19/00231), co-funded by ERD
Funds, “A way of making Europe” from the EU; ITER
agreement OA17/008.
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Genome-wide association study of asthma-COPD over-
lap syndrome identifies new signals of association
C. John1, A. L. Guyatt1, N. Shrine1, T. Olafsdottir2,3, J.
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dical Research Centre, Leicester, United Kingdom
Asthma and COPD are common causes of morbidity and
mortality worldwide. Some individuals have characteristics
of both conditions (“asthma-COPD overlap syndrome”,
ACOS), and evidence suggests they experience significantly
worse outcomes than those with asthma or COPD alone.
Although hundreds of genetic associations with asthma,
COPD, and lung function have been identified, the genetics
of ACOS have been little studied and no genetic variants
have specifically been associated.
We tested 7,693,381 genetic variants for association with
ACOS (defined as self-reported asthma and spirometric
airflow limitation) in 8068 cases and 40,360 healthy
controls from UK Biobank (stage 1). Signals with
P < 5 x 10−6 in this analysis, and P < 0.01 in two
sensitivity analyses in UK Biobank using (i) controls with
asthma but no COPD and (ii) controls with COPD but no
asthma, were meta-analysed among the results from UK
Biobank and 15 independent cohorts with an additional
4301 cases and 48609 controls (stage 2). All cases/controls
were of European ancestry.
Thirty-one genetic variants met criteria for inclusion in
stage 2. Of these, eight were associated at genome-wide
significance (P < 5 x 10−8) and showed stronger evidence
of association in the stage 2 meta-analysis than in UK
Biobank alone, including signals near HLA-DQB1,
C5orf56, GLB1, FAM105A, PHB, TSLP and IL17RD, and
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an intergenic signal on chromosome 5 not previously
associated with asthma, COPD or lung function.
Whilst our results suggest that many genetic variants
associated with ACOS are shared with asthma and/or
COPD, we identify a new signal which is distinct and may
implicate cellular pathways characteristic of ACOS.
C. John: None. A.L. Guyatt: None. N. Shrine: None. T.
Olafsdottir: A. Employment (full or part-time); Significant;
deCODE genetics/Amgen. J. Liu: None. L. Hayden:
None. S.H. Chu: None. J. Koskela: None. J. Luan:
None. X. Li: None. N. Terzikhan: None. H. Xu: None. T.
M. Bartz: None. H. Petersen: None. S. Leng: None. G.
Thorleifsson: A. Employment (full or part-time); Signifi-
cant; deCODE genetics/Amgen. D.A. Meyers: None. E.R.
Bleecker: F. Consultant/Advisory Board; Significant;
ALK-Abello, AztraZeneca, Glaxo Smith Kline, MedIm-
mune, Novartis, Regeneron, Sanofi Genzyme, TEVA.
Other; Significant; AstraZeneca, MedImmune, Boehringer
Ingelheim, Genentech, Novartis, Regeneron, Sanofi Gen-
zyme. L.C. Sakoda: None. C. Iribarren: None. Y.
Tesfaigzi: None. S.A. Gharib: None. J. Dupuis: None.
L. Lahousse: None. V.E. Ortega: None. K. Stefansson:
A. Employment (full or part-time); Significant; deCODE
genetics/Amgen. I. Sayers: None. I.P. Hall: B. Research
Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received);
Significant; GSK, Boehringer Ingelheim, Orion. C. Lan-
genberg: None. S. Ripatti: None. T. Laitinen: None. A.C.
Wu: None. J. Lasky-Su: None. C. Hayward: None. B.
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genetics/Amgen. M.H. Cho: B. Research Grant (principal
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Bayer. D. Speakers Bureau/Honoraria (speakers bureau,
symposia, and expert witness); Significant; Illumina,
AstraZeneca. L.V. Wain: B. Research Grant (principal
investigator, collaborator or consultant and pending grants
as well as grants already received); Significant; GSK. M.D.
Tobin: B. Research Grant (principal investigator, colla-
borator or consultant and pending grants as well as grants
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The landscape of autosomal-recessive pathogenic var-
iants in the European population
H. Fridman1,2,3, H. G. Yntema4, R. Mägi5, R. Andreson6, A.
Metspalu5, S. Carmi2, E. Levy-Lahad1,3, C. Gilissen4, H. G.
Brunner4,7
1Medical Genetics Institute, Shaare Zedek Medical Center,
Jerusalem, Israel, 2Braun School of Public Health and
Community Medicine, The Hebrew University of Jerusalem,
Jerusalem, Israel, 3Faculty of Medicine, The Hebrew
University of Jerusalem, Jerusalem, Israel, 4Department
of Human Genetics, Radboud University Medical Centre,
Nijmegen, Netherlands, 5Estonian Genome Centre, Institute
of Genomics, University of Tartu, Tartu, Estonia, 6Estonian
Biocentre, Institute of Genomics, University of Tartu, Tartu,
Estonia, 7Department of Clinical Genetics, Maastricht
University Medical Center, Maastricht, Netherlands
Background: A major public health goal is to detect at-risk
couples (ARCs) for various autosomal-recessive (AR) dis-
eases. Currently, the number and distribution of recessive
alleles in the population is not known at genomic-scale.
Existing estimates are extrapolations from specific pheno-
types and gene-sets.
Methods: We used 4120 exome-sequences of genetically
unrelated Dutch samples and an independent replication
cohort of 2330 exome-sequences of genetically unrelated
Estonian samples, representing two distinct European
populations. We analyzed 1758 genes classified as AR-
only by OMIM and extracted all exonic and flanking
intronic variants. We created a list of pathogenic/likely-
pathogenic variants (P/LPs), based on automated analysis
and databases of classified variants. We simulated all
possible matings within the Dutch and Estonian cohorts
(8.5M/2.7M theoretical couples, respectively).
Results: We estimate that there are 2.0 recessive
heterozygous P/LPs per individual in the Dutch population
giving rise to 1.3% ARCs. We replicate these results in the
Estonian cohort where we find 1.6 recessive heterozygous
P/LPs per individual, resulting in 1.5% ARCs. The
robustness of our approach was confirmed by the fact that
>97% of variants had a carrier frequency of at most 0.5%
(in both populations), and the remaining ~3% were well-
known population-specific founder mutations.
Conclusions: In two distinct European populations, we
find similar estimates for carrier frequency per person and
for the proportion of ARCs for a recessive disease. This is
the first overall estimate of AR carriership in European
populations and will inform schemes for introducing
preconception carrier screening for AR diseases.
H. Fridman: None. H.G. Yntema: None. R. Mägi:
None. R. Andreson: None. A. Metspalu: None. S. Carmi:
F. Consultant/Advisory Board; Modest; MyHeritage. E.
Levy-Lahad: None. C. Gilissen: None. H.G.
Brunner: None.
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THL Biobank, a multi-omics infrastructure for systems
biology
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A. Joensuu1,2, K. Silander1, M. Perola1,2, S. Soini1
1THL Biobank, Finnish Institute for Health and Welfare
(THL), Helsinki, Finland, 2Research Program for Clinical
and Molecular Metabolism, Faculty of Medicine, University
of Helsinki, Helsinki, Finland
Background: Large genomics projects have pinpointed
specific genomic variants that associate with disease end-
points. Studying the biological pathways of these associations
often require a systems biology approach. Since 1992, Finnish
Institute for Health and Welfare (THL) has collected DNA
samples from all participants of its health examination sur-
veys. Today, THL enables access to vast amounts of genomic
and other omics data through its biobank.
Materials & Methods: THL Biobank currently hosts
omics data from 11 Finnish study cohorts. The collections
include: GWAS chip data N>109,000, (>90,000 imputed in
FinnGen project to a population-specific reference panel);
WES N>12,500; WGS N>2,000; methylation data N>500;
gene expression data N>550 and telomere data N>7,000.
NMR metabolomics is available for N>40,000. The omics
data can be combined with a wide range of questionnaire,
clinical examination and laboratory variables, and study
participants can be followed up (for up to 27 years) from
national registers for disease endpoints and drug purchases.
THL Biobank’s most diverse dataset, DILGOM (a subset of
FINRISK 2007), includes data from all of the above listed
data types. Besides data, cells are available for >10,000 and
RNA for >3,000.
Results & Conclusions: THL Biobank is accessible on
FAIR-principles for researchers and companies worldwide.
Since 2015, 130 biobank projects have been initiated,
including interesting projects in pharmacogenomics, evolu-
tionary genetics, return of genetic information to biobank
participants and cardiovascular and cancer research. Geno-
mic data requests are included in 94% of the biobank
applications (122/130). In 2019, a marked increase was seen
in applications on metabolomic data and recall studies.
A. Joensuu: A. Employment (full or part-time); Modest;
Negen Ltd. K. Silander: None. M. Perola: None. S.
Soini: None.
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Genetic associations with birth weight and bivariate
genetic correlations with birth weight in an Indigenous
American population
L. E. Wedekind1,2, W. Hsueh2, S. Kobes2, W. C. Knowler2,
L. J. Baier2, R. L. Hanson2
1University of Oxford, Nuffield Department of Medicine,
Oxford, United Kingdom, 2National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK), Phoenix
Epidemiology & Clinical Research Branch, Phoenix, AZ,
United States
Birth weight has high heritability (h2=0.54) and substantial
genetic correlations with metabolic traits in adulthood. This
GWAS of birth weight was conducted in an Indigenous
population from the southwestern US. 3700 individuals had
genotypes available from a population-specific Axiom array
(Affymetrix; Santa Clara, CA; 512,319 SNPs) and birth
weight data. Genotypes for another 4.6M variants were
imputed using WGS data from 266 community members.
Birth weight was ascertained from birth and medical
records, and normalised separately by sex via rank-based
transformation.
Gestational age data were available for 60% of partici-
pants; to address missingness, multiple imputation of
gestational age was performed. Genetic associations were
analyzed using a mixed model in SOLAR-Eclipse,
accounting for genetic relationships (inferred from
marker data), adjusting for birth year, gestational age
and the 1st 5 genetic PCs.180 SNPs had suggestive
significance (p < 0.0001) with birth weight; the 10 strongest
associations are listed by chromosome (Chr) and position
(Position37):




UBE4B rs2180184 1 10235946 T C 0.68 G 0.12 0.03 6.24×10−6
ABCC8 - 11 17417205 T C 0.02 G 0.46 0.09 1.14×10−6
- rs2324532 13 40830879 T G 0.11 I 0.18 0.04 8.95×10−6
- - 13 40838524 T G 0.10 G 0.18 0.04 1.02×10−5
- rs35219516 13 40843260 C T 0.90 I -0.18 0.04 6.23×10−6
- - 13 40848849 C T 0.90 I -0.18 0.04 6.57×10−6
- rs61515650 19 1729004 T C 0.81 I 0.15 0.03 3.53×10−6
- rs10589986 19 1729070 CGT C 0.82 I 0.15 0.03 4.34×10−6
DMD rs17341316 X 33349779 G A 0.68 I -0.09 0.02 1.11×10−5
DMD rs5928238 X 33350078 T A 0.71 I -0.10 0.02 9.80×10−6
‡G=directly-genotyped; I=imputed
Missense variant ABCC8 R1420H (chr11:17417205)—
whose activating mutations cause hyperinsulinemia of
infancy—had the strongest association with birth weight
(β=0.46; p = 1.14×10−6). Among 180 SNPs with
suggestive evidence, results for one SNP (LOC105378114
rs73030292, chr6:166190683; p = 4.83×10−5) directionally
replicated a previously reported association at genome-wide
significance (p = 1.15×10−10; Early Growth Genetics
Consortium). This study identifies novel genetic associa-
tions with birth weight and demonstrates ABCC8 R1420H is
a strong determinant of birth weight in this population.
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Racial and age-related differences in breast cancer:
Comprehensive comparison of epidemiological, clinico-
pathological features and genomic signatures
D. Colak1, O. Al-Harazi1, H. Ghebeh1, M. Aleid1, H.
Khalil1, E. Aljarba1, N. Bawyan1, H. Alassiry1, M.
Almarzouqi1, D. S. Ajarim1, B. H. Park2, J. Quackenbush3,
A. S. Al-Zahrani1, N. Kaya1
1King Faisal Specialist Hospital and Research Center,
Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, 2Vanderbilt-
Ingram Cancer Center, Vanderbilt University, Nashville,
TN, United States, 3Dana-Farber Cancer Institute, Boston,
MA, United States
Introduction: Age and ethnicity are important factors in
breast cancer (BC) disparities and outcome. The underlying
biology creating these discrepancies is not well understood.
We aimed to identify ethnic/racial differences in epide-
miological, clinicopathological, and genomic characteristics
of breast cancer in young women (BCYW) as compared to
elderly women across different populations.
Materials and Methods: We used data from Cancer
Incidence in Five Continents Volume X reports, Gulf
Centre for Cancer Registration, including clinical and
survival data from 11,244 Saudi/Arab women, 107,938
African-American and 882,242 non-Hispanic White women
(US NCI SEER database), and transcriptomic profile of
breast tumors in young and elderly women cohorts from
four different ethnic/racial origins.
Results: Our results indicated distinct epidemiological
and biological features in BCYW as compared to the elderly
patients across different populations. Notably higher
immune related processes in young Arab and UK women,
to a certain extent in African-American women. Moreover,
we identified genes and upstream regulators that are distinct
or common in early- vs late-onset BC among four different
populations.
Conclusions: To our knowledge, this is the first study to
examine the molecular, epidemiological, genomic signa-
tures, and survival of women with BC patients in Arab and
Western populations in age-specific cohorts. The
population-specific molecular alterations and distinct clin-
icopathological characteristics may explain the racial and
age-related discrepancies in disease outcome and may lead
to more effective treatment strategies.
Acknowledgement: This study is funded by the Research
Grant (RAC#2110006 to DC). We would like to thank Ms.
Sukina Qanbar for her administrative support.
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None. N. Bawyan: None. H. Alassiry: None. M.
Almarzouqi: None. D.S. Ajarim: None. B.H. Park: None.
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Evidencing the genetic differences of Canary Islanders
in the Spanish diversity landscape
I. Marcelino-Rodriguez1, M. Bolaños-Mendoza1, H.
Rodríguez-Pérez1, J. M. Lorenzo-Salazar2, L. Ciuffreda1, B.
Guillen-Guio1, R. González-Montelongo2, I. Quintela3, Á.
Carracedo4, C. Flores1,2,5
1Research Unit, HUNSC, Universidad de La Laguna, Santa
Cruz de Tenerife, Spain, 2Genomics Division, Instituto
Tecnológico y de Energías Renovables (ITER), Santa Cruz
de Tenerife, Spain, 3Grupo de Medicina Xenomica,
CEGEN-ISCIII-Universidade de Santiago de Compostela,
Santiago de Compostela, Spain, 4Grupo de Medicina
Xenomica, CIBERER–Universidade de Santiago de
Compostela-Fundacion Galega de Medicina Xenomica
(SERGAS), Santiago de Compostela, Spain, 5CIBER de
Enfermedades Respiratorias, Instituto de Salud Carlos III,
Madrid, Spain
Introduction: The Spanish DNA National Bank (NDNAB)
was created to promote genomic research in the country.
Recent efforts have characterized the genetic substructure of
mainland populations and their recent genetic influences.
Leveraging the NDNAB population controls, here we aimed
to analyze the genetic structure of Spain with a particular
focus on their relationships with Canary Islanders, a geo-
graphically isolated population with a sizeable proportion of
African alleles.
Methods: Genotypes from 758,740 variants in 3,526
NDNAB controls, represented by donors from 19 autono-
mous regions including the Canary Islands, were obtained
with the Axiom Spain Biobank Array (Affymetrix).
Population structure was assessed using a combination of
principal component analyses, complementary high-
dimensional reduction techniques (UMAP), and model-
based ancestry estimates.
Results: Approximate population-aggregated clusters
were identified using grandparental geographical origin,
language and ancestry strata. Evident groups were observed
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in major axes of differentiation according to autonomous
regions, most obviously represented by Catalans, Basques
and Galicians as has been described before. However,
another clear axis of differentiation was due to the Canary
Islanders.
Conclusions: These results will aid in selecting NDNAB
controls and guide association testing in genomic studies in
the Spanish population.
Funding: Instituto de Salud Carlos III (CD19/00231),
Ministerio de Ciencia, Innovación y Universidades (RTC-
2017-6471-1; AEI/FEDER, UE), and agreement OA17/008
with ITER. The genotyping service was carried out at
CEGEN-PRB3-ISCIII, supported by grant PT17/0019, of
the PE I+D+i 2013-2016, funded by ISCIII and ERDF.
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Causal effects of gut microbiota on celiac disease: a two-
sample mendelian randomization approach
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Kurilshikov2, A. Zhernakova2, K. Garcia-Etxebarria3, N.
Fernandez-Jimenez1, J. Bilbao1,4
1University of the Basque Country (UPV/EHU) &
BioCruces-Bizkaia Health Research Institute, Leioa, Spain,
2University of Groningen and University Medical Center
Groningen, Groningen, Netherlands, 3Biodonostia Health
Research Institute, Donostia, Spain, 4Spanish Biomedical
Research Center in Diabetes and associated Metabolic
Disorders (CIBERDEM), Madrid, Spain
Introduction: Celiac disease (CeD), the most common
food intolerance, is a complex immune-mediated inflam-
matory condition triggered by ingestion of gluten in
genetically predisposed individuals. Literature suggests that
alterations in the gut microbiota composition and function
precede the onset of CeD. Considering that microbiota
characteristics are determined by host genetics, we spec-
ulate that the genetic makeup of CeD patients could elicit
disease manifestation through alterations in the intestinal
microbiota.
Materials and Methods: To evaluate the causal relation-
ship of gut microbiota with the risk of developing CeD, we
performed a Two-Sample Mendelian Randomization
(2SMR) analysis. Exposure data was obtained from three
raw datasets of a previous Genome Wide Association Study
(GWAS) of gut microbiota composition and function, and
outcome data from summary statistics of the most relevant
GWAS on CeD.
Results: We have identified a number of putative causal
associations between gut microbiota composition and
function with SNPs associated with CeD. Regarding
bacterial composition, most of the associated SNPs are
related to Firmicutes phylum, whose relative abundance has
been reported to be altered in CeD patients. In terms of
functional units, we have linked SNPs located in intronic
regions of known CeD-associated genes, such as LPP or
PUS10, to a variety of bacterial metabolic pathways.
Conclusions: This study represents the first 2SMR
approach to elucidate the causal relationships between
microbiome and CeD from GWASs. Next steps should
focus on deciphering the underlying molecular mechanisms
from a basic and clinical perspective.
Funding: ISCIII 16/00258 and GVSAN2018/111086 to
JRB and GVSAN2019111085 to NFJ.
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Assessing the association of common genetic variants in
EPHB4 and RASA1 with severity phenotypes in cerebral
cavernous malformation
F. M. Choksi1, S. Weinsheimer1, J. Nelson1, L.
Pawlikowska1, C. Fox1, A. Zafar2, M. Mabray2, J.
Zabramski3, A. Akers4, B. Hart2, L. Morrison2, C. E.
McCulloch1, H. Kim1
1University of California San Francisco, San Francisco,
CA, United States, 2University of New Mexico, Albquerque,
NM, United States, 3Barrow Neurological Institute, Phoe-
nix, AZ, United States, 4Angioma Alliance, Durham, NC,
United States
Introduction: Familial cerebral cavernous malformation
(CCM) is an autosomal dominant disease caused by muta-
tions in KRIT1, CCM2 and PDCD10. KRIT1 shares path-
ways with RASA1, as suggested by their interaction with the
Rap1A protein. EPHB4 and RASA1 mutations cause capil-
lary malformation-arteriovenous malformation (CM-AVM),
which resemble lesions seen in familial CCM. We thus
investigated whether common variants in EPHB4 and
RASA1 are modifiers of CCM disease severity, including
intracerebral hemorrhage (ICH), total and large
lesion count.
Methods: Familial CCM cases enrolled in the Brain
Vascular Malformation Consortium were included (n =
354). Total lesions and large lesions (>5mm) were counted
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on MRI; ICH history at enrollment was assessed by medical
records/self-report. Samples were genotyped on the Affy-
metrix Axiom Genome-Wide LAT1 Human Array. We
tested 7 variants with minor allele frequency (MAF) ≥5% (3
in EPHB4, 4 in RASA1) using multivariable regression,
adjusting for age, sex, and 3 principal components (to
account for population stratification). Significance was
based on Bonferroni adjustment for multiple comparisons
(0.05/7= 0.007).
Results: At baseline, 30.1% of cases had ICH, with
median total lesion count of 12 (IQR: 5-44) and large lesion
count of 3 (IQR: 1-5); mean age was 39 ± 21 years. EPHB4
variants were not associated with CCM severity phenotypes
(P > 0.007). One RASA1 intronic variant (rs72783711 A>C)
was significantly associated with ICH (OR=2.33, P <
0.001), but not with total (P = 0.728) or large lesion count
(P = 0.015).
Conclusion: RASA1 variants may be associated with ICH
in CCM. Further investigations with longitudinal and larger
studies are needed to confirm these findings.
Grant support: NIH U54NS065705.
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CFTR variant W1282R is a novel pathogenic cystic
fibrosis mutation
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Dwek Children’s Hospital, Tel Aviv Sourasky Medical
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Introduction: Bi-allelic CFTR variants, causing dysfunc-
tion of the cystic fibrosis transmembrane regulator protein,
result in cystic fibrosis. Controversy exists regarding
pathogenicity of the W1282R CFTR variant, classified as a
variant of unknown significance in scant case reports.
W1282R is not registered in the CFTR2 database and is not
included in expanded population carrier screen panels.
Methods: we report on two male siblings with cystic
fibrosis and compound heterozygosity for W1282X and
W1282R CFTR variants.
Results: a second born male to unrelated parents of
mixed Ukraine and Ashkenazi Jewish descent presented
prenatally with meconium ileus requiring emergency
postnatal surgical intestinal resection followed by choles-
tasis and malabsorption with undetected stool elastase
levels. Parental prenatal ethnic based common mutation
carrier screen was positive for paternal heterozygosity for
the known pathogenic CFTR variant W1282X. Maternal
screen was negative. Sequencing based expanded carrier
screen showed similar results. Next-generation sequencing
of a multi-gene monogenic neonatal cholestasis panel
revealed compound heterozygosity for W1282X and
W1282R. The latter classified as a variant of unknown
significance. Retrospectively, his 19-months old brother
was diagnosed with failure to thrive, abdominal distention
and steatorrhea (fecal fat 12.6 gram/24 hours). Two separate
sweat chloride levels were 101 and 103 mmol/L Eq. NaCL,
respectively. Stool elastase was undetectable. The genetic
diagnosis prompted pancreatic enzyme replacement therapy
that resulted in significant clinical improvement. Both
siblings lack respiratory symptoms.
Conclusions: W1282R is a pathogenic CFTR variant. It
should be included and reported in population genetic
carrier screening panels. Further research will establish
allele frequency.
N. Diamant: None. A. Amir: None. M. Veinberg:
None. T. Barkan: None. A. Haham: None. D.
Marom: None.
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Interrogating and correcting fine-scale genetic structure
in large (>36,000 samples) GWAS datasets using
scalable haplotype sharing methods
R. P. Byrne1, W. van Rheenen2, J. H. Veldink2, R. L.
McLaughlin1
1Smurfit institute of genetics, Trinity College Dublin,
Dublin, Ireland, 2Department of Neurology, Brain Center
Rudolf Magnus, University Medical Center Utrecht,
Utrecht, Netherlands
Introduction: We characterised finescale population
structure in an Amyotrophic Lateral Sclerosis (ALS)
GWAS dataset of 36,052 individuals of European descent
using the scalable haplotype painting algorithm PBWT-
paint, and evaluated its application in correcting subtle
population stratification undetectable using single
marker PCA.
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Methods: We implemented the PBWT-paint algorithm to
generate a haplotype sharing matrix describing coancestry
between 36,052 individuals. To evaluate the effectiveness
of this approach for correcting subtle population stratifica-
tion we fit principal components (PCs) calculated from the
coancestry matrix as covariates in a logistic regression
model GWAS and compared metrics of statistical inflation
(λGC and LD-score regression intercept) to a model using
single marker PCs as covariates. Additionally we explored
the extent of structure captured by PBWT-paint using t-
distributed stochastic neighbour embedding and identified
genetic clusters using Louvain network clustering.
Results: The coancestry matrix revealed both striking
broadscale genetic structure between countries and subtle
genetic structure within countries, making it an appealing
option for correcting overt and cryptic GWAS confounding.
We observed that both the λGC and LD-score regression
intercept were significantly closer to 1 when using PCs of
the haplotype sharing matrix, signifying lower inflation and
confounding from population structure. Notably, the
GWAS analysis corrected using haplotype sharing PCs as
covariates retained the power to detect all significant loci
from the original meta analysis of the data, alongside an
additional hit at the established ALS locus TBK1, suggest-
ing that it has improved power over traditional approaches.
Grants: MND Association (957-799); Science Founda-
tion Ireland (17/CDA/4737); European Research Council
(772376-EScORIAL).
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years of epidemiology in developmental disorders in
France
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the AnDDI-Rares network, C. Binquet12, A. Sandrin1, A.
Verloes13, L. Faivre2,9,10
1Banque Nationale de Données Maladies Rares, DSI-
WIND, APHP, Paris, France, 2Centre de Référence
Anomalies du Développement et Syndromes Malformatifs,
Dijon Bourgogne University Hospital, Dijon, France,
3Centre de Référence Anomalies du Développement et
Syndromes Malformatifs, Hôpital Sud, CHU de Rennes,
Rennes, France, 4Centre de Référence Anomalies du
Développement et Syndromes Malformatifs, CHU Bordeaux
et INSERM U1211, Bordeaux, France, 5Centre de
Référence Anomalies du Développement et Syndromes
Malformatifs, CHRU de Lille, Lille, France, 6Centre de
Référence Anomalies du Développement et Syndromes
Malformatifs, Hôpital Femme-Mère-Enfant, Hospices
Civils de Lyon, Lyon, France, 7Centre de Référence
Anomalies du Développement et Syndromes Malformatifs,
Département de génétique médicale, CHU de Marseille -
Hôpital de la Timone, Marseille, France, 8Centre de
Référence Anomalies du Développement et Syndromes
Malformatifs, CHU Montpellier, Montpellier, France,
9Filière AnDDI-Rares, CHU Dijon, Dijon, France,
10INSERM UMR1231 et FHU Translad, Université de
Bourgogne, Dijon, France, 11Foetopathologie, Hôpital
Necker-Enfants Malades, Paris, France, 12Centre d’Inves-
tigation Clinique - Epidémiologie Clinique, CHU de Dijon,
Dijon, France, 13Centre de Référence Anomalies du
Développement et Syndromes Malformatifs, AP-HP-Nord-
Université de Paris, Hôpital Robert Debré, Department of
Medical Genetics and INSERM UMR1141, Paris, France
Introduction: The French Ministry of Health has imple-
mented a vast epidemiological program on rare diseases
(RD), in parallel of the establishment of reference and
expertise centres for RD in France. A majority of these
centres have adopted the CEMARA web-portal, set up by
the national data repository for all RD, which allows the
collation of data for patients seen within these centres. Since
2007, a minimal data set (MDS) was collected prospectively
for all these patients.
Methods: After a 10-year period, we analyzed anon-
ymously and retrospectively administrative, demographic,
care organization and diagnoses data.
Results: 228,243 individuals were enrolled from 2007 to
2017 through the AnDDI Rares network, including 167,361
affected individuals (median age 11 years, 54% children,
46% adults) with a balanced sex-ratio. Among the 2,872
RD, 1,907 (66,5%) were recorded in less than 10 patients.
45.6% of patients had no diagnosis. Given the centres’
geographical coverage, patients have an average distance to
travel of 25.1 km, suggesting an efficiency of the health
organization for RD. Focus can be done by disease groups
such as chromosomal abnormalities (enabling an extensive
overview) or by diseases; leading to operable large cohorts
of patients with diverse data within the MDS (demographic,
clinical, medical care) and more if filled out.
Conclusions: The main objective of CEMARA is, in the
field of RD, to provide support for epidemiological, clinical
or therapeutic studies, for which a collective and coopera-
tive effort between centres is necessary, and to provide
qualitative/quantitative indications for the establishment of
national health policies.
C. Messiaen: None. C. Racine: None. A. Khatim:
None. S. Odent: None. D. Lacombe: None. S.
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P19.026.C
Phylostratigraphic analysis of co-expression network
reveals evolutionary compositions of preeclampsia
A. A. Babovskaya1, E. A. Trifonova1, A. A. Zarubin1, Z. S.
Mustafin2, S. A. Lashin2, A. V. Markov1, V. A. Stepanov1
1Research Institute of Medical Genetics, Tomsk, Russian
Federation, 2Institute of Cytology and Genetics SB RAS,
Novosibirsk, Russian Federation
Preeclampsia (PE) is a complication of pregnancy char-
acterized by new-onset hypertension and proteinuria of
gestation, with serious consequences for mother and infant.
However, the evolutionary machineries of PE are still lar-
gely unknown. Here, we used a method that combines
phylostratigraphy information with gene co-expression
networks to extensively study the evolutionary composi-
tions of PE. The present co-expression network construction
yielded 3987 nodes based on 129 PE and normal pregnancy
expression samples obtained from the GEO database. A
total of 31 modules were identified as PE related clusters
and 34 modules were identified in control group. Using
WGCNA, we found 6 clusters containing 86 genes asso-
ciated only with PE. We identified 9 hub genes (RAD21,
YY1, CXCL9, CXCL10, IFI44, IFI44L, GYPA, GYPB and
IFIH1) in these clusters using cytoHubba (MCC, rank ˂ 5)
and STRING. As part of evolutionary analysis, we calcu-
lated the phylostratigraphic age index (PAI) and the diver-
gence index (DI) using Orthoscape. We note that 70,9%
genes in network have PAI ≤ 3, but interesting that most of
hub genes (GYPA, GYPB, IFI44, IFI44L, CXCL9,
CXCL10) have PAI˃5 (Vertebrata); more susceptible to
evolutionary processes were genes GYPA, GYPB, IFI44,
IFI44L (DI 3,918-0,834), only YY1 and RAD21 have PAI
≤1(Eukaryota) and low DI (0,054-0,186).These results
demonstrate that most hub genes for this network diverged
from their ancestors. The integrated analysis of the topology
of PE modules and the phylogenetic data revealed an evo-
lutionary pattern of PE in human and identified new
potential biomarkers PE.
A.A. Babovskaya: None. E.A. Trifonova: None. A.A.
Zarubin: None. Z.S. Mustafin: None. S.A. Lashin: None.
A.V. Markov: None. V.A. Stepanov: None.
P19.028.B
A polygenic architecture of medication-use across
medical conditions
P. D. Rohde1, M. Nyegaard2
1Aalborg University, Aalborg, Denmark, 2Aarhus Univer-
sity, Aarhus, Denmark
Introduction: Genomics has been forecasted to revolutio-
nise human health by improving medical treatment through
a better understanding of the genetic epidemiology of
human diseases. Despite great successes of the last decade’s
genome-wide association studies (GWAS), the results have
to a limited extent been translated to genomic medicine. We
propose, that one route to get closer to improved medical
treatment is by understanding the genetics of medication-
use. We hypothesise that, irrespectively of medical condi-
tion, medication-use per se has a unique genetic heritable
architecture.
Methods: Medication-use from 335.744 individuals from
the UK Biobank was obtained, and we conducted a GWAS
on 9 million imputed genetic variants. We estimated the
heritability of medication-use and partitioned the genetic
variance across different categories. Using five-fold cross
validation we performed within sample prediction of
medication-use.
Results: We identified 57 independent loci associated
with variation in medication-use and estimated that 14% of
the total variation was attributable to common genetic
variants. The largest fraction of genetic variance was
captured by variants with low to medium minor allele
frequency. In particular coding and conserved regions, as
well as transcription start sites, displayed significantly
enrichment of heritability. The mean prediction accuracy
was 0.14.
Conclusions: These results demonstrate that medication-
use per se is a complex trait irrespectively of medical
condition. Thus, if the goal is to improve medical treatment
it might be insufficient to solely rely on analyses of complex
diseases as medication-use per se has its own genetic
architecture.
Funding: PDR has received funding from the Lundbeck
Foundation (R287-2018-735).
P.D. Rohde: B. Research Grant (principal investigator,
collaborator or consultant and pending grants as well as
grants already received); Significant; Lundbeck Foundation
(R287-2018-735). M. Nyegaard: None.
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Carnitine and risk of complex disorders, a Mendelian
Randomisation study
710 J. del Picchia
L. ABAR, V. ZUBER, A. DEHGHAN
IMPERIAL COLLEGE LONDON, LONDON, United King-
dom
Background: Carnitine, a water-soluble quaternary amine,
is essential for the normal functioning of all tissues and has
an important role in energy metabolism by transferring
long-chain fatty acids (acyl groups) to the mitochondrial
matrix for β oxidation and depleting the acyl groups out of
the mitochondria. Accumulating evidence from animal and
human studies indicates that carnitine and its acyl-
derivatives may have potential beneficiary effect in lipid
profile modification, glycaemic control, and modification of
vascular cognitive impairment in dementia patients.
Objective: The overarching aim of the study is to
investigate whether carnitine levels have causal effects on
risk of complex disorders including coronary artery disease
(CAD), type2 diabetes (T2D) and Alzheimer’s disease (AD)
by applying Two-sample Mendelian Randomisation (MR)
analysis.
Methods: A meta-analysis of genome-wide association
studies (GWASs) of the Airwave cohort participants and
publicly available results from a meta-analysis of the
KORA and TwinsUK studies was used to identify
instruments for carnitine. Summary statistics data for
CAD, T2D and AD were obtained from publicly available
GWAS meta-analyses conducted by the CARDIoGRAM-
plusC4D, DIAGRAM and IGAP consortiums. MR analyses
were performed using the inverse-variance-weighted
(IVW), weighted-median, MR Pleiotropy RESidual Sum
and Outlier (PRESSO) test and MR-Egger regression.
Results: There was evidence of a significant causal inverse
association between carnitine and coronary artery disease. No
further evidence for a causal effect observed between carnitine
and other outcomes including T2D and AD.
Conclusions: The study findings suggest that carnitine
has a protective effect on the risk of coronary artery disease.
L. Abar: None. V. Zuber: None. A. Dehghan: None.
P19.030.A
The results of the program of DNA diagnostics in
patients with cystic fibrosis in the RF in 2018-2019
E. Zhekaite, E. Kondratyeva, N. Petrova, R. Zinchenko, O.
Pylaeva, S. Kutsev, A. Voronkova, V. Sherman, R.
Budzinsky
Research Centre for Medical Genetics, Moscow, Russian
Federation
Introduction: According to the national cystic fibrosis (CF)
registry 2017, a genetic study was performed in 92.4% (n =
2816) of patients with CF in RF, the frequency of identified
pathogenic variant (PV) was 88.3% (80.2% had 2 PV, in
16.1% one, 3.7% - none). A total of 7.6% (n = 231) CF
patients need genetic diagnostics.
Materials and Methods: within realization the program
of DNA diagnostics in patients with CF in 2018-2019, 350
patients (265 patients from the national registry and 85
patients with CF unspecified) were examined for frequent
PV in CFTR. DNA was isolated from leukocytes using
standard procedures, sequencing was performed in 52
patients, and MLPA was performed 20 patients.
Results: We were able to increase the number of
diagnosed patients, and the percent of identified PV in 18
distant RF regions. As a result of the work carried out, 2 PV
were identified in 168 patients, one in 34, none in 84 (the
diagnosis is not confirmed). 64 blood samples are still being
sequenced.
Conclusion: Due to the improvements in CF diagnostics,
an increased number of regions is added to the national
registry. A larger number of newly diagnosed patients still
need DNA diagnostics. The program will continue in 2020-
2021. The work was carried out with the support of the
“Ostrova” charitable Foundation.
E. Zhekaite: None. E. Kondratyeva: None. N. Petrova:
None. R. Zinchenko: None. O. Pylaeva: None. S. Kutsev:
None. A. Voronkova: None. V. Sherman: None. R.
Budzinsky: None.
P19.031.B
Stochastic variation explains differences in the number
of de novo mutations between families
J. E. Hampstead1, J. M. Goldmann1, W. S. W. Wong2, T.
Turner3, A. Wilfert3, M. A. Jonker4, R. Bernier5, M. A.
Huynen6, L. Gomez7, R. Baker7, D. Ascher7, S. Hazrati7, T.
Conrads7, E. E. Eichler3,8, J. A. Veltman9,10, G. L.
Maxwell11,7, C. Gilissen1
1Department of Human Genetics, Radboud Institute for
Molecular Life Sciences, Radboud University Medical
Center, Nijmegen, Netherlands, 2Coherent Logic Limited,
McLean, VA, United States, 3Department of Genome
Sciences, University of Washington School of Medicine,
Seattle, WA, United States, 4Department for Health
Evidence, Radboud University Medical Center, Nijmegen,
Netherlands, 5Department of Psychiatry and Behavioral
Sciences, University of Washington, Seattle, WA, United
States, 6Center for Molecular and Biomolecular Infor-
matics, Radboud University Medical Center, Nijmegen,
Netherlands, 7Inova Translational Medicine Institute
(ITMI), Inova Health Systems, Falls Church, VA, United
States, 8Howard Hughes Medical Institute, University of
Washington, Seattle, WA, United States, 9Biosciences
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Institute, Faculty of Medical Sciences, Newcastle Univer-
sity, Newcastle Upon Tyne, United Kingdom, 10Department
of Human Genetics, Donders Centre for Neuroscience,
Radboud University Medical Center, Nijmegen, Nether-
lands, 11Department of Obstetrics and Gynecology, Inova
Health Systems, Falls Church, VA, United States
Human germline de novo mutations (DNMs) are both a
driver of evolution and an important cause of genetic disease.
The number of DNMs in the human germline is correlated
with parental age at conception, but parental age explains
only part of the observed variation in the number of DNMs
between individuals. Here, we investigated whether there is a
family-specific contribution to the number of DNMs in off-
spring. We analyzed DNMs from four large whole genome
sequencing cohorts of diverse ancestry. First, we compared
the difference in the number of DNMs in 111 dizygotic twin
pairs to those from 578 pairs of parental age-matched unre-
lated children, but we did not observe a significant family-
specific contribution. Subsequently we compared differences
in DNMs from siblings to those of randomly matched indi-
viduals with correction for parental age, and again observed
no significant differences. Finally, we used a random effects
model to directly estimate the potential impact of family-
specific effects on variation in DNM number using a cohort
of 1590 families with two offspring and a second cohort of
45 families with an average of 9.3 offspring. We estimated a
familial variance component of only 5.2%. Additionally, we
found almost no difference between the observed number of
DNMs in these offspring and those expected based on a
stochastic Poisson model. We therefore conclude that family-
specific contribution to DNM number in offspring is small
and that stochasticity explains a large proportion of the
observed variation.
J.E. Hampstead: None. J.M. Goldmann: None. W.S.
W. Wong: None. T. Turner: None. A. Wilfert: None. M.
A. Jonker: None. R. Bernier: None. M.A. Huynen: None.
L. Gomez: None. R. Baker: None. D. Ascher: None. S.
Hazrati: None. T. Conrads: None. E.E. Eichler: None. J.
A. Veltman: None. G.L. Maxwell: None. C.
Gilissen: None.
P19.032.C
Identifying and characterising germline hypermutators
J. Kaplanis1, P. Danecek1, E. Prigmore1, R. Rahbari1, P.
Short1, J. Korbel2, Genomics England Research
Consortium, M. Hurles1
1Wellcome Sanger Institute, Cambridge, United Kingdom,
2European Molecular Biology Laboratory, Heidelberg,
Germany
The human germline mutation rate is known to vary
between individuals. Most of the variation in the population
is explained by parental age, but little is known about rare
outliers with extreme mutation rates. We have tackled this
problem using both phenotype and genotype driven
approaches.
For our phenotype driven approach, we identified germ-
line hypermutators and sought genetic causes for this trait.
We identified five children with an excessive number of de
novo mutations (DNMs) across ~20,000 individuals from
the Deciphering Developmental Disorders study and
Genomics England Limited dataset. They all have >3.5
times DNMs as expected ranging from 257-426 DNMs per
individual. In four children, the excess DNMs all phased
paternally implicating the father as a germline hypermu-
tator. We identified a potentially causal variant in two of the
fathers: a rare homozygous missense mutation in the gene
MPG and a rare homozygous nonsense mutation in XPC.
For the remaining child, the mutations appear to have
occurred post-zygotically indicating this is unlikely attribu-
table to a parental hypermutator. The genotype-driven
approach focussed on whether variants in DNA repair genes
impact germline mutation rates. First, we interrogated
variants in an established cancer mutator gene, MBD4,
and found they did not have the same effect in the germline.
Second, we performed analyses of the impact of rare
damaging variants in DNA repair genes on individual
germline mutation rate.
Our analyses provide new insights into the role of genetic
variation on the human germline mutation rate and uncover
possible genetic causes of germline hypermutation.
J. Kaplanis: None. P. Danecek: None. E. Prigmore:
None. R. Rahbari: None. P. Short: None. J. Korbel:
None. M. Hurles: E. Ownership Interest (stock, stock
options, patent or other intellectual property); Significant;
Congenica Ltd. F. Consultant/Advisory Board; Significant;
Congenica Ltd.
P19.034.B
Gene-based rare variant analysis of whole-exome
sequencing in relation to eosinophil counts
J. R. Höglund, W. E. Ek, T. Karlsson, Å. Johansson
Uppsala University, Uppsala, Sweden
During the last decade, thousands of associations between
common variants and complex traits and diseases have been
identified. With rapid advancement in high-throughput
sequencing technology, progress in sequencing rare and
low-frequency variants is constantly being made. For rare
variants, region-based analyses have been suggested to be
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more powerful as compared to standard variant association
testing. In this study, we used the sequence kernel asso-
ciation test (SKAT) to test for association with eosinophil
counts, performed in the initial release of the UK Biobank
whole-exome sequencing dataset (N = 49,960). We tested
for five different scenarios, with various single nucleotide
variant (SNV)-weighting functions. The primary SKAT
analyses resulted in 51 significant transcripts throughout the
five scenarios, all colocalizing with at least one GWAS
signal. When adjusting for all significant, primary and
conditional, top GWAS hits, five transcripts mapping to
three regions (CLC, IL-33 and ST20-MTHFS) remained
significant in the SKAT tests. The association with CLC
seems to be driven by two common variants, not previously
associated with eosinophil counts. In contrast, variants with
a minor allele frequency below 0.5% seem to drive the
association with IL-33. For most of the SKAT signals, a
single-marker GWAS seems to capture the majority of
variation in eosinophil count. However, it is plausible that a
larger sample size is needed to fully resolve the effect of
rare variants. This project is funded by SciLifeLab, the
Swedish Research Council (VR), the Å Wiberg, M Borg-
ström, A, M Rudbergs, and the Swedish Heart and Lung
foundation.
J.R. Höglund: None. W.E. Ek: None. T. Karlsson:
None. Å. Johansson: None.
P19.038.C
Clinical application of whole exome and clinical exome
sequencing as a diagnostic tool in Colombian population
A. J. Muñoz-Bolaños, S. J. Maradei, I. T. Bernal, Y. M.
Gómez
BIOTECGEN S.A., Bogotá, Colombia
Introduction: Whole and clinical exome sequencing
(WES, CES) has been used increasingly in clinical diag-
nostics for a variety of indications to identify the underlying
genetic cause of disease. As a clinical diagnostic laboratory,
we sought to review our experience analyzing 124 WES
and CES cases over the past 4 years to better understand the
clinical contexts in which WES/CES can provide a plau-
sible explanation for the presenting symptoms.
Materials and Methods: We reviewed 124 consecutive
cases referred to our laboratory for WES/CES from 2016 to
2019 and performed clinical categorization.
Results: We analyzed 124 cases, with 97 (78.2%)
submitted as proband only, 2 (1.6%) with one additional
family member, and 25 (20.2%) with two additional family
members. A definitive result (Pathogenic and Likely
pathogenic) was provided in 41.1%, a possible/probable
(VOUS) result was provided in 38.7%, a candidate gene
result as the only finding was provided in 3.2%, and a
negative result was provided in 16.9%. Secondary findings
were offered to all participants, of whom 120 opted out
(96.7%), but were found in only 2 cases (1.7%).
Conclusions: Positive results impacted patient care,
regardless of whether the established diagnosis was
treatable. Cases that remained unsolved (VOUS) should
be carefully considered, and variant reclassification must be
followed up. Reanalysis of data generated by WES and CES
may eventually yield a diagnosis for patients with negative
or uncertain results. Even when the results were non-
informative, WES/CES allowed the medical team to
streamline diagnostic evaluations and/or focus on managing
known issues.
A.J. Muñoz-Bolaños: None. S.J. Maradei: None. I.T.
Bernal: None. Y.M. Gómez: None.
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Genetic basis if falling risk susceptibility
K. Trajanoska1, L. J. Seppala2, C. Medina-Gomez1, Y.
Hsu3, S. Zhou4, N. M. van Schoor5, L. C. de Groot6, D.
Karasik3, B. Richards4, D. Kiel3, A. G. Uitterlinden1, J. R.
Perry7, N. van der Velde2, F. Day7, F. Rivadeneira1
1Department of Internal Medicine, Erasmus MC University
Medical Center, Rotterdam, Netherlands, 2Department of
Internal Medicine, Section of Geriatric Medicine, Academic
Medical Center, University of Amsterdam, Amsterdam,
Netherlands, 3Hinda and Arthur Marcus Institute for Aging
Research, Hebrew SeniorLife, Roslindale, MA, United
States, 4Lady Davis Institute, Jewish General Hospital,
McGill University, Montreal, QC, Canada, 5Department of
Epidemiology and Biostatistics, Amsterdam Public Health
research institute, VU University Medical Center, Amster-
dam, Netherlands, 6Wageningen University, Division of
Human Nutrition, Wageningen, Netherlands, 7MRC Epide-
miology Unit, University of Cambridge School of Clinical
Medicine, Cambridge, United Kingdom
Introduction: Both extrinsic and intrinsic factors predis-
pose older people to fall. We performed a genome-wide
association analysis (GWAS) to investigate how much of an
individual’s fall susceptibility can be attributed to genetics
in 89,076 cases and 362,103 controls from the UK
Biobank Study.
Material and Methods: Individuals were genotyped with
the Afymetrix UKBiobank chip. The GWAS model
included age and sex analysed with BOLT-LMM v.2.3.1.
We used LD score regression to: 1). Estimate falling risk
heritability 2). Test for genetic correlation with other traits
and 3). Identify tissues where expression of genes related to
fall-associated variants are enriched. Finally, we tested for
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causal relationships between several risk factors and falls
using Mendelian Randomization (MR).
Results: We identified three novel fall loci mapping to
RP11-6N13.1 on 5q21.3 (rs2431108, OR=1.03, p =
4.20x10−08), near PER4 on 7p21.3 (rs2709062, OR=1.03,
P = 3.4 x 10−08) and near TSHZ3 on 19q12 (rs2111530,
OR = 1.03, p = 1.2x10−08). Falling risk heritability was
modest (2.5%). Falls had positive genetic correlation with
fracture risk (rg=0.35, se=0.05), insomnia (rg=0.42,
se=0.05), neuroticism (rg=0.26, se=0.08) and ADHD
(rg=0.44, se=0.14); and negative genetic correlation with
muscle strength (rg=-0.24, se=0.04), intelligence (rg=
−0.12, se=0.04) and social well-being (rg=−0.29,
se=0.05). Brain and in particular cerebellum tissue showed
the highest gene expression enrichment (FDR<5%) for fall-
associated variants. MR analyses found a causal effect of
high BMI and low relative handgrip on increased
falling risk.
Conclusions: Falling risk constitutes a heritable, hetero-
geneous and polygenic trait genetically correlated with
fracture risk and grip strength. The cerebellum tissue
enrichment of falls-associated variants corroborates the
mediation of postural balance in the etiology of falls.
K. Trajanoska: None. L.J. Seppala: None. C. Medina-
Gomez: None. Y. Hsu: None. S. Zhou: None. N.M. van
Schoor: None. L.C. de Groot: None. D. Karasik: None.
B. Richards: None. D. Kiel: None. A.G. Uitterlinden:
None. J.R. Perry: None. N. van der Velde: None. F. Day:
None. F. Rivadeneira: None.
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Reduced male reproductive success drives selective
constraint on human genes
E. J. Gardner1, M. D. C. Neville1, K. E. Samocha1, M. E. K.
Niemi1, K. J. Barclay2, M. Kolk3, G. Kirov4, H. C. Martin1,
M. E. Hurles1
1Wellcome Sanger Institute, Hinxton, United Kingdom,
2Max Planck Institute for Demographic Research, Rostock,
Germany, 3Stockholm University, Stockholm, Sweden,
4School of Medicine, Cardiff University, Cardiff, United
Kingdom
Sequencing of human populations has revealed highly
variable patterns of natural selection acting on human
genes, with a minority of genes appearing to be under
strong selection against heterozygous variants that abolish
the function of the encoded protein. Although these selec-
tively constrained genes are strongly enriched for dominant
single gene disorders, for most of these genes the nature of
the selective constraint is unknown. We called large dele-
tions from SNP genotyping data on 500K UK Biobank
participants and analysed protein truncating variants from
exome data on 50K UK Biobank participants. We deter-
mined the cumulative burden of likely loss-of-function
variants in each UK Biobank participant, weighted
according to the degree of selective constraint of the
impacted gene(s), which we term their Shet burden. We
found that increasing Shet burden results in substantially
reduced male reproductive success, driven by an increased
risk of childlessness (p = 4x10−15). This reduction in
reproductive success is much weaker in females (p =
0.0026). Shet burden is also associated with reduced fluid
intelligence, educational attainment and household income,
but without strong sex-bias. We present evidence that this
reduced male reproductive success is most likely mediated
by cognitive and behavioural traits, which, due to female
preferences for mating partners likely to invest resources in
their offspring, renders male carriers of such variants less
able to find mating partners. Our findings support a sub-
stantial role for sexual selection due to mate choice pre-
ferences shaping the recent evolution of human genes.
E.J. Gardner: None. M.D.C. Neville: None. K.E.
Samocha: None.M.E.K. Niemi: None. K.J. Barclay: None.
M. Kolk: None. G. Kirov: None. H.C. Martin: None.M.E.
Hurles: E. Ownership Interest (stock, stock options, patent or
other intellectual property); Modest; Congenica.
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Modification of Heritability for Educational Attainment
and Fluid Intelligence by Socioeconomic Deprivation in
the UK Biobank
M. Rask-Andersen, T. Karlsson, W. Ek, Å. Johansson
Uppsala University, Uppsala, Sweden
Educational attainment, measured either in years of educa-
tion or whether an individual has attended college or uni-
versity, constitutes a complex genetic trait that correlates
with cognitive traits, such as intelligence. It is strongly
linked to quality-of-life measurements such as subjective
well-being, paid employment, overall health, mortality and
obesity. Socioeconomic factors have been suggested to
influence the effect of education- and intelligence-
associated genetic variants. However, results from pre-
vious studies on the interaction between socioeconomic
status and education or intelligence have been inconsistent.
We therefore assessed the effect of socioeconomic depri-
vation on education- and intelligence-associated genetic
variants by estimating the SNP heritability for fluid intelli-
gence, educational attainment and years of education, in
subsets of the UK Biobank with different degrees of social
deprivation using LD score regression (LDSC). We also
generated polygenic scores with LDpred and tested for
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interactions with social deprivation. The SNP heritability
for all phenotypes were found to increase with socio-
economic deprivation. Polygenic scores for all phenotypes
were also found to interact with socioeconomic deprivation,
where the effects of polygenic scores increase with
increasing deprivation. These results imply that genetics
have a larger influence on educational and cognitive out-
comes in more socioeconomically deprived UK citizens,
which has serious implications for equality of opportunity.
This project is funded by grants from the Swedish Society
for Medical Research (SSMF), and the Swedish Medical
Research Council (Project Number 2015-03327).
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Genetic structure of the Catalan Pyrenean population
J. Fibla1, P. Moral2, M. M. Alvarez3, J. Serra4, R. Amado5,
M. Feixes6, F. Soldevilla7, I. Maceda8, O. Lao8
1Unitat de Genètica Humana – Genètica de Malalties
Complexes, Universitat de Lleida-IRBLleida, Lleida, Spain,
2Departament de Biologia Evolutiva, Ecologia i Ciències
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3Universitat de Barcelona, Barcelona, Spain, 4Laboratori
d’Anàlisis Clíniques, Hospital Comarcal del Pallars,
Lleida, Spain, 5Hospital Sant Bernabé, Lleida, Spain, 64
Servei d’Atenció Primària, Lleida, Lleida, Spain, 7Funda-
ció Privada Hospital Sant Jaume D’Olot, Girona, Spain,
8Population Genomics Group, Centre Nacional d’Anàlisi
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Parc Científic de Barcelona, Barcelona, Spain
Introduction: Until now, most of the populations con-
sidered in population genetics studies are of urban origin,
representing large geographical or even continental regions.
The study of genetic variation of rural populations such as
the Pyrenean one, can be of great interest. In addition, the
existence of natural barriers and the well characterized
demographic history, make the genetic study of this popu-
lation as an important piece of the puzzle on genetic var-
iation in Europe.
Materials and Methods: We selected for this study a
sample of 435 subjects with their eight grandparents born in
the Catalan Pyrenean counties. DNA was extracted from
blood. Genotyping data was obtained from each subject by
using the Axiom PMDA genotyping array at the CEGEN
facilities. Genotypes were merged with 1000 Genome Phase
III data resulting in a final data set of 2939 individuals and
552.000 common SNPs.
Results: A PCA analysis shows the distinctive European
genetic constitution of the Pyrenean population, as
compared to other continents. Within Europe, the Pyrenean
population could be clearly distinguished from other
European populations. Within Pyrenean a west-east gradi-
ent in genetic variability was noticed. STRUCTURE
analysis reveals a west-east gradient on Norden European
ancestry as well as an inverse gradient on South European
ancestry.
Conclusions: The genetic diversity of the populations of
the Catalan Pyrenees is macro-scale within the European
genetic diversity, following the same macro-spatial patterns
that are observed within Europe and, in particular, with the
populations of the South of Europe.
J. Fibla: None. P. Moral: None. M.M. Alvarez: None.
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Genome-wide association meta-analysis of individuals of
European ancestry identifies new loci explaining a
substantial fraction of dietary intake and heritability
O. Mompeo1, P. Hysi1, A. M. Valdes2, S. E. Berry1, R.
Gibson1, T. D. Spector1, C. Menni1, M. Mangino1
1King’s College London, London, United Kingdom, 2NIHR
Nottingham Biomedical Research Centre, Nottingham,
United Kingdom
Introduction: Dietary intake is highly heritable and has an
impact on cardiovascular disease. However, genetic variants
influencing overall diet intake at a genome-wide significant
level have not been identified. The aim of this study is to
identify genetic loci for the Dietary Approaches to Stop
Hypertension (DASH) diet, a diet quality index previously
associated to cardiovascular disease.
Materials and Methods: We firstly calculated DASH
heritability in TwinsUK (DZ = 706; MZ = 778). We then
conducted a genome-wide analysis (GWA) in both the
UKBiobank cohort (n = 173,456) and TwinsUK (n =
2968) using PLINK 2.0 and GEMMA respectively,
correcting for sex, age, energy intake, smoking and
socioeconomic status. Finally we conducted a GWA
meta-analysis using METAL.
Results: DASH heritability was 40% [95%C.I. 0.26-
0.46], with the remaining 60% [95%C.I. 0.53-0.73] due to
non-shared environmental factors. We identified five novel
independent genomic risk loci: Chr1 (rs66495454, Beta
(SE) = −0.029 (0.0034), P = 3.22 × 10-17); Chr3
(rs56331918, Beta(SE) = 0.022 (0.0036), P = 2.76 × 10-
9); Chr5 (rs550997965, Beta(SE)=-0.020 (0.0036),
P = 1.46e-08); Chr8 (rs73195303, Beta(SE) = −0.025
(0.0044), P = 9.85 × 10-9) and Chr12 (rs1054442, Beta
(SE) = −0.019 (0.0034); P = 3.70 × 10-8). These loci have
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been respectively associated with NEGR1, ARPP21,
ZSWIM6, MSRA and DDN genes all previously linked to
BMI or psychiatric traits. We also identified genetic
correlations between DASH and anthropometric traits,
health-related traits, and educational attainment.
Conclusions: These results confirm the polygenic nature
of the dietary phenotypes and provide important new
insights into the genetic aetiology of diet quality intake.
Grant: MRC AimHy (MR/M016560/1) project by the
Chronic Disease Research and the Denise Coates
Foundation.
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Hereditary haemochromatosis: Lifetime risks of pri-
mary hepatic carcinoma and mortality in the UK
Biobank
J. Atkins1, L. C. Pilling1, J. A. H. Masoli1, C. Kuo2, J. D.
Shearman3, P. C. Adams4, D. Melzer1
1University of Exeter Medical School, Exeter, United
Kingdom, 2Center on Aging, University of Connecticut
Health Center, Farmington, CT, United States, 3South
Warwickshire NHS Foundation Trust, Warwickshire, Uni-
ted Kingdom, 4Department of Medicine, University of
Western Ontario, London, ON, Canada
Background:Hereditary haemochromatosis (HH) is pre-
dominantly caused by the HFE p.C282Y homozygous
mutation. Hepatic carcinomas and mortality risks are raised
in clinically diagnosed HH, especially with liver cirrhosis.
However, outcomes are unclear in mutation carriers in the
community setting without clinically diagnosed HH.
Methods:UK Biobank European descent participants
(n = 451,186, 40-70 years) including 2,890 p.C282Y
homozygotes, followed via hospitalization records, national
cancer registry, primary care records and death certificates.
Cox regression models adjusted for age, assessment center,
genotyping array and genetic principal components. Kaplan
Meier lifetable probabilities of incident diagnoses were
estimated from age 40 to 75.
Results:Incidence of hepatic carcinomas was higher in
male p.C282Y homozygotes compared to those without
mutations (HR: 14.1, 95% CI: 7.6-26.1). However, no
associations were observed in female p.C282Y homozy-
gotes, p.C282Y heterozygotes or p.C282Y/p.H63D com-
pound heterozygotes. Lifetables estimate project that by age
75, 7.2% (95% CI: 3.9-13.1) of male p.C282Y homo-
zygotes develop hepatic carcinoma and 19.5% (95% CI
15.8-24.0) of homozygote men would die, compared to
15.1% (95% CI:14.7-15.5) in those without mutations.
Female p.C282Y homozygotes also had an increased risk of
death from hepatic carcinomas (HR: 3.36, 95% CI:1.06-
10.67).
Conclusions:In a large sample of community volunteers,
p.C282Y homozygosity was associated with substantial
risks of hepatic cancer and excess mortality in males. As
haemochromatosis iron overload is preventable and trea-
table by phlebotomy, early case ascertainment is needed for
hereditary haemochromatosis, including at the community
level. Our findings support the case that p.C282Y homo-
zygous individuals identified incidentally during DNA
sequencing should be notified.
Funding: MRC MR/S009892/1.
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Genetic loci that increase obesity risk but protect against
cardiometabolic comorbidities are embedded in regula-
tory regions of adipocyte function
L. O. Huang1, A. Rauch2,3, E. Mazzaferro4, C. S. Bayrak5,
S. Carribio6, M. Preuss5, N. Chami5, Z. Wang5, U. Schnick5,
N. Yang5, Y. Itan5, A. Vidal-Puig6,7, M. den Hoed4, S.
Mandrup3, T. O. Kilpeläinen1,8, R. J. F. Loos5,9,10
1Novo Nordisk Foundation Center for Basic Metabolic
Research, University of Copenhagen, Copenhagen N,
Denmark, 2Molecular Endocrinology & Stem Cell Research
Unit, Department of Endocrinology and Metabolism,
University of Southern Denmark, Odense, Denmark,
3Functional Genomics & Metabolism Research Unit,
Department of Biochemistry and Molecular Biology,
University of Southern Denmark, Odense, Denmark, 4The
Beijer Laboratory and Department of Immunology, Genet-
ics and Pathology, Uppsala University and SciLifeLab,
Uppsala, Sweden, 5The Charles Bronfman Institute for
Personalized Medicine, Icahn School of Medicine at Mount
Sinai, New York, NY, United States, 6Wellcome Trust
Sanger Institute, Wellcome Trust Genome Campus, Hinx-
ton, United Kingdom, 7Metabolic Research Laboratories,
Addenbrooke’s Treatment Centre, Institute of Metabolic
Science, Addenbrooke’s Hospital, University of Cambridge,
Cambridge, United Kingdom, 8Department of Environ-
mental Medicine and Public Health, Icahn School of
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9The Genetics of Obesity and Related Metabolic Traits
Program, The Icahn School of Medicine at Mount Sinai,
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Introduction: Obesity is typically associated with higher
risk of cardiometabolic complications. However, some
obese individuals, the metabolically healthy obese (MHO),
do not suffer from cardiometabolic comorbidities. Recent
evidence suggests that genetic factors may contribute to this
paradoxical phenotype. We aim to 1) ascertain the genetic
variants that predispose MHO, 2) identify enriched tissues
and gene sets of these variants, 3) examine regulatory roles
of neighbouring eQTL and DNase1 hypersensitive sites of
these variants, and 4) prioritize causal genes.
Materials & Methods: We 1) used publicly available
GWAS statistics and identified loci associated with pairwise
combinations of three adiposity and eight cardiometabolic
traits, 2) conducted DEPICT tissue and gene set enrichment
analyses on identified loci, 3) examined nearby enhancer
dynamics in DNase1 hypersensitive sites during in vitro
adipogenesis, and 4) performed ingenuity pathway analysis
to prioritize causal genes.
Results: We 1) identified 62 independent loci reaching
genome-wide significance, 2) highlighted adipose tissue and
liver as the most significantly enriched tissues, and the
protein-protein interaction partners of OAT gene as the most
significantly enriched pathway, involved in glutamate-
related energy metabolism, 3) confirmed the 62 loci more
likely overlap with adipose tissue eQTLs and DNase1
hypersensitive sites that increase accessibility during
adipogenesis, 4) prioritized 61 putative causal genes may
identify novel biomarkers and future drug targets.
Conclusions: Combining GWAS meta-analysis with
follow-up studies, our findings provide unequivocal insights
into the biological pathways that underlie MHO. Funding:
Danish Council for Independent Research (DFF6110-
00183), Novo Nordisk Foundation (NNF18CC0034900)
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The importance of Human Knockouts in a deeper
characterization of Mendelian disorders
B. Spedicati1, F. Faletra2, R. Palmisano1, C. Barbieri3, G.
Pelliccione2, A. Morgan2, M. Mezzavilla2, M. Cocca2, P.
Gasparini1,2, G. Girotto1,2
1Department of Medicine, Surgery and Health Sciences,
University of Trieste, Trieste, Italy, 2Medical Genetics,
Institute for Maternal and Child Health - I.R.C.C.S. "Burlo
Garofolo", Trieste, Italy, 3Division of Genetics and Cell
Biology, San Raffaele Scientific Institute, Milan, Italy
Rare biallelic Loss of Function (LoF) variants leading to
Human Knockout (HKO) might be efficiently characterized
studying inbred populations, specifically genetic isolates.
WGS data of 947 samples from three Italian isolated cohorts
have been analysed to select biallelic LoF variants; after
filtering, 28 variants in “autosomal recessive” genes were
retained. We identified two groups of HKO: a) individuals
showing clinical features of Mendelian recessive disorders
but without a previous genetic diagnosis and b) subjects
who do not show any clinical characteristic signs/symp-
toms. In group a) interesting examples involve three genes
and three individuals respectively: Patient-1, KO for
GPR68 gene and showing amelogenesis imperfecta clinical
features, Patient-2 KO for F12 gene and presenting
increased APTT values with normal wound healing,
Patient-3 KO for C7 gene and displaying an increased
susceptibility to systemic infections. In group b) Patient-4,
KO for FANCL gene, despite a positive chromosome fra-
gility assay, does not display Fanconi-Anemia hematolo-
gical features but only a clinical history of head/neck
carcinoma and a short stature. We are currently expanding
our collection of KO individuals detecting subjects who are
compound heterozygous carriers of LoF mutations in genes
involved in autosomal recessive disorders and, so far, 54
individuals have been detected. Functional studies to eval-
uate the potential phenotypic consequences of this variants
will be performed. In conclusion, thanks to the study of
HKO we lay the foundation for preventive strategies (as in
the case of group a) but also for searching new protective
variants/genes and therapeutic approaches for the study of
Mendelian disorders.
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The genetic landscape of hypertension - results from a
5690 Romanian individuals
R. Ursu1,2,3, P. Iordache4, V. Radoi1,2,5, G. Ursu6, N. Cucu7,
V. Chirica8, D. Iacob9, C. Sima10, O. Dragoi11, O.
Croitoru12, E. Poenaru12, L. Bohiltea1,5, A. Manolescu13, V.
Jinga12,10
1”Carol Davila” University of Medicine and Pharmacy,
Department of Medical Genetics, Bucharest, Romania,
2Synevo Romania, Central Reference Laboratory, Depart-
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Rusescu”, Bucharest, Romania, 4”Carol Davila”
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Management in Health, Bucharest, Romania, 7University
of Bucharest, Faculty of Biology, Department of Genetics,
Bucharest, Romania, 8”Mina Minovici” National Institute
of Legal Medicine, Bucharest, Romania, 9The National
Institute for Infectious Diseases ”Matei Bals”, Bucharest,
Romania, 10”Prof. Dr. Theodor Burghele” Clinical Hospi-
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Background: The purpose of this study is to idetify high-
risk variants associated with hypertension (HTA) in the
Romanian population.
The current presentation asseses the final results of a 3
part study comprising the first and the largest GWAS on
hypertension in Romanians.
Material and Methods: The total cohort includes a
number of 5690 individuals, of which 2190 with hyperten-
sion and 3500 heathy controls. Genetic testing was
performed at DeCode Genetics, Reykjavik, Iceland. A
multiple GWAS assay has been performed for the
identification of variants associated with hypertension,
HTA risk factors (smoking, alcohol, coffee consumption)
and HTA comorbidities (obesity, diabetes mellitus).
Results: Tissue-specific protein expression, gene function
and gene-gene interactions have been analyzed for assessing
a possible biological explanation for the association
between the identified variants and HTA. Expression
quantitative trait loci (eQTL) were assessed for variants in
the reported locations for a better understanding of their
involvement in HTA. The results revealed over 5000
genetic variants correlated with HTA, some well documen-
ted and in genes known to be involved in HTA (clusters on
chromosomes 1p,1q,3q,4p,5q,7q,12p,15q,17q,20q,a.o. or
CRNKL1,C19Orf12,CCDC51,C20Orf26,ZNF420,
ZNF571, a.o. intragenic variants). Approx. 4100 SNVs
were identified in correlation with diabetes mellitus (DM)
and obesity. Variants correlated with both HTA and DM
were identified (TBX20, ANK2, a.o. genes). Two other
clusters on chromosomes 19q12 and 20p11.21 revealed
associations with both HTA and obesity.
Conclusions: The results revealed several gene clusters
correlated with HTA. The validity of these results for the
Romanian population need to be confirmed by replication
studies. The research is part of EU ProMark, ROMCAN and
AppGenEdu projects.
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Human leukocyte antigen-wide association meta-
analysis of idiopathic pulmonary fibrosis susceptibility
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Pittsburgh, PA, United States, 15Section of Pulmonary,
Critical Care and Sleep Medicine, Yale School of Medicine,
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Idiopathic pulmonary fibrosis (IPF) is a progressive inter-
stitial lung disease with poor prognosis and unknown cause.
The human leukocyte antigen (HLA) region is one of the
most complex regions in the genome and influences the risk
of inflammatory and respiratory conditions. The extreme
genetic diversity of the HLA challenges the interpretation of
association studies, therefore specific imputation strategies
exist to capture HLA alleles and amino acid changes. The
HLA-DQB1*06:02 allele has been previously associated
with fibrotic idiopathic interstitial pneumonias.
We combined bespoke HLA imputation with the latest
SNP imputation (using the Haplotype Reference Consor-
tium panel). We tested the association of 39,570 SNPs,
HLA alleles and amino acid changes across the HLA region
with IPF susceptibility in 1,905 IPF cases and 13,876
controls from three datasets (UK [612 cases, 3,366
controls], Chicago [500 cases, 510 controls] and UUS
[793 cases and 10,000 controls]). Sex and 10 principal
components were included as covariates. The results were
meta-analysed using a fixed-effects weighted analysis.
An intronic variant near ZNRD1ASP (rs3132684,
OR=1.24 (1.14-1.35), P = 2.41 × 10−7) passed a
Bonferroni corrected significance threshold (P<2.8×10−6)
in this meta-analysis. rs3132684 was consistently signifi-
cant (P < 0.05) across all three datasets and is possibly an
eQTL for several classical and non-classical HLA genes.
The HLA-DQB1*06:02 was not associated with IPF
(P = 0.57).
We present the largest study of HLA variation in IPF
susceptibility to date, using a combination of SNP
imputation and HLA imputation. One variant was consis-
tently associated with IPF susceptibility in our data, further
analysis is required to determine the functional effect.
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Influence of the genetic liability on the association
between infections and autism
J. Shorter1,2, M. Krebs1,2, A. Ingason1,2, M. Benros1,2,3, W.
Thompson1,2,4, T. Werge1,2,5
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Several recent studies have suggested a role of infections in
the development of mental health disorders. A genetic lia-
bility, measured through Polygenic Risk Score (PRS), for
infections and mental health disorders could also drive this
association. Here, we studied the genetic liability on the
association between several different types of infections that
led to hospital visits, with the risk of being diagnosed with
autism spectrum disorder (ASD). To study this association,
we used the Danish-based iPSYCH case-control study
population, as well as a cohort of randomly sampled indi-
viduals from the Danish population. We observe that having
certain types of infection, but not all types, can increase the
lifetime risk of autism for those with a genetic liability. This
risk for ASD diagnosis following a severe infection was the
highest for those with the highest PRS for ASD
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Evaluating the causal effects of protein biomarkers on
inflammatory diseases
W. E. Ek, T. Karlsson, J. Höglund, M. Rask-Andersen, Å.
Johansson
Department of Immunology, Genetics and Pathology,
Uppsala, Sweden
Protein biomarkers are indicators, often measured in blood,
that are used to estimate severity or presence of disease. A
number of inflammatory protein biomarkers have been
identified to be associated with development of inflamma-
tory diseases or disease outcomes. These proteins might
therefore serve as potential drug targets, or shed light into
the pathogenesis of the diseases. However, if the biomarker
itself increase the risk (is causal) of getting the disease is
usually not known. Here we applied a two sample Men-
delian randomization (MR) approach, using data from two
cohorts (NSPHS and UK Biobank), to investigate the causal
effect of 20 inflammatory protein biomarkers, known or
suggested, on 18 inflammatory diseases. We identified five
statistically significant biomarkers (IL-12B, IL-15RA,
TNFB, TWEAK, VEGF-A), having a tentative causal effect
on eight different inflammatory diseases (FDR ≤ 0.05). IL-
12B showed a causal effect on psoriatic arthritis, IL-15RA
on eczema, TNFB on Type 1 diabetes, rheumatoid arthritis
and inflammatory polyarthropathies. We also identified a
causal effect of TWEAK on asthma and a causal effect of
VEGF-A on both inflammatory bowel disease and its sub
phenotype ulcerative colitis. The causal effects on disease
progress investigated here, may be used to further evaluate
the potential of these proteins as drug targets
This project is funded by SciLifeLab, the Swedish
Research Council (VR), the Åke Wiberg, M Borgström, A,
M Rudbergs, and the Swedish Heart and Lung foundation.
W.E. Ek: None. T. Karlsson: None. J. Höglund: None.
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Inheritance patterns of polygenic risk scores
M. J. Knol, E. A. Loehrer, R. A. Oldenburg, R. J. H.
Galjaard, J. G. J. van Rooij, M. F. van Dooren, A. G.
Uitterlinden, R. M. W. Hofstra, S. Lamballais, H. H. H.
Adams
Erasmus MC University Medical Center, Rotterdam,
Netherlands
Introduction: Genome-wide association studies have
identified genetic variants that, together in polygenic risk
scores (PRS), confer substantial risk for many complex
traits. While clinical implementation of PRS is underway, it
remains unclear how such scores propagate in pedigrees.
Here, we determine the inheritance patterns of PRS to aid
clinical counselling of genetic liability for complex traits.
Methods: We simulated polygenic risk for six complex
diseases in 10,000 multigenerational families, modelling
both random and consanguineous mating. We determined
inheritance patterns for up to ten generations. Furthermore,
we examined biparental inheritance patterns.
Results: Correlations of polygenic risk ranged from
47.1% to 49.0% for between first-degree relatives and from
23.1% to 24.3% for second-degree relatives (Table 1).
When both parents’ PRS is known, the ranges become
narrower for their offspring, especially for the extremes
(Table 2). In high-risk (>95%) individuals, median
polygenic risk for first- and second-degree offspring was
respectively 85.2% and 69.7%, and approximated popula-
tion average in the fifth generation. Results were similar
across traits, and for random and consanguineous mating.
Discussion: Extreme polygenic risk propagates for
multiple generations and is particularly informative in
biparental inheritance. Future steps include validation in
real multigenerational datasets and extension to larger
number of genetic variants.
Table 1. Correlations between the polygenic risk of the
1st and both the 2nd and 3rd generation.





Correlation 1st and 2nd
generation
Correlation 1st and 3rd
generation
Atrial fibrillation 21.8% 94 47.5% 23.5%
Age-related macular
degeneration
11.6% 34 48.4% 24.2%
Breast cancer 30.4% 172 48.9% 24.2%
Coronary artery disease 14.8% 86 49.0% 24.2%
Inflammatory bowel
disease
11.1% 232 47.1% 23.1%
Type 2 diabetes 44.8% 403 48.7% 24.3%
Table 2. Multigenerational inheritance of breast






0-5% 25-30% 50-55% 75-80% 95-100%
Multigenerational polygenic risk of offspring, given random mating
Generation 2 15.6 (5.1-32.2) 38.1 (17.5-61.1) 52.6 (30.4-74.0) 65.1 (44.2-82.8) 85.2 (67.7-95.0)
3 29.1 (11.9-54.5) 41.7 (18.3-68.2) 52.5 (27.2-76.8) 57.0 (31.4-78.8) 69.7 (44.3-88.2)
4 38.9 (17.2-64.9) 46.0 (21.9-71.1) 50.7 (24.9-74.6) 53.5 (28.5-78.0) 59.6 (32.4-81.8)
5 44.8 (21.1-71.5) 48.2 (23.5-74.0) 50.8 (25.4-75.6) 52.6 (27.5-76.5) 54.6 (28.1-78.4)
6 47.5 (23.0-72.8) 49.2 (24.4-74.6) 50.2 (24.9-74.6) 51.7 (25.9-76.4) 52.1 (26.7-76.5)
7 49.0 (24.4-74.2) 49.3 (24.5-74.6) 49.9 (25.1-75.1) 50.8 (25.6-75.5) 51.1 (25.7-75.6)
8 49.8 (24.9-75.0) 49.9 (25.0-74.6) 50.3 (25.0-75.1) 50.6 (25.5-75.4) 50.8 (25.3-75.6)
9 49.9 (24.9-74.8) 49.7 (24.7-74.8) 50.3 (25.0-75.2) 50.3 (25.2-75.2) 50.3 (25.3-75.4)
10 50.0 (25.0-75.0) 49.9 (24.9-74.8) 50.1 (24.9-75.2) 50.0 (24.9-75.0) 50.2 (25.0-75.1)
Polygenic risk for second generation, given first-generation consanguineous parents
Consanguinity Second-
degree
12.5 (4.0-28.9) 36.6 (18.2-59.4) 51.3 (29.0-72.9) 66.7 (43.9-84.4) 87.7 (71.1-96.0)
Third-
degree
14.7 (4.9-32.5) 38.0 (18.6-60.9) 51.3 (29.0-73.0) 65.2 (42.3-83.6) 85.8 (68.3-95.2)
Polygenic risk for second generation, given polygenic risk of second parent
Polygenic risk
second parent
0-5% 1.9 (0.5-5.7) 9.4 (3.4-20.5) 15.9 (6.6-30.6) 26.6 (13.4-44.4) 51.7 (31.5-70.1)
25-30% 9.4 (3.4-20.5) 28.2 (14.2-45.7) 39.7 (23.1-58.3) 53.7 (34.9-71.0) 77.3 (59.5-89.5)
50-55% 15.9 (6.6-30.6) 39.7 (23.1-58.3) 51.6 (33.1-69.5) 65.9 (47.4-81.1) 85.8 (71.8-94.3)
75-80% 26.6 (13.4-44.4) 53.7 (34.9-71.0) 65.9 (47.4-81.1) 77.9 (61.2-89.1) 91.9 (82.4-97.2)
95-100% 51.7 (31.5-70.1) 77.3 (59.5-89.5) 85.8 (71.8-94.3) 91.9 (82.4-97.2) 98.0 (93.7-99.4)
*Similar patterns were observed for the other traits.
**The top part of the table assumes knowledge of one
parent’s polygenic risk (with both random and consangui-
neous mating), whereas the bottom part assumes knowledge
of both parents’ polygenic risk.
M.J. Knol: None. E.A. Loehrer: None. R.A. Old-
enburg: None. R.J.H. Galjaard: None. J.G.J. van Rooij:
None. M.F. van Dooren: None. A.G. Uitterlinden: None.
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Comparative analysis of WGS data from Bulgarian
centenarians and findings from meta-GWA studies
reveals genetic loci associated with longevity
L. T. Balabanski1,2, D. Serbezov1, R. Vazharova2,3, S.
Karachanak-Yankova1, R. Staneva1, M. Mihaylova1, V.
Damyanova1, D. Nesheva1, Z. Hammoudeh1, M.
Atanasoska2, M. Ganev1, O. Antonova1, V. Spasova1, D.
Nikolova1, S. Hadjidekova1, D. Toncheva1,2
1Department of Medical Genetics, Medical University of
Sofia, Sofia, Bulgaria, 2Genomic Laboratory, Malinov
Clinic, Sofia, Bulgaria, 3Medical Faculty, Sofia University
“St. Kliment Ohridski”, Sofia, Bulgaria
Human lifespan is a complex, multifactorial trait resulting
from the interplay of many genetic variants with small
effect and a wide range of environmental factors. It is
estimated that the heritability of longevity in humans could
be up to 25%. To identify potential factors that contribute to
this phenotype we performed whole-genome sequencing on
DNA samples from 16 centenarians from the Bulgarian
population. Their genotypes were extracted at more than 20
genetic loci associated with high parental lifespan - an
appropriate measure for heritable longevity, from two large
GWAS meta-analyses (AncestryDNA and LifeGen) utilis-
ing the UK Biobank and their own cohorts. We established
that 5 genetic variants were significantly enriched within
our centenarian cohort compared to individuals of non-
Finnish European ancestry in the gnomAD population
database. Only one of them was exonic - the well-
recognised rs429358-T in the APOE gene, while the other
ones: rs10455872-A in LPA, rs6224-G in FURIN,
rs599839-G between CELSR2 and PSRC1 and rs9872864-
G in IP6K1, were non-coding suggesting that mechanisms
regulating gene expression might play a role in longevity.
Interestingly, all these genes are involved in different car-
diometabolic conditions. Combinations of these variants, as
well as with other factors, could therefore be protective
against cardiovascular risk factors - a common cause of
death in many older people, or could potentially slow down
the process of biological ageing. A larger cohort of precious
samples from centenarians could validate these findings and
provide one more piece of the complex puzzle of human
longevity.
Grant reference: DN03/7(18.12.2016), NSF, Bulgaria
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Analysis of population-specific protein-truncating var-
iants in gnomAD suggests novel criteria for annotation
of loss-of-function alleles
Y. A. Barbitoff1,2,3, R. K. Skitchenko1,2,4, J. S. Kornienko1,
E. M. Maksiutenko3, A. V. Predeus1
1Bioinformatics Institute, St. Petersburg, Russian Federa-
tion, 2Dpt. of Genomic Medicine, D.O.Ott Research
Institute of Obstetrics, Gynecology, and Reproduction, St.
Petersburg, Russian Federation, 3Dpt. of Genetics and
Biotechnology, St. Petersburg State University, St.
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Putative loss-of-function (pLoF) variants are of ultimate
relevance to Mendelian disease pathology. As such variants
in disease-related genes are under strong negative natural
selection, their frequency across major ancestral groups is
expected to be highly similar. In this study, we tested this
assumption by systematically assessing the presence of
highly prevalent population-specific PTVs in human genes
using gnomAD data. We discovered unusually high inci-
dence of population-specific pLoF variants in all major
ancestral groups, with a total of 1,972 genes harboring such
population-specific sites. Such prevalence of PTVs does not
conform to a deterministic statistical model developed by
Cassa et al. in 2017, indicating either systematic differences
in disease penetrance in different human populations or the
failure of current annotation criteria to accurately predict the
loss-of-function potential of PTVs. We demonstrate that
high-frequency population-specific PTVs tend to reside in
exons that have low conservation scores and belong to
transcripts with low expression levels, suggesting that these
variants should not be treated as genuine LoF alleles. As
such, additional data resources should be used during
interpretation of genotypes in both population genetics and
clinical genetics studies.
Y.A. Barbitoff: None. R.K. Skitchenko: None. J.S.
Kornienko: None. E.M. Maksiutenko: None. A.V.
Predeus: None.
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Causal relationship between adiponectin and diabetic
retinopathy: a Mendelian randomization study in an
Asian population
Y. C. Huang1,2, F. J. Tsai2,3, Y. W. Chang2, C. M. Wu1, W.
L. Liao4,5
1China Medical University, Taichung, Taiwan, 2Human
Genetic Center, Department of Medical Research, China
Medical University Hospital, Taichung, Taiwan, 3Depart-
ment of Health and Nutrition Biotechnology, Asia Uni-
versity, Taichung, Taiwan, 4Graduate Institute of Integrated
Medicine, China Medical University, Taichung, Taiwan,
5Center for Personalized Medicine, China Medical Uni-
versity Hospital, Taichung, Taiwan
Introduction: Adiponectin (APN), a cytokine released by
adipocytes, is involved in different pathways, such as
insulin sensitivity, inflammation, and atherogenesis. How-
ever, the association between APN and diabetic retinopathy
(DR) has been inconsistent from observational studies. To
clarify the causal relationship, we used a Mendelian
randomization (MR) analysis to test the hypothesis that
elevated circulating APN levels causally results in DR.
Materials and Methods: A GWAS database-catalog of
47 single nucleotide polymorphisms (SNPs) reaching
significance in East-Asians was utilized in 1251 diabetic
patients in Taiwan. APN-SNPs that were genetically
independent, and without pleiotropic effect were selected
as instrumental variables (IV). Including 3 different genetic
risk scores (GRS): GRSAll combined all 47 SNPs, GRSAPN
combined 5 SNPs significantly associated with APN level,
and GRSLimited comprised 16 GRSAll-SNPs with a threshold
(P < 5 × 10−8 for GWAS).
Results: The MR-inverse-variance weighted method
analysis showed that for each 1-SD increase in genetically
induced increase in plasma APN, the OR of having DR was
β = 0.20 (95% CI: -0.46-0.85, P = 0.553) for GRSAPN, 0.61
(95% CI: 0.10-1.13, P = 0.020) for GRSAll, and 0.57 (95%
CI: -0.06 to 1.20, P = 0.078) for GRSLimited. Sensitivity
analysis, including MR-egger regression and the weighted-
median approach, did not provide evidence of the
pleiotropic effect of IVs.
Conclusions: Limited evidence for the causal role of
APN in DR risk among diabetic patients was shown based
on MR analysis in the present study. This work was
supported by research grants from Ministry of Science and
Technology of Taiwan.
Y.C. Huang: None. F.J. Tsai: None. Y.W. Chang:
None. C.M. Wu: None. W.L. Liao: None.
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Investigating causal relations between sleep duration
and risks of adverse obstetric outcomes: a Mendelian
randomization study
Q. Yang1,2, E. Sanderson1,2, M. C. Borges1,2, K. Tilling1,2,3,
D. A. Lawlor1,2,3
1MRC Integrative Epidemiology Unit, University of Bristol,
Bristol, United Kingdom, 2Population Health Sciences,
Bristol Medical School, University of Bristol, Bristol,
United Kingdom, 3NIHR Bristol Biomedical Centre, Uni-
versity Hospitals Bristol NHS Foundation Trust and
University of Bristol, Bristol, United Kingdom
Introduction: Shorter sleep duration has been linked with
higher risks of adverse obstetric outcomes, but it remains
unclear whether those associations are causal.
Materials and Methods: We conducted a two-sample
Mendelian randomization (MR) study with 78 single
nucleotide polymorphisms for sleep duration using
individual-participant data from UK biobank (208171
women), Avon longitudinal study of parents and children
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(7635 women) and born in Bradford (2977 women) to
investigate effects of sleep duration on obstetric outcomes.
Results: Using inverse variance weighted method, there
was little evidence to support an effect of sleep duration on
the risk of pregnancy loss (odds ratio [OR] per additional
hour/day 1.02, 95% confidence interval [CI]: 0.92-1.14),
stillbirth (OR 1.19, 95% CI: 0.87-1.64), miscarriage (OR
0.99, 95% CI: 0.88-1.12), gestational diabetes (OR 0.69,
95% CI: 0.32-1.49), hypertensive disorders in pregnancy
(OR 1.45, 95% CI: 0.90-2.34), perinatal depression (OR
0.85, 95% CI: 0.57-1.28), preterm birth (OR 0.80, 95% CI:
0.37-1.70), low offspring birthweight (OR 0.93, 95% CI:
0.63-1.37) or high offspring birthweight (OR 0.82, 95% CI:
0.52-1.29) Sensitivity analyses using MR-Egger, weighted
median and weighted mode methods provided similar
estimates.
Conclusions: We did not find consistent evidence
supporting linear effects of sleep duration on obstetric
outcomes. However, even with large sample sizes some
estimates are imprecise, and some point estimates suggest a
potentially important clinical effect (e.g. 45% increased
odds of hypertensive disorders. In two-sample MR we
cannot explore the possibility of non-linear effects. All
authors work in a Unit supported by UK Medical Research
Council (MC_UU_00011/3, MC_UU_00011/6).
Q. Yang: None. E. Sanderson: None. M.C. Borges:
None. K. Tilling: None. D.A. Lawlor: B. Research Grant
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pending grants as well as grants already received); Modest;
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Clostridium shows a higher abundance in less neurovas-
cular and neurodegenerative aspects: a microbiome-
wide association study
H. Karamujić-Čomić1, S. Ahmad1, D. Radjabzadeh1, B.
Bonnechere2, R. Kaddurah-Daouk3, A. G. Uitterlinden1, R.
Kraaij1, M. A. Ikram1, N. Amin1, C. M. van Duijn1,2
1Erasmus University Medical Center, Rotterdam, Nether-
lands, 2University of Oxford, Oxford, United Kingdom,
3Duke University, Durham, NC, United States
Introduction: There is an important interplay between the
intestinal microbiome and brain, commonly known as the
gut-brain-axis. Several studies addressed the role of the
microbiome in neurologic diseases. Here, we studied the
role of stool microbiota in cognitive function, neurovascular
aspects, and neurodegenerative aspects in the general
population.
Methods: In the population-based Rotterdam Study, we
studied the association between stool microbial taxa and
cognitive function, and neurovascular and neurodegenera-
tive traits, measured on brain magnetic resonance imaging,
in ~1,200 participants. Stool microbiota were profiled using
16s rRNA gene sequencing. We used linear regression
analysis, accounted for multiple testing, and adjusted for
major confounders, i.e., age, sex, technical covariates,
medication use, alcohol, smoking, body mass index, and
hypertension.
Results: The genus Clostridium sensu stricto 1 showed a
higher abundance in participants with better cognitive
function (beta(β)(standard error(SE)) 0.023(0.01), p =
3.22 × 10−2), larger global brain volume (β(SE) 0.0019
(0.0006), p = 1.83 × 10−3), less white matter hyperinten-
sities (β(SE) -0.024(0.007), p = 5.38 × 10−4), and smaller
lateral ventricular volume (β(SE) −0.013(0.005), p =
1.81 × 10−2). The family Clostridiaceae 1 also showed a
higher abundance in these traits, with the same direction of
effect and very similar effect estimates. The class
Clostridia, order Clostridiales, family Christensenellaceae,
and genus Christensenellaceae R7 group showed a higher
abundance in better cognition. Of note is that the agreement
of our findings with those of studies of Alzheimer’s disease
is high.
Conclusions: Clostridium shows a higher abundance in
participants with better cognitive function, less neurovas-
cular aspects, and less neurodegenerative aspects. We find
that different microbiota are associated to neurovascular and
neurodegenerative pathology.
H. Karamujić-Čomić: None. S. Ahmad: None. D.
Radjabzadeh: None. B. Bonnechere: None. R. Kad-
durah-Daouk: None. A.G. Uitterlinden: None. R. Kraaij:
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The mitochondrial DNA landscape of Thracians from
Bronze Age Bulgaria
D. V. Nesheva1, A. Modi2, S. Sarno3, S. Vai2, S.
Karachanak- Yankova1, D. Luiselli4, E. Pilli2, M. Lari2, C.
Vergata2, Y. Yordanov5, D. Dimitrova6, P. Kalcev7, R.
Staneva1, O. Antonova1, S. Hadjidekova1, A. Galabov8, D.
Toncheva1, D. Caramelli2
1Department of Medical genetics, Medical Faculty, Medical
University - Sofia, Sofia, Bulgaria, 2Department of Biology,
University of Florence, Florence, Italy, 3Department of
Biological, Geological and Environmental Sciences, Uni-
versity of Bologna, Bologna, Italy, 4Department of Cultural
Heritage, University of Bologna, Ravenna, Italy, 5Institute
of Experimental Morphology, Pathology and Anthropology
with Museum, Bulgarian Academy of Sciences, Sofia,
Bulgaria, 6The Regional Historical Museum of Sliven,
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Introduction: Thracians are one of the best documented
civilizations that inhabited the Bulgarian lands during the
Bronze Age. They left evidence in the rich cultural and
historical heritage. By conducting molecular anthro-
pological studies on Thracians mtDNA samples we aim to
reveal their genetic characteristics and contribution to the
gene pool of present day populations.
Materials and methods: We have reconstructed and
analyzed complete mitochondrial genomes from 25 Bronze
Age individuals sampled in three different Bulgarian
necropolises. The molecular phylogenetic analyses were
performed following strict guidelines and standards. The
Thracian mitogenomes were compared with different
modern and ancient populations for understanding possible
genetic relationships.
Results: The obtained mtDNA sequences were assigned
to 21 different haplogroups, representative of the mitochon-
drial variability of Western Eurasia. The presented hap-
logroups in our samples H, K, J and T arose in frequency in
different European populations during the Neolithic. Sub-
lineages of the haplogroup U mark the genetic pool of
European pre-LGM hunter-gatherers. The results support
the hypothesis of Thracians origin from the local people
with a low percentage of gene flow from the Steppe.
Conclusions: The Thracian maternal gene pool is mostly
represented by Western Eurasian haplogroups. After
comparing between the complete mitochondrial sequences
of Thracians and Eurasian (ancient and contemporary)
populations we observed that Thracians genetic profiles
reflect their nexus geographical position between east and
west. This study has an important implication for under-
standing the origins of the peopling in this part of Europe
and for enlarging the knowledge on the ancient Bronze Age
civilizations.
D.V. Nesheva: None. A. Modi: None. S. Sarno: None.
S. Vai: None. S. Karachanak- Yankova: None. D.
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Human mitochondrial eQTLs and the m1A 16S rRNA
modification explain tissue-specific mitochondrial gene
expression patterns
T. Cohen, C. Mordechai, A. Eran, D. Mishmar
Ben Gurion University of the Negev, Beer Sheva, Israel
Expression quantitative trait loci (eQTLs) are instrumental
in genome-wide identification of regulatory elements, yet
were overlooked in the mitochondrial DNA (mtDNA). By
analyzing 5079 RNA-seq samples from 23 tissues we
identified association of ancient mtDNA SNPs (hap-
logroups T2, L2, J2 and V) with tissue-dependent mtDNA
gene-expression. Secondly, the discovery of mtDNA
eQTLs in both coding and non-coding mtDNA regions,
propose the identification of novel mtDNA regulatory ele-
ments. Third, we identified mostly negative correlation
between m1A 947 16S rRNA modification levels and
mtDNA gene-expression in twelve body sites. Such asso-
ciation was compromised in skin which was exposed to sun,
as compared to sun-unexposed skin from the same indivi-
duals, thus suggesting an impact of UV on mtDNA gene
expression. Taken together, our findings reveal that both
mtDNA SNPs and mt-rRNA modification affect mtDNA
gene expression in a tissue-dependent manner.
T. Cohen: None. C. Mordechai: None. A. Eran: None.
D. Mishmar: None.
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The incidence of phacomatoses in the Rostov region
A. V. Antonets1, S. S. Amelina1, E. V. Degtereva1, S. V.
Mordanov1, R. A. Zinchenko2
1Rostov Medical State University, Rostov-on-Don, Russian
Federation, 2Medical Genetic Research Center named after
Academician N.P. Bochkov, Moscow, Russian Federation
Introduction: Phacomatoses, also known as Neurocuta-
neous syndromes (NCS), include a heterogeneous group of
disorders characterized by abnormalities of both the inte-
gument and central nervous system. Disorders classified as
NCS include neurofibromatosis 1 (NF1), tuberous sclerosis
(TS), von Hippel-Lindau (VHL) disease, PHACE syn-
drome, ataxia telangiectasia (AT), linear nevus syndrome
(LNS), Sturge-Weber Syndrome (SWS), hypomelanosis of
Ito (HOI), and incontinentia pigmenti (IP). Most disorders
are inherited as autosomal dominant conditions with vari-
able penetrance or can be caused by somatic mosaic
mutation (SWS).
Materials and Methods: The purpose of the present
research was studying of prevalence of phakomatosis in
Rostov region (12 districts). The total number of investi-
gated population was 497460 persons. The research was
conducted under the original protocol providing for
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detection of more than 2500 various hereditary diseases
(OMIM) and syndromes including all phacomatoses.
Results: The most frequent observed phacomatoses were
NF1, TS, VHL, SWS accounted for 55, 15, 1, 7 cases
correspondingly. The overall prevalence of phacomatoses in
Rostov region was 1:6378, namely NF1 was 1:9045, TS -
1:33164, VHL - 1:497460, SWS 1:71066. For some
patients additional molecular testing was available. Con-
clusion. We estimated the incidence of phacomatoses in the
Rostov region that could allow to plan genetic support.
Phacomatoses should be considered by doctors of different
specialties.
A.V. Antonets: None. S.S. Amelina: None. E.V.
Degtereva: None. S.V. Mordanov: None. R.A.
Zinchenko: None.
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Genetic correlation between pigmentation traits in
european populations
E. pairo-castineira1, J. Cornelissen1, O. Canela-Xandri1,
K. Rawlik2, A. Tenesa1, I. Jackson1
1MRC - Human genetics unit, Edinburgh, United Kingdom,
2Roslin Institute, Edinburgh, United Kingdom
Many of the biology of human pigmentation traits is shared
between them, but there are some specific genes and path-
ways for each trait, and the similiarities and differences
between them still need still to be understood. Recently we
published a GWAS for hair colour variation in Europeans
showing 8 genes related to red hair and more than 100
genes associated to blonde to black hair colour. Another
GWAS found 20 loci related to UV sensitivity, and the
largest study of skin colour variation in Europeans found 9
genes. In this study, we performed a GWAS of 452,264
UKBiobank European individuals for hair colour, skin
colour, and ease of tanning, using DISSECT, calculated the
genetic correlations and studied the commonalities and
differences. We identified 655 independent SNPs related to
red hair in 128 genes, many of them within 3 MB of MC1R,
but we find new associations in regions related to pigmen-
tation such MITF, a transcription factor controlling the
pigmentation, and MFSD12, a gene related to darker skin in
African populations. Using Whole exome sequencing for
50,000 UKBiobank individuals, we identified 44 MC1R
protein coding variants in red hair individuals, of whom
96.4% had 2 MC1R variants. We found 519 genes related to
hair colour, 338 to skin colour and 293 to ease of tanning, of
which 161 were common, with enriched function for mel-
anin synthesis (pval~10-7) and lipid-bidning proteins
(pval~10-9). Hair colour specific genes (288) are enriched
for keratinocyte-expressed genes (pval=) as we expected
from the previous analysis
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Canela-Xandri: None. K. Rawlik: None. A. Tenesa:
None. I. Jackson: None.
P19.073.B
Irish demographic insights utilising rare variants
captured by whole-genome-sequencing
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Genetic structure within Ireland has recently been demon-
strated using common genetic variants. Irish genetic struc-
ture inferred by rarer variants is less well understood. A
population’s demographic history impacts the whole variant
frequency spectrum, including rare variants. These variants
are usually younger than common variation, and often have
a functional impact. Understanding the distribution of rare
variants in Ireland will therefore elucidate genetic history
and disease risk in Ireland.
In this context, we generated 30x short-read whole-
genome-sequencing and microarray genotype data on 880
Irish individuals, 280 of whom had genealogies mapped to
specific regions of Ireland. We filtered variants by standard
quality control thresholds and generated ‘genotype counts’
matrices which recorded the frequencies of each variant in
each Irish region. In parallel we estimated the functional
impact of each variant, and generated haplotype data from
the microarray data on these individuals.
We investigated the impact of the demographic history of
Ireland on the full spectrum of Irish genetic variation using
this data. We report the different site frequency spectra for
the four Irish provinces alongside analysis of haplotype data
that estimates Irish population size for the last 40
generations, detecting evidence of a modest population size
compared to England. Using rare variation to detect
population structure, we calculated FST distances and
proportion of f2 variants between Irish regions, revealing
the structure of rare variant sharing in Ireland. Our results
have implications for the research of rare disease variants
within Ireland and populations of Irish ancestry and inform
on Irish history.
E.H. Gilbert: None. A. Corvin: None. A. Helgason:
None. G. Cavalleri: None.
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 725
P19.075.A
The fine-scale genetic structure & adaptive positive
selection in the Lithuanian population from high-density
SNP data
A. Urnikyte1, A. Flores Bello2, M. Mondal3, A. Molytė1, D.
Comas2, F. Calafell2, E. Bosch2, V. Kucinskas1
1Vilnius University, Vilnius, Lithuania, 2Universitat Pom-
peu Fabra, Barcelona, Spain, 3Estonian Biocentre, Tartu,
Estonia
The analysis of geographically specific regions and the
characterization of fine-scale patterns of genetic diversity
may facilitate a much better understanding of the micro-
evolutionary processes affecting local human populations.
Here we generated genome-wide high-density SNP geno-
type data in 425 individuals from six geographical regions
in Lithuania and combined our dataset with available
ancient and modern data to explore genetic population
structure, ancestry components and signatures of natural
positive selection in the Lithuanian population. Our results
show that Lithuanians are a homogenous population,
genetically differentiated from neighbouring populations
but within the general expected European context. More-
over, we not only confirm that Lithuanians preserve one of
the highest proportions of western, Scandinavian and east-
ern hunter-gather ancestry components found in European
populations but also that of an steppe Early to Middle
Bronze Age pastoralists, which together configure the
genetic distinctiveness of the Lithuanian population.
Finally, among the top signatures of positive selection
detected in Lithuanians, we identified several candidate
genes related with diet (PNLIP, PPARD), pigmentation
(SLC24A5, TYRP1 and PPARD) and the immune response
(BRD2, HLA-DOA, IL26 and IL22).
This study was supported by LITGEN project, which was
approved by the Vilnius Regional Research Ethics Com-
mittee No. 158200-05-329-79, date: 2011-05-03, and by
Direcció General de Recerca, Generalitat de Catalunya
(2017SGR702), Agencia Estatal de Investigación (AEI) and
Fondo Europeo de Desarrollo Regional (FEDER) with
project grants BFU2016-77961-P and CGL2016-75389-P,
and the Unidad de Excelencia María de Maeztu”, funded by
the MINECO (ref: MDM-2014-0370).
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P19.076.B
Positively selected TNKS haplotype: from evolutionary
advantage to the health risk in an Arabian Peninsula
population
E. Muthukrishnan1, A. L. C. d. Santos2,3, O. Gokcumen3,
F. Al-Mulla1, T. A. Thanaraj1
1Dasman Diabetes Institute, Dasman, Kuwait, 2Federal
University of Pernambuco, Recife, Brazil, 3State University
of New York at Buffalo, Buffalo, NY, United States
Introduction: Following the out-of-Africa diaspora, the
Arabian Peninsula has experienced several waves of human
migrations despite the prevailing extreme and varying
environmental conditions. The potential adaptation that
shaped the extant human populations of the hot and dry
environment of the Arabian Peninsula have been scarcely
studied.
Materials and Methods: We explored natural selection
in the Arabian Peninsula region by analyzing 662,750 single
nucleotide variants in 583 Kuwaiti and 96 Saudi Arabian
individuals conducting multiple statistical tests, including
integrated Haplotype Score (iHS), Cross Population
Extended Haplotype Homozygosity (XP-EHH), Population
Branch Statistics (PBS), and log-likelihood ratio scores
(LLRS).
Results: Our integrative approach identified several
genomic regions with strong signals of positive selection
in both the populations, many of which contain loci
associated with metabolic traits, asthma and blood-related
phenotypes. We highlight a haplotype overlapping TNKS
region in chromosome 8, associated with metabolic traits
and hypertension. The TNKS haplotype exemplifies a
general trend in which a more rapid metabolism rate and
hypertension have been selected in the Kuwaiti population,
and potentially conferred some degree of fitness advantage
to the Kuwaiti ancestors for surviving in the extremely dry
and hot ecological environments, while posing a consider-
able health risk to present-day Kuwaitis.
Conclusions: Our results suggest that past adaptive
trends have further predisposed Kuwaiti populations to the
health risks at the genetic level. Overall, the mechanisms
through which the TNKS haplotype conferred a fitness
advantage and how the same haplotype predisposes the
population to metabolic diseases remain fascinating and
could be explored in future research.
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P19.077.C
Association of PPARGC1A gene polymorphism with
strength&power athlete status in two cohorts of
European elite athletes
V. Gineviciene1, A. Utkus1, L. Andruschenko2, M. Aksenov2
1Vilnius University, Vilnius, Lithuania, 2Plekhanov Russian
University of Economics, Moscow, Russian Federation
Introduction: The peroxisome proliferator-activated
receptors γ coactivator-1α (encoded by PPARGC1A gene)
is crucial regulator of energy homeostasis, adaptive ther-
mogenesis, mitochondrial biogenesis and metabolism. The
aim of this case-control study was to investigate the asso-
ciation of PPARGC1A (G>A, Gly482Ser, rs8192678)
polymorphism with athletes’ status in two European Cau-
casians cohorts from Lithuania (LT) and Russia (RU).
Materials and Methods: The study involved 160
professional strength/power athletes (47 LT and 113 RU
(86 weightlifters, 60 powerlifters, 14 throwers)) and 1,202
controls (255 LT and 947 RU, healthy unrelated non-
athletes). Genotyping of PPARGC1A polymorphism was
performed by polymerase chain reaction and restriction
fragment length polymorphism analysis method.
Results: Statistically significant differences in genotype
distribution were observed in all (LT+RU) powerlifters
group (PPARGC1A: GG 62.3%, GA 18%, AA 19.7%)
compared with weightlifters (GG 47.7%, GA 45.3%, AA
7%; P = 0.0009) as well as with throwers (GG 50%, GA
50%, AA 0%; P = 0.019) and with controls (GG 46.3%,
GA 43.4%, AA 10.3%, P = 0.0002). Odds ratio (OR) of
PPARGC1A AA genotype 2.11 (95% CI: 1.09-4.09,
P = 0.026) was larger compared to G/G genotype
OR=1.92 (95% CI: 1.13-3.26, P = 0.016) for powerlifters.
Calculated OR indicate that the AA genotype is more
favourable for powerlifter athletes.
Conclusions: Our results indicate that PPARGC1A AA
genotype is beneficial to sports disciplines characterized by
a predominantly anaerobic energy production and is related
to greater power performance (such as powerlifters). We
conclude that PPARGC1A (rs8192678) polymorphism is
associated with strength/power athlete status in two
European populations.
V. Gineviciene: None. A. Utkus: None. L.
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DNA methylation at five CpG sites of nasal brushings
can predict childhood allergic disease
C. Qi1,2, M. van Breugel2,3, Y. Jiang4,5, I. Petoukhov3, J. M.
Vonk2,6, U. Gehring7, M. Bügel3, E. Forno5,4, W. Chen4,5, J.
C. Celedón4,5, G. H. Koppelman1,2, C. Xu8,9,10
1Dept. of Pediatric Pulmonology and Pediatric Allergy,
Beatrix Children’s Hospital, University Medical Center
Groningen, University of Groningen, Groningen, Nether-
lands, 2University of Groningen, University Medical Center
Groningen, GRIAC Research Institute, Groningen, Nether-
lands, 3MI company, Amsterdam, Netherlands, 4Dept. of
Pediatrics, University of Pittsburgh School of Medicine,
Pittsburgh, PA, United States, 5Division of Pulmonary
Medicine, UPMC Children’s Hospital of Pittsburgh,
Pittsburgh, PA, United States, 6University of Groningen,
University Medical Center Groningen Dept. of Epidemiol-
ogy, Groningen, Netherlands, 7Institute for Risk Assessment
Sciences, Utrecht University, Utrecht, Netherlands, 8,
Centre for Individualised Infection Medicine, CiiM, a joint
venture between the Hannover Medical School and the
Helmholtz Centre for Infection Research, Hannover,
Germany, 9Department of Internal Medicine, Radboud
University Medical Center, Nijmegen, Netherlands,
10Department of Gastroenterology, Hepatology and Endo-
crinology, TWINCORE, Centre for Experimental and
Clinical Infection Research, a joint venture between the
Hannover Medical School and the Helmholtz Centre for
Infection Research, Hannover, Germany
Background: The development of allergic, IgE mediated
disease, such as asthma, rhinitis, and eczema, has a strong
genetic and epigenetic contribution1,2. However, diagnosing
allergic disease in childhood remains challenging, espe-
cially in young children.
Methods: We aimed to predict the presence of allergic
disease (i.e. either asthma, rhinitis or eczema in combination
with ≥1 positive allergen-specific IgE) in children. The
model was built using data including lifestyle, environ-
mental factors, genetic variation, and blood and nasal DNA
methylation (450 K), collected from 348 subjects at 16
years old from a birth cohort, with 67 children having
allergic disease. Elastic net regulation was used to train the
model. The model performance was validated by 10-fold
cross validation and was replicated in an independent cohort
with 481 children.
Results: We observed that most predict power can be
attributed to nasal DNA methylation. Other factors did not
improve the prediction of allergic disease. The final model
was based on nasal DNA methylation levels at only 5 CpGs
with the prediction performance of AUC 0.86 in the
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 727
discovery cohort and AUC 0.83 in the replication cohort.
Matched nasal gene expression data was used to annotate
these CpGs. Genes that were significantly correlated to the 5
CpGs were enriched in immune pathways including
Interleukin-4 and Interleukin-13 signaling, neutrophil
degranulation and leukocyte transendothelial migration.
Conclusions: We present a prediction model for allergic
disease based on only 5 CpGs from nasal epithelial cells.
This model shows great potential to diagnose the presence
of allergic disease in children.
C. Qi: None. M. van Breugel: A. Employment (full or
part-time); Modest; MI company. Y. Jiang: None. I.
Petoukhov: A. Employment (full or part-time); Modest; MI
company. J.M. Vonk: None. U. Gehring: None. M.
Bügel: A. Employment (full or part-time); Modest; MI
company. E. Forno: None.W. Chen: None. J.C. Celedón:
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P19.080.C
Frequency analysis of potentially protective genome
variants in the Lithuanian population
G. Zukauskaite, L. Ambrozaityte, I. Domarkiene, T.
Rancelis, V. Kucinskas
Vilnius University, Faculty of Medicine, Department of
Human and Medical Genetics, Vilnius, Lithuania
The aim of this study is to determine potential protective
genome variants (PGVs) in the general Lithuanian popula-
tion using the data of the project "LITGEN". Exome
sequencing and high-throughput beadchip genotyping data
analysis was performed for 98 and 466 subjects of the
Lithuanian descent, respectively. A catalog of 144 known
PGVs was compiled using databases and publications. The
catalog was set as a reference of PGVs for the LITGEN
data. Allele frequencies were calculated and compared to
the general European population as well as individual
European populations based on 1000G project data. Sta-
tistical analysis (Hardy-Weinberg equilibrium, χ2 or F-test,
p≤0.05) was performed. Six missense variants were sig-
nificantly more frequent in the study group and may have
protection against alcohol dependence (ADH1C, rs698,
p = 0.05), type 2 diabetes (PPARG, rs1801282, p = 0.05;
SLC30A8, rs13266634, p = 0.03 (FIN), p = 0.03 (GBR),
p = 0.04 (CEU)), coronary heart disease (ZC3HC1,
rs11556924, p = 0.04 (GBR), p < 0.01 (FIN)), obesity
(SH2B1, rs7498665, p = 0.03), esophageal cancer
(PLCE1, rs2274223, p = 0.04). Although PGVs may
reduce the risk of disease, there are additional genetic
mechanisms that control this process. Not only the effects of
single genomic variants are important, but their interactions
and interactions between regulatory elements as well.
Detection of PGVs would not only provide a better
understanding of the etiopathogenesis mechanisms and
microevolutionary processes, but could also be used for the
analysis for the development of novel therapies.
This research is part of the LITGEN project (VP1-3.1-
ŠMM-07-K-01-013) and was funded by the European
Social Fund under the Global Grant measure.
G. Zukauskaite: None. L. Ambrozaityte: None. I.
Domarkiene: None. T. Rancelis: None. V.
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P19.081.A
Identification of urinary metabolite quantitative trait
loci in children and their interaction with dietary factors
B. Calvo1,2,3, C. H. Lau4, A. Siskos4, L. Maitre1,2,3, K. B.
Gutzkow5, M. Coen4,6, M. Vrijheid1,2,3, H. Keun4, G.
Escaramís7, M. Bustamante1,2,3, Human Early Life
Exposome (HELIX)
1ISGlobal, Barcelona, Spain, 2Universitat Pompeu Fabra
(UPF), Barcelona, Spain, 3CIBER Epidemiología y Salud
Pública (CIBERESP), Madrid, Spain, 4Imperial College
London, London, United Kingdom, 5Norwegian Institute of
Public Health, Oslo, Norway, 6AstraZeneca, Cambridge,
United Kingdom, 7Universitat de Barcelona (UB), Barce-
lona, Spain
Introduction: Human metabolism is influenced by genetic
and environmental factors. Previous studies have identified
>23 single nucleotide polymorphisms (SNPs) associated
with >28 urine metabolites levels (metabQTLs) in adults,
but there are no publications in children. The aim of the
present study is the identification of urinary metabQTLs in
children.
Material and Methods: Genome-wide association stu-
dies (GWAS) of 44 urine metabolite levels measured with
1H NMR were conducted in 996 children from the Human
Early Life Exposome (HELIX) project.
Results: Twelve statistically significant urine metabQTLs
were identified, involving 11 unique loci and 10 different
metabolites. Comparison with findings in adults revealed
that 6 metabQTLs were already known, 1 had been
described in serum and 2 involved the same locus but
different urinary metabolites. The remaining 2 metabQTLs
represent novel associations: (i) rs2274870 for 3-
hydroxyisobutyrate annotated to Nipsnap Homolog 3A
(NIPSNAP3A), that codes for a protein highly expressed
in the kidneys that participates in the vesicular transport;
and (ii) rs12575496 for taurine, which is in a gene desert
region. We also found that urinary taurine levels were
affected by the combined action of rs12575496 and dietary
patterns of meat and beverages.
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Conclusions: Overall, we identified 12 urinary
metabQTLs in children, being 2 of them novel. A
substantial part of the identified loci affected similarly
urinary metabolite levels in children and in adults. The
metabQTL for taurine seemed to be specific to children and
interacted with dietary patterns.
Funding: ISCIII PI17/01225; FP7-
ENVIRONMENT 308333
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Population-scale comprehensive variant discovery with
PacBio HiFi reads
R. Vogelsang, S. B. Kingan, A. M. Wenger
Pacific Biosciences, Menlo Park, CA, United States
Introduction: Catalogs of human variation continue to
increase in scale, but they remain incomplete by relying on
short-read sequencing and reference-based variant calling.
Short reads have low sensitivity for structural variants (SVs,
differences ≥50 bp), miss variants in segmental duplications
that comprise 5-10% of human genome, and do not phase
haplotypes. Further, large sequences absent in the reference
genome are ignored. Highly accurate long-read (HiFi)
sequencing overcomes these limitations.
Results: Long-read sequencing has been used success-
fully to create ethnicity-specific reference genomes of
Asian, African, and European populations. Each genome
adds up to 10 Mb of unique sequence beyond GRCh38 and
provides a superior target against which to map short reads.
We demonstrate that de novo assembly with HiFi reads
reliably produces genomes that approach GRCh38 in
contiguity and accuracy (contig N50 >30 Mb, accuracy
>Q55).
HiFi reads also provide high precision and recall for
variant detection at 15-fold coverage. For the Genome in a
Bottle benchmark samples, DeepVariant and pbsv achieve
an F1 score of 99.7% for SNVs, 96.6% for indels, and
96.4% for SVs. WhatsHap produces a phase block
N50 >100 kb. HiFi reads resolve 152 of 193 medically
relevant genes noted to be difficult for short reads.
Conclusions: We propose to improve catalogs of human
variation using HiFi reads through: 1) de novo assembly of
a representative male and female from each subpopulation
to discover novel sequences; and 2) whole-genome
sequencing of thousands of individuals to discover small
variants in difficult regions and SVs genome-wide.
R. Vogelsang: A. Employment (full or part-time);
Significant; Pacific Biosciences. S.B. Kingan: A. Employ-
ment (full or part-time); Significant; Pacific Biosciences. A.
M. Wenger: A. Employment (full or part-time); Signifi-
cant; Pacific Biosciences.
P19.083.C
The dynamics of incidence rates for recessive disorders
in growing populations under different mating schemes
L. A. La Rocca1, J. Frank2, A. Bovier1, P. Krawitz2
1Institute for Applied Mathematics, Bonn, Germany, 2Insti-
tute for Genomic Statistics and Bioinformatics, Bonn,
Germany
Despite increasing data from population-wide sequencing
studies, the risk for recessive disorders in consanguineous
partnerships is still heavily debated. An important aspect
that has not sufficiently been investigated theoretically, is
the influence of inbreeding on mutation load and incidence
rates when the population sizes change. We therefore
developed an individual-based population model to study
these dynamics for a wide range of growth and mating
conditions. In the phase of population expansion and shortly
afterwards, our simulations show that there is a drop of
diseased individuals at the expense of an increasing muta-
tion load for random mating. On the other hand both
parameters remain almost constant in highly con-
sanguineous partnerships. This explains the empirical
observation in present times that a high degree of con-
sanguinity is associated with an increased risk of autosomal
recessive disorders. However, the simulations also state that
the higher frequency of severe recessive disorders such as
intellectual disability in inbred populations is a transient
phenomenon before a mutation-selection balance is reached
again. Mathematic simulations can help to gain new insights
in processes, where several factors interact in a complex
manner.
L.A. La Rocca: None. J. Frank: None. A. Bovier:
None. P. Krawitz: None.
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Temporal variation of regulatory organization based on
longitudinal RNA-seq data in twins
A. Ramisch1,2, D. Ribeiro3, J. S. El-Sayed Moustafa4, G.
Leday5, Y. Jiao6,7,8, G. Nicholson8, M. Stevens1,2, M.
Abdalla6,7,8, C. Menni4, C. Holmes8, T. D. Spector4, M. I.
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McCarthy6,7,9, S. Richardson5, O. Delaneau3, K. S. Small4,
E. T. Dermitzakis1,2
1Department of Genetic Medicine and Development,
Faculty of Medicine, University of Geneva, Geneva,
Switzerland, 2Institute of Genetics and Genomics of
Geneva, Geneva, Switzerland, 3Systems and Population
Genetics Group, Department of Computational Biology,
University of Lausanne, Lausanne, Switzerland, 4Depart-
ment of Twin Research and Genetic Epidemiology, King’s
College London, London, United Kingdom, 5Medical
Research Council, Biostatistics Unit, Cambridge, United
Kingdom, 6Wellcome Centre Human Genetics, Nuffield
Department of Medicine, University of Oxford, Oxford,
United Kingdom, 7Oxford Centre for Diabetes, Endocrinol-
ogy and Metabolism, Radcliffe Department of Medicine,
University of Oxford, Oxford, United Kingdom, 8Depart-
ment of Statistics, University of Oxford, Oxford, United
Kingdom, 9Oxford NIHR Biomedical Research Centre,
Oxford University Hospitals Trust, Oxford, United King-
dom
The human genome can be partitioned into domains of
regulations that are necessary to foster gene expression in
development, homeostasis and disease. A study by Dela-
neau et al. (Science 364, eaat8266, 2019) used population-
based chromatin data to identify cis-regulatory domains
(CRDs), which show cell type-specific coordinated chro-
matin activity, follow the local chromatin organization into
topologically associated domains, and were observed to
control coexpression of nearby genes. Since CRDs are also
under strong genetic control, they offer a great insight into
the regulatory organization of the human genome. How-
ever, chromatin data are not available for most human
genetics’ studies, rendering the identification of CRDs
expensive on a large scale. Therefore, we extend our pre-
vious work to characterize regulatory organization of the
genome using only gene expression data from RNA-seq
studies and genotypes. Specifically, we identify coexpres-
sion domains (CODs) as groups of significantly correlated
proximal genes with inter-individual coordinated expression
patterns, and assess their temporal dynamics exploiting a
longitudinal dataset from the MultiMuTHER study,
including 336 individuals with whole-blood RNA-seq data
collected at three time-points over seven years, and imputed
genotypes from the TwinsUK cohort. We identify genetic
variants associated to the coordinated expression regulation
of the CODs, as well as to their age-associated changes.
Using the unique properties of twin studies, we perform a
variance decomposition analysis to estimate COD-
heritability. Finally, we perform association studies to
clinically relevant phenotypes in an attempt to identify
CODs involved in the regulation of cardiometabolic traits
such as cardiovascular diseases and diabetes.
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Moustafa: None. G. Leday: None. Y. Jiao: None. G.
Nicholson: None. M. Stevens: None. M. Abdalla: None.
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Whole-exome sequencing provides insights into mono-
genic disease prevalence in Northwest Russia
R. K. Skitchenko1,2,3, Y. A. Barbitoff2,3, M. Vashisth1,2, O. I.
Poleshchuk2,3, A. E. Shikov2,4, E. A. Serebryakova3, Y. A.
Nasykhova3, D. E. Polev3, A. R. Shuvalova3, I. V.
Shcherbakova3, M. A. Fedyakov4, O. S. Glotov4,3, A. S.
Glotov4,3, A. V. Predeus2
1ITMO, St. Petersburg, Russian Federation, 2Bioinfor-
matics Institute, St. Petersburg, Russian Federation,
3Department of Genomic Medicine, D.O. Ott Research
Institute of Obstetrics, Gynaecology and Reproduction, St.
Petersburg, Russian Federation, 4City Hospital No. 40, St.
Petersburg, Russian Federation
Allele frequency data from large exome and genome
aggregation projects such as the Genome Aggregation
Database (gnomAD) are of ultimate importance to the
interpretation of medical resequencing data. However, allele
frequencies might significantly differ in poorly studied
populations that are underrepresented in large-scale pro-
jects, such as the Russian population. In this work, we
leveraged our access to a large dataset of 1,021 exome
samples to analyze genetic variation in the Northwest
Russia. We compared the spectrum of genetic variants to
the dbSNP build 151, and made estimates of ClinVar-based
autosomal recessive (AR) disease allele prevalence as
compared to gnomAD r. 2.1. In total, around 10% of dis-
covered variants were not present in dbSNP. We report
statistically significant overrepresentation of pathogenic
variants for several Mendelian disorders, including phe-
nylketonuria (PAH, rs5030858), Wilson’s disease (ATP7B,
rs76151636), factor VII deficiency (F7, rs36209567),
kyphoscoliosis type of Ehlers-Danlos syndrome (FKBP14,
rs542489955), and several other recessive pathologies. We
also make primary estimates of monogenic disease inci-
dence in the population, with retinal dystrophy, cystic
fibrosis, and phenylketonuria being the most frequent AR
pathologies. Our observations demonstrate the utility of
population-specific allele frequency data to the diagnosis of
monogenic disorders.
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Autosomal diversity of Russian old settlers living in the
shores of the Arctic Ocean in the Sakha Republic
(Eastern Siberia)
A. V. Solovyev1,2, T. V. Borisova2, A. I. Kushniarevich3, E.
Metspalu3, F. M. Teryutin2,4, V. G. Pshennikova2,4, G. P.
Romanov2,4, A. M. Cherdonova2, A. N. Alekseev1, T. E.
Burtseva2,4, E. K. Khusnutdinova5,6, M. Мetspalu3, R.
Villems3, N. A. Barashkov2,4, S. A. Fedorova2,4
1The Institute for Humanities Research and Indigenous
Studies of the North, Federal Research Center “Yakut
Science Center of Siberian Branch of Russian Academy of
Science”, Yakutsk, Russian Federation, 2M.K. Ammosov
North-Eastern Federal University, Yakutsk, Russian Fed-
eration, 3Estonian Biocentre, Institute of Genomics, Tartu,
Estonia, 4Yakut Scientific Center for Complex Medical
Problems, Yakutsk, Russian Federation, 5Institute of
Biochemistry and Genetics, Ufa Federal Research Center
of the Russian Academy of Sciences, Ufa, Russian
Federation, 6Bashkir State University, Ufa, Russian Fed-
eration
The “Russkoe Ust’e” is a small village located on the shores
of the Arctic Ocean in Northeast Siberia (71°
08’02.2"N149°16’17.4"E), with a total population of 128
people. The main population is Russian old settlers - rus-
koustintsy. The ruskoustintsy have preserved old Russian
traditions and dialect typical for Russians of the 16th cen-
tury, despite living ~400 years neighboring with indigenous
Siberian populations (Paleo-Asiatic, Uralic, Tungusic and
Turkic people) which have expanded in this territory in
various historical period. In our days it’s amazing to see a
Slavic population among the indigenous people of this land.
The aim of this study is to analyze the autosomal diversity
and to reconstruct genetic history of Russian old settlers
living in the Arctic region. DNA samples of 30 unrelated
residents of “Russkoe Ust’e” were collected and genotyped
using the Illumina OmniExpress 730K. The samples were
analyzed using ADMIXTURE approach (Alexander et al.,
2009). Final dataset included 192776 SNP’s presented in
5458 individuals from 365 different worldwide populations.
The ADMIXTURE (K=8) analysis showed that all 30
individuals in average have two major components - Eur-
opean (42.4%) and Siberian (41.3%) and minor different
components (Middle-Eastern, East Asian, American-15%
and 1.3% others). The results do not refute the hypothesis
that the first settlers of “Russkoe Ust’e” were the Russian
Pomors, that fled from the persecution of the Ivan-IV the
Terrible from the old territories of the Velikiy Novgorod
(~1570 year). This study was supported by Ministry of
Science and Higher Education of Russia (basic_part_to_-
NEFU) and RFBR_grants (#18-05-600035_Arctica, #19-
34-60023_Perspektiva).
A.V. Solovyev: None. T.V. Borisova: None. A.I.
Kushniarevich: None. E. Metspalu: None. F.M. Teryu-
tin: None. V.G. Pshennikova: None. G.P. Romanov:
None. A.M. Cherdonova: None. A.N. Alekseev: None. T.
E. Burtseva: None. E.K. Khusnutdinova: None. M.
Мetspalu: None. R. Villems: None. N.A. Barashkov:
None. S.A. Fedorova: None.
P19.089.C
Exploring the genetic architecture of the human
neurological proteome using whole genome sequencing
G. Png1, A. Barysenka2, L. Repetto3, X. Shen3,4,5, E.
Tsafantakis6, M. Karaleftheri7, G. Dedoussis8, A. Gilly1, E.
Zeggini1
1Institute of Translational Genomics, Helmholtz Zentrum
Munich - German Research Center for Environmental
Health, Neuherberg, Germany, 2Helmholtz Zentrum
Munich, Neuherberg, Germany, 3Centre for Global Health
Research, Usher Institute, University of Edinburgh, Edin-
burgh, United Kingdom, 4State Key Laboratory of Biocon-
trol, School of Life Sciences, Sun Yat-sen University,
Guangzhou, China, 5Department of Medical Epidemiology
and Biostatistics, Karolinska Institute, Stockholm, Sweden,
6Anogia Medical Centre,, Anogia, Greece, 7Echinos
Medical Centre, Echinos, Greece, 8Department of Nutrition
and Dietetics, School of Health Science and Education,
Harokopio University of Athens, Athens, Greece
The human proteome has a stronger genetic component
compared to many complex diseases, making it a valuable
resource of potential disease biomarkers and drug targets.
This is especially so for highly polygenic neurological
disorders whose mechanisms remain elusive. Here, we
present the first sequence-based protein quantitative trait
loci (pQTL) analysis of 92 neurological proteins. We per-
form a meta-analysis using deep whole-genome sequencing
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(WGS) data from two isolated Greek cohorts, MANOLIS
(22.5x WGS; N = 1,356) and Pomak (18.4x WGS; N =
1,537). A total of 123 independently-associated variants in
84 loci reach study-wide significance (P < 1.14x10−10) for
63 proteins, all of which are at least nominally significant
(P < 3.78x10−4) and have the same direction of effect in
both cohorts. To further elucidate the genetic architecture,
independent variants were classified into 89 (72%) cis- and
34 (28%) trans-acting pQTLs. Ten variants have con-
sequences equal to or more severe than missense, and 33
overlap regulatory regions. We also discover variants that
have previously been linked to psychiatric disorders. For
example, an intronic trans-pQTL in the ITIH4 gene is
associated with increased NEP levels (rs2239547;
P = 1.19 x 10−129; BETA = 0.637983; SE = 0.026328),
and is an established risk variant for schizophrenia and
bipolar disorder. This analysis represents the largest and
only WGS-based pQTL study of neurological proteins to
date, delivering insight into the rare and common genetic
variant landscape underlying the human neurological pro-
teome and its connection to neurological diseases.
G. Png: None. A. Barysenka: None. L. Repetto: None.
X. Shen: None. E. Tsafantakis: None. M. Karaleftheri:
None. G. Dedoussis: None. A. Gilly: None. E.
Zeggini: None.
P19.090.A
Widespread sexual differences in genetic architecture in
UK Biobank
E. Bernabeu1, O. Canela-Xandri2, K. Rawlik1, A. Talenti1,
J. Prendergast1, A. Tenesa1,2
1The Roslin Institute, University of Edinburgh, Edinburgh,
United Kingdom, 2MRC Human Genetics Unit, University
of Edinburgh, Edinburgh, United Kingdom
Despite males and females sharing nearly identical gen-
omes, there are differences between the sexes in complex
traits and in the risk, incidence, and prevalence of a wide
array of diseases. Gene by sex interactions (GxS) are
thought to underlie some of this sexual dimorphism.
However, the extent and basis of these interactions are
poorly understood.
Here we provide insights into both the scope and
mechanism of GxS across the genome of circa 450,000
individuals of European ancestry and 530 complex traits in
UK Biobank. We report sex differences in heritability for 71
traits, through genetic correlations for 69 traits, and in
associations of genetic variants located in the autosome and
X-chromosome for 103 traits. We also show that sex
specific polygenic risk scores may lead to a modest
improvement of phenotypic prediction and highlight how
sex agnostic analyses could be missing loci of interest.
Finally, we studied the potential functional role of this
dimorphism through sex-biased eQTL and gene-level
analyses.
This study marks the largest examination of the genetics
of sexual dimorphism to date. Our findings parallel previous
reports, proving the widespread presence of sexual genetic
heterogeneity across complex traits, though be it of
generally modest magnitude. This warrants the need for
future studies to consider sex-stratifying analyses, in order
to both shed light into possible sex-specific molecular
mechanisms as well as improve prediction of high-level
phenotypes.
E. Bernabeu: None. O. Canela-Xandri: None. K.
Rawlik: None. A. Talenti: None. J. Prendergast: None.
A. Tenesa: None.
P19.092.C
Experimental system to enhance the discovery and
translatability of causal links between host genetics
and RSV-ALRI susceptibility
A. Destouni
Louisiana State University, Baton Rouge, LA, United
States
Introduction: Respiratory syncytial virus (RSV) is the
most significant cause of acute lower respiratory tract
infections (ALRI) and ALRI caused deaths in children <5
years of age globally. Heritability of RSV-ALRI is 20%
indicating that extensive genotype-by-environment interac-
tions determine phenotypic variation. In this context, RSV-
ALRI GWA studies are underpowered, because adequately
sized infant cohorts have been unattainable. Integrating
GTEx eQTLs from adult lungs is not informative due to the
age-dependent pulmonary/immune RSV induced responses.
Materials and Methods: We developed an experimental
system combining the BXD family of recombinant inbred
strains with the neonatal mouse model of infant RSV-
immunopathology. We infected 28 BXD strains and
measured levels of viral NS1 gene transcription in lungs
to obtain quantitative measure of the host-virus interaction.
Heritability of NS1 transcription was 67%. We mapped
QTLs with Haley-Knott regression (5000 permutations and
2000 bootstraps). The analysis yielded 2 QTL intervals in
chromosomes 14 (LRS=18.8, p = 0.05) and 13
(LRS=11.34, p = 0.63). Two recent genome-wide
association studies (GWAS) of human bronchiolitis asso-
ciated SNPs in VSTM4 and DRGX and JARID2, all three of
which map to homologous regions in our RSV intervals.
Thus, quantifying the viral NS1 transcript level in the
neonatal mouse model captures host variants in conserved
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sequences with associations between host SNPs and
bronchiolitis in human infants.
Conclusions: With the neonatal BXD isogenic panel, we
effectively boost heritability by reducing the environmental
variance in an age-appropriate model. This resource is
poised to expedite the discovery and translatability of causal
links between host genetics and RSV-ALRI susceptibility.
A. Destouni: None.
P19.094.B
Periconceptional environment predicts leukocyte telo-
mere length in a cross-sectional study of 7-9 year old
rural Gambian children
K. Maasen1,2,3, P. T. James4, A. M. Prentice3, S. E.
Moore5,3, C. H. Fall6, G. R. Chandak7, M. Betts3,8, M. J.
Silver3, J. L. Buxton9,10
1Wageningen University, Wageningen, Netherlands,
2Maastricht University Medical Centre, Maastricht, Nether-
lands, 3Medical Research Council Unit The Gambia at the
London School of Hygiene and Tropical Medicine, Fajara,
Gambia, 4London School of Hygiene and Tropical
Medicine, London, United Kingdom, 5King’s College
London, London, United Kingdom, 6University of South-
ampton, Southampton, United Kingdom, 7CSIR-Centre for
Cellular and Molecular Biology, Hyderabad, India, 8Uni-
versity College London, London, United Kingdom, 9King-
ston University, London, United Kingdom, 10UCL Great
Ormond Street Institute of Child Health, London, United
Kingdom
Introduction: Early life exposures are important predictors
of adult disease risk. Although the underlying mechanisms
are largely unknown, maintenance of telomeres may be
involved. We investigated the relationship between seasonal
differences in parental environmental exposures at the time
of conception in rural Gambia and leukocyte telomere
length (LTL) in their offspring.
Materials and Methods: LTL was measured in two
cohorts of children aged 2 yrs (N = 487) and 7-9 yrs (N =
218), using multiplex quantitative PCR. The association
between date of conception and LTL was examined using
Fourier regression models with age, sex, leukocyte cell
composition, maternal periconceptional BMI, child birth
weight, maternal and infant supplementation, and maternal
folate considered as potential confounders.
Results: In the older children, we found evidence for an
effect of season in a crude, seasonality only model
[likelihood ratio test (LRT) χ²2=8.27, p = 0.016]. LTL
was greatest in children conceived in September (in the
rainy season), and smallest in those conceived in March (in
the dry season), with an effect size (LTL peak - nadir) of
0.60 z-scores. This association remained after adjustment
for multiple potential confounders. No effect of season was
evident in the younger children (LRT χ²2=4.24, p = 0.12).
Conclusions: Our results suggest that conception during
the dry season in The Gambia could adversely influence
telomere maintenance in postnatal tissues, resulting in a
detectable effect on mean LTL by mid-childhood but not
before 2 years of age.
Funders: Bill and Melinda Gates Foundation
(0PP1135346), MRC (MR/N006208/1 & MC-A760-
5QX00), DFID & the DBT, India (BT/IN/DBT-MRC/,
DFID/24/GRC/2015-16).
K. Maasen: None. P.T. James: None. A.M. Prentice:
None. S.E. Moore: None. C.H. Fall: None. G.R.
Chandak: None. M. Betts: None. M.J. Silver: None. J.
L. Buxton: None.
P19.095.C
Associations between telomere length shortening and
cardio-metabolic components: a longitudinal study
M. Lin1, P. Weng1, T. Wu2, Y. Wu1, L. Chen3, M. Yen3, Y.
Lee4, C. Tse5, T. Liu6, H. Chen7
1Institute of Public Health, National Yang-Ming University,
Taipei, Taiwan, 2Department of Public Health, Chung-Shan
Medical University, Taichung, Taiwan, 3School of Oral
Hygiene, College of Oral Medicine, Taipei Medical
University, Taipei, Taiwan, 4Department of Internal
Medicine, National Taiwan University Hospital, Taipei,
Taiwan, 5Bureau of Health and Welfare, Lienchiang County
Government, Matsu, Taiwan, 6Lienchiang County Govern-
ment, Matsu, Taiwan, 7Institute of Epidemiology and
Preventative Medicine, College of Public Health, National
Taiwan University, Taipei, Taiwan
Introduction: Telomeres are the tips of chromosomes and
play a critical role in maintaining chromosomal stability by
protecting chromosome ends from damage and degradation.
Telomere length (TL) is shortened progressively with age.
Many studies revealed that age, sex, ethnicity, smoking,
obesity, lack of exercise could result in shorter telomere
length. Several studies also reported significant associations
between shorter TL and deregulated metabolic syndrome
components. The study was aimed to evaluate if the telo-
mere length and shorting are associated with cardio-
metabolic components.
Methods: A total of 2698 adults were recruited from the
Matsu community-based integrated health screening pro-
ject. Relative telomere length was determined at baseline
and after ten years. Multiple regression analyses and GEE
adjusting for other covariates were performed to examine
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the relationship between relative telomere length and
cardio-metabolic components.
Results: We found the metabolic syndrome group had
significantly longer TL attrition (p = 0.028), and higher TL
attrition rate over 10 years (p = 0.014). We further found
statistically significant associations between relative telo-
mere length at baseline and elevation of body mass index
(p = 0.017), diastolic blood pressure (p = 0.043) at baseline
as well as with the systolic blood pressure (p = 0.043) at the
year 2015 after adjusting for age and gender. We also
observed that the longer TL attrition was significantly
associated with increased levels of fasting glucose
(p = 0.006), HbA1C (p = 0.014), triglycerides
(p = 0.015), and total cholesterol (p = 0.034) at the
year 2015.
Conclusions: Our results confirmed the previous knowl-
edge of the associations between telomere length and
cardio-metabolic components.
Grant No: MOST 106-2314-B-010-020-MY3
M. Lin: None. P. Weng: None. T. Wu: None. Y. Wu:
None. L. Chen: None. M. Yen: None. Y. Lee: None. C.
Tse: None. T. Liu: None. H. Chen: None.
P19.096.A
Significant associations between telomere length related
genetic loci and cardio-metabolic components
T. Wu1, P. Weng2, S. Kao2, Y. Wu2, L. Chen3, M. Yen3, Y.
Lee4, C. Tse5, T. Liu6, H. Chen7, M. Lin2
1Department of Public Health, Chung-Shan Medical
University, Taichung, Taiwan, 2Institute of Public Health,
National Yang-Ming University, Taipei, Taiwan, 3School of
Oral Hygiene, College of Oral Medicine, Taipei Medical
University, Taipei, Taiwan, 4Department of Internal
Medicine, National Taiwan University Hospital, Taipei,
Taiwan, 5Bureau of Health and Welfare, Lienchiang County
Government, Matsu, Taiwan, 6Lienchiang County Govern-
ment, Matsu, Taiwan, 7Institute of Epidemiology and
Preventative Medicine, College of Public Health, National
Taiwan University, Taipei, Taiwan
Introduction:Telomeres are at the end of chromosomes
with the repeat sequences of TTAGGG. Telomere length
(TL) would be shortened during DNA replication. Many
studies revealed that age, sex, ethnicity, smoking, obesity,
and lack of exercise were the factors linked with shorter TL
length. Several studies reported significant associations
between shorter TL and deregulated metabolic syndrome
(MetS) components. Moreover, a few genetic loci asso-
ciated with telomere length have been identified. The study
was aimed to evaluate if the TL related genetic loci are
associated with cardio-metabolic components.
Methods: A total of 2543 adults were recruited from the
Matsu community-based integrated health screening pro-
ject. A total of 43 SNPs on 17 TL related genes were
genotyped. Multiple regression analyses adjusting for other
confounding covariates were performed to examine the
relationship between TL related genetic loci and cardio-
metabolic components.
Results: We examined 43 SNPs in 17 genes and found
these 43 SNPs had no significant associations with MetS,
but some SNPs were related to MetS components. The
results of multiple logistic regression showed that
rs78975791, rs622961, rs11191853, rs2287641, and
rs41269537 were associated with lower HDL; rs820152,
rs622961 and rs1684149 were associated with increased
levels of blood sugar; rs4125537 was associated with
elevated TG; rs13265931 and rs6062302 were associated
with wider waist circumference; rs13265931, rs4841210,
and rs75877904 were associated with higher blood pressure
(all with P-value <0.05).
Conclusions: Our study identified several TL related
gene variations were associated with cardio-metabolic
components.
Grant No: MOST 106-2314-B-010-020-MY3
T. Wu: None. P. Weng: None. S. Kao: None. Y. Wu:
None. L. Chen: None. M. Yen: None. Y. Lee: None. C.
Tse: None. T. Liu: None. H. Chen: None. M. Lin: None.
P19.097.B
Leukocyte telomere length is related to brain parench-
ymal fraction and attention/speed in the elderly: Results
of the Austrian Stroke Prevention Study
P. Gampawar, R. Schmidt, H. Schmidt
Medical University of Graz, Graz, Austria
The role of leukocyte telomere length (LTL) in brain aging
is controversial. Here we explored the association between
LTL and 1) global MRI correlates of brain aging including
brain parenchymal fraction (BPF), white matter hyper-
intensities (WMH) as well as 2) global (g-factor) cognition
and the cognitive domains of attention/speed, con-
ceptualization, memory, and visuopractical skills in 909
participants of the Austrian Stroke Prevention Study. There
were 388(42.7%) men, and the mean age was 65.9 ± 8.0
years. Longer LTL was significantly associated with larger
BPF (β = 0.43, p < 0.001) and larger WMH load (β = 0.03,
p = 0.04) after adjusting for age, sex, vascular risk factors,
and ApoE4 carrier status. The effect on BPF was more
significant in the subgroups of women (β = 0.51,
p = 0.001), age > 65 years (β = 0.58, p = 0.002), BMI ≥ 25
(β = 0.40, p = 0.004), education ≤ 10 years (β = 0.42,
p = 0.002), hypertensives (β = 0.51, p = 0.001),
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cardiovascular disease (CVD) (β = 0.58, p = 0.005), non-
diabetics (β = 0.42, p < 0.001) and Apoe4 non-carriers
(β = 0.49, p < 0.001). The effect on WMH was significant
within hypertensives (β = 0.04, p = 0.02), non-diabetics
(β = 0.03, p = 0.01), and in those with education≤10 years
(β = 0.03, p = 0.04), and ApoE4 allele (β = 0.03,
p = 0.02). There was a significant association between LTL
and the cognitive domain of attention/speed, which was
confined to the subgroups of BMI≥25 (β = 0.04, p = 0.05)
and education≤10 years (β = 0.04, p = 0.05). The effect of
LTL on attention/speed was partly mediated in both sub-
groups by BPF (β = 0.02, 95% CI= 0.01:0.03) when tested
by bootstrapping. Our results support a strong protective
role of longer LTL on global brain volume, which in turn
may contribute to better cognitive functions, especially in
the attention/speed domain in the elderly.
P. Gampawar: None. R. Schmidt: None. H.
Schmidt: None.
P19.098.C
Thyroid cancer, obesity and blood glucose: a Mendelian
Randomization study
S. Lee1, E. Lee2, Y. Hwangbo2, Y. Park3, J. Kim4, J. Sung5
1Institute of Health & Environment, Seoul National
University, Seoul, Korea, Republic of, 2Center for Thyroid
Cancer, National Cancer Center, Goyang, Korea, Republic
of, 3Department of Internal Medicine, Seoul National
University College of Medicine, Seoul, Korea, Republic
of, 4Department of Cancer Biomedical Science, Graduate
School of Cancer Science and Policy, National Cancer
Center, Goyang, Korea, Republic of, 5Department of Public
Health, Graduate School of Public Health, Seoul National
University, Seoul, Korea, Republic of
Background: Glucometabolic traits such as obesity,
hyperglycemia and height have been associated with an
increased risk of thyroid cancer (TC). It is, however, largely
unknown whether the risk factors are causal and bear
potential significance for intervention. We attempted to
investigate the causal relationship between thyroid cancer
risk and selected epidemiologic risk factors applying
Mendelian Randomization (MR) approaches
Methods: A total of 17,935 healthy individuals from the
Korean Genome Epidemiology Study and 1,214 thyroid
cancer cases from 2 hospitals were selected with epidemio-
logic, clinical and genome information. Genetic risk scores
of BMI, fasting plasma glucose (FPG) and height were
constructed and used as instrumental variables (IV) to
analyze the causal association in the two-sample IV
analyses. Additionally inverse-weighted variance, weighted
median methods were performed to estimate the causal
effect size of TC risk. Further, MR-Egger regression was
used to assess potential pleiotropic effects as well.
Results: IV analyses demonstrated that BMI, FPG, and
height GRS and risk of overall TC (BMI: OR = 1.05,
p = 0.363; FPG: OR = 1.03, p = 0.396; height: OR = 1.01,
p = 0.379) as well as subgroups of TC did not show
significant associations. Pleiotropic effects were not found,
and statistical power ranged from 0.67 to 0.79.
Conclusion: Our findings suggest that obesity and FPG
may not be the potential intervention target to prevent TC
risk, despite the findings from observational studies.
S. Lee: None. E. Lee: None. Y. Hwangbo: None. Y.
Park: None. J. Kim: None. J. Sung: None.
P19.100.B
Differential genetic and environmental effects on
immune parameters and functions in type 1 diabetes
and health
X. Chu1,2,3, A. W. M. Janssen4, H. Koenen5, L. Chang1, X.
He5, I. Joosten5, C. Xu2,3,4, C. Wijmenga1, M. Netea4,6, C. J.
Tack7, Y. Li1,2,3,4
1Department of Genetics, University of Groningen, Gronin-
gen, Netherlands, 2Centre for Individualised Infection
Medicine, CiiM, a joint venture between the Hannover
Medical School and the Helmholtz Centre for Infection
Research, Hannover, Germany, 3TWINCORE, Centre for
Experimental and Clinical Infection Research, a joint
venture between the Hannover Medical School and the
Helmholtz Centre for Infection Research, Hannover,
Germany, 4Department of Internal Medicine and Radboud
Institute for Center for Infectious Diseases, Radboud
University Medical Center, Nijmegen, Netherlands,
5Department of Laboratory Medicine, Laboratory Medical
Immunology, Radboud University Medical Center, Nijme-
gen, Netherlands, 6Department for Genomics & Immunor-
egulation, Life and Medical Sciences Institute (LIMES),
University of Bonn, Bonn, Germany, 7Department of
Internal Medicine and Radboud Institute for Molecular
Life Sciences, Radboud University Medical Center, Nijme-
gen, Netherlands
Background: Inter-individual variability in immune para-
meters and functions determines the susceptibility to
immune-mediated diseases. Recent studies from the Human
Functional Genomics Project have successfully character-
ized the impact of genetic and environmental factors on
immune response in health. However, how this variability
relates to the risk of developing an autoimmune disease,
such as type 1 diabetes (T1D), is largely unknown.
Methods: Blood samples were collected from 243 T1D
and 534 healthy volunteers of Western European descent.
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>200 immune cell populations and >100 cytokine-stimulus
pairs were measured in both cohorts. We used a systems
approach to comprehensively assess the impact of environ-
mental and genetic factors on immune phenotypes. The
results were compared between T1D patients and healthy
controls.
Results: Age and seasons show impact on both immune
cell abundance and cytokine production upon stimulation,
e.g. resting T regs show higher levels in summer. The T1D
associated genetic factors show stronger impact on T cell
than B cell subpopulations in peripheral blood
(P = 4.17 × 10−5, K.S. test), highlighting the importance
of T cell immunity in T1D. Rs35092096 of the CCR region
associated with CCR5+ CD4+ regulatory T cells
(P = 1.64 × 10−12) showed co-localization (H3 = 0.95)
with T1D, suggesting a shared regulation of this locus.
Genome-wide quantitative trait loci (QTL) mapping
revealed 16 significant loci in T1D. 75% of the identified
QTLs are specific in T1D, implying a distinct regulatory
mechanism of immune parameters and functions between
auto-immune disease and health.
Conclusions: Our approach provides novel insights into
immune trait variability in T1D.
X. Chu: None. A.W.M. Janssen: None. H. Koenen:
None. L. Chang: None. X. He: None. I. Joosten: None. C.
Xu: None. C. Wijmenga: None. M. Netea: None. C.J.
Tack: None. Y. Li: None.
P19.101.C
Evaluation of the causal effect of desaturase activity on
the risk of type 2 diabetes and coronary artery disease
S. Jäger1,2, R. Cuadrat1,2, P. Hoffmann3,4, C.
Wittenbecher1,2,5, M. B. Schulze1,2,6
1Department of Molecular Epidemiology, German Institute
of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal,
Germany, 2German Center for Diabetes Research (DZD),
Neuherberg, Germany, 3Human Genomics Research
Group, Department of Biomedicine, University of Basel,
Basel, Switzerland, 4Institute of Human Genetics, Univer-
sity of Bonn, School of Medicine & University Hospital
Bonn, Bonn, Germany, 5Department of Nutrition, Harvard
T.H. Chan School of Public Health, Boston, MA, United
States, 6Institute of Nutritional Science, University of
Potsdam, Potsdam, Germany
Background: Delta 5-desaturase (D5D) and delta 6-
desaturase (D6D) (estimated from fatty acids measured in
blood fractions) were associated with cardiometabolic risk,
however, causality needs to be clarified.
Material and Methods:We investigated causal effects of
D5D and D6D activities on the risk of type 2 diabetes
(T2DM) and coronary artery disease (CAD) in two sample
Mendelian randomization (MR) studies. Selection of
genetic instruments for D5D (20:4n-6/20:3n-6 ratio) and
D6D activity (18:3n-6/18:2n-6 ratio) relied on genome-wide
association studies (GWAS) and gene-wide screens
(restricted to the FADS-gene region that encodes for both
desaturases) in a representative sub-cohort (n = 1853) of the
European Prospective Investigation into Cancer and Nutri-
tion (EPIC)-Potsdam Study. Outcome associations were
drawn from DIAGRAM and CARDIoGRAM GWAS. We
applied univariable MRs (single desaturases) and multi-
variable MR (combining both) and addressed confounding
by linkage disequilibrium (LD) as all instruments from
FADS1 (D5D) are in LD with FADS2 (D6D) variants.
Results: Univariable MRs revealed risk-increasing total
effects of both, D6D (odds ratio (OR) [95% confidence
interval (CI)] = 1.08 [1.06-1.09]) and D5D (OR = 1.03
[1.01-1.04]) on T2DM; and risk-increasing total effect of
D6D (OR = 1.06 [1.02-1.11]) on CAD. The multivariable
MR could not unambiguously allocate a direct causal effect
to either of the individual desaturases.
Conclusions: Our results suggest that D6D is causally
linked to cardiometabolic risk, which is likely due to
downstream production of fatty acids and products resulting
from high D6D activity. For D5D, higher T2DM risk
reflects the genetic linkage with D6D rather than an
independent effect.
S. Jäger: None. R. Cuadrat: None. P. Hoffmann: None.
C. Wittenbecher: None. M.B. Schulze: None.
P19.102.A
Association of tyrosine kinase 2 polymorphisms with
baseline viral load and advanced fibrosis in chronic
hepatitis C patients
A. M. V. Silva1, L. Alvarado-Arnez2, O. C. L. Bezerra1, T.
Azamor1, M. R. Alves1, T. L. Calvo1, C. Bayma1, J. Silva1,
A. F. Souza1, A. M. Andrade1, J. R. Xavier1, M. S. Maia1, P.
D. Picon3, A. D. Ano Bom1, D. S. Matos1, M. O. Moraes1
1Fundação Oswaldo Cruz (FIOCRUZ), RIO DE JANEIRO,
Brazil, 2Universidad Privada Franz Tamayo – UNIFRANZ,
Bolivia, Cochabamba, Bolivia, Plurinational State of,
3Hospital de Clínicas de Porto Alegre, Porto alegre,
Brazil
Introduction: Single nucleotide polymorphisms (SNPs) in
interferon lambda 3 and 4 (IFNL3/4) are well-established
prognostic markers for Pegylated-Interferon-alpha/ribavirin
(Peg-IFN-α/RBV) treatment in Chronic Hepatitis C (CHC).
In other viral infections, an antagonistic effect between IFN-
λ and IFN-α levels was described. We aimed to evaluate
both a functional and genetic association of SNPs in the
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interferon-alpha 1 receptor (IFNAR1) and tyrosine kinase 2
(TYK2) over clinical parameters in CHC patients.
Materials and Methods: Three IFNAR1 and two TYK2
SNPs were genotyped in 525 CHC patients treated with
Peg-IFN-α/RBV, using TaqMan assays for allelic discrimi-
nation. Gene expression was evaluated for IFNL3, IFNA1,
and IFNAR1 genes in 24 patients stratified by genotypes,
considering different time points (0-1-3-12 weeks of
treatment), using Biomark-HD System. Mann-Whitney,
Kruskal-Wallis and Dunn´s post-test was used for
comparisons.
Results: Heterozygous CHC patients at TYK2
rs12720356 presented an association with a high baseline
viral load (OR=2.0/CI 1.1-3.7/p = 0.03). Also, hetero-
zygous at TYK2 rs3456443 (OR=2.6/CI 1.1-5.9/p = 0.02)
were associated with advanced fibrosis. IFNAR1 SNPs were
not associated with any of the outcomes tested. No
differences were observed when comparing IFNA1,
IFNAR1 and IFNL3 levels between the different treatment
time points. Stratifying according to the different SNP
genotypes, only higher IFNL3 levels were significantly
different in IFNAR1 rs2843710-G carriers. Due to low
sample size gene expression levels were not stratified for
TYK2 genotypes.
Conclusions: High baseline viral load and advanced
fibrosis in CHC patients were associated with TYK2
polymorphisms, which is consistent with the role of this
SNP in TYK2 function controlling viral replication.
A.M.V. Silva: None. L. Alvarado-Arnez: None. O.C.L.
Bezerra: None. T. Azamor: None. M.R. Alves: None. T.
L. Calvo: None. C. Bayma: None. J. Silva: None. A.F.
Souza: None. A.M. Andrade: None. J.R. Xavier: None.
M.S. Maia: None. P.D. Picon: None. A.D. Ano Bom:
None. D.S. Matos: None. M.O. Moraes: None.
P19.103.B
Comprehensive analysis of circulating viral DNA in
maternal plasma at population-scale
V. Eldem1, E. Akdeniz2, B. Nevruz2, I. M. Tekin2, H. Özgür2,
G. Serim2, D. Aydın2, M. Aslan2, M. Durdu2, Ö. Alan2, G.
Özdoğan2, V. Oflas2
1Department of Biology, Faculty of Science, Istanbul
University, Istanbul, Turkey, 2Genoks Genetic Disease
Diagnostic Center, Ankara, Turkey
Introduction: In recent years, low-coverage whole-genome
sequencing has become the method of choice for non-
invasive prenatal testing (NIPT) to evaluate the most com-
mon chromosome aberrations. Although nearly all WGS-
generated NIPT data analysis is limited to detect common
trisomies, the possible re-use of NIPT data increasingly
becomes popular and expanding. Here, we systematically
analyzed NIPT data at the population-scale to characterize
the virome in maternal plasma.
Materials and Methods: A total of 13,802 NIPT data
were generated from Turkish pregnant women during the
period of 2018-2019 at Genoks Diagnostic Center.
Sequencing was performed on BGI SEQ-500, producing
35-bp single-end reads. Following quality filtering, clean
reads that did not map to human reference genome were
blasted against the NCBI viral reference sequence database
(release 97). Only matching reads with e-value < 1e-10, a
percent identity ≥ 97 and alignment length ≥ 32 bp were
kept for further analysis. After removing alignments to
bacteriophages, remaining alignments were used for virus
abundance estimation.
Results: About 110 billion clean reads from 13,802 sam-
ples were used for profiling plasma virome, 3947 samples
(28.6%) have at least one viral hit and 607 samples (4.4%)
have at least two significant alignment hits. Human
herpesvirus 6A and 6B, hepatitis B virus and human
endogenous retrovirus K were enriched in terms of
prevalence and abundance. The maternal blood in the
Turkish population was appeared to have a different viral
distribution compared to pregnant Europeans and Chinese.
Conclusions: WGS-generated NIPT data can be a
powerful approach for detecting circulating viral DNAs.
V. Eldem: None. E. Akdeniz: None. B. Nevruz: None.
I.M. Tekin: None. H. Özgür: None. G. Serim: None. D.
Aydın: None. M. Aslan: None. M. Durdu: None. Ö.
Alan: None. G. Özdoğan: None. V. Oflas: None.
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Whole genome methylation analysis in families with
ALS-linked SOD1 mutations
F. Coppedè1, D. Licastro2, S. Dal Monego2, L. Mosca3, U.
Cavallari3, A. Marocchi3, F. Gerardi4, C. Lunetta4, A.
Stoccoro1, L. Migliore1
1Dept of Translational Research and of New Surgical and
Medical Technologies, University of Pisa, Pisa, Italy,
2AREA Science Park, Basovizza, Trieste, Italy, 3Medical
Genetics Unit, Department of Laboratory Medicine, ASST
Grande Ospedale Metropolitano Niguarda, Milan, Italy,
4NEuromuscular Omnicentre (NEMO), Fondazione Serena
Onlus, Milan, Italy
Introduction: Our previous investigation of the global
levels of 5-methylcytosine (5-mC) in blood DNA samples
from families with SOD1 mutations revealed increased 5-
mC levels in patients with amyotrophic lateral sclerosis
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(ALS) with respect to their unaffected relatives, including
presymptomatic/paucisymptomatic carriers and non-carrier
family members. In the present study we performed a
genome-wide methylation analysis in order to characterize
the methylation differences among groups.
Materials and Methods: A total of 18 blood DNA
samples from 3 different ALS families were collected for
the study, including 4 ALS patients, 10 presymptomatic/
paucisymptomatic carriers, and 4 non-carrier relatives. All
the samples were processed with reduced representation
bisulfite sequencing (RRBS) and analyzed using RnBeads
pipeline.
Results: A preliminary multidimensional scaling analysis
of the dataset suggests that, despite coming from different
families, the 4 ALS patients share a similar methylation
pattern across more than 23.000 investigated CpG islands,
that can be distinguished from the patterns observed in non-
carriers of ALS-linked SOD1 mutations. By contrast,
presymptomatic/paucisymptomatic carriers show a more
heterogeneous CpG island methylation profile. We are now
cleaning the dataset from confounding factors in order to
reveal the gene promoters and the pathways that are
differentially methylated among groups.
Conclusions: The present investigation takes advantage
of well characterized families enriched in presymptomatic/
paucisymptomatic carriers of ALS-linked SOD1 mutations
and could help revealing preclinical methylation signatures
of the disease.
F. Coppedè: None. D. Licastro: None. S. Dal Monego:
None. L. Mosca: None. U. Cavallari: None. A. Marocchi:
None. F. Gerardi: None. C. Lunetta: None. A. Stoccoro:
None. L. Migliore: None.
P20.07.A
Association between asbestos exposure and epigenetic
age acceleration
G. Cugliari1,2, A. Allione1,2, S. Guarrera1,2, C. Viberti1,2, F.
Grosso3, E. Casalone1,2, M. Betti3, D. Ferrante4,5, A.
Aspesi6, C. Casadio7, R. Libener8, E. Piccolini9, D.
Mirabelli10,11,12, C. Magnani4,5,12, I. Dianzani6,12, G.
Matullo1,2,12,13
1Department of Medical Sciences, University of Turin,
Turin, Italy, 2Italian Institute for Genomic Medicine, IIGM,
Turin, Italy, 3Division of Medical Oncology, SS. Antonio e
Biagio General Hospital, Alessandria, Italy, 4Medical
Statistics and Cancer Epidemiology Unit, Department of
Translational Medicine, University of Piemonte Orientale,
Novara, Italy, 5Cancer Epidemiology Unit, CPO-Piemonte,
Novara, Italy, 6Department of Health Sciences, University
of Piemonte Orientale, Novara, Italy, 7Thoracic Surgery
Unit, AOU Maggiore Della Carità, Novara, Italy, 8Pathol-
ogy Unit, SS. Antonio e Biagio General Hospital,
Alessandria, Italy, 9Pneumology Unit, Santo Spirito Hospi-
tal, Casale Monferrato, Italy, 10Cancer Epidemiology Unit,
Department of Medical Sciences, University of Turin, Turin,
Italy, 11Cancer Epidemiology Unit, CPO Piemonte, Turin,
Italy, 12Interdepartmental Center for Studies on Asbestos
and Other Toxic Particulates "G. Scansetti", University of
Turin, Turin, Italy, 13Medical Genetics Unit, AOU Città
della Salute e della Scienza, Turin, Italy
Introduction: Although the mechanisms of carcinogenesis
in Malignant Pleural Mesothelioma (MPM) are incomple-
tely understood, chronic inflammation is critically involved
in the pathogenesis as a possible result of asbestos expo-
sure. Age is one of the strongest predictors of chronic dis-
ease and mortality, but biological responses to aging differ
among people and can have an important role in the con-
sideration of the relationship with disease-related covari-
ates. Aging eludes precise definition at the systemic level
and denotes a multitude of processes at the cellular level.
Material and Methods: We investigated a cohort of
300 subjects exposed between 2000 and 2010. Using
methylation-based "clock" (Horvath), namely extrinsic
epigenetic age acceleration (EEAA), we defined biological
age acceleration for each of three hundred asbestos-exposed
subjects. EEAA is defined as the weighted average of
DNAm age and imputed proportions of naïve CD8+
T cells, memory CD8+ T cells and plasmablasts. Asbestos
exposure-related variation in age acceleration measures and
95% confidence intervals (CIs) were estimated using
multiple regression models.
Results: EEAA showed that biological age acceleration
was statistically significantly associated with increased
asbestos exposure (Horvath’s clock: Estimate= 0.704,
95% CI: 0.067, 1.475, P = 0.043).
Conclusions: DNAm profiles have been used as indices
of biological age and the roles of epigenetic age acceleration
measures were investigated. Our results suggest the
potential application of DNAm profiles, considering age
acceleration measures, in blood to develop non-invasive
tests for asbestos-exposed subjects. In detail, epigenetic age
acceleration may play a role as a proxy of internal dose of
asbestos exposure.
G. Cugliari: None. A. Allione: None. S. Guarrera:
None. C. Viberti: None. F. Grosso: None. E. Casalone:
None. M. Betti: None. D. Ferrante: None. A. Aspesi:
None. C. Casadio: None. R. Libener: None. E. Piccolini:
None. D. Mirabelli: None. C. Magnani: None. I.
Dianzani: None. G. Matullo: None.
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P20.08.B
Autism spectrum disorder-associated CHD8 Suppres-
sion impacts on histone H3 lysine 36 trimethylation and
alters RNA alternative splicing.
E. Kerschbamer1, T. Tripathi1, S. Erdin2,3, E. Salviato4, F.
Di Leva1, E. Sebestyen4, M. Arnoldi1, M. Benelli5, J.
Gusella2,6,3, S. Piazza1, F. Demichelis1, F. Ferrari4,7, M.
Talkowski2,6,3, M. Biagioli1
1University of Trento, Trento, Italy, 2Massachusetts Gen-
eral Hospital, Boston, MA, United States, 3Program in
Medical and Population Genetics, Broad Institute, Boston,
MA, United States, 4IFOM, the FIRC Institute of Molecular
Oncology, Milano, Italy, 5Bioinformatics Unit, Hospital of
Prato, Istituto Toscano Tumori, Prato, Italy, 6Department
of Neurology, Harvard Medical School, Boston, MA,
United States, 7CNR Institute of Molecular Genetics "Luigi
Luca Cavalli-Sforza”, Pavia, Italy
Disruptive mutations in the chromodomain helicase DNA
binding protein 8 (CHD8) have been recurrently and inde-
pendently associated to Autism Spectrum Disorders (ASD).
In normal cellular physiology, CHD8 co-purifies with
MLL1 and MOF transcriptional activation complex, with
elongating RNAPII and directly binds to DNA promoters
and enhancers regions, thus a regulatory role in transcrip-
tional initiation and elongation could be postulated. Here we
investigated how chromatin landscape reacts to CHD8
suppression by analyzing a panel of histone modifications in
induced pluripotent stem cells-derived neural progenitors.
We interrogated transcriptionally active and repressed
regions as well as active and poised enhancers. CHD8
suppression leads to a significant reduction (47.82%) in
histone H3K36me3 at gene bodies, particularly impacting
on transcriptional elongation chromatin states. Highly
expressed, CHD8-bound genes present a stronger and more
significant H3K36me3 reduction compared to CHD8
unbound genomic regions. Genes presenting histone
H3K36me3 reduction are implicated in “macromolecule
catabolic”, “cell cycle” and “mRNA processing” biological
processes and enriched for “essential and constrained
genes”, ‘FMRP targets in brain’, ‘post synaptic genes’,
whose expression peaks early during nervous system. Sig-
nificantly, CHD8-suppression associated histone
H3K36me3 reduction does not functionally impact on
global transcriptional levels, but significantly correlates
with altered alternative splicing pattern of ~ 2000 protein
coding genes implicated in “RNA splicing”, “mitotic cell
cycle phase transition” and “mRNA processing”, especially
affecting alternative first exon and exon skipping events. In
summary, our results point toward broader molecular
consequences of CHD8 suppression, implicating altered
histone deposition/maintenance and RNA processing reg-
ulation as important regulatory processes in ASD.
E. Kerschbamer: None. T. Tripathi: None. S. Erdin:
None. E. Salviato: None. F. Di Leva: None. E. Sebestyen:
None. M. Arnoldi: None. M. Benelli: None. J. Gusella:
None. S. Piazza: None. F. Demichelis: None. F. Ferrari:
None. M. Talkowski: None. M. Biagioli: None.
P20.10.A
Exposure of bisphenol A (BPA) in relation to idiopathic
central precocious puberty (ICPP) in girls and the
epigenetic mechanism
Y. Chen1, J. Y. Chen2, J. Li1, Y. Ding1, G. Y. Chang1, X. Li1,
Q. Li1, Y. R. Wang1, X. Wang1
1Shanghai Children’s Medical Center, Shanghai Jiao Tong
University School of Medicine, Shanghai, China, 2Xin Hua
Hosipital, Shanghai Jiao Tong University School of
Medicine, Shanghai, China
Background: The estrogenic effect of BPA has been
widely demonstrated. The relationship between BPA
exposure and ICPP in girls is still undefined. Changing of
methylation levels of target genes of DNA methyl-
transferases (DNMTs) and HPG axis may be epigenetic
regulation mechanism of BPA exposure induced ICPP in
girls Objectives: To investigate the relationship between
BPA exposure and ICPP in girls and the epigenetic reg-
ulation mechanism.
Methods: 157 6-9 years old girls diagnosed as precocious
puberty were recruited from Shanghai Children’s Medical
Center from July 2017 to August 2018. After detailed
laboratory examinations, 56 girls of them were diagnosed as
ICPP. At the same time, 56 healthy 6-9 years girls were
recruited as control group. All of the participants’ urinary
BPA concentrations were detected. Methylation levels of
CpG islands of target genes from peripheral blood samples
were detected for 56 ICPP girls and 56 healthy girls.
Results: Cases in higher urinary BPA concentration
groups were associated with higher risk of ICPP [specific
gravity (SG) adjusted (OR = 2.09, 95% CI: 1.05-4.17,
p = 0.037); creatinine adjusted (OR = 1.98, 95% CI: 1.01-
3.89, p = 0.046)]. Higher urinary BPA concentration (SG
adjusted) group was associated with higher level of
methylation of CpG islands of DNMT3B (Z=-1.792,
p = 0.037).
Conclusions: BPA exposure may increase the risk of
ICPP in girls. Higher methylation level of CpG islands of
DNMT3B may be associated with higher level of BPA
exposure.
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Wang: None. X. Wang: None.
P20.12.C
The association between cardiometabolic risk factors
and DNA methylation aging across adult lifespan in the
Rhineland study
D. Liu1, N. Aziz1,2, M. M. B. Breteler1,3
1German Center for Neurodegenerative Diseases (DZNE),
Bonn, Germany, 2Department of Neurology, University of
Bonn, Bonn, Germany, 3Institute for Medical Biometry,
Informatics and Epidemiology (IMBIE), Faculty of Medi-
cine, University of Bonn, Bonn, Germany
Introduction: DNA methylation-based biomarkers of aging
(DNAm aging) are associated with cardiometabolic dis-
eases. Although this may be due to their relation with car-
diometabolic risk factors, limited data are available on the
association between cardiometabolic risk factors and
DNAm aging in the general population.
Methods: We performed a cross-sectional analysis of
data from the Rhineland Study, a population-based
prospective cohort study in Bonn, Germany. Four types of
DNAm aging acceleration estimates (including AgeAccel.
Horvath, AgeAccel.Hannum, AgeAccelPheno, and AgeAc-
celGrim), defined as within individual differences between
the epigenetic and chronological age, were calculated. The
effects of 20 cardiometabolic risk factors on DNAm aging
acceleration were assessed using multiple linear regressions.
Results: Among 3327 participants (mean age 55.0 years
(range 30 – 95), 56.0% women), 14 risk factors were
significantly associated with AgeAccelPheno [change in
years (95% CI) per standard deviation increase]: HDL -0.47
(-0.81, -0.12), triglycerides 0.28 (0.04, 0.51), total choles-
terol 0.40 (0.09, 0.70), glucose 0.44 (0.21, 0.67), insulin
0.68 (0.45, 0.91), insulin resistance 0.62 (0.39, 0.85),
diastolic blood pressure 0.35 (0.11, 0.58), systolic blood
pressure 0.29 (0.06, 0.53), C-reactive protein 0.92 (0.70,
1.14), cystatin C 0.77 (0.53, 1.01), glomerular filtration rate
-0.67 (-0.91, -0.44), body mass index 0.99 (0.68, 1.31),
waist circumference 1.03 (0.78, 1.28) and percentage body
fat 0.90 (0.64, 1.15). Comparable results were obtained
when using AgeAccelGrim, AgeAccel.Horvath or AgeAc-
cel.Hannum as outcomes (data not shown).
Conclusions: Multiple cardiometabolic risk factors were
consistently associated with various DNAm aging accel-
eration, which may underlie the association between DNAm
aging and cardiometabolic morbidity and mortality.
D. Liu: None. N. Aziz: None. M.M.B. Breteler: None.
P20.13.A
Large scale chromatin accessibility fine mapping of
cardiovascular disease associated loci in the human liver
C. D. Brown, B. Wenz, S. Ramdas, M. Caliskan, D. Xin, K.
Olthoff, A. Shaked
University of Pennsylvania, Philadelphia, PA, United
States
Genome-wide association studies (GWAS) have identified
thousands of loci associated with human traits. However,
the causal variant, gene, cell type, and mechanism under-
lying these associations remain unclear. Most GWAS var-
iants are in linkage disequilibrium (LD) with many other
non-coding variants, complicating fine-mapping and
mechanistic characterization. Cell-type specific gene reg-
ulation plays a causal role at many complex trait-associated
loci. Changes in chromatin accessibility are key mechan-
isms leading to gene expression differences. To understand
the mechanisms that lead to cardiovascular disease (CVD),
the leading cause of mortality worldwide, we quantified
chromatin accessibility in more than 200 human liver tissue
samples. We identify more than 500,000 open chromatin
regions, many of which exhibit tissue-specific activity, and
identify transcription factor binding sites at nucleotide
resolution. Integration with epigenomic profiles identified
specific cis-regulatory elements such as promoters and
enhancers. We identifiy thousands of cis-regulatory ele-
ments whose chromatin accessibility is associated with local
genetic variants, called chromatin accessibility quantitative
trait loci (caQTLs). At dozens of CVD GWAS loci, chro-
matin interactions and colocalization of molecular QTL and
GWAS signals generate specific hypotheses about causal
variants, affected genes, and cell types. With a combination
of experimental approaches in multiple model systems, we
fine-map complex trait-associated loci to single-nucleotide
resolution. These findings highlight the benefits of inte-
grating multiple cellular traits for the identification and
characterization of disease-causing variants and contribute
to basic understanding of genetic and epigenetic regulation
of gene expression.
C.D. Brown: None. B. Wenz: None. S. Ramdas: None.
M. Caliskan: None. D. Xin: None. K. Olthoff: None. A.
Shaked: None.
P20.14.B
DNA methylation profile in Cystic Fibrosis patients with
C677T variant of MTHFR gene
740 J. del Picchia
M. Ghughunishvili, S. Surmava, T. Tkemaladze, M. Gagua,
E. Abzianidze, E. Kvaratskhelia
Tbilisi State Medical University, Tbilisi, Georgia
Introduction: Cystic fibrosis (CF) is the most common lethal
monogenetic disease in the Caucasian population. Genetic
and epigenetic modifiers may play a considerable role in the
phenotypic heterogeneity of CF disease. Methylenetetrahy-
drofolate reductase (MTHFR) is a key regulatory enzyme in
the metabolism of folate. A common variant of the MTHFR
gene, C677T, is associated with variety of disorders, includ-
ing cancer, chronic inflammation and etc. In this study we
investigated the DNA methylation level of the LINE-1 and
Alu interspersed repetitive sequences (IRS) in CF patients
with the C677T variant of the MTHFR gene.
Materials and methods: The study was approved by the
ethics committee of Tbilisi State Medical University. All
patients were genotyped for the CFTR gene. Genomic DNA
was isolated from peripheral blood mononuclear cells
(PBMCs) of CF patients using QIAamp DNA Mini Kit
(Qiagen, US). For Bisulfite treatment of DNA we used
EpiTect Bisulfite Conversion Kit (Qiagen, US). The
MTHFR C677T polymorphism was detected by PCR-
RELP method. Methylation levels of LINE-1 and Alu were
examined by the combined bisulfite restriction analysis-
interspersed repetitive sequences (COBRA-IRS).
Results: Significant differences were observed in methy-
lation levels of both LINE-1 and Alu sequences between CF
patients with CC and TT genotypes. In patients with TT
genotypes, frequency of uC uC (unmethylated Cytosine)
Alleles was lower than in patients with CC genotypes.
Conclusions: Our results indicated that identification of
CF patients with the MTHFR C677T variant and study of
DNA methylation levels may be useful for personalized
treatment approaches.
M. Ghughunishvili: None. S. Surmava: None. T.
Tkemaladze: None. M. Gagua: None. E. Abzianidze:
None. E. Kvaratskhelia: None.
P20.15.C
Identification of CFTR cis-regulatory variants
M. COLLOBERT1, K. Rouault2,1, C. L’Hostis3,1, M.
Audrézet2,1, C. Férec2,1, S. Moisan2,1
1Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France,
2Laboratory of Molecular Genetics and Histocompatibility,
CHRU Brest, Brest, France, 3Gaétan Saleün association,
Brest, France
Although, more than 2075 variants have been discovered in
Cystic Fibrosis Transmembrane conductance Regulator
(CFTR) gene, responsible of Cystic Fibrosis (CF) or one of
CFTR-related disorders, the congenital bilateral absence of
vas deferens (CBAVD), some patients have an incomplete
genotype or present extremes phenotypes. Development of
chromatin conformation study techniques has identified
several long-range regulatory elements of CFTR gene. 17
cis-regulatory regions of CFTR gene have been sequenced
in 63 CBAVD patients. By comparing to European popu-
lation, some variants display a frequency significantly dif-
ferent. In particular, one variant located in cis-regulatory
region of intron 21, is 40 times more frequent in this group.
Activity tests in Caco-2 intestinal cells have shown strong
cooperative effects of the intron 21 enhancer with several
strong enhancers specific to intestinal cells (Intron 1, 11 and
at + 15.6kb of the CFTR gene) on CFTR promoter activity.
Insertion of the interest variant into intron 21 shows a strong
decrease of CFTR promoter activity and the loss of
enhancers cooperation. Chromatin immunoprecipitation
(ChIP) analyses of HNF1a and EP300 transcription factors
have shown their fixations in intron 1, 11 and 21 enhancers
of CFTR gene. This variant could affect the recruitment of
regulatory elements. In conclusion, some significantly var-
iants are identified in CBAVD patients with incomplete
genotype, notably one regulatory variant localised in the
intron 21 enhancer of CFTR gene. This region plays an
important role in regulation of CFTR locus in combining
with 3 others intestinal specific enhancers.
M. Collobert: None. K. Rouault: None. C. L’Hostis:
None. M. Audrézet: None. C. Férec: None. S.
Moisan: None.
P20.17.B
From man to mouse: The discovery and validation of
CYR61 as a regulator of body composition
S. Metz, T. J. Grevengoed, T. O. Kilpeläinen, M. P. Gillum
Novo Nordisk Foundation Center for Basic Metabolic
Research, Copenhagen, Denmark
Obesity is a major contributor to global burden of chronic
disease, in particular type 2 diabetes and cardiovascular
disease. There is currently a great unmet need for devel-
oping effective and safe anti-obesity treatments. Genomic
studies provide novel molecular targets for the treatment of
obesity by discovering genes and pathways involved
in obesity. We have recently identified an association
between the rare variant Ser316Cys in CYR61, implicated
in angiogenesis, and increased body fat percentage
(P = 1.1 x 10−9), in particular trunk fat percentage
(3.8 x 10−11). The Cys316 minor allele was associated with
a 0.4 % higher body fat percentage and 0.5% higher trunk
fat percentage.
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 741
In a mouse model overexpressing human Cyr61 (hCyr61)
in the fat tissue, we show that the hCyr61-overexpression
leads to increased body fat percentage under high fat diet,
due to a switch in body composition, while body weight did
not differ from wild type mice. The endogenous Cyr61
remained unaffected by hCyr61, but is abundantly
expressed in all fat depots, clearly supporting our hypoth-
esis of CYR61 being involved in fat tissue development.
Our results suggest a critical role of CYR61 in the
regulation of body composition and adipocyte development,
which may be mediated by adipogenesis. Ongoing in vitro
and in vivo experiments will provide further insights into
the mechanistic role of Cyr61 in the development of obesity
and metabolic dysfunction. Ultimately, understanding the
fundamental mechanisms of adipogenesis and CYR61 may
enable new therapeutic options for the treatment of obesity
by lowering fat mass and retaining lean mass.
S. Metz: None. T.J. Grevengoed: None. T.O. Kilpeläi-
nen: None. M.P. Gillum: None.
P20.19.A
The penetrance of aortic arch defects in 22q11DS can be
modulated by dietary vitamin A levels and is dependent
on the maternal genotype
E. Amengual-Cladera1, D. Medina Chavez1, E. Lynton
Pons1, P. Sureda Horrach1, V. J. Asensio Landa1, J.
Rocha2, J. Ruiz Rodriguez1, A. Tubau3, M. Juan3, G.
Lania4, M. Bilio4, A. Baldini4, L. Ruiz Guerra5, C. Vives
Bauza5, M. Logotheti6, E. Pilalis6, A. Chatziioannou6, D.
Heine Suñer1
1Hospital Universitari Son Espases/Institut d’Investigació
Sanitaria de Palma (IDISBA), Palma, Spain, 2Grup de
Biologia Computacional i Bioinformàtica (BIOCOM),
Universitat de les Illes Balears, Palma, Spain, 34Servicio
de Ginecología y Obstetricia, Hospital Universitario Son
Llàtzer, Palma, Spain, 4Institute of genetics and Biophysics
Adriano Buzzati-Traverso, Palma, Spain, 5Grupo Neuro-
biología, Fundació Institut d’Investigació Sanitària de les
Illes Balears (IdISBa, Palma, Spain, 6Institute of Biology,
Medicinal Chemistry and Biotechnology, NHRF, 11635
Athens, Greece; e-NIOS Applications PC, Palma, Spain
22q11DS is caused by a recurrent 3Mb deletion present in
90 % of patients. Despite this genomic homogeneity there is
a great phenotypic variability. This indicates the existence
of genetic and/or epigenetic modifiers. Which are exactly
these modifiers and, in particular, how they act is still
poorly defined, but diet could be one of the candidates. Our
hypothesis is that altered vitamin A (vitA) levels in the diet
of pregnant mothers could modify the penetrance of one of
the phenotypic traits (Aortic Arch Defects; AADs). We
used a mouse model (Df1) with a hemizygous deletion
equivalent to the human 22q11.2DS. Our experimental
setup consisted of 3 diet groups (vitA-supplemented,
-control and vitA-deficient) and 2 types of crosses between
Df1 mothers with WT fathers and WT mothers with Df1
fathers. Embryos were collected at gestational day E18.5
and phenotyped. Serum retinol levels were determined in
the blood of the pregnant females. AADs are more frequent
in the Df1 embryos of WT mothers fed a vitA supplemented
diet (47 %) than in those fed with a vitA deficient diet
(29%). On the contrary, when the mother is Df1 we observe
more AADs in Df1 embryos of mothers fed a vitA deficient
diet (45 %) than in those fed a supplemented diet (27%). In
general, independently of the diet, we find a correlation of
higher frequencies of AADs with lower expression of
mitochondrial genes, and lower expression of key heart
development genes. Ongoing studies on genome differential
methylation will also be presented.
E. Amengual-Cladera: None. D. Medina Chavez:
None. E. Lynton Pons: None. P. Sureda Horrach: None.
V.J. Asensio Landa: None. J. Rocha: None. J. Ruiz
Rodriguez: None. A. Tubau: None. M. Juan: None. G.
Lania: None. M. Bilio: None. A. Baldini: None. L. Ruiz
Guerra: None. C. Vives Bauza: None. M. Logotheti:
None. E. Pilalis: None. A. Chatziioannou: None. D. Heine
Suñer: None.
P20.20.B
The Reversion Curve of cg05575921 Methylation in
Response to Smoking Cessation: A New Dynamic
Epigenetic Tool for Monitoring and Incentivizing
Smoking Cessation.
R. A. Philibert, K. Dawes, M. Dogan, W. Philibert,
B. Hundley, J. Mills, J. Long, A. Gerke, J. Wilson, P.
Nagpal, A. Comellas, E. Hoffman
University of Iowa, Iowa City, IA, United States
Current methods for assessing and monitoring the effec-
tiveness of smoking cessation are either unreliable (i.e. CO
monitors) or confounded by use of nicotine replacement
(i.e. cotinine assays). This prevents the use of highly
effective, socially responsive, incentive-based reinforce-
ment smoking cessation therapies. Recent developments in
epigenetics may address this shortcoming. Previously, we
have shown that a methylation sensitive digital PCR
(MSdPCR) assay of DNA methylation at cg05575921 can
precisely quantitate current cigarette consumption using
DNA from saliva or whole blood. However, whether
changes in that DNA methylation can be used to monitor
the effectiveness of smoking cessation was uncertain. To
determine this, we monitored serum cotinine and
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determined DNA methylation levels for ninety days in
63 subjects participating in a nicotine replacement-free
incentive based smoking cessation program. (NIH R01
HL130883) Overall, 18 of 63 (29%) subjects had unde-
tectable levels of cotinine at the 30 day visit and maintained
undetectable levels through the 90 day exit visit. Corre-
spondingly, cg05575921 levels showed a marked time and
dose-dependent reversion of methylation with cg05575921
levels increasing over 10% with 3 months of cessation in
the heaviest smokers (initial cg05575921< 50%), while
levels in more moderate smokers increasing only 7% after
3 months. We conclude that MSdPCR cg05575921
assessments are a sensitive, rapid method of monitoring the
effectiveness of smoking cessation. Because these DNA
methylation levels are not affected by nicotine replacement
and are quantitative in nature, they can be used in socially
responsible, incentive-based programming for the quanti-
tative reduction of smoking induced harms.
R.A. Philibert: A. Employment (full or part-time);
Significant; Behavioral Diagnostics. E. Ownership Interest
(stock, stock options, patent or other intellectual property);
Significant; Behavioral Diagnostics. K. Dawes: None. M.
Dogan: None. W. Philibert: None. B. Hundley: None. J.
Mills: None. J. Long: None. A. Gerke: None. J. Wilson:
None. P. Nagpal: None. A. Comellas: None. E.
Hoffman: None.
P20.21.C
Leveraging a co-methylation network to predict regula-
tory effects of DNA methylation sites and human
phenotypes
S. Li, C. Qi, P. Deelen, F. Boulogne, N. de Klein, J. van der
Velde, G. Koppelman, L. Franke, M. Swertz, H. Westra
University Medical Centre Groningen, Groningen, Nether-
lands
DNA methylation is an important epigenetic signal with
potential regulatory effects on gene expression, and aberrant
methylation patterns have been previously used as bio-
markers for disease. While we have shown recently that
methylated DNA sites are correlated with gene expression
levels in blood, the function of many other DNA methyla-
tion sites and co-methylation, however, is unclear. Previous
studies have used gene co-expression networks to predict
links between genes and Human Phenotype Ontology
(HPO) terms. Here, we compare co-methylation and co-
regulation patterns, and investigate the functions of DNA
methylation sites to improve gene-symptom predictions.
For this purpose, we have created a co-methylation
network using 33,000 public 450k Illumina methylation
assays from various tissues and cell types. We identified
6,067 significant correlations between DNA methylation
and genes through a meta-analysis using blood, nasal and
brain tissues. These correlations link methylation sites with
genes, and consequently to HPO terms associated with
those genes. Using this data, we will compare the co-
methylation network with our previously published co-
expression network consisting of 32,000 samples in terms
of their power to predict HPO term membership per gene
and methylation site. We expect that this comparison will
assign methylation sites to human phenotypes, and provide
functional interpretation for many others.
Our preliminary results comparing networks in 2905
blood samples show that the co-methylation and co-
expression networks have comparable predictive power.
In the future, we will combine the two networks to improve
prioritization of disease-causing genes.
S. Li: None. C. Qi: None. P. Deelen: None. F.
Boulogne: None. N. de Klein: None. J. van der Velde:
None. G. Koppelman: None. L. Franke: None. M.
Swertz: None. H. Westra: None.
P20.25.A
Difference of significant methylation change by heavy
metal concentration in atopic dermatitis
S. Yu, E. Koh, S. Kim, S. Lee, J. Lee, S. Hwang
Hanyang University, Ansan, Korea, Republic of
As environmental pollution is getting worse, many envir-
onmental diseases are caused by various factors. For this
reason, the importance of research between environmentally
harmful substances and diseases is increasing. In particular,
exposure to harmful substances during pregnancy affects
the fetus and can lead to disease. Therefore, epigenome was
studied to confirm the change caused by environmental
factors. The effect of heavy metals on atopic dermatitis,
which is representative of environmental diseases, was
examined using DNA methylation experiments, one of the
methods for identifying epigenomes. The samples used in
this study were cord blood DNA from some MOCEH
cohort samples. The degree of methylation according to the
concentration of heavy metals was confirmed in 84 children
diagnosed with atopic dermatitis. For methylation profiles,
an experiment was performed using an Infinium Human
Methylation EPIC kit (Illumina, CA, USA) and analyzed
using GenomeStudio (version 2011.1). As a result, 37 genes
in mercury and 58 in lead were found in regions with sig-
nificant methylation differences when exposed to high
concentrations compared to low concentrations. Pathway
analysis was performed using genes selected from each
heavy metal group, and it was confirmed that specific genes
were involved in the cytokine signaling in Immune system.
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In conclusions, the effect of heavy metals on atopic der-
matitis was confirmed. In other words, it was confirmed that
environmental diseases may be caused by harmful envir-
onmental substances. This study was supported by Korea
Environment Industry & Technology Institute(KEITI)
through "the Environmental Health Action Program", fun-
ded by Korea Ministry of Environment(MOE)
(2017001360005).
S. Yu: None. E. Koh: None. S. Kim: None. S. Lee:
None. J. Lee: None. S. Hwang: None.
P20.27.C
Dive into Epigenetics and Gene Regulation - Navigation
using the ENCODE Portal
J. N. Au, I. Gabdank, Y. Luo, M. Kagda, B. Lam, I.
Youngworth, P. Adenekan, U. K. Baymuradov, S. Miyasato,
M. Simison, K. Graham, O. Jolanki, J. P. Jou, J. Lee, C.
Litton, K. Z. Lin, E. O’Neill, P. Sud, F. Tanaka, J. S.
Strattan, B. C. Hitz, J. M. Cherry
Department of Genetics, School of Medicine, Stanford
University, Stanford, CA, United States
The Encyclopedia of DNA Elements (ENCODE) project is
an international collaboration of research groups funded by
the NHGRI, whose main goal is to identify all functional
elements of the human genome. The ENCODE portal
(https://www.encodeproject.org/), established and main-
tained by the ENCODE Data Coordination Center (DCC),
provides unrestricted access to data generated by the
members of the ENCODE consortium and other related
projects such as Model organism Encyclopedia of Reg-
ulatory Networks (modERN), Genomics of Gene Regula-
tion (GGR), Roadmap Epigenomics Project (Roadmap),
and ENCODE G-TEx (EN-Tex). The DCC develops and
updates the data model and uniform processing pipelines
that allow transparency and reproducibility of the experi-
mentally collected and computationally generated data.
With a constant influx of data, the DCC consistently
implements new ways for the users of the ENCODE portal
to search and identify related experiments, understand how
assays were performed, and track the provenance of the
data. Currently, the ENCODE portal hosts more than 15
thousand datasets, representing experimental results for
over 75 distinct tissue and cell types using more than 40
distinct high-throughput genomic assays.
Richness, diversity, and structure of the data on the
ENCODE portal make it an invaluable resource for the
scientific community. The presence of curated and standar-
dized experimental results from assays like RNA-seq, ChIP-
seq, ATAC-seq, and Hi-C allow for convenient accessibility
to any genomics investigator. Here we show how the
ENCODE portal can be used as a multifaceted lens to
investigate various biological and regulatory properties of
chromatin state and gene expression.
U24HG009397-01
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P20.28.A
Impact of natural compounds in the DNA methylation of
RASSF1A in triple-negative breast cancer cell lines and
epi-drug discovery
C. A. RAINHO, J. H. M. Assumpção, F. A. S. France, D. P.
Callegari, B. M. Barbosa, A. A. S. Takeda, J. M. Sforcin
SAO PAULO STATE UNIVERSITY - UNESP, Botucatu,
Brazil
Introduction: Triple-negative breast cancer (TNBC) is an
aggressive subtype of breast cancer frequently associated
with resistance to chemotherapy, a higher risk of recurrence
and metastasis. Combined epi-drugs targeting DNA
methyltransferases (DNMTs) and histone deacetylases
(HDACs) are a promising alternative to reverse acquired
therapy resistance. Since natural origin products are con-
sidered a promising source of epi-drugs, the present study
aimed to identify propolis-derived small molecules able to
interact with human DNMT1 or HDAC2.
Materials and Methods: The effects of propolis
treatment were evaluated in four TNBC cell lines (BT-20,
BT-549, MDA-MB-231, and MDA-MB-436). Cell viability
was accessed by the MTT test and the DNA methylation
analysis was performed by Methylation-Specific Polymer-
ase Chain Reaction (MS-PCR). A set of 3,146 propolis-
derived compounds were retrieved from scientific literature
and used in the molecular screening strategy.
Results: Propolis reduces the cell viability of TNBC cells
and partly demethylates the promoter region of the tumor
suppressor RASSF1A as well as modulates the RASSF1
protein expression levels in BT-549 cells. After filtering and
curating 1,002 propolis-derived chemicals, 58.5% of the
molecules were grouped into five most representative
clusters according to the components’ atomic positions.
After hierarchical clustering, the in silico screening analysis
indicated catechin 3’-O-gallate and propolin-B as possible
new DNMT and HDAC inhibitors, respectively.
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Conclusions: Our data indicate that propolis can
modulate the expression of the RASSF1 gene via epigenetic
mechanisms. Also, the computational approach predicted
that propolis-derived compounds can interact with DNMT1
and HDAC2 and should considered in future studies of new
epi-drugs identification.
C.A. Rainho: None. J.H.M. Assumpção: None. F.A.S.
France: None. D.P. Callegari: None. B.M. Barbosa:
None. A.A.S. Takeda: None. J.M. Sforcin: None.
P20.29.B
Line 1 methylation patterns in placenta and cord blood
at birth reveal associations with neonatal weight and
maternal methylation
O. Rondinone1, S. Motta2, P. Colapietro3, J. Costanza1, M.
Camanni1, E. Beretta2, L. Fontana1, A. Morotti1, S.
Sirchia4, S. Bosari1, S. Tabano3,5, M. Miozzo1,3
1Scientific Direction, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milan, Italy, 21Medical
Genetics, Department of Pathophysiology & Transplanta-
tion, Università degli Studi di Milano, Milan, Italy, 3Med-
ical Genetics, Department of Pathophysiology &
Transplantation, Università degli Studi di Milano, Milan,
Italy, 43Medical Genetics, Department of Health Sciences,
Università degli Studi di Milano, Milan, Italy, 5Medical
Genetics Unit, Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milan, Italy
During intrauterine life, environmental perturbations can
influence newborn outcome by means of DNA methylation
modifications with long-term consequences. L-1 (Long
Interspersed Nucleotide Elements) sequences are transpo-
sable elements accounting for 17% of the human genome,
considered a surrogate for global methylation. To investi-
gate the global methylation at birth in association with
neonatal birth, we recruited at the delivery 195 women with
singleton, spontaneous and uncomplicated pregnancies and
we investigated L-1 methylation by pyrosequencing in cord
and maternal blood and in placental samples. We found a
significant severe L-1 hypomethylation in placenta from
SGA (Small for Gestational Age, ≤10 percentile) compared
with normal and LGA babies (Large for Gestational Age).
This finding suggests a compensatory epigenetic mechan-
ism in response to a reduced growth; or a placental insuf-
ficiency responsible for SGA. This association was not
present in cord blood. A strong correlation (Pearson r=0,79,
pvalue<0,01) of L-1 methylation between maternal (62,7%
+/- 5,3) and cord (mean+/- StDev: 63,3% +/- 5,4) blood
was found. This similarity seems to be lost after birth, based
on the weak correlation (r = 0,26, p value > 0,05) observed
in the L-1 methylation levels of 31 mothers and children
(>4 years of age). In order to explore also the methylation
profiling of gene promoters in these cases, MethylSeq
experiments are ongoing.
O. Rondinone: None. S. Motta: None. P. Colapietro:
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Frameshift mutations at the C-terminus of HIST1H1E
result in a specific DNA hypomethylation signature
A. Ciolfi1, E. Aref-Eshghi2,3, S. Pizzi1, L. Pedace1, E.
Miele1, J. Kerkhof2,3, E. Flex4, S. Martinelli4, F. C. Radio1,
C. A. L. Ruivenkamp5, G. W. E. Santen5, E. K. Bijlsma5, D.
Q. C. M. Barge-Schaapveld5, K. Ounap6,7, V. Mok Siu3, F.
F. Kooy8, B. Dallapiccola1, B. Sadikovic2,3, M. Tartaglia1
1Ospedale Pediatrico Bambino Gesù, Rome, Italy, 2Western
University, London, ON, Canada, 3London Health Sciences
Centre, London, ON, Canada, 4Istituto Superiore di Sanità,
Rome, Italy, 5Leiden University Medical Center, Leiden,
Netherlands, 6Tartu University Hospital, Tartu, Estonia,
7University of Tartu, Tartu, Estonia, 8University of
Antwerp, Antwerp, Belgium
Introduction: Histones regulate dynamic packaging of
nuclear DNA in chromatin to achieve efficient compaction
of the genome as well as to regulate and coordinate DNA
replication, transcription, and repair. Recently, a narrow
spectrum of functionally equivalent frameshift mutations at
the C-terminal tail of HIST1H1E, a member of the linker
histone family, has been causally linked to Rahman syn-
drome. Previous work demonstrated that these mutations
disrupt proper compaction of DNA and affected multiple
cellular processes, resulting in accelerated replicative
senescence, and are associated with a specific methylation
pattern.
Results: Methylome analysis from peripheral blood
samples of six affected subjects led us to identify ~9,000
CpG probes located in ~600 differentially methylated
regions, defining a specific and predominantly hypomethy-
lated pattern. This “episignature” was enriched for genes
involved in neuronal system development and function, in
particular at the synaptic level. A computational classifier
trained on these methylation profiles yielded full sensitivity
and specificity in detecting subjects carrying dominant-
acting HIST1H1E frameshift mutations among healthy
controls or individuals carrying pathogenic lesions in other
proteins of the epigenetic machinery associated with human
disease. Applying this model to a cohort of probands
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without clinical diagnosis allowed us to reach diagnosis for
a previously undiagnosed patient.
Conclusions: We demonstrate an epigenetic signature in
subjects with a defined class of HIST1H1E mutations. We
show that this signature is specific and can be used to reach
molecular diagnosis. These findings further demonstrate the
utility of DNA methylation episignatures as a tool to favor
diagnosis and genetic variant classification.
A. Ciolfi: None. E. Aref-Eshghi: None. S. Pizzi: None.
L. Pedace: None. E. Miele: None. J. Kerkhof: None. E.
Flex: None. S. Martinelli: None. F.C. Radio: None. C.A.
L. Ruivenkamp: None. G.W.E. Santen: None. E.K.
Bijlsma: None. D.Q.C.M. Barge-Schaapveld: None. K.
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P20.32.B
Germline mutations in FAF1 are associated with
hereditary colorectal cancer
L. Bonjoch1, S. Franch-Expósito2, P. Garre3, S. Belhadj4,
J. Muñoz2, C. Arnau-Collell2, M. Díaz-Gay2, A. Gratacós-
Mulleras2, G. Raimondi5, C. Esteban-Jurado2, Y. Soares de
Lima2, C. Herrera-Pariente2, M. Cuatrecasas6, T. Ocaña2,
A. Castells2, C. Fillat5, G. Capellá4, F. Balaguer2, T.
Caldés3, L. Valle4, S. Castellvi-Bel2
1IDIBAPS-Hospital Clínic-CIBERehd, Barcelona, Spain,
2Gastroenterology Department, Centro de Investigación
Biomédica en Red de Enfermedades Hepáticas y Digestivas
(CIBEREHD), Hospital Clínic, IDIBAPS, Barcelona, Spain,
3Molecular Oncology Laboratory, Hospital Clínico San
Carlos, Instituto de Investigación Sanitaria del Hospital
Clínico San Carlos (IdISSC), Madrid, Spain, 4Hereditary
Cancer Program, Catalan Institute of Oncology, IDIBELL,
Hospitalet de Llobregat, Spain, 5Centro de Investigación
Biomédica en Red de Enfermedades Raras (CIBERER),
Gastrointestinal and Pancreatic Oncology, IDIBAPS,
Barcelona, Spain, 6Department of Pathology, Hospital
Clínic, IDIBAPS, Barcelona, Spain
Introduction: A significant proportion of colorectal cancer
(CRC) cases present familial aggregation but the underlying
inherited cause is unknown. The aim of this study is to
identify new genes involved in the germline predisposition
to CRC, by means of an exhaustive functional character-
ization of genetic variants previously prioritized by our
research group in familial CRC cases.
Materials and Methods: We analyzed 75 patients with
familial CRC with an unknown germline basis from 40
families by whole-exome sequencing. An external replica-
tion cohort of 473 families was also examined by targeted-
gene sequencing. We developed a FAF1 knockout cellular
model by CRISPR-Cas gene editing, and the identified
genetic variants were produced by site-directed mutagenesis
and expressed by transfection. Apoptosis, proliferation and
protein-specific functional assays were carried out to
characterize FAF1 role in cancer predisposition.
Results: A predicted pathogenic FAF1 variant
(c.1111G>A; p.Asp371Asn) was detected in the initial
cohort segregating in four patients of the same family. A
second genetic variant was detected in the replication cohort
(c.254G>C; p.Arg85Pro). Both variants showed protein
instability and, once transfected, produced an abnormal
cellular phenotype by promoting apoptosis resistance and
sustaining both NF-κB and Wnt signaling pathways.
Conclusions: Our findings suggest that FAF1 may be
involved in inherited predisposition to CRC, being
resistance to apoptosis the plausible pathogenic mechanism.
Grant support: FJCI-2017-32593, 2019FI_B2_00203,
LCF/BQ/DI18/11660058, Fondo de Investigación Sanitaria/
FEDER (16/01292, 17/00878), AECC
(GCB13131592CAST), Spanish Ministry of Science
(SAF2016-80888-R, BIO2017-89754-C2-2R), PERIS
(SLT002/16/00398, SLT002/16/0037), Generalitat de Cat-
alunya (GRPRE 2017SGR21, GRC 2017SGR653,
2017SGR723, 2017SGR861, 2017SGR1282), COST
Action CA17118, CIBEREHD, CIBERONC, CIBERER.
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Androgenetic alopecia: First functional evidence for an
interaction between two GWAS loci
L. M. Hochfeld1, M. Bertolini2, S. Schoch3, R. C. Betz1, M.
M. Nöthen1, S. Heilmann-Heimbach1
1Institute of Human Genetics; University of Bonn, School of
Medicine & University Hospital Bonn, Bonn, Germany,
2Monasterium Laboratory, Skin and Hair Research Solu-
tions, Münster, Germany, 3Department of Neuropathology;
University of Bonn Medical Center, Bonn, Germany
One of the strongest genetic risk loci for androgenetic
alopecia (AGA) is located in WNT10A (2q35). Here, a
significant regulatory effect of the lead variants on the
expression of the hair cycle regulator WNT10A has been
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reported. Interestingly, one of these variants is located
within a binding site for the transcription factor EBF1,
whose gene is located at another AGA risk locus (5q33.3).
We hypothesized that changes in EBF1 mediated regulation
of WNT10A expression may contribute to the deregulated
hair cycle dynamics observed in AGA. To analyze a
potential interaction between EBF1 and WNT10A, we per-
formed luciferase reporter assays in HEK cells. Our
experiments confirmed that EBF1 activates the WNT10A
promoter and that the WNT10A/EBF1 interaction was
decreased with the AGA risk allele. To further investigate
this potential interaction in AGA-relevant tissue and iden-
tify the relevant cell population we performed immuno-
fluorescence co-staining in human scalp hair follicle. The
strongest co-expression of EBF1 and WNT10A was
observed in hair follicle keratinocytes of the inner and outer
root sheath. A major challenge in complex genetics is to
bridge the gap between association and function. To our
knowledge, our study is the first functional follow-up study
on AGA that (i) together with previous mRNA data enabled
identification of a regulatory mechanism at an AGA risk
locus and (ii) proves functional interaction between two risk
loci that is likely to contribute to the pathophysiological
changes in hair cycle dynamics.
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Integrated analysis of transcriptional regulation in
hypertrophic cardiomyopathy cased by truncating
MYBPC3 mutations
J. Pei1, M. Schuldt2, E. Nagyova1, Z. Gu1, S. E.
Bouhaddani1, J. Calis1, L. M. Dorsch2, N. A. M. van den
Dungen1, N. Lansu1, B. J. Boukens3, I. R. Efimov4, M.
Michels5, M. C. Verhaar1, R. de Weger1, A. Vink1, H. W.
Uh1, C. Cheng1, D. W. Kuster2, M. Mokry1, J. van der
Velden2, F. W. Asselbergs1,6,7
1Universitair Medisch Centrum Utrecht, Utrecht, Nether-
lands, 2Amsterdam UMC, Vrije Universiteit Amsterdam,
Amsterdam, Netherlands, 3Amsterdam UMC, Amsterdam,
Netherlands, 4The George Washington University,
Washington, WA, United States, 5Erasmus Medical Centre,
Rotterdam, Netherlands, 6Netherlands Heart Institute,
Utrecht, Netherlands, 7University College London, London,
United Kingdom
Introduction: Transcription factors (TFs) bind to reg-
ulatory DNA sequences, such as promoters and enhancers,
to control the level of RNA transcription and protein
translation as a reaction to a disease stimulus. However,
little is known about how the patient’s heart epigenetically
responds to pathogenic truncating variants (tv) in the
MYBPC3 gene that cause hypertrophic cardiomyopathy
(HCM), a devastating cardiac disease with high morbidity
and mortality.
Methods and Results: To address the interplay between
the chromatin activity and the subsequent RNA and protein
products in patients, we performed H3K27ac ChIP-seq,
RNA-seq, and proteomics on human cardiac tissues from 13
tvMYBPC3 HCM patients and 10 healthy donors. We
identified 9,310 differentially acetylated regions and 2,033
differentially expressed genes between patients and controls
using Deseq2. Gene enrichment analysis showed biological
processes mostly in extracellular matrix formation and lipid
metabolism. Besides, we identified a list of TFs that showed
altered mRNA expression levels and the acetylation levels
of their binding regions were altered. We also obtained top
2,000 regions and genes that were driving the major
variation among all samples using O2PLS. Allelic imbal-
ance of wild type and mutated MYBPC3 mRNA expression
was observed. After combining results from both
approaches in patients vs. controls, we further detected
the expression levels of 45 proteins significantly changed in
the same direction as changes in their encoding genes.
Notably, several identified proteins have not been linked to
HCM previously.
Conclusions: Our integrated omics analysis identified
novel candidates involved in cellular remodeling and
dysfunction in tvMYBPC3 HCM.
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ImprintSeq: A new sequencing panel to detect methyla-
tion alterations in human imprinted regions
E. Ochoa1, S. Lee1, B. Lan-Leung1, L. Gerontogianni1,2, G.
Pérez de Nanclares3, R. Martinez3, G. Clark1,4, E. Martin4,
L. A. Castano3, L. Bottolo1,2,5, E. R. Maher1
1Department of Medical Genetics, Cambridge, United
Kingdom, 2The Alan Turing Institute, London, United
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Kingdom, 5MRC Biostatistics Unit, Forvie Site, Cambridge,
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Congenital imprinting disorders (CIDs) are a group of
developmental disorders with overlapping clinical and
molecular features that result from genetic and epigenetic
alterations in imprinted genes and imprinting control
regions. Though specific CIDs are associated with locus-
specific imprinting defects, a subset of cases showed mul-
tiple imprinting defects across the genome (multi-locus
imprinting disturbances (MLIDs)). MLID has been descri-
bed in a broad ranfge of CIDS but most frequently
Beckwith-Wiedemann syndrome (BWS), Silver-Russell
syndrome (SRS), Transient neonatal diabetes (TNDM)
and Pseudohypoparathyroidism type 1B (PHP1b). The
specific impact of MLIDs on clinical phenotype is not well
defined though some patients with MLID will have a dis-
cordant epigenotype-phenotype (e.g. clinical features of
SRS and molecular findings associated with SRS). The
availability of an accurate, quantitative and scalable high-
throughput method to interrogate many imprinted regions
simultaneously would be advantageous for MLID research
and clinical diagnostics. We have designed a custom tar-
geted methylation sequencing panel that covered the most
relevant imprinting DMRs. We tested ImprintSeq in healthy
controls (n = 70) and CIDs (n = 142) including BWS (n =
59), SRS (n = 26), TNDM (n = 15) and PHP1b (n = 42).
ImprintSeq allowed the identification of MLIDs and locus
specific methylation defects, as well as provides a useful
tool to explore the significance of MLID in CIDs.EO is
funded by/supported by/receives funding from the National
Institute for Health Research [Cambridge Biomedical
Research Centre at the Cambridge University Hospitals
NHS Foundation Trust]. This research was supported by
the Cambridge NIHR BRC Stratified Medicine Core
Laboratory NGS Hub and a MRC Clinical Infrastructure
Award.
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Identification and characterization of functional BMI-
associated CpGs at the LGALS3BP locus
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Epidemiology, Helmholtz Zentrum München, German
Research Center for Environmental Health, Neuherberg,
Germany, 2Department of Medicine, Karolinska Institutet,
Stockholm, Sweden, 3Institute of Epidemiology, Helmholtz
Zentrum München, German Research Center for Environ-
mental Health, Neuherberg, Germany, 4German Center for
Cardiovascular Research (DZHK), Partner Site Munich
Heart Alliance, Munich, Germany, 5Institute of Neuroge-
nomics, Helmholtz Zentrum München, German Research
Center for Environmental Health, Neuherberg, Germany,
6Research Center for Nutrition and Food Sciences, School
of Life Sciences Weihenstephan, Technische Universität
München, Freising, Germany
Methylation of the LGALS3BP locus (galactoside-binding
soluble 3 binding protein), which encodes an extracellular
matrix lectin, has been linked to body mass index (BMI),
type 2 diabetes and related adverse outcomes of adiposity
through epigenome wide association studies (EWAS).
Revealing the functional role of methylation at these CpG
sites (CpGs) is essential to understand gene regulation and
ultimately metabolic disease pathophysiology.
First, we used statistical analyses to prioritize these CpGs.
An EWAS on BMI (blood, N = 1888; Illumina-
MethylationEPIC array) confirmed four LGALS3BP asso-
ciated CpGs (P<8x10−8). We then applied transcription
wide analyses (Illumina-HumanHT-12v3 array) and
assessed methylation profile correlation in all 23 CpGs at
the locus using samples form blood (N = 1727),
subcutaneous adipocytes (N = 127), peripheral blood
mononuclear cells, omental and subcutaneous adipose
tissue (N = 80). Five CpGs were associated with only the
LGALS3BP transcript (P<4.9x10−08), three of which over-
lap BMI hits. All associated CpGs are contained in a main
cluster region.
Based on our results, we selected BMI-associated CpGs
for functional analyses. Electrophoretic mobility shift
assays (THP-1, Jurkat and HepG2 cells) demonstrated
methylation-specific differential protein binding for all
assessed CpGs (cell-type- and CpG-site-specific). Prelimin-
ary results for dual-luciferase reporter gene assays (THP-1
and Jurkat cells) suggest methylation-dependent transcrip-
tional activity and for liquid chromatography–mass spectro-
metry (HepG2 cells) allow identification of differential
binding proteins.
Our findings support specific molecular mechanisms
involved at each of the CpGs, providing new insights into
the underlying functional basis influenced by BMI-
associated methylation at the LGALS3BP locus.
Monica Gomez-Alonso holds a CONACyT-Mexico
fellowship for doctoral studies.
M. Gomez-Alonso: None. I. Dahlman: None. C.
Gieger: None. A. Peters: None. J. Winkelmann: None.
H. Laumen: None. A. Kretschmer: None. M.
Waldenberger: None.
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P20.43.A
Characterization of the modulatory role of LZTR1 in
the control of RAS-MAPK signaling
M. Motta1, C. Mancini1, M. Fidan2, E. Bellacchio1, F.
Pantaleoni1, K. Schneider-Heieck2, S. Coppola3, G. Borck4,
L. Salviati5, M. Zenker6, I. C. Cirstea2, M. Tartaglia1
1Genetics and Rare Diseases Research Division, Ospedale
Pediatrico Bambino Gesù, Rome, Italy, 2Institute of
Comparative Molecular Endocrinology, Ulm University,
Ulm, Germany, 3National Centre for Rare Diseases, Istituto
Superiore di Sanità, Rome, Italy, 4Institute of Human
Genetics, Ulm University, Ulm, Germany, 5Department of
Pediatrics, Università degli Studi di Padova, Padova, Italy,
6Institute of Human Genetics, University Hospital Magde-
burg, Magdeburg, Germany
Noonan syndrome (NS), the most common RASopathy, is
caused by mutations affecting RAS-MAPK signaling.
Recently, genome scanning has allowed the discovery of
novel NS-related genes, representing signal transducers or
modulators not belonging to the “classical” RAS pathway.
Among them, the leucine zipper-like transcriptional reg-
ulator 1 (LZTR1), encoding a member of the BTB/POZ
protein superfamily, was identified in patients carrying both
dominant or recessive form of NS. Furthermore, constitu-
tional monoallelic mutations in the same gene cause
schwannomatosis, a cancer-prone disorder clinically distinct
from NS. LZTR1 has been suggested to act as substrate
receptor for the CUL3-RING ubiquitin ligase (CRL3)
complex, a multi-subunit RING-class E3 ligase implicated
in protein mono- and poly-ubiquitination. Here we
demonstrate that dominant NS-causing mutations do not
influence protein stability and subcellular localization nor
perturb binding of LZTR1 to CUL3, but specifically affect
the surface of LZTR1 Kelch domain, mediating substrate
recognition. On the contrary, recessive NS-causing variants
behave as loss-of-function mutations, affecting
LZTR1 synthesis, stability, and/or binding to CUL3. Col-
lectively, our data suggest a model in which LZTR1 con-
tributes to the ubiquitination of proteins functioning as
positive modulators of the RAS-MAPK pathway. LZTR1
mutations variably impair binding of these substrates to the
multi-component ligase complex and their efficient ubi-
quitination and degradation, resulting in MAPK signaling
upregulation.
M. Motta: None. C. Mancini: None. M. Fidan: None.
E. Bellacchio: None. F. Pantaleoni: None. K. Schneider-
Heieck: None. S. Coppola: None. G. Borck: None. L.
Salviati: None. M. Zenker: None. I.C. Cirstea: None. M.
Tartaglia: None.
P20.45.C
Pre-pregnancy maternal body mass index (BMI) and
placental methylation: a joint meta-analysis of 2,951
mother-child pairs
N. Fernandez-Jimenez1, R. Fore2, M. Bustamante3, C.
Lesseur4, T. Kvist5, A. Binder6, F. Tian7, J. Martorell-
Marugán8, J. Loke9, L. Santa Marina10, M. Lacasaña11, K.
Bakulski12, J. Lepeule13, J. M. Craig9, C. J. Marsit14, K. B.
Michels15, K. Räikkönen5, M. R. Karagas16, B. Heude17, M.
F. Hivert2, J. R. Bilbao1
1University of the Basque Country (UPV/EHU), Leioa,
Spain, 2Harvard Medical School, Boston, MA, United
States, 3ISGlobal, Institute for Global Health, Barcelona,
Spain, 4Icahn School of Medicine at Mount Sinai, New
York, NY, United States, 5University of Helsinki, Helsinki,
Finland, 6University of Hawaii Cancer Center, Honolulu,
HI, United States, 7Emory University, Atlanta, GA, United
States, 8GENYO Centre for Genomics and Oncological
Research: Pfizer/University of Granada/Andalusian Regio-
nal Government, Granada, Spain, 9Centre for Molecular
and Medical Research, School of Medicine, Faculty of
Health Deakin University, Geelong, Australia, 10Biodonos-
tia Health Research Institute, Donostia, Spain, 11Andalu-
sian School of Public Health (EASP), Granada, Spain,
12University of Michigan, Ann Arbour, MI, United States,
13Univ. Grenoble Alpes, Inserm, CNRS, Grenoble, France,
14Rollins School of Public Health, Emory University,
Atlanta, GA, United States, 15Fielding School of Public
Health, University of California, Los Angeles, Los Angeles,
CA, United States, 16Geisel School of Medicine, Dartmouth
College, Lebanon, NH, United States, 17Universite de Paris,
CRESS, Inserm, INRAE, Paris, France
Introduction: Maternal obesity during pregnancy increases
the future risk for obesity, diabetes and heart disease in
offspring but the molecular mechanisms are still unclear.
Placenta is a key organ in fetal development and enables the
mother-child interplay. The placental methylome could be a
marker of this interaction and reflect the functional changes
derived from in utero exposures.
Methods: To assess whether pre-pregnancy maternal
BMI is associated with DNA methylation in placenta we
combined DNA methylation data from 11 cohorts of the
PACE consortium (AQUA, EARLI, EDEN, Gen3G,
GENEIDA, HEBC, INMA, ITU, MARBLES, NHBCS
and RICHS) analyzed with EPIC (n = 996) and 450K
(n = 1,955) arrays. We modelled the associations with and
without adjustment for cellular heterogeneity, estimated
with a reference-free deconvolution algorithm. We adjusted
all models for maternal age, parity, education and smoking
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status. Finally, we meta-analyzed the estimates of 2,951
placental methylomes using the GWAMA software (fixed
effects).
Preliminary results: We identified 51 and 39 BMI-
associated CpGs passing Bonferroni correction with and
without cell-type adjustment, respectively. Among the
genes closest to the significant CpGs, we found obesity-
related genes such as GPX1, BBS9, EBF2 or PPP2R2A;
type 2 diabetes genes such as DDAH1, CMIP and SGSM2,
and a number of developmental players, suggesting that
maternal BMI impacts the epigenetic regulation of health-
related genes in placenta. In the near future, we will
ascertain the functional impact of these signatures in
placental transcription, and their interaction with the
genomic variation of children and mothers.
Funding: GVSAN2018/111086 to JRB and PI18/01142-
FEDER to LSM.
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P20.46.A
DNA methylation status of interspersed repetitive
sequences and pro-inflammatory cytokines in migraine
patients with MTHFR C667T variant
N. Kraveishvili1,2, M. Kvintradze1, S. Surmava1, M.
Zarandia1, T. Gorgiladze3, E. Kvaratskhelia1, E.
Abzianidze1
1Tbilisi State Medical University, Tbilisi, Georgia, 2Tbilisi
Institute of Medicine, Tbilisi, Georgia, 3Batumi Shota
Rustaveli State University, Batumi, Georgia
Introduction: Epigenetic alterations may have a role in the
pathogenesis of complex diseases such as Migraine. This
study aimed to determine the methylation level of the Line-
1 and Alu interspersed repetitive sequences in migraine
patients with C677T variant of MTHFR gene as well as
methylation status of the TNF-α and IL-8 gene promoters.
Materials and methods: The study was approved by the
ethics committee of Tbilisi State Medical University.
Genomic DNA was isolated from peripheral blood mono-
nuclear cells (PBMCs) of migraine patients and healthy
controls using QIAamp DNA Mini Kit (Qiagen, US).
For Bisulfite treatment of DNA, we used EpiTect Bisulfite
Conversion Kit (Qiagen, US). The MTHFR C677T
polymorphism was detected by PCR-RELP method.
Methylation levels of Line-1 and Alu in were examined
by the combined bisulfite restriction analysis-interspersed
repetitive sequences (COBRA-IRS). Methylation levels of
TNF-α and IL-8 in patients and controls were examined by
methylation-specific real-time qPCR.
Results: For Alu sequences, significant differences were
observed in the frequency of unmethylated Cytosines
between PBMCs of patients with MTHFR C677T poly-
morphism and healthy controls. However, no statistically
significant differences for LINE-1 were detected. In
addition, our results showed significant low level of
methylation in TNF-α and IL-8 promoters in the migraine
patients than those in healthy controls (p≤0.05).
Conclusions: We demonstrated that changes in the DNA
methylation of IRS elements and genes involved in
inflammation might contribute to the pathogenesis of
migraine in patients with MTHFR C677T variant. Such
research could lead to the discovery of diagnostic
biomarkers and therapeutic targets.
N. Kraveishvili: None. M. Kvintradze: None. S.
Surmava: None. M. Zarandia: None. T. Gorgiladze:
None. E. Kvaratskhelia: None. E. Abzianidze: None.
P20.47.B
Circulating miRNAs as potential biomarkers to classify
patients with the different grades of glioma
M. Niemira1, A. Erol1, I. Sidorkiewicz1, A. Bielska1, A.
Szalkowska1, G. Sokolowska1, J. Raczkowska1, E. Siewiec1,
M. Moniuszko2, J. Reszec3, A. Kretowski1
1Clinical Research Centre, Medical University of Bialystok,
Bialystok, Poland, 2Department of Regenerative Medicine
and Immune Regulation, Medical University of Bialystok,
Bialystok, Poland, 3Department of Medical Pathomorphol-
ogy, Medical University of Bialystok, Bialystok, Poland
Introduction: MicroRNA is a single-stranded non-coding
small RNA, which is considered as a new type of ‘onco-
miRs’ or ‘tumour suppressors’. Abnormal expression of
miRNAs contributes to glioma initiation and progression. In
this study, we aimed to determine differentially expressed
miRNAs in the serum between glioblastoma (GBM) and
low-grade (LGG) patients.
Materials and Methods: Serum miRNAs of 40 glio-
blastomas and 12 of low-grade glioma patients (n = 52)
have been isolated. Using the NanoString nCounter
Analysis System expression of 798 miRNAs has been
analysed. Quantitative RT-PCR was further performed to
verify the expression of selected miRNAs with an increased
number of samples. Gene ontology, Ingenuity Pathway
Analysis Software, and Cytoscape with STRING plug-in
tool were employed to the prediction of putative target
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genes and their role in glioma development. Receiver
operating characteristic (ROC) curves were constructed to
determine miRNA sensitivity and specificity.
Results: According to the cut-off criteria (FC>2,
FDR<0.05), a total of 125 DE miRNAs were obtained
including 7 upregulated and 118 downregulated miRNAs.
The analysis predicted 9929 target genes related to RAS/
MAPK signalling pathway, ephrin signalling pathway,
nNOS signalling in neurons, and glioma signalling. ROC
analyses demonstrated that all miRNAs had significant
potential diagnostic value (AUC>0.75). The highest AUC
values (AUC>0.95) were observed for five miRNAs: miR-
324-3p, miR-301b-3p, miR-1271-3p, miR-103a-3p, and
miR-491-3p.
Conclusions: This study highlights the potential for
serum-derived miRNAs as biomarkers for the progression
of glioma and predicting the prognosis of affected patients.
Data were generated by the Centre for Artificial Intelli-
gence of the Medical University of Bialystok.
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None. A. Bielska: None. A. Szalkowska: None. G.
Sokolowska: None. J. Raczkowska: None. E. Siewiec:
None. M. Moniuszko: None. J. Reszec: None. A.
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P20.48.C
Gene-centric compilation of the human ncRNA reper-
toire: A new vista for disease interpretation
R. Barshir, S. Fishilevich, T. Iny Stein, M. Safran, D.
Lancet
Weizmann Institute of Science, Rehovot, Israel
Non-coding RNA (ncRNA) genes, amounting to >20% of
the non-protein-coding genome, assume increasing impor-
tance, with accumulating evidence of involvement in dis-
ease mechanisms. A comprehensive non-redundant gene-
centric view of human ncRNA genes and their annotations
is critical for understanding their involvement in health and
disease, and for whole genome sequencing (WGS) inter-
pretation. GeneCards, the widely used human gene data-
base, is integrating data of ncRNA records and annotations
from EBI’s RNAcentral, and its 15 primary sources, as well
as from Ensembl, NCBI Entrez Gene and HGNC. Many
ncRNA sources are transcript-centric, and for WGS variant
analysis it is essential to transform this information into a
unique and all-encompassing compendium of ncRNA
genes. Utilizing the capacities of GeneCards, being gene-
centric, we clustered overlapping transcript entries from all
sources using an algorithm based on genomic coordinates.
This strategy eliminates redundancies and allows for full
coverage of genomic gene positions. Adhering to
GeneCards strategy, each RNA gene, with affiliated tran-
scripts, appears with annotations from all relevant sources.
The unified compilation includes more than 200,000
ncRNA gene entries, including ~100,000 Piwi-interacting-
RNAs.VarElect, GeneCards’ NGS interpretation tool
[PMID 27357693], allows disease interpretation of variants
mapped to ncRNAs by two routes. First, direct ncRNA-
disease associations are extracted from our knowledgebase,
now augmented by novel ncRNA-disease connections.
Second, our strengthened capacity to associate ncRNAs
with protein-coding genes now enables interpretation of
poorly characterized ncRNAs. The combination of an
extensive ncRNA knowledgebase with gene interpretation
algorithms allows fathoming the disease-related significance
of non-coding variants identified by WGS. Support: Life-
Map Sciences grant
R. Barshir: None. S. Fishilevich: None. T. Iny Stein:
None. M. Safran: None. D. Lancet: B. Research Grant
(principal investigator, collaborator or consultant and
pending grants as well as grants already received);
Significant; LifeMap Sciences.
P20.53.B
Epigenome-wide association study in knee osteoarthritis
generates novel insights into disease mechanisms
P. Kreitmaier1, M. Suderman2, L. Southam1, J. Steinberg1,3,
J. M. Wilkinson4, E. Zeggini1
1Institute of Translational Genomics, Helmholtz Zentrum
München, Neuherberg, Germany, 2MRC Integrative Epide-
miology Unit, Bristol Medical School, University of Bristol,
Bristol, United Kingdom, 3Cancer Research Division,
Cancer Council NSW, Sydney, Australia, 4Department of
Oncology & Metabolism, The University of Sheffield,
Sheffield, United Kingdom
Osteoarthritis (OA) is a common degenerative joint disease.
To promote the development of efficient therapy approa-
ches, it is first necessary to unravel the genomic architecture
of OA. We investigated DNA methylation in cartilage and
synovium tissue from 97 patients, the largest epigenetic data
set for knee OA to date. Genome-wide DNA methylation
data from primary chondrocytes from macroscopically
intact (low-grade) and degraded (high-grade) cartilage as
well as synovium samples were generated from patients that
underwent total knee replacement for OA. We conducted an
epigenome-wide association study (EWAS) to identify
methylation marks of cartilage degeneration. Genotype-
dependent methylation changes (mQTL effects) were
identified in synovium, low-grade and high-grade cartilage
across the genome. We used Mendelian randomization
(MR) to investigate putative causal effects between
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methylation state and OA, and colocalisation analysis to
identify causal loci. The EWAS discovered 15,328 differ-
entially methylated positions exceeding the genome-wide
significance threshold (P < 1.24e-7) between low-grade and
high-grade cartilage. We identified 2,477 differentially
methylated regions linked to cartilage degeneration. The
mQTL analysis revealed widespread associations between
genetic variants and methylation in all three examined tis-
sues, with partial overlap between tissue types. Two of
these mQTLs colocalised with OA-associated variants, thus
helping resolve GWAS signals. The application of MR
identified methylation loci with a putative causal influence
on OA. In this study, we identify widespread epigenomic
profile changes related to cartilage degeneration. We find
likely effector genes for methylation and GWAS signals,
enhancing our understanding of the mechanisms under-
pinning disease development and progression in OA.
P. Kreitmaier: None. M. Suderman: None. L.
Southam: None. J. Steinberg: None. J.M. Wilkinson:
None. E. Zeggini: None.
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A comprehensive transcriptional map of knee
osteoarthritis
G. Katsoula1, L. Southam1, J. Steinberg2, J. M. Wilkinson3,
E. Zeggini1
1Helmholtz Zentrum München, Neuherberg, Germany,
2Cancer Research Division, Cancer Council NSW, Sydney,
Australia, 3Department of Oncology & Metabolism, The
University of Sheffield, Sheffield, United Kingdom
Osteoarthritis is a degenerative joint disease with huge
public health burden and no curative therapy. Therefore, it
is urgent to translate insights from genomics into disease
mechanisms. We molecularly endotype joint tissues from
200 patients undergoing total knee replacement.
We generated RNA-seq data from patient knee tissues
(primary chondrocytes from low-grade and high-grade
cartilage, synoviocytes, and adipocytes) and genotype data
from peripheral blood. We: (1) investigate gene expression
differences between low and high-grade cartilage (2)
examine alterations in chondrocyte population markers
and (3) determine expression quantitative loci (eQTL)
effects in all the aforementioned tissues.
Differential expression analysis identified 4,512 and
4,365 significantly upregulated and downregulated genes
in high-grade cartilage respectively. Strong effects were
observed for genes associated with osteoarthritis pathology
including CRLF1 (P = 1.54e−86, LFC > 2) and CHRDL2,
(P = 9.19e−64, LFC < -2). Functional analyses pointed
significantly enriched terms including skeletal system
development (P = 3.49e−06), ossification (P = 1.48e−05)
and activation of ECM-receptor interaction pathway
(P = 4.14e−06). We detected significant downregulation in
the expression of effector chondrocytes markers in high-
grade cartilage, a chondrocyte population associated with
high metabolic activity in early-stage osteoarthritis. The
eQTL analysis revealed widespread significant associations
between genetic variants and gene expression in all tissues.
We have identified large-scale transcriptional signatures
of disease grade in key tissues of the knee joint in the largest
osteoarthritis transcriptomic analysis to date. The identified
genes and eQTL forward the understanding of molecular
mechanisms in osteoarthritis. The impacted pathways serve
as potential targets for novel therapeutics.
G. Katsoula: None. L. Southam: None. J. Steinberg:
None. J.M. Wilkinson: None. E. Zeggini: None.
P20.55.A
MethylSeq Direct workflow: a fast method for DNA
methylation analysis
E. Schreiber, S. Jackson
ThermoFisher Scientific, South San Francisco, CA, United
States
Introduction: Methylation at carbon 5 in the cytosine (5-
meC) of the CpG dinucleotide is a key epigenetic regulator
of developmental processes in higher eukaryotes. NGS
analysis of DNA methylation associated with cancer and
other pathologies revealed specific loci where CpG
methylation influences the cell physiology. These dis-
coveries can be expanded by analyzing discrete methylation
changes in the large number of archived samples. However,
retrospective studies using the rich resource of FFPE sam-
ples are hampered by the degraded nature of DNA
extracted.
Materials methods and Results: We present a workflow
for DNA methylation analysis method that is compatible
with FFPE tissues. We demonstrate the use of a method for
bisulfite sequencing, termed the MethylSeq Direct work-
flow, using PCR and sequencing reagents of the Applied
Biosystems™ BigDye™ Direct Cycle Sequencing Kit to
determine the methylation status in the p16 and MGMT
gene promoters as examples. FFPE extracted DNA is
bisulfite converted using the Thermo Scientific™ EpiJET™
Bisulfite Conversion Kit. PCR primers specific for bisulfite
converted sequences are designed using Applied Biosys-
tems™ MethylPrimer Express™ Software. PCR using these
M13-tagged primers is used to amplify the locus of interest.
The amplicon is sequenced using BigDye Direct Sequen-
cing reagent and purified using the Applied Biosystems™
BigDye XTerminator™ Kit. The sequencing reaction can
752 J. del Picchia
be analyzed on the Applied Biosystems™ SeqStudio™
Genetic Analyzer, or another model.
Conclusions: The entire workflow for bisulfite conver-
sion, PCR, and DNA sequencing, takes 7 hours, including
an hour of hands-on time enabling the use of archived FFPE
samples for retrospective studies.
E. Schreiber: A. Employment (full or part-time);
Significant; Thermo Fisher Scientific. S. Jackson: A.
Employment (full or part-time); Significant; Thermo Fisher
Scientific.
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DNA methylome- and transcriptome-wide profiling in
peripheral blood mononuclear cells identifies potential
predictors of desensitization to peanut allergy through
oral immunotherapy
A. Arnau Soler1,2, S. Ashley1,2, K. Blümchen3, K. Beyer4, Y.
Lee1,2
1Max Delbrück Center for Molecular Medicine, Berlin,
Germany, 2Clinic for Pediatric Allergy, Experimental and
Clinical Research Center, Charité University Medical
Center, Berlin, Germany, 3Department of Children and
Adolescent Medicine, Division of Pneumology, Allergology
and Cystic Fibrosis, University Hospital Frankfurt, Frank-
furt am Main, Germany, 4Department of Pediatric Pulmo-
nology, Immunology and Intensive Care Medicine, Charité
University Medical Center, Berlin, Germany
Peanut allergy is a common disease and the most common
cause of anaphylaxis in childhood. Peanut oral immu-
notherapy (OIT) can successfully desensitise many peanut-
allergic children. Although such treatment appears effective
and safe for the majority of patients, life-threatening allergic
reactions can still occur in a minority of children. Therefore,
predictors of positive OIT response are still required. Blood
samples were collected at baseline from 38 peanut-allergic
children who successfully completed an OIT trial. Methy-
lation and RNA sequencing data was obtained from isolated
peripheral blood mononuclear cells (PBMCs) following
in vitro cultivation both in medium and peanut antigen
stimulation conditions over 48 hours. We conducted DNA
methylome- and transcriptome-wide profiling of both
positive response to treatment and complete desensitisation,
accurately phenotyped by an oral food challenge before and
after the OIT trial. We developed a random forest classifier
using PBMC multi-omics data. Several significant differ-
entially methylated CpGs, differentially methylated regions
and differentially expressed genes (DEGs) were identified.
A few differentially methylated CpGs identified were
associated with gene expression levels of significant DEGs.
Gene set enrichment analysis revealed many pathways
enriched by DEGs. Our random forest classifier showed
accuracies of over 70% and 90% in distinguishing positive
treatment responders from non-responders and completely
desensitised from non-completely desensitised children,
respectively. Our results identify potential biomarkers of
positive peanut OIT response. If validated, such omics
markers may serve to predict OIT response, to better select
children that could benefit from OIT, and to identify tar-
getable pathways underpinning successful response to OIT
in peanut-allergic children.
A. Arnau Soler: None. S. Ashley: None. K. Blümchen:
None. K. Beyer: None. Y. Lee: None.
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Pharmacotranscriptome effects of melanocortin deriva-
tive in acute stress
I. B. Filippenkov1, V. V. Stavchansky1, L. V. Dergunova1,
N. Y. Glazova1, N. G. Levitskaya2, E. A. Sebentsova1, L. V.
Valieva1, D. D. Khukhareva2, S. A. Limborska1, N. F.
Myasoedov1
1Institute of Molecular Genetics, Russian Academy of
Sciences, Moscow, Russian Federation, 2Lomonosov Mos-
cow State University, Moscow, Russian Federation
Introduction: The pharmacotranscriptome studies of
antistress drugs are an actual for the translation medicine.
The synthetic analogue of melanocortin (MEHFPGP,
Semax) effectively improves cognitive function under acute
stress (AS). The work is devoted to the genome-wide
expression profiling in the rat hippocampus under the action
of Semax after AS.
Materials and Methods: rat model of AS, high-
throughput RNA sequencing (RNA-Seq), real-time RT-
PCR, bioinformatics.
Results: Using RNA-Seq we revealed 1529 differential
expression genes (DEGs) with cut-off>1.5 and padj<0.05 at
4.5h after AS. Semax administration of 100 μg/kg at 30 min
before AS, led to 944 DEGs at 4.5h after AS. Bioinforma-
ticaly, DEGs after AS were associated with a wide range of
catalytic and binding molecular functions of proteins
encoding by them. Simultaneously, Semax significantly
modulated the expression of DEGs associated with catalytic
(Dpp3, Dhcr7, Gpx8), transmembrane transporter (Slc13a5,
Slco2b1, Slc7a15), transcription regulator (Stat2, Etv5,
Irf5), G-protein receptor (Gpr17, Adora1), cytokine recep-
tor (Il3ra, Csf3r) activity and has the effect of compensating
for the effects of AS. Moreover, Semax has an additional
effect on protein metabolism, increasing the activity of
genes involved in protein synthesis (Rpl15, Rps16, Rps27l)
and decreasing the activity of genes involved in protein
degradation (Gba, Cln5, Ctsh).
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Conclusions: The data obtained revealed the anti-
inflammatory and immunomodulatory transcriptional
effects of the melanocortin analog Semax after AS. We
believe that further genome-wide non-coding RNAs profil-
ing can reveal novel insight to the peptide regulation in rat
brain after AS. This work was supported by grant from the
Russian Science Foundation 19-14-00268.
I.B. Filippenkov: None. V.V. Stavchansky: None. L.V.
Dergunova: None. N.Y. Glazova: None. N.G. Levits-
kaya: None. E.A. Sebentsova: None. L.V. Valieva: None.
D.D. Khukhareva: None. S.A. Limborska: B. Research
Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received);
Significant; Grant from the Russian Science Foundation
19-14-00268. N.F. Myasoedov: None.
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Association between prenatal stress and infant DNA
methylation
R. Sharma1,2, C. Zelgert2, P. Zimmermann2, G. Berg3, B.
Fabre3, R. Wilson1, J. Kriebel1, M. Frasch4, M.
Waldenberger1, S. Lobmaier2, M. Antonelli2,3
1Helmholtz Zentrum Munich, Munich, Germany, 2Dept. of
OBGYN, Klinikum rechts der Isar, Technical Univ of
Munich, Munich, Germany, 3IBCN, Facultad de Medicina,
Universidad de Buenos Aires, Buenos Aires, Argentina,
4Dept. of OBGYN & CHDD, Univ of Washington, Seattle,
WA, Seattle, WA, United States
Introduction: Maternal stress before and during pregnancy
can profoundly affect the in-utero and postnatal child
development. We hypothesize that children affected by
prenatal stress and thus epigenetic reprogramming might
show alterations of the fetal autonomic nervous system and
Hypothalamic- Pituitary axis.
Methods: We evaluated epigenome-wide methylation
sites in the saliva of infants born to stressed and non-
stressed mothers. In a prospective study of expecting
mothers, we screened women for chronic stress exposure at
the 28th week using the Cohen Perceived Stress Scale (PSS)
and Prenatal Distress questionnaires (PDQ). Expectant
mothers were classified into the stressed group (SG, PSS-
10 ≥ 19, N = 55); the control group (CG, PSS-10 < 19,
N = 55) matched 1:1 for parity, maternal age and
gestational age. On the day of delivery, maternal blood
and maternal head hair were collected for cortisol measure-
ments. DNA methylation was measured in saliva samples of
the newborn using the EPIC Bead Chip array (758132
CpG). In order to identify associations between cortisol and
methylation, linear regression models adjusting for con-
founders (sex, age and smoking) were run.
Results: Cortisol measurements were 63% higher in SG
versus CG. The top hit of the regression analysis is
cg15652683 (p = 2.16e-06), a CpG annotated to VIPR2
gene (Chr 7q36.3) that function as neurotransmitters and
neuroendocrine hormones.
Conclusions: Our work is ongoing and aims to see if the
prenatal stress can be employed as a predictive biomarker of
child neurodevelopmental outcome.
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Genetic and epigenetic regulation of chaperones in the
pathogenesis of pseudoexfoliation syndrome and
glaucoma
R. S. Kapuganti, B. Padhy, B. Hayat, P. P. Mohanty, D. P.
Alone
National Institute of Science Education and Research,
Bhubaneswar, Khurda, India
Introduction: Pseudoexfoliation (PEX) is a systemic age-
related disorder of protein aggregation with prominent
ocular manifestation. The etiology of PEX is multifactorial
involving both genetic and epigenetic factors. This study
aims to understand the genetic and epigenetic regulation of
molecular chaperones, clusterin (CLU) and heat shock
protein 70 (HSP70), respectively, in PEX pathology.
Materials and Methods: Fluorescence based capillary
electrophoresis was employed for genotyping variants in
CLU in an Indian cohort comprising of 136 PEX patients
and 89 controls. mRNA and proteins levels were checked
through qRT-PCR and western blotting. DNA methylation
of HSP70 was assessed through bisulfite sequencing.
Functional and molecular analysis were done by luciferase
reporter assays, chromatin immunoprecipitation, electro-
phoretic mobility shift assays, CRISPR deletions in
HEK293 and human lens epithelial (HLE-B3) cells.
Results: We found deregulated expression of CLU and
HSP70 in the lens capsule of PEX affected individuals. Two
variants in CLU, rs2279590 and rs3087554 showed a
significant association with PEX as risk factors. Further,
rs2279590 was found to be a functional variant that
regulates CLU expression through interaction with HSF1.
Further, bisulfite sequencing revealed DNA hypermethyla-
tion of HSP70 in PEX patients leading to its transcriptional
silencing which was further validated by its restoration by
DNA methyltransferase inhibitor in HLE-B3 cells.
Conclusions: This study shows that the molecular
chaperones are deregulated in PEX affected individuals,
754 J. del Picchia
contributing to the severity of the disease. CLU and HSP70
expression is regulated through different mechanisms, i.e.,
genetic and epigenetic, implying a complex interlink
between genetic and environmental effects in PEX
pathophysiology.
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EpiWE project, the molecular signature of violence in
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versità degli Studi di Milano, Milan, Italy, 2Department of
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IRCCS Ca’ Granda Ospedale Maggiore Policlinico,,
Milan, Italy, 4Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milano, Università degli Studi di
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Children’s Health and Service for Sexual and Domestic
Violence (SVSeD), Fondazione IRCCS Ca’ Granda Ospe-
dale Maggiore Policlinico,, Milan, Italy, 6Italian National
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Introduction: Violence against women represents a chronic
and global health plague and, due to its serious con-
sequences on women’s health, needs to be approached at
multisciplinary level. The short-term effects of violence are
more evident, while the exhaustive evaluation of long-term
effects still remains a challenge. It has been demonstrated
that the signs ofviolence interfere with genome plasticity
and gene expression through epigenetic mechanisms.
Materials and Methods: Cases were enrolled by
systematic sampling of victims of violence screened at the
Emergency Department in all the italian regions. The
psychological evaluation was performed in a cohort of 700
women. Biological samples from women’s victims were
analysed for differential methylation in a panel of genes
involved in post traumatic stress disorder.
Results: Quantitative methylation evaluation of a panel of
genes already reported as associated with trauma/stress-
related disorders was performed by MassARRAY (Agena,
Bioscience) in 63 victims and 80 controls. The evaluation of
LINE1 methylation, for global methylation assessment is in
progress, (pyrosquencing, Qiagen).
Conclusions: Early detection of post-traumatic stress
disorder cases represent a priority area of research, which is
focused not only on the susceptibility but also on the
resilience or not resilience to PTSD. The interaction
between genome and environmental factors, such as
violence, represents one of the major challenges in precision
and preventive medicine. By knowing the mechanisms
responsible for resilience, we can derive clues about the best
treatment and the best public policy.
A. Piccinini: None. P. Bailo: None. M. Miozzo: None.
S. Tabano: None. A. Kustermann: None. S.F.
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trans-acting sequence variants affecting protein abun-
dances of the genes encoding human ribosomal proteins
J. Ryu, C. Lee
Soongsil University, Seoul, Korea, Republic of
Introduction: Ribosomal protein is the essential compo-
nent of ribosome which is a molecular machinery to
translate the genetic information from the mRNA templates
into proteins. Their expression dysregulation is known to be
involved in the survival and growth of human cells, and
pathogenesis of human disease such as cancer. Never-
theless, little is known for how genetic factor regulated their
gene expression across expression stage from mRNA tran-
scription to translation.
Material and Methods: We analyzed the genetic
associations of the expression level at three different type
expression stages of 27 small ribosomal proteins and 43
large ribosomal proteins using mixed model.
Results: Eighteen quantitative trait loci (QTL) were
found out for protein abundance of 21 ribosomal proteins,
but not for the expression level for mRNA transcript and
ribosomal occupancy of their corresponding genes. Among
these QTLs, three pQTL were associated with three
different long non-coding RNA expression, which target
genes may produce ribosomal components or may control
the metabolic cues for ribosome synthesis, which are
involved in apoptosis, cell division, and cancer.
Conclusions: The results implied that the variants could
be identified through the different translation of target gene
by affecting expression level of lncRNA. Further studies
were needed to understand their underlying mechanism for
regulating gene expression of the ribosomal proteins.
Grant Reference: This work was supported by National
Research Foundation of Korea (NRF) grants funded by the
Ministry of Education (NRF-2018R1A6A3A11049586) and
by the Ministry of Science and ICT (NRF-
2018R1A2B6004867).
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Methylation profile of locally advanced rectal carcino-
mas and neoadjuvant chemoradiotherapy response
L. Matos do Canto1, M. C. Barros-Filho2, D. Marinho3, B.
E. C. Kupper2, M. F. S. Begnami4, C. Scapulatempo-Neto5,
B. M. Havelund1, J. Lindebjerg1, F. A. Marchi2, J.
Baumbach6, S. Aguiar-Jr2, S. R. Rogatto1,7
1Vejle University Hospital, Vejle, Denmark, 2A.C.Camargo
Cancer Center, Sao Paulo, Brazil, 3Psykiatrisk Center Sct
Hans, Roskilde, Denmark, 4Sirio-Libanes Hospital, Sao
Paulo, Brazil, 5Barretos Cancer Hospital, Barretos, Brazil,
6Technical University of Munich, Munich, Germany, 7Dan-
ish Colorectal Cancer Center South, Vejle, Denmark
Introduction: Locally advanced rectal cancer (LARC) is
treated with pre-operative chemoradiotherapy (nCRT) and
surgery. Patients achieving complete pathological response
(pCR, 15% to 30%) present better overall survival and
lower rates of recurrence compared to incomplete respon-
ders (pIR). Predicting treatment response markers are nee-
ded in these cases.
Methods: The methylation status of 32 pre-treatment
LARC biopsies (pCR=11, pIR=21) and 5 normal rectal
(NT) tissues was assessed (Infinium_EPIC_platform-Illu-
mina). Differentially methylated (DM) probes (false
discovery rate <5% and |Δβ|>0.15) were identified using
limma. A predictive classifier was developed using the
recursive feature elimination method and Diagonal Linear
Discriminant Analysis. The classifier performance was
calculated using the leave-one-out cross-validation test
(BRB array tools v.4.4.0). The methylation status of these
CpGs was evaluated in 77 LARC cases (32 array-dependent
and 45 independent) using bisulfite-pyrosequencing.
Results: The comparison between pCR and pIR revealed
24,428 and 75,398 DM CpGs, respectively. The CpGs
exclusively altered in each group (3,470 in pCR vs. NT and
54,440 in pIR vs. NT) were most frequently hypermethy-
lated in pCR (44% vs. 18% in pIR). pCR cases presented
more DM CpGs in promoter regions (49% vs. 37% in pIR)
and CpG islands (66% vs. 36% in pIR). The classifier,
based on 3CpGs, could discriminate cases with 100%
sensitivity and 90% specificity. Pyrosequencing confirmed
the DM status of the 3CpGs in pCR vs. pIR (p-values: CpG-
A: 0.0107, CpG-B: 0.0023, CpG-C: 0.0138). Conclusions:
The methylation profile of pCR cases diverges from pIR.
Three CpGs could predict nCRT response in LARC cases.
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Rogatto: None.
P20.66.C
Predicting the effects of regulatory variants by deep
learning
M. Schubach1,2, L. Krützfeldt1,2, S. Röner1,2, M. Kircher1,2
1Charité - Universitätsmedizin Berlin, Berlin, Germany,
2Berlin Institute of Health (BIH), Berlin, Germany
Machine learning methods are routinely applied in medicine
to prioritize and implicate deleterious genetic variants.
However, their focus has been on coding sequence. Here,
we address regulatory changes, jointly referring to changes
in promoter and distal regulatory elements covering ~5-20%
of the non-coding genome. Pathogenic regulatory variants
still correspond to a minority of known variants and quan-
titative readouts are not commonly available. Further, larger
reporter assay datasets are limited to specific loci or read-
outs of standing variation. While inherently biased and
unsuited for machine learning, these datasets provide
important validation and show that although myriad anno-
tations and scores exist, none consistently predicts experi-
mental regulatory variant effects.
Here, we develop a deep neural network (DNN), trained
on active and non-active regulatory regions from multiple
cell-types. We selected open chromatin peaks from publicly
available DNase data (e.g. HepG2, HEK293T, K562,
iPSCs) and use a multi-task convolutional network based
only on genomic sequence. The multi-task approach
provides critical insights into regulatory mechanisms and
our model outperforms others’ in predicting experimental
variant effects. This method inherently learns sequence
features of epigenetic factors and DNA binders, and enables
us to study sequence correlates of chromatin marks and
transcription factor binding. Using recent methods for DNN
interpretation, we extract important regulatory mechanisms
from our model, identifying motifs of various key players in
cell-type specific transcriptional regulation. We conclude
that DNNs have a high potential in predicting regulatory
effects and tissue-specific regulation, a critical step forward
in the interpretation of genome-wide variants in common
and rare diseases.
M. Schubach: None. L. Krützfeldt: None. S. Röner:
None. M. Kircher: None.
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Epigenome wide association study in Restless-Legs
Syndrome
N. Mirza-Schreiber1, S. Naher1, B. Schormair1, C. Zhao1,
R. Wilson2, M. Waldenberger2, C. Gieger2, M. Müller-
Nurasyid3, A. Peters4, C. Bachmann5, W. Paulus6, C.
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1Institute of Neurogenomics, Helmholtz Zentrum München
GmbH, German Research Center for Environmental
Health, Neuherberg, Germany, 2Institute of Molecular
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man Research Center for Environmental Health, Neuher-
berg, Germany, 3Institute of Genetic Epidemiology,
Helmholtz Zentrum München GmbH, German Research
Center for Environmental Health, Neuherberg, Germany,
4Institute of Epidemiology, Helmholtz Zentrum München
GmbH, German Research Center for Environmental
Health, Neuherberg, Germany, 5Department of Neurology,
Paracelsus Clinic, Osnabrück, Germany, 6Department of
Clinical Neurophysiology, Georg August University Göttin-
gen, Göttingen, Germany, 7Center of Parkinsonism and
Movement Disorders, Paracelsus-Elena Hospital, Kassel,
Germany, 8Neuropsychiatry Center Erding/Munich, Erd-
ing/München, Germany, 9MunichCluster for Systems Neu-
rology, Munich, Germany, 10Institute of Human Genetics,
Technical University of Munich, Munich, Germany
"Epigenetics" refers to the regulation of genetic information
processing. DNA methylation is an important epigenetic
mechanism which impacts gene expression in reaction to
genetic, developmental or environmental conditions. Con-
ventional epigenome-wide associations studies (EWAS)
inquire the relation of phenotypes to the genomic DNA
methylation pattern. We performed an EWAS of blood cell
DNA from Restless-Legs Syndrome (RLS) patients and
age- and sex-matched controls, using the Illumina EPIC
(850K) chip. EWAS results were generated by applying
mixed models in two datasets with 1000 and 2000 subjects,
respectively, submitted to rigorous quality control and
inflation correction, and then combined by meta-analysis.
We obtained three genome-wide significant methylation
sites. The strongest signal (p-value ≤ 1.6e-22) was located
within MLLT6. This site is annotated to be promotor asso-
ciated, suggesting promotor inactivation and consequent
down regulation of MLLT6 expression in RLS patients.
Gene products of MLLT6 and other MLL genes act as
transcriptional regulators of MEIS1, a gene highly asso-
ciated with RLS. Our study is currently in the replication
stage, where we intend to verify our findings. Because DNA
methylation and gene expression are tissue-specific, we also
generate EWAS and other omics results in post-mortem
brain tissue samples of 25 RLS patients and 15 controls
across four different brain regions. We thus aim for a
comprehensive understanding of RLS pathogenesis and
potential entry points for therapy.
Acknowledgments: International EU-RLS-GENE
Consortium
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SNP rs3087898 located next to m6A motif influences
gluten-induced RNA methylation changes that regulate
intestinal inflammation via allele-specific XPO1
translation
A. Olazagoitia-Garmendia1, L. Zhang2, P. Mera3, I.
Irastorza1, D. Serra3, L. Herrero3, J. A. Rodriguez1, C. He2,
J. R. Bilbao1, A. Castellanos-Rubio1
1University of the Basque Country (UPV/EHU), Leioa,
Spain, 2Howard Hugues Medical Institute, University of
Chicago, Chicago, IL, United States, 3Institut de Biomedi-
cina de la Universitat de Barcelona (IBUB), Universitat de
Barcelona, Barcelona, Spain
Celiac disease (CD) is an inflammatory intestinal disorder
that develops in genetically susceptible individuals upon
gluten ingestion. Gluten triggers a proinflammatory
response but the underlying mechanisms remain unclear.
CD-associated SNPs map mainly to noncoding regions, and
their effects are difficult to assess. Additionally, post-
transcriptional RNA modifications, including m6A, have
been shown to play key roles in different autoimmune
diseases. We hypothesize that noncoding CD-associated
SNPs can alter m6A levels in adjacent motifs, affecting
different cell processes and increase CD predisposition.
SNP rs3087898, on the 5’ UTR of XPO1 gene, is close to
an m6A motif. We confirmed methylation in this region,
and observed that the RNA carrying the CD-risk allele is
more methylated and binds YTHDF1 reader more effi-
ciently, promoting higher XPO1 translation. m6A-related
machinery KO produced lower XPO1 protein levels; while
gluten stimulations provoked increased XPO1, METTL3
and YTHDF1 expression and an enhanced XPO1-YTHDF1
interaction, both in vitro and in vivo. Finally, we confirmed
that the genotype of the associated SNP influences XPO1
protein levels in human intestinal biopsy samples. In addi-
tion, biopsies from CD patients stimulated with gluten also
presented XPO1, METTL3 and YTHDF1 induction. We
demonstrate that intergenic SNPs associated to autoimmune
diseases can alter m6A levels and contribute to pathogen-
esis. This is the first approach linking gluten with alterations
in m6A-related mechanisms. We observe that gluten indu-
ces the m6A machinery for an allele-specific increase of
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m6A levels on the 5’UTR of XPO1, leading to augmented
XPO1 and NFkB activation in patients harboring the risk
allele.
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(RUNX1) variants in familial platelet disorder with
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Introduction: RUNX1 bound to core binding factor β
(CBFβ) functions as an essential transcriptional regulator in
hematopoiesis. Pathogenic germline loss-of-function
RUNX1 variants cause autosomal-dominantly inherited
FPDMM, which is associated with thrombocytopenia,
thrombocytopathy, and predisposition to hematological
malignancies. To functionally characterize RUNX1 variants
of uncertain significance (VUS) and, thus, determine their
clinical impact, we established and applied a set of func-
tional assays.
Methods: To address heterodimerization with CBFβ,
expression and phosphorylation, and transcriptional activa-
tion, we applied a flow cytometry-based fluorescence
energy transfer (FRET) assay, western blotting, and
luciferase reporter assays in nephrogenic HEK293T and
hematopoietic HEL cells, respectively. In comparison to
RUNX1 wild-type and six known pathogenic RUNX1
variants, we analyzed nine previously reported germline
missense VUS.
Results: We observed significant impairments in our
functional assays for all known pathogenic variants. Three
out of nine VUS displayed significantly reduced activity
resembling known pathogenic variants. For two VUS, there
was clear evidence for a significant functional impairment,
while two other VUS showed slightly reduced functionality,
and the remaining two displayed activity comparable to
wild-type RUNX1.
Conclusions: We have successfully established func-
tional assays and proven their clinical applicability in
FPDMM families. Our data supports classification of three
RUNX1 VUS as (likely) pathogenic and two RUNX1 VUS
as (likely) benign. For two additional variants, there is clear
evidence for their functional relevance, but further inves-
tigations are required to prove their pathogenicity and to
facilitate conclusive classifications of the remaining
two VUS.
This project has been supported by the European
Hematology Association (EHA).
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Profiling the chromatin landscape of early neurodeve-
lopment using scATAC-seq
C. C. A. Mannens, L. Hu, E. P. Braun, P. Lönnerberg, S.
Linnarsson
Karolinska institutet, Solna, Sweden
Understanding the molecular processes underlying healthy
development of the human brain is crucial in the modelling
and investigation of neurodevelopmental disorders. While
many evolutionarily conserved developmental processes are
well studied in mouse models, our understanding of human-
specific neurodevelopmental processes is limited. Our lab
aims to provide transcriptomic and epigenomic reference
atlases with single-cell resolution. In this ongoing project,
we are characterizing chromatin accessibility of cell types in
the human brain during early development (5 – 13 p.c.w.)
using single-cell ATAC-sequencing.So far, we have
sequenced a few tens of thousands of cells and will profile
up to one million individual human cells, identifying both
region- and cell lineage-specific enhancers as well as enri-
ched motifs and gene accessibility. We use a two-step
approach to feature identification, first performing super-
ficial decomposition and clustering on binned genomic
ranges to stratify peak calling and then performing Hier-
archical Poisson Factorization on more detailed PeakxCell
data to identify lineages and cell types. We have identified
29 clusters and 325.484 unique peaks. 115.048 of these
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peaks are intergenic and 28.622 of these peaks (25%) don’t
align to any known element in the GENCODE GRCh38
reference, indicating the presence of unannotated cell line-
age specific enhancers. To validate the cluster identities and
lineages, our scATAC-seq data will be integrated with the
scRNA-seq data that has been acquired as part of the
Human Developmental Cell Atlas initiative. This combined
resource may serve as a reference for future studies relating
to development of the human nervous system.
European Union - H2020-SC1-BHC-2018-2020 -
BRAINTIME
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Monocyte heterogeneity in health and inflammatory
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United Kingdom, 3Manchester Collaborative Centre for
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Rheumatoid arthritis (RA) is a common chronic inflam-
matory disease affecting 1% of the population. T-cells play
a key role in initiating and/or maintaining the disease and
antigen presentation is important in mediating this. Mono-
cytes, precursors of antigen presenting cells, are typically
characterised by expression of two cell surface proteins
(CD14 and CD16). However, recent studies have shown
further heterogeneity, some associated with RA. Under-
standing monocyte heterogeneity is therefore crucial in
understanding the mechanisms leading to autoimmunity.
We therefore sought to investigate peripheral blood mono-
cyte heterogeneity, using single cell RNA-seq (scRNA-seq),
from three healthy volunteers and three patients with RA.
Overall, we analysed 17,831 profiles and identified fourteen
clusters. There was a clear separation of classical (CD14
+CD16−) and non-classical (CD14−CD16+) monocyte sub-
types, as well as intermediate (CD14+CD16+) and “natural
killer” (0.38%) identities. Interestingly, we identified a
cluster defined by expression of the pro-inflammatory
cytokine interleukin 1 beta (IL-1β) in both healthy and
RA samples (3.62%), which recently has been shown to be
expanded in RA synovia. These findings show that mono-
cytes are indeed more diverse than previously indicated,
highlighting the power of scRNA-seq to uncover this het-
erogeneity. Further work will be required to validate these
findings and functionally define a role for this IL-1β
monocyte subset. However, the presence of pro-
inflammatory monocytes in the blood of healthy indivi-
duals would suggest that they are not a feature of RA
specifically, but may interact with other cell types to
influence or cause disease. Supported by the MRC
(MC_PC_15072) and Versus Arthritis (21745, 20385).
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DNA methylation analysis of multiple imprinted DMRs
in Sotos syndrome reveals IGF2-DMR0 as a DNA
methylation-dependent, P0 promoter-specific enhancer
H. Watanabe1, K. Higashimoto1, N. Miyake2, S. Morita3, T.
Horii3, M. Kimura3, T. Suzuki4, T. Maeda1, H. Hidaka1, S.
Aoki1, H. Yatsuki1, N. Okamoto5, T. Uemura1, I. Hatada3,
N. Matsumoto2, H. Soejima1
1Saga University, Saga, Japan, 2Yokohama City University
Graduate School of Medicine, Yokohama, Japan, 3Gunma
University, Maebashi, Japan, 4Nagoya University, Nagoya,
Japan, 5Osaka Women’s and Children’s Hospital, Osaka,
Japan
Haploinsufficiency of NSD1, which dimethylates histone
H3 lysine 36 (H3K36), causes Sotos syndrome (SoS), an
overgrowth syndrome. DNMT3A and DNMT3B recognizes
H3K36me3 through PWWP domain to exert de novo DNA
methyltransferase activity and establish imprinted differen-
tially methylated regions (DMRs). Since decrease of
H3K36me3 and genome-wide DNA hypomethylation in
SoS were observed, hypomethylation of imprinted DMRs in
SoS was suggested. We explored DNA methylation status
of 28 imprinted DMRs in 31 SoS patients with NSD1 defect
and found that hypomethylation of IGF2-DMR0 and IG-
DMR in a substantial proportion of SoS patients. Luciferase
assay revealed that IGF2-DMR0 enhanced transcription
from the IGF2 P0 promoter but not the P3 and P4 pro-
moters. ChIP-qPCR revealed active enhancer histone
modifications at IGF2-DMR0, with high enrichment of
H3K4me1 and H3K27ac. CRIPSR-Cas9 epigenome editing
revealed that specifically induced hypomethylation at IGF2-
DMR0 increased transcription from the P0 promoter but not
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the P3 and P4 promoters. NSD1 knockdown suggested that
NSD1 targeted IGF2-DMR0; however, IGF2-DMR0 DNA
methylation and IGF2 expression were unaltered. This
study could elucidate the function of IGF2-DMR0 as a
DNA methylation dependent, P0 promoter-specific enhan-
cer. NSD1 may play a role in the establishment or main-
tenance of IGF2-DMR0 methylation during the post-
implantation period.
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Hidaka: None. S. Aoki: None. H. Yatsuki: None. N.
Okamoto: None. T. Uemura: None. I. Hatada: None. N.
Matsumoto: None. H. Soejima: None.
P20.74.B
Methylation profile at 14q32 in a family with DLK1
small deletion associated with Temple syndrome
B. Neus1, D. Monk2, E. Gabau1, C. Aguilera1, A. Ruiz1, N.
Spataro1, M. Guitart1
1Corporació sanitària Parc taulí, SABADELL, Spain, 2IDI-
BELL Institut d’Investigació Biomèdica de Bellvitge,
Hospitalet de Llobregat, Spain
Introduction:Temple syndrome (TS) is a rare condition
caused by an abnormal expression of genes at the imprinted
locus 14q32 that harbors a cluster of imprinted genes. The
parental origin dependent expression pattern of imprinted
genes is regulated by the sperm-derived imprinting control
region, the IG-DMR, that regulates the somatic establish-
ment of the MEG3-DMR on the paternal allele, as well as
the maternally methylated MEG8-DMR and DLK1-DMR
intervals.
Methodology:A female two years old with mild
psychomotor retardation and hypotonia presents a 69 kb
deletion of DLK1 identified by aCGH (8x60K ISCA,
Agilent technologies). The MS-MLPA (MS-MLPA probe-
mix ME032-A1, MRC Holland) technique was used to
determine the inheritance, methylation pattern and dose
analysis. Bisulphite PCR and pyrosequencing was used to
assess methylation at imprinted DMRs not included in the
MS-MLPA assay.
Results:The deletion is inherited from her father and from
her grandmother, also her uncle is a carrier. The methylation
pattern at the IG-DMR and MEG3-DMR was normal in
carriers by MS-MLPA. It was confirmed by pyrosequen-
cing, which also revealed carriers were hypomethylated at
the DLK1 and MEG8-DMRs consistent with maternal
transmission, whilst the proband presented with mild
hypermethylation at the DLK1-DMR.
Conclusions:The loss of expression of DLK1 on the
paternal allele is responsible for the clinical features of
psychomotor retardation and mild hypotonia suggestive of
Temple syndrome. This small deletion narrowed the
minimal region and methylation results supports that
DLK1 loss of function is sufficient to cause the main
features of Temple syndrome.
B. Neus: None. D. Monk: None. E. Gabau: None. C.
Aguilera: None. A. Ruiz: None. N. Spataro: None. M.
Guitart: None.
P20.75.C
Pervasive and CpG-dependent promoter-like character-
istics of transcribed enhancers
R. Steinhaus1,2, T. Gonzalez3,4, D. Seelow1,2, P. N.
Robinson3,5
1Berlin Institute of Health, Berlin, Germany, 2Charité –
Universitätsmedizin Berlin, Berlin, Germany, 3The Jackson
Laboratory for Genomic Medicine, Farmington, CT, United
States, 4Harvey Mudd College, Claremont, CA, United
States, 5Institute for Systems Genomics, University of
Connecticut, Farmington, CT, United States
Introduction: The temporal and spatial expression of genes
is controlled by promoters and enhancers. Findings obtained
over the last decade that not only promoters but also
enhancers are characterized by local transcription have
challenged the traditional notion that promoters and
enhancers represent distinct classes of regulatory elements.
Over half of human promoters are associated with CpG
islands (CGIs), relatively CpG-rich stretches of generally
several hundred nucleotides that are often associated with
housekeeping genes. Only about 6% of transcribed enhan-
cers defined by CAGE-tag analysis are associated
with CGIs.
Results: Here we present a detailed analysis of the
relation between enhancer and promoter characteristics and
the presence or absence of CGIs. We show that transcribed
enhancers share a number of CGI-dependent characteristics
with promoters, including statistically significant local over-
representation of core promoter elements. CGI-associated
enhancers are longer, display higher directionality of
transcription, greater expression, and a lesser degree of
tissue specificity, as well as a higher frequency of
transcription-factor binding events than enhancers not
associated with CGIs. Genes putatively regulated by CGI-
associated enhancers are enriched for transcription regulator
activity.
Conclusions: Our findings show that CGI-associated
enhancers display a series of characteristics related to
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sequence, expression, and function that distinguish them
from transcribed enhancers not associated with CGIs.
R. Steinhaus: None. T. Gonzalez: None. D. Seelow:
None. P.N. Robinson: None.
P20.76.A
Characterisation of cis-regulatory elements of GJB2 and
whole genome sequencing of heterozygous patients with
NSHL
A. Le Nabec, A. Quillévéré, C. Le Maréchal, C. Férec, S.
Moisan
Inserm UMR 1078, Brest, France
Three-dimensional chromatin organization plays a key role
on gene expression. Gene regulation depends on cis-reg-
ulatory elements which can interact with gene promoter by
chromatin loop. Alteration of chromatin architecture and/or
cis-acting elements can lead to cis-ruption disorder.
Numerous unelucidated nonsyndromic hearing loss and
deafness 1 (DFNB1) cases carrying out only one hetero-
zygous pathogenic mutation on Gap Junction Beta 2 (GJB2)
gene, led to strongly suggest the presence of distant cis-
regulation. Thanks to chromatin conformation study we
previously identified several GJB2 cis-regulatory elements
and purposed a DFNB1 3D looping model. Now, to more
characterize these cis-acting elements, we analysed coop-
erative effect of these regions, we combined few regions
together and showed that association of two enhancers
increased the enhancer activity. Moreover, we focused on
10 patients with incomplete genotype. We realized a whole
genome sequencing with HiSeq 4000 by IntegraGen
Genomics. The results are currently being analysed. Our
results allow to confirm an enhancer activity of these cis-
regulatory regions and their cooperative effects. Then, we
expect that whole genome sequencing will allow to identify
other mutations with loss / gain function or CNV which can
explain pathology of our patients.
A. Le Nabec: None. A. Quillévéré: None. C. Le
Maréchal: None. C. Férec: None. S. Moisan: None.
P20.77.B
Identification of Mowat-Wilson Syndrome (MOWS)
ZEB2 gene-desert located enhancers active during
neural differentiation of human induced pluripotent
stem cells
J. C. Birkhoff1, R. W. W. Brouwer1, P. Kolovos2, A. L.
Korporaal1, A. Bermejo-Santos1, I. Boltsis1, K. Nowosad1,3,
M. C. G. N. van den Hout1, F. G. Grosveld1, W. F. J. van
IJcken1, D. Huylebroeck1,4, A. Conidi1
1Erasmus Medical Center, Rotterdam, Netherlands,
2Democritus University of Thrace, Alexandroupolis,
Greece, 3Medical University of Lublin, Lublin, Poland,
4KU Leuven, Leuven, Belgium
Introduction: The transcription factor ZEB2 exerts multi-
ple functions in vivo and uses different mechanisms of
action and protein partners for controlling embryonic and
adult cell fate decisions and maturation. As shown in var-
ious cell type specific knockout mouse models, some of
these mechanisms explain major aspects of human MOWS
(OMIM#235730). ZEB2 is located downstream of a ~3,3
Mb-long gene desert, which is evolutionary conserved in
other vertebrates. We mapped chromatin conformation
changes here over ~7.4 Mb (chr2:143270465-150642631;
GRCh37/hg19) to identify regulatory elements (REs) of
ZEB2.
Material and Methods: Temporal Targeted Chromatin
Capture (T2C) was used in human induced Pluripotent Stem
Cells (iPSCs) during neural differentiation. Candidate REs,
and their co-operations, were characterized by luciferase
assays in transiently transfected cells, including neuropro-
genitor cells (NPCs).
Results: We identified three novel, co-operative enhan-
cers ~500kb upstream the ZEB2 transcription start site.
They display strongest proximity (in T2C) with the ZEB2
promoter at early NPC/rosette cell stage, where ZEB2
mRNA levels increase significantly.
Conclusions: This work illustrates the value of T2C in
terms of high-resolution mapping novel REs at affordable
sequencing cost. We are the first to document the dynamics
of far-distant neural-active REs for ZEB2 located in the
upstream gene desert. T2C can thus be used to identify and
characterize REs that might be affected in those MOWS
patients where no ZEB2 protein-encoding mutation could
be identified.
J.C. Birkhoff: None. R.W.W. Brouwer: None. P.
Kolovos: None. A.L. Korporaal: None. A. Bermejo-
Santos: None. I. Boltsis: None. K. Nowosad: None. M.C.
G.N. van den Hout: None. F.G. Grosveld: None. W.F.J.
van IJcken: None. D. Huylebroeck: None. A.
Conidi: None.
P20.78.C
Loss of imprinting of the human-specific imprinted gene
ZNF597 causes prenatal growth retardation and dys-
morphic features reminiscent of Silver-Russell
syndrome
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K. Yamazawa1, T. Inoue2, Y. Sakemi3, T. Nakashima3, H.
Yamashita3, K. Khono4, H. Fujita5, K. Enomoto6, K.
Nakabayashi7, K. Hata7, M. Nakashima1, T. Matsunaga1, A.
Nakamura2, K. Matsubara2, T. Ogata8, M. Kagami2
1Medical Genetics Center, National Hospital Organization
Tokyo Medical Center, Tokyo, Japan, 2Department of
Molecular Endocrinology, National Research Institute for
Child Health and Development, Tokyo, Japan, 3Department
of Pediatrics, National Hospital Organization Kokura
Medical Center, Fukuoka, Japan, 4Navitas Clinic Kawa-
saki, Kawasaki, Japan, 5Meguro Avenue Kid’s Clinic,
Tokyo, Japan, 6Enomoto Children’s Clinic, Moriya, Japan,
7Department of Maternal-Fetal Biology, National Research
Institute for Child Health and Development, Tokyo, Japan,
8Department of Pediatrics, Hamamatsu University School
of Medicine, Hamamatsu, Japan
Introduction: ZNF597, encoding a zinc finger protein, is
the human-specific maternally expressed imprinted gene
located on 16p13.3. The parent-of-origin expression of
ZNF597 is regulated by the ZNF597:TSS-DMR of which
only paternal allele acquires methylation during post-
implantation period. Overexpression of ZNF597 may con-
tribute to some of the phenotypes associated with maternal
uniparental disomy of chromosome 16 (UPD(16)mat), and
some UPD(16)mat patients presenting with Silver-Russell
syndrome (SRS) phenotype have recently been reported.
Materials and Methods: A 6-year-old boy partially
presented with SRS-like features such as prenatal growth
restriction, macrocephaly at birth, forehead protrusion in
infancy, and clinodactyly of the right fifth finger. Methyla-
tion, expression, microsatellite marker, single nucleotide
polymorphism array, and trio whole-exome sequencing
analyses were conducted.
Results: Isolated hypomethylation of the ZNF597:TSS-
DMR and subsequent loss of imprinting and overexpression
of ZNF597 were confirmed in the patient. Epigenetic
alterations such as UPD and other methylation defects were
excluded. Pathogenic sequence or copy number variants
affecting his phenotypes were not identified, indicating that
primary epimutation occurred postzygotically.
Conclusions: This is the first case of isolated ZNF597
imprinting defect, who showed prenatal growth retardation
and some dysmorphic features reminiscent of SRS. ZNF597
overexpression may comprise the underlying molecular
mechanism of developing SRS phenotype in UPD(16)mat.
Further investigations and case series are needed to
establish a new imprinting disorder entity involving the
ZNF597 domain.
Grants: This work was supported by a Grant-in-Aid for
Scientific Research (B) from the Japan Society for the
Promotion of Science (16H05362).
K. Yamazawa: None. T. Inoue: None. Y. Sakemi:
None. T. Nakashima: None. H. Yamashita: None. K.
Khono: None. H. Fujita: None. K. Enomoto: None. K.
Nakabayashi: None. K. Hata: None. M. Nakashima:
None. T. Matsunaga: None. A. Nakamura: None. K.
Matsubara: None. T. Ogata: None. M. Kagami: None.
P21 New Treatments for Genetic Disorders
P21.1.A
CLOVES syndrome as a consequence of a PIK3CA
variant the" long and far " way to confirm the diagnosis
and therapeutic options
S. Morlot, B. Auber, G. Schmidt, S. von Hardenberg, B.
Schlegelberger
Medical School Hanover, Hannover, Germany
We report on an 8-year-old Iranian boy who was diagnosed
with CLOVES syndrome, a disease within the PIK3CA-
related overgrowth spectrum (PROS) caused by mosaic
pathogenic PIK3CA variants, characterized by congenital
lipomatous asymmetric overgrowth of the trunk as well as
lymphatic, capillary, venous and combined vascular mal-
formations, epidermal nevi, skeletal and spinal anomalies.
The patient presented with a large "portwine", multiple
superficial small hemangiomas, macrodactylia of fingers
and toes, syndactylies and swelling on the right breast. The
patient reported pain in the upper and lower extremities.
Motor and cognitive development was age-appropriate.
Exome analysis from peripheral blood revealed no patho-
genic variant in the genes PTPN11, PIK3CA, AKT3,
PIC3R2, PTEN, SDHB, KLLN, SDHD, GNAQ and AKT1
(Macrogen, Korea)).
We suspected mosaic CLOVES syndrome due to a
postzygotic PIK3CA variants gained in the early embryonic
period. We performed parallel panel sequencing (IDT
custom panel) from different tissues. No pathogenic variant
was detected in the PIK3CA gene in blood and oral mucosa.
In a skin punch (hypertrophic hand) the pathogenic PIK3CA
variant c.328_330del p.(Glu110del) was detected with an
allele frequency of 4%. A fibroblast culture of this punch
reveled the pathogenic PIK3CA variant with an allele
frequency of 44%.
There is no curative therapy available. However in a
clinical trial with the PIK3CA inhibitor BYL719 (Alpelisib)
carried out in 19 patients with CLOVES syndrome
improved symptoms. (Venot et al. 2018; PMID:
29899452)). In Germany Alpesilib is not yet approved for
the treatment of CLOVES syndrome, but its application for
off-label use is aspired.
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P21.5.B
Stability and safety of induced pluripotent stem cells for
cartilage regeneration
M. Poulou1, I. Papathanasiou2, E. Mourmoura2, T.
Brantzos1, I. Sfougataki3, A. Mertzanian3, E. Goussetis3, V.
Trachana4, A. Tsezou2,4, M. Tzetis1
1National and Kapodistrian University of Athens, Faculty of
Medicine, Laboratory of Medical Genetics, Athens, Greece,
2University of Thessaly, Faculty of Medicine, Laboratory of
Cytogenetics and Molecular Genetics, Larissa, Greece,
3Aghia Sofia Children’s Hospital, Bone Marrow Trans-
plantation Unit, Athens, Greece, 4University of Thessaly,
Faculty of Medicine, Dept. of Biology, Larissa, Greece
Introduction: Osteoarthritis (OA), the most common form
of degenerative joint disease of adult population worldwide
is expected to increase in incidence due to aging population.
Pharmacological treatments aim at pain relief, while surgi-
cal joint replacement is costly and requires a long recovery
period. The limited ability of articular cartilage to regenerate
make approaches for cartilage regeneration a reasonable
approach. Patient-specific induced pluripotent stem-cells
(iPSCs) and production of derived mesenchymal stem-cells
(iMSCs) from mesenchymal bone marrow stem-cells (BM-
MSCs) were tested and evaluated regarding their pro-
liferative capacity and stability for potential use for cartilage
regeneration.
Material and Methods: BM-MSCs cells isolated from
the iliac crest of OA patients and normal controls, were
reprogrammed to produce iPSCs and derived iMSCs.
Reprogramming to generate iPSCs, was done using a
modified synthetic mRNA method. Different clones of each
undifferentiated iPSC line were tested for their genetic
stability, pluripotency, teratoma formation and for their
patient-specific origin as previously described. After
mesenchymal differentiation and expansion each iPSC-
MSC line was examined for specific MSC markers. CNV
detection was done using aCGH.
Results: The clinical safety of the produced cells was
proven even in higher passages, by analysis of their genetic
stability through array-CGH of various clones of iPSCs and
iMSCs cells, in comparison to the original MSCs.
Conclusions: Array-CGH revealed a chromosomal
pattern exhibiting mostly polymorphic CNVs thus proving
genetic stability. Some clones acquired CNV deletions after
continuous passaging, a phenomenon extensively observed
and related to culture adaptation. Work sponsored under the
Operational Program “Competitiveness, Entrepreneurship
& Innovation” (EPAnEK)
M. Poulou: None. I. Papathanasiou: None. E. Mour-
moura: None. T. Brantzos: None. I. Sfougataki: None. A.
Mertzanian: None. E. Goussetis: None. V. Trachana:
None. A. Tsezou: None. M. Tzetis: None.
P21.7.A
Efficient and concise protocol for neural conversion of
human fibroblasts as an autologous cell source for an
early cyto-gene therapy of genetic based neurodegen-
erative diseases
S. S. Hosseini Farahabadi1,2, K. Ghaedi1,2, M. Nasr-
Esfahani2
1Department of Cell and Molecular Biology and Micro-
biology, Faculty of Biological Science and Technology,
Isfahan, Iran, Islamic Republic of, 2Department of Cellular
Biotechnology at Cell Science Research Center, Royan
Institute for Biotechnology, ACECR, Isfahan, Iran, Islamic
Republic of
Introduction: A revolutionary new approach to produce
cells is to induce transdifferentiation to make it conven-
tional in therapeutic strategies. In this project, we describe a
brief cocktail of small molecules including Dorsomorphin
(DSM) and Trichostatin A (TSA) to produce safe induced
neuroectodermal cells (iNCs). These iNCs can be used for a
combinatorial cell-gene therapy strategy to treat or cure of
genetic-based neurodegenerative diseases such as Amyo-
trophic Lateral Sclerosis (ALS) in newborns.
Materials and Methods: Human fibroblast cells were
treated with DSM, in presence of TSA and a cocktail of
neurotrophic factors including brain-derived neurotrophic
factor, glial cell line-derived neurotrophic factor and ciliary
neurotrophic factor, in neural induction medium. On day 6,
cells were seeded on culture dishes coated with poly-L-
ornithine + Laminin + Fibronectin. Cell characterization
was carried out by morphological tracking, gene expression
profiling of markers including Vimentin, PAX6 and Nestin
by real time PCR, immunofluorescence staining and flow
cytometry. Statistical analysis was performed by SPSS in
three independent replicate. Comparisons were analyzed by
independent-sample t-test and One-Way ANOVA, p < 0.05.
Results: This protocol mediated neuroectodermal con-
version of human fibroblasts within 12 days with an average
efficiency of 24%, promises a fast strategy to produce
human iNCs for cyto-gene therapy of nervous system
disorders.
Conclusions: Our protocol is a safe conversion protocol
which shortens path of clinical application of iNCs.
Benefiting from these important features, it makes it
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possible for us to edit genetic mutations of newborns with
neural disorders such as ALS with an early cell-gene
therapy strategy.
S.S. Hosseini Farahabadi: None. K. Ghaedi: None. M.
Nasr-Esfahani: None.
P21.8.B
The pharmacological chaperone N-n-Butyl-
deoxygalactonojirimycin enhances β-galactosidase pro-
cessing and activity in the fibroblasts of a patient with
infantile GM1-gangliosidosis
F. Mohamed1, M. Al-Sorkhy2, M. Ghattas2, L. Al-Gazali1,
O. Al-Dirbashi1, F. Al-Jasmi1, B. R. Ali1
1United Arab Emirates University, Al-Ain, United Arab
Emirates, 2Al-Ain University, Al-Ain, United Arab Emi-
rates
Introduction: Variants affecting the conformations of
secretory and membrane proteins are usually retained in the
ER then degraded. However, some partially misfolded ER-
retained proteins may retain some biological activity and are
therefore good drug targets. GM1-Gangliosidosis, a lyso-
somal storage disorder, is associated with mutations in
GLB1 leading to β-galactosidase (β-Gal) deficiency. Deox-
ygalactonojirimycin (DGJ) and its derivatives are pharma-
ceutical chaperones that could bind to mutated β-Gal in the
ER promoting its folding and trafficking to lysosomes.
Patient and Methodology: An Emirati child has been
diagnosed with infantile GM1-Gangliosidosis with GLB1
mutations (p.D151Y). Confocal microscopy and biochem-
ical analysis were used to establish the subcellular
localization of β-Gal and its enzymatic activity was
measured using 0.8mM 4-Methylumbelliferyl β-D-
galactopyranoside.
Results: We show that p.D151Y β-Gal in patient’s
fibroblasts retained <1% residual activity due to impaired
cellular processing and trafficking. Molecular simulation
analysis revealed that the amino acid substitution signifi-
cantly affected the enzyme conformation. However, p.
D151Y β-Gal was amenable for partial rescue by culturing
the fibroblasts in the presence of glycerol or at low
temperature. The DGJ derivatives butyl (NB-DGJ) and
nonyl (NN-DGJ) were examined as potential pharmacolo-
gical chaperones for the mutant enzyme. Although NN-DGJ
showed higher affinity to β-Gal, it didn’t show a significant
enhancement in p.D151Y β-Gal activity. However, NB-
DGJ promoted p.D151Y β-Gal maturation and enhanced its
activity up to ~4.5% of normal control activity within 24hrs
which significantly increased to ~10% over a period of
six days.
Conclusions: NB-DGJ is a promising pharmacological
chaperone in infantile GM1 missense variants.
Grant number: UAEU31R134.
F. Mohamed: None. M. Al-Sorkhy: None. M. Ghattas:
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Jasmi: None. B.R. Ali: None.
P21.9.C
Medical therapy of vascular Ehlers-Danlos syndrome:
Challenging the paradigm of interchangeable antihy-
pertensive drugs
N. Dubacher1,2, S. M. Caspar1,3, J. Meienberg1, G. Matyas1
1Center for Cardiovascular Genetics and Gene Diagnos-
tics, Schlieren-Zurich, Switzerland, 2University Hospital
Balgrist, University of Zurich, Switzerland; Institute for
Biomechanics, ETH Zurich, Zurich, Switzerland, 3Labora-
tory of Translational Nutrition Biology, ETH Zurich,
Schwerzenbach, Zurich, Switzerland
Introduction: Patients with the rare connective tissue dis-
order vascular Ehlers-Danlos syndrome (vEDS) are at
increased risk for fatal aortic ruptures. Using a mouse vEDS
model, we established an objective read-out system for the
assessment of the clinically highly relevant biomechanical
integrity of the murine thoracic aorta. By means of our
novel read-out system, we aimed to assess the effects of
antihypertensive drugs on the biomechanical integrity of the
weakened murine vEDS thoracic aorta as potential medical
therapy in vEDS.
Method: Mice modelling vEDS were treated with the
beta-blockers celiprolol (Selectol®) or bisoprolol (Bilol®) or
the ARB losartan (losartan Actavis®) for 4 weeks. 1.5-mm-
long sections of the ascending and descending murine
thoracic aorta were mounted on a tissue puller and
uniaxially stretched until rupture while recording the tensile
force (in mN).
Results: The rupture force was significantly lower in
untreated heterozygous compared to wild-type mice and
decreased with increasing distance from the heart for both
heterozygotes and wild-types. We showed that celiprolol
but neither bisoprolol nor losartan increased the thoracic
aortic rupture force in heterozygous mice (PMID:31056650
and 31693161).
Conclusions: Our novel and objective read-out system is
suitable for detecting significant differences in the rupture
force of the murine thoracic aorta and allows the assessment
of the effect of candidate drugs on the biomechanical
integrity of the aorta. Although the added value of other
antihypertensive drugs in vEDS, if any, is unknown,
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celiprolol, but not losartan and bisoprolol, is currently the
medical therapy of choice for vEDS, until further evidence
emerges.
N. Dubacher: None. S.M. Caspar: None. J. Meienberg:
None. G. Matyas: None.
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P22.04.A
The story of BRCA1:c.4096+3A>G - is it pathogenic?
V. Stefansdottir1, J. J. Jonsson1,2,3,4
1Department of Genetics and Molecular Medicine, Land-
spitali National University Hospital, Reykjavik, Iceland,
2Dept. of Biochemistry and Molecular Biology, Univ. of
Iceland, Reykjavik, Iceland, 3Faculty of Medicine, Univ. of
Iceland, Reykjavik, Iceland, 4Genetical Committee of the
University of Iceland and Landspitali, Reykjavik, Iceland
The founder pathogenic variants (PV), BRCA1:c.5074G>A
and the BRCA2:c.767_771delCAAAT were for many years
thought to be the only BRCA PVs in the Icelandic popu-
lation. Of the two, the c.767_771delCAAAT is more pre-
valent, with 0.8% carrier rate. Therefore, genetic testing was
mostly limited to these two variants. The extensive elec-
tronic pedigrees used in genetic counselling in Iceland,
show clearly the hereditary breast and ovarian (HBOC)
patterns in families, aiding decision on genetic testing.
However, in one part of the country, the Westfjords, hardly
any invidual tested postive for either of the founder PVs
despite many HBOC families with classic BRCA1 cancer
pattern. By sequencing the BRCA genes, the first patient
tested positive for the BRCA1 c.4096+3A>G in 2010, and
in 2014, another one. The two patients were related within
6°of relatedness. But, the variant had conflicting pathoge-
nity in ClinVar, mostly of unknown significance. In 2017, a
Danish study classified the variant as VUS (1), based
mainly on one homozygous healthy individual. We sought
information from deCode genetics (personal communica-
tion), which established 0.2% population frequency and
pathogenity, with 16 fold risk of ovarian cancer and 3.5 fold
risk of breast cancer. In 2019, an Icelandic study found their
data to accord with the variant being pathogenic (2). Of the
467 tested for this variant, 87 are postive (19%). All posi-
tive individuals trace their ancestry to the Westfjords and no
other significant HBOC PV has been found there. The
variant is now routinely tested for, in HBOC families with
roots in the Westfjords.
V. Stefansdottir: None. J.J. Jonsson: None.
P22.05.B
Evaluating cancer genomics education for mainstream
clinicians in South East London, Kent, Surrey and East
Sussex; can technology bridge the gaps?
A. E. Coulson1, E. Cox2, J. Malawana2, Z. Beydoun3, V.
Reeve3, A. Kulkarni1, V. Tripathi1
1South East Thames Regional Genetics Service, Guy’s and
St Thomas’ NHS Foundation Trust, London, United King-
dom, 2Medics. Academy, London, United Kingdom, 3Guy’s
and St Thomas’ NHS Foundation Trust, London, United
Kingdom
Introduction: Genomic testing in the UK is changing, and
cancer clinicians are increasingly utilising genomics to
inform treatment, prognosis and future risks. The UK
Government has called for improved education in appro-
priately ordering and interpreting genomic tests. We aimed
to evaluate existing local cancer genomics training to
understand training needs and barriers, contributing to the
development of a new online platform (Nucleus) for future-
proof, scalable training.
Materials and Methods: Delegates from Guy’s Hospital
Cancer Genetics course completed questionnaires about
cancer genomics education. This evidence contributed to
development of Nucleus, an online education platform. User
testing of an initial Nucleus module was assessed to
determine the utility of a change in delivery of education.
Results: Delegates identified time (56%) and funding
(44%) as barriers to accessing training. Prior to Nucleus
development, 55% of delegates felt online training was an
acceptable mode for education, though face-to-face was
popular (77%). Following implementation, Nucleus user
testing was highly positive. Users rated it as relevant to
practice (x̄=4.57/5), with appropriate length (x̄=4.29/5) and
pace (x̄=4.14/5), and felt it was easy to navigate.
Conclusions: Education is a priority for the implementa-
tion of new genomic testing services. Face-to-face teaching
is valued but barriers and scalability of training for larger
clinician groups must be considered. Online training can
overcome barriers by providing instant access to relevant
and appropriate education, as demonstrated by Nucleus.
Future work will develop further modules and blended-
learning approaches to education.
A.E. Coulson: None. E. Cox: None. J. Malawana:
None. Z. Beydoun: None. V. Reeve: None. A. Kulkarni:
None. V. Tripathi: None.
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Governance of Cancer Genetic Counseling: A Systema-
tic Literature Review
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L. Abu Jamous, H. Abdelrazeq, A. Tbakhi, M. Odeh
King Hussain Cancer Center, Amman, Jordan
Cancer Genetic Counselling (CGC) involves trained per-
sons to help individuals or family members comprehending
genetic disorders, heredity and risk factors, with the aim to
choose the appropriate course of action in the affected
family members. This research is aimed at informing (using
the systematic literature review method) the existence and
effectiveness of automated CGC governance frameworks.
The gap in the literature revealed the absence of a for-
malised approach to linking CGC processes which are
currently highly dependent on the person involved in
counseling sessions. Although professional guidelines are
used to identify patients at risk, they are not in a standar-
dised form. Few resources exist in CGC service assessment
which are mainly the National Cancer Institute Community
Cancer Centers (NCCCP) and the CGC Assessment Tool
(CGCAT) tool. Also, four core bodies are mainly respon-
sible for generating policies for CGC services with no major
differences between their policy documents. CGC Quality
requirements include accountability, value, safety, equity,
sustainability, effectiveness, etc. Seven core CGC processes
are mainly followed from patient identification to post-
counseling. However, there is no consensus on metrics to
inform the satisfaction of quality requirements of CGC
programmes. Moreover, no comprehensive CGC frame-
works exit that reflect the interaction between standards,
quality requirements, policies, and processes. In conclusion,
without such interactions, automatic governance for each
CGC case is not possible which has led the researchers to
embark on developing a CGC process architectural frame-
work to inform governance of CGC processes, and their
effectiveness in reducing incidence and mortality in relation
to hereditary.
L. Abu Jamous: None. H. Abdelrazeq: None. A.
Tbakhi: None. M. Odeh: None.
P22.09.C
Communication between specialist genetic services,
CCGs and GPs
J. Gordon1, J. Adlard2, R. Jewell2, J. Hayward2
1Hull Teaching Hospitals NHS Trust, Hull, United King-
dom, 2Yorkshire Regional Genetics Service, Leeds, United
Kingdom
Background: Genomics services are advancing rapidly.
Development of these services must allow for effective
information dissemination to, and communication with,
primary care.
Methods: We developed an e-survey to assess Clinical
Commissioning Groups’ (CCGs) mechanisms of informa-
tion dissemination and General Practitioners’ (GPs) access
to specialist advice. All 17 local CCGs were invited to
participate. A semi-structured interview script was devel-
oped for face-to-face interviews.
Results: 82% of surveys were completed. CCGs
disseminated information to GPs mostly by emails to
practice managers (100%) and GPs (93%), educational
events (86%), and CCG newsletters (86%). Overall,
educational events were identified as the most effective
and emails to GPs relatively ineffective. The most common
methods for GPs to access specialist advice were phone
(79%) and electronic ‘advice and guidance’ (A&G) systems
(79%). Phone and electronic advice were the preferred
options for a new genetics advice service.
Three respondents consented to interview. All felt that
short, practical updates on genetics (rather than a full
dedicated session) would be useful at their educational
events. All had website portals for referral information, on
which they felt genetics content would be useful. Simple
updates could also be emailed to CCGs for dissemination
via newsletter. Electronic A&G was the favoured specialist
advice method.
Conclusions: Short, practical educational sessions could
be used to share genetics updates. Simple updates could be
emailed to CCGs (for inclusion in newsletters/emails to
practice managers) or uploaded onto CCG portals. Electro-
nic advice methods, such as A&G and email, should be
considered in genomic medicine service development.
J. Gordon: None. J. Adlard: None. R. Jewell: None. J.
Hayward: None.
P22.10.A
A service evaluation: exploring the communication of
microarray-comparative genome hybridisation copy
number variant results of uncertain significance in a
paediatric setting
M. Jacobs-Pearson1,2, J. Rankin1
1Peninsula Department of Clinical Genetics, Exeter, United
Kingdom, 2School of Biological Sciences, Univeristy of
Manchester, Manchester, United Kingdom
Chromosomal microarray-comparative genome hybridisa-
tion (array-CGH) is a first line diagnostic test for children
presenting in paediatric departments. The clinical sig-
nificance of array-CGH results is not always understood,
introducing uncertainties for interpretation and challenges
for clinicians and patients. The aim of this study was to look
at the experiences of paediatricians in providing uncertain
array-CGH results to their patients; ascertaining their
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confidence in interpretation and communication of uncer-
tain information and reviewing the current support in place.
An online mix-methods questionnaire was used to capture
the data. Descriptive statistical and thematic qualitative
analysis was carried out on the data. Ten paediatricians
across three hospitals took part. All paediatricians had
varied experience in communicating uncertain array-CGH
results and a mixed knowledge of genomic testing and its
possible implications for the patient and their family. This
study demonstrated a general understanding of array-CGH
results and their implications alongside a willingness to
communicate uncertainty to patients. The importance of
ongoing education and support for paediatricians was
highlighted, along with the need for additional patient
information. These findings are important as genomics
becomes embedded throughout clinical practice; gaining
insight into experiences of those on the frontline helps to
improve the support for clinicians and patients alike to
ensure high quality patient care.
M. Jacobs-Pearson: None. J. Rankin: None.
P22.11.B
A nationally agreed cross-professional competency
framework to facilitate genomic testing
A. Pichini1,2, A. Seller2, M. Bishop2
1University Hospitals Bristol NHS Foundation Trust,
Bristol, United Kingdom, 2Health Education England
Genomics Education Programme, Birmingham, United
Kingdom
Building on current medical practice, genomic medicine
highlights unique considerations with regards to consent
including addressing needs of the wider family, the com-
plexity and uncertainty of genomic information, data shar-
ing protocols, and returning results. England is
implementing a national Genomic Medicine Service, lead-
ing to genomic testing being utilised across an increasing
number of specialties and resulting in a requirement for
workforce development around the consent conversation. In
response to this, The Genomics Education Programme has
developed a nationally agreed cross-professional compe-
tency framework outlining the knowledge, skills and
behaviours required to facilitate genomic testing. Using the
principles of the nominal group technique, a one-day expert
consensus meeting reviewed clinical scenarios in iterative
rounds, mapped themes to an initial framework and voted
on areas of inconsistency. A revised framework was open
for consultation with key stakeholders including patient
communities and Royal Medical Colleges before being
finalised. A short-term external evaluation has been con-
ducted, assessing how early adopters are using or intending
to use the framework. Evidence-based competencies are an
important basis to support responsible delivery of genomic
medicine. This framework can be used as a guide for best
practice by clinicians involved in requesting genomic tests.
For those delivering education, the framework provides a
foundation to identify learning needs and structure training,
such that consent conversations can be delivered in a con-
sistent manner across specialties. In addition, these com-
petencies can be used as a reference to evaluate how
consent is facilitated in different specialty areas to enhance
the delivery of genomic medicine.
A. Pichini: None. A. Seller: None. M. Bishop: None.
P22.12.C
Minds made up? The scope for deliberation in predictive
genetic testing
S. D. Doheny, A. Clarke
Division of Cancer and Genetics, Cardiff, United King-
dom
Certain tests are offered to patients in the expectation that
the results of the test will be of more use to the patient than
to clinicians managing their care. In genetics, the paradig-
matic example is the predictive genetic test for Huntington’s
Disease where patients may want to plan for a future with or
without the disease. Similarly, genetic testing for BRCA 1/2
and some other familial cancers may be offered to patients
before they may want to engage in surveillance or pre-
ventative treatment.
Following established guidelines, counseling for these
investigations proceeds by first providing patients with
information about the test while counseling on the aspects
of the test that the patient might want to consider. This is to
prompt reflection by the patient, before proceeding with the
test. The question we raise is: to what extent do patients use
this time to deliberate on the decision to take the test.
To explore the deliberations of patients, we gathered
ethnographic observations of clinic consultations and post
decision interviews with patients, and asked patients to keep
a record of their thoughts during this period. In this paper,
we explore the extent to which patients engage in
deliberation by focusing on the patient’s record of their
reflections and deliberations. In our analysis, we explore
how the temporal span of the patients’ own deliberations
extended beyond that of the clinical setting, and how
various aspects of the decision could prompt a more or less
deliberative engagement on the part of the patient.
S.D. Doheny: None. A. Clarke: None.
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P22.14.B
The use of eConsultation to improve delivery of clinical
genetics to primary care: Preliminary findings of
geneticist data
J. C. Carroll1,2, C. Liddy3,4, A. Afkham5, E. Keely6,7, E. S.
Goh8,9, G. E. Graham10,11, J. A. Permaul1, J. Allanson10,11,
G. Farrell12, R. Heisey2,13, T. Makuwaza1, D. P. Manca14,
M. A. O’Brien2, R. Segal15, E. Grunfeld2,16, on behalf of
CanIMPACT
1Ray D. Wolfe Department of Family Medicine, Mount
Sinai Hospital, Sinai Health System, Toronto, ON, Canada,
2Department of Family & Community Medicine, University
of Toronto, Toronto, ON, Canada, 3Bruyere Research
Institute, Ottawa, ON, Canada, 4Department of Family
Medicine, University of Ottawa, Ottawa, ON, Canada,
5Champlain Local Health Integration Network, Ottawa,
Ottawa, ON, Canada, 6Division of Endocrinology and
Metabolism, Ottawa Hospital, Ottawa, ON, Canada,
7Department of Medicine, University of Ottawa, Ottawa,
ON, Canada, 8Laboratory Medicine and Genetics, Trillium
Health Partners, Mississauga, ON, Canada, 9Department
of Laboratory Medicine & Pathobiology, University of
Toronto, Toronto, ON, Canada, 10Department of Pedia-
trics, University of Ottawa, Ottawa, ON, Canada,
11Department of Genetics, Children’s Hospital of Eastern
Ontario, Ottawa, ON, Canada, 12Memorial University of
Newfoundland, St. John’s, NL, Canada, 13Department of
Family and Community Medicine, Women’s College
Hospital, Toronto, ON, Canada, 14Department of Family
Medicine, University of Alberta, Edmonton, AB, Canada,
15Division of Medical Oncology, University of Ottawa,
Ottawa, ON, Canada, 16Ontario Institute for Cancer
Research, Toronto, ON, Canada
Introduction: Electronic consultation (eConsult) is a secure
online platform connecting primary care providers and
specialists that may help improve wait times for genetics
consultations and educate primary care providers (PCPs)
about genetic conditions. Our objective is to determine if
eConsult is an effective method to improve delivery of
clinical genetics in primary care. Specifically, the percep-
tions of PCPs and geneticists about the effectiveness of
genetics eConsults and their implementation into practice
are examined.
Materials and Methods: A mixed methods implementa-
tion study using data collection forms and interviews was
undertaken with PCPs and 7 geneticists in 2 regions of
Ontario, Canada. PCPs complete a questionnaire evaluating
value and utility of each eConsult. Geneticists track the type
and appropriateness of eConsults. Descriptive thematic
analysis was used for the semi-structured interviews with
geneticists.
Results: In 2019, 112 genetics eConsults were analyzed
(94 adult, 18 pediatric). Cancer eConsults were most
common (56, 50%), with possible genetic syndromes (9,
8%) being next most common. Geneticists did not expect
PCPs to know the answer for 46% (52) of eConsult
questions posed. Interview findings at 3 months show that
geneticists are positive about eConsult and see value in
educating PCPs through eConsults, but challenges include
underuse of the service by PCPs.
Conclusions: Geneticist data without PCPs’ assessment
of utility of eConsults are presented. Results show that
hereditary cancer eConsults are common, PCPs appear to be
asking appropriate questions, and geneticists are generally
positive about eConsult. This study is funded by the
Canadian Institutes of Health Research.
J.C. Carroll: None. C. Liddy: None. A. Afkham: None.
E. Keely: None. E.S. Goh: None. G.E. Graham: None. J.
A. Permaul: None. J. Allanson: None. G. Farrell: None.
R. Heisey: None. T. Makuwaza: None. D.P. Manca:
None. M.A. O’Brien: None. R. Segal: None. E.
Grunfeld: None.
P22.16.A
Creating an Master of Science in Genetic counselling in
Sweden that fulfils EBMG-criteria
R. Pestoff1,2, P. Söderkvist2, C. Ingvoldstad Malmgren3
1Department of Clinical Genetics, Linköping, Sweden,
2Department of of Biomedical and Clinical Sciences,
Linköping University, Linköping, Sweden, 3Department of
Molecular medicine, surgery, rare diseases; Karolinska
Institute, Solna, Sweden
There is a sharp increase in demand for high quality genetic
counselling, however there is no MSc education in genetic
counselling in Sweden. This emerging issue led to pub-
lications on the need for higher education for genetic
counsellors in Sweden, and discussions with several Uni-
versities regarding this possibility. Subsequently, a process
of creating the first MSc in Genetic counselling in Sweden
that fulfils the eligibility criteria for EBMG certification
(European Board of Medical Genetics) as genetic counsellor
has been started at the University of Linköping. Multi-
disciplinary workshops, discussions with the EBMG-board,
compiling research and higher educational programs for
genetic counselling have resulted in a preliminary curricula
adapted to the Swedish context. A 2-year MSc in Genetic
counselling (120 ECTS) with first student admissions in the
fall 2021 is proposed. The responses from stakeholders at
the University of Linköping and the clinical genetics
768 J. del Picchia
community in Sweden have been positive. The proposed
MSc in genetic counselling programme will allow graduates
from Sweden to apply for EBMG professional registration
and lead to strengthening the role and competences of
genetic counsellors as a pivotal member of multidisciplinary
teams regarding genetic disorders and support to families in
Swedish health care.
R. Pestoff: None. P. Söderkvist: None. C. Ingvoldstad
Malmgren: None.
P22.17.B
Rolling out Whole Exome and Whole Genome Sequen-
cing to mainstream services. The experience of the
Oxford Centre for Genomic Medicine.
H. Stewart, E. Blair, C. Campbell, J. Craft, U. Kini, J.
Lowndes
OUH, Oxford, United Kingdom
With the approaching completion of the 100,000 Genomes
Project and the reconfiguration of genetic laboratories,
Clinical Genetic Services have been instrumental in rolling
out Whole Exome/Genome Sequencing for Rare Diseases
to mainstream clinical services. In April 2019, we began
planning, assigning priorities and contacting then meeting
individual lead clinicians and contributors to 100,000
Genomes Project. We held teaching sessions for clinical
teams, taught at regional speciality meetings and hosted
meetings for regional early adopters. Subjects included
testing techniques, use of the National Genomic Test
Directory, Record of Discussion, test request forms, NGIS
and giving genomic results. Teams of educators comprised
clinical scientists, SpRs, genetic counsellors and clinical
geneticists, reaching out to peripheral hospitals and spe-
cialist colleagues. Mainstream clinical teams were encour-
aged to identify ‘Genomic Champions and Practitioners’ to
educate their teams and work together in networks. We used
tools including role-play, interactive discussions, recording
frequently-asked-questions and development of slide-decks
to ensure consistency and avoid duplication of effort. We
worked with Genomic Champions to develop care-path-
ways, using a ‘Do Once and Share’ model. We worked with
colleagues in Wessex and Birmingham to share good
practice and Health Education England developing docu-
ments and competency frameworks. By December 2019 we
had started rapid Whole Exome Sequencing for NICU/
PICU, made ready services in Phase 1 of the WGS roll-out
and are readying those in Phase 2. The Oxford Genomic
Medicine Centre and Genetic Laboratories embedded all
this engagement, education and support in Genomic Aca-
demies, over-arching, virtual structures that received wide-
spread support from mainstream clinicians.
H. Stewart: None. E. Blair: None. C. Campbell: None.
J. Craft: None. U. Kini: None. J. Lowndes: None.
P22.18.C
The efficacy of genetic counselling for familial colorectal
cancer. Initial findings from a randomised controlled
trial
A. Ciuca1, A. Baban1, T. Clancy2,3, R. Moldovan1,2,3
1Babes-Bolyai University, Department of Psychology, Cluj-
Napoca, Romania, 2Manchester Centre for Genomic
Medicine, St Mary’s Hospital, Manchester University
Hospitals NHS Foundation Trust, Manchester Academic
Health Science Centre, Manchester, United Kingdom,
3Division of Evolution and Genomic Sciences, School of
Biological Science, University of Manchester, Manchester,
United Kingdom
Introduction: Genetic counselling (GC) for familial col-
orectal cancer (fCRC) has been shown to improve outcomes
such as emotional distress and screening adherence. This is
the first randomised clinical trial to evaluate the efficacy of
GC for fCRC.
Method: We included individuals affected or at risk for
fCRC (Lynch syndrome, APC-associated polyposis,
MUTYH-associated polyposis or clinically defined fCRC).
Participants are randomised to (1) genetic counselling and
standard care or (2) standard care alone (control). Measures
include: Genetic Counselling Outcome Scale (GCOS),
knowledge, risk perception, emotional distress, screening/
surveillance behaviours, perceived social support, decisio-
nal conflict and quality of life.
Results: We currently recruited 24 participants with an
average age of 42 years old, 80% females, 40% at risk and
60% individuals diagnosed various types of fCRC cancer.
Non-parametric Mann-Whitney-U Test was used to com-
pare differences at post-test between the two groups: delta
change for GCOS (p = 0.06), level of knowledge
(p = 0.03) and trust in knowledge (p = 0.01) are indicative
of improvement. Additionally, Wilcoxon-Signed-Rank Test
was used to compare pre-post scores for the genetic
counselling group: GCOS (p = 0.04), level of knowledge
(p = 0.02), trust and utility of knowledge (p = 0.07),
anxiety (p = 0.05), depression (p = 0.06), intention of
screening (p = 0.15), decisional conflict (p = 0.11).
Conclusions: Our initial data suggest improvement for
the primary endpoint (GCOS) and secondary endpoints
(knowledge, emotional distress, screening intention, and
decisional conflict). We hypothesize that these trends will
be maintained and our findings will be further supported by
the sample (n = 68) we intend to recruit in order to ensure
power for statistical and clinical significance.
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A. Ciuca: None. A. Baban: None. T. Clancy: None. R.
Moldovan: None.
P22.19.A
Optimizing Familial Hypercholesterolaemia care in the
Amsterdam region: the role of GPs
D. A. Haasnoot, C. G. van El, M. C. Cornel, P. Slottje
Amsterdam UMC, location VUMC, Amsterdam, Nether-
lands
Introduction: In the Netherlands in 2013 the national
Familial Hypercholesterolaemia screening programme
ended. While general practitioners (GPs) were always
involved in finding index cases, after 2013 especially
follow-up and active cascade screening was no longer
systematically pursued by an organization. The number of
family screenings dropped. Aim of this study was to explore
views on the role of GPs in FH screening and care, and
identify barriers and facilitators for optimizing care.
Materials and Methods: Two focus groups (17 GPs) and
eight interviews (GPs, vascular specialists, a clinical
geneticist, health law expert and consultants of the Dutch
Expertise Centre for Inheritance Testing of Cardiovascular
Disease (LEEFH) coordinating FH screening) were con-
ducted. Descriptive analyses of data from anonymized
electronic medical records of 26988 patients registered in 50
general practices in Amsterdam, the Netherlands addressed
registration of International Classification of Primary Care
(ICPC-1) codes and free text.
Results: Registration using ICPC code T93.04 (having
FH) was suboptimal and varied between practices. GPs had
specific knowledge gaps. Although GPs acknowledged their
role in discussing with patients the relevance of informing
first degree relatives, active support and checking whether
patients actually had informed the family was welcomed by
some stakeholders, but regarded unfeasible by several GPs.
Conclusions: For optimising FH care more adequate
information should be available for GPs, patients and
family. Knowledge of GPs should be increased. Attunement
between primary and secondary care and LEEFH should be
strengthened. Adequate registration in primary care should
be stimulated.
Funded via APH research institute Innovation grant.
D.A. Haasnoot: None. C.G. van El: None. M.C.
Cornel: None. P. Slottje: None.
P22.21.C
Gamete Donors Retrospective Diagnosis of Genetic
Conditions, Exploration of Referral Pathways for
appropriate genetic counselling
V. Shaikly1, K. A. Sage2
1Fertility Genetics, London, United Kingdom, 2CARE
Fertility UK, Nottingham, United Kingdom
Aim: To gain understanding of the implications for patients
and regional genetic services after receiving notification of a
genetic condition associated with a donor used for assisted
conception treatment.
Methods: This study reports on the experience across 2
private assisted conception centres between January 2018 -
January 2020 for alerts issued by donor banks. The
conditions reported were reviewed and considered in the
context of the patients’ current assisted conception situation.
The implications for patients using the specific donor were
categorised to look for common referral pathways and how
and if these can be met by local genetic services.
Conclusion and recommendations:Potential referrals to
genetic services could arise for patients who: have had a
live birth, have embryos in storage or have donor samples in
storage for future/sibling use. Alternatively access to
genetic counselling services could be provided by the
fertility clinic to reduce the impact on local and regional
genetic services. Patients should be supported by both
genetic services and their fertility clinic when receiving
genetic information about a donor so they can make
empowered and informed decisions about their next steps.
Clear pathways of communication between the fertility
clinic and genetic services are required to provide a
streamlined patient service when a donor is retrospectively
found to have or be at increased risk of passing on a genetic
condition.
V. Shaikly: None. K.A. Sage: None.
P22.22.A
Genetic counsellor, patient and carers’ views on an
Australian clinical genetics service information system
C. Speechly1, R. Stenhouse1, Y. Berman2, K. Barlow-
Stewart1, J. Fleming1, D. Petrie3, B. Culling4
1University of Sydney, Northern Clinical School, St
Leonards, Sydney, Australia, 2Department of Clinical
Genetics, Royal North Shore Hospital, St Leonards, Sydney,
Australia, 3Williams Syndrome Australia, Coogee, Sydney,
Australia, 4Service Delivery, eHealth NSW, Chatswood,
Sydney, Australia
Introduction: The Genetic Information System (GIS) is a
database of familial genetic information, which was intro-
duced into the Australian state of New South Wales and the
Australian Capital Territory in 2010 and 2013; creating a
virtual state-wide service for 31 genetics services. As the
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use and storage of family genetic information in the GIS
impacts clinicians, patients and carers, the aim of this study
was to explore their views about this database.
Materials and Methods: Semi-structured telephone
interviews were conducted with genetic counsellors experi-
enced with the GIS. Findings from these interviews were
used to inform focus groups with past patients/carers from
public clinical genetics services. Interviews and focus
groups were audio-recorded, transcribed and analysed using
thematic analysis.
Results: Clinicians (n = 12) perceived that sharing of
information via the GIS was valuable, although they
identified challenges in achieving consistent data entry,
keeping data current and aligned with other health systems,
and they raised concerns regarding future challenges.
Patients and carers (n = 14) also supported the sharing of
family genetic information; but were cautious about the use
of information for relatives’ healthcare; and the stewardship
of family information. Overall, the majority of participants
identified similar advantages and privacy concerns regard-
ing the sharing of family genetic information and wanted
patients/carers to be better informed about the GIS early in
the genetic counselling process - especially about privacy of
family genetic information.
Discussion: We hope these findings may inform further
development of the GIS; leading to increased patient/carer
knowledge through education and development of patient
resources.
C. Speechly: None. R. Stenhouse: None. Y. Berman:
None. K. Barlow-Stewart: None. J. Fleming: None. D.
Petrie: None. B. Culling: None.
P22.23.B
Adopting a gene through Human Disease Genes website
series facilitates a clinical diagnosis for rare genetic
disorders
A. J. M. Dingemans1, D. E. Stremmelaar1, A. Remortele1, J.
Ewals1, M. Verbruggen1, D. A. Koolen1, H. G. Brunner1, E.
E. Eichler2, J. Gecz3, B. B. A. de Vries1
1Radboudumc, Nijmegen, Netherlands, 2University of
Washington School of Medicine, Seattle, WA, United States,
3University of Adelaide, Adelaide, Australia
The Human Disease Genes website series (HDG) is an
international library of websites for professional informa-
tion on the clinical consequences of novel variants in the
human genome (https://humandiseasegenes.com/). The
HDG is an initiative of the Human Genetics Department of
the Radboud University Medical Center, Nijmegen, in
collaboration with the University of Washington and the
University of Adelaide. Each gene website is moderated by
a dedicated team of clinicians and molecular biologists, and
provides up-to-date - mostly unpublished - clinical infor-
mation on one specific gene or copy number variant. HDG
aims to fill the gap between first publication of several cases
and consecutive publication of a large review paper. Pro-
fessionals can use the information of the disorder for genetic
counseling and will have the opportunity to share clinical
data. Patients and parents/caregivers will find useful infor-
mation on the disease and have the opportunity to share
detailed clinical information through the website of our
partner GenIDA. HDG is also a platform where researchers
can collect and share (functional) data. Recently a new
version of the websites has been launched which not only
allows collection of phenotypic data using HPO, but pro-
vides an up-to-date graphical overview of the clinical data
that have been collected. These tools will be highly valuable
for the clinical practice. Currently, over 400 genes have
been adopted by more than 300 moderators world-wide. If
you wish to adopt a gene and join the team of moderators
please, contact us at the poster or via e-mail: info@hu-
mandiseasegenes.com.
A.J.M. Dingemans: None. D.E. Stremmelaar: None. A.
Remortele: None. J. Ewals: None.M. Verbruggen: None.
D.A. Koolen: None. H.G. Brunner: None. E.E. Eichler:
None. J. Gecz: None. B.B.A. de Vries: None.
P22.24.C
Introducing the genetic counselling profession in Austria
G. F. Schwaninger1,2, C. M. Benjamin2, S. Rudnik-
Schöneborn1, J. Zschoke1
1Institut for Human Genetics, Medical University,
Innsbruck, Austria, 2Center for Medical Education, School
of Medicine, Cardiff University, Cardiff, United Kingdom
Different to most European countries, the genetic counsel-
ling profession has yet to be established in Germany,
Austria and German-speaking Switzerland. In 2019 a
Masters level course was established in Genetic and
Genomic Counselling at the Medical University Innsbruck,
Austria, the first in a German speaking country. The pri-
mary aim of this research study was to help the course
director, who is also the first author, explore the perspec-
tives of key stakeholders in Austrian genetic services
regarding prerequisites, opportunities and challenges of
implementing MSc trained genetic counsellors in Austria.
A qualitative approach using semi-structured interviews
with open-ended questions and thematic analysis was
performed. The nine participants were medical geneticists
at different hierarchy levels, policy makers at universities,
and members of professional committees. Participants were
recruited from human genetics departments and universities
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: Interactive e-Posters 771
in three geographic regions of Austria, to elicit their
opinions and attitudes on the subject.
Emerging factors for the successful integration of the
newly educated genetic counsellors into the Austrian
healthcare system are: Acceptance by medical geneticists,
awareness of the genetic counselling profession amongst the
medical community, a solid legal basis for the profession,
and a precise definition of their professional role within the
medical genetic services.
This study provides evidence to better understand
catalysts and obstacles of the implementation of genetic
counselling education and profession in Austria. It outlines
the challenges of introducing this new healthcare profession
in the German-speaking healthcare systems.
G.F. Schwaninger: None. C.M. Benjamin: None. S.
Rudnik-Schöneborn: None. J. Zschoke: None.
P22.25.A
Demand for genetic counselling services in Germany:
past, present and future
I. Nippert1, J. Schmidtke2, J. Epplen3, R. Glaubitz4, P. R.
Nippert5, H. Tönnies6
1Institut für Humangenetk, Universitätsklinikum Münster,
Münster, Germany, 2Institut für Humangenetik, Medizi-
nische Hochschule Hannover, Hannover, Germany, 3Ruhr-
Universität Bochum, Bochum, Germany, 4amedes-genetics,
Hannover, Germany, 5Westfälische Wilhelms-Universität,
Münster, Germany, 6Geschäftsstelle Gendiagnostik-Kom-
mission, Robert Koch-Institut, Berlin, Germany
Introduction: Medical geneticists are providing the
majority of genetic counselling services in Germany. With
the Act on Genetic Testing (GenDG) the German legislator
has issued far reaching regulations for genetic services,
including genetic counselling.
Objectives: To assess demand for genetic counselling
services before and after the enactment of GenDG.
Material and Methods: Data on genetic counselling
services (2005-2017)provided within the framework of the
German statutory health insurance (GKV) were obtained via
a database query at the Central Institute of the National
Association of Statutory Health Physicians (ZIV-KV) and
via regional (state) associations of statutory health physi-
cians. Additional data on supply and demand were obtained
from the GenBIn database.
Results: Demand for genetic counselling has steadily
increased at an average rate of 6% per year since 2009. The
increase has started well before the enactment of GenDG.
Change in demand is characterized by increased self-
referrals and by increased referrals by other specialists than
obstetricians/gynecologists. Waiting times have increased.
Conclusions: Increased demand may be attributed to a
multiplicity of factors, such as advances in technology,
increased public awareness, increased awareness among
nongeneticist physicians and the GenDG. While demand is
steadily growing, the number of medical geneticists remains
almost constant. Capacity limits may be reached if both
trends continue. GenBIn funded by Robert Koch Institute
(Berlin) on behalf of the Federal Ministry of Health,
Germany
I. Nippert: None. J. Schmidtke: None. J. Epplen:
None. R. Glaubitz: None. P.R. Nippert: None. H.
Tönnies: None.
P22.26.B
Mapping counselling supervision at European level
M. Paneque1, L. Guimarães2, J. Bengoa3, S. Pasalodos4, C.
Cordier5, I. Esteban6, R. Moldovan7, C. Serra-Juhé8
1i3S – Instituto de Investigação e Inovação em Saúde,
Universidade do Porto; IBMC – Institute for Molecular and
Cell Biology, Universidade do Porto; Centre for Predictive
and Preventive Genetics (CGPP), Universidade do Porto,
Porto, Portugal, 2i3S – Instituto de Investigação e Inovação
em Saúde, Universidade do Porto; IBMC – Institute for
Molecular and Cell Biology, Universidade do Porto;
Centre for Predictive and Preventive Genetics (CGPP),
Universidade do Porto; Associação de Apoio à Juventud,
Porto, Portugal, 3Hôpital Necker Enfants Malades, Paris,
France, 4Genomic Medicine Unit, Navarrabiomed, Biome-
dical Research Centre, Navarra, Spain, 5Synlab Genetics,
Lausanne, Switzerland, 6Ninewells Hospitals, Dundee,
United Kingdom, 7Babeş-Bolyai University, Cluj-Napoca,
Romania, 8Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain
Genetic testing is becoming more commonplace in general
and specialist health care, and should always be accom-
panied by genetic counselling, according to legislation in
many European countries and recommendations by pro-
fessional bodies.
Personal and professional competence is necessary to be
able to provide safe and effective genetic counselling.
Clinical and counselling supervision of practitioners plays a
key role in quality assurance of practice and providing a
safety environment for patients and professionals. However,
in many European countries, genetic counsellors are still an
emerging professional group and supervision is not
routinely offered. The relevance of counselling supervision
for the improvement of genetics healthcare services is not
yet widely discussed or established.
This study aimed to explore the current status of genetic
counseling supervision provision across Europe and to
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ascertain factors that might be relevant for the successful
implementation of counselling supervision.
A total of 100 practitioners responded to the online
survey; respondents were from 18 countries, with the
majority working in France (27%) and Spain (17%). Only
34 participants reported having access to genetic counsel-
ling supervision; country of origin, the existence of a
regulation system and years of experience were factors
identified as relevant influencing access and characteristics
of counselling supervision.
Although there is a growing number of genetic counsel-
lors trained at European level, just a few countries have
implemented and required as mandatory the access to
genetic counselling supervision, which is essential to ensure
a safe and effective genetic counselling.
M. Paneque: None. L. Guimarães: None. J. Bengoa:
None. S. Pasalodos: None. C. Cordier: None. I. Esteban:
None. R. Moldovan: None. C. Serra-Juhé: None.
P22.27.C
An e-learning course “virtual genetic counselling in
hereditary cancer” for undergraduate education in
Human Genetics
M. Tawalbeh1, S. Otten-Marré2, U. Clames3, L. Hempel2,
H. Rieder1
1Institute of Human Genetics, University Clinic Duessel-
dorf, Duesseldorf, Germany, 2Communication in Medical
Education Duesseldorf (CoMED), Institute of Psychoso-
matics and Psychotherapy, University Clinic, Duesseldorf,
Germany, 3Multi Media Center, Heinrich-Heine-University,
Duesseldorf, Germany
The identification and adequate care of individuals, which
are at a high risk to develop cancer, is the major benefit of
genetic counselling in families with a suspected family
history of a cancer predisposition syndrome. The process
from the initial suspicion to the final genetic risk assessment
in an individual includes several steps, in which affected
and unaffected family members have to be taken care of. To
demonstrate the psychological impact as well as the inter-
action between the physician and the respective family
members, we set up a video based online accessible virtual
genetic counselling session in a cancer family. A family
with Lynch syndrome was created. Simulation patients were
instructed to act as affected and unaffected family members
according to predefined roles. A specialist in human
genetics was advised to conduct a counselling session
according to a routine situation. Videos were taken from
different camera angles and cut according to the counselling
process. An e-learning module was developed by using an
e-learning course development software (Articulate 360®).
Each video sequence was limited to 2 minutes duration. The
e-learning course was intergrated as a sharable object
reference module (SCORM) in an elearning content man-
agment system (ILIAS®). In the course each step of five
different consultation-hours of the genetic counselling was
visualized by the respective video sequences. Only the most
relevant sections were included so that the students were
able to accomplish the course within 40 min. The course is
available under https://ilias.hhu.de/ilias/goto.php?target=ca
t_663694&client_id=UniRZ.
Funded by the eLearning Foerderfonds, Heinrich-Heine-
University, Duesseldorf, Germany
M. Tawalbeh: None. S. Otten-Marré: None. U.
Clames: None. L. Hempel: None. H. Rieder: None.
P22.28.A
The impact of children affected by psychiatric condi-
tions: The caregivers’ perspective
M. M. Radu1, A. Ciucă1, S. Pintea1, A. Baban1, E.
Predescu2, R. Şipos2, R. Moldovan1,3,4
1Department of Psychology, Babeş-Bolyai University, Cluj-
Napoca, Romania, 2Emergencies Clinical Hospital for
Children, Cluj-Napoca, Romania, 3Division of Evolution
and Genomic Sciences, School of Biological Science,
University of Manchester, Manchester, United Kingdom,
4Manchester Centre for Genomic Medicine, St Mary’s
Hospital, Manchester University Hospitals NHS Founda-
tion Trust, Manchester Academic Health Science Centre,
Manchester, United Kingdom
Introduction: Families of children and adolescents diag-
nosed with psychiatric disorders often find it difficult to deal
with daily responsibilities, distress, stigma or shame. Yet
only few studies investigated the psychological wellbeing
and challenges amongst the caregivers of young people
diagnosed with psychiatric diagnosis.
Methods: A cross sectional study was conducted from
October 2018 to October 2019 in an outpatient pediatric
psychiatry clinic. Family members (e.g. parents, grand-
parents) of young people diagnosed with psychiatric
conditions (e.g. affective disorders, autism spectrum
disorders, attention deficit hyperactivity disorder,
obsessive-compulsive disorder) were invited to participate.
We explored their knowledge about psychiatric disorders,
illness perception, burden of care, stigma, wellbeing and
quality of life.
Results: 70 caregivers (60 females, 10 males, 40.5 ± 8.4
average age) participated in the study. The burden of care is
positively associated with caregivers’ knowledge and
perceptions of the negative consequences the disorder can
have for the patient (r = 0.52, p < 0.01) and relatives
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(r = 0.25, p < 0.05) as well as with the personal blame
towards the patient (r = 0.30, p < 0.01). Both stigma and
burden of care were shown to significantly impact
caregivers’ wellbeing (r= -0.29, p < 0.05; r= -0.42, p <
0.01) and quality of life (r= -0.39, p < 0.01; r= -0.42,
p< 0.01).
Conclusions: Caregivers experience burden of care, low
wellbeing and quality of life and increased levels of stigma.
Insight into the impact of psychiatric disorders on
caregivers can help professionals develop and adapt
psychosocial interventions for families impacted by psy-
chiatric disorders such as psychiatric genetic counselling.
M.M. Radu: None. A. Ciucă: None. S. Pintea: None. A.
Baban: None. E. Predescu: None. R. Şipos: None. R.
Moldovan: None.
P22.29.B
New technology in genetic counselling
I. G. Turbin1,2
1Addenbrooke’s Hospital, Cambridge, United Kingdom,
2University of Manchester, Manchester, United Kingdom
Background: Genetic counselling is in a transitional phase.
There is a radical shift as genetic testing becomes a routine
part of healthcare. With the volume of genetic testing
increasing, and resources stretched, technological solutions
have been developed to help people understand the genetic
testing they are being offered. These include decision aids,
‘chatbots’ and online learning materials.
In this context, the role of new technology and genetic
counsellors remains uncertain. I argue that research is
needed to look at how patients can benefit from both genetic
counsellors and new technology in the genomic age.
Methods: Six films were created by the genetic
counselling team at Addenbrooke’s Hospital and the
Society and Ethics Research Group from Wellcome
Genome Campus. The films use the metaphor of music to
communicate genomic information.
Six genetic consultations in which the films were used
were observed, and the same patients were interviewed.
Ethnographic field notes from the observations and inter-
views were analysed thematically.
Results: Themes emerged around technology, shared
space, body language, emotion, information giving and
personalisation. The qualitative data also allowed for an
exploratory analysis into the relationship between technol-
ogy and power in genetic counselling consultations.
Implications: This research provides insight into the role
of technology in genetics; how it can both hinder and
enhance genetic counselling practice. I also discuss the
results in the context of evidence-based genetic counselling.
I argue that even with technological innovations, time is still
a key element if patients are to benefit from both new
technologies and genetic counselling.
I.G. Turbin: None.
P22.31.A
Survey of the competences of hospital based doctors in
providing care to patients with genetic diseases
V. Curtisova1,2, H. Adamová2
1Department of Human Genetics, Fakultní nemocnice
Olomouc, Olomouc, Czech Republic, 2Palacky University,
Olomouc, Czech Republic
Aim: to assess the knowledge and skills related to clinical
genetics in a group of Czech hospital non-genetic specia-
lists, compare the results with those obtained during an
assessment of the international e-learning project Gen-
Equip and to see if they correlate with their medical spe-
ciality, years from graduation, previous referral of patients
for genetic consultation or testing and self-perceived
knowledge of the management of patients with heritable
conditions.
Methods: the anonymous modified two-part question-
naire developed by the Gen-Equip project was randomly
distributed to physicians of a Czech teaching hospital.
Results: scores of the participants (n = 46) were
significantly lower than those in the Gen-Equip group
(n = 75) - 53.2 vs. 60.5 for part 1 of the test and 48.4 vs
75.3 for part 2 of the test. The scores were significantly
higher in participants who previously referred patients for
genetic consultation (53.8% vs. 43.5%) or for genetic
laboratory testing (53.9 % vs. 44.8 %) than those who had
made no referrals. There was no significant dependence of
the results of the test and the years from graduation, the
specialisation of the participants or their self-perceived
knowledge of the management of patients with heritable
conditions.
Conclusions: the level of knowledge and skills related to
clinical genetics may affect the readiness of physicians to
refer their patients for appropriate genetic care. In our
sample the knowledge and skills were not influenced by the
years from graduation, medical speciality or self-perceived
knowledge of the management of patients with heritable
condition.
V. Curtisova: None. H. Adamová: None.
P22.33.C
A new measure for genetic counselling quality assess-
ment: patients’ perspectives
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M. Carvalho1,2, F. Rodrigues3, J. Saraiva3,4,5, A.
Leonardo6, A. Sousa6, V. Machado7, M. Gonçalves-Rocha8,
J. Sequeiros1, M. Serra de Lemos2,9, M. Paneque1
1IBMC-CGPP, i3S, Porto, Portugal, 2Faculdade de Psico-
logia e de Ciências da Educação, Universidade do Porto,
Porto, Portugal, 3CHUC - Medical Genetics Unit, Hospital
Pediátrico, Centro Hospitalar e Universitário de Coimbra,
Coimbra, Portugal, 4University Clinic of Pediatrics,
Faculty of Medicine, University of Coimbra, Coimbra,
Portugal, 5Clinical Academic Center of Coimbra, Coimbra,
Portugal, 6CHULN-HSM – Serviço de Genética Médica,
Centro Hospitalar Universitário de Lisboa Norte – Hospital
de Santa Maria, Lisboa, Portugal, 7EPER – Hospital de
Santo Espírito da Ilha Terceira, Açores, Portugal, 8Uni-
dade de Genética Médica, Hospital de Braga, Braga,
Portugal, 9Centro de Psicologia, Universidade do Porto,
Porto, Portugal
International genetic testing guidelines recommend appro-
priate genetic counselling provision before and after genetic
testing is undertaken. In spite of that, literature on quality
assessment of genetic counselling is scarce. Measures avail-
able are insufficient, poorly disseminated, and focused mainly
on genetic counselling effects. A theoretically-underpinning
scale for quality assessment by healthcare professionals was
recently published; however, the need for a measure for
patients’ assessment persisted. This study describes the
development and initial validation of a theoretically-informed
scale for genetic counselling quality assessment by patients.
Scale items were developed based on the pre-existing quality
assessment scale for professionals, the reciprocal-engagement
model of genetic counselling practice, and literature on
genetic counselling patients’ perceptions. Items were refined
through cognitive interviews. Patients from five Portuguese
clinical genetics services (n = 123) completed the scale.
Principal component analysis using direct oblimin was con-
ducted to establish the initial construct validity of the scale
and reduce the number of items. Cronbach’s alpha was cal-
culated as a measure of internal reliability. Final scale con-
sisted of 51 items scale organised into six dimensions. The
scale presented adequate internal reliability. Initial evidence of
construct validity was also demonstrated. This scale is the first
theoretically-underpinned measure designed for patient’s
assessment of genetic counselling quality. Genetic counsel-
ling professionals and researchers can use this scale to identify
areas for quality improvement of genetic healthcare services
and design interventions. We discuss practical implications
and clinical utility of this new tool as well as challenges of the
validation process at genetic services.
M. Carvalho: None. F. Rodrigues: None. J. Saraiva:
None. A. Leonardo: None. A. Sousa: None. V. Machado:
None. M. Gonçalves-Rocha: None. J. Sequeiros: None.
M. Serra de Lemos: None. M. Paneque: None.
P22.34.A
Patients’ knowledge about genetics and genetic testing
on the example of neoplasm diagnostics
A. Tupaj, O. Dusza, M. Smerdzyński, M. Malarska
Medical University of Lodz, Lodz, Poland
Introduction: Commercial genetic tests are getting more
and more available. As some of them may don’t have a real
diagnostic value, it is important to help patients in choosing
the right one. We’ve decided to examine peoples’ knowl-
edge about genetics and genetic testing by using the
example of neoplasm diagnostics.
Materials and Methods: We’ve conducted a survey on a
group of 1161 people about their knowledge and opinion
about the genetic testing in neoplasm diagnostics. The survey
was posted on the Internet, the mean age of our patients was
24.84 years old, 80.4% of them were female, 19.6% - male.
Results: The early results of our study show that 61.6%
of patients would perform a genetic test without a specialist
consultation and that the majority of them would trust in the
commercial testing results. At the same time, 48.8% of
respondents were unable to give a correct answer to the
question about the genetic background of neoplasms. Some
respondents were also unable to give an example of a
genetic test, mentioning mammography, cytology or
medical ultrasound.
Conclusions: Our study clearly shows that patients don’t
have sufficient knowledge about genetics but at the same
time they perform or would perform a genetic test without a
specialist’s consultation. As this may lead to the mis-
interpretation of the results, we consider it essential to find a
way to educate patients about diagnostic value of genetic
tests. In our further work we want to consider the role of
General Practitioners in this process.
A. Tupaj: None. O. Dusza: None. M. Smerdzyński:
None. M. Malarska: None.
P22.35.B
Challenges and achievements of genetic education in
Republic of Georgia among medical professionals
E. Abzianidze1,2, E. Kvaratskhelia1,2, M. Tchipashvili1,2, T.
Gigineishvili1,2, E. Imnadze1,2, T. Tkemaladze1,2
1Tbilisi State Medical University, Dept. of Molecular and
Medical Genetics, Tbilisi, Georgia, 2Georgian Society of
Medical Genetics and Epigenetics, Tbilisi, Georgia
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In mid-90’s, teaching of molecular and medical genetics
gained priority at the Tbilisi State Medical University
(TSMU). The University has been able to incorporate
ASHG/APHMG Medical School Core Curriculums (1995,
2001, 2013) into an undergraduate medical program. Stu-
dents’ Scientific Debate Club “FBG - Future Belongs to
Genetics” was established in 1995, which held 25 students’
conferences and events. In 2006 a department of Molecular
& Medical Genetics was established in our university for
the first time in Georgia. We have embedded problem-based
learning (PBL) within the integrated course, centered on
clinical case studies; High quality scientific and educational
literature, including textbooks: Thompson&Thompson
Genetics in Medicine (7th and 8th editions) have been
translated and published by the department. Several local
and international conferences, including “Genomics and
Epigenomics in Personalized Medicine” (2016, 2017),
“Human Genome and Heath” (2018, 2019) have been
organized by the department and the Georgian Society of
Medical Genetics and Epigenetics (GSMGE). In addition,
since 2014 we have been running a Georgian DNA Day
Essay Contest for Georgian and international students. Our
department and GSMGE, in collaboration with ESHG,
encourage young scientists to participate in the annual
conferences organized by ESHG. In 2014 the research and
diagnostic laboratory was founded at the department, where
PhD programs, CME courses and educational courses for
students in genetics, genomics and epigenomics were
designed and developed. As a result, nowadays, many
medical professionals in Georgia have sound understanding
of genetics and can successfully deploy their knowledge in
their clinical practice, when needed.
E. Abzianidze: None. E. Kvaratskhelia: None. M.
Tchipashvili: None. T. Gigineishvili: None. E. Imnadze:
None. T. Tkemaladze: None.
P22.36.C
Measuring physician practice and preparedness for
genomic medicine: a national survey
E. King1,2, A. Nisselle1,2,3, B. McClaren1,2,3, S. Metcalfe1,2,3,
C. L. Gaff1,2,3, on behalf of the Australian Genomics
Workforce & Education Working Group
1Australian Genomics Health Alliance, Parkville, Australia,
2Murdoch Children’s Research Institute, Parkville, Austra-
lia, 3The University of Melbourne, Parkville, Australia
Even as genomic medicine is implemented globally,
there remains a lack of rigorous, national assessments of
physicians’ current genomic practice and continuing geno-
mic education (CGE) needs. We therefore developed an
expert-reviewed survey based in theory (behavioural
change) and empirical qualitative data (McClaren et al.,
Front Genet 2019). Domains included: personal character-
istics (demographics, specialty, years of practice); current
genomic medicine practice; perception of how proximal
genomic medicine is to practice; preparedness to practice
genomics (competence and confidence); and preferences for
future roles and models of care in genomic medicine and for
CGE. The survey was deployed nationally through medical
colleges, societies, hospitals, social media and snowballing
in 2019, with 409 analysable responses from physicians
across Australia. Respondents represented 30 specialties
(majority paediatricians, 20%), from mainly public hospi-
tals (70%) in metropolitan areas (75%). Only 13% of
respondents ordered whole exome/genome sequencing tests
in their practice, with the main reason for not ordering tests
being relevance to practice (39%). A third (32%) referred
patients to a clinical genetics service for testing and this was
largely unchanged (34%) when reporting future preferences.
Two-thirds of respondents felt genomics will soon impact
their practice and, while a third recently completed CGE,
only a quarter felt prepared. Respondents lacked confidence
in genomic knowledge and ability to explain concepts to
patients and incorporate test results in patient management.
These data can inform genetic services (re test referral
patterns) and support genomic education providers to best
meet learner needs and develop a competent, genomic lit-
erate workforce.
Grant reference: GNT1113531
E. King: None. A. Nisselle: None. B. McClaren: None.
S. Metcalfe: None. C.L. Gaff: None.
P22.37.A
The Young Geneticists Network (YGN): using social
media to unite trainees in Human Genetics around the
world
F. Riccardi1,2, C. Azevedo Soares3,4, R. Marcinkute5, S. P.
Calapod6, the Young Geneticists Network
1Department of Medical Genetics, La Timone children
Hospital, AP-HM, France, Marseille, France, 2Marseille
Medical Genetics, INSERM UMR 1251, Aix-Marseille
Université, Marseille, France, 3Serviço de Genética Méd-
ica, Centro de Genética Médica Jacinto Magalhães, Centro
Hospitalar Universitário do Porto, Porto, Portugal, 4Unit
for Multidisciplinary Research in Biomedicine, Instituto de
Ciências Biomédicas Abel Salazar/Universidade do Porto,
Porto, Portugal, 5Department of Clinical Genetics, Guy’s
and St Thomas’ NHS Foundation Trust, London, United
Kingdom, 6Medical Genetics Centre, St. Mary Children’s
Hospital, Iasi, Romania
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Human Genetics is a popular field for postgraduate students.
However, training is very heterogeneous and partitioned
with isolated trainees learning highly-specific expertise
areas. There was a need for an international group easily
accessible online to connect young human geneticists
around the world. We aim to present how this group
operates and develops. Based on the Facebook social media,
we created the “Young Geneticists Network" private group
in February 2018 (https://www.facebook.com/groups/
young.geneticist/). All people registered on Facebook can
request to join the YGN group. Requests are reviewed by
administrators. All members can post and share text, photos,
and multimedia related to Human Genetics topics with other
members who receive notifications. We present anonymous
group insights data obtained until November 2019.We
gathered 529 members from 57 different countries and
selected 14 volunteer moderators. The majority of the
members were under 34 years old (74.9%) and female
(74.6%). Six European countries gathered most of the
members (55%): France (108), Italy (71), Romania (30),
The Netherlands (28), Portugal (27) and the United King-
dom (27). We counted 37 posts with 74 comments and 408
reactions from the community. The YGN is a collaborative
group that allows members to share training opportunities
(online courses, funding resources,...) and queries related to
Human Genetics. We are able to engage a global audience
of peers in a very short period. We believe this group will
expand and allow better international collaboration to
standardize training and facilitate international large-scale
genetics projects.
F. Riccardi: None. C. Azevedo Soares: None. R.
Marcinkute: None. S.P. Calapod: None.
P22.39.C
Exploring the genomic education needs within the NHS
workforce: a cardiac genetic nurse perspective.
A. Braddel, M. Watson
Wessex Clinical Genetics Service, Southampton, United
Kingdom
Introduction: Nurses represent the largest professional
group within the National Health Service (NHS) and are
central to the integration of genomics into routine health-
care. Cardiac Genetic Nurse (CGN) roles have been
developed in recent years to streamline the care for patients
and families affected by an inherited cardiac condition. Like
many nurses, CGNs prior exposure to genomics and the
implications surrounding inherited conditions is limited.
This study aimed to explore the education needs and sup-
port required for CGNs to fulfil their role.
Materials and Methods: CGNs were given the oppor-
tunity to express their interest in participating, during an
Association of Inherited Cardiac Conditions conference and
a British Heart Foundation study day. A purposive sampling
approach was adopted to invite CGNs working within
various NHS Trusts across the United Kingdom to
participate. Semi-structured interviews were conducted with
CGNs (n = 7), which were recorded, transcribed and
independently coded by two researchers.
Results: Through thematic analysis, it emerged that
CGNs have a hybrid role requiring a broad range of skills
and, despite some overlap, are distinct from the role of a
genetic counsellor. A key theme identified was the skills
associated with managing the uncertainty of genetic
information. The interviews highlighted that effective
learning requires immersion in the clinical environment
and the need for a CGN-specific competency framework to
be developed.
Conclusions: This study demonstrates the need to define
the competencies required for the role of a CGN, to
standardise practice nationally and ensure that nursing and
genetic counselling resources are applied effectively.
A. Braddel: None. M. Watson: None.
P22.40.A
We need to talk about the Fragile X Syndrome: a genetic
short film (episode one)
L. Vitro1, L. D. França1, L. Menezes1, M. Ramos2, R.
Mello3, D. Gongora4, L. Videira4, E. Leite5, S. M.
Vasconcelos6, A. Malinverni7, G. Carvalheira2
1Genetics Division, Department of Morphology and Genet-
ics, EPM/EPE, Unifesp, Sao Paulo, Brazil, 2Genetics
Division, Department of Morphology and Genetics, EPM,
Unifesp, Sao Paulo, Brazil, 3Department of Speech
Therapy, EPM, Unifesp, Sao Paulo, Brazil, 4Department
of Institutional Communication, Unifesp, Sao Paulo, Brazil,
5Administration of Escola Paulista de Enfermagem, EPE,
Unifesp, Sao Paulo, Brazil, 6Department of Health
Information Technology, EPM, Unifesp, Sao Paulo, Brazil,
7Pathology Laboratory, Department of Pathology, EPM,
Unifesp, Sao Paulo, Brazil
Introduction: Fragile X Syndrome (FXS) is a dominant X-
linked disease. It is considered the second most common
cause of intellectual disability (ID), with an incidence of
5:10,000, being prevalent in males. The majority of FXS is
caused by FMR1 mutations. As it is a X-linked disorder,
females with premutation (range from 55 to 200 CGG
repeats) may present early ovarian failure, while males may
present tremors and ataxia. On the other hand, individuals
with complete mutation (greater than 200 CGG repeats)
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could present moderate to severe ID (30% females and 90%
males), due to FMR1 silencing. As this disorder presents
complex etiology, FXS education documentary had been
prepared, containing the main syndrome’s themes: historical
data, genetic causes and their phenotypic consequences.
Materials and Methods: This documentary is a short
film divided in three episodes, which the first one will be
available on the website http://ucgenetica.sites.unifesp.br/
index.php/pt/. In this episode, the molecular mechanisms of
FXS genetic explain how the symptoms are manifested and
their clinical consequences. To promote accessibility, the
LIBRAS language and English subtitles were used.
Results: This documentary had been presented to 83
undergraduate nursing students. The evaluation revealed
that 98% of the students assimilated the FXS genetic
content.
Conclusions: This documentary proved to be an efficient
strategy to disseminate FXS information, using a simple and
objective language. The next step is to assess whether this
short film will have the same applicability, in a playful way,
to inform family members, students in public schools, and
the general population.
L. Vitro: None. L.D. França: None. L. Menezes: None.
M. Ramos: None. R. Mello: None. D. Gongora: None. L.
Videira: None. E. Leite: None. S.M. Vasconcelos: None.
A. Malinverni: None. G. Carvalheira: None.
P22.41.B
Development of the course in laboratory genetics and
genomics for medical students in the Republic of
Georgia
E. Kvaratskhelia, M. Zarandia, T. Tkemaladze, E.
Ekaladze, N. Tevzadze, E. Abzianidze
Tbilisi State Medical University, Tbilisi, Georgia
Introduction: A new elective course “Principles of
Laboratory Genetics and Genomics” has been developed for
undergraduate medical students at Tbilisi State Medical
University in the United State Medical Doctor Program.
The aim of this course is to offer students an opportunity to
conduct experiments based on molecular genetics to
understand the role of genetic analysis in the diagnosis of
human diseases.
Methods: In this course, third year medical students who
have passed molecular biology and medical genetics
enrolled. Since October 2019 this course has been run
twice with 21 participants. Course components include
basic genetic concepts, current molecular genetics meth-
odologies (hands-on labs), and interpretation of results (total
20hr.). In addition, the course includes a scientific paper
discussion session and an essay writing task. Laboratory
activities include DNA extraction, PCR of repetitive
elements, gene mutation detection, and Real Time PCR-
based DNA profiling. We used kits and reagents developed
for educational purposes, e.g. Crime Scene Investigation Kit
(BioRad).
Results: Students were motivated and enthusiastic to
perform well in the lab; they were able to develop their
collaborative skills when working together on inquiry-based
lab lessons. Post-course evaluation showed that 75% of
learners agreed or strongly agreed that the course had
increased their understanding in the methods of laboratory
genetics and the sessions had educational value.
Conclusions: Our pilot course is effective in improving
the level of genetic knowledge and practical genetic skills
among medical students. In addition, using lab activities,
students will be inspired and encouraged to participate in
biomedical research projects.
E. Kvaratskhelia: None. M. Zarandia: None. T.
Tkemaladze: None. E. Ekaladze: None. N. Tevzadze:
None. E. Abzianidze: None.
P22.43.A
Experiences with mainstreaming of rapid gene panel
DNA diagnostics in breast cancer patients
K. J. A. F. van Kaam1, B. A. H. Caanen1, M. L. Haadsma2,
A. M. van Remortele2, A. R. Mensenkamp2, R. J. Blok1, M.
van Geel1, E. M. Leter1, W. A. G. van Zelst-Stams2, M. J. L.
Ligtenberg2, N. Hoogerbrugge2
1MUMC+, Maastricht, Netherlands, 2Radboud University
Medical Center, Nijmegen, Netherlands
Introduction: Genetic test results can now be available
within 2-3 weeks and are therefore increasingly considered
for determining treatment options in breast cancer patients.
To facilitate timely test results, we aimed to shift counsel-
ling and requests for rapid DNA diagnostics for these
patients from clinical geneticists to treating physicians and
evaluate this transition towards mainstreaming.
Methods: Nine regional hospitals were included from
July 2018 onwards. Treating physicians were asked for their
needs and barriers to participate. DNA diagnostics consisted
of gene panel analysis for BRCA1, BRCA2, PALB2,
CHEK2 and ATM.
Results: The website www.DNAfirst.nl was developed to
provide treating physicians with hands-on information.
Barriers included time investment during consultation and
perceived incompetence of providing breast cancer screen-
ing advice for family members. Up to December 2019, 351
requests for DNA diagnostics were made and 42 pathogenic
variants were found (12%). All patients with a pathogenic
variant were subsequently referred to a clinical geneticist.
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32/42 pathogenic variants were found in patients meeting
the Dutch criteria for DNA testing for hereditary breast
cancer (n = 271), whereas 10/42 of pathogenic variants
were found in patients who did not meet these criteria (n =
57) or for whom this was unknown (n = 23). Structured
evaluation of quality of care and experiences of doctors and
patients is ongoing and results will be available shortly.
Conclusions: Mainstreaming of rapid gene panel DNA
diagnostics in breast cancer patients appears to be feasible.
K.J.A.F. van Kaam: None. B.A.H. Caanen: None. M.
L. Haadsma: None. A.M. van Remortele: None. A.R.
Mensenkamp: None. R.J. Blok: None. M. van Geel:
None. E.M. Leter: None. W.A.G. van Zelst-Stams: None.
M.J.L. Ligtenberg: None. N. Hoogerbrugge: None.
P22.44.B
Implementing BRCA mainstreaming in Australia: a
qualitative study
R. O Shea1, N. Rankin1, M. Kentwell2, M. Gleeson3, K. M.
Tucker4, L. Salmon5, S. Lewis1, N. Taylor6
1Faculty of Medicine and Health, University of Sydney,
Sydney, Australia, 2Parkville Familial Cancer Centre, Peter
MacCallum Cancer Centre and Royal Melbourne Hospital,
Parkville, Victoria, Melbourne, Australia, 3Hunter Family
Cancer Service, Newcastle, Australia, 4Hereditary Cancer
Clinic, Prince of Wales Hospital and Clinical School,
University of New South Wales, Sydney, Australia,
5Department of Clinical Genetics, Austin Health, Mel-
bourne, Australia, 6Faculty of Medicine and Health,
University of Sydney and Cancer Research Division,
Cancer Council NSW, Sydney, Australia
Background: Sub-optimal referrals and identification of
hereditary cancers are evident internationally. Mainstream-
ing programs for BRCA gene testing for epithelial ovarian
cancer have been introduced to address this problem.
However, the successes and challenges of integrating
genetics into the Australian oncology health system are
unknown.
Methods: Study invitations were emailed through the
heads of departments in oncology, genetics and the
Mainstreaming Working Party in Australia. Semi-
structured telephone interviews were designed using the
Consolidated Framework for Implementation Research
(CFIR). Interviews were transcribed and inductive content
analysis was conducted.
Results: Twenty-two participants from 8 health organisa-
tions participated and the following themes were found:
Theme 1: Embracing the shift to mainstream genetic testing:
clinical utility of testing, preferences on the mainstreaming
process, considerations for future adaptation and a patient
centred process, Theme 2: Role delineation and responsi-
bilities for mainstream genetic testing: communication
networks, genetics point of contact, role delineation,
collaboration. Theme 3: Influencing factors on sustaining
mainstreaming: ongoing training needs, resources and
funding, real world adaptation, private and public system
complexity, champions and engagement. Theme 4: Inter-
ventions for mainstreaming: embedded genetic counsellor
in oncology, results follow up and tracking system,
flowchart of mainstreaming processes.
Conclusions: Our findings identify that participants
recognise the need for integration of genetic testing in
oncology, but that further adaptation of interventions and
processes is essential to sustain a feasible model. An
understanding of individual and organisational factors that
influence mainstreaming programs will help to prepare for
future integration of genetic testing in other cancer types.
R. O Shea: None. N. Rankin: None. M. Kentwell:
Other; Modest; Astrazeneca. M. Gleeson: Other; Modest;
Astrazeneca. K.M. Tucker: Other; Modest; Astrazeneca. L.
Salmon: None. S. Lewis: None. N. Taylor: None.
P22.47.B
Diagnostic yield and recognized barriers of an adult
Neurogenetics clinic
A. Peleg1, L. Sagie-Dain1,2, D. Golan3,2
1Human Genetics Institute, Lady Davis Carmel Medical
Center, Haifa, Israel, 2Ruth and Bruce Rappaport Faculty
of Medicine, Technion - Israel Institute of Technology,
Haifa, Israel, 3Department of neurology, Lady Davis
Carmel Medical Center, Haifa, Israel
Background: The advent of molecular genetic technologies
paved a path for the diagnosis of many neurological dis-
orders. Joint evaluation by a neurologist and a medical
genetics specialist can potentially increase diagnostic
effectiveness by ensuring the exclusion of non-genetic
mimics and by rationally selecting appropriate genetic
diagnostic tools. Therefore, a monthly adult Neurogenetics
clinic was established.
Methods: A retrospective review of medical records.
Results: 85 patients were evaluated. Age: 47.1 ± 15.7,
Male: 40(47%), 44 (51%) had a positive family history.
Disease duration was typically long (11.4 ± 0.9 years).
Futile use of expensive diagnostic modalities was very
common [45(52%) had repeated MRI, 28(32%) hospitalized
for observation in neurologic departments, 12(14%) had a
normal metabolic workup, 4 (4%) with a non-conclusive
muscle biopsy, 1 with a normal cerebral angiography].
Following clinical evaluation molecular genetic testing was
offered to 70 (82%) patients. In the other 15(18%) routine
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workup for the exclusion of non-genetic mimics was not
complete, obtainable information regarding family members
was missing or that a neurogenetic disorder seemed
improbable. 29 (34%) patients received a definitive
diagnosis, either a genetic (29%) or non-genetic (5%).
The adherence to genetic testing recommendations was
62%. The reasons for non-adherence were lack of public
funding for the required test (56%) and patient decision not
to proceed (44%).
Conclusions: Given the frequent futile use of expensive
modalities due to diagnostic uncertainty and the complexity
of clinical genomic data analysis, a comprehensive multi-
disciplinary neurogenetic clinics seems reimbursement and
cost effective for the patients and medical health
institutions.
A. Peleg: None. L. Sagie-Dain: None. D. Golan: None.
P22.48.C
A survey of the pregnant women about their preferences
for the prenatal tests with different characteristics in
Russia
E. Baranova1, E. Zayaeva2, L. Zhuchenko2, S.
Shchelykalina3, V. Izhevskaya4
1Federal State Budgetary Educational Institution of Further
Professional Education "Russian Medical Academy of
Continuous Professional Education" of the Ministry of
Healthcare of the Russian Federation, Moscow, Russian
Federation, 2Federal State Budgetary Educational Institu-
tion of Further Professional Education Russian Medical
Academy of Continuous Professional Education of the
Ministry of Healthcare of the Russian Federation, Moscow,
Russia, Moscow, Russian Federation, 3Pirogov Russian
National Research Medical University, Moscow, Russia,
Moscow, Russian Federation, 4Research Centre for Med-
ical Genetics, Moscow, Russia, Moscow, Russian Federa-
tion
The aim of this study was to assess the opinions of pregnant
women about prenatal tests in Russia. Materials and meth-
ods: Totally 800 questionnaires were collected from preg-
nant women living in 16 regions of Russia. Results: The
statement “Every pregnant woman must undergo combined
screening in the first trimester” was agreed by the majority
of respondents - 90.16%. 63.38% of the respondents did not
know before our survey about NIPT. After explaining its
capabilities, 74.74% believe that it should be used. It was
revealed that despite the high compliance to the early pre-
natal screening between pregnant women in general, only a
little more than half of the women with an increased risk of
chromosome abnormalities were ready to undergo invasive
diagnosis in the fetus and only a quarter of the pregnant
women were ready to terminate the pregnancy with chro-
mosome abnormalities in the fetus. Women who were ready
to terminate the pregnancy were statistically significantly
older, had more pregnancies, were at a later gestational age.
It was more important for them to receive the test results as
early as possible with as much additional information as
possible and have the state/insurance type of payment for
the test (Mann-Whitney, p < 0.002). Conclusion: The sur-
vey will allow comparing the results with other countries
where NIPT is used in early prenatal screening and to
develop recommendations for our country. This work was
supported by the RFBR grant No. 18-013-01175.
E. Baranova: None. E. Zayaeva: None. L. Zhuchenko:
None. S. Shchelykalina: None. V. Izhevskaya: None.
P22.49.A
The contribution of an oncogenetics consultation while
offering a theranostic approach of genome-wide
analyses
G. BERTOLONE1,2, E. COSSET1, A. BAURAND2,1, C.
SAWKA2,1, M. ROBERT2, A. LANCON1,2, M. REDA3, C.
RICHARD4, C. BINQUET5, R. BOIDOT6, V.
DERANGERE7, V. GOUSSOT8, J. ALBUISSON7, L.
FAVIER3, F. GHIRINGHELLI3, S. NAMBOT2,1, L.
FAIVRE2,1
1Service des consultations d’oncogénétique, Centre
Georges François Leclerc, 1 rue du Pr Marion, BP
77980, Dijon, France, 2Centre de génétique, CHU de
Dijon, Hôpital d’enfants, Dijon, France, 3Service d’onco-
logie médicale, Centre Georges François Leclerc, 1 rue du
Pr Marion, BP 77980, Dijon, France, 4Plateforme de
transfert en biologie cancérologique, Centre Georges
François Leclerc, 1 rue du Pr Marion, BP 77980, Dijon,
France, 5Inserm 1231, Université de Bourgogne Franche-
Comté Centre d’investigation clinique et d ’épidémiologie
clinique 1432, CHU de Dijon, Hôpital d’enfants, Dijon,
France, 6Unité de biologie moléculaire Centre Georges
François Leclerc, 1 rue du Pr Marion, BP 77980, Dijon,
France, 7Biologie et pathologie des tumeurs, Centre
Georges François Leclerc, 1 rue du Pr Marion, BP
77980, Dijon, France, 8Unité de biologie clinique, Centre
Georges François Leclerc, 1 rue du Pr Marion, BP 77980,
Dijon, France
Introduction: Targeted therapies have emerged, requiring a
better delineation of the tumor genetic characteristics. In
this context, the EXOMA study (2016-2019) proposed
somatic/constitutional exome for patients with advanced
cancer. Considering the risk for identifying genetic predis-
position, with genetic counseling and management
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implications, a genetic consultation was proposed; which
value needed to be assessed.
Methods: A 20 minutes consultation, with a prior
collection of family history by the patient, was carried out
within 15 days of inclusion in EXOMA. Tumoral and
constitutional analyses were limited to 317 genes involved
in oncogenesis.
Results: In 36/716 patients (5%), a constitutional
pathogenic variant was identified in 13 actionable genes,
but half were already identified in the care circuit. Among
18 cases identified by the exome, 10/18 did not meet the
predisposition search criteria, and in 2/10, the variation can
be considered as incidental (unrelated to the presented
cancer). In 3/18 cases, a genetic consultation had been
previously performed, but the analyses were limited to
BRCA/MMR. In 5/18 cases, the criteria for the search of
predisposition were present but not identified by the
oncologist. In 18 additional patients, a variant was identified
in genes that do not lead to a specific surveillance protocol
in France, such as ATM/CHECK2.
Conclusions: In 2.5% of patients, a constitutional genetic
predisposition, related or not to the clinical presentation,
was identified, making it important to inform the patient
beforehand. This low percentage should be balanced with
the burden of proposing such urgent circuits. Other modes
of information are being explored.
G. Bertolone: None. E. Cosset: None. A. Baurand:
None. C. Sawka: None. M. Robert: None. A. Lancon:
None. M. Reda: None. C. Richard: None. C. Binquet:
None. R. Boidot: None. V. Derangere: None. V. Goussot:
None. J. Albuisson: None. L. Favier: None. F. Ghir-
inghelli: None. S. Nambot: None. L. Faivre: None.
P22.52.A
The impact of a “Psychiatric Genetics for Genetic
Counselors” workshop on genetic counsellor attendees:
an exploratory study
A. Dillon1, M. Watson1, J. Austin2, K. McGhee3
1Wessex Clinical Genetics Service, University Hospital
Southampton NHS Foundation Trust, Southampton, United
Kingdom, 2BC Mental Health and Addictions Research
Institute, Vancouver, BC, Canada, 3Bournemouth Univer-
sity, Bournemouth, United Kingdom
Introduction: Genetic counselling is the process of sup-
porting patients’ and families’ adaption to genetic infor-
mation. Psychiatric genetic counseling has been proven to
be effective in improving patients’ empowerment, self-
efficacy, and knowledge even in the absence of genetic
testing. Despite this, only one specialist psychiatric genetic
counselling clinic currently exists. In order to engage and
empower genetic counsellors in providing psychiatric
genetic counselling worldwide, a two-day workshop:
“Psychiatric Genetic Counseling for Genetic Counselors”,
was developed and implemented. The aim of the present
study was to qualitatively explore the impact of the
workshop.
Materials and Methods: Semi-structured interviews
were carried out with twelve genetic counsellors who
attended the workshop between 2015 and 2018. Interviews
were then transcribed, and thematic analysis was used to
identify themes from the data. Constant comparative
method was employed on the qualitative data themes
throughout analysis.
Results: 100% of participants reported an increase in
empowerment in offering psychiatric genetic counselling to
patients. Participants also reflected how the workshop
normalised mental illness and aided the counsellors in
identifying sources of their personal stigma. The workshop
also provided participants with a practical tool to describe
multifactorial inheritance, the Jar Model.
Conclusions: The “Psychiatric Genetic Counseling for
Genetic Counselors” workshop empowered genetic coun-
sellors to feel confident and comfortable offering psychia-
tric genetic counselling to patients.
A. Dillon: None. M. Watson: None. J. Austin: None. K.
McGhee: None.
P22.54.C
What happens during and after the disclosure of ACMG
59 secondary genomic findings? A systematic review of
the literature
F. M. Facio, J. C. Sapp, K. L. Lewis, L. G. Biesecker
National Human Genome Research Institute, Bethesda,
MD, United States
The American College of Medical Genetics and Genomics
(ACMG) released its initial guidelines for the return of
secondary genomic findings (SF) in 2013. The main reason
for returning SF include the opportunity to tailor medical
care to the individual and his/her at-risk relatives. We
conducted a systematic review to summarize the published
data supporting the communication of SF and downstream
actions taken by individual recipients.
We searched six major biomedical databases (CINAHL,
Embase, PubMed, Scopus, Web of Science, and PsychInfo)
to identify peer-reviewed publications between 01/Jan/2012
and 18/Jun/2019 describing how SF findings are commu-
nicated, and/or any outcomes associated with disclosure,
including psychosocial impact, healthcare behaviors, family
communication/cascade testing.
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A total of 1751 citations were retrieved. After de-
duplication, 990 citations were screened and 847 rejected.
The remaining 143 citations were reviewed, and 20 met
inclusion criteria. Most studies (n = 10) investigated both
process and outcomes, and a few of these reported similar
rates of compliance with post-disclosure recommendations
(~70%); rates of family communication were as high as
90%. Other studies focused on the disclosure process (n= 4)
or post-disclosure outcomes (n = 6) only. Across studies the
psychosocial impact of receiving SF was minimal.
Since the release of the ACMG guidelines, only twenty
studies have examined the disclosure process or evaluated
clinical utility. Our review suggests that not all SF
recipients communicate results to their doctors or relatives,
and a substantial fraction may not engage in the
recommended healthcare behaviors. These early published
experiences may help shape research priorities as we move
towards personalized medicine.
F.M. Facio: None. J.C. Sapp: None. K.L. Lewis: None.
L.G. Biesecker: None.
P22.56.B
Single-gene pathology in pediatric patients referred for
genetic counseling for a period of five years
M. Stoyanova1,2, L. Angelova1, M. Hachmeriyan1,2, M.
Levkova1,2, V. Miteva1,2
1Department of Medical Genetics, Medical University,
Varna, Bulgaria, 2Laboratory of Medical Genetics, Uni-
versity Hospital Saint Marina, Varna, Bulgaria
Introduction: As a whole, the group of single-gene dis-
orders is often considered to be primarily affecting child-
hood - almost 90% of this pathology is manifested by
puberty. Our aim is to evaluate the activity of the Genetics
Counselling Unit in diagnosis of children with clinically
suspected monogenic pathology.
Materials and methods: The study includes pediatric
patients referred to the Genetics Unit of the University
Hospital Saint Marina, Varna for a period of five years
(2015-2019), who were genetically consulted for suspected
or confirmed single-gene disorders Clinical phenotyping,
imaging examinations, literature review and specialized
computer programs/dysmorphology databases were applied.
Appropriate molecular genetic and metabolic investigations
were offered.
Results: 343 out of 706 (48,5%) consulted children,
including 94(27,4%) infants, were clinically suspective for
single-gene disorders. Тhe great majority - 276(80,5%)
were referred by Pediatric clinics of the hospital. Molecular
genetic testing (in Bulgarian Genetic laboratories or abroad)
was performed to 212 children(61,8%). In 83% it was
financed completely privately. Based on these analyses, 105
(49,5%) patients were detected with single-gene conditions,
mainly autosomal recessive entities in 83(79%) of them.
The spectrum of all genetic diagnoses is presented in details
and analyzed. The identified genetic defects in some
patients led to the detection of carriers in close relatives
and prenatal diagnosis.
Conclusions: Although individually rare, single gene
disorders totally are responsible for a significant proportion
of childhood pathology. Genetic counseling is an integral
part of medical care for patients and their families.
Reimbursement of genetic testing by National Health
Insurance Fund would increase detection rate.
M. Stoyanova: None. L. Angelova: None. M. Hach-
meriyan: None. M. Levkova: None. V. Miteva: None.
P22.58.A
Completely new set of free educational inheritance quiz
apps for students: their use and international uptake.
A. P. Tobias1, E. S. Tobias2
1University of Edinburgh, Edinburgh, United Kingdom,
2University of Glasgow, Glasgow, United Kingdom
Introduction: Undergraduate medical and science students
frequently search for self-assessment quizzes to help them
learn the inheritance modes of well-known genetic dis-
orders. Addressing this, a new set of quiz apps has recently
been created by the authors and released on both app stores
for undergraduate students. These apps are separate from
the already-popular Clinical Genomics Guide and Clinical
Genomics Quiz apps that the authors previously created for
post-graduates and professionals.
Methods: Three new multi-platform, self-contained apps
were created using the authors’ Apple & Google developer
licences. Each app contains 15 multiple-choice questions,
testing knowledge of conditions’ inheritance-modes (auto-
somal dominant, recessive, X-linked or mitochondrial). The
apps award points for questions answered correctly at first
attempt. Upon quiz completion, total and percentage scores
are displayed and the app teaches students the correct
answers to all incorrectly-answered questions. The apps are
compatible with all currently used iPhone (iOS) and
Android smartphones and tablets.
Results: Having passed strict, extensive testing by Apple
and Google, the Genetic Inheritance Quiz A, B and C apps
(progressing in difficulty) are available, free, on both
official App Stores. They have been installed >750 times
worldwide in 4 months. Feedback comments for the apps,
rated 5-stars overall, have been highly positive, commend-
ing the layout, corrected-answer-list, usability, “massive”
helpfulness and “fun”. Links to the apps are provided from
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the ESHG Education page and from www.genomicsapps.
org.
Conclusions: Although time-consuming to create, they
have been found useful to many individuals internationally.
Feedback and suggestions for future additions would be
welcomed at: edward.tobias@glasgow.ac.uk
A.P. Tobias: None. E.S. Tobias: None.
P22.59.B
Support groups for brca carriers and their relatives:
motivations and satisfaction of participants
B. Bertonazzi, L. Godino, L. Polpatelli, S. Miccoli, D.
Turchetti
Sant’Orsola-Malpighi Hospital, Bologna, Italy
To assess helpfulness and satisfaction about support or
focus groups and psychoeducational interventions in BRCA
carriers, plus recurrent themes expressed by participants, we
have conducted a systematic review and a prospective
explorative cohort study. Peer-reviewed papers published
between January 1995 and May 2019 were searched using
five databases. Of 1505 studies identified, 27 were reviewed
in full-text, 9 met the inclusion criteria. Satisfaction and
usefulness of support groups was analyzed by three studies,
which reported high level of satisfaction, appreciation of
psychological support and interest for future psychoeduca-
tional groups. Major themes emerged were distress and
feelings of guilt about transmission to offspring, when to
disclose information to relatives, anxiety and depression
related. Between September 2018 and January 2020 we
arranged six support groups for BRCA carriers and their
families. Of 43 individuals participating to at least one
group, 23 (53%) participated to more than one. Main rea-
sons reported for participating were: desire to meet other
BRCA carriers (17; 40%) and the need for further infor-
mation (14; 33%). 95% felt comfortable and 90% con-
sidered the group very useful. Twenty-seven participants
(62,7%) declared their expectations had been completely
satisfied; almost all declared they would participate to future
groups. Major themes emerged were: how and when to
disclose the information to offspring (particularly sons),
why minors cannot be tested, differences between BRCA1
and BRCA2, prophylactic surgery, diet and hormone ther-
apy. Our findings support the usefulness of support groups
for longitudinal follow-up of BRCA families.
Supported by GOforLife and Susan G. Komen
Italia Onlus.
1
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None. S. Miccoli: None. D. Turchetti: None.
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Patients’ understanding of routine genetic testing
M. Levkova1,2, M. Hachmeriyan1,2, V. Miteva1,2, M.
Stoyanova1,2, L. Angelova1
1Department of Medical Genetics, Medical University
Varna, Varna, Bulgaria, 2Laboratory of Medical Genetics,
University Hospital St Marina, Varna, Bulgaria
Introduction: Over the past decade, there has been a major
increase in the number of genetic tests available. However,
it is still not clear whether the patients could interpret the
result themselves even for a routine genetic testing such as
thrombophilia.
Materials and Methods: We present a survey among
111 randomly selected patients, carried out at the
Laboratory of Medical genetics, Varna. All of the
participants underwent a genetic testing for hereditary
predisposition to thrombophilia and their knowledge was
evaluated before and after the test using Likert scale.
Correlation analysis and t-tests were applied.
Results: Mean age of the participants was 33.77 ± 5.79
years. 74.77% of them had a masters degree. Most of the
questionned (70.27%) were referred to genetic testing by a
medical specialist, 29.73% decided on their own to test
themselves due to family predisposition. There was a
positive correlation between receiving information from a
medical doctor (p = 0.014) and the degree of understanding
about the test. A negative correlation existed (p = 0.001)
between the level of knowledge and informing on your own
about the test. There was no statistically significant
difference (p = 0.891) for the correlation between the
source of information and awareness of the result. However,
the degree of understanding was higher (p = 0.003), when
the result was explained by a medical specialist. The
education level did not correlate with a better pre or post test
knowledge (p = 0.949).
Conclusions: Our findings demonstrate the importance of
pre and post test counseling of the patient and its crucial
role in providing information about genetic testing to the
patients.
M. Levkova: None. M. Hachmeriyan: None. V.
Miteva: None. M. Stoyanova: None. L. Angelova: None.
P22.61.A
Mapping of resources for undiagnosed and newly
diagnosed ultra-rare disease networks
G. H. Gumus1, S. Broley2, C. Patch3,4, M. Montolio del
Olmo5, K. Boycott6, L. Faivre7, B. Zurek8, M. Macek9, H.
Graessner10,11, S. Bellagambi12, D. Stemkens13, C. van
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Doorne14, A. Metcalfe15, A. Costa16, G. Robert16, L.
Roberts17, M. Pritchard17, H. Scheffer18, V. Boulanger19, J.
Lewis20, H. Cederroth21, M. Cederroth21, P. Arias22, V.
Bros-Facer1
1EURORDIS-Rare Diseases Europe, Paris, France,
2Genetic Services of Western Australia, Perth, Australia,
3Genomics England, Queen Mary University, London,
United Kingdom, 4Society and Ethics Research, Connecting
Science, Wellcome Genome Campus, Cambridge, United
Kingdom, 5Duchenne Parent Project, Madrid, Spain, 6Chil-
dren’s Hospital of Eastern Ontario Research Institute,
University of Ottawa, Ottawa, ON, Canada, 7Centre de
Géntétique et FHU TRANSLAD, CHU de Dijon et
Université de Bourgogne, Dijon, France, 8University of
Tübingen, Tubingen, Germany, 9Charles University and
Motol University Hospital, Prague, Czech Republic, 10Cen-
tre for Rare Diseases, University and University Hospital of
Tübingen, Tubingen, Germany, 11European Reference Net-
work for Rare Neurological Diseases (ERN-RND), Tübin-
gen, Germany, 12UNIAMO FIMR Italian Alliance for Rare
Diseases, Rome, Italy, 13VSOP, Dutch Patient Alliance for
Rare and Genetic Diseases, Soest, Netherlands, 14European
Federation of Hereditary Ataxias, United Kingdom, Lon-
don, United Kingdom, 15Faculty of Health and Wellbeing,
Sheffield Hallam University, Sheffield, United Kingdom,
16Florence Nightingale Faculty of Nursing & Midwifery,
King’s College London, London, United Kingdom,
17Genetic Alliance UK (SWAN UK), London, United
Kingdom, 18Radboud University Nijmegen Medical Centre,
Nijmegen, Netherlands, 19National Organization for Rare
Disorders, Danbury, CT, United States, 20Genetic and Rare
Diseases Information Center, ICF International,, Rockville,
MD, United States, 21Wilhelm Foundation, Sandbacken,
Brottby, Sweden, 22Spanish Federation of Rare Diseases
(FEDER), Madrid, Spain
Introduction: Every year, 65000 children across Europe
are born with an undiagnosed disease (1). The diagnostic
odyssey lasts 5 years on average for a rare disease patient
(2). This delay in diagnosis prevents patients from accessing
proper care and treatment. Several initiatives have been
established to improve the lives of people with undiagnosed
rare diseases. However, currently, there is not a compre-
hensive mapping of resources for undiagnosed or newly
diagnosed Ultra-Rare diseases. Within the EU funded pro-
ject, Solve-RD, EURORDIS initiated the Community
Engagement Task Force (CETF), a multi-stakeholder
community of patients, scientists, and clinicians, to sup-
port the needs of the undiagnosed and recently diagnosed
patients and leave a legacy of a strengthened undiagnosed
community.
Methodology: Key stakeholders in the field of diagnosis
were invited to become members of CETF. These include
Undiagnosed Diseases Network International (UDNI),
SWAN (Syndrome Without A Name) Europe, Patient
Advocacy Groups within the European Reference Networks
and The Global Commission to End the Diagnostic
Odyssey for Children.
Results: Members gathered through 3 teleconferences
and a face-to-face meeting over 15 months where they
discussed issues addressing specific needs of undiagnosed
rare disease patients and their families such as lack of
information for medical professionals and the need for
standardization when receiving a diagnosis. Resources
(toolkits, surveys, factsheets, illustrations) were compiled
to develop a roadmap.
Conclusions: Regular and meaningful engagement of
representatives across key initiatives represents the start of
an active undiagnosed community. Importantly, patients as
equal and valued partners are driving forward active
collaborations with different stakeholders.
G.H. Gumus: None. S. Broley: None. C. Patch: None.
M. Montolio del Olmo: None. K. Boycott: None. L.
Faivre: None. B. Zurek: None. M. Macek: None. H.
Graessner: None. S. Bellagambi: None. D. Stemkens:
None. C. van Doorne: None. A. Metcalfe: None. A.
Costa: None. G. Robert: None. L. Roberts: None. M.
Pritchard: None. H. Scheffer: None. V. Boulanger: None.
J. Lewis: None. H. Cederroth: None. M. Cederroth:
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Dying to see you; Deaths on a Clinical genetics waiting
list; what are the consequences?
L. Bradley, S. Lynch
National Centre for Medical Genetics, Dublin 12, Ireland
Introduction: The value of a Clinical Genetics consultation
is difficult to quantify. In order to estimate negative effects
and by default the value of a genetics consultation; we
sought to identify the consequences to the patient and
families who died on the waiting-list. Methods Audit
records of 40 referrals who died prior to appointment.
Results: Age range at referral: 11 days to 82yrs. Thirty
five of the 40 had never been seen; 5/40 died awaiting a
follow up appointment. The majority (26/40) were cancer
referrals. Ten had developmental delay/dysmorphism; 3
were cardiac genetic referrals, & a dementia referral. We
determined that 15/40 deaths posed a significant risk to
genetic health in their relatives [proband not seen, no family
contact, no genetic testing & no DNA stored]; 10/40 posed
a moderate risk [DNA stored or predictive test available but
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no family contact]; 13/40 posed a minimal risk [proband
never counselled] and in 2/40 cases the families were fully
counselled. From the 25 probands where the death posed a
moderate or significant risk, we identified a minimum of
118 (~5 individuals per proband) first degree living
relatives. DNA was stored on only 5/25 precluding ability
to risk stratify in 20 families unless another relative is
subsequently genetically diagnosed. Most families did not
avail of offers of appointments posthumously raising
concern that relatives remain unaware of their genetic risks.
Conclusions: Our study reveals that the relatives of 65%
(25/40) of probands are substantially disenfranchised if their
affected relative dies whilst awaiting an appointment.
L. Bradley: None. S. Lynch: None.
P22.63.C
Impact of terminating the pregnancy after receiving a
diagnosis of Down syndrome from an South African
perspective
C. J. Scott, M. F. Urban, D. Skinner
Stellenbosch University, Cape Town, South Africa
Introduction: Advances in prenatal testing technologies
lead to more women receiving a prenatal diagnosis of Down
syndrome (DS). As this is an incurable disabling condition,
they are confronted with the decision of having a termina-
tion of pregnancy (TOP). This has long-term psychosocial
implications which are poorly understood. The aim of this
study was to gain an understanding of the experiences of
South African women who have had a TOP for DS and the
psychosocial impact thereof.
Methods: A phenomenological qualitative approach was
used. Eight participants were purposively selected from a
prenatal clinic at a state sector hospital in South Africa
(SA). They were interviewed shortly after being admitted to
hospital for the TOP and again 6 to 12 months afterwards.
The audio-recordings were transcribed and thematic
analysis was used.
Results: Prenatal testing services are not widely acces-
sible in SA and therefore the participants all had a second-
trimester TOP. The themes identified with regards to the
psychological implications were: grief, impact of seeing
stillborn, guilt, isolation, finding meaning, decision satisfac-
tion and finding peace. The social impact included change
in workplace, TOP stigma, moving house and change in
relationships. The participants valued support from religious
groups, partners, family, friends, health care workers and
employers.
Conclusions: The major long-term psychosocial impact
of a TOP made it difficult for the women to return to their
normal daily routine. Understanding the impact of this event
will deepen knowledge on how to best care for these
women and may subsequently improve prenatal testing and
counselling practices.
C.J. Scott: None. M.F. Urban: None. D.
Skinner: None.
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P23.02.B
Managing actionable secondary findings beyond high-
penetrant genes through personalised health
surveillance
R. Koesters, T. Hasenberg, K. U. Beiser, E. Felber
Megeno S.A., Esch-sur-Alzette, Luxembourg
Genome-informed prevention holds the promise of
improving clinical outcomes among individuals at sig-
nificant risk for developing a disease with a strong genetic
component, by enabling personalised phenotypic surveil-
lance for monitoring predictive biomarkers and detecting
early disease symptoms. However, in the context of low-
penetrance diseases, gathering reliable phenotypic infor-
mation to facilitate such early detection is challenging, since
many at-risk individuals will never develop the disease. In
particular, there is a risk of overdiagnosis and over-
treatment, leading to an inefficient use of scarce healthcare
resources. Furthermore, it is crucial that clinically healthy
individuals are not prematurely designated as patients. To
address these issues, we have developed a rigorous, 100-
point-scale scoring scheme for prioritising low-penetrance
diseases to facilitate long-term risk monitoring and early
disease detection. A key variable to our scoring scheme is
“at-home phenotyping”, that is, the ease and accuracy with
which an at-risk individual can regularly sample and
monitor relevant phenotypic markers over time, without
recourse to their medical professional. We have applied the
scoring scheme to evaluate and rank 23 monogenic dis-
orders characterised by reduced penetrance and variable
expressivity. The scores for the 23 disorders ranged from
40.0 to 88.3, with a mean of 65.3 (median of 65.8). Dis-
orders with the highest scores were hereditary hemochro-
matosis (88.3), familial hypercholesterolemia (86.7), and
hereditary hyperparathyroidism (85.0). By systematically
evaluating and ranking medically relevant gene-disease
associations, it may be possible to prioritise low-penetrance
disorders for facilitating long-term personalised health sur-
veillance in an efficient and responsible manner.
R. Koesters: A. Employment (full or part-time);
Significant; Megeno S.A. T. Hasenberg: A. Employment
(full or part-time); Significant; Megeno S.A. K.U. Beiser:
A. Employment (full or part-time); Significant; Megeno S.
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Significant; Megeno S.A..
P23.03.C
Parental communication of BRCA1/2 mutation status to
children:links between gender norms and health
practices
F. Gauna1, C. Noguès1,2, E. Mouret-Fourme3, I. Coupier4,
V. Mari5, J. Moretta-Serra6, A. Bouhnik1, S. Carof7,1
1Aix-Marseille Univ, INSERM, IRD, SESSTIM, Sciences
Economiques & Sociales de la Santé & Traitement de
l’Information Médicale, Marseille, France, 2Département
d’Anticipation et de Suivi des Cancers, Oncogénétique
clinique, Institut Paoli-Calmettes, Marseille, France,
3Department of Genetics, Institut Curie, Paris, France,
4Gastroenterology and Genetic Department, Montpellier
Hospital, Montpellier, France, 5Unité d’Oncogénétique,
Centre Antoine Lacassagne, Nice, France, 6Institut Paoli
Calmette, Department d’Anticipation et de Suivi du Cancer,
Pôle Clinique Consultations d’Oncologie Genétique, Mar-
seille, France, 7Institut Gustave Roussy (IGR), Villejuif,
France
Objective: Our study aimed to determine psychosocial
factors associated with the gendered of uptake of genetic
counseling among children of BRCA1/2 mutation carriers.
Methods: We conducted a qualitative study using semi-
structured interviews from a comprehensive approach. Data
were analyzed using thematic analysis.
Results: Thirty mutation carriers (23 women, 7 men)
aged from 40 to 60 years took part in the interviews. The
participants included are parents of an overall of 72 children
(31 minors including 17 girls and 41 adults including 24
women). The themes included: mutation discovery, body
and risk management and communication to their children
from disclosure to genetic test up-taking. We explored the
role of both parents in the transmission of cancer prevention
practices, considering their own risk management, the
disclosure of the mutation to their children and their role on
the genetic test up-taking of their children. We found that
gender differences are explained both by different social
roles, but also by different relationship to cancers linked to
BRCA and perceived as "feminine" and also by different
health practices.
Conclusions: Cancer prevention is shaped by the
complex links between gender norms and health practices.
This has practical implications since the genetic risk
communication and genetic test up-taking could be better
framed taking this information into account
F. Gauna: None. C. Noguès: None. E. Mouret-Fourme:
None. I. Coupier: None. V. Mari: None. J. Moretta-
Serra: None. A. Bouhnik: None. S. Carof: None.
P23.06.C
Cancer worry and willingness to undergo colonoscopy at
different risk levels; results from a population-based
survey in Sweden
C. Hawranek1, J. Maxon1, A. Andersson1, B. Van
Guelpen1,2, B. Numan1, A. Rosén1
1Department of Radiation sciences, Oncology, Umeå
university, Umeå, Sweden, 2Wallenberg Centre for Mole-
cular Medicine, Umeå University, Umeå, Sweden
Introduction: Inherited genetic risk factors are known to
induce cancer worry in at-risk individuals, affecting risk
perception and screening uptake. The Cancer Worry Scale
(CWS) has been used to evaluate cancer worry in these
populations. This is the first population-based study
describing the distribution of cancer worry and willingness
to partake in screening for colorectal cancer (CRC).
Materials and Methods: Data was sourced through a
probability-based citizen panel. In total, 1800 individuals
between ages 18-74 were invited. 943 respondents (52%
response rate) completed an 6-item CWS (min 6, max 24)
and questions on willingness to undergo colonoscopy in
hypothetical situations of having a 5%, 10% or 70% lifetime
risk of developing CRC.
Results: Cancer worry scores were significantly higher
among women [mean 10.10 (SD 3.09)] than men [mean
9.17 (SD 2.59)], p < 0.01. Personal cancer history was
associated with higher worry scores [11.00 (SD 3.63)] vs
[9.46 (SD 2.72)], p < 0.05, but age, educational level and
country of birth was not, p > 0.05. Women’s higher scores
persisted regardless of previous cancer or not. In the CRC-
screening scenarios, the proportion willing to undergo
colonoscopy increased with increasing levels of hypothe-
tical risk; 58% (5% lifetime risk), 80% (10% lifetime risk)
and 92% (70% lifetime risk).
Conclusions: Gender and cancer history was related to
increased cancer worry in this population-based sample.
Willingness to undergo colonoscopy increased significantly
with the presented increased risk of CRC. Interestingly, our
population-based results overlapped with previously
reported CSW-scores in several different cancer
populations.
Grants: Cancer research foundation in Norrland
and Forte.
C. Hawranek: None. J. Maxon: None. A. Andersson:
None. B. Van Guelpen: None. B. Numan: None. A.
Rosén: None.
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P23.08.B
Clinical utility of genomic sequencing: A measurement
toolkit
R. Z. Hayeems1,2,3, D. Dimmock4, D. Bick5, J. Belmont6, R.
Green7, B. Lanpher8, R. Mendoza3, V. Jobanputra9, S.
Taylor10, S. Kulkarni11, M. Grove12, E. Ashley12, .. On
Behalf of The Medical Genome Initiative13
1Program in Child Health Evaluative Sciences, The
Hospital for Sick Children, Toronto, ON, Canada, 2Insti-
tute of Health Policy Management and Evaluation,
University of Toronto, Toronto, ON, Canada, 3Centre for
Genetic Medicine, The Hospital for Sick Children, Toronto,
ON, Canada, 4Rady Children’s Hospital Institute for
Genomic Medicine, San Diego, CA, United States, 5Hud-
sonAlpha Institute for Biotechnology, Huntsville, AL,
United States, 6Illumina Inc., Houston, TX, United States,
7Broad Institute of MIT and Harvard, Cambridge, MA,
United States, 8Mayo Clinic, Rochester, MN, United States,
9New York Genome Center, New York, NY, United States,
10Illumina Inc., San Diego, CA, United States, 11Baylor
Genetics and Baylor College of Medicine, Houston, TX,
United States, 12Stanford Medicine, Stanford, CA, United
States, 13The Medical Genome Initiative, San Diego, CA,
United States
Background: Whole genome sequencing (WGS) is posi-
tioned to become the most robust strategy for achieving
timely diagnosis of rare diseases. Despite its favorable
diagnostic performance compared to conventional testing
strategies, routine use of WGS is hampered by insufficient
evidence of clinical utility. Largely, this evidence gap stems
from complexities and inconsistencies in how this concept
is defined and measured. For example, what constitutes
clinical utility for WGS varies by stakeholder perspective,
clinical context, and test application. A rapidly evolving
technology landscape and challenges associated with
executing robust comparative study designs in the context
of rare disease further impede progress in this area.
Methods: An expert working group, representing a range
of clinical settings in which WGS is in translation, was
formed to provide practical guidance to practitioners and
researchers to address the challenge of measuring clinical
utility.
Results: Following a consensus-based process and
aligned with a broad definition of clinical utility, we
propose a conceptually-grounded and empirically-guided
measurement toolkit focused on four domains of clinical
utility: diagnostic thinking efficacy, therapeutic efficacy,
patient outcome efficacy and societal efficacy. For each
domain, we offer specific indicators and measurement
strategies that can be integrated into new and ongoing
studies.
Conclusions: While we focus on diagnostic applications
of WGS for rare germline diseases, this toolkit offers a
flexible framework for best practices related to measuring
clinical utility for a range of WGS applications. As such, it
provides a resource for laboratories, clinicians, and
researchers looking to characterize the value of WGS
beyond the laboratory.
R.Z. Hayeems: None. D. Dimmock: None. D. Bick:
None. J. Belmont: A. Employment (full or part-time);
Significant; Illumina Inc.. E. Ownership Interest (stock, stock
options, patent or other intellectual property); Significant;
Illumina Inc.. R. Green: None. B. Lanpher: None. R.
Mendoza: None. V. Jobanputra: None. S. Taylor: A.
Employment (full or part-time); Significant; Illumina Inc.. E.
Ownership Interest (stock, stock options, patent or other
intellectual property); Significant; Illumina Inc.. S. Kulkarni:
None. M. Grove: None. E. Ashley: None. .. On Behalf of
The Medical Genome Initiative: None.
P23.09.C
The relationship between COMT polymorphism, par-
enting behaviour and problem behaviors: a prospective
study
J. Wagner1, B. Viljetic1, S. Rucevic2, T. Borovac3, S.
Vučković2, D. Krupić2
1Medical faculty, University of Osijek, Osijek, Croatia,
2Faculty of humanities and social sciences, University of
Osijek, Osijek, Croatia, 3Faculty of education, University of
Osijek, Osijek, Croatia
Introduction: Both genetic (i.e., Catechol-O-
methyltransferase Val158Met/COMT-rs4680) and environ-
mental factors (e.g., negative parenting practices including
authoritarian and permissive parenting styles) have been
implicated as vulnerability factors for future problem
behaviors. The present study examined the susceptibility
properties of COMT genotype to adverse and favorable
parenting styles in relation to childhood problem behaviors.
Materials and Methods: The sample was composed of
community children (N = 175; 80 boys; T1age = 6.98;
T2age = 9.78) and their parents chosen through a multistage
stage random sampling procedure. At T1, children were
genotyped for COMT-rs4680, whereas parents rated their
parenting styles. DNA was extracted from buccal swabs and
genotyped using TaqmanTM SNP genotyping assay on
Applied Biosystems™ 7500 Real-Time PCR System. At
T2, teachers rated children’s problem behaviors. As in
previous studies, we divided the sample into those with the
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high-activity Val/Val genotype (20.9%) and those with 1 or
more Met alleles (79.1%).
Results: Using a regression analysis, a significant
interactive effect was observed only for the authoritarian
parenting and COMT genotype. Specifically, children who
had faced authoritarian parents and were Val homozygotes
exhibited more future problem behaviors (p = .041) than
did their Met-carrying counterparts. Notably, in the absence
of authoritarian parenting practices, Val homozygotes
displayed significantly lower aggression scores than did
Met carriers (p = .039).
Conclusions: These results suggest that Val homozygotes
are more malleable to the effect of negative home
environment on problem behaviors.
Grant: Presented study is a part of the ECLAT
longitudinal study 2017-2021 funded by the Croatian
science foundation (HRZZ-IP-2016-06-3917-ECLAT).
J. Wagner: None. B. Viljetic: None. S. Rucevic: None.
T. Borovac: None. S. Vučković: None. D. Krupić: None.
P23.10.A
Addressing genetic findings with familial implications in
clinical consent
A. M. Phillips1, E. Niemiec2, H. C. Howard2, K. Kagkelari3,
P. Borry1, D. F. Vears4
1University of Leuven, Leuven, Belgium, 2Uppsala Uni-
versity, Uppsala, Sweden, 3University of Crete, Heraklion,
Greece, 4University of Melbourne, Melbourne, Australia
When a disease-causing genetic variant is identified in an
individual, communicating this information to family
members can play an essential role in the early diagnosis of
relatives. Yet, many patients struggle with communicating
these results and it is unclear to what extent this is discussed
during the consent process. To better understand if and how
the communication of genetic information to family mem-
bers is addressed in the clinical context, we systematically
searched for consent forms for diagnostic genomic
sequencing online and used content analysis to analyze the
forms. We identified 68 consent forms from 11 countries.
The forms indicated that genetic findings were often pre-
sented as familial in nature, yet varied in how findings with
familial implications were discussed. A minority of provi-
ders addressed communication of genetic information with
family members, with differences in whether the health
professional or the patient would be responsible for this
process. Several forms offered patients options regarding
communication that contradicted national guidelines and
legislation regarding the disclosure of results in the absence
of patient consent. This is concerning because it shows how
patients and clinicians could be misled about whether or not
communication is permissible in cases where the patient
does not consent. Our research questions whether providers
and health professionals receive adequate education and
training, especially with regards to the ethical problems
raised by genetic findings. Based on our analysis, we make
recommendations for how to address genetic findings with
familial implications in the clinical consent process.
A.M. Phillips: None. E. Niemiec: None. H.C. Howard:
None. K. Kagkelari: None. P. Borry: None. D.F.
Vears: None.
P23.14.B
Attitudes of Costa Rican individuals towards donation
of personal genetic data for research
G. Chavarria-Soley1,2, M. Francis1,2, F. Jimenez1,2, A.
Avila2, M. Castro-Gomez2, H. Raventos1,2
1Escuela de Biologia, Universidad de Costa Rica, San
Pedro, Costa Rica, 2Centro de Investigacion en Biologia
Celular y Molecular, Universidad de Costa Rica, San
Pedro, Costa Rica
Introduction: Technological advances in molecular
genetics have resulted in the generation of vast amounts of
genomic data. Sharing study data within the research
community raises important issues such as trust, privacy,
and potential consequences. The goal of this study is to
explore public attitudes and concerns in a sample of Costa
Rican individuals regarding the donation of personal
genetic data for research purposes.
Materials and Methods: A total of 224 Costa Rican
individuals answered the anonymous online survey “Your
DNA, Your Say”. The survey covers basic demographic
information, attitudes, trust in research professionals, and
concerns regarding donation of medical and genetic data.
Results: A majority of individuals (93%) are willing to
donate their DNA and medical information to at least one
kind of research professional (from three categories:
medical doctor, non-profit researcher, for-profit researcher).
Willingness to donate differs significantly according to the
potential use of the data and is lowest in the case of for-
profit research. The top concerns about sharing of genetic
data are discrimination by health or life insurance
companies and employers. When asked about levels of
trust in different professionals and the government, the top
ranked categories were the person’s own medical doctor and
researchers at a university in the person’s country.
Conclusions: This is the first study dealing with the
attitude toward sharing of genetic and medical information
in Costa Rica. In general, we found a higher willingness to
share genetic information for research purposes than what
has been reported for other non- Latin American countries.
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Human genome and gene-editing: opinions of National
Ethics/Bioethics Committees in Europe.
G. Floridia1, C. Mannelli2, C. Petrini1
1Istituto Superiore di Sanità, Rome, Italy, 2Candiolo Cancer
Istitute, FPO-IRCCS, Italian Ministry of Health, University
of Turin, Candiolo, Rome, Turin, Italy
Introduction: Advanced genome editing (GE) technolo-
gies, as the CRISPR/Cas9 system, are very promising for
prevention and treatment of human diseases. Ethical con-
cerns arise from the use of GE on human germ-cell lines
and embryos, whose debate has been amplified by the birth
of two Chinese gene-edited twin girls. In the last few years
National Ethics/Bioethics Committees (NC) in Europe have
been releasing documents about the use of GE, in particular
on human genome.
Materials and Methods: In this work we summarise and
analyse the following documents released by European NC:
a) “Statement from the Danish Council on Ethics on genetic
modification of future humans In response to advances in
the CRISPR technology”, 2016; b) “GE: an ethical review”,
Nuffield Council on Bioethics” (NuCoB), 2016; c) Opinion
N25/2016, Swiss National Advisory Commission on
Biomedical Ethics, 2016 ; d) “Recent developments in
human genome modification: GE”, Hellenic NC, 2016; e)
“Ethical issues in GE using CRISPR/CAS9”, Italian
National Bioethics Committee, 2017; f) "GE and human
reproduction", NuCoB 2018; g) ”Intervening in the Human
Germline”, German Ethics Council, 2019.
Results: Different ethical opinions, even inside a same
Committee, are expressed about genetic modifications
concerning early embryos not finalised to reproduction
and germ cells/fertilised cells edited for therapeutic
purposes, e.g. to remove disease susceptibility in the
offspring.
Conclusions: Bioethical viewpoints across European NC
vary indeed in a considerable way, from those focused
mainly on the potential benefits of these methodologies to
those more cautious.
G. Floridia: None. C. Mannelli: None. C.
Petrini: None.
P23.20.B
What public concerns exist regarding genetic informa-
tion: Japanese experiences and beyond
K. Muto1, A. Nagai1, I. Ri1, Z. Yamagata2
1The University of Tokyo, Tokyo, Japan, 2University of
Yamanashi, Yamanashi, Japan
In Japan, direct-to-consumer genetic testing has been also
freely accessible without any regulations since 1990s. The
Japanese government finally launched a comprehensive
policy for promoting cancer genomic medicine and storing
anonymized patients’ clinical and genomic data to the
National Data Repository in 2017. However, discussions
regarding the prevention of genetic discrimination have not
yet been active. The objectives of this survey were to
determine the extent of genetic literacy and attitudes of the
Japanese public toward genomic medicine and to estimate
the prevalence of genetic discrimination. Cross-sectional
and anonymous online surveys were distributed to adults in
Japan in February 2017 and again in January 2020. The
findings of the surveys conducted in 2017 (N = 10,881) and
2020 (N = 10,245) were compared, referring to our dataset
since 2005. The recognition rate of “genome” became
higher (69.7% in 2005, 73.2% in 2017, 85.1% in 2020
respectively). Respondents’ experiences of being required
to submit personal genetic information were “life insurance
for medical benefits or death benefits” (2.1% in 2017, 1.5%
in 2020 respectively) and “from my partner or his/her
relatives” (0.3% in both years). Overall benefits of using
genetic information were recognized higher than concerns.
As genome medicine becomes more familiar to people in
the near future, their concerns about the utilization of
genetic information may increase. The policy to prevent
genetic discrimination should be considered urgently.
K. Muto: None. A. Nagai: None. I. Ri: None. Z.
Yamagata: None.
P23.21.C
Public’s awareness of and attitudes towards research
biobanks in Latvia: concerns regarding genetic and
medical data donation for research
V. Rovite1, S. Mezinska2, L. Tzivian2, J. Kaleja3, I. Mileiko3,
D. Santare2
1Latvian Biomedical Research and Study centre, Riga,
Latvia, 2University of Latvia, Institute of Clinical and
Preventive Medicine, Riga, Latvia, 3University of Latvia,
Riga, Latvia
Introduction: In 2018 Latvia signed the declaration
‘Towards access to at least 1 million sequenced genomes in
the European Union by 2022’, which aims to link genomic
health data throughout the EU. The genetic research in
Latvia is currently regulated by several national regulations,
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but the most have been developed more than 15 years ago
and do not meet current international standards preventing
the successful functioning of biobanks and genetic research
data obtainment in Latvia. The aim of the study was to
analyze the public’s attitudes, concerns and trust in research
biobanking and genetic research in Latvia.
Materials and Methods: The questionnaire was based on
2010 Eurobarometer questionnaire (questions number B12-
B18 in the original questionnaire). Five nationally relevant
questions were added. The survey was conducted in March
2019 and used multi-stage stratified random sampling to
obtain a representative sample of the general population of
Latvia (aged 18 to 75 years). Statistical analysis was
performed using SPSS software, v. 23.
Results: 1017 responders participated in the survey.
35.6% expressed concerns donating their medical history
data and 27.5% their genetic data to the research,
respondents were less concerned for donating their lifestyle
information (25.8%), blood (25.5%) or tissue (26.7%).
59.6% supported the data and biological sample exchange
between EU member states for research purposes. 25.6% of
respondents were familiar with term “biobank”, 19.2% have
heard about national biobank.
Conclusions: The survey participants had higher con-
cerns for donating their genetic and medical data to research
than biological samples or lifestyle data.
V. Rovite: None. S. Mezinska: None. L. Tzivian: None.
J. Kaleja: None. I. Mileiko: None. D. Santare: None.
P23.23.B
How much do cancer patients value whole genome
sequencing? A cross-sectional survey using the
willingness-to-pay technique
M. Best1, P. Butow1, G. Davies1, C. Napier2, N. Bartley1, M.
Ballinger3, B. B. Biesecker4, I. Juraskova1, B. Meiser5, T.
Schlub6, D. Thomas3, D. Goldstein7, Members of the
PiGeOn Project
1School of Psychology, University of Sydney, Australia,
2University of Sydney, School of Psychology, Sydney,
Australia, 3Garvan Institute of Medical Research, Sydney,
Australia, 4RTI International, Washington, DC, United
States, 5Psychosocial Research Group, University of NSW,
Australia, 6School of Public Health, University of Sydney,
Australia, 7Prince of Wales Hospital, Sydney, Australia
Introduction: Genomic Sequencing (GS) to identify high
cancer risk will soon enter clinical practice at significant
cost to the health system. This study aimed to quantify
perceived value of GS to cancer patients and their relatives,
and factors associated with value.
Materials and Methods: Participants were recruited on
consent to a genomics study. Eligible participants (with
cancer of likely genetic aetiology, or a first-degree relative)
completed a questionnaire prior to GS. Willingness-to-pay
was assessed via a hypothetical trade-off scenario of
actionable result return-rates of 1%, 10%, 20%, 30%,
40% or 50% respectively.
Results: Of 348 probands and 213 relatives (92%
response rate), 81% would have GS for as little as a 1%
actionable return-rate. Participants would pay a median of
$1,000 for return-rates of at least 20% (probands) or 30%
(relatives), and $300 for lower return-rates. 114 (35%)
probands and 64 (31%) relatives would pay $1,000 for a 1%
actionable return rate, while 108 (33%) of probands and 76
(36%) of relatives would not pay $1,000 even for a 50%
return rate. Probands with common cancers and negative
attitudes to uncertainty were more likely to have GS; those
with higher education were more willing to pay $1,000 and
$3,000 at lower return-rates.
Conclusions: This study found high interest in, but lower
willingness-to-pay for GS in patients with cancers of likely
genetic aetiology and their first-degree relatives, possibly
due to inability to pay. To avoid inequity, the health system
should consider universal coverage of GS. Funded by
NHMRC and CINSW.
M. Best: None. P. Butow: None. G. Davies: None. C.
Napier: None. N. Bartley: None. M. Ballinger: None. B.
B. Biesecker: None. I. Juraskova: None. B. Meiser:
None. T. Schlub: None. D. Thomas: None. D.
Goldstein: None.
P23.26.B
Genetic testing decision-making: deciding between con-
trol and fate
B. M. Zimmermann1, D. Shaw1, K. Heinimann2, L.
Knabben3, B. Elger1, I. Koné1
1University of Basel, Institute of Biomedical Ethics, Basel,
Switzerland, 2University Hospital Basel, Institute for
Medical Genetics and Pathology, Basel, Switzerland, 3Uni-
versity Hospital of Bern, Department of Obstetrics and
Gynecology, Bern, Switzerland
Individuals considering genetic testing for cancer predis-
position must reflect on factual knowledge, relational con-
siderations and emotions. Genetic counselling supports their
decision-making process. However, factors influencing the
genetic testing decision-making process have not been
studied in Switzerland so far. This study thus aims to
investigate the decision-making process of people under-
going genetic counselling for cancer predisposition in
Switzerland. Grounded theory is the methodological
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approach of this qualitative interview study. Eighteen
individuals were retrospectively asked about their decision-
making process, including both acceptors and decliners of
genetic testing. Additionally, participants were asked in
hypothetical vignettes whether they would undergo genetic
testing for nonactionable genetic variants. Two healthcare
professionals providing genetic counselling were inter-
viewed for data triangulation. We found that the underlying
life philosophy of either leaving life to fate or preferring
control influences genetic testing decision-making impor-
tantly. However, other factors might shape this decision:
People look for certainty; anticipate consequences; are
socially influenced; simplify risks; decide intuitively or
reflectively, and trust in science to different degrees. Our
results visualise a theory of genetic testing decision-making
that comprises both acceptors and decliners. It might help
healthcare professionals and carriers informing family
members to anticipate differing life philosophies, and, thus,
differing attitudes towards genetic testing for both action-
able and non-actionable genetic variants.
B.M. Zimmermann: None. D. Shaw: None. K.
Heinimann: A. Employment (full or part-time); Modest;
University Hospital Basel. L. Knabben: A. Employment
(full or part-time); Modest; University Hospital Bern. B.
Elger: None. I. Koné: None.
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The impact of incidental findings in clinical exome
sequencing, a qualitative interview study
V. van der Schoot1, S. J. Viellevoije2, F. Tammer2, H. G.
Brunner2, Y. Arens1, H. G. Yntema2, A. J. M. Oerlemans2
1MUMC+, Maastricht, Netherlands, 2Radboudumc, Nijme-
gen, Netherlands
Introduction: Incidental findings (IFs) in clinical exome
sequencing are variants unrelated to the initial clinical
question, that could be of medical relevance to patients and/
or their families. The management and disclosure of IFs is a
topic of debate. Little is known about the impact of IFs on
patients’ lives.
Materials and Methods: We conducted 20 semi-
structured face-to-face interviews with patients and/or their
relatives who had an oncological (n = 10) or cardiological
(n = 10) IF disclosed.
Results: Almost all patients indicated they would
undergo genetic testing again. For participants, the impact
of an IF consists of the psychological, physical and the
financial impact. These dimensions are interrelated and
appear to be influenced by the actionability, understanding
the implications of the IF, the pre-test health of the patient
and the social context.
Conclusions: Disclosure of IFs in exome sequencing
does not seem to greatly affect the lives of patients and their
family if patients are enabled to realize the actionability of
the IF and get a grip on the consequences of the finding. We
observe a difference in perceived impact of oncological and
cardiological IFs. We propose a coordinating role for the
clinical geneticist to facilitate the empowerment of patients
with an IF.
V. van der Schoot: None. S.J. Viellevoije: None. F.
Tammer: None. H.G. Brunner: None. Y. Arens: None.
H.G. Yntema: None. A.J.M. Oerlemans: None.
P23.28.A
GenIDA, a participatory international database to
collect and analyze medically relevant information on
genetic forms of intellectual disability or autism: novel
findings on Koolen de Vries syndrome and comparative
analysis of behavioral and language features in KdVS,
Kleefstra and KBG syndromes
J. Mandel1,2, F. Colin1,2, T. Mazzucotelli1, N. Collot1, P.
Parrend3, J. Kummeling4, C. Ockeloen4, T. Kleefstra4, D.
Koolen4
1IGBMC, Illkirch, Eurometropole Strasbourg, France,
2University of Strasbourg, Strasbourg, France, 3iCube lab
CNRS UMR7357 Université de Strasbourg, Strasbourg,
France, 4Dept of Human Genetics, Radboud University
Medical Cantre, Nijmegen, Netherlands
Introduction: GenIDA was launched in 2017 as a partici-
patory and international study of specific genetic forms of
intellectual disability (ID) with or without autism or epi-
lepsy. The extreme heterogeneity of these neurodevelop-
mental disorders and the rarity of identified cases for many
of the implicated genes render the goal of defining the
clinical spectrum, comorbidities and natural history a
daunting task. We reasoned that a participatory approach
would be a relevant alternative whereby clinical information
is entered and updated by the family of the proband using a
structured online questionnaire in 5 languages at https://
genida.unistra.fr We used the Koolen-de Vries syndrome
(KdvS 17q21.31del / KANSL1mut) for a proof-of-concept
of the approach.
Methods and Results: The current questionnaire has 41
multiple choice questions and 92 sub-questions analyzed
automatically, and 5 open text qualitative questions.
Currently, the questionnaire has been filled for 808 patients
with a known genetic diagnosis. The KdVS cohort is the
largest, with 202 probands. Results obtained for the
frequency of epilepsy or other previously reported comor-
bidities are consistent with published data. Inclusion of
probands from a wide age range generates data on natural
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history. A major finding was the identification of recurrent
respiratory problems in 40% of patients, including asthma
(39 cases) and pneumonia (31 cases, mostly before 10y).
We could study use, perceived efficacy and reported
adverse effects of antiepileptic drugs. We compared
behavioral and language aspects for KdVS, Kleefstra
syndrome (n = 114) and KBG syndrome (n = 38),
showing major differences.
Conclusion: The data validate our participatory
approach.
J. Mandel: None. F. Colin: None. T. Mazzucotelli:
None. N. Collot: None. P. Parrend: None. J. Kummeling:
None. C. Ockeloen: None. T. Kleefstra: None. D.
Koolen: None.
P23.31.A
The social shaping of a diagnosis in Next Generation
Sequencing
J. M. L. Kuiper1, P. Borry2, D. Vears2, I. Van Hoyweghen1
1Centre for Sociological Research, KU Leuven, Leuven,
Belgium, 2Centre for Biomedical Ethics and Law, KU
Leuven, Leuven, Belgium
Although Next Generation Sequencing (NGS) has increased
our ability to test and diagnose, the type of data that is
generated by NGS techniques and their interpretation leaves
room for a considerable amount of uncertainty. NGS not
only generates a vast amount of data, the results are often
not very clear-cut. In many instances, analysis does not
reveal a straightforward diagnostic cause for the symptoms,
requiring a more complex interpretation and negotiation
process. The type of delineation work this lack of clarity
necessitates is not uncommon in medicine: diagnostic
definitions and criteria change over time, which allows new
diagnoses to arise and others to be lumped together, split or
dissolved. In NGS, the boundaries of what counts as ‘evi-
dence’ for variant interpretation, what is relevant to report to
patients, and what constitutes a diagnosis is continuously
reshaped in everyday practice. In this early implementation
phase of NGS, in which standardization efforts are not yet
solidified, the boundary struggles in laboratory and clinical
practice are particularly visible. To explore the complexities
in the social shaping of diagnosis in NGS settings, we cri-
tically review the literature on the sociology of health and
illness, sociology of diagnosis, and science and technology
studies on the meaning and social construction of diagnosis.
We then assess the current state of NGS practice through
this lens. We discuss what it entails to give and receive a
diagnosis using NGS, how this differs from diagnoses
identified through more ‘traditional’ diagnostic technolo-
gies, and what role uncertainty plays in this.
J.M.L. Kuiper: None. P. Borry: None. D. Vears: None.
I. Van Hoyweghen: None.
P23.32.B
The psychological impact of receiving an incidental
finding with Non-Invasive Prenatal Testing (NIPT)
I. M. Bakkeren1, L. Henneman2, M. N. Bekker3, E. H. van
Vliet-Lachotzki4, R. H. Galjaard1
1Erasmus Medical Centre, Rotterdam, Netherlands,
2Amsterdam UMC, Amsterdam, Netherlands, 3Utrecht
University Medical Center, Utrecht, Netherlands, 4Dutch
Genetic Alliance (VSOP), Soest, Netherlands
Since April 2017, the non-invasive prenatal test (NIPT) is
offered to all pregnant women in the Netherlands as a first
trimester prenatal screening test. Findings other than tris-
omy 21, 18 or 13 are reported on request of the pregnant
woman, 78% of women chose to have these reported. The
first year, a total of 207 incidental findings (IF) other than
the three common trisomies were detected. This survey
study examined women’s experiences of being informed of
an IF and its psychological impact. One-hundred thirteen
(54.6%) women completed the questionnaire. Most women
(59.3%) chose for IF because they wanted to know as much
as possible about the health of their unborn child. Slightly
more than half (57.5%) did not find deciding for IF difficult,
however only 25.6% felt they had an idea of what IF could
be before having NIPT. Almost all (98.2%) women met
with a clinical geneticist to discuss their IF, for 82.3% of
them this helped in understanding their result. Sixteen
women (14.2%) ended their pregnancy because of
abnormalities resulting from the IF, whereas 85 (75.2%)
gave birth to a child without anomalies. For most women
(85.9%) the IF caused them great worry. However, a vast
majority (89.3%) would opt for NIPT again in a future
pregnancy, of whom 71% would opt for IF again. This
study gives an insight in how pregnant women experience
receiving an IF from NIPT. For most women the IF caused
worry, however most of them would opt for NIPT with
IF again.
I.M. Bakkeren: None. L. Henneman: None. M.N.
Bekker: None. E.H. van Vliet-Lachotzki: None. R.H.
Galjaard: None.
P23.33.C
Opportunistic screening for actionable pharmacogenetic
variants: why not apply knowledge to patient-data that
is already available?
792 J. del Picchia
T. Rigter1, M. E. Jansen1, G. M. W. R. de Wert2, M. C.
Cornel1
1AmsterdamUMC (location VUmc), Amsterdam Public
Health Institute, Dept. Clinical Genetics, section Commu-
nity Genetics, Amsterdam, Netherlands, 2Maastricht Uni-
versity, Department of Health, Ethics and Society,
Maastricht, Netherlands
Analyzing clinical exome and genome sequences beyond
the primary indication (opportunistic screening) has been
subject to international debate. Arguments evolved around
the 2013 American College of Medical Genetics recom-
mendations to analyze and disclose a minimum list of
actionable variants. Reasons to support opportunistic
screening include, utilizing available data as an opportunity
to identify and manage risks for the selected highly pene-
trant genetic disorders. Experts, however, have also ques-
tioned the clinical validity and utility of these findings and
posed serious ethical and social issues around informed
consent, equity, potential psychosocial harm of receiving
results and impact on health care budgets. Pharmacogenetic
variants have received little attention in these debates, while
guidelines with actionable gene-drug prescriptions are
available. The “Dutch Consortium for Ethical, Legal, and
Social Issues of Personalized Medicine (ELSI-PM)” orga-
nized a workshop on opportunistic screening for pharma-
cogenetic variants, for relevant Dutch stakeholders. We
aimed to elucidate the arguments for and against offering
opportunistic pharmacogenetic screening to patients
undergoing sequencing with an overview of variants rele-
vant for future drug prescriptions; their personal “myD-
NAmedicationcard”. Participants agreed that such practice
would pertain screening, should therefore meet corre-
sponding screening criteria, and does not automatically fall
under the duty of the physician offering the initial sequen-
cing. Although many argued that it could be beneficial to
have your personal pharmacogenetic information readily
available when requiring drugs, many uncertainties
emerged. Pilot studies could provide more insight in con-
sequences of opportunistic pharmacogenetic screening.
ELSI-PM is funded by ZonMw (Netherlands Organisation
for Health Research & Development; grantno. 846003102)
T. Rigter: None. M.E. Jansen: None. G.M.W.R. de
Wert: None. M.C. Cornel: None.
P23.34.A
Extent of knowledge about prenatal diagnostic testing in
Poland
M. L. Podstawka, M. Malarska
Medical University of Lodz, Lodz, Poland
Aim: The aim was to assess the extent of knowledge of
prenatal diagnostic testing among Polish people.
Methods: This study was conducted via an online
anonymous survey published on social media, targeted at
Polish citizens of different age, sex, residence and
educational background. 1034 respondents answered a
series of questions.
Results: The results revealed that among respondents
there are still many false beliefs about the antenatal
examination, as well as many concerns regarding health
service in general. Among other results, it was observed that
53% do not know what amniocentesis is and of those who
know 25% do not understand the risks associated with the
procedure, 38.2% do not know what indications for CVS
are, only 30% know what a free-DNA test is, 9% think that
an ultrasound scan is harmful to the fetus and 26.4% of the
respondents with children did not have any prenatal tests
done during pregnancy.
Conclusions: Currently in Poland, the extent of knowl-
edge and understanding of prenatal diagnostic testing is
rather pooras survey answers showed that people do not
understand the procedures used in prenatal tests, their
effectiveness and possible risks. Additionally, some of the
respondents left remarks which suggested that they have a
problem with access to prenatal diagnostics due to lack of
information about the antenatal examinations. What became
clear is that there is a need to raise awareness about this
issue, as well as educate patients and improve health service
in Poland.
M.L. Podstawka: None. M. Malarska: None.
P23.35.B
Family factors in a prenatal clinic; the extended
trajectory of a single decision
A. J. Clarke1, S. Doheny1, O. Uzun2
1Cardiff University, Cardiff, United Kingdom, 2Cardiff and
Vale University Health Board, Cardiff, United Kingdom
Decisions about whether to continue or terminate a preg-
nancy, when the fetus is affected by a genetic condition and/
or a malformation, are often difficult. Research into such
decisions is also difficult and sensitive. These decisions can
raise many issues: ethical, social and practical.
We report on the multiple factors considered by one
family in the course of making their decision about a
pregnancy in which the fetus was found to be affected by
Down syndrome and a cardiac malformation.
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We used multiple data sources to achieve this, collecting
audio recordings of fetal cardiology clinics, a diary of
thoughts and feelings kept by the pregnant woman until
after the pregnancy, an audio recording of one family
conversation and one interview at follow-up after the end of
the study. We concentrate on the diary and the recorded
family discussion as such material is not often accessed.
The topics discussed include the contrasting feelings of
the couple about a possible termination of the pregnancy,
the perceived opinions of friends and family members, the
efforts of the pregnant woman’s mother to be supportive,
and the family’s efforts to ‘read’ the opinions of antenatal
clinic professionals. We also note the family’s under-
standings of the research process and its implications for
“informed consent”.
This approach to research - recruiting patients as active
participants in research into their experiences and decisions
- adds substantially to our appreciation of their situation and
their decisions and will be of value for reflective practice
and training.
ESRC Grant ES/R003092/1
A.J. Clarke: None. S. Doheny: None. O. Uzun: None.
P23.36.C
Medical Genetics in Preventive Healthcare in Europe:
Current Status and Future Directions
A. Blazkova1,2, M. Zapp1, G. Lenzini1
1University of Luxembourg, Esch-sur-Alzette, Luxembourg,
2Megeno S.A., Esch-sur-Alzette, Luxembourg
The potential of predictive and presymptomatic genetic
testing to foster preventive healthcare has been widely
recognised. However, the extent to which genetic tests are
currently utilised for prevention purposes remains
unknown. In this study, we explore the practices of a large
sample of European prevention centres (PCs) - i.e. medical
institutions specialised in health maintenance and disease
prevention - regarding their use of medical genetics. We
identified PCs located within the European Economic Area
based on their membership of relevant professional orga-
nisations, participation in academic and business events
related to preventive medicine, and a comprehensive online
search. We reviewed PCs’ websites and information mate-
rials, such as marketing brochures and videos, to gain
insights into the availability of genomics-guided preventive
services. In cases where provided information was deemed
insufficient, PCs were contacted with additional questions
via email. Those PCs who did not reply to our email
inquiries within two weeks were subsequently contacted via
a phone call. Our search identified 74 PCs located in 20
European countries. The highest number of PCs were based
in Germany (17/74; 23%), followed by Spain (9/74; 12%)
and the Czech Republic (7/74; 9%). Of these, only six (8%)
PCs fully incorporate genetic testing into their services to
personalise preventive healthcare pathways for their custo-
mers. These PCs also employ qualified genetics profes-
sionals who support customers through genetic counseling.
The paucity of genome-informed services among PCs
indicates a slow rate of adoption of genomics in preventive
healthcare.
A. Blazkova: A. Employment (full or part-time); Modest;
Megeno S.A.. M. Zapp: None. G. Lenzini: B. Research
Grant (principal investigator, collaborator or consultant and
pending grants as well as grants already received);
Significant; Megeno S.A..
P23.37.A
The latent class analysis to clarify the factors associated
with the structure of the public attitude toward the
genome research at the survey in Japan.
Z. Yamagata1, K. Muto2
1University of Yamanashi, Chuo, Japan, 2The Institute of
Medical Science, The University of Tokyo,, Tokyo, Japan
Aim: The aim of this study was to clarify the structure of
the public attitude toward the genome research by the latent
class analysis.
Methods: The nationwide surveys about the attitude
toward the genome research were conducted in 2016 in
Japan. The participants were comprised of 2,000 people
(age, 20-69), selected from the Japanese general population
by using the two-step stratified random sampling method.
Results: Five clusters were assumed as an explanation
model of six variables related to the knowledge of genome
and attitudes toward genomic research promotion about
three themes; basic genome research, genome research
related to agriculture and medicine at the survey in 2016.
They were able to be named “Group of aggressive
promotion” (41.5%), “Group of passive support”(20.8%),
“Group not making judgment” (19.2%), “Group making
prudent judgment” (18.5%), and “Group not interested in
genome”. The results in 2008 and 2009 were almost the
same as that in2005. It is possible to forecast to which
cluster to belong according to respondent’s attribute, and we
can forecast the reaction to other questions by using a
cluster oppositely. For examples, “Group of aggressive
promotion” is the layer of a high academic background, and
is positive to donate their blood for the genome research,
“Group making prudent judgment” is high academic back
ground persons as same as “Group of aggressive promo-
tion”, and is interesting in the science and technology, but is
negative to the blood donation for the research.
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Z. Yamagata: None. K. Muto: None.
P23.38.B
Exploring responsibility about reproduction in the
accounts of individuals at risk for and af-fected by late
onset neurological diseases: a qualitative study
Á. Mendes1, J. Sequeiros1, A. Clarke2
1UnIGENe and CGPP, IBMC - i3S, Universidade do Porto,
Porto, Portugal, 2Institute of Medical Genetics, School of
Medicine, Cardiff University, Cardiff, United Kingdom
People with a family history of hereditary disease com-
monly face difficult questions about reproduction. This
study reports accounts of their reproductive decisions from
people at-risk for or affected by the incurable, late-onset
neurological diseases, familial amyloid polyneuropathy
ATTRVal30Met and Machado-Joseph disease. We draw on
individual and family semi-structured interviews with par-
ticipants recruited through the respective national patients’
associations (n = 35, 19 women; mean age: 39.2y, range
17-68). Data were analysed thematically. Findings revealed
that participants drew on various - sometimes ambivalent
and competing - relations to their awareness of genetic risk
and their wish to have children. The elimination of genetic
risk was perceived as responsible behaviour by some par-
ticipants. For others, however, responsibility entailed
accepting risks, because they prioritized values such as
parenthood, family relationships and the value of life, above
any concern about genetic disease. Some accounts were
fraught with ambivalence, repentance and guilt, especially
when children were born before participants knew of their
or their partner’s risk. Hope for future scientific advances
was often emphasized by those participants who already
had children at-risk. We discuss the findings in the context
of the participants’ negotiations between reproductive risks
and their sense of responsibility to self and others (including
those not yet born), and how the accumulated multi-
generational experience with the disease influence partici-
pants’ decisions. We conclude that ‘genetic responsibility’
is present not only in the accounts of those who chose not to
have children but also in those who knew their situation
beforehand and still chose to have at-risk children.
Á. Mendes: None. J. Sequeiros: None. A.
Clarke: None.
P23.39.C
ELSI challenges raised by sequencing technology in
French pediatric oncology services
S. Le Tirant1, E. Rial-Sebbag1, S. Julia1,2, L. Hervouet3, S.
de Montgolfier3,4
1LEASP, UMR 1027 Inserm / Université Paul Sabatier,
Toulouse, France, 2CHU de Toulouse, Service de Génétique
médicale, Hôpital Purpan, Toulouse, France, 3Institut de
Recherche Interdisciplinaire sur les Enjeux Sociaux (UMR
8156 CNRS - 997 INSERM - EHESS - UP13), Campus
Condorcet, Aubervilliers, France, 4Université Paris Est
Créteil / INSPE, Créteil, France
Introduction: The use sequencing technology becomes
common practice in pediatric oncology to better understand
the tumor process and to adapt treatments. This exam can
eventually reveal constitutional information of interest for
family members linked to the child cancer or incidental
findings. This highlights some ethical, legal and societal
issues related to the information that should be delivered to
patients that are minors and to their relatives, the right to
know or not about this data and overall the consent to these
somatic genetic tests.
Materials and Methods: We surveyed the current and
coming French bioethics legislation and the one on health
applied to minors, the relevant international texts and
recommendations formulated by legal bodies and profes-
sional societies. In addition, different consents forms were
compared. Focus groups with patients and parents were
organized in several pediatric oncology units to identify the
information needs and to shed light on path improvements
(professionals involved and temporal organization of such
proposals).
Results: Initial results show disparate medical practices
and an absence of specific rules regarding the somatic
genetic above all when realized on minors. However, the
application of general principles of health care law offers
precisions and some solutions have been planned in the
French draft bill on bioethics.
Conclusions: The need to regulate this practice and the
communication of these data remains essential to respect the
right of information of patients, their ability to consent and
to improve the care of minors. This study was realized as
part of the project INCa-SHS n°2018-127.
S. Le Tirant: None. E. Rial-Sebbag: None. S. Julia:
None. L. Hervouet: None. S. de Montgolfier: None.
P23.40.A
Intellectual functioning of adults with Silver-Russell
syndrome due to IGF2/H19 hypomethylation in the
11p15 region
M. Burgevin1, A. Lacroix1, G. Brown1, M. Mikaty2, A.
Toutain3, M. Vincent4, D. Martin-Coignard5, F. Petit6, R.
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Coutant7, C. Thauvin-Robinet8, B. Donadille9, I.
Netchine10, S. Odent2,11
1Univ Rennes, LP3C (Laboratoire de Psychologie: Cogni-
tion, Comportement, Communication), EA 1285, Rennes,
France, 2Service de Génétique Clinique, Centre de
Référence Maladies Rares CLAD-Ouest, CHU de Rennes,
ENR ITHACA, Rennes, France, 3Service de Génétique,
CHU de Tours, Hôpital Bretonneau, UMR 1253, iBrain,
Université de Tours, Inserm, Tours, France, 4Service de
Génétique Médicale, CHU de Nantes, Nantes, France,
5Service de Génétique, CH du Mans, Le Mans, France,
6Clinique de Génétique, Centre de référence CLAD Nord-
Ouest, CHU Lille, Lille, France, 7Service d’endocrinologie
et diabétologie pédiatrique, CHU Angers, Angers, France,
8Service de Génétique Médicale, Centre de Référence
Maladies Rares « Déficiences intellectuelles de causes
rares », CHU Dijon Bourgogne, Dijon, France, 9Service
d’endocrinologie, Hôpital Saint Antoine, Paris, France,
10Sorbonne Universités, Inserm, UMR S 938, Centre de
Recherche Saint Antoine, Hôpital Armand Trousseau,
Explorations Fonctionnelles Endocriniennes, Paris,
France, 11Univ Rennes, CNRS, IGDR (Institut de génétique
et développement de Rennes) - UMR 6290,, Rennes,
France
Introduction: Silver-Russell syndrome (SRS,
OMIM#180860, ORPHA#813) is characterized by severe
intrauterine and postnatal growth retardation, relative mac-
rocephaly at birth, body asymmetry, prominent forehead
and feeding difficulties during childhood. Two main
molecular mechanisms have been identified: a maternal
uniparental disomy of chromosome 7 (5-10%), and
methylation abnormalities of the 11p15.5 region (40-60%).
To date, few studies have focused on the intellectual and
cognitive profile of individuals with SRS. However, these
are important concerns for families. The few existing stu-
dies are mainly focused on pediatric cohorts, but it is
important to evaluate the intellectual profile and cognitive
abilities of patients with SSR across lifespan.
Materials and Methods: Ten adults aged 18-39 years
completed the Wechsler scale for adults. All of the patients
had SRS due to epimutation in the 11p15 region. Measures
of interest included patients’ intelligence quotient (IQ) and
four cognitive domains: verbal comprehension, perceptual
reasoning, working memory, and processing speed. Clinical
and medical information were also collected from inter-
views and questionnaires.
Results: The mean IQ score was in the average range (M
= 95.40, SD = 18.55). Patients had better performance in
verbal comprehension compared to other domains. Frequent
daily difficulties were reported by patients: learning
disabilities and low self-esteem were perceived in 60% of
adults.
Conclusions: This study is one of the first to document
the intellectual functioning of adults with SRS. It shows that
early intervention and multidisciplinary care from child-
hood to adulthood appear to be important in this syndrome
for care potential medical, cognitive and psychosocial
problems.
M. Burgevin: None. A. Lacroix: None. G. Brown:
None. M. Mikaty: None. A. Toutain: None. M. Vincent:
None. D. Martin-Coignard: None. F. Petit: None. R.
Coutant: None. C. Thauvin-Robinet: None. B. Dona-
dille: None. I. Netchine: None. S. Odent: None.
P23.42.C
Reporting and receiving uncertain prenatal whole
exome sequencing results: How might healthcare
providers and patients handle uncertainty?
J. E. Klapwijk1,2, H. T. Brüggenwirth1, K. E. M. Diderich1,
K. Dijkstra2, S. R. Riedijk1
1Department of Clinical Genetics, Erasmus Medical Centre,
Rotterdam, Netherlands, 2Department of Psychology,
Education, and Child Studies, Erasmus University Rotter-
dam, Rotterdam, Netherlands
Introduction: Application of prenatal whole exome
sequencing (WES) offers a much broader scope of results,
but can also generate more uncertainty. We aimed to
investigate how uncertain prenatal WES results might be
handled by healthcare professionals (HCP’s) and patients
and which individual characteristics may play a role.
Exploring the impact of uncertainty in decision-making is
instrumental in optimizing counselling in a prenatal setting.
Materials and Methods: Two experiments were con-
ducted among 51 medical students (HCP’s) and 76
psychology students (in the role of patients) respectively.
Vignettes covering several types of uncertain prenatal WES
results were ranked on perceived uncertainty. Medical
students answered whether they would report each result to
the couple (experiment 1). Psychology students indicated
whether they would want to receive the result (experiment
2). In both experiments participants indicated how certain
they were about their choice.
Results: In experiment 1, highly uncertain results were
reported less often (59%) than results low in uncertainty
(98%), p < .001. Furthermore, medical students reported
more uncertainty with their choice when vignettes were
high and moderate versus low in uncertainty, p < .001. In
experiment 2, psychology students chose less often to
receive highly uncertain results (71%) than results low in
uncertainty (87%), p = .012. They reported more
796 J. del Picchia
uncertainty about their choice when results were moderately
and highly uncertain versus low in uncertainty, p < .001.
Conclusions: In this study we validated the widespread
hypothesis that the willingness both to convey and receive
uncertain prenatal WES results decreased as uncertainty
increased.
J.E. Klapwijk: None. H.T. Brüggenwirth: None. K.E.
M. Diderich: None. K. Dijkstra: None. S.R.
Riedijk: None.
P23.44.B
Ensuring ethical and legal compliance of cutting-edge
DNA sequencing technologies: practical considerations
from the H2020 project EASI-Genomics
E. Gennet, M. Coubault-Azzouz, G. Chassang, E. Rial-
Sebbag
Inserm UMR1027, TOULOUSE, France
EASI-Genomics (‘European Advanced infraStructure for
Innovative Genomics) is a European Infrastructure unifying
the major European genomic centers providing external
access to their facilities for performing genome sequencing
(human, animal, vegetal) for research purposes. The
mission of EASI-Genomics is to facilitate access to
cutting-edge DNA sequencing technologies to researchers
from both academia and industry, within or outside of
Europe.
Partners of the project have set up a process in order to
ensure compliance with the relevant European ethical and
legal framework at stake in human, animal or plant
sequencing: a memorandum of understanding, a standard
material transfer agreement and an interdisciplinary ethics
check of each selected researcher before being allowed to
access the sequencing services.
After a year of experience and two calls for projects, some
conclusions can be drawn on the main obstacles, limitations
and learning curves of such a process in guaranteeing
compliance to the European ethical and legal framework.
But most of all, this experience permitted to identify some
recurring issues that may need particular attention and
efforts to ensure ELSI compliance. This is for instance the
question of sequencing of ancient DNA in compliance with
access and benefit sharing principles, or of the necessary
safeguards regarding CRISPR-CAS9 engineered
biomaterials.
EASI-Genomics has received funding from the European
Union’s Horizon 2020 research and innovation program
under grant agreement No 824110.
E. Gennet: None. M. Coubault-Azzouz: None. G.
Chassang: None. E. Rial-Sebbag: None.
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